<SEC-DOCUMENT>0000875045-25-000049.txt : 20251030
<SEC-HEADER>0000875045-25-000049.hdr.sgml : 20251030
<ACCEPTANCE-DATETIME>20251030063148
ACCESSION NUMBER:		0000875045-25-000049
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		146
CONFORMED PERIOD OF REPORT:	20250930
FILED AS OF DATE:		20251030
DATE AS OF CHANGE:		20251030

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BIOGEN INC.
		CENTRAL INDEX KEY:			0000875045
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				330112644
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-19311
		FILM NUMBER:		251432056

	BUSINESS ADDRESS:	
		STREET 1:		225 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		7814642000

	MAIL ADDRESS:	
		STREET 1:		225 BINNEY STREET
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOGEN IDEC INC.
		DATE OF NAME CHANGE:	20070427

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BIOGEN IDEC INC
		DATE OF NAME CHANGE:	20031112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	IDEC PHARMACEUTICALS CORP / DE
		DATE OF NAME CHANGE:	19970530
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>biib-20250930.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:56b2dfbb-fb98-49e8-bcdc-e902c065377c,g:9aa702a5-e336-43c4-a300-999553ccda1f,d:59d9e1af10a84fa9992f9418986a77c7-->
<html xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:biib="http://www.biogenidec.com/20250930" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:currency="http://xbrl.sec.gov/currency/2025" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:srt="http://fasb.org/srt/2025" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>biib-20250930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-25">0000875045</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="f-26">12/31</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-27">2025</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-28">Q3</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-29">false</ix:nonNumeric><ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-30">146,702,272</ix:nonFraction><ix:nonFraction unitRef="product" contextRef="c-624" decimals="INF" name="biib:LesseeOperatingLeaseNumberOfRenewalOptions" format="ixt-sec:numwordsen" scale="0" id="f-1379">three</ix:nonFraction><ix:nonNumeric contextRef="c-625" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="f-1380">five years</ix:nonNumeric><ix:nonFraction unitRef="product" contextRef="c-626" decimals="INF" name="biib:LesseeOperatingLeaseNumberOfRenewalOptions" format="ixt-sec:numwordsen" scale="0" id="f-1381">one</ix:nonFraction><ix:nonNumeric contextRef="c-627" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="f-1382">six month</ix:nonNumeric><ix:nonFraction unitRef="usd" contextRef="c-840" decimals="-5" name="biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" format="ixt:num-dot-decimal" scale="6" id="f-1923">50.0</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="biib-20250930.xsd"/></ix:references><ix:resources><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>biib:segment</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="employee"><xbrli:measure>biib:Employee</xbrli:measure></xbrli:unit><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="wholesaler"><xbrli:measure>biib:wholesaler</xbrli:measure></xbrli:unit><xbrli:unit id="product"><xbrli:measure>biib:product</xbrli:measure></xbrli:unit><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-10-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:LEQEMBICollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:LEQEMBICollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:LEQEMBICollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:LEQEMBICollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">biib:AlcyoneTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-02</xbrli:startDate><xbrli:endDate>2024-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-02</xbrli:startDate><xbrli:endDate>2024-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-02</xbrli:startDate><xbrli:endDate>2024-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">biib:MeasurementInputProbabilityRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">biib:Phase3ClinicalTrialFelzartamabTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">biib:Phase3ClinicalTrialFelzartamabOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">biib:Phase3ClinicalTrialFelzartamabAMRMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">biib:Phase3ClinicalTrialFelzartamabIgANMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FelzartamabAndIzastobartHIB210Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">biib:MilestonePaymentFutureDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">biib:HumanImmunologyBiosciencesPreExistingInLicenseCommitmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FelzartamabAndIzastobartHIB210Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">biib:MilestonePaymentRegulatoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">biib:HumanImmunologyBiosciencesPreExistingInLicenseCommitmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FelzartamabAndIzastobartHIB210Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">biib:MilestonePaymentCommercialMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">biib:HumanImmunologyBiosciencesPreExistingInLicenseCommitmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FelzartamabIgANMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FelzartamabAMRMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FelzartamabPMNMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OtherClinicalProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FelzartamabIgANMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FelzartamabAMRMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FelzartamabPMNMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:PaymentDueAtFirstAnniversaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:PaymentDueAtSecondAnniversaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:PaymentDueAtSecondAnniversaryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">biib:IonisPharmaceuticalsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-03-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-09-26</xbrli:startDate><xbrli:endDate>2023-09-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SKYCLARYSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SKYCLARYSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-240"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SKYCLARYSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SKYCLARYSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-242"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SKYCLARYSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-243"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SKYCLARYSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-244"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:QALSODYMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:QALSODYMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-246"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:QALSODYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:QALSODYMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-248"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:QALSODYMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-249"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:QALSODYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-250"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RareDiseaseProductRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-251"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RareDiseaseProductRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-252"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RareDiseaseProductRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-253"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RareDiseaseProductRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-254"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RareDiseaseProductRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-255"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RareDiseaseProductRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-256"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-257"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-258"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-259"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-260"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-261"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-262"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-263"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-264"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-265"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-266"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-267"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-268"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-269"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-270"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-271"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-272"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-273"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-274"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-275"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-276"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-277"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-278"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-279"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-280"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TOFIDENCEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-281"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TOFIDENCEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-282"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TOFIDENCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-283"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TOFIDENCEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-284"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TOFIDENCEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-285"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TOFIDENCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-286"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-287"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-288"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-289"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-290"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-291"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-292"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZURZUVAEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-293"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZURZUVAEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-294"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZURZUVAEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-295"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZURZUVAEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-296"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZURZUVAEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-297"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZURZUVAEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-298"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-299"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-300"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-301"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-302"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-303"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-304"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OtherProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-305"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OtherProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-306"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-307"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OtherProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-308"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OtherProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-309"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-310"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-311"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-312"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-313"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-314"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-315"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-317"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-318"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-319"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-320"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-321"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-322"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-324"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-325"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-326"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-327"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-328"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-329"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-330"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-332"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-333"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-334"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-335"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-336"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-337"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-338"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-339"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-340"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-341"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-342"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-343"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-344"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-345"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-346"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-347"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-348"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-349"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-350"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-351"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-352"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-353"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-354"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-355"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-356"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-357"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-358"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-359"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-360"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-361"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-362"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-363"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-364"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-365"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-366"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-367"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-368"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-369"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-370"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-371"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-372"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-373"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-374"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SKYCLARYSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-375"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SKYCLARYSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-376"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SKYCLARYSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-377"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SKYCLARYSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-378"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SKYCLARYSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-379"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SKYCLARYSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-380"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:QALSODYMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-381"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:QALSODYMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-382"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:QALSODYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-383"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:QALSODYMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-384"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:QALSODYMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-385"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:QALSODYMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-386"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RareDiseaseProductRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-387"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RareDiseaseProductRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-388"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RareDiseaseProductRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-389"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RareDiseaseProductRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-390"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RareDiseaseProductRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-391"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RareDiseaseProductRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-392"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-393"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-394"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-395"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-396"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-397"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-398"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-399"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-400"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-401"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-405"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-406"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-407"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-408"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-409"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-410"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-411"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-412"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-413"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-414"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-415"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-416"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TOFIDENCEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-417"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TOFIDENCEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-418"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TOFIDENCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-419"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TOFIDENCEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-420"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TOFIDENCEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-421"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TOFIDENCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-422"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-423"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-424"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-425"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-426"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-427"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-428"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZURZUVAEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-429"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZURZUVAEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZURZUVAEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-431"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZURZUVAEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-432"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZURZUVAEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-433"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZURZUVAEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-434"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-435"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-436"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-437"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-438"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-439"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-440"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OtherProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-441"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OtherProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-442"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-443"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OtherProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-444"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OtherProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-445"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OtherProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-446"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-447"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-448"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-449"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-450"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-451"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-452"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-453"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-454"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-455"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-456"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-457"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-458"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-459"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-460"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-461"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-462"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-463"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-464"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-465"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-466"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-467"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-468"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-469"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-470"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-471"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RoyaltyAttributedToOCREVUSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-472"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RoyaltyAttributedToOCREVUSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-473"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RoyaltyAttributedToOCREVUSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-474"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RoyaltyAttributedToOCREVUSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-475"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-476"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-477"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-478"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-479"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:LEQEMBICollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-480"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AlzheimersCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-481"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AlzheimersCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-482"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AlzheimersCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-483"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AlzheimersCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-484"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ContractManufacturingAndOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-485"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ContractManufacturingAndOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-486"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ContractManufacturingAndOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-487"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ContractManufacturingAndOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-488"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-489"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-490"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-491"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-492"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-493"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:NonrecurringAdjustmentAxis">us-gaap:FairValueAdjustmentToInventoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-494"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:NonrecurringAdjustmentAxis">us-gaap:FairValueAdjustmentToInventoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-495"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:NonrecurringAdjustmentAxis">us-gaap:FairValueAdjustmentToInventoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-496"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:NonrecurringAdjustmentAxis">us-gaap:FairValueAdjustmentToInventoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-497"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ClinicalInventoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:NonrecurringAdjustmentAxis">us-gaap:FairValueAdjustmentToInventoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-498"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ClinicalInventoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:NonrecurringAdjustmentAxis">us-gaap:FairValueAdjustmentToInventoryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-499"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-500"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-501"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-502"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-503"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">biib:PriorityReviewVoucherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-504"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">biib:PriorityReviewVoucherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-505"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-506"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-507"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:AcquiredAndInLicensedRightsAndPatentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-508"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-509"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:PriorityReviewVoucherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-511"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-512"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-513"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-514"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-515"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-516"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-517"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-518"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-519"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-520"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-521"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-522"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-523"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-524"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-525"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-526"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-527"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-528"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-529"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-530"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-532"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-533"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-534"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-535"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">biib:MeasurementInputProbabilityRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-536"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-537"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-538"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-539"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-540"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-541"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.25SeniorNotesdueMay12030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-542"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.25SeniorNotesdueMay12030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-543"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.25SeniorNotesdueMay12030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-544"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.25SeniorNotesdueMay12030Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-545"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A5.050SeniorNotesDueJanuary152031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-546"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A5.050SeniorNotesDueJanuary152031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-547"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A5.050SeniorNotesDueJanuary152031Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-548"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A5.050SeniorNotesDueJanuary152031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-549"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A5.750SeniorNotesDueMay152035Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-550"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A5.750SeniorNotesDueMay152035Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-551"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A5.750SeniorNotesDueMay152035Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-552"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A5.750SeniorNotesDueMay152035Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-553"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-554"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-555"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-556"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-557"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3.15SeniorNotesdueMay12050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-558"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3.15SeniorNotesdueMay12050Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-559"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3.15SeniorNotesdueMay12050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-560"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3.15SeniorNotesdueMay12050Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-561"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotes3.250DueFebruary152051Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-562"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotes3.250DueFebruary152051Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-563"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotes3.250DueFebruary152051Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-564"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotes3.250DueFebruary152051Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-565"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A6.450SeniorNotesDueMay152055Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-566"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A6.450SeniorNotesDueMay152055Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-567"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A6.450SeniorNotesDueMay152055Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-568"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A6.450SeniorNotesDueMay152055Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-569"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:NonCurrentPortionOfNotesPayableAndTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-570"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:NonCurrentPortionOfNotesPayableAndTermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-571"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-05-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-572"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-573"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-574"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-575"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-576"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-577"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-578"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-579"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-580"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:EquitySecuritiesNonCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-581"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:EquitySecuritiesNonCurrentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-582"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-583"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-584"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-585"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-586"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-587"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-588"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-589"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-590"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-591"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-592"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-593"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-594"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-595"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-596"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-597"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-598"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-599"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-600"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-601"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-602"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-603"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-604"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-605"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-606"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-607"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-609"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-610"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-611"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-612"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-613"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-614"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-615"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-616"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-617"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-618"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-619"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-620"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-621"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-622"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-623"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-624"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">biib:HeadquartersLeaseFiveYearRenewalOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-03-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-625"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">biib:HeadquartersLeaseFiveYearRenewalOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-626"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">biib:HeadquartersLeaseSixMonthRenewalOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-03-01</xbrli:startDate><xbrli:endDate>2025-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-627"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">biib:HeadquartersLeaseSixMonthRenewalOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-628"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A5.050SeniorNotesDueJanuary152031Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-05-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-629"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A5.750SeniorNotesDueMay152035Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-05-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A6.450SeniorNotesDueMay152055Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-05-12</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-631"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2025SeniorNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-632"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-09-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-633"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-634"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:TheCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-635"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:TheCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-636"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:TheCreditFacilityFloatingRate364DayTrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-637"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:TheCreditFacilityFloatingRateThreeYearTrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-638"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:TheCreditFacilityTerminatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-639"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">biib:FloatingRate364DayTrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2023TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-640"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">biib:FloatingRate364DayTrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2023TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-641"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">biib:FloatingRate364DayTrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:TheCreditFacilityFloatingRateThreeYearTrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-642"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">biib:TermLoan2023ThreeYearTrancheMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2023TermLoanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-643"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-644"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-645"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-646"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-647"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-648"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-649"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-650"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-651"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-652"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-653"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-654"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-655"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-656"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-657"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-658"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-659"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-660"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-661"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-662"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-663"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-664"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-665"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-666"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-667"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-668"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-669"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-670"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-671"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-672"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-673"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-674"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-675"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-676"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-677"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-678"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-679"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-680"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-681"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-682"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-683"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-684"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-685"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-686"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-687"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-688"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-689"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-690"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-691"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-692"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-693"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-694"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-695"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-696"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-697"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-698"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-699"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-700"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-701"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-704"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-705"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-706"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-707"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-708"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-709"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-710"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-711"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-712"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-713"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-714"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-715"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-716"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-717"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-718"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-719"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-720"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-721"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-722"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-723"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-724"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-725"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-726"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-727"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-728"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-729"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:SageAndDenaliMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-730"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:SageAndSangamoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-732"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-733"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-734"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:SageAndSangamoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-735"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-736"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OCREVUSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-03-01</xbrli:startDate><xbrli:endDate>2017-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-737"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OCREVUSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-03-01</xbrli:startDate><xbrli:endDate>2017-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-738"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OCREVUSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-03-01</xbrli:startDate><xbrli:endDate>2017-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-739"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OCREVUSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-03-01</xbrli:startDate><xbrli:endDate>2017-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-740"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RituxanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-741"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:LUNSUMIOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-742"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:LUNSUMIOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-743"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:GAZYVAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-744"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-745"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:LEQEMBIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:LEQEMBICollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-746"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:LEQEMBIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:LEQEMBICollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-747"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-748"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-749"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:LEQEMBIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:LEQEMBICollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-750"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:LEQEMBIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:LEQEMBICollaborationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-751"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-752"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-753"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-754"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-755"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-756"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-757"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-758"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-759"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-760"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-761"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-762"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-763"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-764"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-765"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-766"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-767"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-768"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-769"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-770"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-771"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-772"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-773"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-774"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-775"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-776"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZorevunersenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:StokeTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-01</xbrli:startDate><xbrli:endDate>2025-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-777"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZorevunersenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-01</xbrli:startDate><xbrli:endDate>2025-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-778"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:StokeTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-02-01</xbrli:startDate><xbrli:endDate>2025-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-779"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">biib:MilestonePaymentDevelopmentalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:StokeTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-780"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">biib:MilestonePaymentCommercialMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:StokeTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-781"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:StokeTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-782"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:StokeTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-783"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-784"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-785"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-786"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-787"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-788"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-789"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-790"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-791"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-792"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-793"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-02-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-794"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">biib:MilestonePaymentFutureDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-795"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FelzartamabAndIzastobartHIB210Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">biib:MilestonePaymentOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">biib:HumanImmunologyBiosciencesPreExistingInLicenseCommitmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-796"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FelzartamabAndIzastobartHIB210Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">biib:MilestonePaymentTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">biib:HumanImmunologyBiosciencesPreExistingInLicenseCommitmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-797"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">biib:CityTherapeuticsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-798"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">biib:CityTherapeuticsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-799"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">biib:CityTherapeuticsInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-800"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">biib:MilestonePaymentResearchMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">biib:CityTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-801"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">biib:MilestonePaymentDevelopmentalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">biib:CityTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-802"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">biib:MilestonePaymentSalesBasedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">biib:CityTherapeuticsInc.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-803"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">biib:IMRALDIPatentLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-804"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">biib:ConvergenceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-805"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">biib:ConvergenceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-806"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">biib:GenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-09-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-808"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-809"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-810"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-811"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-812"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-813"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-814"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-815"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-816"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-817"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-818"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-819"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">biib:ResearchAndDiscoveryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-820"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">biib:ResearchAndDiscoveryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-821"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">biib:ResearchAndDiscoveryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-822"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">biib:ResearchAndDiscoveryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-823"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">biib:EarlyStageProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-824"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">biib:EarlyStageProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-825"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">biib:EarlyStageProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-826"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">biib:EarlyStageProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-827"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">biib:LateStageProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-828"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">biib:LateStageProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-829"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">biib:LateStageProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-830"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">biib:LateStageProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">biib:MarketedProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-832"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">biib:MarketedProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-833"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">biib:MarketedProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-834"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">biib:MarketedProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-835"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:ServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-07-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-836"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:ServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-837"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:ServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-838"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:ServiceOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-839"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:VanquaBioInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-01</xbrli:startDate><xbrli:endDate>2025-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-840"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000875045</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-01</xbrli:startDate><xbrli:endDate>2025-10-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i59d9e1af10a84fa9992f9418986a77c7_1"></div><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:2pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington,&#160;D.C. 20549</span></div><div style="margin-top:5pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:18pt;font-weight:700;line-height:120%">Form&#160;<ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-Q</ix:nonNumeric> </span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:4.756%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.044%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:14pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="f-2">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3">September 30, 2025</ix:nonNumeric> </span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OR</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:4.756%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:93.044%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:14pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="f-4">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission File Number <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">0-19311</ix:nonNumeric></span></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><img src="biib-20250930_g1.jpg" alt="biogenlogoa11.jpg" style="height:30px;margin-bottom:5pt;vertical-align:text-bottom;width:92px" id="i-1"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:24pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-6">BIOGEN INC.</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:47.948%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.560%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.192%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-7">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-8">33-0112644</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(State or other jurisdiction of<br/>incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-9">225 Binney Street</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-10">Cambridge</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-11">MA</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-12">02142</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-13">617</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-14">679-2000</ix:nonNumeric> </span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(Address, including zip code, and telephone number, including</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">area code, of registrant&#8217;s principal executive offices)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="margin-top:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:35.463%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.080%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.619%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.970%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trading Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-15">Common Stock, $0.0005 par value</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-16">BIIB</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-17">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:1pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days:&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-18">Yes</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files):&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-19">Yes</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and "emerging growth company" in Rule 12b-2 of the Exchange Act:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:21.920%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.979%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.568%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.052%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.981%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-20">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">x</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="f-21">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-22">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:1pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-23">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;No&#160;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:6pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The number of shares of the issuer&#8217;s Common Stock, $0.0005&#160;par value, outstanding as of October&#160;28, 2025, was <ix:nonFraction unitRef="shares" contextRef="c-2" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-24">146,702,272</ix:nonFraction> shares.</span></div><div style="margin-top:10pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:2pt solid #000000;padding:0 1pt"/></tr></table></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i59d9e1af10a84fa9992f9418986a77c7_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC.</span></div><div style="text-align:center"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FORM&#160;10-Q &#8212; Quarterly Report</span></div><div style="text-align:center"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">For the Quarterly Period Ended September 30, 2025</span><span style="color:#578196;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:14pt;text-align:center"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:8.124%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:79.866%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.710%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PART&#160;I&#160;&#8212; </span><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_16">FINANCIAL INFORMATION</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_19">Financial Statements (unaudited)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_22">Condensed Consolidated Statements of Income&#160;&#8212; For the Three and Nine Months Ended September 30, 2025 and 2024</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_22">8</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_25">Condensed Consolidated Statements of Comprehensive Income &#8212; For the Three and Nine Months Ended September 30, 2025 and 2024</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_25">9</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_28">Condensed Consolidated Balance Sheets&#160;&#8212; As of September 30, 2025 and December&#160;31, 2024</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_28">10</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_31">Condensed Consolidated Statements of Cash Flow&#160;&#8212; For the Nine Months Ended September 30, 2025 and 2024</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_31">11</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_34">Condensed Consolidated Statements of Equity &#8212; For the Three and Nine Months Ended September 30, 2025 and 2024</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_34">12</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_37">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_37">14</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_136">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_136">54</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_280">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_280">84</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_286">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_286">86</a></span></div></td></tr><tr style="height:15pt"><td colspan="9" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">PART&#160;II&#160;&#8212; </span><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_289">OTHER INFORMATION</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_292">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_292">87</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_295">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_295">87</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_298">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_298">103</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_301">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_301">103</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Item 6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_307">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_307">104</a></span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_313">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_313">105</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i59d9e1af10a84fa9992f9418986a77c7_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div></div><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:700;line-height:120%">NOTE&#160;REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This report contains forward-looking statements that are being made pursuant to the provisions of the Private Securities Litigation Reform Act of 1995 (the PSLRA) with the intention of obtaining the benefits of the &#8220;Safe Harbor&#8221; provisions of the PSLRA. These forward-looking statements may be accompanied by such words as &#8220;aim,&#8221; &#8220;anticipate,&#8221; "assume," &#8220;believe,&#8221; &#8220;contemplate,&#8221; &#8220;continue," "could," &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;forecast,&#8221; &#8220;goal,&#8221; &#8220;guidance,&#8221; &#8220;hope,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;objective,&#8221; "outlook," &#8220;plan,&#8221; &#8220;possible,&#8221; "potential," &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would&#8221; or the negative of these words or other words and terms of similar meaning. Given their forward-looking nature, these statements involve substantial risks and uncertainties and may be based on inaccurate assumptions. This report includes, among others, forward-looking statements regarding:</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our expected financial and operating performance; </span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our long-term strategy and supporting business plans, including our product pipeline; </span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our expectations about continued growth through acquisitions and key collaborative relationships and funding arrangements; </span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our belief that our long-term competitive position depends upon our success in discovering and developing innovative, cost-effective products that serve unmet medical needs, along with our ability to manufacture products efficiently and to launch and market them effectively in a highly competitive environment; </span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our ability to obtain and maintain adequate coverage, pricing and reimbursement from third-party payors; </span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our expectations regarding certain legal and regulatory proceedings and investigations; and </span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our belief that our existing funds, when combined with cash generated from operations and our access to additional financing resources, if needed, are sufficient to satisfy our operating, working capital, strategic alliance, milestone payment, capital expenditure and debt service requirements for the foreseeable future. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These forward-looking statements are based on management's current beliefs and assumptions and on information currently available to management. Given their nature, we cannot assure that any outcome expressed in these forward-looking statements will be realized in whole or in part. We caution that these statements are subject to risks and uncertainties, many of which are outside of our control and could cause future events or results to be materially different from those stated or implied in this document, including, among others, factors relating to:</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our substantial dependence on the anticipated amount, timing and accounting of revenue from our products, including from the successful development of new products and approval of additional indications for our existing products, including but not limited to LEQEMBI and SKYCLARYS;  </span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the anticipated amount, timing and accounting of contingent, milestone, royalty and other payments under licensing, collaboration, acquisition or divestiture agreements; tax positions and contingencies; collectability of receivables; pre-approval inventory; cost of sales; research and development costs; compensation and other selling, general and administrative expense; amortization of intangible assets; foreign currency exchange risk; estimated fair value of assets and liabilities; and impairment assessments, including for goodwill balances;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">expectations, plans, prospects and the timing of actions relating to product approvals, approvals of additional indications for our existing products, sales, pricing, growth, reimbursement and launch of our marketed and pipeline products all of which is subject to governmental and regulatory oversight, and therefore subject to risks and uncertainties, including but not limited to those related to approvals, unfavorable or delayed reimbursements and coverage determinations, and changes in reimbursement policies or practices of payors and other third parties;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the potential impact of increased product competition in the biopharmaceutical and healthcare industry, as well as any other markets in which we compete, including increased competition from new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways, including generic, prodrugs or biosimilar versions of our marketed products or competing products, including but not limited to, increased competition from TECFIDERA generic entrants in the U.S. and international markets and a biosimilar entrant of TYSABRI;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">patent terms, patent term extensions, patent office actions and expected availability and periods of regulatory exclusivities, as well as our ability to adequately enforce existing patents, including our European patent related to TECFIDERA;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our ability to effectively implement our corporate strategy which includes significant investment in product and pipeline candidates, including but not limited to felzartamab, litifilimab and nusinersen;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the successful execution of our strategic and growth initiatives, including acquisitions, and our ability to realize the anticipated benefits from our acquisitions of Reata and HI-Bio and the potential acquisition of Alcyone, including future performance of the SKYCLARYS product, further development of the felzartamab product, future development of drug delivery solutions and anticipated synergies;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the drivers for growing our business, including our plans and intention to commit resources relating to discovery, research and development programs and business development opportunities, including collaboration agreements, as well as the potential benefits and results of, and the anticipated completion of, certain business development transactions, reorganizations and cost-reduction measures, including our Fit for Growth program;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the expectations, development plans and anticipated timelines, including costs and timing of potential clinical trials, regulatory filing approvals and/or discontinuation, of our products, drug candidates and pipeline programs, including collaborations with third parties including but not limited to Eisai and Supernus, as well as the potential therapeutic scope of the development and commercialization of our and our collaborators&#8217; pipeline products;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the impacts of disruptions, turnover or changes in strategy, priorities or capabilities at our collaborators resulting from, for example, a change in control, and the related impacts on the commercialization or manufacturing of our shared products;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the timing, outcome and impact of administrative, regulatory, legal and other proceedings, including those related to our patents and other proprietary and intellectual property rights, tax audits, assessments and settlements, pricing matters, sales and promotional practices, product liability, investigations and other matters;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our ability to commercialize biosimilars, which is subject to risks such as our reliance on third parties, competitive challenges, regulatory compliance, adequate supply, intellectual property and regulatory challenges and failure to gain market and patient acceptance;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our ability to finance our present and future operations and business initiatives and obtain funding for such activities on favorable terms;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our ability to attract, retain and motivate qualified individuals for management and other employee positions in a highly competitive environment, including potential difficulty in retaining talent following acquisitions or following the discontinuation or underperformance of one or more marketed, pre-clinical or clinical programs;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">adverse safety events involving our marketed or pipeline products, generic, prodrugs or biosimilar versions of our marketed products or any other products from the same class as one of our products;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the current and potential impacts of geopolitical tensions, acts of war and other large-scale crises, including impacts to our operations, sales and the possible disruptions or delay in our plans to conduct clinical trial activities in areas of geopolitical tension, including tensions between the U.S., China and other countries, regions affected by Russia's invasion of Ukraine and the military conflict in the Middle East;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the direct and indirect impact of global health outbreaks or adverse weather events on our business and operations, including sales, expense, reserves and allowances, the supply chain, manufacturing, research and development costs, clinical trials and employees;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our use of information technology systems and data and the potential impacts of any breakdowns, interruptions, invasions, corruptions, data breaches, destructions and/or other cybersecurity incidents of such systems or those of our business partners;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our incorporation of technologies using AI into some of our processes;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the potential impact of healthcare reform in the U.S., including the IRA (or other legislative or executive acts that may modify or replace the IRA, such as the OBBBA) and the impact of the IRA Medicare Part D redesign, and measures being taken worldwide designed to reduce healthcare costs and limit the overall level of government expenditures, including the impact of pricing actions and reduced reimbursement for our products, as well as the potential impact of legislative and regulatory changes and priorities, including actions related to the MFN drug pricing policy;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our manufacturing capacity, including our ability to effectively manufacture biosimilars, reliance on third-party contract manufacturing organizations, plans and timing relating to changes in our manufacturing capabilities, our ability to adequately address global bulk supply risks, our ability to fully utilize our manufacturing facilities, including our Solothurn facility, activities in new or existing manufacturing facilities and the expected timeline for the gene therapy, clinical packaging and other manufacturing facility in RTP, North Carolina to be operational;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the impact of the continued uncertainty of the credit and economic conditions in certain countries and our ability to collect accounts receivable in such countries;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the impact of the increased volatility in the financial markets on our ability to obtain financing;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">lease commitments, purchase obligations and the timing and satisfaction of other contractual obligations;</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">changes in our effective tax rate and obligations in various jurisdictions in which we are subject to taxation; and</span></div><div style="margin-top:7pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the impact of new laws, regulatory actions, judicial decisions, accounting standards and tariffs or trade restrictions, including any newly imposed U.S. tariffs and any responsive non-U.S. tariffs applicable to our products or operations, as well as the potential global macroeconomic effect of tariffs or trade restrictions.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These forward-looking statements involve risks and uncertainties, including those that are described in </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Part II, Item 1A. Risk Factors</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Part I,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> included in this report and elsewhere in this report, that could cause actual results to differ materially from those reflected in such statements. The factors identified above should not be construed as an exhaustive list of factors that could affect our future results and should be read in conjunction with the other cautionary statements that are included in our 2024 Form 10-K. Because some of these risks and uncertainties cannot be predicted or quantified and some are beyond our control, you should not rely on our forward-looking statements as predictions of future events and you should not place undue reliance on these statements. Moreover, we operate in a very competitive and rapidly changing environment, new risks and uncertainties may emerge from time to time and it is not possible for us to predict all risks nor identify all uncertainties. Forward-looking statements speak only as of the date of this report and are based on information and estimates available to us at this time. Except as required by law, we do not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise. You should read this report with the understanding that our actual future results, performance, events and circumstances might be materially different from what we expect.</span></div><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:700;line-height:120%">NOTE REGARDING COMPANY AND PRODUCT REFERENCES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References in this report to:</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">&#8220;Biogen,&#8221; the &#8220;company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Biogen Inc. and its consolidated subsidiaries; and</span></div><div style="margin-top:6pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">&#8220;RITUXAN&#8221; refers to both RITUXAN (the trade name for rituximab in the U.S., Canada and Japan) and MabThera (the trade name for rituximab outside the U.S., Canada and Japan).</span></div><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:700;line-height:120%">NOTE&#160;REGARDING TRADEMARKS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ADUHELM&#174;, AVONEX&#174;, BYOOVIZ&#174;, PLEGRIDY&#174;, QALSODY&#174;, RITUXAN&#174;, RITUXAN HYCELA&#174;, SKYCLARYS&#174;, SPINRAZA&#174;, TECFIDERA&#174;, TYSABRI&#174; and VUMERITY&#174; are registered trademarks of Biogen. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BENEPALI&#8482;, FLIXABI&#8482;, FUMADERM&#8482;, IMRALDI&#8482; and OPUVIZ&#8482; are trademarks of Biogen.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ACTEMRA&#174;, COLUMVI&#174;, ENBREL&#174;, EYLEA&#174;, GAZYVA&#174;, LEQEMBI&#174;, HUMIRA&#174;, LUCENTIS&#174;, LUNSUMIO&#174;, OCREVUS&#174;, REMICADE&#174;, ZURZUVAE&#8482;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and other trademarks referenced in this report are the property of their respective owners.</span></div><div id="i59d9e1af10a84fa9992f9418986a77c7_2049"></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:700;line-height:120%">NOTE&#160;REGARDING DISCLOSURES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we have used, or expect in the future to use, our investor relations website (investors.biogen.com), the Biogen LinkedIn account (linkedin.com/company/biogen) and the Biogen X account (https://x.com/biogen) as a means of disclosing information to the public in a broad, non-exclusionary manner, including for purposes of the SEC&#8217;s Regulation Fair Disclosure (Reg FD). Accordingly, investors should monitor our investor relations website and these social media channels in addition to our press releases, SEC filings, public conference calls and websites, as the information posted on them could be material to investors.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i59d9e1af10a84fa9992f9418986a77c7_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:400;line-height:120%">DEFINED TERMS</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:27.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:70.204%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024 Form 10-K</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Annual Report on Form 10-K for the year ended December 31, 2024</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020 Share Repurchase Program</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Board of Directors authorized program to repurchase up to $5.0 billion of our common stock</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2024 ESPP</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen Inc. 2024 Employee Stock Purchase Plan</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2015 ESPP</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen Inc. 2015 Employee Stock Purchase Plan</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2023 Term Loan</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$1.5&#160;billion term loan credit agreement</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025 Senior Notes</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Senior Unsecured Notes Issued in May 2025</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AbbVie</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AbbVie Inc.</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AI</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Artificial Intelligence</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Alcyone</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Alcyone Therapeutics, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ALS</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amyotrophic Lateral Sclerosis</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AMR</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Antibody-Mediated Rejection</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AOCI</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accumulated Other Comprehensive Income (Loss)</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ASO</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Antisense Oligonucleotide</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ASU</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounting Standards Update</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BLA</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biologics License Application</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CCPA</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">California Consumer Privacy Act</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CLE</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cutaneous Lupus Erythematosus</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CLL</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Chronic Lymphocytic Leukemia</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CMS</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Centers for Medicare &amp; Medicaid Services</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CNS</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Central Nervous System</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CODM</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Chief Operating Decision Maker</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Convergence</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Convergence Pharmaceuticals Ltd.</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CRL</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Complete Response Letter</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">CROs</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract Research Organizations</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">DEA</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Drug Enforcement Agency</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Denali</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Denali Therapeutics Inc.</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">District Court</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. District Court for the District of Massachusetts</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">DOJ</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Department of Justice</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">EC</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">European Commission</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Eisai</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Eisai Co., Ltd.</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">EMA</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">European Medicines Agency</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">E.U.</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">European Union</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FA</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Friedreich Ataxia</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FASB</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financial Accounting Standards Board</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FCPA</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign Corrupt Practices Act</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FDA</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Food and Drug Administration</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fit for Growth</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost saving program initiated in 2023</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">G7</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Group of Seven (comprised of Canada, France, Germany, Italy, Japan, the U.K. and the U.S.)</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Genentech</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Genentech, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GILTI</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Global Intangible Low Tax Income</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GloBE</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Global Anti-Base Erosion</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GMP</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Good Manufacturing Practices</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">HHS</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Department of Health and Human Services</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">HI-Bio</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Human Immunology Biosciences, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Humana</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Humana Inc.</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IgAN</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Immunoglobulin A Nephropathy</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-bottom:0.5pt solid #0070c0;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IND</span></td><td colspan="3" style="border-bottom:0.5pt solid #0070c0;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investigational New Drug</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:14pt;font-weight:400;line-height:120%">DEFINED TERMS (continued)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:27.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:70.204%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IPR&amp;D</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">In-process Research and Development</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IRA</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inflation Reduction Act of 2022</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IT</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Information Technology</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IV</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intravenous</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">LEQEMBI Collaboration Agreement</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amended and Restated Collaboration Agreement entered into by Biogen MA Inc. and Eisai Co., Ltd. on October 22, 2017, as amended on March 13, 2022</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">LRRK2</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Leucine-Rich Repeat Kinase 2</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MAA</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketing Authorization Application</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MDD</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Major Depressive Disorder</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MorphoSys</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MorphoSys AG</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MFN</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Most-Favored-Nation</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">MS</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NDA</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">New Drug Application</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Neurimmune</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Neurimmune SubOne AG</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OBBBA</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">One Big Beautiful Bill Act</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OECD</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Organization for Economic Co-operation and Development</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ODD</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Orphan Drug Designation</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Organon</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Organon LLC</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PDUFA</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prescription Drug User Fee Act</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PMN</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Primary Membranous Nephropathy</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PPACA</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Patient Protection and Affordable Care Act</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PPD</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Postpartum Depression</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PPMS</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Primary Progressive MS</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PRV</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Priority Review Voucher</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">R&amp;D</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and Development</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reata</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reata Pharmaceuticals, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RMS</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Relapsing MS</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RNAi</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RNA interference</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RRMS</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Relapsing-Remitting MS</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">RTP</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research Triangle Park</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sage</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sage Therapeutics, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Samsung Bioepis</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Samsung Bioepis Co., Ltd.</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Samsung BioLogics</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Samsung BioLogics Co., Ltd.</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sangamo</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sangamo Therapeutics, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SEC</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Securities and Exchange Commission</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SG&amp;A</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, General and Administrative</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SLE</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Systemic Lupus Erythematosus</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SMA</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Spinal Muscular Atrophy</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SOD1</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Superoxide Dismutase 1</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Supernus</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Supernus Pharmaceuticals, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SWISSMEDIC</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Swiss Agency for Therapeutic Products</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Transition Toll Tax</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">A one-time mandatory deemed repatriation tax on accumulated foreign subsidiaries' previously untaxed foreign earnings</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.K.</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United Kingdom</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. GAAP</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounting Principles Generally Accepted in the U.S.</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">VA</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Veterans Affairs</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vanqua</span></td><td colspan="3" style="border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vanqua Bio, Inc.</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-bottom:0.5pt solid #0070c0;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">VAT</span></td><td colspan="3" style="border-bottom:0.5pt solid #0070c0;border-top:0.5pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Value-added Tax</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i59d9e1af10a84fa9992f9418986a77c7_16"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PART&#160;I FINANCIAL INFORMATION</span></div><div id="i59d9e1af10a84fa9992f9418986a77c7_19"></div><div style="text-align:center"><span><br/></span></div><div id="i59d9e1af10a84fa9992f9418986a77c7_22"></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF INCOME</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited, in millions, except per share amounts)</span></div><div><span><br/></span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.361%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.602%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Product revenue, net</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-31">1,846.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-32">1,769.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-33">5,452.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-34">5,380.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue from anti-CD20 therapeutic programs</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-35">493.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-36">446.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-37">1,339.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-38">1,284.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alzheimer's collaboration revenue</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-39">42.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-40">18.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-41">130.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-42">33.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract manufacturing, royalty and other revenue</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-43">151.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-44">231.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-45">689.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-46">522.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-47">2,534.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-48">2,465.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-49">7,611.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-50">7,221.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost and expense:</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of sales, excluding amortization and impairment of acquired intangible assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-51">674.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-52">638.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="f-53">1,908.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="f-54">1,726.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="f-55">436.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="f-56">516.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="f-57">1,269.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="f-58">1,467.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquired in-process research and development, upfront and milestone expense</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="biib:ResearchAndDevelopmentExpenseIncludingAcquiredInProcessCost" scale="6" id="f-59">2.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" name="biib:ResearchAndDevelopmentExpenseIncludingAcquiredInProcessCost" scale="6" id="f-60">26.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="biib:ResearchAndDevelopmentExpenseIncludingAcquiredInProcessCost" scale="6" id="f-61">249.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="biib:ResearchAndDevelopmentExpenseIncludingAcquiredInProcessCost" scale="6" id="f-62">42.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="f-63">594.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="f-64">588.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-65">1,751.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-66">1,723.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization and impairment of acquired intangible assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="f-67">135.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="f-68">130.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="f-69">378.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="f-70">295.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Collaboration profit sharing/(loss reimbursement)</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="biib:Collaborationprofitlosssharing" scale="6" id="f-71">87.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" name="biib:Collaborationprofitlosssharing" scale="6" id="f-72">69.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="biib:Collaborationprofitlosssharing" scale="6" id="f-73">220.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="biib:Collaborationprofitlosssharing" scale="6" id="f-74">197.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Gain) loss on fair value remeasurement of contingent consideration</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="f-75">5.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="f-76">23.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="f-77">28.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="f-78">23.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-79">7.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-80">6.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-81">42.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-82">24.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gain on sale of priority review voucher, net</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:GainLossOnDispositionOfIntangibleAssets" format="ixt:fixed-zero" scale="6" id="f-83">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" name="us-gaap:GainLossOnDispositionOfIntangibleAssets" format="ixt:fixed-zero" scale="6" id="f-84">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:GainLossOnDispositionOfIntangibleAssets" format="ixt:fixed-zero" scale="6" id="f-85">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="us-gaap:GainLossOnDispositionOfIntangibleAssets" scale="6" id="f-86">88.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="f-87">34.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="f-88">14.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="f-89">151.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="f-90">193.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cost and expense</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="f-91">1,977.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="f-92">2,014.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="f-93">5,998.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="us-gaap:CostsAndExpenses" format="ixt:num-dot-decimal" scale="6" id="f-94">5,606.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income before income tax (benefit) expense</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="f-95">557.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="f-96">451.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-97">1,612.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-98">1,614.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax (benefit) expense</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-99">90.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-100">62.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-101">270.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-102">249.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to Biogen Inc.</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-103">466.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-104">388.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-105">1,341.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-106">1,365.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income per share:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic earnings per share attributable to Biogen Inc.</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-19" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-107">3.18</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-20" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-108">2.67</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-109">9.16</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-21" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-110">9.38</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted earnings per share attributable to Biogen Inc.</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-19" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-111">3.17</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-20" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-112">2.66</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-113">9.14</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-21" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-114">9.35</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average shares used in calculating:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic earnings per share attributable to Biogen Inc.</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-19" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-115">146.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-20" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-116">145.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-117">146.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-21" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-118">145.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted earnings per share attributable to Biogen Inc.</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-19" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-119">147.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-20" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-120">146.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-121">146.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-21" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-122">146.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i59d9e1af10a84fa9992f9418986a77c7_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited, in millions)</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.116%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.157%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.015%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net income attributable to Biogen Inc.</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-123">466.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-124">388.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-125">1,341.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-126">1,365.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains (losses) on cash flow hedges, net of tax</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="f-127">26.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="f-128">41.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="f-129">137.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="f-130">6.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gains (losses) on pension benefit obligation, net of tax</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" format="ixt:fixed-zero" scale="6" id="f-131">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="f-132">0.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="f-133">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="f-134">0.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Currency translation adjustments, net of tax</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="f-135">3.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="f-136">41.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="f-137">57.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="f-138">14.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other comprehensive income (loss), net of tax</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-139">23.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-140">0.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-141">78.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-142">8.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive income (loss) attributable to Biogen Inc.</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="f-143">489.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="f-144">388.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-145">1,263.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="6" id="f-146">1,373.5</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="i59d9e1af10a84fa9992f9418986a77c7_28"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited, in millions, except per share amounts)</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.835%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.130%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of September 30, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ASSETS</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-147">3,862.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-148">2,375.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" scale="6" id="f-149">97.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="f-150">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable, net of allowance for doubtful accounts of $<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="f-151">3.1</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="f-152">2.2</ix:nonFraction>, respectively</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="f-153">1,374.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="f-154">1,404.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Due from anti-CD20 therapeutic programs</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="f-155">475.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="f-156">464.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="f-157">2,209.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="f-158">2,460.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:OtherAssetsCurrent" scale="6" id="f-159">916.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="us-gaap:OtherAssetsCurrent" scale="6" id="f-160">752.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="f-161">8,936.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="f-162">7,456.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="f-163">3,075.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="f-164">3,181.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="f-165">330.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="f-166">356.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-167">9,331.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-168">9,691.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-169">6,490.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-170">6,478.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax asset</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="f-171">312.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="6" id="f-172">324.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investments and other assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="f-173">729.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="f-174">560.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-175">29,207.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-176">28,049.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">LIABILITIES AND EQUITY</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of notes payable</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:NotesPayableCurrent" format="ixt:fixed-zero" scale="6" id="f-177">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="us-gaap:NotesPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="f-178">1,748.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Taxes payable</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:TaxesPayableCurrent" scale="6" id="f-179">103.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="us-gaap:TaxesPayableCurrent" scale="6" id="f-180">548.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="f-181">413.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="f-182">424.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-183">2,773.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-184">2,807.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-185">3,290.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-186">5,528.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Notes payable</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-187">6,285.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-188">4,547.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="f-189">358.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="f-190">190.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term operating lease liabilities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="f-191">305.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="f-192">334.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="f-193">761.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="f-194">732.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="f-195">11,000.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="f-196">11,333.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commitments, contingencies and guarantees</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-22" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-197"></ix:nonFraction></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-23" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-198"></ix:nonFraction></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Biogen Inc. shareholders&#8217; equity:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-22" decimals="3" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-199">0.001</ix:nonFraction> per share</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="f-200">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="f-201">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-22" decimals="4" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-202">0.0005</ix:nonFraction> per share</span></div></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="f-203">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="f-204">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:AdditionalPaidInCapital" scale="6" id="f-205">797.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="us-gaap:AdditionalPaidInCapital" scale="6" id="f-206">569.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-207">214.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-208">136.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="f-209">20,601.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="f-210">19,259.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Treasury stock, at cost</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="f-211">2,977.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="f-212">2,977.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total equity</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-213">18,207.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-214">16,716.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and equity</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-215">29,207.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-216">28,049.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><div id="i59d9e1af10a84fa9992f9418986a77c7_31"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOW</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited, in millions)</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.736%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.691%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:700;line-height:100%">Cash flow from operating activities:</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-217">1,341.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-218">1,365.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash flow from operating activities:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="f-219">579.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="f-220">489.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Impairment of intangible assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="f-221">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="f-222">20.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Excess and obsolescence charges related to inventory</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:InventoryWriteDown" scale="6" id="f-223">13.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="us-gaap:InventoryWriteDown" scale="6" id="f-224">68.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Amortization of acquired inventory step-up</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="biib:AmortizationOfInventoryStepUp" scale="6" id="f-225">165.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="biib:AmortizationOfInventoryStepUp" scale="6" id="f-226">185.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="f-227">231.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="f-228">216.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="f-229">28.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="f-230">23.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="f-231">194.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="f-232">99.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(Gain) loss on strategic investments</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi" scale="6" id="f-233">33.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi" scale="6" id="f-234">22.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Gain on sale of priority review voucher, net</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:fixed-zero" scale="6" id="f-235">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="6" id="f-236">88.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="f-237">49.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="f-238">95.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities, net of effects of business acquired:</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="f-239">74.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="f-240">127.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Due from anti-CD20 therapeutic programs</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="f-241">11.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="f-242">15.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="f-243">35.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="f-244">207.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Accrued expense and other current liabilities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="f-245">32.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="f-246">84.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Income tax assets and liabilities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="f-247">764.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable" scale="6" id="f-248">62.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Other changes in operating assets and liabilities, net</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="f-249">179.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet" scale="6" id="f-250">65.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Net cash flow provided by (used in) operating activities</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-251">1,692.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="f-252">2,114.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:700;line-height:100%">Cash flow from investing activities:</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="f-253">109.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="f-254">114.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" scale="6" id="f-255">91.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" format="ixt:fixed-zero" scale="6" id="f-256">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Acquisition of HI-Bio, net of cash acquired</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:fixed-zero" scale="6" id="f-257">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="f-258">1,074.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Proceeds from sale of equity interest in Samsung Bioepis</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" format="ixt:fixed-zero" scale="6" id="f-259">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" scale="6" id="f-260">406.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Proceeds from sale of priority review voucher</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="6" id="f-261">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="6" id="f-262">88.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Acquisitions of intangible assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="f-263">15.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="us-gaap:PaymentsToAcquireIntangibleAssets" scale="6" id="f-264">179.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Proceeds from sales of strategic investments</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ProceedsFromSaleOfOtherInvestments" scale="6" id="f-265">56.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="us-gaap:ProceedsFromSaleOfOtherInvestments" scale="6" id="f-266">96.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="f-267">20.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="f-268">4.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Net cash flow provided by (used in) investing activities</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="f-269">139.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="f-270">780.6</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:700;line-height:100%">Cash flow from financing activities:</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Payments related to issuance of stock for share-based compensation arrangements, net</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="f-271">13.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="f-272">34.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Proceeds from borrowings</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-273">1,733.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:fixed-zero" scale="6" id="f-274">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Repayments of borrowings</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="f-275">1,750.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="f-276">650.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Cash paid for contingent consideration</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="6" id="f-277">141.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" format="ixt:fixed-zero" scale="6" id="f-278">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="f-279">6.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="f-280">6.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Net cash flow provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="f-281">164.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="f-282">691.4</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Net increase (decrease) in cash and cash equivalents</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="f-283">1,388.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="6" id="f-284">642.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-285">99.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-286">6.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Cash and cash equivalents, beginning of the period</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-287">2,375.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-288">1,049.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">Cash and cash equivalents, end of the period</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-289">3,862.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.6pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-290">1,699.2</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:3pt;text-align:center"><span><br/></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><div id="i59d9e1af10a84fa9992f9418986a77c7_34"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF EQUITY</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited, in millions)</span></div><div style="text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:20.112%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.934%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.934%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.934%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.934%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.934%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.666%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.259%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.934%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.934%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:7.456%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="57" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30, 2025</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>other<br/>comprehensive<br/>income (loss)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained<br/>earnings</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>equity</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, June 30, 2025</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-34" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="f-291">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="f-292">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-35" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-293">170.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-294">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-295">714.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-296">238.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-297">20,135.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-39" decimals="-5" sign="-" name="us-gaap:TreasuryStockCommonShares" scale="6" id="f-298">23.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-299">2,977.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-300">17,634.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="f-301">466.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="f-302">466.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-303">23.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-304">23.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under stock option and stock purchase plans</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="f-305">6.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="f-306">6.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under stock award plan</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-44" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="6" id="f-307">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="6" id="f-308">1.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="6" id="f-309">1.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Compensation related to share-based payments</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-310">78.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-311">78.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, September 30, 2025</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-45" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="f-312">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="f-313">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-46" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-314">170.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-315">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-316">797.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-317">214.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-318">20,601.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-50" decimals="-5" sign="-" name="us-gaap:TreasuryStockCommonShares" scale="6" id="f-319">23.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-320">2,977.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-321">18,207.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="57" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30, 2025</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>other<br/>comprehensive<br/>income (loss)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained<br/>earnings</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>equity</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, December 31, 2024</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-51" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="f-322">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="f-323">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-52" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-324">169.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-325">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-326">569.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-327">136.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-328">19,259.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-56" decimals="-5" sign="-" name="us-gaap:TreasuryStockCommonShares" scale="6" id="f-329">23.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-330">2,977.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-331">16,716.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-5" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-332">1,341.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-333">1,341.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-334">78.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-335">78.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under stock option and stock purchase plans</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-59" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued" scale="6" id="f-336">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="f-337">28.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="f-338">28.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under stock award plan</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-59" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="6" id="f-339">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="6" id="f-340">41.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="6" id="f-341">41.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Compensation related to share-based payments</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-342">240.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-343">240.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="f-344">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:StockholdersEquityOther" scale="6" id="f-345">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, September 30, 2025</span></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-45" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="f-346">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="f-347">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-46" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-348">170.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-349">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-350">797.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-351">214.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-352">20,601.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-50" decimals="-5" sign="-" name="us-gaap:TreasuryStockCommonShares" scale="6" id="f-353">23.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-354">2,977.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-355">18,207.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF EQUITY - (Continued)</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(unaudited, in millions)</span></div><div style="text-align:center"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:20.112%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.934%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.934%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.934%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.934%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.934%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.666%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.259%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.934%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.934%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.341%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.456%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="57" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30, 2024</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:7.5pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>other<br/>comprehensive<br/>income (loss)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained<br/>earnings</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>equity</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:21pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, June 30, 2024</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-61" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="f-356">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="f-357">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-62" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-358">169.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-359">0.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-360">407.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-361">146.0</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-362">18,604.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-66" decimals="-5" sign="-" name="us-gaap:TreasuryStockCommonShares" scale="6" id="f-363">23.8</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-364">2,977.1</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-365">15,889.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="f-366">388.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="f-367">388.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-368">0.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-369">0.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under stock option and stock purchase plans</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="f-370">7.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="f-371">7.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under stock award plan</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="6" id="f-372">1.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="6" id="f-373">1.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Compensation related to share-based payments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-374">75.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-375">75.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, September 30, 2024</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-71" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="f-376">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="f-377">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-72" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-378">169.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-379">0.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-380">488.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-381">145.7</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-382">18,993.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-76" decimals="-5" sign="-" name="us-gaap:TreasuryStockCommonShares" scale="6" id="f-383">23.8</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-384">2,977.1</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-385">16,358.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="57" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30, 2024</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional<br/>paid-in<br/>capital</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>other<br/>comprehensive<br/>income (loss)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Retained<br/>earnings</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Treasury stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Biogen Inc.<br/>shareholders&#8217;<br/>equity</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, December 31, 2023</span></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-77" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="f-386">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="f-387">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-78" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-388">168.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-389">0.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-390">302.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-391">153.7</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-392">17,627.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-82" decimals="-5" sign="-" name="us-gaap:TreasuryStockCommonShares" scale="6" id="f-393">23.8</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-394">2,977.1</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-395">14,799.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-5" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-396">1,365.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-5" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-397">1,365.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-398">8.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-399">8.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under stock option and stock purchase plans</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-87" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued" scale="6" id="f-400">0.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="f-401">31.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued" scale="6" id="f-402">31.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under stock award plan</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-87" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="6" id="f-403">0.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="6" id="f-404">66.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="6" id="f-405">66.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Compensation related to share-based payments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-406">224.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-407">224.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="f-408">3.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-5" name="us-gaap:StockholdersEquityOther" scale="6" id="f-409">3.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, September 30, 2024</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-71" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="f-410">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="f-411">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-72" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-412">169.5</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-413">0.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-414">488.5</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="f-415">145.7</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-416">18,993.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-76" decimals="-5" sign="-" name="us-gaap:TreasuryStockCommonShares" scale="6" id="f-417">23.8</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-5" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-418">2,977.1</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="f-419">16,358.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See accompanying notes to these unaudited condensed consolidated financial statements.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><div id="i59d9e1af10a84fa9992f9418986a77c7_37"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div></div><div><span><br/></span></div><div id="i59d9e1af10a84fa9992f9418986a77c7_40"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-420" continuedAt="f-420-1" escape="true"><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 1:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Summary of Significant Accounting Policies</span></div></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References in these notes to "Biogen," the "company," "we," "us" and "our" refer to Biogen Inc. and its consolidated subsidiaries.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Business Overview</span></div><ix:nonNumeric contextRef="c-1" name="biib:BusinessOverviewPolicyTextBlock" id="f-421" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering innovative therapies for people living with serious and complex diseases. We have a broad portfolio of medicines to treat MS, have introduced the first approved treatment for SMA, co-developed treatments to address a defining pathology of Alzheimer&#8217;s disease and launched the first approved treatment to target a genetic cause of ALS. We market the first and only drug approved in the U.S., the E.U. and certain international markets for the treatment of FA in adults and adolescents aged 16 years and older. We are focused on advancing our pipeline in neurology, specialized immunology and rare diseases. We support our drug discovery and development efforts through internal research and development programs, external collaborations and acquisitions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY and TYSABRI for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of FA; and QALSODY for the treatment of ALS.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Supernus on the commercialization of ZURZUVAE for the treatment of PPD. We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, CLL and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL, follicular lymphoma and, following its approval in October 2025, lupus nephritis; OCREVUS for the treatment of PPMS and RMS; LUNSUMIO for the treatment of relapsed or refractory follicular lymphoma; COLUMVI, a bispecific antibody for the treatment of non-Hodgkin's lymphoma; and have the option to add other potential anti-CD20 therapies, pursuant to our collaboration arrangements with Genentech, a wholly-owned member of the Roche Group.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We commercialize a portfolio of biosimilars of advanced biologics including: BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS, in certain international markets. We also have commercialization rights related to OPUVIZ, an aflibercept biosimilar referencing EYLEA, in certain international markets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these unaudited condensed consolidated financial statements (condensed consolidated financial statements).</span></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-422" continuedAt="f-422-1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair statement of our financial statements for interim periods in accordance with U.S.&#160;GAAP. The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our 2024 Form&#160;10-K. Our accounting policies are described in the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2024 Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the three and nine</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, 2025, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate as <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-423">one</ix:nonFraction> operating segment, focused on discovering, developing and delivering innovative therapies for people living with serious and complex diseases.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2025 we began presenting acquired in-process research and development, upfront and milestone expense as a separate line item in our condensed consolidated statements of income. Acquired in-process research and development, upfront and milestone expense includes costs incurred in connection with collaboration and license agreements such as upfront and milestone payments and, when applicable, premiums on equity securities and asset acquisitions of acquired in-process research and development, which were previously </span></div></ix:nonNumeric></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-420-1" continuedAt="f-420-2"><ix:continuation id="f-422-1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">included in research and development expense. Prior periods have been reclassified to conform to the current period presentation. The reclassification had no impact on our total cost and expense, net income attributable to Biogen Inc., earnings per share or total equity.</span></div></ix:continuation><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Consolidation</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationPolicyTextBlock" id="f-424" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than <ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="biib:InterestInSubsidiary" scale="-2" id="f-425">100.0</ix:nonFraction>% of the economics, we record net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.</span></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Use of Estimates</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-426" continuedAt="f-426-1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenue and expense and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and assumptions. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results may differ from these estimates.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-420-2"><ix:continuation id="f-426-1"><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to our significant accounting policies disclosed in </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1, Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our audited consolidated financial statements included in our 2024 Form&#160;10-K.</span></div></ix:continuation><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">New Accounting Pronouncements</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-427" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have had, or may have, a material impact on our condensed consolidated financial statements or disclosures.</span></div></ix:nonNumeric><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:16.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:35.303%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.028%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:24.635%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Standard</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effects on the financial statements</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:112%">ASU No. 2023-09, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:112%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:112%">This standard establishes incremental disaggregation of income tax disclosures pertaining to the effective tax rate reconciliation and income taxes paid. The amendments in this update are required to be applied on a prospective basis with the option to apply it retrospectively.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Annual reporting for fiscal years beginning after December 15, 2024. Early adoption is permitted.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:112%">We are currently evaluating the potential impact that this new standard will have on our consolidated financial statements and related disclosures, and expect to apply this standard prospectively upon adoption.</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:112%">ASU No. 2024-03, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:112%">Income Statement (Subtopic 220-40): Reporting Comprehensive Income - Expense Disaggregation Disclosures</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:112%">This standard requires disclosure in the notes to the financial statements, at each interim and annual reporting period, of specified information about certain costs and expense including purchases of inventory, employee compensation, depreciation and intangible asset amortization included in each relevant expense caption. This standard also requires a qualitative description of the amounts remaining in relevant expense captions that are not separately disaggregated, as well as disclosure of the total amount of selling expenses, and, in annual reporting periods, an entity&#8217;s definition of selling expenses.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Annual reporting for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:112%">We are currently evaluating the potential impact that this new standard will have on our consolidated financial statements and related disclosures.</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:112%">ASU No. 2025-07, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:112%">Derivatives and Hedging (Topic 815) and Revenue from Contracts with Customers (Topic 606): Derivatives Scope Refinements and Scope Clarification for Share-Based Noncash Consideration from a Customer in a Revenue Contract</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:112%">This standard refines and expands the existing scope exceptions that exclude certain contracts, including certain R&amp;D funding arrangements, from derivative accounting, and clarifies the accounting for share-based noncash consideration received from a customer.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Annual reporting for fiscal years beginning after December 15, 2026, and interim periods within those annual reporting periods. Early adoption is permitted.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:112%">We have early adopted this new standard on a modified retrospective basis as of January 1, 2025. Adoption did not have a material impac</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:112%">t on our condensed consolidated financial statements and related disclosures.</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><div id="i59d9e1af10a84fa9992f9418986a77c7_43"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="f-428" continuedAt="f-428-1" escape="true"><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 2:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Acquisitions</span></div></td></tr></table></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Alcyone Therapeutics, Inc.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2025 we entered into a definitive agreement to acquire all of the issued and outstanding shares of Alcyone Therapeutics, Inc., a clinical-stage biotechnology company focused on pediatric care through precision CNS therapeutics and dosing platforms. Alcyone's lead asset is ThecaFlex DRx, an implantable subcutaneous port and catheter device being investigated for the intrathecal delivery of ASOs, which is designed to provide an alternative to repeat lumbar punctures in chronic intrathecal administration of medicines.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have agreed to pay an upfront cash payment of $<ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-5" name="us-gaap:PaymentsToAcquireProductiveAssets" format="ixt:num-dot-decimal" scale="6" id="f-429">85.0</ix:nonFraction>&#160;million upon closing, plus additional potential amounts payable upon the achievement of certain milestones related to the development and regulatory approval of ThecaFlex DRx for administering SPINRAZA and additional pipeline products.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to account for this proposed acquisition as an asset acquisition as the value being acquired primarily relates to a single asset and plan to record the upfront payment within acquired in-process research and development, upfront and milestone expense within our condensed consolidated statements of income upon the completion of this proposed acquisition. We anticipate the</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> proposed acquisition to close during the fourth quarter of 2025, subject to the satisfaction of customary closing conditions. U</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nder the terms of this proposed acquisition, we expect to oversee the end-to-end development, manufacturing and commercialization of ThecaFlex DRx</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alcyone's remaining therapeutic assets would be divested from Alcyone into Neela Therapeutics, Inc., a newly formed independent company, prior to the closing of this proposed acquisition. We anticipate to make a convertible debt investment of up to</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> $<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:InvestmentOwnedAtCost" format="ixt:num-dot-decimal" scale="6" id="f-430">5.0</ix:nonFraction>&#160;million in Neela Therapeutics. Inc.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Human Immunology Biosciences</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 2, 2024, we completed the acquisition of all of the issued and outstanding shares of HI-Bio, a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases. HI-Bio's lead asset, felzartamab, an anti-CD38 antibody, is currently being evaluated for several indications, including three leading indications, AMR, PMN and IgAN. Felzartamab has received Breakthrough Therapy Designation and ODD from the FDA for development in the treatment of PMN and AMR. Subsequent to our acquisition, felzartamab received ODD in the E.U. in IgAN and solid organ transplantation. The acquisition of HI-Bio is expected to augment our pipeline and build on our expertise in immunology.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of this acquisition, we paid shareholders of HI-Bio approximately $<ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="9" id="f-431">1.15</ix:nonFraction>&#160;billion at closing and may pay up to a total of </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" format="ixt:num-dot-decimal" scale="6" id="f-432">650.0</ix:nonFraction>&#160;million in contingent development and regulatory milestone payments.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The $<ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="9" id="f-433">1.15</ix:nonFraction>&#160;billion paid includes approximately $<ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-5" name="biib:PaymentsToAcquireBusinessGrossNonVestedEquityAwards" format="ixt:num-dot-decimal" scale="6" id="f-434">74.5</ix:nonFraction>&#160;million related to HI-Bio's outstanding, non-vested equity awards, inclusive of employer taxes, of which $<ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-435">56.4</ix:nonFraction>&#160;million was recognized as share-based compensation payments to settle non-vested equity awards attributable to the post-acquisition service period and therefore not reflected as a component of total purchase price paid. Of the total $<ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-436">56.4</ix:nonFraction>&#160;million, we recognized approximately $<ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-437"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-438">42.5</ix:nonFraction></ix:nonFraction>&#160;million as a charge to research and development expense with the remaining $<ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-439"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-440">13.9</ix:nonFraction></ix:nonFraction>&#160;million as a charge to selling, general and </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">administrative expense within our condensed consolidated statements of income for the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three and nine months ended September 30, 2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These amounts were associated with the accelerated vesting of stock options and RSUs previously granted to HI-Bio employees and required no future services to vest.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon closing we also paid an additional </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-5" name="biib:BusinessCombinationConsiderationTransferredWorkingCapitalAdjustment" format="ixt:num-dot-decimal" scale="6" id="f-441">43.7</ix:nonFraction>&#160;million related to working capital adjustments as of the transaction close date, which was included as a component of total purchase price paid.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We funded this acquisition through available cash on hand and accounted for this acquisition as a business combination using the acquisition method of accounting in accordance with</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASC Topic 805, Business Combinations</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and recorded assets acquired and liabilities assumed at their respective fair values as of the acquisition date.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-428-1" continuedAt="f-428-2"><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Purchase Price Consideration</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" id="f-442" continuedAt="f-442-1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total consideration transferred for the acquisition of HI-Bio is summarized as follows:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.823%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.393%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of July&#160;2, 2024</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash consideration paid to HI-Bio shareholders</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="6" id="f-443">1,137.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" scale="6" id="f-444">485.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total consideration</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-5" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="6" id="f-445">1,622.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><ix:continuation id="f-442-1" continuedAt="f-442-2"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></ix:continuation><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:continuation id="f-442-2"> Represents total consideration paid to shareholders of HI-Bio of $<ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-5" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="9" id="f-446">1.15</ix:nonFraction>&#160;billion, plus an additional $<ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-5" name="biib:BusinessCombinationConsiderationTransferredWorkingCapitalAdjustment" format="ixt:num-dot-decimal" scale="6" id="f-447">43.7</ix:nonFraction>&#160;million related to working capital adjustments as of the transaction close date, less $<ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-448">56.4</ix:nonFraction>&#160;million of cash paid for HI-Bio's outstanding, non-vested equity awards, inclusive of employer taxes, which were recognized as compensation attributable to the post-acquisition service period and therefore not reflected as a component of total consideration.</ix:continuation> </span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingent Consideration:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We may make certain contingent payments to the former shareholders of HI-Bio upon the achievement of certain development and regulatory milestones. As of the acquisition date, the maximum aggregate amount payable for these potential milestones was $<ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" format="ixt:num-dot-decimal" scale="6" id="f-449">650.0</ix:nonFraction>&#160;million. The acquisition-date fair value of these milestones was approximately $<ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="f-450">485.1</ix:nonFraction>&#160;million and was estimated utilizing a probability-adjusted discounted cash flow calculation using an appropriate discount rate dependent on the nature and timing of the milestone payments, which ranged from </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-98" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="f-451">6.2</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="c-99" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="f-452">7.0</ix:nonFraction>%, and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">probabilities of technological and regulatory success ranging from <ix:nonFraction unitRef="number" contextRef="c-100" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="f-453">67.0</ix:nonFraction>% to near-certain probability.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of the total contingent consideration, approximately $<ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="f-454">279.3</ix:nonFraction>&#160;million related to milestones classified as short-term and reflected as a component of accrued expense and other with the remaining $<ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-455">205.8</ix:nonFraction>&#160;million reflected as a component of other long-term liabilities within our condensed consolidated balance sheets. The short-term liability related to the fourth patient dosed in a Phase 3 clinical trial of felzartamab in a first and s</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">econd indication, which would each result in the achievement of a $<ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="f-456"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="f-457">150.0</ix:nonFraction></ix:nonFraction>&#160;million milestone payment. During the second quarter of 2025 the first milestone related to the fourth patient dosed in a phase 3 clinical trial of felzartamab for AMR was achieved, resulting in a $<ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="f-458">150.0</ix:nonFraction>&#160;million milestone payment made to the former shareholders of HI-Bio, which was paid during the third quarter of 2025. In October 2025 the second milestone related to the fourth patient dosed in a phase 3 clinical trial of felzartamab for IgAN was achieved, resulting in a $<ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="f-459">150.0</ix:nonFraction>&#160;million milestone payment to be made to the former shareholders of HI-Bio, which we expect will be paid during the fourth quarter of 2025.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent changes in the fair value of the contingent consideration obligation are being recognized as (gain) loss on fair value remeasurement of contingent consideration within our condensed consolidated statements of income. This fair value measurement is based on significant inputs that are not observable in the market and thus represent Level 3 fair value measurements. For additional information related to the fair value of this obligation, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 8, Fair Value Measurements</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Contractual Commitments: </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We acquired HI-Bio's pre-existing in-license commitments under third-party agreements with MorphoSys, which included tiered royalties on potential future sales ranging from high-single digit to mid-teen percentages, as well as potential development, regulatory and commercial milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-5" name="biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" format="ixt:num-dot-decimal" scale="6" id="f-460">130.0</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-5" name="biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" format="ixt:num-dot-decimal" scale="6" id="f-461">230.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-5" name="biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" format="ixt:num-dot-decimal" scale="6" id="f-462">640.0</ix:nonFraction>&#160;million, respectively. At the transaction close date the achievement of these milestones was not considered probable and therefore not recorded in our financial statements.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-428-2"><div style="margin-bottom:3pt;margin-top:9pt;padding-left:9pt;text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Purchase Price Allocation</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We finalized purchase accounting for this acquisition in the second quarter of 2025.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" id="f-463" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date, and reflects measurement period adjustments made to the amounts initially recorded as of the acquisition date on July&#160;2, 2024. The related impact to our condensed consolidated statements of income that would have been recognized in previous periods if the adjustments were recognized as of the acquisition date is immaterial.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:77.847%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:19.369%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts Recognized as of Acquisition Date<br/>(as adjusted)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" scale="6" id="f-464">62.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intangible assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IPR&amp;D - felzartamab (IgAN)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="f-465">920.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IPR&amp;D - felzartamab (AMR)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="f-466">450.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IPR&amp;D - felzartamab (PMN)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="f-467">265.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other clinical programs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" scale="6" id="f-468">7.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expense and other assets</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" scale="6" id="f-469">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-5" name="biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets" scale="6" id="f-470">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" scale="6" id="f-471">1.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-5" name="biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities" scale="6" id="f-472">35.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax liability</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" scale="6" id="f-473">309.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-5" name="biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities" scale="6" id="f-474">1.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="6" id="f-475">1,361.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-5" name="us-gaap:Goodwill" scale="6" id="f-476">261.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets acquired and liabilities assumed</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" format="ixt:num-dot-decimal" scale="6" id="f-477">1,622.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Includes measurement period adjustments recorded in 2025 that increased prepaid expense and other assets by $<ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-5" name="biib:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpenseAndOther" format="ixt:num-dot-decimal" scale="6" id="f-478">0.4</ix:nonFraction>&#160;million, net deferred tax liability by $<ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-5" name="biib:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability" format="ixt:num-dot-decimal" scale="6" id="f-479">4.9</ix:nonFraction>&#160;million and goodwill by $<ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-5" name="biib:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-480">4.5</ix:nonFraction>&#160;million.</span></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intang</span><span style="background-color:#ffffff;color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ible assets:</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Intangible assets comprised of approximately $<ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="9" id="f-481">1.6</ix:nonFraction>&#160;billion of IPR&amp;D related to HI-Bio's lead asset felzartamab. This includes $<ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="6" id="f-482">920.0</ix:nonFraction>&#160;million of IPR&amp;D related to felzartamab indication for IgAN, $<ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="6" id="f-483">450.0</ix:nonFraction>&#160;million of IPR&amp;D related to felzartamab indication for AMR and $<ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="6" id="f-484">265.0</ix:nonFraction>&#160;million of IPR&amp;D related to felzartamab indication for PMN. The estimated fair values of the program related intangible assets were determined using a multi-period excess earnings method, a form of the income approach, utilizing cash flow analyses and a discount rate of <ix:nonFraction unitRef="number" contextRef="c-116" decimals="3" name="biib:IntangibleAssetMeasurementInput" scale="-2" id="f-485">14.5</ix:nonFraction>%. These fair value measurements were based on significant inputs that are not observable in the market and thus represent Level 3 fair value measurements.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Goodwill was calculated as the excess of the consideration transferred over the net assets recognized and represents the future economic benefits arising from the other assets acq</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">uired that could not be individually identified and separately recognized. We recognized goodwill of approximately $<ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-486">261.0</ix:nonFraction>&#160;million, which includes measurement period adjustments, and is not deductible for tax purposes. The goodwill recognized from our acquisition of HI-Bio is primarily the result of the deferred tax consequences from the transaction recorded for financial statement purposes.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisition-related expense:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Acquisition-related expense, primarily comprised</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of advisory and legal fees, and other transaction costs, totaled approximately $<ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-5" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:num-dot-decimal" scale="6" id="f-487"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-5" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:num-dot-decimal" scale="6" id="f-488">2.8</ix:nonFraction></ix:nonFraction>&#160;million and were recorded within selling, general and administrative expense within our consolidated statements of income for the year ended December 31, 2024, included in our </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Form 10-K</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><div id="i59d9e1af10a84fa9992f9418986a77c7_49"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" id="f-489" escape="true"><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 3:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Dispositions</span></div></td></tr></table></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Sale of Joint Venture Equity Interest in Samsung Bioepis</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022 we completed the sale of our <ix:nonFraction unitRef="number" contextRef="c-118" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="f-490">49.9</ix:nonFraction>% equity interest in Samsung Bioepis to Samsung BioLogics in exchange for total consideration of approximately $<ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-5" name="us-gaap:EquityMethodInvestmentSoldCarryingAmount" format="ixt:num-dot-decimal" scale="9" id="f-491">2.3</ix:nonFraction>&#160;billion. Under the terms of this transaction, we received approximately $<ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-8" name="us-gaap:ProceedsFromDivestitureOfInterestInJointVenture" format="ixt:num-dot-decimal" scale="9" id="f-492">1.0</ix:nonFraction>&#160;billion in cash at closing, with approximately $<ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-8" name="biib:PayablesToDivestitureOfInterestInJointVenture" format="ixt:num-dot-decimal" scale="9" id="f-493">1.3</ix:nonFraction>&#160;billion in cash to be deferred over two payments. The first deferred payment of </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-5" name="biib:PayablesToDivestitureOfInterestInJointVenture" format="ixt:num-dot-decimal" scale="6" id="f-494">812.5</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was received in April 2023 and</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the second deferred payment of $<ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-5" name="biib:PayablesToDivestitureOfInterestInJointVenture" format="ixt:num-dot-decimal" scale="6" id="f-495">437.5</ix:nonFraction>&#160;million</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was received in April 2024.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">nine</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> months ended September 30, 2024, we recognized</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> a gain</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> of approximately </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$<ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-5" name="us-gaap:GainLossOnDispositionOfAssets1" format="ixt:num-dot-decimal" scale="6" id="f-496">7.5</ix:nonFraction>&#160;million </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">to reflect the change in fair value associated with the passage of time related to the second deferred payment </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">due to us, which was received in April 2024 and</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> recorded in other (income) expense, net within our condensed consolidated statements of income.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3, Dispositions</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2024 Form 10-K.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Sale of Priority Review Voucher</span></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In April 2024 we completed the sale of our rare pediatric disease PRV, generated by the development associated with SPINRAZA, to a third party. In consideration for the PRV we received a cash payment of $<ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-5" name="us-gaap:ProceedsFromSaleOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-497">103.0</ix:nonFraction>&#160;million upon the closing of the PRV purchase, of which approximately $<ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-5" name="biib:ProceedsPaidToCollaborativeArrangementCounterparty" format="ixt:num-dot-decimal" scale="6" id="f-498">14.4</ix:nonFraction>&#160;million was paid to Ionis. Our net portion of approximately $<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="us-gaap:GainLossOnDispositionOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-499"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="us-gaap:GainLossOnDispositionOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-500">88.6</ix:nonFraction></ix:nonFraction>&#160;million was recognized in gain on sale of priority review voucher, net within our condensed consolidated statements of income for the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">nine</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> months ended September 30, 2024.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Sale of TOFIDENCE</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2025 we completed the sale of our regulatory and commercial rights in the U.S. for TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA, to Organon. Under the terms of this transaction, we received a payment of approximately $<ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-5" name="us-gaap:ProceedsFromSaleOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-501">51.0</ix:nonFraction>&#160;million </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in July 2025 a</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nd recognized a de minimis loss within our condensed consolidated statements of income for the nine months ended September 30, 2025.</span></div></ix:nonNumeric><div id="i59d9e1af10a84fa9992f9418986a77c7_55"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="f-502" continuedAt="f-502-1" escape="true"><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 4:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Restructuring</span></div></td></tr></table></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2023 Fit for Growth Restructuring Program</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023 we initiated cost saving measures as part of our Fit for Growth program to reduce operating costs, while improving operating efficiency and effectiveness. The Fit for Growth program is expected to generate approximately $<ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-8" name="biib:RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction" format="ixt:num-dot-decimal" scale="9" id="f-503">1.0</ix:nonFraction>&#160;billion in gross operating expense savings by the end of 2025, some of which will be reinvested in various initiatives. The Fit for Growth program is currently estimated to include net headcount reductions of approximately <ix:nonFraction unitRef="employee" contextRef="c-129" decimals="INF" name="us-gaap:RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" format="ixt:num-dot-decimal" scale="0" id="f-504">1,400</ix:nonFraction> employees and we expect to incur total restructuring charges of approximately $<ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-5" name="us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1" format="ixt:num-dot-decimal" scale="6" id="f-505">310.0</ix:nonFraction>&#160;million, which were substantially achieved as of September 30, 2025.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-502-1" continuedAt="f-502-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="f-506" continuedAt="f-506-1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total charges incurred from our 2023 Fit for Growth program are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.092%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.434%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accelerated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:fixed-zero" scale="6" id="f-507">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-5" name="us-gaap:OtherRestructuringCosts" scale="6" id="f-508">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-509">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:fixed-zero" scale="6" id="f-510">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-5" name="us-gaap:OtherRestructuringCosts" scale="6" id="f-511">9.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-512">9.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:fixed-zero" scale="6" id="f-513">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-5" name="us-gaap:OtherRestructuringCosts" scale="6" id="f-514">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-515">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:fixed-zero" scale="6" id="f-516">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-5" name="us-gaap:OtherRestructuringCosts" scale="6" id="f-517">3.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-518">3.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-5" name="us-gaap:SeveranceCosts1" scale="6" id="f-519">7.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-5" name="us-gaap:OtherRestructuringCosts" format="ixt:fixed-zero" scale="6" id="f-520">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-521">7.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-5" name="us-gaap:SeveranceCosts1" scale="6" id="f-522">4.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-5" name="us-gaap:OtherRestructuringCosts" format="ixt:fixed-zero" scale="6" id="f-523">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-136" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-524">4.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total charges</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-5" name="us-gaap:SeveranceCosts1" scale="6" id="f-525">7.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-5" name="us-gaap:OtherRestructuringCosts" scale="6" id="f-526">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-137" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-527">8.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-5" name="us-gaap:SeveranceCosts1" scale="6" id="f-528">4.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-5" name="us-gaap:OtherRestructuringCosts" scale="6" id="f-529">12.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-138" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-530">17.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accelerated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:fixed-zero" scale="6" id="f-531">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-5" sign="-" name="us-gaap:OtherRestructuringCosts" scale="6" id="f-532">2.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-139" decimals="-5" sign="-" name="us-gaap:RestructuringCharges" scale="6" id="f-533">2.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:fixed-zero" scale="6" id="f-534">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-5" name="us-gaap:OtherRestructuringCosts" scale="6" id="f-535">12.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-536">12.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:fixed-zero" scale="6" id="f-537">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-5" name="us-gaap:OtherRestructuringCosts" scale="6" id="f-538">6.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-141" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-539">6.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:fixed-zero" scale="6" id="f-540">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-5" name="us-gaap:OtherRestructuringCosts" scale="6" id="f-541">10.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-542">10.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-5" name="us-gaap:SeveranceCosts1" scale="6" id="f-543">41.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-5" name="us-gaap:OtherRestructuringCosts" format="ixt:fixed-zero" scale="6" id="f-544">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-545">41.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-5" name="us-gaap:SeveranceCosts1" scale="6" id="f-546">20.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-5" name="us-gaap:OtherRestructuringCosts" format="ixt:fixed-zero" scale="6" id="f-547">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-548">20.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total charges</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-5" name="us-gaap:SeveranceCosts1" scale="6" id="f-549">41.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-5" name="us-gaap:OtherRestructuringCosts" scale="6" id="f-550">4.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-551">45.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-5" name="us-gaap:SeveranceCosts1" scale="6" id="f-552">20.2</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-5" name="us-gaap:OtherRestructuringCosts" scale="6" id="f-553">23.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-554">43.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Costs:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Includes costs associated with items such as asset abandonment and write-offs, facility closure costs, pre-tax gains and losses resulting from the termination of certain leases, employee non-severance expense, consulting fees and other costs.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Reata Integration</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the close of our Reata acquisition in September 2023, we implemented an integration plan designed to realize operating synergies through cost savings and avoidance. Under this initiative, we estimated we would incur total integration charges of approximately $<ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-5" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" format="ixt:num-dot-decimal" scale="6" id="f-555">35.0</ix:nonFraction>&#160;million related to severance and employment costs, which were substantially incurred during 2023.</span></div><ix:continuation id="f-506-1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total charges incurred from our Reata integration are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.753%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.326%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.606%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accelerated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:fixed-zero" scale="6" id="f-556">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-5" name="us-gaap:OtherRestructuringCosts" scale="6" id="f-557">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-558">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:fixed-zero" scale="6" id="f-559">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-5" name="us-gaap:OtherRestructuringCosts" scale="6" id="f-560">1.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-561">1.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:fixed-zero" scale="6" id="f-562">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-5" name="us-gaap:OtherRestructuringCosts" scale="6" id="f-563">3.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-564">3.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:fixed-zero" scale="6" id="f-565">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-5" name="us-gaap:OtherRestructuringCosts" scale="6" id="f-566">2.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-150" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-567">2.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:fixed-zero" scale="6" id="f-568">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-5" name="us-gaap:OtherRestructuringCosts" format="ixt:fixed-zero" scale="6" id="f-569">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="6" id="f-570">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-5" name="us-gaap:SeveranceCosts1" scale="6" id="f-571">0.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-5" name="us-gaap:OtherRestructuringCosts" format="ixt:fixed-zero" scale="6" id="f-572">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-573">0.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total charges</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:fixed-zero" scale="6" id="f-574">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-5" name="us-gaap:OtherRestructuringCosts" scale="6" id="f-575">5.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-153" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-576">5.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-5" name="us-gaap:SeveranceCosts1" scale="6" id="f-577">0.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-5" name="us-gaap:OtherRestructuringCosts" scale="6" id="f-578">4.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-579">5.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accelerated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:fixed-zero" scale="6" id="f-580">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-5" name="us-gaap:OtherRestructuringCosts" scale="6" id="f-581">5.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-155" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-582">5.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:fixed-zero" scale="6" id="f-583">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-5" name="us-gaap:OtherRestructuringCosts" scale="6" id="f-584">4.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-585">4.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:fixed-zero" scale="6" id="f-586">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-5" name="us-gaap:OtherRestructuringCosts" scale="6" id="f-587">10.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-588">10.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-5" name="us-gaap:SeveranceCosts1" format="ixt:fixed-zero" scale="6" id="f-589">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-5" name="us-gaap:OtherRestructuringCosts" scale="6" id="f-590">8.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-591">8.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-5" sign="-" name="us-gaap:SeveranceCosts1" scale="6" id="f-592">0.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-5" name="us-gaap:OtherRestructuringCosts" format="ixt:fixed-zero" scale="6" id="f-593">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-5" sign="-" name="us-gaap:RestructuringCharges" scale="6" id="f-594">0.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-5" name="us-gaap:SeveranceCosts1" scale="6" id="f-595">3.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-5" name="us-gaap:OtherRestructuringCosts" format="ixt:fixed-zero" scale="6" id="f-596">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-597">3.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total charges</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-5" sign="-" name="us-gaap:SeveranceCosts1" scale="6" id="f-598">0.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-5" name="us-gaap:OtherRestructuringCosts" scale="6" id="f-599">15.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-600">15.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-5" name="us-gaap:SeveranceCosts1" scale="6" id="f-601">3.2</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-5" name="us-gaap:OtherRestructuringCosts" scale="6" id="f-602">13.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-603">17.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-502-2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Reata we assumed responsibility for a single-tenant, build-to-suit building of approximately <ix:nonFraction unitRef="sqft" contextRef="c-163" decimals="0" name="biib:OperatingLeaseArea" format="ixt:num-dot-decimal" scale="0" id="f-604">327,400</ix:nonFraction> square feet of office and laboratory space located in Plano, Texas, with an initial lease term of <ix:nonNumeric contextRef="c-163" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="f-605">16</ix:nonNumeric> years. We do not intend to occupy this building and are evaluating opportunities to sublease the property. For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Form 10-K.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Restructuring Reserve</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" id="f-606" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Charges and spending related to workforce reductions are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.546%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Workforce Reductions</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of January 1</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="f-607">31.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="f-608">75.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-609">35.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-610">11.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-5" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-611">25.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-5" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-612">42.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency and other adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-5" name="us-gaap:RestructuringReserveTranslationAdjustment" scale="6" id="f-613">1.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-5" sign="-" name="us-gaap:RestructuringReserveTranslationAdjustment" scale="6" id="f-614">0.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of March 31</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="f-615">40.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="f-616">45.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-5" sign="-" name="us-gaap:RestructuringCharges" scale="6" id="f-617">0.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-618">6.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-5" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-619">9.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-5" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-620">11.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency and other adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-5" name="us-gaap:RestructuringReserveTranslationAdjustment" scale="6" id="f-621">1.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-5" name="us-gaap:RestructuringReserveTranslationAdjustment" format="ixt:fixed-zero" scale="6" id="f-622">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of June 30</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="f-623">29.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="f-624">40.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-625">7.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-626">6.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-5" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-627">17.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-5" name="us-gaap:PaymentsForRestructuring" scale="6" id="f-628">4.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency and other adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-5" name="us-gaap:RestructuringReserveTranslationAdjustment" format="ixt:fixed-zero" scale="6" id="f-629">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-5" name="us-gaap:RestructuringReserveTranslationAdjustment" scale="6" id="f-630">2.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of September 30</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="f-631">19.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="f-632">40.2</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><div id="i59d9e1af10a84fa9992f9418986a77c7_58"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="f-633" continuedAt="f-633-1" escape="true"><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 5:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Revenue</span></div></td></tr></table></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Product Revenue</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="f-634" continuedAt="f-634-1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue by product is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:31.550%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.445%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TECFIDERA</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-635">44.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-636">123.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-637">168.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-638">40.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-639">192.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-640">232.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">VUMERITY</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-641">189.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-642">25.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-643">214.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-644">134.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-645">23.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-646">158.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Fumarate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-647">234.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-648">148.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-649">382.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-650">175.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-651">215.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-652">390.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AVONEX</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-653">133.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-654">55.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-198" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-655">188.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-656">115.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-657">60.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-658">176.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PLEGRIDY</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-659">27.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-660">30.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-204" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-661">58.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-205" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-662">27.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-206" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-663">33.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-207" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-664">61.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Interferon</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-208" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-665">161.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-209" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-666">85.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-667">246.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-668">143.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-669">94.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-670">237.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TYSABRI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-214" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-671">247.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-215" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-672">184.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-216" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-673">431.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-674">227.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-675">178.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-676">406.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FAMPYRA</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-220" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-677">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-221" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-678">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-679">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-680">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-681">19.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-225" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-682">19.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Multiple Sclerosis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-226" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-683">642.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-227" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-684">418.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-685">1,061.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-686">546.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-687">507.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-231" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-688">1,053.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rare Disease:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SPINRAZA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-232" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-689">153.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-233" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-690">220.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-234" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-691">374.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-235" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-692">153.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-236" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-693">228.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-237" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-694">381.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SKYCLARYS</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-238" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-695">74.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-239" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-696">58.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-240" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-697">132.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-241" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-698">81.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-699">20.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-243" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-700">102.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">QALSODY</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-244" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-701">7.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-702">19.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-703">26.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-704">5.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-248" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-705">5.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-249" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-706">11.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Rare Disease</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-250" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-707">235.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-251" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-708">298.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-252" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-709">533.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-253" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-710">240.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-254" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-711">254.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-255" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-712">494.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biosimilars:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BENEPALI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-256" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-713">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-257" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-714">121.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-258" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-715">121.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-259" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-716">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-260" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-717">118.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-261" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-718">118.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IMRALDI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-262" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-719">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-263" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-720">52.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-264" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-721">52.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-265" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-722">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-266" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-723">54.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-267" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-724">54.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FLIXABI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-268" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-725">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-269" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-726">15.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-270" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-727">15.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-271" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-728">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-272" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-729">16.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-273" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-730">16.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BYOOVIZ</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-274" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-731">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-275" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-732">5.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-276" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-733">7.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-277" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-734">4.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-278" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-735">3.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-279" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-736">8.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TOFIDENCE</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-280" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-737">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-281" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-738">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-282" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-739">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-283" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-740">0.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-284" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-741">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-285" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-742">0.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Biosimilars</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-286" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-743">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-287" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-744">194.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-288" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-745">196.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-289" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-746">4.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-290" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-747">192.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-291" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-748">196.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ZURZUVAE</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-292" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-749">55.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-293" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-750">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-294" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-751">55.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-295" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-752">22.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-296" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-753">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-297" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-754">22.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-298" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-755">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-299" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-756">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-300" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-757">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-301" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-758">0.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-302" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-759">1.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-303" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-760">2.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-304" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-761">55.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-305" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-762">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-306" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-763">55.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-307" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-764">22.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-308" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-765">1.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-309" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-766">24.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue, net</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-310" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-767">935.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-311" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-768">911.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-3" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-769">1,846.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-312" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-770">813.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-313" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-771">956.4</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-772">1,769.4</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Effective January 1, 2025, our collaboration and license agreement for FAMPYRA global commercialization rights was terminated.</span></div><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> SKYCLARYS became commercially available in the E.U. during the first quarter of 2024.</span></div><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> QALSODY became commercially available in the E.U. during the second quarter of 2024.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Other includes FUMADERM and ADUHELM.</span></div></ix:nonNumeric></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-633-1" continuedAt="f-633-2"><ix:continuation id="f-634-1"><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:31.550%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.445%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TECFIDERA</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-314" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-773">131.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-315" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-774">436.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-316" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-775">567.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-317" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-776">127.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-318" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-777">611.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-319" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-778">739.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">VUMERITY</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-320" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-779">494.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-321" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-780">71.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-322" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-781">565.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-323" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-782">385.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-324" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-783">66.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-325" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-784">451.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Fumarate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-326" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-785">626.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-327" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-786">507.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-328" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-787">1,133.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-329" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-788">512.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-330" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-789">677.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-331" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-790">1,190.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AVONEX</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-332" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-791">363.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-333" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-792">169.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-334" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-793">533.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-335" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-794">344.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-336" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-795">193.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-337" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-796">537.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PLEGRIDY</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-338" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-797">80.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-339" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-798">106.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-340" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-799">186.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-341" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-800">84.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-342" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-801">109.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-343" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-802">194.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Interferon</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-344" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-803">443.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-345" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-804">276.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-346" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-805">719.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-347" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-806">428.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-348" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-807">303.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-349" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-808">732.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TYSABRI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-350" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-809">720.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-351" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-810">547.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-352" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-811">1,267.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-353" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-812">690.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-354" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-813">609.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-355" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-814">1,299.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FAMPYRA</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-356" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-815">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-357" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-816">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-358" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-817">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-359" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-818">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-360" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-819">57.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-361" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-820">57.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Multiple Sclerosis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-362" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-821">1,790.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-363" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-822">1,331.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-364" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-823">3,121.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-365" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-824">1,631.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-366" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-825">1,648.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-367" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-826">3,279.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rare Disease:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SPINRAZA</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-368" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-827">456.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-369" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-828">733.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-370" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-829">1,190.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-371" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-830">458.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-372" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-831">692.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-373" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-832">1,151.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SKYCLARYS</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-374" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-833">221.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-375" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-834">165.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-376" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-835">387.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-377" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-836">230.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-378" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-837">49.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-379" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-838">280.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">QALSODY</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-380" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-839">22.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-381" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-840">39.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-382" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-841">61.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-383" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-842">14.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-384" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-843">6.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-385" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-844">20.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Rare Disease</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-386" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-845">700.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-387" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-846">938.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-388" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-847">1,639.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-389" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-848">703.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-390" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-849">749.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-391" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-850">1,452.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biosimilars:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BENEPALI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-392" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-851">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-393" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-852">345.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-394" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-853">345.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-395" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-854">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-396" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-855">354.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-397" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-856">354.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IMRALDI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-398" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-857">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-399" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-858">146.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-400" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-859">146.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-401" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-860">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-402" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-861">162.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-403" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-862">162.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FLIXABI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-404" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-863">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-405" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-864">42.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-406" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-865">42.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-407" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-866">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-408" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-867">47.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-409" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-868">47.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BYOOVIZ</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-410" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-869">8.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-411" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-870">15.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-412" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-871">24.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-413" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-872">18.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-414" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-873">9.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-415" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-874">27.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TOFIDENCE</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-416" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-875">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-417" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-876">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-418" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-877">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-419" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-878">1.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-420" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-879">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-421" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-880">1.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Biosimilars</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-422" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-881">8.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-423" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-882">550.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-424" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-883">559.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-425" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-884">19.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-426" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-885">572.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-427" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-886">591.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ZURZUVAE</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-428" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-887">129.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-429" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-888">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-430" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-889">129.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-431" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-890">49.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-432" decimals="-5" name="us-gaap:Revenues" format="ixt:fixed-zero" scale="6" id="f-891">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-433" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-892">49.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-434" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-893">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-435" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-894">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-436" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-895">2.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-437" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-896">2.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-438" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-897">5.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-439" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-898">7.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-440" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-899">129.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-441" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-900">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-442" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-901">131.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-443" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-902">51.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-444" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-903">5.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-445" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-904">56.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue, net</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-446" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-905">2,630.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-447" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-906">2,821.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-907">5,452.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-448" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-908">2,405.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-449" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-909">2,975.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-910">5,380.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Effective January 1, 2025, our collaboration and license agreement for FAMPYRA global commercialization rights was terminated.</span></div><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> SKYCLARYS became commercially available in the E.U. during the first quarter of 2024.</span></div><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> QALSODY became commercially available in the E.U. during the second quarter of 2024.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Other includes FUMADERM and ADUHELM.</span></div></ix:continuation><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized revenue from <ix:nonFraction unitRef="wholesaler" contextRef="c-20" decimals="INF" name="biib:NumberOfWholesalers" format="ixt-sec:numwordsen" scale="0" id="f-911"><ix:nonFraction unitRef="wholesaler" contextRef="c-1" decimals="INF" name="biib:NumberOfWholesalers" format="ixt-sec:numwordsen" scale="0" id="f-912"><ix:nonFraction unitRef="wholesaler" contextRef="c-19" decimals="INF" name="biib:NumberOfWholesalers" format="ixt-sec:numwordsen" scale="0" id="f-913"><ix:nonFraction unitRef="wholesaler" contextRef="c-21" decimals="INF" name="biib:NumberOfWholesalers" format="ixt-sec:numwordsen" scale="0" id="f-914">two</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> wholesalers accounting for <ix:nonFraction unitRef="number" contextRef="c-450" decimals="INF" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="f-915">27.8</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-451" decimals="INF" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="f-916">16.0</ix:nonFraction>% of gross product revenue for the three months ended September 30, 2025, and <ix:nonFraction unitRef="number" contextRef="c-452" decimals="INF" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="f-917">27.3</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-453" decimals="INF" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="f-918">15.4</ix:nonFraction>% of gross product revenue for the nine months ended September 30, 2025.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized revenue from <ix:nonFraction unitRef="wholesaler" contextRef="c-20" decimals="INF" name="biib:NumberOfWholesalers" format="ixt-sec:numwordsen" scale="0" id="f-919"><ix:nonFraction unitRef="wholesaler" contextRef="c-1" decimals="INF" name="biib:NumberOfWholesalers" format="ixt-sec:numwordsen" scale="0" id="f-920"><ix:nonFraction unitRef="wholesaler" contextRef="c-19" decimals="INF" name="biib:NumberOfWholesalers" format="ixt-sec:numwordsen" scale="0" id="f-921"><ix:nonFraction unitRef="wholesaler" contextRef="c-21" decimals="INF" name="biib:NumberOfWholesalers" format="ixt-sec:numwordsen" scale="0" id="f-922">two</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> wholesalers accounting for <ix:nonFraction unitRef="number" contextRef="c-454" decimals="3" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="f-923">25.9</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-455" decimals="3" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="f-924">14.8</ix:nonFraction>% of gross product revenue for the three months ended September 30, 2024, and <ix:nonFraction unitRef="number" contextRef="c-456" decimals="3" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="f-925">25.6</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-457" decimals="3" name="biib:EntityWidePercentageOfRevenueFromMajorDistributors" scale="-2" id="f-926">12.9</ix:nonFraction>% of gross product revenue for the nine months ended September 30, 2024.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-633-2" continuedAt="f-633-3"><ix:nonNumeric contextRef="c-1" name="biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" id="f-927" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An analysis of the change in reserves for discounts and allowances is summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.155%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.109%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.109%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.109%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.114%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-458" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-928">162.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-459" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-929">880.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-460" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-930">48.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="f-931">1,091.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current provisions relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-461" decimals="-5" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" scale="6" id="f-932">607.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-462" decimals="-5" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" format="ixt:num-dot-decimal" scale="6" id="f-933">2,052.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-463" decimals="-5" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" scale="6" id="f-934">20.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" format="ixt:num-dot-decimal" scale="6" id="f-935">2,680.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments relating to prior years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-461" decimals="-5" sign="-" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" scale="6" id="f-936">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-462" decimals="-5" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" scale="6" id="f-937">82.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-463" decimals="-5" sign="-" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" scale="6" id="f-938">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" scale="6" id="f-939">79.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/credits relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-461" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" scale="6" id="f-940">497.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-462" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" format="ixt:num-dot-decimal" scale="6" id="f-941">1,271.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-463" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" scale="6" id="f-942">0.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" format="ixt:num-dot-decimal" scale="6" id="f-943">1,768.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/credits relating to sales in prior years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-461" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" scale="6" id="f-944">111.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-462" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" scale="6" id="f-945">479.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-463" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" scale="6" id="f-946">11.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" scale="6" id="f-947">602.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, September 30, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-464" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-948">163.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-465" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="f-949">1,101.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-466" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-950">57.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="f-951">1,322.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" id="f-952" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:66.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.397%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.253%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reduction of accounts receivable</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-467" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-953">259.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-468" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-954">154.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Component of accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-469" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="f-955">1,062.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-470" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-956">937.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue-related reserves</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="f-957">1,322.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="f-958">1,091.6</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:7pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Revenue from Anti-CD20 Therapeutic Programs</span></div><ix:nonNumeric contextRef="c-1" name="biib:RevenuesfromantiCD20therapeuticprogramsTableTextBlock" id="f-959" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from anti-CD20 therapeutic programs is summarized in the table below. For the purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.309%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.431%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalty revenue on sales of OCREVUS</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-471" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-960">386.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-472" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-961">346.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-473" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-962">1,029.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-474" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-963">985.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen&#8217;s share of pre-tax profits in the U.S. for RITUXAN, GAZYVA and LUNSUMIO</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-475" decimals="-5" name="biib:ShareOfCoPromotionProfits" scale="6" id="f-964">101.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-476" decimals="-5" name="biib:ShareOfCoPromotionProfits" scale="6" id="f-965">94.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-477" decimals="-5" name="biib:ShareOfCoPromotionProfits" scale="6" id="f-966">292.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-478" decimals="-5" name="biib:ShareOfCoPromotionProfits" scale="6" id="f-967">285.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-475" decimals="-5" name="biib:OtherrevenuesfromantiCD20therapeuticprograms" scale="6" id="f-968">6.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-476" decimals="-5" name="biib:OtherrevenuesfromantiCD20therapeuticprograms" scale="6" id="f-969">4.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-477" decimals="-5" name="biib:OtherrevenuesfromantiCD20therapeuticprograms" scale="6" id="f-970">18.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-478" decimals="-5" name="biib:OtherrevenuesfromantiCD20therapeuticprograms" scale="6" id="f-971">13.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-972">493.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-973">446.2</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-974">1,339.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-975">1,284.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:7pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Genentech, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Alzheimer's Collaboration Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alzheimer's collaboration revenue consists of our <ix:nonFraction unitRef="number" contextRef="c-479" decimals="2" name="biib:ShareOfNonControlingInterestRecognized" scale="-2" id="f-976">50.0</ix:nonFraction>% share of LEQEMBI product revenue, net and cost of sales, including royalties, as we are not the principal. We began recognizing Alzheimer's collaboration revenue upon the accelerated approval of LEQEMBI in the U.S. during the first quarter of 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2025, we recognized Alzheimer's collaboration revenue of approximately $<ix:nonFraction unitRef="usd" contextRef="c-480" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-977">42.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-481" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-978">130.6</ix:nonFraction> million, respectively, compared to $<ix:nonFraction unitRef="usd" contextRef="c-482" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-979">18.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-483" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-980">33.2</ix:nonFraction> million, respectively, in the prior year comparative periods.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Eisai, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-633-3"><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Contract Manufacturing, Royalty and Other Revenue</span></div><ix:nonNumeric contextRef="c-1" name="biib:OtherrevenuesTableTextBlock" id="f-981" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract manufacturing, royalty and other revenue is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.285%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract manufacturing revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-484" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-982">141.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-485" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-983">221.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-486" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-984">648.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-487" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-985">474.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalty and other revenue</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-488" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-986">9.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-489" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-987">9.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-490" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-988">40.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-491" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-989">48.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total contract manufacturing, royalty and other revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-990">151.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-991">231.6</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-992">689.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-993">522.4</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:7pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Manufacturing Revenue</span></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract manufacturing revenue primarily reflects amounts earned under contract manufacturing agreements with our strategic customers and batches of LEQEMBI related to our collaboration with Eisai.</span></div><div style="margin-top:7pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalty and Other Revenue</span></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty and other revenue primarily reflects royalty revenue on biosimilar products from our license arrangements with Samsung Bioepis and royalties we receive from net sales on products related to patents that we have out-licensed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our license arrangements with Samsung Bioepis and our collaboration arrangements with Eisai, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div></ix:continuation><div id="i59d9e1af10a84fa9992f9418986a77c7_64"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:InventoryDisclosureTextBlock" id="f-994" escape="true"><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 6:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Inventory</span></div></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="f-995" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventory are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="f-996">296.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="6" id="f-997">317.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="f-998">1,635.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="f-999">1,882.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="f-1000">440.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="f-1001">353.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="biib:InventoryNetCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1002">2,371.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="biib:InventoryNetCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1003">2,554.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Classification:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="f-1004">2,209.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="f-1005">2,460.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments and other assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:InventoryNoncurrent" scale="6" id="f-1006">162.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="us-gaap:InventoryNoncurrent" scale="6" id="f-1007">93.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="biib:InventoryNetCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1008">2,371.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="biib:InventoryNetCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1009">2,554.4</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term inventory is included in investments and other assets within our condensed consolidated balance sheets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our acquisition of Reata in September 2023 we recorded a fair value step-up adjustment related to the acquired inventory of SKYCLARYS of approximately $<ix:nonFraction unitRef="usd" contextRef="c-492" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" format="ixt:num-dot-decimal" scale="9" id="f-1010">1.3</ix:nonFraction>&#160;billion. This fair value step-up adjustment is being amortized to cost of sales within our condensed consolidated statements of income as the inventory is sold or used for clinical purposes. We expect this amount to be fully amortized by the end of 2028. For the three and nine months ended September 30, 2025, amortization from the fair value step-up adjustment was approximately $<ix:nonFraction unitRef="usd" contextRef="c-493" decimals="-5" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-1011">61.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-494" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="f-1012">165.4</ix:nonFraction> million, respectively. For the three and nine months ended September 30, 2024, amortization from the fair value step-up adjustment was approximately $<ix:nonFraction unitRef="usd" contextRef="c-495" decimals="-5" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="6" id="f-1013">50.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-496" decimals="-5" name="us-gaap:ProfitLoss" scale="6" id="f-1014">185.1</ix:nonFraction> million, respectively, which includes approximately $<ix:nonFraction unitRef="usd" contextRef="c-497" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-1015">2.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-498" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-1016">48.5</ix:nonFraction> million, respectively, of inventory used for clinical purposes, which is reflected in research and development expense within our condensed consolidated statements of income. For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Form 10-K.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><div id="i59d9e1af10a84fa9992f9418986a77c7_67"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="f-1017" continuedAt="f-1017-1" escape="true"><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 7:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Intangible Assets and Goodwill</span></div></td></tr></table></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Intangible Assets</span></div><ix:nonNumeric contextRef="c-1" name="biib:IntangibleAssetsExcludingGoodwillTableTextBlock" id="f-1018" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net of accumulated amortization, impairment charges and adjustments are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.607%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.958%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.671%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.684%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Life</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Completed technology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-499" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-1019">2</ix:nonNumeric>-<ix:nonNumeric contextRef="c-500" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-1020">31</ix:nonNumeric> years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="f-1021">14,087.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1022">6,558.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="f-1023">7,528.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="f-1024">14,138.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1025">6,254.1</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="f-1026">7,884.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite until commercialization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-501" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1027">1,639.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-501" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1028">1,639.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-502" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1029">1,642.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-502" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1030">1,642.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Priority review voucher</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-503" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="f-1031">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-503" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="f-1032">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-504" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="f-1033">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-504" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="f-1034">100.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks&#160;and trade names</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-505" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="f-1035">64.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-505" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="f-1036">64.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-506" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="f-1037">64.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-506" decimals="-5" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="6" id="f-1038">64.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1039">15,890.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1040">6,558.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1041">9,331.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1042">15,945.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="f-1043">6,254.1</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="f-1044">9,691.2</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amortization and Impairments</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, 2025, amortization and impairment of acquired intangible assets totale</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d $<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="f-1045">135.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="f-1046">378.4</ix:nonFraction> million, respectively, compared to $<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="f-1047">130.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets" scale="6" id="f-1048">295.5</ix:nonFraction> million, respectively, </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the prior year comparative periods.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, 2025, amortization of acquired intangible assets, excluding impairment charges, totaled </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-1049">135.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-1050">374.9</ix:nonFraction> million, respectively, </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compared to </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-1051">110.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="f-1052">275.3</ix:nonFraction> million, respectively, in the prior year comparative periods. </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Th</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e increases were primarily due to amortization for the acquired intangible assets associated with SKYCLARYS and TYSABRI.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2025, we had <ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" format="ixt:fixed-zero" scale="6" id="f-1053">no</ix:nonFraction> impairment charges. For the nine months ended September 30, 2025, amortization and impairment of acquired intangible assets reflects the impact of a $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="f-1054">3.5</ix:nonFraction> million impairment charge related to a compound acquired from HI-Bio. For the three and nine months ended September 30, 2024, amortization and impairment of acquired intangible assets reflects impairment charges of approximately $<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="f-1055"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" id="f-1056">20.2</ix:nonFraction></ix:nonFraction> million related to intangible assets associated with the termination of Samsung Bioepis' commercialization rights during the third quarter of 2024.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Completed Technology</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Completed technology primarily relates to our other marketed products and programs acquired through asset acquisitions, licenses and business combinations. Completed technology intangible assets are amortized over their estimated useful lives, which range between <ix:nonNumeric contextRef="c-499" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-1057">2</ix:nonNumeric> to <ix:nonNumeric contextRef="c-500" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-1058">31</ix:nonNumeric> years, with a remaining weighted average useful life of <ix:nonNumeric contextRef="c-507" name="biib:FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife" format="ixt-sec:duryear" id="f-1059">12</ix:nonNumeric> years.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IPR&amp;D Related to Business Combinations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPR&amp;D represents the fair value assigned to research and development assets that we acquired as part of a business combination and had not yet reached technological feasibility at the date of acquisition. Included in IPR&amp;D balances are adjustments related to foreign currency exchange rate fluctuations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value associated with our IPR&amp;D assets as of September 30, 2025 and December 31, 2024, primarily relates to the IPR&amp;D programs we acquired in connection with our acquisition of HI-Bio in July 2024, with an estimated fair value of approximately $<ix:nonFraction unitRef="usd" contextRef="c-508" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="9" id="f-1060"><ix:nonFraction unitRef="usd" contextRef="c-509" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="9" id="f-1061">1.6</ix:nonFraction></ix:nonFraction>&#160;billion.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Priority Review Voucher</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Reata in September 2023 we acquired a rare pediatric disease PRV which may be used to obtain priority review by the FDA for a future regulatory submission or sold to a third party. We recorded the PRV based on its estimated fair value of $<ix:nonFraction unitRef="usd" contextRef="c-510" decimals="-5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" format="ixt:num-dot-decimal" scale="6" id="f-1062">100.0</ix:nonFraction>&#160;million as an intangible asset.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-1017-1"><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Estimated Future Amortization of Intangible Assets</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="f-1063" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future amortization of finite-lived intangible assets for the next five years is expected to be as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025 (remaining three months)</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" scale="6" id="f-1064">130.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" scale="6" id="f-1065">485.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" scale="6" id="f-1066">490.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" scale="6" id="f-1067">525.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" scale="6" id="f-1068">580.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2030</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" scale="6" id="f-1069">650.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:7pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Goodwill</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfGoodwillTextBlock" id="f-1070" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a roll forward of the changes in our goodwill balance:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:78.724%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.346%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill, December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-1071">6,478.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill resulting from HI-Bio acquisition</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-5" name="us-gaap:GoodwillPurchaseAccountingAdjustments" scale="6" id="f-1072">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="f-1073">7.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill, September 30, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="f-1074">6,490.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Goodwill resulting from the HI-Bio acquisition relates to HI-Bio measurement period adjustments recognized during 2025 related to certain income tax adjustments. For additional information on our acquisition of HI-Bio, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Other includes adjustments related to foreign currency exchange rate fluctuations.</span></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2025, we had</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonFraction unitRef="usd" contextRef="c-22" decimals="INF" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:fixed-zero" scale="0" id="f-1075">no</ix:nonFraction> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">impairment losses related to goodwill.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><div id="i59d9e1af10a84fa9992f9418986a77c7_70"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-1076" continuedAt="f-1076-1" escape="true"><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 8:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Fair Value Measurements</span></div></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="f-1077" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.796%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements on a Recurring Basis</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-511" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-1078">3,398.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-512" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1079">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-513" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-1080">3,398.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-514" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1081">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-515" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-1082">71.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-516" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-1083">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-517" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-1084">71.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-518" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-1085">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-519" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-1086">26.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-520" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-1087">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-521" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-1088">26.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-522" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="f-1089">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-511" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="f-1090">103.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-512" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="f-1091">103.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-513" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1092">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-514" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1093">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-511" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="f-1094">9.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-512" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1095">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-513" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="f-1096">9.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-514" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1097">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-current assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Convertible note</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-511" decimals="-5" name="us-gaap:NotesReceivableFairValueDisclosure" scale="6" id="f-1098">30.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-512" decimals="-5" name="us-gaap:NotesReceivableFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1099">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-513" decimals="-5" name="us-gaap:NotesReceivableFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1100">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-514" decimals="-5" name="us-gaap:NotesReceivableFairValueDisclosure" scale="6" id="f-1101">30.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan assets for deferred compensation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-511" decimals="-5" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" scale="6" id="f-1102">51.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-512" decimals="-5" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1103">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-513" decimals="-5" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" scale="6" id="f-1104">51.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-514" decimals="-5" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1105">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-511" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-1106">3,691.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-512" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="f-1107">103.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-513" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-1108">3,557.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-514" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="f-1109">30.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-511" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="f-1110">89.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-512" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:fixed-zero" scale="6" id="f-1111">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-513" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" scale="6" id="f-1112">89.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-514" decimals="-5" name="us-gaap:DerivativeLiabilitiesCurrent" format="ixt:fixed-zero" scale="6" id="f-1113">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-511" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="6" id="f-1114">148.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-512" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:fixed-zero" scale="6" id="f-1115">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-513" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:fixed-zero" scale="6" id="f-1116">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-514" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="6" id="f-1117">148.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-current liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-511" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="f-1118">10.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-512" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="f-1119">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-513" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" scale="6" id="f-1120">10.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-514" decimals="-5" name="us-gaap:DerivativeLiabilitiesNoncurrent" format="ixt:fixed-zero" scale="6" id="f-1121">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-511" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="6" id="f-1122">242.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-512" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:fixed-zero" scale="6" id="f-1123">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-513" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:fixed-zero" scale="6" id="f-1124">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-514" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="6" id="f-1125">242.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-511" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="f-1126">490.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-512" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1127">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-513" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="f-1128">99.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-514" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="f-1129">391.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As part of our strategic research arrangement with City Therapeutics we invested in a convertible note, for which we elected the fair value option. For additional information on the arrangement with City Therapeutics, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> to these condensed consolidated financial statements.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.420%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.796%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements on a Recurring Basis</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-523" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-1130">1,664.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-524" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1131">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-525" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-1132">1,664.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-526" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1133">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-523" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="f-1134">179.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-524" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" scale="6" id="f-1135">179.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-525" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1136">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-526" decimals="-5" name="us-gaap:InvestmentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1137">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-523" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="f-1138">62.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-524" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1139">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-525" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" scale="6" id="f-1140">62.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-526" decimals="-5" name="us-gaap:ForeignCurrencyContractAssetFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1141">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-current assets:</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan assets for deferred compensation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-523" decimals="-5" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" scale="6" id="f-1142">42.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-524" decimals="-5" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1143">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-525" decimals="-5" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" scale="6" id="f-1144">42.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-526" decimals="-5" name="biib:PlanAssetsForDeferredCompensationFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1145">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-523" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-1146">1,949.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-524" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="f-1147">179.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-525" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-1148">1,770.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-526" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1149">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-523" decimals="-5" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="f-1150">11.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-524" decimals="-5" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1151">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-525" decimals="-5" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" scale="6" id="f-1152">11.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-526" decimals="-5" name="us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1153">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-523" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="6" id="f-1154">291.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-524" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:fixed-zero" scale="6" id="f-1155">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-525" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:fixed-zero" scale="6" id="f-1156">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-526" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="6" id="f-1157">291.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-current liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-523" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="6" id="f-1158">221.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-524" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:fixed-zero" scale="6" id="f-1159">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-525" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" format="ixt:fixed-zero" scale="6" id="f-1160">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-526" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="6" id="f-1161">221.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-523" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="f-1162">524.5</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-524" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1163">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-525" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="f-1164">11.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-526" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="f-1165">512.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-1076-1" continuedAt="f-1076-2"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketable equity securities represent investments in publicly traded equity securities. Our ability to liquidate our investment in Denali may be limited by the size of our interest, the volume of market-related activity, our concentrated level of ownership and potential restrictions resulting from our status as a collaborator. Therefore, we may realize significantly less than the current value of such investments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2025 Sage was acquired by Supernus. Prior to this acquisition, we disposed of all of our shares of Sage common stock in a block trade.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our investments in Denali and Sage common stock, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2024 Form 10-K.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="6" id="f-1166"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="INF" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="6" id="f-1167">no</ix:nonFraction></ix:nonFraction> material impairments of our assets measured and carried at fair value as of September 30, 2025 and December 31, 2024. In addition, there have been no changes to our valuation techniques as of September 30, 2025 and December 31, 2024.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of our validation procedures related to prices provided by third-party pricing services and our option pricing valuation model, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1, Summary of Significant Accounting Policies - Fair Value Measurements,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2024 Form 10-K. </span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Level 3 Assets and Liabilities Held at Fair Value</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="f-1168" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present quantitative information, as of the dates indicated, about the valuation techniques and significant unobservable inputs used in the valuation of our Level 3 financial assets and liabilities measured at fair value on a recurring basis:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.069%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.772%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quantitative Information about Level 3 Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable Input(s)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-527" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="f-1169">391.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discounted cash flow</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-528" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="f-1170">5.4</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-529" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="f-1171">5.5</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-530" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="f-1172">5.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected timing of achievement of development milestones</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025 - 2030</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:25.069%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.543%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.772%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quantitative Information about Level 3 Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable Input(s)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-531" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="f-1173">512.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discounted cash flow</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-532" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="f-1174">6.2</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-533" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="f-1175">6.3</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-534" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="f-1176">6.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected timing of achievement of development milestones</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025 - 2030</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average discount rates were calculated based on the relative fair values of each distinct contingent consideration obligation related to our acquisition of HI-Bio in July 2024. In addition, we apply various probabilities of technological and regulatory success to the valuation models to estimate the fair values of these contingent consideration obligations, which ranged from approximately <ix:nonFraction unitRef="number" contextRef="c-535" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="f-1177">70.0</ix:nonFraction>% to near certain probability as of September 30, 2025 and December 31, 2024.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> no tr</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ansfers of assets or liabilities into or out of Level 3 as of September 30, 2025 and December 31, 2024.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-1076-2" continuedAt="f-1076-3"><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration Obligations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of HI-Bio in July 2024 we agreed to make additional payments based upon the achievement of certain milestone events. <ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="f-1178" continuedAt="f-1178-1" escape="true">The following table provides a roll forward of the fair value of our contingent consideration obligations, which were classified as Level 3 measurements:</ix:nonNumeric></span></div><ix:continuation id="f-1178-1"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.683%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value, beginning of period</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="f-1179">534.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:fixed-zero" scale="6" id="f-1180">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="f-1181">512.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:fixed-zero" scale="6" id="f-1182">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration resulting from HI-Bio acquisition</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" format="ixt:fixed-zero" scale="6" id="f-1183">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" scale="6" id="f-1184">485.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" format="ixt:fixed-zero" scale="6" id="f-1185">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" scale="6" id="f-1186">485.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in fair value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="f-1187">5.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="f-1188">23.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="6" id="f-1189">28.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="f-1190">23.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" scale="6" id="f-1191">149.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" format="ixt:fixed-zero" scale="6" id="f-1192">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" scale="6" id="f-1193">150.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" format="ixt:fixed-zero" scale="6" id="f-1194">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value, end of period</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="f-1195">391.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="f-1196">508.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="f-1197">391.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="f-1198">508.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the fair value of our contingent consideration obligations, other than changes due to payments, are recognized as a (gain) loss on fair value remeasurement of contingent consideration in our condensed consolidated statements of income. The fair values of the contingent consideration liabilities were based on a probability-adjusted discounted cash flow calculation using Level 3 fair value measurements and inputs. For additional information on the valuation techniques and inputs utilized in the valuation of our financial assets and liabilities, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1, Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2024 Form 10-K.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2025 and December 31, 2024, approximately $<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="6" id="f-1199">148.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="6" id="f-1200">291.2</ix:nonFraction> million, respectively, of the fair value of the total contingent consideration obligations were classified as short-term and reflected as a component of accrued expense and other with the remaining $<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="6" id="f-1201">242.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="6" id="f-1202">221.6</ix:nonFraction> million, respectively, reflected as a component of other long-term liabilities in our condensed consolidated balance sheets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or the three and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, 2025</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, changes in fair value of our contingent consideration obligations were primarily due to the passage of time.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2025 the first milestone related to the fourth patient dosed in a phase 3 clinical trial of felzartamab for AMR was achieved, resulting in a $<ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="f-1203"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="f-1204">150.0</ix:nonFraction></ix:nonFraction>&#160;million milestone payment made to the former shareholders of HI-Bio, which was paid during the third quarter of 2025. In October 2025 the second milestone related to the fourth patient dosed in a phase 3 clinical trial of felzartamab for IgAN was achieved, resulting in a $<ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="f-1205"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="f-1206">150.0</ix:nonFraction></ix:nonFraction>&#160;million milestone payment to be made to the former shareholders of HI-Bio, which we expect will be paid during the fourth quarter of 2025.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Financial Instruments Not Carried at Fair Value</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Financial Instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the short-term nature of certain financial instruments, the carrying value reflected in our condensed consolidated balance sheets for current accounts receivable, due from anti-CD20 therapeutic programs, other current assets, accounts payable and accrued expense and other, approximates fair value.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-1076-3"><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Instruments</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" id="f-1207" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:42.091%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.369%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.374%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Current portion:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-536" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1208">4.050</ix:nonFraction>% Senior Notes due September 15, 2025</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-537" decimals="-5" name="biib:NotesPayableCurrentFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1209">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-537" decimals="-5" name="us-gaap:NotesPayableCurrent" format="ixt:fixed-zero" scale="6" id="f-1210">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-538" decimals="-5" name="biib:NotesPayableCurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-1211">1,741.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-538" decimals="-5" name="us-gaap:NotesPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="f-1212">1,748.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of notes payable</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-539" decimals="-5" name="biib:NotesPayableCurrentFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1213">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-539" decimals="-5" name="us-gaap:NotesPayableCurrent" format="ixt:fixed-zero" scale="6" id="f-1214">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-540" decimals="-5" name="biib:NotesPayableCurrentFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-1215">1,741.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-540" decimals="-5" name="us-gaap:NotesPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="f-1216">1,748.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Non-current portion:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-541" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1217">2.250</ix:nonFraction>% Senior Notes due May 1, 2030</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-542" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-1218">1,367.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-542" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="f-1219">1,495.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-543" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-1220">1,295.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-544" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="f-1221">1,494.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-545" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1222">5.050</ix:nonFraction>% Senior Notes due January 15, 2031</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-546" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="f-1223">410.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-546" decimals="-5" name="us-gaap:NotesPayable" scale="6" id="f-1224">397.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-547" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1225">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-548" decimals="-5" name="us-gaap:NotesPayable" format="ixt:fixed-zero" scale="6" id="f-1226">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-549" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1227">5.750</ix:nonFraction>% Senior Notes due May 15, 2035</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-550" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="f-1228">680.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-550" decimals="-5" name="us-gaap:NotesPayable" scale="6" id="f-1229">645.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-551" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1230">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-552" decimals="-5" name="us-gaap:NotesPayable" format="ixt:fixed-zero" scale="6" id="f-1231">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-553" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1232">5.200</ix:nonFraction>% Senior Notes due September 15, 2045</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-554" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-1233">1,026.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-554" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="f-1234">1,101.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-555" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-1235">1,008.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-556" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="f-1236">1,101.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-557" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1237">3.150</ix:nonFraction>% Senior Notes due May 1, 2050</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-558" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="f-1238">970.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-558" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="f-1239">1,475.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-559" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="f-1240">943.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-560" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="f-1241">1,475.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-561" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1242">3.250</ix:nonFraction>% Senior Notes due February 15, 2051</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-562" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="f-1243">458.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-562" decimals="-5" name="us-gaap:NotesPayable" scale="6" id="f-1244">479.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-563" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="f-1245">448.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-564" decimals="-5" name="us-gaap:NotesPayable" scale="6" id="f-1246">476.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-565" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1247">6.450</ix:nonFraction>% Senior Notes due May 15, 2055</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-566" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" scale="6" id="f-1248">748.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-566" decimals="-5" name="us-gaap:NotesPayable" scale="6" id="f-1249">690.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-567" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="f-1250">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-568" decimals="-5" name="us-gaap:NotesPayable" format="ixt:fixed-zero" scale="6" id="f-1251">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current portion of notes payable</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-569" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-1252">5,663.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-569" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="f-1253">6,285.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-570" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-1254">3,696.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-570" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="f-1255">4,547.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total notes payable</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-1256">5,663.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="f-1257">6,285.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="us-gaap:NotesPayableFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="f-1258">5,437.2</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="us-gaap:NotesPayable" format="ixt:num-dot-decimal" scale="6" id="f-1259">6,295.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> In May 2025 we issued our 2025 Senior Notes for an aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="c-571" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="f-1260">1.75</ix:nonFraction>&#160;billion. In June 2025 we used the net proceeds from the sale of our 2025 Senior Notes to redeem in full our <ix:nonFraction unitRef="number" contextRef="c-537" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1261">4.050</ix:nonFraction>% Senior Notes due September 15, 2025, prior to maturity. For additional information, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 13, Indebtedness</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of each of our series of Senior Notes were determined through market, observable and corroborated sources. The changes in the fair values of our Senior Notes as of September 30, 2025, compared to December 31, 2024, are primarily related to decreases in U.S. treasury yields and credit spreads used to value our Senior Notes since December 31, 2024. For additional information related to our Senior Notes, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 13,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indebtedness,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2024 Form 10-K.</span></div></ix:continuation><div id="i59d9e1af10a84fa9992f9418986a77c7_76"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" id="f-1262" continuedAt="f-1262-1" escape="true"><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 9:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Financial Instruments</span></div></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="f-1263" escape="true"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-572" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-1264">3,116.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-573" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-1265">1,664.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-574" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="f-1266">202.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-575" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:fixed-zero" scale="6" id="f-1267">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-576" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" scale="6" id="f-1268">79.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-577" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:fixed-zero" scale="6" id="f-1269">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-1270">3,398.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="us-gaap:CashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-1271">1,664.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of our money market funds, short-term debt securities and commercial paper, including accrued interest, approximate fair value due to their short-term maturities.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-1262-1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketable equity securities gains (losses) are recorded in other (income) expense, net in our condensed consolidated statements of income. <ix:nonNumeric contextRef="c-1" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="f-1272" continuedAt="f-1272-1" escape="true">The following tables summarize our marketable debt and equity securities, classified as available-for-sale:</ix:nonNumeric></span></div><ix:continuation id="f-1272-1" continuedAt="f-1272-2"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.252%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.580%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-578" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="f-1273">71.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-578" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-1274">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-578" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="f-1275">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-578" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-1276">71.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-579" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="f-1277">26.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-579" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-1278">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-579" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="f-1279">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-579" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-1280">26.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="f-1281">97.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-1282">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="f-1283">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-1284">97.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, non-current</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-580" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCost" scale="6" id="f-1285">227.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-580" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-1286">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-580" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-1287">123.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-580" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="f-1288">103.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCost" scale="6" id="f-1289">227.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-1290">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-1291">123.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="f-1292">103.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:41.252%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.576%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.580%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, non-current</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-581" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCost" scale="6" id="f-1293">668.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-581" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-1294">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-581" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-1295">489.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-581" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="f-1296">179.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="us-gaap:EquitySecuritiesFvNiCost" scale="6" id="f-1297">668.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-1298">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-1299">489.0</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="f-1300">179.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Summary of Contractual Maturities: Available-for-Sale Debt Securities</span></div><ix:continuation id="f-1272-2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value and amortized cost of our marketable debt securities classified as available-for-sale by contractual maturity are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.537%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.353%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2025</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="6" id="f-1301">97.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" scale="6" id="f-1302">97.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" scale="6" id="f-1303">97.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" scale="6" id="f-1304">97.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The average maturity of our marketable debt securities classified as available-for-sale as of September 30, 2025, was approximately <ix:nonNumeric contextRef="c-1" name="biib:DebtSecuritiesAvailableForSaleAverageMaturity" format="ixt-sec:durmonth" id="f-1305">2</ix:nonNumeric> months.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Strategic Investments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies, which are reflected within our disclosures included in </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 8, Fair Value Measurements,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these condensed consolidated financial statements, as well as venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2025 and December 31, 2024, our strategic investment portfolio was comprised of investments totaling $<ix:nonFraction unitRef="usd" contextRef="c-582" decimals="-5" name="biib:StrategicInvestmentPortfolio" scale="6" id="f-1306">167.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-583" decimals="-5" name="biib:StrategicInvestmentPortfolio" scale="6" id="f-1307">226.7</ix:nonFraction> million, respectively, which are included in investments and other assets within our condensed consolidated balance sheets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in our strategic investment portfolio as of September 30, 2025, compared to December 31, 2024, was primarily due to the decrease in the fair value of our investment in Denali common stock as well as the sale of our remaining investment in Sage common stock during the third quarter of 2025.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our investments in Denali and Sage common stock, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2024 Form 10-K.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><div id="i59d9e1af10a84fa9992f9418986a77c7_82"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="f-1308" continuedAt="f-1308-1" escape="true"><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 10:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Derivative Instruments</span></div></td></tr></table></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Foreign Currency Forward Contracts - Hedging Instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the global nature of our operations, portions of our revenue and operating expense are recorded in currencies other than the U.S.&#160;dollar. The value of revenue and operating expense measured in U.S.&#160;dollars is therefore subject to changes in foreign currency exchange rates. We enter into foreign currency forward contracts and foreign currency options with financial institutions with the primary objective to mitigate the impact of foreign currency exchange rate fluctuations on our international revenue and operating expense.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency forward contracts and foreign currency options in effect as of September 30, 2025 and December 31, 2024, had durations of <ix:nonNumeric contextRef="c-499" name="us-gaap:DerivativeRemainingMaturity1" format="ixt-sec:durmonth" id="f-1309">1</ix:nonNumeric> to <ix:nonNumeric contextRef="c-500" name="us-gaap:DerivativeRemainingMaturity1" format="ixt-sec:durmonth" id="f-1310">24</ix:nonNumeric> months and <ix:nonNumeric contextRef="c-584" name="us-gaap:DerivativeRemainingMaturity1" format="ixt-sec:durmonth" id="f-1311">1</ix:nonNumeric> to <ix:nonNumeric contextRef="c-585" name="us-gaap:DerivativeRemainingMaturity1" format="ixt-sec:durmonth" id="f-1312">12</ix:nonNumeric> months, respectively. These contracts have been designated as cash flow hedges and unrealized gains and losses on the portion of these foreign currency forward contracts and foreign currency options that are included in the effectiveness test are reported in AOCI. Realized gains and losses of such contracts and options are recognized in revenue when the sale of product in the currency being hedged is recognized and in operating expense when the expense in the currency being hedged is recorded. We recognize all cash flow hedge reclassifications from AOCI and fair value changes of excluded portions in the same line item in our condensed consolidated statements of income that have been impacted by the hedged item.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" id="f-1313" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notional amount of foreign currency forward contracts and foreign currency options that were entered into to hedge forecasted revenue and operating expense is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Euro</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-586" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-1314">1,524.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-587" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-1315">1,062.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">British pound</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-588" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="f-1316">35.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-589" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="f-1317">133.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Swiss franc</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-590" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="f-1318">68.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-591" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:fixed-zero" scale="6" id="f-1319">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canadian dollar</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-592" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="f-1320">9.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-593" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="f-1321">38.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total foreign currency forward contracts and options</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-594" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-1322">1,637.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-595" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-1323">1,235.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="biib:DerivativeInstrumentsUnrealizedGainLossTableTextBlock" id="f-1324" escape="true"><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pre-tax portion of the fair value of these foreign currency forward contracts and foreign currency options that were included in AOCI in total equity is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.964%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.785%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gains</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="biib:UnrealizedGainOnDerivatives" scale="6" id="f-1325">9.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="biib:UnrealizedGainOnDerivatives" scale="6" id="f-1326">50.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized (losses)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="biib:UnrealizedLossOnDerivatives" scale="6" id="f-1327">112.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="biib:UnrealizedLossOnDerivatives" scale="6" id="f-1328">0.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unrealized gains (losses)</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:UnrealizedGainLossOnDerivatives" scale="6" id="f-1329">103.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="us-gaap:UnrealizedGainLossOnDerivatives" scale="6" id="f-1330">50.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect net unrealized losses of approximately $<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="biib:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months" format="ixt:num-dot-decimal" scale="6" id="f-1331">103.4</ix:nonFraction>&#160;million to be settled over the next 24 months, of which approximately $<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" format="ixt:num-dot-decimal" scale="6" id="f-1332">90.8</ix:nonFraction>&#160;million of these net unrealized losses are expected to be settled over the next 12 months, with any amounts in AOCI to be reported as an adjustment to revenue or operating expense. We consider the impact of our and our counterparties&#8217; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of September 30, 2025 and December 31, 2024, credit risk did not materially change the fair value of our foreign currency forward contracts and forward currency options.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-1308-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" id="f-1333" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the effect of foreign currency forward contracts and forward currency options designated as hedging instruments in our condensed consolidated statements of income:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:22.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.198%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.345%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.154%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.641%"/><td style="width:0.1%"/></tr><tr><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Reclassified from AOCI into Operating Income (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses) Excluded from Effectiveness Testing and<br/>Recognized in Operating Income (in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-596" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="f-1334">29.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-597" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="f-1335">7.6</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-598" decimals="-5" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="f-1336">8.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-599" decimals="-5" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="f-1337">2.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-600" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="f-1338">6.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-601" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="f-1339">1.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-602" decimals="-5" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" format="ixt:fixed-zero" scale="6" id="f-1340">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-603" decimals="-5" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="f-1341">0.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Reclassified from AOCI into Operating Income (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses) Excluded from Effectiveness Testing and<br/>Recognized in Operating Income (in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-604" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="f-1342">41.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-605" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="f-1343">2.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-606" decimals="-5" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="f-1344">7.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-607" decimals="-5" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="f-1345">4.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-608" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="f-1346">14.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-609" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="f-1347">8.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-610" decimals="-5" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="f-1348">1.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-611" decimals="-5" sign="-" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" scale="6" id="f-1349">1.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Foreign Currency Forward Contracts - Other Derivative Instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also enter into other foreign currency forward contracts, usually with durations of one month or less, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate notional amount of these outstanding foreign currency forward contracts was $<ix:nonFraction unitRef="usd" contextRef="c-612" decimals="-5" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="6" id="f-1350">1,066.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-613" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="f-1351">738.7</ix:nonFraction> million as of September 30, 2025 and December 31, 2024, respectively. Net losses of $<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" scale="6" id="f-1352">0.5</ix:nonFraction> million and net gains of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" scale="6" id="f-1353">34.9</ix:nonFraction> million</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">related to these contracts were recorded as a component of other (income) expense, net for the three and nine months ended September 30, 2025, respectively, compared to net gains of $<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" sign="-" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" scale="6" id="f-1354">23.4</ix:nonFraction> million and net losses of $<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" scale="6" id="f-1355">6.6</ix:nonFraction> million, respectively, in the prior year comparative periods.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Summary of Derivative Instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While certain of our derivative instruments are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our condensed consolidated balance sheets. The amounts in the table below would not be substantially different if the derivative assets and liabilities were offset.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="f-1356" escape="true"><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:28.328%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.328%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.372%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.376%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Cash Flow Hedging Instruments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-614" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="f-1357">7.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-615" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="f-1358">58.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-616" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="f-1359">87.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-617" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="f-1360">0.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-618" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="f-1361">10.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-619" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:fixed-zero" scale="6" id="f-1362">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other Derivative Instruments:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-620" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="f-1363">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-621" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="f-1364">4.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-622" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="f-1365">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-623" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="f-1366">11.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="i59d9e1af10a84fa9992f9418986a77c7_85"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="f-1367" continuedAt="f-1367-1" escape="true"><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 11:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Property, Plant and Equipment</span></div></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-1367-1">Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Accumulated depreciation on property, plant and equipment was $<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1368">2,868.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="f-1369">2,670.8</ix:nonFraction> million as of September 30, 2025 and December 31, 2024, respectively. For the three and nine months ended September 30, 2025, depreciation expense totaled approximately $<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-1370">66.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-1371">204.8</ix:nonFraction> million, respectively, compared to $<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-1372">72.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="us-gaap:Depreciation" scale="6" id="f-1373">213.9</ix:nonFraction> million, respectively, in the prior year comparative peri</ix:continuation>ods.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><div id="i59d9e1af10a84fa9992f9418986a77c7_91"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeasesTextBlock" id="f-1374" escape="true"><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 12:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Leases</span></div></td></tr></table></div><div style="margin-top:6pt"><span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">New Corporate Headquarters Lease</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2025 we entered into a lease agreement with MIT Investment Management Company and BioMed Realty for the lease of approximately <ix:nonFraction unitRef="sqft" contextRef="c-40" decimals="0" name="biib:OperatingLeaseArea" format="ixt:num-dot-decimal" scale="0" id="f-1375">580,000</ix:nonFraction> square feet of office and research and development space located at 75 Broadway, Cambridge, Massachusetts, which will be used as our new global corporate headquarters, as well as integrating our research and development and technical operations teams alongside our North American commercial organization. As part of a multi-year real estate consolidation plan that is expected to result in a reduction of approximately <ix:nonFraction unitRef="number" contextRef="c-40" decimals="2" name="biib:ReductionOfRealEstateFootprint" scale="-2" id="f-1376">40</ix:nonFraction>% of our real estate footprint in Massachusetts, this new lease is intended to replace two existing leases, both in Cambridge, Massachusetts, including our current corporate headquarters. We expect the initial lease term of approximately <ix:nonNumeric contextRef="c-40" name="us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" format="ixt-sec:duryear" id="f-1377">15.5</ix:nonNumeric> years to commence on May 31, 2028. The estimated minimum lease payments as a result of the new lease total approximately $<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-5" name="us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" format="ixt:num-dot-decimal" scale="9" id="f-1378">1.5</ix:nonFraction>&#160;billion over the initial lease term. We have an option to extend the lease for three extension periods of five years each and one six month short-term extension, at then market-based rates. We will account for this lease as a right-of-use asset and lease liability upon the lease commencement date.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our accounting policies relating to leases, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1, Summary of Significant Accounting Policies - Leases</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2024 Form 10-K.</span></div></ix:nonNumeric><div id="i59d9e1af10a84fa9992f9418986a77c7_100"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DebtDisclosureTextBlock" id="f-1383" continuedAt="f-1383-1" escape="true"><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 13:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Indebtedness</span></div></td></tr></table></div><div style="margin-top:6pt"><span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2025 Senior Notes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 12, 2025, we issued senior unsecured notes for an aggregate principal amount of $<ix:nonFraction unitRef="usd" contextRef="c-571" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="f-1384">1.75</ix:nonFraction>&#160;billion, consisting of the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$<ix:nonFraction unitRef="usd" contextRef="c-628" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1385">400.0</ix:nonFraction>&#160;million of <ix:nonFraction unitRef="number" contextRef="c-628" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1386">5.050</ix:nonFraction>% Senior Notes due January 15, 2031, valued at <ix:nonFraction unitRef="number" contextRef="c-628" decimals="5" name="biib:PercentageParValueOfSeniorNotes" scale="-2" id="f-1387">99.981</ix:nonFraction>% of par;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$<ix:nonFraction unitRef="usd" contextRef="c-629" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1388">650.0</ix:nonFraction>&#160;million of <ix:nonFraction unitRef="number" contextRef="c-629" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1389">5.750</ix:nonFraction>% Senior Notes due May 15, 2035, valued at <ix:nonFraction unitRef="number" contextRef="c-629" decimals="5" name="biib:PercentageParValueOfSeniorNotes" scale="-2" id="f-1390">99.924</ix:nonFraction>% of par; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$<ix:nonFraction unitRef="usd" contextRef="c-630" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="f-1391">700.0</ix:nonFraction>&#160;million of <ix:nonFraction unitRef="number" contextRef="c-630" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1392">6.450</ix:nonFraction>% Senior Notes due May 15, 2055, valued at <ix:nonFraction unitRef="number" contextRef="c-630" decimals="5" name="biib:PercentageParValueOfSeniorNotes" scale="-2" id="f-1393">99.657</ix:nonFraction>% of par.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our 2025 Senior Notes are senior unsecured obligations and may be redeemed at our option at any time at <ix:nonFraction unitRef="number" contextRef="c-631" decimals="0" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="f-1394">100</ix:nonFraction>% of the principal amount plus accrued interest and, until a specified period before maturity, a specified make-whole amount. Our 2025 Senior Notes contain a change-of-control provision that, under certain circumstances, may require us to purchase our 2025 Senior Notes at a price equal to <ix:nonFraction unitRef="number" contextRef="c-631" decimals="2" name="biib:DebtInstrumentMakeWholeProvisionRedemptionPricePercentage" scale="-2" id="f-1395">101</ix:nonFraction>% of the principal amount plus accrued and unpaid interest to the date of repurchase.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incurred approximately $<ix:nonFraction unitRef="usd" contextRef="c-631" decimals="-5" name="us-gaap:PaymentsOfFinancingCosts" format="ixt:num-dot-decimal" scale="6" id="f-1396">13.9</ix:nonFraction>&#160;million of costs associated with this offering which have been recorded as a reduction to the carrying amount of the debt on our condensed consolidated balance sheets. These costs will be amortized as additional interest expense using the effective interest rate method over the period from issuance through maturity. The discounts will be amortized as additional interest expense over the period from issuance through maturity using the effective interest rate method.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on our 2031 Senior Notes is payable January 15 and July 15 of each year, commencing January 15, 2026. Interest on our 2035 Senior Notes and 2055 Senior Notes is payable May 15 and November 15 of each year, commencing on November 15, 2025.</span></div><div style="margin-top:6pt"><span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.050% Senior Notes due September 15, 2025</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 15, 2015, we issued $<ix:nonFraction unitRef="usd" contextRef="c-632" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="9" id="f-1397">1.75</ix:nonFraction>&#160;billion aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="c-537" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1398">4.050</ix:nonFraction>% Senior Notes due September 15, 2025, at <ix:nonFraction unitRef="number" contextRef="c-633" decimals="5" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="f-1399">99.764</ix:nonFraction>% of par. In June 2025 we used the net proceeds from the sale of our 2025 Senior Notes to redeem our <ix:nonFraction unitRef="number" contextRef="c-537" decimals="5" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-1400">4.050</ix:nonFraction>% Senior Notes due September 15, 2025, prior to their maturity. No gain or loss was recognized upon redemption.</span></div><div style="margin-top:6pt"><span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2023 Term Loan Credit Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Reata in September 2023 we entered into a $<ix:nonFraction unitRef="usd" contextRef="c-634" decimals="-3" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="f-1401">1.5</ix:nonFraction>&#160;billion term loan credit agreement. On the closing date of the Reata acquisition we drew $<ix:nonFraction unitRef="usd" contextRef="c-635" decimals="-8" name="us-gaap:DebtInstrumentCarryingAmount" scale="9" id="f-1402">1.0</ix:nonFraction> billion from the 2023 Term Loan, comprised of a $<ix:nonFraction unitRef="usd" contextRef="c-636" decimals="-3" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-1403">500.0</ix:nonFraction>&#160;million floating rate 364-day tranche and a $<ix:nonFraction unitRef="usd" contextRef="c-637" decimals="-3" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-1404">500.0</ix:nonFraction>&#160;million floating rate three-year tranche. The remaining unused commitment of $<ix:nonFraction unitRef="usd" contextRef="c-638" decimals="-3" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-1405">500.0</ix:nonFraction>&#160;million was terminated. As of December 31, 2023, we repaid </span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-1383-1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-639" decimals="-5" name="us-gaap:RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths" format="ixt:num-dot-decimal" scale="6" id="f-1406">350.0</ix:nonFraction>&#160;million of the 364--day tranche. The remaining $<ix:nonFraction unitRef="usd" contextRef="c-640" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-1407">150.0</ix:nonFraction>&#160;million portion of the 364-day tranche was repaid during the first quarter of 2024. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, during the first quarter of 2024 we repaid $<ix:nonFraction unitRef="usd" contextRef="c-641" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-1408">250.0</ix:nonFraction>&#160;million of the three-year tranche, with the remaining $<ix:nonFraction unitRef="usd" contextRef="c-642" decimals="-5" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="f-1409">250.0</ix:nonFraction>&#160;million portion being subsequently repaid in full during the second quarter of 2024. For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2024 Form 10-K.</span></div></ix:continuation><div id="i59d9e1af10a84fa9992f9418986a77c7_103"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-1410" continuedAt="f-1410-1" escape="true"><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 14:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Equity</span></div></td></tr></table></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Share Repurchases</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020 our Board of Directors authorized our 2020 Share Repurchase Program, which is a program to repurchase up to $<ix:nonFraction unitRef="usd" contextRef="c-643" decimals="INF" name="srt:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="9" id="f-1411">5.0</ix:nonFraction> billion of our common stock. Our 2020 Share Repurchase Program does not have an expiration date. All shares repurchased under our 2020 Share Repurchase Program were retired. There were <ix:nonFraction unitRef="shares" contextRef="c-21" decimals="0" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:fixed-zero" scale="0" id="f-1412"><ix:nonFraction unitRef="shares" contextRef="c-20" decimals="0" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:fixed-zero" scale="0" id="f-1413"><ix:nonFraction unitRef="shares" contextRef="c-19" decimals="0" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:fixed-zero" scale="0" id="f-1414"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="0" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:fixed-zero" scale="0" id="f-1415">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> share repurchases of our common stock during the three and nine months ended September 30, 2025 and 2024. Approximately $<ix:nonFraction unitRef="usd" contextRef="c-644" decimals="-8" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" scale="9" id="f-1416">2.1</ix:nonFraction> billion remained available under our 2020 Share Repurchase Program as of September 30, 2025.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Income (Loss)</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="f-1417" continuedAt="f-1417-1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the changes in AOCI, net of tax by component:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.648%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.981%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.981%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.981%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.989%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30, 2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges,<br/>Net of Tax</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency<br/>Translation Adjustments,<br/>Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, June 30, 2025</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-645" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-1418">112.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-646" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-1419">15.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-647" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-1420">110.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-1421">238.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-648" decimals="-5" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="f-1422">6.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-649" decimals="-5" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" format="ixt:fixed-zero" scale="6" id="f-1423">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-650" decimals="-5" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="f-1424">3.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="f-1425">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from AOCI</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-648" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="f-1426">20.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-649" decimals="-5" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" format="ixt:fixed-zero" scale="6" id="f-1427">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-650" decimals="-5" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" format="ixt:fixed-zero" scale="6" id="f-1428">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="f-1429">20.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-648" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-1430">26.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-649" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:fixed-zero" scale="6" id="f-1431">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-650" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-1432">3.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-1433">23.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, September 30, 2025</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-651" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-1434">85.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-652" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-1435">15.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-653" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-1436">113.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-1437">214.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30, 2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency<br/>Translation Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2024</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-654" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-1438">51.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-655" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-1439">16.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-656" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-1440">171.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-1441">136.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-657" decimals="-5" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="f-1442">161.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-658" decimals="-5" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="f-1443">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-659" decimals="-5" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="f-1444">57.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="f-1445">103.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from AOCI</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-657" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="f-1446">24.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-658" decimals="-5" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" format="ixt:fixed-zero" scale="6" id="f-1447">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-659" decimals="-5" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" format="ixt:fixed-zero" scale="6" id="f-1448">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="f-1449">24.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-657" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-1450">137.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-658" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-1451">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-659" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-1452">57.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-1453">78.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, September 30, 2025</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-651" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-1454">85.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-652" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-1455">15.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-653" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-1456">113.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-1457">214.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-1410-1"><ix:continuation id="f-1417-1"><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:14.981%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.981%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.981%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.989%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges,<br/>Net of Tax</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Pension Benefit Obligation,<br/>Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency<br/>Translation Adjustments,<br/>Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-660" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-1458">9.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-661" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-1459">2.7</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-662" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-1460">153.1</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-1461">146.0</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-663" decimals="-5" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="f-1462">49.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-664" decimals="-5" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="f-1463">0.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-665" decimals="-5" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="f-1464">41.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="f-1465">7.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from AOCI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-663" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="f-1466">8.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-664" decimals="-5" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" format="ixt:fixed-zero" scale="6" id="f-1467">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-665" decimals="-5" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" format="ixt:fixed-zero" scale="6" id="f-1468">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="f-1469">8.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-663" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-1470">41.0</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-664" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-1471">0.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-665" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-1472">41.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-1473">0.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-666" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-1474">31.2</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-667" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-1475">2.4</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-668" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-1476">112.1</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-1477">145.7</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency Translation Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-669" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-1478">25.0</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-670" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-1479">2.6</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-671" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-1480">126.1</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-1481">153.7</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-672" decimals="-5" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="f-1482">11.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-673" decimals="-5" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="f-1483">0.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-674" decimals="-5" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="f-1484">14.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="f-1485">2.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from AOCI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-672" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="f-1486">5.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-673" decimals="-5" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" format="ixt:fixed-zero" scale="6" id="f-1487">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-674" decimals="-5" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" format="ixt:fixed-zero" scale="6" id="f-1488">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="f-1489">5.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-672" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-1490">6.2</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-673" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-1491">0.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-674" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-1492">14.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="f-1493">8.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-666" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-1494">31.2</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-667" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-1495">2.4</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-668" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-1496">112.1</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-1497">145.7</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" id="f-1498" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts reclassified from AOCI:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.192%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.911%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.814%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts Reclassified from AOCI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income Statement Location</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on cash flow hedges</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-675" decimals="-5" sign="-" name="us-gaap:Revenues" scale="6" id="f-1499">29.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-676" decimals="-5" sign="-" name="us-gaap:Revenues" scale="6" id="f-1500">7.6</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-677" decimals="-5" sign="-" name="us-gaap:Revenues" scale="6" id="f-1501">41.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-678" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-1502">2.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-675" decimals="-5" sign="-" name="us-gaap:OperatingExpenses" scale="6" id="f-1503">6.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-676" decimals="-5" name="us-gaap:OperatingExpenses" scale="6" id="f-1504">1.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-677" decimals="-5" sign="-" name="us-gaap:OperatingExpenses" scale="6" id="f-1505">14.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-678" decimals="-5" name="us-gaap:OperatingExpenses" scale="6" id="f-1506">8.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-675" decimals="-5" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="f-1507">0.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-676" decimals="-5" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="f-1508">0.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-677" decimals="-5" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="f-1509">0.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-678" decimals="-5" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="f-1510">0.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-675" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-1511">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-676" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-1512">1.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-677" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-1513">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-678" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-1514">0.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax (benefit) expense</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total reclassifications, net of tax</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-679" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-1515">20.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-680" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-1516">8.1</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-681" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-1517">24.5</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-682" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-1518">5.2</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><div id="i59d9e1af10a84fa9992f9418986a77c7_106"></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-1519" escape="true"><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 15:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Earnings per Share</span></div></td></tr></table></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="f-1520" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted shares outstanding used in our earnings per share calculation are calculated as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.806%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.625%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Biogen Inc.</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-1521">466.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-1522">388.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-1523">1,341.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-1524">1,365.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-19" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-1525">146.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-20" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-1526">145.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-1527">146.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-21" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-1528">145.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time-vested restricted stock units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-683" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="f-1529">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-684" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="f-1530">0.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-685" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="f-1531">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-686" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="f-1532">0.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-687" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="6" id="f-1533">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-688" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="f-1534">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-689" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="6" id="f-1535">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-690" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="f-1536">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dilutive potential common shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-19" decimals="-5" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="f-1537">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-20" decimals="-5" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="f-1538">0.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="f-1539">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-21" decimals="-5" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="6" id="f-1540">0.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares used in calculating diluted earnings per share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-19" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-1541">147.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-20" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-1542">146.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-1543">146.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-21" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-1544">146.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant.</span></div></ix:nonNumeric><div id="i59d9e1af10a84fa9992f9418986a77c7_109"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-1545" continuedAt="f-1545-1" escape="true"><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 16:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Share-Based Payments</span></div></td></tr></table></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Share-based Compensation Expense</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-1546" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.285%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-691" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1547">28.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-692" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1548">69.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-693" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1549">91.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-694" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1550">124.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-695" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1551">49.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-696" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1552">61.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-697" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1553">149.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-698" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1554">150.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="f-1555">78.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="f-1556">131.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="f-1557">240.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="f-1558">275.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalized share-based compensation costs </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="f-1559">3.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="f-1560">2.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="f-1561">9.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="f-1562">8.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in total cost and expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="f-1563">75.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="f-1564">128.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="f-1565">231.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="f-1566">267.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax effect</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="f-1567">14.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="f-1568">24.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="f-1569">45.3</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" scale="6" id="f-1570">50.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in net income attributable to Biogen Inc.</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-699" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1571">60.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-700" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1572">104.5</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-701" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1573">185.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-702" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1574">216.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of HI-Bio in July 2024 we recognized HI-Bio equity-based compensation expense, inclusive of employer taxes, of approximately $<ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-1575">56.4</ix:nonFraction>&#160;million attributable to the post-acquisition service period, of which $<ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-1576"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-1577">42.5</ix:nonFraction></ix:nonFraction>&#160;million was recognized as a charge to research and development expense with the remaining $<ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-1578"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-1579">13.9</ix:nonFraction></ix:nonFraction>&#160;million as a charge to selling, general and administrative expense within our condensed consolidated statements of income for the three and nine months ended September 30, 2024. These amounts were associated with the accelerated vesting of stock options and RSUs previously granted to HI-Bio employees and required no future services to vest. For additional information on our acquisition of HI-Bio, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" id="f-1580" escape="true"><ix:continuation id="f-1545-1"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.285%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time-vested restricted stock units</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-703" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1581">60.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-704" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1582">59.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-705" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1583">186.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-706" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1584">174.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in stock</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-707" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1585">15.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-708" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1586">13.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-709" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1587">44.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-710" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1588">35.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-711" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1589">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-712" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1590">1.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-713" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1591">6.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-714" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1592">8.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in cash</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-715" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="6" id="f-1593">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-716" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1594">0.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-717" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="6" id="f-1595">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-718" decimals="-5" sign="-" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1596">2.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-719" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1597">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-720" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1598">1.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-721" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1599">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-722" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1600">2.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Market stock units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-723" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="6" id="f-1601">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-724" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1602">0.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-725" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="6" id="f-1603">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-726" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1604">0.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">HI-Bio equity awards</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="6" id="f-1605">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-727" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1606">56.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:fixed-zero" scale="6" id="f-1607">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-728" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-1608">56.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="f-1609">78.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="f-1610">131.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="f-1611">240.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" scale="6" id="f-1612">275.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalized share-based compensation costs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="f-1613">3.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="f-1614">2.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="f-1615">9.4</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" scale="6" id="f-1616">8.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in total cost and expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="f-1617">75.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="f-1618">128.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="f-1619">231.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses" scale="6" id="f-1620">267.4</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Relates to the HI-Bio equity-based compensation expense attributable to the post-acquisition service period, associated with the accelerated vesting of stock options and RSUs previously granted to HI-Bio employees and required no future services to vest. For additional information on our acquisition of HI-Bio, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div></ix:continuation></ix:nonNumeric><div id="i59d9e1af10a84fa9992f9418986a77c7_112"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-1621" continuedAt="f-1621-1" escape="true"><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 17:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Income Taxes</span></div></td></tr></table></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:112%">2025 OBBBA Tax Provisions</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 4, 2025, the U.S. signed into law the H.R.1 legislation formally titled "An Act to Provide for Reconciliation Pursuant to Title II of H. Con. Res. 14", commonly referred to as the OBBBA.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The OBBBA contains tax provisions, such as the permanent extension or revision of certain expiring provisions of the Tax Cuts and Jobs Act enacted in 2017, modifications to the international tax framework and the restoration of favorable tax treatment for certain business provisions. The provisions of the OBBBA have multiple effective dates, with certain provisions effective in 2025 and others implemented through 2027. The OBBBA did not result in any material adjustments to our total income tax provision for the three and nine months ended September 30, 2025, and we have adjusted our deferred tax balances to reflect the impacts of the OBBBA enactment.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Tax Rate</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="f-1622" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.683%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Statutory rate</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-19" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-1623">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-20" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-1624">21.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-1625">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-21" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-1626">21.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-19" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-1627">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-20" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-1628">2.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-1629">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-21" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-1630">1.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Taxes on foreign earnings, including valuation allowances</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-19" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="f-1631">5.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-20" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="f-1632">11.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="f-1633">7.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-21" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="f-1634">7.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-19" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="f-1635">1.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-20" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="f-1636">1.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="f-1637">1.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-21" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="f-1638">1.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchased inventory valuation step-up and intangible assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-19" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" scale="-2" id="f-1639">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-20" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" scale="-2" id="f-1640">3.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" scale="-2" id="f-1641">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-21" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" scale="-2" id="f-1642">2.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GILTI</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-19" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent" scale="-2" id="f-1643">1.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-20" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent" scale="-2" id="f-1644">1.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent" scale="-2" id="f-1645">1.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-21" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent" scale="-2" id="f-1646">1.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation awards</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-19" decimals="3" name="biib:EffectiveTaxRateReconciliationShareBasedCompensationAwards" format="ixt:fixed-zero" scale="-2" id="f-1647">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-20" decimals="3" name="biib:EffectiveTaxRateReconciliationShareBasedCompensationAwards" format="ixt:fixed-zero" scale="-2" id="f-1648">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="biib:EffectiveTaxRateReconciliationShareBasedCompensationAwards" scale="-2" id="f-1649">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-21" decimals="3" name="biib:EffectiveTaxRateReconciliationShareBasedCompensationAwards" scale="-2" id="f-1650">0.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OBBBA enactment</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-19" decimals="3" sign="-" name="biib:EffectiveTaxRateReconciliationOneBigBeautifulBillActEnactment" scale="-2" id="f-1651">2.1</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-20" decimals="3" name="biib:EffectiveTaxRateReconciliationOneBigBeautifulBillActEnactment" format="ixt:fixed-zero" scale="-2" id="f-1652">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="biib:EffectiveTaxRateReconciliationOneBigBeautifulBillActEnactment" scale="-2" id="f-1653">0.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-21" decimals="3" name="biib:EffectiveTaxRateReconciliationOneBigBeautifulBillActEnactment" format="ixt:fixed-zero" scale="-2" id="f-1654">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, including permanent items</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-19" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-1655">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-20" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-1656">1.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-1657">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-21" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-1658">0.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-19" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1659">16.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-20" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1660">13.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1661">16.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-21" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-1662">15.4</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-1621-1"><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Tax Rate</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2025, compared to the same periods in 2024, the increases in our effective tax rates were partially driven by changes in the territorial mix of our profitability, partially offset by the impact of the OBBBA enactment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The nine months ended September 30, 2025, compared to the same period in 2024, also reflects the impacts of certain share-based compensation awards that vested during the first quarter of 2025 and a decrease in our estimate of Pillar Two minimum tax liabilities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2024, our effective tax rates benefited from a decrease in our valuation allowance, partially offset by the impact of certain foreign uncertain tax positions. </span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Accounting for Uncertainty in Income Taxes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in various U.S. states and in U.S. federal and other foreign jurisdictions. With few exceptions, we are no longer subject to U.S. federal tax examination for years before 2021 or state, local or non-U.S. income tax examinations for years before 2013.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. Internal Revenue Service and other national tax authorities routinely examine our intercompany transfer pricing with respect to intellectual property related transactions and it is possible that they may disagree with one or more positions we have taken with respect to such valuations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is reasonably possible that we will adjust the value of our uncertain tax positions related to certain transfer pricing, collaboration matters, withholding taxes and other issues as we receive additional information from various taxing authorities, including reaching settlements with such authorities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate that it is reasonably possible that our gross unrecognized tax benefits, exclusive of interest, could</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">decrease by up to approximately $<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" format="ixt:num-dot-decimal" scale="6" id="f-1663">35.0</ix:nonFraction>&#160;million in the next 12 months as a result of various audit closures, settlements and expiration of the statute of limitations.</span></div></ix:continuation><div id="i59d9e1af10a84fa9992f9418986a77c7_115"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:AdditionalFinancialInformationDisclosureTextBlock" id="f-1664" continuedAt="f-1664-1" escape="true"><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 18:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Other Consolidated Financial Statement Detail</span></div></td></tr></table></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Other (Income) Expense, Net</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" id="f-1665" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of other (income) expense, net, are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:44.714%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.822%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.822%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.822%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.387%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.825%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="f-1666">31.6</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="f-1667">11.6</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="f-1668">87.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="f-1669">49.1</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="f-1670">67.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="f-1671">59.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="f-1672">200.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="f-1673">190.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gains) losses on investments, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" sign="-" name="us-gaap:RealizedInvestmentGainsLosses" scale="6" id="f-1674">3.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" name="us-gaap:RealizedInvestmentGainsLosses" scale="6" id="f-1675">39.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:RealizedInvestmentGainsLosses" scale="6" id="f-1676">34.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" sign="-" name="us-gaap:RealizedInvestmentGainsLosses" scale="6" id="f-1677">22.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange (gains) losses, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="f-1678">10.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="f-1679">4.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="f-1680">16.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" scale="6" id="f-1681">25.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-1682">15.8</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-1683">0.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-1684">12.0</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-1685">4.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other (income) expense, net</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="f-1686">34.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="f-1687">14.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="f-1688">151.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" sign="-" name="us-gaap:OtherOperatingIncomeExpenseNet" scale="6" id="f-1689">193.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:4pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The (gains) losses on investments, net, as reflected in the table above, relate to equity securities of certain biotechnology companies, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:GainLossOnInvestmentsTextBlock" id="f-1690" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes our (gains) losses on investments, net that relate to our equity securities held during the following periods:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.514%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.765%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.771%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net (gains) losses recognized on equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="f-1691">3.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="f-1692">39.1</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="f-1693">34.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="us-gaap:EquitySecuritiesFvNiGainLoss" scale="6" id="f-1694">21.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Net (gains) losses realized on equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="f-1695">7.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="f-1696">10.9</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="f-1697">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" scale="6" id="f-1698">5.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unrealized (gains) losses recognized on equity securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="f-1699">3.2</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" sign="-" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="f-1700">28.2</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="f-1701">32.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" scale="6" id="f-1702">27.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-1664-1" continuedAt="f-1664-2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net unrealized gains recognized during the three months ended September 30, 2025, primarily reflect an increase in the aggregate fair value of our investment in Denali common stock of approximately $<ix:nonFraction unitRef="usd" contextRef="c-729" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="f-1703">3.8</ix:nonFraction>&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net unrealized gains recognized during the three months ended September 30, 2024, primarily reflect an increase in the aggregate fair value of our investments in Denali and Sangamo common stock of approximately $<ix:nonFraction unitRef="usd" contextRef="c-730" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="f-1704">53.3</ix:nonFraction>&#160;million, partially offset by a decrease in the fair value of Sage common stock of approximately $<ix:nonFraction unitRef="usd" contextRef="c-731" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="f-1705">22.7</ix:nonFraction>&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net unrealized losses recognized during the nine months ended September 30, 2025, primarily reflect a decrease in the aggregate fair value of our investment in Denali common stock of approximately $<ix:nonFraction unitRef="usd" contextRef="c-732" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="f-1706">41.9</ix:nonFraction>&#160;million, partially offset by an increase in the fair value of Sage common stock of approximately $<ix:nonFraction unitRef="usd" contextRef="c-733" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="f-1707">23.0</ix:nonFraction>&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net unrealized losses recognized during the nine months ended September 30, 2024, primarily reflect a decrease in the aggregate fair value of our investments in Sage common stock of approximately $<ix:nonFraction unitRef="usd" contextRef="c-734" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="f-1708">90.2</ix:nonFraction>&#160;million, partially offset by an increase in the fair value of Denali and Sangamo common stock of approximately $<ix:nonFraction unitRef="usd" contextRef="c-735" decimals="-5" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="6" id="f-1709">70.1</ix:nonFraction>&#160;million.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Accrued Expense and Other</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="f-1710" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expense and other consists of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue-related reserves for discounts and allowances</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-469" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="6" id="f-1711">1,062.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-470" decimals="-5" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="6" id="f-1712">937.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee compensation and benefits</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="f-1713">310.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="f-1714">375.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="biib:Collaborationexpensesaccrual" scale="6" id="f-1715">268.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="biib:Collaborationexpensesaccrual" scale="6" id="f-1716">309.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalties and licensing fees</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:AccruedRoyaltiesCurrent" scale="6" id="f-1717">320.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="us-gaap:AccruedRoyaltiesCurrent" scale="6" id="f-1718">190.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="6" id="f-1719">148.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" scale="6" id="f-1720">291.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:ConstructionPayableCurrentAndNoncurrent" scale="6" id="f-1721">89.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="us-gaap:ConstructionPayableCurrentAndNoncurrent" scale="6" id="f-1722">11.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="f-1723">574.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="6" id="f-1724">692.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-1725">2,773.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-1726">2,807.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:10pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Long-term Liabilities</span></div></ix:continuation><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-1664-2">Other long-term liabilities were $<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="f-1727">761.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="f-1728">732.3</ix:nonFraction> million as of September 30, 2025 and December 31, 2024, respectively, and included accrued income taxes totaling $<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:AccruedIncomeTaxesNoncurrent" scale="6" id="f-1729">164.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="us-gaap:AccruedIncomeTaxesNoncurrent" scale="6" id="f-1730">156.7</ix:nonFraction> million, respectively</ix:continuation>.</span></div><div id="i59d9e1af10a84fa9992f9418986a77c7_118"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="f-1731" continuedAt="f-1731-1" escape="true"><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 19:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Collaborative and Other Relationships</span></div></td></tr></table></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Genentech, Inc. (Roche Group)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, CLL and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL, follicular lymphoma,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and, following its approval in October 2025, lupus nephritis; OCREVUS for the treatment of PPMS and RMS; LUNSUMIO for the treatment of relapsed or refractory follicular lymphoma; COLUMVI, a bispecific antibody for the treatment of non-Hodgkin's lymphoma; and have the option to add other potential anti-CD20 therapies, pursuant to our collaboration arrangements with Genentech, a wholly-owned member of the Roche Group. For purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RITUXAN</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Genentech and its affiliates are responsible for the worldwide manufacture of RITUXAN as well as all development and commercialization activities as follows:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.67pt">U.S.:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have co-exclusively licensed our rights to develop, commercialize and market RITUXAN in the U.S.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.67pt">Canada:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have co-exclusively licensed our rights to develop, commercialize and market RITUXAN in Canada.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">GAZYVA</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Roche Group and its sub-licensees maintain sole responsibility for the development, manufacture and commercialization of GAZYVA in the U.S. The level of gross sales of GAZYVA in the U.S. has impacted our percentage of the co-promotion profits for RITUXAN and LUNSUMIO, as summarized in the table below.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-1731-1" continuedAt="f-1731-2"><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCREVUS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of our collaboration arrangements with Genentech, we receive a tiered royalty on U.S. net sales from <ix:nonFraction unitRef="number" contextRef="c-736" decimals="INF" name="biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" scale="-2" id="f-1732">13.5</ix:nonFraction>% and increasing up to <ix:nonFraction unitRef="number" contextRef="c-737" decimals="INF" name="biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" scale="-2" id="f-1733">24.0</ix:nonFraction>% if annual net sales exceed $<ix:nonFraction unitRef="usd" contextRef="c-738" decimals="-5" name="biib:Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage" format="ixt:num-dot-decimal" scale="6" id="f-1734">900.0</ix:nonFraction>&#160;million. There will be a <ix:nonFraction unitRef="number" contextRef="c-738" decimals="INF" name="biib:Reductioninroyaltyrate" scale="-2" id="f-1735">50.0</ix:nonFraction>% reduction to these royalties upon the first entry of an FDA approved biosimilar to OCREVUS.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we receive a gross <ix:nonFraction unitRef="number" contextRef="c-739" decimals="INF" name="biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" scale="-2" id="f-1736">3.0</ix:nonFraction>% royalty on net sales of OCREVUS outside the U.S., with the royalty period lasting <ix:nonNumeric contextRef="c-738" name="biib:PeriodOfCollaborationAgreement" format="ixt-sec:duryear" id="f-1737">11</ix:nonNumeric> years from the first commercial sale of OCREVUS on a country-by-country basis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The commercialization of OCREVUS does not impact the percentage of the co-promotion profits we receive for RITUXAN, LUNSUMIO or GAZYVA. Genentech is solely responsible for development and commercialization of OCREVUS and funding future costs. Genentech cannot develop OCREVUS in CLL, non-Hodgkin's lymphoma or rheumatoid arthritis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OCREVUS royalty revenue is based on our estimates from third party and market research data of OCREVUS sales occurring during the corresponding period. Differences between actual and estimated royalty revenue will be adjusted for in the period in which they become known, which is generally expected to be the following quarter.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">LUNSUMIO</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are entitled to a tiered share of co-promotion operating profits and losses in the U.S., as summarized in the table below. In addition, we receive low-single digit royalties on sales of LUNSUMIO outside the U.S.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COLUMVI</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Genentech has sole decision-making rights on the commercialization of COLUMVI within the U.S. and we receive tiered royalties in the mid-single digit range on net sales of COLUMVI in the U.S. Under the terms of this agreement, we have no payment obligations. The commercialization of COLUMVI does not impact the percentage of the co-promotion profits we receive for RITUXAN, LUNSUMIO or GAZYVA.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Profit-sharing Formulas</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RITUXAN and LUNSUMIO Profit Share</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current pretax co-promotion profit-sharing formula for RITUXAN and LUNSUMIO in the U.S. provides for a <ix:nonFraction unitRef="number" contextRef="c-740" decimals="INF" name="biib:PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion" scale="-2" id="f-1738">30.0</ix:nonFraction>% share on the first $<ix:nonFraction unitRef="usd" contextRef="c-741" decimals="-5" name="biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" format="ixt:num-dot-decimal" scale="6" id="f-1739">50.0</ix:nonFraction>&#160;million of combined co-promotion operating profits earned each calendar year. <ix:nonNumeric contextRef="c-1" name="biib:CoPromotionProfitSharingFormulaTableTextBlock" id="f-1740" continuedAt="f-1740-1" escape="true">As a result of the FDA approval of LUNSUMIO our share of the combined annual co-promotion profits for RITUXAN and LUNSUMIO in excess of $<ix:nonFraction unitRef="usd" contextRef="c-741" decimals="-5" name="biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" format="ixt:num-dot-decimal" scale="6" id="f-1741">50.0</ix:nonFraction>&#160;million varies upon the following events, as summarized in the table below:</ix:nonNumeric></span></div><ix:continuation id="f-1740-1"><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:80.891%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.909%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After LUNSUMIO Approval until the First Threshold Date</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-740" decimals="3" name="biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" scale="-2" id="f-1742">37.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After First Threshold Date until the Second Threshold Date</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-740" decimals="3" name="biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" scale="-2" id="f-1743">35.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After Second Threshold Date</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-740" decimals="3" name="biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour" scale="-2" id="f-1744">30.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:continuation><div style="margin-top:6pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">First Threshold Date</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means the earlier of (i)&#160;the first day of the calendar quarter following the date U.S. gross sales of GAZYVA within any consecutive 12-month period have reached $<ix:nonFraction unitRef="usd" contextRef="c-742" decimals="-5" name="biib:ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne" format="ixt:num-dot-decimal" scale="6" id="f-1745">500.0</ix:nonFraction>&#160;million or (ii)&#160;the first date in any calendar year in which U.S. gross sales of LUNSUMIO have reached $<ix:nonFraction unitRef="usd" contextRef="c-742" decimals="-5" name="biib:ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne" format="ixt:num-dot-decimal" scale="6" id="f-1746">150.0</ix:nonFraction>&#160;million.</span></div><div style="margin-top:6pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Second Threshold Date</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means the later of (i) the first date in any calendar year in which U.S. gross sales of LUNSUMIO have reached $<ix:nonFraction unitRef="usd" contextRef="c-742" decimals="-5" name="biib:SalesTriggerGrossSalesThreshold" format="ixt:num-dot-decimal" scale="6" id="f-1747">350.0</ix:nonFraction>&#160;million or (ii) January 1 of the calendar year following the calendar year in which the First Threshold Date occurs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023 the First Threshold Date was achieved. As a result, beginning in April 2023 the pre-tax profit share for RITUXAN and LUNSUMIO was <ix:nonFraction unitRef="number" contextRef="c-741" decimals="INF" name="biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" scale="-2" id="f-1748">35.0</ix:nonFraction>%.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">GAZYVA Profit Share</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current pretax profit-sharing formula for GAZYVA provides for a <ix:nonFraction unitRef="number" contextRef="c-743" decimals="INF" name="biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" scale="-2" id="f-1749">35.0</ix:nonFraction>% share of operating profits earned each calendar year.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Genentech, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2024 Form 10-K.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-1731-2" continuedAt="f-1731-3"><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Ionis Pharmaceuticals, Inc.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2017 SMA Collaboration Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017 we entered into a collaboration agreement with Ionis to identify new ASO drug candidates for the potential treatment of SMA. Under this agreement, we have options to license therapies arising out of this collaboration and will be responsible for the development and commercialization of such therapies.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021 we exercised our option with Ionis and obtained a worldwide, exclusive, royalty-bearing license to develop and commercialize salanersen (BIIB115), an investigational ASO in development for SMA.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may pay Ionis up to $<ix:nonFraction unitRef="usd" contextRef="c-744" decimals="-5" name="biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" format="ixt:num-dot-decimal" scale="6" id="f-1750">155.0</ix:nonFraction>&#160;million in additional development and regulatory milestone payments related to salanersen, including a $<ix:nonFraction unitRef="usd" contextRef="c-744" decimals="-5" name="biib:EstimatedAdditionalPaymentsUponInitiationOfNewPhases" format="ixt:num-dot-decimal" scale="6" id="f-1751">45.0</ix:nonFraction>&#160;million milestone payment due upon the initiation of a Phase 3 trial. Upon commercialization, we may also pay Ionis up to $<ix:nonFraction unitRef="usd" contextRef="c-744" decimals="-5" name="biib:ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold" format="ixt:num-dot-decimal" scale="6" id="f-1752">400.0</ix:nonFraction>&#160;million in additional performance-based milestone payments and tiered royalties on potential net sales of such therapies ranging from the mid-teens to high-twenties percentages.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Ionis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2024 Form 10-K.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Eisai Co., Ltd.</span></div><div style="margin-top:5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">LEQEMBI (lecanemab) Collaboration</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration agreement with Eisai to jointly develop and commercialize LEQEMBI (lecanemab), an anti-amyloid antibody for the treatment of Alzheimer's disease. The FDA granted traditional approval of LEQEMBI in July 2023. Prior to receiving traditional approval, LEQEMBI had been granted accelerated approval by the FDA in January 2023, at which time it became commercially available in the U.S. Outside of the U.S., LEQEMBI is now approved in the E.U. (April 2025), Australia (September 2025), China (January 2024), Japan (September 2023) and other international markets. LEQEMBI monthly IV maintenance dosing for the treatment of early Alzheimer's disease was approved in the U.S. and China in January 2025 and September 2025, respectively, and LEQEMBI subcutaneous autoinjector (IQLIK) for weekly maintenance dosing was approved in the U.S. in August 2025.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All costs, including research, development, sales and marketing expense, are shared equally between us and Eisai. We also share profits and losses equally. We currently have a supply agreement with Eisai to manufacture LEQEMBI drug substance and drug product through the end of 2031.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the limitations in the LEQEMBI Collaboration Agreement, Eisai has final decision-making authority on all matters relating to the collaboration and serves as the lead of LEQEMBI development and regulatory submissions globally. We co-commercialize and co-promote LEQEMBI with Eisai. Our Collaboration Agreement provides that each commercialization plan shall allocate the responsibilities for the activities under the plan in an equitable fashion taking into account Biogen's and Eisai's respective capabilities and provides a meaningful role for each party.   </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon commercialization of LEQEMBI in the U.S., we began recognizing our <ix:nonFraction unitRef="number" contextRef="c-479" decimals="2" name="biib:ShareOfNonControlingInterestRecognized" scale="-2" id="f-1753">50.0</ix:nonFraction>% share of LEQEMBI product revenue, net and cost of sales, including royalties, within Alzheimer's collaboration revenue in our condensed consolidated statements of income, as we are not the principal.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our share of LEQEMBI sales and marketing expense and development expense are recorded within selling, general and administrative expense and research and development expense, respectively, within our condensed consolidated statements of income.</span></div><ix:nonNumeric contextRef="c-1" name="biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" id="f-1754" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of development and sales and marketing expense related to the LEQEMBI Collaboration is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.285%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total development expense incurred by the collaboration related to the advancement of LEQEMBI</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-745" decimals="-5" name="biib:ExpenseIncurredByCollaboration" scale="6" id="f-1755">70.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-746" decimals="-5" name="biib:ExpenseIncurredByCollaboration" scale="6" id="f-1756">77.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-747" decimals="-5" name="biib:ExpenseIncurredByCollaboration" scale="6" id="f-1757">178.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-748" decimals="-5" name="biib:ExpenseIncurredByCollaboration" scale="6" id="f-1758">255.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of the LEQEMBI Collaboration development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-745" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1759">35.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-746" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1760">38.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-747" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1761">89.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-748" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1762">127.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total sales and marketing expense incurred by the LEQEMBI Collaboration</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-749" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1763">176.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-750" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1764">164.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-751" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1765">525.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-752" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1766">476.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of the LEQEMBI Collaboration sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-749" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1767">88.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-750" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1768">82.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-751" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1769">262.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-752" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1770">238.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-1731-3" continuedAt="f-1731-4"><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts receivable from Eisai related to the agreements discussed above were approximately $<ix:nonFraction unitRef="usd" contextRef="c-753" decimals="-5" name="biib:AccountsReceivableFromCollaborator" format="ixt:num-dot-decimal" scale="6" id="f-1771">103.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-754" decimals="-5" name="biib:AccountsReceivableFromCollaborator" format="ixt:num-dot-decimal" scale="6" id="f-1772">16.7</ix:nonFraction>&#160;million as of September 30, 2025 and December 31, 2024, respectively. Amounts payable to Eisai related to the agreements discussed above were approximately $<ix:nonFraction unitRef="usd" contextRef="c-753" decimals="-5" name="biib:AccountsPayableToCollaborator" format="ixt:num-dot-decimal" scale="6" id="f-1773">97.9</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-754" decimals="-5" name="biib:AccountsPayableToCollaborator" format="ixt:num-dot-decimal" scale="6" id="f-1774">138.0</ix:nonFraction>&#160;million as of September 30, 2025 and December 31, 2024, respectively.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arra</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ngements with Eisai, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2024 Form 10-K.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">UCB</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration agreement with UCB, effective November 2003, to jointly develop and commercialize dapirolizumab pegol, an anti-CD40L pegylated Fab, for the potential treatment of SLE and other future agreed indications. Either we or UCB may propose development of dapirolizumab pegol in additional indications. If the parties do not agree to add an indication as an agreed indication to the collaboration, we or UCB may, at the sole expense of the applicable party, pursue development in such excluded indication(s), subject to an opt-in right of the non-pursuing party after proof of clinical activity.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All costs incurred for agreed indications, including research, development, sales and marketing expense, are shared equally between us and UCB. If marketing approval is obtained, both companies will jointly commercialize dapirolizumab pegol and share profits and losses equally.</span></div><ix:nonNumeric contextRef="c-1" name="biib:SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock" id="f-1775" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of development expense related to the UCB collaboration agreement is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.285%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total UCB collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-755" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1776">23.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-756" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1777">19.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-757" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1778">62.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-758" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1779">52.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of the UCB collaboration development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-755" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1780">11.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-756" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1781">9.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-757" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1782">31.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-758" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1783">26.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Supernus Pharmaceuticals, Inc. (previously Sage Therapeutics, Inc.)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020 we entered into a global collaboration and license agreement with Sage to jointly develop and commercialize ZURZUVAE (zuranolone) for the treatment of PPD. In July 2025 Sage was acquired by Supernus. ZURZUVAE was approved in the U.S. in August 2023 and in the E.U. in September 2025.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under this collaboration, both companies will share equal responsibility and costs for development as well as profits and losses for commercialization in the U.S. Outside of the U.S., we are responsible for development and commercialization, excluding Japan, Taiwan and South Korea, with respect to zuranolone and may pay Supernus </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">potential tiered royalties in the high-teens to low-twenties percentages. During the fourth quarter of 2023 we accrued a milestone payment due t</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o Supernus</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of $<ix:nonFraction unitRef="usd" contextRef="c-759" decimals="-5" name="biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" format="ixt:num-dot-decimal" scale="6" id="f-1784">75.0</ix:nonFraction>&#160;million upon the first commercial sale of ZURZUVAE for PPD in the U.S., which was recorded within intangible assets, net in our condensed consolidated balance sheets, and subsequently paid in January 2024.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We share <ix:nonFraction unitRef="number" contextRef="c-22" decimals="2" name="biib:ShareOfNetProfitFromSageTherapeuticsPercent" scale="-2" id="f-1785">50.0</ix:nonFraction>% of the net collaboration results in the U.S. with Supernus, which are recognized in collaboration profit sharing/(loss reimbursement) in our condensed consolidated statements of income. For the three and nine months ended September 30, 2025, we recognized net profit-sharing expense of approximately $<ix:nonFraction unitRef="usd" contextRef="c-760" decimals="-5" name="biib:Collaborationprofitlosssharing" scale="6" id="f-1786">20.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-761" decimals="-5" name="biib:Collaborationprofitlosssharing" scale="6" id="f-1787">48.6</ix:nonFraction> million, respectively, to reflect Supernus' <ix:nonFraction unitRef="number" contextRef="c-22" decimals="2" name="biib:ShareOfNetProfitFromSageTherapeuticsPercent" scale="-2" id="f-1788">50.0</ix:nonFraction>% share of the net collaboration results in the U.S., compared to net profit-sharing expense of approximately $<ix:nonFraction unitRef="usd" contextRef="c-762" decimals="-5" name="biib:Collaborationprofitlosssharing" scale="6" id="f-1789">9.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-763" decimals="-5" name="biib:Collaborationprofitlosssharing" scale="6" id="f-1790">20.5</ix:nonFraction> million, respectively, in the prior year comparative periods.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-1731-4" continuedAt="f-1731-5"><ix:nonNumeric contextRef="c-1" name="biib:SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock" id="f-1791" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A summary of development and sales and marketing expense related to the Supernus collaboration is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.379%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.700%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Supernus collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-764" decimals="-5" sign="-" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1792">1.7</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-765" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1793">8.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-766" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1794">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-767" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1795">29.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of the Supernus collaboration development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-764" decimals="-5" sign="-" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1796">0.9</ix:nonFraction>)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-765" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1797">4.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-766" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1798">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-767" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1799">14.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total sales and marketing expense incurred by the Supernus collaboration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-768" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1800">41.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-769" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1801">28.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-770" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1802">131.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-771" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1803">82.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of the Supernus collaboration sales and marketing expense reflected in selling, general and administrative expense and collaboration profit sharing/(loss reimbursement) in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-768" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1804">20.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-769" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1805">14.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-770" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1806">65.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-771" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1807">41.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Denali Therapeutics Inc.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020 we entered into a collaboration and license agreement with Denali to co-develop and co-commercialize BIIB122, a small molecule inhibitor of LRRK2 for Parkinson's disease (LRRK2 Collaboration).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the LRRK2 Collaboration, both companies share responsibility and costs for global development based on specified percentages as well as profits and losses for commercialization in the U.S. and China. Outside the U.S. and China we are responsible for commercialization and may pay Denali potential tiered royalties.</span></div><ix:nonNumeric contextRef="c-1" name="biib:SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" id="f-1808" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A summary of development expense related to the Denali collaboration is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.285%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Denali collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-772" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1809">11.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-773" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1810">14.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-774" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1811">36.3</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-775" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1812">44.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of the Denali collaboration development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-772" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1813">6.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-773" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1814">8.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-774" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1815">21.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-775" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1816">26.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Stoke Therapeutics, Inc.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2025 we entered into a collaboration and license agreement with Stoke to co-develop and commercialize zorevunersen, an investigational ASO that targets the SCN1A gene for the potential treatment of Dravet syndrome, a rare form of genetic epilepsy associated with refractory seizures and neurodevelopmental impairments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of this agreement, Stoke will continue to lead global development and retain exclusive development and commercialization rights for zorevunersen in the U.S., Canada and Mexico and we will have exclusive rights to commercialize zorevunersen in the rest of the world. Both companies will share responsibility for external clinical development costs, where Stoke is responsible for <ix:nonFraction unitRef="number" contextRef="c-776" decimals="3" name="biib:PercentageOfFutureDevelopmentCosts" scale="-2" id="f-1817">70.0</ix:nonFraction>% of these development costs and we are responsible for the remaining <ix:nonFraction unitRef="number" contextRef="c-777" decimals="3" name="biib:PercentageOfFutureDevelopmentCosts" scale="-2" id="f-1818">30.0</ix:nonFraction>% of these development costs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the closing of this transaction we made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-778" decimals="-5" name="biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" format="ixt:num-dot-decimal" scale="6" id="f-1819">165.0</ix:nonFraction>&#160;million to Stoke, which was recognized as acquired in-process research and development, upfront and milestone expense within our condensed consolidated statements of income for the nine months ended September 30, 2025. We may also pay Stoke potential development and commercial milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="c-779" decimals="-5" name="biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" format="ixt:num-dot-decimal" scale="6" id="f-1820">50.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-780" decimals="-5" name="biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" format="ixt:num-dot-decimal" scale="6" id="f-1821">335.0</ix:nonFraction>&#160;million, respectively, if all the specified milestones set forth in this collaboration are achieved. In addition, we may pay Stoke tiered royalties on potential net sales of any products developed under this collaboration in the low-double digit to high-teen percentages.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have an exclusive option to license certain future follow-on ASO products targeting the SCN1A gene in all territories worldwide other than the U.S., Canada and Mexico, in exchange for separate milestone, cost sharing and royalty considerations.</span></div><ix:nonNumeric contextRef="c-1" name="biib:SummaryOfActivityRelatedToCollaborationTableTextBlock" id="f-1822" escape="true"><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of development expense related to the Stoke collaboration agreement is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:57.087%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.221%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.932%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30, 2025</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30, 2025</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Stoke collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-781" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1823">9.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-782" decimals="-5" name="biib:Expenseincurredbythecollaboration" scale="6" id="f-1824">21.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of the Stoke collaboration development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-781" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1825">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-782" decimals="-5" name="biib:Expensereflectedwithinstatementsofincome" scale="6" id="f-1826">6.6</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-1731-5" continuedAt="f-1731-6"><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Samsung Bioepis Co., Lt</span><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">d.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2019 Development and Commercialization Agreement</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019 we completed a transaction with Samsung Bioepis and secured the exclusive rights to commercialize <ix:nonFraction unitRef="product" contextRef="c-783" decimals="INF" name="biib:ContingentCommercializedRightsNumberOfProducts" format="ixt-sec:numwordsen" scale="0" id="f-1827">two</ix:nonFraction> potential ophthalmology biosimilar products, BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS, and OPUVIZ, an aflibercept biosimilar referencing EYLEA, in major markets worldwide, including the U.S., Canada, Europe, Japan and Australia. The agreement established that Samsung Bioepis will be responsible for development and will supply both products to us at a pre-specified gross margin of approximately <ix:nonFraction unitRef="number" contextRef="c-783" decimals="INF" name="biib:EquityMethodInvestmentsExpectedProfitShare" scale="-2" id="f-1828">45.0</ix:nonFraction>%.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2024 we notified Samsung Bioepis of our decision to terminate our 2019 Development and Commercialization Agreement (the DCA Agreement) solely within the U.S. and Canada. As a result of this termination we recognized impairment charges of approximately $<ix:nonFraction unitRef="usd" contextRef="c-784" decimals="-5" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" scale="6" id="f-1829">20.2</ix:nonFraction> million, </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which were recorded within amortization and impairment of acquired intangible assets within our condensed consolidated statements of income for the</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine months ended September 30, 2024. Biogen will transfer commercialization rights for BYOOVIZ and OPUVIZ in the U.S. and Canada back to Samsung Bioepis over a period of up to 18 months. During this transition period, we will continue to commercialize BYOOVIZ. The termination does not impact the other markets in the DCA Agreement.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may pay Samsung Bioepis up to approximately $<ix:nonFraction unitRef="usd" contextRef="c-785" decimals="-5" name="biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" scale="6" id="f-1830">150.0</ix:nonFraction> million for achieving additional sales-based milestones associated with the remaining major markets covered by the agreement.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2013 Commercial Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2013 we entered into an agreement with Samsung Bioepis to commercialize, over a 10-year term, three anti-TNF biosimilar product candidates which include IMRALDI, an adalimumab biosimilar referencing HUMIRA, FLIXABI, an infliximab biosimilar referencing REMICADE, and BENEPALI, an etanercept biosimilar referencing ENBREL, in Europe.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2024 we exercised an option to extend this agreement by an additional <ix:nonNumeric contextRef="c-786" name="biib:CollaborativeArrangementTermExtension" format="ixt-sec:durwordsen" id="f-1831">five years</ix:nonNumeric> and paid Samsung Bioepis an option exercise fee of $<ix:nonFraction unitRef="usd" contextRef="c-786" decimals="-5" name="biib:ContractOptionExerciseFee" scale="6" id="f-1832">60.0</ix:nonFraction> million, which was recognized in intangible assets, net within our condensed consolidated balance sheets as of December 31, 2024.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We reflect revenue on sales of BENEPALI, IMRALDI and FLIXABI to third parties in product revenue, net in our condensed consolidated statements of income and record the related cost of revenue and sales and marketing expense in our condensed consolidated statements of income to their respective line items when these costs are incurred. Royalty payments to AbbVie on sales of IMRALDI are recognized in cost of sales within our condensed consolidated statements of income.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We share <ix:nonFraction unitRef="number" contextRef="c-786" decimals="INF" name="biib:EquityMethodInvestmentsExpectedProfitShare" scale="-2" id="f-1833">50.0</ix:nonFraction>% of the profit or loss related to our 2013 commercial agreement with Samsung Bioepis, which is recognized in collaboration profit sharing/(loss reimbursement) in our condensed consolidated statements of income. For the </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine months ended September 30, 2025, we recognized net profit-sharing expense of approximately $<ix:nonFraction unitRef="usd" contextRef="c-787" decimals="-5" name="biib:Collaborationprofitlosssharing" format="ixt:num-dot-decimal" scale="6" id="f-1834">66.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-788" decimals="-5" name="biib:Collaborationprofitlosssharing" format="ixt:num-dot-decimal" scale="6" id="f-1835">171.7</ix:nonFraction>&#160;million, respectively, to reflect Samsung Bioepis' <ix:nonFraction unitRef="number" contextRef="c-786" decimals="INF" name="biib:EquityMethodInvestmentsExpectedProfitShare" scale="-2" id="f-1836">50.0</ix:nonFraction>% sharing of the net collaboration profits, compared to net profit-sharing expense of approximately $<ix:nonFraction unitRef="usd" contextRef="c-789" decimals="-5" name="biib:Collaborationprofitlosssharing" scale="6" id="f-1837">60.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-790" decimals="-5" name="biib:Collaborationprofitlosssharing" scale="6" id="f-1838">176.8</ix:nonFraction> million, respectively, in the prior year comparative periods.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Services</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Simultaneous with the formation of Samsung Bioepis, we also entered into a license agreement with Samsung Bioepis. Under this license agreement, we granted Samsung Bioepis an exclusive license to use, develop, manufacture and commercialize biosimilar products created by Samsung Bioepis using Biogen product-specific technology. In exchange, we receive single-digit royalties on biosimilar products developed and commercialized by Samsung Bioepis. Royalty revenue under the license agreement is recognized as a component of contract manufa</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cturing, royalty and other revenue in our condensed consolidated statements of income.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts receivable from Samsung Bioepis related to the agreements discussed above were approximately $<ix:nonFraction unitRef="usd" contextRef="c-791" decimals="-5" name="us-gaap:AccountsReceivableNet" format="ixt:num-dot-decimal" scale="6" id="f-1839">4.8</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-792" decimals="-5" name="us-gaap:AccountsReceivableNet" format="ixt:num-dot-decimal" scale="6" id="f-1840">7.6</ix:nonFraction>&#160;million as of September 30, 2025 and December 31, 2024, respectively. Amounts payable to Samsung Bioepis related to the agreements discussed above were $<ix:nonFraction unitRef="usd" contextRef="c-791" decimals="-5" name="us-gaap:AccountsPayableCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1841">45.3</ix:nonFraction>&#160;million and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-792" decimals="-5" name="us-gaap:AccountsPayableCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="f-1842">60.8</ix:nonFraction>&#160;million as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2025 and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2024, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Samsung Bioepis and our other significant collaboration arrangements, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2024 Form 10-K. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-1731-6" continuedAt="f-1731-7"><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Other Research and Discovery Arrangements and Funding Arrangements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These arrangements may include the potential for future milestone payments based on the achievement of certain clinical and commercial development payable over a period of several years.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalty Pharma Funding Arrangement</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2025 we entered into a funding agreement with Royalty Pharma under which we will receive up to $<ix:nonFraction unitRef="usd" contextRef="c-793" decimals="-5" name="biib:CollaborativeArrangementExpectedDevelopmentCostFundsYearOne" format="ixt:num-dot-decimal" scale="6" id="f-1843">200.0</ix:nonFraction>&#160;million in 2025 and up to $<ix:nonFraction unitRef="usd" contextRef="c-793" decimals="-5" name="biib:CollaborativeArrangementExpectedDevelopmentCostFundsYearTwo" format="ixt:num-dot-decimal" scale="6" id="f-1844">50.0</ix:nonFraction>&#160;million in 2026 to co-fund our development costs for the litifilimab program. As there is a substantive transfer of risk to the financial partner for the amount invested, the development funding will be recognized by us as an obligation to perform contractual services. We plan to recognize this funding as a reduction to research and development expense within our condensed consolidated statements of income, proportionate to the related expense. For the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three and nine months ended September 30, 2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we recorded reductions to research and development e</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">xpense of $<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="biib:ReductionOfResearchAndDevelopmentExpense" scale="6" id="f-1845">50.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="biib:ReductionOfResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="6" id="f-1846">150.0</ix:nonFraction>&#160;million, respectiv</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ely, within our condensed consolidated statements of income.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the litifilimab clinical trials are successful for the indications based on the applicable clinical trials, upon regulatory approval in the U.S. or certain major markets in the world, Royalty Pharma will be eligible to receive approval-based fixed milestone payments of up to a total of $<ix:nonFraction unitRef="usd" contextRef="c-794" decimals="-5" name="biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" format="ixt:num-dot-decimal" scale="6" id="f-1847">250.0</ix:nonFraction>&#160;million. The milestone payments due upon approval will be recorded as a component of other (income) expense, net within our condensed consolidated statements of income, when incurred.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If litifilimab receives regulatory approval, Royalty Pharma will be eligible to receive royalties of a mid-single digit percentage of the applicable net sales. Royalties on net sales will be recorded as cost of sales within our condensed consolidated statements of income.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MorphoSys AG</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our acquisition of HI-Bio in July 2024, we </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">acquired HI-Bio's pre-existing in-license commitments under third-party agreements with MorphoSys, which included tiered royalties on potential future sales ranging from high-single digit to mid-teen percentages, as well as potential development, regulatory and commercial milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-5" name="biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" format="ixt:num-dot-decimal" scale="6" id="f-1848">130.0</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-5" name="biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" format="ixt:num-dot-decimal" scale="6" id="f-1849">230.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-5" name="biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" format="ixt:num-dot-decimal" scale="6" id="f-1850">640.0</ix:nonFraction>&#160;million, respectively. These amounts included milestone payments due upon the first patient dosed in a Phase 3 clinical trial of felzartamab in a first and second indication of $<ix:nonFraction unitRef="usd" contextRef="c-795" decimals="-5" name="biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" format="ixt:num-dot-decimal" scale="6" id="f-1851">35.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-796" decimals="-5" name="biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" format="ixt:num-dot-decimal" scale="6" id="f-1852">30.0</ix:nonFraction>&#160;million, respectively. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2025 we accrued a milestone payment due to MorphoSys of $<ix:nonFraction unitRef="usd" contextRef="c-795" decimals="-5" name="biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" format="ixt:num-dot-decimal" scale="6" id="f-1853">35.0</ix:nonFraction>&#160;million upon the first patient dosed in a Phase 3 clinical trial of felzartamab for the treatment of AMR, which was recorded within acquired in-process research and development, upfront and milestone expense in our condensed consolidated statements of income for the nine months ended September 30, 2025, and paid in April 2025.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2025 we accrued a milestone payment due to MorphoSys of $<ix:nonFraction unitRef="usd" contextRef="c-796" decimals="-5" name="biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" format="ixt:num-dot-decimal" scale="6" id="f-1854">30.0</ix:nonFraction>&#160;million upon the first patient dosed in a Phase 3 clinical trial of felzartamab for the treatment of IgAN, which was recorded within acquired in-process research and development, upfront and milestone expense in our condensed consolidated statements of income for the nine months ended September 30, 2025, and paid in July 2025.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">City Therapeutics, Inc.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2025 we entered into a strategic research arrangement with City Therapeutics to develop select novel RNAi therapies. Through this arrangement, City Therapeutics will leverage its next-generation RNAi engineering technologies to develop an RNAi trigger molecule combined with our proprietary drug delivery technology. The collaboration will initially focus on a single target that mediates key CNS diseases, utilizing tissue enhanced delivery technologies with the aim of allowing for systemic administration of medicines. We will be responsible for IND-enabling studies and global clinical development along with any regulatory submissions and all activities related to commercialization.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the closing of this transaction we made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-797" decimals="-5" name="biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" format="ixt:num-dot-decimal" scale="6" id="f-1855"><ix:nonFraction unitRef="usd" contextRef="c-798" decimals="-5" name="biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" format="ixt:num-dot-decimal" scale="6" id="f-1856">16.0</ix:nonFraction></ix:nonFraction>&#160;million to City Therapeutics, which was recognized as acquired in-process research and development, upfront and milestone expense within our condensed consolidated statements of income for the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine months ended September 30, 2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and invested $<ix:nonFraction unitRef="usd" contextRef="c-799" decimals="-5" name="biib:CollaborativeArrangementsInvestmentsInCounterparty" format="ixt:num-dot-decimal" scale="6" id="f-1857">30.0</ix:nonFraction>&#160;million in exchange for a City Therapeutics convertible note, representing a minority equity interest in City Therapeutics, if converted. This convertible note was recorded as a component of investments and other assets within our condensed consolidated balance sheets as of</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> September 30, 2025.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-1731-7"><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also pay City Therapeutics potential research, development and sales-based milestone payments of up to $<ix:nonFraction unitRef="usd" contextRef="c-800" decimals="-5" name="biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" format="ixt:num-dot-decimal" scale="6" id="f-1858">21.5</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-801" decimals="-5" name="biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" format="ixt:num-dot-decimal" scale="6" id="f-1859">360.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-802" decimals="-5" name="biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" format="ixt:num-dot-decimal" scale="6" id="f-1860">625.0</ix:nonFraction>&#160;million, respectively, plus tiered royalties on potential future net sales, ranging from high-single digit to low-double digit percentages.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have the option to select one additional target in the collaboration, subject to an additional payment and availability of the target.</span></div></ix:continuation><div id="i59d9e1af10a84fa9992f9418986a77c7_124"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:VariableInterestEntityDisclosureTextBlock" id="f-1861" escape="true"><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 20:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Investments in Variable Interest Entities</span></div></td></tr></table></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Unconsolidated Variable Interest Entities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have relationships with various variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2025 and December 31, 2024, the carrying value of our investments in certain biotechnology companies representing potential unconsolidated variable interest entities totaled $<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" scale="6" id="f-1862">44.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" scale="6" id="f-1863">23.6</ix:nonFraction> million, respectively. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our condensed consolidated statements of income as they are incurred. We have provided no financing to these variable interest entities other than previous contractually required amounts. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our investments in variable interest entities, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 20, Investments in Variable Interest Entities,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2024 Form 10-K.</span></div></ix:nonNumeric><div id="i59d9e1af10a84fa9992f9418986a77c7_127"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LegalMattersAndContingenciesTextBlock" id="f-1864" continuedAt="f-1864-1" escape="true"><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 21:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Litigation</span></div></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently involved in various claims, investigations and legal proceedings, including the matters described below. For information as to our accounting policies relating to claims and legal proceedings, including use of estimates and contingencies, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1, Summary of Significant Accounting Policies,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2024 Form 10-K.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to some loss contingencies, an estimate of the possible loss or range of loss cannot be made until management has further information, including, for example, (i) which claims, if any, will survive dispositive motion practice; (ii) information to be obtained through discovery; (iii) information as to the parties' damages claims and supporting evidence; (iv) the parties&#8217; legal theories; and (v) the parties' settlement positions. If an estimate of the possible loss or range of loss can be made at this time, it is included in the potential loss contingency description below.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The claims and legal proceedings in which we are involved also include challenges to the scope, validity or enforceability of the patents relating to our products, pipeline or processes and challenges to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability to continue to engage in certain activities; and (iii) payment of significant damages, royalties, penalties and/or license fees to third parties.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Loss Contingencies</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Securities Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and certain current and former officers are defendants in three securities actions pending in the District Court, one filed by Nadia Shash and Amjad Khan in November 2020, which relates to statements about ADUHELM, one filed by the Oklahoma Firefighters Pension and Retirement System in February 2022, which relates to statements about ADUHELM, and one filed by Thomas Allen Gray in June 2024, which relates to statements about LEQEMBI, TECFIDERA and VUMERITY. All allege violations of federal securities laws under 15 U.S.C. &#167;78j(b) and &#167;78t(a) and 17 C.F.R. &#167;240.10b-5 and seek declarations of the actions as class actions and monetary relief.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-1864-1" continuedAt="f-1864-2"><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Actions</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and members of the Board of Directors are named as defendants in five derivative actions pending in the District Court, one filed by The Booth Family Trust in February 2022, one filed by Elaine Wang in July 2022, one filed by Jonathan Blaufarb (Blaufarb I) in July 2024, one filed by Lawrence Hollin in October 2024 and one filed by Jonathan Blaufarb (Blaufarb II) in October 2024. The Booth, Wang and Blaufarb II actions relate to ADUHELM and other matters, and the Blaufarb I and Hollin actions relate to statements about LEQEMBI, our compliance controls, 2023 earnings guidance and other matters. The actions allege breach of fiduciary duty, waste of corporate assets and other common law claims, and violations of the Securities Exchange Act of 1934, 15 U.S.C. &#167;78a et seq. The actions seek declaratory and injunctive relief, monetary relief payable to Biogen, and attorneys&#8217; fees and costs payable to the plaintiffs. All derivative actions are stayed.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">IMRALDI Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IMRALDI is an adalimumab biosimilar manufactured by Samsung Bioepis that Biogen commercializes in Europe.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, Fresenius Kabi filed a claim for damages and injunctive relief against Biogen France SAS in the Tribunal de Grande Instance de Paris alleging infringement of the French counterpart of EP &#8216;3 145 488 Patent (the EP '488 Patent) by a formulation of IMRALDI no longer commercialized in France. Fresenius Kabi alleges damages of &#8364;<ix:nonFraction unitRef="eur" contextRef="c-803" decimals="-4" name="us-gaap:LossContingencyDamagesSoughtValue" format="ixt:num-dot-decimal" scale="0" id="f-1865">13,450,000</ix:nonFraction> plus interest and costs. Biogen disputes infringement and the validity of the patent.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2025 the Higher Regional Court of D&#252;sseldorf held that a formulation of IMRALDI we no longer commercialize in Germany infringed the German counterpart of the EP '488 Patent and enjoined infringement and declared Fresenius Kabi's right to seek damages. Biogen has requested review of the decision by Germany's Federal Court of Justice and has challenged the validity of the patent in a separate proceeding.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation with Former Convergence Shareholders</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015 Biogen acquired Convergence, a U.K. company. In 2019 Shareholder Representative Services LLC, on behalf of former shareholders of Convergence, asserted claims of $<ix:nonFraction unitRef="usd" contextRef="c-804" decimals="-5" name="us-gaap:LossContingencyEstimateOfPossibleLoss" scale="6" id="f-1866">200.0</ix:nonFraction> million for alleged breaches of the contract pursuant to which we acquired Convergence and in June 2023 it and former Convergence shareholders filed a suit against us in the High Court of Justice of England and Wales asserting one of the 2019 claims and seeking payment of $<ix:nonFraction unitRef="usd" contextRef="c-805" decimals="-5" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="6" id="f-1867">49.9</ix:nonFraction>&#160;million, plus interest and costs. A final decision is pending.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Humana Patient Assistance Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2025 Humana filed suit against Biogen Inc., Biogen U.S. Corp. and Advanced Care Scripts, Inc. in Jefferson Circuit Court in Kentucky alleging damages related to providing MS patients with free medications and to charitable contributions to non-profit organizations that provide financial assistance to MS patients. Humana alleges breach of contract, fraud and other claims under various state laws and seeks damages, attorneys' fees and costs.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Genentech Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023 Genentech Inc. filed suit in the U.S. District Court for the Northern District of California claiming that it was owed royalties on sales of TYSABRI that occurred after the expiration of a patent licensed by Genentech to Biogen. In September 2025 the Court ordered that Biogen is liable to pay Genentech damages of approximately $<ix:nonFraction unitRef="usd" contextRef="c-806" decimals="-5" name="us-gaap:LossContingencyDamagesSoughtValue" format="ixt:num-dot-decimal" scale="6" id="f-1868">88.3</ix:nonFraction>&#160;million plus interest (approximately $<ix:nonFraction unitRef="usd" contextRef="c-806" decimals="-5" name="us-gaap:LitigationSettlementInterest" format="ixt:num-dot-decimal" scale="6" id="f-1869">35.9</ix:nonFraction>&#160;million as of September 30, 2025), which continues to accrue. Final judgment has not yet entered.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lender Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2025, by agreement of the parties, the court discontinued with prejudice the previously disclosed suit filed in 2024 by BioPharma Credit PLC, BPCR Limited Partnership, and BioPharma Credit Investments V (Master) LP against us and Reata Pharmaceuticals, Inc. in the Supreme Court of the State of New York alleging breach of a loan agreement.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Antitrust Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2024 we were sued by Local No. 1 Health Fund and in September 2024 we were sued by the Mayor and City Council of Baltimore, New York State Teamsters Council Health and Hospital Fund, Teamsters Local 237 Welfare Fund and Teamsters Local 237 Retirees' Benefit Fund, in cases filed in the U.S. District Court for the Northern District of Illinois. After the cases were consolidated for pre-trial purposes, these plaintiffs and UFCW Local 1500 Welfare Fund sued us in a consolidated amended complaint filed in November 2024. The plaintiffs allege violations of federal antitrust laws including 15 U.S.C. &#167;&#167; 1, 2 and 13(c) and of various state laws, based on our contracts with </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-1864-2" continuedAt="f-1864-3"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pharmacy benefit managers related to TECFIDERA and VUMERITY. Plaintiffs seek declarations of the actions as class actions, monetary, declaratory and equitable relief, and attorneys' fees and costs. In June 2025 the court dismissed the case without prejudice and granted the plaintiffs leave to amend the complaint. In August 2025 plaintiffs filed a second amended complaint adding Jacksonville Police Officers and Fire Fighters Health Insurance Trust as a plaintiff, alleging violation of the same laws as alleged in the dismissed complaint, and adding a claim under the Racketeer Influenced and Corrupt Organizations Act, 18 U.S.C. &#167;1962(c). The plaintiffs filed a third amended complaint in October 2025, removing the New York State Teamsters Council Health and Hospital Fund as a party.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2025 Walgreen Co. and The Kroger Co. filed a complaint alleging violations of 15 U.S.C. &#167;&#167; 1 and 2 based on our contracts with pharmacy benefit managers related to TECFIDERA and VUMERITY and seeking monetary, declaratory and equitable relief, and attorneys' fees and costs.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Neurimmune Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2025 we filed suit against Neurimmune Holding AG and Neurimmune Subone AG (collectively, "Neurimmune") in the District Court seeking declaratory judgment and permanent injunctive relief regarding our rights under a terminated collaboration agreement related to aducanumab. In September 2025 Neurimmune asserted counterclaims for declaratory judgment, breach of contract and unfair competition under Massachusetts G.L. 93A and seeking monetary, declaratory and equitable relief and attorneys' fees and costs.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">TECFIDERA E.U. Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023 we sued Neuraxpharm Pharmaceuticals S.L. and Neuraxpharm Netherlands B.V. (collectively, Neuraxpharm), Zaklady Farmaceutyzne Polpharma S.A. (Polpharma), Sandoz B.V. (Sandoz), Mylan Ireland Ltd. and Mylan B.V. in the District Court of Amsterdam, Netherlands for damages, alleging violation of our regulatory marketing protection by their sales of generic versions of TECFIDERA. In March 2024 we obtained an injunction against Sandoz enjoining Netherlands sales of its generic version of TECFIDERA. In October 2024 Neuraxpharm, Polpharma and Sandoz counterclaimed for damages based on our actions to enforce TECFIDERA's regulatory marketing protection.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2024 we obtained an injunction in the Danish Maritime and Commercial High Court against Sandoz A/S (reversed on appeal) enjoining Danish sales of its generic version of TECFIDERA and in June 2024 we sued Sandoz A/S for damages, alleging violation of our regulatory marketing protection. In November 2024 Sandoz A/S counterclaimed for damages based on our actions to enforce TECFIDERA's regulatory marketing protection. These cases are stayed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2025 the European General Court annulled the May 2023 European Commission decision granting TECFIDERA an additional year of regulatory marketing protection extending until February 2025.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Other Matters</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Government Investigations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2025 the SEC Division of Enforcement informed us that it has closed the matter in which we had received subpoenas seeking information relating to ADUHELM and its launch and our equity plans, and in April and May 2025 the DOJ and SEC informed us that they closed the matters in which we had received subpoenas seeking information relating to our business operations in several foreign countries.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Italian Competition Authority is investigating Biogen and other companies in relation to our biosimilar product BYOOVIZ.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2025 we received a Civil Investigative Demand from the Louisiana Department of Justice for information regarding our policies relating to the purchase of drugs by healthcare organizations that are covered entities under Section 340B of the Public Health Service Act.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">TYSABRI Biosimilar Patent Matter</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022 we filed an action in the U.S. District Court for the District of Delaware against Sandoz Inc., other Sandoz entities and Polpharma Biologics S.A. under the Biologics Price Competition and Innovation Act, 42 U.S.C. &#167;262, seeking a declaratory judgment of patent infringement. No trial date is set.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-1864-3"><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Hatch-Waxman Act Litigation relating to VUMERITY Orange-Book Listed Patents</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2023 Biogen and Alkermes Pharma Ireland Limited filed patent infringement proceedings relating to VUMERITY Orange-Book listed patents (U.S. Patent Nos. 8,669,281, 9,090,558 and 10,080,733) pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984 (the Hatch-Waxman Act) in the U.S. District Court for the District of Delaware against Zydus Worldwide DMCC, Zydus Pharmaceuticals (USA) Inc. and Zydus Lifesciences Limited. In July 2025 the parties reached a settlement and the court dismissed the case pursuant to the parties' stipulation of dismissal.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Eisai Matter</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2025 we filed a request for arbitration in the International Court of Arbitration of the International Chamber of Commerce seeking adoption of a budget and commercialization plan for the European Territory that allocates commercialization activities to Biogen and Eisai in an equitable fashion taking into account our respective capabilities and provides a meaningful role for each party.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Liability and Other Legal Proceedings</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also involved in product liability claims and other legal proceedings incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.</span></div></ix:continuation><div id="i59d9e1af10a84fa9992f9418986a77c7_130"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingDisclosureTextBlock" id="f-1870" continuedAt="f-1870-1" escape="true"><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 22:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Segment Information</span></div></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate and are managed as <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-1871">one</ix:nonFraction> operating segment, and derive revenue from activities related to the discovery, development and delivery of innovative therapies for people living with serious and complex diseases.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development organization is responsible for the research and discovery of new product candidates and supports development and registration efforts for potential future products. Our pharmaceutical, operations and technology organization manages the development of the manufacturing processes, clinical trial supply, commercial product supply, distribution, buildings and facilities. Our commercial organization is responsible for U.S. and international development of our commercial products. We are also supported by corporate staff functions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our CEO, as the CODM, manages and allocates resources to the operations of our company on a total company basis by assessing the overall level of resources available and deciding how to best deploy these resources across functions, therapeutic areas and research and development projects that are in line with our long-term company-wide strategic goals. In making these decisions, our CEO is provided with and uses consolidated financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets. The CODM performs this assessment based on the segment&#8217;s net income. Through this analysis, which includes a comparison to budgeted results, the CODM assesses performance and how to allocate resources across the functions discussed above. The measure of segment assets used in determining how to manage and allocate resources is reported within our condensed consolidated balance sheets as total assets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table presented below, which was prepared in accordance with the accounting policies discussed in </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1, Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2024 Form 10-K, contains additional information on enterprise-wide disclosures about product revenue, other revenue and long-lived assets, as well as our segment&#8217;s revenue and profits, including significant segment expense and other segment items. Revenue is primarily attributed to individual countries based on location of the customer or licensee.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:67.5pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">BIOGEN INC. AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES&#160;TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#00587f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited, continued)</span></div></div><ix:continuation id="f-1870-1" continuedAt="f-1870-2"><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Additional Segment Information</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" id="f-1872" continuedAt="f-1872-1" escape="true"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes additional information about reported segment revenue, significant segment expense and segment measure of profitability:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.110%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.841%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.256%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.116%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-807" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-1873">2,534.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-808" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-1874">2,465.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-809" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-1875">7,611.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-810" decimals="-5" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="f-1876">7,221.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less cost and expense:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of sales, excluding amortization and impairment of acquired intangible assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product cost of sales</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-811" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-1877">384.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-812" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-1878">468.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-813" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="f-1879">1,261.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-814" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="f-1880">1,204.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalty cost of sales</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-815" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-1881">290.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-816" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-1882">170.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-817" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-1883">647.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-818" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="f-1884">522.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and discovery</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-819" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="f-1885">41.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-820" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="f-1886">48.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-821" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="f-1887">131.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-822" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="f-1888">141.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Early stage programs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-823" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="f-1889">59.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-824" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="f-1890">64.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-825" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="f-1891">184.2</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-826" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="f-1892">214.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Late stage programs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-827" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="f-1893">60.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-828" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="f-1894">56.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-829" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="f-1895">154.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-830" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="f-1896">135.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketed products</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-831" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="f-1897">107.7</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-832" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="f-1898">126.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-833" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="f-1899">284.9</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-834" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="f-1900">414.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other research and development costs</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-835" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="f-1901">167.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-836" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="f-1902">221.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-837" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="f-1903">513.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-838" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" scale="6" id="f-1904">560.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquired in-process research and development, upfront and milestone expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="biib:ResearchAndDevelopmentExpenseIncludingAcquiredInProcessCost" scale="6" id="f-1905">2.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" name="biib:ResearchAndDevelopmentExpenseIncludingAcquiredInProcessCost" scale="6" id="f-1906">26.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="biib:ResearchAndDevelopmentExpenseIncludingAcquiredInProcessCost" scale="6" id="f-1907">249.4</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="biib:ResearchAndDevelopmentExpenseIncludingAcquiredInProcessCost" scale="6" id="f-1908">42.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="f-1909">594.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="f-1910">588.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-1911">1,751.1</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="f-1912">1,723.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other segment expense</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-807" decimals="-5" name="us-gaap:SegmentReportingOtherItemAmount" scale="6" id="f-1913">360.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-808" decimals="-5" name="us-gaap:SegmentReportingOtherItemAmount" scale="6" id="f-1914">307.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-809" decimals="-5" name="us-gaap:SegmentReportingOtherItemAmount" format="ixt:num-dot-decimal" scale="6" id="f-1915">1,091.0</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-810" decimals="-5" name="us-gaap:SegmentReportingOtherItemAmount" scale="6" id="f-1916">895.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net Income attributable to Biogen Inc.</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-807" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-1917">466.5</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-808" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-1918">388.5</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-809" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-1919">1,341.8</ix:nonFraction>&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-810" decimals="-5" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="f-1920">1,365.5</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:37.992%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.353%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.355%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Other research and development costs primarily consist of indirect costs incurred in support of overall research and development activities and non-specific programs, including activities that benefit multiple programs, such as management costs, as well as depreciation, information technology and facility-based expenses and are not allocated to a specific program or stage.</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:2pt;padding-left:9pt;text-indent:-9pt"><ix:continuation id="f-1872-1" continuedAt="f-1872-2"><ix:continuation id="f-1870-2" continuedAt="f-1870-3"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></ix:continuation></ix:continuation><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:continuation id="f-1872-2"><ix:continuation id="f-1870-3"> Other segment expense includes: amortization and impairment of acquired intangible assets; collaboration profit sharing/(loss reimbursement); (gain) loss on fair value remeasurement of contingent consideration; restructuring charges; gain on sale of priority review voucher, net; other (income) expense, net; and income tax (benefit) expense</ix:continuation></ix:continuation>.</span></div><div id="i59d9e1af10a84fa9992f9418986a77c7_133"></div><ix:nonNumeric contextRef="c-1" name="us-gaap:SubsequentEventsTextBlock" id="f-1921" escape="true"><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:87.205%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 23:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Subsequent Events</span></div></td></tr></table></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Vanqua Bio, Inc.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2025 we entered into a license agreement with Vanqua to acquire the worldwide rights to Vanqua's preclinical oral C5aR1 antagonist compound. In connection with the closing of this transaction, we expect to make an upfront payment to Vanqua of $<ix:nonFraction unitRef="usd" contextRef="c-839" decimals="-5" name="biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner" format="ixt:num-dot-decimal" scale="6" id="f-1922">70.0</ix:nonFraction>&#160;million during the fourth quarter of 2025, which will be recognized within acquired in-process research and development, upfront and milestone expense in our condensed consolidated statements of income.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Sale of BYOOVIZ and OPUVIZ Rights</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2025 we completed the sale of our remaining commercial rights to two ophthalmology assets in Europe: BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS, and OPUVIZ, an aflibercept biosimilar referencing EYLEA. Samsung Bioepis will have full responsibility for commercialization of BYOOVIZ upon the transfer of commercial rights from Biogen back to Samsung Bioepis, effective as of January 2026.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to recognize a minimal gain within our condensed consolidated statements of income during the fourth quarter of 2025.</span></div></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><div id="i59d9e1af10a84fa9992f9418986a77c7_136"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div></div><div><span style="color:#000000;font-family:'Franklin Gothic Demi',sans-serif;font-size:14pt;font-weight:700;line-height:120%">ITEM&#160;2.&#160;&#160;&#160;&#160;MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following discussion should be read in conjunction with our unaudited condensed consolidated financial statements (condensed consolidated financial statements) and the accompanying notes beginning on page&#160;8 of this quarterly report on Form&#160;10-Q and our audited consolidated financial statements and the accompanying notes included in our 2024 Form&#160;10-K.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations of HI-Bio, along with the estimated fair values of the assets acquired and liabilities assumed in the acquisition, have been included in our condensed consolidated financial statements since the closing of the HI-Bio acquisition on July&#160;2, 2024.</span></div><div id="i59d9e1af10a84fa9992f9418986a77c7_139"></div><div style="margin-top:11pt"><span style="color:#0070c0;font-family:'Franklin Gothic Demi',sans-serif;font-size:14pt;font-weight:400;line-height:120%">EXECUTIVE SUMMARY</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Demi',sans-serif;font-size:12pt;font-weight:400;line-height:120%">INTRODUCTION</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering innovative therapies for people living with serious and complex diseases. We have a broad portfolio of medicines to treat MS, have introduced the first approved treatment for SMA, co-developed treatments to address a defining pathology of Alzheimer&#8217;s disease and launched the first approved treatment to target a genetic cause of ALS. We market the first and only drug approved in the U.S., the E.U. and certain international markets for the treatment of FA in adults and adolescents aged 16 years and older. We are focused on advancing our pipeline in neurology, specialized immunology and rare diseases. We support our drug discovery and development efforts through internal research and development programs, external collaborations and acquisitions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY and TYSABRI for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of FA; and QALSODY for the treatment of ALS.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Supernus on the commercialization of ZURZUVAE for the treatment of PPD. We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, CLL and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL, follicular lymphoma and, following its approval in October 2025, lupus nephritis; OCREVUS for the treatment of PPMS and RMS; LUNSUMIO for the treatment of relapsed or refractory follicular lymphoma; COLUMVI, a bispecific antibody for the treatment of non-Hodgkin's lymphoma; and have the option to add other potential anti-CD20 therapies, pursuant to our collaboration arrangements with Genentech, a wholly-owned member of the Roche Group.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We commercialize a portfolio of biosimilars of advanced biologics including: BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS, in certain international markets. We also have commercialization rights related to OPUVIZ, an aflibercept biosimilar referencing EYLEA, in certain international markets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We seek to ensure an uninterrupted supply of medicines to patients around the world. To that end, we regularly review our manufacturing capacity, capabilities, processes and facilities. In order to support our future growth and drug development pipeline, we expanded our large molecule production capacity and built a large-scale biologics manufacturing facility in Solothurn, Switzerland. Solothurn is operational and has been approved for the manufacture of LEQEMBI. We believe that the Solothurn facility will support our anticipated near to mid-term needs for the manufacturing of biologic assets. The plant represents a significant increase in our overall manufacturing capacity. Additionally, we continue to invest to modernize, automate and support the capacity requirements for our pipeline and existing products at our existing manufacturing facilities in RTP, North Carolina. If we are unable to fully utilize our manufacturing facilities, we will incur additional excess capacity charges which would have a negative effect on our financial condition and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the longer term, our revenue growth will depend upon the successful clinical development, regulatory approval and launch of new commercial products as well as additional indications for our existing products, our ability to obtain and maintain patents and other rights related to our marketed products, assets originating from our research and development efforts and/or successful execution of external business development opportunities.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Demi',sans-serif;font-size:12pt;font-weight:400;line-height:120%">BUSINESS ENVIRONMENT</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biopharmaceutical industry and the markets in which we operate are intensely competitive. Many of our competitors are working to develop or have commercialized products similar to those we market. In addition, the commercialization of certain of our own approved products, products of our collaborators and pipeline product candidates may negatively impact future sales of our existing products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products and revenue streams continue to face increasing competition in many markets from the introduction of new originator therapies, generics, biosimilars of existing products and products approved under abbreviated regulatory pathways. Some of these products are likely to be sold at substantially lower prices than branded products. Accordingly, the introduction of such products as well as other lower-priced competing products has, and in the future, may significantly reduce both the price that we are able to charge for our products and the volume of products we sell, which can negatively impact our revenue. In addition, in some markets, when a generic or biosimilar version of one of our products is commercialized, it may be automatically substituted for our product and significantly reduce our revenue in a short period of time.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of our products depend, to a significant extent, on the availability and extent of adequate coverage, pricing and reimbursement from government health administration authorities, private health insurers and other organizations. When a new pharmaceutical product is approved, the availability of government and private reimbursement for that product may be uncertain, as is the pricing and amount for which that product will be reimbursed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug prices are under significant scrutiny in the markets in which our products are prescribed; for example the IRA has certain provisions related to drug pricing, including the ability for the U.S. government to set prices for certain drugs in Medicare. We expect drug pricing and other healthcare costs will continue to be subject to political and societal pressures on a global basis. As the policy environment remains dynamic, we will continue to monitor how uncertainty with respect to how the U.S. and foreign tariffs and the U.S. and international pricing may impact our business in the future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our ability to set the price for our products varies significantly from country to country and, as a result, so can the price or reimbursement of our products. Governments may use a variety of cost-containment measures to control the cost of products, including price cuts, mandatory rebates, value-based pricing and reference pricing (i.e., referencing prices in other countries and using those reference prices to set a price).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our failure to obtain or maintain adequate coverage, pricing or reimbursement for our products could have an adverse effect on our business, reputation, revenue and results of operations, could curtail or eliminate our ability to adequately fund research and development programs for the discovery and commercialization of new products and/or could cause a decline or volatility in our stock price.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the impact of competition, pricing actions and other measures being taken worldwide designed to reduce healthcare costs and limit the overall level of government expenditures, our sales and operations could also be affected by other risks of doing business internationally, including the impact of public health epidemics on employees, the global economy and the delivery of healthcare treatments, geopolitical events, tariffs, supply chain disruptions, foreign currency exchange fluctuations, changes in intellectual property legal protections and changes in trade regulations and procedures.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a detailed discussion on our business environment, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1. Business</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, in our 2024 Form 10-K. For additional information on our competition and pricing risks that could negatively impact our product sales, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> included in this report.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Demi',sans-serif;font-size:11pt;font-weight:400;line-height:120%">TECFIDERA</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Multiple TECFIDERA generic entrants are now in North America, Brazil and certain European countries and have deeply discounted prices compared to TECFIDERA. The generic competition for TECFIDERA has significantly reduced our TECFIDERA revenue and we expect that TECFIDERA revenue will continue to decline. We are defending the validity of our EP 2 653 873 patent related to TECFIDERA which expires in 2028 in opposition proceedings before the Technical Boards of Appeal of the European Patent Office in November 2025. We are also engaged in litigation in Europe to defend and enforce national counterparts of our EP 2 653 873 patent, with mixed results as we have been unsuccessful in enjoining generic entry in several significant European markets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 21, Litigation</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included in this report.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Demi',sans-serif;font-size:11pt;font-weight:400;line-height:120%">TYSABRI</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A biosimilar entrant of TYSABRI was approved in the U.S. and the E.U. in 2023. We expect that future sales of TYSABRI will continue to be adversely affected by the entrance of this biosimilar in certain international markets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Demi',sans-serif;font-size:11pt;font-weight:400;line-height:120%">GOODWILL</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We review our goodwill for impairment annually, as of October 31, and whenever events or changes in circumstances indicate that the carrying value of the goodwill may not be recoverable. As part of this analysis, we compare the fair value of our one reporting unit to its carrying value through the assessment of qualitative, and, if necessary, quantitative factors. If the carrying value of the net assets assigned to the reporting unit exceeds the fair value of our reporting unit, we will record an impairment loss equal to the difference. As of our most recent annual impairment analysis, we had no accumulated impairment losses related to goodwill.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An interim goodwill impairment test based on quantitative factors may be required if adverse events indicate an impairment might be present. We monitor changes to our share price between annual impairment tests, and we believe that general deterioration in macroeconomic and industry-specific conditions may not be indicators of a goodwill impairment, as such conditions may not represent a significant adverse change to our underlying operating performance, cash flows, financial condition or liquidity. Should our market capitalization decline below the carrying value of our net assets for a sustained period, we would consider the length and severity of the decline and the reason for the decline when assessing whether potential goodwill impairment exists.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on goodwill, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7, Intangible Assets and Goodwill</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Demi',sans-serif;font-size:12pt;font-weight:400;line-height:120%">BUSINESS UPDATE REGARDING MACROECONOMIC CONDITIONS AND OTHER POTENTIAL DISRUPTIONS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant portions of our business are conducted in Europe, Asia and other international geographies. Factors such as global health outbreaks, adverse weather events, geopolitical events, tariffs, inflation, labor or raw material shortages and other supply chain disruptions could result in product shortages or other difficulties and delays or increased costs in manufacturing our products. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Economic conditions remain uncertain as markets continue to be impacted in part by elevated inflation, higher interest rates, extreme weather events, global supply chain uncertainties and risks associated with geopolitical conflicts. Global supply chain disruptions, such as strikes, work stoppages, port congestion, port closures, trade restrictions, capacity constraints and other logistical problems, may affect our ability to do business.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Demi',sans-serif;font-size:11pt;font-weight:400;line-height:120%">INTERNATIONAL TRADE</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Global disputes and interruptions in international relationships, including tariffs, trade protection measures, embargoes, import or export licensing requirements and the imposition of trade sanctions or similar restrictions, may affect our ability to do business and the costs that we incur in providing products to our patients.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. has imposed a baseline tariff on imports from all countries, subject to certain exceptions. Trade-related tensions between the U.S. and China have led to a series of tariffs and sanctions being imposed by the U.S. on imports from China and retaliatory tariffs imposed by China on U.S. imports.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. Secretary of Commerce has further initiated an investigation to determine the effects on the national security of imports of pharmaceuticals and pharmaceutical ingredients, including finished drug products, medical countermeasures, critical inputs such as active pharmaceutical ingredients, key starting materials and derivative products of those items, under Section 232 of the Trade Expansion Act of 1962.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is a high degree of uncertainty concerning what future steps countries and economic blocs will take in response to changes in global trade rules and economics.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have significant manufacturing presence in the U.S. While our portfolio is evolving, approximately three quarters of our 2024 U.S. product revenue was attributable to products which were largely manufactured in the U.S. However, we, and the pharmaceutical industry, do utilize partners and production facilities located outside the U.S. for certain raw materials, ingredients, processes and components for our pharmaceutical products and their delivery devices. Engaging alternative suppliers may involve seeking additional regulatory approvals and incurring additional costs and risks associated with new suppliers. This may be costly in terms of time and resources needed or result in delays.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Key products that are currently manufactured mainly outside the U.S. are TECFIDERA, VUMERITY and LEQEMBI. In 2024 we initiated a technology transfer process to enable us to manufacture LEQEMBI in the U.S.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although certain starting materials for SKYCLARYS rely on a single supplier based in China, the manufacturing process, including active pharmaceutical ingredients and drug substance, is primarily conducted in the U.S.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are working to mitigate potential exposure from tariffs across our network. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently do not expect a material impact in 2025 from potential tariffs as previously announced by the U.S. Administration during 2025, even if the exemption for pharmaceuticals were to be removed. This is based on the expected timing of any potential tariffs, our manufacturing footprint, and our inventory levels and positioning, although the actual impact of tariffs on our business and financial condition may differ materially from our current expectations. We will continue to monitor the current and future global tariff landscape as it evolves.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Demi',sans-serif;font-size:11pt;font-weight:400;line-height:120%">GEOPOLITICAL TENSIONS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ongoing geopolitical tensions related to Russia's invasion of Ukraine and the military conflict in the Middle East have resulted in global business disruptions and economic volatility. For example, sanctions and other restrictions have been levied on the government and businesses in Russia. Although we do not have affiliates or employees in either Russia or Ukraine, we do provide various therapies to patients in Russia through a distributor. Government sanctions on the export of certain manufacturing materials to Russia may delay or limit our ability to get new products approved. The impact of the conflict on our operations and financial performance remains uncertain and will depend on future developments, including the severity and duration of the conflict between Russia and Ukraine, its impact on regional and global economic conditions and whether the conflict spreads or has effects on countries outside Ukraine and Russia.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to monitor the ongoing conflict between Russia and Ukraine as well as the military conflict in the Middle East and assess any potential impacts on our business, supply chain, partners or customers, as well as any factors that could have an adverse effect on our results of operations. Revenue generated from sales in Russia and Ukraine represent less than 1.0% of total revenue for the three and nine months ended September 30, 2025 and 2024. Additionally, revenue generated from sales in the Middle East region represents less than 2.0% of total revenue for the three and nine months ended September 30, 2025 and 2024.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Demi',sans-serif;font-size:12pt;font-weight:400;line-height:120%">INFLATION REDUCTION ACT OF 2022</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In August 2022 the IRA was signed into law in the U.S. The IRA introduced new tax provisions, including a 15.0% corporate alternative minimum tax and a 1.0% excise tax on stock repurchases. The provisions of the IRA are effective for periods after December 31, 2022. The IRA did not result in any material adjustments to our income tax provision for the three and nine months ended September 30, 2025 and 2024. Preliminary guidance has been issued by the IRS and we expect additional guidance and regulations to be issued in future periods. We continue to assess its potential impact on our business and results of operations as further information becomes available.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The IRA also contains substantial drug pricing reforms that may have a significant impact on the pharmaceutical industry in the U.S. This includes the following:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;allowing CMS to negotiate prices for select high-cost Medicare Part D drugs (beginning in 2026) and Part B drugs (beginning in 2028) to reduce out-of-pocket prescription drug costs for beneficiaries, potentially resulting in higher contributions from plans and manufacturers;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii)&#160;&#160;&#160;&#160;drug inflationary rebate requirements to penalize manufacturers from raising the prices of Medicare covered single-source drugs and biologics beyond the inflation-adjusted rate, beginning in 2022 for Part D drugs and 2023 for Part B drugs;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii)&#160;&#160;&#160;&#160;to incentivize biosimilar development, the IRA provides an 8.0% Medicare Part B add-on payment for qualifying biosimilar products for a five-year period; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iv)&#160;&#160;&#160;&#160;Medicare Part D redesign which replaces the current coverage gap provisions and establishes a $2,000 cap for out-of-pocket costs for Medicare beneficiaries beginning in 2025, with manufacturers being responsible for up to 10.0% of costs up to the $2,000 cap and up to 20.0% after that cap is reached. Manufacturers that qualify as either specified or specified small manufacturers will phase-in the new manufacturer liability for prescription drug costs over a 7-year period from 2025 to 2031 for certain Medicare Part D drugs dispensed to certain beneficiaries. In April 2024 CMS informed us that we qualified for the specified manufacturer exception pertaining to the Medicare Part D redesign.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect the IRA's drug pricing controls and Medicare Part D redesign may have an adverse impact on our full-year sales, particularly for our products that are more substantially reliant on Medicare reimbursement. We anticipate the IRA Medicare Part D redesign will have a modest net unfavorable impact to our 2025 revenue, ranging from approximately $50.0&#160;million to $100.0&#160;million, concentrated in our SKYCLARYS and MS portfolio product revenue, approximately a third of which could be associated with SKYCLARYS.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of impact from this legislation on our business depends on a number of forthcoming implementation actions by regulatory authorities, which may be further impacted by other legislative acts that may modify or replace the IRA, such as the OBBBA, as discussed below. The full extent of the IRA's impacts on our sales and, in turn, our business, remains uncertain.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Demi',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2025 LEGISLATION AND TAX REFORM</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 4, 2025, the U.S. signed into law the H.R.1 legislation formally titled "An Act to Provide for Reconciliation Pursuant to Title II of H. Con. Res. 14", commonly referred to as the OBBBA.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The OBBBA contains tax provisions, such as the permanent extension or revision of certain expiring provisions of the Tax Cuts and Jobs Act enacted in 2017, modifications to the international tax framework and the restoration of favorable tax treatment for certain business provisions. The provisions of the OBBBA have multiple effective dates, with certain provisions effective in 2025 and others implemented through 2027.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The OBBBA did not result in any material adjustments to our total income tax provision for the three and nine months ended September 30, 2025, and we have adjusted our deferred tax balances to reflect the impacts of the OBBBA enactment. However, given the complexity of tax laws, related regulations and interpretations, our current estimates may require revision as additional information becomes available regarding the application of the OBBBA provisions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The OBBBA also enacts significant potential changes to Medicaid funding and rescinds or does not continue elements of the PPACA. The OBBBA implements additional eligibility rules on government health plans, expands administrative procedures around enrollment, modifies how states can obtain federal funding for Medicaid and no longer extends ACA premium subsidies. Additional federal and state guidance is expected to be issued in order to implement these OBBBA provisions, most of which have effective dates in 2027 and 2028.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At this time, we are unable to determine the overall impact that the OBBBA will have on our business, results of operations and financial condition, or the impact the OBBBA will have on the pharmaceutical industry as a whole because any such impact will depend upon developing interpretations of the OBBBA provisions and implementing regulations, which may be material.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><div id="i59d9e1af10a84fa9992f9418986a77c7_142"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div><span style="color:#0070c0;font-family:'Franklin Gothic Demi',sans-serif;font-size:14pt;font-weight:400;line-height:120%">FINANCIAL HIGHLIGHTS</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"></div></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As described below under </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Results of Operations</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, our net income and diluted earnings per share attributable to Biogen Inc. for the three months ended September 30, 2025, compared to the three months ended September 30, 2024, reflects the following:</span></div><div id="i59d9e1af10a84fa9992f9418986a77c7_145"></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="border-bottom:1pt solid #0070c0;border-top:1pt solid #0070c0;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TOTAL REVENUE</span></td></tr></table></div><div><img src="biib-20250930_g2.jpg" alt="6" style="height:91px;margin-bottom:5pt;vertical-align:text-bottom;width:300px" id="i-2"/></div><div style="text-align:center"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Increased</span></div><div style="text-align:center"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$68.9 million or 2.8%</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="border-bottom:1pt solid #0070c0;border-top:1pt solid #0070c0;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DILUTED EARNINGS PER SHARE</span></td></tr></table></div><div><img src="biib-20250930_g3.jpg" alt="22" style="height:91px;margin-bottom:5pt;vertical-align:text-bottom;width:300px" id="i-3"/></div><div style="text-align:center"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Increased</span></div><div style="text-align:center"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$0.51 or 19.2%</span></div><div id="i59d9e1af10a84fa9992f9418986a77c7_148"></div></div></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:67.906%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="border-bottom:1pt solid #0070c0;border-top:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PRODUCT REVENUE, NET</span></div></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div><img src="biib-20250930_g4.jpg" alt="6" style="height:115px;margin-bottom:5pt;vertical-align:text-bottom;width:300px" id="i-4"/></div><div style="text-align:center"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Increased</span></div><div style="text-align:center"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$77.5 million or 4.4%</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="6" style="border-bottom:1pt solid #0070c0;padding:0 1pt"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.6pt">MS revenue increased $7.6 million, or 0.7%</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.6pt">Rare disease revenue increased $38.5 million, or 7.8%</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:0.5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:3.9pt">The increase in MS product revenue was primarily due to an increase in U.S. VUMERITY driven by higher demand, timing of shipments and favorable pricing dynamics, partially offset by a decrease in global TECFIDERA demand due to increased competition outside the U.S. from generic competition. MS product revenue in the U.S. also benefited from favorable commercial mix and approximately $38.0&#160;million of favorable changes in estimates from discounts and allowances.</span></div><div style="margin-top:0.5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:3.9pt">The increase in rare disease product revenue was primarily due to our new product launches, including global SKYCLARYS revenue of $132.9 million and global QALSODY revenue of $26.4 million in the third quarter of 2025.</span></div><div style="margin-top:0.5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:3.9pt">ZURZUVAE revenue of $55.3 million in the third quarter of 2025 was driven by the continued launch in the U.S.</span></div><div id="i59d9e1af10a84fa9992f9418986a77c7_151"></div></div></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:67.906%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="border-bottom:1pt solid #0070c0;border-top:1pt solid #0070c0;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TOTAL COST AND EXPENSE</span></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div><img src="biib-20250930_g5.jpg" alt="6" style="height:124px;margin-bottom:5pt;vertical-align:text-bottom;width:300px" id="i-5"/></div><div style="text-align:center"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Decreased</span></div><div style="text-align:center"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">$37.4 million or 1.9%</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="6" style="border-bottom:1pt solid #0070c0;padding:0 1pt"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.6pt">Cost of sales increased $35.7 million, or 5.6%</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.6pt">R&amp;D expense decreased $80.1 million, or 15.5%</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.6pt">SG&amp;A expense increased $6.4 million, or 1.1%</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="margin-top:0.5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:3.34pt">The increase in cost of sales was primarily due to a charge recorded during the third quarter of 2025 of approximately $104.3&#160;million related to a litigation matter and higher SKYCLARYS inventory step-up amortization costs, partially offset by lower cost of contract manufacturing revenue driven by the timing of batch releases and lower inventory write-offs during the third quarter of 2025.</span></div><div style="margin-top:0.5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:3.9pt">The decrease in R&amp;D expense was primarily driven by continued cost reduction measures realized in connection with our portfolio prioritization initiatives and our Fit for Growth program, offset in part by higher spend on clinical trials, including litifilimab and felzartamab. Higher clinical trial spend related to litifilimab was offset by $50.0 million in R&amp;D funding received from Royalty Pharma.</span></div><div style="margin-top:0.5pt;padding-left:9pt;text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8.5pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:3.34pt">The increase in SG&amp;A expense was primarily due to increases in operational spending on sales and marketing activities in support of LEQEMBI and SKYCLARYS as we continue to expand our U.S. and international product launches.</span></div><div id="i59d9e1af10a84fa9992f9418986a77c7_154"></div></div></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:67.906%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="border-bottom:1pt solid #0070c0;border-top:1pt solid #0070c0;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FINANCIAL CONDITION, LIQUIDITY AND CAPITAL RESOURCES</span></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:3.9pt">Cash, cash equivalents and marketable securities totaled approximately $4.0 billion as of September 30, 2025, compared to approximately $2.4 billion as of December 31, 2024.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:3.9pt">We generated approximately $1.7 billion of net cash flow from operations for the nine months ended September 30, 2025, compared to approximately $2.1 billion in the prior year comparative period.</span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:3.9pt">The year-over-year reduction in net cash flow from operations was due in part to higher worldwide tax payments in 2025 of approximately $840.7&#160;million driven by the timing of estimated payments.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%;padding-left:3.9pt">In May 2025 we issued our 2025 Senior Notes for an aggregate principal amount of $1.75&#160;billion. In June 2025 we used the net proceeds to redeem our 4.050% Senior Notes due September 15, 2025, prior to maturity.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><div id="i59d9e1af10a84fa9992f9418986a77c7_160"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div></div><div><span style="color:#0070c0;font-family:'Franklin Gothic Demi',sans-serif;font-size:14pt;font-weight:400;line-height:120%">RECENT DEVELOPMENTS</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Demi',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2025 ACQUISITIONS, COLLABORATIVE AND OTHER RELATIONSHIPS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Demi',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ALCYONE THERAPEUTICS, INC.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2025 we entered into a definitive agreement to acquire all of the issued and outstanding shares of Alcyone Therapeutics, Inc., a clinical-stage biotechnology company focused on pediatric care through precision CNS therapeutics and dosing platforms. Alcyone's lead asset is ThecaFlex DRx, an implantable subcutaneous port and catheter device being investigated for the intrathecal delivery of ASOs, which is designed to provide an alternative to repeat lumbar punctures in chronic intrathecal administration of medicines.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have agreed to pay an upfront cash payment of $85.0&#160;million upon closing, plus additional potential amounts payable upon the achievement of certain milestones related to the development and regulatory approval of ThecaFlex DRx for administering SPINRAZA and additional pipeline products.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to account for this proposed acquisition as an asset acquisition as the value being acquired primarily relates to a single asset and plan to record the upfront payment within acquired in-process research and development, upfront and milestone expense within our condensed consolidated statements of income upon the completion of this proposed acquisition. We anticipate the</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> proposed acquisition to close during the fourth quarter of 2025, subject to the satisfaction of customary closing conditions. U</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nder the terms of this proposed acquisition, we expect to oversee the end-to-end development, manufacturing and commercialization of ThecaFlex DRx</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alcyone's remaining therapeutic assets would be divested from Alcyone into Neela Therapeutics, Inc., a newly formed independent company, prior to the closing of this proposed acquisition. We anticipate to make a convertible debt investment of up to </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">$5.0&#160;million in Neela Therapeutics. Inc.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our proposed acquisition of Alcyone, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Demi',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CITY THERAPEUTICS, INC. COLLABORATION</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2025 we entered into a strategic research arrangement with City Therapeutics to develop select novel RNAi therapies. Through this arrangement, City Therapeutics will leverage its next-generation RNAi engineering technologies to develop an RNAi trigger molecule combined with our proprietary drug delivery technology. The collaboration will initially focus on a single target that mediates key CNS diseases, utilizing tissue enhanced delivery technologies with the aim of allowing for systemic administration of medicines. We will be responsible for IND-enabling studies and global clinical development along with any regulatory submissions and all activities related to commercialization.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the closing of this transaction we made an upfront payment of $16.0&#160;million to City Therapeutics, which was recognized as acquired in-process research and development, upfront and milestone expense within our condensed consolidated statements of income for the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine months ended September 30, 2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and invested $30.0&#160;million in exchange for a City Therapeutics convertible note, representing a minority equity interest in City Therapeutics, if converted. This convertible note was recorded as a component of investments and other assets within our condensed consolidated balance sheets as of</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> September 30, 2025.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our strategic research arrangement with City Therapeutics, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Demi',sans-serif;font-size:12pt;font-weight:400;line-height:120%">STOKE THERAPEUTICS, INC. COLLABORATION</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2025 we entered into a collaboration and license agreement with Stoke to co-develop and commercialize zorevunersen, an investigational ASO that targets the SCN1A gene for the potential treatment of Dravet syndrome, a rare form of genetic epilepsy associated with refractory seizures and neurodevelopmental impairments. Zorevunersen dosed its first patient in August 2025, advancing zorevunersen to a global Phase 3 trial. Under the terms of this agreement, Stoke will continue to lead global development and retain exclusive development and commercialization rights for zorevunersen in the U.S., Canada and Mexico and we will have exclusive rights to commercialize zorevunersen in the rest of the world.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the closing of this transaction we made an upfront payment of $165.0&#160;million to Stoke, which was recognized as acquired in-process research and development, upfront and milestone expense within our condensed consolidated statements of income for the nine months ended September 30, 2025.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have an exclusive option to license certain future follow-on ASO products targeting the SCN1A gene in all territories worldwide other than the U.S., Canada and Mexico, in exchange for separate milestone, cost sharing and royalty considerations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangement with Stoke, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Demi',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ROYALTY PHARMA FUNDING ARRANGEMENT</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2025 we entered into a funding agreement with Royalty Pharma under which we will receive up to $200.0&#160;million in 2025 and up to $50.0&#160;million in 2026 to co-fund our development costs for the litifilimab program. As there is a substantive transfer of risk to the financial partner for the amount invested, the development funding will be recognized by us as an obligation to perform contractual services. We plan to recognize this funding as a reduction to research and development expense within our condensed consolidated statements of income, proportionate to the related expense. For the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three and nine months ended September 30, 2025, </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we recorded reductions to research and development e</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">xpense of $50.0 million and $150.0&#160;million, respectiv</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ely, within our condensed consolidated statements of income.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the litifilimab clinical trials are successful for the indications based on the applicable clinical trials, upon regulatory approval in the U.S. or certain major markets in the world, Royalty Pharma will be eligible to receive approval-based fixed milestone payments of up to a total of $250.0&#160;million. The milestone payments due upon approval will be recorded as a component of other (income) expense, net within our condensed consolidated statements of income, when incurred.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If litifilimab receives regulatory approval, Royalty Pharma will be eligible to receive royalties of a mid-single digit percentage of the applicable net sales. Royalties on net sales will be recorded as cost of sales within our condensed consolidated statements of income.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our funding arrangement with Royalty Pharma, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Demi',sans-serif;font-size:12pt;font-weight:400;line-height:120%">DEVELOPMENTS IN KEY COLLABORATIVE RELATIONSHIPS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Demi',sans-serif;font-size:12pt;font-weight:400;line-height:120%">LEQEMBI (lecanemab)</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">United States</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Key developments related to LEQEMBI in the U.S. consisted of the following:</span></div><div style="margin-top:5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">In August 2025 the FDA approved the BLA for LEQEMBI subcutaneous autoinjector (IQLIK) for weekly maintenance dosing.</span></div><div style="margin-top:5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">In January 2025 the FDA approved LEQEMBI monthly IV maintenance dosing for the treatment of early Alzheimer's disease.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rest of World</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Key developments related to LEQEMBI (lecanemab) in rest of world markets consisted of the following:</span></div><div style="margin-top:5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">In October 2025 Health Canada issued a Notice of Compliance with Conditions for LEQEMBI for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment or mild dementia due to Alzheimer's disease who are either apolipoprotein E &#949;4 non-carriers or heterozygotes and who have confirmed amyloid pathology.</span></div><div style="margin-top:5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">In September 2025 the National Medical Products Administration in China approved LEQEMBI monthly IV maintenance dosing for the treatment of early Alzheimer's disease.</span></div><div style="margin-top:5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">In September 2025 the Therapeutic Goods Administration of Australia approved LEQEMBI for adults who are either apolipoprotein E &#949;4 non-carriers or heterozygous carriers.</span></div><div style="margin-top:5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">In June 2025 we filed a request for arbitration in the International Court of Arbitration of the International Chamber of Commerce seeking adoption of a budget and commercialization plan for the European Territory that allocates commercialization activities to Biogen and Eisai in an equitable fashion taking into account our respective capabilities and provides a meaningful role for each party.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div></div><div style="margin-top:5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">In April 2025 the EC approved LEQEMBI in the E.U. for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer's disease who are apolipoprotein E &#949;4 non-carriers or heterozygotes with confirmed amyloid pathology.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Demi',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ZURZUVAE (zuranolone)</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">In September 2025 the EC approved ZURZUVAE in the E.U. for the treatment of PPD in adults following childbirth, offering the first and only treatment indicated for PPD in the E.U.</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">In August 2025 the Medicines and Healthcare products Regulatory Agency in the U.K. granted marketing authorization for ZURZUVAE for moderate to severe PPD in the U.K.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Demi',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SALANERSEN (BIIB115)</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">In June 2025 we announced positive topline results from the Phase 1b study of salanersen, an ASO being developed for the treatment of SMA. Interim Phase 1b data shows children with SMA previously treated with gene therapy experienced a substantial slowing of neurodegeneration and clinically meaningful improvements in motor function following initiation of salanersen. We are currently engaging with regulators about the possibility of advancing salanersen to a Phase 3 registrational study.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Demi',sans-serif;font-size:12pt;font-weight:400;line-height:120%">OTHER KEY DEVELOPMENTS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Demi',sans-serif;font-size:12pt;font-weight:400;line-height:120%">FELZARTAMAB</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">In June 2025 we announced the initiation of dosing in the global Phase 3 PREVAIL study. This study will evaluate the efficacy and safety of the investigational drug felzartamab compared to placebo on proteinuria and preservation of kidney function in adults diagnosed with IgAN. In connection with the initiation of this dosing we accrued a $30.0&#160;million milestone payment to MorphoSys, which was subsequently paid in July 2025. Additionally, in June 2025 we announced the initiation of dosing in the global Phase 3 PROMINENT study. This study will evaluate the efficacy and safety of the investigational drug felzartamab compared to tacrolimus in adults diagnosed with PMN.</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">In March 2025 we announced the initiation of dosing in the global Phase 3 TRANSCEND study. This study will evaluate the efficacy and safety of the investigational drug felzartamab compared to placebo in adult kidney transplant recipients diagnosed with late AMR. In connection with the initiation of this dosing we paid a $35.0&#160;million milestone payment to MorphoSys in April 2025.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Demi',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SPINRAZA (nusinersen)</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">In September 2025 the FDA issued a CRL for the supplemental NDA for a higher dose regimen of nusinersen for the treatment of SMA. The CRL requested an update to the technical information to be included in the Chemistry Manufacturing and Controls module of the supplemental NDA and did not cite any deficiencies in the clinical data of the high dose regimen. The CRL provided options for resolution and we have announced a plan to resubmit the application promptly based upon readily available information.</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">In January 2025 the FDA accepted for review the supplemental NDA and the EMA validated the application for a higher dose regimen of nusinersen for SMA. The higher dose regimen of nusinersen comprises a more rapid loading regimen, two 50 mg-doses 14 days apart, and higher maintenance regimen, 28 mg, every four months, compared to the currently approved dose of SPINRAZA.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Demi',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SKYCLARYS (omaveloxolone)</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">In June 2025 we announced the initiation of dosing in the global Phase 3 BRAVE study. This study will evaluate the efficacy and safety of omaveloxolone in children with FA between the ages of two and sixteen years old.</span></div><div style="margin-top:5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">In April 2025 SKYCLARYS was approved by the Medicines and Healthcare products Regulatory Agency in the U.K. and in Brazil. In March 2025 SKYCLARYS was approved by Health Canada.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Demi',sans-serif;font-size:12pt;font-weight:400;line-height:120%">QALSODY (tofersen)</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">In July 2025 the Medicines and Healthcare products Regulatory Agency in the U.K. approved QALSODY for the treatment of ALS in adults who have a mutation in the SOD1 gene.</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">In March 2025 Health Canada issued marketing authorization with conditions for QALSODY for the treatment of ALS in adults who have a mutation in the SOD1 gene. The authorization is conditional, pending the results of trials to verify its clinical benefit.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Demi',sans-serif;font-size:12pt;font-weight:400;line-height:120%">BIIB080</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">In April 2025 the FDA granted Fast Track designation to BIIB080, an investigational ASO therapy targeting tau for the potential treatment of Alzheimer's disease.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Demi',sans-serif;font-size:12pt;font-weight:400;line-height:112%">DISCONTINUED PROGRAMS AND STUDIES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Demi',sans-serif;font-size:12pt;font-weight:400;line-height:112%">SALE OF TOFIDENCE</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2025 we completed the sale of our regulatory and commercial rights in the U.S. for TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA, to Organon. Under the terms of this transaction, we received a payment of approximately $51.0&#160;million </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in July 2025 a</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nd recognized a de minimis loss within our condensed consolidated statements of income for the nine months ended September 30, 2025.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our sale of TOFIDENCE, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3, Dispositions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Demi',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CORPORATE MATTERS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Demi',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2025 SENIOR NOTES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 12, 2025, we issued our 2025 Senior Notes for an aggregate principal amount of $1.75&#160;billion. In June 2025 we used the net proceeds from the sale of our 2025 Senior Notes to redeem our 4.050% Senior Notes due September 15, 2025, prior to maturity.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information relating to our 2025 Senior Notes, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 13, Indebtedness</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Demi',sans-serif;font-size:12pt;font-weight:400;line-height:120%">NEW CORPORATE HEADQUARTERS LEASE</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2025 we entered into a lease agreement with MIT Investment Management Company and BioMed Realty for the lease of approximately 580,000 square feet of office and research and development space located at 75 Broadway, Cambridge, Massachusetts, which will be used as our new global corporate headquarters, as well as integrating our research and development and technical operations teams alongside our North American commercial organization. As part of a multi-year real estate consolidation plan that is expected to result in a reduction of approximately 40% of our real estate footprint in Massachusetts, this new lease is intended to replace two existing leases, both in Cambridge, Massachusetts, including our current corporate headquarters. We expect the initial lease term of approximately 15.5 years to commence on May 31, 2028.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our lease agreement, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 12, Leases, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our condensed consolidated financial statements included in this report.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><div id="i59d9e1af10a84fa9992f9418986a77c7_163"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div></div><div style="margin-top:13pt"><span style="color:#00587f;font-family:'Franklin Gothic Demi',sans-serif;font-size:14pt;font-weight:400;line-height:120%">RESULTS OF OPERATIONS</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Demi',sans-serif;font-size:12pt;font-weight:400;line-height:120%">REVENUE</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following revenue discussion should be read in conjunction with </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 5, Revenue</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included in this report. Revenue is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.703%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product revenue, net:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">935.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">813.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">122.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">911.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">956.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(44.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,846.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,769.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">493.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">446.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Alzheimer's collaboration revenue</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract manufacturing, royalty and other revenue</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">151.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">231.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(80.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(34.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,534.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,465.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product revenue, net:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,630.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,405.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">224.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rest of world</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,821.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">37.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,975.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(153.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,452.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,380.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,339.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,284.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Alzheimer's collaboration revenue</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">130.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">293.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract manufacturing, royalty and other revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">689.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">522.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">166.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,611.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,221.2&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">390.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Alzheimer's collaboration revenue consists of our 50.0% share of LEQEMBI product revenue, net and cost of sales, including royalties.</span></div><div id="i59d9e1af10a84fa9992f9418986a77c7_166"></div><div style="margin-top:12pt"><span style="color:#0070c0;font-family:'Franklin Gothic Demi',sans-serif;font-size:12pt;font-weight:400;line-height:120%">PRODUCT REVENUE</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product revenue is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:19.367%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.186%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.186%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.786%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="57" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%<br/>Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%<br/>Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$<br/>Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">642.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">418.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,061.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">546.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">507.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,053.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rare Disease</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">235.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">298.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">533.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">240.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">254.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">494.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biosimilars</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">194.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">196.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">192.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">196.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue, net</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">935.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">911.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,846.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">813.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">956.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,769.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="57" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="21" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%<br/>Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%<br/>Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$<br/>Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,790.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,331.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,121.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,631.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,648.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,279.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(157.9)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rare Disease</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">700.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">938.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,639.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">703.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">749.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,452.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">186.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biosimilars</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">550.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">559.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">572.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">591.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(32.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue, net</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,630.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,821.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,452.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,405.8&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,975.1&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,380.9&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Other includes ZURZUVAE, FUMADERM and ADUHELM.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><div id="i59d9e1af10a84fa9992f9418986a77c7_169"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:67.906%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Demi',sans-serif;font-size:12pt;font-weight:400;line-height:100%">MULTIPLE SCLEROSIS</span></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-bottom:15pt"><img src="biib-20250930_g6.jpg" alt="6" style="height:250px;margin-bottom:5pt;vertical-align:text-bottom;width:300px" id="i-6"/></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.6pt">Global VUMERITY revenue increased $56.5 million, from $158.1 million in 2024 to $214.6 million in 2025, or 35.7%, primarily due to an increase in U.S. VUMERITY driven by higher demand, timing of shipments and favorable pricing dynamics, as well as a favorable change in estimate of approximately $13.0&#160;million related to rebates and discounts in the U.S.</span></div><div style="text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.6pt">Global TYSABRI revenue increased $25.7 million, from $406.1 million in 2024 to $431.8 million in 2025, or 6.3%, primarily due to higher net pricing in the U.S. and a favorable change in estimate related to rebates and discounts in the U.S., partially offset by a decrease in global TYSABRI demand due to increased competition, including the impacts from a biosimilar entrant of TYSABRI in Europe.</span></div><div style="text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.6pt">Global Interferon revenue increased $9.4 million, from $237.5 million in 2024 to $246.9 million in 2025, or 4.0%, primarily due to a favorable change in estimate of approximately $18.0&#160;million related to rebates and discounts. This increase was partially offset by a decrease in rest of world Interferon revenue as patients continue to transition to higher efficacy therapies.</span></div><div style="margin-top:2pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.6pt">Global TECFIDERA revenue decreased $64.6 million, from $232.8 million in 2024 to $168.2 million in 2025, or 27.7%, driven by a decrease in demand resulting from multiple TECFIDERA generic entrants.</span></div></div></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:67.906%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="6" style="border-bottom:0.5pt solid #679acb;padding:0 1pt"/></tr></table></div><div id="i59d9e1af10a84fa9992f9418986a77c7_172"></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-bottom:15pt"><img src="biib-20250930_g7.jpg" alt="4" style="height:250px;margin-bottom:5pt;vertical-align:text-bottom;width:300px" id="i-7"/></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.6pt">Global VUMERITY revenue increased $114.3 million, from $451.4 million in 2024 to $565.7 million in 2025, or 25.3%, primarily due to an increase in U.S. VUMERITY driven by higher demand and a favorable change in estimate of approximately $40.0&#160;million related to rebates and discounts in the U.S., partially offset by charges related to the IRA redesign.</span></div><div style="text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.6pt">Global TYSABRI revenue decreased $31.7 million, from $1,299.6 million in 2024 to $1,267.9 million in 2025, or 2.4%, primarily due to increased competition in rest of world, including the impacts from a biosimilar entrant of TYSABRI in Europe. The decrease was partially offset by a favorable change in estimate of approximately $16.0&#160;million related to rebates and discounts and favorable inventory dynamics in the U.S.</span></div><div style="text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.6pt">Global Interferon revenue decreased $12.1 million, from $732.0 million in 2024 to $719.9 million in 2025, or 1.7%, driven by a decrease in demand as patients transition to higher efficacy therapies, offset in part by a favorable change in estimate of approximately $32.0&#160;million related to rebates and discounts in the U.S.</span></div><div style="margin-top:2pt;text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:3.6pt">Global TECFIDERA revenue decreased $171.4 million, from $739.3 million in 2024 to $567.9 million in 2025, or 23.2%, driven by a decrease in demand as a result of multiple TECFIDERA generic entrants.</span></div><div id="i59d9e1af10a84fa9992f9418986a77c7_175"></div></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:67.906%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"/></tr></table><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MS revenue includes sales from TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA. Effective January 1, 2025, our collaboration and license agreement for FAMPYRA global commercialization rights was terminated and we expect to recognize minimal revenue in 2025.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2025 we expect total MS revenue will continue to decline as a result of increasing competition for many of our MS products in both the U.S. and rest of world markets. We expect TECFIDERA revenue will be adversely impacted by accelerating generic competition in certain markets in the E.U. for at least the remainder of the year. Additionally, a biosimilar entrant of TYSABRI was approved in the U.S. and the E.U. in 2023. We expect that future sales of TYSABRI will continue to be adversely affected by the entrance of this biosimilar in certain international markets.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><div id="i59d9e1af10a84fa9992f9418986a77c7_178"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:67.906%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Demi',sans-serif;font-size:12pt;font-weight:400;line-height:100%">RARE DISEASE</span></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><img src="biib-20250930_g8.jpg" alt="6" style="height:432px;margin-bottom:5pt;vertical-align:text-bottom;width:300px" id="i-8"/></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:12.3pt">U.S. SPINRAZA revenue increased $0.1 million, from $153.1 million in 2024 to $153.2 million in 2025, or 0.1%.</span></div><div style="margin-top:3pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:12.3pt">Rest of world SPINRAZA revenue decreased $7.5 million, from $228.3 million in 2024 to $220.8 million in 2025, or 3.3%, partially due to lower demand and pricing adjustments during the third quarter of 2025, partially offset by the favorable impact of foreign currency exchange.</span></div><div style="margin-top:3pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:12.3pt">Global SKYCLARYS revenue increased $30.6 million, from $102.3 million in 2024 to $132.9 million in 2025, or 29.9%, primarily related to an increase in rest of world sales volumes driven by the continued launch in Europe and certain markets in the Middle East, partially offset by an unfavorable Medicare-related adjustment in the U.S. during the third quarter of 2025 resulting from the IRA redesign.</span></div><div style="margin-top:3pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:12.3pt">Global QALSODY revenue increased $15.3 million, from $11.1 million in 2024 to $26.4 million in 2025, or 137.8%, primarily related to an increase in rest of world sales volumes driven by the continued launch in international markets.</span></div></div></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:67.906%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="6" style="border-bottom:0.25pt dotted #0070c0;padding:0 1pt"/></tr></table></div><div id="i59d9e1af10a84fa9992f9418986a77c7_181"></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div><img src="biib-20250930_g9.jpg" alt="4" style="height:345px;margin-bottom:5pt;vertical-align:text-bottom;width:300px" id="i-9"/></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:12.3pt">U.S. SPINRAZA revenue decreased $2.0 million, from $458.9 million in 2024 to $456.9 million in 2025, or 0.4%.</span></div><div style="margin-top:3pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:12.3pt">Rest of world SPINRAZA revenue increased $40.8 million, from $692.9 million in 2024 to $733.7 million in 2025, or 5.9%, partially due to a one-time VAT refund received in 2025 of approximately $18.1&#160;million and the timing of shipments in rest of world markets, partially offset by lower demand and the unfavorable impact of foreign currency exchange.</span></div><div style="margin-top:3pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:12.3pt">Global SKYCLARYS revenue increased $106.8 million, from $280.3 million in 2024 to $387.1 million in 2025, or 38.1%, primarily related to an increase in rest of world sales volumes driven by the continued launch in Europe and certain markets in the Middle East.</span></div><div style="margin-top:3pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%;padding-left:12.3pt">Global QALSODY revenue</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.5pt;font-weight:400;line-height:120%">increased $41.2 million, from $20.7 million in 2024 to $61.9 million in 2025, or 199.0%, primarily related to an increase in rest of world sales volumes driven by the continued launch in international markets.</span></div><div id="i59d9e1af10a84fa9992f9418986a77c7_184"></div></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:67.906%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rare disease revenue includes sales from SPINRAZA, QALSODY and SKYCLARYS, which became commercially available in the E.U. during the first quarter of 2024.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2025 we expect growth in rare disease revenue as we continue to launch SKYCLARYS in the U.S., Europe and in certain rest of world markets. We anticipate global SPINRAZA revenue growth to be relatively flat in 2025.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><div id="i59d9e1af10a84fa9992f9418986a77c7_187"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:67.906%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Demi',sans-serif;font-size:11pt;font-weight:400;line-height:100%">BIOSIMILARS</span></td></tr></table></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div style="margin-bottom:15pt"><img src="biib-20250930_g10.jpg" alt="6" style="height:576px;margin-bottom:5pt;vertical-align:text-bottom;width:316px" id="i-10"/></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div style="text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.34pt">For the three months ended September 30, 2025, compared to the same period of 2024, the increase in biosimilar revenue was primarily due to an increase in pricing driven by a one-time VAT refund received during the third quarter of 2025. The increase was offset by a decrease in sales volumes related to IMRALDI.</span></div><div style="margin-top:3pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">For the nine months ended September 30, 2025, compared to the same period in 2024, the decrease in biosimilar revenue was primarily due to a decrease in sales volumes related to IMRALDI, the unfavorable impact of foreign currency exchange and a decrease in pricing due to competitive pressures in Europe</span><span style="color:#ee2724;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt"><span><br/></span></div><div id="i59d9e1af10a84fa9992f9418986a77c7_193"></div></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.894%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:67.906%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="6" style="border-bottom:0.25pt dotted #0070c0;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biosimilars revenue includes sales from BENEPALI, IMRALDI, FLIXABI, BYOOVIZ and TOFIDENCE. In 2025 we completed the sale of our rights to TOFIDENCE and BYOOVIZ.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to work with our third-party contract manufacturers for IMRALDI and BENEPALI to address supply constraints. If not resolved these supply constraints could have an adverse impact on 2025 sales. In addition, one of our contract manufacturers for IMRALDI and BENEPALI was acquired by a third party in December 2024. We have evaluated the impact this will have on our biosimilars business and have mitigation activities in progress designed to ensure supply continuity.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><div id="i59d9e1af10a84fa9992f9418986a77c7_196"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Demi',sans-serif;font-size:12pt;font-weight:400;line-height:120%">REVENUE FROM ANTI-CD20 THERAPEUTIC PROGRAMS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our share of RITUXAN, including RITUXAN HYCELA, GAZYVA and LUNSUMIO collaboration operating profits in the U.S., royalty revenue on sales of OCREVUS and other revenue from anti-CD20 therapeutic programs are summarized in the table below. For purposes of this discussion, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.987%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.993%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalty revenue on sales of OCREVUS</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">386.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">346.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,029.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">985.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen&#8217;s share of pre-tax profits in the U.S. for RITUXAN, GAZYVA and LUNSUMIO</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">94.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">292.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">285.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">493.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">446.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,339.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,284.7&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Demi',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ROYALTY REVENUE ON SALES OF OCREVUS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2025, compared to the same periods in 2024, the increases in royalty revenue on sales of OCREVUS were primarily due to sales growth of OCREVUS in the U.S.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OCREVUS royalty revenue is based on our estimates from third party and market research data of OCREVUS sales occurring during the corresponding period. Differences between actual and estimated royalty revenue will be adjusted for in the period in which they become known, which is generally expected to be the following quarter.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Demi',sans-serif;font-size:12pt;font-weight:400;line-height:120%">BIOGEN'S SHARE OF PRE-TAX PROFITS IN THE U.S. FOR RITUXAN, GAZYVA AND LUNSUMIO</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2025, compared to the same periods in 2024, the increases in our share of pre-tax profits in the U.S. for RITUXAN, GAZYVA and LUNSUMIO were primarily due to increases in sales volumes of GAZYVA of 8.7% and 12.9%, respectively.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Demi',sans-serif;font-size:12pt;font-weight:400;line-height:120%">OTHER REVENUE FROM ANTI-CD20 THERAPEUTIC PROGRAMS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other revenue from anti-CD20 therapeutic programs consists of our share of pre-tax co-promotion profits from RITUXAN in Canada, royalty revenue on sales of LUNSUMIO outside the U.S. and royalty revenue on net sales of COLUMVI in the U.S.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Genentech, including information regarding the pre-tax profit-sharing formula and its impact on future revenue from anti-CD20 therapeutic programs, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div id="i59d9e1af10a84fa9992f9418986a77c7_199"></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Demi',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ALZHEIMER'S COLLABORATION REVENUE</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alzheimer's collaboration revenue consists of our 50.0% share of LEQEMBI product revenue, net and cost of sales, including royalties, as we are not the principal. We began recognizing Alzheimer's collaboration revenue upon the accelerated approval of LEQEMBI in the U.S. during the first quarter of 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2025, we recognized Alzheimer's collaboration revenue of approximately $42.7 million and $130.6 million, respectively, compared to $18.6 million and $33.2 million, respectively, in the prior year comparative periods. The increases were primarily due to higher sales volumes driven by the continued launch of LEQEMBI in the U.S. and international markets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, for the nine months ended September 30, 2025, Alzheimer's collaboration revenue reflects the favorable impact from the timing of shipments to China during the second quarter of 2025 as we optimized our global inventory positions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Eisai, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our condensed consolidated financial statements included in this report.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><div id="i59d9e1af10a84fa9992f9418986a77c7_202"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Demi',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CONTRACT MANUFACTURING, ROYALTY AND OTHER REVENUE</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract manufacturing, royalty and other revenue is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.455%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.285%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract manufacturing revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">141.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">221.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">648.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">474.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalty and other revenue</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total contract manufacturing, royalty and other revenue</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">151.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">231.6&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">689.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">522.4&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Demi',sans-serif;font-size:11pt;font-weight:400;line-height:120%">CONTRACT MANUFACTURING REVENUE</span></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract manufacturing revenue primarily reflects amounts earned under contract manufacturing agreements with our strategic customers and batches of LEQEMBI related to our collaboration with Eisai.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended September 30, 2025, compared to the same period in 2024, the decrease in contract manufacturing revenue was primarily due to lower manufacturing batch releases during the third quarter of 2025 driven by the acceleration of timing for manufacturing batch releases during the first half of 2025, as discussed below.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2025, compared to the same period in 2024, the increase in contract manufacturing revenue was primarily driven by the accelerated timing of certain batch commitments related to our contract manufacturing business during the first half of 2025 in preparation for expected plant maintenance activities in the fourth quarter of 2025.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Full-year contract manufacturing revenue for 2025 is anticipated to remain relatively flat when compared to 2024, due in part to planned plant maintenance activities in the fourth quarter of 2025.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Demi',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ROYALTY AND OTHER REVENUE</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty and other revenue primarily reflects royalty revenue on biosimilar products from our license arrangements with Samsung Bioepis and royalties we receive from net sales on products related to patents that we have out-licensed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our license arrangements with Samsung Bioepis and our collaboration arrangements with Eisai, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our condensed consolidated financial statements included in this report.</span></div><div id="i59d9e1af10a84fa9992f9418986a77c7_205"></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Demi',sans-serif;font-size:12pt;font-weight:400;line-height:120%">RESERVES FOR DISCOUNTS AND ALLOWANCES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from product sales is recorded net of reserves established for applicable discounts and allowances, including those associated with the implementation of pricing actions in certain international markets where we operate.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect the IRA's drug pricing controls and Medicare Part D redesign may have an adverse impact on our full-year sales, particularly for our products that are more substantially reliant on Medicare reimbursement. We anticipate the IRA Medicare Part D redesign will have a modest net unfavorable impact to our 2025 revenue, ranging from approximately $50.0&#160;million to $100.0&#160;million, concentrated in our SKYCLARYS and MS portfolio product revenue, approximately a third of which could be associated with SKYCLARYS. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The degree of impact from this legislation on our business depends on a number of forthcoming implementation actions by regulatory authorities, which may be further impacted by other legislative acts that may modify or replace the IRA, such as the OBBBA. The full extent of the IRA's impacts on our sales and, in turn, our business, remains uncertain.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reserves for discounts, contractual adjustments and returns that reduced gross product revenue are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.040%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.284%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contractual adjustments</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">632.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">643.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,970.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,971.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discounts</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">213.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">207.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">609.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">612.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Returns</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total discounts and allowances</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">849.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">856.4&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,601.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,612.5&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2025, reserves for discounts and allowances as a percentage of gross product revenue were 31.2% and 32.0%, respectively, compared to 32.6% and 32.4%, respectively, in the prior year comparative periods. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Demi',sans-serif;font-size:11pt;font-weight:400;line-height:120%">CONTRACTUAL ADJUSTMENTS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contractual adjustments primarily relate to Medicaid and managed care rebates in the U.S., pharmacy rebates, co-payment (copay) assistance, VA, 340B discounts, specialty pharmacy program fees and other government rebates or applicable allowances.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2025, compared to the same periods in 2024, the decreases in contractual adjustments were driven by favorable changes in estimates of approximately $45.0&#160;million and $105.0&#160;million, respectively, primarily due to lower managed care rebates, as well as lower co-pay assistance and Medicaid rebates in the U.S., offset in part by higher Medicare manufacturer reserves driven by the IRA Medicare Part D redesign and higher government rebates in rest of world.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Demi',sans-serif;font-size:11pt;font-weight:400;line-height:120%">DISCOUNTS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discounts include trade term discounts, wholesaler incentives and volume related discounts.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended September 30, 2025, compared to the same period in 2024, the increase in discounts was primarily driven by higher volume discounts in the U.S. and rest of world for TYSABRI, partially offset by lower purchase discounts in rest of world.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2025, compared to the same period in 2024, the decrease in discounts was primarily driven by lower purchase discounts in rest of world and lower volume discounts for U.S. biosimilars, partially offset by higher volume discounts in the U.S. for TYSABRI.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Demi',sans-serif;font-size:11pt;font-weight:400;line-height:120%">RETURNS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product return reserves are established for returns made by wholesalers. In accordance with contractual terms, wholesalers are permitted to return product for reasons such as damaged or expired product. The majority of wholesaler returns are due to product expiration. Provisions for estimated product returns are recognized in the period the related revenue is recognized, resulting in a reduction to product sales.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For the three and nine months ended September 30, 2025, compared to the same periods in 2024, the decreases in returns were primarily driven by lower returns in the U.S., partially offset by higher returns in rest of world.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our revenue reserves, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 5, Revenue,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><div id="i59d9e1af10a84fa9992f9418986a77c7_208"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Demi',sans-serif;font-size:14pt;font-weight:400;line-height:120%">COST AND EXPENSE</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of total cost and expense is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.412%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.613%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.615%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of sales, excluding amortization and impairment of acquired intangible assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">674.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">638.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">436.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">516.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(80.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquired in-process research and development, upfront and milestone expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(92.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">594.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">588.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and impairment of acquired intangible assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">135.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">130.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration profit sharing/(loss reimbursement)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gain) loss on fair value remeasurement of contingent consideration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(18.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(76.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">130.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total cost and expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,977.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,014.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(37.4)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of sales, excluding amortization and impairment of acquired intangible assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,908.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,726.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">181.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,269.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,467.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(197.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(13.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquired in-process research and development, upfront and milestone expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">249.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">206.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">486.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,751.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,723.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization and impairment of acquired intangible assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">378.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">295.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration profit sharing/(loss reimbursement)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">220.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">197.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gain) loss on fair value remeasurement of contingent consideration</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gain on sale of priority review voucher, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(88.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">nm</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">151.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">193.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(42.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(21.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total cost and expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,998.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,606.7&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">392.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">nm</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Not meaningful</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><div id="i59d9e1af10a84fa9992f9418986a77c7_211"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Demi',sans-serif;font-size:12pt;font-weight:400;line-height:120%">COST OF SALES, EXCLUDING AMORTIZATION AND IMPAIRMENT OF ACQUIRED INTANGIBLE ASSETS</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.040%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.284%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">384.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">468.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,261.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,204.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalty</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">290.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">647.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">522.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total cost of sales</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">674.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">638.7&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,908.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,726.9&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Demi',sans-serif;font-size:11pt;font-weight:700;line-height:120%">PRODUCT COST OF SALES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended September 30, 2025, compared to the same period in 2024, the decrease in product cost of sales was primarily due to lower cost of contract manufacturing revenue driven by the timing of batch releases and lower inventory write-offs, partially offset by higher SKYCLARYS inventory step-up amortization costs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2025, compared to the same period in 2024, the increase in product cost of sales was primarily due to higher contract manufacturing revenue driven by the timing of batch releases and higher SKYCLARYS inventory step-up amortization costs, partially offset by lower inventory write-offs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract manufacturing revenue includes LEQEMBI inventory produced for Eisai. Cost of sales as a percentage of revenue was adversely affected by LEQEMBI batches due to lower margins associated with this business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our acquisition of Reata in September 2023 we recorded a fair value step-up adjustment related to the acquired inventory of SKYCLARYS. This fair value step-up adjustment is being amortized to cost of sales within our condensed consolidated statements of income as the inventory is sold or used for clinical purposes. We expect this amount to be fully amortized by the end of 2028. For the three and nine months ended September 30, 2025, amortization from the fair value step-up adjustment was approximately $61.5&#160;million and $165.4 million, respectively, compared to $48.4 million and $136.6 million, respectively, in the prior year comparative periods.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Eisai, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our condensed consolidated financial statements included in this report. For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2024 Form 10-K.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:5pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Write Downs and Other Charges</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had no significant gross idle capacity charges for the three and nine months ended September 30, 2025 and 2024.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Demi',sans-serif;font-size:11pt;font-weight:700;line-height:120%">ROYALTY COST OF SALES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, 2025, compared to the same periods in 2024,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the increases in royalty cost of sales were primarily due to a charge recorded during the third quarter of 2025 of approximately $104.3&#160;million related to a litigation matter. For additional information on our litigation matters, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 21, Litigation</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included in this report.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><div id="i59d9e1af10a84fa9992f9418986a77c7_214"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.491%"><div><span style="color:#0070c0;font-family:'Franklin Gothic Demi',sans-serif;font-size:12pt;font-weight:400;line-height:120%">RESEARCH AND DEVELOPMENT</span></div><div><img src="biib-20250930_g11.jpg" alt="29" style="height:766px;margin-bottom:5pt;vertical-align:text-bottom;width:317px" id="i-11"/></div><div><span><br/></span></div><div><span><br/></span></div></div><div style="display:inline-block;max-width:7.017%;min-width:6.017%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.492%"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">Research and development expense, as a percentage of total revenue, was 17.2% and 20.9% for the three months ended September 30, 2025 and 2024, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">For the three months ended September 30, 2025, compared to the same period in 2024, the decrease in research and development was primarily driven by continued cost reduction measures realized in connection with our portfolio prioritization initiatives and our Fit for Growth program as well as $42.5&#160;million of equity-based compensation expense recognized in 2024 related to the HI-Bio acquisition. This decrease was offset in part by higher spend on clinical trials, including litifilimab and felzartamab. Higher clinical trial spend related to litifilimab was offset by $50.0 million in research and development funding received from Royalty Pharma.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">EARLY STAGE PROGRAMS</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">Q3 2025 vs. Q3 2024</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">The decrease in early stage program expense was driven by a decrease in costs associated with:</span></div><div style="margin-top:1pt;text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:3.42pt">advancement of felzartamab for AMR, IgAN and PMN to late stage.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">The decrease was partially offset by an increase in costs associated with:</span></div><div style="margin-top:1pt;text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:3.42pt">development of salanersen for the treatment of SMA</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">LATE STAGE PROGRAMS</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">Q3 2025 vs. Q3 2024</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">The increase in late stage program expense was driven by an increase in costs associated with:</span></div><div style="margin-top:1pt;text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:3.42pt">the development of felzartamab for AMR, IgAN and PMN; and</span></div><div style="margin-top:1pt;text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:3.42pt">development of litifilimab for the treatment of CLE and SLE, offset by Royalty Pharma funding of $50.0 million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">MARKETED PROGRAMS</span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">Q3 2025 vs. Q3 2024</span></div><div style="margin-top:3pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">The decrease in marketed program expense was driven by a decrease in costs associated with:</span></div><div style="margin-top:1pt;text-indent:-9pt"><span style="background-color:#ffffff;color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:3.42pt">decreased spend on LEQEMBI for the treatment of Alzheimer's disease.</span></div><div style="margin-top:1pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">The decrease was partially offset by an increase in costs associated with:</span></div><div style="margin-top:1pt;text-indent:-9pt"><span style="background-color:#ffffff;color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:3.42pt">i</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">ncreased spend on SKYCLARYS for the treatment of pediatric FA.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><div id="i59d9e1af10a84fa9992f9418986a77c7_217"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.581%"><div><img src="biib-20250930_g12.jpg" alt="4" style="height:864px;margin-bottom:5pt;vertical-align:text-bottom;width:317px" id="i-12"/></div><div><span><br/></span></div></div><div style="display:inline-block;max-width:6.837%;min-width:5.837%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.582%"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">Research and development expense, as a percentage of total revenue, was 16.7% and 20.3% for the nine months ended September 30, 2025 and 2024, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2025, compared to the same period in 2024, the decrease in research and development was primarily driven by continued cost reduction measures realized in connection with our portfolio prioritization initiatives and our Fit for Growth program, approximately $48.5&#160;million of step-up amortization related to SKYCLARYS inventory recorded in the second quarter of 2024 and approximately $42.5&#160;million of equity-based compensation expense recognized in 2024 related to the HI-Bio acquisition. This decrease was offset in part by higher spend on clinical trials, including litifilimab and felzartamab. Higher clinical trial spend related to litifilimab was offset by $150.0&#160;million in research and development funding received from Royalty Pharma.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.4pt;font-weight:400;line-height:120%">EARLY STAGE PROGRAMS</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.4pt;font-weight:400;line-height:120%">YTD 2025 vs. YTD 2024</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">The decrease in early stage programs was driven by a decrease in costs associated with:</span></div><div style="padding-left:9pt;text-indent:-13.5pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:7.92pt">discontinuation of BIIB121 for the treatment of Angelman syndrome;</span></div><div style="padding-left:9pt;text-indent:-13.5pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:7.92pt">advancement of litifilimab for the treatment of CLE into late stage;</span></div><div style="padding-left:9pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:7.92pt">discontinuation of BIIB143 for the treatment of diabetic neuropathic pain; and</span></div><div style="padding-left:9pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:7.92pt">discontinuation of BIIB105 for the treatment of ALS.</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">The decrease was partially offset by an increase in costs associated with:</span></div><div style="padding-left:9pt;text-indent:-13.5pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:7.92pt">development of BIIB080 for the treatment of Alzheimer's disease; </span></div><div style="padding-left:9pt;text-indent:-13.5pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:7.92pt">development of salanersen for the treatment of SMA;</span></div><div style="padding-left:9pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:7.92pt">development of felzartamab for IgAN and PMN prior to advancement to late stage; and</span></div><div style="padding-left:9pt;text-indent:-13.5pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:7.92pt">development of felzartamab for lupus nephritis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.4pt;font-weight:400;line-height:120%">LATE STAGE PROGRAMS</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.4pt;font-weight:400;line-height:120%">YTD 2025 vs. YTD 2024</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">The increase in late stage programs was driven by an increase in costs associated with:</span></div><div style="padding-left:9pt;text-indent:-13.5pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:7.92pt">development of felzartamab for AMR, IgAN and PMN; and</span></div><div style="margin-top:1pt;padding-left:9pt;text-indent:-13.5pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:7.92pt">development of litifilimab for the treatment of CLE and SLE, offset by Royalty Pharma funding of $150.0&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.4pt;font-weight:400;line-height:120%">MARKETED PROGRAMS</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:9.4pt;font-weight:400;line-height:120%">YTD 2025 vs. YTD 2024</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">The decrease in marketed programs was driven by a decrease in costs associated with:</span></div><div style="padding-left:9pt;text-indent:-13.5pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:7.92pt">decreased spend on LEQEMBI for the treatment of Alzheimer's disease; and</span></div><div style="padding-left:9pt;text-indent:-13.5pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%;padding-left:7.92pt">$48.5&#160;million of step-up amortization related to S</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9.3pt;font-weight:400;line-height:120%">KYCLARYS inventory recorded in the prior year comparative period.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><div id="i59d9e1af10a84fa9992f9418986a77c7_223"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense is reported above based on the following classifications. The development stage reported is based upon the program status when incurred. Therefore, the same program could be reflected in different development stages in the same year. For several of our programs, the research and development activities are part of our collaborative and other relationships. Our costs reflect our share of the total costs incurred.</span></div><div style="margin-top:3pt;padding-left:27pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:12pt">Research and discovery:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> represents costs incurred to support our discovery research and translational science efforts. </span></div><div style="margin-top:3pt;padding-left:27pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:12pt">Early stage programs:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are programs in Phase 1 or Phase 2 development.</span></div><div style="margin-top:3pt;padding-left:27pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:12pt">Late stage programs:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are programs in Phase 3 development or in registration stage.</span></div><div style="margin-top:3pt;padding-left:27pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:12pt">Marketed products:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> includes costs associated with product lifecycle management activities including, if applicable, costs associated with the development of new indications for existing products.</span></div><div style="margin-top:3pt;padding-left:27pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:12pt">Other research and development costs:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> A significant amount of our research and development costs consist of indirect costs incurred in support of overall research and development activities and non-specific programs, including activities that benefit multiple programs, such as management costs, as well as depreciation, information technology and facility-based expenses. These costs are considered other research and development costs in the table above and are not allocated to a specific program or stage.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our core research and development expense to decrease in 2025, due to our portfolio prioritization initiatives, our Fit for Growth program and the research and development funding received from Royalty Pharma. We intend to continue committing significant resources to targeted research and development opportunities while continuing to invest in our pipeline, such as our acquisition of HI-Bio in July 2024, where there is a significant unmet need and where a drug candidate has the potential to be highly differentiated.</span></div><div id="i59d9e1af10a84fa9992f9418986a77c7_226"></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Demi',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ACQUIRED IN-PROCESS RESEARCH AND DEVELOPMENT, UPFRONT AND MILESTONE EXPENSE</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2025 we began presenting acquired in-process research and development, upfront and milestone expense as a separate line item in our condensed consolidated statements of income. Acquired in-process research and development, upfront and milestone expense includes costs incurred in connection with collaboration and license agreements such as upfront and milestone payments and, when applicable, premiums on equity securities and asset acquisitions of acquired in-process research and development, which were previously included in research and development expense.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2025, compared to the same period in 2024, the increase in acquired in-process research and development, upfront and milestone expense was primarily due to a $30.0&#160;million milestone payment to MorphoSys accrued during the second quarter of 2025 in connection with the first patient dosed in a Phase 3 clinical trial of felzartamab for the treatment of IgAN, a $16.0&#160;million upfront payment made to City Therapeutics in connection with the closing of our strategic research arrangement in May 2025, a $165.0&#160;million upfront payment made to Stoke in connection with the closing of our collaboration and license agreement in February 2025, as well as a $35.0&#160;million milestone payment to MorphoSys accrued during the first quarter of 2025 in connection with the first patient dosed in a Phase 3 clinical trial of felzartamab for the treatment of AMR.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our arrangements with Stoke, MorphoSys and City Therapeutics, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div id="i59d9e1af10a84fa9992f9418986a77c7_229"></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Demi',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SELLING, GENERAL AND ADMINISTRATIVE</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2025, compared to the same periods in 2024, selling, general and administrative expense increased by approximately 1.1% and 1.6%, respectively, primarily due to increases in operational spending on sales and marketing activities in support of LEQEMBI and SKYCLARYS as we continue to expand our U.S. and international product launches. The increases were partially offset by the realization of our cost-reduction measures in connection with our Fit for Growth program.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect a slight increase in full-year 2025 selling, general and administrative expense, as compared to full-year 2024, due to continued spend related to LEQEMBI and SKYCLARYS product launches in the U.S. and international markets.</span></div><div id="i59d9e1af10a84fa9992f9418986a77c7_232"></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Demi',sans-serif;font-size:12pt;font-weight:400;line-height:120%">AMORTIZATION AND IMPAIRMENT OF ACQUIRED INTANGIBLE ASSETS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our amortization expense is based on the economic consumption and impairment of intangible assets. Our most significant amortizable intangible assets are related to TYSABRI, AVONEX, SPINRAZA, VUMERITY and SKYCLARYS.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, 2025, amortization of acquired intangible assets, excluding impairment charges, totaled </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$135.7 million and $374.9 million, respectively, </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compared to </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$110.1 million and $275.3 million, respectively, in the prior year comparative periods. The increases were primarily due to amortization for the acquired intangible assets associated with SKYCLARYS and TYSABRI.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2025, we had no impairment charges. For the nine months ended September 30, 2025, amortization and impairment of acquired intangible assets reflects the impact of a $3.5 million impairment charge related to a compound acquired from HI-Bio. For the three and nine months ended September 30, 2024, amortization and impairment of acquired intangible assets reflects impairment charges of approximately $20.2 million related to intangible assets associated with the termination of Samsung Bioepis' commercialization rights during the third quarter of 2024.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the amortization and impairment of our acquired intangible assets, please read </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 7, Intangible Assets and Goodwill</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included in this report.</span></div><div id="i59d9e1af10a84fa9992f9418986a77c7_235"></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Demi',sans-serif;font-size:12pt;font-weight:400;line-height:120%">COLLABORATION PROFIT SHARING/(LOSS REIMBURSEMENT)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration profit sharing/(loss reimbursement) includes Samsung Bioepis' 50.0% share of the profit or loss related to our biosimilars 2013 commercial agreement with Samsung Bioepis and collaboration profit sharing/(loss reimbursement) related to Supernus' 50.0% share of the profit or loss in the U.S. related to ZURZUVAE for PPD.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine months ended September 30, 2025, we recognized net profit-sharing expense of approximately $66.5&#160;million and $171.7&#160;million, respectively, to reflect Samsung Bioepis' 50.0% sharing of the net collaboration profits, compared to net profit-sharing expense of approximately $60.3 million and $176.8 million, respectively, in the prior year comparative periods.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the three and nine months ended September 30, 2025, we recognized net profit-sharing expense of approximately $20.7 million and $48.6 million, respectively, to reflect Supernus' 50.0% share of the net collaboration results in the U.S., compared to net profit-sharing expense of approximately $9.0 million and $20.5 million, respectively, in the prior year comparative periods.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration and license arrangements with Samsung Bioepis and Supernus, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div id="i59d9e1af10a84fa9992f9418986a77c7_238"></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Demi',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(GAIN) LOSS ON FAIR VALUE REMEASUREMENT OF CONTINGENT CONSIDERATION</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consideration payable for certain of our business combinations include future payments that are contingent upon the occurrence of a particular event or events. We record an obligation for such contingent consideration payments at fair value on the acquisition date. We then revalue our contingent consideration obligations each reporting period. Changes in the fair value of our contingent consideration obligations, other than changes due to payments, are recognized as a (gain) loss on fair value remeasurement of contingent consideration in our condensed consolidated statements of income. In connection with our acquisition of HI-Bio in July 2024 we recorded contingent consideration obligations related to potential milestone payments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine months ended September 30, 2025, changes in fair value of our contingent consideration obligations were primarily due to the passage of time.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2025 the first milestone related to the fourth patient dosed in a phase 3 clinical trial of felzartamab for AMR was achieved, resulting in a $150.0&#160;million milestone payment made to the former shareholders of HI-Bio, which was paid during the third quarter of 2025. In October 2025 the second milestone related to the fourth patient dosed in a phase 3 clinical trial of felzartamab for IgAN was achieved, resulting in a $150.0&#160;million milestone payment to be made to the former shareholders of HI-Bio, which we expect will be paid during the fourth quarter of 2025.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our acquisition of HI-Bio, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included in this report.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><div id="i59d9e1af10a84fa9992f9418986a77c7_241"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Demi',sans-serif;font-size:12pt;font-weight:400;line-height:120%">RESTRUCTURING CHARGES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Demi',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2023 FIT FOR GROWTH RESTRUCTURING PROGRAM</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023 we initiated cost saving measures as part of our Fit for Growth program to reduce operating costs, while improving operating efficiency and effectiveness. The Fit for Growth program is expected to generate approximately $1.0&#160;billion in gross operating expense savings by the end of 2025, some of which will be reinvested in various initiatives. The Fit for Growth program is currently estimated to include net headcount reductions of approximately 1,400 employees and we expect to incur total restructuring charges of approximately $310.0&#160;million, which were substantially achieved as of September 30, 2025.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total charges incurred from our 2023 Fit for Growth program are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:26.677%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.287%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accelerated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total charges</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accelerated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total charges</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.1&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.3&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Costs:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Includes costs associated with items such as asset abandonment and write-offs, facility closure costs, pre-tax gains and losses resulting from the termination of certain leases, employee non-severance expense, consulting fees and other costs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our cost saving initiatives, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 4, Restructuring,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div id="i59d9e1af10a84fa9992f9418986a77c7_247"></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Demi',sans-serif;font-size:12pt;font-weight:400;line-height:120%">OTHER (INCOME) EXPENSE, NET</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended September 30, 2025, compared to the same period in 2024, the change in other (income) expense, net primarily reflects higher net gains on our holdings in equity securities in 2024, compared to net losses in 2025, as well as higher interest income in 2025 driven by higher cash balances.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine months ended September 30, 2025, compared to the same period in 2024, the change in other (income) expense, net primarily reflects higher interest income in 2025 driven by higher cash balances.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect net interest expense will decrease as a result of higher interest income in 2025 driven by higher cash balances, partially offset by higher interest expense as a result of the issuance of our 2025 Senior Notes. For additional information related to our 2025 Senior Notes, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 13, Indebtedness</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Demi',sans-serif;font-size:11pt;font-weight:400;line-height:120%">NET (GAINS) LOSSES IN EQUITY SECURITIES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended September 30, 2025, net unrealized gains and realized losses on our holdings in equity securities were approximately $3.2 million and $7.0 million, respectively, compared to net unrealized and realized gains of approximately $28.2 million and $10.9 million, respectively, in the prior year comparative period. </span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">The net unrealized gains recognized during the three months ended September 30, 2025, primarily reflect an increase in the aggregate fair value of our investment in Denali common stock of approximately $3.8&#160;million.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">The net unrealized gains recognized during the three months ended September 30, 2024, primarily reflect an increase in the aggregate fair value of our investments in Denali and Sangamo common stock of approximately $53.3&#160;million, partially offset by a decrease in the fair value of Sage common stock of approximately $22.7&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2025, net unrealized and realized losses on our holdings in equity securities were approximately $32.5 million and $1.6 million, respectively, compared to net unrealized losses and realized gains of approximately $27.3 million and $5.4 million, respectively, in the prior year comparative period.</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">The net unrealized losses recognized during the nine months ended September 30, 2025, primarily reflect a decrease in the aggregate fair value of our investment in Denali common stock of approximately $41.9&#160;million, partially offset by an increase in the fair value of Sage common stock of approximately $23.0&#160;million.</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">The net unrealized losses recognized during the nine months ended September 30, 2024, primarily reflect a decrease in the aggregate fair value of our investments in Sage common stock of approximately $90.2&#160;million, partially offset by an increase in the fair value of Denali and Sangamo common stock of approximately $70.1&#160;million.</span></div><div id="i59d9e1af10a84fa9992f9418986a77c7_250"></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Demi',sans-serif;font-size:12pt;font-weight:400;line-height:120%">INCOME TAX PROVISION</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.040%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.284%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income before income tax (benefit) expense</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">557.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">451.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,612.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,614.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax (benefit) expense</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">90.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">270.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">249.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective tax rate fluctuates from year to year due to the global nature of our operations. The factors that most significantly impact our effective tax rate include changes in tax laws, variability in the allocation of our taxable earnings among multiple jurisdictions, the amount and characterization of our research and development expense, the levels of certain deductions and credits, acquisitions and licensing transactions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2025, compared to the same periods in 2024, the increases in our effective tax rates were partially driven by changes in the territorial mix of our profitability, partially offset by the impact of the OBBBA enactment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The nine months ended September 30, 2025, compared to the same period in 2024, also reflects the impacts of certain share-based compensation awards that vested during the first quarter of 2025 and a decrease in our estimate of Pillar Two minimum tax liabilities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2024, our effective tax rates benefited from a decrease in our valuation allowance, partially offset by the impact of certain foreign uncertain tax positions. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Demi',sans-serif;font-size:11pt;font-weight:700;line-height:112%">PILLAR TWO</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The OECD has issued model rules, which generally provide for a jurisdictional minimum effective tax rate of 15.0% as defined in those rules. Various countries have or are in the process of enacting legislation intended to implement the principles. Our income tax provision for the three and nine months ended September 30, 2025 and 2024, reflects currently enacted legislation and guidance related to the OECD model rules. This enacted legislation and guidance related to the OECD model rules did not result in any material adjustments to our income tax provision or income tax balances as of September 30, 2025 and December 31, 2024. On June 28, 2025, the G7 issued a statement stating that the G7 will work with the OECD to adjust the model rules such that the model rules would work side-by-side with the U.S. GILTI tax. At this stage, we do not believe the G7 statement impacts our financial results as of September 30, 2025.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Demi',sans-serif;font-size:11pt;font-weight:700;line-height:112%">2025 OBBBA TAX PROVISIONS</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 4, 2025, the U.S. signed into law the OBBBA. The OBBBA contains tax provisions, such as the permanent extension or revision of certain expiring provisions of the Tax Cuts and Jobs Act enacted in 2017, modifications to the international tax framework and the restoration of favorable tax treatment for certain business provisions. The provisions of the OBBBA have multiple effective dates, with certain provisions effective in 2025 and others implemented through 2027.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The OBBBA did not result in any material adjustments to our total income tax provision for the three and nine months ended September 30, 2025, and we have adjusted our deferred tax balances to reflect the impacts of the OBBBA enactment. However, given the complexity of tax laws, related regulations and interpretations, our current estimates may require revision as additional information becomes available regarding the application of the OBBBA provisions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For additional information on our income taxes, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Note 17, Income Taxes</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, to our condensed consolidated financial statements included in this report.</span></div><div id="i59d9e1af10a84fa9992f9418986a77c7_256"></div><div style="margin-top:9pt"><span style="color:#00587f;font-family:'Franklin Gothic Demi',sans-serif;font-size:14pt;font-weight:400;line-height:120%">FINANCIAL CONDITION, LIQUIDITY AND CAPITAL RESOURCES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial condition is summarized as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.806%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.397%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.285%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ Change</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financial assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,862.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,375.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,487.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable securities &#8212; current</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">nm</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total cash, cash equivalents and marketable securities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,960.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,375.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,585.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Borrowings:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion notes payable</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,748.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,748.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">nm</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Notes payable</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,285.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,547.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,737.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total borrowings</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,285.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,295.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10.7)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Working capital:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8,936.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,456.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,479.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3,290.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5,528.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,238.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(40.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total working capital</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,646.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,928.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,718.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">192.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">nm</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Not meaningful</span></div><div id="i59d9e1af10a84fa9992f9418986a77c7_259"></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Demi',sans-serif;font-size:14pt;font-weight:400;line-height:120%">OVERVIEW</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have historically financed and expect to continue to fund our operating and capital expenditures primarily through cash flow earned through our operations and borrowings, as well as our existing cash resources. We believe that generic and biosimilar competition for many of our key products, the continued overall decline of our MS business and our investments in the launch of key new products and the development of our pipeline will have a significant adverse impact on our future cash flow from operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our existing funds, when combined with cash generated from operations and our access to additional financing resources, if needed, are sufficient to satisfy our operating, working capital, strategic alliance, milestone payment, capital expenditure and debt service requirements for the foreseeable future. In addition, we may choose to opportunistically return cash to shareholders and pursue other business initiatives, including acquisition and licensing activities. We may also seek additional funding through a combination of new collaborative agreements, strategic alliances and additional equity and debt financings or from other sources should we identify a significant new opportunity.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2025 the first milestone related to the fourth patient dosed in a phase 3 clinical trial of felzartamab for AMR was achieved, resulting in a $150.0&#160;million milestone payment made to the former shareholders of HI-Bio, which was paid during the third quarter of 2025. In October 2025 the second milestone related to the fourth patient dosed in a phase 3 clinical trial of felzartamab for IgAN was achieved, resulting in a $150.0&#160;million milestone payment to be made to the former shareholders of HI-Bio, which we expect will be paid during the fourth quarter of 2025.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on certain risks that could negatively impact our financial position or future results of operations, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 3. Quantitative and Qualitative Disclosures About Market Risk</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> included in this report.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Demi',sans-serif;font-size:14pt;font-weight:400;line-height:115%">LIQUIDITY</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Demi',sans-serif;font-size:12pt;font-weight:400;line-height:115%">WORKING CAPITAL</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Working capital is defined as current assets less current liabilities. Our working capital was $5.6 billion and $1.9 billion as of September 30, 2025 and December 31, 2024, respectively. The change in working capital reflects an increase in total current assets of approximately $1.5 billion and a decrease in total current liabilities of approximately $2.2 billion. The changes in total current assets and total current liabilities were primarily driven by the following:</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Demi',sans-serif;font-size:11pt;font-weight:400;line-height:120%">CURRENT ASSETS</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">$1,585.4 million increase in cash, cash equivalents and current marketable securities;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">$30.7 million decrease in accounts receivable, net related to our ongoing operations; and</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">$251.1 million</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">decrease</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in inventory primarily due to timing of production</span><span style="color:#ee2724;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Demi',sans-serif;font-size:11pt;font-weight:400;line-height:120%">CURRENT LIABILITIES</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">$1.7 billion decrease in the current portion of notes payable due to the redemption of our 4.050% Senior Notes due September 15, 2025, during the second quarter of 2025 prior to maturity; </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">$445.0 million decrease in taxes payable primarily due to the timing of tax payments; and</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">$34.1 million decrease in accrued expense and other primarily due to the timing of our annual incentive compensation payment and collaboration-related payments, partially offset by an increase in derivative contract liabilities.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Demi',sans-serif;font-size:12pt;font-weight:400;line-height:115%">CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2025, we had cash, cash equivalents and marketable securities totaling approximately $4.0 billion compared to approximately $2.4 billion as of December 31, 2024. The increase in the balance was primarily due to cash flows from operations, which includes $150.0&#160;million of research and development funding received from Royalty Pharma, partially offset by worldwide tax payments of approximately $840.7&#160;million, an upfront payment made to Stoke of $165.0&#160;million in connection with the closing of our collaboration and license agreement, a milestone payment made to the former shareholders of HI-Bio of $150.0&#160;million and a $46.0&#160;million milestone and convertible note payment made in connection with our strategic research arrangement with City Therapeutics. During the second quarter of 2025 we received $1.75&#160;billion in net proceeds from the issuance of our 2025 Senior Notes, which was offset by a $1.75&#160;billion payment made for the redemption of our 4.050% Senior Notes due September 15, 2025, prior to maturity.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until required for another use in our business, we typically invest our cash reserves in bank deposits, certificates of deposit, commercial paper, corporate notes, U.S.&#160;and foreign government instruments, overnight reverse repurchase agreements and other interest-bearing marketable debt instruments in accordance with our investment policy. It is our policy to mitigate credit risk in our cash reserves and marketable securities by maintaining a well-diversified portfolio that limits the amount of exposure as to institution, maturity and investment type. We have experienced no significant limitations in our liquidity resulting from uncertainties in the banking sector.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value of our significant common stock investments in our strategic investment portfolio:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:62.003%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.762%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.385%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.765%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Denali</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Sage</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">179.7&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> In July 2025 Sage was acquired by Supernus.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Prior to this acquisition, we disposed of all of our shares of Sage common stock in a block trade.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our condensed consolidated financial statements included in this report</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our 2025 Senior Notes, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 13, Indebtedness</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included in this report.</span></div><div id="i59d9e1af10a84fa9992f9418986a77c7_262"></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Demi',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CASH FLOW</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our cash flow activity:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:55.728%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.558%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions, except percentages)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">%&#160;Change</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash flow provided by (used in) operating activities</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,692.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,114.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20.0)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash flow provided by (used in) investing activities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(139.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(780.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(82.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net cash flow provided by (used in) financing activities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(164.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(691.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(76.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Demi',sans-serif;font-size:11pt;font-weight:400;line-height:120%">OPERATING ACTIVITIES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating cash flow is derived by adjusting our net income for:</span></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.4pt">non-cash operating items such as depreciation and amortization, impairment charges, unrealized (gain) loss on strategic investments and share-based compensation;</span></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.4pt">changes in operating assets and liabilities, which reflect timing differences between the receipt and payment of cash associated with transactions and when they are recognized in results of operations;&#160;and</span></div><div style="margin-top:3pt;padding-left:22.5pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.4pt">(gains) losses on the disposal of assets, deferred income taxes, changes in the fair value of contingent payments associated with our acquisitions of businesses and acquired in-process research and development.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2025, compared to the same period in 2024, the decrease in net cash flow provided by operating activities was primarily due to lower net income in 2025, which included $249.4&#160;million of acquired in-process research and development, upfront and milestone payments, higher worldwide tax payments in 2025, as compared to the same period in 2024, of approximately $840.7&#160;million and $287.4&#160;million, respectively, driven by the timing of estimated payments, the timing of customer payments and higher employee-benefit payments made during the first quarter of 2025, compared to the same period in 2024. The decrease was offset in part by lower inventory levels and $150.0&#160;million of research and development funding received from Royalty Pharma in 2025.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Demi',sans-serif;font-size:11pt;font-weight:400;line-height:120%">INVESTING ACTIVITIES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2025, compared to the same period in 2024, the change in net cash flow in investing activities was primarily due to the acquisition of HI-Bio for $1.15&#160;billion in 2024, partially offset by cash proceeds received from the sale of TOFIDENCE of approximately $51.0&#160;million during the third quarter of 2025, the 2024 receipt of $437.5&#160;million from Samsung BioLogics related to the sale of our 49.9% equity interest in Samsung Bioepis and the 2024 receipt of $103.0&#160;million from the sale of one of our two PRVs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Demi',sans-serif;font-size:11pt;font-weight:400;line-height:120%">FINANCING ACTIVITIES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the nine months ended September 30, 2025, compared to the same period in 2024, the change in net cash flow in financing activities was primarily due to $1.75&#160;billion in net proceeds received from the issuance of our 2025 Senior Notes, which was offset by a $1.75&#160;billion payment made for the redemption of our 4.050% Senior Notes due September 15, 2025, as well as the first $150.0&#160;million milestone payment made to the former shareholders of HI-Bio, which was paid during the third quarter of 2025. Net cash flow used in financing activities during the nine months ended September 30, 2024, included the repayment of our 2023 Term Loan for $650.0&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our Senior Notes and our 2023 Term Loan, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 13, Indebtedness</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included in this report.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><div id="i59d9e1af10a84fa9992f9418986a77c7_265"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Demi',sans-serif;font-size:14pt;font-weight:400;line-height:120%">CAPITAL RESOURCES</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Demi',sans-serif;font-size:12pt;font-weight:400;line-height:120%">DEBT AND CREDIT FACILITIES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Demi',sans-serif;font-size:11pt;font-weight:700;line-height:120%">LONG-TERM DEBT AND TERM LOAN CREDIT AGREEMENTS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our long-term obligations primarily consist of long-term debt related to our Senior Notes with final maturity dates ranging between 2030 and 2055. As of September 30, 2025, our outstanding balance related to long-term debt was $6.3 billion, net of discounts and debt offering costs.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2025 SENIOR NOTES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 12, 2025, we issued our 2025 Senior Notes for an aggregate principal amount of $1.75&#160;billion. In June 2025 we used the net proceeds from the sale of our 2025 Senior Notes to redeem our 4.050% Senior Notes due September 15, 2025, prior to maturity.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information relating to our 2025 Senior Notes, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 13, Indebtedness</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023 TERM LOAN</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Reata in September 2023 we entered into a $1.5&#160;billion term loan credit agreement. On the closing date of the Reata acquisition we drew $1.0 billion from the 2023 Term Loan, comprised of a $500.0&#160;million floating rate 364-day tranche and a $500.0&#160;million floating rate three-year tranche. The remaining unused commitment of $500.0&#160;million was terminated. As of December 31, 2023, we repaid $350.0&#160;million of the 364--day tranche. The remaining $150.0&#160;million portion of the 364-day tranche was repaid during the first quarter of 2024.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, during the first quarter of 2024 we repaid $250.0&#160;million of the three-year tranche, with the remaining $250.0&#160;million portion being subsequently repaid in full during the second quarter of 2024.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Demi',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2024 REVOLVING CREDIT FACILITY</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2024 we entered into a $1.5&#160;billion, five-year senior unsecured revolving credit facility under which we are permitted to draw funds for working capital and general corporate purposes. The terms of the revolving credit facility include a financial covenant that requires us not to exceed a maximum consolidated leverage ratio. This revolving credit facility replaced the revolving credit facility that we entered into in January 2020. As of September 30, 2025 and December 31, 2024, we had no outstanding borrowings and were in compliance with all covenants under this facility.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a summary of the fair and carrying values of our outstanding borrowings as of September 30, 2025 and December 31, 2024, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 8, Fair Value Measurements,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our credit facility please read, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 13, Indebtedness</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2024 Form 10-K.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Demi',sans-serif;font-size:12pt;font-weight:400;line-height:120%">SHARE REPURCHASE PROGRAMS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020 our Board of Directors authorized our 2020 Share Repurchase Program, which is a program to repurchase up to $5.0 billion of our common stock. Our 2020 Share Repurchase Program does not have an expiration date. All shares repurchased under our 2020 Share Repurchase Program were retired. There were no share repurchases of our common stock during the three and nine months ended September 30, 2025 and 2024. Approximately $2.1 billion remained available under our 2020 Share Repurchase Program as of September 30, 2025.</span></div><div id="i59d9e1af10a84fa9992f9418986a77c7_268"></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Demi',sans-serif;font-size:14pt;font-weight:700;line-height:120%">CONTRACTUAL OBLIGATIONS AND OFF-BALANCE SHEET ARRANGEMENTS</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Demi',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CONTRACTUAL OBLIGATIONS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contractual obligations primarily consist of our obligations under non-cancellable operating leases, long-term debt obligations and defined benefit and other purchase obligations, excluding amounts related to uncertain tax positions, funding commitments, research and development funding arrangements with third parties, contingent development, regulatory and commercial milestone payments and contingent payments, as described below.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, certain of our collaboration and licensing arrangements include royalty payment obligations. For additional information on our royalty payments please read, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 22, Commitments and Contingencies</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2024 Form 10-K.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2025 we entered into a lease agreement with MIT Investment Management Company and BioMed Realty for the lease of approximately 580,000 square feet of office and research and development space located at 75 Broadway, Cambridge, Massachusetts, which will be used as our new global corporate headquarters, as well as integrating our research and development and technical operations teams alongside our North American commercial organization. As part of a multi-year real estate consolidation plan that is expected to result in a reduction of approximately 40% of our real estate footprint in Massachusetts, this new lease is intended to replace two existing leases, both in Cambridge, Massachusetts, including our current corporate headquarters. We expect the initial lease term of approximately 15.5 years to commence on May 31, 2028. The estimated minimum lease payments as a result of the new lease total approximately $1.5&#160;billion over the initial lease term. We have an option to extend the lease for three extension periods of five years each and one six month short-term extension, at then market-based rates. We will account for this lease as a right-of-use asset and lease liability upon the lease commencement date.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aside from our new lease agreement, there have been no material changes in our contractual obligations, including those related to our other lease agreements, since December 31, 2024.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Demi',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CONTINGENT CONSIDERATION RELATED TO BUSINESS COMBINATIONS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of HI-Bio in July 2024 we may make additional payments based upon the achievement of certain milestone events. We recognized the contingent consideration obligations associated with this acquisition at its fair value on the acquisition date and we revalue this obligation each reporting period. We may pay up to a total of $650.0&#160;million </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in contingent development and regulatory milestone payments.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The acquisition-date fair value of these milestones was approximately $485.1&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2025 the first milestone related to the fourth patient dosed in a phase 3 clinical trial of felzartamab for AMR was achieved, resulting in a $150.0&#160;million milestone payment made to the former shareholders of HI-Bio, which was paid during the third quarter of 2025. In October 2025 the second milestone related to the fourth patient dosed in a phase 3 clinical trial of felzartamab for IgAN was achieved, resulting in a $150.0&#160;million milestone payment to be made to the former shareholders of HI-Bio, which we expect will be paid during the fourth quarter of 2025.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our acquisition of HI-Bio, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our condensed consolidated financial statements included in this report.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Demi',sans-serif;font-size:12pt;font-weight:400;line-height:120%">CONTINGENT DEVELOPMENT, REGULATORY AND COMMERCIAL MILESTONE PAYMENTS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our development plans as of September 30, 2025, we could make potential future milestone payments to third parties of up to approximately $3.8 billion, including approximately $0.5 billion in development milestones, approximately $0.6 billion in regulatory milestones and approximately $2.7 billion in commercial milestones, as part of our various collaborations, including licensing and development programs. Payments under these agreements generally become due and payable upon achievement of certain development, regulatory or commercial milestones. Because the achievement of these milestones was not considered probable as of September 30, 2025, such contingencies have not been recorded in our financial statements. Amounts related to contingent milestone payments are not considered contractual obligations as they are contingent on the successful achievement of certain development, regulatory or commercial milestones.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If certain research milestones are met, we may pay up to approximately $6.0&#160;million in additional milestones in 2025 under our current agreements, excluding opt-in payments.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Demi',sans-serif;font-size:12pt;font-weight:400;line-height:120%">OTHER FUNDING COMMITMENTS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2025, we have several ongoing clinical studies in various clinical trial stages. Our most significant clinical trial expenditures are to CROs. The contracts with CROs are generally cancellable, with notice, at our option. We recorded accrued expense of approximately $43.4 million in our condensed consolidated balance sheets for expenditures incurred by CROs as of September 30, 2025. We have approximately $484.5 million in cancellable future commitments based on existing CRO contracts as of September 30, 2025.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Demi',sans-serif;font-size:12pt;font-weight:400;line-height:120%">TAX RELATED OBLIGATIONS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We exclude liabilities pertaining to uncertain tax positions from our summary of contractual obligations as we cannot make a reliable estimate of the period of cash settlement with the respective taxing authorities. As of September 30, 2025, we have approximately $168.7 million of liabilities associated with uncertain tax positions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2024, we had accrued income tax liabilities of approximately $234.0&#160;million under the Transition Toll Tax, which was subsequently paid in full in April 2025.</span></div><div id="i59d9e1af10a84fa9992f9418986a77c7_274"></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Demi',sans-serif;font-size:14pt;font-weight:700;line-height:120%">NEW ACCOUNTING STANDARDS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of new accounting standards please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1, Summary of Significant Accounting Policies,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report.</span></div><div id="i59d9e1af10a84fa9992f9418986a77c7_277"></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Demi',sans-serif;font-size:14pt;font-weight:700;line-height:120%">CRITICAL ACCOUNTING ESTIMATES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP, requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenue and expense and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and assumptions. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results may differ from these estimates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to our critical accounting estimates since our 2024 Form&#160;10-K. For a discussion of our other critical accounting estimates, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Part&#160;II,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item&#160;7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2024 Form&#160;10-K. </span></div><div id="i59d9e1af10a84fa9992f9418986a77c7_280"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Franklin Gothic Demi',sans-serif;font-size:14pt;font-weight:700;line-height:120%">ITEM 3.&#160;&#160;&#160;&#160;QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to certain risks that may affect our results of operations, cash flow and fair values of assets and liabilities, including volatility in foreign currency exchange rates, interest rate movements and equity price exposure as well as changes in economic conditions in the markets in which we operate as a result of the conflict between Russia and Ukraine and the military conflict in the Middle East. We manage the impact of foreign currency exchange rates and interest rates through various financial instruments, including derivative instruments such as foreign currency forward contracts, foreign currency options, interest rate lock contracts and interest rate swap contracts. We do not enter into financial instruments for trading or speculative purposes. The counterparties to these contracts are major financial institutions, and there is no significant concentration of exposure with any one counterparty.  </span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Demi',sans-serif;font-size:12pt;font-weight:400;line-height:120%">FOREIGN CURRENCY EXCHANGE RISK</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our results of operations are subject to foreign currency exchange rate fluctuations due to the global nature of our operations. As a result, our consolidated financial position, results of operations and cash flow can be affected by market fluctuations in foreign currency exchange rates, primarily with respect to the Euro, British pound sterling, Canadian dollar and Swiss franc.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the financial results of our global activities are reported in U.S. dollars, the functional currency for most of our foreign subsidiaries is their respective local currency. Fluctuations in the foreign currency exchange rates of the countries in which we do business will affect our operating results, often in ways that are difficult to predict. In particular, as the U.S. dollar strengthens versus other currencies, the value of the non-U.S. revenue will decline when reported in U.S. dollars. The impact to net income as a result of a strengthening U.S. dollar will be partially mitigated by the value of non-U.S. expense, which will also decline when reported in U.S. dollars. As the U.S. dollar weakens versus other currencies, the value of the non-U.S. revenue and expense will increase when reported in U.S. dollars.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established revenue and operating expense hedging and balance sheet risk management programs to protect against volatility of future foreign currency cash flow and changes in fair value caused by volatility in foreign currency exchange rates.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2018 the International Practices Task Force of the Center for Audit Quality categorized Argentina as a country with a projected three-year cumulative inflation rate greater than 100.0%, which indicated that Argentina's economy is highly inflationary. This categorization did not have a material impact on our results of operations or financial position as of September 30, 2025, and is not expected to have a material impact on our results of operations or financial position in the future.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Demi',sans-serif;font-size:12pt;font-weight:700;line-height:120%">REVENUE AND OPERATING EXPENSE HEDGING PROGRAM</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our foreign currency hedging program is designed to mitigate, over time, a portion of the impact resulting from volatility in exchange rate changes on revenue and operating expense. We use foreign currency forward contracts and foreign currency options to manage foreign currency risk, with the majority of our forward contracts and options used to hedge certain forecasted revenue and operating expense transactions denominated in foreign currencies in the next 24 months. We do not engage in currency speculation. For a more detailed disclosure of our revenue and operating expense hedging program, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 10, Derivative Instruments,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to mitigate the impact of foreign currency exchange rate changes on revenue and net income diminishes as significant foreign currency exchange rate fluctuations are sustained over extended periods of time. In particular, devaluation or significant deterioration of foreign currency exchange rates are difficult to mitigate and likely to negatively impact earnings. The cash flow from these contracts are reported as operating activities in our condensed consolidated statements of cash flow.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Demi',sans-serif;font-size:12pt;font-weight:400;line-height:120%">BALANCE SHEET RISK MANAGEMENT HEDGING PROGRAM</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also use forward contracts to mitigate the foreign currency exposure related to certain balance sheet items. The primary objective of our balance sheet risk management program is to mitigate the exposure of foreign currency denominated net monetary assets and liabilities of foreign affiliates. In these instances, we principally utilize currency forward contracts. We have not elected hedge accounting for the balance sheet related items. The cash flow from these contracts are reported as operating activities in our condensed consolidated statements of cash flow.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following quantitative information includes the impact of currency movements on forward contracts used in our revenue, operating expense and balance sheet hedging programs. As of September 30, 2025 and December 31, 2024, a hypothetical adverse 10.0% movement in foreign currency exchange rates compared to the U.S. dollar across all maturities would result in a hypothetical decrease in the fair value of forward contracts of approximately $289.4 million and $191.7 million, respectively. The estimated fair value change was determined by measuring the impact of the hypothetical exchange rate movement on outstanding forward contracts. Our use of this methodology to quantify the market risk of such instruments is subject to assumptions and the actual impact could be significantly different. The quantitative information about market risk is limited because it does not take into account all foreign currency operating transactions.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Demi',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CREDIT RISK</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject us to concentrations of credit risk include cash and cash equivalents, investments, derivatives and accounts receivable. We attempt to minimize the risks related to cash and cash equivalents and investments by investing in a broad and diverse range of financial instruments. We have established guidelines related to credit ratings and maturities intended to safeguard principal balances and maintain liquidity. Our investment portfolio is maintained in accordance with our investment policy, which defines allowable investments, specifies credit quality standards and limits the credit exposure of any single issuer. We minimize credit risk resulting from derivative instruments by choosing only highly rated financial institutions as counterparties.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We operate in certain countries where weakness in economic conditions, including the effects of the conflict between Russia and Ukraine and the military conflict in the Middle East, can result in extended collection periods. We continue to monitor these conditions, including the volatility associated with international economies and the relevant financial markets, and assess their possible impact on our business. To date, we have not experienced any significant losses with respect to the collection of our accounts receivable.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that our allowance for doubtful accounts was adequate as of September 30, 2025 and December 31, 2024.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><div id="i59d9e1af10a84fa9992f9418986a77c7_286"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Franklin Gothic Demi',sans-serif;font-size:14pt;font-weight:700;line-height:120%">ITEM 4. &#160;&#160;&#160;&#160;CONTROLS AND PROCEDURES</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Demi',sans-serif;font-size:12pt;font-weight:700;line-height:120%">DISCLOSURE CONTROLS AND PROCEDURES AND INTERNAL CONTROL OVER FINANCIAL REPORTING</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Demi',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CONTROLS AND PROCEDURES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules&#160;13a-15(e) or 15d-15(e) under the Securities Exchange Act of 1934, as amended), as of September 30, 2025. Based upon that evaluation, our principal executive officer and principal financial officer concluded that, as of the end of the period covered by this report, our disclosure controls and procedures are effective in ensuring that:</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;the information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act is recorded, processed, summarized and reported within the time periods specified in the U.S. Securities and Exchange Commission&#8217;s rules and forms; and </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In designing and evaluating our disclosure controls and procedures, our management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Demi',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting during the quarter ended September 30, 2025, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><div id="i59d9e1af10a84fa9992f9418986a77c7_289"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div></div><div style="margin-top:14pt;text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Demi',sans-serif;font-size:14pt;font-weight:700;line-height:120%">PART&#160;II OTHER INFORMATION</span></div><div id="i59d9e1af10a84fa9992f9418986a77c7_292"></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Franklin Gothic Demi',sans-serif;font-size:14pt;font-weight:700;line-height:120%">ITEM&#160;1.&#160;&#160;&#160;&#160;LEGAL PROCEEDINGS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of legal proceedings as of September 30, 2025, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 21, Litigation,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our condensed consolidated financial statements included in this report, which is incorporated into this item by reference.</span></div><div id="i59d9e1af10a84fa9992f9418986a77c7_295"></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Demi',sans-serif;font-size:14pt;font-weight:400;line-height:120%">ITEM&#160;1A.&#160;&#160;&#160;&#160;RISK FACTORS</span></div><div style="margin-top:6pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Business</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are substantially dependent on revenue from our products. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue depends upon continued sales of our products as well as the financial rights we have in our anti-CD20 therapeutic programs. A significant portion of our revenue is concentrated on sales of our products in increasingly competitive markets. Any of the following negative developments relating to any of our products or any of our anti-CD20 therapeutic programs may adversely affect our revenue and results of operations or our stock price: </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the introduction, greater acceptance or more favorable reimbursement of competing products, including new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">safety or efficacy issues;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">limitations and additional pressures on product pricing or price increases, including those relating to inflation and those resulting from governmental or regulatory requirements, including those relating to any future potential drug price negotiation under the IRA or other legislative or executive acts; increased competition, including from generic or biosimilar versions of our products; or changes in, or implementation of, reimbursement policies and practices of payors and other third parties;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">adverse legal, administrative, geopolitical, regulatory or legislative developments; and</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our ability to maintain a positive reputation among patients, healthcare providers and others, which may be impacted by our pricing and reimbursement decisions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">LEQEMBI is in the early stages of commercial launch in the U.S. and certain international markets and SKYCLARYS is in the early stages of commercial launch in certain European markets. In addition to risks associated with new product launches and the other factors described in these Risk Factors, Biogen&#8217;s and Eisai&#8217;s ability to successfully commercialize LEQEMBI and our ability to successfully commercialize SKYCLARYS may be adversely affected due to:</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Eisai&#8217;s ability to obtain and maintain adequate reimbursement for LEQEMBI;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the effectiveness of Eisai's and Biogen&#8217;s commercial strategy for marketing LEQEMBI;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">requirements such as participation in a registry and the use of imaging or other diagnostics for LEQEMBI;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our ability to obtain approval in other markets;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the approval and/or greater acceptance of other new products for the same or similar indications;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Eisai&#8217;s and Biogen&#8217;s ability to maintain a positive reputation among patients, healthcare providers and others in the Alzheimer&#8217;s disease community, which may be impacted by pricing and reimbursement decisions relating to LEQEMBI, which are made by Eisai and/or third parties;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Biogen's ability to obtain and maintain adequate reimbursement for SKYCLARYS; and</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the effectiveness of Biogen's commercial strategy for marketing SKYCLARYS.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our long-term success depends upon the successful development of new products and additional indications for our existing products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our long-term success depends upon the successful development of new products from our research and development activities or our licenses or acquisitions from third parties, as well as the development of additional indications for our existing products. Product development is very expensive and involves a high degree of uncertainty and risk and is not always successful. Only a small number of research and development programs result in the commercialization of a product. It is difficult to predict the success and the time and cost of product development of novel approaches for the treatment of diseases. The development of novel approaches for the treatment of diseases, including development efforts in new modalities such as those based on the ASO platform and gene therapy, presents additional challenges and risks, including obtaining approval from regulatory authorities that have limited experience with the development of such therapies. For example, we are currently seeking approval </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of a subcutaneous formulation of LEQEMBI as a starting dose in the U.S. and any delays or challenges may impact our ability to realize the anticipated benefits from LEQEMBI.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trial data are subject to differing interpretations and even if we view data as sufficient to support the safety, effectiveness and/or approval of a product candidate, regulatory authorities may disagree and may require additional data, limit the scope of the approval or deny approval altogether. Furthermore, the approval of a product candidate by one regulatory agency does not mean that other regulatory agencies will also approve such product candidate.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Success in preclinical work or early stage clinical trials does not ensure that later stage or larger scale clinical trials will be successful. Clinical trials may indicate that our product candidates lack efficacy, have harmful side effects, result in unexpected adverse events or raise other concerns that may significantly reduce or delay the likelihood of regulatory approval. This may result in terminated programs, significant restrictions on use, safety warnings in an approved label, adverse placement within the treatment paradigm or significant reduction in the commercial potential of the product candidate.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we could successfully develop new products or additional indications for our existing products, we may make a strategic decision to discontinue development of a product candidate or an additional indication for our existing products if, for example, we believe commercialization will be difficult relative to the standard of care or we prioritize other opportunities in our pipeline.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to compete effectively, our business and market position would suffer.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biopharmaceutical industry and the markets in which we operate are intensely competitive. We compete in the marketing and sale of our products, the development of new products and processes, the acquisition of rights to new products with commercial potential and the hiring and retention of personnel. We compete with companies that have a greater number of products on the market and in the product pipeline, substantially greater financial, marketing, research and development and other resources, and other technological or competitive advantages. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products continue to face increasing competition from the introduction of new originator therapies, generics, prodrugs and biosimilars of existing products and products approved under abbreviated regulatory pathways. Some of these products are likely to be sold at substantially lower prices than our branded products. The introduction of such products as well as other lower-priced competing products has in the past reduced, and may in the future significantly reduce, both the price that we are able to charge for our products and the volume of products we sell, which has and may continue to negatively impact our revenue. In addition, in some markets, when a generic or biosimilar version of one of our products is commercialized, it has in the past and may in the future be automatically substituted for our product and significantly reduce our revenue in a short period of time.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to compete, maintain and grow our business may be adversely affected by a number of factors, including:</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the introduction of other products, including products that may be more efficacious, safer, less expensive or more convenient alternatives to our products, including our own products and products of our collaborators;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the off-label use by physicians of therapies indicated for other conditions to treat patients; </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">patient dynamics, including the size of the patient population and our ability to identify, attract and maintain new and current patients to our therapies;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the reluctance of physicians to prescribe, and patients to use, our products without additional data on the efficacy and safety of such products;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">damage to physician and patient confidence in any of our products, generic or biosimilars of our products or any other product from the same class as one of our products, or to our sales and reputation as a result of label changes, pricing and reimbursement decisions or adverse experiences or events that may occur with patients treated with our products or generic or biosimilars of our products;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">inability to obtain and maintain appropriate pricing and adequate reimbursement for our products compared to our competitors in key markets; and</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our ability to obtain and maintain patent, data or market exclusivity for our products.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business may be adversely affected if we do not successfully execute or realize the anticipated benefits of our strategic and growth initiatives.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The successful execution of our strategic and growth initiatives depends upon internal development projects, commercial initiatives and external opportunities, which may include the acquisition and in-licensing of products, technologies, companies, the entry into strategic alliances and collaborations or our Fit for Growth program, as well as our ability to execute on strategic decisions and initiatives.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we believe we have a number of promising programs in our pipeline, failure or delay of internal development projects to advance or difficulties in executing on our commercial initiatives could impact our current and future growth, resulting in additional reliance on external development opportunities for growth. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supporting the further development of our existing products and potential new products in our pipeline will require significant capital expenditures and management resources, including investments in research and development, sales and marketing, manufacturing capabilities and other areas of our business.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have made, and may continue to make, significant operating and capital expenditures for potential new products prior to regulatory approval with no assurance that such investment will be recouped, which may adversely affect our financial condition, business and operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The availability of high quality, fairly valued external product development is limited and the opportunity to acquire or in-license is highly competitive. As such, we are not certain that we will be able to identify suitable candidates for acquisition or in-licensing or if we will be able to reach agreement to make any such acquisition or in-license if suitable candidates are identified.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may fail to initiate or complete transactions for many reasons, including failure to obtain regulatory or other approvals as well as a result of disputes or litigation. Furthermore, we may not be able to achieve the full strategic and financial benefits expected to result from transactions, collaborations or strategic decisions, such as the decision to retain the biosimilars business, or the benefits may be delayed or not occur at all. We may also face additional costs or liabilities in completed transactions that were not contemplated prior to completion.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any failure in the execution of a transaction, in the integration of an acquired asset or business or in achieving expected synergies could result in slower growth, higher than expected costs, the recording of asset impairment charges and other actions which could adversely affect our business, financial condition and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We face risks associated with our Fit for Growth program that may impair our ability to achieve anticipated savings and operational efficiencies or that may otherwise harm our business. These risks include delays in implementation of cost optimization actions, loss of workforce capabilities, higher than anticipated separation expenses, litigation and the failure to meet financial and operational targets. In addition, the calculation of the anticipated cost savings and other benefits resulting from our Fit for Growth program are subject to many estimates and assumptions. These estimates and assumptions are subject to significant business, economic, competitive and other uncertainties and contingencies, many of which are beyond our control. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">I</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">f these estimates and assumptions are incorrect or if we experience delays or unforeseen events, our business and financial results could be adversely affected.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Sales of our products depend, to a significant extent, on the availability and extent of adequate coverage, pricing and reimbursement from government health administration authorities, private health insurers and other organizations, which are subject to increasing and intense pressure from political, social, competitive and other sources. Our inability to obtain and maintain adequate coverage, or a reduction in pricing or reimbursement, could have an adverse effect on our business, reputation, revenue and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of our products depend, to a significant extent, on the availability and extent of adequate coverage, pricing and reimbursement from governmental health administration authorities, private health insurers and other organizations. When a new pharmaceutical product is approved, the availability of government and private reimbursement for that product, diagnosis of the condition it treats and the cost to administer it may be uncertain, as is the pricing and amount for which that product will be reimbursed. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pricing and reimbursement for our products may be adversely affected by a number of factors, including:</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">changes in, and implementation of, federal, state or foreign government regulations or private third-party payors&#8217; reimbursement policies;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">pressure by employers on private health insurance plans to reduce costs;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">consolidation and increasing assertiveness of governmental health administration authorities, private health insurers and other organizations seeking price discounts or rebates in connection with the placement of our products on their formularies and, in some cases, the imposition of restrictions on access or coverage of particular drugs or pricing determined based on perceived value;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our ability to receive reimbursement for our products or our ability to receive comparable reimbursement to that of competing products; and</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our value-based contracting program pursuant to which we aim to tie the pricing of our products to their clinical values by either aligning price to patient outcomes or adjusting price for patients who discontinue therapy for any reason, including efficacy or tolerability concerns.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to set the price for our products varies significantly from country to country and, as a result, so can the price of our products. Governments may use a variety of cost-containment measures to control the cost of products, including price cuts, mandatory rebates, value-based pricing and reference pricing (i.e., referencing prices in other countries and using those reference prices to set a price). Drug prices are under significant scrutiny in the markets in which our products are prescribed; for example the IRA has certain provisions related to drug pricing, including the ability for the U.S. government to set prices for certain drugs in Medicare. We expect drug pricing and other healthcare costs to continue to be subject to political or societal pressures on a global basis. Certain countries set prices by reference to the prices in other countries where our products are marketed. Our inability to obtain and maintain adequate prices in a particular country has limited, and may in the future limit, the revenue from our products within that country and has, and may in the future, also adversely affect our ability to secure acceptable prices in existing and potential new markets, which has limited, and may in the future limit, market growth and result in reductions in revenue. This has created, or may create, the opportunity for third-party cross-border trade or influence our decision to sell or not to sell a product, thus adversely affecting our geographic expansion plans and revenue. Additionally, in certain jurisdictions governmental health agencies are permitted to adjust, retroactively and/or prospectively, reimbursement rates for our products. Reimbursement for our products by governments, including the timing of any reimbursements, are also affected by budgetary or political constraints, particularly in challenging economic environments. Government agencies often do not set their own budgets and therefore, have limited control over the amount of money they can spend. In addition, these agencies experience political pressure that dictate the manner in which they spend money. There can be no assurance that the economic, budgeting or political issues will not worsen and adversely impact sales or reimbursements of our products.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competition from current and future competitors has and may continue to negatively impact our ability to maintain pricing and our market share. New products marketed by our competitors have caused and could continue to cause our revenue to decrease due to potential price reductions and lower sales volumes. Additionally, the introduction of generic or biosimilar versions of our products, follow-on products, prodrugs or products approved under abbreviated regulatory pathways has and may significantly reduce the price and the volume of products we sell.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many third-party payors continue to adopt benefit plan changes that shift a greater portion of prescription costs to patients, including more limited benefit plan designs, higher patient co-pay or co-insurance obligations and limitations on patients' use of commercial manufacturer co-pay payment assistance programs (including through co-pay accumulator adjustment or maximization programs). Significant consolidation in the health insurance industry has resulted in a few large insurers and pharmacy benefit managers exerting greater pressure in pricing and usage negotiations with drug manufacturers, significantly increasing discounts and rebates required of manufacturers and limiting patient access and usage. Further consolidation among insurers, pharmacy benefit managers and other payors would increase the negotiating leverage such entities have over us and other drug manufacturers. Additional discounts, rebates, coverage or plan changes, restrictions or exclusions as described above could have a material adverse effect on sales of our affected products.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our failure to obtain or maintain adequate coverage, pricing or reimbursement for our products could have an adverse effect on our business, reputation, revenue and results of operations, could curtail or eliminate our ability to adequately fund research and development programs and/or could cause a decline or volatility in our stock price.</span></div><div style="margin-top:5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on relationships with collaborators and other third parties for revenue, and for the development, regulatory approval, commercialization and marketing of certain of our products and product candidates, which are outside of our full control, and if these relationships fail, our business may be adversely affected.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on a number of collaborative and other third-party relationships for revenue and the development, regulatory approval, commercialization and marketing of certain of our products and product candidates. We also outsource certain aspects of our regulatory affairs and clinical development relating to our products and product candidates to third parties. Reliance on third parties subjects us to a number of risks, including:</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">we may be unable to control the resources our collaborators or third parties devote to our programs, products or product candidates, which may affect our ability to achieve development goals or milestones;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">disputes may arise under an agreement, including with respect to the achievement and payment of milestones, payment of development or commercial costs, ownership of rights to technology developed, and the underlying agreement may fail to provide us with significant protection or may fail to be effectively enforced if the collaborators or third parties fail to perform; </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the interests of our collaborators or third parties may not always align with our interests, and such parties may not protect and enforce any intellectual property rights or pursue regulatory approvals or market a product in the same manner or to the same extent that we would, which could adversely affect our revenue, or may adopt tax strategies that could have an adverse effect on our business, results of operations or financial condition; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the inability of the parties to cooperate effectively, which could adversely affect product sales or the clinical development or regulatory approvals of product candidates under joint control, could result in termination of the research, development or commercialization of product candidates or could result in litigation or arbitration;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">any failure on the part of our collaborators or third parties to comply with applicable laws, including tax laws, regulatory requirements and/or applicable contractual obligations or to fulfill any responsibilities they may have to protect and enforce any intellectual property rights underlying our products could have an adverse effect on our revenue or reputation as well as involve us in possible legal proceedings; </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">disruptions, turnover or changes in strategy, priorities or capabilities at our collaborators resulting from, for example, a change in control, may impact the commercialization or manufacturing of our shared products and may result in loss of revenue or higher operating expense; and</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">any improper conduct or actions on the part of our collaborators or third parties could subject us to civil or criminal investigations and monetary and injunctive penalties, require management attention, impact the accuracy and timing of our financial reporting and/or adversely impact our business and our reputation.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given these risks, there is considerable uncertainty regarding the success of our current and future collaborative efforts. If these efforts fail, our product development or commercialization of new products could be delayed, revenue from products could decline and/or we may not realize the anticipated benefits of these arrangements.</span></div><div style="margin-top:5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our results of operations may be adversely affected by current and potential future healthcare reforms including those contained in the PPACA, IRA, OBBBA and executive orders.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., federal and state legislatures, health agencies and third-party payors continue to focus on the cost of healthcare. Legislative and regulatory proposals, enactments to reform healthcare insurance programs (including those in the IRA and OBBBA) and increasing pressure from social sources could significantly influence the manner in which our products are prescribed, purchased and reimbursed. For example, provisions of the PPACA have resulted in changes in the way healthcare is paid for by both governmental and private insurers, including increased rebates owed by manufacturers under the Medicaid Drug Rebate Program, annual fees and taxes on manufacturers of certain branded prescription drugs, the requirement that manufacturers participate in a discount program for certain outpatient drugs under Medicare Part D and under Section 340B of the Public Health Service Act and similar state legislation. These changes have had and are expected to continue to have a significant impact on our business. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2025 the U.S. signed into law the OBBBA, which enacts significant potential changes to Medicaid funding and rescinds or does not continue elements of the PPACA. The OBBBA implements additional eligibility rules on government health plans, expands administrative procedures around enrollment, modifies how states can obtain federal funding for Medicaid and no longer extends ACA premium subsidies. Additional federal and state guidance is expected to be issued in order to implement these OBBBA provisions, most of which have effective dates in 2027 and 2028. At this time, we are unable to determine the overall impact that the OBBBA will have on our business, results of operations and financial condition, or the impact the OBBBA will have on the pharmaceutical industry as a whole because any such impact will depend upon developing interpretations of the OBBBA provisions and implementing regulations, which may be material.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may face uncertainties as a result of efforts to repeal, substantially modify or invalidate some or all of the provisions of the PPACA. There is no assurance that the PPACA, as currently enacted or as amended in the future, will not adversely affect our business and financial results, and we cannot predict how future federal or state legislative or administrative changes relating to healthcare reform will affect our business.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is substantial public attention on the costs of prescription drugs and we expect drug pricing and other healthcare costs to continue to be subject to political and societal pressures globally. In addition, there have been, and are expected to continue to be, legislative proposals to address prescription drug pricing. We face uncertainties regarding potential healthcare reforms, governmental policy and prioritization. The uncertainty about the future of the PPACA and healthcare laws may put downward pressure on drug pricing and increase our regulatory burdens and operating costs. For example, we expect the IRA's drug pricing controls and Medicare Part D redesign to have an adverse impact on sales, particularly for our products that are more substantially reliant on Medicare reimbursement.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the current government administration has introduced various measures to address prescription drug pricing and access, including through issuance of an executive order aiming to establish a MFN drug pricing policy that would tie U.S. drug prices to the prices paid for drugs in other countries. If HHS sets MFN pricing targets for prescription drugs, including the use of international pricing reference to set drug prices in the U.S., or if legislation is passed enabling generic drug or biosimilar entry sooner than expected, our business could be materially harmed, including with respect to our ability to set adequate pricing for new drugs to recover our research and development costs. The timing and extent of implementation of any of the measures described above is uncertain and we cannot fully predict their impact on our product candidates and our business. The adoption of these and any other </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">government controls and measures, and tightening of restrictive policies in jurisdictions with existing controls and measures, could exclude or limit our product candidates from coverage, limit payments for pharmaceuticals, limit our ability to launch products in certain markets and impact healthcare systems and drug markets in the U.S. and abroad, thereby negatively affecting our revenue and adversely impacting our business.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is also significant economic pressure on state budgets, that may result in states increasingly seeking to achieve budget savings through mechanisms that limit coverage or payment for our drugs. Some states have considered legislation and ballot initiatives that would control the prices of drugs, including laws to allow importation of pharmaceutical products from lower cost jurisdictions outside the U.S. and laws intended to impose price controls on state drug purchases. State Medicaid programs are requesting manufacturers to pay supplemental rebates and requiring prior authorization by the state program for use of any drug for which supplemental rebates are not being paid. Government efforts to reduce Medicaid expense may lead to increased use of managed care organizations by Medicaid programs. This may result in managed care organizations influencing prescription decisions for a larger segment of the population and a corresponding limitation on prices and reimbursement for our products. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the E.U. and some other international markets, the government provides healthcare at low cost to consumers and regulates pharmaceutical prices, patient eligibility or reimbursement levels to control costs for the government-sponsored healthcare system. Many countries have announced or implemented measures, and may in the future implement new or additional measures, to reduce healthcare costs to limit the overall level of government expenditures. These measures vary by country and may include, among other things, patient access restrictions, suspensions on price increases, prospective and possible retroactive price reductions and other recoupments and increased mandatory discounts or rebates, recoveries of past price increases and greater importation of drugs from lower-cost countries. These measures have negatively impacted our revenue and may continue to adversely affect our revenue and results of operations in the future.</span></div><div style="margin-top:5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our success in commercializing biosimilars is subject to risks and uncertainties inherent in the development, manufacture and commercialization of biosimilars. If we are unsuccessful in such activities, our business may be adversely affected.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development, manufacture and commercialization of biosimilar products require specialized expertise and are very costly and subject to complex regulation. Our success in commercializing biosimilars is subject to a number of risks, including:</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Reliance on Third Parties.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We are dependent, in part, on the efforts of collaboration partners and other third parties for the development and manufacturing of biosimilars products. These third parties are independent entities subject to their own unique operational, strategic and financial risks that are outside of our control and may be affected by events outside of our control. For example, one of our contract manufacturers for IMRALDI and BENEPALI was acquired by a third party in December 2024 which may impact the contract manufacturer's operational, strategic or financial risk. If these third parties fail to perform successfully, or reduce their third party manufacturing production, our biosimilar product development or commercialization of biosimilar products could be delayed, revenue from biosimilar products could decline and/or we may not realize the anticipated benefits of these arrangements;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Competitive Challenges.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Biosimilar products face significant competition, including from innovator products and biosimilar products offered by other companies that may receive greater acceptance or more favorable reimbursement. Local tendering processes may restrict biosimilar products from being marketed and sold in some jurisdictions. The number of competitors in a jurisdiction, the timing of approval and the ability to market biosimilar products successfully in a timely and cost-effective manner are additional factors that may impact our success in this business area;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Regulatory Compliance.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Biosimilar products may face regulatory hurdles or delays due to the evolving and uncertain regulatory and commercial pathway of biosimilars products in certain jurisdictions;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Ability to Provide Adequate Supply.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Manufacturing biosimilars is complex. If we encounter any persistent manufacturing or supply chain difficulties we may be unable to meet demand. We are dependent on a third-party for the manufacture of our biosimilar products and such third-party may not perform its obligations in a timely and cost-effective manner or in compliance with applicable regulations and may be unable or unwilling to increase production capacity commensurate with demand for our existing or future biosimilar products;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Intellectual Property and Regulatory Challenges.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Biosimilar products may face extensive intellectual property clearances and infringement litigation, injunctions or regulatory challenges, which could prevent the commercial launch of a product or delay it for many years or result in imposition of monetary damages, penalties or other civil sanctions and damage our reputation; and</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Failure to Gain Market and Patient Acceptance.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Market success of biosimilar products will be adversely affected if patients, physicians and/or payors do not accept biosimilar products as safe and efficacious products offering a more competitive price or other benefit over existing therapies.</span></div><div style="margin-top:6pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Risks Related to Intellectual Property</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain and maintain adequate protection for our data, intellectual property and other proprietary rights, our business may be harmed. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success, including our long-term viability and growth, depends, in part, on our ability to obtain and defend patent and other intellectual property rights, including certain regulatory forms of exclusivity, that are important to the commercialization of our products and product candidates. Patent protection and/or regulatory exclusivity in the U.S. and other important markets remains uncertain and depends, in part, upon decisions of the patent offices, courts, administrative bodies and lawmakers in these countries. We may fail to obtain, defend or preserve patent and other intellectual property rights, including certain regulatory forms of exclusivity, or the protection we obtain may not be of sufficient breadth and degree to protect our commercial interests in all countries where we conduct business, which could result in financial, business or reputational harm to us or could cause a decline or volatility in our stock price. In addition, settlements of such proceedings often result in reducing the period of exclusivity and other protections, resulting in a reduction in revenue from affected products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In many markets, including the U.S., manufacturers may be allowed to rely on the safety and efficacy data of the innovator's product and do not need to conduct clinical trials before marketing a competing version of a product after there is no longer patent or regulatory exclusivity. In such cases, manufacturers often charge significantly lower prices and a major portion of the company's revenue may be reduced in a short period of time. In addition, manufacturers of generics and biosimilars may choose to launch or attempt to launch their products before the expiration of our patent or other intellectual property protections.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, our products may be determined to infringe patents or other intellectual property rights held by third parties. Legal proceedings, administrative challenges or other types of proceedings are and may in the future be necessary to determine the validity, scope or non-infringement of certain patent rights claimed by third parties to be pertinent to the manufacture, use or sale of our products.&#160;Legal proceedings may also be necessary to determine the rights, obligations and payments claimed during and after the expiration of intellectual property license agreements we have entered with third parties. Such proceedings are unpredictable and are often protracted and expensive. Negative outcomes of such proceedings could hinder or prevent us from manufacturing and marketing our products, require us to seek a license for the infringed product or technology or result in the assessment of significant monetary damages against us that may exceed amounts, if any, accrued in our financial statements. A failure to obtain necessary licenses for an infringed product or technology could prevent us from manufacturing or selling our products. Furthermore, payments under any licenses that we are able to obtain could reduce our profits from the covered products and services. Any of these circumstances could result in financial, business or reputational harm to us or could cause our stock price to decline or experience periods of volatility.</span></div><div style="margin-top:6pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:103%">Risks Related to Development, Clinical Testing and Regulation of Our Products and Product Candidates</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Successful preclinical work or early/late stage clinical trials does not ensure success in later stage trials, regulatory approval or commercial viability of a product.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Positive results in preclinical work or early/late stage clinical trials have in the past and may in the future fail to be replicated in subsequent or confirmatory trials. Additionally, success in preclinical work or early/late stage clinical trials does not ensure that later stage or larger scale clinical trials will be successful or that regulatory approval will be obtained. Even if later stage clinical trials are successful, regulatory authorities may delay or decline approval of our product candidates. Regulatory authorities may disagree with our view of the data, require additional studies, disagree with our trial design or endpoints. Regulatory authorities may also fail to approve the facilities or processes used to manufacture a product candidate, our dosing or delivery methods or companion devices. Regulatory authorities have in the past and may in the future grant marketing approval that is more restricted than anticipated, including limiting indications to narrow patient populations and the imposition of safety monitoring, educational requirements, requiring confirmatory trials and risk evaluation and mitigation strategies. The occurrence of any of these events could result in significant costs and expense, have an adverse effect on our business, financial condition and results of operations and/or cause our stock price to decline or experience periods of volatility.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical trials and the development of biopharmaceutical products is a lengthy and complex process. If we fail to adequately manage our clinical activities, our clinical trials or potential regulatory approvals may be delayed or denied.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conducting clinical trials is a complex, time-consuming and expensive process. Our ability to complete clinical trials in a timely fashion depends on a number of key factors, including protocol design, regulatory and institutional review </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">board approval, patient enrollment rates and compliance with current Good Clinical Practices. If we or our third-party clinical trial providers or third-party CROs do not successfully carry out these clinical activities, our clinical trials or the potential regulatory approval of a product candidate may be delayed or denied.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have opened clinical trial sites and are enrolling patients in a number of countries where our experience is limited. In most cases, we use the services of third parties to carry out our clinical trial related activities and rely on such parties to accurately report their results. Our reliance on third parties for these activities may impact our ability to control the timing, conduct, expense and quality of our clinical trials. One CRO has responsibility for a substantial portion of our activities and reporting related to our clinical trials and if such CRO does not adequately perform, many of our trials may be significantly affected, including adversely affecting our expenses associated with such trials. We may need to replace our CROs, which may result in the delay of the affected trials or otherwise adversely affect our efforts to obtain regulatory approvals and commercialize our product candidates.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Adverse safety events or restrictions on use and safety warnings for our products can negatively affect our business, product sales and stock price.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Adverse safety events involving our products, generic or biosimilar versions of our products or products from the same class as one of our products may have a negative impact on our business. Discovery of safety issues with our products could create product liability and have or could cause additional regulatory scrutiny and requirements for additional labeling or safety monitoring, withdrawal of products from the market and/or the imposition of fines or criminal penalties. Adverse safety events may also damage physician, patient and/or investor confidence in our products and our reputation. Any of these could result in adverse impacts on our results of operations. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory authorities are making greater amounts of stand-alone safety information directly available to the public through periodic safety update reports, patient registries and other reporting requirements. The reporting of adverse safety events involving our products or products similar to ours and public rumors about such events may increase claims against us and may also cause our product sales to decline or lead to periods of stock price volatility.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restrictions on use or safety warnings that may be required to be included in the label of our products may significantly reduce expected revenue for those products or require significant expense or divert management time.</span></div><div style="margin-top:6pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Operations</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A breakdown or breach of our information systems could subject us to liability or interrupt our business operations.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are increasingly dependent upon information systems and data to operate our business. Changes in how we operate have caused us to modify our business practices in ways that heighten this dependence, including changing the requirement that most of our office-based employees in the U.S. and our other key markets work from the office, with many of our employees now working in hybrid or full-remote positions. As a result, we are increasingly dependent upon our information systems to operate our business and our ability to effectively manage our business depends on the security, reliability and adequacy of our information systems and data, which includes use of cloud technologies, including Software as a Service (SaaS), Platform as a Service (PaaS) and Infrastructure as a Service (IaaS). Breakdowns, invasions, corruptions, destructions and/or breaches, which may include impacts such as, but not limited to, comprising the capacity, reliability or security of our information systems or those of our business partners, including our cloud technologies, and/or unauthorized access to our data and information could subject us to significant liability, negatively impact our business operations, and/or require replacement of technology and/or sizeable ransom payments. Our information systems, including our cloud technologies, continue to increase in multitude and complexity, increasing our vulnerability when breakdowns, malicious intrusions and random attacks occur.&#160;Data privacy or security breaches also pose a risk that sensitive data, including intellectual property, trade secrets or personal information belonging to us, patients, customers or other business partners, may be exposed to unauthorized persons or to the public.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cybersecurity threats and incidents are increasing in their frequency, sophistication and intensity, and are becoming increasingly difficult to detect, particularly when they impact vendors, customers or suppliers, and other companies in our supply chain. Cybersecurity threats and incidents are often carried out by motivated, well-resourced, skilled and persistent threat actors, including nation states, organized crime groups, &#8220;hacktivists&#8221; and may include or target employees or contractors acting with careless or malicious intent. Recent developments in the threat landscape include use of adversarial AI techniques and machine learning, as well as an increased number of cyber extortion attacks, with higher financial ransom demand amounts and increasing sophistication and variety of ransomware techniques and methodology. Geopolitical instability may increase the risk of cybersecurity threats. Cybersecurity threats or incidents may include deployment of harmful malware and key loggers, ransomware, a denial-of-service attack, a malicious website, the use of social engineering and other means to affect the confidentiality, integrity and availability of our information systems and data. Cybersecurity threats and incidents also include manufacturing, hardware or software supply chain attacks, which could cause a delay in the manufacturing of products or products </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">produced for contract manufacturing or lead to a data privacy or security breach. Our key business partners face similar risks and any security breach of their systems could adversely affect our security posture. In addition, our increased use of cloud technologies heightens these and other operational risks, and any failure by cloud or other technology service providers to adequately safeguard their systems and prevent cyber-attacks could disrupt our operations and result in misappropriation, corruption or loss of confidential or propriety information.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we continue to build and improve our systems and infrastructure, including our business continuity plans, there can be no assurance that our efforts will detect and prevent cybersecurity threats or incidents in our systems and any such incidents could materially adversely affect our business and operations and/or result in the loss of critical or sensitive information, which could result in material financial, legal, operational or reputational harm to us, loss of competitive advantage or loss of consumer confidence. Our liability insurance may not be sufficient in type or amount to cover us against claims related to security breaches, cyber-attacks and other related breaches.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulations continue to change as regulators worldwide consider new rules. For example, the SEC has adopted additional disclosure rules regarding cyber security risk management, strategy, governance and incident reporting by public companies. These regulations or other regulations being considered in Europe and around the world may impact the manner in which we operate.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulators currently impose new data privacy and security requirements, including monetary fines for privacy violations. For example, the E.U.&#8217;s General Data Protection Regulation established regulations regarding the handling of personal data, and provides an enforcement authority and imposes large penalties for noncompliance. U.S. data privacy and security laws, such as the CCPA, and others that may be passed, similarly introduce requirements with respect to personal information, and non-compliance with the CCPA may result in liability through private actions (subject to statutorily defined damages in the event of certain data breaches) and enforcement. Failure to comply with these current and future laws, policies, industry standards or legal obligations or any security incident resulting in the unauthorized access to, or acquisition, release or transfer of personal information may result in governmental enforcement actions, litigation, fines and penalties or adverse publicity and could cause patients, healthcare providers and the general public to lose trust in us, which could have a material adverse effect on our business.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The increasing use of AI-based software presents new risks and challenges and could adversely affect our business and reputation.</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As with many developing technologies, AI-based software presents risks and challenges. For example, algorithms may be flawed, data sets may be insufficient, of poor quality or contain biased information; and inappropriate or controversial data practices could impair results. The use of AI-based software is increasingly being used in the biopharmaceutical industry, including by us, for research, marketing, manufacturing and commercialization, and we anticipate increasing our usage of technology that uses AI in the future. If the analyses that AI-based software assist in producing are deficient or inaccurate, we could be subjected to competitive harm, potential legal liability and brand or reputational harm. Use of AI-based software internally, by third parties or by threat actors may also lead to cybersecurity risks or the release of confidential proprietary information, including personal data, which may impact our ability to realize the benefit of our intellectual property or violate our internal policies, data protection laws or contractual requirements. The use of AI-based software may also result in unauthorized access of personal data or the intellectual property of third parties. Since the use of AI is subject to new or evolving laws and regulations, compliance may impose operational costs and limit our ability to use AI-based software, and failure to comply may result in potential government actions, litigation, fines, penalties or adverse publicity.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Manufacturing issues could substantially increase our costs, limit supply of our products and/or reduce our revenue.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of manufacturing our products is complex, highly regulated and subject to numerous risks, including:</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Risks of Reliance on Third Parties and Single Source Providers.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We rely on third-party suppliers and manufacturers for many aspects of our manufacturing process for our products and product candidates. In some cases, due to the unique manner in which our products are manufactured, we rely on single source providers of raw materials and manufacturing supplies. These third parties are independent entities subject to their own unique operational, strategic and financial risks that are outside of our control and may be affected by events outside of our control. Additionally, these third parties may not perform their obligations in a timely and cost-effective manner or in compliance with applicable regulations, and they may be unable or unwilling to increase production capacity commensurate with demand for our existing or future products. Finding alternative providers could take a significant amount of time and involve significant expense due to the specialized nature of the services and the need to obtain regulatory approval of any significant changes to our suppliers or manufacturing methods. We cannot be certain that we could reach agreement with alternative providers or that the FDA or other regulatory authorities would approve our use of such alternatives.</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Global Bulk Supply Risks. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on our manufacturing facilities for the production of drug substance for our large molecule products and product candidates. Our global bulk supply of these products and product </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div></div><div style="margin-top:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">candidates depends on the uninterrupted and efficient operation of these facilities, which could be adversely affected by equipment failures, labor or raw material shortages, geopolitical instability, public health epidemics, natural disasters, adverse weather events, power failures, cyber-attacks and many other factors.</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Risks Relating to Compliance with current GMP (cGMP).</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We and our third-party providers are required to maintain compliance with cGMP and other stringent requirements, as applicable, and are subject to inspections by the FDA and other regulatory authorities to confirm compliance. Any delay, interruption or other issues that arise in the manufacture, fill-finish, packaging or storage of our products as a result of a failure of our facilities or operations or those of third parties to receive regulatory approval or pass any regulatory agency inspection could significantly impair our ability to develop and commercialize our products. Significant noncompliance could also result in the imposition of monetary penalties or other civil or criminal sanctions and damage our reputation.</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:12pt">Risk of Product Loss.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The manufacturing process for our products is extremely susceptible to product loss due to contamination, oxidation, equipment failure or improper installation or operation of equipment or vendor or operator error. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered in our products or manufacturing facilities, we may need to close our manufacturing facilities for an extended period of time to investigate and remediate the contaminant.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any adverse developments affecting our manufacturing operations or the operations of our third-party suppliers and manufacturers may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls or other interruptions in the commercial supply of our products.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, factors such as geopolitical instability, public health epidemics, natural disasters, adverse weather events, labor or raw material shortages, imposition of tariffs or trade restrictions, power failures, cyber-attacks and other supply chain disruptions could result in difficulties and delays in manufacturing our products, which could have an adverse impact on our results of operations or result in product shortages. We may also have to take inventory write-offs and incur other charges and expense for products that fail to meet specifications, undertake costly remediation efforts or seek more costly manufacturing alternatives. Such developments could increase our manufacturing costs, cause us to lose revenue or market share as patients and physicians turn to competing therapeutics, diminish our profitability or damage our reputation. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, although we have business continuity plans to reduce the potential for manufacturing disruptions or delays and reduce the severity of a disruptive event, there is no guarantee that these plans will be adequate, which could adversely affect our business and operations.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Management, personnel and other organizational changes may disrupt our operations, and we may have difficulty retaining personnel or attracting and retaining qualified replacements on a timely basis for the management and other personnel who may leave the Company, which could disrupt our business and adversely affect our operations.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in management, other personnel and our overall retention rate may disrupt our business, and any such disruption could adversely affect our operations, programs, growth, financial condition or results of operations. New members of management may have different perspectives on programs and opportunities for our business, which may cause us to focus on new opportunities or reduce or change emphasis on our existing programs.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success is dependent upon our ability to attract and retain qualified management and other personnel in a highly competitive environment. Qualified individuals are in high demand, and we may incur significant costs to attract or retain them. We may face difficulty in attracting and retaining talent for a number of reasons, including management changes, integration related to the acquisition of HI-Bio, the underperformance or discontinuation of one or more marketed, pre-clinical or clinical programs, recruitment by competitors or changes in the overall labor market. Changes in our organizational structure or in our flexible working arrangements could also impact productivity and morale as well as our ability to attract, retain and motivate employees. We cannot ensure that we will be able to hire or retain the personnel necessary for our operations or that the loss of any personnel will not have a material impact on our financial condition and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with the extensive legal and regulatory requirements affecting the healthcare industry, we could face increased costs, penalties and a loss of business.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our activities, and the activities of our collaborators, distributors and other third-party providers, are subject to extensive government regulation and oversight in the U.S.&#160;and in foreign jurisdictions, and are subject to change and evolving interpretations, which could require us to incur substantial costs associated with compliance or to alter one or more of our business practices. The FDA and comparable foreign agencies directly regulate many of our most critical business activities, including the conduct of preclinical and clinical studies, product manufacturing, advertising and promotion, product distribution, adverse event reporting, product risk management and our compliance with good practice quality guidelines and regulations. Our interactions with physicians and other </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">healthcare providers that prescribe or purchase our products are also subject to laws and government regulation designed to prevent fraud and abuse in the sale and use of products and place significant restrictions on the marketing practices of healthcare companies. Healthcare companies are facing heightened scrutiny of their relationships with healthcare providers and have been the target of lawsuits and investigations alleging violations of laws and government regulation, including claims asserting submission of incorrect pricing information, impermissible off-label promotion of pharmaceutical products, payments intended to influence the referral of healthcare business, submission of false claims for government reimbursement, antitrust violations or violations related to environmental matters. There is also enhanced scrutiny of company-sponsored patient assistance programs, including testing, insurance premium and co-pay assistance programs and donations to third-party charities that provide such assistance. The U.S. government has challenged some of our donations to third-party charities that provide patient assistance. If we, or our vendors or donation recipients, are found to fail to comply with relevant laws, regulations or government guidance in the operation of these or other patient assistance programs, we could be subject to significant fines or penalties. Risks relating to compliance with laws and regulations may be heightened as we continue to expand our global operations and enter new therapeutic areas with different patient populations, which may have different product distribution methods, marketing programs or patient assistance programs from those we currently utilize or support. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Conditions and regulations governing the healthcare industry are subject to change, with possible retroactive effect, including:</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">new laws, regulations or judicial decisions, or new interpretations of existing laws, regulations or judicial decisions, related to healthcare availability, pricing or marketing practices, compliance with employment practices, method of delivery, payment for healthcare products and services, compliance with health information and data privacy and security laws and regulations, tracking and reporting payments and other transfers of value made to physicians and teaching hospitals, extensive anti-bribery and anti-corruption prohibitions, product serialization and labeling requirements and used product take-back requirements; </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">changes and the potential imposition of new or changing standards in the FDA and foreign regulatory approval processes, staffing, resources or perspectives that may delay or prevent certain processes, including, but not limited to, the approval of new products, product labels and/or formulations and approvals required for manufacturing facilities and may result in lost market opportunity; </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">government shutdowns, funding disputes, reorganizations, furloughs or reductions in staffing and/or resources or changes in priorities or focus may result in delays to the review and approval process, slowing the time necessary for new drug candidates and other regulatory matters to be reviewed and/or approved, which may adversely affect our business;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">requirements that provide for increased transparency of clinical trial results and quality data, such as the EMA's clinical transparency policy, which could impact our ability to protect trade secrets and competitively-sensitive information contained in approval applications or could be misinterpreted leading to reputational damage, misperception or legal action, which could harm our business; and</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">changes in FDA and foreign regulations that may require additional safety monitoring, labeling changes, restrictions on product distribution or use or other measures after the introduction of our products to market, which could increase our costs of doing business, adversely affect the future permitted uses of approved products or otherwise adversely affect the market for our products.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, conditions and regulations governing the healthcare industry in the U.S. are subject to greater risk of change and uncertainty as a result of changes in legislative and regulatory priorities and personnel.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Violations of governmental regulation may be punishable by criminal and civil sanctions, including fines and civil monetary penalties and exclusion from participation in government programs, including Medicare and Medicaid, as well as against executives overseeing our business. We could also be required to repay amounts we received from government payors or pay additional rebates and interest if we are found to have miscalculated the pricing information we submitted to the government. In addition, legal proceedings and investigations are inherently unpredictable, and large judgments or settlements sometimes occur. While we believe that we have appropriate compliance controls, policies and procedures in place to comply with the laws or regulations of the jurisdictions in which we operate, there is a risk that acts committed by our employees, agents, distributors, collaborators or third-party providers might violate such laws or regulations. Whether or not we have complied with the law, an investigation or litigation related to alleged unlawful conduct could increase our expense, damage our reputation, divert management time and attention and adversely affect our business.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our sales and operations are subject to the risks of doing business internationally.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are increasing our presence in international markets, subjecting us to many risks that could adversely affect our business and revenue. There is no guarantee that our efforts and strategies to expand sales in international markets will succeed. Emerging market countries may be especially vulnerable to periods of global and local political, legal, regulatory and financial instability and may have a higher incidence of corruption and fraudulent business practices. Certain countries may require local clinical trial data as part of the drug registration process in addition to global clinical trials, which can add to overall drug development and registration timelines. We may also be required to increase our reliance on third-party agents or distributors and unfamiliar operations and arrangements previously utilized by companies we collaborate with or acquire in emerging markets.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our sales and operations are subject to the risks of doing business internationally, including:</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the impact of public health epidemics on the global economy and the delivery of healthcare treatments;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">less favorable intellectual property or other applicable laws; </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the inability to obtain necessary foreign regulatory approvals of products in a timely manner; </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">limitations and additional pressures on our ability to obtain and maintain product pricing, reimbursement or receive price increases, including those resulting from governmental or regulatory requirements;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">increased cost of goods due to factors such as inflation and supply chain disruptions;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">additional complexity in manufacturing or conducting clinical research internationally, including materials manufactured in China or working with CROs in China;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">delays in clinical trials relating to geopolitical instability related to Russia's invasion of Ukraine and the military conflict in the Middle East;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the inability to successfully complete subsequent or confirmatory clinical trials in countries where our experience is limited;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">longer payment and reimbursement cycles and uncertainties regarding the collectability of accounts receivable; </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">fluctuations in foreign currency exchange rates that may adversely impact our revenue, net income and value of certain of our investments; </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the imposition of governmental controls; </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">diverse data privacy and protection requirements;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">increasingly complex standards for complying with foreign laws and regulations that may differ substantially from country to country and may conflict with corresponding U.S. laws and regulations; </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the anti-bribery and anti-corruption legislation across the globe, including the U.K. Bribery Act 2010, and elsewhere and escalation of investigations and prosecutions pursuant to such laws;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">compliance with complex import and export control laws;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">changes in tax laws; and</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the imposition of tariffs or reciprocal tariffs, trade protection measures, embargoes, import or export licensing requirements and the imposition of trade sanctions and other similar restrictions.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our international operations are also subject to regulation under U.S. law. For example, the U.S. federal government has initiated Section 232 investigations including with respect to pharmaceutical imports into the U.S. The result of these Section 232 investigations and any subsequent rulemaking could result in the government taking actions such as trade protection measures, embargoes, import or export licensing requirements, the imposition of trade sanctions or similar restrictions, which could have adverse consequences to our business and operations.</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the U.S. FCPA prohibits U.S. companies and their representatives from paying, offering to pay, promising to pay or authorizing the payment of anything of value to any foreign government official, government staff member, political party or political candidate for the purpose of obtaining or retaining business or to otherwise obtain favorable treatment or influence a person working in an official capacity. In many countries, the healthcare professionals we regularly interact with may meet the FCPA's definition of a foreign government official. Failure to comply with domestic or foreign laws could result in various adverse consequences, including possible delay in approval or refusal to approve a product, recalls, seizures or withdrawal of an approved product from the market, disruption in the supply or availability of our products or suspension of export or import privileges, the imposition of civil or criminal sanctions, the prosecution of executives overseeing our international operations and damage to our reputation. Any significant impairment of our ability to sell products outside of the U.S. could adversely impact our business and financial results. In addition, while we believe that we have appropriate compliance controls, policies and procedures in place to comply with the FCPA, there is a risk that acts committed by our employees, agents, distributors, collaborators or third-party providers might violate the FCPA and we might be held responsible. If our employees, agents, distributors, collaborators or third-party providers are found to have engaged in such practices, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we could suffer severe penalties and may be subject to other liabilities, which could negatively affect our business, operating results and financial condition.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We built a large-scale biologics manufacturing facility and are building a gene therapy, clinical packaging and other manufacturing facility, which will result in the incurrence of significant investment with no assurance that such investment will be recouped.</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to support our future growth and drug development pipeline, we have expanded our large molecule production capacity by building a large-scale biologics manufacturing facility in Solothurn, Switzerland with no assurance that the additional capacity will be required or this investment will be recouped.</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the Solothurn facility was approved by the FDA for LEQEMBI, there can be no assurance that the regulatory authorities will approve the Solothurn facility for the manufacturing of other products.</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we are building a new gene therapy, clinical packaging and other manufacturing facility as well as modernizing and automating our existing manufacturing facilities in RTP, North Carolina with no assurance that these investments will be fully utilized. </span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to fully utilize our manufacturing facilities, our business may be harmed. Charges resulting from excess capacity may occur and would have a negative effect on our financial condition and results of operations.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The illegal distribution and sale by third parties of counterfeit or unfit versions of our products or stolen products could have a negative impact on our reputation and business.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties might illegally distribute and sell counterfeit or unfit versions of our products, which do not meet our rigorous manufacturing, distribution and testing standards. A patient who receives a counterfeit or unfit drug may be at risk for a number of dangerous health consequences. Our reputation and business could suffer harm as a result of counterfeit or unfit drugs sold under our brand name. Inventory that is stolen from warehouses, plants or while in-transit, and that is subsequently improperly stored and sold through unauthorized channels, could adversely impact patient safety, our reputation and our business.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The increasing use of social media platforms presents new risks and challenges.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Social media is increasingly being used to communicate about our products and the diseases our therapies are designed to treat. Social media practices in the biopharmaceutical industry continue to evolve and regulations relating to such use are not always clear and create uncertainty and risk of noncompliance with regulations applicable to our business. For example, patients may use social media channels to comment on the effectiveness of a product or to report an alleged adverse event. When such disclosures occur, there is a risk that we may fail to monitor and comply with applicable adverse event reporting obligations or we may not be able to defend the company or the public's legitimate interests in the face of the political and market pressures generated by social media due to restrictions on what we may say about our products. There is also a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us on social media. We may also encounter criticism on social media regarding our company, management, product candidates or products. The immediacy of social media precludes us from having real-time control over postings made regarding us via social media, whether matters of fact or opinion. Our reputation could be damaged by the negative publicity generated from false or misleading social media posts concerning us, which we may not be able to reverse. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face restrictive regulatory actions or incur other harm to our business.</span></div><div style="margin-top:6pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Holding Our Common Stock</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operating results are subject to significant fluctuations.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our quarterly revenue, expense and net income have fluctuated in the past and are likely to fluctuate significantly in the future due to the risks described in these </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk Factors</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as well as the timing of charges and expense that we may take. We have recorded, or may in the future be required to record, charges that include:</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the cost of restructurings or other initiatives to streamline our operations and reallocate resources;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the costs associated with decisions to terminate research and development programs;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">impairments with respect to investments, fixed assets and long-lived assets, including IPR&amp;D and other intangible assets; </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">inventory write-downs for failed quality specifications, charges for excess capacity, charges for excess or obsolescence and charges for inventory write-downs relating to product suspensions, expirations or recalls; </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">changes in the fair value of contingent consideration or our equity investments;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">bad debt expense and increased bad debt reserves;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">outcomes of litigation and other legal or administrative proceedings, regulatory matters and tax matters;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">payments in connection with acquisitions, divestitures and other business development activities and under license and collaboration agreements;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">failure to meet certain contractual commitments; and</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the impact of public health epidemics on employees, the global economy and the delivery of healthcare.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue and certain assets and liabilities are also subject to foreign currency exchange rate fluctuations due to the global nature of our operations. Our efforts to mitigate the impact of fluctuating currency exchange rates may not be successful. As a result, currency fluctuations among our reporting currency, the U.S.&#160;dollar, and other currencies in which we do business will affect our operating results, often in unpredictable ways. Our net income may also fluctuate due to the impact of charges we may be required to take with respect to foreign currency hedge transactions. In particular, we may incur higher than expected charges from early termination of a hedge relationship.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating results during any one period do not necessarily suggest the results of future periods.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our investments in properties may not be fully realized.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own or lease real estate primarily consisting of buildings that contain research laboratories, office space and manufacturing operations. We may decide to consolidate or co-locate certain aspects of our business operations or dispose of one or more of our properties, some of which may be located in markets that are experiencing high vacancy rates and decreasing property values. If we determine that the fair value of any of our owned properties is lower than their book value, we may not realize the full investment in these properties and incur significant impairment charges or additional depreciation when the expected useful lives of certain assets have been shortened due to the anticipated closing of facilities. If we decide to fully or partially vacate a property, we may incur significant cost, including facility closing costs, employee separation and retention expense, lease termination fees, rent expense in excess of sublease income and impairment of leasehold improvements and accelerated depreciation of assets. Any of these events may have an adverse impact on our results of operations.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to access the capital and credit markets on favorable terms, which could increase financing costs.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek access to the capital and credit markets to supplement our existing funds and cash generated from operations for working capital, capital expenditure, debt refinancing, debt service requirements and other business initiatives. The capital and credit markets are experiencing, and have in the past experienced, extreme volatility and disruption, which leads to uncertainty and liquidity issues for both borrowers and investors. In the event of adverse market conditions, we may be unable to obtain capital or credit market financing on favorable terms which could significantly increase our financing costs. Changes in credit ratings issued by nationally recognized credit rating agencies could also adversely affect our cost of financing and the market price of our securities.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our indebtedness could adversely affect us and limit our ability to plan for or respond to changes in our business. </span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our indebtedness, together with our significant contingent liabilities, including milestone and royalty payment obligations, could have important consequences to our business; for example, such obligations could: </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">increase our vulnerability to general adverse economic and industry conditions;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">limit our ability to access capital markets and incur additional debt in the future;</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">require us to dedicate a substantial portion of our cash flow from operations to payments on our indebtedness, thereby reducing the availability of our cash flow for other purposes, including business development, research and development and mergers and acquisitions;&#160;and</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">limit our flexibility in planning for, or reacting to, changes in our business and the industry in which we operate, thereby placing us at a disadvantage compared to our competitors that have less debt.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our investment portfolio is subject to market, interest and credit risk that may reduce its value.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a portfolio of marketable securities for investment of our cash as well as investments in equity securities of certain biotechnology companies. Changes in the value of our investment portfolio has in the past and may in the future adversely affect our earnings. The value of our investments may decline due to, among other things, increases in interest rates, downgrades of the bonds and other securities in our portfolio, negative company-specific news, biotechnology market sentiment, instability in the global financial markets that reduces the liquidity of securities in our portfolio, declines in the value of collateral underlying the securities in our portfolio and other factors. Each of these events may cause us to record charges to reduce the carrying value of our investment portfolio or sell investments for less than our acquisition cost. Although we attempt to mitigate these risks through diversification of our investments and continuous monitoring of our portfolio's overall risk profile, the value of our investments may nevertheless decline.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">There can be no assurance that we will repurchase shares or that we will repurchase shares at favorable prices, which may negatively affect our stock price.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time our Board of Directors authorizes share repurchase programs. The amount and timing of share repurchases are subject to capital availability and our determination that share repurchases are in the best interest of our shareholders and are in compliance with all respective laws and our applicable agreements. Our ability to repurchase shares will depend upon, among other factors, our cash balances and potential future capital requirements for strategic transactions, our results of operations, our financial condition and other factors beyond our control that we may deem relevant. Additionally, the IRA includes an excise tax on share repurchases, which will increase the cost of share repurchases. A reduction in repurchases under, or the completion of, our share repurchase programs could have a negative effect on our stock price. We can provide no assurance that we will repurchase shares at favorable prices, if at all.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Some of our collaboration agreements contain change in control provisions that may discourage a third party from attempting to acquire us.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of our collaboration agreements include change in control provisions that could reduce the potential acquisition price an acquirer is willing to pay or discourage a takeover attempt that could be viewed as beneficial to shareholders. Upon a change in control, some of these provisions could result in reduced milestone, profit or royalty payments to us or give our collaboration partner rights to terminate our collaboration agreement, acquire operational control or force the purchase or sale of the programs that are the subject of the collaboration agreement.</span></div><div style="margin-top:6pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our effective tax rate fluctuates, and we may incur obligations in tax jurisdictions in excess of accrued amounts in our financial statements.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a global company, we are subject to taxation in numerous countries, states and other jurisdictions. As a result, our effective tax rate is derived from a combination of applicable tax rates, including withholding taxes, in the various places that we operate. In preparing our financial statements, we estimate the amount of tax that will become payable in each of such places. Our effective tax rate may be different than experienced in the past or our current expectations due to many factors, including changes in the mix of our profitability from country to country, the results of examinations and audits of our tax filings, adjustments to the value of our uncertain tax positions, interpretations by tax authorities or other bodies with jurisdiction, the result of tax cases, changes in accounting for income taxes and changes in tax laws, especially in the U.S. (including the OBBBA) and Switzerland, and regulations either prospectively or retrospectively and the effects of the integrations of Reata and HI-Bio. Our estimates concerning the impact of the OBBBA remain subject to developing interpretations of the provisions of the OBBBA, which may require further adjustments and changes in our estimates, and could have a material adverse effect on our business.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inability to secure or sustain acceptable arrangements with tax authorities and future changes in the tax laws, among other things, may result in tax obligations in excess of amounts accrued in our financial statements.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The enactment of some or all of the recommendations set forth or that may be forthcoming in the OECD&#8217;s project on &#8220;Base Erosion and Profit Shifting&#8221; by tax authorities and economic blocs in the countries in which we operate, could unfavorably impact our effective tax rate. Many countries have or are in the process of enacting legislation intended to implement the OECD GloBE Model Rules. The impact on the Company will depend on the timing of implementation, the exact nature of each country's GloBE legislation, guidance and regulations (including the implications of the G7 statement on the Model Rules) thereon and their application by tax authorities either prospectively or retrospectively.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business involves environmental and operational risks, which include the cost of compliance and the risk of contamination or injury.</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business and the business of several of our strategic partners involve the controlled use of hazardous materials, chemicals, biologics and radioactive compounds which make us subject to changing and evolving rules and interpretations, which could require us to incur substantial costs associated with compliance or to alter one or more of our business practices. Although we believe that our safety procedures for handling and disposing of such materials comply with state, federal and foreign standards, there will always be the risk of accidental contamination or injury. If we were to become liable for an accident, or if we were to suffer an extended facility shutdown, we could incur significant costs, damages and penalties that could harm our business. Manufacturing of our products and product candidates also requires permits from government agencies for water supply and wastewater discharge. If we do not obtain appropriate permits, including permits for sufficient quantities of water and wastewater, we could incur significant costs and limits on our manufacturing volumes that could harm our business. Additionally, regulators have passed new environmental disclosure rules. For example, the E.U., California and certain other </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">countries we do business in have promulgated new climate disclosure rules that will generally require additional disclosure. These new rules collectively will impose additional disclosure requirements relating to climate-related risks and emissions disclosures. We expect to be subject to these new laws and regulations if or when they go into effect, which would impose extensive reporting obligations about greenhouse gas emissions and climate-related financial risks. These recently enacted and proposed regulations may require us to incur compliance and disclosure costs and will likely require substantial management attention.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><div id="i59d9e1af10a84fa9992f9418986a77c7_298"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Franklin Gothic Demi',sans-serif;font-size:14pt;font-weight:400;line-height:120%">ITEM&#160;2.&#160;&#160;&#160;&#160;UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Demi',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our common stock repurchase activity under our 2020 Share Repurchase Program during the third quarter of 2025:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.040%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.620%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Number&#160;of<br/>Shares&#160;Purchased<br/>(#)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Average&#160;Price<br/>Paid&#160;per&#160;Share<br/>($)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;Number&#160;of<br/>Shares&#160;Purchased<br/>as&#160;Part&#160;of&#160;Publicly<br/>Announced Programs<br/>(#)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approximate Dollar Value<br/>of Shares That May Yet Be Purchased Under<br/>Our Programs<br/>($ in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">July 1, 2025 - July 31, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,050.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">August 1, 2025 - August 31, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,050.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">September 1, 2025 - September 30, 2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,050.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:33.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:31.105%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.578%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">There were no share repurchases during the third quarter of 2025.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020 our Board of Directors authorized our 2020 Share Repurchase Program, which is a program to repurchase up to $5.0 billion of our common stock. Our 2020 Share Repurchase Program does not have an expiration date. All shares repurchased under our 2020 Share Repurchase Program were retired. There were no share repurchases of our common stock during the three and nine months ended September 30, 2025 and 2024. Approximately $2.1 billion remained available under our 2020 Share Repurchase Program as of September 30, 2025.</span></div><div id="i59d9e1af10a84fa9992f9418986a77c7_301"></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Franklin Gothic Demi',sans-serif;font-size:14pt;font-weight:700;line-height:120%">ITEM&#160;5.&#160;&#160;&#160;&#160;OTHER INFORMATION</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Demi',sans-serif;font-size:12pt;font-weight:400;line-height:120%">TRADING ARRANGEMENTS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, our officers (as defined in Rule 16a-1(f)) and directors may enter into, amend or terminate <ix:nonNumeric contextRef="c-19" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-1924"><ix:nonNumeric contextRef="c-19" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-1925">Rule 10b5-1</ix:nonNumeric></ix:nonNumeric> or <ix:nonNumeric contextRef="c-19" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-1926"><ix:nonNumeric contextRef="c-19" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-1927">non-Rule 10b5-1</ix:nonNumeric></ix:nonNumeric> trading arrangements (as each such term is defined in Item 408 of Regulation S-K). During the third quarter of 2025 there were no trading arrangements for the purchase or sale of our securities entered into, amended or terminated by our officers and directors.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><div id="i59d9e1af10a84fa9992f9418986a77c7_307"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:14pt"><span style="color:#000000;font-family:'Franklin Gothic Demi',sans-serif;font-size:14pt;font-weight:700;line-height:120%">ITEM&#160;6.&#160;&#160;&#160;&#160;EXHIBITS</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exhibits listed below are filed or furnished as part of this Quarterly Report on Form&#160;10-Q.</span></div><div id="i59d9e1af10a84fa9992f9418986a77c7_310"></div><div style="-sec-extract:summary;margin-top:14pt;text-align:center"><span style="color:#0070c0;font-family:'Franklin Gothic Demi',sans-serif;font-size:14pt;font-weight:400;line-height:120%">EXHIBIT&#160;INDEX&#160;</span></div><div style="margin-top:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:15.444%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.024%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:77.232%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Number</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Description of Exhibit</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="biib-2025930xex311.htm">Certification of the Chief Executive Officer Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2+</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="biib-2025930xex312.htm">Certification of the Chief Financial Officer Pursuant to Section&#160;302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1++</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="biib-2025930xex321.htm">Certification Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101++</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The following materials from Biogen Inc.&#8217;s Quarterly Report on Form&#160;10-Q for the quarter ended September 30, 2025, formatted in iXBRL (Inline Extensible Business Reporting Language): (i)&#160;the Condensed Consolidated Statements of Income, (ii)&#160;the Condensed Consolidated Statements of Comprehensive Income, (iii) the Condensed Consolidated Balance Sheets, (iv)&#160;the Condensed Consolidated Statements of Cash Flow, (v) the Condensed Consolidated Statements of Equity and (vi)&#160;Notes to Condensed Consolidated Financial Statements.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104++</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The cover page from this Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, formatted in Inline XBRL.</span></div></td></tr></table></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+&#160;&#160;&#160;&#160;Filed herewith </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">++&#160;&#160;&#160;&#160;Furnished herewith</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><div id="i59d9e1af10a84fa9992f9418986a77c7_313"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%;text-decoration:underline" href="#i59d9e1af10a84fa9992f9418986a77c7_7">Table of Contents</a></span></div></div><div style="margin-top:14pt;text-align:center"><span style="color:#1c5a7d;font-family:'Franklin Gothic Demi',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></div><div style="margin-top:5pt;padding-left:297pt;text-indent:-13.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:44.590%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">BIOGEN INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;&#160;&#160;R</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">OBIN</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> C. K</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">RAMER</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robin C. Kramer</span></td></tr><tr><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(principal financial officer)</span></td></tr></table></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">October&#160;30, 2025 </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>biib-2025930xex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i4be884a1ecda4b478561ee4791bfc6f4_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Christopher A. Viehbacher, certify that&#58;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">I have reviewed this quarterly report of Biogen Inc.&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&#8211;15(e) and 15d&#8211;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&#8211;15(f) and 15d&#8211;15(f)) for the registrant and have&#58;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.23pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font><br></font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-18pt"><font><br></font></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:51.462%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.557%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; October&#160;30, 2025</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; C</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">HRISTOPHER</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> A. V</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">IEHBACHER</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Christopher A. Viehbacher</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>biib-2025930xex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i091d7298f34a4a85ab29aa4c3385d34d_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Robin C. Kramer, certify that&#58;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">I have reviewed this quarterly report of Biogen Inc.&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&#8211;15(e) and 15d&#8211;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a&#8211;15(f) and 15d&#8211;15(f)) for the registrant and have&#58;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:25.23pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.01pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:9pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.62pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font><br></font></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:51.462%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.557%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; October&#160;30, 2025</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; R</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">OBIN</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> C. K</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">RAMER</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robin C. Kramer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr></table></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>biib-2025930xex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i921e9f66a951452eb898ce47156f7fc3_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a)&#160;and (b)&#160;of section 1350, chapter 63 of title 18, United States Code), each of the undersigned officers of Biogen Inc., a Delaware corporation (the &#8220;Company&#8221;), does hereby certify, to such officer&#8217;s knowledge, that&#58;</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Quarterly Report on Form 10-Q for the quarter ended September 30, 2025 (the &#8220;Form 10-Q&#8221;) of the Company fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:9pt;text-indent:24.75pt"><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:51.462%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.557%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; October&#160;30, 2025</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; C</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">HRISTOPHER</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> A. V</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">IEHBACHER</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Christopher A. Viehbacher</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;principal executive officer&#93;</font></td></tr></table></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div><font><br></font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:51.462%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.557%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; October&#160;30, 2025</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;R</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">OBIN</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> C. K</font><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">RAMER</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robin C. Kramer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#91;principal financial officer&#93;</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:4pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A signed original of this written statement required by Section&#160;906 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>biib-20250930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:56b2dfbb-fb98-49e8-bcdc-e902c065377c,g:9aa702a5-e336-43c4-a300-999553ccda1f-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:biib="http://www.biogenidec.com/20250930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.biogenidec.com/20250930">
  <xs:import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/currency/2025" schemaLocation="https://xbrl.sec.gov/currency/2025/currency-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20250930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20250930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20250930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="biib-20250930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.biogenidec.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofIncomeUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited">
        <link:definition>9952151 - Statement - Condensed Consolidated Statements of Income (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited">
        <link:definition>9952152 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited">
        <link:definition>9952153 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>9952154 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlowsUnaudited" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited">
        <link:definition>9952155 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementofEquityStatement" roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement">
        <link:definition>9952156 - Statement - Condensed Consolidated Statement of Equity Statement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>9952157 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Acquisitions" roleURI="http://www.biogenidec.com/role/Acquisitions">
        <link:definition>9952158 - Disclosure - Acquisitions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Dispositions" roleURI="http://www.biogenidec.com/role/Dispositions">
        <link:definition>9952159 - Disclosure - Dispositions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringBusinessTransformationandOtherCostSavingInitiatives" roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiatives">
        <link:definition>9952160 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenues" roleURI="http://www.biogenidec.com/role/Revenues">
        <link:definition>9952161 - Disclosure - Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.biogenidec.com/role/Inventory">
        <link:definition>9952162 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwill" roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwill">
        <link:definition>9952163 - Disclosure - Intangible Assets and Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.biogenidec.com/role/FairValueMeasurements">
        <link:definition>9952164 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://www.biogenidec.com/role/FinancialInstruments">
        <link:definition>9952165 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstruments" roleURI="http://www.biogenidec.com/role/DerivativeInstruments">
        <link:definition>9952166 - Disclosure - Derivative Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipment" roleURI="http://www.biogenidec.com/role/PropertyPlantandEquipment">
        <link:definition>9952167 - Disclosure - Property, Plant and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.biogenidec.com/role/Leases">
        <link:definition>9952168 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Indebtedness" roleURI="http://www.biogenidec.com/role/Indebtedness">
        <link:definition>9952169 - Disclosure - Indebtedness</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Equity" roleURI="http://www.biogenidec.com/role/Equity">
        <link:definition>9952170 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsperShare" roleURI="http://www.biogenidec.com/role/EarningsperShare">
        <link:definition>9952171 - Disclosure - Earnings per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedPayments" roleURI="http://www.biogenidec.com/role/SharebasedPayments">
        <link:definition>9952172 - Disclosure - Share-based Payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.biogenidec.com/role/IncomeTaxes">
        <link:definition>9952173 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetail" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail">
        <link:definition>9952174 - Disclosure - Other Consolidated Financial Statement Detail</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationships" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationships">
        <link:definition>9952175 - Disclosure - Collaborative and Other Relationships</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinVariableInterestEntities" roleURI="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities">
        <link:definition>9952176 - Disclosure - Investments in Variable Interest Entities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Litigation" roleURI="http://www.biogenidec.com/role/Litigation">
        <link:definition>9952177 - Disclosure - Litigation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformation" roleURI="http://www.biogenidec.com/role/SegmentInformation">
        <link:definition>9952178 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.biogenidec.com/role/SubsequentEvents">
        <link:definition>9952179 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>9955511 - Disclosure - Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsTables" roleURI="http://www.biogenidec.com/role/AcquisitionsTables">
        <link:definition>9955512 - Disclosure - Acquisitions (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringBusinessTransformationandOtherCostSavingInitiativesTables" roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTables">
        <link:definition>9955513 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesTables" roleURI="http://www.biogenidec.com/role/RevenuesTables">
        <link:definition>9955514 - Disclosure - Revenues (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.biogenidec.com/role/InventoryTables">
        <link:definition>9955515 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillTables" roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables">
        <link:definition>9955516 - Disclosure - Intangible Assets and Goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables">
        <link:definition>9955517 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables">
        <link:definition>9955518 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsTables" roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables">
        <link:definition>9955519 - Disclosure - Derivative Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityTables" roleURI="http://www.biogenidec.com/role/EquityTables">
        <link:definition>9955520 - Disclosure - Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsperShareTables" roleURI="http://www.biogenidec.com/role/EarningsperShareTables">
        <link:definition>9955521 - Disclosure - Earnings per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsTables" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables">
        <link:definition>9955522 - Disclosure - Share-Based Payments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.biogenidec.com/role/IncomeTaxesTables">
        <link:definition>9955523 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailTables" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables">
        <link:definition>9955524 - Disclosure - Other Consolidated Financial Statement Detail (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsTables" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables">
        <link:definition>9955525 - Disclosure - Collaborative and Other Relationships (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationTables" roleURI="http://www.biogenidec.com/role/SegmentInformationTables">
        <link:definition>9955526 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>9955527 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsNarrativeDetails" roleURI="http://www.biogenidec.com/role/AcquisitionsNarrativeDetails">
        <link:definition>9955528 - Disclosure - Acquisitions - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsPurchasePriceConsiderationDetails" roleURI="http://www.biogenidec.com/role/AcquisitionsPurchasePriceConsiderationDetails">
        <link:definition>9955529 - Disclosure - Acquisitions - Purchase Price Consideration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsPreliminatyPurchasePriceAllocationDetails" roleURI="http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails">
        <link:definition>9955530 - Disclosure - Acquisitions - Preliminaty Purchase Price Allocation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DispositionsDetailsTextual" roleURI="http://www.biogenidec.com/role/DispositionsDetailsTextual">
        <link:definition>9955531 - Disclosure - Dispositions (Details Textual)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails" roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails">
        <link:definition>9955532 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives - FIt for Growth Initiative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails" roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails">
        <link:definition>9955533 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails" roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails">
        <link:definition>9955534 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives - Total Charges cost saving initiative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails" roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails">
        <link:definition>9955535 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives - Restructuring Reserve Roll Forward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesbyproductDetails" roleURI="http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails">
        <link:definition>9955536 - Disclosure - Revenues - Revenues by product (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesReservesforDiscountsandAllowancesDetails1" roleURI="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1">
        <link:definition>9955537 - Disclosure - Revenues Reserves for Discounts and Allowances (Details 1)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesReservesforDiscountsandAllowancesDetails2" roleURI="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2">
        <link:definition>9955538 - Disclosure - Revenues- Reserves for Discounts and Allowances (Details 2)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails" roleURI="http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails">
        <link:definition>9955539 - Disclosure - Revenues - Revenues from Anti-CD20 Therapeutic Programs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesOtherRevenuesDetails" roleURI="http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails">
        <link:definition>9955540 - Disclosure - Revenues - Other Revenues (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesNarrativeDetails" roleURI="http://www.biogenidec.com/role/RevenuesNarrativeDetails">
        <link:definition>9955541 - Disclosure - Revenues - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryComponentsofInventoryDetails" roleURI="http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails">
        <link:definition>9955542 - Disclosure - Inventory - Components of Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryNarrativeDetails" roleURI="http://www.biogenidec.com/role/InventoryNarrativeDetails">
        <link:definition>9955543 - Disclosure - Inventory - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails" roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails">
        <link:definition>9955544 - Disclosure - Intangible Assets and Goodwill - Summary of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails_1" roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails_1">
        <link:definition>9955544 - Disclosure - Intangible Assets and Goodwill - Summary of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillNarrativeDetails" roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails">
        <link:definition>9955545 - Disclosure - Intangible Assets and Goodwill - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillEstimatedFutureAmortizationofIntangibleAssetsDetails" roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillEstimatedFutureAmortizationofIntangibleAssetsDetails">
        <link:definition>9955546 - Disclosure - Intangible Assets and Goodwill - Estimated Future Amortization of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillChangesinGoodwillDetails" roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillChangesinGoodwillDetails">
        <link:definition>9955547 - Disclosure - Intangible Assets and Goodwill - Changes in Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails">
        <link:definition>9955548 - Disclosure - Fair Value Measurements - Assets and Liabilities at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativeDetails" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails">
        <link:definition>9955549 - Disclosure - Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasuresLevel3AssetsandLiabilitiesHeldatFairValueDetails" roleURI="http://www.biogenidec.com/role/FairValueMeasuresLevel3AssetsandLiabilitiesHeldatFairValueDetails">
        <link:definition>9955550 - Disclosure - Fair Value Measures - Level 3 Assets and Liabilities Held at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsContingentConsiderationObligationsDetails" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsContingentConsiderationObligationsDetails">
        <link:definition>9955551 - Disclosure - Fair Value Measurements - Contingent Consideration Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDebtInstrumentsDetails" roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDebtInstrumentsDetails">
        <link:definition>9955552 - Disclosure - Fair Value Measurements - Debt Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsSummaryoffinancialassetswithmaturitiesoflessthan90daysincludedwithincashandcashequivalentsDetails" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsSummaryoffinancialassetswithmaturitiesoflessthan90daysincludedwithincashandcashequivalentsDetails">
        <link:definition>9955553 - Disclosure - Financial Instruments - Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsMarketabledebtandequitysecuritiesDetails" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsMarketabledebtandequitysecuritiesDetails">
        <link:definition>9955554 - Disclosure - Financial Instruments - Marketable debt and equity securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsSummaryofContractualMaturitiesDetails" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsSummaryofContractualMaturitiesDetails">
        <link:definition>9955555 - Disclosure - Financial Instruments - Summary of Contractual Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsNarrativeDetails" roleURI="http://www.biogenidec.com/role/FinancialInstrumentsNarrativeDetails">
        <link:definition>9955556 - Disclosure - Financial Instruments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsNarrativeDetails" roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsNarrativeDetails">
        <link:definition>9955557 - Disclosure - Derivative Instruments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsNotionalAmountofForeignCurrencyForwardContractsandForeignCurrencyOptionsDetails" roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsNotionalAmountofForeignCurrencyForwardContractsandForeignCurrencyOptionsDetails">
        <link:definition>9955558 - Disclosure - Derivative Instruments - Notional Amount of Foreign Currency Forward Contracts and Foreign Currency Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsPretaxPortionoftheFairValueofForeignCurrencyForwardContractsandForeignCurrencyOptionsDetails" roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsPretaxPortionoftheFairValueofForeignCurrencyForwardContractsandForeignCurrencyOptionsDetails">
        <link:definition>9955559 - Disclosure - Derivative Instruments - Pre-tax Portion of the Fair Value of Foreign Currency Forward Contracts and Foreign Currency Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsEffectofForeignCurrencyForwardContractsandForwardCurrencyOptionsDesignatedasHedgingInstrumentsDetails" roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsEffectofForeignCurrencyForwardContractsandForwardCurrencyOptionsDesignatedasHedgingInstrumentsDetails">
        <link:definition>9955560 - Disclosure - Derivative Instruments - Effect of Foreign Currency Forward Contracts and Forward Currency Options Designated as Hedging Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeInstrumentsSummaryofFairValueandPresentationofDerivativesDetails" roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsSummaryofFairValueandPresentationofDerivativesDetails">
        <link:definition>9955561 - Disclosure - Derivative Instruments - Summary of Fair Value and Presentation of Derivatives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentDetails" roleURI="http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails">
        <link:definition>9955562 - Disclosure - Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.biogenidec.com/role/LeasesNarrativeDetails">
        <link:definition>9955563 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IndebtednessNarrativeDetails" roleURI="http://www.biogenidec.com/role/IndebtednessNarrativeDetails">
        <link:definition>9955564 - Disclosure - Indebtedness - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityNarrativeDetails" roleURI="http://www.biogenidec.com/role/EquityNarrativeDetails">
        <link:definition>9955565 - Disclosure - Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityAccumulatedOtherComprehensiveIncomeLossDetails" roleURI="http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails">
        <link:definition>9955566 - Disclosure - Equity - Accumulated Other Comprehensive Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityReclassifiedFromAOCIDetails" roleURI="http://www.biogenidec.com/role/EquityReclassifiedFromAOCIDetails">
        <link:definition>9955567 - Disclosure - Equity - Reclassified From AOCI (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsperShareDetails" roleURI="http://www.biogenidec.com/role/EarningsperShareDetails">
        <link:definition>9955568 - Disclosure - Earnings per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails">
        <link:definition>9955569 - Disclosure - Share-Based Payments - Share-Based Compensation Expense Included In Statements Of Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SharebasedPaymentsNarrativeDetails" roleURI="http://www.biogenidec.com/role/SharebasedPaymentsNarrativeDetails">
        <link:definition>9955570 - Disclosure - Share-based Payments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails" roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails">
        <link:definition>9955571 - Disclosure - Share-Based Payments - Share-Based Compensation Expense by Share-Based Compensation Program (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTaxRateDetails" roleURI="http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails">
        <link:definition>9955572 - Disclosure - Income Taxes - Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>9955573 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailOtherIncomeExpenseNetDetails" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherIncomeExpenseNetDetails">
        <link:definition>9955574 - Disclosure - Other Consolidated Financial Statement Detail - Other (Income) Expense, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailGainsLossesonInvestmentsNetDetails" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailGainsLossesonInvestmentsNetDetails">
        <link:definition>9955575 - Disclosure - Other Consolidated Financial Statement Detail - (Gains) Losses on Investments, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementNarrativeDetails" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementNarrativeDetails">
        <link:definition>9955576 - Disclosure - Other Consolidated Financial Statement - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherConsolidatedFinancialStatementDetailAccruedExpenseandOtherDetails" roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailAccruedExpenseandOtherDetails">
        <link:definition>9955577 - Disclosure - Other Consolidated Financial Statement Detail - Accrued Expense and Other (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsOCREVUSDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails">
        <link:definition>9955578 - Disclosure - Collaborative and Other Relationships - OCREVUS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsCopromotionProfitSharingFormulaDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCopromotionProfitSharingFormulaDetails">
        <link:definition>9955579 - Disclosure - Collaborative and Other Relationships - Co-promotion Profit Sharing Formula (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsProfitSharingDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails">
        <link:definition>9955580 - Disclosure - Collaborative and Other Relationships - Profit Sharing (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsPretaxProfitSharingFormulaDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsPretaxProfitSharingFormulaDetails">
        <link:definition>9955581 - Disclosure - Collaborative and Other Relationships - Pretax Profit Sharing Formula (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsIonisPharmaceuticalsIncDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsIonisPharmaceuticalsIncDetails">
        <link:definition>9955582 - Disclosure - Collaborative and Other Relationships - Ionis Pharmaceuticals, Inc (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsEisaiDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails">
        <link:definition>9955583 - Disclosure - Collaborative and Other Relationships - Eisai (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoLEQEMBICollaborationDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoLEQEMBICollaborationDetails">
        <link:definition>9955584 - Disclosure - Collaborative and Other Relationships - Summary of Activity Related to LEQEMBI Collaboration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails">
        <link:definition>9955585 - Disclosure - Collaborative and Other Relationships - Summary of Activity Related to the UCB Collaboration (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsSageTherapeuticsIncDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSageTherapeuticsIncDetails">
        <link:definition>9955586 - Disclosure - Collaborative and Other Relationships - Sage Therapeutics, Inc. (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails">
        <link:definition>9955587 - Disclosure - Collaborative and Other Relationships - Summary of Activity Related to Sage Therapeutics (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails">
        <link:definition>9955588 - Disclosure - Collaborative and Other Relationships - Summary of Activity Related To Denali Therapeutics (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsStokeTherapeuticsIncDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsStokeTherapeuticsIncDetails">
        <link:definition>9955589 - Disclosure - Collaborative and Other Relationships - Stoke Therapeutics, Inc. (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoStokeTherapeuticsDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoStokeTherapeuticsDetails">
        <link:definition>9955590 - Disclosure - Collaborative and Other Relationships Summary of Activity Related to Stoke Therapeutics (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsSamsungBioepisDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails">
        <link:definition>9955591 - Disclosure - Collaborative and Other Relationships - Samsung Bioepis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborativeandOtherRelationshipsOtherResearchandDiscoveryArrangementsandFundingArrangementsDetails" roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherResearchandDiscoveryArrangementsandFundingArrangementsDetails">
        <link:definition>9955592 - Disclosure - Collaborative and Other Relationships - Other Research and Discovery Arrangements and Funding Arrangements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsinVariableInterestEntitiesDetails" roleURI="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails">
        <link:definition>9955593 - Disclosure - Investments in Variable Interest Entities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LitigationDetails" roleURI="http://www.biogenidec.com/role/LitigationDetails">
        <link:definition>9955594 - Disclosure - Litigation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationNarrativeDetails" roleURI="http://www.biogenidec.com/role/SegmentInformationNarrativeDetails">
        <link:definition>9955595 - Disclosure - Segment Information - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationAdditionalSegmentInformationDetails" roleURI="http://www.biogenidec.com/role/SegmentInformationAdditionalSegmentInformationDetails">
        <link:definition>9955596 - Disclosure - Segment Information - Additional Segment Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsDetails" roleURI="http://www.biogenidec.com/role/SubsequentEventsDetails">
        <link:definition>9955597 - Disclosure - Subsequent Events (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="biib_Revenuesfromanticd20therapeuticprogramsMember" abstract="true" name="Revenuesfromanticd20therapeuticprogramsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_LEQEMBICollaborationMember" abstract="true" name="LEQEMBICollaborationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_ResearchAndDevelopmentExpenseIncludingAcquiredInProcessCost" abstract="false" name="ResearchAndDevelopmentExpenseIncludingAcquiredInProcessCost" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets" abstract="false" name="AmortizationAndImpairmentOfAcquiredIntangibleAssets" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_Collaborationprofitlosssharing" abstract="false" name="Collaborationprofitlosssharing" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_AmortizationOfInventoryStepUp" abstract="false" name="AmortizationOfInventoryStepUp" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_DivestituresAbstract" abstract="true" name="DivestituresAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="biib_InvestmentsInVariableInterestEntitiesAbstract" abstract="true" name="InvestmentsInVariableInterestEntitiesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="biib_BusinessOverviewPolicyTextBlock" abstract="false" name="BusinessOverviewPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" abstract="false" name="AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" abstract="false" name="SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" abstract="false" name="RevenuesfromantiCD20therapeuticprogramsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="biib_OtherrevenuesTableTextBlock" abstract="false" name="OtherrevenuesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="biib_IntangibleAssetsExcludingGoodwillTableTextBlock" abstract="false" name="IntangibleAssetsExcludingGoodwillTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock" abstract="false" name="DerivativeInstrumentsUnrealizedGainLossTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="biib_CoPromotionProfitSharingFormulaTableTextBlock" abstract="false" name="CoPromotionProfitSharingFormulaTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" abstract="false" name="SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock" abstract="false" name="SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="biib_SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock" abstract="false" name="SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" abstract="false" name="SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="biib_SummaryOfActivityRelatedToCollaborationTableTextBlock" abstract="false" name="SummaryOfActivityRelatedToCollaborationTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="biib_InterestInSubsidiary" abstract="false" name="InterestInSubsidiary" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="biib_AlcyoneTherapeuticsInc.Member" abstract="true" name="AlcyoneTherapeuticsInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_HumanImmunologyBiosciencesMember" abstract="true" name="HumanImmunologyBiosciencesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_MeasurementInputProbabilityRateMember" abstract="true" name="MeasurementInputProbabilityRateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_Phase3ClinicalTrialFelzartamabOneMember" abstract="true" name="Phase3ClinicalTrialFelzartamabOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_Phase3ClinicalTrialFelzartamabTwoMember" abstract="true" name="Phase3ClinicalTrialFelzartamabTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_Phase3ClinicalTrialFelzartamabAMRMember" abstract="true" name="Phase3ClinicalTrialFelzartamabAMRMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_Phase3ClinicalTrialFelzartamabIgANMember" abstract="true" name="Phase3ClinicalTrialFelzartamabIgANMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_MilestonePaymentFutureDevelopmentMember" abstract="true" name="MilestonePaymentFutureDevelopmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_MilestonePaymentRegulatoryMember" abstract="true" name="MilestonePaymentRegulatoryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_MilestonePaymentCommercialMember" abstract="true" name="MilestonePaymentCommercialMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_FelzartamabAndIzastobartHIB210Member" abstract="true" name="FelzartamabAndIzastobartHIB210Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_FelzartamabIgANMember" abstract="true" name="FelzartamabIgANMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_FelzartamabAMRMember" abstract="true" name="FelzartamabAMRMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_FelzartamabPMNMember" abstract="true" name="FelzartamabPMNMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_HumanImmunologyBiosciencesPreExistingInLicenseCommitmentsMember" abstract="true" name="HumanImmunologyBiosciencesPreExistingInLicenseCommitmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_PaymentsToAcquireBusinessGrossNonVestedEquityAwards" abstract="false" name="PaymentsToAcquireBusinessGrossNonVestedEquityAwards" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_BusinessCombinationConsiderationTransferredWorkingCapitalAdjustment" abstract="false" name="BusinessCombinationConsiderationTransferredWorkingCapitalAdjustment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" abstract="false" name="EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_IntangibleAssetMeasurementInput" abstract="false" name="IntangibleAssetMeasurementInput" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="biib_OtherClinicalProgramsMember" abstract="true" name="OtherClinicalProgramsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpenseAndOther" abstract="false" name="BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpenseAndOther" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability" abstract="false" name="BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill" abstract="false" name="BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_SamsungBiosimilarAgreementMember" abstract="true" name="SamsungBiosimilarAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_FutureContingentMilestoneTypesAxis" abstract="true" name="FutureContingentMilestoneTypesAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="biib_FutureContingentMilestoneTypesDomain" abstract="true" name="FutureContingentMilestoneTypesDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_PaymentDueAtFirstAnniversaryMember" abstract="true" name="PaymentDueAtFirstAnniversaryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_PaymentDueAtSecondAnniversaryMember" abstract="true" name="PaymentDueAtSecondAnniversaryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_IonisPharmaceuticalsInc.Member" abstract="true" name="IonisPharmaceuticalsInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_PayablesToDivestitureOfInterestInJointVenture" abstract="false" name="PayablesToDivestitureOfInterestInJointVenture" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_ProceedsPaidToCollaborativeArrangementCounterparty" abstract="false" name="ProceedsPaidToCollaborativeArrangementCounterparty" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_A2023CostSavingInitiativesMember" abstract="true" name="A2023CostSavingInitiativesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_ReataIntegrationMember" abstract="true" name="ReataIntegrationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_ReataPharmaceuticalsIncMember" abstract="true" name="ReataPharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction" abstract="false" name="RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_OperatingLeaseArea" abstract="false" name="OperatingLeaseArea" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:areaItemType"/>
  <xs:element id="biib_A2023And2022CostSavingInitiativesMember" abstract="true" name="A2023And2022CostSavingInitiativesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_MSProductRevenuesMember" abstract="true" name="MSProductRevenuesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_FumarateMember" abstract="true" name="FumarateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_TECFIDERAMember" abstract="true" name="TECFIDERAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_VUMERITYMember" abstract="true" name="VUMERITYMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_InterferonMember" abstract="true" name="InterferonMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_AVONEXMember" abstract="true" name="AVONEXMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_PLEGRIDYMember" abstract="true" name="PLEGRIDYMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_TysabriProductMember" abstract="true" name="TysabriProductMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_FAMPYRAMember" abstract="true" name="FAMPYRAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_RareDiseaseProductRevenueMember" abstract="true" name="RareDiseaseProductRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_QALSODYMember" abstract="true" name="QALSODYMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_SPINRAZAMember" abstract="true" name="SPINRAZAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_SKYCLARYSMember" abstract="true" name="SKYCLARYSMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_BiosimilarsMember" abstract="true" name="BiosimilarsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_BENEPALIMember" abstract="true" name="BENEPALIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_IMRALDIMember" abstract="true" name="IMRALDIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_FLIXABIMember" abstract="true" name="FLIXABIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_BYOOVIZMember" abstract="true" name="BYOOVIZMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_TOFIDENCEMember" abstract="true" name="TOFIDENCEMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_OtherProductsMember" abstract="true" name="OtherProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_ZURZUVAEMember" abstract="true" name="ZURZUVAEMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_FUMADERMAndADUHELMMember" abstract="true" name="FUMADERMAndADUHELMMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_ReserveforCashDiscountsMember" abstract="true" name="ReserveforCashDiscountsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_ContractualAdjustmentsMember" abstract="true" name="ContractualAdjustmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" abstract="false" name="CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" abstract="false" name="AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" abstract="false" name="PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" abstract="false" name="PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_RoyaltyAttributedToOCREVUSMember" abstract="true" name="RoyaltyAttributedToOCREVUSMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_RocheGroupGenentechMember" abstract="true" name="RocheGroupGenentechMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_ShareOfCoPromotionProfits" abstract="false" name="ShareOfCoPromotionProfits" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_OtherrevenuesfromantiCD20therapeuticprograms" abstract="false" name="OtherrevenuesfromantiCD20therapeuticprograms" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_OtherrevenuesAbstract" abstract="true" name="OtherrevenuesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="biib_ContractManufacturingAndOtherRevenueMember" abstract="true" name="ContractManufacturingAndOtherRevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_AlzheimersCollaborationMember" abstract="true" name="AlzheimersCollaborationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_DistributorOneMember" abstract="true" name="DistributorOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_DistributorTwoMember" abstract="true" name="DistributorTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_EntityWidePercentageOfRevenueFromMajorDistributors" abstract="false" name="EntityWidePercentageOfRevenueFromMajorDistributors" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="biib_NumberOfWholesalers" abstract="false" name="NumberOfWholesalers" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="biib_ShareOfNonControlingInterestRecognized" abstract="false" name="ShareOfNonControlingInterestRecognized" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="biib_InventoryNetCurrentAndNoncurrent" abstract="false" name="InventoryNetCurrentAndNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_EisaiMember" abstract="true" name="EisaiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_ClinicalInventoryMember" abstract="true" name="ClinicalInventoryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_AcquiredAndInLicensedRightsAndPatentsMember" abstract="true" name="AcquiredAndInLicensedRightsAndPatentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_PriorityReviewVoucherMember" abstract="true" name="PriorityReviewVoucherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife" abstract="false" name="FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="biib_PlanAssetsForDeferredCompensationFairValueDisclosure" abstract="false" name="PlanAssetsForDeferredCompensationFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" abstract="true" name="SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_A2.25SeniorNotesdueMay12030Member" abstract="true" name="A2.25SeniorNotesdueMay12030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_A5.050SeniorNotesDueJanuary152031Member" abstract="true" name="A5.050SeniorNotesDueJanuary152031Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_A5.750SeniorNotesDueMay152035Member" abstract="true" name="A5.750SeniorNotesDueMay152035Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" abstract="true" name="SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_A3.15SeniorNotesdueMay12050Member" abstract="true" name="A3.15SeniorNotesdueMay12050Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_SeniorNotes3.250DueFebruary152051Member" abstract="true" name="SeniorNotes3.250DueFebruary152051Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_A6.450SeniorNotesDueMay152055Member" abstract="true" name="A6.450SeniorNotesDueMay152055Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_NonCurrentPortionOfNotesPayableAndTermLoanMember" abstract="true" name="NonCurrentPortionOfNotesPayableAndTermLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_NotesPayableCurrentFairValueDisclosure" abstract="false" name="NotesPayableCurrentFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_CorporateDebtSecuritiesCurrentMember" abstract="true" name="CorporateDebtSecuritiesCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_GovernmentSecuritiesCurrentMember" abstract="true" name="GovernmentSecuritiesCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_EquitySecuritiesNonCurrentMember" abstract="true" name="EquitySecuritiesNonCurrentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" abstract="false" name="EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" abstract="false" name="EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_StrategicInvestmentsMember" abstract="true" name="StrategicInvestmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_DebtSecuritiesAvailableForSaleAverageMaturity" abstract="false" name="DebtSecuritiesAvailableForSaleAverageMaturity" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="biib_StrategicInvestmentPortfolio" abstract="false" name="StrategicInvestmentPortfolio" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months" abstract="false" name="ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_UnrealizedGainOnDerivatives" abstract="false" name="UnrealizedGainOnDerivatives" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_UnrealizedLossOnDerivatives" abstract="false" name="UnrealizedLossOnDerivatives" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_CashflowsrevenueMember" abstract="true" name="CashflowsrevenueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_CashflowsoperatingexpensesMember" abstract="true" name="CashflowsoperatingexpensesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_HeadquartersLeaseFiveYearRenewalOptionMember" abstract="true" name="HeadquartersLeaseFiveYearRenewalOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_HeadquartersLeaseSixMonthRenewalOptionMember" abstract="true" name="HeadquartersLeaseSixMonthRenewalOptionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_ReductionOfRealEstateFootprint" abstract="false" name="ReductionOfRealEstateFootprint" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="biib_LesseeOperatingLeaseNumberOfRenewalOptions" abstract="false" name="LesseeOperatingLeaseNumberOfRenewalOptions" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="biib_A2025SeniorNotesMember" abstract="true" name="A2025SeniorNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_TheCreditFacilityMember" abstract="true" name="TheCreditFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_TheCreditFacilityFloatingRate364DayTrancheMember" abstract="true" name="TheCreditFacilityFloatingRate364DayTrancheMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_TheCreditFacilityFloatingRateThreeYearTrancheMember" abstract="true" name="TheCreditFacilityFloatingRateThreeYearTrancheMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_TheCreditFacilityTerminatedMember" abstract="true" name="TheCreditFacilityTerminatedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_A2023TermLoanMember" abstract="true" name="A2023TermLoanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_FloatingRate364DayTrancheMember" abstract="true" name="FloatingRate364DayTrancheMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_TermLoan2023ThreeYearTrancheMember" abstract="true" name="TermLoan2023ThreeYearTrancheMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_PercentageParValueOfSeniorNotes" abstract="false" name="PercentageParValueOfSeniorNotes" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage" abstract="false" name="DebtInstrumentMakeWholeProvisionRedemptionPricePercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="biib_A2020ShareRepurchaseProgramMember" abstract="true" name="A2020ShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" abstract="true" name="ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="biib_TimeVestedRestrictedStockUnitsMember" abstract="true" name="TimeVestedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_PerformanceStockUnitsSettledinStockMember" abstract="true" name="PerformanceStockUnitsSettledinStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_BasicAndDilutedEarningsPerShareAbstract" abstract="true" name="BasicAndDilutedEarningsPerShareAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" abstract="false" name="ShareBasedCompensationExpenseIncludedInCostsAndExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_EmployeeStockPurchasePlanMember" abstract="true" name="EmployeeStockPurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_PerformanceStockUnitsSettledinCashMember" abstract="true" name="PerformanceStockUnitsSettledinCashMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_MarketStockUnitsMember" abstract="true" name="MarketStockUnitsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" abstract="true" name="SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="biib_EffectiveTaxRateReconciliationShareBasedCompensationAwards" abstract="false" name="EffectiveTaxRateReconciliationShareBasedCompensationAwards" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="biib_EffectiveTaxRateReconciliationOneBigBeautifulBillActEnactment" abstract="false" name="EffectiveTaxRateReconciliationOneBigBeautifulBillActEnactment" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="biib_SageAndDenaliMember" abstract="true" name="SageAndDenaliMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_SageAndSangamoMember" abstract="true" name="SageAndSangamoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_DenaliTherapeuticsIncMember" abstract="true" name="DenaliTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_SageTherapeuticsIncMember" abstract="true" name="SageTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_Collaborationexpensesaccrual" abstract="false" name="Collaborationexpensesaccrual" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_OCREVUSMember" abstract="true" name="OCREVUSMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" abstract="false" name="FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage" abstract="false" name="Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_Reductioninroyaltyrate" abstract="false" name="Reductioninroyaltyrate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="biib_PeriodOfCollaborationAgreement" abstract="false" name="PeriodOfCollaborationAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="biib_RituxanMember" abstract="true" name="RituxanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_LUNSUMIOMember" abstract="true" name="LUNSUMIOMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" abstract="false" name="PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" abstract="false" name="PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour" abstract="false" name="PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" abstract="false" name="CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_GAZYVAMember" abstract="true" name="GAZYVAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion" abstract="false" name="PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne" abstract="false" name="ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne" abstract="false" name="ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_SalesTriggerGrossSalesThreshold" abstract="false" name="SalesTriggerGrossSalesThreshold" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_EstimatedAdditionalPaymentsUponInitiationOfNewPhases" abstract="false" name="EstimatedAdditionalPaymentsUponInitiationOfNewPhases" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold" abstract="false" name="ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_AccountsReceivableFromCollaborator" abstract="false" name="AccountsReceivableFromCollaborator" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_AccountsPayableToCollaborator" abstract="false" name="AccountsPayableToCollaborator" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_LEQEMBIMember" abstract="true" name="LEQEMBIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_E2609andBAN2401Member" abstract="true" name="E2609andBAN2401Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_ExpenseIncurredByCollaboration" abstract="false" name="ExpenseIncurredByCollaboration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_Expensereflectedwithinstatementsofincome" abstract="false" name="Expensereflectedwithinstatementsofincome" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_Expenseincurredbythecollaboration" abstract="false" name="Expenseincurredbythecollaboration" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_UCBPharmaSAMember" abstract="true" name="UCBPharmaSAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" abstract="false" name="PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_ShareOfNetProfitFromSageTherapeuticsPercent" abstract="false" name="ShareOfNetProfitFromSageTherapeuticsPercent" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="biib_StokeTherapeuticsIncMember" abstract="true" name="StokeTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_MilestonePaymentDevelopmentalMember" abstract="true" name="MilestonePaymentDevelopmentalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_ZorevunersenMember" abstract="true" name="ZorevunersenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_PercentageOfFutureDevelopmentCosts" abstract="false" name="PercentageOfFutureDevelopmentCosts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" abstract="false" name="UpfrontAndMilestonePaymentsMadeToCollaborativePartner" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_ContingentCommercializedRightsNumberOfProducts" abstract="false" name="ContingentCommercializedRightsNumberOfProducts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="biib_EquityMethodInvestmentsExpectedProfitShare" abstract="false" name="EquityMethodInvestmentsExpectedProfitShare" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="biib_CollaborativeArrangementTermExtension" abstract="false" name="CollaborativeArrangementTermExtension" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="biib_ContractOptionExerciseFee" abstract="false" name="ContractOptionExerciseFee" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_MilestonePaymentOneMember" abstract="true" name="MilestonePaymentOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_MilestonePaymentTwoMember" abstract="true" name="MilestonePaymentTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_MilestonePaymentResearchMember" abstract="true" name="MilestonePaymentResearchMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_MilestonePaymentSalesBasedMember" abstract="true" name="MilestonePaymentSalesBasedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_CityTherapeuticsInc.Member" abstract="true" name="CityTherapeuticsInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_CollaborativeArrangementExpectedDevelopmentCostFundsYearOne" abstract="false" name="CollaborativeArrangementExpectedDevelopmentCostFundsYearOne" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_CollaborativeArrangementExpectedDevelopmentCostFundsYearTwo" abstract="false" name="CollaborativeArrangementExpectedDevelopmentCostFundsYearTwo" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_ReductionOfResearchAndDevelopmentExpense" abstract="false" name="ReductionOfResearchAndDevelopmentExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_CollaborativeArrangementsInvestmentsInCounterparty" abstract="false" name="CollaborativeArrangementsInvestmentsInCounterparty" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" abstract="false" name="InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="biib_IMRALDIPatentLitigationMember" abstract="true" name="IMRALDIPatentLitigationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_ConvergenceMember" abstract="true" name="ConvergenceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_GenentechMember" abstract="true" name="GenentechMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_ReportableSegmentMember" abstract="true" name="ReportableSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_ResearchAndDiscoveryMember" abstract="true" name="ResearchAndDiscoveryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_EarlyStageProgramsMember" abstract="true" name="EarlyStageProgramsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_LateStageProgramsMember" abstract="true" name="LateStageProgramsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_MarketedProductsMember" abstract="true" name="MarketedProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="biib_VanquaBioInc.Member" abstract="true" name="VanquaBioInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>biib-20250930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:56b2dfbb-fb98-49e8-bcdc-e902c065377c,g:9aa702a5-e336-43c4-a300-999553ccda1f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="simple" xlink:href="biib-20250930.xsd#CondensedConsolidatedStatementsofIncomeUnaudited"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_a7ed90c6-3d80-42a9-9c37-451308c4ef9f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_7b021df9-c2b7-4f6e-8734-6e0acf0c0ed1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_a7ed90c6-3d80-42a9-9c37-451308c4ef9f" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_7b021df9-c2b7-4f6e-8734-6e0acf0c0ed1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_0a8478db-f05e-4b46-88e6-9ba0dc79c7b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_a7ed90c6-3d80-42a9-9c37-451308c4ef9f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_0a8478db-f05e-4b46-88e6-9ba0dc79c7b6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchAndDevelopmentExpenseIncludingAcquiredInProcessCost_d76bec47-d123-4da3-a162-fa69c44b731c" xlink:href="biib-20250930.xsd#biib_ResearchAndDevelopmentExpenseIncludingAcquiredInProcessCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_a7ed90c6-3d80-42a9-9c37-451308c4ef9f" xlink:to="loc_biib_ResearchAndDevelopmentExpenseIncludingAcquiredInProcessCost_d76bec47-d123-4da3-a162-fa69c44b731c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_22022aa7-05e3-4f45-99c3-d604525b876f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_a7ed90c6-3d80-42a9-9c37-451308c4ef9f" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_22022aa7-05e3-4f45-99c3-d604525b876f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_f51a635a-cc0f-4762-9bec-7b75551efa8d" xlink:href="biib-20250930.xsd#biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_a7ed90c6-3d80-42a9-9c37-451308c4ef9f" xlink:to="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_f51a635a-cc0f-4762-9bec-7b75551efa8d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationprofitlosssharing_ab3965c1-29ae-4e71-bf1b-5774f9f5770d" xlink:href="biib-20250930.xsd#biib_Collaborationprofitlosssharing"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_a7ed90c6-3d80-42a9-9c37-451308c4ef9f" xlink:to="loc_biib_Collaborationprofitlosssharing_ab3965c1-29ae-4e71-bf1b-5774f9f5770d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_6d7a6773-8596-43f3-85b2-49ce2f426b68" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_a7ed90c6-3d80-42a9-9c37-451308c4ef9f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_6d7a6773-8596-43f3-85b2-49ce2f426b68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_c6f181c5-0172-4340-ad86-e1ce3ff50f8a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCharges"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_a7ed90c6-3d80-42a9-9c37-451308c4ef9f" xlink:to="loc_us-gaap_RestructuringCharges_c6f181c5-0172-4340-ad86-e1ce3ff50f8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_5d856ecd-a8fe-4456-9a10-b9e944c660a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_a7ed90c6-3d80-42a9-9c37-451308c4ef9f" xlink:to="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_5d856ecd-a8fe-4456-9a10-b9e944c660a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_1691ad2a-f7d0-432f-8a39-65f74d83bff5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_a7ed90c6-3d80-42a9-9c37-451308c4ef9f" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_1691ad2a-f7d0-432f-8a39-65f74d83bff5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_74d7beca-7b89-4ec7-81d1-250b31ccadf8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_d2128b60-2b74-4920-97a6-f26168f9e6dc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_74d7beca-7b89-4ec7-81d1-250b31ccadf8" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_d2128b60-2b74-4920-97a6-f26168f9e6dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cee58f87-bea8-44de-b053-55773dcff13b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_74d7beca-7b89-4ec7-81d1-250b31ccadf8" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_cee58f87-bea8-44de-b053-55773dcff13b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ef727529-c4e4-4782-9b4f-7667ecee1e3e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_50ec72ca-1284-4a08-8fb6-d0df742a60d1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ef727529-c4e4-4782-9b4f-7667ecee1e3e" xlink:to="loc_us-gaap_Revenues_50ec72ca-1284-4a08-8fb6-d0df742a60d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_d1723524-6302-433e-aa43-72f3e25e7141" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ef727529-c4e4-4782-9b4f-7667ecee1e3e" xlink:to="loc_us-gaap_CostsAndExpenses_d1723524-6302-433e-aa43-72f3e25e7141" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" xlink:type="simple" xlink:href="biib-20250930.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_73b6c4e0-b2bc-4b01-89a9-89370991a0cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_10d167ee-5d63-4926-be0b-8a0f069fe0f2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_73b6c4e0-b2bc-4b01-89a9-89370991a0cc" xlink:to="loc_us-gaap_NetIncomeLoss_10d167ee-5d63-4926-be0b-8a0f069fe0f2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_32f3fc7f-6069-4ed6-91b3-0a733739cd0e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_73b6c4e0-b2bc-4b01-89a9-89370991a0cc" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_32f3fc7f-6069-4ed6-91b3-0a733739cd0e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_9f086cca-8fd8-4e69-8e09-0bb2dbac9097" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_83f333a2-07b0-4e68-b3f5-bc1ca1eaee75" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_9f086cca-8fd8-4e69-8e09-0bb2dbac9097" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_83f333a2-07b0-4e68-b3f5-bc1ca1eaee75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_d642b35b-4834-48d2-b759-6696c2cae43c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_9f086cca-8fd8-4e69-8e09-0bb2dbac9097" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_d642b35b-4834-48d2-b759-6696c2cae43c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_641432b8-8d50-4bf5-badd-1789faa2c16b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_9f086cca-8fd8-4e69-8e09-0bb2dbac9097" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_641432b8-8d50-4bf5-badd-1789faa2c16b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="biib-20250930.xsd#CondensedConsolidatedBalanceSheetsUnaudited"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_30b26649-11b7-40c6-a311-e7dcca288bb8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9d9716dc-d477-4910-8a13-0494d6a6cd30" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_30b26649-11b7-40c6-a311-e7dcca288bb8" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_9d9716dc-d477-4910-8a13-0494d6a6cd30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_5d3ff453-5ecb-433a-87ff-517dc412e83e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_30b26649-11b7-40c6-a311-e7dcca288bb8" xlink:to="loc_us-gaap_Liabilities_5d3ff453-5ecb-433a-87ff-517dc412e83e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_d6fcc247-e1e3-469f-b4f0-7436699a8a4b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_30b26649-11b7-40c6-a311-e7dcca288bb8" xlink:to="loc_us-gaap_CommitmentsAndContingencies_d6fcc247-e1e3-469f-b4f0-7436699a8a4b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_5b23d4ce-a017-424d-b8c7-0ce85dd44233" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f702b716-ff5e-40b6-96a7-e162a686f20a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_5b23d4ce-a017-424d-b8c7-0ce85dd44233" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f702b716-ff5e-40b6-96a7-e162a686f20a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_1e6de91e-7343-4550-9d35-6696bce4d81b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_5b23d4ce-a017-424d-b8c7-0ce85dd44233" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_1e6de91e-7343-4550-9d35-6696bce4d81b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_66a38bf4-0f10-4817-a814-86c66b2ad0ae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_5b23d4ce-a017-424d-b8c7-0ce85dd44233" xlink:to="loc_us-gaap_InventoryNet_66a38bf4-0f10-4817-a814-86c66b2ad0ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_31c3de22-02e5-45cf-920a-394a79a3caf1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_5b23d4ce-a017-424d-b8c7-0ce85dd44233" xlink:to="loc_us-gaap_OtherAssetsCurrent_31c3de22-02e5-45cf-920a-394a79a3caf1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_da494b4f-434e-42fd-b22b-5d6f8f614e46" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_5b23d4ce-a017-424d-b8c7-0ce85dd44233" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_da494b4f-434e-42fd-b22b-5d6f8f614e46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_56ec1b87-354f-44fa-b79f-204834945947" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_3bdbbc0e-e933-409b-baa0-6732b8ad8eb3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_56ec1b87-354f-44fa-b79f-204834945947" xlink:to="loc_us-gaap_AssetsCurrent_3bdbbc0e-e933-409b-baa0-6732b8ad8eb3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_c376bf85-1eff-4d92-af52-4e8deaffd6bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_56ec1b87-354f-44fa-b79f-204834945947" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_c376bf85-1eff-4d92-af52-4e8deaffd6bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_2455c0d5-ab40-4721-8684-b2829932b865" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_56ec1b87-354f-44fa-b79f-204834945947" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_2455c0d5-ab40-4721-8684-b2829932b865" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_ce9ffcb7-18eb-45ec-9577-fce15e8b706f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_56ec1b87-354f-44fa-b79f-204834945947" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_ce9ffcb7-18eb-45ec-9577-fce15e8b706f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_c0367632-2815-4bf8-9087-d452aa8b859e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_56ec1b87-354f-44fa-b79f-204834945947" xlink:to="loc_us-gaap_Goodwill_c0367632-2815-4bf8-9087-d452aa8b859e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_a6d1ec24-468a-495c-966e-6539f750875e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_56ec1b87-354f-44fa-b79f-204834945947" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_a6d1ec24-468a-495c-966e-6539f750875e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_b667a8b6-adb2-4e9b-a883-6137c23825ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_56ec1b87-354f-44fa-b79f-204834945947" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_b667a8b6-adb2-4e9b-a883-6137c23825ad" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_3cbe16b8-0f89-45b0-92cc-d5e65bbfdf6c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_e653841d-2410-47e7-b18d-ee624b18922f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_3cbe16b8-0f89-45b0-92cc-d5e65bbfdf6c" xlink:to="loc_us-gaap_NotesPayableCurrent_e653841d-2410-47e7-b18d-ee624b18922f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_a3341ddc-5218-4300-8961-9feb213715e8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_3cbe16b8-0f89-45b0-92cc-d5e65bbfdf6c" xlink:to="loc_us-gaap_AccountsPayableCurrent_a3341ddc-5218-4300-8961-9feb213715e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_fa0f9e4a-d219-4e34-892f-e1348ab81774" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_3cbe16b8-0f89-45b0-92cc-d5e65bbfdf6c" xlink:to="loc_us-gaap_TaxesPayableCurrent_fa0f9e4a-d219-4e34-892f-e1348ab81774" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_eef98e10-114d-4eef-b0c5-8e2470bad116" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_3cbe16b8-0f89-45b0-92cc-d5e65bbfdf6c" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_eef98e10-114d-4eef-b0c5-8e2470bad116" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_a4245cd5-c25d-44dd-aa53-e45abb17c79a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_f4262e66-6964-4e1c-932f-35d4da65d878" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a4245cd5-c25d-44dd-aa53-e45abb17c79a" xlink:to="loc_us-gaap_LiabilitiesCurrent_f4262e66-6964-4e1c-932f-35d4da65d878" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_aefd5881-c2cd-46b5-86ea-e03f04aa0357" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a4245cd5-c25d-44dd-aa53-e45abb17c79a" xlink:to="loc_us-gaap_LongTermDebt_aefd5881-c2cd-46b5-86ea-e03f04aa0357" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_50377876-5403-4c7a-9f4f-9ee13c412fc9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a4245cd5-c25d-44dd-aa53-e45abb17c79a" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_50377876-5403-4c7a-9f4f-9ee13c412fc9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_97bdbbf6-4c82-4238-b1a8-cce8f1809e22" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a4245cd5-c25d-44dd-aa53-e45abb17c79a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_97bdbbf6-4c82-4238-b1a8-cce8f1809e22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_f2472a4d-0a1d-4510-8827-a2e7dd124639" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a4245cd5-c25d-44dd-aa53-e45abb17c79a" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_f2472a4d-0a1d-4510-8827-a2e7dd124639" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5f57e8ce-4ae3-4e74-bd08-a4f806f189ee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_b3aa97c9-b48e-4d15-9d1c-a69ce7785c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5f57e8ce-4ae3-4e74-bd08-a4f806f189ee" xlink:to="loc_us-gaap_TreasuryStockValue_b3aa97c9-b48e-4d15-9d1c-a69ce7785c3d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_a237c12e-f115-4984-acfa-552591f674af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5f57e8ce-4ae3-4e74-bd08-a4f806f189ee" xlink:to="loc_us-gaap_AdditionalPaidInCapital_a237c12e-f115-4984-acfa-552591f674af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7629ea18-936a-4c71-b95f-1318dfaed08b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5f57e8ce-4ae3-4e74-bd08-a4f806f189ee" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7629ea18-936a-4c71-b95f-1318dfaed08b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_849cf58f-a309-4d7a-9a62-0a697bea32ce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5f57e8ce-4ae3-4e74-bd08-a4f806f189ee" xlink:to="loc_us-gaap_PreferredStockValue_849cf58f-a309-4d7a-9a62-0a697bea32ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_1ea80610-6ae9-4a19-805c-b1fd87e4583c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5f57e8ce-4ae3-4e74-bd08-a4f806f189ee" xlink:to="loc_us-gaap_CommonStockValue_1ea80610-6ae9-4a19-805c-b1fd87e4583c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_090a18b3-429b-4004-9562-e35a74d585c5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_5f57e8ce-4ae3-4e74-bd08-a4f806f189ee" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_090a18b3-429b-4004-9562-e35a74d585c5" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="biib-20250930.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_71e7dd85-d0f7-4572-8c98-0b59c0a30262" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_a831a2e5-612f-4f0c-9810-66ab4c03534b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_71e7dd85-d0f7-4572-8c98-0b59c0a30262" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_a831a2e5-612f-4f0c-9810-66ab4c03534b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_54454df3-7580-4bbc-87bb-ff8a30d21b94" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_71e7dd85-d0f7-4572-8c98-0b59c0a30262" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_54454df3-7580-4bbc-87bb-ff8a30d21b94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_f7e655fb-5756-4b11-9137-e4a2d5f2e5c8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_71e7dd85-d0f7-4572-8c98-0b59c0a30262" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_f7e655fb-5756-4b11-9137-e4a2d5f2e5c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_cd1060ae-caf9-47a0-9e41-e798d83c73d1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_71e7dd85-d0f7-4572-8c98-0b59c0a30262" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_cd1060ae-caf9-47a0-9e41-e798d83c73d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_df949bff-cbed-4d0e-ad8f-1763f66a954d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_71e7dd85-d0f7-4572-8c98-0b59c0a30262" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_df949bff-cbed-4d0e-ad8f-1763f66a954d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_ebd8c7bc-4c23-42a2-a5a3-911ef6f79b50" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0b651eb3-4bff-40be-b520-6ab1ab828a63" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_ebd8c7bc-4c23-42a2-a5a3-911ef6f79b50" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0b651eb3-4bff-40be-b520-6ab1ab828a63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_cee0bc28-1fa0-4cb5-8a3a-a0fd6270e201" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_ebd8c7bc-4c23-42a2-a5a3-911ef6f79b50" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_cee0bc28-1fa0-4cb5-8a3a-a0fd6270e201" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_62d1d825-9b5a-494c-a020-c7e2161a602c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_ebd8c7bc-4c23-42a2-a5a3-911ef6f79b50" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_62d1d825-9b5a-494c-a020-c7e2161a602c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5ad19676-8229-427d-9a6a-8de31fd63f3d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0f73b950-3dc0-4d3d-af90-043c25c07abc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5ad19676-8229-427d-9a6a-8de31fd63f3d" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0f73b950-3dc0-4d3d-af90-043c25c07abc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_55d5ec70-b672-4e42-ac85-c41fa73943b4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5ad19676-8229-427d-9a6a-8de31fd63f3d" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_55d5ec70-b672-4e42-ac85-c41fa73943b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_3f44afad-9e09-4b86-8865-cb300b8df568" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5ad19676-8229-427d-9a6a-8de31fd63f3d" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_3f44afad-9e09-4b86-8865-cb300b8df568" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_a8733093-ebea-44a7-a261-8dd92882e3d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5ad19676-8229-427d-9a6a-8de31fd63f3d" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_a8733093-ebea-44a7-a261-8dd92882e3d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_ae1969f0-1c3f-47a5-9c00-6b03cabd77a7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5ad19676-8229-427d-9a6a-8de31fd63f3d" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_ae1969f0-1c3f-47a5-9c00-6b03cabd77a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_96dd446a-0932-4d45-9353-e4e853f06f47" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5ad19676-8229-427d-9a6a-8de31fd63f3d" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_96dd446a-0932-4d45-9353-e4e853f06f47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfOtherInvestments_fa1b0240-4c77-4265-95b4-3f0bc7041b92" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfOtherInvestments"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5ad19676-8229-427d-9a6a-8de31fd63f3d" xlink:to="loc_us-gaap_ProceedsFromSaleOfOtherInvestments_fa1b0240-4c77-4265-95b4-3f0bc7041b92" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_a4cc0af0-1c25-4829-ba23-e4a3f74b1bff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5ad19676-8229-427d-9a6a-8de31fd63f3d" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_a4cc0af0-1c25-4829-ba23-e4a3f74b1bff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3df62b75-e53b-4040-9df1-c60551ca30c4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_d691d31b-93cd-4306-badd-8aefc89aeb68" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3df62b75-e53b-4040-9df1-c60551ca30c4" xlink:to="loc_us-gaap_ProfitLoss_d691d31b-93cd-4306-badd-8aefc89aeb68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_dc1576cc-66c8-4a89-b572-d0054ce71c68" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3df62b75-e53b-4040-9df1-c60551ca30c4" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_dc1576cc-66c8-4a89-b572-d0054ce71c68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_8e0d68e9-1f79-461a-9fb4-e6e5b0807c7e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3df62b75-e53b-4040-9df1-c60551ca30c4" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_8e0d68e9-1f79-461a-9fb4-e6e5b0807c7e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_2552191e-9908-45fc-aa62-84efea5f9cef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWriteDown"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3df62b75-e53b-4040-9df1-c60551ca30c4" xlink:to="loc_us-gaap_InventoryWriteDown_2552191e-9908-45fc-aa62-84efea5f9cef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationOfInventoryStepUp_57cc49a2-1396-4ec6-99e7-8ac8be26d439" xlink:href="biib-20250930.xsd#biib_AmortizationOfInventoryStepUp"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3df62b75-e53b-4040-9df1-c60551ca30c4" xlink:to="loc_biib_AmortizationOfInventoryStepUp_57cc49a2-1396-4ec6-99e7-8ac8be26d439" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_59370cc7-019f-4a2c-9f9e-6c8531fe7f71" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3df62b75-e53b-4040-9df1-c60551ca30c4" xlink:to="loc_us-gaap_ShareBasedCompensation_59370cc7-019f-4a2c-9f9e-6c8531fe7f71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_3cccc458-9863-455b-9f58-6d146b318cb6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3df62b75-e53b-4040-9df1-c60551ca30c4" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_3cccc458-9863-455b-9f58-6d146b318cb6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_225f1fbd-4287-4ae7-9919-1ea38009d640" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3df62b75-e53b-4040-9df1-c60551ca30c4" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_225f1fbd-4287-4ae7-9919-1ea38009d640" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_4ba7d710-5567-458c-bf41-527c0fa20c6c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3df62b75-e53b-4040-9df1-c60551ca30c4" xlink:to="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_4ba7d710-5567-458c-bf41-527c0fa20c6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_97cb51e3-d024-4f7c-a91c-63333d59c40c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3df62b75-e53b-4040-9df1-c60551ca30c4" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_97cb51e3-d024-4f7c-a91c-63333d59c40c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_0e637a12-fa64-4e17-b52e-610c5590ec9c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3df62b75-e53b-4040-9df1-c60551ca30c4" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_0e637a12-fa64-4e17-b52e-610c5590ec9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_487af380-4731-421d-b3da-ad52dc68355d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3df62b75-e53b-4040-9df1-c60551ca30c4" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_487af380-4731-421d-b3da-ad52dc68355d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_faf6150e-2e6c-40cd-931a-6d9399987763" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3df62b75-e53b-4040-9df1-c60551ca30c4" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_faf6150e-2e6c-40cd-931a-6d9399987763" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_c5b83752-2733-4d80-bf2d-58ac80d016cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3df62b75-e53b-4040-9df1-c60551ca30c4" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_c5b83752-2733-4d80-bf2d-58ac80d016cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_16314f54-5a4c-4427-9d9a-451a89b5a59f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3df62b75-e53b-4040-9df1-c60551ca30c4" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_16314f54-5a4c-4427-9d9a-451a89b5a59f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_49f968c4-1d03-4f70-8843-0cdd1e5abc1f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:calculationArc order="16" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3df62b75-e53b-4040-9df1-c60551ca30c4" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_49f968c4-1d03-4f70-8843-0cdd1e5abc1f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsPurchasePriceConsiderationDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#AcquisitionsPurchasePriceConsiderationDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/AcquisitionsPurchasePriceConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_1ba0fd8f-4dfd-4c97-80f6-e6561182085a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_05e67eb2-12c7-40ca-84d4-a733f2fe4978" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_1ba0fd8f-4dfd-4c97-80f6-e6561182085a" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_05e67eb2-12c7-40ca-84d4-a733f2fe4978" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_b48d5929-28ab-4af7-a207-61d54f2fc254" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_1ba0fd8f-4dfd-4c97-80f6-e6561182085a" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_b48d5929-28ab-4af7-a207-61d54f2fc254" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#AcquisitionsPreliminatyPurchasePriceAllocationDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_9705a603-a95a-4a21-9c46-a204c799b918" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_9ed841c2-7026-48b8-95eb-1446ea3361bc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_9705a603-a95a-4a21-9c46-a204c799b918" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_9ed841c2-7026-48b8-95eb-1446ea3361bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_020243be-690e-49e3-8706-2bc0ed57f7db" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_9705a603-a95a-4a21-9c46-a204c799b918" xlink:to="loc_us-gaap_Goodwill_020243be-690e-49e3-8706-2bc0ed57f7db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_f6d17317-7722-4f9b-b2c6-830a1a145908" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_92f63fc2-9ab0-4edd-a657-58be04da4765" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_f6d17317-7722-4f9b-b2c6-830a1a145908" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_92f63fc2-9ab0-4edd-a657-58be04da4765" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_46137601-2185-4ef1-9d03-5f51fc650d83" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_f6d17317-7722-4f9b-b2c6-830a1a145908" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_46137601-2185-4ef1-9d03-5f51fc650d83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_7e4a2b77-4f10-4738-b946-c3e534f0498b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_f6d17317-7722-4f9b-b2c6-830a1a145908" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_7e4a2b77-4f10-4738-b946-c3e534f0498b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_68272cec-e87a-45b1-a57e-acd85f0e9b1b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_f6d17317-7722-4f9b-b2c6-830a1a145908" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_68272cec-e87a-45b1-a57e-acd85f0e9b1b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities_dd9ba8e6-361c-4b20-a1de-445ce022b9d1" xlink:href="biib-20250930.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_f6d17317-7722-4f9b-b2c6-830a1a145908" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities_dd9ba8e6-361c-4b20-a1de-445ce022b9d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets_fb30e095-f498-4204-b71c-c43d3bfdc5e0" xlink:href="biib-20250930.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_f6d17317-7722-4f9b-b2c6-830a1a145908" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets_fb30e095-f498-4204-b71c-c43d3bfdc5e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities_2b5d1a75-ffb1-489c-8044-f87c60c4177a" xlink:href="biib-20250930.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_f6d17317-7722-4f9b-b2c6-830a1a145908" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities_2b5d1a75-ffb1-489c-8044-f87c60c4177a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_aa31b3de-b97a-441e-baf7-34069285c0fa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_f6d17317-7722-4f9b-b2c6-830a1a145908" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_aa31b3de-b97a-441e-baf7-34069285c0fa" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_b0ac02c3-285f-4a5e-8bad-39ba7c901421" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfCoPromotionProfits_2272d03d-0065-4ff9-9192-eb8fa8237eee" xlink:href="biib-20250930.xsd#biib_ShareOfCoPromotionProfits"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_b0ac02c3-285f-4a5e-8bad-39ba7c901421" xlink:to="loc_biib_ShareOfCoPromotionProfits_2272d03d-0065-4ff9-9192-eb8fa8237eee" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#InventoryComponentsofInventoryDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_InventoryNetCurrentAndNoncurrent_5aa14b85-8ee2-4020-b750-17ca162572c5" xlink:href="biib-20250930.xsd#biib_InventoryNetCurrentAndNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_1ca2dd83-02b7-432f-99eb-3d2f0e41380c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_InventoryNetCurrentAndNoncurrent_5aa14b85-8ee2-4020-b750-17ca162572c5" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_1ca2dd83-02b7-432f-99eb-3d2f0e41380c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_83d3e866-c989-4b79-ba74-98e88b1b7790" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_InventoryNetCurrentAndNoncurrent_5aa14b85-8ee2-4020-b750-17ca162572c5" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_83d3e866-c989-4b79-ba74-98e88b1b7790" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_3c814d93-e72f-4f5c-b140-3f7f5c48b7df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_biib_InventoryNetCurrentAndNoncurrent_5aa14b85-8ee2-4020-b750-17ca162572c5" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_3c814d93-e72f-4f5c-b140-3f7f5c48b7df" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6701741f-7a6b-4deb-be2a-dbe1dd30058b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_38b4ce96-a4eb-4687-88da-e181fcdf21cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6701741f-7a6b-4deb-be2a-dbe1dd30058b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_38b4ce96-a4eb-4687-88da-e181fcdf21cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_3d34f443-3430-4f0d-9f73-97674810d713" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_6701741f-7a6b-4deb-be2a-dbe1dd30058b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_3d34f443-3430-4f0d-9f73-97674810d713" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_173ba01d-0e49-4532-b163-2e1d3ee4c7c3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_0962a849-927b-4d18-8138-7f3464d6e3fe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_173ba01d-0e49-4532-b163-2e1d3ee4c7c3" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_0962a849-927b-4d18-8138-7f3464d6e3fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7c1b7123-0cc5-4e0d-a1a9-9568d0c69708" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_173ba01d-0e49-4532-b163-2e1d3ee4c7c3" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_7c1b7123-0cc5-4e0d-a1a9-9568d0c69708" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails_1" xlink:type="simple" xlink:href="biib-20250930.xsd#IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails_1"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_59c32c8f-d589-4b9c-8ef7-5b06818cf603" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_f6b9e8b6-6435-4bd5-8963-8385c4d27003" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_59c32c8f-d589-4b9c-8ef7-5b06818cf603" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_f6b9e8b6-6435-4bd5-8963-8385c4d27003" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_17c224ba-4714-4c1e-89de-88b95fd3a2fa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_59c32c8f-d589-4b9c-8ef7-5b06818cf603" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_17c224ba-4714-4c1e-89de-88b95fd3a2fa" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsSummaryofContractualMaturitiesDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#FinancialInstrumentsSummaryofContractualMaturitiesDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsSummaryofContractualMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_213a8ac3-4a1d-4fff-9918-972f99dc858c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_aa098ee4-e4c2-4320-95ed-355b4fa876db" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_213a8ac3-4a1d-4fff-9918-972f99dc858c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_aa098ee4-e4c2-4320-95ed-355b4fa876db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_e190573e-0127-408f-b95d-01f7d3f4f523" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_a9916471-0d05-42e9-a899-73e0e0ce44b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_e190573e-0127-408f-b95d-01f7d3f4f523" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_a9916471-0d05-42e9-a899-73e0e0ce44b9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsPretaxPortionoftheFairValueofForeignCurrencyForwardContractsandForeignCurrencyOptionsDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#DerivativeInstrumentsPretaxPortionoftheFairValueofForeignCurrencyForwardContractsandForeignCurrencyOptionsDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsPretaxPortionoftheFairValueofForeignCurrencyForwardContractsandForeignCurrencyOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_afd91a9e-ae6f-4278-82fb-b520b38c7fd2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedGainOnDerivatives_e3de7b70-2cb4-41d3-a948-78947c98c4d5" xlink:href="biib-20250930.xsd#biib_UnrealizedGainOnDerivatives"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_UnrealizedGainLossOnDerivatives_afd91a9e-ae6f-4278-82fb-b520b38c7fd2" xlink:to="loc_biib_UnrealizedGainOnDerivatives_e3de7b70-2cb4-41d3-a948-78947c98c4d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedLossOnDerivatives_61f3e3a1-5273-4c03-b512-3a4461b6ce87" xlink:href="biib-20250930.xsd#biib_UnrealizedLossOnDerivatives"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_UnrealizedGainLossOnDerivatives_afd91a9e-ae6f-4278-82fb-b520b38c7fd2" xlink:to="loc_biib_UnrealizedLossOnDerivatives_61f3e3a1-5273-4c03-b512-3a4461b6ce87" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsperShareDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#EarningsperShareDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/EarningsperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_fc394daf-0a28-420b-82b7-8d091e2f1ba5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_81fbf657-e267-4a89-b8d5-fe25d1767004" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_fc394daf-0a28-420b-82b7-8d091e2f1ba5" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_81fbf657-e267-4a89-b8d5-fe25d1767004" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b1c24e82-8cf9-4203-a97e-4766c306dcf6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e2e0ee97-555f-439a-836a-a9aa3dd200dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b1c24e82-8cf9-4203-a97e-4766c306dcf6" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e2e0ee97-555f-439a-836a-a9aa3dd200dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_ef635852-ad70-42b7-9c5a-dfe4d9a7cfde" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_b1c24e82-8cf9-4203-a97e-4766c306dcf6" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_ef635852-ad70-42b7-9c5a-dfe4d9a7cfde" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_582d4b9e-badf-4011-8e91-e1415e729f93" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_068775ed-48d6-45a5-a8dd-395eea876f42" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_582d4b9e-badf-4011-8e91-e1415e729f93" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_068775ed-48d6-45a5-a8dd-395eea876f42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_1f94bf97-e7ea-475d-a162-a36a8c87e37e" xlink:href="biib-20250930.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_582d4b9e-badf-4011-8e91-e1415e729f93" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_1f94bf97-e7ea-475d-a162-a36a8c87e37e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#IncomeTaxesTaxRateDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ba96b322-7e21-467a-959c-692a68c9b2b3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_edba24de-63af-48fb-bda3-9fc37236147e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ba96b322-7e21-467a-959c-692a68c9b2b3" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_edba24de-63af-48fb-bda3-9fc37236147e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_012a7b88-f3b0-4381-9786-7732e78df674" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ba96b322-7e21-467a-959c-692a68c9b2b3" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_012a7b88-f3b0-4381-9786-7732e78df674" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_fdd84602-aced-422f-8450-4d98c01a1f4d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ba96b322-7e21-467a-959c-692a68c9b2b3" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_fdd84602-aced-422f-8450-4d98c01a1f4d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_4d6de993-7921-4d6d-a181-eb1cbf463dda" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ba96b322-7e21-467a-959c-692a68c9b2b3" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_4d6de993-7921-4d6d-a181-eb1cbf463dda" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_d17f9abf-3aab-474c-b153-c4d53574d3b3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ba96b322-7e21-467a-959c-692a68c9b2b3" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_d17f9abf-3aab-474c-b153-c4d53574d3b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent_c250203a-f3c8-4efe-91db-30925914bddb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ba96b322-7e21-467a-959c-692a68c9b2b3" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent_c250203a-f3c8-4efe-91db-30925914bddb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveTaxRateReconciliationShareBasedCompensationAwards_1e0734be-1ee2-496d-a263-5b3a1017a2a1" xlink:href="biib-20250930.xsd#biib_EffectiveTaxRateReconciliationShareBasedCompensationAwards"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ba96b322-7e21-467a-959c-692a68c9b2b3" xlink:to="loc_biib_EffectiveTaxRateReconciliationShareBasedCompensationAwards_1e0734be-1ee2-496d-a263-5b3a1017a2a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveTaxRateReconciliationOneBigBeautifulBillActEnactment_0dbde912-b7b4-4641-a750-95d0d3265dcd" xlink:href="biib-20250930.xsd#biib_EffectiveTaxRateReconciliationOneBigBeautifulBillActEnactment"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ba96b322-7e21-467a-959c-692a68c9b2b3" xlink:to="loc_biib_EffectiveTaxRateReconciliationOneBigBeautifulBillActEnactment_0dbde912-b7b4-4641-a750-95d0d3265dcd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_a519407e-1751-4fbb-a494-868115f993ff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ba96b322-7e21-467a-959c-692a68c9b2b3" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_a519407e-1751-4fbb-a494-868115f993ff" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SegmentInformationAdditionalSegmentInformationDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#SegmentInformationAdditionalSegmentInformationDetails"/>
  <link:calculationLink xlink:role="http://www.biogenidec.com/role/SegmentInformationAdditionalSegmentInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d5ad8185-8ac1-4dba-a460-db8b5eb12b62" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_5deb21bc-4c7f-426c-be4a-37f1f20af41a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_d5ad8185-8ac1-4dba-a460-db8b5eb12b62" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_5deb21bc-4c7f-426c-be4a-37f1f20af41a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_fa940bcd-ade8-4973-976c-47cc7947011b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_d5ad8185-8ac1-4dba-a460-db8b5eb12b62" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_fa940bcd-ade8-4973-976c-47cc7947011b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount_de29dc4a-0002-475c-85ea-606f9aa6d858" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_d5ad8185-8ac1-4dba-a460-db8b5eb12b62" xlink:to="loc_us-gaap_SegmentReportingOtherItemAmount_de29dc4a-0002-475c-85ea-606f9aa6d858" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_e8615d53-a9c4-40bc-9688-29bcc8985459" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_d5ad8185-8ac1-4dba-a460-db8b5eb12b62" xlink:to="loc_us-gaap_Revenues_e8615d53-a9c4-40bc-9688-29bcc8985459" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_dc421a4b-2934-4e39-b91b-7d35f9f52db7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_d5ad8185-8ac1-4dba-a460-db8b5eb12b62" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_dc421a4b-2934-4e39-b91b-7d35f9f52db7" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>biib-20250930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:56b2dfbb-fb98-49e8-bcdc-e902c065377c,g:9aa702a5-e336-43c4-a300-999553ccda1f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="simple" xlink:href="biib-20250930.xsd#CondensedConsolidatedStatementsofIncomeUnaudited"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d45e5861-6d83-4706-9cc4-f7e7ad800a2e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_886022d4-0a04-4756-946a-debee53503d2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_d45e5861-6d83-4706-9cc4-f7e7ad800a2e" xlink:to="loc_us-gaap_StatementTable_886022d4-0a04-4756-946a-debee53503d2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_eaec2e1c-f38b-47a1-8f5b-636322933b4f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_886022d4-0a04-4756-946a-debee53503d2" xlink:to="loc_srt_ProductOrServiceAxis_eaec2e1c-f38b-47a1-8f5b-636322933b4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_eaec2e1c-f38b-47a1-8f5b-636322933b4f_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_eaec2e1c-f38b-47a1-8f5b-636322933b4f" xlink:to="loc_srt_ProductsAndServicesDomain_eaec2e1c-f38b-47a1-8f5b-636322933b4f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_cfad0fe2-d371-407c-ba56-a11f4f8be0aa" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_eaec2e1c-f38b-47a1-8f5b-636322933b4f" xlink:to="loc_srt_ProductsAndServicesDomain_cfad0fe2-d371-407c-ba56-a11f4f8be0aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_abb30ed3-3994-49ec-981f-2ede689dce94" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_cfad0fe2-d371-407c-ba56-a11f4f8be0aa" xlink:to="loc_us-gaap_ProductMember_abb30ed3-3994-49ec-981f-2ede689dce94" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_c977b936-e73f-496c-9215-2d58f64f4185" xlink:href="biib-20250930.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_cfad0fe2-d371-407c-ba56-a11f4f8be0aa" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_c977b936-e73f-496c-9215-2d58f64f4185" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LEQEMBICollaborationMember_f7095065-5486-4f5b-b758-d9f42fb6d5df" xlink:href="biib-20250930.xsd#biib_LEQEMBICollaborationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_cfad0fe2-d371-407c-ba56-a11f4f8be0aa" xlink:to="loc_biib_LEQEMBICollaborationMember_f7095065-5486-4f5b-b758-d9f42fb6d5df" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_72626907-42d9-4441-a844-8c638d5d25b8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_cfad0fe2-d371-407c-ba56-a11f4f8be0aa" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_72626907-42d9-4441-a844-8c638d5d25b8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_150d1923-6a8e-4c4a-b7b8-b94725e56780" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d45e5861-6d83-4706-9cc4-f7e7ad800a2e" xlink:to="loc_us-gaap_Revenues_150d1923-6a8e-4c4a-b7b8-b94725e56780" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_ea3ef817-d9a3-4dd4-8ff6-06803e916c06" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d45e5861-6d83-4706-9cc4-f7e7ad800a2e" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_ea3ef817-d9a3-4dd4-8ff6-06803e916c06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_ad6879d3-0539-46ea-87c6-05e26a82721a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ea3ef817-d9a3-4dd4-8ff6-06803e916c06" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_ad6879d3-0539-46ea-87c6-05e26a82721a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_1c94f666-efde-40de-9dd0-0cc2873b9a40" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ea3ef817-d9a3-4dd4-8ff6-06803e916c06" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_1c94f666-efde-40de-9dd0-0cc2873b9a40" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchAndDevelopmentExpenseIncludingAcquiredInProcessCost_29ade13f-4e70-4358-bd0d-7868ea62ba93" xlink:href="biib-20250930.xsd#biib_ResearchAndDevelopmentExpenseIncludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ea3ef817-d9a3-4dd4-8ff6-06803e916c06" xlink:to="loc_biib_ResearchAndDevelopmentExpenseIncludingAcquiredInProcessCost_29ade13f-4e70-4358-bd0d-7868ea62ba93" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_ba3575bf-37d6-4332-91ec-2d5b88330e94" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ea3ef817-d9a3-4dd4-8ff6-06803e916c06" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_ba3575bf-37d6-4332-91ec-2d5b88330e94" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_7db72cad-e9be-4a69-a9c8-9b08efb4092c" xlink:href="biib-20250930.xsd#biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ea3ef817-d9a3-4dd4-8ff6-06803e916c06" xlink:to="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_7db72cad-e9be-4a69-a9c8-9b08efb4092c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationprofitlosssharing_df5d003e-83fb-4aee-919a-d616acac5d41" xlink:href="biib-20250930.xsd#biib_Collaborationprofitlosssharing"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ea3ef817-d9a3-4dd4-8ff6-06803e916c06" xlink:to="loc_biib_Collaborationprofitlosssharing_df5d003e-83fb-4aee-919a-d616acac5d41" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_0b334ebc-1fb7-4e19-a67b-007e1daca07a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ea3ef817-d9a3-4dd4-8ff6-06803e916c06" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_0b334ebc-1fb7-4e19-a67b-007e1daca07a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_f4d8f71a-0e2b-4a23-9eb5-43847a38a653" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ea3ef817-d9a3-4dd4-8ff6-06803e916c06" xlink:to="loc_us-gaap_RestructuringCharges_f4d8f71a-0e2b-4a23-9eb5-43847a38a653" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_3b12e6b4-0ede-438a-8c70-36ccf643ec4a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ea3ef817-d9a3-4dd4-8ff6-06803e916c06" xlink:to="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_3b12e6b4-0ede-438a-8c70-36ccf643ec4a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_043f350b-e4f6-40bc-9494-b8e4c8ddf831" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ea3ef817-d9a3-4dd4-8ff6-06803e916c06" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_043f350b-e4f6-40bc-9494-b8e4c8ddf831" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_4a460612-e796-47d9-8e50-eba4fa3e9361" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ea3ef817-d9a3-4dd4-8ff6-06803e916c06" xlink:to="loc_us-gaap_CostsAndExpenses_4a460612-e796-47d9-8e50-eba4fa3e9361" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8f5c5a1f-da29-4c00-8b14-10190b52a93b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d45e5861-6d83-4706-9cc4-f7e7ad800a2e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8f5c5a1f-da29-4c00-8b14-10190b52a93b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_817a3c1d-d40f-4b30-9386-bbabfdee5aad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d45e5861-6d83-4706-9cc4-f7e7ad800a2e" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_817a3c1d-d40f-4b30-9386-bbabfdee5aad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6a7d80b8-90dd-49a9-b86b-1652780afe12" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d45e5861-6d83-4706-9cc4-f7e7ad800a2e" xlink:to="loc_us-gaap_NetIncomeLoss_6a7d80b8-90dd-49a9-b86b-1652780afe12" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_ef850a01-4fe1-460e-bdd3-d43540a40f96" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d45e5861-6d83-4706-9cc4-f7e7ad800a2e" xlink:to="loc_us-gaap_EarningsPerShareAbstract_ef850a01-4fe1-460e-bdd3-d43540a40f96" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_9f59b65e-84d5-422c-8e46-26c5592bbee3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ef850a01-4fe1-460e-bdd3-d43540a40f96" xlink:to="loc_us-gaap_EarningsPerShareBasic_9f59b65e-84d5-422c-8e46-26c5592bbee3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_0e0fefc3-8680-4be9-8b60-da9ff5357b4c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ef850a01-4fe1-460e-bdd3-d43540a40f96" xlink:to="loc_us-gaap_EarningsPerShareDiluted_0e0fefc3-8680-4be9-8b60-da9ff5357b4c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3c968243-d2be-4ff0-9abc-a05306da6e1f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_d45e5861-6d83-4706-9cc4-f7e7ad800a2e" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3c968243-d2be-4ff0-9abc-a05306da6e1f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_db461b1c-4fb7-41b3-8ade-a773c8ea97f3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3c968243-d2be-4ff0-9abc-a05306da6e1f" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_db461b1c-4fb7-41b3-8ade-a773c8ea97f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0658623e-0937-43ab-8f63-08e7fd81418f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3c968243-d2be-4ff0-9abc-a05306da6e1f" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0658623e-0937-43ab-8f63-08e7fd81418f" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="biib-20250930.xsd#CondensedConsolidatedBalanceSheetsUnaudited"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_461942dd-e915-4e4f-bee0-59b76b9303b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d0415f1a-ee63-4504-902b-e8d7436f7343" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_461942dd-e915-4e4f-bee0-59b76b9303b2" xlink:to="loc_us-gaap_StatementTable_d0415f1a-ee63-4504-902b-e8d7436f7343" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9f52ab71-f274-4442-bf6a-cdfcc80a9e56" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_d0415f1a-ee63-4504-902b-e8d7436f7343" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9f52ab71-f274-4442-bf6a-cdfcc80a9e56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_9f52ab71-f274-4442-bf6a-cdfcc80a9e56_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9f52ab71-f274-4442-bf6a-cdfcc80a9e56" xlink:to="loc_us-gaap_RelatedPartyDomain_9f52ab71-f274-4442-bf6a-cdfcc80a9e56_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_7c80b873-8c59-4071-b230-8049357423ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9f52ab71-f274-4442-bf6a-cdfcc80a9e56" xlink:to="loc_us-gaap_RelatedPartyDomain_7c80b873-8c59-4071-b230-8049357423ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_7fb9259b-f2c3-457d-9968-a3d0f075cf6a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_7c80b873-8c59-4071-b230-8049357423ea" xlink:to="loc_us-gaap_NonrelatedPartyMember_7fb9259b-f2c3-457d-9968-a3d0f075cf6a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_02b44010-7817-468e-9168-bb89d24b7695" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_7c80b873-8c59-4071-b230-8049357423ea" xlink:to="loc_us-gaap_RelatedPartyMember_02b44010-7817-468e-9168-bb89d24b7695" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_267c8b4c-6adf-456a-81b2-6e5ecaff1833" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_461942dd-e915-4e4f-bee0-59b76b9303b2" xlink:to="loc_us-gaap_AssetsAbstract_267c8b4c-6adf-456a-81b2-6e5ecaff1833" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_558cc113-df49-4d9d-881a-59c808b181b0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_267c8b4c-6adf-456a-81b2-6e5ecaff1833" xlink:to="loc_us-gaap_AssetsCurrentAbstract_558cc113-df49-4d9d-881a-59c808b181b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_550cc690-7de9-4df0-9827-0ef9ffe053e5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_558cc113-df49-4d9d-881a-59c808b181b0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_550cc690-7de9-4df0-9827-0ef9ffe053e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_268f45da-8a5d-44d1-967d-52473d1896d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_558cc113-df49-4d9d-881a-59c808b181b0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_268f45da-8a5d-44d1-967d-52473d1896d4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_57964c52-c779-480e-80bb-7e7b3655b990" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_558cc113-df49-4d9d-881a-59c808b181b0" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_57964c52-c779-480e-80bb-7e7b3655b990" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_c35b8ddb-cd6d-4579-9fe4-1e937fcd9f0b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_558cc113-df49-4d9d-881a-59c808b181b0" xlink:to="loc_us-gaap_InventoryNet_c35b8ddb-cd6d-4579-9fe4-1e937fcd9f0b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_a77a7c2e-5d1d-40f4-b10c-2271f6e30461" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_558cc113-df49-4d9d-881a-59c808b181b0" xlink:to="loc_us-gaap_OtherAssetsCurrent_a77a7c2e-5d1d-40f4-b10c-2271f6e30461" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_2fc68ed5-dbe1-402f-89af-8b1de442b1dc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_558cc113-df49-4d9d-881a-59c808b181b0" xlink:to="loc_us-gaap_AssetsCurrent_2fc68ed5-dbe1-402f-89af-8b1de442b1dc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_5aeb8a85-7648-4e17-96dd-f43aef5a64bf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_267c8b4c-6adf-456a-81b2-6e5ecaff1833" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_5aeb8a85-7648-4e17-96dd-f43aef5a64bf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_3f01165e-410a-4b84-a6f0-0a0a82b1fb6a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_267c8b4c-6adf-456a-81b2-6e5ecaff1833" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_3f01165e-410a-4b84-a6f0-0a0a82b1fb6a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_212d32dc-be09-4b1a-bca0-ec343762e8f6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_267c8b4c-6adf-456a-81b2-6e5ecaff1833" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_212d32dc-be09-4b1a-bca0-ec343762e8f6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_5342c22f-008d-4d2c-95c9-9f6ad15fc909" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_267c8b4c-6adf-456a-81b2-6e5ecaff1833" xlink:to="loc_us-gaap_Goodwill_5342c22f-008d-4d2c-95c9-9f6ad15fc909" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_2fb783d2-2de1-46b0-9587-0af56fc2fbb4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_267c8b4c-6adf-456a-81b2-6e5ecaff1833" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_2fb783d2-2de1-46b0-9587-0af56fc2fbb4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_3fbc1837-ce72-4b04-9a85-a04ecb89799a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_267c8b4c-6adf-456a-81b2-6e5ecaff1833" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_3fbc1837-ce72-4b04-9a85-a04ecb89799a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_a88a19bd-529c-4d58-b758-190ba822d79a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_267c8b4c-6adf-456a-81b2-6e5ecaff1833" xlink:to="loc_us-gaap_Assets_a88a19bd-529c-4d58-b758-190ba822d79a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_24496f9b-cb5c-4cec-af4c-82d9da59b088" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_461942dd-e915-4e4f-bee0-59b76b9303b2" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_24496f9b-cb5c-4cec-af4c-82d9da59b088" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_56e324ce-c451-4313-82fa-97c853284674" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_24496f9b-cb5c-4cec-af4c-82d9da59b088" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_56e324ce-c451-4313-82fa-97c853284674" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_2665e89a-e6ad-4840-894a-0f5ab26335b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_56e324ce-c451-4313-82fa-97c853284674" xlink:to="loc_us-gaap_NotesPayableCurrent_2665e89a-e6ad-4840-894a-0f5ab26335b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_bd011b66-4b8e-4406-9631-b3c8092a75f0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_56e324ce-c451-4313-82fa-97c853284674" xlink:to="loc_us-gaap_TaxesPayableCurrent_bd011b66-4b8e-4406-9631-b3c8092a75f0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_f60c8165-f346-4030-8c76-f5d892a72a59" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_56e324ce-c451-4313-82fa-97c853284674" xlink:to="loc_us-gaap_AccountsPayableCurrent_f60c8165-f346-4030-8c76-f5d892a72a59" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_270c08fb-461f-4bbc-9beb-03d3d312953c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_56e324ce-c451-4313-82fa-97c853284674" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_270c08fb-461f-4bbc-9beb-03d3d312953c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_ef024627-0c9c-4293-a54d-351fc09545cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_56e324ce-c451-4313-82fa-97c853284674" xlink:to="loc_us-gaap_LiabilitiesCurrent_ef024627-0c9c-4293-a54d-351fc09545cb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_3871f3c8-ed84-4dd9-9468-e2e9157a2544" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_24496f9b-cb5c-4cec-af4c-82d9da59b088" xlink:to="loc_us-gaap_LongTermDebt_3871f3c8-ed84-4dd9-9468-e2e9157a2544" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_081f2720-87ec-4362-98a7-3f8cedbef315" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_24496f9b-cb5c-4cec-af4c-82d9da59b088" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_081f2720-87ec-4362-98a7-3f8cedbef315" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c7e951cb-3ae0-4ffc-9abd-9ef036168ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_24496f9b-cb5c-4cec-af4c-82d9da59b088" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c7e951cb-3ae0-4ffc-9abd-9ef036168ea3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_dd7caab0-c7a8-49b8-a695-2724b578f74b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_24496f9b-cb5c-4cec-af4c-82d9da59b088" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_dd7caab0-c7a8-49b8-a695-2724b578f74b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_280b268d-7173-42a2-ab2b-7c90b09d9308" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_24496f9b-cb5c-4cec-af4c-82d9da59b088" xlink:to="loc_us-gaap_Liabilities_280b268d-7173-42a2-ab2b-7c90b09d9308" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_172eb857-eee5-4689-b405-0860fa0d0b06" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_24496f9b-cb5c-4cec-af4c-82d9da59b088" xlink:to="loc_us-gaap_CommitmentsAndContingencies_172eb857-eee5-4689-b405-0860fa0d0b06" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_3110e7de-885c-428c-a4f0-3adccdac1794" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_24496f9b-cb5c-4cec-af4c-82d9da59b088" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_3110e7de-885c-428c-a4f0-3adccdac1794" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_2868bae6-46b9-464d-8105-709f7fdf0452" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_3110e7de-885c-428c-a4f0-3adccdac1794" xlink:to="loc_us-gaap_StockholdersEquityAbstract_2868bae6-46b9-464d-8105-709f7fdf0452" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_09854da7-341e-45dc-ae8d-60d25fa3861b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2868bae6-46b9-464d-8105-709f7fdf0452" xlink:to="loc_us-gaap_PreferredStockValue_09854da7-341e-45dc-ae8d-60d25fa3861b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_9577c7b3-bf50-4db7-b349-6947336a291b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2868bae6-46b9-464d-8105-709f7fdf0452" xlink:to="loc_us-gaap_CommonStockValue_9577c7b3-bf50-4db7-b349-6947336a291b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_f22ea236-4817-4d74-9ee7-399e3f968bef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2868bae6-46b9-464d-8105-709f7fdf0452" xlink:to="loc_us-gaap_AdditionalPaidInCapital_f22ea236-4817-4d74-9ee7-399e3f968bef" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ea88b8b9-097b-4600-be01-551ead211e14" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2868bae6-46b9-464d-8105-709f7fdf0452" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ea88b8b9-097b-4600-be01-551ead211e14" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6f8f3f7f-86e9-47d0-9c15-a0394dad0ff6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2868bae6-46b9-464d-8105-709f7fdf0452" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6f8f3f7f-86e9-47d0-9c15-a0394dad0ff6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_b9125a27-0549-4466-89eb-20878120df98" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2868bae6-46b9-464d-8105-709f7fdf0452" xlink:to="loc_us-gaap_TreasuryStockValue_b9125a27-0549-4466-89eb-20878120df98" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_fadebe94-0ded-4164-b68c-f526abbcc643" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_3110e7de-885c-428c-a4f0-3adccdac1794" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_fadebe94-0ded-4164-b68c-f526abbcc643" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_07a81f9d-f3d4-4655-b648-2e2ef5898db9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_24496f9b-cb5c-4cec-af4c-82d9da59b088" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_07a81f9d-f3d4-4655-b648-2e2ef5898db9" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="biib-20250930.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_dd136dde-bf77-4377-b707-3231a0b6fed7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2477b17d-21c4-4a78-8b55-f812ece45f87" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_dd136dde-bf77-4377-b707-3231a0b6fed7" xlink:to="loc_us-gaap_StatementTable_2477b17d-21c4-4a78-8b55-f812ece45f87" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9e1222d7-d8b4-4784-b7d2-2b910e7785e0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2477b17d-21c4-4a78-8b55-f812ece45f87" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9e1222d7-d8b4-4784-b7d2-2b910e7785e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_9e1222d7-d8b4-4784-b7d2-2b910e7785e0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9e1222d7-d8b4-4784-b7d2-2b910e7785e0" xlink:to="loc_us-gaap_RelatedPartyDomain_9e1222d7-d8b4-4784-b7d2-2b910e7785e0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_7fbd87ac-9910-46f7-b58f-7a154e988bb6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9e1222d7-d8b4-4784-b7d2-2b910e7785e0" xlink:to="loc_us-gaap_RelatedPartyDomain_7fbd87ac-9910-46f7-b58f-7a154e988bb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_3895ca18-686a-4106-9dba-966b3f73c413" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_7fbd87ac-9910-46f7-b58f-7a154e988bb6" xlink:to="loc_us-gaap_NonrelatedPartyMember_3895ca18-686a-4106-9dba-966b3f73c413" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_37a4c6bb-30ff-4206-9382-991bf54006a7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_7fbd87ac-9910-46f7-b58f-7a154e988bb6" xlink:to="loc_us-gaap_RelatedPartyMember_37a4c6bb-30ff-4206-9382-991bf54006a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cd246f2e-e764-4e00-bb39-d3d6c96cb385" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dd136dde-bf77-4377-b707-3231a0b6fed7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cd246f2e-e764-4e00-bb39-d3d6c96cb385" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_356d1be7-758c-4345-978b-4a8aea9a58ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cd246f2e-e764-4e00-bb39-d3d6c96cb385" xlink:to="loc_us-gaap_ProfitLoss_356d1be7-758c-4345-978b-4a8aea9a58ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b7fdf5bf-4b82-4a6b-9bac-2705b475a9fc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cd246f2e-e764-4e00-bb39-d3d6c96cb385" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b7fdf5bf-4b82-4a6b-9bac-2705b475a9fc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_243c547e-613f-4e9d-ab6d-fe46df563796" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b7fdf5bf-4b82-4a6b-9bac-2705b475a9fc" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_243c547e-613f-4e9d-ab6d-fe46df563796" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_62698183-8e9a-4957-ba58-5067008613f6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b7fdf5bf-4b82-4a6b-9bac-2705b475a9fc" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_62698183-8e9a-4957-ba58-5067008613f6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_3d71d1bc-db5f-4cda-861e-3d9eae505465" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWriteDown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b7fdf5bf-4b82-4a6b-9bac-2705b475a9fc" xlink:to="loc_us-gaap_InventoryWriteDown_3d71d1bc-db5f-4cda-861e-3d9eae505465" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationOfInventoryStepUp_79b5e5ff-ad6d-4afa-91e6-3e149ca96fcc" xlink:href="biib-20250930.xsd#biib_AmortizationOfInventoryStepUp"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b7fdf5bf-4b82-4a6b-9bac-2705b475a9fc" xlink:to="loc_biib_AmortizationOfInventoryStepUp_79b5e5ff-ad6d-4afa-91e6-3e149ca96fcc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_a7522c13-d5ec-42d7-b10c-0992c6a19e88" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b7fdf5bf-4b82-4a6b-9bac-2705b475a9fc" xlink:to="loc_us-gaap_ShareBasedCompensation_a7522c13-d5ec-42d7-b10c-0992c6a19e88" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_1d74ae5c-4fef-4f36-b6d1-4944468f940d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b7fdf5bf-4b82-4a6b-9bac-2705b475a9fc" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_1d74ae5c-4fef-4f36-b6d1-4944468f940d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_71ebe307-393b-4338-b915-07fc58c8498c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b7fdf5bf-4b82-4a6b-9bac-2705b475a9fc" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_71ebe307-393b-4338-b915-07fc58c8498c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_da4863f7-e2fc-43b1-9c42-31c4cb7e49f0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b7fdf5bf-4b82-4a6b-9bac-2705b475a9fc" xlink:to="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_da4863f7-e2fc-43b1-9c42-31c4cb7e49f0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_3be97799-9e04-4181-80de-f91e1a949254" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b7fdf5bf-4b82-4a6b-9bac-2705b475a9fc" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_3be97799-9e04-4181-80de-f91e1a949254" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_19a1f0bd-5b89-4e7f-8caf-22ff631623ee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b7fdf5bf-4b82-4a6b-9bac-2705b475a9fc" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_19a1f0bd-5b89-4e7f-8caf-22ff631623ee" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f79ab08d-e2a8-4786-821f-8dc99536073f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b7fdf5bf-4b82-4a6b-9bac-2705b475a9fc" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f79ab08d-e2a8-4786-821f-8dc99536073f" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_cbb1178f-d346-43e3-80f1-896ddc812b1e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f79ab08d-e2a8-4786-821f-8dc99536073f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_cbb1178f-d346-43e3-80f1-896ddc812b1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_6eb7ac91-0399-4503-a08a-8c92ec3a0454" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f79ab08d-e2a8-4786-821f-8dc99536073f" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_6eb7ac91-0399-4503-a08a-8c92ec3a0454" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_a9f7ff1d-3ca8-48d9-bbe5-5943e7c60338" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f79ab08d-e2a8-4786-821f-8dc99536073f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_a9f7ff1d-3ca8-48d9-bbe5-5943e7c60338" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_4e6e7dd6-0eb0-442f-bcdb-7a2dd22951bc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f79ab08d-e2a8-4786-821f-8dc99536073f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_4e6e7dd6-0eb0-442f-bcdb-7a2dd22951bc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_4e199406-cd24-4071-8a08-c832f4410cd1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f79ab08d-e2a8-4786-821f-8dc99536073f" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_4e199406-cd24-4071-8a08-c832f4410cd1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d0a97931-5e82-4f89-b2fc-e0891e16ffe7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b7fdf5bf-4b82-4a6b-9bac-2705b475a9fc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d0a97931-5e82-4f89-b2fc-e0891e16ffe7" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_71245389-0d77-4554-86cf-57ea25ce65e8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dd136dde-bf77-4377-b707-3231a0b6fed7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_71245389-0d77-4554-86cf-57ea25ce65e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_30d7605d-f8b6-4f5e-84a4-84c12fea562e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_71245389-0d77-4554-86cf-57ea25ce65e8" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_30d7605d-f8b6-4f5e-84a4-84c12fea562e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_14c6541e-2f6c-4642-b4bc-e6018f02129c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_71245389-0d77-4554-86cf-57ea25ce65e8" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_14c6541e-2f6c-4642-b4bc-e6018f02129c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_f0025d1e-3529-473f-8fb5-d5238176d79d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_71245389-0d77-4554-86cf-57ea25ce65e8" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_f0025d1e-3529-473f-8fb5-d5238176d79d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_693df65f-cae9-4201-a464-d06efb240620" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_71245389-0d77-4554-86cf-57ea25ce65e8" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_693df65f-cae9-4201-a464-d06efb240620" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_a92a831c-f9d9-47a1-b68f-9a3992d38c99" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_71245389-0d77-4554-86cf-57ea25ce65e8" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_a92a831c-f9d9-47a1-b68f-9a3992d38c99" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_70faeb3f-6358-478c-bd72-e0ebaedfbfb4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_71245389-0d77-4554-86cf-57ea25ce65e8" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_70faeb3f-6358-478c-bd72-e0ebaedfbfb4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfOtherInvestments_ce65c10c-6c9e-4b63-b597-bba320a02704" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfOtherInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_71245389-0d77-4554-86cf-57ea25ce65e8" xlink:to="loc_us-gaap_ProceedsFromSaleOfOtherInvestments_ce65c10c-6c9e-4b63-b597-bba320a02704" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_2c46967d-2a26-43bf-aa34-32c97f002556" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_71245389-0d77-4554-86cf-57ea25ce65e8" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_2c46967d-2a26-43bf-aa34-32c97f002556" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2611b026-29c7-4285-b02e-13d2d8d46985" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_71245389-0d77-4554-86cf-57ea25ce65e8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2611b026-29c7-4285-b02e-13d2d8d46985" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1fbc34cb-1c03-4a5d-b251-67a864a05a46" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dd136dde-bf77-4377-b707-3231a0b6fed7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1fbc34cb-1c03-4a5d-b251-67a864a05a46" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_78f3fded-abbc-43b1-9406-dc590bfb3d88" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1fbc34cb-1c03-4a5d-b251-67a864a05a46" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_78f3fded-abbc-43b1-9406-dc590bfb3d88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_32cd0855-254c-4552-be9d-9173c560f14e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1fbc34cb-1c03-4a5d-b251-67a864a05a46" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_32cd0855-254c-4552-be9d-9173c560f14e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_4bbee05b-e49c-4d76-a64d-827b1e33e90f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1fbc34cb-1c03-4a5d-b251-67a864a05a46" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_4bbee05b-e49c-4d76-a64d-827b1e33e90f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_a7cc9773-1e30-4d36-b215-d7b9f86b3759" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1fbc34cb-1c03-4a5d-b251-67a864a05a46" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_a7cc9773-1e30-4d36-b215-d7b9f86b3759" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_49b15d99-9e99-4947-8513-33d6eeb1588f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1fbc34cb-1c03-4a5d-b251-67a864a05a46" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_49b15d99-9e99-4947-8513-33d6eeb1588f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ff514b97-c3f9-4088-be20-1e17f0c4a897" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1fbc34cb-1c03-4a5d-b251-67a864a05a46" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ff514b97-c3f9-4088-be20-1e17f0c4a897" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_b57b7c7f-521f-40ce-8c81-7af1dcfb8e19" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dd136dde-bf77-4377-b707-3231a0b6fed7" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_b57b7c7f-521f-40ce-8c81-7af1dcfb8e19" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_927a6365-845f-4926-baa8-87b4c42ea0ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dd136dde-bf77-4377-b707-3231a0b6fed7" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_927a6365-845f-4926-baa8-87b4c42ea0ec" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_30fe9c8b-919b-4842-84e2-aa0ca6032ab9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_dd136dde-bf77-4377-b707-3231a0b6fed7" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_30fe9c8b-919b-4842-84e2-aa0ca6032ab9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_35f8f7df-6fe8-43f6-b84f-5453d17df056" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement" xlink:type="simple" xlink:href="biib-20250930.xsd#CondensedConsolidatedStatementofEquityStatement"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_195822ba-b0b2-4a3f-9834-7ecaf7ab02bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_57bd61bf-2114-48af-8c82-7d5b9501313c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_195822ba-b0b2-4a3f-9834-7ecaf7ab02bb" xlink:to="loc_us-gaap_StatementTable_57bd61bf-2114-48af-8c82-7d5b9501313c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7d57ac9f-fbc4-41e5-94e5-57c9147315b3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_57bd61bf-2114-48af-8c82-7d5b9501313c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_7d57ac9f-fbc4-41e5-94e5-57c9147315b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7d57ac9f-fbc4-41e5-94e5-57c9147315b3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7d57ac9f-fbc4-41e5-94e5-57c9147315b3" xlink:to="loc_us-gaap_EquityComponentDomain_7d57ac9f-fbc4-41e5-94e5-57c9147315b3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3b9c2084-feeb-41df-83d0-ed28dc2b8fc6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7d57ac9f-fbc4-41e5-94e5-57c9147315b3" xlink:to="loc_us-gaap_EquityComponentDomain_3b9c2084-feeb-41df-83d0-ed28dc2b8fc6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_24c50dfd-4c20-4e41-b012-e1c8af4d9719" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3b9c2084-feeb-41df-83d0-ed28dc2b8fc6" xlink:to="loc_us-gaap_PreferredStockMember_24c50dfd-4c20-4e41-b012-e1c8af4d9719" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9ea72d27-1632-431e-a378-835412af3c91" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3b9c2084-feeb-41df-83d0-ed28dc2b8fc6" xlink:to="loc_us-gaap_CommonStockMember_9ea72d27-1632-431e-a378-835412af3c91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_30c19878-6973-4d99-9d2d-3fa2982883f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3b9c2084-feeb-41df-83d0-ed28dc2b8fc6" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_30c19878-6973-4d99-9d2d-3fa2982883f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e41b89c3-b4a1-459f-8247-914dc4950081" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3b9c2084-feeb-41df-83d0-ed28dc2b8fc6" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e41b89c3-b4a1-459f-8247-914dc4950081" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_2d99e740-1893-4282-9e4c-4b3cc4142c39" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3b9c2084-feeb-41df-83d0-ed28dc2b8fc6" xlink:to="loc_us-gaap_RetainedEarningsMember_2d99e740-1893-4282-9e4c-4b3cc4142c39" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_5ff65438-610b-4b97-898a-44df98b574ff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3b9c2084-feeb-41df-83d0-ed28dc2b8fc6" xlink:to="loc_us-gaap_TreasuryStockCommonMember_5ff65438-610b-4b97-898a-44df98b574ff" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_6ba0d405-b930-4ff3-9741-3d93cae4d3a1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_3b9c2084-feeb-41df-83d0-ed28dc2b8fc6" xlink:to="loc_us-gaap_ParentMember_6ba0d405-b930-4ff3-9741-3d93cae4d3a1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_6cf3ff7b-0d93-4ddf-a01f-5827040e39a3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_195822ba-b0b2-4a3f-9834-7ecaf7ab02bb" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_6cf3ff7b-0d93-4ddf-a01f-5827040e39a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_29d3f5f4-5a9f-44dd-a40a-97a7c3756128" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_195822ba-b0b2-4a3f-9834-7ecaf7ab02bb" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_29d3f5f4-5a9f-44dd-a40a-97a7c3756128" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_9fd530d7-943e-4b41-832c-0a29498f9ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_195822ba-b0b2-4a3f-9834-7ecaf7ab02bb" xlink:to="loc_us-gaap_TreasuryStockCommonShares_9fd530d7-943e-4b41-832c-0a29498f9ca2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_e49a2727-328a-4755-9b88-3492a6dfe1b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_195822ba-b0b2-4a3f-9834-7ecaf7ab02bb" xlink:to="loc_us-gaap_ProfitLoss_e49a2727-328a-4755-9b88-3492a6dfe1b9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_dedd9e92-62ba-4d66-a31a-e6b5b1f3eb1a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_195822ba-b0b2-4a3f-9834-7ecaf7ab02bb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_dedd9e92-62ba-4d66-a31a-e6b5b1f3eb1a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_a2794bb1-8f24-4c05-8dc8-29df7e80154c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_195822ba-b0b2-4a3f-9834-7ecaf7ab02bb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_a2794bb1-8f24-4c05-8dc8-29df7e80154c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_07257577-b543-47e2-8080-4e959c3f008d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_195822ba-b0b2-4a3f-9834-7ecaf7ab02bb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_07257577-b543-47e2-8080-4e959c3f008d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_563cdeba-7d69-4d48-9ea6-e3da8f0fef16" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_195822ba-b0b2-4a3f-9834-7ecaf7ab02bb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_563cdeba-7d69-4d48-9ea6-e3da8f0fef16" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_0fc42d2d-8f14-45c2-b75d-0ae65724dfb7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_195822ba-b0b2-4a3f-9834-7ecaf7ab02bb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_0fc42d2d-8f14-45c2-b75d-0ae65724dfb7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_faf90ea6-b861-496a-90b3-55ed48abaca4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_195822ba-b0b2-4a3f-9834-7ecaf7ab02bb" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_faf90ea6-b861-496a-90b3-55ed48abaca4" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_4acf8a29-be5a-4e26-aa7d-364c3147c90a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_195822ba-b0b2-4a3f-9834-7ecaf7ab02bb" xlink:to="loc_us-gaap_StockholdersEquityOther_4acf8a29-be5a-4e26-aa7d-364c3147c90a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b11f0801-c6d7-4487-aebc-0f72c4ae57e3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_bd62f8e0-2048-4466-933b-01d9df9ad6d0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_1d58c66b-25c3-4aa7-9840-4bb0b492fb3a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonShares"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsNarrativeDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#AcquisitionsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/AcquisitionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_f7d67cd1-3cd1-4159-aaca-2d8c9b582bbf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7e7e98b1-e67d-4d84-9084-5dfe0afd3d77" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f7d67cd1-3cd1-4159-aaca-2d8c9b582bbf" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7e7e98b1-e67d-4d84-9084-5dfe0afd3d77" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_690c8bf5-203c-4b11-b3be-1400a0b7a6cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7e7e98b1-e67d-4d84-9084-5dfe0afd3d77" xlink:to="loc_us-gaap_AssetAcquisitionAxis_690c8bf5-203c-4b11-b3be-1400a0b7a6cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_690c8bf5-203c-4b11-b3be-1400a0b7a6cc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_690c8bf5-203c-4b11-b3be-1400a0b7a6cc" xlink:to="loc_us-gaap_AssetAcquisitionDomain_690c8bf5-203c-4b11-b3be-1400a0b7a6cc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_9421ca58-c6d8-47bc-9ceb-a57b5a9a530f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_690c8bf5-203c-4b11-b3be-1400a0b7a6cc" xlink:to="loc_us-gaap_AssetAcquisitionDomain_9421ca58-c6d8-47bc-9ceb-a57b5a9a530f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AlcyoneTherapeuticsInc.Member_6f01e371-7a40-4170-9555-4217737931a9" xlink:href="biib-20250930.xsd#biib_AlcyoneTherapeuticsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_9421ca58-c6d8-47bc-9ceb-a57b5a9a530f" xlink:to="loc_biib_AlcyoneTherapeuticsInc.Member_6f01e371-7a40-4170-9555-4217737931a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_3c89c7a0-c820-4b16-8484-54d815e83b5d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7e7e98b1-e67d-4d84-9084-5dfe0afd3d77" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_3c89c7a0-c820-4b16-8484-54d815e83b5d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3c89c7a0-c820-4b16-8484-54d815e83b5d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3c89c7a0-c820-4b16-8484-54d815e83b5d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3c89c7a0-c820-4b16-8484-54d815e83b5d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_41a75bf6-dfb6-4323-9505-cffa5baa8cbd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3c89c7a0-c820-4b16-8484-54d815e83b5d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_41a75bf6-dfb6-4323-9505-cffa5baa8cbd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_HumanImmunologyBiosciencesMember_92d2a8d3-f0da-47ef-bd36-0e89e5462347" xlink:href="biib-20250930.xsd#biib_HumanImmunologyBiosciencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_41a75bf6-dfb6-4323-9505-cffa5baa8cbd" xlink:to="loc_biib_HumanImmunologyBiosciencesMember_92d2a8d3-f0da-47ef-bd36-0e89e5462347" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_19b8fef3-56b4-4638-b8b9-9eb3b4c36f93" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7e7e98b1-e67d-4d84-9084-5dfe0afd3d77" xlink:to="loc_srt_RestatementAxis_19b8fef3-56b4-4638-b8b9-9eb3b4c36f93" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_19b8fef3-56b4-4638-b8b9-9eb3b4c36f93_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RestatementAxis_19b8fef3-56b4-4638-b8b9-9eb3b4c36f93" xlink:to="loc_srt_RestatementDomain_19b8fef3-56b4-4638-b8b9-9eb3b4c36f93_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_eaba02b5-6981-4ce5-aa6b-237cb5bd736f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RestatementAxis_19b8fef3-56b4-4638-b8b9-9eb3b4c36f93" xlink:to="loc_srt_RestatementDomain_eaba02b5-6981-4ce5-aa6b-237cb5bd736f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_894b4115-2486-42ad-b85b-71cb4cf93adf" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RestatementDomain_eaba02b5-6981-4ce5-aa6b-237cb5bd736f" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_894b4115-2486-42ad-b85b-71cb4cf93adf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_6d4724d2-f0e8-4cb4-9a7e-22a9eb4d7896" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7e7e98b1-e67d-4d84-9084-5dfe0afd3d77" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_6d4724d2-f0e8-4cb4-9a7e-22a9eb4d7896" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6d4724d2-f0e8-4cb4-9a7e-22a9eb4d7896_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6d4724d2-f0e8-4cb4-9a7e-22a9eb4d7896" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6d4724d2-f0e8-4cb4-9a7e-22a9eb4d7896_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c761baf8-e8a3-49cb-8402-cc375a82484a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6d4724d2-f0e8-4cb4-9a7e-22a9eb4d7896" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c761baf8-e8a3-49cb-8402-cc375a82484a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b6568bf3-a5f6-4e1b-b394-9f5e41573323" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c761baf8-e8a3-49cb-8402-cc375a82484a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b6568bf3-a5f6-4e1b-b394-9f5e41573323" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_17003101-6e72-43b0-93b5-4f2d6eb9e34c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c761baf8-e8a3-49cb-8402-cc375a82484a" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_17003101-6e72-43b0-93b5-4f2d6eb9e34c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_61c8e071-6524-4141-a83d-ab03b532f29d" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7e7e98b1-e67d-4d84-9084-5dfe0afd3d77" xlink:to="loc_srt_RangeAxis_61c8e071-6524-4141-a83d-ab03b532f29d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_61c8e071-6524-4141-a83d-ab03b532f29d_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_61c8e071-6524-4141-a83d-ab03b532f29d" xlink:to="loc_srt_RangeMember_61c8e071-6524-4141-a83d-ab03b532f29d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_752ea745-e902-4a43-8658-f44598e69684" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_61c8e071-6524-4141-a83d-ab03b532f29d" xlink:to="loc_srt_RangeMember_752ea745-e902-4a43-8658-f44598e69684" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5ddb765c-149c-41f9-8eee-55bf759efd90" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_752ea745-e902-4a43-8658-f44598e69684" xlink:to="loc_srt_MinimumMember_5ddb765c-149c-41f9-8eee-55bf759efd90" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2f02f4db-d599-42c2-abc2-339a0770a0e4" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_752ea745-e902-4a43-8658-f44598e69684" xlink:to="loc_srt_MaximumMember_2f02f4db-d599-42c2-abc2-339a0770a0e4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_88b12faa-2aea-4094-af93-a711ac9c5fc8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7e7e98b1-e67d-4d84-9084-5dfe0afd3d77" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_88b12faa-2aea-4094-af93-a711ac9c5fc8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_88b12faa-2aea-4094-af93-a711ac9c5fc8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_88b12faa-2aea-4094-af93-a711ac9c5fc8" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_88b12faa-2aea-4094-af93-a711ac9c5fc8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_32d2bc1e-64e7-4075-94d7-cd93c7845b06" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_88b12faa-2aea-4094-af93-a711ac9c5fc8" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_32d2bc1e-64e7-4075-94d7-cd93c7845b06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_840e77fd-c432-4d7e-97e1-4592258a0564" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_32d2bc1e-64e7-4075-94d7-cd93c7845b06" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_840e77fd-c432-4d7e-97e1-4592258a0564" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MeasurementInputProbabilityRateMember_80c82bb1-123d-4373-b23d-9542e9d7638e" xlink:href="biib-20250930.xsd#biib_MeasurementInputProbabilityRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_32d2bc1e-64e7-4075-94d7-cd93c7845b06" xlink:to="loc_biib_MeasurementInputProbabilityRateMember_80c82bb1-123d-4373-b23d-9542e9d7638e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_c587ee3e-383f-4384-a5a4-d8f52b75b4ce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7e7e98b1-e67d-4d84-9084-5dfe0afd3d77" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_c587ee3e-383f-4384-a5a4-d8f52b75b4ce" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_c587ee3e-383f-4384-a5a4-d8f52b75b4ce_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_c587ee3e-383f-4384-a5a4-d8f52b75b4ce" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_c587ee3e-383f-4384-a5a4-d8f52b75b4ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_8f2803d2-197f-40aa-ad21-790356b228ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_c587ee3e-383f-4384-a5a4-d8f52b75b4ce" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_8f2803d2-197f-40aa-ad21-790356b228ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Phase3ClinicalTrialFelzartamabOneMember_6f06a6d8-f529-410d-b000-284b8fb860fb" xlink:href="biib-20250930.xsd#biib_Phase3ClinicalTrialFelzartamabOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_8f2803d2-197f-40aa-ad21-790356b228ea" xlink:to="loc_biib_Phase3ClinicalTrialFelzartamabOneMember_6f06a6d8-f529-410d-b000-284b8fb860fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Phase3ClinicalTrialFelzartamabTwoMember_3cdf54ff-c5d4-4a14-9eea-3ad04385c18c" xlink:href="biib-20250930.xsd#biib_Phase3ClinicalTrialFelzartamabTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_8f2803d2-197f-40aa-ad21-790356b228ea" xlink:to="loc_biib_Phase3ClinicalTrialFelzartamabTwoMember_3cdf54ff-c5d4-4a14-9eea-3ad04385c18c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Phase3ClinicalTrialFelzartamabAMRMember_82dae44e-af08-4a6a-97c2-3be697df4501" xlink:href="biib-20250930.xsd#biib_Phase3ClinicalTrialFelzartamabAMRMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_8f2803d2-197f-40aa-ad21-790356b228ea" xlink:to="loc_biib_Phase3ClinicalTrialFelzartamabAMRMember_82dae44e-af08-4a6a-97c2-3be697df4501" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Phase3ClinicalTrialFelzartamabIgANMember_d9bf0d05-a7bc-4fac-8ed8-35cf84d77271" xlink:href="biib-20250930.xsd#biib_Phase3ClinicalTrialFelzartamabIgANMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_8f2803d2-197f-40aa-ad21-790356b228ea" xlink:to="loc_biib_Phase3ClinicalTrialFelzartamabIgANMember_d9bf0d05-a7bc-4fac-8ed8-35cf84d77271" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MilestonePaymentFutureDevelopmentMember_01b08581-a1f8-448c-8166-487bb13ae14c" xlink:href="biib-20250930.xsd#biib_MilestonePaymentFutureDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_8f2803d2-197f-40aa-ad21-790356b228ea" xlink:to="loc_biib_MilestonePaymentFutureDevelopmentMember_01b08581-a1f8-448c-8166-487bb13ae14c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MilestonePaymentRegulatoryMember_601a28e7-7843-46cc-92f1-9d73bbc7b016" xlink:href="biib-20250930.xsd#biib_MilestonePaymentRegulatoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_8f2803d2-197f-40aa-ad21-790356b228ea" xlink:to="loc_biib_MilestonePaymentRegulatoryMember_601a28e7-7843-46cc-92f1-9d73bbc7b016" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MilestonePaymentCommercialMember_ec785440-9dab-4634-8a30-60d6073baf26" xlink:href="biib-20250930.xsd#biib_MilestonePaymentCommercialMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_8f2803d2-197f-40aa-ad21-790356b228ea" xlink:to="loc_biib_MilestonePaymentCommercialMember_ec785440-9dab-4634-8a30-60d6073baf26" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_93c41c48-827d-4e9f-a884-924bf799b7de" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7e7e98b1-e67d-4d84-9084-5dfe0afd3d77" xlink:to="loc_srt_ProductOrServiceAxis_93c41c48-827d-4e9f-a884-924bf799b7de" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_93c41c48-827d-4e9f-a884-924bf799b7de_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_93c41c48-827d-4e9f-a884-924bf799b7de" xlink:to="loc_srt_ProductsAndServicesDomain_93c41c48-827d-4e9f-a884-924bf799b7de_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_bdd2bae7-40a1-438b-a396-110968cee7c8" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_93c41c48-827d-4e9f-a884-924bf799b7de" xlink:to="loc_srt_ProductsAndServicesDomain_bdd2bae7-40a1-438b-a396-110968cee7c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FelzartamabAndIzastobartHIB210Member_496fb3be-6151-4da4-af7d-9fed67b7977f" xlink:href="biib-20250930.xsd#biib_FelzartamabAndIzastobartHIB210Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_bdd2bae7-40a1-438b-a396-110968cee7c8" xlink:to="loc_biib_FelzartamabAndIzastobartHIB210Member_496fb3be-6151-4da4-af7d-9fed67b7977f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FelzartamabIgANMember_935acb56-ff7e-4914-8f8e-f5c7389e1ebd" xlink:href="biib-20250930.xsd#biib_FelzartamabIgANMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_bdd2bae7-40a1-438b-a396-110968cee7c8" xlink:to="loc_biib_FelzartamabIgANMember_935acb56-ff7e-4914-8f8e-f5c7389e1ebd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FelzartamabAMRMember_828c5b93-39c5-45e6-a608-98da26648bec" xlink:href="biib-20250930.xsd#biib_FelzartamabAMRMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_bdd2bae7-40a1-438b-a396-110968cee7c8" xlink:to="loc_biib_FelzartamabAMRMember_828c5b93-39c5-45e6-a608-98da26648bec" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FelzartamabPMNMember_4d112cec-9324-405a-9603-63b5b5d07437" xlink:href="biib-20250930.xsd#biib_FelzartamabPMNMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_bdd2bae7-40a1-438b-a396-110968cee7c8" xlink:to="loc_biib_FelzartamabPMNMember_4d112cec-9324-405a-9603-63b5b5d07437" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_3530620a-9590-44d7-adcd-178cd053d78f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7e7e98b1-e67d-4d84-9084-5dfe0afd3d77" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_3530620a-9590-44d7-adcd-178cd053d78f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_3530620a-9590-44d7-adcd-178cd053d78f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_3530620a-9590-44d7-adcd-178cd053d78f" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_3530620a-9590-44d7-adcd-178cd053d78f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_37caa68a-a645-4d71-81fa-2c8338b2baf1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_3530620a-9590-44d7-adcd-178cd053d78f" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_37caa68a-a645-4d71-81fa-2c8338b2baf1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_HumanImmunologyBiosciencesPreExistingInLicenseCommitmentsMember_fabe672b-a9b4-4e04-97b4-fe781feaf843" xlink:href="biib-20250930.xsd#biib_HumanImmunologyBiosciencesPreExistingInLicenseCommitmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_37caa68a-a645-4d71-81fa-2c8338b2baf1" xlink:to="loc_biib_HumanImmunologyBiosciencesPreExistingInLicenseCommitmentsMember_fabe672b-a9b4-4e04-97b4-fe781feaf843" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_27c2d4f3-f13b-410a-9d39-b79aa022e14b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7e7e98b1-e67d-4d84-9084-5dfe0afd3d77" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_27c2d4f3-f13b-410a-9d39-b79aa022e14b" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_27c2d4f3-f13b-410a-9d39-b79aa022e14b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_27c2d4f3-f13b-410a-9d39-b79aa022e14b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_27c2d4f3-f13b-410a-9d39-b79aa022e14b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_aa008903-99ad-4a4d-b3b5-f9ed9af39bf5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_27c2d4f3-f13b-410a-9d39-b79aa022e14b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_aa008903-99ad-4a4d-b3b5-f9ed9af39bf5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_19ebb11b-072a-43eb-aa8b-3c50a3d4e4df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_aa008903-99ad-4a4d-b3b5-f9ed9af39bf5" xlink:to="loc_us-gaap_SubsequentEventMember_19ebb11b-072a-43eb-aa8b-3c50a3d4e4df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_d56b93ba-0291-4ecf-93e1-71aca12f1c69" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f7d67cd1-3cd1-4159-aaca-2d8c9b582bbf" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_d56b93ba-0291-4ecf-93e1-71aca12f1c69" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedAtCost_9dc93466-259f-44bf-8ee9-1e8a822a2c8c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentOwnedAtCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f7d67cd1-3cd1-4159-aaca-2d8c9b582bbf" xlink:to="loc_us-gaap_InvestmentOwnedAtCost_9dc93466-259f-44bf-8ee9-1e8a822a2c8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_532785a9-13f2-4e50-b2b4-7ba1f1bf2893" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f7d67cd1-3cd1-4159-aaca-2d8c9b582bbf" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_532785a9-13f2-4e50-b2b4-7ba1f1bf2893" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_a0effd61-55e2-455f-a53d-b4b9a65a0e45" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f7d67cd1-3cd1-4159-aaca-2d8c9b582bbf" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_a0effd61-55e2-455f-a53d-b4b9a65a0e45" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsToAcquireBusinessGrossNonVestedEquityAwards_262cdbcc-afa8-46ad-9a32-ffc9736080c8" xlink:href="biib-20250930.xsd#biib_PaymentsToAcquireBusinessGrossNonVestedEquityAwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f7d67cd1-3cd1-4159-aaca-2d8c9b582bbf" xlink:to="loc_biib_PaymentsToAcquireBusinessGrossNonVestedEquityAwards_262cdbcc-afa8-46ad-9a32-ffc9736080c8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1b8d6a2a-bb46-4f7b-982d-0df3c990dd78" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f7d67cd1-3cd1-4159-aaca-2d8c9b582bbf" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1b8d6a2a-bb46-4f7b-982d-0df3c990dd78" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationConsiderationTransferredWorkingCapitalAdjustment_b61db1ab-a4d4-4edc-bad5-d2f80ce28e15" xlink:href="biib-20250930.xsd#biib_BusinessCombinationConsiderationTransferredWorkingCapitalAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f7d67cd1-3cd1-4159-aaca-2d8c9b582bbf" xlink:to="loc_biib_BusinessCombinationConsiderationTransferredWorkingCapitalAdjustment_b61db1ab-a4d4-4edc-bad5-d2f80ce28e15" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_96e99efd-c6f0-4369-b7c8-6cc4ef2d9834" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f7d67cd1-3cd1-4159-aaca-2d8c9b582bbf" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_96e99efd-c6f0-4369-b7c8-6cc4ef2d9834" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_72fbe50f-ac2f-4462-a1c2-b156bb0f1713" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f7d67cd1-3cd1-4159-aaca-2d8c9b582bbf" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_72fbe50f-ac2f-4462-a1c2-b156bb0f1713" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_dade706f-fa85-43f5-9d03-af1411382084" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f7d67cd1-3cd1-4159-aaca-2d8c9b582bbf" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_dade706f-fa85-43f5-9d03-af1411382084" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_56a5008b-ad82-4ce2-a20c-23e76574a108" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f7d67cd1-3cd1-4159-aaca-2d8c9b582bbf" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_56a5008b-ad82-4ce2-a20c-23e76574a108" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_74b89006-2bdb-436c-9f92-d77a15c877c1" xlink:href="biib-20250930.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f7d67cd1-3cd1-4159-aaca-2d8c9b582bbf" xlink:to="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_74b89006-2bdb-436c-9f92-d77a15c877c1" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_ea089e34-fcbf-4994-8daa-2fd4ec8e4df3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f7d67cd1-3cd1-4159-aaca-2d8c9b582bbf" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_ea089e34-fcbf-4994-8daa-2fd4ec8e4df3" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IntangibleAssetMeasurementInput_a2330d4a-f995-492c-9b0a-e58bae684ee9" xlink:href="biib-20250930.xsd#biib_IntangibleAssetMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f7d67cd1-3cd1-4159-aaca-2d8c9b582bbf" xlink:to="loc_biib_IntangibleAssetMeasurementInput_a2330d4a-f995-492c-9b0a-e58bae684ee9" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_8bd899cc-2a42-45eb-92d6-e520ef620b3d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f7d67cd1-3cd1-4159-aaca-2d8c9b582bbf" xlink:to="loc_us-gaap_Goodwill_8bd899cc-2a42-45eb-92d6-e520ef620b3d" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_37b0e47b-66b3-4374-a8f4-12dbe7b12aed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f7d67cd1-3cd1-4159-aaca-2d8c9b582bbf" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_37b0e47b-66b3-4374-a8f4-12dbe7b12aed" xlink:type="arc" order="15"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsPurchasePriceConsiderationDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#AcquisitionsPurchasePriceConsiderationDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/AcquisitionsPurchasePriceConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_60e07ecf-0f6a-42d8-b934-483d5b8e8fcf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ea229f88-3c72-4f3d-95c8-455cb958535b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_60e07ecf-0f6a-42d8-b934-483d5b8e8fcf" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ea229f88-3c72-4f3d-95c8-455cb958535b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_a99c29cb-87fb-44ed-a14b-e6f3f7b23040" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ea229f88-3c72-4f3d-95c8-455cb958535b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_a99c29cb-87fb-44ed-a14b-e6f3f7b23040" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a99c29cb-87fb-44ed-a14b-e6f3f7b23040_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a99c29cb-87fb-44ed-a14b-e6f3f7b23040" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_a99c29cb-87fb-44ed-a14b-e6f3f7b23040_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ae7b455a-0b7d-4dbd-8cd0-045eb5a9cdd1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a99c29cb-87fb-44ed-a14b-e6f3f7b23040" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ae7b455a-0b7d-4dbd-8cd0-045eb5a9cdd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_HumanImmunologyBiosciencesMember_dfdfaf8e-e149-48d5-83f2-84ae9aedcb5c" xlink:href="biib-20250930.xsd#biib_HumanImmunologyBiosciencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ae7b455a-0b7d-4dbd-8cd0-045eb5a9cdd1" xlink:to="loc_biib_HumanImmunologyBiosciencesMember_dfdfaf8e-e149-48d5-83f2-84ae9aedcb5c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_f8a7ad0a-f625-4204-9f21-cf1492838a67" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_60e07ecf-0f6a-42d8-b934-483d5b8e8fcf" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_f8a7ad0a-f625-4204-9f21-cf1492838a67" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_43131edb-6333-410f-8efc-c5401f67f597" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_60e07ecf-0f6a-42d8-b934-483d5b8e8fcf" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_43131edb-6333-410f-8efc-c5401f67f597" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_83c4a909-6e7d-420d-8281-f69c1e3dbac2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_60e07ecf-0f6a-42d8-b934-483d5b8e8fcf" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_83c4a909-6e7d-420d-8281-f69c1e3dbac2" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#AcquisitionsPreliminatyPurchasePriceAllocationDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_bad494bc-85df-4584-a49a-a818b1ef1f8a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f1835275-8d78-4ce3-8c69-cbebffcdc299" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bad494bc-85df-4584-a49a-a818b1ef1f8a" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f1835275-8d78-4ce3-8c69-cbebffcdc299" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1e313502-03e7-4a90-9654-0b8c3293e3c4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f1835275-8d78-4ce3-8c69-cbebffcdc299" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1e313502-03e7-4a90-9654-0b8c3293e3c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1e313502-03e7-4a90-9654-0b8c3293e3c4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1e313502-03e7-4a90-9654-0b8c3293e3c4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1e313502-03e7-4a90-9654-0b8c3293e3c4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fb61c96d-d5c6-45ab-835f-1c3b4c61e513" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1e313502-03e7-4a90-9654-0b8c3293e3c4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fb61c96d-d5c6-45ab-835f-1c3b4c61e513" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_HumanImmunologyBiosciencesMember_55254a21-8aa2-456f-aac5-562139c1d6b0" xlink:href="biib-20250930.xsd#biib_HumanImmunologyBiosciencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fb61c96d-d5c6-45ab-835f-1c3b4c61e513" xlink:to="loc_biib_HumanImmunologyBiosciencesMember_55254a21-8aa2-456f-aac5-562139c1d6b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b927ac48-e36b-4665-a283-6fee43b61012" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f1835275-8d78-4ce3-8c69-cbebffcdc299" xlink:to="loc_srt_ProductOrServiceAxis_b927ac48-e36b-4665-a283-6fee43b61012" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b927ac48-e36b-4665-a283-6fee43b61012_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_b927ac48-e36b-4665-a283-6fee43b61012" xlink:to="loc_srt_ProductsAndServicesDomain_b927ac48-e36b-4665-a283-6fee43b61012_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_279c900a-79e0-4b23-b78c-1cf53024c338" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_b927ac48-e36b-4665-a283-6fee43b61012" xlink:to="loc_srt_ProductsAndServicesDomain_279c900a-79e0-4b23-b78c-1cf53024c338" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FelzartamabIgANMember_4b95ee88-2680-416e-9e9c-d705118bf251" xlink:href="biib-20250930.xsd#biib_FelzartamabIgANMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_279c900a-79e0-4b23-b78c-1cf53024c338" xlink:to="loc_biib_FelzartamabIgANMember_4b95ee88-2680-416e-9e9c-d705118bf251" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FelzartamabAMRMember_320bfb74-1328-4b0c-bfb9-c78ab380f110" xlink:href="biib-20250930.xsd#biib_FelzartamabAMRMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_279c900a-79e0-4b23-b78c-1cf53024c338" xlink:to="loc_biib_FelzartamabAMRMember_320bfb74-1328-4b0c-bfb9-c78ab380f110" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FelzartamabPMNMember_efac30a9-7b06-4e7e-9c6d-67c8c796c75f" xlink:href="biib-20250930.xsd#biib_FelzartamabPMNMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_279c900a-79e0-4b23-b78c-1cf53024c338" xlink:to="loc_biib_FelzartamabPMNMember_efac30a9-7b06-4e7e-9c6d-67c8c796c75f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_58e43337-f981-485f-823d-c30bb49c67fa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f1835275-8d78-4ce3-8c69-cbebffcdc299" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_58e43337-f981-485f-823d-c30bb49c67fa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_58e43337-f981-485f-823d-c30bb49c67fa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_58e43337-f981-485f-823d-c30bb49c67fa" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_58e43337-f981-485f-823d-c30bb49c67fa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_dadcc16a-eba3-48db-8adf-1e84c4cd1138" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_58e43337-f981-485f-823d-c30bb49c67fa" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_dadcc16a-eba3-48db-8adf-1e84c4cd1138" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_2014d73a-be84-4887-b1af-77285ab5021e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_dadcc16a-eba3-48db-8adf-1e84c4cd1138" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_2014d73a-be84-4887-b1af-77285ab5021e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherClinicalProgramsMember_fadc1ab2-60cd-4b7d-9593-f7d324d63bf1" xlink:href="biib-20250930.xsd#biib_OtherClinicalProgramsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_dadcc16a-eba3-48db-8adf-1e84c4cd1138" xlink:to="loc_biib_OtherClinicalProgramsMember_fadc1ab2-60cd-4b7d-9593-f7d324d63bf1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_a77202af-3b0f-45c6-b964-0dff620f7962" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bad494bc-85df-4584-a49a-a818b1ef1f8a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_a77202af-3b0f-45c6-b964-0dff620f7962" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_ae82d449-79f5-47f8-af0d-3faeb28ec455" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bad494bc-85df-4584-a49a-a818b1ef1f8a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_ae82d449-79f5-47f8-af0d-3faeb28ec455" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_d8f34be0-d4df-47b1-963e-fea912207f9f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bad494bc-85df-4584-a49a-a818b1ef1f8a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_d8f34be0-d4df-47b1-963e-fea912207f9f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets_a01d61c5-4fd7-49e2-ac4b-4ad006e37da3" xlink:href="biib-20250930.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bad494bc-85df-4584-a49a-a818b1ef1f8a" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets_a01d61c5-4fd7-49e2-ac4b-4ad006e37da3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_aea01524-614d-4162-bf22-fb0cd963fc04" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bad494bc-85df-4584-a49a-a818b1ef1f8a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_aea01524-614d-4162-bf22-fb0cd963fc04" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities_48556654-32b4-4c03-8135-19e5344ffc98" xlink:href="biib-20250930.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bad494bc-85df-4584-a49a-a818b1ef1f8a" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities_48556654-32b4-4c03-8135-19e5344ffc98" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_b23146ab-f516-47a9-9326-cc3dec4745c7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bad494bc-85df-4584-a49a-a818b1ef1f8a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_b23146ab-f516-47a9-9326-cc3dec4745c7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities_affa0085-98f8-4123-9bc1-d929d83b8d1b" xlink:href="biib-20250930.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bad494bc-85df-4584-a49a-a818b1ef1f8a" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities_affa0085-98f8-4123-9bc1-d929d83b8d1b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_5224dd4d-74c2-4fdc-889e-8dd153f33405" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bad494bc-85df-4584-a49a-a818b1ef1f8a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_5224dd4d-74c2-4fdc-889e-8dd153f33405" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_c2679f3f-afd1-43be-afc0-a96511c78179" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bad494bc-85df-4584-a49a-a818b1ef1f8a" xlink:to="loc_us-gaap_Goodwill_c2679f3f-afd1-43be-afc0-a96511c78179" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_2db7f113-b996-488d-bf90-9137e38b117f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bad494bc-85df-4584-a49a-a818b1ef1f8a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_2db7f113-b996-488d-bf90-9137e38b117f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpenseAndOther_4c862c54-0a72-4356-a880-71b0b0878245" xlink:href="biib-20250930.xsd#biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpenseAndOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bad494bc-85df-4584-a49a-a818b1ef1f8a" xlink:to="loc_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpenseAndOther_4c862c54-0a72-4356-a880-71b0b0878245" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability_2c476de9-562a-47e1-8331-bd24c745a3c6" xlink:href="biib-20250930.xsd#biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bad494bc-85df-4584-a49a-a818b1ef1f8a" xlink:to="loc_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability_2c476de9-562a-47e1-8331-bd24c745a3c6" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill_9835dacd-b699-431d-ae07-9d61933db437" xlink:href="biib-20250930.xsd#biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bad494bc-85df-4584-a49a-a818b1ef1f8a" xlink:to="loc_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill_9835dacd-b699-431d-ae07-9d61933db437" xlink:type="arc" order="13"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DispositionsDetailsTextual" xlink:type="simple" xlink:href="biib-20250930.xsd#DispositionsDetailsTextual"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DispositionsDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_67baed22-d951-4d90-a97b-5439a6f2bc13" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e04b440f-d5ec-4efe-8063-a3c8434f2d66" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_67baed22-d951-4d90-a97b-5439a6f2bc13" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e04b440f-d5ec-4efe-8063-a3c8434f2d66" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_b3059bf5-2b02-481c-8fea-8d66bf2adf8d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e04b440f-d5ec-4efe-8063-a3c8434f2d66" xlink:to="loc_us-gaap_TypeOfArrangementAxis_b3059bf5-2b02-481c-8fea-8d66bf2adf8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b3059bf5-2b02-481c-8fea-8d66bf2adf8d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b3059bf5-2b02-481c-8fea-8d66bf2adf8d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b3059bf5-2b02-481c-8fea-8d66bf2adf8d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cc6fc5a8-27ea-406c-be1e-ccd8e2f82f63" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b3059bf5-2b02-481c-8fea-8d66bf2adf8d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cc6fc5a8-27ea-406c-be1e-ccd8e2f82f63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_18d9212a-08f2-4d73-aad8-44c6eee23c25" xlink:href="biib-20250930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cc6fc5a8-27ea-406c-be1e-ccd8e2f82f63" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_18d9212a-08f2-4d73-aad8-44c6eee23c25" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f98c9d40-4fda-4c7d-b45b-df070baf1fb7" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e04b440f-d5ec-4efe-8063-a3c8434f2d66" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f98c9d40-4fda-4c7d-b45b-df070baf1fb7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_f98c9d40-4fda-4c7d-b45b-df070baf1fb7_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f98c9d40-4fda-4c7d-b45b-df070baf1fb7" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_f98c9d40-4fda-4c7d-b45b-df070baf1fb7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_539c6050-b758-4149-ace4-b49520203ccc" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f98c9d40-4fda-4c7d-b45b-df070baf1fb7" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_539c6050-b758-4149-ace4-b49520203ccc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_e859d11f-dcac-44d6-ac26-13e08fdac83e" xlink:href="biib-20250930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_539c6050-b758-4149-ace4-b49520203ccc" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_e859d11f-dcac-44d6-ac26-13e08fdac83e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis_d6c41310-7fc2-48bf-81ef-037d86ff5716" xlink:href="biib-20250930.xsd#biib_FutureContingentMilestoneTypesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e04b440f-d5ec-4efe-8063-a3c8434f2d66" xlink:to="loc_biib_FutureContingentMilestoneTypesAxis_d6c41310-7fc2-48bf-81ef-037d86ff5716" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_d6c41310-7fc2-48bf-81ef-037d86ff5716_default" xlink:href="biib-20250930.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_d6c41310-7fc2-48bf-81ef-037d86ff5716" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_d6c41310-7fc2-48bf-81ef-037d86ff5716_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_87e2823c-4321-45d8-961c-1cbfea8b35d1" xlink:href="biib-20250930.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_d6c41310-7fc2-48bf-81ef-037d86ff5716" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_87e2823c-4321-45d8-961c-1cbfea8b35d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentDueAtFirstAnniversaryMember_344e80c8-c577-4366-a1a2-a14569852499" xlink:href="biib-20250930.xsd#biib_PaymentDueAtFirstAnniversaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_87e2823c-4321-45d8-961c-1cbfea8b35d1" xlink:to="loc_biib_PaymentDueAtFirstAnniversaryMember_344e80c8-c577-4366-a1a2-a14569852499" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentDueAtSecondAnniversaryMember_b7537020-b8e6-4780-9ed2-d791584c6d9d" xlink:href="biib-20250930.xsd#biib_PaymentDueAtSecondAnniversaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_87e2823c-4321-45d8-961c-1cbfea8b35d1" xlink:to="loc_biib_PaymentDueAtSecondAnniversaryMember_b7537020-b8e6-4780-9ed2-d791584c6d9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a72a1c41-9a2c-4676-9cf8-552c838431ba" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e04b440f-d5ec-4efe-8063-a3c8434f2d66" xlink:to="loc_srt_CounterpartyNameAxis_a72a1c41-9a2c-4676-9cf8-552c838431ba" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a72a1c41-9a2c-4676-9cf8-552c838431ba_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_a72a1c41-9a2c-4676-9cf8-552c838431ba" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a72a1c41-9a2c-4676-9cf8-552c838431ba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9267bafa-72f0-4284-b6ee-b65e62af8797" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_a72a1c41-9a2c-4676-9cf8-552c838431ba" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9267bafa-72f0-4284-b6ee-b65e62af8797" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IonisPharmaceuticalsInc.Member_636b4968-5e56-4659-ba37-24d85aa36cd9" xlink:href="biib-20250930.xsd#biib_IonisPharmaceuticalsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9267bafa-72f0-4284-b6ee-b65e62af8797" xlink:to="loc_biib_IonisPharmaceuticalsInc.Member_636b4968-5e56-4659-ba37-24d85aa36cd9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_7e514f23-9eb6-4444-a014-dddee40bfae4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_67baed22-d951-4d90-a97b-5439a6f2bc13" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_7e514f23-9eb6-4444-a014-dddee40bfae4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount_3f4fabf6-e38f-47c8-8e05-525628400ca1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentSoldCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_67baed22-d951-4d90-a97b-5439a6f2bc13" xlink:to="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount_3f4fabf6-e38f-47c8-8e05-525628400ca1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture_5e42630a-0c15-4f59-bd08-c7236efcae1a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromDivestitureOfInterestInJointVenture"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_67baed22-d951-4d90-a97b-5439a6f2bc13" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture_5e42630a-0c15-4f59-bd08-c7236efcae1a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PayablesToDivestitureOfInterestInJointVenture_ac77362c-fa20-47e2-884d-908bc8f795b0" xlink:href="biib-20250930.xsd#biib_PayablesToDivestitureOfInterestInJointVenture"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_67baed22-d951-4d90-a97b-5439a6f2bc13" xlink:to="loc_biib_PayablesToDivestitureOfInterestInJointVenture_ac77362c-fa20-47e2-884d-908bc8f795b0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_51a52fae-e40a-45e7-bf6b-d69d8cccf728" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_67baed22-d951-4d90-a97b-5439a6f2bc13" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_51a52fae-e40a-45e7-bf6b-d69d8cccf728" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_afb244d3-c50b-4e6d-8af0-3de25d41bd81" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_67baed22-d951-4d90-a97b-5439a6f2bc13" xlink:to="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_afb244d3-c50b-4e6d-8af0-3de25d41bd81" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ProceedsPaidToCollaborativeArrangementCounterparty_090a0a53-752d-413c-9491-565c02591b44" xlink:href="biib-20250930.xsd#biib_ProceedsPaidToCollaborativeArrangementCounterparty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_67baed22-d951-4d90-a97b-5439a6f2bc13" xlink:to="loc_biib_ProceedsPaidToCollaborativeArrangementCounterparty_090a0a53-752d-413c-9491-565c02591b44" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_d7e91d85-a9d7-4e5d-afd8-73c898ae6143" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_67baed22-d951-4d90-a97b-5439a6f2bc13" xlink:to="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_d7e91d85-a9d7-4e5d-afd8-73c898ae6143" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_6393a7ef-ab8f-4662-a23a-552538790825" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_84d9c36c-ba9e-4a5e-a9a1-8f0d18558ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_6393a7ef-ab8f-4662-a23a-552538790825" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_84d9c36c-ba9e-4a5e-a9a1-8f0d18558ff8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_68057f01-a66c-4939-bc08-545750db5095" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_84d9c36c-ba9e-4a5e-a9a1-8f0d18558ff8" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_68057f01-a66c-4939-bc08-545750db5095" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_68057f01-a66c-4939-bc08-545750db5095_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_68057f01-a66c-4939-bc08-545750db5095" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_68057f01-a66c-4939-bc08-545750db5095_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9cc45d23-a324-4522-999f-8eab9cf8f027" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_68057f01-a66c-4939-bc08-545750db5095" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9cc45d23-a324-4522-999f-8eab9cf8f027" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_6aa047e4-1482-4656-addb-3214f40e9594" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9cc45d23-a324-4522-999f-8eab9cf8f027" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_6aa047e4-1482-4656-addb-3214f40e9594" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b185655a-5543-48ca-b468-a37c96059624" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9cc45d23-a324-4522-999f-8eab9cf8f027" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b185655a-5543-48ca-b468-a37c96059624" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember_a4ba561d-a40a-48b5-9004-87cc09203eae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringChargesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9cc45d23-a324-4522-999f-8eab9cf8f027" xlink:to="loc_us-gaap_RestructuringChargesMember_a4ba561d-a40a-48b5-9004-87cc09203eae" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_a8009977-a10e-46fb-86ab-b3848267f066" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_84d9c36c-ba9e-4a5e-a9a1-8f0d18558ff8" xlink:to="loc_us-gaap_RestructuringPlanAxis_a8009977-a10e-46fb-86ab-b3848267f066" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_a8009977-a10e-46fb-86ab-b3848267f066_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_a8009977-a10e-46fb-86ab-b3848267f066" xlink:to="loc_us-gaap_RestructuringPlanDomain_a8009977-a10e-46fb-86ab-b3848267f066_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_71e282d8-4b9f-4d67-9cac-0a6cc841536f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_a8009977-a10e-46fb-86ab-b3848267f066" xlink:to="loc_us-gaap_RestructuringPlanDomain_71e282d8-4b9f-4d67-9cac-0a6cc841536f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2023CostSavingInitiativesMember_b995a1ed-8922-4925-9b11-9ea4171cc72b" xlink:href="biib-20250930.xsd#biib_A2023CostSavingInitiativesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_71e282d8-4b9f-4d67-9cac-0a6cc841536f" xlink:to="loc_biib_A2023CostSavingInitiativesMember_b995a1ed-8922-4925-9b11-9ea4171cc72b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataIntegrationMember_69956d8c-66df-463a-aedb-37879e9d2e26" xlink:href="biib-20250930.xsd#biib_ReataIntegrationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_71e282d8-4b9f-4d67-9cac-0a6cc841536f" xlink:to="loc_biib_ReataIntegrationMember_69956d8c-66df-463a-aedb-37879e9d2e26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_8902cfba-5d14-4cf0-b81f-5583cc3aadfa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeveranceCosts1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_6393a7ef-ab8f-4662-a23a-552538790825" xlink:to="loc_us-gaap_SeveranceCosts1_8902cfba-5d14-4cf0-b81f-5583cc3aadfa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringCosts_fd8fbf69-3f8b-4bee-81ce-20d95153a403" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherRestructuringCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_6393a7ef-ab8f-4662-a23a-552538790825" xlink:to="loc_us-gaap_OtherRestructuringCosts_fd8fbf69-3f8b-4bee-81ce-20d95153a403" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_cf93ee59-c414-482c-8248-1ae40c4ff55b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_6393a7ef-ab8f-4662-a23a-552538790825" xlink:to="loc_us-gaap_RestructuringCharges_cf93ee59-c414-482c-8248-1ae40c4ff55b" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_6ee5054f-83ba-4021-9f5a-60b932230971" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9a6b8ba6-2f53-4485-96fd-bdffe90a1bd9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_6ee5054f-83ba-4021-9f5a-60b932230971" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9a6b8ba6-2f53-4485-96fd-bdffe90a1bd9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_3a95b401-b218-4549-a3b2-4b9f83ccb3bd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9a6b8ba6-2f53-4485-96fd-bdffe90a1bd9" xlink:to="loc_us-gaap_RestructuringPlanAxis_3a95b401-b218-4549-a3b2-4b9f83ccb3bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_3a95b401-b218-4549-a3b2-4b9f83ccb3bd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_3a95b401-b218-4549-a3b2-4b9f83ccb3bd" xlink:to="loc_us-gaap_RestructuringPlanDomain_3a95b401-b218-4549-a3b2-4b9f83ccb3bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_f1aede96-8c1e-410b-bec7-4acd2e99d1f5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_3a95b401-b218-4549-a3b2-4b9f83ccb3bd" xlink:to="loc_us-gaap_RestructuringPlanDomain_f1aede96-8c1e-410b-bec7-4acd2e99d1f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2023CostSavingInitiativesMember_20a91af3-2bff-4df6-9589-416901ce83f8" xlink:href="biib-20250930.xsd#biib_A2023CostSavingInitiativesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_f1aede96-8c1e-410b-bec7-4acd2e99d1f5" xlink:to="loc_biib_A2023CostSavingInitiativesMember_20a91af3-2bff-4df6-9589-416901ce83f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataIntegrationMember_3f548ba6-a459-4785-89f6-719c433566e7" xlink:href="biib-20250930.xsd#biib_ReataIntegrationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_f1aede96-8c1e-410b-bec7-4acd2e99d1f5" xlink:to="loc_biib_ReataIntegrationMember_3f548ba6-a459-4785-89f6-719c433566e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_e7030e15-4fe1-4cc6-8a24-7995e9bf123e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9a6b8ba6-2f53-4485-96fd-bdffe90a1bd9" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_e7030e15-4fe1-4cc6-8a24-7995e9bf123e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e7030e15-4fe1-4cc6-8a24-7995e9bf123e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e7030e15-4fe1-4cc6-8a24-7995e9bf123e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e7030e15-4fe1-4cc6-8a24-7995e9bf123e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e1267ca5-63fb-495e-8bc7-95a6b62a81a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e7030e15-4fe1-4cc6-8a24-7995e9bf123e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e1267ca5-63fb-495e-8bc7-95a6b62a81a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember_0be67af1-24a5-4c2e-a9a5-3d425f9ee1a9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringChargesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e1267ca5-63fb-495e-8bc7-95a6b62a81a0" xlink:to="loc_us-gaap_RestructuringChargesMember_0be67af1-24a5-4c2e-a9a5-3d425f9ee1a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_02675edc-25a3-4f48-b2e9-ff4defc9b87a" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9a6b8ba6-2f53-4485-96fd-bdffe90a1bd9" xlink:to="loc_srt_RangeAxis_02675edc-25a3-4f48-b2e9-ff4defc9b87a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_02675edc-25a3-4f48-b2e9-ff4defc9b87a_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_02675edc-25a3-4f48-b2e9-ff4defc9b87a" xlink:to="loc_srt_RangeMember_02675edc-25a3-4f48-b2e9-ff4defc9b87a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8207849c-514e-49bc-a82a-4e9b7a4838ff" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_02675edc-25a3-4f48-b2e9-ff4defc9b87a" xlink:to="loc_srt_RangeMember_8207849c-514e-49bc-a82a-4e9b7a4838ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_322145cb-7468-420d-aeda-e4b38610bbe1" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8207849c-514e-49bc-a82a-4e9b7a4838ff" xlink:to="loc_srt_MinimumMember_322145cb-7468-420d-aeda-e4b38610bbe1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_72cf42fe-a650-4ad9-9c1c-16cfc42f1bf2" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8207849c-514e-49bc-a82a-4e9b7a4838ff" xlink:to="loc_srt_MaximumMember_72cf42fe-a650-4ad9-9c1c-16cfc42f1bf2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_571f0e69-367f-41ee-bfe6-b4d9c107acc9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9a6b8ba6-2f53-4485-96fd-bdffe90a1bd9" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_571f0e69-367f-41ee-bfe6-b4d9c107acc9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_571f0e69-367f-41ee-bfe6-b4d9c107acc9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_571f0e69-367f-41ee-bfe6-b4d9c107acc9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_571f0e69-367f-41ee-bfe6-b4d9c107acc9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_48fc4a14-1a9d-4532-ad93-7b43b36abc3a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_571f0e69-367f-41ee-bfe6-b4d9c107acc9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_48fc4a14-1a9d-4532-ad93-7b43b36abc3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_HumanImmunologyBiosciencesMember_2438091c-eda1-4390-8553-c62be75e2df9" xlink:href="biib-20250930.xsd#biib_HumanImmunologyBiosciencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_48fc4a14-1a9d-4532-ad93-7b43b36abc3a" xlink:to="loc_biib_HumanImmunologyBiosciencesMember_2438091c-eda1-4390-8553-c62be75e2df9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember_af4d7823-1427-4fa8-9ddb-f299c89650d6" xlink:href="biib-20250930.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_48fc4a14-1a9d-4532-ad93-7b43b36abc3a" xlink:to="loc_biib_ReataPharmaceuticalsIncMember_af4d7823-1427-4fa8-9ddb-f299c89650d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction_c95820e0-350e-477b-8350-bd65cb726933" xlink:href="biib-20250930.xsd#biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_6ee5054f-83ba-4021-9f5a-60b932230971" xlink:to="loc_biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction_c95820e0-350e-477b-8350-bd65cb726933" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated_e5a74287-92a0-43d5-9616-28e4c8d4d766" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_6ee5054f-83ba-4021-9f5a-60b932230971" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated_e5a74287-92a0-43d5-9616-28e4c8d4d766" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_043a2cd4-30f2-4bf4-9269-8510fa25ee31" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeveranceCosts1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_6ee5054f-83ba-4021-9f5a-60b932230971" xlink:to="loc_us-gaap_SeveranceCosts1_043a2cd4-30f2-4bf4-9269-8510fa25ee31" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1_6ce46798-7c3e-4389-82e2-29c2a0101d3d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_6ee5054f-83ba-4021-9f5a-60b932230971" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1_6ce46798-7c3e-4389-82e2-29c2a0101d3d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_9919a836-fbc6-4a34-9358-6772dcb5671d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_6ee5054f-83ba-4021-9f5a-60b932230971" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_9919a836-fbc6-4a34-9358-6772dcb5671d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OperatingLeaseArea_56c4d51f-b435-4cd2-9513-93409e441eb9" xlink:href="biib-20250930.xsd#biib_OperatingLeaseArea"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_6ee5054f-83ba-4021-9f5a-60b932230971" xlink:to="loc_biib_OperatingLeaseArea_56c4d51f-b435-4cd2-9513-93409e441eb9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_a23b2cf6-2ec7-4bed-aa74-f025fa8c507f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_6ee5054f-83ba-4021-9f5a-60b932230971" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_a23b2cf6-2ec7-4bed-aa74-f025fa8c507f" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_6e5b289c-7c88-4434-931e-87b0e3f61d9c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8a9f17a7-ffaf-4d10-aaf0-b868b319ddbd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_6e5b289c-7c88-4434-931e-87b0e3f61d9c" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8a9f17a7-ffaf-4d10-aaf0-b868b319ddbd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_1afd214f-fda9-4e2c-accd-30d25392b44d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8a9f17a7-ffaf-4d10-aaf0-b868b319ddbd" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_1afd214f-fda9-4e2c-accd-30d25392b44d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_1afd214f-fda9-4e2c-accd-30d25392b44d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_1afd214f-fda9-4e2c-accd-30d25392b44d" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_1afd214f-fda9-4e2c-accd-30d25392b44d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_f5721712-0b23-4d7a-8df5-ba3ed6886f9b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_1afd214f-fda9-4e2c-accd-30d25392b44d" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_f5721712-0b23-4d7a-8df5-ba3ed6886f9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_b666a6ee-c03a-4baf-ad6c-78d558990549" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_f5721712-0b23-4d7a-8df5-ba3ed6886f9b" xlink:to="loc_us-gaap_EmployeeSeveranceMember_b666a6ee-c03a-4baf-ad6c-78d558990549" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_22fed26a-8b61-45c7-bf57-8526271c71af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8a9f17a7-ffaf-4d10-aaf0-b868b319ddbd" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_22fed26a-8b61-45c7-bf57-8526271c71af" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_22fed26a-8b61-45c7-bf57-8526271c71af_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_22fed26a-8b61-45c7-bf57-8526271c71af" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_22fed26a-8b61-45c7-bf57-8526271c71af_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_b98435bd-d31e-42a2-b9c7-c74806deaec0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_22fed26a-8b61-45c7-bf57-8526271c71af" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_b98435bd-d31e-42a2-b9c7-c74806deaec0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember_8553cbfa-eaaf-4385-90b0-c896e931ca43" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringChargesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b98435bd-d31e-42a2-b9c7-c74806deaec0" xlink:to="loc_us-gaap_RestructuringChargesMember_8553cbfa-eaaf-4385-90b0-c896e931ca43" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_629bdf2c-88ed-43b5-ad17-34815ce0e6bf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_6e5b289c-7c88-4434-931e-87b0e3f61d9c" xlink:to="loc_us-gaap_RestructuringCharges_629bdf2c-88ed-43b5-ad17-34815ce0e6bf" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_e18a4fb0-beba-4030-ad6d-c638cc600aba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5ab65e39-7b03-4092-87c5-81c07e8da125" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_e18a4fb0-beba-4030-ad6d-c638cc600aba" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5ab65e39-7b03-4092-87c5-81c07e8da125" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_844dbdd3-7b49-437c-b632-17e2627ffe18" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5ab65e39-7b03-4092-87c5-81c07e8da125" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_844dbdd3-7b49-437c-b632-17e2627ffe18" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_844dbdd3-7b49-437c-b632-17e2627ffe18_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_844dbdd3-7b49-437c-b632-17e2627ffe18" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_844dbdd3-7b49-437c-b632-17e2627ffe18_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_3e62f831-3395-45a2-8ef4-cbb36d67e1c1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_844dbdd3-7b49-437c-b632-17e2627ffe18" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_3e62f831-3395-45a2-8ef4-cbb36d67e1c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_d2aa9870-a779-4c12-afcf-9adac0506787" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_3e62f831-3395-45a2-8ef4-cbb36d67e1c1" xlink:to="loc_us-gaap_EmployeeSeveranceMember_d2aa9870-a779-4c12-afcf-9adac0506787" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_24c6c1e8-00b6-4419-853d-fca7ea622e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5ab65e39-7b03-4092-87c5-81c07e8da125" xlink:to="loc_us-gaap_RestructuringPlanAxis_24c6c1e8-00b6-4419-853d-fca7ea622e8e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_24c6c1e8-00b6-4419-853d-fca7ea622e8e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_24c6c1e8-00b6-4419-853d-fca7ea622e8e" xlink:to="loc_us-gaap_RestructuringPlanDomain_24c6c1e8-00b6-4419-853d-fca7ea622e8e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_d99efd33-db6c-4eff-b9bb-2f52729506cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_24c6c1e8-00b6-4419-853d-fca7ea622e8e" xlink:to="loc_us-gaap_RestructuringPlanDomain_d99efd33-db6c-4eff-b9bb-2f52729506cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2023CostSavingInitiativesMember_7f0d5c71-ed40-4d18-a975-96bfb373853c" xlink:href="biib-20250930.xsd#biib_A2023CostSavingInitiativesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_d99efd33-db6c-4eff-b9bb-2f52729506cc" xlink:to="loc_biib_A2023CostSavingInitiativesMember_7f0d5c71-ed40-4d18-a975-96bfb373853c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2023And2022CostSavingInitiativesMember_c7ee3dc7-9211-4e14-b2b7-92ee4ff3f7aa" xlink:href="biib-20250930.xsd#biib_A2023And2022CostSavingInitiativesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_d99efd33-db6c-4eff-b9bb-2f52729506cc" xlink:to="loc_biib_A2023And2022CostSavingInitiativesMember_c7ee3dc7-9211-4e14-b2b7-92ee4ff3f7aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_6e12e44a-7cd9-4b9f-8233-908e40adfc11" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_e18a4fb0-beba-4030-ad6d-c638cc600aba" xlink:to="loc_us-gaap_RestructuringReserve_6e12e44a-7cd9-4b9f-8233-908e40adfc11" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_d7282506-8116-45bd-bf6d-fc853b245d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_e18a4fb0-beba-4030-ad6d-c638cc600aba" xlink:to="loc_us-gaap_RestructuringCharges_d7282506-8116-45bd-bf6d-fc853b245d0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_58654aaf-5354-49cb-96e6-bc9a27a3c1d0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_e18a4fb0-beba-4030-ad6d-c638cc600aba" xlink:to="loc_us-gaap_PaymentsForRestructuring_58654aaf-5354-49cb-96e6-bc9a27a3c1d0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveTranslationAdjustment_d5255eef-b94a-41c1-b2a3-910ba4a2bb4d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserveTranslationAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_e18a4fb0-beba-4030-ad6d-c638cc600aba" xlink:to="loc_us-gaap_RestructuringReserveTranslationAdjustment_d5255eef-b94a-41c1-b2a3-910ba4a2bb4d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_2aa58fe1-f692-493c-b06b-f2761f22e73b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserve"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#RevenuesRevenuesbyproductDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_ce898dbf-8b0e-40e0-9368-343ea0ac9552" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_f63d7168-da8c-4b2f-ba19-76738d0354a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ce898dbf-8b0e-40e0-9368-343ea0ac9552" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_f63d7168-da8c-4b2f-ba19-76738d0354a4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0ccfe227-cdec-48c8-b59b-94f785fe4bb1" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_f63d7168-da8c-4b2f-ba19-76738d0354a4" xlink:to="loc_srt_ProductOrServiceAxis_0ccfe227-cdec-48c8-b59b-94f785fe4bb1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0ccfe227-cdec-48c8-b59b-94f785fe4bb1_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_0ccfe227-cdec-48c8-b59b-94f785fe4bb1" xlink:to="loc_srt_ProductsAndServicesDomain_0ccfe227-cdec-48c8-b59b-94f785fe4bb1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b7318ba9-81a5-41d5-a548-1d538b7bcaf3" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_0ccfe227-cdec-48c8-b59b-94f785fe4bb1" xlink:to="loc_srt_ProductsAndServicesDomain_b7318ba9-81a5-41d5-a548-1d538b7bcaf3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_7b439004-5663-4b81-a01e-0d56f48a22fa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b7318ba9-81a5-41d5-a548-1d538b7bcaf3" xlink:to="loc_us-gaap_ProductMember_7b439004-5663-4b81-a01e-0d56f48a22fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MSProductRevenuesMember_295b8686-a987-4959-8b0f-f80bd755c7ac" xlink:href="biib-20250930.xsd#biib_MSProductRevenuesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_7b439004-5663-4b81-a01e-0d56f48a22fa" xlink:to="loc_biib_MSProductRevenuesMember_295b8686-a987-4959-8b0f-f80bd755c7ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FumarateMember_dd91b5d3-167d-4fea-a755-3a7594466340" xlink:href="biib-20250930.xsd#biib_FumarateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_MSProductRevenuesMember_295b8686-a987-4959-8b0f-f80bd755c7ac" xlink:to="loc_biib_FumarateMember_dd91b5d3-167d-4fea-a755-3a7594466340" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TECFIDERAMember_204defd6-e93e-4309-a5cb-e56f9b5375c4" xlink:href="biib-20250930.xsd#biib_TECFIDERAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FumarateMember_dd91b5d3-167d-4fea-a755-3a7594466340" xlink:to="loc_biib_TECFIDERAMember_204defd6-e93e-4309-a5cb-e56f9b5375c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_VUMERITYMember_2e53aae3-e0b1-4c2b-bd3b-3d26472be820" xlink:href="biib-20250930.xsd#biib_VUMERITYMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_FumarateMember_dd91b5d3-167d-4fea-a755-3a7594466340" xlink:to="loc_biib_VUMERITYMember_2e53aae3-e0b1-4c2b-bd3b-3d26472be820" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InterferonMember_b0f40e0e-d68f-47d6-bbe3-9d283f0f1875" xlink:href="biib-20250930.xsd#biib_InterferonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_MSProductRevenuesMember_295b8686-a987-4959-8b0f-f80bd755c7ac" xlink:to="loc_biib_InterferonMember_b0f40e0e-d68f-47d6-bbe3-9d283f0f1875" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AVONEXMember_8387ac62-b4d2-4041-97ec-1ab5151428e7" xlink:href="biib-20250930.xsd#biib_AVONEXMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_InterferonMember_b0f40e0e-d68f-47d6-bbe3-9d283f0f1875" xlink:to="loc_biib_AVONEXMember_8387ac62-b4d2-4041-97ec-1ab5151428e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PLEGRIDYMember_1eab6b52-e09c-41ec-a125-f787a919f998" xlink:href="biib-20250930.xsd#biib_PLEGRIDYMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_InterferonMember_b0f40e0e-d68f-47d6-bbe3-9d283f0f1875" xlink:to="loc_biib_PLEGRIDYMember_1eab6b52-e09c-41ec-a125-f787a919f998" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TysabriProductMember_5214f673-ea83-422f-a9c0-b7195487cc8c" xlink:href="biib-20250930.xsd#biib_TysabriProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_7b439004-5663-4b81-a01e-0d56f48a22fa" xlink:to="loc_biib_TysabriProductMember_5214f673-ea83-422f-a9c0-b7195487cc8c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FAMPYRAMember_44a8ba4d-a1eb-48c9-88d7-7e77441a5369" xlink:href="biib-20250930.xsd#biib_FAMPYRAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_7b439004-5663-4b81-a01e-0d56f48a22fa" xlink:to="loc_biib_FAMPYRAMember_44a8ba4d-a1eb-48c9-88d7-7e77441a5369" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RareDiseaseProductRevenueMember_02f210f2-8f13-4b53-a3a6-0ffa9bf6219b" xlink:href="biib-20250930.xsd#biib_RareDiseaseProductRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_7b439004-5663-4b81-a01e-0d56f48a22fa" xlink:to="loc_biib_RareDiseaseProductRevenueMember_02f210f2-8f13-4b53-a3a6-0ffa9bf6219b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_QALSODYMember_497f96c3-7bf4-441d-988e-af8db6e02caa" xlink:href="biib-20250930.xsd#biib_QALSODYMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RareDiseaseProductRevenueMember_02f210f2-8f13-4b53-a3a6-0ffa9bf6219b" xlink:to="loc_biib_QALSODYMember_497f96c3-7bf4-441d-988e-af8db6e02caa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SPINRAZAMember_e9568cc8-5025-4039-b650-607826fda3e2" xlink:href="biib-20250930.xsd#biib_SPINRAZAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RareDiseaseProductRevenueMember_02f210f2-8f13-4b53-a3a6-0ffa9bf6219b" xlink:to="loc_biib_SPINRAZAMember_e9568cc8-5025-4039-b650-607826fda3e2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SKYCLARYSMember_b7e9bbaa-6980-4bcf-aa09-e6aa82493b0c" xlink:href="biib-20250930.xsd#biib_SKYCLARYSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_RareDiseaseProductRevenueMember_02f210f2-8f13-4b53-a3a6-0ffa9bf6219b" xlink:to="loc_biib_SKYCLARYSMember_b7e9bbaa-6980-4bcf-aa09-e6aa82493b0c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BiosimilarsMember_477233a2-6f10-40c1-bde5-c16a883b01b0" xlink:href="biib-20250930.xsd#biib_BiosimilarsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_7b439004-5663-4b81-a01e-0d56f48a22fa" xlink:to="loc_biib_BiosimilarsMember_477233a2-6f10-40c1-bde5-c16a883b01b0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BENEPALIMember_55bf2d47-b74b-427b-8e8a-730efc5543d6" xlink:href="biib-20250930.xsd#biib_BENEPALIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BiosimilarsMember_477233a2-6f10-40c1-bde5-c16a883b01b0" xlink:to="loc_biib_BENEPALIMember_55bf2d47-b74b-427b-8e8a-730efc5543d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IMRALDIMember_d57aa97f-a66f-4cc6-9e57-e53b72c46a33" xlink:href="biib-20250930.xsd#biib_IMRALDIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BiosimilarsMember_477233a2-6f10-40c1-bde5-c16a883b01b0" xlink:to="loc_biib_IMRALDIMember_d57aa97f-a66f-4cc6-9e57-e53b72c46a33" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FLIXABIMember_75bd89e4-d270-477d-bbb0-debcbfc5f550" xlink:href="biib-20250930.xsd#biib_FLIXABIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BiosimilarsMember_477233a2-6f10-40c1-bde5-c16a883b01b0" xlink:to="loc_biib_FLIXABIMember_75bd89e4-d270-477d-bbb0-debcbfc5f550" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BYOOVIZMember_7f716630-a0dc-465c-b5c7-0c7a57636d05" xlink:href="biib-20250930.xsd#biib_BYOOVIZMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BiosimilarsMember_477233a2-6f10-40c1-bde5-c16a883b01b0" xlink:to="loc_biib_BYOOVIZMember_7f716630-a0dc-465c-b5c7-0c7a57636d05" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TOFIDENCEMember_566bec5f-f635-4359-8f6c-47e3dd5de17f" xlink:href="biib-20250930.xsd#biib_TOFIDENCEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BiosimilarsMember_477233a2-6f10-40c1-bde5-c16a883b01b0" xlink:to="loc_biib_TOFIDENCEMember_566bec5f-f635-4359-8f6c-47e3dd5de17f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherProductsMember_cb98bb96-7116-4fd1-a119-1b3f54acecc1" xlink:href="biib-20250930.xsd#biib_OtherProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ProductMember_7b439004-5663-4b81-a01e-0d56f48a22fa" xlink:to="loc_biib_OtherProductsMember_cb98bb96-7116-4fd1-a119-1b3f54acecc1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ZURZUVAEMember_ac6b6514-eb96-4192-828e-cf4f54b8e5a7" xlink:href="biib-20250930.xsd#biib_ZURZUVAEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_OtherProductsMember_cb98bb96-7116-4fd1-a119-1b3f54acecc1" xlink:to="loc_biib_ZURZUVAEMember_ac6b6514-eb96-4192-828e-cf4f54b8e5a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FUMADERMAndADUHELMMember_617c2e90-063d-49f2-b3c5-718d3de794e7" xlink:href="biib-20250930.xsd#biib_FUMADERMAndADUHELMMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_OtherProductsMember_cb98bb96-7116-4fd1-a119-1b3f54acecc1" xlink:to="loc_biib_FUMADERMAndADUHELMMember_617c2e90-063d-49f2-b3c5-718d3de794e7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_713ec4c8-d661-4ed5-bea8-87a9d3d2ff5f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_f63d7168-da8c-4b2f-ba19-76738d0354a4" xlink:to="loc_srt_StatementGeographicalAxis_713ec4c8-d661-4ed5-bea8-87a9d3d2ff5f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_713ec4c8-d661-4ed5-bea8-87a9d3d2ff5f_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_713ec4c8-d661-4ed5-bea8-87a9d3d2ff5f" xlink:to="loc_srt_SegmentGeographicalDomain_713ec4c8-d661-4ed5-bea8-87a9d3d2ff5f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_769636b8-341a-4a81-a8f6-b755aa51c788" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_713ec4c8-d661-4ed5-bea8-87a9d3d2ff5f" xlink:to="loc_srt_SegmentGeographicalDomain_769636b8-341a-4a81-a8f6-b755aa51c788" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_e26da37c-b943-4dec-9fd3-6d31f4a35ada" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_769636b8-341a-4a81-a8f6-b755aa51c788" xlink:to="loc_country_US_e26da37c-b943-4dec-9fd3-6d31f4a35ada" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_49f69c9b-da41-491d-9f68-52acc3370e36" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_769636b8-341a-4a81-a8f6-b755aa51c788" xlink:to="loc_us-gaap_NonUsMember_49f69c9b-da41-491d-9f68-52acc3370e36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_be6a1b8f-44e1-47f3-851a-adea80c79800" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ce898dbf-8b0e-40e0-9368-343ea0ac9552" xlink:to="loc_us-gaap_Revenues_be6a1b8f-44e1-47f3-851a-adea80c79800" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1" xlink:type="simple" xlink:href="biib-20250930.xsd#RevenuesReservesforDiscountsandAllowancesDetails1"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_c1281fe2-c13a-425e-87ca-95fd8a54e56d" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_5076763a-728e-495c-9cb8-076d009f55bc" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_c1281fe2-c13a-425e-87ca-95fd8a54e56d" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_5076763a-728e-495c-9cb8-076d009f55bc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_0233fdc7-c2a0-41d2-b645-95293c61b90a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_5076763a-728e-495c-9cb8-076d009f55bc" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_0233fdc7-c2a0-41d2-b645-95293c61b90a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_0233fdc7-c2a0-41d2-b645-95293c61b90a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_0233fdc7-c2a0-41d2-b645-95293c61b90a" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_0233fdc7-c2a0-41d2-b645-95293c61b90a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_2e68c2af-d9dd-4d4c-b2e4-71732a9b8792" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_0233fdc7-c2a0-41d2-b645-95293c61b90a" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_2e68c2af-d9dd-4d4c-b2e4-71732a9b8792" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReserveforCashDiscountsMember_998c3ad5-9272-4046-aea5-66e51cb7130b" xlink:href="biib-20250930.xsd#biib_ReserveforCashDiscountsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_2e68c2af-d9dd-4d4c-b2e4-71732a9b8792" xlink:to="loc_biib_ReserveforCashDiscountsMember_998c3ad5-9272-4046-aea5-66e51cb7130b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractualAdjustmentsMember_3489b713-85bb-4923-aea2-a040a6cc9ca7" xlink:href="biib-20250930.xsd#biib_ContractualAdjustmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_2e68c2af-d9dd-4d4c-b2e4-71732a9b8792" xlink:to="loc_biib_ContractualAdjustmentsMember_3489b713-85bb-4923-aea2-a040a6cc9ca7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_3541921e-9b2b-414d-a7b3-80611dcc1d9d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesReturnsAndAllowancesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_2e68c2af-d9dd-4d4c-b2e4-71732a9b8792" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesMember_3541921e-9b2b-414d-a7b3-80611dcc1d9d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_b5be9b10-c4da-4cac-9524-c536b78f41ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_c1281fe2-c13a-425e-87ca-95fd8a54e56d" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_b5be9b10-c4da-4cac-9524-c536b78f41ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_49bf50f8-ffda-42a3-b049-e7aad26fc8f2" xlink:href="biib-20250930.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_c1281fe2-c13a-425e-87ca-95fd8a54e56d" xlink:to="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_49bf50f8-ffda-42a3-b049-e7aad26fc8f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_be0952e6-cfbd-4782-a914-576d8e6fdb4a" xlink:href="biib-20250930.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_c1281fe2-c13a-425e-87ca-95fd8a54e56d" xlink:to="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_be0952e6-cfbd-4782-a914-576d8e6fdb4a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_b473d173-446d-473d-896d-07b071d4b124" xlink:href="biib-20250930.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_c1281fe2-c13a-425e-87ca-95fd8a54e56d" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_b473d173-446d-473d-896d-07b071d4b124" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_2f2533a1-d67c-420f-8b6b-6ee74f159140" xlink:href="biib-20250930.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_c1281fe2-c13a-425e-87ca-95fd8a54e56d" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_2f2533a1-d67c-420f-8b6b-6ee74f159140" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_c6382139-4b74-4f98-9391-f5a809ca686c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2" xlink:type="simple" xlink:href="biib-20250930.xsd#RevenuesReservesforDiscountsandAllowancesDetails2"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_5a0c89e9-d574-432d-9780-f07c9e9ef1e0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2bcae2bd-9267-471c-bb1c-bf1250ad71f1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_5a0c89e9-d574-432d-9780-f07c9e9ef1e0" xlink:to="loc_us-gaap_StatementTable_2bcae2bd-9267-471c-bb1c-bf1250ad71f1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_7aced7d7-46ce-4e3d-9f2d-032611d35e55" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_2bcae2bd-9267-471c-bb1c-bf1250ad71f1" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_7aced7d7-46ce-4e3d-9f2d-032611d35e55" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7aced7d7-46ce-4e3d-9f2d-032611d35e55_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_7aced7d7-46ce-4e3d-9f2d-032611d35e55" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7aced7d7-46ce-4e3d-9f2d-032611d35e55_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_0b3eb539-122b-4be4-8251-c92e2321cbdf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_7aced7d7-46ce-4e3d-9f2d-032611d35e55" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_0b3eb539-122b-4be4-8251-c92e2321cbdf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_d9000f17-2184-401a-aefd-e567ed82b15d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_0b3eb539-122b-4be4-8251-c92e2321cbdf" xlink:to="loc_us-gaap_AccountsReceivableMember_d9000f17-2184-401a-aefd-e567ed82b15d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_1d0509f2-e2ce-4a23-a60c-1fd691ec3292" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_0b3eb539-122b-4be4-8251-c92e2321cbdf" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_1d0509f2-e2ce-4a23-a60c-1fd691ec3292" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_945b1955-637e-4a87-9474-5f78ff4ae6b4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_5a0c89e9-d574-432d-9780-f07c9e9ef1e0" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_945b1955-637e-4a87-9474-5f78ff4ae6b4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_4a12711c-a3da-4757-82ee-0da6a8fe5a47" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_8c02e42b-a4ca-4d2f-a61e-a5dae7010b10" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_4a12711c-a3da-4757-82ee-0da6a8fe5a47" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_8c02e42b-a4ca-4d2f-a61e-a5dae7010b10" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_3d186023-fa05-432d-a564-a604fc801c96" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_8c02e42b-a4ca-4d2f-a61e-a5dae7010b10" xlink:to="loc_srt_ProductOrServiceAxis_3d186023-fa05-432d-a564-a604fc801c96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3d186023-fa05-432d-a564-a604fc801c96_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_3d186023-fa05-432d-a564-a604fc801c96" xlink:to="loc_srt_ProductsAndServicesDomain_3d186023-fa05-432d-a564-a604fc801c96_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a05fcad4-6fbc-4d43-81c0-f532fa3c0270" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_3d186023-fa05-432d-a564-a604fc801c96" xlink:to="loc_srt_ProductsAndServicesDomain_a05fcad4-6fbc-4d43-81c0-f532fa3c0270" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_d2dc7da5-8811-4e57-836f-6ed7cb66c42e" xlink:href="biib-20250930.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a05fcad4-6fbc-4d43-81c0-f532fa3c0270" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_d2dc7da5-8811-4e57-836f-6ed7cb66c42e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RoyaltyAttributedToOCREVUSMember_aace41ed-744a-4152-b4ee-2220675a5f44" xlink:href="biib-20250930.xsd#biib_RoyaltyAttributedToOCREVUSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a05fcad4-6fbc-4d43-81c0-f532fa3c0270" xlink:to="loc_biib_RoyaltyAttributedToOCREVUSMember_aace41ed-744a-4152-b4ee-2220675a5f44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_22d6d801-5124-47d8-85a9-d31a38082a02" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_8c02e42b-a4ca-4d2f-a61e-a5dae7010b10" xlink:to="loc_srt_MajorCustomersAxis_22d6d801-5124-47d8-85a9-d31a38082a02" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_22d6d801-5124-47d8-85a9-d31a38082a02_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_22d6d801-5124-47d8-85a9-d31a38082a02" xlink:to="loc_srt_NameOfMajorCustomerDomain_22d6d801-5124-47d8-85a9-d31a38082a02_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_5c85afec-b255-40f0-abbe-8454eabdea99" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_22d6d801-5124-47d8-85a9-d31a38082a02" xlink:to="loc_srt_NameOfMajorCustomerDomain_5c85afec-b255-40f0-abbe-8454eabdea99" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RocheGroupGenentechMember_fe4bc481-50be-43b7-bfb6-1b1f71a6d5be" xlink:href="biib-20250930.xsd#biib_RocheGroupGenentechMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_5c85afec-b255-40f0-abbe-8454eabdea99" xlink:to="loc_biib_RocheGroupGenentechMember_fe4bc481-50be-43b7-bfb6-1b1f71a6d5be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfCoPromotionProfits_4b6753d6-2731-4038-8f4b-0343633a562b" xlink:href="biib-20250930.xsd#biib_ShareOfCoPromotionProfits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_4a12711c-a3da-4757-82ee-0da6a8fe5a47" xlink:to="loc_biib_ShareOfCoPromotionProfits_4b6753d6-2731-4038-8f4b-0343633a562b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_a624087f-d94a-44de-a4e8-9c95161890fe" xlink:href="biib-20250930.xsd#biib_OtherrevenuesfromantiCD20therapeuticprograms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_4a12711c-a3da-4757-82ee-0da6a8fe5a47" xlink:to="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_a624087f-d94a-44de-a4e8-9c95161890fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_9886ebe3-5b91-43b9-ae68-39683f430696" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_4a12711c-a3da-4757-82ee-0da6a8fe5a47" xlink:to="loc_us-gaap_Revenues_9886ebe3-5b91-43b9-ae68-39683f430696" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#RevenuesOtherRevenuesDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_b09a2001-c672-4411-99f1-f7c993a9162b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_3b95e9ec-edb3-4642-95d2-e86eb67ec056" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b09a2001-c672-4411-99f1-f7c993a9162b" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_3b95e9ec-edb3-4642-95d2-e86eb67ec056" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_de6e9305-40e9-449e-902a-1e23932e2ae2" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_3b95e9ec-edb3-4642-95d2-e86eb67ec056" xlink:to="loc_srt_ProductOrServiceAxis_de6e9305-40e9-449e-902a-1e23932e2ae2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_de6e9305-40e9-449e-902a-1e23932e2ae2_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_de6e9305-40e9-449e-902a-1e23932e2ae2" xlink:to="loc_srt_ProductsAndServicesDomain_de6e9305-40e9-449e-902a-1e23932e2ae2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_48531804-9a25-42e6-84ef-6b1324590284" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_de6e9305-40e9-449e-902a-1e23932e2ae2" xlink:to="loc_srt_ProductsAndServicesDomain_48531804-9a25-42e6-84ef-6b1324590284" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractManufacturingAndOtherRevenueMember_29803d94-c45a-4c63-8bdc-5c8f73ba50e5" xlink:href="biib-20250930.xsd#biib_ContractManufacturingAndOtherRevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_48531804-9a25-42e6-84ef-6b1324590284" xlink:to="loc_biib_ContractManufacturingAndOtherRevenueMember_29803d94-c45a-4c63-8bdc-5c8f73ba50e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_bad51b97-467f-4cb4-8c93-c6bd5ec96bf8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_48531804-9a25-42e6-84ef-6b1324590284" xlink:to="loc_us-gaap_RoyaltyMember_bad51b97-467f-4cb4-8c93-c6bd5ec96bf8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_ebfad02a-8039-4916-b7b0-3ed3aba731ff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_48531804-9a25-42e6-84ef-6b1324590284" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_ebfad02a-8039-4916-b7b0-3ed3aba731ff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_f5f620b5-8bf8-43c0-9ae2-bb61e1119a2a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b09a2001-c672-4411-99f1-f7c993a9162b" xlink:to="loc_us-gaap_Revenues_f5f620b5-8bf8-43c0-9ae2-bb61e1119a2a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesNarrativeDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#RevenuesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/RevenuesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_e9c166f4-2b80-4bfa-94d5-261403e435f1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_482f297f-acbc-4908-8b75-2c37d5b717f2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e9c166f4-2b80-4bfa-94d5-261403e435f1" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_482f297f-acbc-4908-8b75-2c37d5b717f2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ef1f7f15-2768-475f-a923-85bdd785d541" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_482f297f-acbc-4908-8b75-2c37d5b717f2" xlink:to="loc_srt_ProductOrServiceAxis_ef1f7f15-2768-475f-a923-85bdd785d541" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ef1f7f15-2768-475f-a923-85bdd785d541_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_ef1f7f15-2768-475f-a923-85bdd785d541" xlink:to="loc_srt_ProductsAndServicesDomain_ef1f7f15-2768-475f-a923-85bdd785d541_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_03848153-b251-4e45-b26e-201c6d65c6a5" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_ef1f7f15-2768-475f-a923-85bdd785d541" xlink:to="loc_srt_ProductsAndServicesDomain_03848153-b251-4e45-b26e-201c6d65c6a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_63ee8170-abd4-4ddd-893f-bb555d6e5f4d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_03848153-b251-4e45-b26e-201c6d65c6a5" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_63ee8170-abd4-4ddd-893f-bb555d6e5f4d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LEQEMBICollaborationMember_16cc753a-b64d-45a5-8e8d-19f8637fd1a5" xlink:href="biib-20250930.xsd#biib_LEQEMBICollaborationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_03848153-b251-4e45-b26e-201c6d65c6a5" xlink:to="loc_biib_LEQEMBICollaborationMember_16cc753a-b64d-45a5-8e8d-19f8637fd1a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AlzheimersCollaborationMember_81c7eedc-5378-49cf-ac54-97347c6a31d8" xlink:href="biib-20250930.xsd#biib_AlzheimersCollaborationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_03848153-b251-4e45-b26e-201c6d65c6a5" xlink:to="loc_biib_AlzheimersCollaborationMember_81c7eedc-5378-49cf-ac54-97347c6a31d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_826d84e1-ed44-4f5b-bf16-38d67047fff5" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_482f297f-acbc-4908-8b75-2c37d5b717f2" xlink:to="loc_srt_MajorCustomersAxis_826d84e1-ed44-4f5b-bf16-38d67047fff5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_826d84e1-ed44-4f5b-bf16-38d67047fff5_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_826d84e1-ed44-4f5b-bf16-38d67047fff5" xlink:to="loc_srt_NameOfMajorCustomerDomain_826d84e1-ed44-4f5b-bf16-38d67047fff5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_05a3aa7c-4039-4b4c-a0dc-611d3cce71a3" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_826d84e1-ed44-4f5b-bf16-38d67047fff5" xlink:to="loc_srt_NameOfMajorCustomerDomain_05a3aa7c-4039-4b4c-a0dc-611d3cce71a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DistributorOneMember_b92723d2-eb05-4399-bd8c-fa2eda3ca127" xlink:href="biib-20250930.xsd#biib_DistributorOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_05a3aa7c-4039-4b4c-a0dc-611d3cce71a3" xlink:to="loc_biib_DistributorOneMember_b92723d2-eb05-4399-bd8c-fa2eda3ca127" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DistributorTwoMember_bd639c10-6e09-4c6d-941b-4f973a52bbe4" xlink:href="biib-20250930.xsd#biib_DistributorTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_05a3aa7c-4039-4b4c-a0dc-611d3cce71a3" xlink:to="loc_biib_DistributorTwoMember_bd639c10-6e09-4c6d-941b-4f973a52bbe4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_0862ef71-4814-4e6f-ac9b-516db558df76" xlink:href="biib-20250930.xsd#biib_EntityWidePercentageOfRevenueFromMajorDistributors"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e9c166f4-2b80-4bfa-94d5-261403e435f1" xlink:to="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_0862ef71-4814-4e6f-ac9b-516db558df76" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfWholesalers_f01d0551-1f53-49c8-8c74-eef9e587c557" xlink:href="biib-20250930.xsd#biib_NumberOfWholesalers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e9c166f4-2b80-4bfa-94d5-261403e435f1" xlink:to="loc_biib_NumberOfWholesalers_f01d0551-1f53-49c8-8c74-eef9e587c557" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_d7e9b526-00fa-4467-a432-5db5043f0857" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e9c166f4-2b80-4bfa-94d5-261403e435f1" xlink:to="loc_us-gaap_Revenues_d7e9b526-00fa-4467-a432-5db5043f0857" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfNonControlingInterestRecognized_c9ce4b0f-15d9-401e-9b86-f5844b343500" xlink:href="biib-20250930.xsd#biib_ShareOfNonControlingInterestRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e9c166f4-2b80-4bfa-94d5-261403e435f1" xlink:to="loc_biib_ShareOfNonControlingInterestRecognized_c9ce4b0f-15d9-401e-9b86-f5844b343500" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryNarrativeDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#InventoryNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/InventoryNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_91f20c8b-ac2c-4d15-953e-b5ada7fccb61" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_1db0b6e4-73d5-49cf-b932-a3be3827c5fe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryCurrentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_91f20c8b-ac2c-4d15-953e-b5ada7fccb61" xlink:to="loc_us-gaap_InventoryCurrentTable_1db0b6e4-73d5-49cf-b932-a3be3827c5fe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_d30464b7-4132-428f-97a7-067e2944ff29" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_1db0b6e4-73d5-49cf-b932-a3be3827c5fe" xlink:to="loc_us-gaap_TypeOfArrangementAxis_d30464b7-4132-428f-97a7-067e2944ff29" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d30464b7-4132-428f-97a7-067e2944ff29_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d30464b7-4132-428f-97a7-067e2944ff29" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d30464b7-4132-428f-97a7-067e2944ff29_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_90e65ebe-d5a5-45b4-82b1-adf176d5d2d9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d30464b7-4132-428f-97a7-067e2944ff29" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_90e65ebe-d5a5-45b4-82b1-adf176d5d2d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_158d6aa1-e42f-47e7-a989-ed5df1dac2a9" xlink:href="biib-20250930.xsd#biib_EisaiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_90e65ebe-d5a5-45b4-82b1-adf176d5d2d9" xlink:to="loc_biib_EisaiMember_158d6aa1-e42f-47e7-a989-ed5df1dac2a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_f4b0c814-df70-413e-b1fb-452962222454" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_1db0b6e4-73d5-49cf-b932-a3be3827c5fe" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_f4b0c814-df70-413e-b1fb-452962222454" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f4b0c814-df70-413e-b1fb-452962222454_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f4b0c814-df70-413e-b1fb-452962222454" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f4b0c814-df70-413e-b1fb-452962222454_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_24729b73-4c39-4843-84a4-5cba803c63b8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f4b0c814-df70-413e-b1fb-452962222454" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_24729b73-4c39-4843-84a4-5cba803c63b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember_b0d6744c-5d34-4097-a756-b8e1cf7df38c" xlink:href="biib-20250930.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_24729b73-4c39-4843-84a4-5cba803c63b8" xlink:to="loc_biib_ReataPharmaceuticalsIncMember_b0d6744c-5d34-4097-a756-b8e1cf7df38c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrecurringAdjustmentAxis_e9d368b2-0f58-4f53-9b48-179bf7f9e506" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonrecurringAdjustmentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_1db0b6e4-73d5-49cf-b932-a3be3827c5fe" xlink:to="loc_us-gaap_NonrecurringAdjustmentAxis_e9d368b2-0f58-4f53-9b48-179bf7f9e506" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrecurringAdjustmentDomain_e9d368b2-0f58-4f53-9b48-179bf7f9e506_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonrecurringAdjustmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_NonrecurringAdjustmentAxis_e9d368b2-0f58-4f53-9b48-179bf7f9e506" xlink:to="loc_us-gaap_NonrecurringAdjustmentDomain_e9d368b2-0f58-4f53-9b48-179bf7f9e506_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrecurringAdjustmentDomain_cf81bbef-b5cf-4058-85fe-3f53cbc4d079" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonrecurringAdjustmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_NonrecurringAdjustmentAxis_e9d368b2-0f58-4f53-9b48-179bf7f9e506" xlink:to="loc_us-gaap_NonrecurringAdjustmentDomain_cf81bbef-b5cf-4058-85fe-3f53cbc4d079" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentToInventoryMember_5efa30f1-5c21-4dd9-bb99-1f157b80ea1a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentToInventoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonrecurringAdjustmentDomain_cf81bbef-b5cf-4058-85fe-3f53cbc4d079" xlink:to="loc_us-gaap_FairValueAdjustmentToInventoryMember_5efa30f1-5c21-4dd9-bb99-1f157b80ea1a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ab88ef47-1cfa-413d-b003-0a47ac72e86b" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_1db0b6e4-73d5-49cf-b932-a3be3827c5fe" xlink:to="loc_srt_ProductOrServiceAxis_ab88ef47-1cfa-413d-b003-0a47ac72e86b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ab88ef47-1cfa-413d-b003-0a47ac72e86b_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_ab88ef47-1cfa-413d-b003-0a47ac72e86b" xlink:to="loc_srt_ProductsAndServicesDomain_ab88ef47-1cfa-413d-b003-0a47ac72e86b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_175d97be-873b-4b93-afc1-2dd1bd7c1229" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_ab88ef47-1cfa-413d-b003-0a47ac72e86b" xlink:to="loc_srt_ProductsAndServicesDomain_175d97be-873b-4b93-afc1-2dd1bd7c1229" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ClinicalInventoryMember_d2e2dd41-f345-46f2-938c-834f7f6dcf17" xlink:href="biib-20250930.xsd#biib_ClinicalInventoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_175d97be-873b-4b93-afc1-2dd1bd7c1229" xlink:to="loc_biib_ClinicalInventoryMember_d2e2dd41-f345-46f2-938c-834f7f6dcf17" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_6af4056f-f90c-4087-ae46-f555b6a8ff1e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_91f20c8b-ac2c-4d15-953e-b5ada7fccb61" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_6af4056f-f90c-4087-ae46-f555b6a8ff1e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_f2f999ea-42a0-45cd-be17-5b7194c8362b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_91f20c8b-ac2c-4d15-953e-b5ada7fccb61" xlink:to="loc_us-gaap_ProfitLoss_f2f999ea-42a0-45cd-be17-5b7194c8362b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_a54907bc-3129-44d2-b519-81362fbc24c7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_91f20c8b-ac2c-4d15-953e-b5ada7fccb61" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_a54907bc-3129-44d2-b519-81362fbc24c7" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_83be8ef7-837c-4dda-96c3-07089a0ac87b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9c1c4458-fc6c-4d52-877b-2f49e692af04" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_83be8ef7-837c-4dda-96c3-07089a0ac87b" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9c1c4458-fc6c-4d52-877b-2f49e692af04" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_eba4ba20-e4c9-4460-a490-1d61c2e4ca87" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9c1c4458-fc6c-4d52-877b-2f49e692af04" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_eba4ba20-e4c9-4460-a490-1d61c2e4ca87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_eba4ba20-e4c9-4460-a490-1d61c2e4ca87_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_eba4ba20-e4c9-4460-a490-1d61c2e4ca87" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_eba4ba20-e4c9-4460-a490-1d61c2e4ca87_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d2ffbcd8-5a7c-4510-8d4a-d5dedb44bbe4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_eba4ba20-e4c9-4460-a490-1d61c2e4ca87" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d2ffbcd8-5a7c-4510-8d4a-d5dedb44bbe4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AcquiredAndInLicensedRightsAndPatentsMember_cb4fe8c6-1f34-4288-bd63-4e4980063f7a" xlink:href="biib-20250930.xsd#biib_AcquiredAndInLicensedRightsAndPatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d2ffbcd8-5a7c-4510-8d4a-d5dedb44bbe4" xlink:to="loc_biib_AcquiredAndInLicensedRightsAndPatentsMember_cb4fe8c6-1f34-4288-bd63-4e4980063f7a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2f0b964e-7cfd-4dee-8788-603360e9b3e7" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9c1c4458-fc6c-4d52-877b-2f49e692af04" xlink:to="loc_srt_RangeAxis_2f0b964e-7cfd-4dee-8788-603360e9b3e7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2f0b964e-7cfd-4dee-8788-603360e9b3e7_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2f0b964e-7cfd-4dee-8788-603360e9b3e7" xlink:to="loc_srt_RangeMember_2f0b964e-7cfd-4dee-8788-603360e9b3e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_154be98c-bd0d-4d80-b5a9-957366dafa39" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2f0b964e-7cfd-4dee-8788-603360e9b3e7" xlink:to="loc_srt_RangeMember_154be98c-bd0d-4d80-b5a9-957366dafa39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c1b05cd1-6796-437a-96af-6a87b35d95a3" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_154be98c-bd0d-4d80-b5a9-957366dafa39" xlink:to="loc_srt_MinimumMember_c1b05cd1-6796-437a-96af-6a87b35d95a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c2d9de09-dc57-42d6-bdc3-d894a78f7811" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_154be98c-bd0d-4d80-b5a9-957366dafa39" xlink:to="loc_srt_MaximumMember_c2d9de09-dc57-42d6-bdc3-d894a78f7811" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_0c7085e9-bfd4-43ca-9a9e-7df54a57c270" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_83be8ef7-837c-4dda-96c3-07089a0ac87b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_0c7085e9-bfd4-43ca-9a9e-7df54a57c270" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_047fd9c8-ffad-48ae-876d-d6e050cc197c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_83be8ef7-837c-4dda-96c3-07089a0ac87b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_047fd9c8-ffad-48ae-876d-d6e050cc197c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_aeb8cfce-dccc-4da4-ba0c-4ef9cc21d7a3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_047fd9c8-ffad-48ae-876d-d6e050cc197c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_aeb8cfce-dccc-4da4-ba0c-4ef9cc21d7a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_52037f4a-92e0-4a9d-8672-5b8298a24dfa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_047fd9c8-ffad-48ae-876d-d6e050cc197c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_52037f4a-92e0-4a9d-8672-5b8298a24dfa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_4c7dab15-8082-406c-abb7-3e6567e085c4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_047fd9c8-ffad-48ae-876d-d6e050cc197c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_4c7dab15-8082-406c-abb7-3e6567e085c4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_a8cb4b1d-7c8e-4d08-8f6f-221c2b4439d2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_237b3ebd-683f-461e-87bd-5d1a7293213c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_a8cb4b1d-7c8e-4d08-8f6f-221c2b4439d2" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_237b3ebd-683f-461e-87bd-5d1a7293213c" xlink:type="arc" order="2" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_1dad985e-6c35-4ceb-be2b-70dbfb885402" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_237b3ebd-683f-461e-87bd-5d1a7293213c" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_1dad985e-6c35-4ceb-be2b-70dbfb885402" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1dad985e-6c35-4ceb-be2b-70dbfb885402_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_1dad985e-6c35-4ceb-be2b-70dbfb885402" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_1dad985e-6c35-4ceb-be2b-70dbfb885402_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0a3c56d8-bcad-44d5-9a71-35fed64d68f1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_1dad985e-6c35-4ceb-be2b-70dbfb885402" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0a3c56d8-bcad-44d5-9a71-35fed64d68f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_4bda9138-539e-4fa6-ad92-44f604bd53bc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0a3c56d8-bcad-44d5-9a71-35fed64d68f1" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_4bda9138-539e-4fa6-ad92-44f604bd53bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PriorityReviewVoucherMember_8cf9d1b7-e922-4a1c-900a-2932ff37da8f" xlink:href="biib-20250930.xsd#biib_PriorityReviewVoucherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0a3c56d8-bcad-44d5-9a71-35fed64d68f1" xlink:to="loc_biib_PriorityReviewVoucherMember_8cf9d1b7-e922-4a1c-900a-2932ff37da8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_77942702-437a-4615-ad92-268d19661db1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0a3c56d8-bcad-44d5-9a71-35fed64d68f1" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_77942702-437a-4615-ad92-268d19661db1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_faaf0525-cdad-467d-8cd1-e45908f5422c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_a8cb4b1d-7c8e-4d08-8f6f-221c2b4439d2" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_faaf0525-cdad-467d-8cd1-e45908f5422c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#IntangibleAssetsandGoodwillNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_a68ed16f-85bb-4f63-a459-168fc6ba4251" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_6368c69d-c4c8-4c7b-b041-ccc5b2349125" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_a68ed16f-85bb-4f63-a459-168fc6ba4251" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_6368c69d-c4c8-4c7b-b041-ccc5b2349125" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_633469b6-c945-4336-81be-08e89960e021" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_6368c69d-c4c8-4c7b-b041-ccc5b2349125" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_633469b6-c945-4336-81be-08e89960e021" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_633469b6-c945-4336-81be-08e89960e021_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_633469b6-c945-4336-81be-08e89960e021" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_633469b6-c945-4336-81be-08e89960e021_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_34fbae99-cfd1-408b-8287-4d32260e65d3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_633469b6-c945-4336-81be-08e89960e021" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_34fbae99-cfd1-408b-8287-4d32260e65d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember_a0c2c5d0-93d2-49cc-821b-14a291422e64" xlink:href="biib-20250930.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_34fbae99-cfd1-408b-8287-4d32260e65d3" xlink:to="loc_biib_ReataPharmaceuticalsIncMember_a0c2c5d0-93d2-49cc-821b-14a291422e64" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_HumanImmunologyBiosciencesMember_ffed3894-6483-4566-87bb-ba78286d283f" xlink:href="biib-20250930.xsd#biib_HumanImmunologyBiosciencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_34fbae99-cfd1-408b-8287-4d32260e65d3" xlink:to="loc_biib_HumanImmunologyBiosciencesMember_ffed3894-6483-4566-87bb-ba78286d283f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5d149553-c194-4f9b-9ced-6fe0fb8abe60" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_6368c69d-c4c8-4c7b-b041-ccc5b2349125" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5d149553-c194-4f9b-9ced-6fe0fb8abe60" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5d149553-c194-4f9b-9ced-6fe0fb8abe60_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5d149553-c194-4f9b-9ced-6fe0fb8abe60" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5d149553-c194-4f9b-9ced-6fe0fb8abe60_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0ba85607-2105-4a41-81ec-31a21b7f808e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5d149553-c194-4f9b-9ced-6fe0fb8abe60" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0ba85607-2105-4a41-81ec-31a21b7f808e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AcquiredAndInLicensedRightsAndPatentsMember_f2ead4a0-adb5-4fa9-92ea-8a15d986902f" xlink:href="biib-20250930.xsd#biib_AcquiredAndInLicensedRightsAndPatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0ba85607-2105-4a41-81ec-31a21b7f808e" xlink:to="loc_biib_AcquiredAndInLicensedRightsAndPatentsMember_f2ead4a0-adb5-4fa9-92ea-8a15d986902f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_c87d7b6c-1e1e-4907-9b0f-9af3c571f8bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0ba85607-2105-4a41-81ec-31a21b7f808e" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_c87d7b6c-1e1e-4907-9b0f-9af3c571f8bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SKYCLARYSMember_4235a197-411b-4025-b92f-cefd8e5ad07e" xlink:href="biib-20250930.xsd#biib_SKYCLARYSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0ba85607-2105-4a41-81ec-31a21b7f808e" xlink:to="loc_biib_SKYCLARYSMember_4235a197-411b-4025-b92f-cefd8e5ad07e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PriorityReviewVoucherMember_2c1279b2-f0af-4964-ade2-e8f6f4900df5" xlink:href="biib-20250930.xsd#biib_PriorityReviewVoucherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0ba85607-2105-4a41-81ec-31a21b7f808e" xlink:to="loc_biib_PriorityReviewVoucherMember_2c1279b2-f0af-4964-ade2-e8f6f4900df5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_51dbf624-bb73-4d1c-84f6-d9b1cad8a0d0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_6368c69d-c4c8-4c7b-b041-ccc5b2349125" xlink:to="loc_srt_RangeAxis_51dbf624-bb73-4d1c-84f6-d9b1cad8a0d0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_51dbf624-bb73-4d1c-84f6-d9b1cad8a0d0_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_51dbf624-bb73-4d1c-84f6-d9b1cad8a0d0" xlink:to="loc_srt_RangeMember_51dbf624-bb73-4d1c-84f6-d9b1cad8a0d0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_43705632-93b7-4885-89e9-71cb7a50db86" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_51dbf624-bb73-4d1c-84f6-d9b1cad8a0d0" xlink:to="loc_srt_RangeMember_43705632-93b7-4885-89e9-71cb7a50db86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5b10f89d-1068-4f20-9c0d-e84163ca7c08" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_43705632-93b7-4885-89e9-71cb7a50db86" xlink:to="loc_srt_MinimumMember_5b10f89d-1068-4f20-9c0d-e84163ca7c08" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3556637e-1b7e-495f-9b3b-757c5cac0582" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_43705632-93b7-4885-89e9-71cb7a50db86" xlink:to="loc_srt_MaximumMember_3556637e-1b7e-495f-9b3b-757c5cac0582" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_0a0b607a-7159-4816-a48a-1805b720f72d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_6368c69d-c4c8-4c7b-b041-ccc5b2349125" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_0a0b607a-7159-4816-a48a-1805b720f72d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0a0b607a-7159-4816-a48a-1805b720f72d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_0a0b607a-7159-4816-a48a-1805b720f72d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0a0b607a-7159-4816-a48a-1805b720f72d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_d96817e7-9fb9-485d-a9b0-a25ae1a866ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_0a0b607a-7159-4816-a48a-1805b720f72d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_d96817e7-9fb9-485d-a9b0-a25ae1a866ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_2c771741-a3a3-4727-bf24-1f70719802fb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_d96817e7-9fb9-485d-a9b0-a25ae1a866ba" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_2c771741-a3a3-4727-bf24-1f70719802fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PriorityReviewVoucherMember_ac7b8548-8d08-4610-b7b5-594eac557814" xlink:href="biib-20250930.xsd#biib_PriorityReviewVoucherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_d96817e7-9fb9-485d-a9b0-a25ae1a866ba" xlink:to="loc_biib_PriorityReviewVoucherMember_ac7b8548-8d08-4610-b7b5-594eac557814" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SKYCLARYSMember_f9293e76-2208-47d8-8780-d976e9fe0a57" xlink:href="biib-20250930.xsd#biib_SKYCLARYSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_d96817e7-9fb9-485d-a9b0-a25ae1a866ba" xlink:to="loc_biib_SKYCLARYSMember_f9293e76-2208-47d8-8780-d976e9fe0a57" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_67d50564-0ce1-40a2-902f-60a83abc48c7" xlink:href="biib-20250930.xsd#biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_a68ed16f-85bb-4f63-a459-168fc6ba4251" xlink:to="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_67d50564-0ce1-40a2-902f-60a83abc48c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_ea48d777-bc03-45d4-9835-261f8bfd0033" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_a68ed16f-85bb-4f63-a459-168fc6ba4251" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_ea48d777-bc03-45d4-9835-261f8bfd0033" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_d2b4c8aa-e2f2-425a-94b4-a2fe863f3b41" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_a68ed16f-85bb-4f63-a459-168fc6ba4251" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_d2b4c8aa-e2f2-425a-94b4-a2fe863f3b41" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_7f6eadd7-8579-4e98-b5f0-82e0ed7e0dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_a68ed16f-85bb-4f63-a459-168fc6ba4251" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_7f6eadd7-8579-4e98-b5f0-82e0ed7e0dc5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife_668a822c-5b15-4f34-9cf4-89b1ea088ac1" xlink:href="biib-20250930.xsd#biib_FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_a68ed16f-85bb-4f63-a459-168fc6ba4251" xlink:to="loc_biib_FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife_668a822c-5b15-4f34-9cf4-89b1ea088ac1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_906762fc-c53c-4e94-b90a-2776913976b0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_a68ed16f-85bb-4f63-a459-168fc6ba4251" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_906762fc-c53c-4e94-b90a-2776913976b0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_02ac482d-3215-4a83-b376-3ea94cc68108" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_a68ed16f-85bb-4f63-a459-168fc6ba4251" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_02ac482d-3215-4a83-b376-3ea94cc68108" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillChangesinGoodwillDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#IntangibleAssetsandGoodwillChangesinGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillChangesinGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_1f9781bf-a471-43cf-99b2-89b9406122e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_0f6ac338-f0ea-495c-a249-da44b8387214" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_1f9781bf-a471-43cf-99b2-89b9406122e7" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_0f6ac338-f0ea-495c-a249-da44b8387214" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_58758a0d-b04f-429b-9125-430db14156a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_0f6ac338-f0ea-495c-a249-da44b8387214" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_58758a0d-b04f-429b-9125-430db14156a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_58758a0d-b04f-429b-9125-430db14156a0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_58758a0d-b04f-429b-9125-430db14156a0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_58758a0d-b04f-429b-9125-430db14156a0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9e03f663-7704-4ee2-b289-0ded3988bd76" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_58758a0d-b04f-429b-9125-430db14156a0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9e03f663-7704-4ee2-b289-0ded3988bd76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_HumanImmunologyBiosciencesMember_61a20354-bfb1-4cbb-9974-7acd1aab806a" xlink:href="biib-20250930.xsd#biib_HumanImmunologyBiosciencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9e03f663-7704-4ee2-b289-0ded3988bd76" xlink:to="loc_biib_HumanImmunologyBiosciencesMember_61a20354-bfb1-4cbb-9974-7acd1aab806a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember_41b5d1b8-8f5c-4ed8-8f08-7e91b8ed01e3" xlink:href="biib-20250930.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9e03f663-7704-4ee2-b289-0ded3988bd76" xlink:to="loc_biib_ReataPharmaceuticalsIncMember_41b5d1b8-8f5c-4ed8-8f08-7e91b8ed01e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_32eb03a0-4bc1-4065-b882-3511829995b4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_1f9781bf-a471-43cf-99b2-89b9406122e7" xlink:to="loc_us-gaap_GoodwillRollForward_32eb03a0-4bc1-4065-b882-3511829995b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_9a701614-939b-43d5-ad16-5c49db8b0b71" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_32eb03a0-4bc1-4065-b882-3511829995b4" xlink:to="loc_us-gaap_Goodwill_9a701614-939b-43d5-ad16-5c49db8b0b71" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_08bc1f7a-1f48-4105-b0c0-dcd32414e615" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_32eb03a0-4bc1-4065-b882-3511829995b4" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_08bc1f7a-1f48-4105-b0c0-dcd32414e615" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_887c133d-f206-41e7-a39c-0c0eed0c1f0b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_32eb03a0-4bc1-4065-b882-3511829995b4" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_887c133d-f206-41e7-a39c-0c0eed0c1f0b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_da586d2e-5736-4331-b001-6cc845426361" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_506c8cda-87e2-48e1-bfcd-5f059d67f630" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_1f9781bf-a471-43cf-99b2-89b9406122e7" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_506c8cda-87e2-48e1-bfcd-5f059d67f630" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_15b5452f-9cef-4d2d-8730-c48b26e3e649" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_14d1ee2d-6e9f-4d28-a0cb-260431b78b06" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_15b5452f-9cef-4d2d-8730-c48b26e3e649" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_14d1ee2d-6e9f-4d28-a0cb-260431b78b06" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_92ea03f1-5744-4746-b7fb-7e98ac9dd0a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_14d1ee2d-6e9f-4d28-a0cb-260431b78b06" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_92ea03f1-5744-4746-b7fb-7e98ac9dd0a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_92ea03f1-5744-4746-b7fb-7e98ac9dd0a4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_92ea03f1-5744-4746-b7fb-7e98ac9dd0a4" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_92ea03f1-5744-4746-b7fb-7e98ac9dd0a4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_23c0f137-9532-4b2d-ab9d-514af73ed473" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_92ea03f1-5744-4746-b7fb-7e98ac9dd0a4" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_23c0f137-9532-4b2d-ab9d-514af73ed473" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_b595354e-3363-4ada-baba-7c51b6f15e6e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_23c0f137-9532-4b2d-ab9d-514af73ed473" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_b595354e-3363-4ada-baba-7c51b6f15e6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_aa5f654c-3b1a-4b4a-b80d-4d7c95e7ff36" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_23c0f137-9532-4b2d-ab9d-514af73ed473" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_aa5f654c-3b1a-4b4a-b80d-4d7c95e7ff36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_f404a6e6-d03c-469b-87fa-08cbebf1e34a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_23c0f137-9532-4b2d-ab9d-514af73ed473" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_f404a6e6-d03c-469b-87fa-08cbebf1e34a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c787359d-b8b0-4bfc-9e50-3e9b3ce29df3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_14d1ee2d-6e9f-4d28-a0cb-260431b78b06" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c787359d-b8b0-4bfc-9e50-3e9b3ce29df3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_c787359d-b8b0-4bfc-9e50-3e9b3ce29df3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c787359d-b8b0-4bfc-9e50-3e9b3ce29df3" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_c787359d-b8b0-4bfc-9e50-3e9b3ce29df3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_0274fc20-39ab-42be-9e6c-7a36697cffdd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c787359d-b8b0-4bfc-9e50-3e9b3ce29df3" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_0274fc20-39ab-42be-9e6c-7a36697cffdd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_b819e92d-6689-463b-b786-01dffa072873" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_0274fc20-39ab-42be-9e6c-7a36697cffdd" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_b819e92d-6689-463b-b786-01dffa072873" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_512ed7ba-1e5c-4d3c-b732-6d2823c09668" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_14d1ee2d-6e9f-4d28-a0cb-260431b78b06" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_512ed7ba-1e5c-4d3c-b732-6d2823c09668" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_512ed7ba-1e5c-4d3c-b732-6d2823c09668_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_512ed7ba-1e5c-4d3c-b732-6d2823c09668" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_512ed7ba-1e5c-4d3c-b732-6d2823c09668_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_22e88ea0-b1a1-4684-9e3d-1b0c866f05b7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_512ed7ba-1e5c-4d3c-b732-6d2823c09668" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_22e88ea0-b1a1-4684-9e3d-1b0c866f05b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_b8955259-52bb-43bd-84cf-7b65ffdfc481" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_22e88ea0-b1a1-4684-9e3d-1b0c866f05b7" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_b8955259-52bb-43bd-84cf-7b65ffdfc481" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_80479a04-d5d1-4f5c-a75a-314bb51215f5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_22e88ea0-b1a1-4684-9e3d-1b0c866f05b7" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_80479a04-d5d1-4f5c-a75a-314bb51215f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_71a0b86f-bec2-4a77-b8f9-6f5dbd996ef3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_15b5452f-9cef-4d2d-8730-c48b26e3e649" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_71a0b86f-bec2-4a77-b8f9-6f5dbd996ef3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_cfdf3980-e39d-4b80-bd0f-c7e8c3b0160d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_71a0b86f-bec2-4a77-b8f9-6f5dbd996ef3" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_cfdf3980-e39d-4b80-bd0f-c7e8c3b0160d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_783c28db-315f-4672-8589-1fba40ec6e1f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_cfdf3980-e39d-4b80-bd0f-c7e8c3b0160d" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_783c28db-315f-4672-8589-1fba40ec6e1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_9beba727-62be-4d62-99c6-ac9a5949f5bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_cfdf3980-e39d-4b80-bd0f-c7e8c3b0160d" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_9beba727-62be-4d62-99c6-ac9a5949f5bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_fb2a2282-e2c0-40a6-a731-933ec00c2812" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_cfdf3980-e39d-4b80-bd0f-c7e8c3b0160d" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_fb2a2282-e2c0-40a6-a731-933ec00c2812" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableFairValueDisclosure_942af886-a3ff-4282-9197-d45aba9ddcb1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesReceivableFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_cfdf3980-e39d-4b80-bd0f-c7e8c3b0160d" xlink:to="loc_us-gaap_NotesReceivableFairValueDisclosure_942af886-a3ff-4282-9197-d45aba9ddcb1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_ac203318-0c55-489a-8627-82b07bba07c2" xlink:href="biib-20250930.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_cfdf3980-e39d-4b80-bd0f-c7e8c3b0160d" xlink:to="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_ac203318-0c55-489a-8627-82b07bba07c2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_9799a140-aa99-42d1-8119-286e3beb745c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_cfdf3980-e39d-4b80-bd0f-c7e8c3b0160d" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_9799a140-aa99-42d1-8119-286e3beb745c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_4a9f4b8c-f0a9-404d-8889-6cda761b094c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_71a0b86f-bec2-4a77-b8f9-6f5dbd996ef3" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_4a9f4b8c-f0a9-404d-8889-6cda761b094c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesAbstract_da654fd4-b8db-4dbc-acea-b51c3e4c846e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_4a9f4b8c-f0a9-404d-8889-6cda761b094c" xlink:to="loc_us-gaap_DerivativeLiabilitiesAbstract_da654fd4-b8db-4dbc-acea-b51c3e4c846e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_d3d0f63d-c9f1-4d48-a7b6-414c3235471d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLiabilitiesAbstract_da654fd4-b8db-4dbc-acea-b51c3e4c846e" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_d3d0f63d-c9f1-4d48-a7b6-414c3235471d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_91b40387-7d04-437b-8008-1bfc2653195f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLiabilitiesAbstract_da654fd4-b8db-4dbc-acea-b51c3e4c846e" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_91b40387-7d04-437b-8008-1bfc2653195f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrentAbstract_f69fd8da-a652-402e-af61-b2c1d854f3c9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrentAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_4a9f4b8c-f0a9-404d-8889-6cda761b094c" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrentAbstract_f69fd8da-a652-402e-af61-b2c1d854f3c9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_bc9a0e67-5070-4ae2-83fc-a5d7f8c4d02a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrentAbstract_f69fd8da-a652-402e-af61-b2c1d854f3c9" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_bc9a0e67-5070-4ae2-83fc-a5d7f8c4d02a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_6f770536-ac59-4c4e-9ff5-2d6548a49b57" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrentAbstract_f69fd8da-a652-402e-af61-b2c1d854f3c9" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_6f770536-ac59-4c4e-9ff5-2d6548a49b57" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_c5388c58-5fb9-4df3-9c6b-a05d8e0f0bb1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_4a9f4b8c-f0a9-404d-8889-6cda761b094c" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_c5388c58-5fb9-4df3-9c6b-a05d8e0f0bb1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_08c6250a-1ef3-4650-ae16-e087a79a81ef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_71a0b86f-bec2-4a77-b8f9-6f5dbd996ef3" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_08c6250a-1ef3-4650-ae16-e087a79a81ef" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_003c146a-972a-4528-9924-a86e933860ca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_99ac9ced-e273-42df-b04c-abf675d7f59c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_15b5452f-9cef-4d2d-8730-c48b26e3e649" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_99ac9ced-e273-42df-b04c-abf675d7f59c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_72cea673-d083-4910-b75e-bd9d24ba16b8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_3e0382b5-42be-4ab7-aa09-64f15f8f9827" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72cea673-d083-4910-b75e-bd9d24ba16b8" xlink:to="loc_us-gaap_DebtInstrumentTable_3e0382b5-42be-4ab7-aa09-64f15f8f9827" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1d8c88d0-d43c-4962-ac65-15e28ede485e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3e0382b5-42be-4ab7-aa09-64f15f8f9827" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1d8c88d0-d43c-4962-ac65-15e28ede485e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1d8c88d0-d43c-4962-ac65-15e28ede485e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1d8c88d0-d43c-4962-ac65-15e28ede485e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1d8c88d0-d43c-4962-ac65-15e28ede485e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_284f5c0e-bbf0-46f6-9d2c-995a6ba93b0a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1d8c88d0-d43c-4962-ac65-15e28ede485e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_284f5c0e-bbf0-46f6-9d2c-995a6ba93b0a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_HumanImmunologyBiosciencesMember_b5dfa71b-1084-4f67-a987-57babcc2c0c7" xlink:href="biib-20250930.xsd#biib_HumanImmunologyBiosciencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_284f5c0e-bbf0-46f6-9d2c-995a6ba93b0a" xlink:to="loc_biib_HumanImmunologyBiosciencesMember_b5dfa71b-1084-4f67-a987-57babcc2c0c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_e37f54b6-abdc-45cf-9baf-41f3503b09e3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3e0382b5-42be-4ab7-aa09-64f15f8f9827" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_e37f54b6-abdc-45cf-9baf-41f3503b09e3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_e37f54b6-abdc-45cf-9baf-41f3503b09e3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_e37f54b6-abdc-45cf-9baf-41f3503b09e3" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_e37f54b6-abdc-45cf-9baf-41f3503b09e3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_da2b7abe-c40c-405c-b704-4231de1894fb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_e37f54b6-abdc-45cf-9baf-41f3503b09e3" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_da2b7abe-c40c-405c-b704-4231de1894fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MeasurementInputProbabilityRateMember_26779190-5cd2-414c-a434-724db1ad74a8" xlink:href="biib-20250930.xsd#biib_MeasurementInputProbabilityRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_da2b7abe-c40c-405c-b704-4231de1894fb" xlink:to="loc_biib_MeasurementInputProbabilityRateMember_26779190-5cd2-414c-a434-724db1ad74a8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c80b2fcc-c6ab-4dfa-b819-b070324298c4" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3e0382b5-42be-4ab7-aa09-64f15f8f9827" xlink:to="loc_srt_RangeAxis_c80b2fcc-c6ab-4dfa-b819-b070324298c4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c80b2fcc-c6ab-4dfa-b819-b070324298c4_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_c80b2fcc-c6ab-4dfa-b819-b070324298c4" xlink:to="loc_srt_RangeMember_c80b2fcc-c6ab-4dfa-b819-b070324298c4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c2a2bcf0-2f8d-4d4c-84e3-1b8710f0b6a4" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_c80b2fcc-c6ab-4dfa-b819-b070324298c4" xlink:to="loc_srt_RangeMember_c2a2bcf0-2f8d-4d4c-84e3-1b8710f0b6a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a776bce2-5fb6-4f52-94e1-09969e934da5" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c2a2bcf0-2f8d-4d4c-84e3-1b8710f0b6a4" xlink:to="loc_srt_MaximumMember_a776bce2-5fb6-4f52-94e1-09969e934da5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_0d415657-3cd0-453a-9af6-ced13c884377" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_3e0382b5-42be-4ab7-aa09-64f15f8f9827" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_0d415657-3cd0-453a-9af6-ced13c884377" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_0d415657-3cd0-453a-9af6-ced13c884377_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_0d415657-3cd0-453a-9af6-ced13c884377" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_0d415657-3cd0-453a-9af6-ced13c884377_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_0aa85944-13cf-4b27-8e88-cf17417ff0d3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_0d415657-3cd0-453a-9af6-ced13c884377" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_0aa85944-13cf-4b27-8e88-cf17417ff0d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Phase3ClinicalTrialFelzartamabOneMember_0f2003cf-3dfd-4f7a-8c35-142cd327a382" xlink:href="biib-20250930.xsd#biib_Phase3ClinicalTrialFelzartamabOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_0aa85944-13cf-4b27-8e88-cf17417ff0d3" xlink:to="loc_biib_Phase3ClinicalTrialFelzartamabOneMember_0f2003cf-3dfd-4f7a-8c35-142cd327a382" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Phase3ClinicalTrialFelzartamabTwoMember_68d41f09-90dd-410a-867d-5f241dd159f6" xlink:href="biib-20250930.xsd#biib_Phase3ClinicalTrialFelzartamabTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_0aa85944-13cf-4b27-8e88-cf17417ff0d3" xlink:to="loc_biib_Phase3ClinicalTrialFelzartamabTwoMember_68d41f09-90dd-410a-867d-5f241dd159f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_6acafe35-17ae-4a8d-bee4-d9463ddd407d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72cea673-d083-4910-b75e-bd9d24ba16b8" xlink:to="loc_us-gaap_AssetImpairmentCharges_6acafe35-17ae-4a8d-bee4-d9463ddd407d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_e993e4a4-eada-45de-8b0d-fea79647a20d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72cea673-d083-4910-b75e-bd9d24ba16b8" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_e993e4a4-eada-45de-8b0d-fea79647a20d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_eb649bd4-1044-4c7c-89fa-e246e8817e1a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72cea673-d083-4910-b75e-bd9d24ba16b8" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_eb649bd4-1044-4c7c-89fa-e246e8817e1a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_8c746559-84d7-4c5e-86f5-c764b42d8627" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72cea673-d083-4910-b75e-bd9d24ba16b8" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_8c746559-84d7-4c5e-86f5-c764b42d8627" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasuresLevel3AssetsandLiabilitiesHeldatFairValueDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#FairValueMeasuresLevel3AssetsandLiabilitiesHeldatFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasuresLevel3AssetsandLiabilitiesHeldatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_214c8cf6-97de-4155-9427-aef79f1e183f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_7ae727e2-64f8-4843-bd8d-b1f63edab6a1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_214c8cf6-97de-4155-9427-aef79f1e183f" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_7ae727e2-64f8-4843-bd8d-b1f63edab6a1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_be472a89-728b-41c5-b094-d53461e61ad3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_7ae727e2-64f8-4843-bd8d-b1f63edab6a1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_be472a89-728b-41c5-b094-d53461e61ad3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_be472a89-728b-41c5-b094-d53461e61ad3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_be472a89-728b-41c5-b094-d53461e61ad3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_be472a89-728b-41c5-b094-d53461e61ad3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d31becaa-34fe-45fd-82b3-2646efd5b47c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_be472a89-728b-41c5-b094-d53461e61ad3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d31becaa-34fe-45fd-82b3-2646efd5b47c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_390ea95e-6d3f-45fa-8ac2-8ac6fd667857" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d31becaa-34fe-45fd-82b3-2646efd5b47c" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_390ea95e-6d3f-45fa-8ac2-8ac6fd667857" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_67b83ed8-8907-459f-bbda-20481e8310b5" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_7ae727e2-64f8-4843-bd8d-b1f63edab6a1" xlink:to="loc_srt_RangeAxis_67b83ed8-8907-459f-bbda-20481e8310b5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_67b83ed8-8907-459f-bbda-20481e8310b5_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_67b83ed8-8907-459f-bbda-20481e8310b5" xlink:to="loc_srt_RangeMember_67b83ed8-8907-459f-bbda-20481e8310b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_adc75c71-c257-4aac-b29c-f39f989bd865" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_67b83ed8-8907-459f-bbda-20481e8310b5" xlink:to="loc_srt_RangeMember_adc75c71-c257-4aac-b29c-f39f989bd865" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_510a8258-a840-452f-9740-e7f67386f6d2" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_adc75c71-c257-4aac-b29c-f39f989bd865" xlink:to="loc_srt_MinimumMember_510a8258-a840-452f-9740-e7f67386f6d2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d379d64c-01cd-4c68-bc84-55041faa1f05" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_adc75c71-c257-4aac-b29c-f39f989bd865" xlink:to="loc_srt_MaximumMember_d379d64c-01cd-4c68-bc84-55041faa1f05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_3b36772c-9851-4061-8d97-6f74ab7d4383" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_adc75c71-c257-4aac-b29c-f39f989bd865" xlink:to="loc_srt_WeightedAverageMember_3b36772c-9851-4061-8d97-6f74ab7d4383" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_f60d7376-cd7b-4b27-b476-0e50d34af899" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_7ae727e2-64f8-4843-bd8d-b1f63edab6a1" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_f60d7376-cd7b-4b27-b476-0e50d34af899" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_f60d7376-cd7b-4b27-b476-0e50d34af899_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_f60d7376-cd7b-4b27-b476-0e50d34af899" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_f60d7376-cd7b-4b27-b476-0e50d34af899_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_fb1180d0-c10c-42b1-8898-3c9a6fa8025a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_f60d7376-cd7b-4b27-b476-0e50d34af899" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_fb1180d0-c10c-42b1-8898-3c9a6fa8025a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_7044f6db-2053-4246-9a6c-477ff1708170" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_fb1180d0-c10c-42b1-8898-3c9a6fa8025a" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_7044f6db-2053-4246-9a6c-477ff1708170" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_72500bf1-a6c3-479c-848e-6f64695cfe03" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_214c8cf6-97de-4155-9427-aef79f1e183f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_72500bf1-a6c3-479c-848e-6f64695cfe03" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_7ba21797-5b67-49e6-9554-d68b2f928fe3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_214c8cf6-97de-4155-9427-aef79f1e183f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_7ba21797-5b67-49e6-9554-d68b2f928fe3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDebtInstrumentsDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#FairValueMeasurementsDebtInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDebtInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_77f8cd89-0b59-435b-b492-3d552d601ce8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_ffae3fb3-1007-4b9e-8bae-0b3946225b38" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_77f8cd89-0b59-435b-b492-3d552d601ce8" xlink:to="loc_us-gaap_DebtInstrumentTable_ffae3fb3-1007-4b9e-8bae-0b3946225b38" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_7092e690-92df-42e9-9517-8217d3c96a15" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ffae3fb3-1007-4b9e-8bae-0b3946225b38" xlink:to="loc_us-gaap_DebtInstrumentAxis_7092e690-92df-42e9-9517-8217d3c96a15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7092e690-92df-42e9-9517-8217d3c96a15_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_7092e690-92df-42e9-9517-8217d3c96a15" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7092e690-92df-42e9-9517-8217d3c96a15_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d4c3db1c-1add-40c5-9dde-07ddf2f5f187" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_7092e690-92df-42e9-9517-8217d3c96a15" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d4c3db1c-1add-40c5-9dde-07ddf2f5f187" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_b34beec2-eada-4575-9030-1da361cab2da" xlink:href="biib-20250930.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4c3db1c-1add-40c5-9dde-07ddf2f5f187" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_b34beec2-eada-4575-9030-1da361cab2da" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2.25SeniorNotesdueMay12030Member_71444e59-e2da-4418-9ae7-6cd2ebdee57b" xlink:href="biib-20250930.xsd#biib_A2.25SeniorNotesdueMay12030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4c3db1c-1add-40c5-9dde-07ddf2f5f187" xlink:to="loc_biib_A2.25SeniorNotesdueMay12030Member_71444e59-e2da-4418-9ae7-6cd2ebdee57b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A5.050SeniorNotesDueJanuary152031Member_6d46b71c-1d6e-4964-98f6-ae8371251b76" xlink:href="biib-20250930.xsd#biib_A5.050SeniorNotesDueJanuary152031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4c3db1c-1add-40c5-9dde-07ddf2f5f187" xlink:to="loc_biib_A5.050SeniorNotesDueJanuary152031Member_6d46b71c-1d6e-4964-98f6-ae8371251b76" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A5.750SeniorNotesDueMay152035Member_033cc7b4-94bf-4215-a311-4e9cbd6a61b9" xlink:href="biib-20250930.xsd#biib_A5.750SeniorNotesDueMay152035Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4c3db1c-1add-40c5-9dde-07ddf2f5f187" xlink:to="loc_biib_A5.750SeniorNotesDueMay152035Member_033cc7b4-94bf-4215-a311-4e9cbd6a61b9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_1ba06f0b-2457-483e-8e8d-7dac091038f8" xlink:href="biib-20250930.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4c3db1c-1add-40c5-9dde-07ddf2f5f187" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_1ba06f0b-2457-483e-8e8d-7dac091038f8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A3.15SeniorNotesdueMay12050Member_260379bb-0c2b-408f-986c-978aad77a437" xlink:href="biib-20250930.xsd#biib_A3.15SeniorNotesdueMay12050Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4c3db1c-1add-40c5-9dde-07ddf2f5f187" xlink:to="loc_biib_A3.15SeniorNotesdueMay12050Member_260379bb-0c2b-408f-986c-978aad77a437" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotes3.250DueFebruary152051Member_9a07b3ff-2087-4acd-b16d-17e01cd9f08f" xlink:href="biib-20250930.xsd#biib_SeniorNotes3.250DueFebruary152051Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4c3db1c-1add-40c5-9dde-07ddf2f5f187" xlink:to="loc_biib_SeniorNotes3.250DueFebruary152051Member_9a07b3ff-2087-4acd-b16d-17e01cd9f08f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A6.450SeniorNotesDueMay152055Member_c3ac5b62-1b0a-431a-984d-f414142ba7dc" xlink:href="biib-20250930.xsd#biib_A6.450SeniorNotesDueMay152055Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4c3db1c-1add-40c5-9dde-07ddf2f5f187" xlink:to="loc_biib_A6.450SeniorNotesDueMay152055Member_c3ac5b62-1b0a-431a-984d-f414142ba7dc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NonCurrentPortionOfNotesPayableAndTermLoanMember_012c0c46-69c7-4dd1-8698-ce08a3af9a2f" xlink:href="biib-20250930.xsd#biib_NonCurrentPortionOfNotesPayableAndTermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4c3db1c-1add-40c5-9dde-07ddf2f5f187" xlink:to="loc_biib_NonCurrentPortionOfNotesPayableAndTermLoanMember_012c0c46-69c7-4dd1-8698-ce08a3af9a2f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_47a94d76-99c8-405a-8ffb-6a02a15aef2b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ffae3fb3-1007-4b9e-8bae-0b3946225b38" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_47a94d76-99c8-405a-8ffb-6a02a15aef2b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_47a94d76-99c8-405a-8ffb-6a02a15aef2b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_47a94d76-99c8-405a-8ffb-6a02a15aef2b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_47a94d76-99c8-405a-8ffb-6a02a15aef2b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_8efb4807-c3e5-43f6-97ac-ac33ca45ab11" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_47a94d76-99c8-405a-8ffb-6a02a15aef2b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_8efb4807-c3e5-43f6-97ac-ac33ca45ab11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_eed9dc94-6fd0-402d-a566-558be146744d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_8efb4807-c3e5-43f6-97ac-ac33ca45ab11" xlink:to="loc_us-gaap_SeniorNotesMember_eed9dc94-6fd0-402d-a566-558be146744d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NotesPayableCurrentFairValueDisclosure_d0ad71da-9c7c-4c82-9ac0-a34b82fa9120" xlink:href="biib-20250930.xsd#biib_NotesPayableCurrentFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_77f8cd89-0b59-435b-b492-3d552d601ce8" xlink:to="loc_biib_NotesPayableCurrentFairValueDisclosure_d0ad71da-9c7c-4c82-9ac0-a34b82fa9120" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_a03fc63a-62c9-47e4-af46-4b7c1bae5a05" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_77f8cd89-0b59-435b-b492-3d552d601ce8" xlink:to="loc_us-gaap_NotesPayableCurrent_a03fc63a-62c9-47e4-af46-4b7c1bae5a05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_4097c647-6b0b-4488-be41-7c8e998a8a46" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayableFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_77f8cd89-0b59-435b-b492-3d552d601ce8" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_4097c647-6b0b-4488-be41-7c8e998a8a46" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_3f137267-b9ae-410c-9767-d78614304d08" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_77f8cd89-0b59-435b-b492-3d552d601ce8" xlink:to="loc_us-gaap_NotesPayable_3f137267-b9ae-410c-9767-d78614304d08" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9cf88d3e-f6c9-4a57-b415-d60f479a0ece" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_77f8cd89-0b59-435b-b492-3d552d601ce8" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9cf88d3e-f6c9-4a57-b415-d60f479a0ece" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsSummaryoffinancialassetswithmaturitiesoflessthan90daysincludedwithincashandcashequivalentsDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#FinancialInstrumentsSummaryoffinancialassetswithmaturitiesoflessthan90daysincludedwithincashandcashequivalentsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsSummaryoffinancialassetswithmaturitiesoflessthan90daysincludedwithincashandcashequivalentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_d879c17f-82cf-456d-bfc4-b61419c43e50" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_9a33c62f-5e67-4c12-b97c-d475393f48a8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_d879c17f-82cf-456d-bfc4-b61419c43e50" xlink:to="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_9a33c62f-5e67-4c12-b97c-d475393f48a8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_d48b230d-0104-47ba-b01d-b2d9df7c320e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_9a33c62f-5e67-4c12-b97c-d475393f48a8" xlink:to="loc_us-gaap_InvestmentTypeAxis_d48b230d-0104-47ba-b01d-b2d9df7c320e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_d48b230d-0104-47ba-b01d-b2d9df7c320e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_d48b230d-0104-47ba-b01d-b2d9df7c320e" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_d48b230d-0104-47ba-b01d-b2d9df7c320e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_febe4545-43a5-439e-b755-cb1592d9f321" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_d48b230d-0104-47ba-b01d-b2d9df7c320e" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_febe4545-43a5-439e-b755-cb1592d9f321" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_fe788442-55e9-4943-8584-04b7a6bd9af1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_febe4545-43a5-439e-b755-cb1592d9f321" xlink:to="loc_us-gaap_CommercialPaperMember_fe788442-55e9-4943-8584-04b7a6bd9af1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_96eb1738-fc95-4d41-9bac-5ca8fd210068" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_febe4545-43a5-439e-b755-cb1592d9f321" xlink:to="loc_us-gaap_MoneyMarketFundsMember_96eb1738-fc95-4d41-9bac-5ca8fd210068" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_a25c15b8-04a7-418a-b7a4-dd6dff3d7b04" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_febe4545-43a5-439e-b755-cb1592d9f321" xlink:to="loc_us-gaap_DebtSecuritiesMember_a25c15b8-04a7-418a-b7a4-dd6dff3d7b04" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_2caf7d1c-7380-4f20-bfb2-5173ec2a7fb3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_d879c17f-82cf-456d-bfc4-b61419c43e50" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_2caf7d1c-7380-4f20-bfb2-5173ec2a7fb3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsMarketabledebtandequitysecuritiesDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#FinancialInstrumentsMarketabledebtandequitysecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsMarketabledebtandequitysecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_37e1a58a-532c-4151-b66d-64023b4fcc78" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_8f26c8fb-d140-454c-8275-1a7bceb84cd9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_37e1a58a-532c-4151-b66d-64023b4fcc78" xlink:to="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_8f26c8fb-d140-454c-8275-1a7bceb84cd9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_55cc3639-f7e6-4194-88f9-8d04fac8134f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_8f26c8fb-d140-454c-8275-1a7bceb84cd9" xlink:to="loc_us-gaap_FinancialInstrumentAxis_55cc3639-f7e6-4194-88f9-8d04fac8134f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_55cc3639-f7e6-4194-88f9-8d04fac8134f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_55cc3639-f7e6-4194-88f9-8d04fac8134f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_55cc3639-f7e6-4194-88f9-8d04fac8134f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e118f575-0f8e-4199-b357-cf5bfaa40392" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_55cc3639-f7e6-4194-88f9-8d04fac8134f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e118f575-0f8e-4199-b357-cf5bfaa40392" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CorporateDebtSecuritiesCurrentMember_94862858-a414-426d-a44d-9ae268bab769" xlink:href="biib-20250930.xsd#biib_CorporateDebtSecuritiesCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e118f575-0f8e-4199-b357-cf5bfaa40392" xlink:to="loc_biib_CorporateDebtSecuritiesCurrentMember_94862858-a414-426d-a44d-9ae268bab769" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GovernmentSecuritiesCurrentMember_88bf6b8f-d27a-42ad-b972-36f54e664c8c" xlink:href="biib-20250930.xsd#biib_GovernmentSecuritiesCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e118f575-0f8e-4199-b357-cf5bfaa40392" xlink:to="loc_biib_GovernmentSecuritiesCurrentMember_88bf6b8f-d27a-42ad-b972-36f54e664c8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesNonCurrentMember_ff96cc8d-7f3b-42a9-b061-2ee8b216ee5b" xlink:href="biib-20250930.xsd#biib_EquitySecuritiesNonCurrentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e118f575-0f8e-4199-b357-cf5bfaa40392" xlink:to="loc_biib_EquitySecuritiesNonCurrentMember_ff96cc8d-7f3b-42a9-b061-2ee8b216ee5b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract_14227c70-4a22-4b3a-bd2d-08611f618510" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_37e1a58a-532c-4151-b66d-64023b4fcc78" xlink:to="loc_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract_14227c70-4a22-4b3a-bd2d-08611f618510" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_97bcd95b-5bbe-4116-85b2-20af7105da32" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract_14227c70-4a22-4b3a-bd2d-08611f618510" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_97bcd95b-5bbe-4116-85b2-20af7105da32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c4cb05b8-3538-4f0c-9bf1-dd5e7a96a8f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract_14227c70-4a22-4b3a-bd2d-08611f618510" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c4cb05b8-3538-4f0c-9bf1-dd5e7a96a8f8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d21735d3-e461-4b3a-87f7-a27372f1e4eb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract_14227c70-4a22-4b3a-bd2d-08611f618510" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d21735d3-e461-4b3a-87f7-a27372f1e4eb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4d55295f-672f-470e-b8ec-f7b86388f146" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract_14227c70-4a22-4b3a-bd2d-08611f618510" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4d55295f-672f-470e-b8ec-f7b86388f146" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_e656aff7-58db-453b-a340-c7395a3cf6ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_37e1a58a-532c-4151-b66d-64023b4fcc78" xlink:to="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_e656aff7-58db-453b-a340-c7395a3cf6ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost_2d79f56c-7f5a-4f8d-b724-d09fb8263e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_e656aff7-58db-453b-a340-c7395a3cf6ad" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCost_2d79f56c-7f5a-4f8d-b724-d09fb8263e6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_6d5a1008-5079-45b2-8830-d442188aba23" xlink:href="biib-20250930.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_e656aff7-58db-453b-a340-c7395a3cf6ad" xlink:to="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_6d5a1008-5079-45b2-8830-d442188aba23" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_1ea6a2ee-4b71-4381-acc4-01dbd3525d02" xlink:href="biib-20250930.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_e656aff7-58db-453b-a340-c7395a3cf6ad" xlink:to="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_1ea6a2ee-4b71-4381-acc4-01dbd3525d02" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_6ed93b11-b01d-4f1c-a0a5-3a5eda251c94" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_e656aff7-58db-453b-a340-c7395a3cf6ad" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_6ed93b11-b01d-4f1c-a0a5-3a5eda251c94" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_fc2b96e7-fee6-460f-8c4e-8e7d27b8711c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_e4f317d8-732d-40fe-a2ba-7ca529fcebf5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_fc2b96e7-fee6-460f-8c4e-8e7d27b8711c" xlink:to="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_e4f317d8-732d-40fe-a2ba-7ca529fcebf5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_34ce332a-d39f-4fa3-95e0-05b41e0e291f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_e4f317d8-732d-40fe-a2ba-7ca529fcebf5" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_34ce332a-d39f-4fa3-95e0-05b41e0e291f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_34ce332a-d39f-4fa3-95e0-05b41e0e291f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_34ce332a-d39f-4fa3-95e0-05b41e0e291f" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_34ce332a-d39f-4fa3-95e0-05b41e0e291f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_fc7da3be-f625-45f6-8815-87ff8fc864a1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_34ce332a-d39f-4fa3-95e0-05b41e0e291f" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_fc7da3be-f625-45f6-8815-87ff8fc864a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_e2470ec8-8a6b-4b56-81b3-48f030c5cd80" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_fc7da3be-f625-45f6-8815-87ff8fc864a1" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_e2470ec8-8a6b-4b56-81b3-48f030c5cd80" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_2252353a-ccba-45c4-961d-aa34dbf6f9c3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_e4f317d8-732d-40fe-a2ba-7ca529fcebf5" xlink:to="loc_us-gaap_FinancialInstrumentAxis_2252353a-ccba-45c4-961d-aa34dbf6f9c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2252353a-ccba-45c4-961d-aa34dbf6f9c3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_2252353a-ccba-45c4-961d-aa34dbf6f9c3" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_2252353a-ccba-45c4-961d-aa34dbf6f9c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4c366f1e-595d-4ae3-9a0e-1e9969dc973c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_2252353a-ccba-45c4-961d-aa34dbf6f9c3" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4c366f1e-595d-4ae3-9a0e-1e9969dc973c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StrategicInvestmentsMember_7349d9f2-b538-4ead-85e8-02d7f7abef3a" xlink:href="biib-20250930.xsd#biib_StrategicInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4c366f1e-595d-4ae3-9a0e-1e9969dc973c" xlink:to="loc_biib_StrategicInvestmentsMember_7349d9f2-b538-4ead-85e8-02d7f7abef3a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DebtSecuritiesAvailableForSaleAverageMaturity_a7dcedb3-d79e-496c-bb0e-9fdd9b9b4ecc" xlink:href="biib-20250930.xsd#biib_DebtSecuritiesAvailableForSaleAverageMaturity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_fc2b96e7-fee6-460f-8c4e-8e7d27b8711c" xlink:to="loc_biib_DebtSecuritiesAvailableForSaleAverageMaturity_a7dcedb3-d79e-496c-bb0e-9fdd9b9b4ecc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StrategicInvestmentPortfolio_006e8bfe-af47-4ace-8247-3dcce4c9c72d" xlink:href="biib-20250930.xsd#biib_StrategicInvestmentPortfolio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_fc2b96e7-fee6-460f-8c4e-8e7d27b8711c" xlink:to="loc_biib_StrategicInvestmentPortfolio_006e8bfe-af47-4ace-8247-3dcce4c9c72d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#DerivativeInstrumentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_a0dd5028-d82b-4e32-b4b6-bc1d383a0fb7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_35efd3b5-ba13-44b2-84cf-605085f446ed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_a0dd5028-d82b-4e32-b4b6-bc1d383a0fb7" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_35efd3b5-ba13-44b2-84cf-605085f446ed" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0846bff6-38e6-4041-8586-a4b5c724b937" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_35efd3b5-ba13-44b2-84cf-605085f446ed" xlink:to="loc_srt_RangeAxis_0846bff6-38e6-4041-8586-a4b5c724b937" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0846bff6-38e6-4041-8586-a4b5c724b937_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_0846bff6-38e6-4041-8586-a4b5c724b937" xlink:to="loc_srt_RangeMember_0846bff6-38e6-4041-8586-a4b5c724b937_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a25739b0-d720-4aff-b54b-59a28f4b2c34" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_0846bff6-38e6-4041-8586-a4b5c724b937" xlink:to="loc_srt_RangeMember_a25739b0-d720-4aff-b54b-59a28f4b2c34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9092caa5-c1fe-4f5f-af43-28a4493ec722" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a25739b0-d720-4aff-b54b-59a28f4b2c34" xlink:to="loc_srt_MinimumMember_9092caa5-c1fe-4f5f-af43-28a4493ec722" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1876fd04-d139-4f48-a335-2c409d321cb6" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a25739b0-d720-4aff-b54b-59a28f4b2c34" xlink:to="loc_srt_MaximumMember_1876fd04-d139-4f48-a335-2c409d321cb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_c168bbe3-795b-4c1f-8b21-2adf90b51cef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_35efd3b5-ba13-44b2-84cf-605085f446ed" xlink:to="loc_us-gaap_HedgingDesignationAxis_c168bbe3-795b-4c1f-8b21-2adf90b51cef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_c168bbe3-795b-4c1f-8b21-2adf90b51cef_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_c168bbe3-795b-4c1f-8b21-2adf90b51cef" xlink:to="loc_us-gaap_HedgingDesignationDomain_c168bbe3-795b-4c1f-8b21-2adf90b51cef_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_95a8748d-cfb2-414c-8501-37cc450a52f9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_c168bbe3-795b-4c1f-8b21-2adf90b51cef" xlink:to="loc_us-gaap_HedgingDesignationDomain_95a8748d-cfb2-414c-8501-37cc450a52f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_9190c1f6-1b8f-4daf-be56-d48b4f6038e5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_95a8748d-cfb2-414c-8501-37cc450a52f9" xlink:to="loc_us-gaap_NondesignatedMember_9190c1f6-1b8f-4daf-be56-d48b4f6038e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_ab93d3ef-a927-4957-b57b-b3e7845a0600" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeRemainingMaturity1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_a0dd5028-d82b-4e32-b4b6-bc1d383a0fb7" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_ab93d3ef-a927-4957-b57b-b3e7845a0600" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months_83c6ab7c-d818-4cef-ae4e-553dd025e7ca" xlink:href="biib-20250930.xsd#biib_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_a0dd5028-d82b-4e32-b4b6-bc1d383a0fb7" xlink:to="loc_biib_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months_83c6ab7c-d818-4cef-ae4e-553dd025e7ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_84268e93-0e35-4b0f-97b1-05eae3ea0491" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_a0dd5028-d82b-4e32-b4b6-bc1d383a0fb7" xlink:to="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_84268e93-0e35-4b0f-97b1-05eae3ea0491" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_4022df00-04ef-4c48-8609-a8ef66cdca9a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_a0dd5028-d82b-4e32-b4b6-bc1d383a0fb7" xlink:to="loc_us-gaap_DerivativeNotionalAmount_4022df00-04ef-4c48-8609-a8ef66cdca9a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_41eef1f1-664d-4fd6-81a0-4b8c21734dca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_a0dd5028-d82b-4e32-b4b6-bc1d383a0fb7" xlink:to="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_41eef1f1-664d-4fd6-81a0-4b8c21734dca" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsNotionalAmountofForeignCurrencyForwardContractsandForeignCurrencyOptionsDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#DerivativeInstrumentsNotionalAmountofForeignCurrencyForwardContractsandForeignCurrencyOptionsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsNotionalAmountofForeignCurrencyForwardContractsandForeignCurrencyOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_b1a6d5bd-e03a-45e5-a10b-e9b992050eab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_18b11584-d336-40a7-a226-89b7c51202db" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_b1a6d5bd-e03a-45e5-a10b-e9b992050eab" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_18b11584-d336-40a7-a226-89b7c51202db" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_1687c563-198e-45e7-bc94-fb2c2e49af5b" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CurrencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_18b11584-d336-40a7-a226-89b7c51202db" xlink:to="loc_srt_CurrencyAxis_1687c563-198e-45e7-bc94-fb2c2e49af5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_1687c563-198e-45e7-bc94-fb2c2e49af5b_default" xlink:href="https://xbrl.sec.gov/currency/2025/currency-2025.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_1687c563-198e-45e7-bc94-fb2c2e49af5b" xlink:to="loc_currency_AllCurrenciesDomain_1687c563-198e-45e7-bc94-fb2c2e49af5b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_b5a7b27f-807e-43bc-b39f-c0ec5d9801ff" xlink:href="https://xbrl.sec.gov/currency/2025/currency-2025.xsd#currency_AllCurrenciesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_1687c563-198e-45e7-bc94-fb2c2e49af5b" xlink:to="loc_currency_AllCurrenciesDomain_b5a7b27f-807e-43bc-b39f-c0ec5d9801ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_4369c9ed-12ee-47cd-9146-ac8d69e12e06" xlink:href="https://xbrl.sec.gov/currency/2025/currency-2025.xsd#currency_EUR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_b5a7b27f-807e-43bc-b39f-c0ec5d9801ff" xlink:to="loc_currency_EUR_4369c9ed-12ee-47cd-9146-ac8d69e12e06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_GBP_7fccb827-487c-458b-8d9e-4d36a5ca7088" xlink:href="https://xbrl.sec.gov/currency/2025/currency-2025.xsd#currency_GBP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_b5a7b27f-807e-43bc-b39f-c0ec5d9801ff" xlink:to="loc_currency_GBP_7fccb827-487c-458b-8d9e-4d36a5ca7088" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CHF_1a667af7-89fa-4628-bfff-45c24d1c702d" xlink:href="https://xbrl.sec.gov/currency/2025/currency-2025.xsd#currency_CHF"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_b5a7b27f-807e-43bc-b39f-c0ec5d9801ff" xlink:to="loc_currency_CHF_1a667af7-89fa-4628-bfff-45c24d1c702d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CAD_fcb9d51a-9533-4f68-bf05-87e791501562" xlink:href="https://xbrl.sec.gov/currency/2025/currency-2025.xsd#currency_CAD"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_b5a7b27f-807e-43bc-b39f-c0ec5d9801ff" xlink:to="loc_currency_CAD_fcb9d51a-9533-4f68-bf05-87e791501562" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_e0f657ae-af8a-44d2-a356-b94a90693317" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_18b11584-d336-40a7-a226-89b7c51202db" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_e0f657ae-af8a-44d2-a356-b94a90693317" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_e0f657ae-af8a-44d2-a356-b94a90693317_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_e0f657ae-af8a-44d2-a356-b94a90693317" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_e0f657ae-af8a-44d2-a356-b94a90693317_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_90386b75-afaa-4c9c-b049-6c00fa62604e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_e0f657ae-af8a-44d2-a356-b94a90693317" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_90386b75-afaa-4c9c-b049-6c00fa62604e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_3341cd05-2fa3-4b6c-aaae-d197ccb080c1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_90386b75-afaa-4c9c-b049-6c00fa62604e" xlink:to="loc_us-gaap_ForeignExchangeContractMember_3341cd05-2fa3-4b6c-aaae-d197ccb080c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_ca2865b5-9c55-42d4-a18e-a7885cd7d30e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_18b11584-d336-40a7-a226-89b7c51202db" xlink:to="loc_us-gaap_HedgingDesignationAxis_ca2865b5-9c55-42d4-a18e-a7885cd7d30e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_ca2865b5-9c55-42d4-a18e-a7885cd7d30e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_ca2865b5-9c55-42d4-a18e-a7885cd7d30e" xlink:to="loc_us-gaap_HedgingDesignationDomain_ca2865b5-9c55-42d4-a18e-a7885cd7d30e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_6cacfb62-e873-4237-b452-45ea6ada12e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_ca2865b5-9c55-42d4-a18e-a7885cd7d30e" xlink:to="loc_us-gaap_HedgingDesignationDomain_6cacfb62-e873-4237-b452-45ea6ada12e7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_b97ba3a8-e1b3-47e6-9c7b-c3924e880f95" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_6cacfb62-e873-4237-b452-45ea6ada12e7" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_b97ba3a8-e1b3-47e6-9c7b-c3924e880f95" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_e56f332c-3365-4b4c-ac64-328cf319c1b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_b1a6d5bd-e03a-45e5-a10b-e9b992050eab" xlink:to="loc_us-gaap_DerivativeNotionalAmount_e56f332c-3365-4b4c-ac64-328cf319c1b6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsEffectofForeignCurrencyForwardContractsandForwardCurrencyOptionsDesignatedasHedgingInstrumentsDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#DerivativeInstrumentsEffectofForeignCurrencyForwardContractsandForwardCurrencyOptionsDesignatedasHedgingInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsEffectofForeignCurrencyForwardContractsandForwardCurrencyOptionsDesignatedasHedgingInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_3ee2fe3f-836d-4f7d-aeb5-d225a3b50840" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b178afb5-37fb-4858-b73e-a7be6eadef32" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_3ee2fe3f-836d-4f7d-aeb5-d225a3b50840" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b178afb5-37fb-4858-b73e-a7be6eadef32" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_a81622c2-8028-4bb9-a0c1-c214cc85c34f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b178afb5-37fb-4858-b73e-a7be6eadef32" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_a81622c2-8028-4bb9-a0c1-c214cc85c34f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_a81622c2-8028-4bb9-a0c1-c214cc85c34f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_a81622c2-8028-4bb9-a0c1-c214cc85c34f" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_a81622c2-8028-4bb9-a0c1-c214cc85c34f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_f9a321f7-0ef2-4909-8658-89130bf19067" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_a81622c2-8028-4bb9-a0c1-c214cc85c34f" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_f9a321f7-0ef2-4909-8658-89130bf19067" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_07b94c5d-0f63-4bcb-b27a-a3ab60979ace" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_f9a321f7-0ef2-4909-8658-89130bf19067" xlink:to="loc_us-gaap_ForeignExchangeContractMember_07b94c5d-0f63-4bcb-b27a-a3ab60979ace" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_eed5620e-c9dd-4bc4-92d8-89862bc16a8c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b178afb5-37fb-4858-b73e-a7be6eadef32" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_eed5620e-c9dd-4bc4-92d8-89862bc16a8c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_eed5620e-c9dd-4bc4-92d8-89862bc16a8c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_eed5620e-c9dd-4bc4-92d8-89862bc16a8c" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_eed5620e-c9dd-4bc4-92d8-89862bc16a8c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8c2bf510-7104-494b-9e58-3e866bdf825f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_eed5620e-c9dd-4bc4-92d8-89862bc16a8c" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8c2bf510-7104-494b-9e58-3e866bdf825f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_215a0d97-104c-455b-932c-921632419513" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8c2bf510-7104-494b-9e58-3e866bdf825f" xlink:to="loc_us-gaap_SalesMember_215a0d97-104c-455b-932c-921632419513" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenseMember_463951fc-3346-4da1-8a53-dce2ae9d30d6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8c2bf510-7104-494b-9e58-3e866bdf825f" xlink:to="loc_us-gaap_OperatingExpenseMember_463951fc-3346-4da1-8a53-dce2ae9d30d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_8669092b-0278-4d1f-a15c-f3ceb11a4567" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b178afb5-37fb-4858-b73e-a7be6eadef32" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_8669092b-0278-4d1f-a15c-f3ceb11a4567" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_8669092b-0278-4d1f-a15c-f3ceb11a4567_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_8669092b-0278-4d1f-a15c-f3ceb11a4567" xlink:to="loc_us-gaap_HedgingRelationshipDomain_8669092b-0278-4d1f-a15c-f3ceb11a4567_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_78f224d8-ea35-48da-8835-ccb3321f7b4d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_8669092b-0278-4d1f-a15c-f3ceb11a4567" xlink:to="loc_us-gaap_HedgingRelationshipDomain_78f224d8-ea35-48da-8835-ccb3321f7b4d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashflowsrevenueMember_87e6a219-99c6-42e4-b137-8fdfc833342d" xlink:href="biib-20250930.xsd#biib_CashflowsrevenueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_78f224d8-ea35-48da-8835-ccb3321f7b4d" xlink:to="loc_biib_CashflowsrevenueMember_87e6a219-99c6-42e4-b137-8fdfc833342d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashflowsoperatingexpensesMember_2be4d217-3e06-4c52-85d1-8bca00c51a0d" xlink:href="biib-20250930.xsd#biib_CashflowsoperatingexpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_78f224d8-ea35-48da-8835-ccb3321f7b4d" xlink:to="loc_biib_CashflowsoperatingexpensesMember_2be4d217-3e06-4c52-85d1-8bca00c51a0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_07d3c4ac-46a2-4441-8665-96679956eee1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_3ee2fe3f-836d-4f7d-aeb5-d225a3b50840" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_07d3c4ac-46a2-4441-8665-96679956eee1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_6686c415-ba49-4695-ad82-4eafe550cd64" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_3ee2fe3f-836d-4f7d-aeb5-d225a3b50840" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_6686c415-ba49-4695-ad82-4eafe550cd64" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsSummaryofFairValueandPresentationofDerivativesDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#DerivativeInstrumentsSummaryofFairValueandPresentationofDerivativesDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsSummaryofFairValueandPresentationofDerivativesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_7fae1a23-adb2-4f0e-b3d3-18dba1b694ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_85f2a9a1-570a-455a-a133-6b4e01896c4b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_7fae1a23-adb2-4f0e-b3d3-18dba1b694ad" xlink:to="loc_us-gaap_DerivativeTable_85f2a9a1-570a-455a-a133-6b4e01896c4b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_7186f2be-df18-4a2b-8031-753210c434be" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_85f2a9a1-570a-455a-a133-6b4e01896c4b" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_7186f2be-df18-4a2b-8031-753210c434be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_7186f2be-df18-4a2b-8031-753210c434be_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_7186f2be-df18-4a2b-8031-753210c434be" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_7186f2be-df18-4a2b-8031-753210c434be_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_622a0e40-5ee5-4d09-8097-8d53ad90aaef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_7186f2be-df18-4a2b-8031-753210c434be" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_622a0e40-5ee5-4d09-8097-8d53ad90aaef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_3fa567da-a0ec-4677-808b-2774fffadb7f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_622a0e40-5ee5-4d09-8097-8d53ad90aaef" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_3fa567da-a0ec-4677-808b-2774fffadb7f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_9404de19-8875-45a6-8403-674766ebba04" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_622a0e40-5ee5-4d09-8097-8d53ad90aaef" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_9404de19-8875-45a6-8403-674766ebba04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_67e24dde-e646-4f4b-bf9a-e9a67bd1abeb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_622a0e40-5ee5-4d09-8097-8d53ad90aaef" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_67e24dde-e646-4f4b-bf9a-e9a67bd1abeb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_bfb2c9b8-5e02-4ec8-943f-5eb65ec36fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_85f2a9a1-570a-455a-a133-6b4e01896c4b" xlink:to="loc_us-gaap_HedgingDesignationAxis_bfb2c9b8-5e02-4ec8-943f-5eb65ec36fe2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_bfb2c9b8-5e02-4ec8-943f-5eb65ec36fe2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_bfb2c9b8-5e02-4ec8-943f-5eb65ec36fe2" xlink:to="loc_us-gaap_HedgingDesignationDomain_bfb2c9b8-5e02-4ec8-943f-5eb65ec36fe2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_ada57321-ab33-48ea-a044-1fc5846626b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_bfb2c9b8-5e02-4ec8-943f-5eb65ec36fe2" xlink:to="loc_us-gaap_HedgingDesignationDomain_ada57321-ab33-48ea-a044-1fc5846626b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_86557774-73a9-4b8c-b978-15ebe03f6e14" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_ada57321-ab33-48ea-a044-1fc5846626b9" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_86557774-73a9-4b8c-b978-15ebe03f6e14" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_e020c343-eb81-4200-8e3b-4873d041f173" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_ada57321-ab33-48ea-a044-1fc5846626b9" xlink:to="loc_us-gaap_NondesignatedMember_e020c343-eb81-4200-8e3b-4873d041f173" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_abbc45ef-381c-4fa6-ad8f-ca1b0b450337" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_85f2a9a1-570a-455a-a133-6b4e01896c4b" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_abbc45ef-381c-4fa6-ad8f-ca1b0b450337" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_abbc45ef-381c-4fa6-ad8f-ca1b0b450337_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_abbc45ef-381c-4fa6-ad8f-ca1b0b450337" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_abbc45ef-381c-4fa6-ad8f-ca1b0b450337_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_8273dd0d-fee4-4490-bef9-98e2061e1934" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_abbc45ef-381c-4fa6-ad8f-ca1b0b450337" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_8273dd0d-fee4-4490-bef9-98e2061e1934" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_ec012c95-2c23-42e3-9dff-6e54c47fb3ef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_8273dd0d-fee4-4490-bef9-98e2061e1934" xlink:to="loc_us-gaap_ForeignExchangeContractMember_ec012c95-2c23-42e3-9dff-6e54c47fb3ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_8d27f978-3d97-4d98-aaa1-eb866209dcd7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_85f2a9a1-570a-455a-a133-6b4e01896c4b" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_8d27f978-3d97-4d98-aaa1-eb866209dcd7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_8d27f978-3d97-4d98-aaa1-eb866209dcd7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_8d27f978-3d97-4d98-aaa1-eb866209dcd7" xlink:to="loc_us-gaap_HedgingRelationshipDomain_8d27f978-3d97-4d98-aaa1-eb866209dcd7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_8e4c188e-79b2-4c5d-88c1-b49eb475b9c8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_8d27f978-3d97-4d98-aaa1-eb866209dcd7" xlink:to="loc_us-gaap_HedgingRelationshipDomain_8e4c188e-79b2-4c5d-88c1-b49eb475b9c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_d82d34a0-479e-44ca-9872-b775ce95b6ed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_8e4c188e-79b2-4c5d-88c1-b49eb475b9c8" xlink:to="loc_us-gaap_CashFlowHedgingMember_d82d34a0-479e-44ca-9872-b775ce95b6ed" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_3d9d0fc9-2a7d-4d30-98ec-3cb617ca2221" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_7fae1a23-adb2-4f0e-b3d3-18dba1b694ad" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_3d9d0fc9-2a7d-4d30-98ec-3cb617ca2221" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_37529cac-df4f-445b-a56e-982d9421f8fc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_7fae1a23-adb2-4f0e-b3d3-18dba1b694ad" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_37529cac-df4f-445b-a56e-982d9421f8fc" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_a014e81d-9a7f-488d-9baf-be46bbf87357" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_799e8d88-aa42-4d2f-bb15-441c5e374266" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a014e81d-9a7f-488d-9baf-be46bbf87357" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_799e8d88-aa42-4d2f-bb15-441c5e374266" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_2efb24d6-2718-4854-bafd-5770aaff850f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_799e8d88-aa42-4d2f-bb15-441c5e374266" xlink:to="loc_us-gaap_LeaseContractualTermAxis_2efb24d6-2718-4854-bafd-5770aaff850f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_2efb24d6-2718-4854-bafd-5770aaff850f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseContractualTermAxis_2efb24d6-2718-4854-bafd-5770aaff850f" xlink:to="loc_us-gaap_LeaseContractualTermDomain_2efb24d6-2718-4854-bafd-5770aaff850f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_86ff991e-4a4f-4271-80bb-cede2de29425" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseContractualTermAxis_2efb24d6-2718-4854-bafd-5770aaff850f" xlink:to="loc_us-gaap_LeaseContractualTermDomain_86ff991e-4a4f-4271-80bb-cede2de29425" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_HeadquartersLeaseFiveYearRenewalOptionMember_0cac393c-b7eb-4148-92f6-22f5711b1f18" xlink:href="biib-20250930.xsd#biib_HeadquartersLeaseFiveYearRenewalOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_86ff991e-4a4f-4271-80bb-cede2de29425" xlink:to="loc_biib_HeadquartersLeaseFiveYearRenewalOptionMember_0cac393c-b7eb-4148-92f6-22f5711b1f18" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_HeadquartersLeaseSixMonthRenewalOptionMember_e6a9c196-f2ab-4640-a448-9206356284fd" xlink:href="biib-20250930.xsd#biib_HeadquartersLeaseSixMonthRenewalOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_86ff991e-4a4f-4271-80bb-cede2de29425" xlink:to="loc_biib_HeadquartersLeaseSixMonthRenewalOptionMember_e6a9c196-f2ab-4640-a448-9206356284fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_01123649-8fdd-44b1-bd01-349a21ae4b10" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_799e8d88-aa42-4d2f-bb15-441c5e374266" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_01123649-8fdd-44b1-bd01-349a21ae4b10" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_01123649-8fdd-44b1-bd01-349a21ae4b10_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_01123649-8fdd-44b1-bd01-349a21ae4b10" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_01123649-8fdd-44b1-bd01-349a21ae4b10_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_90dccb6a-2b7b-4c4a-b342-5b8208c488eb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_01123649-8fdd-44b1-bd01-349a21ae4b10" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_90dccb6a-2b7b-4c4a-b342-5b8208c488eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_fbd8219b-c80e-44ca-9640-34255f4e292a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BuildingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_90dccb6a-2b7b-4c4a-b342-5b8208c488eb" xlink:to="loc_us-gaap_BuildingMember_fbd8219b-c80e-44ca-9640-34255f4e292a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OperatingLeaseArea_81a3fa94-ba7b-412d-bf97-2599ba5c0d66" xlink:href="biib-20250930.xsd#biib_OperatingLeaseArea"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a014e81d-9a7f-488d-9baf-be46bbf87357" xlink:to="loc_biib_OperatingLeaseArea_81a3fa94-ba7b-412d-bf97-2599ba5c0d66" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReductionOfRealEstateFootprint_f7a3edfc-0cb1-4835-ac4e-80c9abc7a326" xlink:href="biib-20250930.xsd#biib_ReductionOfRealEstateFootprint"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a014e81d-9a7f-488d-9baf-be46bbf87357" xlink:to="loc_biib_ReductionOfRealEstateFootprint_f7a3edfc-0cb1-4835-ac4e-80c9abc7a326" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_e1215b32-59a5-4b21-a04e-ef334ef47023" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a014e81d-9a7f-488d-9baf-be46bbf87357" xlink:to="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_e1215b32-59a5-4b21-a04e-ef334ef47023" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount_f1477ba3-224c-4e1d-951e-bfab36ddb101" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a014e81d-9a7f-488d-9baf-be46bbf87357" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount_f1477ba3-224c-4e1d-951e-bfab36ddb101" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LesseeOperatingLeaseNumberOfRenewalOptions_ec881781-5796-4f29-89f5-8dba142be0b7" xlink:href="biib-20250930.xsd#biib_LesseeOperatingLeaseNumberOfRenewalOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a014e81d-9a7f-488d-9baf-be46bbf87357" xlink:to="loc_biib_LesseeOperatingLeaseNumberOfRenewalOptions_ec881781-5796-4f29-89f5-8dba142be0b7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_23eb9273-d3aa-4250-ba5c-eb4f8e5829de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a014e81d-9a7f-488d-9baf-be46bbf87357" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_23eb9273-d3aa-4250-ba5c-eb4f8e5829de" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessNarrativeDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#IndebtednessNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/IndebtednessNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_ba8b1c75-b50d-48e0-a7e3-7b82471f87ca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_8657dc9b-0d64-4558-a355-adfed96f1cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba8b1c75-b50d-48e0-a7e3-7b82471f87ca" xlink:to="loc_us-gaap_DebtInstrumentTable_8657dc9b-0d64-4558-a355-adfed96f1cd7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_19933f15-58a9-49c0-ac6b-1bbd18561798" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_8657dc9b-0d64-4558-a355-adfed96f1cd7" xlink:to="loc_us-gaap_DebtInstrumentAxis_19933f15-58a9-49c0-ac6b-1bbd18561798" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_19933f15-58a9-49c0-ac6b-1bbd18561798_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_19933f15-58a9-49c0-ac6b-1bbd18561798" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_19933f15-58a9-49c0-ac6b-1bbd18561798_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_da87b828-1e92-4f46-8855-9d8860337f15" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_19933f15-58a9-49c0-ac6b-1bbd18561798" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_da87b828-1e92-4f46-8855-9d8860337f15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A5.050SeniorNotesDueJanuary152031Member_eed2c8a4-14b1-47f0-afb9-7bf1e6c7b17e" xlink:href="biib-20250930.xsd#biib_A5.050SeniorNotesDueJanuary152031Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_da87b828-1e92-4f46-8855-9d8860337f15" xlink:to="loc_biib_A5.050SeniorNotesDueJanuary152031Member_eed2c8a4-14b1-47f0-afb9-7bf1e6c7b17e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A5.750SeniorNotesDueMay152035Member_7e835fcf-c3cb-46b8-b2a5-aa3b8e11d03e" xlink:href="biib-20250930.xsd#biib_A5.750SeniorNotesDueMay152035Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_da87b828-1e92-4f46-8855-9d8860337f15" xlink:to="loc_biib_A5.750SeniorNotesDueMay152035Member_7e835fcf-c3cb-46b8-b2a5-aa3b8e11d03e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A6.450SeniorNotesDueMay152055Member_670dd7a4-3c2b-4e3e-866d-ebc8d2b177cc" xlink:href="biib-20250930.xsd#biib_A6.450SeniorNotesDueMay152055Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_da87b828-1e92-4f46-8855-9d8860337f15" xlink:to="loc_biib_A6.450SeniorNotesDueMay152055Member_670dd7a4-3c2b-4e3e-866d-ebc8d2b177cc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2025SeniorNotesMember_38094599-06a3-4da1-8392-aaa48480c3bb" xlink:href="biib-20250930.xsd#biib_A2025SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_da87b828-1e92-4f46-8855-9d8860337f15" xlink:to="loc_biib_A2025SeniorNotesMember_38094599-06a3-4da1-8392-aaa48480c3bb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_2b746eba-be72-4420-b5a1-ad3064961814" xlink:href="biib-20250930.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_da87b828-1e92-4f46-8855-9d8860337f15" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_2b746eba-be72-4420-b5a1-ad3064961814" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TheCreditFacilityMember_0adf6741-e464-418a-9ced-b4f83a57daee" xlink:href="biib-20250930.xsd#biib_TheCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_da87b828-1e92-4f46-8855-9d8860337f15" xlink:to="loc_biib_TheCreditFacilityMember_0adf6741-e464-418a-9ced-b4f83a57daee" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TheCreditFacilityFloatingRate364DayTrancheMember_dae210d0-dd55-4418-8dfe-abc949dff387" xlink:href="biib-20250930.xsd#biib_TheCreditFacilityFloatingRate364DayTrancheMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_da87b828-1e92-4f46-8855-9d8860337f15" xlink:to="loc_biib_TheCreditFacilityFloatingRate364DayTrancheMember_dae210d0-dd55-4418-8dfe-abc949dff387" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TheCreditFacilityFloatingRateThreeYearTrancheMember_ba8068b6-94d2-4fee-936b-a1a8bc3e86d9" xlink:href="biib-20250930.xsd#biib_TheCreditFacilityFloatingRateThreeYearTrancheMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_da87b828-1e92-4f46-8855-9d8860337f15" xlink:to="loc_biib_TheCreditFacilityFloatingRateThreeYearTrancheMember_ba8068b6-94d2-4fee-936b-a1a8bc3e86d9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TheCreditFacilityTerminatedMember_8f4e7318-06dc-48d3-92f3-959ece5c2f7d" xlink:href="biib-20250930.xsd#biib_TheCreditFacilityTerminatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_da87b828-1e92-4f46-8855-9d8860337f15" xlink:to="loc_biib_TheCreditFacilityTerminatedMember_8f4e7318-06dc-48d3-92f3-959ece5c2f7d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2023TermLoanMember_057990f4-df99-43e3-97cf-0b9f79d68845" xlink:href="biib-20250930.xsd#biib_A2023TermLoanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_da87b828-1e92-4f46-8855-9d8860337f15" xlink:to="loc_biib_A2023TermLoanMember_057990f4-df99-43e3-97cf-0b9f79d68845" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_c845b140-b696-46ac-a68f-053f81bab882" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_8657dc9b-0d64-4558-a355-adfed96f1cd7" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_c845b140-b696-46ac-a68f-053f81bab882" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_c845b140-b696-46ac-a68f-053f81bab882_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c845b140-b696-46ac-a68f-053f81bab882" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_c845b140-b696-46ac-a68f-053f81bab882_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_74637c4b-5ebf-4cab-8f5a-aa044dbfee3e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c845b140-b696-46ac-a68f-053f81bab882" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_74637c4b-5ebf-4cab-8f5a-aa044dbfee3e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_3851fc41-3a06-4c8e-88c3-bc650c630c4c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_74637c4b-5ebf-4cab-8f5a-aa044dbfee3e" xlink:to="loc_us-gaap_SeniorNotesMember_3851fc41-3a06-4c8e-88c3-bc650c630c4c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_164897d0-343d-4781-8014-684c42864b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_74637c4b-5ebf-4cab-8f5a-aa044dbfee3e" xlink:to="loc_us-gaap_LineOfCreditMember_164897d0-343d-4781-8014-684c42864b1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_0439654f-c8ac-46de-9c08-38f5087c72f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_8657dc9b-0d64-4558-a355-adfed96f1cd7" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_0439654f-c8ac-46de-9c08-38f5087c72f4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0439654f-c8ac-46de-9c08-38f5087c72f4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0439654f-c8ac-46de-9c08-38f5087c72f4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_0439654f-c8ac-46de-9c08-38f5087c72f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2f90759b-380f-440c-abb9-5404a9b3a52b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0439654f-c8ac-46de-9c08-38f5087c72f4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2f90759b-380f-440c-abb9-5404a9b3a52b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember_1c667202-010f-47d4-9d96-f99ce03b41c0" xlink:href="biib-20250930.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2f90759b-380f-440c-abb9-5404a9b3a52b" xlink:to="loc_biib_ReataPharmaceuticalsIncMember_1c667202-010f-47d4-9d96-f99ce03b41c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_63fb2382-1918-4207-9d2d-551bcd96ce9a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_8657dc9b-0d64-4558-a355-adfed96f1cd7" xlink:to="loc_us-gaap_CreditFacilityAxis_63fb2382-1918-4207-9d2d-551bcd96ce9a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_63fb2382-1918-4207-9d2d-551bcd96ce9a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_63fb2382-1918-4207-9d2d-551bcd96ce9a" xlink:to="loc_us-gaap_CreditFacilityDomain_63fb2382-1918-4207-9d2d-551bcd96ce9a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_988e830d-79ed-48bd-bca2-89dcc9f1797d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_63fb2382-1918-4207-9d2d-551bcd96ce9a" xlink:to="loc_us-gaap_CreditFacilityDomain_988e830d-79ed-48bd-bca2-89dcc9f1797d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_da2e16bc-24b0-474c-af95-7f0f11973ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_988e830d-79ed-48bd-bca2-89dcc9f1797d" xlink:to="loc_us-gaap_SecuredDebtMember_da2e16bc-24b0-474c-af95-7f0f11973ca2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FloatingRate364DayTrancheMember_a5522cf1-5c92-466f-8c7e-146486fe8aab" xlink:href="biib-20250930.xsd#biib_FloatingRate364DayTrancheMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_988e830d-79ed-48bd-bca2-89dcc9f1797d" xlink:to="loc_biib_FloatingRate364DayTrancheMember_a5522cf1-5c92-466f-8c7e-146486fe8aab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TermLoan2023ThreeYearTrancheMember_cd074f85-66f1-4efb-94e1-5a63357876c5" xlink:href="biib-20250930.xsd#biib_TermLoan2023ThreeYearTrancheMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_988e830d-79ed-48bd-bca2-89dcc9f1797d" xlink:to="loc_biib_TermLoan2023ThreeYearTrancheMember_cd074f85-66f1-4efb-94e1-5a63357876c5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_bef94cb7-9b60-4556-9c1c-182c75dc68e0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba8b1c75-b50d-48e0-a7e3-7b82471f87ca" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_bef94cb7-9b60-4556-9c1c-182c75dc68e0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_2b60fa1b-694b-4c0c-87eb-a380a6c1bdaa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba8b1c75-b50d-48e0-a7e3-7b82471f87ca" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_2b60fa1b-694b-4c0c-87eb-a380a6c1bdaa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageParValueOfSeniorNotes_93be783a-cc5f-46d1-bf65-7b46016e2829" xlink:href="biib-20250930.xsd#biib_PercentageParValueOfSeniorNotes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba8b1c75-b50d-48e0-a7e3-7b82471f87ca" xlink:to="loc_biib_PercentageParValueOfSeniorNotes_93be783a-cc5f-46d1-bf65-7b46016e2829" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_d26216e1-19e2-4fa4-850f-b26e29437d10" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba8b1c75-b50d-48e0-a7e3-7b82471f87ca" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_d26216e1-19e2-4fa4-850f-b26e29437d10" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_1f57f6aa-0e7b-4134-b985-09b6f90222de" xlink:href="biib-20250930.xsd#biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba8b1c75-b50d-48e0-a7e3-7b82471f87ca" xlink:to="loc_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_1f57f6aa-0e7b-4134-b985-09b6f90222de" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_a2e964f1-569e-464f-85a1-579b6dd80967" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba8b1c75-b50d-48e0-a7e3-7b82471f87ca" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_a2e964f1-569e-464f-85a1-579b6dd80967" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_ccbeab60-9ed2-4453-9c0f-e76116f185ce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba8b1c75-b50d-48e0-a7e3-7b82471f87ca" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_ccbeab60-9ed2-4453-9c0f-e76116f185ce" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_59f26757-3c73-485b-b83f-4c9751ead1fe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba8b1c75-b50d-48e0-a7e3-7b82471f87ca" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_59f26757-3c73-485b-b83f-4c9751ead1fe" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths_f0a7cbf5-08d3-4cb7-8d7e-bb29037b2f2e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba8b1c75-b50d-48e0-a7e3-7b82471f87ca" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths_f0a7cbf5-08d3-4cb7-8d7e-bb29037b2f2e" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityNarrativeDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#EquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_b40d9727-0c5e-4dff-ac12-31d59b41b955" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_2e2d3508-9492-4312-93c1-667567b8c5fe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_b40d9727-0c5e-4dff-ac12-31d59b41b955" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_2e2d3508-9492-4312-93c1-667567b8c5fe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramAxis_1dbcd75a-c767-4a18-8506-470bd29d04b5" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2e2d3508-9492-4312-93c1-667567b8c5fe" xlink:to="loc_srt_ShareRepurchaseProgramAxis_1dbcd75a-c767-4a18-8506-470bd29d04b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramDomain_1dbcd75a-c767-4a18-8506-470bd29d04b5_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ShareRepurchaseProgramAxis_1dbcd75a-c767-4a18-8506-470bd29d04b5" xlink:to="loc_srt_ShareRepurchaseProgramDomain_1dbcd75a-c767-4a18-8506-470bd29d04b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramDomain_fd3b7f9a-417f-4860-9b43-9704eee358b7" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ShareRepurchaseProgramAxis_1dbcd75a-c767-4a18-8506-470bd29d04b5" xlink:to="loc_srt_ShareRepurchaseProgramDomain_fd3b7f9a-417f-4860-9b43-9704eee358b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2020ShareRepurchaseProgramMember_9488a852-bb2b-4aad-b0cc-ff52a6f83aaa" xlink:href="biib-20250930.xsd#biib_A2020ShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ShareRepurchaseProgramDomain_fd3b7f9a-417f-4860-9b43-9704eee358b7" xlink:to="loc_biib_A2020ShareRepurchaseProgramMember_9488a852-bb2b-4aad-b0cc-ff52a6f83aaa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StockRepurchaseProgramAuthorizedAmount1_cbdb5843-489a-4905-ad00-5faaa6f9c3a3" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b40d9727-0c5e-4dff-ac12-31d59b41b955" xlink:to="loc_srt_StockRepurchaseProgramAuthorizedAmount1_cbdb5843-489a-4905-ad00-5faaa6f9c3a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_1d2669a4-ff15-4147-9941-ff15ad1257d2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b40d9727-0c5e-4dff-ac12-31d59b41b955" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_1d2669a4-ff15-4147-9941-ff15ad1257d2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_7efd64b9-ec3f-4037-bd1c-7f107f7c597b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_b40d9727-0c5e-4dff-ac12-31d59b41b955" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_7efd64b9-ec3f-4037-bd1c-7f107f7c597b" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#EquityAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_d73d8dca-5233-489e-9930-c5a8d2af4007" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_5d3f118b-e617-4947-b6a2-69b7052be62b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_d73d8dca-5233-489e-9930-c5a8d2af4007" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_5d3f118b-e617-4947-b6a2-69b7052be62b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9ad93a31-4eeb-422f-b6ca-31522a1af98a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_5d3f118b-e617-4947-b6a2-69b7052be62b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9ad93a31-4eeb-422f-b6ca-31522a1af98a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9ad93a31-4eeb-422f-b6ca-31522a1af98a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9ad93a31-4eeb-422f-b6ca-31522a1af98a" xlink:to="loc_us-gaap_EquityComponentDomain_9ad93a31-4eeb-422f-b6ca-31522a1af98a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c9385f94-645d-44ff-98be-d9c1e6df5db0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9ad93a31-4eeb-422f-b6ca-31522a1af98a" xlink:to="loc_us-gaap_EquityComponentDomain_c9385f94-645d-44ff-98be-d9c1e6df5db0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_1a22bf71-9e15-4561-b9e9-e9102296d32f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c9385f94-645d-44ff-98be-d9c1e6df5db0" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_1a22bf71-9e15-4561-b9e9-e9102296d32f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_b9df7803-02ed-408c-88e4-f591b2812e33" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c9385f94-645d-44ff-98be-d9c1e6df5db0" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_b9df7803-02ed-408c-88e4-f591b2812e33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_89a4866d-e74b-4b42-989c-183ba2237f13" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c9385f94-645d-44ff-98be-d9c1e6df5db0" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_89a4866d-e74b-4b42-989c-183ba2237f13" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_66eee872-3628-4a25-ab31-5350ec777944" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_c9385f94-645d-44ff-98be-d9c1e6df5db0" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_66eee872-3628-4a25-ab31-5350ec777944" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_faf3c22d-5922-4b7f-843e-c7bb0d6ecd1a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_d73d8dca-5233-489e-9930-c5a8d2af4007" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_faf3c22d-5922-4b7f-843e-c7bb0d6ecd1a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_076a2fbb-7358-4a07-968c-539b11af5df8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_faf3c22d-5922-4b7f-843e-c7bb0d6ecd1a" xlink:to="loc_us-gaap_StockholdersEquity_076a2fbb-7358-4a07-968c-539b11af5df8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_ca8187ef-b237-4e78-998f-a663faf975f3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_faf3c22d-5922-4b7f-843e-c7bb0d6ecd1a" xlink:to="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_ca8187ef-b237-4e78-998f-a663faf975f3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_a179033b-41c6-4c94-aea4-cc48b33e72eb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_faf3c22d-5922-4b7f-843e-c7bb0d6ecd1a" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_a179033b-41c6-4c94-aea4-cc48b33e72eb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_b94cff59-5c15-42a4-83a9-10ec3a57db24" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_faf3c22d-5922-4b7f-843e-c7bb0d6ecd1a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_b94cff59-5c15-42a4-83a9-10ec3a57db24" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f83506d2-06dd-437e-8ced-55a3756fdb87" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityReclassifiedFromAOCIDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#EquityReclassifiedFromAOCIDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EquityReclassifiedFromAOCIDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_2ecac9ca-fdb5-4fb4-b8e3-c0244f2826b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_e86ebae8-8fa0-479a-8e38-4a45577c3002" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_2ecac9ca-fdb5-4fb4-b8e3-c0244f2826b6" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_e86ebae8-8fa0-479a-8e38-4a45577c3002" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_dd4cc053-6f44-4641-8be0-fa1f8fb903fa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_e86ebae8-8fa0-479a-8e38-4a45577c3002" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_dd4cc053-6f44-4641-8be0-fa1f8fb903fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_dd4cc053-6f44-4641-8be0-fa1f8fb903fa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_dd4cc053-6f44-4641-8be0-fa1f8fb903fa" xlink:to="loc_us-gaap_EquityComponentDomain_dd4cc053-6f44-4641-8be0-fa1f8fb903fa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e39ef7c8-0361-42c2-bc85-6dad25df77fc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_dd4cc053-6f44-4641-8be0-fa1f8fb903fa" xlink:to="loc_us-gaap_EquityComponentDomain_e39ef7c8-0361-42c2-bc85-6dad25df77fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_207526a3-a16a-4fbc-986f-f8d81d61f2cf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_e39ef7c8-0361-42c2-bc85-6dad25df77fc" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_207526a3-a16a-4fbc-986f-f8d81d61f2cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_240945da-d7f7-45c1-952e-bc47f8336e2d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_e86ebae8-8fa0-479a-8e38-4a45577c3002" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_240945da-d7f7-45c1-952e-bc47f8336e2d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_240945da-d7f7-45c1-952e-bc47f8336e2d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_240945da-d7f7-45c1-952e-bc47f8336e2d" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_240945da-d7f7-45c1-952e-bc47f8336e2d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_7871ac58-6de7-4de4-b0ad-701a6ff6212b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_240945da-d7f7-45c1-952e-bc47f8336e2d" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_7871ac58-6de7-4de4-b0ad-701a6ff6212b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_87afd186-0fe3-443a-99ca-9afb65a24e92" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_7871ac58-6de7-4de4-b0ad-701a6ff6212b" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_87afd186-0fe3-443a-99ca-9afb65a24e92" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_a4765d0c-ccd7-40f6-bde5-6397651796ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_2ecac9ca-fdb5-4fb4-b8e3-c0244f2826b6" xlink:to="loc_us-gaap_Revenues_a4765d0c-ccd7-40f6-bde5-6397651796ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_96343375-c7f6-4f55-8c17-531341b6b8e3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_2ecac9ca-fdb5-4fb4-b8e3-c0244f2826b6" xlink:to="loc_us-gaap_OperatingExpenses_96343375-c7f6-4f55-8c17-531341b6b8e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_b29c0109-31c9-4812-ab81-ed3eeec3accc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_2ecac9ca-fdb5-4fb4-b8e3-c0244f2826b6" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_b29c0109-31c9-4812-ab81-ed3eeec3accc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_6c20f344-5b95-4276-a928-1a65165e881e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_2ecac9ca-fdb5-4fb4-b8e3-c0244f2826b6" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_6c20f344-5b95-4276-a928-1a65165e881e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_799e0d6f-3b88-49bc-acf2-d0c45dfe498f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_2ecac9ca-fdb5-4fb4-b8e3-c0244f2826b6" xlink:to="loc_us-gaap_NetIncomeLoss_799e0d6f-3b88-49bc-acf2-d0c45dfe498f" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsperShareDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#EarningsperShareDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/EarningsperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9a2e22a0-99f9-456e-9636-99a7524bc20b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5cfb5404-f808-4d64-af19-3855236e6a9a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9a2e22a0-99f9-456e-9636-99a7524bc20b" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5cfb5404-f808-4d64-af19-3855236e6a9a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4478065f-02c3-4922-bb78-59a32bd519d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5cfb5404-f808-4d64-af19-3855236e6a9a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4478065f-02c3-4922-bb78-59a32bd519d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4478065f-02c3-4922-bb78-59a32bd519d5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4478065f-02c3-4922-bb78-59a32bd519d5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_4478065f-02c3-4922-bb78-59a32bd519d5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9432660f-cc90-43c7-a1fa-92e89ebc59b8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4478065f-02c3-4922-bb78-59a32bd519d5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9432660f-cc90-43c7-a1fa-92e89ebc59b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_6bbbc5ed-7c44-49bd-8587-dd0b2eabf3fe" xlink:href="biib-20250930.xsd#biib_TimeVestedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9432660f-cc90-43c7-a1fa-92e89ebc59b8" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_6bbbc5ed-7c44-49bd-8587-dd0b2eabf3fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_3a82a7cf-47f7-4ce4-bf97-7bfbf20d5ec4" xlink:href="biib-20250930.xsd#biib_PerformanceStockUnitsSettledinStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9432660f-cc90-43c7-a1fa-92e89ebc59b8" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_3a82a7cf-47f7-4ce4-bf97-7bfbf20d5ec4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract_2d88358b-ee1e-4ce5-871b-e03d7c2b351e" xlink:href="biib-20250930.xsd#biib_BasicAndDilutedEarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9a2e22a0-99f9-456e-9636-99a7524bc20b" xlink:to="loc_biib_BasicAndDilutedEarningsPerShareAbstract_2d88358b-ee1e-4ce5-871b-e03d7c2b351e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_ee015258-8600-4ac8-9aa2-b06d32433281" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_2d88358b-ee1e-4ce5-871b-e03d7c2b351e" xlink:to="loc_us-gaap_NetIncomeLossAbstract_ee015258-8600-4ac8-9aa2-b06d32433281" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0868672d-f2e7-4bec-9701-450342032b9e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetIncomeLossAbstract_ee015258-8600-4ac8-9aa2-b06d32433281" xlink:to="loc_us-gaap_NetIncomeLoss_0868672d-f2e7-4bec-9701-450342032b9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_f31af191-6097-448b-bc1f-dc7354373cda" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_2d88358b-ee1e-4ce5-871b-e03d7c2b351e" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_f31af191-6097-448b-bc1f-dc7354373cda" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b1a07ae4-03f9-4255-86fc-ceef9a3627a3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_f31af191-6097-448b-bc1f-dc7354373cda" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b1a07ae4-03f9-4255-86fc-ceef9a3627a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_0127cec7-2725-46f9-aaef-3efed3dd09cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_f31af191-6097-448b-bc1f-dc7354373cda" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_0127cec7-2725-46f9-aaef-3efed3dd09cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_fc2a10b4-d60c-4197-a815-be337ac5f2a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_0127cec7-2725-46f9-aaef-3efed3dd09cb" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_fc2a10b4-d60c-4197-a815-be337ac5f2a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_8e0c1605-e5aa-46dd-8564-05b16ecdc489" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_0127cec7-2725-46f9-aaef-3efed3dd09cb" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_8e0c1605-e5aa-46dd-8564-05b16ecdc489" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7e518926-6aba-40bc-92f6-b9fe41a7c87b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_f31af191-6097-448b-bc1f-dc7354373cda" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7e518926-6aba-40bc-92f6-b9fe41a7c87b" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a74da35c-ef3d-4613-b5fe-7699a565c885" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_36290e60-3684-47d8-9d87-5c5f354d76b4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a74da35c-ef3d-4613-b5fe-7699a565c885" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_36290e60-3684-47d8-9d87-5c5f354d76b4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_031465e7-64bb-44e8-aff2-4e52c44c75a6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_36290e60-3684-47d8-9d87-5c5f354d76b4" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_031465e7-64bb-44e8-aff2-4e52c44c75a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_031465e7-64bb-44e8-aff2-4e52c44c75a6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_031465e7-64bb-44e8-aff2-4e52c44c75a6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_031465e7-64bb-44e8-aff2-4e52c44c75a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_25d8ae45-bdf4-4644-95b8-f9ea864872be" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_031465e7-64bb-44e8-aff2-4e52c44c75a6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_25d8ae45-bdf4-4644-95b8-f9ea864872be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7a235e3f-723e-439c-afc2-33b79191ebec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_25d8ae45-bdf4-4644-95b8-f9ea864872be" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7a235e3f-723e-439c-afc2-33b79191ebec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_848d2bd5-b416-4aec-8194-4b4ca9e868c3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_25d8ae45-bdf4-4644-95b8-f9ea864872be" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_848d2bd5-b416-4aec-8194-4b4ca9e868c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_68dbbe6c-afdf-45a3-865d-36d183088dab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_25d8ae45-bdf4-4644-95b8-f9ea864872be" xlink:to="loc_us-gaap_ParentMember_68dbbe6c-afdf-45a3-865d-36d183088dab" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_1198b903-8e3f-4f8c-9eb8-87f4aac2924d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a74da35c-ef3d-4613-b5fe-7699a565c885" xlink:to="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_1198b903-8e3f-4f8c-9eb8-87f4aac2924d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_a64fb206-3e30-4d81-9e8b-758dbb908f96" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_1198b903-8e3f-4f8c-9eb8-87f4aac2924d" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_a64fb206-3e30-4d81-9e8b-758dbb908f96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_13890d7b-9187-44d2-ae98-9c7984082741" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_1198b903-8e3f-4f8c-9eb8-87f4aac2924d" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_13890d7b-9187-44d2-ae98-9c7984082741" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_58a09bb9-57c5-461d-ab07-9c0e41e9c8e3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_1198b903-8e3f-4f8c-9eb8-87f4aac2924d" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_58a09bb9-57c5-461d-ab07-9c0e41e9c8e3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_7a82ac42-580f-4073-b608-77a12457219c" xlink:href="biib-20250930.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_1198b903-8e3f-4f8c-9eb8-87f4aac2924d" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_7a82ac42-580f-4073-b608-77a12457219c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_6719bd4f-a099-41fc-90e1-fd11390bec62" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_1198b903-8e3f-4f8c-9eb8-87f4aac2924d" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_6719bd4f-a099-41fc-90e1-fd11390bec62" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SharebasedPaymentsNarrativeDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#SharebasedPaymentsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SharebasedPaymentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_baa190eb-b213-42c7-89b1-1803afa2c12b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e28a60dc-8638-4204-8df6-898a3f72931f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_baa190eb-b213-42c7-89b1-1803afa2c12b" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e28a60dc-8638-4204-8df6-898a3f72931f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_79b37483-2fe6-4591-a3e8-a0fbd70c68e5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e28a60dc-8638-4204-8df6-898a3f72931f" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_79b37483-2fe6-4591-a3e8-a0fbd70c68e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_79b37483-2fe6-4591-a3e8-a0fbd70c68e5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_79b37483-2fe6-4591-a3e8-a0fbd70c68e5" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_79b37483-2fe6-4591-a3e8-a0fbd70c68e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c54d7100-055b-4ae0-99a7-67185e7810c9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_79b37483-2fe6-4591-a3e8-a0fbd70c68e5" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c54d7100-055b-4ae0-99a7-67185e7810c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_HumanImmunologyBiosciencesMember_a5c9cbdd-288a-46d3-9ef4-b072fb504ab0" xlink:href="biib-20250930.xsd#biib_HumanImmunologyBiosciencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c54d7100-055b-4ae0-99a7-67185e7810c9" xlink:to="loc_biib_HumanImmunologyBiosciencesMember_a5c9cbdd-288a-46d3-9ef4-b072fb504ab0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_fc3923de-7780-4350-b1a9-e6c54bd88279" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e28a60dc-8638-4204-8df6-898a3f72931f" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_fc3923de-7780-4350-b1a9-e6c54bd88279" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_fc3923de-7780-4350-b1a9-e6c54bd88279_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_fc3923de-7780-4350-b1a9-e6c54bd88279" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_fc3923de-7780-4350-b1a9-e6c54bd88279_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_42b4af5b-79de-4b0b-a497-424b47958d62" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_fc3923de-7780-4350-b1a9-e6c54bd88279" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_42b4af5b-79de-4b0b-a497-424b47958d62" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c24a4967-08c4-4fda-9978-0f2289515663" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_42b4af5b-79de-4b0b-a497-424b47958d62" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c24a4967-08c4-4fda-9978-0f2289515663" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_3e9a0549-5fa5-4cdc-9165-64071bad0e22" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_42b4af5b-79de-4b0b-a497-424b47958d62" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_3e9a0549-5fa5-4cdc-9165-64071bad0e22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_b8aadb9c-5f35-4397-80a1-9f3410cd2f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e28a60dc-8638-4204-8df6-898a3f72931f" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_b8aadb9c-5f35-4397-80a1-9f3410cd2f5c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_b8aadb9c-5f35-4397-80a1-9f3410cd2f5c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_b8aadb9c-5f35-4397-80a1-9f3410cd2f5c" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_b8aadb9c-5f35-4397-80a1-9f3410cd2f5c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_4688784f-6661-48ee-b8f6-de454bc040cd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_b8aadb9c-5f35-4397-80a1-9f3410cd2f5c" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_4688784f-6661-48ee-b8f6-de454bc040cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_94aaf298-3fe7-4a6a-bb1e-286b8365b928" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_baa190eb-b213-42c7-89b1-1803afa2c12b" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_94aaf298-3fe7-4a6a-bb1e-286b8365b928" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e0f85b38-4e72-4472-9f4f-68debec334e1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9de6c384-3645-4806-ae8b-9190694408a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e0f85b38-4e72-4472-9f4f-68debec334e1" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9de6c384-3645-4806-ae8b-9190694408a0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_72d34b21-d3fa-458a-98f0-9ff26388efab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9de6c384-3645-4806-ae8b-9190694408a0" xlink:to="loc_us-gaap_AwardTypeAxis_72d34b21-d3fa-458a-98f0-9ff26388efab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_72d34b21-d3fa-458a-98f0-9ff26388efab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_72d34b21-d3fa-458a-98f0-9ff26388efab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_72d34b21-d3fa-458a-98f0-9ff26388efab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a2464a3a-7a57-4f01-a665-dfaafd5a491d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_72d34b21-d3fa-458a-98f0-9ff26388efab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a2464a3a-7a57-4f01-a665-dfaafd5a491d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_44d7d03d-922c-433c-b6e6-c1f5508fd91b" xlink:href="biib-20250930.xsd#biib_TimeVestedRestrictedStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a2464a3a-7a57-4f01-a665-dfaafd5a491d" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_44d7d03d-922c-433c-b6e6-c1f5508fd91b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_4f892344-7529-4a9e-94c1-805abf137589" xlink:href="biib-20250930.xsd#biib_PerformanceStockUnitsSettledinStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a2464a3a-7a57-4f01-a665-dfaafd5a491d" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_4f892344-7529-4a9e-94c1-805abf137589" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EmployeeStockPurchasePlanMember_0778e956-c46e-4b0c-9c1b-f97c81ed1541" xlink:href="biib-20250930.xsd#biib_EmployeeStockPurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a2464a3a-7a57-4f01-a665-dfaafd5a491d" xlink:to="loc_biib_EmployeeStockPurchasePlanMember_0778e956-c46e-4b0c-9c1b-f97c81ed1541" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember_5703b15d-192d-4695-91c7-7263dd6499a8" xlink:href="biib-20250930.xsd#biib_PerformanceStockUnitsSettledinCashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a2464a3a-7a57-4f01-a665-dfaafd5a491d" xlink:to="loc_biib_PerformanceStockUnitsSettledinCashMember_5703b15d-192d-4695-91c7-7263dd6499a8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ff673677-8e61-4175-a4e3-745cba5c2bfb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a2464a3a-7a57-4f01-a665-dfaafd5a491d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ff673677-8e61-4175-a4e3-745cba5c2bfb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MarketStockUnitsMember_34e88326-0fd6-4044-8833-feb978104389" xlink:href="biib-20250930.xsd#biib_MarketStockUnitsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a2464a3a-7a57-4f01-a665-dfaafd5a491d" xlink:to="loc_biib_MarketStockUnitsMember_34e88326-0fd6-4044-8833-feb978104389" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b6d88784-542c-49e8-bf3f-bb3e57812d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9de6c384-3645-4806-ae8b-9190694408a0" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b6d88784-542c-49e8-bf3f-bb3e57812d9b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b6d88784-542c-49e8-bf3f-bb3e57812d9b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b6d88784-542c-49e8-bf3f-bb3e57812d9b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_b6d88784-542c-49e8-bf3f-bb3e57812d9b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8f917de4-7bdb-4f0f-bb92-616cac9e3a50" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b6d88784-542c-49e8-bf3f-bb3e57812d9b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8f917de4-7bdb-4f0f-bb92-616cac9e3a50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_HumanImmunologyBiosciencesMember_78980fa2-470c-4d48-b722-d75eb0b43c06" xlink:href="biib-20250930.xsd#biib_HumanImmunologyBiosciencesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8f917de4-7bdb-4f0f-bb92-616cac9e3a50" xlink:to="loc_biib_HumanImmunologyBiosciencesMember_78980fa2-470c-4d48-b722-d75eb0b43c06" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_d80b5c62-4037-41ba-96e9-de6db8a08267" xlink:href="biib-20250930.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e0f85b38-4e72-4472-9f4f-68debec334e1" xlink:to="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_d80b5c62-4037-41ba-96e9-de6db8a08267" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_f9191ad4-b94a-4682-bc1e-62a660a841c2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_d80b5c62-4037-41ba-96e9-de6db8a08267" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_f9191ad4-b94a-4682-bc1e-62a660a841c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_ed232291-6303-4059-a92a-0894246e493b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_d80b5c62-4037-41ba-96e9-de6db8a08267" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_ed232291-6303-4059-a92a-0894246e493b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_0c02a140-d178-4a47-860f-acaf9841878c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_d80b5c62-4037-41ba-96e9-de6db8a08267" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_0c02a140-d178-4a47-860f-acaf9841878c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_21803203-c484-4283-89fc-0d294a6c11eb" xlink:href="biib-20250930.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_d80b5c62-4037-41ba-96e9-de6db8a08267" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_21803203-c484-4283-89fc-0d294a6c11eb" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementNarrativeDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#OtherConsolidatedFinancialStatementNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5fa8c30b-592c-4803-b33c-26585779a644" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_52b998da-c8c1-499e-894d-f7d31db37d38" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5fa8c30b-592c-4803-b33c-26585779a644" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_52b998da-c8c1-499e-894d-f7d31db37d38" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_e66e6ffa-036e-4650-970d-f9cf98ac2052" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_52b998da-c8c1-499e-894d-f7d31db37d38" xlink:to="loc_dei_LegalEntityAxis_e66e6ffa-036e-4650-970d-f9cf98ac2052" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_e66e6ffa-036e-4650-970d-f9cf98ac2052_default" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_e66e6ffa-036e-4650-970d-f9cf98ac2052" xlink:to="loc_dei_EntityDomain_e66e6ffa-036e-4650-970d-f9cf98ac2052_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_4ebd73b0-24da-4ee0-be86-89fb308eec38" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_e66e6ffa-036e-4650-970d-f9cf98ac2052" xlink:to="loc_dei_EntityDomain_4ebd73b0-24da-4ee0-be86-89fb308eec38" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SageAndDenaliMember_519778ce-7967-4701-8aa7-a62750ad3ebb" xlink:href="biib-20250930.xsd#biib_SageAndDenaliMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_4ebd73b0-24da-4ee0-be86-89fb308eec38" xlink:to="loc_biib_SageAndDenaliMember_519778ce-7967-4701-8aa7-a62750ad3ebb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SageAndSangamoMember_9ef14b35-295d-4070-a5f2-05a1e8c8d07d" xlink:href="biib-20250930.xsd#biib_SageAndSangamoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_4ebd73b0-24da-4ee0-be86-89fb308eec38" xlink:to="loc_biib_SageAndSangamoMember_9ef14b35-295d-4070-a5f2-05a1e8c8d07d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_85291a5f-e530-441d-b6ea-cead60ff4e13" xlink:href="biib-20250930.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_4ebd73b0-24da-4ee0-be86-89fb308eec38" xlink:to="loc_biib_DenaliTherapeuticsIncMember_85291a5f-e530-441d-b6ea-cead60ff4e13" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SageTherapeuticsIncMember_275ffc31-f24f-4e0a-9db7-d7c8e81b5487" xlink:href="biib-20250930.xsd#biib_SageTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_4ebd73b0-24da-4ee0-be86-89fb308eec38" xlink:to="loc_biib_SageTherapeuticsIncMember_275ffc31-f24f-4e0a-9db7-d7c8e81b5487" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_d0b46e4c-edb6-43c0-82ca-c07deb3a1e7f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5fa8c30b-592c-4803-b33c-26585779a644" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_d0b46e4c-edb6-43c0-82ca-c07deb3a1e7f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_116d36e4-0dfa-4832-9959-d383c8228769" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5fa8c30b-592c-4803-b33c-26585779a644" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_116d36e4-0dfa-4832-9959-d383c8228769" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_cc2ba6fc-484e-432e-8df5-62e88e3cdda8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5fa8c30b-592c-4803-b33c-26585779a644" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_cc2ba6fc-484e-432e-8df5-62e88e3cdda8" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailAccruedExpenseandOtherDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#OtherConsolidatedFinancialStatementDetailAccruedExpenseandOtherDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailAccruedExpenseandOtherDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_76caf9ac-8348-412e-9190-522eba732d24" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_28afc469-5d54-43d5-bfbe-4fa83f1057a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_76caf9ac-8348-412e-9190-522eba732d24" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_28afc469-5d54-43d5-bfbe-4fa83f1057a5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_14e32f3e-419c-4f40-9a27-b7fc7d106ab9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_28afc469-5d54-43d5-bfbe-4fa83f1057a5" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_14e32f3e-419c-4f40-9a27-b7fc7d106ab9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_14e32f3e-419c-4f40-9a27-b7fc7d106ab9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_14e32f3e-419c-4f40-9a27-b7fc7d106ab9" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_14e32f3e-419c-4f40-9a27-b7fc7d106ab9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_bb32572b-32c5-46d1-b040-2ac2b7dfd269" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_14e32f3e-419c-4f40-9a27-b7fc7d106ab9" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_bb32572b-32c5-46d1-b040-2ac2b7dfd269" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_f2f3d9e7-0c93-4fd0-b008-ff886f628063" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_bb32572b-32c5-46d1-b040-2ac2b7dfd269" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_f2f3d9e7-0c93-4fd0-b008-ff886f628063" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_ccac2acd-ccf9-4103-aea0-520ccba2f46d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_76caf9ac-8348-412e-9190-522eba732d24" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_ccac2acd-ccf9-4103-aea0-520ccba2f46d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_5249cb8a-e38e-4b35-9569-a2e81efdd827" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_76caf9ac-8348-412e-9190-522eba732d24" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_5249cb8a-e38e-4b35-9569-a2e81efdd827" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationexpensesaccrual_d4dcb4fc-efce-4278-9443-a1515a429aa2" xlink:href="biib-20250930.xsd#biib_Collaborationexpensesaccrual"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_76caf9ac-8348-412e-9190-522eba732d24" xlink:to="loc_biib_Collaborationexpensesaccrual_d4dcb4fc-efce-4278-9443-a1515a429aa2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_1c95a46c-9376-4c72-898b-3094691c188c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_76caf9ac-8348-412e-9190-522eba732d24" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_1c95a46c-9376-4c72-898b-3094691c188c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_7307f09c-9c00-4840-b77c-cd7ba6827199" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_76caf9ac-8348-412e-9190-522eba732d24" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_7307f09c-9c00-4840-b77c-cd7ba6827199" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_9d7cab6a-054b-4ea1-8639-25a0a4f4d4f1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConstructionPayableCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_76caf9ac-8348-412e-9190-522eba732d24" xlink:to="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_9d7cab6a-054b-4ea1-8639-25a0a4f4d4f1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_c65bc367-273a-4207-8dfa-a92869d1478c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_76caf9ac-8348-412e-9190-522eba732d24" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_c65bc367-273a-4207-8dfa-a92869d1478c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_ddedc5b9-85d3-423c-a12a-ecdfa090b82a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_76caf9ac-8348-412e-9190-522eba732d24" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_ddedc5b9-85d3-423c-a12a-ecdfa090b82a" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#CollaborativeandOtherRelationshipsOCREVUSDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3f9b2dd5-8436-4326-878f-1d1461022807" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2c3b6b28-7b1a-4adb-ac49-7fa24ad51f22" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3f9b2dd5-8436-4326-878f-1d1461022807" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2c3b6b28-7b1a-4adb-ac49-7fa24ad51f22" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0e7a2ded-3314-4be4-8d35-7f5ac3419ab3" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2c3b6b28-7b1a-4adb-ac49-7fa24ad51f22" xlink:to="loc_srt_ProductOrServiceAxis_0e7a2ded-3314-4be4-8d35-7f5ac3419ab3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0e7a2ded-3314-4be4-8d35-7f5ac3419ab3_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_0e7a2ded-3314-4be4-8d35-7f5ac3419ab3" xlink:to="loc_srt_ProductsAndServicesDomain_0e7a2ded-3314-4be4-8d35-7f5ac3419ab3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_37031531-304f-4fe9-872c-4f5a3b8001c7" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_0e7a2ded-3314-4be4-8d35-7f5ac3419ab3" xlink:to="loc_srt_ProductsAndServicesDomain_37031531-304f-4fe9-872c-4f5a3b8001c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OCREVUSMember_3cbca0dc-1b74-421f-b4eb-c7a961211af4" xlink:href="biib-20250930.xsd#biib_OCREVUSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_37031531-304f-4fe9-872c-4f5a3b8001c7" xlink:to="loc_biib_OCREVUSMember_3cbca0dc-1b74-421f-b4eb-c7a961211af4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_81a2933e-a896-4af1-bd81-ffdce8795b9f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2c3b6b28-7b1a-4adb-ac49-7fa24ad51f22" xlink:to="loc_srt_RangeAxis_81a2933e-a896-4af1-bd81-ffdce8795b9f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_81a2933e-a896-4af1-bd81-ffdce8795b9f_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_81a2933e-a896-4af1-bd81-ffdce8795b9f" xlink:to="loc_srt_RangeMember_81a2933e-a896-4af1-bd81-ffdce8795b9f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d36222c0-84b8-4276-ab2e-ea9fc3203cb4" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_81a2933e-a896-4af1-bd81-ffdce8795b9f" xlink:to="loc_srt_RangeMember_d36222c0-84b8-4276-ab2e-ea9fc3203cb4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4751fd3f-75af-4035-a132-acf258818348" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d36222c0-84b8-4276-ab2e-ea9fc3203cb4" xlink:to="loc_srt_MinimumMember_4751fd3f-75af-4035-a132-acf258818348" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a5ca6a95-4405-4040-9585-3bf7eb225952" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d36222c0-84b8-4276-ab2e-ea9fc3203cb4" xlink:to="loc_srt_MaximumMember_a5ca6a95-4405-4040-9585-3bf7eb225952" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_48bf5883-8410-47be-8693-d1079b47c13d" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2c3b6b28-7b1a-4adb-ac49-7fa24ad51f22" xlink:to="loc_srt_StatementGeographicalAxis_48bf5883-8410-47be-8693-d1079b47c13d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_48bf5883-8410-47be-8693-d1079b47c13d_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_48bf5883-8410-47be-8693-d1079b47c13d" xlink:to="loc_srt_SegmentGeographicalDomain_48bf5883-8410-47be-8693-d1079b47c13d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_326f61b6-df79-41f9-8006-f92e819690f6" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_48bf5883-8410-47be-8693-d1079b47c13d" xlink:to="loc_srt_SegmentGeographicalDomain_326f61b6-df79-41f9-8006-f92e819690f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_e20e271f-a049-479d-b683-7a8cb6e05ba4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_326f61b6-df79-41f9-8006-f92e819690f6" xlink:to="loc_us-gaap_ForeignCountryMember_e20e271f-a049-479d-b683-7a8cb6e05ba4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_6e3b3434-b2ed-41fe-ae5b-9f8d6e858e87" xlink:href="biib-20250930.xsd#biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3f9b2dd5-8436-4326-878f-1d1461022807" xlink:to="loc_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_6e3b3434-b2ed-41fe-ae5b-9f8d6e858e87" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage_670711fb-cbf4-4604-a67a-7862af54ba1e" xlink:href="biib-20250930.xsd#biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3f9b2dd5-8436-4326-878f-1d1461022807" xlink:to="loc_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage_670711fb-cbf4-4604-a67a-7862af54ba1e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Reductioninroyaltyrate_520518f5-157c-4e87-99d0-4f66ea457a10" xlink:href="biib-20250930.xsd#biib_Reductioninroyaltyrate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3f9b2dd5-8436-4326-878f-1d1461022807" xlink:to="loc_biib_Reductioninroyaltyrate_520518f5-157c-4e87-99d0-4f66ea457a10" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PeriodOfCollaborationAgreement_d23f4365-fe6d-40c5-99bd-356b38e1284f" xlink:href="biib-20250930.xsd#biib_PeriodOfCollaborationAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3f9b2dd5-8436-4326-878f-1d1461022807" xlink:to="loc_biib_PeriodOfCollaborationAgreement_d23f4365-fe6d-40c5-99bd-356b38e1284f" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCopromotionProfitSharingFormulaDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#CollaborativeandOtherRelationshipsCopromotionProfitSharingFormulaDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCopromotionProfitSharingFormulaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_faaa16e0-2af2-4587-aaad-f8e33de2b7c2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ef407031-a288-4865-9ef4-a229ab3c8cb3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_faaa16e0-2af2-4587-aaad-f8e33de2b7c2" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ef407031-a288-4865-9ef4-a229ab3c8cb3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_44ad9d69-6e94-456c-bd98-92c5744133b5" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ef407031-a288-4865-9ef4-a229ab3c8cb3" xlink:to="loc_srt_ProductOrServiceAxis_44ad9d69-6e94-456c-bd98-92c5744133b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_44ad9d69-6e94-456c-bd98-92c5744133b5_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_44ad9d69-6e94-456c-bd98-92c5744133b5" xlink:to="loc_srt_ProductsAndServicesDomain_44ad9d69-6e94-456c-bd98-92c5744133b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8984da6d-64e2-4449-b42e-bfac46fd3a30" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_44ad9d69-6e94-456c-bd98-92c5744133b5" xlink:to="loc_srt_ProductsAndServicesDomain_8984da6d-64e2-4449-b42e-bfac46fd3a30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RituxanMember_aa1a7f7d-6b07-4699-a725-c7af6a13b045" xlink:href="biib-20250930.xsd#biib_RituxanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8984da6d-64e2-4449-b42e-bfac46fd3a30" xlink:to="loc_biib_RituxanMember_aa1a7f7d-6b07-4699-a725-c7af6a13b045" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LUNSUMIOMember_2c80d1a7-0c9c-472f-bad5-81fa21ae36f8" xlink:href="biib-20250930.xsd#biib_LUNSUMIOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8984da6d-64e2-4449-b42e-bfac46fd3a30" xlink:to="loc_biib_LUNSUMIOMember_2c80d1a7-0c9c-472f-bad5-81fa21ae36f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_56007c6c-5690-4402-bce6-ab487b3beebb" xlink:href="biib-20250930.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_faaa16e0-2af2-4587-aaad-f8e33de2b7c2" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_56007c6c-5690-4402-bce6-ab487b3beebb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_aa6ccd7d-a4f5-4337-9e8e-1b80c3bbfaa8" xlink:href="biib-20250930.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_faaa16e0-2af2-4587-aaad-f8e33de2b7c2" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_aa6ccd7d-a4f5-4337-9e8e-1b80c3bbfaa8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour_5a7b38ad-f53d-4f73-acb1-3e9ee9594f73" xlink:href="biib-20250930.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_faaa16e0-2af2-4587-aaad-f8e33de2b7c2" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour_5a7b38ad-f53d-4f73-acb1-3e9ee9594f73" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_fd2c68bd-59dd-4228-bfff-d3e1a9dda03b" xlink:href="biib-20250930.xsd#biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_faaa16e0-2af2-4587-aaad-f8e33de2b7c2" xlink:to="loc_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_fd2c68bd-59dd-4228-bfff-d3e1a9dda03b" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#CollaborativeandOtherRelationshipsProfitSharingDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c14bc148-a6e7-4ed4-a15c-ec7fcec82a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_237b5a5f-3a89-4c34-8aab-845faffeb8e2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c14bc148-a6e7-4ed4-a15c-ec7fcec82a1e" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_237b5a5f-3a89-4c34-8aab-845faffeb8e2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_339ba0f3-a508-440c-bbdf-1b5ed6350c25" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_237b5a5f-3a89-4c34-8aab-845faffeb8e2" xlink:to="loc_srt_ProductOrServiceAxis_339ba0f3-a508-440c-bbdf-1b5ed6350c25" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_339ba0f3-a508-440c-bbdf-1b5ed6350c25_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_339ba0f3-a508-440c-bbdf-1b5ed6350c25" xlink:to="loc_srt_ProductsAndServicesDomain_339ba0f3-a508-440c-bbdf-1b5ed6350c25_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ff83705b-d82f-4747-9e15-9006f8415efa" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_339ba0f3-a508-440c-bbdf-1b5ed6350c25" xlink:to="loc_srt_ProductsAndServicesDomain_ff83705b-d82f-4747-9e15-9006f8415efa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RituxanMember_198e9108-beb0-4eb4-90a7-719b9fc433b1" xlink:href="biib-20250930.xsd#biib_RituxanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ff83705b-d82f-4747-9e15-9006f8415efa" xlink:to="loc_biib_RituxanMember_198e9108-beb0-4eb4-90a7-719b9fc433b1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LUNSUMIOMember_2cd8fbaa-1b3c-47c0-a449-fa969c78ff10" xlink:href="biib-20250930.xsd#biib_LUNSUMIOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ff83705b-d82f-4747-9e15-9006f8415efa" xlink:to="loc_biib_LUNSUMIOMember_2cd8fbaa-1b3c-47c0-a449-fa969c78ff10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GAZYVAMember_ad2dbc6b-6864-48bd-bcc0-06bb63a49334" xlink:href="biib-20250930.xsd#biib_GAZYVAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ff83705b-d82f-4747-9e15-9006f8415efa" xlink:to="loc_biib_GAZYVAMember_ad2dbc6b-6864-48bd-bcc0-06bb63a49334" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_a5c071c2-ef99-48a0-93a2-603592e237c2" xlink:href="biib-20250930.xsd#biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c14bc148-a6e7-4ed4-a15c-ec7fcec82a1e" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_a5c071c2-ef99-48a0-93a2-603592e237c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_02f1252a-d313-4eb4-99f8-a062c50a315b" xlink:href="biib-20250930.xsd#biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c14bc148-a6e7-4ed4-a15c-ec7fcec82a1e" xlink:to="loc_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_02f1252a-d313-4eb4-99f8-a062c50a315b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_aefc8bbb-e308-4b3d-a12c-4fc95c03bd3c" xlink:href="biib-20250930.xsd#biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c14bc148-a6e7-4ed4-a15c-ec7fcec82a1e" xlink:to="loc_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_aefc8bbb-e308-4b3d-a12c-4fc95c03bd3c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SalesTriggerGrossSalesThreshold_d6cc1316-4994-4501-8126-f4bba5305b12" xlink:href="biib-20250930.xsd#biib_SalesTriggerGrossSalesThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c14bc148-a6e7-4ed4-a15c-ec7fcec82a1e" xlink:to="loc_biib_SalesTriggerGrossSalesThreshold_d6cc1316-4994-4501-8126-f4bba5305b12" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_01be8b4f-55cd-40fc-98a6-169905dfd1a8" xlink:href="biib-20250930.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c14bc148-a6e7-4ed4-a15c-ec7fcec82a1e" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_01be8b4f-55cd-40fc-98a6-169905dfd1a8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_1154cc6f-d144-47b7-8dfc-7b00d641f0f0" xlink:href="biib-20250930.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c14bc148-a6e7-4ed4-a15c-ec7fcec82a1e" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_1154cc6f-d144-47b7-8dfc-7b00d641f0f0" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsPretaxProfitSharingFormulaDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#CollaborativeandOtherRelationshipsPretaxProfitSharingFormulaDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsPretaxProfitSharingFormulaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ec1bc6a3-47ca-4017-b613-9a1fe4664e65" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3ff4dc1d-9704-4a36-ba53-3827706f84cf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ec1bc6a3-47ca-4017-b613-9a1fe4664e65" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3ff4dc1d-9704-4a36-ba53-3827706f84cf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_1c415d3e-e316-4987-bb88-79daf24470b7" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3ff4dc1d-9704-4a36-ba53-3827706f84cf" xlink:to="loc_srt_ProductOrServiceAxis_1c415d3e-e316-4987-bb88-79daf24470b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1c415d3e-e316-4987-bb88-79daf24470b7_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_1c415d3e-e316-4987-bb88-79daf24470b7" xlink:to="loc_srt_ProductsAndServicesDomain_1c415d3e-e316-4987-bb88-79daf24470b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6f9cb677-603f-4044-9ccc-2632ea4d001e" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_1c415d3e-e316-4987-bb88-79daf24470b7" xlink:to="loc_srt_ProductsAndServicesDomain_6f9cb677-603f-4044-9ccc-2632ea4d001e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GAZYVAMember_53b52fef-1b0b-4329-b9e1-271111e9dae8" xlink:href="biib-20250930.xsd#biib_GAZYVAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6f9cb677-603f-4044-9ccc-2632ea4d001e" xlink:to="loc_biib_GAZYVAMember_53b52fef-1b0b-4329-b9e1-271111e9dae8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LUNSUMIOMember_c0ddf446-841b-4de4-9c9f-ea8e0bf21fd2" xlink:href="biib-20250930.xsd#biib_LUNSUMIOMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6f9cb677-603f-4044-9ccc-2632ea4d001e" xlink:to="loc_biib_LUNSUMIOMember_c0ddf446-841b-4de4-9c9f-ea8e0bf21fd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_7e614b95-f605-47c7-8455-704ad4f3381e" xlink:href="biib-20250930.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ec1bc6a3-47ca-4017-b613-9a1fe4664e65" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_7e614b95-f605-47c7-8455-704ad4f3381e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_eff7458d-84e2-4015-8346-6c65c7dbe691" xlink:href="biib-20250930.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ec1bc6a3-47ca-4017-b613-9a1fe4664e65" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_eff7458d-84e2-4015-8346-6c65c7dbe691" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_6edf0984-3ca6-4ffd-aeac-8ca8f3ffbdc5" xlink:href="biib-20250930.xsd#biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ec1bc6a3-47ca-4017-b613-9a1fe4664e65" xlink:to="loc_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_6edf0984-3ca6-4ffd-aeac-8ca8f3ffbdc5" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsIonisPharmaceuticalsIncDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#CollaborativeandOtherRelationshipsIonisPharmaceuticalsIncDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsIonisPharmaceuticalsIncDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5cec73c9-515d-424b-b41a-dd037c99b294" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_62d80242-0c8e-4521-90b8-70d7be1ac98c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5cec73c9-515d-424b-b41a-dd037c99b294" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_62d80242-0c8e-4521-90b8-70d7be1ac98c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_c0d0fb5f-e21c-41d7-93d2-f44fb0fbb536" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_62d80242-0c8e-4521-90b8-70d7be1ac98c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_c0d0fb5f-e21c-41d7-93d2-f44fb0fbb536" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c0d0fb5f-e21c-41d7-93d2-f44fb0fbb536_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c0d0fb5f-e21c-41d7-93d2-f44fb0fbb536" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c0d0fb5f-e21c-41d7-93d2-f44fb0fbb536_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b7e9f2f0-c4e4-490c-a6c2-5467bb47e6c3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c0d0fb5f-e21c-41d7-93d2-f44fb0fbb536" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b7e9f2f0-c4e4-490c-a6c2-5467bb47e6c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IonisPharmaceuticalsInc.Member_b0c592c5-4998-4390-a80a-709c0f210a6f" xlink:href="biib-20250930.xsd#biib_IonisPharmaceuticalsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b7e9f2f0-c4e4-490c-a6c2-5467bb47e6c3" xlink:to="loc_biib_IonisPharmaceuticalsInc.Member_b0c592c5-4998-4390-a80a-709c0f210a6f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_e25593ae-569f-40f7-98c1-8bcee283b095" xlink:href="biib-20250930.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5cec73c9-515d-424b-b41a-dd037c99b294" xlink:to="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_e25593ae-569f-40f7-98c1-8bcee283b095" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponInitiationOfNewPhases_c012454d-279b-4bd7-b924-4302f8ed09d6" xlink:href="biib-20250930.xsd#biib_EstimatedAdditionalPaymentsUponInitiationOfNewPhases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5cec73c9-515d-424b-b41a-dd037c99b294" xlink:to="loc_biib_EstimatedAdditionalPaymentsUponInitiationOfNewPhases_c012454d-279b-4bd7-b924-4302f8ed09d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_1384fa73-28af-4582-b963-4bb6a8c54706" xlink:href="biib-20250930.xsd#biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5cec73c9-515d-424b-b41a-dd037c99b294" xlink:to="loc_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_1384fa73-28af-4582-b963-4bb6a8c54706" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#CollaborativeandOtherRelationshipsEisaiDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f84fdd27-ac64-473d-915f-960a9925a596" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9ecf05d0-e97f-411f-84b6-fb358f8c7c71" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f84fdd27-ac64-473d-915f-960a9925a596" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9ecf05d0-e97f-411f-84b6-fb358f8c7c71" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_54e0b6be-cf94-433a-89c6-a793e333276a" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9ecf05d0-e97f-411f-84b6-fb358f8c7c71" xlink:to="loc_srt_ProductOrServiceAxis_54e0b6be-cf94-433a-89c6-a793e333276a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_54e0b6be-cf94-433a-89c6-a793e333276a_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_54e0b6be-cf94-433a-89c6-a793e333276a" xlink:to="loc_srt_ProductsAndServicesDomain_54e0b6be-cf94-433a-89c6-a793e333276a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2ed12cb9-50a3-4610-8053-0dd746e33af5" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_54e0b6be-cf94-433a-89c6-a793e333276a" xlink:to="loc_srt_ProductsAndServicesDomain_2ed12cb9-50a3-4610-8053-0dd746e33af5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LEQEMBICollaborationMember_bf88d076-c58a-4c28-a9b9-d8c156e850f4" xlink:href="biib-20250930.xsd#biib_LEQEMBICollaborationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_2ed12cb9-50a3-4610-8053-0dd746e33af5" xlink:to="loc_biib_LEQEMBICollaborationMember_bf88d076-c58a-4c28-a9b9-d8c156e850f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_e3cbdd8b-4da1-4d1d-ba41-1c34f45d2c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9ecf05d0-e97f-411f-84b6-fb358f8c7c71" xlink:to="loc_us-gaap_TypeOfArrangementAxis_e3cbdd8b-4da1-4d1d-ba41-1c34f45d2c1f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e3cbdd8b-4da1-4d1d-ba41-1c34f45d2c1f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e3cbdd8b-4da1-4d1d-ba41-1c34f45d2c1f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_e3cbdd8b-4da1-4d1d-ba41-1c34f45d2c1f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ce0d163a-cc09-426c-883e-a728981e8c52" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e3cbdd8b-4da1-4d1d-ba41-1c34f45d2c1f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ce0d163a-cc09-426c-883e-a728981e8c52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_ea078ca7-fe2b-453d-af57-c46d956f23f2" xlink:href="biib-20250930.xsd#biib_EisaiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ce0d163a-cc09-426c-883e-a728981e8c52" xlink:to="loc_biib_EisaiMember_ea078ca7-fe2b-453d-af57-c46d956f23f2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfNonControlingInterestRecognized_6b0728ca-2c01-4a16-9958-47bff4041bab" xlink:href="biib-20250930.xsd#biib_ShareOfNonControlingInterestRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f84fdd27-ac64-473d-915f-960a9925a596" xlink:to="loc_biib_ShareOfNonControlingInterestRecognized_6b0728ca-2c01-4a16-9958-47bff4041bab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AccountsReceivableFromCollaborator_aa2bb41f-66e5-45d8-845b-cb9f4c502a7b" xlink:href="biib-20250930.xsd#biib_AccountsReceivableFromCollaborator"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f84fdd27-ac64-473d-915f-960a9925a596" xlink:to="loc_biib_AccountsReceivableFromCollaborator_aa2bb41f-66e5-45d8-845b-cb9f4c502a7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AccountsPayableToCollaborator_a28f3ed3-1fa1-488a-ab8b-2e4e562b85a3" xlink:href="biib-20250930.xsd#biib_AccountsPayableToCollaborator"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f84fdd27-ac64-473d-915f-960a9925a596" xlink:to="loc_biib_AccountsPayableToCollaborator_a28f3ed3-1fa1-488a-ab8b-2e4e562b85a3" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoLEQEMBICollaborationDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoLEQEMBICollaborationDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoLEQEMBICollaborationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4615b3f5-fdb1-4558-98c0-fc18c16c9f59" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4e8e37c0-cc66-472b-830e-250be5a1d306" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4615b3f5-fdb1-4558-98c0-fc18c16c9f59" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4e8e37c0-cc66-472b-830e-250be5a1d306" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_82d36eac-f9db-4aea-98b2-79e928cbb038" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4e8e37c0-cc66-472b-830e-250be5a1d306" xlink:to="loc_srt_ProductOrServiceAxis_82d36eac-f9db-4aea-98b2-79e928cbb038" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_82d36eac-f9db-4aea-98b2-79e928cbb038_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_82d36eac-f9db-4aea-98b2-79e928cbb038" xlink:to="loc_srt_ProductsAndServicesDomain_82d36eac-f9db-4aea-98b2-79e928cbb038_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_541c5cdf-e99b-481b-8d25-c6cb487512da" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_82d36eac-f9db-4aea-98b2-79e928cbb038" xlink:to="loc_srt_ProductsAndServicesDomain_541c5cdf-e99b-481b-8d25-c6cb487512da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LEQEMBIMember_c30188cc-4082-4753-9561-97d85cac7d3a" xlink:href="biib-20250930.xsd#biib_LEQEMBIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_541c5cdf-e99b-481b-8d25-c6cb487512da" xlink:to="loc_biib_LEQEMBIMember_c30188cc-4082-4753-9561-97d85cac7d3a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_E2609andBAN2401Member_72df79a8-ebe2-4571-bbd4-0faadd2313a3" xlink:href="biib-20250930.xsd#biib_E2609andBAN2401Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_541c5cdf-e99b-481b-8d25-c6cb487512da" xlink:to="loc_biib_E2609andBAN2401Member_72df79a8-ebe2-4571-bbd4-0faadd2313a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_df4a8965-61b7-4aac-8411-59df4c97aa35" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4e8e37c0-cc66-472b-830e-250be5a1d306" xlink:to="loc_us-gaap_TypeOfArrangementAxis_df4a8965-61b7-4aac-8411-59df4c97aa35" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_df4a8965-61b7-4aac-8411-59df4c97aa35_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_df4a8965-61b7-4aac-8411-59df4c97aa35" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_df4a8965-61b7-4aac-8411-59df4c97aa35_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8e997131-207a-43c7-8122-6b9651966b90" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_df4a8965-61b7-4aac-8411-59df4c97aa35" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8e997131-207a-43c7-8122-6b9651966b90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LEQEMBICollaborationMember_8226b11b-bfe2-4a0b-b15f-19eee9c53a5b" xlink:href="biib-20250930.xsd#biib_LEQEMBICollaborationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8e997131-207a-43c7-8122-6b9651966b90" xlink:to="loc_biib_LEQEMBICollaborationMember_8226b11b-bfe2-4a0b-b15f-19eee9c53a5b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_88d0f3c2-6e1a-4d98-bcac-92fd246fa5c3" xlink:href="biib-20250930.xsd#biib_EisaiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8e997131-207a-43c7-8122-6b9651966b90" xlink:to="loc_biib_EisaiMember_88d0f3c2-6e1a-4d98-bcac-92fd246fa5c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_a7c3ff28-48cb-42bb-8cbb-9310eb7d69e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4e8e37c0-cc66-472b-830e-250be5a1d306" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_a7c3ff28-48cb-42bb-8cbb-9310eb7d69e7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a7c3ff28-48cb-42bb-8cbb-9310eb7d69e7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a7c3ff28-48cb-42bb-8cbb-9310eb7d69e7" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a7c3ff28-48cb-42bb-8cbb-9310eb7d69e7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_88916b65-584b-4de9-8810-334fb99c8bee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a7c3ff28-48cb-42bb-8cbb-9310eb7d69e7" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_88916b65-584b-4de9-8810-334fb99c8bee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_4aacf6ca-6679-4623-a95b-f5eb4bbd7084" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_88916b65-584b-4de9-8810-334fb99c8bee" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_4aacf6ca-6679-4623-a95b-f5eb4bbd7084" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ExpenseIncurredByCollaboration_37afc6d8-4d7b-45b4-afef-3c970b005662" xlink:href="biib-20250930.xsd#biib_ExpenseIncurredByCollaboration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4615b3f5-fdb1-4558-98c0-fc18c16c9f59" xlink:to="loc_biib_ExpenseIncurredByCollaboration_37afc6d8-4d7b-45b4-afef-3c970b005662" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_d233cc34-d856-40f9-bea7-56a03dd22801" xlink:href="biib-20250930.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4615b3f5-fdb1-4558-98c0-fc18c16c9f59" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_d233cc34-d856-40f9-bea7-56a03dd22801" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration_14cbdf75-14c4-4b02-b66a-1b5febd7ce6c" xlink:href="biib-20250930.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4615b3f5-fdb1-4558-98c0-fc18c16c9f59" xlink:to="loc_biib_Expenseincurredbythecollaboration_14cbdf75-14c4-4b02-b66a-1b5febd7ce6c" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_46e520a2-f53c-47a5-aac2-785e6d813e23" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4f94bbc1-c198-408b-a8e6-95ecce5ceb4d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_46e520a2-f53c-47a5-aac2-785e6d813e23" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4f94bbc1-c198-408b-a8e6-95ecce5ceb4d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_6dd044e0-d9ef-4112-824f-726c1c8593aa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4f94bbc1-c198-408b-a8e6-95ecce5ceb4d" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_6dd044e0-d9ef-4112-824f-726c1c8593aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6dd044e0-d9ef-4112-824f-726c1c8593aa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6dd044e0-d9ef-4112-824f-726c1c8593aa" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6dd044e0-d9ef-4112-824f-726c1c8593aa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2572668d-bc91-4bc4-8111-f76c1dc41df5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6dd044e0-d9ef-4112-824f-726c1c8593aa" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2572668d-bc91-4bc4-8111-f76c1dc41df5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_266dce96-451e-435e-9d97-054da808de27" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2572668d-bc91-4bc4-8111-f76c1dc41df5" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_266dce96-451e-435e-9d97-054da808de27" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5e9d0773-aaad-4d6a-b4ee-fc39be8e9749" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4f94bbc1-c198-408b-a8e6-95ecce5ceb4d" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5e9d0773-aaad-4d6a-b4ee-fc39be8e9749" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5e9d0773-aaad-4d6a-b4ee-fc39be8e9749_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5e9d0773-aaad-4d6a-b4ee-fc39be8e9749" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5e9d0773-aaad-4d6a-b4ee-fc39be8e9749_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d3fabeec-7b11-4019-ac38-d9f27a025f91" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5e9d0773-aaad-4d6a-b4ee-fc39be8e9749" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d3fabeec-7b11-4019-ac38-d9f27a025f91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UCBPharmaSAMember_072de8c6-de84-435e-a77b-fba5178ba9cb" xlink:href="biib-20250930.xsd#biib_UCBPharmaSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d3fabeec-7b11-4019-ac38-d9f27a025f91" xlink:to="loc_biib_UCBPharmaSAMember_072de8c6-de84-435e-a77b-fba5178ba9cb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration_fe688c10-9c9e-457f-9e34-aaec34c3f95e" xlink:href="biib-20250930.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_46e520a2-f53c-47a5-aac2-785e6d813e23" xlink:to="loc_biib_Expenseincurredbythecollaboration_fe688c10-9c9e-457f-9e34-aaec34c3f95e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_f36d2675-952e-4f6a-a242-45f0ac632341" xlink:href="biib-20250930.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_46e520a2-f53c-47a5-aac2-785e6d813e23" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_f36d2675-952e-4f6a-a242-45f0ac632341" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSageTherapeuticsIncDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#CollaborativeandOtherRelationshipsSageTherapeuticsIncDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSageTherapeuticsIncDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ba92615f-08b4-4539-b23f-5aeabd1e756a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_757e7b53-9e78-4546-b75b-07f64776119d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ba92615f-08b4-4539-b23f-5aeabd1e756a" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_757e7b53-9e78-4546-b75b-07f64776119d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_7c260e08-5315-4bfa-b2f5-cb871f2c6c49" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_757e7b53-9e78-4546-b75b-07f64776119d" xlink:to="loc_srt_StatementScenarioAxis_7c260e08-5315-4bfa-b2f5-cb871f2c6c49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_7c260e08-5315-4bfa-b2f5-cb871f2c6c49_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_7c260e08-5315-4bfa-b2f5-cb871f2c6c49" xlink:to="loc_srt_ScenarioUnspecifiedDomain_7c260e08-5315-4bfa-b2f5-cb871f2c6c49_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_ebf42d09-11eb-4f92-89fe-bced1dbf4b85" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_7c260e08-5315-4bfa-b2f5-cb871f2c6c49" xlink:to="loc_srt_ScenarioUnspecifiedDomain_ebf42d09-11eb-4f92-89fe-bced1dbf4b85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_528e7a39-f59e-4c77-bbde-0c782bae1060" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_ebf42d09-11eb-4f92-89fe-bced1dbf4b85" xlink:to="loc_srt_ScenarioForecastMember_528e7a39-f59e-4c77-bbde-0c782bae1060" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_ecd1a3ed-d5cb-426a-9632-e6b8e9231915" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_757e7b53-9e78-4546-b75b-07f64776119d" xlink:to="loc_us-gaap_TypeOfArrangementAxis_ecd1a3ed-d5cb-426a-9632-e6b8e9231915" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ecd1a3ed-d5cb-426a-9632-e6b8e9231915_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ecd1a3ed-d5cb-426a-9632-e6b8e9231915" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ecd1a3ed-d5cb-426a-9632-e6b8e9231915_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f0024b46-451a-4632-85ad-ffde61d6eeb6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ecd1a3ed-d5cb-426a-9632-e6b8e9231915" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f0024b46-451a-4632-85ad-ffde61d6eeb6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SageTherapeuticsIncMember_417f433b-ef4f-41b3-9886-1d74990cf00a" xlink:href="biib-20250930.xsd#biib_SageTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f0024b46-451a-4632-85ad-ffde61d6eeb6" xlink:to="loc_biib_SageTherapeuticsIncMember_417f433b-ef4f-41b3-9886-1d74990cf00a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_0d1b41f3-fb3b-4372-af2f-9271573972ab" xlink:href="biib-20250930.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ba92615f-08b4-4539-b23f-5aeabd1e756a" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_0d1b41f3-fb3b-4372-af2f-9271573972ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationprofitlosssharing_0ed3b50c-12d3-4ce7-a12d-a34bc307c1ee" xlink:href="biib-20250930.xsd#biib_Collaborationprofitlosssharing"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ba92615f-08b4-4539-b23f-5aeabd1e756a" xlink:to="loc_biib_Collaborationprofitlosssharing_0ed3b50c-12d3-4ce7-a12d-a34bc307c1ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfNetProfitFromSageTherapeuticsPercent_b0b93239-bb7e-4803-92b0-599df3d09b5d" xlink:href="biib-20250930.xsd#biib_ShareOfNetProfitFromSageTherapeuticsPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ba92615f-08b4-4539-b23f-5aeabd1e756a" xlink:to="loc_biib_ShareOfNetProfitFromSageTherapeuticsPercent_b0b93239-bb7e-4803-92b0-599df3d09b5d" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_82df1531-c229-4804-97f8-8c97aae1b78d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3d97e3c8-db78-4af9-9855-ad1c9f0afeca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_82df1531-c229-4804-97f8-8c97aae1b78d" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3d97e3c8-db78-4af9-9855-ad1c9f0afeca" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_dc5070f3-d8e8-405a-856e-6ce5eb0873fe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3d97e3c8-db78-4af9-9855-ad1c9f0afeca" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_dc5070f3-d8e8-405a-856e-6ce5eb0873fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_dc5070f3-d8e8-405a-856e-6ce5eb0873fe_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_dc5070f3-d8e8-405a-856e-6ce5eb0873fe" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_dc5070f3-d8e8-405a-856e-6ce5eb0873fe_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0ebfe085-ce56-47ea-bfa2-d264dcde1a90" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_dc5070f3-d8e8-405a-856e-6ce5eb0873fe" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0ebfe085-ce56-47ea-bfa2-d264dcde1a90" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1ab9b915-088c-43eb-89f8-1f6f036df70b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0ebfe085-ce56-47ea-bfa2-d264dcde1a90" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1ab9b915-088c-43eb-89f8-1f6f036df70b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_b0d687e1-5ff3-4c84-ad52-f272b2f0f93a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0ebfe085-ce56-47ea-bfa2-d264dcde1a90" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_b0d687e1-5ff3-4c84-ad52-f272b2f0f93a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3eebfa53-f40c-4a60-ade0-9a303b7a3d1b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3d97e3c8-db78-4af9-9855-ad1c9f0afeca" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3eebfa53-f40c-4a60-ade0-9a303b7a3d1b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3eebfa53-f40c-4a60-ade0-9a303b7a3d1b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3eebfa53-f40c-4a60-ade0-9a303b7a3d1b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3eebfa53-f40c-4a60-ade0-9a303b7a3d1b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0b2951bf-fda4-4edd-bea5-591bd5fb9d17" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3eebfa53-f40c-4a60-ade0-9a303b7a3d1b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0b2951bf-fda4-4edd-bea5-591bd5fb9d17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SageTherapeuticsIncMember_24406832-5e72-4a53-9933-c7230329ac09" xlink:href="biib-20250930.xsd#biib_SageTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0b2951bf-fda4-4edd-bea5-591bd5fb9d17" xlink:to="loc_biib_SageTherapeuticsIncMember_24406832-5e72-4a53-9933-c7230329ac09" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration_75a0e4f8-aa83-4177-86e5-54fff9d28de2" xlink:href="biib-20250930.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_82df1531-c229-4804-97f8-8c97aae1b78d" xlink:to="loc_biib_Expenseincurredbythecollaboration_75a0e4f8-aa83-4177-86e5-54fff9d28de2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_5fe8cabc-0146-412c-86f7-5a0d73badcea" xlink:href="biib-20250930.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_82df1531-c229-4804-97f8-8c97aae1b78d" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_5fe8cabc-0146-412c-86f7-5a0d73badcea" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_90691e29-125a-484b-9f74-f20936f78fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3d4047ad-30cb-43ef-a70e-afe5f128830f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_90691e29-125a-484b-9f74-f20936f78fcd" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3d4047ad-30cb-43ef-a70e-afe5f128830f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_a70648e3-a3db-45c3-9709-238c5d09c337" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3d4047ad-30cb-43ef-a70e-afe5f128830f" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_a70648e3-a3db-45c3-9709-238c5d09c337" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_a70648e3-a3db-45c3-9709-238c5d09c337_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a70648e3-a3db-45c3-9709-238c5d09c337" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_a70648e3-a3db-45c3-9709-238c5d09c337_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0f42cac9-a566-4f10-b710-75dfc0324755" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a70648e3-a3db-45c3-9709-238c5d09c337" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0f42cac9-a566-4f10-b710-75dfc0324755" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1d3ba0fb-6fd3-4c17-b6e6-7bcd7acf6c28" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0f42cac9-a566-4f10-b710-75dfc0324755" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1d3ba0fb-6fd3-4c17-b6e6-7bcd7acf6c28" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8348b9d5-5d0f-4e82-9417-abfb038c1eed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3d4047ad-30cb-43ef-a70e-afe5f128830f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8348b9d5-5d0f-4e82-9417-abfb038c1eed" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8348b9d5-5d0f-4e82-9417-abfb038c1eed_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8348b9d5-5d0f-4e82-9417-abfb038c1eed" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8348b9d5-5d0f-4e82-9417-abfb038c1eed_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_541d5113-2650-4d1b-aeb0-be27ab888c0c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8348b9d5-5d0f-4e82-9417-abfb038c1eed" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_541d5113-2650-4d1b-aeb0-be27ab888c0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_4c41a538-c309-4d72-a849-73719a3efbac" xlink:href="biib-20250930.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_541d5113-2650-4d1b-aeb0-be27ab888c0c" xlink:to="loc_biib_DenaliTherapeuticsIncMember_4c41a538-c309-4d72-a849-73719a3efbac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration_602c7bcb-a220-4c62-923c-beb6d9540fd2" xlink:href="biib-20250930.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_90691e29-125a-484b-9f74-f20936f78fcd" xlink:to="loc_biib_Expenseincurredbythecollaboration_602c7bcb-a220-4c62-923c-beb6d9540fd2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_44206236-847b-4f9c-8111-37298470bdf5" xlink:href="biib-20250930.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_90691e29-125a-484b-9f74-f20936f78fcd" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_44206236-847b-4f9c-8111-37298470bdf5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsStokeTherapeuticsIncDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#CollaborativeandOtherRelationshipsStokeTherapeuticsIncDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsStokeTherapeuticsIncDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eabf8907-64dc-47f4-b6c6-c44613bbd2cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1dc155a9-83f6-48a6-b6c9-b579050410bf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eabf8907-64dc-47f4-b6c6-c44613bbd2cb" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1dc155a9-83f6-48a6-b6c9-b579050410bf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_267a26fb-9649-4364-84e6-d50bd1dd4c2c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1dc155a9-83f6-48a6-b6c9-b579050410bf" xlink:to="loc_us-gaap_TypeOfArrangementAxis_267a26fb-9649-4364-84e6-d50bd1dd4c2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_267a26fb-9649-4364-84e6-d50bd1dd4c2c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_267a26fb-9649-4364-84e6-d50bd1dd4c2c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_267a26fb-9649-4364-84e6-d50bd1dd4c2c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_67aebfa7-9035-40e1-b50c-d7b7868811ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_267a26fb-9649-4364-84e6-d50bd1dd4c2c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_67aebfa7-9035-40e1-b50c-d7b7868811ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StokeTherapeuticsIncMember_97997a01-8af3-4c81-9c58-8129e9c62445" xlink:href="biib-20250930.xsd#biib_StokeTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_67aebfa7-9035-40e1-b50c-d7b7868811ad" xlink:to="loc_biib_StokeTherapeuticsIncMember_97997a01-8af3-4c81-9c58-8129e9c62445" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_6090aa74-36d3-49bb-aa3a-d3cd6f8ce936" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1dc155a9-83f6-48a6-b6c9-b579050410bf" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_6090aa74-36d3-49bb-aa3a-d3cd6f8ce936" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_6090aa74-36d3-49bb-aa3a-d3cd6f8ce936_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_6090aa74-36d3-49bb-aa3a-d3cd6f8ce936" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_6090aa74-36d3-49bb-aa3a-d3cd6f8ce936_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_2560f60b-5a32-4a93-aee9-ed2e0e52b94c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_6090aa74-36d3-49bb-aa3a-d3cd6f8ce936" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_2560f60b-5a32-4a93-aee9-ed2e0e52b94c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MilestonePaymentDevelopmentalMember_17ee12f0-f608-48e7-abba-10c110477a79" xlink:href="biib-20250930.xsd#biib_MilestonePaymentDevelopmentalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_2560f60b-5a32-4a93-aee9-ed2e0e52b94c" xlink:to="loc_biib_MilestonePaymentDevelopmentalMember_17ee12f0-f608-48e7-abba-10c110477a79" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MilestonePaymentCommercialMember_85b00194-3b59-4b7d-902c-3e961596f0dc" xlink:href="biib-20250930.xsd#biib_MilestonePaymentCommercialMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_2560f60b-5a32-4a93-aee9-ed2e0e52b94c" xlink:to="loc_biib_MilestonePaymentCommercialMember_85b00194-3b59-4b7d-902c-3e961596f0dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2965917c-56f3-406f-a94b-d452d3fb8e7a" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1dc155a9-83f6-48a6-b6c9-b579050410bf" xlink:to="loc_srt_ProductOrServiceAxis_2965917c-56f3-406f-a94b-d452d3fb8e7a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2965917c-56f3-406f-a94b-d452d3fb8e7a_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_2965917c-56f3-406f-a94b-d452d3fb8e7a" xlink:to="loc_srt_ProductsAndServicesDomain_2965917c-56f3-406f-a94b-d452d3fb8e7a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_99c9af74-1071-4183-99fa-702e77908662" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_2965917c-56f3-406f-a94b-d452d3fb8e7a" xlink:to="loc_srt_ProductsAndServicesDomain_99c9af74-1071-4183-99fa-702e77908662" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ZorevunersenMember_fd3db454-a8af-4b6b-990f-94480c667458" xlink:href="biib-20250930.xsd#biib_ZorevunersenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_99c9af74-1071-4183-99fa-702e77908662" xlink:to="loc_biib_ZorevunersenMember_fd3db454-a8af-4b6b-990f-94480c667458" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfFutureDevelopmentCosts_5b9fe583-ada8-4895-9df8-4770d7ec291d" xlink:href="biib-20250930.xsd#biib_PercentageOfFutureDevelopmentCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eabf8907-64dc-47f4-b6c6-c44613bbd2cb" xlink:to="loc_biib_PercentageOfFutureDevelopmentCosts_5b9fe583-ada8-4895-9df8-4770d7ec291d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_82274780-8c2b-411f-ab0e-b60de8e741fc" xlink:href="biib-20250930.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eabf8907-64dc-47f4-b6c6-c44613bbd2cb" xlink:to="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_82274780-8c2b-411f-ab0e-b60de8e741fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_c43e588a-1b4d-4a52-910e-532a5525e322" xlink:href="biib-20250930.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eabf8907-64dc-47f4-b6c6-c44613bbd2cb" xlink:to="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_c43e588a-1b4d-4a52-910e-532a5525e322" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoStokeTherapeuticsDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoStokeTherapeuticsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoStokeTherapeuticsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_249c4435-1f5f-4b0b-a795-2a584366c55b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_00bbcb24-dfca-4e2b-8160-85c23aa87017" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_249c4435-1f5f-4b0b-a795-2a584366c55b" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_00bbcb24-dfca-4e2b-8160-85c23aa87017" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_38c2901a-a113-4727-a0a6-6c7943712a21" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_00bbcb24-dfca-4e2b-8160-85c23aa87017" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_38c2901a-a113-4727-a0a6-6c7943712a21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_38c2901a-a113-4727-a0a6-6c7943712a21_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_38c2901a-a113-4727-a0a6-6c7943712a21" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_38c2901a-a113-4727-a0a6-6c7943712a21_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_f3c9f327-d9de-4543-ac75-c31bd62c9ae7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_38c2901a-a113-4727-a0a6-6c7943712a21" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_f3c9f327-d9de-4543-ac75-c31bd62c9ae7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f2fb40e4-e936-42f3-af67-447bec389759" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f3c9f327-d9de-4543-ac75-c31bd62c9ae7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f2fb40e4-e936-42f3-af67-447bec389759" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_f32dbdc6-e566-4919-b78f-2167265f5cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_00bbcb24-dfca-4e2b-8160-85c23aa87017" xlink:to="loc_us-gaap_TypeOfArrangementAxis_f32dbdc6-e566-4919-b78f-2167265f5cb1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f32dbdc6-e566-4919-b78f-2167265f5cb1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f32dbdc6-e566-4919-b78f-2167265f5cb1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f32dbdc6-e566-4919-b78f-2167265f5cb1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c0796cda-6848-40fc-9120-94caee8d7e2c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f32dbdc6-e566-4919-b78f-2167265f5cb1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c0796cda-6848-40fc-9120-94caee8d7e2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StokeTherapeuticsIncMember_f13184a5-43c7-48f2-ba22-e2030ed5013c" xlink:href="biib-20250930.xsd#biib_StokeTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c0796cda-6848-40fc-9120-94caee8d7e2c" xlink:to="loc_biib_StokeTherapeuticsIncMember_f13184a5-43c7-48f2-ba22-e2030ed5013c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration_ca6eab49-a50a-4119-ad7d-ff6665bc5552" xlink:href="biib-20250930.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_249c4435-1f5f-4b0b-a795-2a584366c55b" xlink:to="loc_biib_Expenseincurredbythecollaboration_ca6eab49-a50a-4119-ad7d-ff6665bc5552" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_a86b8bc5-1311-49ef-b0f7-c21cb9b216b3" xlink:href="biib-20250930.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_249c4435-1f5f-4b0b-a795-2a584366c55b" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_a86b8bc5-1311-49ef-b0f7-c21cb9b216b3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#CollaborativeandOtherRelationshipsSamsungBioepisDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9e5bb8f3-69d8-403e-9e1f-106c85edbd15" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6844e592-ed67-45f7-9dc3-afdd22cd4875" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9e5bb8f3-69d8-403e-9e1f-106c85edbd15" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6844e592-ed67-45f7-9dc3-afdd22cd4875" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_dcfac655-f1af-4693-a899-6b77cf7a3447" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6844e592-ed67-45f7-9dc3-afdd22cd4875" xlink:to="loc_us-gaap_TypeOfArrangementAxis_dcfac655-f1af-4693-a899-6b77cf7a3447" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dcfac655-f1af-4693-a899-6b77cf7a3447_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_dcfac655-f1af-4693-a899-6b77cf7a3447" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_dcfac655-f1af-4693-a899-6b77cf7a3447_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bc96f08d-22b4-4798-bb42-0db01f7ebf1f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_dcfac655-f1af-4693-a899-6b77cf7a3447" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bc96f08d-22b4-4798-bb42-0db01f7ebf1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_76b17b7e-b918-4e5f-bb9b-c339e8fac10e" xlink:href="biib-20250930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bc96f08d-22b4-4798-bb42-0db01f7ebf1f" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_76b17b7e-b918-4e5f-bb9b-c339e8fac10e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_dc9a7c20-e32e-4243-84b7-a7f868abd02f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6844e592-ed67-45f7-9dc3-afdd22cd4875" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_dc9a7c20-e32e-4243-84b7-a7f868abd02f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_dc9a7c20-e32e-4243-84b7-a7f868abd02f_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_dc9a7c20-e32e-4243-84b7-a7f868abd02f" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_dc9a7c20-e32e-4243-84b7-a7f868abd02f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_6d042f1d-ef57-4410-9229-5f0fb52976f3" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_dc9a7c20-e32e-4243-84b7-a7f868abd02f" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_6d042f1d-ef57-4410-9229-5f0fb52976f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_26a55312-0ff9-461a-a2c8-778fb3aa5d57" xlink:href="biib-20250930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_6d042f1d-ef57-4410-9229-5f0fb52976f3" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_26a55312-0ff9-461a-a2c8-778fb3aa5d57" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e5b3f037-8164-4dbe-ac91-0a977d3414bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6844e592-ed67-45f7-9dc3-afdd22cd4875" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e5b3f037-8164-4dbe-ac91-0a977d3414bb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_e5b3f037-8164-4dbe-ac91-0a977d3414bb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e5b3f037-8164-4dbe-ac91-0a977d3414bb" xlink:to="loc_us-gaap_RelatedPartyDomain_e5b3f037-8164-4dbe-ac91-0a977d3414bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_94fd4805-79ef-4572-af15-cfd4ca7eeda6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e5b3f037-8164-4dbe-ac91-0a977d3414bb" xlink:to="loc_us-gaap_RelatedPartyDomain_94fd4805-79ef-4572-af15-cfd4ca7eeda6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_60415dcd-1a9e-4400-b1b2-9e18d7a7c31b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_94fd4805-79ef-4572-af15-cfd4ca7eeda6" xlink:to="loc_us-gaap_RelatedPartyMember_60415dcd-1a9e-4400-b1b2-9e18d7a7c31b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContingentCommercializedRightsNumberOfProducts_f60f1b93-231e-4f64-8901-edd3e25d5df9" xlink:href="biib-20250930.xsd#biib_ContingentCommercializedRightsNumberOfProducts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9e5bb8f3-69d8-403e-9e1f-106c85edbd15" xlink:to="loc_biib_ContingentCommercializedRightsNumberOfProducts_f60f1b93-231e-4f64-8901-edd3e25d5df9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquityMethodInvestmentsExpectedProfitShare_ead47756-f971-4796-bacf-d90e6833991a" xlink:href="biib-20250930.xsd#biib_EquityMethodInvestmentsExpectedProfitShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9e5bb8f3-69d8-403e-9e1f-106c85edbd15" xlink:to="loc_biib_EquityMethodInvestmentsExpectedProfitShare_ead47756-f971-4796-bacf-d90e6833991a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_1823a3cd-ed1b-4bce-8bb0-55f502efcf45" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9e5bb8f3-69d8-403e-9e1f-106c85edbd15" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_1823a3cd-ed1b-4bce-8bb0-55f502efcf45" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_f1872426-3f78-4cb4-8c59-9ea097edc139" xlink:href="biib-20250930.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9e5bb8f3-69d8-403e-9e1f-106c85edbd15" xlink:to="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_f1872426-3f78-4cb4-8c59-9ea097edc139" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborativeArrangementTermExtension_46e548e4-9e6f-4959-a4a7-d63d207e91bd" xlink:href="biib-20250930.xsd#biib_CollaborativeArrangementTermExtension"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9e5bb8f3-69d8-403e-9e1f-106c85edbd15" xlink:to="loc_biib_CollaborativeArrangementTermExtension_46e548e4-9e6f-4959-a4a7-d63d207e91bd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractOptionExerciseFee_222f21a1-eff9-4ae7-b221-305c1a1f6d9a" xlink:href="biib-20250930.xsd#biib_ContractOptionExerciseFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9e5bb8f3-69d8-403e-9e1f-106c85edbd15" xlink:to="loc_biib_ContractOptionExerciseFee_222f21a1-eff9-4ae7-b221-305c1a1f6d9a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationprofitlosssharing_686474f3-ee17-43a6-8f87-cc7eb8260f3d" xlink:href="biib-20250930.xsd#biib_Collaborationprofitlosssharing"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9e5bb8f3-69d8-403e-9e1f-106c85edbd15" xlink:to="loc_biib_Collaborationprofitlosssharing_686474f3-ee17-43a6-8f87-cc7eb8260f3d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_35aacef2-3f90-499e-93d0-15688c3881df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9e5bb8f3-69d8-403e-9e1f-106c85edbd15" xlink:to="loc_us-gaap_AccountsReceivableNet_35aacef2-3f90-499e-93d0-15688c3881df" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_2bf4e335-1c9d-49db-973d-f93020e41203" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9e5bb8f3-69d8-403e-9e1f-106c85edbd15" xlink:to="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_2bf4e335-1c9d-49db-973d-f93020e41203" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherResearchandDiscoveryArrangementsandFundingArrangementsDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#CollaborativeandOtherRelationshipsOtherResearchandDiscoveryArrangementsandFundingArrangementsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherResearchandDiscoveryArrangementsandFundingArrangementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4ff30919-b8d5-405c-bec8-4c2cd4771a75" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_89ac59ca-8fde-4f7f-89e5-1483374c7a63" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4ff30919-b8d5-405c-bec8-4c2cd4771a75" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_89ac59ca-8fde-4f7f-89e5-1483374c7a63" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_593e9e2f-ee59-4bc4-b9bb-8bd08d01c26b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_89ac59ca-8fde-4f7f-89e5-1483374c7a63" xlink:to="loc_us-gaap_TypeOfArrangementAxis_593e9e2f-ee59-4bc4-b9bb-8bd08d01c26b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_593e9e2f-ee59-4bc4-b9bb-8bd08d01c26b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_593e9e2f-ee59-4bc4-b9bb-8bd08d01c26b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_593e9e2f-ee59-4bc4-b9bb-8bd08d01c26b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8d7fcec5-1860-48e2-a536-a92390120d47" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_593e9e2f-ee59-4bc4-b9bb-8bd08d01c26b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8d7fcec5-1860-48e2-a536-a92390120d47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_8032802c-4523-4d8f-bdd5-064d375db143" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8d7fcec5-1860-48e2-a536-a92390120d47" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_8032802c-4523-4d8f-bdd5-064d375db143" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_1f613176-13dc-4dd5-a726-0ca8bd5f85b0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_89ac59ca-8fde-4f7f-89e5-1483374c7a63" xlink:to="loc_srt_ProductOrServiceAxis_1f613176-13dc-4dd5-a726-0ca8bd5f85b0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1f613176-13dc-4dd5-a726-0ca8bd5f85b0_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_1f613176-13dc-4dd5-a726-0ca8bd5f85b0" xlink:to="loc_srt_ProductsAndServicesDomain_1f613176-13dc-4dd5-a726-0ca8bd5f85b0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_745f0559-b080-4381-a540-957a6310bf59" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_1f613176-13dc-4dd5-a726-0ca8bd5f85b0" xlink:to="loc_srt_ProductsAndServicesDomain_745f0559-b080-4381-a540-957a6310bf59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FelzartamabAndIzastobartHIB210Member_43367e76-e86e-4db7-899d-6b4d78593212" xlink:href="biib-20250930.xsd#biib_FelzartamabAndIzastobartHIB210Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_745f0559-b080-4381-a540-957a6310bf59" xlink:to="loc_biib_FelzartamabAndIzastobartHIB210Member_43367e76-e86e-4db7-899d-6b4d78593212" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_9acff1c4-ecbb-4f97-80a8-c3668d6135bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_89ac59ca-8fde-4f7f-89e5-1483374c7a63" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_9acff1c4-ecbb-4f97-80a8-c3668d6135bb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_9acff1c4-ecbb-4f97-80a8-c3668d6135bb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_9acff1c4-ecbb-4f97-80a8-c3668d6135bb" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_9acff1c4-ecbb-4f97-80a8-c3668d6135bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_5a9e743c-dd69-436c-856a-f538e3556fe3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_9acff1c4-ecbb-4f97-80a8-c3668d6135bb" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_5a9e743c-dd69-436c-856a-f538e3556fe3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_HumanImmunologyBiosciencesPreExistingInLicenseCommitmentsMember_c6489fca-dca2-423c-bce4-13c3ca04a443" xlink:href="biib-20250930.xsd#biib_HumanImmunologyBiosciencesPreExistingInLicenseCommitmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_5a9e743c-dd69-436c-856a-f538e3556fe3" xlink:to="loc_biib_HumanImmunologyBiosciencesPreExistingInLicenseCommitmentsMember_c6489fca-dca2-423c-bce4-13c3ca04a443" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_dbcb985f-1588-4d83-8c03-637d163c93c8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_89ac59ca-8fde-4f7f-89e5-1483374c7a63" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_dbcb985f-1588-4d83-8c03-637d163c93c8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_dbcb985f-1588-4d83-8c03-637d163c93c8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_dbcb985f-1588-4d83-8c03-637d163c93c8" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_dbcb985f-1588-4d83-8c03-637d163c93c8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_e07c0779-e543-451a-b3f7-658ee7959e1b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_dbcb985f-1588-4d83-8c03-637d163c93c8" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_e07c0779-e543-451a-b3f7-658ee7959e1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MilestonePaymentOneMember_295be84e-6578-4552-b8d6-59b4f59a557d" xlink:href="biib-20250930.xsd#biib_MilestonePaymentOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_e07c0779-e543-451a-b3f7-658ee7959e1b" xlink:to="loc_biib_MilestonePaymentOneMember_295be84e-6578-4552-b8d6-59b4f59a557d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MilestonePaymentTwoMember_219088e2-35f7-4cbf-8bff-8f262ec435fe" xlink:href="biib-20250930.xsd#biib_MilestonePaymentTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_e07c0779-e543-451a-b3f7-658ee7959e1b" xlink:to="loc_biib_MilestonePaymentTwoMember_219088e2-35f7-4cbf-8bff-8f262ec435fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MilestonePaymentFutureDevelopmentMember_c65387ce-ef81-4fe8-ae38-bd43ae50844b" xlink:href="biib-20250930.xsd#biib_MilestonePaymentFutureDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_e07c0779-e543-451a-b3f7-658ee7959e1b" xlink:to="loc_biib_MilestonePaymentFutureDevelopmentMember_c65387ce-ef81-4fe8-ae38-bd43ae50844b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MilestonePaymentRegulatoryMember_5913b5c8-b9ef-444b-acdc-476484c3d53e" xlink:href="biib-20250930.xsd#biib_MilestonePaymentRegulatoryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_e07c0779-e543-451a-b3f7-658ee7959e1b" xlink:to="loc_biib_MilestonePaymentRegulatoryMember_5913b5c8-b9ef-444b-acdc-476484c3d53e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MilestonePaymentCommercialMember_754a049f-f86e-4f6f-ae84-b65dfe7dbf69" xlink:href="biib-20250930.xsd#biib_MilestonePaymentCommercialMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_e07c0779-e543-451a-b3f7-658ee7959e1b" xlink:to="loc_biib_MilestonePaymentCommercialMember_754a049f-f86e-4f6f-ae84-b65dfe7dbf69" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MilestonePaymentResearchMember_0a184846-4783-4121-97f4-4554e36a5dd3" xlink:href="biib-20250930.xsd#biib_MilestonePaymentResearchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_e07c0779-e543-451a-b3f7-658ee7959e1b" xlink:to="loc_biib_MilestonePaymentResearchMember_0a184846-4783-4121-97f4-4554e36a5dd3" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MilestonePaymentDevelopmentalMember_a8f0cb7a-a5a0-4727-9e19-574b288ddbbb" xlink:href="biib-20250930.xsd#biib_MilestonePaymentDevelopmentalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_e07c0779-e543-451a-b3f7-658ee7959e1b" xlink:to="loc_biib_MilestonePaymentDevelopmentalMember_a8f0cb7a-a5a0-4727-9e19-574b288ddbbb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MilestonePaymentSalesBasedMember_9301e503-83f9-4a15-9e5f-f0f5324b8843" xlink:href="biib-20250930.xsd#biib_MilestonePaymentSalesBasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_e07c0779-e543-451a-b3f7-658ee7959e1b" xlink:to="loc_biib_MilestonePaymentSalesBasedMember_9301e503-83f9-4a15-9e5f-f0f5324b8843" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_3a910f35-8c2f-4c31-9cd0-d9ebb9fad362" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_89ac59ca-8fde-4f7f-89e5-1483374c7a63" xlink:to="loc_srt_CounterpartyNameAxis_3a910f35-8c2f-4c31-9cd0-d9ebb9fad362" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3a910f35-8c2f-4c31-9cd0-d9ebb9fad362_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_3a910f35-8c2f-4c31-9cd0-d9ebb9fad362" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3a910f35-8c2f-4c31-9cd0-d9ebb9fad362_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7793b331-4cde-4b20-9f6c-65c4a9a3ce9d" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_3a910f35-8c2f-4c31-9cd0-d9ebb9fad362" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7793b331-4cde-4b20-9f6c-65c4a9a3ce9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CityTherapeuticsInc.Member_21680640-9c16-43a7-9424-7a2394d78431" xlink:href="biib-20250930.xsd#biib_CityTherapeuticsInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7793b331-4cde-4b20-9f6c-65c4a9a3ce9d" xlink:to="loc_biib_CityTherapeuticsInc.Member_21680640-9c16-43a7-9424-7a2394d78431" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborativeArrangementExpectedDevelopmentCostFundsYearOne_dcad44fb-7160-4b1e-9b74-f24abd8417f9" xlink:href="biib-20250930.xsd#biib_CollaborativeArrangementExpectedDevelopmentCostFundsYearOne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4ff30919-b8d5-405c-bec8-4c2cd4771a75" xlink:to="loc_biib_CollaborativeArrangementExpectedDevelopmentCostFundsYearOne_dcad44fb-7160-4b1e-9b74-f24abd8417f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborativeArrangementExpectedDevelopmentCostFundsYearTwo_4ed3eba7-3593-428c-a995-aeaa13a27f76" xlink:href="biib-20250930.xsd#biib_CollaborativeArrangementExpectedDevelopmentCostFundsYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4ff30919-b8d5-405c-bec8-4c2cd4771a75" xlink:to="loc_biib_CollaborativeArrangementExpectedDevelopmentCostFundsYearTwo_4ed3eba7-3593-428c-a995-aeaa13a27f76" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReductionOfResearchAndDevelopmentExpense_b4a7a0b4-fc0c-444c-bd31-e3ee19291887" xlink:href="biib-20250930.xsd#biib_ReductionOfResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4ff30919-b8d5-405c-bec8-4c2cd4771a75" xlink:to="loc_biib_ReductionOfResearchAndDevelopmentExpense_b4a7a0b4-fc0c-444c-bd31-e3ee19291887" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_669ca649-8721-42b3-8cf5-3fdef7a6c059" xlink:href="biib-20250930.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4ff30919-b8d5-405c-bec8-4c2cd4771a75" xlink:to="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_669ca649-8721-42b3-8cf5-3fdef7a6c059" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_deb40634-491c-45ea-9a36-e6294674efe9" xlink:href="biib-20250930.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4ff30919-b8d5-405c-bec8-4c2cd4771a75" xlink:to="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_deb40634-491c-45ea-9a36-e6294674efe9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborativeArrangementsInvestmentsInCounterparty_d8c5b5f8-54b9-48ff-938e-de63ee63e7c6" xlink:href="biib-20250930.xsd#biib_CollaborativeArrangementsInvestmentsInCounterparty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4ff30919-b8d5-405c-bec8-4c2cd4771a75" xlink:to="loc_biib_CollaborativeArrangementsInvestmentsInCounterparty_d8c5b5f8-54b9-48ff-938e-de63ee63e7c6" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/LitigationDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#LitigationDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/LitigationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_75fb51ef-2e12-41c7-a62e-dd59c73b793d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_8e8d9b64-d6c7-4fca-825f-017295edc79a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_75fb51ef-2e12-41c7-a62e-dd59c73b793d" xlink:to="loc_us-gaap_LossContingenciesTable_8e8d9b64-d6c7-4fca-825f-017295edc79a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_fdd949f8-5618-4d61-b262-5b7d2e8d6a91" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_8e8d9b64-d6c7-4fca-825f-017295edc79a" xlink:to="loc_srt_LitigationCaseAxis_fdd949f8-5618-4d61-b262-5b7d2e8d6a91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_fdd949f8-5618-4d61-b262-5b7d2e8d6a91_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_fdd949f8-5618-4d61-b262-5b7d2e8d6a91" xlink:to="loc_srt_LitigationCaseTypeDomain_fdd949f8-5618-4d61-b262-5b7d2e8d6a91_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_07f3d8e5-457f-415e-a372-b525041a4e13" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_fdd949f8-5618-4d61-b262-5b7d2e8d6a91" xlink:to="loc_srt_LitigationCaseTypeDomain_07f3d8e5-457f-415e-a372-b525041a4e13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IMRALDIPatentLitigationMember_40297f51-d2f5-4a53-9c44-a79d3b0103c9" xlink:href="biib-20250930.xsd#biib_IMRALDIPatentLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_07f3d8e5-457f-415e-a372-b525041a4e13" xlink:to="loc_biib_IMRALDIPatentLitigationMember_40297f51-d2f5-4a53-9c44-a79d3b0103c9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ConvergenceMember_f265e71a-aaf4-4a32-b55f-86d11f27ba94" xlink:href="biib-20250930.xsd#biib_ConvergenceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_07f3d8e5-457f-415e-a372-b525041a4e13" xlink:to="loc_biib_ConvergenceMember_f265e71a-aaf4-4a32-b55f-86d11f27ba94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GenentechMember_5317bcbe-afef-4b95-a3fa-db982d256771" xlink:href="biib-20250930.xsd#biib_GenentechMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_07f3d8e5-457f-415e-a372-b525041a4e13" xlink:to="loc_biib_GenentechMember_5317bcbe-afef-4b95-a3fa-db982d256771" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_8ca7a996-7530-40e2-969f-f514efd023aa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_75fb51ef-2e12-41c7-a62e-dd59c73b793d" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_8ca7a996-7530-40e2-969f-f514efd023aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_67be47fd-6f2e-499c-9156-37d0ce047d85" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_75fb51ef-2e12-41c7-a62e-dd59c73b793d" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_67be47fd-6f2e-499c-9156-37d0ce047d85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementInterest_a0a47f85-ea0e-4d1e-8b13-d20089ef671b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LitigationSettlementInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_75fb51ef-2e12-41c7-a62e-dd59c73b793d" xlink:to="loc_us-gaap_LitigationSettlementInterest_a0a47f85-ea0e-4d1e-8b13-d20089ef671b" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SegmentInformationAdditionalSegmentInformationDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#SegmentInformationAdditionalSegmentInformationDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SegmentInformationAdditionalSegmentInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_bfbe9772-2964-446f-9134-6c0efe85d607" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAssetReconcilingItemLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_7db722c2-dc44-4f65-99f3-d6eccc50f1d8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_bfbe9772-2964-446f-9134-6c0efe85d607" xlink:to="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_7db722c2-dc44-4f65-99f3-d6eccc50f1d8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_d81e3df8-af12-4c59-9ca7-f445d7cf4a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_7db722c2-dc44-4f65-99f3-d6eccc50f1d8" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_d81e3df8-af12-4c59-9ca7-f445d7cf4a3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_d81e3df8-af12-4c59-9ca7-f445d7cf4a3c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d81e3df8-af12-4c59-9ca7-f445d7cf4a3c" xlink:to="loc_us-gaap_SegmentDomain_d81e3df8-af12-4c59-9ca7-f445d7cf4a3c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_408c6aee-6ad1-474a-917d-f23448439b87" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d81e3df8-af12-4c59-9ca7-f445d7cf4a3c" xlink:to="loc_us-gaap_SegmentDomain_408c6aee-6ad1-474a-917d-f23448439b87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReportableSegmentMember_95d152cd-bb1d-4084-8e3b-b70a1be08594" xlink:href="biib-20250930.xsd#biib_ReportableSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_408c6aee-6ad1-474a-917d-f23448439b87" xlink:to="loc_biib_ReportableSegmentMember_95d152cd-bb1d-4084-8e3b-b70a1be08594" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0e6af525-4cf9-4fc5-a2ec-291e624c0efb" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_7db722c2-dc44-4f65-99f3-d6eccc50f1d8" xlink:to="loc_srt_ProductOrServiceAxis_0e6af525-4cf9-4fc5-a2ec-291e624c0efb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0e6af525-4cf9-4fc5-a2ec-291e624c0efb_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_0e6af525-4cf9-4fc5-a2ec-291e624c0efb" xlink:to="loc_srt_ProductsAndServicesDomain_0e6af525-4cf9-4fc5-a2ec-291e624c0efb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_92baefe2-3a42-4c1d-8274-c88e20e97539" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_0e6af525-4cf9-4fc5-a2ec-291e624c0efb" xlink:to="loc_srt_ProductsAndServicesDomain_92baefe2-3a42-4c1d-8274-c88e20e97539" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_e9611d40-d40a-409d-9e01-ccc428808b84" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_92baefe2-3a42-4c1d-8274-c88e20e97539" xlink:to="loc_us-gaap_ProductMember_e9611d40-d40a-409d-9e01-ccc428808b84" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_5963419d-951e-4a4b-a3ff-2123dc3f1bb1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RoyaltyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_92baefe2-3a42-4c1d-8274-c88e20e97539" xlink:to="loc_us-gaap_RoyaltyMember_5963419d-951e-4a4b-a3ff-2123dc3f1bb1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ff572c78-406d-42a3-a0f2-8107656f6139" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_7db722c2-dc44-4f65-99f3-d6eccc50f1d8" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ff572c78-406d-42a3-a0f2-8107656f6139" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_ff572c78-406d-42a3-a0f2-8107656f6139_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ff572c78-406d-42a3-a0f2-8107656f6139" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_ff572c78-406d-42a3-a0f2-8107656f6139_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_19bfb6c5-e66d-4395-a9ad-5ca0cabb074b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ff572c78-406d-42a3-a0f2-8107656f6139" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_19bfb6c5-e66d-4395-a9ad-5ca0cabb074b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchAndDiscoveryMember_8f396e89-40d5-4d51-b9ce-fc45e505820b" xlink:href="biib-20250930.xsd#biib_ResearchAndDiscoveryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_19bfb6c5-e66d-4395-a9ad-5ca0cabb074b" xlink:to="loc_biib_ResearchAndDiscoveryMember_8f396e89-40d5-4d51-b9ce-fc45e505820b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EarlyStageProgramsMember_0bf131e1-7d5b-4af2-af05-7c7571ef4d67" xlink:href="biib-20250930.xsd#biib_EarlyStageProgramsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_19bfb6c5-e66d-4395-a9ad-5ca0cabb074b" xlink:to="loc_biib_EarlyStageProgramsMember_0bf131e1-7d5b-4af2-af05-7c7571ef4d67" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LateStageProgramsMember_c2f8fb01-44fd-46d9-87ac-92ed445793f7" xlink:href="biib-20250930.xsd#biib_LateStageProgramsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_19bfb6c5-e66d-4395-a9ad-5ca0cabb074b" xlink:to="loc_biib_LateStageProgramsMember_c2f8fb01-44fd-46d9-87ac-92ed445793f7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MarketedProductsMember_99366a39-0f4c-4a55-bca6-1e005eda1593" xlink:href="biib-20250930.xsd#biib_MarketedProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_19bfb6c5-e66d-4395-a9ad-5ca0cabb074b" xlink:to="loc_biib_MarketedProductsMember_99366a39-0f4c-4a55-bca6-1e005eda1593" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceOtherMember_841691d1-8195-409a-a576-475db928baee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ServiceOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_19bfb6c5-e66d-4395-a9ad-5ca0cabb074b" xlink:to="loc_us-gaap_ServiceOtherMember_841691d1-8195-409a-a576-475db928baee" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_b5139b9b-0150-49a1-bf1a-ec67ea683a60" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_bfbe9772-2964-446f-9134-6c0efe85d607" xlink:to="loc_us-gaap_Revenues_b5139b9b-0150-49a1-bf1a-ec67ea683a60" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_37566419-4e32-47c6-aa69-1bed7774064f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_bfbe9772-2964-446f-9134-6c0efe85d607" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_37566419-4e32-47c6-aa69-1bed7774064f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_fdc1b1cd-15f8-4cb3-a83e-c6b6c9df330d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_bfbe9772-2964-446f-9134-6c0efe85d607" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_fdc1b1cd-15f8-4cb3-a83e-c6b6c9df330d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchAndDevelopmentExpenseIncludingAcquiredInProcessCost_34096662-90a5-4cc8-bc75-0dfb496fee9c" xlink:href="biib-20250930.xsd#biib_ResearchAndDevelopmentExpenseIncludingAcquiredInProcessCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_bfbe9772-2964-446f-9134-6c0efe85d607" xlink:to="loc_biib_ResearchAndDevelopmentExpenseIncludingAcquiredInProcessCost_34096662-90a5-4cc8-bc75-0dfb496fee9c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_c32a5f5a-2c91-4978-abe6-ab6ef6ef25a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_bfbe9772-2964-446f-9134-6c0efe85d607" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_c32a5f5a-2c91-4978-abe6-ab6ef6ef25a4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount_7ef7bb2b-6497-418f-bba8-134dd3a40484" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_bfbe9772-2964-446f-9134-6c0efe85d607" xlink:to="loc_us-gaap_SegmentReportingOtherItemAmount_7ef7bb2b-6497-418f-bba8-134dd3a40484" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_fc5b03cc-50d7-4051-920f-dd6b084bfa72" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_bfbe9772-2964-446f-9134-6c0efe85d607" xlink:to="loc_us-gaap_NetIncomeLoss_fc5b03cc-50d7-4051-920f-dd6b084bfa72" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#SubsequentEventsDetails"/>
  <link:definitionLink xlink:role="http://www.biogenidec.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_bdac9a5b-9cc7-4b34-bbab-8229f1786afa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_91e195bd-d6a5-4205-add7-31894e83ff14" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_bdac9a5b-9cc7-4b34-bbab-8229f1786afa" xlink:to="loc_us-gaap_SubsequentEventTable_91e195bd-d6a5-4205-add7-31894e83ff14" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_66fca5aa-133a-467f-9865-5adb049f5d6d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_91e195bd-d6a5-4205-add7-31894e83ff14" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_66fca5aa-133a-467f-9865-5adb049f5d6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_66fca5aa-133a-467f-9865-5adb049f5d6d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_66fca5aa-133a-467f-9865-5adb049f5d6d" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_66fca5aa-133a-467f-9865-5adb049f5d6d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a5b735e9-3a2a-4733-8b11-a44c96566445" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_66fca5aa-133a-467f-9865-5adb049f5d6d" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_a5b735e9-3a2a-4733-8b11-a44c96566445" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_2d3a81fe-ead7-479a-92b4-fd28acd742f5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_a5b735e9-3a2a-4733-8b11-a44c96566445" xlink:to="loc_us-gaap_SubsequentEventMember_2d3a81fe-ead7-479a-92b4-fd28acd742f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_62bcbd43-956b-4380-893f-fa7343e64bb0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_91e195bd-d6a5-4205-add7-31894e83ff14" xlink:to="loc_us-gaap_TypeOfArrangementAxis_62bcbd43-956b-4380-893f-fa7343e64bb0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_62bcbd43-956b-4380-893f-fa7343e64bb0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_62bcbd43-956b-4380-893f-fa7343e64bb0" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_62bcbd43-956b-4380-893f-fa7343e64bb0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_04831eba-449a-477e-bb48-f7dbe448902b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_62bcbd43-956b-4380-893f-fa7343e64bb0" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_04831eba-449a-477e-bb48-f7dbe448902b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_VanquaBioInc.Member_64c47b83-dad3-44dc-893c-5b1865f9550b" xlink:href="biib-20250930.xsd#biib_VanquaBioInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_04831eba-449a-477e-bb48-f7dbe448902b" xlink:to="loc_biib_VanquaBioInc.Member_64c47b83-dad3-44dc-893c-5b1865f9550b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5cd4d146-0704-4fa6-b704-cc8e31530c65" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_91e195bd-d6a5-4205-add7-31894e83ff14" xlink:to="loc_srt_ProductOrServiceAxis_5cd4d146-0704-4fa6-b704-cc8e31530c65" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5cd4d146-0704-4fa6-b704-cc8e31530c65_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_5cd4d146-0704-4fa6-b704-cc8e31530c65" xlink:to="loc_srt_ProductsAndServicesDomain_5cd4d146-0704-4fa6-b704-cc8e31530c65_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c7a6033b-342a-4254-8081-8af2f237f356" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_5cd4d146-0704-4fa6-b704-cc8e31530c65" xlink:to="loc_srt_ProductsAndServicesDomain_c7a6033b-342a-4254-8081-8af2f237f356" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_b60d3b0d-9e30-438a-9789-c4877c2ee1b4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_c7a6033b-342a-4254-8081-8af2f237f356" xlink:to="loc_us-gaap_LicenseMember_b60d3b0d-9e30-438a-9789-c4877c2ee1b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_5016ffef-24a6-4f9a-ac4c-3854afe90280" xlink:href="biib-20250930.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_bdac9a5b-9cc7-4b34-bbab-8229f1786afa" xlink:to="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_5016ffef-24a6-4f9a-ac4c-3854afe90280" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>biib-20250930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:56b2dfbb-fb98-49e8-bcdc-e902c065377c,g:9aa702a5-e336-43c4-a300-999553ccda1f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_currency_CHF_1cb48055-d404-4ad5-acc7-32fc9dedd035_terseLabel_en-US" xlink:label="lab_currency_CHF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Swiss franc</link:label>
    <link:label id="lab_currency_CHF_label_en-US" xlink:label="lab_currency_CHF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Switzerland, Francs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CHF" xlink:href="https://xbrl.sec.gov/currency/2025/currency-2025.xsd#currency_CHF"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_CHF" xlink:to="lab_currency_CHF" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_4f552df8-9cb9-4bde-85d3-340b55378c34_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_9a28f5ef-17ae-448c-a13c-9f0394e80c85_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementAxis_3312fbda-2b0c-4f21-90fa-58e9b30ad783_terseLabel_en-US" xlink:label="lab_srt_RestatementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revision of Prior Period [Axis]</link:label>
    <link:label id="lab_srt_RestatementAxis_label_en-US" xlink:label="lab_srt_RestatementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revision of Prior Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementAxis" xlink:to="lab_srt_RestatementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_ee27e66a-c487-49d1-9e04-8d8c4c0f137d_verboseLabel_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_label_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets Excluding Goodwill [Table Text Block]</link:label>
    <link:label id="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_documentation_en-US" xlink:label="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intangible assets excluding goodwill.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:href="biib-20250930.xsd#biib_IntangibleAssetsExcludingGoodwillTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:to="lab_biib_IntangibleAssetsExcludingGoodwillTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1_b17c2014-e275-4529-93de-bf9cb13b5797_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Expected Cost Remaining</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Expected Cost Remaining</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_b718b10b-46fa-4bf3-87a9-535310d1c462_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable debt and equity securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ZorevunersenMember_6a8ecfeb-b6d3-4651-9f4f-f6c94cf34e4a_terseLabel_en-US" xlink:label="lab_biib_ZorevunersenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Zorevunersen</link:label>
    <link:label id="lab_biib_ZorevunersenMember_label_en-US" xlink:label="lab_biib_ZorevunersenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Zorevunersen [Member]</link:label>
    <link:label id="lab_biib_ZorevunersenMember_documentation_en-US" xlink:label="lab_biib_ZorevunersenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Zorevunersen</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ZorevunersenMember" xlink:href="biib-20250930.xsd#biib_ZorevunersenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ZorevunersenMember" xlink:to="lab_biib_ZorevunersenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_f389a44f-92bd-438b-a356-579e5632082d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">(Gains) losses on investments, net</link:label>
    <link:label id="lab_us-gaap_RealizedInvestmentGainsLosses_label_en-US" xlink:label="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Realized Investment Gains (Losses)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RealizedInvestmentGainsLosses" xlink:to="lab_us-gaap_RealizedInvestmentGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_bcde5d48-8b1b-4adf-94d8-e1698ec06c44_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_7bf8cc7d-574d-4eea-b5c4-64c45aaff0d0_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_b42190e2-2b8b-4f79-8fc6-8a0a0b405b56_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_d4873afc-0a59-449c-a296-9a008261d1d3_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other Consolidated Financial Statement Detail</link:label>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Financial Information Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:to="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_79d9d26f-5d84-4074-a18a-cfefb4512d80_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New accounting pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_StokeTherapeuticsIncMember_3e687bac-47f2-4112-84f8-8032e6a83e79_terseLabel_en-US" xlink:label="lab_biib_StokeTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stoke Therapeutics Inc</link:label>
    <link:label id="lab_biib_StokeTherapeuticsIncMember_label_en-US" xlink:label="lab_biib_StokeTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stoke Therapeutics Inc [Member]</link:label>
    <link:label id="lab_biib_StokeTherapeuticsIncMember_documentation_en-US" xlink:label="lab_biib_StokeTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stoke Therapeutics Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StokeTherapeuticsIncMember" xlink:href="biib-20250930.xsd#biib_StokeTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StokeTherapeuticsIncMember" xlink:to="lab_biib_StokeTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_00412048-4aea-4ec3-b995-cc347738a795_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred, Liabilities Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_df669de2-4099-4b6d-a82d-3258d3376820_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term debt securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesMember" xlink:to="lab_us-gaap_DebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_431a6ffb-387f-496e-90c7-692e33c1098e_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_67feab81-496b-4d84-b77a-07a28c1fe261_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DenaliTherapeuticsIncMember_141f189a-8b3c-4ac4-97d7-089947e43719_terseLabel_en-US" xlink:label="lab_biib_DenaliTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Denali Therapeutics</link:label>
    <link:label id="lab_biib_DenaliTherapeuticsIncMember_label_en-US" xlink:label="lab_biib_DenaliTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Denali Therapeutics Inc [Member]</link:label>
    <link:label id="lab_biib_DenaliTherapeuticsIncMember_documentation_en-US" xlink:label="lab_biib_DenaliTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Denali Therapeutics Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember" xlink:href="biib-20250930.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DenaliTherapeuticsIncMember" xlink:to="lab_biib_DenaliTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_5f5d5660-0576-4a34-bb35-10b9a17f905f_terseLabel_en-US" xlink:label="lab_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty percentage to be received</link:label>
    <link:label id="lab_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_label_en-US" xlink:label="lab_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Royalties Percentage To Be Received On Sale Of Product</link:label>
    <link:label id="lab_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_documentation_en-US" xlink:label="lab_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Future royalties percentage to be received on sale of product.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" xlink:href="biib-20250930.xsd#biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" xlink:to="lab_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_5c23819d-8d56-4b58-bc6e-66d46ae52045_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SPINRAZAMember_15738d45-c730-4468-ad71-63f05e1500d7_terseLabel_en-US" xlink:label="lab_biib_SPINRAZAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SPINRAZA</link:label>
    <link:label id="lab_biib_SPINRAZAMember_label_en-US" xlink:label="lab_biib_SPINRAZAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SPINRAZA [Member]</link:label>
    <link:label id="lab_biib_SPINRAZAMember_documentation_en-US" xlink:label="lab_biib_SPINRAZAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">SPINRAZA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SPINRAZAMember" xlink:href="biib-20250930.xsd#biib_SPINRAZAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SPINRAZAMember" xlink:to="lab_biib_SPINRAZAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_685950ba-0d13-45fa-bad7-57823d1f2810_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_2566e993-b3eb-465b-8cb0-96683ede334a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Asset, Indefinite-Lived [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_9b711f63-20d3-4772-9e71-0d7888f8f016_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under stock award plan (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets_2b118202-2611-40db-8788-7ec259f0ce68_terseLabel_en-US" xlink:label="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease assets</link:label>
    <link:label id="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets_label_en-US" xlink:label="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Operating Lease Assets</link:label>
    <link:label id="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets_documentation_en-US" xlink:label="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Operating Lease Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets" xlink:href="biib-20250930.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets" xlink:to="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_19418bbd-f46d-4801-9202-2802807535c5_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_9cae2e08-b13e-4600-88f3-081b4306048e_verboseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_979ed8f3-d08b-42b3-ae33-51e4b0a205e1_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_A2023TermLoanMember_0593267d-d3d8-432e-ad26-79ab70303d56_terseLabel_en-US" xlink:label="lab_biib_A2023TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023 Term Loan</link:label>
    <link:label id="lab_biib_A2023TermLoanMember_label_en-US" xlink:label="lab_biib_A2023TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2023 Term Loan [Member]</link:label>
    <link:label id="lab_biib_A2023TermLoanMember_documentation_en-US" xlink:label="lab_biib_A2023TermLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2023 Term Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2023TermLoanMember" xlink:href="biib-20250930.xsd#biib_A2023TermLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2023TermLoanMember" xlink:to="lab_biib_A2023TermLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets_30119720-cb83-4112-a428-492d1b847f68_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of intangible assets</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:to="lab_us-gaap_ProceedsFromSaleOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_128659c7-39d9-4ad7-afc0-1ee2d627c41a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_22b52c05-fbeb-4859-a4a4-55f5ab2297e6_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_5b1e02b7-c615-434f-9123-9413169af569_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, by Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_e230e37e-4de6-4d84-a134-c6498bce46d8_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_60291929-99ee-4b9e-9526-1b00939a4070_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_66bef8bd-4b9e-4cca-96b7-e849319f5ded_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset impairment charges</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_UCBPharmaSAMember_aec5d7ea-82cf-47ed-95b7-74b1fb815797_terseLabel_en-US" xlink:label="lab_biib_UCBPharmaSAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">UCB Pharma S.A.</link:label>
    <link:label id="lab_biib_UCBPharmaSAMember_label_en-US" xlink:label="lab_biib_UCBPharmaSAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UCB Pharma S.A. [Member]</link:label>
    <link:label id="lab_biib_UCBPharmaSAMember_documentation_en-US" xlink:label="lab_biib_UCBPharmaSAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">UCB Pharma S.A.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UCBPharmaSAMember" xlink:href="biib-20250930.xsd#biib_UCBPharmaSAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UCBPharmaSAMember" xlink:to="lab_biib_UCBPharmaSAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_3e62e0f2-e3e4-485b-9502-edf79fa134ba_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_5977e349-07c8-4fa3-8fe2-7d262cb53d60_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ResearchAndDiscoveryMember_7ed62d0a-35f5-46fe-b825-7f92dc638115_terseLabel_en-US" xlink:label="lab_biib_ResearchAndDiscoveryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and discovery</link:label>
    <link:label id="lab_biib_ResearchAndDiscoveryMember_label_en-US" xlink:label="lab_biib_ResearchAndDiscoveryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Discovery [Member]</link:label>
    <link:label id="lab_biib_ResearchAndDiscoveryMember_documentation_en-US" xlink:label="lab_biib_ResearchAndDiscoveryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Discovery</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchAndDiscoveryMember" xlink:href="biib-20250930.xsd#biib_ResearchAndDiscoveryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ResearchAndDiscoveryMember" xlink:to="lab_biib_ResearchAndDiscoveryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EstimatedAdditionalPaymentsUponInitiationOfNewPhases_9673e712-401b-4285-b28e-140ce42435af_terseLabel_en-US" xlink:label="lab_biib_EstimatedAdditionalPaymentsUponInitiationOfNewPhases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated additional payments upon initiation of new phases</link:label>
    <link:label id="lab_biib_EstimatedAdditionalPaymentsUponInitiationOfNewPhases_label_en-US" xlink:label="lab_biib_EstimatedAdditionalPaymentsUponInitiationOfNewPhases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Additional Payments Upon Initiation Of New Phases</link:label>
    <link:label id="lab_biib_EstimatedAdditionalPaymentsUponInitiationOfNewPhases_documentation_en-US" xlink:label="lab_biib_EstimatedAdditionalPaymentsUponInitiationOfNewPhases" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Estimated Additional Payments Upon Initiation Of New Phases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponInitiationOfNewPhases" xlink:href="biib-20250930.xsd#biib_EstimatedAdditionalPaymentsUponInitiationOfNewPhases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EstimatedAdditionalPaymentsUponInitiationOfNewPhases" xlink:to="lab_biib_EstimatedAdditionalPaymentsUponInitiationOfNewPhases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_72e1f823-f609-45d8-a7b7-f4808bba4d7f_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_6b75b053-4717-4a68-abe3-1964ca0ef6b2_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_03d53205-ef2f-4793-b88a-b4bfa6c17656_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_22867e3f-be43-4154-9ecb-afd9fde510cd_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dispositions</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_c87468b8-554a-48b9-92ef-e504c4527ce3_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_8669b976-0a46-433b-b277-ee1692355831_verboseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_63010298-94f6-42a9-b7b4-1c3ee4e896cd_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated life (in years)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_TOFIDENCEMember_8199abf8-2df5-42be-870a-2acd1339b13e_terseLabel_en-US" xlink:label="lab_biib_TOFIDENCEMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TOFIDENCE</link:label>
    <link:label id="lab_biib_TOFIDENCEMember_label_en-US" xlink:label="lab_biib_TOFIDENCEMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">TOFIDENCE [Member]</link:label>
    <link:label id="lab_biib_TOFIDENCEMember_documentation_en-US" xlink:label="lab_biib_TOFIDENCEMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">TOFIDENCE</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TOFIDENCEMember" xlink:href="biib-20250930.xsd#biib_TOFIDENCEMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TOFIDENCEMember" xlink:to="lab_biib_TOFIDENCEMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SageAndDenaliMember_b3c1a118-d227-4d81-8d8c-d71e55ba725b_terseLabel_en-US" xlink:label="lab_biib_SageAndDenaliMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sage and Denali</link:label>
    <link:label id="lab_biib_SageAndDenaliMember_label_en-US" xlink:label="lab_biib_SageAndDenaliMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sage and Denali [Member]</link:label>
    <link:label id="lab_biib_SageAndDenaliMember_documentation_en-US" xlink:label="lab_biib_SageAndDenaliMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sage and Denali</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SageAndDenaliMember" xlink:href="biib-20250930.xsd#biib_SageAndDenaliMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SageAndDenaliMember" xlink:to="lab_biib_SageAndDenaliMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_ee7f6a98-c578-4a94-a64a-5c068c3c5406_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DistributorTwoMember_a3b97f3b-ff20-489c-869c-8d61c7149a7f_terseLabel_en-US" xlink:label="lab_biib_DistributorTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Distributor Two</link:label>
    <link:label id="lab_biib_DistributorTwoMember_label_en-US" xlink:label="lab_biib_DistributorTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Distributor Two [Member]</link:label>
    <link:label id="lab_biib_DistributorTwoMember_documentation_en-US" xlink:label="lab_biib_DistributorTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Distributor two.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DistributorTwoMember" xlink:href="biib-20250930.xsd#biib_DistributorTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DistributorTwoMember" xlink:to="lab_biib_DistributorTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_e0ab8555-3f97-4bf0-8c76-3670f1c07de6_negatedLabel_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Adjustments Relating To Prior Years</link:label>
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_label_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments To Product Revenue Reserves Relating To Sales In Prior Years</link:label>
    <link:label id="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_documentation_en-US" xlink:label="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments to product revenue reserves relating to sales in prior years.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:href="biib-20250930.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:to="lab_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_d1bcd5dc-77a2-45de-abb2-9b0a5194dd19_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAdjustmentToInventoryMember_cd9d7567-05df-42a8-a91f-e199ba81306f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentToInventoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Pro Forma Information, Nonrecurring Adjustment, Inventory, Fair Value Adjustment</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentToInventoryMember_label_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentToInventoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Pro Forma Information, Nonrecurring Adjustment, Inventory, Fair Value Adjustment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentToInventoryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentToInventoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentToInventoryMember" xlink:to="lab_us-gaap_FairValueAdjustmentToInventoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_MarketStockUnitsMember_19fc4b67-cd9e-4267-868d-3b5a0e838177_verboseLabel_en-US" xlink:label="lab_biib_MarketStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Market stock units</link:label>
    <link:label id="lab_biib_MarketStockUnitsMember_label_en-US" xlink:label="lab_biib_MarketStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Market Stock Units [Member]</link:label>
    <link:label id="lab_biib_MarketStockUnitsMember_documentation_en-US" xlink:label="lab_biib_MarketStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Market stock units.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MarketStockUnitsMember" xlink:href="biib-20250930.xsd#biib_MarketStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MarketStockUnitsMember" xlink:to="lab_biib_MarketStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7d7bbc1c-3c47-4809-a885-737c282b799c_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income before income tax (benefit) expense</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_1cc9650b-2a09-4cf6-88aa-bfd77bb5eb14_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_d94c02f4-c1e0-4eac-b872-0d2f5e3c6ff6_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of fair and carrying value of debt instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_de229ff1-1ff0-4ef3-a252-db9d0f5d739c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_6f195bec-1f07-4e5a-9efd-e558e28de9bd_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of priority review voucher</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_310720ba-e3f3-44e3-8bac-73982508ceed_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_3440447a-80cd-464c-a795-1189fbcbafaf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Capitalized share-based compensation costs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Amount Capitalized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ContingentCommercializedRightsNumberOfProducts_eb4d8e47-7d1c-490b-afb9-48d55cf56b96_terseLabel_en-US" xlink:label="lab_biib_ContingentCommercializedRightsNumberOfProducts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Commercialized Rights, Number Of Products</link:label>
    <link:label id="lab_biib_ContingentCommercializedRightsNumberOfProducts_label_en-US" xlink:label="lab_biib_ContingentCommercializedRightsNumberOfProducts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Commercialized Rights, Number Of Products</link:label>
    <link:label id="lab_biib_ContingentCommercializedRightsNumberOfProducts_documentation_en-US" xlink:label="lab_biib_ContingentCommercializedRightsNumberOfProducts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contingent Commercialized Rights, Number Of Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContingentCommercializedRightsNumberOfProducts" xlink:href="biib-20250930.xsd#biib_ContingentCommercializedRightsNumberOfProducts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ContingentCommercializedRightsNumberOfProducts" xlink:to="lab_biib_ContingentCommercializedRightsNumberOfProducts" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_MilestonePaymentCommercialMember_4a0fcdb9-68e7-4e51-85c1-249ff3b1691f_terseLabel_en-US" xlink:label="lab_biib_MilestonePaymentCommercialMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone Payment, Commercial</link:label>
    <link:label id="lab_biib_MilestonePaymentCommercialMember_label_en-US" xlink:label="lab_biib_MilestonePaymentCommercialMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Payment, Commercial [Member]</link:label>
    <link:label id="lab_biib_MilestonePaymentCommercialMember_documentation_en-US" xlink:label="lab_biib_MilestonePaymentCommercialMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone Payment, Commercial</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MilestonePaymentCommercialMember" xlink:href="biib-20250930.xsd#biib_MilestonePaymentCommercialMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MilestonePaymentCommercialMember" xlink:to="lab_biib_MilestonePaymentCommercialMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AlzheimersCollaborationMember_12edc015-eda2-4274-aa1d-218cc55cd34c_terseLabel_en-US" xlink:label="lab_biib_AlzheimersCollaborationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Alzheimer's Collaboration</link:label>
    <link:label id="lab_biib_AlzheimersCollaborationMember_label_en-US" xlink:label="lab_biib_AlzheimersCollaborationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alzheimer's Collaboration [Member]</link:label>
    <link:label id="lab_biib_AlzheimersCollaborationMember_documentation_en-US" xlink:label="lab_biib_AlzheimersCollaborationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Alzheimer's Collaboration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AlzheimersCollaborationMember" xlink:href="biib-20250930.xsd#biib_AlzheimersCollaborationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AlzheimersCollaborationMember" xlink:to="lab_biib_AlzheimersCollaborationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_LesseeOperatingLeaseNumberOfRenewalOptions_238a90cc-d421-4e9e-a86a-b5077989d772_terseLabel_en-US" xlink:label="lab_biib_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of renewal options</link:label>
    <link:label id="lab_biib_LesseeOperatingLeaseNumberOfRenewalOptions_label_en-US" xlink:label="lab_biib_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Number Of Renewal Options</link:label>
    <link:label id="lab_biib_LesseeOperatingLeaseNumberOfRenewalOptions_documentation_en-US" xlink:label="lab_biib_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Number Of Renewal Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:href="biib-20250930.xsd#biib_LesseeOperatingLeaseNumberOfRenewalOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:to="lab_biib_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_2af5dd20-933d-4de0-85d2-15a9d9505342_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_IMRALDIMember_dc489ee8-7b25-43b0-9bcc-bb8ed5e54e48_terseLabel_en-US" xlink:label="lab_biib_IMRALDIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IMRALDI</link:label>
    <link:label id="lab_biib_IMRALDIMember_label_en-US" xlink:label="lab_biib_IMRALDIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IMRALDI [Member]</link:label>
    <link:label id="lab_biib_IMRALDIMember_documentation_en-US" xlink:label="lab_biib_IMRALDIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">IMRALDI [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IMRALDIMember" xlink:href="biib-20250930.xsd#biib_IMRALDIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IMRALDIMember" xlink:to="lab_biib_IMRALDIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_090eab42-5289-44b5-8bfa-338eef590779_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Restructuring reserve, beginning</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_2e5cf41d-af57-4dd1-982f-4ee4cdd53809_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Restructuring reserve, ending</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_7e3be1c6-8820-4f02-a94a-ef80d98872f9_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued income taxes</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Income Taxes, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_106df3a5-b974-4b23-8a48-dae21a766668_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense included in condensed consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_7a98a6f1-ac61-4583-9d1c-63d7a5e2cf83_terseLabel_en-US" xlink:label="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of revenues from major distributors</link:label>
    <link:label id="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_label_en-US" xlink:label="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Wide Percentage Of Revenue From Major Distributors</link:label>
    <link:label id="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors_documentation_en-US" xlink:label="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Entity wide percentage of revenue from major distributors.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:href="biib-20250930.xsd#biib_EntityWidePercentageOfRevenueFromMajorDistributors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:to="lab_biib_EntityWidePercentageOfRevenueFromMajorDistributors" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_47ed2997-00a0-431f-a6a5-feb143eab9de_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_2adc5db9-b891-4cc1-9773-cae9357b7cc7_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivatives [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesFairValueLineItems" xlink:to="lab_us-gaap_DerivativesFairValueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_89a4fc2e-dbcc-4829-8206-f99ee6ba2e3b_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_c1d9d2c7-3f65-482c-9a0c-84045d9fec54_terseLabel_en-US" xlink:label="lab_biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments in Variable Interest Entities [Abstract]</link:label>
    <link:label id="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_label_en-US" xlink:label="lab_biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments in Variable Interest Entities [Abstract]</link:label>
    <link:label id="lab_biib_InvestmentsInVariableInterestEntitiesAbstract_documentation_en-US" xlink:label="lab_biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investments In Variable Interest Entities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:href="biib-20250930.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:to="lab_biib_InvestmentsInVariableInterestEntitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_4a76b253-1a82-4ac9-b75e-8a75b8d89409_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_ae834c72-363d-460d-957d-21ac6954ee9a_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_b356df81-a88f-4b15-8d2f-22877e2bac65_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_fb7ad690-870d-440b-a1a9-5b13cccad908_terseLabel_en-US" xlink:label="lab_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected additional milestone payments when meeting certain sales threshold</link:label>
    <link:label id="lab_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_label_en-US" xlink:label="lab_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected Additional Milestone Payments When Meeting Certain Sales Threshold</link:label>
    <link:label id="lab_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_documentation_en-US" xlink:label="lab_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expected Additional Milestone Payments When Meeting Certain Sales Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold" xlink:href="biib-20250930.xsd#biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold" xlink:to="lab_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_878a0ae0-7e05-455c-babd-96de099d42ed_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative arrangements and non-collaborative arrangement transactions</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_fe2dd41e-a047-4233-80b3-1b56164813e5_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_631290a4-d94f-4b1b-ad8b-58a64f80cffe_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_80225bdf-03da-4d3b-9f1c-6e89bec11076_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_MilestonePaymentDevelopmentalMember_b997a985-0a40-40d7-bda3-660998724eca_terseLabel_en-US" xlink:label="lab_biib_MilestonePaymentDevelopmentalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone Payment, Developmental</link:label>
    <link:label id="lab_biib_MilestonePaymentDevelopmentalMember_label_en-US" xlink:label="lab_biib_MilestonePaymentDevelopmentalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Payment, Developmental [Member]</link:label>
    <link:label id="lab_biib_MilestonePaymentDevelopmentalMember_documentation_en-US" xlink:label="lab_biib_MilestonePaymentDevelopmentalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone Payment, Developmental</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MilestonePaymentDevelopmentalMember" xlink:href="biib-20250930.xsd#biib_MilestonePaymentDevelopmentalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MilestonePaymentDevelopmentalMember" xlink:to="lab_biib_MilestonePaymentDevelopmentalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FumarateMember_30955e5c-0df3-44ef-aebb-f4f6400e3514_terseLabel_en-US" xlink:label="lab_biib_FumarateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fumarate</link:label>
    <link:label id="lab_biib_FumarateMember_label_en-US" xlink:label="lab_biib_FumarateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fumarate [Member]</link:label>
    <link:label id="lab_biib_FumarateMember_documentation_en-US" xlink:label="lab_biib_FumarateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fumarate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FumarateMember" xlink:href="biib-20250930.xsd#biib_FumarateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FumarateMember" xlink:to="lab_biib_FumarateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9d930c0f-fda0-455e-86c6-963973dcf7e4_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_ce1ef458-3625-4565-bab6-dbd1690e05cb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeveranceCosts1_1cc4c559-3348-4ff3-aa9b-684c0933062e_terseLabel_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Severance Costs</link:label>
    <link:label id="lab_us-gaap_SeveranceCosts1_label_en-US" xlink:label="lab_us-gaap_SeveranceCosts1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Severance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeveranceCosts1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1" xlink:to="lab_us-gaap_SeveranceCosts1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_a4b24c80-61ce-41b8-88ff-16f0684239e3_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_f4ee805d-9490-4c0b-8ffc-91aca8952c54_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_A3.15SeniorNotesdueMay12050Member_6ef87c70-2586-454f-a0dc-c7f468f7c5b1_terseLabel_en-US" xlink:label="lab_biib_A3.15SeniorNotesdueMay12050Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">3.150% Senior Notes due May 1, 2050</link:label>
    <link:label id="lab_biib_A3.15SeniorNotesdueMay12050Member_label_en-US" xlink:label="lab_biib_A3.15SeniorNotesdueMay12050Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">3.15% Senior Notes due May 1, 2050 [Member]</link:label>
    <link:label id="lab_biib_A3.15SeniorNotesdueMay12050Member_documentation_en-US" xlink:label="lab_biib_A3.15SeniorNotesdueMay12050Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">3.15% Senior Notes due May 1, 2050 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A3.15SeniorNotesdueMay12050Member" xlink:href="biib-20250930.xsd#biib_A3.15SeniorNotesdueMay12050Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A3.15SeniorNotesdueMay12050Member" xlink:to="lab_biib_A3.15SeniorNotesdueMay12050Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_37fefcb2-1ad8-4497-8b9f-b4ecbaa980db_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions of intangible assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenseMember_320af3bf-b9c7-4b05-8aaa-150026c0deef_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expense</link:label>
    <link:label id="lab_us-gaap_OperatingExpenseMember_label_en-US" xlink:label="lab_us-gaap_OperatingExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenseMember" xlink:to="lab_us-gaap_OperatingExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BYOOVIZMember_93f6985c-3e2a-4dac-9fc2-e97ca314d589_terseLabel_en-US" xlink:label="lab_biib_BYOOVIZMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BYOOVIZ</link:label>
    <link:label id="lab_biib_BYOOVIZMember_label_en-US" xlink:label="lab_biib_BYOOVIZMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BYOOVIZ [Member]</link:label>
    <link:label id="lab_biib_BYOOVIZMember_documentation_en-US" xlink:label="lab_biib_BYOOVIZMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BYOOVIZ</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BYOOVIZMember" xlink:href="biib-20250930.xsd#biib_BYOOVIZMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BYOOVIZMember" xlink:to="lab_biib_BYOOVIZMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</link:label>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:to="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_452e34d2-f2cd-4d0d-b0b8-8d404f705fd2_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration resulting from HI-Bio acquisition</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_46a49e15-5fc1-473b-97d7-5eb5c17a3cbd_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost and net</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_f82e94c1-1ede-4abe-b344-775cd4900837_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">4.050% Senior Notes due 2025</link:label>
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_label_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_documentation_en-US" xlink:label="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:href="biib-20250930.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:to="lab_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_16e7fdbc-b406-4a32-9e6c-92611a47f13f_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance, shares</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_43325a22-ef41-4a69-8dfa-14a0b399c47e_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance, shares</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_0de9f4a9-0c60-4aed-b784-679bec826a25_terseLabel_en-US" xlink:label="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront and milestone paymentsmade to collaborative partner</link:label>
    <link:label id="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_label_en-US" xlink:label="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upfront And Milestone Payments Made To Collaborative Partner</link:label>
    <link:label id="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_documentation_en-US" xlink:label="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total upfront and milestone payments made to collaborative partner.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:href="biib-20250930.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:to="lab_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_a72b9f97-2c61-4603-b734-48ecfaba34b6_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues by product</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year</link:label>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_label_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:to="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_1a0632b7-4514-41ef-929d-68b5ccc9c352_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated future amortization for acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_56f25cd4-9a87-43c4-9fb8-dd099ea49ea3_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AlcyoneTherapeuticsInc.Member_777d4461-b604-406b-9045-8a5be76effdb_terseLabel_en-US" xlink:label="lab_biib_AlcyoneTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Alcyone Therapeutics, Inc.</link:label>
    <link:label id="lab_biib_AlcyoneTherapeuticsInc.Member_label_en-US" xlink:label="lab_biib_AlcyoneTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alcyone Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_biib_AlcyoneTherapeuticsInc.Member_documentation_en-US" xlink:label="lab_biib_AlcyoneTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Alcyone Therapeutics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AlcyoneTherapeuticsInc.Member" xlink:href="biib-20250930.xsd#biib_AlcyoneTherapeuticsInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AlcyoneTherapeuticsInc.Member" xlink:to="lab_biib_AlcyoneTherapeuticsInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_d8b969e7-a096-470c-aa6d-51204dc475f8_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_96115c67-0e8a-483f-b573-1231b94468a5_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income tax (benefit) expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_ed67a518-e5c0-4570-8038-ff46ef5a835c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsSvcCstMember" xlink:to="lab_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_78a419cf-cf31-4970-9841-4564f0e7a038_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PriorityReviewVoucherMember_65c1de5c-2343-4ebf-90c0-327a6652c4b6_terseLabel_en-US" xlink:label="lab_biib_PriorityReviewVoucherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Priority review voucher</link:label>
    <link:label id="lab_biib_PriorityReviewVoucherMember_label_en-US" xlink:label="lab_biib_PriorityReviewVoucherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Priority Review Voucher [Member]</link:label>
    <link:label id="lab_biib_PriorityReviewVoucherMember_documentation_en-US" xlink:label="lab_biib_PriorityReviewVoucherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Priority Review Voucher</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PriorityReviewVoucherMember" xlink:href="biib-20250930.xsd#biib_PriorityReviewVoucherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PriorityReviewVoucherMember" xlink:to="lab_biib_PriorityReviewVoucherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_172748b3-b92b-46e5-a949-fb7ef25c8765_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_e12ca2cf-dcb1-438f-b59f-87be1c071f85_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_133cb016-654c-49c2-9991-f266c6a9873e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) on cash flow hedges, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ReductionOfResearchAndDevelopmentExpense_d62749dd-d051-4240-92d4-09ba5d8d0825_terseLabel_en-US" xlink:label="lab_biib_ReductionOfResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reduction of research and development expense</link:label>
    <link:label id="lab_biib_ReductionOfResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_biib_ReductionOfResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reduction Of Research And Development Expense</link:label>
    <link:label id="lab_biib_ReductionOfResearchAndDevelopmentExpense_documentation_en-US" xlink:label="lab_biib_ReductionOfResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reduction Of Research And Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReductionOfResearchAndDevelopmentExpense" xlink:href="biib-20250930.xsd#biib_ReductionOfResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ReductionOfResearchAndDevelopmentExpense" xlink:to="lab_biib_ReductionOfResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FelzartamabPMNMember_adcba479-5b2a-441e-8065-383a5d55fb51_terseLabel_en-US" xlink:label="lab_biib_FelzartamabPMNMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Felzartamab (PMN)</link:label>
    <link:label id="lab_biib_FelzartamabPMNMember_label_en-US" xlink:label="lab_biib_FelzartamabPMNMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Felzartamab (PMN) [Member]</link:label>
    <link:label id="lab_biib_FelzartamabPMNMember_documentation_en-US" xlink:label="lab_biib_FelzartamabPMNMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Felzartamab (PMN)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FelzartamabPMNMember" xlink:href="biib-20250930.xsd#biib_FelzartamabPMNMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FelzartamabPMNMember" xlink:to="lab_biib_FelzartamabPMNMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ResearchAndDevelopmentExpenseIncludingAcquiredInProcessCost_e46b8591-e58a-4861-b929-685be6f18221_terseLabel_en-US" xlink:label="lab_biib_ResearchAndDevelopmentExpenseIncludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired in-process research and development, upfront and milestone expense</link:label>
    <link:label id="lab_biib_ResearchAndDevelopmentExpenseIncludingAcquiredInProcessCost_label_en-US" xlink:label="lab_biib_ResearchAndDevelopmentExpenseIncludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Expense (Including Acquired in Process Cost)</link:label>
    <link:label id="lab_biib_ResearchAndDevelopmentExpenseIncludingAcquiredInProcessCost_documentation_en-US" xlink:label="lab_biib_ResearchAndDevelopmentExpenseIncludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Expense (Including Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchAndDevelopmentExpenseIncludingAcquiredInProcessCost" xlink:href="biib-20250930.xsd#biib_ResearchAndDevelopmentExpenseIncludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ResearchAndDevelopmentExpenseIncludingAcquiredInProcessCost" xlink:to="lab_biib_ResearchAndDevelopmentExpenseIncludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_33cece6b-cf02-41e7-b34c-efcd73dbfab3_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring, Business Transformation and Other Cost Saving Initiatives</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Phase3ClinicalTrialFelzartamabAMRMember_59f4c76e-3193-4044-a7d7-c1ea9198f038_terseLabel_en-US" xlink:label="lab_biib_Phase3ClinicalTrialFelzartamabAMRMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Phase 3 Clinical Trial, Felzartamab AMR</link:label>
    <link:label id="lab_biib_Phase3ClinicalTrialFelzartamabAMRMember_label_en-US" xlink:label="lab_biib_Phase3ClinicalTrialFelzartamabAMRMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Phase 3 Clinical Trial, Felzartamab AMR [Member]</link:label>
    <link:label id="lab_biib_Phase3ClinicalTrialFelzartamabAMRMember_documentation_en-US" xlink:label="lab_biib_Phase3ClinicalTrialFelzartamabAMRMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Phase 3 Clinical Trial, Felzartamab AMR</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Phase3ClinicalTrialFelzartamabAMRMember" xlink:href="biib-20250930.xsd#biib_Phase3ClinicalTrialFelzartamabAMRMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Phase3ClinicalTrialFelzartamabAMRMember" xlink:to="lab_biib_Phase3ClinicalTrialFelzartamabAMRMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_4e36f11f-dcdd-44f6-a76d-e953e4fcbdc2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquisition of HI-Bio, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_68a8e877-66cc-402d-894a-94efa1cd8d62_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, redemption price, percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PercentageParValueOfSeniorNotes_dc1563ca-713f-4887-b22b-7f02c9f41f5d_terseLabel_en-US" xlink:label="lab_biib_PercentageParValueOfSeniorNotes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage par value of senior notes</link:label>
    <link:label id="lab_biib_PercentageParValueOfSeniorNotes_label_en-US" xlink:label="lab_biib_PercentageParValueOfSeniorNotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Par Value Of Senior Notes</link:label>
    <link:label id="lab_biib_PercentageParValueOfSeniorNotes_documentation_en-US" xlink:label="lab_biib_PercentageParValueOfSeniorNotes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage Par Value Of Senior Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageParValueOfSeniorNotes" xlink:href="biib-20250930.xsd#biib_PercentageParValueOfSeniorNotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageParValueOfSeniorNotes" xlink:to="lab_biib_PercentageParValueOfSeniorNotes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_536490a9-2490-4a5c-97f0-2c43900d49ae_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flow provided by (used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_532e495b-998c-434c-b515-6e7fed486f9a_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">(Gain) loss on strategic investments</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Equity Securities, FV-NI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:to="lab_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_6cfe6ff2-ba7c-4f0e-ba14-8d9305180759_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_0f2430ee-8385-4a7b-a451-daca1d19ba20_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_MilestonePaymentSalesBasedMember_a9bcf80b-37e6-4180-8d28-0923eabe8356_terseLabel_en-US" xlink:label="lab_biib_MilestonePaymentSalesBasedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone Payment, Sales-Based</link:label>
    <link:label id="lab_biib_MilestonePaymentSalesBasedMember_label_en-US" xlink:label="lab_biib_MilestonePaymentSalesBasedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Payment, Sales-Based [Member]</link:label>
    <link:label id="lab_biib_MilestonePaymentSalesBasedMember_documentation_en-US" xlink:label="lab_biib_MilestonePaymentSalesBasedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone Payment, Sales-Based</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MilestonePaymentSalesBasedMember" xlink:href="biib-20250930.xsd#biib_MilestonePaymentSalesBasedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MilestonePaymentSalesBasedMember" xlink:to="lab_biib_MilestonePaymentSalesBasedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BENEPALIMember_cbfb9296-4411-440d-8242-a123a3264685_terseLabel_en-US" xlink:label="lab_biib_BENEPALIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BENEPALI</link:label>
    <link:label id="lab_biib_BENEPALIMember_label_en-US" xlink:label="lab_biib_BENEPALIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BENEPALI [Member]</link:label>
    <link:label id="lab_biib_BENEPALIMember_documentation_en-US" xlink:label="lab_biib_BENEPALIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BENEPALI [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BENEPALIMember" xlink:href="biib-20250930.xsd#biib_BENEPALIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BENEPALIMember" xlink:to="lab_biib_BENEPALIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_cffcefc0-80c8-4d7d-9673-2339c2dd4c4c_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_08f064cf-13fa-4e4b-b8d8-24cc42e9b77f_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_916f3eff-ae66-4d6c-85be-371c889a0430_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_8391bd11-2316-4858-a873-2ce67e95c2d4_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative liability, fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability, Subject to Master Netting Arrangement, before Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_baa880da-d283-4832-a077-d0580c4dbad6_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025 (remaining three months)</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_9f702b06-dd13-49dc-8762-5fae115391ee_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_TheCreditFacilityMember_da26c357-8c97-4fb8-89c3-8dcff08a8fe7_terseLabel_en-US" xlink:label="lab_biib_TheCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">The Credit Facility</link:label>
    <link:label id="lab_biib_TheCreditFacilityMember_label_en-US" xlink:label="lab_biib_TheCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The Credit Facility [Member]</link:label>
    <link:label id="lab_biib_TheCreditFacilityMember_documentation_en-US" xlink:label="lab_biib_TheCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The Credit Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TheCreditFacilityMember" xlink:href="biib-20250930.xsd#biib_TheCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TheCreditFacilityMember" xlink:to="lab_biib_TheCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_NonCurrentPortionOfNotesPayableAndTermLoanMember_b73c91dd-1c0f-4550-8d99-0ab8a816ac4e_terseLabel_en-US" xlink:label="lab_biib_NonCurrentPortionOfNotesPayableAndTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-current portion of notes payable</link:label>
    <link:label id="lab_biib_NonCurrentPortionOfNotesPayableAndTermLoanMember_label_en-US" xlink:label="lab_biib_NonCurrentPortionOfNotesPayableAndTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Current Portion Of Notes Payable And Term Loan [Member]</link:label>
    <link:label id="lab_biib_NonCurrentPortionOfNotesPayableAndTermLoanMember_documentation_en-US" xlink:label="lab_biib_NonCurrentPortionOfNotesPayableAndTermLoanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-Current Portion Of Notes Payable And Term Loan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NonCurrentPortionOfNotesPayableAndTermLoanMember" xlink:href="biib-20250930.xsd#biib_NonCurrentPortionOfNotesPayableAndTermLoanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NonCurrentPortionOfNotesPayableAndTermLoanMember" xlink:to="lab_biib_NonCurrentPortionOfNotesPayableAndTermLoanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_31267e15-776b-4077-934d-20390a35b918_terseLabel_en-US" xlink:label="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:label id="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_documentation_en-US" xlink:label="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="biib-20250930.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_bcd8cabe-b184-48d0-9d2c-cb26a87c71f5_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product revenue, net</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_21aa223c-a61d-47d4-a593-97e3cf76810a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_72f5f635-05fc-4ea9-a984-d2a6a748268d_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_a0e1d611-73cd-4faa-91ad-81595fa2cef0_verboseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of reportable segment</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_ddbe4a3d-8448-417c-a103-42b2337cb690_terseLabel_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total reserves included in consolidated balance sheets</link:label>
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_label_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary Of Product Revenue Reserves Included In Consolidated Balance Sheets [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_documentation_en-US" xlink:label="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary of total product revenue reserves included in consolidated balance sheets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:href="biib-20250930.xsd#biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:to="lab_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesMember_b8733c3e-d270-497a-a1e0-93f1db08600e_terseLabel_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_SalesMember_label_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesMember" xlink:to="lab_us-gaap_SalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_InventoryNetCurrentAndNoncurrent_d144c316-728f-46e0-b49d-10e2088ccd71_totalLabel_en-US" xlink:label="lab_biib_InventoryNetCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_biib_InventoryNetCurrentAndNoncurrent_label_en-US" xlink:label="lab_biib_InventoryNetCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net Current and Noncurrent</link:label>
    <link:label id="lab_biib_InventoryNetCurrentAndNoncurrent_documentation_en-US" xlink:label="lab_biib_InventoryNetCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inventory, Net Current and Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InventoryNetCurrentAndNoncurrent" xlink:href="biib-20250930.xsd#biib_InventoryNetCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InventoryNetCurrentAndNoncurrent" xlink:to="lab_biib_InventoryNetCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherRestructuringCosts_398e0ad4-7175-47fa-b3c3-afb7bb970ad7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherRestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accelerated Depreciation and Other Costs</link:label>
    <link:label id="lab_us-gaap_OtherRestructuringCosts_label_en-US" xlink:label="lab_us-gaap_OtherRestructuringCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Restructuring Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherRestructuringCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherRestructuringCosts" xlink:to="lab_us-gaap_OtherRestructuringCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_53d7ad5e-4f92-47cb-b6c8-6b832757903f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under stock option and stock purchase plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Treasury Stock Reissued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_d0b5a4c3-2977-4d4a-b2f0-f394db69f143_verboseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investments in Variable Interest Entities</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Interest Entity Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:to="lab_us-gaap_VariableInterestEntityDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_2a4502ac-9dbf-4bb7-85f6-58cc2bdc3b70_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1ae54ba2-16b6-40de-a44b-a702e81a3bc8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ContractOptionExerciseFee_cfd27a6f-ba5c-45bb-b575-a9d75e469978_terseLabel_en-US" xlink:label="lab_biib_ContractOptionExerciseFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option exercise fee</link:label>
    <link:label id="lab_biib_ContractOptionExerciseFee_label_en-US" xlink:label="lab_biib_ContractOptionExerciseFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract Option Exercise Fee</link:label>
    <link:label id="lab_biib_ContractOptionExerciseFee_documentation_en-US" xlink:label="lab_biib_ContractOptionExerciseFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract Option Exercise Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractOptionExerciseFee" xlink:href="biib-20250930.xsd#biib_ContractOptionExerciseFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ContractOptionExerciseFee" xlink:to="lab_biib_ContractOptionExerciseFee" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_EUR_af612117-dda3-406b-a730-c8f68cd409a1_terseLabel_en-US" xlink:label="lab_currency_EUR" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Euro</link:label>
    <link:label id="lab_currency_EUR_label_en-US" xlink:label="lab_currency_EUR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Euro Member Countries, Euro</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR" xlink:href="https://xbrl.sec.gov/currency/2025/currency-2025.xsd#currency_EUR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_EUR" xlink:to="lab_currency_EUR" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_2c537347-5c63-4eb0-9954-052401f7fe55_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency cash flow hedge gain (loss) to be reclassified during next 12 months</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:to="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_LUNSUMIOMember_7dee4318-8c1e-4d14-ba71-11b57f36bb05_terseLabel_en-US" xlink:label="lab_biib_LUNSUMIOMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LUNSUMIO</link:label>
    <link:label id="lab_biib_LUNSUMIOMember_label_en-US" xlink:label="lab_biib_LUNSUMIOMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">LUNSUMIO [Member]</link:label>
    <link:label id="lab_biib_LUNSUMIOMember_documentation_en-US" xlink:label="lab_biib_LUNSUMIOMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">LUNSUMIO</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LUNSUMIOMember" xlink:href="biib-20250930.xsd#biib_LUNSUMIOMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_LUNSUMIOMember" xlink:to="lab_biib_LUNSUMIOMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_00cddc2f-a599-4d70-b41f-4ad1c13543e6_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PayablesToDivestitureOfInterestInJointVenture_ba22aded-6c84-401e-88af-4a2b24bd874e_terseLabel_en-US" xlink:label="lab_biib_PayablesToDivestitureOfInterestInJointVenture" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payables to divestiture of interest in joint venture</link:label>
    <link:label id="lab_biib_PayablesToDivestitureOfInterestInJointVenture_label_en-US" xlink:label="lab_biib_PayablesToDivestitureOfInterestInJointVenture" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payables To Divestiture Of Interest In Joint Venture</link:label>
    <link:label id="lab_biib_PayablesToDivestitureOfInterestInJointVenture_documentation_en-US" xlink:label="lab_biib_PayablesToDivestitureOfInterestInJointVenture" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payables To Divestiture Of Interest In Joint Venture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PayablesToDivestitureOfInterestInJointVenture" xlink:href="biib-20250930.xsd#biib_PayablesToDivestitureOfInterestInJointVenture"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PayablesToDivestitureOfInterestInJointVenture" xlink:to="lab_biib_PayablesToDivestitureOfInterestInJointVenture" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_709bf672-c48b-4ef3-b96a-2d13fa6093b5_verboseLabel_en-US" xlink:label="lab_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Limit of gross sale of GAZYVA to be achieved in any 12 months under option one</link:label>
    <link:label id="lab_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_label_en-US" xlink:label="lab_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Threshold Of Gross Sales To Be Achieved In Any Twelve Consecutive Months Under Option One</link:label>
    <link:label id="lab_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_documentation_en-US" xlink:label="lab_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Threshold of gross sales to be achieved in any twelve consecutive months under option one.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne" xlink:href="biib-20250930.xsd#biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne" xlink:to="lab_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock_1d507d4d-3765-4e90-a8dd-ffd0c9df6121_terseLabel_en-US" xlink:label="lab_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Unrealized Gain (Loss)</link:label>
    <link:label id="lab_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock_label_en-US" xlink:label="lab_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Unrealized Gain (Loss) [Table Text Block]</link:label>
    <link:label id="lab_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock_documentation_en-US" xlink:label="lab_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock" xlink:href="biib-20250930.xsd#biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock" xlink:to="lab_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_14d5f57a-53c0-4b9a-97f2-d03ae33ea144_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_fdd04fca-a20a-4fc0-b37d-8d9b33afe37f_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_1194fe09-6ce1-45b9-96e0-c2772240989f_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_ec74ae72-a226-4c84-a832-3d06324d8391_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repayments of borrowings</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_d704a6ce-34d3-4143-8263-7b177699bb8d_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PaymentDueAtFirstAnniversaryMember_ac902993-21b9-43c5-ae43-85932ef42a0f_terseLabel_en-US" xlink:label="lab_biib_PaymentDueAtFirstAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment Due At First Anniversary</link:label>
    <link:label id="lab_biib_PaymentDueAtFirstAnniversaryMember_label_en-US" xlink:label="lab_biib_PaymentDueAtFirstAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment Due At First Anniversary [Member]</link:label>
    <link:label id="lab_biib_PaymentDueAtFirstAnniversaryMember_documentation_en-US" xlink:label="lab_biib_PaymentDueAtFirstAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payment Due At First Anniversary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentDueAtFirstAnniversaryMember" xlink:href="biib-20250930.xsd#biib_PaymentDueAtFirstAnniversaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentDueAtFirstAnniversaryMember" xlink:to="lab_biib_PaymentDueAtFirstAnniversaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock_559c1ad3-bd96-42ad-a591-1295970c088f_terseLabel_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of activity related to the UCB collaboration</link:label>
    <link:label id="lab_biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock_label_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of Activity Related to the UCB Collaboration [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock_documentation_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary of Activity Related to the UCB Collaboration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock" xlink:href="biib-20250930.xsd#biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock" xlink:to="lab_biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_5286f6e7-ae07-4c81-82ec-edc3c450a653_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:to="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentOwnedAtCost_85022a03-e0c5-4ed1-b559-77e664221b22_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentOwnedAtCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment owned, cost</link:label>
    <link:label id="lab_us-gaap_InvestmentOwnedAtCost_label_en-US" xlink:label="lab_us-gaap_InvestmentOwnedAtCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Owned, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedAtCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentOwnedAtCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentOwnedAtCost" xlink:to="lab_us-gaap_InvestmentOwnedAtCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_d511836c-1047-4789-af3a-bd3d62a3106b_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_de53dc96-5420-4f58-b2df-d11b6faf78ad_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_InterferonMember_265f7e55-934e-4fd7-af90-4655fa6bd475_terseLabel_en-US" xlink:label="lab_biib_InterferonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interferon</link:label>
    <link:label id="lab_biib_InterferonMember_label_en-US" xlink:label="lab_biib_InterferonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interferon [Member]</link:label>
    <link:label id="lab_biib_InterferonMember_documentation_en-US" xlink:label="lab_biib_InterferonMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interferon</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InterferonMember" xlink:href="biib-20250930.xsd#biib_InterferonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InterferonMember" xlink:to="lab_biib_InterferonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FUMADERMAndADUHELMMember_a2bba442-ac85-4b6c-8b9a-0bdd17f51fef_terseLabel_en-US" xlink:label="lab_biib_FUMADERMAndADUHELMMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FUMADERM And ADUHELM</link:label>
    <link:label id="lab_biib_FUMADERMAndADUHELMMember_label_en-US" xlink:label="lab_biib_FUMADERMAndADUHELMMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">FUMADERM And ADUHELM [Member]</link:label>
    <link:label id="lab_biib_FUMADERMAndADUHELMMember_documentation_en-US" xlink:label="lab_biib_FUMADERMAndADUHELMMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">FUMADERM And ADUHELM</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FUMADERMAndADUHELMMember" xlink:href="biib-20250930.xsd#biib_FUMADERMAndADUHELMMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FUMADERMAndADUHELMMember" xlink:to="lab_biib_FUMADERMAndADUHELMMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_f0a1db45-480d-4d33-9246-8cc686dc5b32_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_2bcb0032-57c8-4d31-a3f8-9cc824d3e456_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_259b9bc2-6d74-4c48-a9b1-48028d42ff6a_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Reserves</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_e4190b66-2458-4052-8065-9f248f3aaf1c_verboseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue-related reserves for discounts and allowances</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_78b9a2ab-31d7-406c-9c7e-8127ec1496cb_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Investments and other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_059f48c1-1b8c-4892-b794-934e85ddf423_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_67475d67-07f9-4755-92d1-00458526216b_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_e9e5903e-4fb5-409e-9f59-a9c1726ad4be_verboseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_c547305d-9224-4df8-af21-24dc62e07c3f_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_6680a318-9a58-4eec-a189-72f9cc620fcc_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</link:label>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_label_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:to="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_d691bc3a-06b3-41e3-ba9c-68113ec0f90e_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Fair value, beginning of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_4ce1d8e3-baf8-4c27-91aa-e497a2c4a5b2_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Fair value, end of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_dde13b25-2d42-41b2-854f-8ff754222a79_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_fd9c87ad-55c5-4b2e-89c5-2955433f7258_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of fair value and presentation of derivatives</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_04f75681-9426-49f5-9d02-7bd71e58fd6b_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ReataIntegrationMember_7f36e0cf-a020-497f-a594-cae46c568aa6_terseLabel_en-US" xlink:label="lab_biib_ReataIntegrationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reata Integration</link:label>
    <link:label id="lab_biib_ReataIntegrationMember_label_en-US" xlink:label="lab_biib_ReataIntegrationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reata Integration [Member]</link:label>
    <link:label id="lab_biib_ReataIntegrationMember_documentation_en-US" xlink:label="lab_biib_ReataIntegrationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reata Integration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataIntegrationMember" xlink:href="biib-20250930.xsd#biib_ReataIntegrationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ReataIntegrationMember" xlink:to="lab_biib_ReataIntegrationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_25ab0c2d-1d5b-4bbf-918f-4fa50652281b_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EarlyStageProgramsMember_bb6e5551-9e88-4270-8e97-a947e6da592e_terseLabel_en-US" xlink:label="lab_biib_EarlyStageProgramsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Early stage programs</link:label>
    <link:label id="lab_biib_EarlyStageProgramsMember_label_en-US" xlink:label="lab_biib_EarlyStageProgramsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Early Stage Programs [Member]</link:label>
    <link:label id="lab_biib_EarlyStageProgramsMember_documentation_en-US" xlink:label="lab_biib_EarlyStageProgramsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Early Stage Programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EarlyStageProgramsMember" xlink:href="biib-20250930.xsd#biib_EarlyStageProgramsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EarlyStageProgramsMember" xlink:to="lab_biib_EarlyStageProgramsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_a5388920-07ea-4fb3-a0d1-88e494dfbf8f_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryCurrentTable_33710773-96b8-42d0-afca-e0921e9e572f_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:label id="lab_us-gaap_InventoryCurrentTable_label_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryCurrentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryCurrentTable" xlink:to="lab_us-gaap_InventoryCurrentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_3dc716b5-1ced-4199-a86e-f06aa7a37973_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_10d3ec0e-71ad-4a9d-8779-a352db1d03b7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNoncurrent_57c5b0eb-d2eb-4315-a9e3-ddd816ee5e17_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, noncurrent</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_label_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNoncurrent" xlink:to="lab_us-gaap_InventoryNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_InterestInSubsidiary_4c9fc4c8-6094-401f-9db8-b77f558a5d70_verboseLabel_en-US" xlink:label="lab_biib_InterestInSubsidiary" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Interest in subsidiary (less than given percentage)</link:label>
    <link:label id="lab_biib_InterestInSubsidiary_label_en-US" xlink:label="lab_biib_InterestInSubsidiary" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest In Subsidiary</link:label>
    <link:label id="lab_biib_InterestInSubsidiary_documentation_en-US" xlink:label="lab_biib_InterestInSubsidiary" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest in subsidiary.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InterestInSubsidiary" xlink:href="biib-20250930.xsd#biib_InterestInSubsidiary"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InterestInSubsidiary" xlink:to="lab_biib_InterestInSubsidiary" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonrelatedPartyMember_656cd4ed-da81-4205-80d6-6507ca87774a_terseLabel_en-US" xlink:label="lab_us-gaap_NonrelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nonrelated Party</link:label>
    <link:label id="lab_us-gaap_NonrelatedPartyMember_label_en-US" xlink:label="lab_us-gaap_NonrelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonrelated Party [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonrelatedPartyMember" xlink:to="lab_us-gaap_NonrelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_290be209-6bd0-4f58-8e56-b5d96bea7d71_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_ca489110-4c50-4259-a419-87192a841d77_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_3ba52213-6c32-4f37-8de3-0f99d74c2de0_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_E2609andBAN2401Member_b81d8a17-ecc1-47a9-b8aa-3ac00916799b_terseLabel_en-US" xlink:label="lab_biib_E2609andBAN2401Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">E2609 and BAN2401</link:label>
    <link:label id="lab_biib_E2609andBAN2401Member_label_en-US" xlink:label="lab_biib_E2609andBAN2401Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">E2609 and BAN2401 [Member]</link:label>
    <link:label id="lab_biib_E2609andBAN2401Member_documentation_en-US" xlink:label="lab_biib_E2609andBAN2401Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">E2609 and BAN2401 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_E2609andBAN2401Member" xlink:href="biib-20250930.xsd#biib_E2609andBAN2401Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_E2609andBAN2401Member" xlink:to="lab_biib_E2609andBAN2401Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent_c8a30d66-658c-4e8c-a982-20379749d85e_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative liabilities</link:label>
    <link:label id="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConstructionPayableCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent" xlink:to="lab_us-gaap_ConstructionPayableCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year</link:label>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:to="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FelzartamabAMRMember_adb8246c-4d0e-4810-a9d6-2e499928bb00_terseLabel_en-US" xlink:label="lab_biib_FelzartamabAMRMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Felzartamab (AMR)</link:label>
    <link:label id="lab_biib_FelzartamabAMRMember_label_en-US" xlink:label="lab_biib_FelzartamabAMRMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Felzartamab (AMR) [Member]</link:label>
    <link:label id="lab_biib_FelzartamabAMRMember_documentation_en-US" xlink:label="lab_biib_FelzartamabAMRMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Felzartamab (AMR)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FelzartamabAMRMember" xlink:href="biib-20250930.xsd#biib_FelzartamabAMRMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FelzartamabAMRMember" xlink:to="lab_biib_FelzartamabAMRMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_d258aa14-fcfa-4955-84a2-2c790b401eea_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrentAbstract_822deca0-6fe4-40b4-a7a9-07f5caa73dfb_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-current liabilities:</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedges, Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_257fab49-e425-4c1a-864d-58821a7d749a_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_33dceecd-37c8-4c30-8c5a-b6002440dfc5_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_3615b382-9e40-4203-9d49-3c1ac9dd5997_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Type Categorization [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_ca058898-bd98-466d-a56a-8e91c2ed33fc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) on foreign currency derivative instruments not designated as hedging instruments</link:label>
    <link:label id="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_label_en-US" xlink:label="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:to="lab_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonrecurringAdjustmentDomain_d916392f-8610-4387-a081-e5a5984188d9_terseLabel_en-US" xlink:label="lab_us-gaap_NonrecurringAdjustmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Pro Forma Information, Nonrecurring Adjustment [Domain]</link:label>
    <link:label id="lab_us-gaap_NonrecurringAdjustmentDomain_label_en-US" xlink:label="lab_us-gaap_NonrecurringAdjustmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Pro Forma Information, Nonrecurring Adjustment [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrecurringAdjustmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonrecurringAdjustmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonrecurringAdjustmentDomain" xlink:to="lab_us-gaap_NonrecurringAdjustmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_f3df13c9-afdd-4b74-813f-44e779217afa_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_e94eed3e-b885-44c9-a157-6467d7798f40_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCost_5ada80ff-7748-432b-81b3-1113e9dd5650_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiCost_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiCost" xlink:to="lab_us-gaap_EquitySecuritiesFvNiCost" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Collaborationexpensesaccrual_c6222e11-9606-4d05-bbbd-73a96af016b5_terseLabel_en-US" xlink:label="lab_biib_Collaborationexpensesaccrual" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration expense</link:label>
    <link:label id="lab_biib_Collaborationexpensesaccrual_label_en-US" xlink:label="lab_biib_Collaborationexpensesaccrual" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration expenses accrual</link:label>
    <link:label id="lab_biib_Collaborationexpensesaccrual_documentation_en-US" xlink:label="lab_biib_Collaborationexpensesaccrual" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration expenses accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationexpensesaccrual" xlink:href="biib-20250930.xsd#biib_Collaborationexpensesaccrual"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Collaborationexpensesaccrual" xlink:to="lab_biib_Collaborationexpensesaccrual" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_7d771083-3b76-4764-9a16-b55436a185e2_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OtherrevenuesTableTextBlock_e05ea1aa-b785-4b21-b840-87af5009d8f0_terseLabel_en-US" xlink:label="lab_biib_OtherrevenuesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other revenues</link:label>
    <link:label id="lab_biib_OtherrevenuesTableTextBlock_label_en-US" xlink:label="lab_biib_OtherrevenuesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other revenues [Table Text Block]</link:label>
    <link:label id="lab_biib_OtherrevenuesTableTextBlock_documentation_en-US" xlink:label="lab_biib_OtherrevenuesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other revenues [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesTableTextBlock" xlink:href="biib-20250930.xsd#biib_OtherrevenuesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherrevenuesTableTextBlock" xlink:to="lab_biib_OtherrevenuesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_MilestonePaymentFutureDevelopmentMember_0d0f3b82-dc70-4089-9287-cb6ec586d96e_terseLabel_en-US" xlink:label="lab_biib_MilestonePaymentFutureDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone Payment, Future Development</link:label>
    <link:label id="lab_biib_MilestonePaymentFutureDevelopmentMember_label_en-US" xlink:label="lab_biib_MilestonePaymentFutureDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Payment, Future Development [Member]</link:label>
    <link:label id="lab_biib_MilestonePaymentFutureDevelopmentMember_documentation_en-US" xlink:label="lab_biib_MilestonePaymentFutureDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone Payment, Future Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MilestonePaymentFutureDevelopmentMember" xlink:href="biib-20250930.xsd#biib_MilestonePaymentFutureDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MilestonePaymentFutureDevelopmentMember" xlink:to="lab_biib_MilestonePaymentFutureDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_c7ced8d4-8f07-454e-ac81-5359de2d8410_verboseLabel_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan</link:label>
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_label_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_biib_EmployeeStockPurchasePlanMember_documentation_en-US" xlink:label="lab_biib_EmployeeStockPurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Employee stock purchase plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EmployeeStockPurchasePlanMember" xlink:href="biib-20250930.xsd#biib_EmployeeStockPurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EmployeeStockPurchasePlanMember" xlink:to="lab_biib_EmployeeStockPurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_dda85a63-bf56-42e7-897a-a739d538687b_verboseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock units</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_2a221693-adab-4e82-a8ed-eb9ed2ae29fb_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total cost and expense</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_119a3b09-4b9a-480c-8dfb-f87999efb296_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_8bf8e3c9-3683-462f-a0ae-9cbf461cf2e0_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derivative contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Contract, Asset, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:to="lab_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_a2f02670-e330-459a-befe-e1dade2303a6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_A5.050SeniorNotesDueJanuary152031Member_00e2fe2e-a6f1-4801-b7ec-a4c6ed9e4f7f_terseLabel_en-US" xlink:label="lab_biib_A5.050SeniorNotesDueJanuary152031Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">5.050% Senior Notes due January 15, 2031</link:label>
    <link:label id="lab_biib_A5.050SeniorNotesDueJanuary152031Member_label_en-US" xlink:label="lab_biib_A5.050SeniorNotesDueJanuary152031Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">5.050% Senior Notes due January 15, 2031 [Member]</link:label>
    <link:label id="lab_biib_A5.050SeniorNotesDueJanuary152031Member_documentation_en-US" xlink:label="lab_biib_A5.050SeniorNotesDueJanuary152031Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">5.050% Senior Notes due January 15, 2031</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A5.050SeniorNotesDueJanuary152031Member" xlink:href="biib-20250930.xsd#biib_A5.050SeniorNotesDueJanuary152031Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A5.050SeniorNotesDueJanuary152031Member" xlink:to="lab_biib_A5.050SeniorNotesDueJanuary152031Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_c93154e2-73b3-4709-944c-741a54c8e648_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_3068f8b4-e49a-4edf-863f-a60858c17fbb_terseLabel_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_label_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:to="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_cf08f648-864e-44bf-8188-50854cb3a2d6_terseLabel_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Analysis of change In reserves</link:label>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_label_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Analysis Of Amount Of And Change In Product Revenue Reserves [Table Text Block]</link:label>
    <link:label id="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_documentation_en-US" xlink:label="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Analysis of amount of and change in product revenue reserves.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:href="biib-20250930.xsd#biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:to="lab_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage_afdbe3d6-2deb-410c-8ad5-e914d2feec1d_terseLabel_en-US" xlink:label="lab_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty operating profit threshold for highest royalty rate percentage</link:label>
    <link:label id="lab_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage_label_en-US" xlink:label="lab_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty operating profit threshold for highest royalty rate percentage</link:label>
    <link:label id="lab_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage_documentation_en-US" xlink:label="lab_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty operating profit threshold for highest royalty rate percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage" xlink:href="biib-20250930.xsd#biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage" xlink:to="lab_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_8464fbb6-4801-46fe-914c-6838981ff781_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_0c22f1b8-27d3-4cb2-9f90-4c21f334b57e_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AccountsPayableToCollaborator_8484d18b-1fd6-4bc8-9a8d-dc1f7e6e8fb8_terseLabel_en-US" xlink:label="lab_biib_AccountsPayableToCollaborator" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amounts payable</link:label>
    <link:label id="lab_biib_AccountsPayableToCollaborator_label_en-US" xlink:label="lab_biib_AccountsPayableToCollaborator" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, To Collaborator</link:label>
    <link:label id="lab_biib_AccountsPayableToCollaborator_documentation_en-US" xlink:label="lab_biib_AccountsPayableToCollaborator" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accounts Payable, To Collaborator</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AccountsPayableToCollaborator" xlink:href="biib-20250930.xsd#biib_AccountsPayableToCollaborator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AccountsPayableToCollaborator" xlink:to="lab_biib_AccountsPayableToCollaborator" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_7b02f7b5-e295-4d7f-9301-4c89d08f306b_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total transaction value</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_be4395df-e89a-492c-9b00-2823c5a20ba1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term of contract</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:to="lab_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_f23d1a45-c87b-4861-a13c-39958e7fdc91_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_a99e0502-61c9-4e8f-92cf-692d743844fd_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross unrealized gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_29158ecb-efb3-4dcb-9e22-61420624abc4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_A6.450SeniorNotesDueMay152055Member_4ebabba4-0c98-4c22-a38d-f3ea2fd844a5_terseLabel_en-US" xlink:label="lab_biib_A6.450SeniorNotesDueMay152055Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">6.450% Senior Notes due May 15, 2055</link:label>
    <link:label id="lab_biib_A6.450SeniorNotesDueMay152055Member_label_en-US" xlink:label="lab_biib_A6.450SeniorNotesDueMay152055Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">6.450% Senior Notes due May 15, 2055 [Member]</link:label>
    <link:label id="lab_biib_A6.450SeniorNotesDueMay152055Member_documentation_en-US" xlink:label="lab_biib_A6.450SeniorNotesDueMay152055Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">6.450% Senior Notes due May 15, 2055</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A6.450SeniorNotesDueMay152055Member" xlink:href="biib-20250930.xsd#biib_A6.450SeniorNotesDueMay152055Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A6.450SeniorNotesDueMay152055Member" xlink:to="lab_biib_A6.450SeniorNotesDueMay152055Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="lab_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_9808d347-9632-40c7-ad53-eb653fe2cab4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:to="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_b926aa41-a0e4-4f3a-b4d5-a9ecd6b707ae_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_d7a00f4b-2ad1-4608-acff-c5cb010874ad_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_9ce10b2b-d8e6-4365-b138-3f0d5d1fa3f8_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Exchange Contract</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringChargesMember_348845fd-b32f-4fcb-a22d-4462e63f311f_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringChargesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringChargesMember_label_en-US" xlink:label="lab_us-gaap_RestructuringChargesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringChargesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringChargesMember" xlink:to="lab_us-gaap_RestructuringChargesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_5587dcb4-0347-472e-9154-434f5467dbdb_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Taxes on foreign earnings, including valuation allowances</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_3db63e1c-10dd-4f3c-84af-e368158487fe_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_IMRALDIPatentLitigationMember_332d481a-b570-4601-a18a-a9c648a15324_terseLabel_en-US" xlink:label="lab_biib_IMRALDIPatentLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">IMRALDI Patent Litigation</link:label>
    <link:label id="lab_biib_IMRALDIPatentLitigationMember_label_en-US" xlink:label="lab_biib_IMRALDIPatentLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IMRALDI Patent Litigation [Member]</link:label>
    <link:label id="lab_biib_IMRALDIPatentLitigationMember_documentation_en-US" xlink:label="lab_biib_IMRALDIPatentLitigationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">IMRALDI Patent Litigation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IMRALDIPatentLitigationMember" xlink:href="biib-20250930.xsd#biib_IMRALDIPatentLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IMRALDIPatentLitigationMember" xlink:to="lab_biib_IMRALDIPatentLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_39122fc8-689d-484a-aaa3-bd10db3fb694_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Change in Contingent Consideration, Liability, Increase (Decrease)</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_c2598c7c-5b80-48e8-829a-9697bf883bbb_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Change in Contingent Consideration, Liability, Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities_ab89d78c-8c06-47cc-a09c-25f4d75b2fa6_negatedTerseLabel_en-US" xlink:label="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities_label_en-US" xlink:label="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Liabilities</link:label>
    <link:label id="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities_documentation_en-US" xlink:label="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities" xlink:href="biib-20250930.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities" xlink:to="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_aa9fc247-ada7-4aba-88f2-9eb69cd88114_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3252f339-0455-43ee-b04f-12b5f0262c27_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets_038decaa-c782-48f1-8e5b-f5f459666ff2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gain on sale of priority review voucher, net</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets_8b773c3c-d8b6-4b30-96be-51e8a0ef9830_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain on sale of priority review voucher, net</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:to="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_HeadquartersLeaseFiveYearRenewalOptionMember_96c4867e-5d48-4693-866a-832bc13d6107_terseLabel_en-US" xlink:label="lab_biib_HeadquartersLeaseFiveYearRenewalOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Headquarters Lease, Five Year Renewal Option</link:label>
    <link:label id="lab_biib_HeadquartersLeaseFiveYearRenewalOptionMember_label_en-US" xlink:label="lab_biib_HeadquartersLeaseFiveYearRenewalOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Headquarters Lease, Five Year Renewal Option [Member]</link:label>
    <link:label id="lab_biib_HeadquartersLeaseFiveYearRenewalOptionMember_documentation_en-US" xlink:label="lab_biib_HeadquartersLeaseFiveYearRenewalOptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Headquarters Lease, Five Year Renewal Option</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_HeadquartersLeaseFiveYearRenewalOptionMember" xlink:href="biib-20250930.xsd#biib_HeadquartersLeaseFiveYearRenewalOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_HeadquartersLeaseFiveYearRenewalOptionMember" xlink:to="lab_biib_HeadquartersLeaseFiveYearRenewalOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_2ae9ee2f-7b35-4868-9639-53d35df264f4_verboseLabel_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">After First Threshold Date until the Second Threshold Date</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_c36423ab-5ac0-4a30-880f-6e3cd3a6028c_terseLabel_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">After Second GAZYVA Threshold Date</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_label_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option Three</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_documentation_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of co promotion operating profits greater than first fifty million option two sub option three.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" xlink:href="biib-20250930.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" xlink:to="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_641d3650-7d0e-4a8d-85cf-c8c638f555d3_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingency, Information about Litigation Matters [Abstract]</link:label>
    <link:label id="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_label_en-US" xlink:label="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Information about Litigation Matters [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:to="lab_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_A2023And2022CostSavingInitiativesMember_69cf174c-b264-4cfe-873a-0b5554996b16_terseLabel_en-US" xlink:label="lab_biib_A2023And2022CostSavingInitiativesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023 and 2022 Cost Saving Initiatives</link:label>
    <link:label id="lab_biib_A2023And2022CostSavingInitiativesMember_label_en-US" xlink:label="lab_biib_A2023And2022CostSavingInitiativesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2023 and 2022 Cost Saving Initiatives [Member]</link:label>
    <link:label id="lab_biib_A2023And2022CostSavingInitiativesMember_documentation_en-US" xlink:label="lab_biib_A2023And2022CostSavingInitiativesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2023 and 2022 Cost Saving Initiatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2023And2022CostSavingInitiativesMember" xlink:href="biib-20250930.xsd#biib_A2023And2022CostSavingInitiativesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2023And2022CostSavingInitiativesMember" xlink:to="lab_biib_A2023And2022CostSavingInitiativesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyMember_d3019d33-24ed-4eb1-8c6c-82415d8a84c8_terseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty and other revenue</link:label>
    <link:label id="lab_us-gaap_RoyaltyMember_label_en-US" xlink:label="lab_us-gaap_RoyaltyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RoyaltyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyMember" xlink:to="lab_us-gaap_RoyaltyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_0684f463-5953-4a88-8795-ed8f491827b7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Investment Income [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Investment Income [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:to="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FloatingRate364DayTrancheMember_38b39baf-6013-4288-b48d-be9b6ffd52be_terseLabel_en-US" xlink:label="lab_biib_FloatingRate364DayTrancheMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Floating Rate 364-Day Tranche</link:label>
    <link:label id="lab_biib_FloatingRate364DayTrancheMember_label_en-US" xlink:label="lab_biib_FloatingRate364DayTrancheMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Floating Rate 364-Day Tranche [Member]</link:label>
    <link:label id="lab_biib_FloatingRate364DayTrancheMember_documentation_en-US" xlink:label="lab_biib_FloatingRate364DayTrancheMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Floating Rate 364-Day Tranche</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FloatingRate364DayTrancheMember" xlink:href="biib-20250930.xsd#biib_FloatingRate364DayTrancheMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FloatingRate364DayTrancheMember" xlink:to="lab_biib_FloatingRate364DayTrancheMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_b2e7056e-a0c7-46a0-87b3-862b72f77b81_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_c3f21d28-95ea-4947-bbff-4861c07fb743_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory, current</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_3f4c6652-d161-482e-b58a-de79e8dbd214_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_5bd96d13-50a8-4207-a82b-c7968d6317f2_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_08a88bfc-b964-4977-ad19-53046af960f2_verboseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_9eb4193b-f203-45f7-a962-a6fc4dcc7fbc_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill resulting from HI-Bio acquisition</link:label>
    <link:label id="lab_us-gaap_GoodwillPurchaseAccountingAdjustments_label_en-US" xlink:label="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Measurement Period Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:to="lab_us-gaap_GoodwillPurchaseAccountingAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_1ccde676-c517-471b-a56d-f1090062676c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indebtedness</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_53fa05a3-b9ef-46c6-85a6-17596bb6be66_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_MeasurementInputProbabilityRateMember_40a43974-043d-4c5e-bc15-e8477acbc6e0_terseLabel_en-US" xlink:label="lab_biib_MeasurementInputProbabilityRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input, Probability Rate</link:label>
    <link:label id="lab_biib_MeasurementInputProbabilityRateMember_label_en-US" xlink:label="lab_biib_MeasurementInputProbabilityRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Probability Rate [Member]</link:label>
    <link:label id="lab_biib_MeasurementInputProbabilityRateMember_documentation_en-US" xlink:label="lab_biib_MeasurementInputProbabilityRateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Measurement Input, Probability Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MeasurementInputProbabilityRateMember" xlink:href="biib-20250930.xsd#biib_MeasurementInputProbabilityRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MeasurementInputProbabilityRateMember" xlink:to="lab_biib_MeasurementInputProbabilityRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill_e1d0f00a-9475-4787-abd3-c7dfd630f2de_terseLabel_en-US" xlink:label="lab_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill, measurement period adjustment</link:label>
    <link:label id="lab_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill_label_en-US" xlink:label="lab_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Goodwill</link:label>
    <link:label id="lab_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill_documentation_en-US" xlink:label="lab_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill" xlink:href="biib-20250930.xsd#biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill" xlink:to="lab_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_NotesPayableCurrentFairValueDisclosure_fd2ff70f-0ea9-4f47-81f5-3b96b43fbac4_terseLabel_en-US" xlink:label="lab_biib_NotesPayableCurrentFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes payable, current, fair value disclosure</link:label>
    <link:label id="lab_biib_NotesPayableCurrentFairValueDisclosure_label_en-US" xlink:label="lab_biib_NotesPayableCurrentFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Current, Fair Value Disclosure</link:label>
    <link:label id="lab_biib_NotesPayableCurrentFairValueDisclosure_documentation_en-US" xlink:label="lab_biib_NotesPayableCurrentFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Notes Payable, Current, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NotesPayableCurrentFairValueDisclosure" xlink:href="biib-20250930.xsd#biib_NotesPayableCurrentFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NotesPayableCurrentFairValueDisclosure" xlink:to="lab_biib_NotesPayableCurrentFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_f155cb63-1a38-4295-b431-66b9c62ba189_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of intangible assets (excluding goodwill)</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_9ec5bef5-6cce-433c-948f-be145fc77a49_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of roll forward of the changes in goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_1bd7e202-8ade-4e1e-ba4f-0e090c4e10fe_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanDomain" xlink:to="lab_us-gaap_RestructuringPlanDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_3574b346-06e9-4b3b-9401-0241c6c58e87_terseLabel_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Decrease in unrecognized tax benefits is reasonably possible</link:label>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_label_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease in Unrecognized Tax Benefits is Reasonably Possible</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:to="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7924d493-0b00-436e-aeac-591111160f9f_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diluted earnings per share attributable to Biogen Inc. (in USD per share)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_c3dac1cd-71d7-4c1f-84dd-c30047763139_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Shares used in calculating diluted earnings per share</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_cff19724-5c0d-49ce-872a-a1ff5bf9353f_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Assets from Segment to Consolidated [Table]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of Assets from Segment to Consolidated [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable" xlink:to="lab_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_9c610782-a09c-4d28-a710-2f6fffeb355c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CollaborativeArrangementExpectedDevelopmentCostFundsYearTwo_168b091c-e608-4831-9753-190d2810cd2e_terseLabel_en-US" xlink:label="lab_biib_CollaborativeArrangementExpectedDevelopmentCostFundsYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected receipts to co-fund development costs, noncurrent</link:label>
    <link:label id="lab_biib_CollaborativeArrangementExpectedDevelopmentCostFundsYearTwo_label_en-US" xlink:label="lab_biib_CollaborativeArrangementExpectedDevelopmentCostFundsYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Expected Development Cost Funds, Year Two</link:label>
    <link:label id="lab_biib_CollaborativeArrangementExpectedDevelopmentCostFundsYearTwo_documentation_en-US" xlink:label="lab_biib_CollaborativeArrangementExpectedDevelopmentCostFundsYearTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Expected Development Cost Funds, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborativeArrangementExpectedDevelopmentCostFundsYearTwo" xlink:href="biib-20250930.xsd#biib_CollaborativeArrangementExpectedDevelopmentCostFundsYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CollaborativeArrangementExpectedDevelopmentCostFundsYearTwo" xlink:to="lab_biib_CollaborativeArrangementExpectedDevelopmentCostFundsYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_92d37a6f-3b52-4e6a-8cb4-877eb9c04b7b_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Collaborationprofitlosssharing_6334654a-19cf-4a39-8070-ef8a4d3c6cd6_terseLabel_en-US" xlink:label="lab_biib_Collaborationprofitlosssharing" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration profit sharing/(loss reimbursement)</link:label>
    <link:label id="lab_biib_Collaborationprofitlosssharing_label_en-US" xlink:label="lab_biib_Collaborationprofitlosssharing" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration profit (loss) sharing</link:label>
    <link:label id="lab_biib_Collaborationprofitlosssharing_documentation_en-US" xlink:label="lab_biib_Collaborationprofitlosssharing" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration profit (loss) sharing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationprofitlosssharing" xlink:href="biib-20250930.xsd#biib_Collaborationprofitlosssharing"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Collaborationprofitlosssharing" xlink:to="lab_biib_Collaborationprofitlosssharing" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_36880aad-9080-4161-8098-a9a5fc6263d2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_GAZYVAMember_b1c14207-fe7a-47e2-9d1e-3bd498696dc7_terseLabel_en-US" xlink:label="lab_biib_GAZYVAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GAZYVA</link:label>
    <link:label id="lab_biib_GAZYVAMember_label_en-US" xlink:label="lab_biib_GAZYVAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GAZYVA [Member]</link:label>
    <link:label id="lab_biib_GAZYVAMember_documentation_en-US" xlink:label="lab_biib_GAZYVAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">GAZYVA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GAZYVAMember" xlink:href="biib-20250930.xsd#biib_GAZYVAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GAZYVAMember" xlink:to="lab_biib_GAZYVAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_b6f22867-c136-462d-887f-613a40d6f84b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Trading, and Equity Securities, FV-NI, Cost [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Trading, and Equity Securities, FV-NI, Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract" xlink:to="lab_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_79de1fc9-f789-49d3-85af-05d87b9516af_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinCashMember_8333b6d4-2a25-4d40-85cc-cd9fc3836647_terseLabel_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinCashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance stock units settled in cash</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinCashMember_label_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinCashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Stock Units Settled in Cash [Member]</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinCashMember_documentation_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinCashMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Performance Stock Units Settled in Cash [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember" xlink:href="biib-20250930.xsd#biib_PerformanceStockUnitsSettledinCashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PerformanceStockUnitsSettledinCashMember" xlink:to="lab_biib_PerformanceStockUnitsSettledinCashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OtherProductsMember_35de0614-fdf9-42dc-bffe-51bed92455c8_terseLabel_en-US" xlink:label="lab_biib_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_biib_OtherProductsMember_label_en-US" xlink:label="lab_biib_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Products [Member]</link:label>
    <link:label id="lab_biib_OtherProductsMember_documentation_en-US" xlink:label="lab_biib_OtherProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherProductsMember" xlink:href="biib-20250930.xsd#biib_OtherProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherProductsMember" xlink:to="lab_biib_OtherProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_15e31584-9e85-4c69-a383-c56838f42a2c_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_6c3fbf36-a8b6-4c10-a0f8-6a97f39f2187_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PaymentDueAtSecondAnniversaryMember_155599fe-45bc-4979-894e-7a132ccf026c_terseLabel_en-US" xlink:label="lab_biib_PaymentDueAtSecondAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment Due At Second Anniversary</link:label>
    <link:label id="lab_biib_PaymentDueAtSecondAnniversaryMember_label_en-US" xlink:label="lab_biib_PaymentDueAtSecondAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment Due At Second Anniversary [Member]</link:label>
    <link:label id="lab_biib_PaymentDueAtSecondAnniversaryMember_documentation_en-US" xlink:label="lab_biib_PaymentDueAtSecondAnniversaryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payment Due At Second Anniversary</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentDueAtSecondAnniversaryMember" xlink:href="biib-20250930.xsd#biib_PaymentDueAtSecondAnniversaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentDueAtSecondAnniversaryMember" xlink:to="lab_biib_PaymentDueAtSecondAnniversaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_28d8c153-1b31-4764-b811-9b4059b73eac_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_908e666f-8a9c-474b-acbd-f6780ee2f4a5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for contingent consideration</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment for Contingent Consideration Liability, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_55a414b5-5cd5-4908-bab6-24d07a5ca39e_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c1b7a66b-737b-4571-b184-3b6fb62a7e90_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b06bbfff-3081-4124-8e62-626ca1e1ceef_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CashflowsrevenueMember_c9d0d270-5bbf-4e95-9eb8-f9a7a57e3f05_terseLabel_en-US" xlink:label="lab_biib_CashflowsrevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows, revenue</link:label>
    <link:label id="lab_biib_CashflowsrevenueMember_label_en-US" xlink:label="lab_biib_CashflowsrevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows, revenue [Member]</link:label>
    <link:label id="lab_biib_CashflowsrevenueMember_documentation_en-US" xlink:label="lab_biib_CashflowsrevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash flows, revenue [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashflowsrevenueMember" xlink:href="biib-20250930.xsd#biib_CashflowsrevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CashflowsrevenueMember" xlink:to="lab_biib_CashflowsrevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Expensereflectedwithinstatementsofincome_507a8a83-d269-4b16-bf80-679a23f89b5e_terseLabel_en-US" xlink:label="lab_biib_Expensereflectedwithinstatementsofincome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expense reflected within statements of income</link:label>
    <link:label id="lab_biib_Expensereflectedwithinstatementsofincome_label_en-US" xlink:label="lab_biib_Expensereflectedwithinstatementsofincome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense reflected within statements of income</link:label>
    <link:label id="lab_biib_Expensereflectedwithinstatementsofincome_documentation_en-US" xlink:label="lab_biib_Expensereflectedwithinstatementsofincome" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expense reflected within statements of income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome" xlink:href="biib-20250930.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Expensereflectedwithinstatementsofincome" xlink:to="lab_biib_Expensereflectedwithinstatementsofincome" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_dd09cf93-1d7b-4690-908f-fcdc67c3d284_terseLabel_en-US" xlink:label="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]</link:label>
    <link:label id="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_label_en-US" xlink:label="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]</link:label>
    <link:label id="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_documentation_en-US" xlink:label="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:href="biib-20250930.xsd#biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:to="lab_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_74a56b48-9f8f-41c1-a73c-3c2a9c6a02ca_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_f7a4d72d-24e3-4450-a4db-e358d4abe0b8_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Significant Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_e36d0b35-2d2a-44c5-968a-38b547b34478_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_be04266b-3c11-4811-be97-59bd2adabe94_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Earnings per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_1668cefa-3e7a-476a-b796-dbb6649be7d0_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_1a255793-955e-4265-9b4b-296ee360f036_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_e3cbd2cf-139a-4efd-86e4-1bb855053045_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_HeadquartersLeaseSixMonthRenewalOptionMember_0fe71367-28d5-4c68-b8a7-4f1bd0eb65e3_terseLabel_en-US" xlink:label="lab_biib_HeadquartersLeaseSixMonthRenewalOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Headquarters Lease, Six Month Renewal Option</link:label>
    <link:label id="lab_biib_HeadquartersLeaseSixMonthRenewalOptionMember_label_en-US" xlink:label="lab_biib_HeadquartersLeaseSixMonthRenewalOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Headquarters Lease, Six Month Renewal Option [Member]</link:label>
    <link:label id="lab_biib_HeadquartersLeaseSixMonthRenewalOptionMember_documentation_en-US" xlink:label="lab_biib_HeadquartersLeaseSixMonthRenewalOptionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Headquarters Lease, Six Month Renewal Option</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_HeadquartersLeaseSixMonthRenewalOptionMember" xlink:href="biib-20250930.xsd#biib_HeadquartersLeaseSixMonthRenewalOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_HeadquartersLeaseSixMonthRenewalOptionMember" xlink:to="lab_biib_HeadquartersLeaseSixMonthRenewalOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_77d8d9f3-7ff1-40c1-8238-295a78dcea24_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionDomain" xlink:to="lab_us-gaap_AssetAcquisitionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_b3e94b71-e459-4e0a-89d9-0c86188ae4cd_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:to="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayable_cf45dcf5-bdb9-4aaa-b093-9e8a13e0c03b_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Carrying Value</link:label>
    <link:label id="lab_us-gaap_NotesPayable_label_en-US" xlink:label="lab_us-gaap_NotesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayable" xlink:to="lab_us-gaap_NotesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_1cd32f89-c20f-4ceb-9655-d7e26b3f676d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Income [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:to="lab_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_32b4dbac-5990-4b7c-8778-b5d949fe73f9_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_A2020ShareRepurchaseProgramMember_d19766fe-32ce-464a-86e8-13717b5eeb4a_terseLabel_en-US" xlink:label="lab_biib_A2020ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020 Share Repurchase Program</link:label>
    <link:label id="lab_biib_A2020ShareRepurchaseProgramMember_label_en-US" xlink:label="lab_biib_A2020ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2020 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_biib_A2020ShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_biib_A2020ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2020 Share Repurchase Program [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2020ShareRepurchaseProgramMember" xlink:href="biib-20250930.xsd#biib_A2020ShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2020ShareRepurchaseProgramMember" xlink:to="lab_biib_A2020ShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_b0377a12-472c-474a-8386-a755f5508143_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementInterest_0b8b6d5f-609c-43a3-9b0a-b130be220d22_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Settlement Interest</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementInterest_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Settlement Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LitigationSettlementInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementInterest" xlink:to="lab_us-gaap_LitigationSettlementInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ConvergenceMember_c47e3152-2918-4cdc-a74f-d631fee7da1b_terseLabel_en-US" xlink:label="lab_biib_ConvergenceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convergence</link:label>
    <link:label id="lab_biib_ConvergenceMember_label_en-US" xlink:label="lab_biib_ConvergenceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convergence [Member]</link:label>
    <link:label id="lab_biib_ConvergenceMember_documentation_en-US" xlink:label="lab_biib_ConvergenceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convergence</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ConvergenceMember" xlink:href="biib-20250930.xsd#biib_ConvergenceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ConvergenceMember" xlink:to="lab_biib_ConvergenceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ProceedsPaidToCollaborativeArrangementCounterparty_bb3ecdb4-6927-42ce-948d-e5e6647a3e43_terseLabel_en-US" xlink:label="lab_biib_ProceedsPaidToCollaborativeArrangementCounterparty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds Paid To Collaborative Arrangement Counterparty</link:label>
    <link:label id="lab_biib_ProceedsPaidToCollaborativeArrangementCounterparty_label_en-US" xlink:label="lab_biib_ProceedsPaidToCollaborativeArrangementCounterparty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds Paid To Collaborative Arrangement Counterparty</link:label>
    <link:label id="lab_biib_ProceedsPaidToCollaborativeArrangementCounterparty_documentation_en-US" xlink:label="lab_biib_ProceedsPaidToCollaborativeArrangementCounterparty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds Paid To Collaborative Arrangement Counterparty</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ProceedsPaidToCollaborativeArrangementCounterparty" xlink:href="biib-20250930.xsd#biib_ProceedsPaidToCollaborativeArrangementCounterparty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ProceedsPaidToCollaborativeArrangementCounterparty" xlink:to="lab_biib_ProceedsPaidToCollaborativeArrangementCounterparty" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StockRepurchaseProgramAuthorizedAmount1_e2877a63-9719-4b14-8489-8b8d33d9ff19_terseLabel_en-US" xlink:label="lab_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock repurchase program, authorized amount</link:label>
    <link:label id="lab_srt_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program, Authorized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities_e0ece535-a065-4ab0-bf28-14bb8e5e4dc7_negatedTerseLabel_en-US" xlink:label="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities_label_en-US" xlink:label="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Operating Lease Liabilities</link:label>
    <link:label id="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities_documentation_en-US" xlink:label="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Operating Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities" xlink:href="biib-20250930.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities" xlink:to="lab_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_a8a8adb6-eb17-44c6-8513-263f31472137_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesMember" xlink:to="lab_us-gaap_AccruedLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_bbcf5b8c-b648-496f-9175-09730cf337f4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_aab5b680-cf83-42cc-8957-c759e943a970_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments related to issuance of stock for share-based compensation arrangements, net</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ShareRepurchaseProgramDomain_c024bb45-6c1b-4357-8da4-4826ba0d499a_terseLabel_en-US" xlink:label="lab_srt_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_srt_ShareRepurchaseProgramDomain_label_en-US" xlink:label="lab_srt_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ShareRepurchaseProgramDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ShareRepurchaseProgramDomain" xlink:to="lab_srt_ShareRepurchaseProgramDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_RituxanMember_5b4684fe-9f42-4b2f-b756-7528f673dc0e_terseLabel_en-US" xlink:label="lab_biib_RituxanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RITUXAN</link:label>
    <link:label id="lab_biib_RituxanMember_label_en-US" xlink:label="lab_biib_RituxanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">RITUXAN [Member]</link:label>
    <link:label id="lab_biib_RituxanMember_documentation_en-US" xlink:label="lab_biib_RituxanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">RITUXAN.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RituxanMember" xlink:href="biib-20250930.xsd#biib_RituxanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RituxanMember" xlink:to="lab_biib_RituxanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_3f310b2a-4cc6-4dea-b2e3-4cf18ee2e805_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_f4790573-08f0-4677-9463-aaac03a6f514_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_62e885c5-05c8-4d91-abe8-9e89536a82e5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net current period other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_LateStageProgramsMember_982636dd-d9e2-4f9c-98a5-cc19eb418fcd_terseLabel_en-US" xlink:label="lab_biib_LateStageProgramsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Late stage programs</link:label>
    <link:label id="lab_biib_LateStageProgramsMember_label_en-US" xlink:label="lab_biib_LateStageProgramsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Late Stage Programs [Member]</link:label>
    <link:label id="lab_biib_LateStageProgramsMember_documentation_en-US" xlink:label="lab_biib_LateStageProgramsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Late Stage Programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LateStageProgramsMember" xlink:href="biib-20250930.xsd#biib_LateStageProgramsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_LateStageProgramsMember" xlink:to="lab_biib_LateStageProgramsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_6bcbd3a5-b085-40c1-bd2b-057e24dff5fd_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of the effect of cash flow derivatives designated as hedging instruments on the condensed consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_3ef7204d-9616-4f98-b78d-59ab9fcc12d3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_8ac48920-3704-4a20-9097-5133a9eed500_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Quoted Prices in Active Markets (Level 1)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_4ce6ddfb-e785-4b62-8942-70753054b5c5_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) on sale</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets1" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0a690202-82cd-4518-b0b7-4f93f4f0c68f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_9648aafe-fcd4-4fea-99cf-a93c9345c777_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Liability Assumed, Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_28ddff93-0eb3-4120-9372-687c48a98435_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued expense and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_c21c3af7-2d1e-402f-971c-81205ff4ec92_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Diluted earnings per share attributable to Biogen Inc. (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_09418b40-babe-4076-8e63-07dbaec5870e_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net of allowance for doubtful accounts of $3.1 and $2.2, respectively</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_901bd48b-2041-4310-a270-6b53f1916216_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_f82a1129-74bf-479d-a125-812f14697fdc_periodStartLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance, treasury stock, shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_cbd56871-beaf-4127-9409-17fb27b965d6_periodEndLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance, treasury stock, shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_02301a05-7aa8-4467-a7bb-6158ea05ecac_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CorporateDebtSecuritiesCurrentMember_488ccd74-875f-4106-b0b3-1b3a179d54b1_terseLabel_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities Current</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesCurrentMember_label_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities Current [Member]</link:label>
    <link:label id="lab_biib_CorporateDebtSecuritiesCurrentMember_documentation_en-US" xlink:label="lab_biib_CorporateDebtSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Corporate debt securities Current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CorporateDebtSecuritiesCurrentMember" xlink:href="biib-20250930.xsd#biib_CorporateDebtSecuritiesCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CorporateDebtSecuritiesCurrentMember" xlink:to="lab_biib_CorporateDebtSecuritiesCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Phase3ClinicalTrialFelzartamabTwoMember_bc54297e-9e2b-4c4c-87b9-be5d92045221_terseLabel_en-US" xlink:label="lab_biib_Phase3ClinicalTrialFelzartamabTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Phase 3 Clinical Trial, Felzartamab Two</link:label>
    <link:label id="lab_biib_Phase3ClinicalTrialFelzartamabTwoMember_label_en-US" xlink:label="lab_biib_Phase3ClinicalTrialFelzartamabTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Phase 3 Clinical Trial, Felzartamab Two [Member]</link:label>
    <link:label id="lab_biib_Phase3ClinicalTrialFelzartamabTwoMember_documentation_en-US" xlink:label="lab_biib_Phase3ClinicalTrialFelzartamabTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Phase 3 Clinical Trial, Felzartamab Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Phase3ClinicalTrialFelzartamabTwoMember" xlink:href="biib-20250930.xsd#biib_Phase3ClinicalTrialFelzartamabTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Phase3ClinicalTrialFelzartamabTwoMember" xlink:to="lab_biib_Phase3ClinicalTrialFelzartamabTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_99849277-5c6e-473a-b44f-f1a8077c416e_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_a8841056-653a-4a8c-a7ca-9e902e68e863_verboseLabel_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">After LUNSUMIO Approval until the First Threshold Date</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_40e70085-4344-4fdb-a476-69d983a2f0b1_terseLabel_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Until Second GAZYVA Threshold Date</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_label_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option Two</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_documentation_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of co promotion operating profits greater than first fifty million option two sub option two.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" xlink:href="biib-20250930.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" xlink:to="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_c8cc889b-e121-485d-b0f1-f31815840185_verboseLabel_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Business Overview</link:label>
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_label_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Overview [Policy Text Block]</link:label>
    <link:label id="lab_biib_BusinessOverviewPolicyTextBlock_documentation_en-US" xlink:label="lab_biib_BusinessOverviewPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Describes an overview of the company and its operations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessOverviewPolicyTextBlock" xlink:href="biib-20250930.xsd#biib_BusinessOverviewPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BusinessOverviewPolicyTextBlock" xlink:to="lab_biib_BusinessOverviewPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityOther_4901beb1-a75a-48a6-b3ee-fa66e50467a8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOther_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOther" xlink:to="lab_us-gaap_StockholdersEquityOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_a521e308-8c3e-4da9-9925-2e3f3b102a31_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_29422b66-7d1e-4243-a145-c81eece3d2fb_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_f5e6602b-4804-4578-a1be-7a7ab85f8451_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt, gross</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ExpenseIncurredByCollaboration_e80cdc78-e2a1-43da-a1df-a3b22cac05d3_terseLabel_en-US" xlink:label="lab_biib_ExpenseIncurredByCollaboration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total development expense incurred by the collaboration related to the advancement of LEQEMBI</link:label>
    <link:label id="lab_biib_ExpenseIncurredByCollaboration_label_en-US" xlink:label="lab_biib_ExpenseIncurredByCollaboration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense Incurred By Collaboration</link:label>
    <link:label id="lab_biib_ExpenseIncurredByCollaboration_documentation_en-US" xlink:label="lab_biib_ExpenseIncurredByCollaboration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total expense incurred by collaboration.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ExpenseIncurredByCollaboration" xlink:href="biib-20250930.xsd#biib_ExpenseIncurredByCollaboration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ExpenseIncurredByCollaboration" xlink:to="lab_biib_ExpenseIncurredByCollaboration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_44f324d2-a954-42a3-b0b4-36380ba19221_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee compensation and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AcquiredAndInLicensedRightsAndPatentsMember_61e3747c-91cc-48bf-b59e-938f520028cf_terseLabel_en-US" xlink:label="lab_biib_AcquiredAndInLicensedRightsAndPatentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired and in-licensed rights and patents</link:label>
    <link:label id="lab_biib_AcquiredAndInLicensedRightsAndPatentsMember_label_en-US" xlink:label="lab_biib_AcquiredAndInLicensedRightsAndPatentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquired And In Licensed Rights And Patents [Member]</link:label>
    <link:label id="lab_biib_AcquiredAndInLicensedRightsAndPatentsMember_documentation_en-US" xlink:label="lab_biib_AcquiredAndInLicensedRightsAndPatentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Acquired And In Licensed Rights And Patents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AcquiredAndInLicensedRightsAndPatentsMember" xlink:href="biib-20250930.xsd#biib_AcquiredAndInLicensedRightsAndPatentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AcquiredAndInLicensedRightsAndPatentsMember" xlink:to="lab_biib_AcquiredAndInLicensedRightsAndPatentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_98d429a5-734b-48e2-8e1a-b95d8e1de3e2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_cdee5a71-6fbb-40f9-be35-6ae3f315cc45_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Gains/(Losses) Excluded from Effectiveness Testing and Recognized in Operating Income (in millions)</link:label>
    <link:label id="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_label_en-US" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Derivative Instruments, Net, Pretax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:to="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrExpirationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_ecd_TrdArrExpirationDate_label_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrExpirationDate" xlink:to="lab_ecd_TrdArrExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_44a07bbc-e117-41e2-82d6-e2835949d40c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2030</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_A2025SeniorNotesMember_bdc54255-f11a-4542-9a64-26a1486028b4_terseLabel_en-US" xlink:label="lab_biib_A2025SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025 Senior Notes</link:label>
    <link:label id="lab_biib_A2025SeniorNotesMember_label_en-US" xlink:label="lab_biib_A2025SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2025 Senior Notes [Member]</link:label>
    <link:label id="lab_biib_A2025SeniorNotesMember_documentation_en-US" xlink:label="lab_biib_A2025SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2025 Senior Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2025SeniorNotesMember" xlink:href="biib-20250930.xsd#biib_A2025SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2025SeniorNotesMember" xlink:to="lab_biib_A2025SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PaymentsToAcquireBusinessGrossNonVestedEquityAwards_c79ac67b-9a02-4c3b-9b41-a3336042b502_terseLabel_en-US" xlink:label="lab_biib_PaymentsToAcquireBusinessGrossNonVestedEquityAwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-vested equity awards</link:label>
    <link:label id="lab_biib_PaymentsToAcquireBusinessGrossNonVestedEquityAwards_label_en-US" xlink:label="lab_biib_PaymentsToAcquireBusinessGrossNonVestedEquityAwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments To Acquire Business, Gross, Non-Vested Equity Awards</link:label>
    <link:label id="lab_biib_PaymentsToAcquireBusinessGrossNonVestedEquityAwards_documentation_en-US" xlink:label="lab_biib_PaymentsToAcquireBusinessGrossNonVestedEquityAwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments To Acquire Business, Gross, Non-Vested Equity Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsToAcquireBusinessGrossNonVestedEquityAwards" xlink:href="biib-20250930.xsd#biib_PaymentsToAcquireBusinessGrossNonVestedEquityAwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentsToAcquireBusinessGrossNonVestedEquityAwards" xlink:to="lab_biib_PaymentsToAcquireBusinessGrossNonVestedEquityAwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_637fcb16-3b7a-4420-923d-1168a82c59e3_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_6722e319-2752-4a1c-88c8-da82028b844f_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net unrealized (gains) losses recognized on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_2b65675b-3bc7-4f3c-8797-0f61f3c3fb66_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_781feb5d-a212-4936-b879-ba4bd20e5abd_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_c6c58800-39a9-4f12-8d70-e45ede4b794a_verboseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expense</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_9a646ddb-b094-4390-9695-b7e3fdd7a5f3_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAbstract" xlink:to="lab_us-gaap_NetIncomeLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_5458d6b0-9e5f-49cb-b0b1-2a38b7494ca7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range of outcomes, value, high</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Range of Outcomes, Maximum, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_8c8f42df-7bf3-4fde-a411-10b8deccac5c_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_MilestonePaymentResearchMember_a56e36bf-a615-4da0-bc29-ee488f7692a7_terseLabel_en-US" xlink:label="lab_biib_MilestonePaymentResearchMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone Payment, Research</link:label>
    <link:label id="lab_biib_MilestonePaymentResearchMember_label_en-US" xlink:label="lab_biib_MilestonePaymentResearchMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Payment, Research [Member]</link:label>
    <link:label id="lab_biib_MilestonePaymentResearchMember_documentation_en-US" xlink:label="lab_biib_MilestonePaymentResearchMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone Payment, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MilestonePaymentResearchMember" xlink:href="biib-20250930.xsd#biib_MilestonePaymentResearchMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MilestonePaymentResearchMember" xlink:to="lab_biib_MilestonePaymentResearchMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_d991124f-0cbc-4674-8be4-3b995dd8498b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Cost [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_363244f8-72f4-4792-b0a9-f66482c8be43_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PeriodOfCollaborationAgreement_fc8e3881-5446-472c-a2f2-aa076cc6b752_terseLabel_en-US" xlink:label="lab_biib_PeriodOfCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration agreement term</link:label>
    <link:label id="lab_biib_PeriodOfCollaborationAgreement_label_en-US" xlink:label="lab_biib_PeriodOfCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Period Of Collaboration Agreement</link:label>
    <link:label id="lab_biib_PeriodOfCollaborationAgreement_documentation_en-US" xlink:label="lab_biib_PeriodOfCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Period Of Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PeriodOfCollaborationAgreement" xlink:href="biib-20250930.xsd#biib_PeriodOfCollaborationAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PeriodOfCollaborationAgreement" xlink:to="lab_biib_PeriodOfCollaborationAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_30a28517-6b43-4b23-a609-1706df678d13_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_547ce110-bf43-4416-ae89-ac74d737aa70_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Separately Recognized Transaction [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Separately Recognized Transaction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:to="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SalesTriggerGrossSalesThreshold_ba591d0d-87f1-4c46-ac51-becd1969fe45_terseLabel_en-US" xlink:label="lab_biib_SalesTriggerGrossSalesThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales trigger gross sales threshold</link:label>
    <link:label id="lab_biib_SalesTriggerGrossSalesThreshold_label_en-US" xlink:label="lab_biib_SalesTriggerGrossSalesThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Trigger Gross Sales Threshold</link:label>
    <link:label id="lab_biib_SalesTriggerGrossSalesThreshold_documentation_en-US" xlink:label="lab_biib_SalesTriggerGrossSalesThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sales trigger gross sales threshold.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SalesTriggerGrossSalesThreshold" xlink:href="biib-20250930.xsd#biib_SalesTriggerGrossSalesThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SalesTriggerGrossSalesThreshold" xlink:to="lab_biib_SalesTriggerGrossSalesThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_be347606-d980-4b35-b342-c68e730b19a7_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due in one year or less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FLIXABIMember_cdb48b6d-6ec1-4601-9942-aa97e60c543b_terseLabel_en-US" xlink:label="lab_biib_FLIXABIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FLIXABI</link:label>
    <link:label id="lab_biib_FLIXABIMember_label_en-US" xlink:label="lab_biib_FLIXABIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">FLIXABI [Member]</link:label>
    <link:label id="lab_biib_FLIXABIMember_documentation_en-US" xlink:label="lab_biib_FLIXABIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">FLIXABI [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FLIXABIMember" xlink:href="biib-20250930.xsd#biib_FLIXABIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FLIXABIMember" xlink:to="lab_biib_FLIXABIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_c9cb8ee4-cb4b-49d0-a1fb-da251d9f50a2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gain on sale of priority review voucher, net</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_6e7e32ca-45b0-476f-9626-c169e77fe2a2_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_7f5e2532-6400-43b8-8842-8497a742a85c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_CAD_bc205a20-1681-4dab-b4b1-48e05f509883_terseLabel_en-US" xlink:label="lab_currency_CAD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Canadian dollar</link:label>
    <link:label id="lab_currency_CAD_label_en-US" xlink:label="lab_currency_CAD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Canada, Dollars</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CAD" xlink:href="https://xbrl.sec.gov/currency/2025/currency-2025.xsd#currency_CAD"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_CAD" xlink:to="lab_currency_CAD" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsAbstract_8fdf2755-a138-4622-8376-b80ff5f0c41e_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsAbstract_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract" xlink:to="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_81d34b21-417c-4b20-ba31-d46ab8051e1a_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">State taxes</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_a42836f2-7ffa-4d4e-8d9f-f4e95707b0cc_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other (income) expense, net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_d3529f7d-5999-4b5d-8182-f1d2dd28a51e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other (income) expense, net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_edee1738-e936-41aa-83da-54904bd06268_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other (income) expense, net</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Operating Income (Expense), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_7c007c6c-0490-4a38-863d-7917e881abbc_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Operating and Nonoperating</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_47a7d878-fe17-4249-8090-876be4d88c0b_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from borrowings</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_f62cd891-05a4-4643-8586-a1e3f3e90a00_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_HumanImmunologyBiosciencesPreExistingInLicenseCommitmentsMember_d6d2f813-5e84-4f25-a414-efb59337a1ce_terseLabel_en-US" xlink:label="lab_biib_HumanImmunologyBiosciencesPreExistingInLicenseCommitmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Human Immunology Biosciences Pre-Existing In License Commitments</link:label>
    <link:label id="lab_biib_HumanImmunologyBiosciencesPreExistingInLicenseCommitmentsMember_label_en-US" xlink:label="lab_biib_HumanImmunologyBiosciencesPreExistingInLicenseCommitmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Human Immunology Biosciences Pre-Existing In License Commitments [Member]</link:label>
    <link:label id="lab_biib_HumanImmunologyBiosciencesPreExistingInLicenseCommitmentsMember_documentation_en-US" xlink:label="lab_biib_HumanImmunologyBiosciencesPreExistingInLicenseCommitmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Human Immunology Biosciences Pre-Existing In License Commitments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_HumanImmunologyBiosciencesPreExistingInLicenseCommitmentsMember" xlink:href="biib-20250930.xsd#biib_HumanImmunologyBiosciencesPreExistingInLicenseCommitmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_HumanImmunologyBiosciencesPreExistingInLicenseCommitmentsMember" xlink:to="lab_biib_HumanImmunologyBiosciencesPreExistingInLicenseCommitmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_968c604b-cf61-403c-858d-4c79d8077de8_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_d149a261-2734-472c-8d96-78e629cb430b_verboseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Collaborative and Other Relationships</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_cf42e2d5-05d7-4c14-bdbd-294d3cfc217a_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_7c36459e-528e-487b-902c-008f32846cef_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of assets and liabilities recorded at fair value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_e63b096a-2edf-42c4-b3f8-88c7e0ed689e_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_3186800f-56c0-4a8d-922b-0e2b6b51e5bc_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total identifiable net assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_15c197f3-b1ab-4841-acc9-3f6f756315f8_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares used in calculating:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount_77b0ce3e-cb5a-4d4f-96a6-13b908b72560_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated minimum lease payments</link:label>
    <link:label id="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount_label_en-US" xlink:label="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecorded Unconditional Purchase Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" xlink:to="lab_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_e2a292df-491c-409f-81e3-3fdfb4ca7d02_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_12e7a7c4-e094-43f6-a711-ef4ed589be52_terseLabel_en-US" xlink:label="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated additional payments upon achievement of development and commercial milestones</link:label>
    <link:label id="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_label_en-US" xlink:label="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimated Additional Payments Upon Achievement Of Development And Commercial Milestones</link:label>
    <link:label id="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_documentation_en-US" xlink:label="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Estimated additional payments upon achievement of development and commercial milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:href="biib-20250930.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:to="lab_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_41067a2e-40ef-4a5b-87ab-aa6e754e47ac_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_859d3dc6-56d5-4029-a9e6-7c2654bd9245_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flow provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_395b38da-c8e5-4ee0-afe6-3b059a5e47e6_terseLabel_en-US" xlink:label="lab_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization and impairment of acquired intangible assets</link:label>
    <link:label id="lab_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_label_en-US" xlink:label="lab_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization and Impairment of Acquired Intangible Assets</link:label>
    <link:label id="lab_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_documentation_en-US" xlink:label="lab_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amortization and Impairment of Acquired Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets" xlink:href="biib-20250930.xsd#biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets" xlink:to="lab_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_MSProductRevenuesMember_279f461a-2e29-4e2e-bc65-28bed69babe8_terseLabel_en-US" xlink:label="lab_biib_MSProductRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MS Product Revenues</link:label>
    <link:label id="lab_biib_MSProductRevenuesMember_label_en-US" xlink:label="lab_biib_MSProductRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MS Product Revenues [Member]</link:label>
    <link:label id="lab_biib_MSProductRevenuesMember_documentation_en-US" xlink:label="lab_biib_MSProductRevenuesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">MS Product Revenues [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MSProductRevenuesMember" xlink:href="biib-20250930.xsd#biib_MSProductRevenuesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MSProductRevenuesMember" xlink:to="lab_biib_MSProductRevenuesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_500f77a4-68c2-444f-accd-3dd375ae93eb_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_833d1f30-ccb2-45e3-935a-e3e4481103e4_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under stock award plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_a312076d-84a7-472f-a1ae-4d33a3062cf7_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount remaining under 2019 share repurchase program</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program, Remaining Authorized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_d6782c86-50ce-4411-bbf7-8841ce80f030_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of sales, excluding amortization and impairment of acquired intangible assets</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Product and Service Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationOneBigBeautifulBillActEnactment_1981e5f7-2e93-48d6-9376-2588dd189f9d_terseLabel_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationOneBigBeautifulBillActEnactment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OBBBA enactment</link:label>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationOneBigBeautifulBillActEnactment_label_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationOneBigBeautifulBillActEnactment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Tax Rate Reconciliation, One Big Beautiful Bill Act Enactment</link:label>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationOneBigBeautifulBillActEnactment_documentation_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationOneBigBeautifulBillActEnactment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Tax Rate Reconciliation, One Big Beautiful Bill Act Enactment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveTaxRateReconciliationOneBigBeautifulBillActEnactment" xlink:href="biib-20250930.xsd#biib_EffectiveTaxRateReconciliationOneBigBeautifulBillActEnactment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EffectiveTaxRateReconciliationOneBigBeautifulBillActEnactment" xlink:to="lab_biib_EffectiveTaxRateReconciliationOneBigBeautifulBillActEnactment" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ContractManufacturingAndOtherRevenueMember_3e2c3155-c4cd-4703-966d-dbadc79d036b_terseLabel_en-US" xlink:label="lab_biib_ContractManufacturingAndOtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract manufacturing revenue</link:label>
    <link:label id="lab_biib_ContractManufacturingAndOtherRevenueMember_label_en-US" xlink:label="lab_biib_ContractManufacturingAndOtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract manufacturing and other revenue [Member]</link:label>
    <link:label id="lab_biib_ContractManufacturingAndOtherRevenueMember_documentation_en-US" xlink:label="lab_biib_ContractManufacturingAndOtherRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other corporate revenues [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractManufacturingAndOtherRevenueMember" xlink:href="biib-20250930.xsd#biib_ContractManufacturingAndOtherRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ContractManufacturingAndOtherRevenueMember" xlink:to="lab_biib_ContractManufacturingAndOtherRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_670e9df0-fbde-4289-9a55-b7192ac89425_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_LEQEMBIMember_b7f2a082-e031-4a80-bed8-f80fb9d30d97_terseLabel_en-US" xlink:label="lab_biib_LEQEMBIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LEQEMBI</link:label>
    <link:label id="lab_biib_LEQEMBIMember_label_en-US" xlink:label="lab_biib_LEQEMBIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">LEQEMBI [Member]</link:label>
    <link:label id="lab_biib_LEQEMBIMember_documentation_en-US" xlink:label="lab_biib_LEQEMBIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">LEQEMBI</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LEQEMBIMember" xlink:href="biib-20250930.xsd#biib_LEQEMBIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_LEQEMBIMember" xlink:to="lab_biib_LEQEMBIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_c08934f5-23fb-40ab-8643-aa3a96def983_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_e8b6d8ac-f1f5-49b1-a218-680b1319d7e8_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of equity interest in Samsung Bioepis</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentSoldCarryingAmount_0fac6893-a08f-4f22-a44a-bc28ef2eb4b4_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Amount Sold</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentSoldCarryingAmount_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Amount Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentSoldCarryingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:to="lab_us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_a6cc5285-c7d3-47b7-bf7a-672bd3656221_negatedLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Tax credits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_ec129ec4-219c-47c3-8596-e109d6b73a27_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other(2)</link:label>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Other Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:to="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_ce4fa7d3-91fc-4d3d-a4bc-dda4adf3a84b_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionAxis" xlink:to="lab_us-gaap_AssetAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_GBP_3d91a05e-f3ef-4cd9-a8c7-18286d23697d_terseLabel_en-US" xlink:label="lab_currency_GBP" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">British pound</link:label>
    <link:label id="lab_currency_GBP_label_en-US" xlink:label="lab_currency_GBP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">United Kingdom, Pounds</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_GBP" xlink:href="https://xbrl.sec.gov/currency/2025/currency-2025.xsd#currency_GBP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_GBP" xlink:to="lab_currency_GBP" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_TheCreditFacilityFloatingRateThreeYearTrancheMember_e5f790f9-491b-4217-969a-d2924fa569fd_terseLabel_en-US" xlink:label="lab_biib_TheCreditFacilityFloatingRateThreeYearTrancheMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">The Credit Facility Floating Rate Three-Year Tranche</link:label>
    <link:label id="lab_biib_TheCreditFacilityFloatingRateThreeYearTrancheMember_label_en-US" xlink:label="lab_biib_TheCreditFacilityFloatingRateThreeYearTrancheMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The Credit Facility Floating Rate Three-Year Tranche [Member]</link:label>
    <link:label id="lab_biib_TheCreditFacilityFloatingRateThreeYearTrancheMember_documentation_en-US" xlink:label="lab_biib_TheCreditFacilityFloatingRateThreeYearTrancheMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The Credit Facility Floating Rate Three-Year Tranche</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TheCreditFacilityFloatingRateThreeYearTrancheMember" xlink:href="biib-20250930.xsd#biib_TheCreditFacilityFloatingRateThreeYearTrancheMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TheCreditFacilityFloatingRateThreeYearTrancheMember" xlink:to="lab_biib_TheCreditFacilityFloatingRateThreeYearTrancheMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_6c06d005-bfe1-47e3-af94-30f117f754b4_verboseLabel_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Effect of dilutive securities:</link:label>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract" xlink:to="lab_us-gaap_DilutiveSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EisaiMember_6a2e0e46-e884-43b6-82ae-666422fabfc3_terseLabel_en-US" xlink:label="lab_biib_EisaiMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Eisai</link:label>
    <link:label id="lab_biib_EisaiMember_label_en-US" xlink:label="lab_biib_EisaiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Eisai [Member]</link:label>
    <link:label id="lab_biib_EisaiMember_documentation_en-US" xlink:label="lab_biib_EisaiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Eisai [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember" xlink:href="biib-20250930.xsd#biib_EisaiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EisaiMember" xlink:to="lab_biib_EisaiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_ada60a90-8b9c-429c-984b-ba832e110ed0_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_99a9d9dd-2ae3-446d-b891-75bde151fad3_terseLabel_en-US" xlink:label="lab_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Co promotion operating profit threshold to determine share of co promotion operating profit prior to amendment</link:label>
    <link:label id="lab_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_label_en-US" xlink:label="lab_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Co Promotion Operating Profit Threshold To Determine Share Of Co Promotion Operating Profit Prior To Amendment</link:label>
    <link:label id="lab_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_documentation_en-US" xlink:label="lab_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Co promotion operating profit threshold to determine share of co promotion operating profit prior to amendment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" xlink:href="biib-20250930.xsd#biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" xlink:to="lab_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DistributorOneMember_3b5d44e5-08cc-4773-814f-b1c801ab8210_terseLabel_en-US" xlink:label="lab_biib_DistributorOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Distributor One</link:label>
    <link:label id="lab_biib_DistributorOneMember_label_en-US" xlink:label="lab_biib_DistributorOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Distributor One [Member]</link:label>
    <link:label id="lab_biib_DistributorOneMember_documentation_en-US" xlink:label="lab_biib_DistributorOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Distributor one.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DistributorOneMember" xlink:href="biib-20250930.xsd#biib_DistributorOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DistributorOneMember" xlink:to="lab_biib_DistributorOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_f9072d4b-d84e-4ec1-a646-f5351ba3bc1f_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of roll forward of the changes in goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_4727fcee-f471-4fe6-ac57-9227804471ac_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax assets and liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Income Taxes Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_6942d5b2-405a-491e-859a-84507b596529_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_78ff30c6-9d99-4e35-8104-9a1d57bce390_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in fair value</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_31c703ad-e9c1-4189-a0d0-4d4d177bec1c_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_ed1ce427-6cc6-405f-99e8-126ffccf7a43_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of revenue from segments to consolidated</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of Revenue from Segments to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_5e202a13-3163-4645-b03d-de03c4c089b4_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of credit facility, maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0c4bfe98-d719-4082-989f-a41537d051c1_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_9ec28f3a-8a00-476d-b62e-9a63f4d18c5a_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued expense and other</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_8d919334-0892-41ae-8cbb-155e446c4c16_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total accrued expense and other</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_da5bd506-62ed-4a41-a61d-b4ed77decc90_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock_0fd71289-05f5-4f2a-a7b3-32a8864e51f1_terseLabel_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Activity Related to Sage Therapeutics</link:label>
    <link:label id="lab_biib_SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock_label_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of Activity Related to Sage Therapeutics [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock_documentation_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary of Activity Related to Sage Therapeutics</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock" xlink:href="biib-20250930.xsd#biib_SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock" xlink:to="lab_biib_SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EquitySecuritiesNonCurrentMember_13126343-1307-4a73-9d95-735676c2715c_terseLabel_en-US" xlink:label="lab_biib_EquitySecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Securities, Non-Current</link:label>
    <link:label id="lab_biib_EquitySecuritiesNonCurrentMember_label_en-US" xlink:label="lab_biib_EquitySecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, Non-Current [Member]</link:label>
    <link:label id="lab_biib_EquitySecuritiesNonCurrentMember_documentation_en-US" xlink:label="lab_biib_EquitySecuritiesNonCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Securities, Non-Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesNonCurrentMember" xlink:href="biib-20250930.xsd#biib_EquitySecuritiesNonCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquitySecuritiesNonCurrentMember" xlink:to="lab_biib_EquitySecuritiesNonCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths_8593c589-73cd-47d5-8055-7d721275985b_terseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayments of short-term debt, maturing in more than three months</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Short-Term Debt, Maturing in More than Three Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths" xlink:to="lab_us-gaap_RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_fa328127-2eff-498c-a917-981d5c1b37ff_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_970dddde-719e-4ce2-bd26-f8f0ed6c6fc3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_001d647f-3d3e-4ee7-b188-53ce4a7ddc79_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_35b83d0c-24dd-4db5-9ae4-ce677f13fb42_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems" xlink:to="lab_us-gaap_SubsequentEventLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_MarketedProductsMember_df0dc7a2-eca4-4b1b-983b-15fd12ef7007_terseLabel_en-US" xlink:label="lab_biib_MarketedProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketed products</link:label>
    <link:label id="lab_biib_MarketedProductsMember_label_en-US" xlink:label="lab_biib_MarketedProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketed Products [Member]</link:label>
    <link:label id="lab_biib_MarketedProductsMember_documentation_en-US" xlink:label="lab_biib_MarketedProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Marketed Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MarketedProductsMember" xlink:href="biib-20250930.xsd#biib_MarketedProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MarketedProductsMember" xlink:to="lab_biib_MarketedProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_ec46c0a1-c88a-4002-aeb9-210a930228de_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ReataPharmaceuticalsIncMember_cb81f773-135d-4bb9-8d01-b0fabc833ba2_terseLabel_en-US" xlink:label="lab_biib_ReataPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reata Pharmaceuticals, Inc</link:label>
    <link:label id="lab_biib_ReataPharmaceuticalsIncMember_label_en-US" xlink:label="lab_biib_ReataPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reata Pharmaceuticals, Inc [Member]</link:label>
    <link:label id="lab_biib_ReataPharmaceuticalsIncMember_documentation_en-US" xlink:label="lab_biib_ReataPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reata Pharmaceuticals, Inc</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember" xlink:href="biib-20250930.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ReataPharmaceuticalsIncMember" xlink:to="lab_biib_ReataPharmaceuticalsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_339027d9-0fc2-4058-89dd-da80404b1594_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Dilutive potential common shares</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted, Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_401c0872-aac0-4bfd-9e1d-826118ab9dc7_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableCurrent_6c5b0841-710a-44d6-bd93-f56eca7cf830_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of notes payable</link:label>
    <link:label id="lab_us-gaap_NotesPayableCurrent_afd8f23e-932f-4cc0-a35b-16f8a03acd56_verboseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current portion of carrying value</link:label>
    <link:label id="lab_us-gaap_NotesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableCurrent" xlink:to="lab_us-gaap_NotesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Expenseincurredbythecollaboration_83d7a80e-8325-457c-87d9-67732937cc2b_terseLabel_en-US" xlink:label="lab_biib_Expenseincurredbythecollaboration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expense incurred by the collaboration</link:label>
    <link:label id="lab_biib_Expenseincurredbythecollaboration_label_en-US" xlink:label="lab_biib_Expenseincurredbythecollaboration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expense incurred by the collaboration</link:label>
    <link:label id="lab_biib_Expenseincurredbythecollaboration_documentation_en-US" xlink:label="lab_biib_Expenseincurredbythecollaboration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expense incurred by the collaboration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration" xlink:href="biib-20250930.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Expenseincurredbythecollaboration" xlink:to="lab_biib_Expenseincurredbythecollaboration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_aff0091d-0281-4b28-82f5-3fd923695bca_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of significant accounting policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_2c665d3c-5faf-4f7c-930d-71d703614885_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_a47cecc4-e13e-47c7-8969-5ecba0b65ea5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsMember" xlink:to="lab_us-gaap_OtherCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_1564c819-32f2-4803-941f-2ae21d55a992_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination [Abstract]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract" xlink:to="lab_us-gaap_BusinessCombinationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_f4881ea8-35b7-4440-9a8b-241a09f7cdf4_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency forward contracts that were entered into to hedge forecasted revenue</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_TheCreditFacilityTerminatedMember_4b42ea6a-c8ad-47ea-b9b3-9dedccc6a0cc_terseLabel_en-US" xlink:label="lab_biib_TheCreditFacilityTerminatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">The Credit Facility, Terminated</link:label>
    <link:label id="lab_biib_TheCreditFacilityTerminatedMember_label_en-US" xlink:label="lab_biib_TheCreditFacilityTerminatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The Credit Facility, Terminated [Member]</link:label>
    <link:label id="lab_biib_TheCreditFacilityTerminatedMember_documentation_en-US" xlink:label="lab_biib_TheCreditFacilityTerminatedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The Credit Facility, Terminated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TheCreditFacilityTerminatedMember" xlink:href="biib-20250930.xsd#biib_TheCreditFacilityTerminatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TheCreditFacilityTerminatedMember" xlink:to="lab_biib_TheCreditFacilityTerminatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_26f03a59-911e-435e-8ae2-a69a4f1ca885_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_9b9bd7aa-af4b-45be-a8a7-491800039d4e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_65843ab8-fefe-48f2-a294-d18864d155aa_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments of financing costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Financing Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfFinancingCosts" xlink:to="lab_us-gaap_PaymentsOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_588547a6-cc01-4822-98c7-b0e1429b0da2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncurrent Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentAssetsMember" xlink:to="lab_us-gaap_OtherNoncurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ZURZUVAEMember_8d03b809-e51b-4d3d-bd47-d731f202b088_terseLabel_en-US" xlink:label="lab_biib_ZURZUVAEMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ZURZUVAE</link:label>
    <link:label id="lab_biib_ZURZUVAEMember_label_en-US" xlink:label="lab_biib_ZURZUVAEMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ZURZUVAE [Member]</link:label>
    <link:label id="lab_biib_ZURZUVAEMember_documentation_en-US" xlink:label="lab_biib_ZURZUVAEMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ZURZUVAE</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ZURZUVAEMember" xlink:href="biib-20250930.xsd#biib_ZURZUVAEMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ZURZUVAEMember" xlink:to="lab_biib_ZURZUVAEMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_d778a793-6fab-47f6-906d-f6e9a5390782_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_b12551b2-2d8a-47b0-8bf2-09b36e8ab133_negatedLabel_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments/Returns Relating To Sales in Prior Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_label_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments Returns Applied Against Product Revenue Reserves Relating To Prior Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_documentation_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments/ returns applied against product revenue reserves relating to prior year.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:href="biib-20250930.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:to="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_d86e2d58-70a8-4188-a9f5-eea1c13ae8f7_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SummaryOfActivityRelatedToCollaborationTableTextBlock_e57a985e-9966-4701-9e52-d133d86c2cb0_terseLabel_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToCollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Activity Related to Stoke Therapeutics Collaboration</link:label>
    <link:label id="lab_biib_SummaryOfActivityRelatedToCollaborationTableTextBlock_label_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToCollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary Of Activity Related To Collaboration [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryOfActivityRelatedToCollaborationTableTextBlock_documentation_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToCollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary Of Activity Related To Collaboration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfActivityRelatedToCollaborationTableTextBlock" xlink:href="biib-20250930.xsd#biib_SummaryOfActivityRelatedToCollaborationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfActivityRelatedToCollaborationTableTextBlock" xlink:to="lab_biib_SummaryOfActivityRelatedToCollaborationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_29bb5e3d-d6ab-4a1e-b9b5-e80e86dfa9e4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_dc5b5058-2efd-49ca-a3e3-caa20662ab0f_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic earnings per share attributable to Biogen Inc. (in USD per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_630fb6e2-4de7-4031-80bf-2bc4c283512b_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial Paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_0e343ce5-2049-44bf-bfe1-860fb20ca388_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_TysabriProductMember_317d4f73-bdaf-4665-a321-e34822449a6c_terseLabel_en-US" xlink:label="lab_biib_TysabriProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TYSABRI</link:label>
    <link:label id="lab_biib_TysabriProductMember_label_en-US" xlink:label="lab_biib_TysabriProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">TYSABRI product [Member]</link:label>
    <link:label id="lab_biib_TysabriProductMember_documentation_en-US" xlink:label="lab_biib_TysabriProductMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">TYSABRI product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TysabriProductMember" xlink:href="biib-20250930.xsd#biib_TysabriProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TysabriProductMember" xlink:to="lab_biib_TysabriProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_8172952a-9876-40a8-8a38-3b4003c801e3_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_946643d7-a723-4742-b08b-138ddd8c752a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_9677959b-2927-41e0-9e61-3dee9e6ccbbe_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ShareOfCoPromotionProfits_84471e29-0b2b-4822-ab3c-728ef1fc025c_terseLabel_en-US" xlink:label="lab_biib_ShareOfCoPromotionProfits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA</link:label>
    <link:label id="lab_biib_ShareOfCoPromotionProfits_label_en-US" xlink:label="lab_biib_ShareOfCoPromotionProfits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Of Co Promotion Profits</link:label>
    <link:label id="lab_biib_ShareOfCoPromotionProfits_documentation_en-US" xlink:label="lab_biib_ShareOfCoPromotionProfits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share of co promotion profits.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfCoPromotionProfits" xlink:href="biib-20250930.xsd#biib_ShareOfCoPromotionProfits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShareOfCoPromotionProfits" xlink:to="lab_biib_ShareOfCoPromotionProfits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_51992cbd-4ba1-43d4-91f5-8d711f559ca0_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture_526abfca-3ef9-45e8-a8c5-59f6a1943a03_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from divestiture of interest in joint venture</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Divestiture of Interest in Joint Venture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromDivestitureOfInterestInJointVenture"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_a1e12d3d-4984-4f11-a974-94eb7b35e480_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueAbstract_dd040de8-34fe-4d11-bce7-bad82e03fddc_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueAbstract_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueAbstract" xlink:to="lab_us-gaap_DisaggregationOfRevenueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfOtherInvestments_da3b9904-892b-4f38-9193-5660ad3709b9_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sales of strategic investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfOtherInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfOtherInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Other Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfOtherInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfOtherInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfOtherInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleOfOtherInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_bc19abc7-1fd7-4d11-9019-af809a9d7c9e_terseLabel_en-US" xlink:label="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss) before reclassifications</link:label>
    <link:label id="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OCI, before Reclassifications, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:to="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationShareBasedCompensationAwards_507a3e2a-5f87-4b82-bced-048e446e10ea_terseLabel_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationShareBasedCompensationAwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation awards</link:label>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationShareBasedCompensationAwards_label_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationShareBasedCompensationAwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Tax Rate Reconciliation, Share-Based Compensation Awards</link:label>
    <link:label id="lab_biib_EffectiveTaxRateReconciliationShareBasedCompensationAwards_documentation_en-US" xlink:label="lab_biib_EffectiveTaxRateReconciliationShareBasedCompensationAwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Tax Rate Reconciliation, Share-Based Compensation Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveTaxRateReconciliationShareBasedCompensationAwards" xlink:href="biib-20250930.xsd#biib_EffectiveTaxRateReconciliationShareBasedCompensationAwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EffectiveTaxRateReconciliationShareBasedCompensationAwards" xlink:to="lab_biib_EffectiveTaxRateReconciliationShareBasedCompensationAwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_8f7cd183-a8ea-4393-942c-3b1d771abd63_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based payment arrangement, expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_45a9e45e-dc2e-4426-9db5-2842c716ad7f_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAssetReconcilingItemLineItems_2f8cfe72-6fe1-4371-8d5c-5d7fa3c02586_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAssetReconcilingItemLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting, Asset Reconciling Item [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAssetReconcilingItemLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAssetReconcilingItemLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Asset Reconciling Item [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAssetReconcilingItemLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems" xlink:to="lab_us-gaap_SegmentReportingAssetReconcilingItemLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_928a7c0d-d629-4cb6-94dd-08c67fdd1e5b_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_dd58f90c-7cee-4c77-a7e8-03ee1941dc04_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_NotesPayableFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_NotesPayableFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayableFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableFairValueDisclosure" xlink:to="lab_us-gaap_NotesPayableFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_1de75a2e-ba99-4269-aea6-7ed3994ea5cf_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_8e52c3df-0566-4f9a-84a0-a1d02b63b585_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_2b1f55cb-c12d-446e-9ee7-14108ebbf19c_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_b33aa6af-359c-47d7-9746-6ef6a71c1110_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_53373230-81bc-4433-b39a-2376e9fff9d3_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unfunded status of postretirement benefit plans</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife_56df6bd6-ee04-412d-bcaa-6c379943354b_terseLabel_en-US" xlink:label="lab_biib_FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average remaining useful life</link:label>
    <link:label id="lab_biib_FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife_label_en-US" xlink:label="lab_biib_FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Weighted-Average Remaining Useful Life</link:label>
    <link:label id="lab_biib_FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife_documentation_en-US" xlink:label="lab_biib_FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Weighted-Average Remaining Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife" xlink:href="biib-20250930.xsd#biib_FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife" xlink:to="lab_biib_FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_0b32070f-26a4-47e7-8fd9-a9d41ac1ccd2_negatedLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Amounts reclassified from AOCI</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:to="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ContractualAdjustmentsMember_8eeba09c-4fb2-4411-9030-fc74534f6076_terseLabel_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual adjustments</link:label>
    <link:label id="lab_biib_ContractualAdjustmentsMember_label_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Adjustments [Member]</link:label>
    <link:label id="lab_biib_ContractualAdjustmentsMember_documentation_en-US" xlink:label="lab_biib_ContractualAdjustmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contractual adjustments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractualAdjustmentsMember" xlink:href="biib-20250930.xsd#biib_ContractualAdjustmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ContractualAdjustmentsMember" xlink:to="lab_biib_ContractualAdjustmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_a84947c3-e29f-4d7e-8d27-e49d989d1e1b_totalLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Subtotal</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_82b7598c-f50b-41b5-b286-6751cb2902de_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Subtotal</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_88e917b9-bf14-4650-95ad-2b32a515532d_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_ebc57bb8-7f32-4690-8b37-3f84c354c30b_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Common [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonMember" xlink:to="lab_us-gaap_TreasuryStockCommonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_c75312a1-33c9-44d1-a9dc-970a57b26c28_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SKYCLARYSMember_a5a2ccfb-2d91-482a-907a-9726aa925d6b_terseLabel_en-US" xlink:label="lab_biib_SKYCLARYSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SKYCLARYS</link:label>
    <link:label id="lab_biib_SKYCLARYSMember_label_en-US" xlink:label="lab_biib_SKYCLARYSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SKYCLARYS [Member]</link:label>
    <link:label id="lab_biib_SKYCLARYSMember_documentation_en-US" xlink:label="lab_biib_SKYCLARYSMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">SKYCLARYS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SKYCLARYSMember" xlink:href="biib-20250930.xsd#biib_SKYCLARYSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SKYCLARYSMember" xlink:to="lab_biib_SKYCLARYSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_55d24ee2-a20c-4c28-bd91-3a93f115e5dd_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_051dfbe1-be29-4523-a763-df2de30db4e2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities, noncurrent</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Reductioninroyaltyrate_b082e5ec-59b4-4eff-ae1f-dd3a1ec5d28b_terseLabel_en-US" xlink:label="lab_biib_Reductioninroyaltyrate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reduction in royalty rate</link:label>
    <link:label id="lab_biib_Reductioninroyaltyrate_label_en-US" xlink:label="lab_biib_Reductioninroyaltyrate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reduction in royalty rate</link:label>
    <link:label id="lab_biib_Reductioninroyaltyrate_documentation_en-US" xlink:label="lab_biib_Reductioninroyaltyrate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reduction in royalty rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Reductioninroyaltyrate" xlink:href="biib-20250930.xsd#biib_Reductioninroyaltyrate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Reductioninroyaltyrate" xlink:to="lab_biib_Reductioninroyaltyrate" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_02814ad0-7d2c-4cd3-a030-8a42b5cbae8c_terseLabel_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense included in total cost and expense</link:label>
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_label_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Expense Included In Costs And Expenses</link:label>
    <link:label id="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_documentation_en-US" xlink:label="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share based compensation expense included in costs and expenses.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:href="biib-20250930.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:to="lab_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_3aaf518b-12d2-48d1-bbd6-97b0fe901711_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_11cd8c57-3c44-42a9-83de-ef035ba1c150_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income (loss) attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_c00d1be4-a424-477f-aeb1-dcd4675b6d70_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_12261396-c84e-4386-9ee1-85bb0838fc61_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Due in one year or less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SecuredDebtMember_a9212ea4-631f-4070-a7f0-3ef7551a86fb_terseLabel_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Secured Debt</link:label>
    <link:label id="lab_us-gaap_SecuredDebtMember_label_en-US" xlink:label="lab_us-gaap_SecuredDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Secured Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuredDebtMember" xlink:to="lab_us-gaap_SecuredDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_b6e896e5-8beb-4331-a17d-f31125642f93_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability_3d4d584a-9d89-438f-845c-e85cc5a80812_terseLabel_en-US" xlink:label="lab_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability, measurement period adjustment</link:label>
    <link:label id="lab_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability_label_en-US" xlink:label="lab_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Tax Liability</link:label>
    <link:label id="lab_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability_documentation_en-US" xlink:label="lab_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Tax Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability" xlink:href="biib-20250930.xsd#biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability" xlink:to="lab_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_e204f83d-927f-4cad-884b-15ac702acc70_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_4c0578fd-55ca-4a5b-aeeb-f812a16abc92_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_ede577a8-e894-49df-bda8-fcaf74f73fd8_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FelzartamabIgANMember_c6fa452d-65d4-48cb-b302-ed0278380782_terseLabel_en-US" xlink:label="lab_biib_FelzartamabIgANMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Felzartamab (IgAN)</link:label>
    <link:label id="lab_biib_FelzartamabIgANMember_label_en-US" xlink:label="lab_biib_FelzartamabIgANMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Felzartamab (IgAN) [Member]</link:label>
    <link:label id="lab_biib_FelzartamabIgANMember_documentation_en-US" xlink:label="lab_biib_FelzartamabIgANMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Felzartamab (IgAN)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FelzartamabIgANMember" xlink:href="biib-20250930.xsd#biib_FelzartamabIgANMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FelzartamabIgANMember" xlink:to="lab_biib_FelzartamabIgANMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_b29da576-a9e5-41e1-bcdd-23abc60dc585_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Notes payable</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_f45f719a-ebff-4cfe-aa51-ed84dcbe2814_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_63e7e7b9-172a-44c4-b15f-546ccfb0c796_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_bb6a25e8-41a2-4c6f-a6c0-94ee5a8d5451_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_36071dd5-71e4-4b0e-b5a7-9257ce3b1b13_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_00682ca8-7002-48e8-b201-df7b1c6fe62e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Separately Recognized Transaction [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Separately Recognized Transaction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:to="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_8c5b9cc3-0cb5-44ac-85ab-23746bb60571_verboseLabel_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Plan assets for deferred compensation</link:label>
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_label_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Assets For Deferred Compensation Fair Value Disclosure</link:label>
    <link:label id="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_documentation_en-US" xlink:label="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair values as of the balance sheet date of all assets of deferred compensation plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:href="biib-20250930.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:to="lab_biib_PlanAssetsForDeferredCompensationFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_a5700085-433e-48d8-acd5-ba5450a22aef_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flow from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingOtherItemAmount_9eb3ff60-9310-4863-9365-06303d0305a8_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingOtherItemAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other segment expense</link:label>
    <link:label id="lab_us-gaap_SegmentReportingOtherItemAmount_label_en-US" xlink:label="lab_us-gaap_SegmentReportingOtherItemAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Other Segment Item, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingOtherItemAmount" xlink:to="lab_us-gaap_SegmentReportingOtherItemAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_1b4bb1bf-60f0-4e7e-8d0e-64d504365f6d_terseLabel_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Provisions Relating To Sales In Current Year</link:label>
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_label_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Provisions To Product Revenue Reserves Relating To Sales In Current Year</link:label>
    <link:label id="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_documentation_en-US" xlink:label="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Current provisions to product revenue reserves relating to sales in current year.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:href="biib-20250930.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:to="lab_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_b3883c76-24ae-40dd-baf6-28b3c0cbabd2_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_57bb5190-4a7a-419e-b373-7170b17c51cb_terseLabel_en-US" xlink:label="lab_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, make whole provision redemption price, percentage</link:label>
    <link:label id="lab_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_label_en-US" xlink:label="lab_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Make Whole Provision Redemption Price, Percentage</link:label>
    <link:label id="lab_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_documentation_en-US" xlink:label="lab_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Make Whole Provision Redemption Price, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage" xlink:href="biib-20250930.xsd#biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage" xlink:to="lab_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_7a32901d-b840-45b1-8cd0-adb0715e2168_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_2954500c-e2df-433c-862a-c458327ab750_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2029</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_f7eacdb3-88d9-4d4c-ac28-7ace3cd0e195_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_0e86b9f9-93a1-4c9a-b2f1-79785bada217_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development:</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_e65323e4-54ae-4689-988b-6127d429d47f_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_MilestonePaymentRegulatoryMember_e62a34a3-f2e2-4246-bd21-af18e2f9d43a_terseLabel_en-US" xlink:label="lab_biib_MilestonePaymentRegulatoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone Payment, Regulatory</link:label>
    <link:label id="lab_biib_MilestonePaymentRegulatoryMember_label_en-US" xlink:label="lab_biib_MilestonePaymentRegulatoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Payment, Regulatory [Member]</link:label>
    <link:label id="lab_biib_MilestonePaymentRegulatoryMember_documentation_en-US" xlink:label="lab_biib_MilestonePaymentRegulatoryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone Payment, Regulatory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MilestonePaymentRegulatoryMember" xlink:href="biib-20250930.xsd#biib_MilestonePaymentRegulatoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MilestonePaymentRegulatoryMember" xlink:to="lab_biib_MilestonePaymentRegulatoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_d722b4e6-1a98-4a39-8d44-f368350d4bbc_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Significant Other Observable Inputs (Level 2)</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ReserveforCashDiscountsMember_d9a29517-b869-4923-8ec3-22736d7fea64_terseLabel_en-US" xlink:label="lab_biib_ReserveforCashDiscountsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discounts</link:label>
    <link:label id="lab_biib_ReserveforCashDiscountsMember_label_en-US" xlink:label="lab_biib_ReserveforCashDiscountsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reserve for Cash Discounts [Member]</link:label>
    <link:label id="lab_biib_ReserveforCashDiscountsMember_documentation_en-US" xlink:label="lab_biib_ReserveforCashDiscountsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reserve for Cash Discounts [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReserveforCashDiscountsMember" xlink:href="biib-20250930.xsd#biib_ReserveforCashDiscountsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ReserveforCashDiscountsMember" xlink:to="lab_biib_ReserveforCashDiscountsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_NumberOfWholesalers_8763d4b5-751c-45cb-8969-a54fa8a1aa02_terseLabel_en-US" xlink:label="lab_biib_NumberOfWholesalers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of wholesalers</link:label>
    <link:label id="lab_biib_NumberOfWholesalers_label_en-US" xlink:label="lab_biib_NumberOfWholesalers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Wholesalers</link:label>
    <link:label id="lab_biib_NumberOfWholesalers_documentation_en-US" xlink:label="lab_biib_NumberOfWholesalers" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Wholesalers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfWholesalers" xlink:href="biib-20250930.xsd#biib_NumberOfWholesalers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_NumberOfWholesalers" xlink:to="lab_biib_NumberOfWholesalers" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_A5.750SeniorNotesDueMay152035Member_1d0b948a-f919-4987-846c-366497c4aaed_terseLabel_en-US" xlink:label="lab_biib_A5.750SeniorNotesDueMay152035Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">5.750% Senior Notes due May 15, 2035</link:label>
    <link:label id="lab_biib_A5.750SeniorNotesDueMay152035Member_label_en-US" xlink:label="lab_biib_A5.750SeniorNotesDueMay152035Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">5.750% Senior Notes due May 15, 2035 [Member]</link:label>
    <link:label id="lab_biib_A5.750SeniorNotesDueMay152035Member_documentation_en-US" xlink:label="lab_biib_A5.750SeniorNotesDueMay152035Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">5.750% Senior Notes due May 15, 2035</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A5.750SeniorNotesDueMay152035Member" xlink:href="biib-20250930.xsd#biib_A5.750SeniorNotesDueMay152035Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A5.750SeniorNotesDueMay152035Member" xlink:to="lab_biib_A5.750SeniorNotesDueMay152035Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_cfca3a5c-3f41-4577-a7e9-5fe5d59579c8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Phase3ClinicalTrialFelzartamabIgANMember_e134cda1-4b1e-4c20-b239-b0669983e2c2_terseLabel_en-US" xlink:label="lab_biib_Phase3ClinicalTrialFelzartamabIgANMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Phase 3 Clinical Trial, Felzartamab IgAN</link:label>
    <link:label id="lab_biib_Phase3ClinicalTrialFelzartamabIgANMember_label_en-US" xlink:label="lab_biib_Phase3ClinicalTrialFelzartamabIgANMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Phase 3 Clinical Trial, Felzartamab IgAN [Member]</link:label>
    <link:label id="lab_biib_Phase3ClinicalTrialFelzartamabIgANMember_documentation_en-US" xlink:label="lab_biib_Phase3ClinicalTrialFelzartamabIgANMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Phase 3 Clinical Trial, Felzartamab IgAN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Phase3ClinicalTrialFelzartamabIgANMember" xlink:href="biib-20250930.xsd#biib_Phase3ClinicalTrialFelzartamabIgANMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Phase3ClinicalTrialFelzartamabIgANMember" xlink:to="lab_biib_Phase3ClinicalTrialFelzartamabIgANMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyMember_17093fdb-7c7a-4e9e-ac47-b31e7792ff39_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_us-gaap_RelatedPartyMember_label_en-US" xlink:label="lab_us-gaap_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related Party [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyMember" xlink:to="lab_us-gaap_RelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EquityMethodInvestmentsExpectedProfitShare_dc83f093-e24a-4978-920c-e4bd94f2911d_terseLabel_en-US" xlink:label="lab_biib_EquityMethodInvestmentsExpectedProfitShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected profit share percentage</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentsExpectedProfitShare_label_en-US" xlink:label="lab_biib_EquityMethodInvestmentsExpectedProfitShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments, Expected Profit Share</link:label>
    <link:label id="lab_biib_EquityMethodInvestmentsExpectedProfitShare_documentation_en-US" xlink:label="lab_biib_EquityMethodInvestmentsExpectedProfitShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Method Investments, Expected Profit Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquityMethodInvestmentsExpectedProfitShare" xlink:href="biib-20250930.xsd#biib_EquityMethodInvestmentsExpectedProfitShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquityMethodInvestmentsExpectedProfitShare" xlink:to="lab_biib_EquityMethodInvestmentsExpectedProfitShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_9ff3afe8-d97c-4ba7-9947-1d67aa1a9f6f_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermDomain" xlink:to="lab_us-gaap_LeaseContractualTermDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_a708880d-04ce-461b-84cb-3b60c1fa88d8_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Severance Costs</link:label>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_label_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Severance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeSeveranceMember" xlink:to="lab_us-gaap_EmployeeSeveranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_c520f8d2-c0ae-4a4c-9d2a-64eb615f6e2b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_d3cb9c23-e230-4aba-a96d-9297e8163516_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_be290eb0-81bf-4df3-b66e-3d3de2639caa_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities, net of effects of business acquired:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_fd52d46f-6ab9-4347-9966-652084dd2e6a_terseLabel_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</link:label>
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_label_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</link:label>
    <link:label id="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_documentation_en-US" xlink:label="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:href="biib-20250930.xsd#biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:to="lab_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_6f908a70-6b0f-4bed-9b02-d402f3c7c3f7_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DivestituresAbstract_91ff809e-cc5d-4cdf-b1d7-5135dc910a11_terseLabel_en-US" xlink:label="lab_biib_DivestituresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Divestitures [Abstract]</link:label>
    <link:label id="lab_biib_DivestituresAbstract_label_en-US" xlink:label="lab_biib_DivestituresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Divestitures [Abstract]</link:label>
    <link:label id="lab_biib_DivestituresAbstract_documentation_en-US" xlink:label="lab_biib_DivestituresAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Divestitures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DivestituresAbstract" xlink:href="biib-20250930.xsd#biib_DivestituresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DivestituresAbstract" xlink:to="lab_biib_DivestituresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_66e53e37-9815-4388-848f-f4d7402db7d0_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4470a5f2-a937-486c-a9cf-7bbc869d0536_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6c00aaaf-9c30-4e88-88f3-479e966fb34a_verboseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a14ef9af-4c8e-4150-8df6-f3798a0170a0_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, beginning of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c9aa9e41-65c3-4004-9014-2e91d85c138c_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents, end of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_5437f27e-18c2-40df-9b42-5cd86887eaf1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SageAndSangamoMember_6d39a4ca-3e9c-4106-8541-17bec8d27f14_terseLabel_en-US" xlink:label="lab_biib_SageAndSangamoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sage and Sangamo</link:label>
    <link:label id="lab_biib_SageAndSangamoMember_label_en-US" xlink:label="lab_biib_SageAndSangamoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sage and Sangamo [Member]</link:label>
    <link:label id="lab_biib_SageAndSangamoMember_documentation_en-US" xlink:label="lab_biib_SageAndSangamoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sage and Sangamo</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SageAndSangamoMember" xlink:href="biib-20250930.xsd#biib_SageAndSangamoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SageAndSangamoMember" xlink:to="lab_biib_SageAndSangamoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_3ba2271c-9ebe-41a2-a00d-a69ead544c14_verboseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Taxes payable</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent" xlink:to="lab_us-gaap_TaxesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_24d8a409-a8e5-48da-875f-0e4eda7ac34c_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative contracts</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:to="lab_us-gaap_DerivativeLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_e8eef7dd-3602-4f45-bd70-2c71fa9c5acd_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable equity securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_InvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_f7c4aaf5-4ba8-4392-900b-75e55193a8f6_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_d7461423-3977-4b52-86b4-b308c8b02cbe_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_e8c63bbc-56b3-4b92-89e6-34e3b91f4226_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_8d0179b7-4a91-474e-9a2f-250d2bf616f7_terseLabel_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of co promotion operating profits first fifty million</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_label_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Co Promotion Operating Profits First Fifty Million</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_documentation_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of co promotion operating profits first fifty million.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion" xlink:href="biib-20250930.xsd#biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion" xlink:to="lab_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BusinessCombinationConsiderationTransferredWorkingCapitalAdjustment_b62a3175-6a50-48ea-bb2d-b15606a076d8_terseLabel_en-US" xlink:label="lab_biib_BusinessCombinationConsiderationTransferredWorkingCapitalAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Working capital adjustment</link:label>
    <link:label id="lab_biib_BusinessCombinationConsiderationTransferredWorkingCapitalAdjustment_label_en-US" xlink:label="lab_biib_BusinessCombinationConsiderationTransferredWorkingCapitalAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred, Working Capital Adjustment</link:label>
    <link:label id="lab_biib_BusinessCombinationConsiderationTransferredWorkingCapitalAdjustment_documentation_en-US" xlink:label="lab_biib_BusinessCombinationConsiderationTransferredWorkingCapitalAdjustment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred, Working Capital Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationConsiderationTransferredWorkingCapitalAdjustment" xlink:href="biib-20250930.xsd#biib_BusinessCombinationConsiderationTransferredWorkingCapitalAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BusinessCombinationConsiderationTransferredWorkingCapitalAdjustment" xlink:to="lab_biib_BusinessCombinationConsiderationTransferredWorkingCapitalAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ParentMember_ca4e3c4a-a606-45fd-82f9-8805b4d72503_terseLabel_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Parent</link:label>
    <link:label id="lab_us-gaap_ParentMember_0eaf0580-3376-4a1b-9d17-fadb5a620614_verboseLabel_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense included in net income attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_ParentMember_label_en-US" xlink:label="lab_us-gaap_ParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember" xlink:to="lab_us-gaap_ParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_b2bd715a-0903-4926-a8bc-4e32c6ff6fe1_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_61b07f05-acb8-4648-8d3b-635196a02aed_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_c50fffcc-0a1e-4301-a927-b6e89caf7d76_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_e004ce47-33f9-4e38-b625-4d5c3715d856_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_2bd21127-32d2-4d7d-ba1e-826ef1b06580_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative, notional amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_76afe3c9-f9a5-4f29-b607-a14b570276ec_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total foreign currency forward contracts and options</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e3a8a7e7-0b46-4ed9-ab1c-05e551730f3b_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_7c72bd39-fee0-45e1-a854-bf751b0f43d8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Asset Acquired and Liability Assumed</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Asset Acquired and Liability Assumed [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_4b7b7561-e649-45bb-b4e5-90df00bdfa66_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Phase3ClinicalTrialFelzartamabOneMember_aad2391a-ec4f-406a-8bde-483535b4b6f7_terseLabel_en-US" xlink:label="lab_biib_Phase3ClinicalTrialFelzartamabOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Phase 3 Clinical Trial, Felzartamab One</link:label>
    <link:label id="lab_biib_Phase3ClinicalTrialFelzartamabOneMember_label_en-US" xlink:label="lab_biib_Phase3ClinicalTrialFelzartamabOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Phase 3 Clinical Trial, Felzartamab One [Member]</link:label>
    <link:label id="lab_biib_Phase3ClinicalTrialFelzartamabOneMember_documentation_en-US" xlink:label="lab_biib_Phase3ClinicalTrialFelzartamabOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Phase 3 Clinical Trial, Felzartamab One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Phase3ClinicalTrialFelzartamabOneMember" xlink:href="biib-20250930.xsd#biib_Phase3ClinicalTrialFelzartamabOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Phase3ClinicalTrialFelzartamabOneMember" xlink:to="lab_biib_Phase3ClinicalTrialFelzartamabOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CoPromotionProfitSharingFormulaTableTextBlock_579ed459-d778-4d2f-ac8f-0eeecea1435e_terseLabel_en-US" xlink:label="lab_biib_CoPromotionProfitSharingFormulaTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Co Promotion Profit Sharing Formula</link:label>
    <link:label id="lab_biib_CoPromotionProfitSharingFormulaTableTextBlock_label_en-US" xlink:label="lab_biib_CoPromotionProfitSharingFormulaTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Co Promotion Profit Sharing Formula [Table Text Block]</link:label>
    <link:label id="lab_biib_CoPromotionProfitSharingFormulaTableTextBlock_documentation_en-US" xlink:label="lab_biib_CoPromotionProfitSharingFormulaTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Co-promotion profit sharing formula.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CoPromotionProfitSharingFormulaTableTextBlock" xlink:href="biib-20250930.xsd#biib_CoPromotionProfitSharingFormulaTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CoPromotionProfitSharingFormulaTableTextBlock" xlink:to="lab_biib_CoPromotionProfitSharingFormulaTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_1b8f4814-290a-4ff3-b4c7-76e9091cb32f_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flow from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OperatingLeaseArea_0c1a3251-8dc8-45a3-a1b6-656276b2534a_terseLabel_en-US" xlink:label="lab_biib_OperatingLeaseArea" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease area</link:label>
    <link:label id="lab_biib_OperatingLeaseArea_label_en-US" xlink:label="lab_biib_OperatingLeaseArea" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease Area</link:label>
    <link:label id="lab_biib_OperatingLeaseArea_documentation_en-US" xlink:label="lab_biib_OperatingLeaseArea" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease Area</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OperatingLeaseArea" xlink:href="biib-20250930.xsd#biib_OperatingLeaseArea"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OperatingLeaseArea" xlink:to="lab_biib_OperatingLeaseArea" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_423459fe-748b-415a-9a4c-1b3ab8583926_terseLabel_en-US" xlink:label="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_label_en-US" xlink:label="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms_documentation_en-US" xlink:label="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other revenues from anti-CD20 therapeutic programs consists of revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada and royalty revenue on sales of Ocrevus.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:href="biib-20250930.xsd#biib_OtherrevenuesfromantiCD20therapeuticprograms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:to="lab_biib_OtherrevenuesfromantiCD20therapeuticprograms" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_af917c61-6353-4713-806c-632f9f785679_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_2fb99667-abb2-4fa2-9e6a-79986287a979_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_fb7f41d9-f943-4cd8-b460-265190efbe68_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_4d394e55-371b-4be4-9684-7b0c28c30358_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember" xlink:to="lab_us-gaap_CashFlowHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_91eef7a5-db9a-419f-9ef3-9b44ac5a06e2_netLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_4605b86f-91ae-4ea8-a9d0-2591f82ea394_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_9d22ecac-c8cc-4e94-88cf-71e40cfbc904_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Goodwill, beginning of period</link:label>
    <link:label id="lab_us-gaap_Goodwill_dcb4c7c1-29d6-4aef-943b-4c2512856c55_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Goodwill, end of period</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_9c728b10-8102-4538-bd9c-04414a1ccb99_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss contingency, estimate of possible loss</link:label>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_label_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:to="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_fca63fea-93d8-475b-8d9b-bc5d6cbc8f6a_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermAxis" xlink:to="lab_us-gaap_LeaseContractualTermAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesReceivableFairValueDisclosure_1af9093e-51d0-4a79-8967-f22427a1cf56_terseLabel_en-US" xlink:label="lab_us-gaap_NotesReceivableFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible note</link:label>
    <link:label id="lab_us-gaap_NotesReceivableFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_NotesReceivableFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Receivable, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesReceivableFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesReceivableFairValueDisclosure" xlink:to="lab_us-gaap_NotesReceivableFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_HumanImmunologyBiosciencesMember_def8c4da-730d-4200-b299-5f3ec0c18452_terseLabel_en-US" xlink:label="lab_biib_HumanImmunologyBiosciencesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Human Immunology Biosciences</link:label>
    <link:label id="lab_biib_HumanImmunologyBiosciencesMember_label_en-US" xlink:label="lab_biib_HumanImmunologyBiosciencesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Human Immunology Biosciences [Member]</link:label>
    <link:label id="lab_biib_HumanImmunologyBiosciencesMember_documentation_en-US" xlink:label="lab_biib_HumanImmunologyBiosciencesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Human Immunology Biosciences</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_HumanImmunologyBiosciencesMember" xlink:href="biib-20250930.xsd#biib_HumanImmunologyBiosciencesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_HumanImmunologyBiosciencesMember" xlink:to="lab_biib_HumanImmunologyBiosciencesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_42c298f0-8be1-4072-83e9-71df9bd7f48c_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rest of World</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_TheCreditFacilityFloatingRate364DayTrancheMember_b4decfb7-b089-4418-9880-07cf3d58fe9b_terseLabel_en-US" xlink:label="lab_biib_TheCreditFacilityFloatingRate364DayTrancheMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility Floating Rate 364-Day Tranche</link:label>
    <link:label id="lab_biib_TheCreditFacilityFloatingRate364DayTrancheMember_label_en-US" xlink:label="lab_biib_TheCreditFacilityFloatingRate364DayTrancheMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The Credit Facility Floating Rate 364-Day Tranche [Member]</link:label>
    <link:label id="lab_biib_TheCreditFacilityFloatingRate364DayTrancheMember_documentation_en-US" xlink:label="lab_biib_TheCreditFacilityFloatingRate364DayTrancheMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Credit Facility Floating Rate 364-Day Tranche</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TheCreditFacilityFloatingRate364DayTrancheMember" xlink:href="biib-20250930.xsd#biib_TheCreditFacilityFloatingRate364DayTrancheMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TheCreditFacilityFloatingRate364DayTrancheMember" xlink:to="lab_biib_TheCreditFacilityFloatingRate364DayTrancheMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_149d2e24-4444-415c-8e0a-2fe946e92e0b_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total marketable debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_StrategicInvestmentsMember_ac1009c6-bdc0-4302-b0c1-e155596e270a_terseLabel_en-US" xlink:label="lab_biib_StrategicInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Strategic Investments</link:label>
    <link:label id="lab_biib_StrategicInvestmentsMember_label_en-US" xlink:label="lab_biib_StrategicInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Strategic Investments [Member]</link:label>
    <link:label id="lab_biib_StrategicInvestmentsMember_documentation_en-US" xlink:label="lab_biib_StrategicInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Strategic investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StrategicInvestmentsMember" xlink:href="biib-20250930.xsd#biib_StrategicInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StrategicInvestmentsMember" xlink:to="lab_biib_StrategicInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_c96d4641-1377-4c78-9b67-baa64bad379c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Asset Acquired, Inventory, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_4fbd4cd2-885b-453f-9f9a-1f903e5bae3b_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_476cf7c6-a4ae-4441-baff-1cdba11fa777_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_5a5245d1-39f6-4591-93ae-da8a3e53550e_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated impairment losses related to goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_592029f7-1a00-4cc7-8a1d-ed6b4bed0cb9_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated impairment losses related to goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_1c4ed78b-520e-49af-ae54-6c8600e90913_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:to="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryLineItems_8e8dea27-d7d9-45b7-ae62-1d6890325528_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:label id="lab_us-gaap_InventoryLineItems_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems" xlink:to="lab_us-gaap_InventoryLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FutureContingentMilestoneTypesDomain_f205ccdc-c9a7-4b38-ad06-079dfc9a3a78_terseLabel_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future Contingent Milestone Types [Domain]</link:label>
    <link:label id="lab_biib_FutureContingentMilestoneTypesDomain_label_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Contingent Milestone Types [Domain]</link:label>
    <link:label id="lab_biib_FutureContingentMilestoneTypesDomain_documentation_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Future Contingent Milestone Types [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain" xlink:href="biib-20250930.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain" xlink:to="lab_biib_FutureContingentMilestoneTypesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_44f5b9a9-fd28-423a-9556-7fdab2cc2534_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_907e7d49-bf65-43a7-921f-35c12a9ba989_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Component of accrued expenses and other</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_8bf1d5bf-1cde-492f-aefc-7d59f42cda7b_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase (decrease) in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_69f9f494-04cc-48a1-a30b-25cb1b9b7fc0_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net (gains) losses recognized on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_5e986b12-65b2-4d5f-ae22-bfbed06cc437_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_TECFIDERAMember_b4e0c32b-8534-4e9b-aec9-ec5c6bd35c05_terseLabel_en-US" xlink:label="lab_biib_TECFIDERAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TECFIDERA</link:label>
    <link:label id="lab_biib_TECFIDERAMember_label_en-US" xlink:label="lab_biib_TECFIDERAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">TECFIDERA [Member]</link:label>
    <link:label id="lab_biib_TECFIDERAMember_documentation_en-US" xlink:label="lab_biib_TECFIDERAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">TECFIDERA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TECFIDERAMember" xlink:href="biib-20250930.xsd#biib_TECFIDERAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TECFIDERAMember" xlink:to="lab_biib_TECFIDERAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_375e8357-72e2-4425-91e9-9b80f6118e39_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_c07c5748-0530-4853-8010-cc53f2232793_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_8635d081-a5d9-47e3-9c87-3b32137a9c07_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash flow provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_060df26a-fcc5-4c7e-9000-4be4ad1b7217_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_c1ffc150-6712-4ef3-9225-d65f6e3f46f7_verboseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basis of presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_98d69b81-c3ab-4b08-ad8a-6d4481825ac0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PercentageOfFutureDevelopmentCosts_8e53aa2f-59ec-46c9-92f9-91ba1eccae6d_terseLabel_en-US" xlink:label="lab_biib_PercentageOfFutureDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of future development costs</link:label>
    <link:label id="lab_biib_PercentageOfFutureDevelopmentCosts_label_en-US" xlink:label="lab_biib_PercentageOfFutureDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Future Development Costs</link:label>
    <link:label id="lab_biib_PercentageOfFutureDevelopmentCosts_documentation_en-US" xlink:label="lab_biib_PercentageOfFutureDevelopmentCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage Of Future Development Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfFutureDevelopmentCosts" xlink:href="biib-20250930.xsd#biib_PercentageOfFutureDevelopmentCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfFutureDevelopmentCosts" xlink:to="lab_biib_PercentageOfFutureDevelopmentCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OCREVUSMember_cca7d5a1-84f9-47cc-a681-36e213a356fa_terseLabel_en-US" xlink:label="lab_biib_OCREVUSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OCREVUS</link:label>
    <link:label id="lab_biib_OCREVUSMember_label_en-US" xlink:label="lab_biib_OCREVUSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OCREVUS [Member]</link:label>
    <link:label id="lab_biib_OCREVUSMember_documentation_en-US" xlink:label="lab_biib_OCREVUSMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">OCREVUS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OCREVUSMember" xlink:href="biib-20250930.xsd#biib_OCREVUSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OCREVUSMember" xlink:to="lab_biib_OCREVUSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_4fcd8395-ea18-4217-992e-fcbac2bdf175_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_6de60aee-81e5-46f3-8d0d-861b1512ffe7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisition related costs</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Acquisition-Related Cost, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_a3009b1b-2c6f-48a2-8d19-f106690913cc_verboseLabel_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Litigation</link:label>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Matters and Contingencies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:to="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_38213a37-de76-4183-bb76-8ef779d9e9ea_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingMember_63b8c4ed-e2f7-4ed1-bc0f-1c8ddaa440fb_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Building</link:label>
    <link:label id="lab_us-gaap_BuildingMember_label_en-US" xlink:label="lab_us-gaap_BuildingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BuildingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember" xlink:to="lab_us-gaap_BuildingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_e07b647f-afaf-4c0a-b076-7932227fcc6e_negatedTerseLabel_en-US" xlink:label="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax</link:label>
    <link:label id="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_documentation_en-US" xlink:label="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="biib-20250930.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_MilestonePaymentOneMember_d6f97d9a-3ebd-475b-9e3d-a8394a8380a2_terseLabel_en-US" xlink:label="lab_biib_MilestonePaymentOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone Payment, One</link:label>
    <link:label id="lab_biib_MilestonePaymentOneMember_label_en-US" xlink:label="lab_biib_MilestonePaymentOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Payment, One [Member]</link:label>
    <link:label id="lab_biib_MilestonePaymentOneMember_documentation_en-US" xlink:label="lab_biib_MilestonePaymentOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone Payment, One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MilestonePaymentOneMember" xlink:href="biib-20250930.xsd#biib_MilestonePaymentOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MilestonePaymentOneMember" xlink:to="lab_biib_MilestonePaymentOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_4fbcc25e-0d65-4d7e-b5e0-bf372a9b0481_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_5885e380-91d4-4d53-ab4b-de76a1b25dfb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_397e32e6-31de-48e7-8540-79a12b4fd7a3_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Not designated as hedging instrument</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_288a8c16-a6e1-4f4f-85de-10b81509571d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinStockMember_fc73348d-a7d5-4f3d-961a-f2937a4bb556_terseLabel_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance stock units settled in stock</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinStockMember_label_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Stock Units Settled in Stock [Member]</link:label>
    <link:label id="lab_biib_PerformanceStockUnitsSettledinStockMember_documentation_en-US" xlink:label="lab_biib_PerformanceStockUnitsSettledinStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Performance Stock Units Settled in Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember" xlink:href="biib-20250930.xsd#biib_PerformanceStockUnitsSettledinStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PerformanceStockUnitsSettledinStockMember" xlink:to="lab_biib_PerformanceStockUnitsSettledinStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_4e303c31-26e4-4eda-808e-3f5cc4512c4d_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated_533d3a3d-53a9-4d21-8763-a5be6e668edf_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected number of positions eliminated</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Expected Number of Positions Eliminated</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" xlink:to="lab_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_be6e2da1-0d34-42da-9945-e2898ec74917_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration obligations</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_WeightedAverageMember_b5877d06-0d03-4ded-a1d3-7201bfe67d7a_terseLabel_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average</link:label>
    <link:label id="lab_srt_WeightedAverageMember_label_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_WeightedAverageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_WeightedAverageMember" xlink:to="lab_srt_WeightedAverageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_a34cc4c6-1830-4ea6-9244-822d8a150f6f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_d64029df-a5e3-4c21-9075-c8b14f4ce9fc_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_44daf9d2-e6aa-4b72-9a9c-1c6752d0830f_terseLabel_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Samsung Bioepis</link:label>
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_label_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Samsung Biosimilar Agreement [Member]</link:label>
    <link:label id="lab_biib_SamsungBiosimilarAgreementMember_documentation_en-US" xlink:label="lab_biib_SamsungBiosimilarAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Samsung bio-similar agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember" xlink:href="biib-20250930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SamsungBiosimilarAgreementMember" xlink:to="lab_biib_SamsungBiosimilarAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_ea469c00-a9e1-45f6-b99e-8f5de83b155a_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_94bd65e9-adcb-49b8-a741-2026f9e8f55b_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_b1e9dacf-d31f-4f9b-9750-48f6d54f4d3f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax asset</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_6921dc3d-2656-48ac-8343-db0e9e6c45a9_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments to acquire productive assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_191e6b2c-380d-4e1b-b752-823a9f46a102_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_9c983186-782f-47cc-a40d-540986d9df19_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_a4605d48-abae-404b-81fb-bdc22bebf69b_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalties and licensing fees</link:label>
    <link:label id="lab_us-gaap_AccruedRoyaltiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Royalties, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRoyaltiesCurrent" xlink:to="lab_us-gaap_AccruedRoyaltiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_UnrealizedGainOnDerivatives_30fd23b7-65b9-4dd2-a112-ad664b315f29_terseLabel_en-US" xlink:label="lab_biib_UnrealizedGainOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains</link:label>
    <link:label id="lab_biib_UnrealizedGainOnDerivatives_label_en-US" xlink:label="lab_biib_UnrealizedGainOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain on Derivatives</link:label>
    <link:label id="lab_biib_UnrealizedGainOnDerivatives_documentation_en-US" xlink:label="lab_biib_UnrealizedGainOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unrealized Gain on Derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedGainOnDerivatives" xlink:href="biib-20250930.xsd#biib_UnrealizedGainOnDerivatives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UnrealizedGainOnDerivatives" xlink:to="lab_biib_UnrealizedGainOnDerivatives" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_57ff145d-c260-4a9c-9f6b-9e0a3022c81c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_GenentechMember_c9a901d5-f22d-48c6-b97d-f1dd59108dc2_terseLabel_en-US" xlink:label="lab_biib_GenentechMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Genentech</link:label>
    <link:label id="lab_biib_GenentechMember_label_en-US" xlink:label="lab_biib_GenentechMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Genentech [Member]</link:label>
    <link:label id="lab_biib_GenentechMember_documentation_en-US" xlink:label="lab_biib_GenentechMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Genentech</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GenentechMember" xlink:href="biib-20250930.xsd#biib_GenentechMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GenentechMember" xlink:to="lab_biib_GenentechMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_34dd1057-e3e2-4919-bc55-98712a861bb1_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bd2bc6cb-0bbf-40cc-8118-f2ba0fc3cc80_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_5ed7d992-9331-4043-b09b-8b109552d049_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment for (Proceeds from) Other Investing Activity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_7ed3357b-c0cc-44de-95d6-b98cd4d271ca_verboseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payments</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ClinicalInventoryMember_4e8465b0-c421-407b-90d9-a50a017a5d9f_terseLabel_en-US" xlink:label="lab_biib_ClinicalInventoryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical Inventory</link:label>
    <link:label id="lab_biib_ClinicalInventoryMember_label_en-US" xlink:label="lab_biib_ClinicalInventoryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Clinical Inventory [Member]</link:label>
    <link:label id="lab_biib_ClinicalInventoryMember_documentation_en-US" xlink:label="lab_biib_ClinicalInventoryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Clinical Inventory</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ClinicalInventoryMember" xlink:href="biib-20250930.xsd#biib_ClinicalInventoryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ClinicalInventoryMember" xlink:to="lab_biib_ClinicalInventoryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_9281f52f-c5fa-42ad-a660-c3d710f047ab_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Asset Acquired, Cash and Cash Equivalent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_8f1af39d-105e-4a32-8a71-3f6a64719e18_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected cost</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Expected Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_27ade9ce-75b7-44ec-a1b0-b4bb2428d9b8_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_3207163b-3bcb-4881-9144-05ab502b47e5_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_d1ef2d4e-72a6-4b74-a624-b1e6a6ed6841_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_0cd7b824-7a15-496f-86da-34ec2ff8ecbc_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_bbf38922-4775-49d5-b9f5-9474362fa2b1_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_15ca357a-4cab-42f8-b3e8-1eff42bf18e0_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_5b4e8926-67b0-477d-94f0-e78a6b5f18d2_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Biogen Inc. shareholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesCurrent_0b0edc50-9ee6-462a-8147-5cf37cd142ee_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative contracts</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesCurrent" xlink:to="lab_us-gaap_DerivativeLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonrecurringAdjustmentAxis_93b3ab52-157d-485f-a863-fb243fee836d_terseLabel_en-US" xlink:label="lab_us-gaap_NonrecurringAdjustmentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Pro Forma Information, Nonrecurring Adjustment [Axis]</link:label>
    <link:label id="lab_us-gaap_NonrecurringAdjustmentAxis_label_en-US" xlink:label="lab_us-gaap_NonrecurringAdjustmentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Pro Forma Information, Nonrecurring Adjustment [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrecurringAdjustmentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonrecurringAdjustmentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonrecurringAdjustmentAxis" xlink:to="lab_us-gaap_NonrecurringAdjustmentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpenseAndOther_816b071f-61e6-472b-af59-c7c74a40622d_terseLabel_en-US" xlink:label="lab_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpenseAndOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment, prepaid expense and other</link:label>
    <link:label id="lab_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpenseAndOther_label_en-US" xlink:label="lab_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpenseAndOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Prepaid Expense And Other</link:label>
    <link:label id="lab_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpenseAndOther_documentation_en-US" xlink:label="lab_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpenseAndOther" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Prepaid Expense And Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpenseAndOther" xlink:href="biib-20250930.xsd#biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpenseAndOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpenseAndOther" xlink:to="lab_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpenseAndOther" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_8ab72cde-544c-455e-8638-2d13371d43d6_terseLabel_en-US" xlink:label="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of share based compensation expense associated with different programs [Abstract]</link:label>
    <link:label id="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_label_en-US" xlink:label="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of share based compensation expense associated with different programs [Abstract]</link:label>
    <link:label id="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_documentation_en-US" xlink:label="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary of share-based compensation expense associated with different programs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:href="biib-20250930.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:to="lab_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_9664e464-9b7a-4d1c-bc6e-161d23f162bc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, interest rate, stated percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_d367430c-9b6a-44f3-b7c1-3f92594a01e9_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_13b84b66-7197-44be-a647-3249fc3d1580_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_0c63cef2-4614-4b14-a22c-0f917cedfd03_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_98c54733-9ad5-4f6c-ba11-621f56407709_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative asset, fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset, Subject to Master Netting Arrangement, before Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNet_67bd3242-6334-4a0a-810d-b993db3132be_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNet_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNet" xlink:to="lab_us-gaap_AccountsReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_e296a8b0-f9ab-4130-a0d3-89f8795df8f2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_5213b46f-90fd-41b9-91ff-06f29a8df5a0_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FutureContingentMilestoneTypesAxis_37398ade-ea46-4f9a-a95d-e385768a029d_terseLabel_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future Contingent Milestone Types [Axis]</link:label>
    <link:label id="lab_biib_FutureContingentMilestoneTypesAxis_label_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Contingent Milestone Types [Axis]</link:label>
    <link:label id="lab_biib_FutureContingentMilestoneTypesAxis_documentation_en-US" xlink:label="lab_biib_FutureContingentMilestoneTypesAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Future Contingent Milestone Types [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis" xlink:href="biib-20250930.xsd#biib_FutureContingentMilestoneTypesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis" xlink:to="lab_biib_FutureContingentMilestoneTypesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_c9564562-1fdd-4e29-beb0-f67323a070ea_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RestatementDomain_1a8e3860-067c-48e5-8e27-6c80331ed152_terseLabel_en-US" xlink:label="lab_srt_RestatementDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revision of Prior Period [Domain]</link:label>
    <link:label id="lab_srt_RestatementDomain_label_en-US" xlink:label="lab_srt_RestatementDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revision of Prior Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RestatementDomain" xlink:to="lab_srt_RestatementDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CollaborativeArrangementTermExtension_e201d8c2-8963-4987-8fb2-a9b787c8cd98_terseLabel_en-US" xlink:label="lab_biib_CollaborativeArrangementTermExtension" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration agreement term</link:label>
    <link:label id="lab_biib_CollaborativeArrangementTermExtension_label_en-US" xlink:label="lab_biib_CollaborativeArrangementTermExtension" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Term Extension</link:label>
    <link:label id="lab_biib_CollaborativeArrangementTermExtension_documentation_en-US" xlink:label="lab_biib_CollaborativeArrangementTermExtension" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Term Extension</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborativeArrangementTermExtension" xlink:href="biib-20250930.xsd#biib_CollaborativeArrangementTermExtension"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CollaborativeArrangementTermExtension" xlink:to="lab_biib_CollaborativeArrangementTermExtension" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_66903814-0b35-4652-bfdb-b408395fd2cb_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Related Party, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Related and Nonrelated Parties [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_c45e4141-6c03-45dc-83ea-114516030cef_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_A2.25SeniorNotesdueMay12030Member_b989c28b-8070-49b9-86e9-2bbdd7f30d92_terseLabel_en-US" xlink:label="lab_biib_A2.25SeniorNotesdueMay12030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2.250% Senior Notes due May 1, 2030</link:label>
    <link:label id="lab_biib_A2.25SeniorNotesdueMay12030Member_label_en-US" xlink:label="lab_biib_A2.25SeniorNotesdueMay12030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2.25% Senior Notes due May 1, 2030 [Member]</link:label>
    <link:label id="lab_biib_A2.25SeniorNotesdueMay12030Member_documentation_en-US" xlink:label="lab_biib_A2.25SeniorNotesdueMay12030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2.25% Senior Notes due May 1, 2030 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2.25SeniorNotesdueMay12030Member" xlink:href="biib-20250930.xsd#biib_A2.25SeniorNotesdueMay12030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2.25SeniorNotesdueMay12030Member" xlink:to="lab_biib_A2.25SeniorNotesdueMay12030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_e0559963-830c-42c1-afd8-900956105067_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_41150c0b-84e3-4411-8957-54d0d0392c11_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reduction of accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_6827a164-9254-4064-a08c-131fa4982248_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_6d9d1e7a-b318-4228-840d-c2f47e60cb8c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring and Related Costs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ReductionOfRealEstateFootprint_9e5eae01-d024-46ea-91cb-7b2519882886_terseLabel_en-US" xlink:label="lab_biib_ReductionOfRealEstateFootprint" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reduction of real estate footprint</link:label>
    <link:label id="lab_biib_ReductionOfRealEstateFootprint_label_en-US" xlink:label="lab_biib_ReductionOfRealEstateFootprint" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reduction Of Real Estate Footprint</link:label>
    <link:label id="lab_biib_ReductionOfRealEstateFootprint_documentation_en-US" xlink:label="lab_biib_ReductionOfRealEstateFootprint" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reduction Of Real Estate Footprint</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReductionOfRealEstateFootprint" xlink:href="biib-20250930.xsd#biib_ReductionOfRealEstateFootprint"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ReductionOfRealEstateFootprint" xlink:to="lab_biib_ReductionOfRealEstateFootprint" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_5185b36f-8efb-47aa-91d6-d561883d4313_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from (Payment for) Other Financing Activity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_currency_AllCurrenciesDomain_ee5eabb6-db68-4480-88f4-dc6578ef4b4c_terseLabel_en-US" xlink:label="lab_currency_AllCurrenciesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:label id="lab_currency_AllCurrenciesDomain_label_en-US" xlink:label="lab_currency_AllCurrenciesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain" xlink:href="https://xbrl.sec.gov/currency/2025/currency-2025.xsd#currency_AllCurrenciesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_AllCurrenciesDomain" xlink:to="lab_currency_AllCurrenciesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioPreviouslyReportedMember_2ae28695-26a4-460b-9ec1-8365cf4a75b7_terseLabel_en-US" xlink:label="lab_srt_ScenarioPreviouslyReportedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Previously Reported</link:label>
    <link:label id="lab_srt_ScenarioPreviouslyReportedMember_label_en-US" xlink:label="lab_srt_ScenarioPreviouslyReportedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Previously Reported [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioPreviouslyReportedMember" xlink:to="lab_srt_ScenarioPreviouslyReportedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_96e05843-01b1-4f62-9415-beae1807dff7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_RoyaltyAttributedToOCREVUSMember_6b0537e8-99d4-4a7d-80ed-f8ec3aedb631_terseLabel_en-US" xlink:label="lab_biib_RoyaltyAttributedToOCREVUSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty Attributed To OCREVUS</link:label>
    <link:label id="lab_biib_RoyaltyAttributedToOCREVUSMember_label_en-US" xlink:label="lab_biib_RoyaltyAttributedToOCREVUSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Attributed To OCREVUS [Member]</link:label>
    <link:label id="lab_biib_RoyaltyAttributedToOCREVUSMember_documentation_en-US" xlink:label="lab_biib_RoyaltyAttributedToOCREVUSMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty Attributed To OCREVUS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RoyaltyAttributedToOCREVUSMember" xlink:href="biib-20250930.xsd#biib_RoyaltyAttributedToOCREVUSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RoyaltyAttributedToOCREVUSMember" xlink:to="lab_biib_RoyaltyAttributedToOCREVUSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BiosimilarsMember_5c2162f5-be94-4d20-bfb5-c8eb0053ec54_terseLabel_en-US" xlink:label="lab_biib_BiosimilarsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Biosimilars</link:label>
    <link:label id="lab_biib_BiosimilarsMember_label_en-US" xlink:label="lab_biib_BiosimilarsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Biosimilars [Member]</link:label>
    <link:label id="lab_biib_BiosimilarsMember_documentation_en-US" xlink:label="lab_biib_BiosimilarsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Biosimilars</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BiosimilarsMember" xlink:href="biib-20250930.xsd#biib_BiosimilarsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BiosimilarsMember" xlink:to="lab_biib_BiosimilarsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_976ed740-adef-4497-b06d-01256a9b4e53_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ShareRepurchaseProgramAxis_91184123-fa26-48e4-9665-7c0262edf03e_terseLabel_en-US" xlink:label="lab_srt_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_srt_ShareRepurchaseProgramAxis_label_en-US" xlink:label="lab_srt_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ShareRepurchaseProgramAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ShareRepurchaseProgramAxis" xlink:to="lab_srt_ShareRepurchaseProgramAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_02054675-a8db-4a0c-8748-2aa46ea33d2c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_4bc4b963-0e52-4d58-aa87-b67079bdff5a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payment</link:label>
    <link:label id="lab_us-gaap_PaymentsForRestructuring_label_en-US" xlink:label="lab_us-gaap_PaymentsForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRestructuring" xlink:to="lab_us-gaap_PaymentsForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_41a2d51e-93f5-4922-9f1a-1cfc61037667_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_UnrealizedLossOnDerivatives_c1a3708d-90a0-45aa-9511-769f0d65424a_negatedTerseLabel_en-US" xlink:label="lab_biib_UnrealizedLossOnDerivatives" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unrealized (losses)</link:label>
    <link:label id="lab_biib_UnrealizedLossOnDerivatives_label_en-US" xlink:label="lab_biib_UnrealizedLossOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Loss on Derivatives</link:label>
    <link:label id="lab_biib_UnrealizedLossOnDerivatives_documentation_en-US" xlink:label="lab_biib_UnrealizedLossOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unrealized Loss on Derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedLossOnDerivatives" xlink:href="biib-20250930.xsd#biib_UnrealizedLossOnDerivatives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_UnrealizedLossOnDerivatives" xlink:to="lab_biib_UnrealizedLossOnDerivatives" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_8696323e-d91a-4821-8e19-21f672380125_terseLabel_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash equivalents, at carrying value</link:label>
    <link:label id="lab_us-gaap_CashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ShareOfNetProfitFromSageTherapeuticsPercent_82a145e8-bd33-4a91-a344-f54ddf95bc5f_terseLabel_en-US" xlink:label="lab_biib_ShareOfNetProfitFromSageTherapeuticsPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share of net profit from sage therapeutics, Percent</link:label>
    <link:label id="lab_biib_ShareOfNetProfitFromSageTherapeuticsPercent_label_en-US" xlink:label="lab_biib_ShareOfNetProfitFromSageTherapeuticsPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Of Net Profit From Sage Therapeutics, Percent</link:label>
    <link:label id="lab_biib_ShareOfNetProfitFromSageTherapeuticsPercent_documentation_en-US" xlink:label="lab_biib_ShareOfNetProfitFromSageTherapeuticsPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Of Net Profit From Sage Therapeutics, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfNetProfitFromSageTherapeuticsPercent" xlink:href="biib-20250930.xsd#biib_ShareOfNetProfitFromSageTherapeuticsPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShareOfNetProfitFromSageTherapeuticsPercent" xlink:to="lab_biib_ShareOfNetProfitFromSageTherapeuticsPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_d9f72353-48ee-4836-bdf0-6fa4fecb774a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under stock option and stock purchase plans, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Treasury Stock Reissued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_5b5de4fa-f793-42f6-8a55-fd7b028f06e2_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation related to share-based payments</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_612910e0-4ed9-4002-ae12-b10c482cd11d_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Treasury stock, at cost</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OtherClinicalProgramsMember_e33c1ddb-aa9d-4051-8277-a469aadd88b6_terseLabel_en-US" xlink:label="lab_biib_OtherClinicalProgramsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other clinical programs</link:label>
    <link:label id="lab_biib_OtherClinicalProgramsMember_label_en-US" xlink:label="lab_biib_OtherClinicalProgramsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Clinical Programs [Member]</link:label>
    <link:label id="lab_biib_OtherClinicalProgramsMember_documentation_en-US" xlink:label="lab_biib_OtherClinicalProgramsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Clinical Programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherClinicalProgramsMember" xlink:href="biib-20250930.xsd#biib_OtherClinicalProgramsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherClinicalProgramsMember" xlink:to="lab_biib_OtherClinicalProgramsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_ee67d453-f107-4b4d-b690-eb8e1367405e_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In-process research and development</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_504f8488-a247-402b-95af-3d7bc4f591db_verboseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">In-process research and development</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour_37ebe7b7-16ca-4e98-9db8-970ac783e39d_terseLabel_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">After Second Threshold Date</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour_label_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option Four</link:label>
    <link:label id="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour_documentation_en-US" xlink:label="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour" xlink:href="biib-20250930.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour" xlink:to="lab_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_TermLoan2023ThreeYearTrancheMember_867ebe65-c135-47be-b18a-6712ea579f0e_terseLabel_en-US" xlink:label="lab_biib_TermLoan2023ThreeYearTrancheMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023 Term Loan Three-Year Tranche</link:label>
    <link:label id="lab_biib_TermLoan2023ThreeYearTrancheMember_label_en-US" xlink:label="lab_biib_TermLoan2023ThreeYearTrancheMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Term Loan 2023 Three-Year Tranche [Member]</link:label>
    <link:label id="lab_biib_TermLoan2023ThreeYearTrancheMember_documentation_en-US" xlink:label="lab_biib_TermLoan2023ThreeYearTrancheMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term Loan 2023 Three-Year Tranche</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TermLoan2023ThreeYearTrancheMember" xlink:href="biib-20250930.xsd#biib_TermLoan2023ThreeYearTrancheMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TermLoan2023ThreeYearTrancheMember" xlink:to="lab_biib_TermLoan2023ThreeYearTrancheMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_d883cd6e-a786-4132-9313-7d90c5a5aac2_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCountryMember_e5065c5b-10c3-4f50-b653-4bfffcc25702_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Tax Authority</link:label>
    <link:label id="lab_us-gaap_ForeignCountryMember_label_en-US" xlink:label="lab_us-gaap_ForeignCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Tax Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCountryMember" xlink:to="lab_us-gaap_ForeignCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_22847645-408d-4abe-bbb9-0d86713bee8e_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_6f59d80b-a7b2-4103-bc28-81f703636125_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss contingency, damages sought, value</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Damages Sought, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:to="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_GovernmentSecuritiesCurrentMember_850516b6-4801-48a2-af26-d570bdcf9687_terseLabel_en-US" xlink:label="lab_biib_GovernmentSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government Securities Current</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesCurrentMember_label_en-US" xlink:label="lab_biib_GovernmentSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Government Securities Current [Member]</link:label>
    <link:label id="lab_biib_GovernmentSecuritiesCurrentMember_documentation_en-US" xlink:label="lab_biib_GovernmentSecuritiesCurrentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Government securities Current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GovernmentSecuritiesCurrentMember" xlink:href="biib-20250930.xsd#biib_GovernmentSecuritiesCurrentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_GovernmentSecuritiesCurrentMember" xlink:to="lab_biib_GovernmentSecuritiesCurrentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_813d2f7b-1832-40cc-a059-a3a7b419e95d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_05e42f56-20f5-4029-bf0f-d781294748ad_terseLabel_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_label_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs [Table Text Block]</link:label>
    <link:label id="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_documentation_en-US" xlink:label="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenues from anti-CD20 therapeutic programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:href="biib-20250930.xsd#biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:to="lab_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ReportableSegmentMember_f6d3fc09-5621-46f4-a119-2bfbb27d8b98_terseLabel_en-US" xlink:label="lab_biib_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reportable Segment</link:label>
    <link:label id="lab_biib_ReportableSegmentMember_label_en-US" xlink:label="lab_biib_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reportable Segment [Member]</link:label>
    <link:label id="lab_biib_ReportableSegmentMember_documentation_en-US" xlink:label="lab_biib_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reportable Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReportableSegmentMember" xlink:href="biib-20250930.xsd#biib_ReportableSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ReportableSegmentMember" xlink:to="lab_biib_ReportableSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_QALSODYMember_9ff0cdb3-edc9-4c8c-9bf2-db22201effe9_terseLabel_en-US" xlink:label="lab_biib_QALSODYMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">QALSODY</link:label>
    <link:label id="lab_biib_QALSODYMember_label_en-US" xlink:label="lab_biib_QALSODYMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">QALSODY [Member]</link:label>
    <link:label id="lab_biib_QALSODYMember_documentation_en-US" xlink:label="lab_biib_QALSODYMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">QALSODY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_QALSODYMember" xlink:href="biib-20250930.xsd#biib_QALSODYMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_QALSODYMember" xlink:to="lab_biib_QALSODYMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1c467c3e-4558-49a1-911c-6bd9d9abdc5f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_RocheGroupGenentechMember_870484f8-22e0-4d17-99ae-c8042a5e29d4_terseLabel_en-US" xlink:label="lab_biib_RocheGroupGenentechMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Genentech</link:label>
    <link:label id="lab_biib_RocheGroupGenentechMember_label_en-US" xlink:label="lab_biib_RocheGroupGenentechMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Roche Group Genentech Member</link:label>
    <link:label id="lab_biib_RocheGroupGenentechMember_documentation_en-US" xlink:label="lab_biib_RocheGroupGenentechMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Roche group Genentech.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RocheGroupGenentechMember" xlink:href="biib-20250930.xsd#biib_RocheGroupGenentechMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RocheGroupGenentechMember" xlink:to="lab_biib_RocheGroupGenentechMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_24ab542d-b9c3-419e-9b0e-02416e90056b_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_9107325d-9f02-4005-ab35-c823dca71caa_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_bbe3c97e-bb3f-4423-b129-8580155d41e9_terseLabel_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">5.200% Senior Notes due September 15, 2045</link:label>
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_label_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]</link:label>
    <link:label id="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_documentation_en-US" xlink:label="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:href="biib-20250930.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:to="lab_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_6ddb0afd-4c81-40f7-8ce0-95b86e381bac_terseLabel_en-US" xlink:label="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential future milestone payments commitment to third party</link:label>
    <link:label id="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_label_en-US" xlink:label="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Potential Future Milestone Payments Commitment To Third Party Approximately</link:label>
    <link:label id="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_documentation_en-US" xlink:label="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Potential future milestone payments commitment to third party approximately.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:href="biib-20250930.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:to="lab_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_41b0887e-d6bd-4ad8-b180-669343e823ac_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</link:label>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_label_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:to="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_644c4c23-1736-4f0e-8d33-461232d6ede1_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_e6c4d7a6-6716-4720-8060-dc07849c358a_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_1303373c-5116-4dfc-a3db-c0d641ebff77_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_a529638a-a497-4ac3-9007-694a7b96a82b_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value $0.001 per share</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_a96fe6ff-ad2e-48d6-ac6a-ee0441de2970_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_800a3aa7-1477-49f3-84d7-f09c5da87a91_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_7453a4d5-8e4b-4d42-9025-b75a0d9d02c8_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value $0.0005 per share</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction_69debe39-e6cb-470b-b753-48ea63149012_terseLabel_en-US" xlink:label="lab_biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected operating expense reduction</link:label>
    <link:label id="lab_biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction_label_en-US" xlink:label="lab_biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring And Related Activities, Expected Operating Expense Reduction</link:label>
    <link:label id="lab_biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction_documentation_en-US" xlink:label="lab_biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restructuring And Related Activities, Expected Operating Expense Reduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction" xlink:href="biib-20250930.xsd#biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction" xlink:to="lab_biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_OtherrevenuesAbstract_b968b22e-7109-4b9c-8b39-e92500c435c5_terseLabel_en-US" xlink:label="lab_biib_OtherrevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other revenues [Abstract]</link:label>
    <link:label id="lab_biib_OtherrevenuesAbstract_label_en-US" xlink:label="lab_biib_OtherrevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other revenues [Abstract]</link:label>
    <link:label id="lab_biib_OtherrevenuesAbstract_documentation_en-US" xlink:label="lab_biib_OtherrevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesAbstract" xlink:href="biib-20250930.xsd#biib_OtherrevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_OtherrevenuesAbstract" xlink:to="lab_biib_OtherrevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_be7e0e58-9fe0-4ba4-a2b6-f73ebe3b1708_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expense and other assets(1)</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Asset Acquired, Prepaid Expense and Other Asset, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_adbaca54-1b96-445f-a289-52159be88f5a_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Commitments, contingencies and guarantees</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_38020dfd-fddd-415c-93e7-42807c93a314_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Expense included in consolidated statements of income</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Recognized Amount [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_bfc9b52f-25e4-46fc-a6b1-e5172acfe314_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets:</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Asset Acquired, Identifiable Intangible Asset, Finite-Lived</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_e7422e7e-f356-4f2c-bc1b-c620849114a4_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CollaborativeArrangementExpectedDevelopmentCostFundsYearOne_e5a21cb6-0b15-420e-803a-2dd48a137459_terseLabel_en-US" xlink:label="lab_biib_CollaborativeArrangementExpectedDevelopmentCostFundsYearOne" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected receipts to co-fund development costs, current</link:label>
    <link:label id="lab_biib_CollaborativeArrangementExpectedDevelopmentCostFundsYearOne_label_en-US" xlink:label="lab_biib_CollaborativeArrangementExpectedDevelopmentCostFundsYearOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Expected Development Cost Funds, Year One</link:label>
    <link:label id="lab_biib_CollaborativeArrangementExpectedDevelopmentCostFundsYearOne_documentation_en-US" xlink:label="lab_biib_CollaborativeArrangementExpectedDevelopmentCostFundsYearOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Expected Development Cost Funds, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborativeArrangementExpectedDevelopmentCostFundsYearOne" xlink:href="biib-20250930.xsd#biib_CollaborativeArrangementExpectedDevelopmentCostFundsYearOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CollaborativeArrangementExpectedDevelopmentCostFundsYearOne" xlink:to="lab_biib_CollaborativeArrangementExpectedDevelopmentCostFundsYearOne" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AVONEXMember_0a116456-504a-4a46-bd90-958e401014e8_terseLabel_en-US" xlink:label="lab_biib_AVONEXMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AVONEX</link:label>
    <link:label id="lab_biib_AVONEXMember_label_en-US" xlink:label="lab_biib_AVONEXMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AVONEX [Member]</link:label>
    <link:label id="lab_biib_AVONEXMember_documentation_en-US" xlink:label="lab_biib_AVONEXMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AVONEX</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AVONEXMember" xlink:href="biib-20250930.xsd#biib_AVONEXMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AVONEXMember" xlink:to="lab_biib_AVONEXMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_LEQEMBICollaborationMember_411e24e1-9dee-4ea1-972c-bd19e84c05c6_terseLabel_en-US" xlink:label="lab_biib_LEQEMBICollaborationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Alzheimer's collaboration revenue</link:label>
    <link:label id="lab_biib_LEQEMBICollaborationMember_label_en-US" xlink:label="lab_biib_LEQEMBICollaborationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">LEQEMBI Collaboration [Member]</link:label>
    <link:label id="lab_biib_LEQEMBICollaborationMember_documentation_en-US" xlink:label="lab_biib_LEQEMBICollaborationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">LEQEMBI Collaboration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LEQEMBICollaborationMember" xlink:href="biib-20250930.xsd#biib_LEQEMBICollaborationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_LEQEMBICollaborationMember" xlink:to="lab_biib_LEQEMBICollaborationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_VUMERITYMember_fdec2b9c-7104-4bd1-a68e-359d7e53ac7e_terseLabel_en-US" xlink:label="lab_biib_VUMERITYMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">VUMERITY</link:label>
    <link:label id="lab_biib_VUMERITYMember_label_en-US" xlink:label="lab_biib_VUMERITYMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">VUMERITY [Member]</link:label>
    <link:label id="lab_biib_VUMERITYMember_documentation_en-US" xlink:label="lab_biib_VUMERITYMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">VUMERITY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_VUMERITYMember" xlink:href="biib-20250930.xsd#biib_VUMERITYMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_VUMERITYMember" xlink:to="lab_biib_VUMERITYMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_b158b0f1-3420-4c00-839c-6b413d4f91c2_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity, ownership interest</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_MilestonePaymentTwoMember_cfc935a7-2f06-4d25-abeb-ba8f344d9bcc_terseLabel_en-US" xlink:label="lab_biib_MilestonePaymentTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone Payment, Two</link:label>
    <link:label id="lab_biib_MilestonePaymentTwoMember_label_en-US" xlink:label="lab_biib_MilestonePaymentTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Payment, Two [Member]</link:label>
    <link:label id="lab_biib_MilestonePaymentTwoMember_documentation_en-US" xlink:label="lab_biib_MilestonePaymentTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone Payment, Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MilestonePaymentTwoMember" xlink:href="biib-20250930.xsd#biib_MilestonePaymentTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_MilestonePaymentTwoMember" xlink:to="lab_biib_MilestonePaymentTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_48b5c605-5c11-435d-897d-97b710361732_verboseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, and Marketable Security [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PLEGRIDYMember_f9e3d1f4-8487-4af4-a750-fd28b14a0382_terseLabel_en-US" xlink:label="lab_biib_PLEGRIDYMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PLEGRIDY</link:label>
    <link:label id="lab_biib_PLEGRIDYMember_label_en-US" xlink:label="lab_biib_PLEGRIDYMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PLEGRIDY [Member]</link:label>
    <link:label id="lab_biib_PLEGRIDYMember_documentation_en-US" xlink:label="lab_biib_PLEGRIDYMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">PLEGRIDY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PLEGRIDYMember" xlink:href="biib-20250930.xsd#biib_PLEGRIDYMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PLEGRIDYMember" xlink:to="lab_biib_PLEGRIDYMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_aa8d10b0-df14-42ac-bd60-6fddb938f421_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_c2391bca-8bd2-427a-8324-31be4374dc14_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_2019c695-b7ab-494a-9852-5ccdc51f4492_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_a1d51dfc-c7d9-4831-994d-b26347c0ea05_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Liability Assumed, Deferred Tax Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_f4411a20-ab1b-47d1-beea-2002e311fe30_verboseLabel_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Time-vested restricted stock units</link:label>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_label_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Time Vested Restricted Stock Units [Member]</link:label>
    <link:label id="lab_biib_TimeVestedRestrictedStockUnitsMember_documentation_en-US" xlink:label="lab_biib_TimeVestedRestrictedStockUnitsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Time vested restricted stock units.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember" xlink:href="biib-20250930.xsd#biib_TimeVestedRestrictedStockUnitsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_TimeVestedRestrictedStockUnitsMember" xlink:to="lab_biib_TimeVestedRestrictedStockUnitsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_1cc11250-3547-493a-b9fd-18461031ff50_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Unrealized gains (losses) on pension benefit obligation, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_51ce3b03-7c96-4821-bc68-f5f9b9ec226a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Gains/(Losses) Reclassified from AOCI into Operating Income (in millions)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_b52f6713-5083-4f01-bc2f-b38a84103054_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_a121794f-5dbe-4d0b-ab93-1d2f2906f70f_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_971a0ffe-98a5-430f-96ea-dd08c60517a8_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_afa5abff-e4f7-4c35-b8a4-a8b631db6243_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2e0b9566-1a47-49c3-a49c-7debbe7c47ec_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_A2023CostSavingInitiativesMember_9d7f60b1-2e19-4d49-9c19-d848277067ed_terseLabel_en-US" xlink:label="lab_biib_A2023CostSavingInitiativesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023 Cost Saving Initiatives</link:label>
    <link:label id="lab_biib_A2023CostSavingInitiativesMember_label_en-US" xlink:label="lab_biib_A2023CostSavingInitiativesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2023 Cost Saving Initiatives [Member]</link:label>
    <link:label id="lab_biib_A2023CostSavingInitiativesMember_documentation_en-US" xlink:label="lab_biib_A2023CostSavingInitiativesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2023 Cost Saving Initiatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2023CostSavingInitiativesMember" xlink:href="biib-20250930.xsd#biib_A2023CostSavingInitiativesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_A2023CostSavingInitiativesMember" xlink:to="lab_biib_A2023CostSavingInitiativesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnDerivatives_61e9de0f-5b96-4032-b44f-0ecf2422a0ce_totalLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net unrealized gains (losses)</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnDerivatives_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrealized Gain (Loss) on Derivatives</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnDerivatives" xlink:to="lab_us-gaap_UnrealizedGainLossOnDerivatives" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AccountsReceivableFromCollaborator_f0f0f9bd-54e1-41f9-9a57-cec9a0d6f77b_terseLabel_en-US" xlink:label="lab_biib_AccountsReceivableFromCollaborator" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amounts receivable</link:label>
    <link:label id="lab_biib_AccountsReceivableFromCollaborator_label_en-US" xlink:label="lab_biib_AccountsReceivableFromCollaborator" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, From Collaborator</link:label>
    <link:label id="lab_biib_AccountsReceivableFromCollaborator_documentation_en-US" xlink:label="lab_biib_AccountsReceivableFromCollaborator" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accounts Receivable, From Collaborator</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AccountsReceivableFromCollaborator" xlink:href="biib-20250930.xsd#biib_AccountsReceivableFromCollaborator"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AccountsReceivableFromCollaborator" xlink:to="lab_biib_AccountsReceivableFromCollaborator" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_label_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:to="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_573ad142-0e66-4715-a76c-700f4737b23a_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_43ad2bb0-7519-46df-8b7a-0139721c45c0_negatedLabel_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments/Returns Relating To Sales in Current Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_label_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments Returns Applied Against Product Revenue Reserves Relating To Current Year</link:label>
    <link:label id="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_documentation_en-US" xlink:label="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments/ returns applied against product revenue reserves relating to current year.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:href="biib-20250930.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:to="lab_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_200405cd-3804-436f-b3f7-5933c853e9cf_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract]</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_de4e2779-143e-4ab0-b87a-9b9daed4ee45_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Asset, Finite-Lived [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_bd4c0cb5-3f2f-405b-a53b-72e7104290e0_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_b7c8b8bf-8068-4652-a019-525c0ee05d87_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesAbstract_a66dc178-b2b8-4f7e-88d8-ca16f09f175e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current liabilities:</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesAbstract" xlink:to="lab_us-gaap_DerivativeLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_4a7ca03e-307a-4f89-8c5d-0894138e43e3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other changes in operating assets and liabilities, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Assets and Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_7832200e-4f44-466b-955c-2765e2e65644_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gain (Loss), Foreign Currency Transaction, before Tax</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss), Foreign Currency Transaction, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CashflowsoperatingexpensesMember_6911f0ca-9c4c-4522-98aa-6a09c874ae9b_terseLabel_en-US" xlink:label="lab_biib_CashflowsoperatingexpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows, operating expenses</link:label>
    <link:label id="lab_biib_CashflowsoperatingexpensesMember_label_en-US" xlink:label="lab_biib_CashflowsoperatingexpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows, operating expenses [Member]</link:label>
    <link:label id="lab_biib_CashflowsoperatingexpensesMember_documentation_en-US" xlink:label="lab_biib_CashflowsoperatingexpensesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash flows, operating expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashflowsoperatingexpensesMember" xlink:href="biib-20250930.xsd#biib_CashflowsoperatingexpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CashflowsoperatingexpensesMember" xlink:to="lab_biib_CashflowsoperatingexpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_f1573ef1-c4a2-4aff-879b-185189afa5d1_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_26c46bf5-df6f-4086-af50-d96fea6026da_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_40a98eee-1c62-4bd5-91d7-b1f42610ac13_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_163a8a7b-3159-4727-9809-d1095205fc1a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_IonisPharmaceuticalsInc.Member_27ca3869-50d8-4b2e-9a1b-315df264920b_terseLabel_en-US" xlink:label="lab_biib_IonisPharmaceuticalsInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ionis</link:label>
    <link:label id="lab_biib_IonisPharmaceuticalsInc.Member_label_en-US" xlink:label="lab_biib_IonisPharmaceuticalsInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ionis Pharmaceuticals Inc. [Member]</link:label>
    <link:label id="lab_biib_IonisPharmaceuticalsInc.Member_documentation_en-US" xlink:label="lab_biib_IonisPharmaceuticalsInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ionis Pharmaceuticals Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IonisPharmaceuticalsInc.Member" xlink:href="biib-20250930.xsd#biib_IonisPharmaceuticalsInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IonisPharmaceuticalsInc.Member" xlink:to="lab_biib_IonisPharmaceuticalsInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent_79843db1-fbf0-4339-ab94-d4b001a13df9_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GILTI</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, GILTI, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_29250004-21e7-44ed-8239-e1b97f36febf_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrentAndNoncurrent_dec97c9d-4a44-4b9f-8c9b-07c5c025f62c_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccountsPayableCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ServiceOtherMember_f59ffa78-e5e4-4d05-9297-df1653bd5104_terseLabel_en-US" xlink:label="lab_us-gaap_ServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other research and development costs</link:label>
    <link:label id="lab_us-gaap_ServiceOtherMember_label_en-US" xlink:label="lab_us-gaap_ServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Service, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceOtherMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ServiceOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceOtherMember" xlink:to="lab_us-gaap_ServiceOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_05b3404a-e7ee-40a6-8011-d3fac97d8830_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_b9c17a7f-a15c-43e5-b0dd-a9dec36ca320_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_f2259d4d-0d7b-42bc-89b5-4f192f3bfe63_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_424472f4-f858-40fe-8935-1e3f39b30c1f_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanAxis" xlink:to="lab_us-gaap_RestructuringPlanAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_VanquaBioInc.Member_03468fa0-7091-46d2-a956-b67d1a40a2e2_terseLabel_en-US" xlink:label="lab_biib_VanquaBioInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vanqua Bio, Inc.</link:label>
    <link:label id="lab_biib_VanquaBioInc.Member_label_en-US" xlink:label="lab_biib_VanquaBioInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vanqua Bio, Inc. [Member]</link:label>
    <link:label id="lab_biib_VanquaBioInc.Member_documentation_en-US" xlink:label="lab_biib_VanquaBioInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vanqua Bio, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_VanquaBioInc.Member" xlink:href="biib-20250930.xsd#biib_VanquaBioInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_VanquaBioInc.Member" xlink:to="lab_biib_VanquaBioInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_17da81d8-713d-4eb2-b38d-47a5fec62dac_terseLabel_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Activity Related to BAN2401 and Elenbecestat Collaboration</link:label>
    <link:label id="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_label_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of Activity Related to E2609 and BAN2401 Collaboration [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_documentation_en-US" xlink:label="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Table Text Block] for Summary of Activity Related to E2609 and BAN2401 Collaboration [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" xlink:href="biib-20250930.xsd#biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" xlink:to="lab_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ShareOfNonControlingInterestRecognized_dbe9e97b-eece-4682-8555-564eb5c0db70_terseLabel_en-US" xlink:label="lab_biib_ShareOfNonControlingInterestRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share of non-controling interest recognized</link:label>
    <link:label id="lab_biib_ShareOfNonControlingInterestRecognized_label_en-US" xlink:label="lab_biib_ShareOfNonControlingInterestRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Of Non-Controling Interest Recognized</link:label>
    <link:label id="lab_biib_ShareOfNonControlingInterestRecognized_documentation_en-US" xlink:label="lab_biib_ShareOfNonControlingInterestRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Of Non-Controling Interest Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfNonControlingInterestRecognized" xlink:href="biib-20250930.xsd#biib_ShareOfNonControlingInterestRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ShareOfNonControlingInterestRecognized" xlink:to="lab_biib_ShareOfNonControlingInterestRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_62ef2bd1-f67d-4f7d-b780-d15f48993aa1_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repurchase of common stock, at cost (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_a1665199-721f-41d3-8e1d-866dbf2c497f_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Components of inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnInvestmentsTextBlock_390a3354-8787-4246-a103-eb7ad0aaa407_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) on investments in equity securities</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestmentsTextBlock_label_en-US" xlink:label="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Securities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestmentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnInvestmentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestmentsTextBlock" xlink:to="lab_us-gaap_GainLossOnInvestmentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_7c83a465-4c4f-4e00-ac49-9aed4c6f8eab_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveTranslationAdjustment_ced7d5ba-4bcb-49da-b34a-b41809bbdd50_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveTranslationAdjustment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency and other adjustments</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveTranslationAdjustment_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveTranslationAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveTranslationAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserveTranslationAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveTranslationAdjustment" xlink:to="lab_us-gaap_RestructuringReserveTranslationAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_15758b9f-d922-49bf-9b2a-edda6d2d8975_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_4feb1c6f-3a1d-4317-aae7-3b35c27ab5f1_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of assets and liabilities recorded at fair value</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_dfb6db55-d8a4-4a29-809e-d1eb37f2118a_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_DebtSecuritiesAvailableForSaleAverageMaturity_9d739c4b-d286-4525-9ebd-0d9fba4e6c98_terseLabel_en-US" xlink:label="lab_biib_DebtSecuritiesAvailableForSaleAverageMaturity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Average maturity of our marketable debt securities classified as available-for-sale</link:label>
    <link:label id="lab_biib_DebtSecuritiesAvailableForSaleAverageMaturity_label_en-US" xlink:label="lab_biib_DebtSecuritiesAvailableForSaleAverageMaturity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Average Maturity</link:label>
    <link:label id="lab_biib_DebtSecuritiesAvailableForSaleAverageMaturity_documentation_en-US" xlink:label="lab_biib_DebtSecuritiesAvailableForSaleAverageMaturity" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Average Maturity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DebtSecuritiesAvailableForSaleAverageMaturity" xlink:href="biib-20250930.xsd#biib_DebtSecuritiesAvailableForSaleAverageMaturity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_DebtSecuritiesAvailableForSaleAverageMaturity" xlink:to="lab_biib_DebtSecuritiesAvailableForSaleAverageMaturity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_7b4056fd-9ccb-4bb5-bda2-0e4becfe7c59_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_3f8dad01-719d-4e7c-8cfc-2501c6944335_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to Biogen Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTable_d680f3a7-2d31-4a73-8dc4-5e6a233d2590_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable" xlink:to="lab_us-gaap_SubsequentEventTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_69dcec82-ac89-401f-9a2b-670ccc749c11_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_IntangibleAssetMeasurementInput_b21feb24-2515-469f-a20b-9f6b8a67d7fe_terseLabel_en-US" xlink:label="lab_biib_IntangibleAssetMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement input</link:label>
    <link:label id="lab_biib_IntangibleAssetMeasurementInput_label_en-US" xlink:label="lab_biib_IntangibleAssetMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Asset, Measurement Input</link:label>
    <link:label id="lab_biib_IntangibleAssetMeasurementInput_documentation_en-US" xlink:label="lab_biib_IntangibleAssetMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intangible Asset, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IntangibleAssetMeasurementInput" xlink:href="biib-20250930.xsd#biib_IntangibleAssetMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_IntangibleAssetMeasurementInput" xlink:to="lab_biib_IntangibleAssetMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesReturnsAndAllowancesMember_32d3fd85-4cd1-4538-91ad-09f36781a825_terseLabel_en-US" xlink:label="lab_us-gaap_SalesReturnsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Returns</link:label>
    <link:label id="lab_us-gaap_SalesReturnsAndAllowancesMember_label_en-US" xlink:label="lab_us-gaap_SalesReturnsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Returns and Allowances [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesReturnsAndAllowancesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesReturnsAndAllowancesMember" xlink:to="lab_us-gaap_SalesReturnsAndAllowancesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_1821af29-89b0-4181-89dd-abae767b6693_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_6d0b7a93-27e0-4272-a125-217e87b034f6_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other, including permanent items</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months_edd5219c-9be4-499f-9b5a-a1b40e954db8_terseLabel_en-US" xlink:label="lab_biib_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency cash flow hedge gain (loss) to be reclassified during next 15 months</link:label>
    <link:label id="lab_biib_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months_label_en-US" xlink:label="lab_biib_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Cash Flow Hedge Gain (Loss) To Be Reclassified During Next 15 Months</link:label>
    <link:label id="lab_biib_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months_documentation_en-US" xlink:label="lab_biib_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Foreign Currency Cash Flow Hedge Gain (Loss) To Be Reclassified During Next 15 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months" xlink:href="biib-20250930.xsd#biib_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months" xlink:to="lab_biib_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_6ab640eb-7ffa-4181-903c-c01d11c1b212_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_741d461d-1614-48b4-96b5-1bf658e12ab1_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_60cac670-a1b8-491f-b6b5-98ad21de6165_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SeniorNotes3.250DueFebruary152051Member_50981f65-93a9-4764-9564-320d87ae5cb6_terseLabel_en-US" xlink:label="lab_biib_SeniorNotes3.250DueFebruary152051Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">3.250% Senior Notes due February 15, 2051</link:label>
    <link:label id="lab_biib_SeniorNotes3.250DueFebruary152051Member_label_en-US" xlink:label="lab_biib_SeniorNotes3.250DueFebruary152051Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes 3.250%, Due February 15, 2051 [Member]</link:label>
    <link:label id="lab_biib_SeniorNotes3.250DueFebruary152051Member_documentation_en-US" xlink:label="lab_biib_SeniorNotes3.250DueFebruary152051Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes 3.250%, Due February 15, 2051</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotes3.250DueFebruary152051Member" xlink:href="biib-20250930.xsd#biib_SeniorNotes3.250DueFebruary152051Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SeniorNotes3.250DueFebruary152051Member" xlink:to="lab_biib_SeniorNotes3.250DueFebruary152051Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_ce505c9f-1783-4d20-aaf9-f0f5240bc3ff_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_StrategicInvestmentPortfolio_e5979913-f9a1-4b6c-bd1b-2748735af8f5_terseLabel_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Strategic investment portfolio</link:label>
    <link:label id="lab_biib_StrategicInvestmentPortfolio_label_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Strategic Investment Portfolio</link:label>
    <link:label id="lab_biib_StrategicInvestmentPortfolio_documentation_en-US" xlink:label="lab_biib_StrategicInvestmentPortfolio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Strategic investment portfolio.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StrategicInvestmentPortfolio" xlink:href="biib-20250930.xsd#biib_StrategicInvestmentPortfolio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_StrategicInvestmentPortfolio" xlink:to="lab_biib_StrategicInvestmentPortfolio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_23119242-4a15-4c6a-98c7-54f5011329f1_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Summary of share-based compensation expense associated with each of our share-based compensating programs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeRemainingMaturity1_effaaf2f-25e2-48c9-94dc-d13828ae9130_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeRemainingMaturity1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative, remaining maturity</link:label>
    <link:label id="lab_us-gaap_DerivativeRemainingMaturity1_label_en-US" xlink:label="lab_us-gaap_DerivativeRemainingMaturity1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Remaining Maturity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeRemainingMaturity1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeRemainingMaturity1" xlink:to="lab_us-gaap_DerivativeRemainingMaturity1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_terseLabel_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_label_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:to="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_dcf946af-19cc-473b-a902-4fde117f0f33_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of intangible assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_81c9d746-0436-4f5b-ad9d-06f32aa506fb_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gains (losses) on cash flow hedges</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:to="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_209462ce-fc9c-4b0c-991e-7c98d0efb2ac_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_fdf4bdb0-4b86-44c1-884e-ff3432673dbd_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_f46ae71c-2ad4-4956-9bd7-0bfe1f396043_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_88d7bd67-f639-4801-9f17-95b2a2fe9f4a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_323e8a89-0d63-4718-b5cc-554b1b4fae0f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_64673357-0b8d-446b-b87e-2f952bd19c40_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ce1f0c8e-5f18-45ea-b935-18e1f142d1f8_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net income to net cash flow from operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_42f7d757-489b-4385-a042-46816e6ae682_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flow from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_499a9b3b-2a3a-492c-a834-bbfe65a89f0f_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets acquired and liabilities assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less), and Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_b7276ae2-ddf4-4c05-8c70-e6cb03830e77_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_f0bd4de9-c757-4416-a4cb-c20d201c1628_negatedLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Income tax effect</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SageTherapeuticsIncMember_f6be7c32-a6b0-48d8-9c32-f352e0059e34_terseLabel_en-US" xlink:label="lab_biib_SageTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sage Therapeutics</link:label>
    <link:label id="lab_biib_SageTherapeuticsIncMember_label_en-US" xlink:label="lab_biib_SageTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sage Therapeutics Inc. [Member]</link:label>
    <link:label id="lab_biib_SageTherapeuticsIncMember_documentation_en-US" xlink:label="lab_biib_SageTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sage Therapeutics Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SageTherapeuticsIncMember" xlink:href="biib-20250930.xsd#biib_SageTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SageTherapeuticsIncMember" xlink:to="lab_biib_SageTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CollaborativeArrangementsInvestmentsInCounterparty_fb58b0c6-c63c-4593-801e-758d63dd554c_terseLabel_en-US" xlink:label="lab_biib_CollaborativeArrangementsInvestmentsInCounterparty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative arrangements, investments in counterparty</link:label>
    <link:label id="lab_biib_CollaborativeArrangementsInvestmentsInCounterparty_label_en-US" xlink:label="lab_biib_CollaborativeArrangementsInvestmentsInCounterparty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements, Investments In Counterparty</link:label>
    <link:label id="lab_biib_CollaborativeArrangementsInvestmentsInCounterparty_documentation_en-US" xlink:label="lab_biib_CollaborativeArrangementsInvestmentsInCounterparty" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements, Investments In Counterparty</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborativeArrangementsInvestmentsInCounterparty" xlink:href="biib-20250930.xsd#biib_CollaborativeArrangementsInvestmentsInCounterparty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CollaborativeArrangementsInvestmentsInCounterparty" xlink:to="lab_biib_CollaborativeArrangementsInvestmentsInCounterparty" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_CityTherapeuticsInc.Member_ddf90351-6877-425a-bb81-54c597e02441_terseLabel_en-US" xlink:label="lab_biib_CityTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Therapeutics, Inc.</link:label>
    <link:label id="lab_biib_CityTherapeuticsInc.Member_label_en-US" xlink:label="lab_biib_CityTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_biib_CityTherapeuticsInc.Member_documentation_en-US" xlink:label="lab_biib_CityTherapeuticsInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">City Therapeutics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CityTherapeuticsInc.Member" xlink:href="biib-20250930.xsd#biib_CityTherapeuticsInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_CityTherapeuticsInc.Member" xlink:to="lab_biib_CityTherapeuticsInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_2bc38018-ad9c-4935-888a-3823855885b1_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_7b511e72-c173-4fd1-b5bc-1a499cf4d82d_verboseLabel_en-US" xlink:label="lab_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Limit of gross sale of GAZYVA to be achieved in preceding 12 months under option one</link:label>
    <link:label id="lab_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_df5566d0-f92e-40e2-a3a5-8f02573f55d6_terseLabel_en-US" xlink:label="lab_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Threshold of Gross Sales Of To Be Achieved In Preceding Twelve Consecutive Months Under Option One</link:label>
    <link:label id="lab_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_label_en-US" xlink:label="lab_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Threshold Of Gross Sales Of To Be Achieved In Preceding Twelve Consecutive Months Under Option One</link:label>
    <link:label id="lab_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_documentation_en-US" xlink:label="lab_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Threshold of gross sales of to be achieved in preceding twelve consecutive months under option one.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne" xlink:href="biib-20250930.xsd#biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne" xlink:to="lab_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d47a8cb3-2981-4920-8410-b8b90ac1735c_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic earnings per share attributable to Biogen Inc. (in USD per share)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_69507f68-d072-441e-864f-8425e32755ed_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of common shares outstanding</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_f42e3ade-9c96-4d29-ba24-64548e990f66_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWriteDown_ecdca4c8-1ff6-44f5-b272-8d65e31b5aa7_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Excess and obsolescence charges related to inventory</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown" xlink:to="lab_us-gaap_InventoryWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_AmortizationOfInventoryStepUp_8e214a08-0ead-43e8-8168-a3f24e8f1c31_terseLabel_en-US" xlink:label="lab_biib_AmortizationOfInventoryStepUp" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of acquired inventory step-up</link:label>
    <link:label id="lab_biib_AmortizationOfInventoryStepUp_label_en-US" xlink:label="lab_biib_AmortizationOfInventoryStepUp" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization Of Inventory Step-Up</link:label>
    <link:label id="lab_biib_AmortizationOfInventoryStepUp_documentation_en-US" xlink:label="lab_biib_AmortizationOfInventoryStepUp" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amortization Of Inventory Step-Up</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationOfInventoryStepUp" xlink:href="biib-20250930.xsd#biib_AmortizationOfInventoryStepUp"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_AmortizationOfInventoryStepUp" xlink:to="lab_biib_AmortizationOfInventoryStepUp" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_45efbd14-8c1e-4051-a639-9c904c0c7a8e_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted earnings per share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_e8d93cad-2081-43e6-b946-44d27ee31093_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_bb56ce30-cb33-4863-ab99-d71611db1589_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_0174e4ad-c617-4e1c-a615-7925e5fac17d_verboseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cost and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract" xlink:to="lab_us-gaap_CostsAndExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FAMPYRAMember_cca32f26-7b69-4781-ba1d-4d1d3b263cff_terseLabel_en-US" xlink:label="lab_biib_FAMPYRAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FAMPYRA</link:label>
    <link:label id="lab_biib_FAMPYRAMember_label_en-US" xlink:label="lab_biib_FAMPYRAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">FAMPYRA [Member]</link:label>
    <link:label id="lab_biib_FAMPYRAMember_documentation_en-US" xlink:label="lab_biib_FAMPYRAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">FAMPYRA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FAMPYRAMember" xlink:href="biib-20250930.xsd#biib_FAMPYRAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FAMPYRAMember" xlink:to="lab_biib_FAMPYRAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_f103cd38-cb19-4509-9700-49ab11b3e362_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Purchased inventory valuation step-up and intangible assets</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Depreciation and Amortization, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_63b4f590-afeb-4370-9df7-3fc827995ec0_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_b2178f1a-be44-46e8-97d4-923de3454ac1_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less: Net (gains) losses realized on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Realized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:to="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_9d9d6305-31a9-4cfe-b97c-33a9ec523abc_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Use of estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements_a80b62b0-4372-4e9e-96a3-3001a1d64684_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_fc1492ef-0eb7-4174-974a-d194feddd03d_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_22b9190a-47f5-4ba8-b4b9-3625c10ecbb0_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Currency translation adjustments, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract_d656afab-c171-4c94-a432-d20892ddfeb8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract" xlink:to="lab_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_0a415c7e-2e07-4410-ba3f-e2bea8f8b5e4_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative contracts</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Contracts, Liability, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:to="lab_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_0a50a7b4-580c-4cdf-b3ce-a713d930302a_terseLabel_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract manufacturing, royalty and other revenue</link:label>
    <link:label id="lab_us-gaap_ProductAndServiceOtherMember_label_en-US" xlink:label="lab_us-gaap_ProductAndServiceOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductAndServiceOtherMember" xlink:to="lab_us-gaap_ProductAndServiceOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_72a4c5a4-48a4-427e-93f0-8af1d67f197c_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_afbf3662-f744-4af1-8472-52e303efbb85_verboseLabel_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Basic and diluted earnings per share</link:label>
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_label_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic And Diluted Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_biib_BasicAndDilutedEarningsPerShareAbstract_documentation_en-US" xlink:label="lab_biib_BasicAndDilutedEarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Basic and diluted earnings per share.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract" xlink:href="biib-20250930.xsd#biib_BasicAndDilutedEarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract" xlink:to="lab_biib_BasicAndDilutedEarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_a85a116d-5243-4419-959e-486411f5b5a3_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CurrencyAxis_444a54fd-7953-45ea-801f-9d2bbe35359e_terseLabel_en-US" xlink:label="lab_srt_CurrencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency [Axis]</link:label>
    <link:label id="lab_srt_CurrencyAxis_label_en-US" xlink:label="lab_srt_CurrencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CurrencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CurrencyAxis" xlink:to="lab_srt_CurrencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_176e56d1-6b43-4198-bf6d-b59d830a4ca6_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total marketable debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock_4a9dd4ca-9e6b-48fe-8d42-1532c6e79619_terseLabel_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Activity Related to Denali Therapeutics Collaboration</link:label>
    <link:label id="lab_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock_label_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of Activity Related to Denali Therapeutics Collaboration [Table Text Block]</link:label>
    <link:label id="lab_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock_documentation_en-US" xlink:label="lab_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary of Activity Related to Denali Therapeutics Collaboration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" xlink:href="biib-20250930.xsd#biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" xlink:to="lab_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_RareDiseaseProductRevenueMember_bb3f273c-b9d0-42ea-8431-b675a073f580_terseLabel_en-US" xlink:label="lab_biib_RareDiseaseProductRevenueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rare Disease Product Revenue</link:label>
    <link:label id="lab_biib_RareDiseaseProductRevenueMember_label_en-US" xlink:label="lab_biib_RareDiseaseProductRevenueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rare Disease Product Revenue [Member]</link:label>
    <link:label id="lab_biib_RareDiseaseProductRevenueMember_documentation_en-US" xlink:label="lab_biib_RareDiseaseProductRevenueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Rare Disease Product Revenue</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RareDiseaseProductRevenueMember" xlink:href="biib-20250930.xsd#biib_RareDiseaseProductRevenueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_RareDiseaseProductRevenueMember" xlink:to="lab_biib_RareDiseaseProductRevenueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:to="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_1f1096bc-593c-4d97-8bf8-f8f9efa83527_verboseLabel_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Trademarks and trade names</link:label>
    <link:label id="lab_us-gaap_TrademarksAndTradeNamesMember_label_en-US" xlink:label="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trademarks and Trade Names [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksAndTradeNamesMember" xlink:to="lab_us-gaap_TrademarksAndTradeNamesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_3ab20930-095c-4d43-8375-81e4d9a2815b_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_5c2695f4-1a78-49df-af14-b88953aac5af_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_FelzartamabAndIzastobartHIB210Member_4d62aee7-c6ce-4758-b4dc-cdedce0d13b6_terseLabel_en-US" xlink:label="lab_biib_FelzartamabAndIzastobartHIB210Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Felzartamab And Izastobart/HIB210</link:label>
    <link:label id="lab_biib_FelzartamabAndIzastobartHIB210Member_label_en-US" xlink:label="lab_biib_FelzartamabAndIzastobartHIB210Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Felzartamab And Izastobart/HIB210 [Member]</link:label>
    <link:label id="lab_biib_FelzartamabAndIzastobartHIB210Member_documentation_en-US" xlink:label="lab_biib_FelzartamabAndIzastobartHIB210Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Felzartamab And Izastobart/HIB210</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FelzartamabAndIzastobartHIB210Member" xlink:href="biib-20250930.xsd#biib_FelzartamabAndIzastobartHIB210Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_FelzartamabAndIzastobartHIB210Member" xlink:to="lab_biib_FelzartamabAndIzastobartHIB210Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_9a9bc029-7d6e-47d5-ac60-068b91b8f7da_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_5da10a80-869f-465e-b781-e05304768e21_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_d357887a-207f-48dd-85c4-fdaea0fa9aeb_terseLabel_en-US" xlink:label="lab_biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from anti-CD20 therapeutic programs</link:label>
    <link:label id="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_label_en-US" xlink:label="lab_biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues from anti-cd20 therapeutic programs [Member]</link:label>
    <link:label id="lab_biib_Revenuesfromanticd20therapeuticprogramsMember_documentation_en-US" xlink:label="lab_biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenues from anti-cd20 therapeutic programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:href="biib-20250930.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:to="lab_biib_Revenuesfromanticd20therapeuticprogramsMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>biib-20250930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:56b2dfbb-fb98-49e8-bcdc-e902c065377c,g:9aa702a5-e336-43c4-a300-999553ccda1f-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.biogenidec.com/role/CoverPage" xlink:type="simple" xlink:href="biib-20250930.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_40516abd-950d-4d49-80e2-8b2a1a1c2ec2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_1282b63a-0381-42a6-8584-67e0a88b357a" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40516abd-950d-4d49-80e2-8b2a1a1c2ec2" xlink:to="loc_dei_DocumentType_1282b63a-0381-42a6-8584-67e0a88b357a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_95923fce-46d5-47a9-bff2-45f67056115a" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40516abd-950d-4d49-80e2-8b2a1a1c2ec2" xlink:to="loc_dei_DocumentQuarterlyReport_95923fce-46d5-47a9-bff2-45f67056115a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_648213a7-1839-41dd-95eb-688f99203cca" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40516abd-950d-4d49-80e2-8b2a1a1c2ec2" xlink:to="loc_dei_DocumentPeriodEndDate_648213a7-1839-41dd-95eb-688f99203cca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_e216d8be-3f40-4d9c-b0ec-74e40262014a" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40516abd-950d-4d49-80e2-8b2a1a1c2ec2" xlink:to="loc_dei_DocumentTransitionReport_e216d8be-3f40-4d9c-b0ec-74e40262014a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_fe058178-56bc-4e31-96e7-321721e88dd5" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40516abd-950d-4d49-80e2-8b2a1a1c2ec2" xlink:to="loc_dei_EntityFileNumber_fe058178-56bc-4e31-96e7-321721e88dd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_be6259c0-ba69-44af-8f49-1f4c1e276cbe" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40516abd-950d-4d49-80e2-8b2a1a1c2ec2" xlink:to="loc_dei_EntityRegistrantName_be6259c0-ba69-44af-8f49-1f4c1e276cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_0e5d8fa9-37ed-472a-ba74-40dc592508a1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40516abd-950d-4d49-80e2-8b2a1a1c2ec2" xlink:to="loc_dei_EntityCentralIndexKey_0e5d8fa9-37ed-472a-ba74-40dc592508a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_b9a77da3-579a-4938-8750-0a06ae20bdc3" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40516abd-950d-4d49-80e2-8b2a1a1c2ec2" xlink:to="loc_dei_CurrentFiscalYearEndDate_b9a77da3-579a-4938-8750-0a06ae20bdc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_4a937953-09b2-4130-ba8e-68a1de05e8c6" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40516abd-950d-4d49-80e2-8b2a1a1c2ec2" xlink:to="loc_dei_DocumentFiscalYearFocus_4a937953-09b2-4130-ba8e-68a1de05e8c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_529483eb-89cb-497a-8c56-06f99591b8c0" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40516abd-950d-4d49-80e2-8b2a1a1c2ec2" xlink:to="loc_dei_DocumentFiscalPeriodFocus_529483eb-89cb-497a-8c56-06f99591b8c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_d05a25cc-2481-4edc-96fd-fac26da19690" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40516abd-950d-4d49-80e2-8b2a1a1c2ec2" xlink:to="loc_dei_AmendmentFlag_d05a25cc-2481-4edc-96fd-fac26da19690" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_9a873b65-2468-4cc7-9740-9be48f929cf8" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40516abd-950d-4d49-80e2-8b2a1a1c2ec2" xlink:to="loc_dei_EntityIncorporationStateCountryCode_9a873b65-2468-4cc7-9740-9be48f929cf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_9828f481-b91b-4c4f-a969-7eaf2c11927a" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40516abd-950d-4d49-80e2-8b2a1a1c2ec2" xlink:to="loc_dei_EntityTaxIdentificationNumber_9828f481-b91b-4c4f-a969-7eaf2c11927a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_0b451a51-0d69-42be-a40e-698c1136e5e5" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40516abd-950d-4d49-80e2-8b2a1a1c2ec2" xlink:to="loc_dei_EntityAddressAddressLine1_0b451a51-0d69-42be-a40e-698c1136e5e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_364e6f86-1f21-495a-a456-e1756fcee374" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40516abd-950d-4d49-80e2-8b2a1a1c2ec2" xlink:to="loc_dei_EntityAddressCityOrTown_364e6f86-1f21-495a-a456-e1756fcee374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_89f24450-3282-4ae4-9d7e-1b0e3f9cd53a" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40516abd-950d-4d49-80e2-8b2a1a1c2ec2" xlink:to="loc_dei_EntityAddressStateOrProvince_89f24450-3282-4ae4-9d7e-1b0e3f9cd53a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_0560d24e-2820-4117-be81-8c99f1b2e3a0" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40516abd-950d-4d49-80e2-8b2a1a1c2ec2" xlink:to="loc_dei_EntityAddressPostalZipCode_0560d24e-2820-4117-be81-8c99f1b2e3a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_72c23310-ca54-450d-91b9-ed04406d267a" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40516abd-950d-4d49-80e2-8b2a1a1c2ec2" xlink:to="loc_dei_CityAreaCode_72c23310-ca54-450d-91b9-ed04406d267a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_d7a975a3-43bc-45d9-8eec-221b057ae3e3" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40516abd-950d-4d49-80e2-8b2a1a1c2ec2" xlink:to="loc_dei_LocalPhoneNumber_d7a975a3-43bc-45d9-8eec-221b057ae3e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_f30fefbb-a1cc-4f56-a241-0802456597d7" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40516abd-950d-4d49-80e2-8b2a1a1c2ec2" xlink:to="loc_dei_Security12bTitle_f30fefbb-a1cc-4f56-a241-0802456597d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_210adef5-a10a-464a-9218-3791598974fb" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40516abd-950d-4d49-80e2-8b2a1a1c2ec2" xlink:to="loc_dei_TradingSymbol_210adef5-a10a-464a-9218-3791598974fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_e136c37d-27db-4e08-9c05-5a4a3313d025" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40516abd-950d-4d49-80e2-8b2a1a1c2ec2" xlink:to="loc_dei_SecurityExchangeName_e136c37d-27db-4e08-9c05-5a4a3313d025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_59a9abc0-aa4d-424a-9e9c-9bb4295d2e08" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40516abd-950d-4d49-80e2-8b2a1a1c2ec2" xlink:to="loc_dei_EntityCurrentReportingStatus_59a9abc0-aa4d-424a-9e9c-9bb4295d2e08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_22df5795-f1bd-4f72-aaf8-09ee4d0870ea" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40516abd-950d-4d49-80e2-8b2a1a1c2ec2" xlink:to="loc_dei_EntityInteractiveDataCurrent_22df5795-f1bd-4f72-aaf8-09ee4d0870ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_78befc0d-b897-411e-ad85-692d529bdbcd" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40516abd-950d-4d49-80e2-8b2a1a1c2ec2" xlink:to="loc_dei_EntityFilerCategory_78befc0d-b897-411e-ad85-692d529bdbcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_16978b30-803f-4585-a4f5-f24b403b5241" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40516abd-950d-4d49-80e2-8b2a1a1c2ec2" xlink:to="loc_dei_EntitySmallBusiness_16978b30-803f-4585-a4f5-f24b403b5241" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_472aabbf-785a-4ea4-94d8-c957a1e67c2d" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40516abd-950d-4d49-80e2-8b2a1a1c2ec2" xlink:to="loc_dei_EntityEmergingGrowthCompany_472aabbf-785a-4ea4-94d8-c957a1e67c2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_e3658864-2e13-43cb-a7dc-045198521fe8" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40516abd-950d-4d49-80e2-8b2a1a1c2ec2" xlink:to="loc_dei_EntityShellCompany_e3658864-2e13-43cb-a7dc-045198521fe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_e4ea354e-ae3d-41dc-9984-f197a0b62bb5" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_40516abd-950d-4d49-80e2-8b2a1a1c2ec2" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_e4ea354e-ae3d-41dc-9984-f197a0b62bb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="simple" xlink:href="biib-20250930.xsd#CondensedConsolidatedStatementsofIncomeUnaudited"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_fb489b4b-6a5f-4b79-8d19-9d98ad74661d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_886022d4-0a04-4756-946a-debee53503d2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_fb489b4b-6a5f-4b79-8d19-9d98ad74661d" xlink:to="loc_us-gaap_StatementTable_886022d4-0a04-4756-946a-debee53503d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_eaec2e1c-f38b-47a1-8f5b-636322933b4f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_886022d4-0a04-4756-946a-debee53503d2" xlink:to="loc_srt_ProductOrServiceAxis_eaec2e1c-f38b-47a1-8f5b-636322933b4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_cfad0fe2-d371-407c-ba56-a11f4f8be0aa" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_eaec2e1c-f38b-47a1-8f5b-636322933b4f" xlink:to="loc_srt_ProductsAndServicesDomain_cfad0fe2-d371-407c-ba56-a11f4f8be0aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_abb30ed3-3994-49ec-981f-2ede689dce94" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_cfad0fe2-d371-407c-ba56-a11f4f8be0aa" xlink:to="loc_us-gaap_ProductMember_abb30ed3-3994-49ec-981f-2ede689dce94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_c977b936-e73f-496c-9215-2d58f64f4185" xlink:href="biib-20250930.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_cfad0fe2-d371-407c-ba56-a11f4f8be0aa" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_c977b936-e73f-496c-9215-2d58f64f4185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LEQEMBICollaborationMember_f7095065-5486-4f5b-b758-d9f42fb6d5df" xlink:href="biib-20250930.xsd#biib_LEQEMBICollaborationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_cfad0fe2-d371-407c-ba56-a11f4f8be0aa" xlink:to="loc_biib_LEQEMBICollaborationMember_f7095065-5486-4f5b-b758-d9f42fb6d5df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_72626907-42d9-4441-a844-8c638d5d25b8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_cfad0fe2-d371-407c-ba56-a11f4f8be0aa" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_72626907-42d9-4441-a844-8c638d5d25b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_d45e5861-6d83-4706-9cc4-f7e7ad800a2e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_886022d4-0a04-4756-946a-debee53503d2" xlink:to="loc_us-gaap_StatementLineItems_d45e5861-6d83-4706-9cc4-f7e7ad800a2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_150d1923-6a8e-4c4a-b7b8-b94725e56780" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d45e5861-6d83-4706-9cc4-f7e7ad800a2e" xlink:to="loc_us-gaap_Revenues_150d1923-6a8e-4c4a-b7b8-b94725e56780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_ea3ef817-d9a3-4dd4-8ff6-06803e916c06" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostsAndExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d45e5861-6d83-4706-9cc4-f7e7ad800a2e" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_ea3ef817-d9a3-4dd4-8ff6-06803e916c06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_ad6879d3-0539-46ea-87c6-05e26a82721a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ea3ef817-d9a3-4dd4-8ff6-06803e916c06" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_ad6879d3-0539-46ea-87c6-05e26a82721a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_1c94f666-efde-40de-9dd0-0cc2873b9a40" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ea3ef817-d9a3-4dd4-8ff6-06803e916c06" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_1c94f666-efde-40de-9dd0-0cc2873b9a40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchAndDevelopmentExpenseIncludingAcquiredInProcessCost_29ade13f-4e70-4358-bd0d-7868ea62ba93" xlink:href="biib-20250930.xsd#biib_ResearchAndDevelopmentExpenseIncludingAcquiredInProcessCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ea3ef817-d9a3-4dd4-8ff6-06803e916c06" xlink:to="loc_biib_ResearchAndDevelopmentExpenseIncludingAcquiredInProcessCost_29ade13f-4e70-4358-bd0d-7868ea62ba93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_ba3575bf-37d6-4332-91ec-2d5b88330e94" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ea3ef817-d9a3-4dd4-8ff6-06803e916c06" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_ba3575bf-37d6-4332-91ec-2d5b88330e94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_7db72cad-e9be-4a69-a9c8-9b08efb4092c" xlink:href="biib-20250930.xsd#biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ea3ef817-d9a3-4dd4-8ff6-06803e916c06" xlink:to="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_7db72cad-e9be-4a69-a9c8-9b08efb4092c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationprofitlosssharing_df5d003e-83fb-4aee-919a-d616acac5d41" xlink:href="biib-20250930.xsd#biib_Collaborationprofitlosssharing"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ea3ef817-d9a3-4dd4-8ff6-06803e916c06" xlink:to="loc_biib_Collaborationprofitlosssharing_df5d003e-83fb-4aee-919a-d616acac5d41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_0b334ebc-1fb7-4e19-a67b-007e1daca07a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ea3ef817-d9a3-4dd4-8ff6-06803e916c06" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_0b334ebc-1fb7-4e19-a67b-007e1daca07a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_f4d8f71a-0e2b-4a23-9eb5-43847a38a653" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ea3ef817-d9a3-4dd4-8ff6-06803e916c06" xlink:to="loc_us-gaap_RestructuringCharges_f4d8f71a-0e2b-4a23-9eb5-43847a38a653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_3b12e6b4-0ede-438a-8c70-36ccf643ec4a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ea3ef817-d9a3-4dd4-8ff6-06803e916c06" xlink:to="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_3b12e6b4-0ede-438a-8c70-36ccf643ec4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_043f350b-e4f6-40bc-9494-b8e4c8ddf831" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ea3ef817-d9a3-4dd4-8ff6-06803e916c06" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_043f350b-e4f6-40bc-9494-b8e4c8ddf831" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_4a460612-e796-47d9-8e50-eba4fa3e9361" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_ea3ef817-d9a3-4dd4-8ff6-06803e916c06" xlink:to="loc_us-gaap_CostsAndExpenses_4a460612-e796-47d9-8e50-eba4fa3e9361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8f5c5a1f-da29-4c00-8b14-10190b52a93b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d45e5861-6d83-4706-9cc4-f7e7ad800a2e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_8f5c5a1f-da29-4c00-8b14-10190b52a93b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_817a3c1d-d40f-4b30-9386-bbabfdee5aad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d45e5861-6d83-4706-9cc4-f7e7ad800a2e" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_817a3c1d-d40f-4b30-9386-bbabfdee5aad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6a7d80b8-90dd-49a9-b86b-1652780afe12" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d45e5861-6d83-4706-9cc4-f7e7ad800a2e" xlink:to="loc_us-gaap_NetIncomeLoss_6a7d80b8-90dd-49a9-b86b-1652780afe12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_ef850a01-4fe1-460e-bdd3-d43540a40f96" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d45e5861-6d83-4706-9cc4-f7e7ad800a2e" xlink:to="loc_us-gaap_EarningsPerShareAbstract_ef850a01-4fe1-460e-bdd3-d43540a40f96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_9f59b65e-84d5-422c-8e46-26c5592bbee3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ef850a01-4fe1-460e-bdd3-d43540a40f96" xlink:to="loc_us-gaap_EarningsPerShareBasic_9f59b65e-84d5-422c-8e46-26c5592bbee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_0e0fefc3-8680-4be9-8b60-da9ff5357b4c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_ef850a01-4fe1-460e-bdd3-d43540a40f96" xlink:to="loc_us-gaap_EarningsPerShareDiluted_0e0fefc3-8680-4be9-8b60-da9ff5357b4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3c968243-d2be-4ff0-9abc-a05306da6e1f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_d45e5861-6d83-4706-9cc4-f7e7ad800a2e" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3c968243-d2be-4ff0-9abc-a05306da6e1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_db461b1c-4fb7-41b3-8ade-a773c8ea97f3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3c968243-d2be-4ff0-9abc-a05306da6e1f" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_db461b1c-4fb7-41b3-8ade-a773c8ea97f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0658623e-0937-43ab-8f63-08e7fd81418f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3c968243-d2be-4ff0-9abc-a05306da6e1f" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_0658623e-0937-43ab-8f63-08e7fd81418f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" xlink:type="simple" xlink:href="biib-20250930.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1295a0ac-c044-4174-a43d-a16da01a5b58" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b5e0407d-48ce-4fb0-b762-4ff522caf6f3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1295a0ac-c044-4174-a43d-a16da01a5b58" xlink:to="loc_us-gaap_NetIncomeLoss_b5e0407d-48ce-4fb0-b762-4ff522caf6f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_71126261-9ad9-4c3e-9bbf-d87b5a317552" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_1295a0ac-c044-4174-a43d-a16da01a5b58" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_71126261-9ad9-4c3e-9bbf-d87b5a317552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_0d40aafe-a12b-45d1-88fd-2a55f18aecb5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_71126261-9ad9-4c3e-9bbf-d87b5a317552" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_0d40aafe-a12b-45d1-88fd-2a55f18aecb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_47a8cd49-9dc6-49cf-a119-b19e5f87feb5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_71126261-9ad9-4c3e-9bbf-d87b5a317552" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_47a8cd49-9dc6-49cf-a119-b19e5f87feb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_92fb0d1e-a3ed-4f14-9258-ea5128b0172c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_71126261-9ad9-4c3e-9bbf-d87b5a317552" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_92fb0d1e-a3ed-4f14-9258-ea5128b0172c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_6372f38f-5e70-4584-ac48-0fdf4f26f783" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_71126261-9ad9-4c3e-9bbf-d87b5a317552" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_6372f38f-5e70-4584-ac48-0fdf4f26f783" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_98ee8d7b-54a9-45ef-aa50-2d1fbc45dd25" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_71126261-9ad9-4c3e-9bbf-d87b5a317552" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_98ee8d7b-54a9-45ef-aa50-2d1fbc45dd25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple" xlink:href="biib-20250930.xsd#CondensedConsolidatedBalanceSheetsUnaudited"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_41f62781-7a56-4270-99e7-6e327d0172e1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_d0415f1a-ee63-4504-902b-e8d7436f7343" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_41f62781-7a56-4270-99e7-6e327d0172e1" xlink:to="loc_us-gaap_StatementTable_d0415f1a-ee63-4504-902b-e8d7436f7343" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9f52ab71-f274-4442-bf6a-cdfcc80a9e56" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d0415f1a-ee63-4504-902b-e8d7436f7343" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9f52ab71-f274-4442-bf6a-cdfcc80a9e56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_7c80b873-8c59-4071-b230-8049357423ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9f52ab71-f274-4442-bf6a-cdfcc80a9e56" xlink:to="loc_us-gaap_RelatedPartyDomain_7c80b873-8c59-4071-b230-8049357423ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_7fb9259b-f2c3-457d-9968-a3d0f075cf6a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_7c80b873-8c59-4071-b230-8049357423ea" xlink:to="loc_us-gaap_NonrelatedPartyMember_7fb9259b-f2c3-457d-9968-a3d0f075cf6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_02b44010-7817-468e-9168-bb89d24b7695" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_7c80b873-8c59-4071-b230-8049357423ea" xlink:to="loc_us-gaap_RelatedPartyMember_02b44010-7817-468e-9168-bb89d24b7695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_461942dd-e915-4e4f-bee0-59b76b9303b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_d0415f1a-ee63-4504-902b-e8d7436f7343" xlink:to="loc_us-gaap_StatementLineItems_461942dd-e915-4e4f-bee0-59b76b9303b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_267c8b4c-6adf-456a-81b2-6e5ecaff1833" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_461942dd-e915-4e4f-bee0-59b76b9303b2" xlink:to="loc_us-gaap_AssetsAbstract_267c8b4c-6adf-456a-81b2-6e5ecaff1833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_558cc113-df49-4d9d-881a-59c808b181b0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_267c8b4c-6adf-456a-81b2-6e5ecaff1833" xlink:to="loc_us-gaap_AssetsCurrentAbstract_558cc113-df49-4d9d-881a-59c808b181b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_550cc690-7de9-4df0-9827-0ef9ffe053e5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_558cc113-df49-4d9d-881a-59c808b181b0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_550cc690-7de9-4df0-9827-0ef9ffe053e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_268f45da-8a5d-44d1-967d-52473d1896d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_558cc113-df49-4d9d-881a-59c808b181b0" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_268f45da-8a5d-44d1-967d-52473d1896d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_57964c52-c779-480e-80bb-7e7b3655b990" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_558cc113-df49-4d9d-881a-59c808b181b0" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_57964c52-c779-480e-80bb-7e7b3655b990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_c35b8ddb-cd6d-4579-9fe4-1e937fcd9f0b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_558cc113-df49-4d9d-881a-59c808b181b0" xlink:to="loc_us-gaap_InventoryNet_c35b8ddb-cd6d-4579-9fe4-1e937fcd9f0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_a77a7c2e-5d1d-40f4-b10c-2271f6e30461" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_558cc113-df49-4d9d-881a-59c808b181b0" xlink:to="loc_us-gaap_OtherAssetsCurrent_a77a7c2e-5d1d-40f4-b10c-2271f6e30461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_2fc68ed5-dbe1-402f-89af-8b1de442b1dc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_558cc113-df49-4d9d-881a-59c808b181b0" xlink:to="loc_us-gaap_AssetsCurrent_2fc68ed5-dbe1-402f-89af-8b1de442b1dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_5aeb8a85-7648-4e17-96dd-f43aef5a64bf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_267c8b4c-6adf-456a-81b2-6e5ecaff1833" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_5aeb8a85-7648-4e17-96dd-f43aef5a64bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_3f01165e-410a-4b84-a6f0-0a0a82b1fb6a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_267c8b4c-6adf-456a-81b2-6e5ecaff1833" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_3f01165e-410a-4b84-a6f0-0a0a82b1fb6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_212d32dc-be09-4b1a-bca0-ec343762e8f6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_267c8b4c-6adf-456a-81b2-6e5ecaff1833" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_212d32dc-be09-4b1a-bca0-ec343762e8f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_5342c22f-008d-4d2c-95c9-9f6ad15fc909" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_267c8b4c-6adf-456a-81b2-6e5ecaff1833" xlink:to="loc_us-gaap_Goodwill_5342c22f-008d-4d2c-95c9-9f6ad15fc909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_2fb783d2-2de1-46b0-9587-0af56fc2fbb4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_267c8b4c-6adf-456a-81b2-6e5ecaff1833" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_2fb783d2-2de1-46b0-9587-0af56fc2fbb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_3fbc1837-ce72-4b04-9a85-a04ecb89799a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_267c8b4c-6adf-456a-81b2-6e5ecaff1833" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_3fbc1837-ce72-4b04-9a85-a04ecb89799a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_a88a19bd-529c-4d58-b758-190ba822d79a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_267c8b4c-6adf-456a-81b2-6e5ecaff1833" xlink:to="loc_us-gaap_Assets_a88a19bd-529c-4d58-b758-190ba822d79a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_24496f9b-cb5c-4cec-af4c-82d9da59b088" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_461942dd-e915-4e4f-bee0-59b76b9303b2" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_24496f9b-cb5c-4cec-af4c-82d9da59b088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_56e324ce-c451-4313-82fa-97c853284674" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_24496f9b-cb5c-4cec-af4c-82d9da59b088" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_56e324ce-c451-4313-82fa-97c853284674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_2665e89a-e6ad-4840-894a-0f5ab26335b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_56e324ce-c451-4313-82fa-97c853284674" xlink:to="loc_us-gaap_NotesPayableCurrent_2665e89a-e6ad-4840-894a-0f5ab26335b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxesPayableCurrent_bd011b66-4b8e-4406-9631-b3c8092a75f0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxesPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_56e324ce-c451-4313-82fa-97c853284674" xlink:to="loc_us-gaap_TaxesPayableCurrent_bd011b66-4b8e-4406-9631-b3c8092a75f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_f60c8165-f346-4030-8c76-f5d892a72a59" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_56e324ce-c451-4313-82fa-97c853284674" xlink:to="loc_us-gaap_AccountsPayableCurrent_f60c8165-f346-4030-8c76-f5d892a72a59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_270c08fb-461f-4bbc-9beb-03d3d312953c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_56e324ce-c451-4313-82fa-97c853284674" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_270c08fb-461f-4bbc-9beb-03d3d312953c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_ef024627-0c9c-4293-a54d-351fc09545cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_56e324ce-c451-4313-82fa-97c853284674" xlink:to="loc_us-gaap_LiabilitiesCurrent_ef024627-0c9c-4293-a54d-351fc09545cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_3871f3c8-ed84-4dd9-9468-e2e9157a2544" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_24496f9b-cb5c-4cec-af4c-82d9da59b088" xlink:to="loc_us-gaap_LongTermDebt_3871f3c8-ed84-4dd9-9468-e2e9157a2544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_081f2720-87ec-4362-98a7-3f8cedbef315" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_24496f9b-cb5c-4cec-af4c-82d9da59b088" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_081f2720-87ec-4362-98a7-3f8cedbef315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c7e951cb-3ae0-4ffc-9abd-9ef036168ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_24496f9b-cb5c-4cec-af4c-82d9da59b088" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c7e951cb-3ae0-4ffc-9abd-9ef036168ea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_dd7caab0-c7a8-49b8-a695-2724b578f74b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_24496f9b-cb5c-4cec-af4c-82d9da59b088" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_dd7caab0-c7a8-49b8-a695-2724b578f74b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_280b268d-7173-42a2-ab2b-7c90b09d9308" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_24496f9b-cb5c-4cec-af4c-82d9da59b088" xlink:to="loc_us-gaap_Liabilities_280b268d-7173-42a2-ab2b-7c90b09d9308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_172eb857-eee5-4689-b405-0860fa0d0b06" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_24496f9b-cb5c-4cec-af4c-82d9da59b088" xlink:to="loc_us-gaap_CommitmentsAndContingencies_172eb857-eee5-4689-b405-0860fa0d0b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_3110e7de-885c-428c-a4f0-3adccdac1794" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_24496f9b-cb5c-4cec-af4c-82d9da59b088" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_3110e7de-885c-428c-a4f0-3adccdac1794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_2868bae6-46b9-464d-8105-709f7fdf0452" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_3110e7de-885c-428c-a4f0-3adccdac1794" xlink:to="loc_us-gaap_StockholdersEquityAbstract_2868bae6-46b9-464d-8105-709f7fdf0452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_09854da7-341e-45dc-ae8d-60d25fa3861b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2868bae6-46b9-464d-8105-709f7fdf0452" xlink:to="loc_us-gaap_PreferredStockValue_09854da7-341e-45dc-ae8d-60d25fa3861b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_9577c7b3-bf50-4db7-b349-6947336a291b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2868bae6-46b9-464d-8105-709f7fdf0452" xlink:to="loc_us-gaap_CommonStockValue_9577c7b3-bf50-4db7-b349-6947336a291b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_f22ea236-4817-4d74-9ee7-399e3f968bef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2868bae6-46b9-464d-8105-709f7fdf0452" xlink:to="loc_us-gaap_AdditionalPaidInCapital_f22ea236-4817-4d74-9ee7-399e3f968bef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ea88b8b9-097b-4600-be01-551ead211e14" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2868bae6-46b9-464d-8105-709f7fdf0452" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ea88b8b9-097b-4600-be01-551ead211e14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6f8f3f7f-86e9-47d0-9c15-a0394dad0ff6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2868bae6-46b9-464d-8105-709f7fdf0452" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6f8f3f7f-86e9-47d0-9c15-a0394dad0ff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_b9125a27-0549-4466-89eb-20878120df98" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_2868bae6-46b9-464d-8105-709f7fdf0452" xlink:to="loc_us-gaap_TreasuryStockValue_b9125a27-0549-4466-89eb-20878120df98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_fadebe94-0ded-4164-b68c-f526abbcc643" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_3110e7de-885c-428c-a4f0-3adccdac1794" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_fadebe94-0ded-4164-b68c-f526abbcc643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_07a81f9d-f3d4-4655-b648-2e2ef5898db9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_24496f9b-cb5c-4cec-af4c-82d9da59b088" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_07a81f9d-f3d4-4655-b648-2e2ef5898db9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="biib-20250930.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_cc32996a-784d-4473-a669-826f5b0563e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_bacc5eb0-7711-4fc1-b47a-f98f48f9e34c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_cc32996a-784d-4473-a669-826f5b0563e4" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_bacc5eb0-7711-4fc1-b47a-f98f48f9e34c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_3e18c087-ede6-450b-b41d-9daa8b55e567" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_cc32996a-784d-4473-a669-826f5b0563e4" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_3e18c087-ede6-450b-b41d-9daa8b55e567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_cf738265-54f1-426f-b658-3f5dfb1c95eb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_cc32996a-784d-4473-a669-826f5b0563e4" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_cf738265-54f1-426f-b658-3f5dfb1c95eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="simple" xlink:href="biib-20250930.xsd#CondensedConsolidatedStatementsofCashFlowsUnaudited"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_a69b76e8-1d45-43e4-afc5-60778aa95be0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2477b17d-21c4-4a78-8b55-f812ece45f87" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_a69b76e8-1d45-43e4-afc5-60778aa95be0" xlink:to="loc_us-gaap_StatementTable_2477b17d-21c4-4a78-8b55-f812ece45f87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9e1222d7-d8b4-4784-b7d2-2b910e7785e0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2477b17d-21c4-4a78-8b55-f812ece45f87" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9e1222d7-d8b4-4784-b7d2-2b910e7785e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_7fbd87ac-9910-46f7-b58f-7a154e988bb6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_9e1222d7-d8b4-4784-b7d2-2b910e7785e0" xlink:to="loc_us-gaap_RelatedPartyDomain_7fbd87ac-9910-46f7-b58f-7a154e988bb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrelatedPartyMember_3895ca18-686a-4106-9dba-966b3f73c413" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonrelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_7fbd87ac-9910-46f7-b58f-7a154e988bb6" xlink:to="loc_us-gaap_NonrelatedPartyMember_3895ca18-686a-4106-9dba-966b3f73c413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_37a4c6bb-30ff-4206-9382-991bf54006a7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_7fbd87ac-9910-46f7-b58f-7a154e988bb6" xlink:to="loc_us-gaap_RelatedPartyMember_37a4c6bb-30ff-4206-9382-991bf54006a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_dd136dde-bf77-4377-b707-3231a0b6fed7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2477b17d-21c4-4a78-8b55-f812ece45f87" xlink:to="loc_us-gaap_StatementLineItems_dd136dde-bf77-4377-b707-3231a0b6fed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cd246f2e-e764-4e00-bb39-d3d6c96cb385" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dd136dde-bf77-4377-b707-3231a0b6fed7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cd246f2e-e764-4e00-bb39-d3d6c96cb385" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_356d1be7-758c-4345-978b-4a8aea9a58ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cd246f2e-e764-4e00-bb39-d3d6c96cb385" xlink:to="loc_us-gaap_ProfitLoss_356d1be7-758c-4345-978b-4a8aea9a58ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b7fdf5bf-4b82-4a6b-9bac-2705b475a9fc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_cd246f2e-e764-4e00-bb39-d3d6c96cb385" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b7fdf5bf-4b82-4a6b-9bac-2705b475a9fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_243c547e-613f-4e9d-ab6d-fe46df563796" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b7fdf5bf-4b82-4a6b-9bac-2705b475a9fc" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_243c547e-613f-4e9d-ab6d-fe46df563796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_62698183-8e9a-4957-ba58-5067008613f6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b7fdf5bf-4b82-4a6b-9bac-2705b475a9fc" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_62698183-8e9a-4957-ba58-5067008613f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_3d71d1bc-db5f-4cda-861e-3d9eae505465" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b7fdf5bf-4b82-4a6b-9bac-2705b475a9fc" xlink:to="loc_us-gaap_InventoryWriteDown_3d71d1bc-db5f-4cda-861e-3d9eae505465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationOfInventoryStepUp_79b5e5ff-ad6d-4afa-91e6-3e149ca96fcc" xlink:href="biib-20250930.xsd#biib_AmortizationOfInventoryStepUp"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b7fdf5bf-4b82-4a6b-9bac-2705b475a9fc" xlink:to="loc_biib_AmortizationOfInventoryStepUp_79b5e5ff-ad6d-4afa-91e6-3e149ca96fcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_a7522c13-d5ec-42d7-b10c-0992c6a19e88" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b7fdf5bf-4b82-4a6b-9bac-2705b475a9fc" xlink:to="loc_us-gaap_ShareBasedCompensation_a7522c13-d5ec-42d7-b10c-0992c6a19e88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_1d74ae5c-4fef-4f36-b6d1-4944468f940d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b7fdf5bf-4b82-4a6b-9bac-2705b475a9fc" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_1d74ae5c-4fef-4f36-b6d1-4944468f940d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_71ebe307-393b-4338-b915-07fc58c8498c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b7fdf5bf-4b82-4a6b-9bac-2705b475a9fc" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_71ebe307-393b-4338-b915-07fc58c8498c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_da4863f7-e2fc-43b1-9c42-31c4cb7e49f0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b7fdf5bf-4b82-4a6b-9bac-2705b475a9fc" xlink:to="loc_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi_da4863f7-e2fc-43b1-9c42-31c4cb7e49f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_3be97799-9e04-4181-80de-f91e1a949254" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b7fdf5bf-4b82-4a6b-9bac-2705b475a9fc" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_3be97799-9e04-4181-80de-f91e1a949254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_19a1f0bd-5b89-4e7f-8caf-22ff631623ee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b7fdf5bf-4b82-4a6b-9bac-2705b475a9fc" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_19a1f0bd-5b89-4e7f-8caf-22ff631623ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f79ab08d-e2a8-4786-821f-8dc99536073f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b7fdf5bf-4b82-4a6b-9bac-2705b475a9fc" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f79ab08d-e2a8-4786-821f-8dc99536073f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_cbb1178f-d346-43e3-80f1-896ddc812b1e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f79ab08d-e2a8-4786-821f-8dc99536073f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_cbb1178f-d346-43e3-80f1-896ddc812b1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_6eb7ac91-0399-4503-a08a-8c92ec3a0454" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f79ab08d-e2a8-4786-821f-8dc99536073f" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_6eb7ac91-0399-4503-a08a-8c92ec3a0454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_a9f7ff1d-3ca8-48d9-bbe5-5943e7c60338" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f79ab08d-e2a8-4786-821f-8dc99536073f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_a9f7ff1d-3ca8-48d9-bbe5-5943e7c60338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_4e6e7dd6-0eb0-442f-bcdb-7a2dd22951bc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f79ab08d-e2a8-4786-821f-8dc99536073f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable_4e6e7dd6-0eb0-442f-bcdb-7a2dd22951bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_4e199406-cd24-4071-8a08-c832f4410cd1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_f79ab08d-e2a8-4786-821f-8dc99536073f" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet_4e199406-cd24-4071-8a08-c832f4410cd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d0a97931-5e82-4f89-b2fc-e0891e16ffe7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_b7fdf5bf-4b82-4a6b-9bac-2705b475a9fc" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_d0a97931-5e82-4f89-b2fc-e0891e16ffe7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_71245389-0d77-4554-86cf-57ea25ce65e8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dd136dde-bf77-4377-b707-3231a0b6fed7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_71245389-0d77-4554-86cf-57ea25ce65e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_30d7605d-f8b6-4f5e-84a4-84c12fea562e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_71245389-0d77-4554-86cf-57ea25ce65e8" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_30d7605d-f8b6-4f5e-84a4-84c12fea562e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_14c6541e-2f6c-4642-b4bc-e6018f02129c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_71245389-0d77-4554-86cf-57ea25ce65e8" xlink:to="loc_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_14c6541e-2f6c-4642-b4bc-e6018f02129c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_f0025d1e-3529-473f-8fb5-d5238176d79d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_71245389-0d77-4554-86cf-57ea25ce65e8" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_f0025d1e-3529-473f-8fb5-d5238176d79d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_693df65f-cae9-4201-a464-d06efb240620" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_71245389-0d77-4554-86cf-57ea25ce65e8" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_693df65f-cae9-4201-a464-d06efb240620" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_a92a831c-f9d9-47a1-b68f-9a3992d38c99" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_71245389-0d77-4554-86cf-57ea25ce65e8" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_a92a831c-f9d9-47a1-b68f-9a3992d38c99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_70faeb3f-6358-478c-bd72-e0ebaedfbfb4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireIntangibleAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_71245389-0d77-4554-86cf-57ea25ce65e8" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_70faeb3f-6358-478c-bd72-e0ebaedfbfb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfOtherInvestments_ce65c10c-6c9e-4b63-b597-bba320a02704" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfOtherInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_71245389-0d77-4554-86cf-57ea25ce65e8" xlink:to="loc_us-gaap_ProceedsFromSaleOfOtherInvestments_ce65c10c-6c9e-4b63-b597-bba320a02704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_2c46967d-2a26-43bf-aa34-32c97f002556" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_71245389-0d77-4554-86cf-57ea25ce65e8" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_2c46967d-2a26-43bf-aa34-32c97f002556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2611b026-29c7-4285-b02e-13d2d8d46985" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_71245389-0d77-4554-86cf-57ea25ce65e8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_2611b026-29c7-4285-b02e-13d2d8d46985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1fbc34cb-1c03-4a5d-b251-67a864a05a46" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dd136dde-bf77-4377-b707-3231a0b6fed7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1fbc34cb-1c03-4a5d-b251-67a864a05a46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_78f3fded-abbc-43b1-9406-dc590bfb3d88" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1fbc34cb-1c03-4a5d-b251-67a864a05a46" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_78f3fded-abbc-43b1-9406-dc590bfb3d88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_32cd0855-254c-4552-be9d-9173c560f14e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1fbc34cb-1c03-4a5d-b251-67a864a05a46" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_32cd0855-254c-4552-be9d-9173c560f14e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_4bbee05b-e49c-4d76-a64d-827b1e33e90f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1fbc34cb-1c03-4a5d-b251-67a864a05a46" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_4bbee05b-e49c-4d76-a64d-827b1e33e90f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_a7cc9773-1e30-4d36-b215-d7b9f86b3759" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1fbc34cb-1c03-4a5d-b251-67a864a05a46" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_a7cc9773-1e30-4d36-b215-d7b9f86b3759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_49b15d99-9e99-4947-8513-33d6eeb1588f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1fbc34cb-1c03-4a5d-b251-67a864a05a46" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_49b15d99-9e99-4947-8513-33d6eeb1588f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ff514b97-c3f9-4088-be20-1e17f0c4a897" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1fbc34cb-1c03-4a5d-b251-67a864a05a46" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ff514b97-c3f9-4088-be20-1e17f0c4a897" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_b57b7c7f-521f-40ce-8c81-7af1dcfb8e19" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dd136dde-bf77-4377-b707-3231a0b6fed7" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_b57b7c7f-521f-40ce-8c81-7af1dcfb8e19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_927a6365-845f-4926-baa8-87b4c42ea0ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dd136dde-bf77-4377-b707-3231a0b6fed7" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_927a6365-845f-4926-baa8-87b4c42ea0ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_30fe9c8b-919b-4842-84e2-aa0ca6032ab9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dd136dde-bf77-4377-b707-3231a0b6fed7" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_30fe9c8b-919b-4842-84e2-aa0ca6032ab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_35f8f7df-6fe8-43f6-b84f-5453d17df056" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_dd136dde-bf77-4377-b707-3231a0b6fed7" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_35f8f7df-6fe8-43f6-b84f-5453d17df056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement" xlink:type="simple" xlink:href="biib-20250930.xsd#CondensedConsolidatedStatementofEquityStatement"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_ad1f8837-664b-469a-9f4b-bd54e9583462" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_57bd61bf-2114-48af-8c82-7d5b9501313c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_ad1f8837-664b-469a-9f4b-bd54e9583462" xlink:to="loc_us-gaap_StatementTable_57bd61bf-2114-48af-8c82-7d5b9501313c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7d57ac9f-fbc4-41e5-94e5-57c9147315b3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_57bd61bf-2114-48af-8c82-7d5b9501313c" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_7d57ac9f-fbc4-41e5-94e5-57c9147315b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_3b9c2084-feeb-41df-83d0-ed28dc2b8fc6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7d57ac9f-fbc4-41e5-94e5-57c9147315b3" xlink:to="loc_us-gaap_EquityComponentDomain_3b9c2084-feeb-41df-83d0-ed28dc2b8fc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_24c50dfd-4c20-4e41-b012-e1c8af4d9719" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3b9c2084-feeb-41df-83d0-ed28dc2b8fc6" xlink:to="loc_us-gaap_PreferredStockMember_24c50dfd-4c20-4e41-b012-e1c8af4d9719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9ea72d27-1632-431e-a378-835412af3c91" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3b9c2084-feeb-41df-83d0-ed28dc2b8fc6" xlink:to="loc_us-gaap_CommonStockMember_9ea72d27-1632-431e-a378-835412af3c91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_30c19878-6973-4d99-9d2d-3fa2982883f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3b9c2084-feeb-41df-83d0-ed28dc2b8fc6" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_30c19878-6973-4d99-9d2d-3fa2982883f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e41b89c3-b4a1-459f-8247-914dc4950081" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3b9c2084-feeb-41df-83d0-ed28dc2b8fc6" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_e41b89c3-b4a1-459f-8247-914dc4950081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_2d99e740-1893-4282-9e4c-4b3cc4142c39" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3b9c2084-feeb-41df-83d0-ed28dc2b8fc6" xlink:to="loc_us-gaap_RetainedEarningsMember_2d99e740-1893-4282-9e4c-4b3cc4142c39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_5ff65438-610b-4b97-898a-44df98b574ff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3b9c2084-feeb-41df-83d0-ed28dc2b8fc6" xlink:to="loc_us-gaap_TreasuryStockCommonMember_5ff65438-610b-4b97-898a-44df98b574ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_6ba0d405-b930-4ff3-9741-3d93cae4d3a1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ParentMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_3b9c2084-feeb-41df-83d0-ed28dc2b8fc6" xlink:to="loc_us-gaap_ParentMember_6ba0d405-b930-4ff3-9741-3d93cae4d3a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_195822ba-b0b2-4a3f-9834-7ecaf7ab02bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_57bd61bf-2114-48af-8c82-7d5b9501313c" xlink:to="loc_us-gaap_StatementLineItems_195822ba-b0b2-4a3f-9834-7ecaf7ab02bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_6cf3ff7b-0d93-4ddf-a01f-5827040e39a3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_195822ba-b0b2-4a3f-9834-7ecaf7ab02bb" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_6cf3ff7b-0d93-4ddf-a01f-5827040e39a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_29d3f5f4-5a9f-44dd-a40a-97a7c3756128" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_195822ba-b0b2-4a3f-9834-7ecaf7ab02bb" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_29d3f5f4-5a9f-44dd-a40a-97a7c3756128" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_9fd530d7-943e-4b41-832c-0a29498f9ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_195822ba-b0b2-4a3f-9834-7ecaf7ab02bb" xlink:to="loc_us-gaap_TreasuryStockCommonShares_9fd530d7-943e-4b41-832c-0a29498f9ca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_e49a2727-328a-4755-9b88-3492a6dfe1b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_195822ba-b0b2-4a3f-9834-7ecaf7ab02bb" xlink:to="loc_us-gaap_ProfitLoss_e49a2727-328a-4755-9b88-3492a6dfe1b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_dedd9e92-62ba-4d66-a31a-e6b5b1f3eb1a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_195822ba-b0b2-4a3f-9834-7ecaf7ab02bb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_dedd9e92-62ba-4d66-a31a-e6b5b1f3eb1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_a2794bb1-8f24-4c05-8dc8-29df7e80154c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_195822ba-b0b2-4a3f-9834-7ecaf7ab02bb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued_a2794bb1-8f24-4c05-8dc8-29df7e80154c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_07257577-b543-47e2-8080-4e959c3f008d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_195822ba-b0b2-4a3f-9834-7ecaf7ab02bb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued_07257577-b543-47e2-8080-4e959c3f008d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_563cdeba-7d69-4d48-9ea6-e3da8f0fef16" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_195822ba-b0b2-4a3f-9834-7ecaf7ab02bb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures_563cdeba-7d69-4d48-9ea6-e3da8f0fef16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_0fc42d2d-8f14-45c2-b75d-0ae65724dfb7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_195822ba-b0b2-4a3f-9834-7ecaf7ab02bb" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures_0fc42d2d-8f14-45c2-b75d-0ae65724dfb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_faf90ea6-b861-496a-90b3-55ed48abaca4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_195822ba-b0b2-4a3f-9834-7ecaf7ab02bb" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_faf90ea6-b861-496a-90b3-55ed48abaca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_4acf8a29-be5a-4e26-aa7d-364c3147c90a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityOther"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_195822ba-b0b2-4a3f-9834-7ecaf7ab02bb" xlink:to="loc_us-gaap_StockholdersEquityOther_4acf8a29-be5a-4e26-aa7d-364c3147c90a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b11f0801-c6d7-4487-aebc-0f72c4ae57e3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_195822ba-b0b2-4a3f-9834-7ecaf7ab02bb" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b11f0801-c6d7-4487-aebc-0f72c4ae57e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_bd62f8e0-2048-4466-933b-01d9df9ad6d0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_195822ba-b0b2-4a3f-9834-7ecaf7ab02bb" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_bd62f8e0-2048-4466-933b-01d9df9ad6d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_1d58c66b-25c3-4aa7-9840-4bb0b492fb3a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_195822ba-b0b2-4a3f-9834-7ecaf7ab02bb" xlink:to="loc_us-gaap_TreasuryStockCommonShares_1d58c66b-25c3-4aa7-9840-4bb0b492fb3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="biib-20250930.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_cb49f0e8-2589-48dd-8fca-908ba4fc1b76" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_5cdbf172-42ff-47c0-852c-f21151ac8b8f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cb49f0e8-2589-48dd-8fca-908ba4fc1b76" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_5cdbf172-42ff-47c0-852c-f21151ac8b8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Acquisitions" xlink:type="simple" xlink:href="biib-20250930.xsd#Acquisitions"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Acquisitions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_3bf234b7-3a44-4a36-9f35-0aace399a8b0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_7dc12f37-078a-43b9-aac9-e3e54e07369e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_3bf234b7-3a44-4a36-9f35-0aace399a8b0" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_7dc12f37-078a-43b9-aac9-e3e54e07369e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Dispositions" xlink:type="simple" xlink:href="biib-20250930.xsd#Dispositions"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Dispositions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_DivestituresAbstract_8b54877c-5550-4d32-ac36-600f14bcb30a" xlink:href="biib-20250930.xsd#biib_DivestituresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_2e5a7feb-cab1-4a1f-a2ff-6c70698ec65e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DivestituresAbstract_8b54877c-5550-4d32-ac36-600f14bcb30a" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_2e5a7feb-cab1-4a1f-a2ff-6c70698ec65e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiatives" xlink:type="simple" xlink:href="biib-20250930.xsd#RestructuringBusinessTransformationandOtherCostSavingInitiatives"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiatives" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_256dbc32-a8cd-43a7-9510-7d72d8447c5e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_aa15ec06-84db-416f-9d5a-f8c63da12aba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_256dbc32-a8cd-43a7-9510-7d72d8447c5e" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_aa15ec06-84db-416f-9d5a-f8c63da12aba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Revenues" xlink:type="simple" xlink:href="biib-20250930.xsd#Revenues"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Revenues" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4ab3be4f-1284-4353-88c7-76be3fb3337d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_246b057a-f852-4a74-8325-2cac0a951045" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4ab3be4f-1284-4353-88c7-76be3fb3337d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_246b057a-f852-4a74-8325-2cac0a951045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Inventory" xlink:type="simple" xlink:href="biib-20250930.xsd#Inventory"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_533a2964-9d8b-4700-aaeb-e3d829b4af92" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_8cd03307-cd64-465b-ae66-513ca2bad0d1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_533a2964-9d8b-4700-aaeb-e3d829b4af92" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_8cd03307-cd64-465b-ae66-513ca2bad0d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwill" xlink:type="simple" xlink:href="biib-20250930.xsd#IntangibleAssetsandGoodwill"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwill" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5525b42c-f13c-43b8-babf-503af3a4cbad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_bb29e981-8a1d-4d23-99a2-6ae5885a3a25" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5525b42c-f13c-43b8-babf-503af3a4cbad" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_bb29e981-8a1d-4d23-99a2-6ae5885a3a25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="biib-20250930.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_3f1bc410-b196-4c17-b5e1-e585a84fba46" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_4ff3a7ab-3cd0-492a-ad75-4d25a56f3376" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3f1bc410-b196-4c17-b5e1-e585a84fba46" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_4ff3a7ab-3cd0-492a-ad75-4d25a56f3376" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="simple" xlink:href="biib-20250930.xsd#FinancialInstruments"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0660a3d3-5544-46fd-9fcc-02e4a84c2f22" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_0848acaf-6e8a-4b00-8c13-396b17bb8eda" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0660a3d3-5544-46fd-9fcc-02e4a84c2f22" xlink:to="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_0848acaf-6e8a-4b00-8c13-396b17bb8eda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="simple" xlink:href="biib-20250930.xsd#DerivativeInstruments"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstruments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_82c78940-abd4-4063-8a4a-8be0ef9d721e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_c7783333-2732-4c97-a753-e3005b969004" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_82c78940-abd4-4063-8a4a-8be0ef9d721e" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_c7783333-2732-4c97-a753-e3005b969004" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantandEquipment" xlink:type="simple" xlink:href="biib-20250930.xsd#PropertyPlantandEquipment"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_e0bde018-eed9-42ff-ac4e-fa5c5e547540" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_dbb7079f-c696-40fc-9265-7ab1b3cf76f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_e0bde018-eed9-42ff-ac4e-fa5c5e547540" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_dbb7079f-c696-40fc-9265-7ab1b3cf76f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Leases" xlink:type="simple" xlink:href="biib-20250930.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_369458fb-687f-4a7b-b801-fcd015fa4b5a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_88e67d43-1721-4f04-9dac-7a88172dfed6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_369458fb-687f-4a7b-b801-fcd015fa4b5a" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_88e67d43-1721-4f04-9dac-7a88172dfed6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Indebtedness" xlink:type="simple" xlink:href="biib-20250930.xsd#Indebtedness"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Indebtedness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_5748dc62-cba2-478b-ae35-efdca7209d84" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_a3a551f5-9755-43b9-90e2-15095f3b7f07" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_5748dc62-cba2-478b-ae35-efdca7209d84" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_a3a551f5-9755-43b9-90e2-15095f3b7f07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Equity" xlink:type="simple" xlink:href="biib-20250930.xsd#Equity"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Equity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_d37043b2-179e-4622-a8f1-5fc8b785ee4c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_a8174c14-0c8c-44ea-bddc-cf65e850f80d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_d37043b2-179e-4622-a8f1-5fc8b785ee4c" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_a8174c14-0c8c-44ea-bddc-cf65e850f80d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsperShare" xlink:type="simple" xlink:href="biib-20250930.xsd#EarningsperShare"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EarningsperShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_da854a03-7eef-4e44-97c6-a5bc439622c9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_2fbd7727-933b-47f9-aace-fff236fce3cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_da854a03-7eef-4e44-97c6-a5bc439622c9" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_2fbd7727-933b-47f9-aace-fff236fce3cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SharebasedPayments" xlink:type="simple" xlink:href="biib-20250930.xsd#SharebasedPayments"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SharebasedPayments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1f4bd926-ebd6-47b0-8c65-7e21d8e1e4f3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_ef30930a-f3ff-4273-8202-d77bb5d8e08b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1f4bd926-ebd6-47b0-8c65-7e21d8e1e4f3" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_ef30930a-f3ff-4273-8202-d77bb5d8e08b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="simple" xlink:href="biib-20250930.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_f5f067be-b9af-4f19-a79c-dca7936262e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_6bb88868-6fff-43a3-9ef5-9a5e86632e75" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f5f067be-b9af-4f19-a79c-dca7936262e4" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_6bb88868-6fff-43a3-9ef5-9a5e86632e75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="simple" xlink:href="biib-20250930.xsd#OtherConsolidatedFinancialStatementDetail"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1cd03092-d222-46b8-8e69-6bc1455eac7b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_59f4d8e9-ee0a-4163-9548-30e2a5da5654" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1cd03092-d222-46b8-8e69-6bc1455eac7b" xlink:to="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_59f4d8e9-ee0a-4163-9548-30e2a5da5654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationships" xlink:type="simple" xlink:href="biib-20250930.xsd#CollaborativeandOtherRelationships"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationships" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_258d37da-7449-4d9a-99c9-3e32dba2109c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_c0f4ff5d-65fa-4e93-b5e4-a1a561f6e4df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_258d37da-7449-4d9a-99c9-3e32dba2109c" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_c0f4ff5d-65fa-4e93-b5e4-a1a561f6e4df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities" xlink:type="simple" xlink:href="biib-20250930.xsd#InvestmentsinVariableInterestEntities"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_abaf2612-9fe7-4410-8bd3-4b81bcfbf075" xlink:href="biib-20250930.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_cd0a2c9f-b15a-4f71-9974-ca1a2042098c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_VariableInterestEntityDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_abaf2612-9fe7-4410-8bd3-4b81bcfbf075" xlink:to="loc_us-gaap_VariableInterestEntityDisclosureTextBlock_cd0a2c9f-b15a-4f71-9974-ca1a2042098c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/Litigation" xlink:type="simple" xlink:href="biib-20250930.xsd#Litigation"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/Litigation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_34a2bd8b-e746-4699-83e1-c9c8df0f810d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_e3331233-de02-4c0c-9553-c469dde2b2a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_34a2bd8b-e746-4699-83e1-c9c8df0f810d" xlink:to="loc_us-gaap_LegalMattersAndContingenciesTextBlock_e3331233-de02-4c0c-9553-c469dde2b2a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SegmentInformation" xlink:type="simple" xlink:href="biib-20250930.xsd#SegmentInformation"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SegmentInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_1469bdbf-c421-4865-be89-c6b87e4e2773" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_308e024d-5653-4828-97f3-4959524672c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_1469bdbf-c421-4865-be89-c6b87e4e2773" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_308e024d-5653-4828-97f3-4959524672c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SubsequentEvents" xlink:type="simple" xlink:href="biib-20250930.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_97e26159-856d-490b-9f38-84cc46c7a927" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_63b353b9-f7d4-45bb-8d87-e6ab5a96b82e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_97e26159-856d-490b-9f38-84cc46c7a927" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_63b353b9-f7d4-45bb-8d87-e6ab5a96b82e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="biib-20250930.xsd#SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5a1528c3-478f-4298-aa1e-6a5d4721af67" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessOverviewPolicyTextBlock_6c2a75c0-56b4-4589-9c95-77c85daee1ce" xlink:href="biib-20250930.xsd#biib_BusinessOverviewPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5a1528c3-478f-4298-aa1e-6a5d4721af67" xlink:to="loc_biib_BusinessOverviewPolicyTextBlock_6c2a75c0-56b4-4589-9c95-77c85daee1ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_a69d1fe5-c2b6-44d2-9423-3968def74c55" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5a1528c3-478f-4298-aa1e-6a5d4721af67" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_a69d1fe5-c2b6-44d2-9423-3968def74c55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_fd766f16-019b-445a-9c7e-de7a6a61b560" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5a1528c3-478f-4298-aa1e-6a5d4721af67" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_fd766f16-019b-445a-9c7e-de7a6a61b560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_e6ce0c7a-1e4c-4632-a5a5-11edac377afe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5a1528c3-478f-4298-aa1e-6a5d4721af67" xlink:to="loc_us-gaap_UseOfEstimates_e6ce0c7a-1e4c-4632-a5a5-11edac377afe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_c07fb6e7-205d-4628-b6ba-de2721f5c2ca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5a1528c3-478f-4298-aa1e-6a5d4721af67" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_c07fb6e7-205d-4628-b6ba-de2721f5c2ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsTables" xlink:type="simple" xlink:href="biib-20250930.xsd#AcquisitionsTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AcquisitionsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_5e7f2cd0-f288-4a6e-b6d9-0881a8b400d2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_bb28d581-7914-4b1c-a85c-1d5525fd727f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_5e7f2cd0-f288-4a6e-b6d9-0881a8b400d2" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_bb28d581-7914-4b1c-a85c-1d5525fd727f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_a71b1137-8361-45da-aa3d-e06eb7e33abe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_5e7f2cd0-f288-4a6e-b6d9-0881a8b400d2" xlink:to="loc_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_a71b1137-8361-45da-aa3d-e06eb7e33abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTables" xlink:type="simple" xlink:href="biib-20250930.xsd#RestructuringBusinessTransformationandOtherCostSavingInitiativesTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_5b4918bf-5c47-4aa8-8cde-94cfdd70d2f7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_e87d7da4-ee20-414f-a194-6dbb64e3ba9f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_5b4918bf-5c47-4aa8-8cde-94cfdd70d2f7" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_e87d7da4-ee20-414f-a194-6dbb64e3ba9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_e4989b41-e108-4373-9a67-3fea8a4d3b11" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_5b4918bf-5c47-4aa8-8cde-94cfdd70d2f7" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_e4989b41-e108-4373-9a67-3fea8a4d3b11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesTables" xlink:type="simple" xlink:href="biib-20250930.xsd#RevenuesTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a3636f0d-55fa-4f21-b3a5-342367bd1ffd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_e1f4c27a-0d78-4c5b-b711-1b6b91b5035d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a3636f0d-55fa-4f21-b3a5-342367bd1ffd" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_e1f4c27a-0d78-4c5b-b711-1b6b91b5035d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_7a65de7a-ebbd-4d29-b450-5c0ce1dca30e" xlink:href="biib-20250930.xsd#biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a3636f0d-55fa-4f21-b3a5-342367bd1ffd" xlink:to="loc_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock_7a65de7a-ebbd-4d29-b450-5c0ce1dca30e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_4ed9c883-10bc-44e8-b5fe-40b57a32d88a" xlink:href="biib-20250930.xsd#biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a3636f0d-55fa-4f21-b3a5-342367bd1ffd" xlink:to="loc_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock_4ed9c883-10bc-44e8-b5fe-40b57a32d88a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_2da99637-c429-44f7-8f6b-c18da2cde9c0" xlink:href="biib-20250930.xsd#biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a3636f0d-55fa-4f21-b3a5-342367bd1ffd" xlink:to="loc_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock_2da99637-c429-44f7-8f6b-c18da2cde9c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesTableTextBlock_460a60bb-e6b5-47a9-ae4e-9b76d07fc45f" xlink:href="biib-20250930.xsd#biib_OtherrevenuesTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_a3636f0d-55fa-4f21-b3a5-342367bd1ffd" xlink:to="loc_biib_OtherrevenuesTableTextBlock_460a60bb-e6b5-47a9-ae4e-9b76d07fc45f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryTables" xlink:type="simple" xlink:href="biib-20250930.xsd#InventoryTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_9104f9df-a91b-4fa4-8050-7c9289d9d54f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_506175c3-249e-43b9-8364-26a5eac3bf92" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_9104f9df-a91b-4fa4-8050-7c9289d9d54f" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_506175c3-249e-43b9-8364-26a5eac3bf92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables" xlink:type="simple" xlink:href="biib-20250930.xsd#IntangibleAssetsandGoodwillTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6b6a37fe-cd0b-4964-a3c3-324a6753aa06" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_8c5b5390-144b-4493-bd19-784d3e0b7065" xlink:href="biib-20250930.xsd#biib_IntangibleAssetsExcludingGoodwillTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6b6a37fe-cd0b-4964-a3c3-324a6753aa06" xlink:to="loc_biib_IntangibleAssetsExcludingGoodwillTableTextBlock_8c5b5390-144b-4493-bd19-784d3e0b7065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_5c7dd05e-0f92-4c46-8384-ccb209c32abc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6b6a37fe-cd0b-4964-a3c3-324a6753aa06" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_5c7dd05e-0f92-4c46-8384-ccb209c32abc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_80614a44-e638-4fa9-9b06-b4c8ca44a874" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6b6a37fe-cd0b-4964-a3c3-324a6753aa06" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_80614a44-e638-4fa9-9b06-b4c8ca44a874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="biib-20250930.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_8455fb59-8963-416f-b813-aa9a50e9b261" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_43066505-ab1b-4c70-a6c3-6815f56e1e73" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8455fb59-8963-416f-b813-aa9a50e9b261" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_43066505-ab1b-4c70-a6c3-6815f56e1e73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_ee0faedc-c8e4-4ec9-8fdf-442d5fab193a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8455fb59-8963-416f-b813-aa9a50e9b261" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_ee0faedc-c8e4-4ec9-8fdf-442d5fab193a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_a98d3f9e-790e-4898-b83d-744c4d27d4a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8455fb59-8963-416f-b813-aa9a50e9b261" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_a98d3f9e-790e-4898-b83d-744c4d27d4a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_8001c34c-ee89-4d6b-82a0-f0401bf4c5d1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_8455fb59-8963-416f-b813-aa9a50e9b261" xlink:to="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_8001c34c-ee89-4d6b-82a0-f0401bf4c5d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="simple" xlink:href="biib-20250930.xsd#FinancialInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c4e8afd1-0a6b-49a2-9203-43979792e1dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_a34d4559-d0d1-4613-9fbe-730c099b0296" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c4e8afd1-0a6b-49a2-9203-43979792e1dd" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_a34d4559-d0d1-4613-9fbe-730c099b0296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_ce1ce07f-d8dc-4931-9065-0fc104f9c07d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c4e8afd1-0a6b-49a2-9203-43979792e1dd" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_ce1ce07f-d8dc-4931-9065-0fc104f9c07d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="simple" xlink:href="biib-20250930.xsd#DerivativeInstrumentsTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_7c690e7b-bd01-4b48-9b0a-3893642835f9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_f7699484-4be0-4562-a879-c3fe802dd43c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_7c690e7b-bd01-4b48-9b0a-3893642835f9" xlink:to="loc_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock_f7699484-4be0-4562-a879-c3fe802dd43c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock_63afbbf6-d354-44b4-944a-5655754d2b9c" xlink:href="biib-20250930.xsd#biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_7c690e7b-bd01-4b48-9b0a-3893642835f9" xlink:to="loc_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock_63afbbf6-d354-44b4-944a-5655754d2b9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_c53d73eb-0850-4930-b307-dac7d6f42562" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_7c690e7b-bd01-4b48-9b0a-3893642835f9" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_c53d73eb-0850-4930-b307-dac7d6f42562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_763ff517-4663-4951-a850-f7e741adc8b1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_7c690e7b-bd01-4b48-9b0a-3893642835f9" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_763ff517-4663-4951-a850-f7e741adc8b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityTables" xlink:type="simple" xlink:href="biib-20250930.xsd#EquityTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_69d1c9ca-295d-48e8-a43f-949a13da89c4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_b5a04d2c-553a-4c0c-a273-b31ec84a8337" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_69d1c9ca-295d-48e8-a43f-949a13da89c4" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_b5a04d2c-553a-4c0c-a273-b31ec84a8337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_3bf834f9-84c1-4662-90e7-ee0e35721fd8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_69d1c9ca-295d-48e8-a43f-949a13da89c4" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock_3bf834f9-84c1-4662-90e7-ee0e35721fd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsperShareTables" xlink:type="simple" xlink:href="biib-20250930.xsd#EarningsperShareTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EarningsperShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_426e45c3-18a1-4638-b847-4d7326147014" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_891db44b-797f-4545-ba84-50934457c870" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_426e45c3-18a1-4638-b847-4d7326147014" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_891db44b-797f-4545-ba84-50934457c870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="simple" xlink:href="biib-20250930.xsd#ShareBasedPaymentsTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b20b3f31-68f8-4b58-b70a-54886072c787" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_96aaec1e-9b6c-4032-8caa-1286f8a67801" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b20b3f31-68f8-4b58-b70a-54886072c787" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_96aaec1e-9b6c-4032-8caa-1286f8a67801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_9a50e410-c9d1-4ccf-a67b-73b749b37f0c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b20b3f31-68f8-4b58-b70a-54886072c787" xlink:to="loc_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_9a50e410-c9d1-4ccf-a67b-73b749b37f0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="biib-20250930.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_6cea05cf-ea5b-44ff-aacb-eff9b745fbda" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_a60f5317-4266-4ce9-9022-b2f69f550e3c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6cea05cf-ea5b-44ff-aacb-eff9b745fbda" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_a60f5317-4266-4ce9-9022-b2f69f550e3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="simple" xlink:href="biib-20250930.xsd#OtherConsolidatedFinancialStatementDetailTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_87bfd42f-e9b1-4d0d-b871-0715fa2fc85c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_290dbf42-3232-46c9-99a5-fc93c7922fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_87bfd42f-e9b1-4d0d-b871-0715fa2fc85c" xlink:to="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_290dbf42-3232-46c9-99a5-fc93c7922fcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestmentsTextBlock_3cebcf1b-8c59-46d9-9883-899e699517ef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnInvestmentsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_87bfd42f-e9b1-4d0d-b871-0715fa2fc85c" xlink:to="loc_us-gaap_GainLossOnInvestmentsTextBlock_3cebcf1b-8c59-46d9-9883-899e699517ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_6df6f185-3c64-4d75-81a5-a5954364e655" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_87bfd42f-e9b1-4d0d-b871-0715fa2fc85c" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_6df6f185-3c64-4d75-81a5-a5954364e655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables" xlink:type="simple" xlink:href="biib-20250930.xsd#CollaborativeandOtherRelationshipsTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2f0fae28-6a93-49f9-9bc5-db966b5c5c62" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CoPromotionProfitSharingFormulaTableTextBlock_0478d58e-616a-40b0-8ee3-706bdf48af0e" xlink:href="biib-20250930.xsd#biib_CoPromotionProfitSharingFormulaTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2f0fae28-6a93-49f9-9bc5-db966b5c5c62" xlink:to="loc_biib_CoPromotionProfitSharingFormulaTableTextBlock_0478d58e-616a-40b0-8ee3-706bdf48af0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_de51ed5f-987b-42a2-ada0-0512f89e3389" xlink:href="biib-20250930.xsd#biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2f0fae28-6a93-49f9-9bc5-db966b5c5c62" xlink:to="loc_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock_de51ed5f-987b-42a2-ada0-0512f89e3389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock_1ec2477c-9dd2-4eff-8137-fdc3ff656121" xlink:href="biib-20250930.xsd#biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2f0fae28-6a93-49f9-9bc5-db966b5c5c62" xlink:to="loc_biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock_1ec2477c-9dd2-4eff-8137-fdc3ff656121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock_c385f93a-1214-4611-bc6a-7efd9f6b6666" xlink:href="biib-20250930.xsd#biib_SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2f0fae28-6a93-49f9-9bc5-db966b5c5c62" xlink:to="loc_biib_SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock_c385f93a-1214-4611-bc6a-7efd9f6b6666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock_e16fdd60-a9cc-43c7-a02b-1d09b0292cc4" xlink:href="biib-20250930.xsd#biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2f0fae28-6a93-49f9-9bc5-db966b5c5c62" xlink:to="loc_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock_e16fdd60-a9cc-43c7-a02b-1d09b0292cc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfActivityRelatedToCollaborationTableTextBlock_f9f6b146-e16f-47ce-afbe-debc0368eb3e" xlink:href="biib-20250930.xsd#biib_SummaryOfActivityRelatedToCollaborationTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2f0fae28-6a93-49f9-9bc5-db966b5c5c62" xlink:to="loc_biib_SummaryOfActivityRelatedToCollaborationTableTextBlock_f9f6b146-e16f-47ce-afbe-debc0368eb3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SegmentInformationTables" xlink:type="simple" xlink:href="biib-20250930.xsd#SegmentInformationTables"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SegmentInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_5f4d0647-cd02-423e-abbb-6e65422a24b5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_e0d884c2-95a3-4a9e-93a8-f234309e92d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_5f4d0647-cd02-423e-abbb-6e65422a24b5" xlink:to="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_e0d884c2-95a3-4a9e-93a8-f234309e92d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5b23c148-23e5-482d-86ab-afbf4d5db576" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_7af98541-2419-4c45-8872-177b61f9fefd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5b23c148-23e5-482d-86ab-afbf4d5db576" xlink:to="loc_us-gaap_NumberOfReportableSegments_7af98541-2419-4c45-8872-177b61f9fefd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InterestInSubsidiary_256d5e97-79e9-4994-b935-64caf9c5669e" xlink:href="biib-20250930.xsd#biib_InterestInSubsidiary"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5b23c148-23e5-482d-86ab-afbf4d5db576" xlink:to="loc_biib_InterestInSubsidiary_256d5e97-79e9-4994-b935-64caf9c5669e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsNarrativeDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#AcquisitionsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AcquisitionsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_e94d8b7f-317a-4d75-8eaf-afdcf0adf513" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7e7e98b1-e67d-4d84-9084-5dfe0afd3d77" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_e94d8b7f-317a-4d75-8eaf-afdcf0adf513" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7e7e98b1-e67d-4d84-9084-5dfe0afd3d77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_690c8bf5-203c-4b11-b3be-1400a0b7a6cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7e7e98b1-e67d-4d84-9084-5dfe0afd3d77" xlink:to="loc_us-gaap_AssetAcquisitionAxis_690c8bf5-203c-4b11-b3be-1400a0b7a6cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_9421ca58-c6d8-47bc-9ceb-a57b5a9a530f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_690c8bf5-203c-4b11-b3be-1400a0b7a6cc" xlink:to="loc_us-gaap_AssetAcquisitionDomain_9421ca58-c6d8-47bc-9ceb-a57b5a9a530f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AlcyoneTherapeuticsInc.Member_6f01e371-7a40-4170-9555-4217737931a9" xlink:href="biib-20250930.xsd#biib_AlcyoneTherapeuticsInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_9421ca58-c6d8-47bc-9ceb-a57b5a9a530f" xlink:to="loc_biib_AlcyoneTherapeuticsInc.Member_6f01e371-7a40-4170-9555-4217737931a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_3c89c7a0-c820-4b16-8484-54d815e83b5d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7e7e98b1-e67d-4d84-9084-5dfe0afd3d77" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_3c89c7a0-c820-4b16-8484-54d815e83b5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_41a75bf6-dfb6-4323-9505-cffa5baa8cbd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_3c89c7a0-c820-4b16-8484-54d815e83b5d" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_41a75bf6-dfb6-4323-9505-cffa5baa8cbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_HumanImmunologyBiosciencesMember_92d2a8d3-f0da-47ef-bd36-0e89e5462347" xlink:href="biib-20250930.xsd#biib_HumanImmunologyBiosciencesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_41a75bf6-dfb6-4323-9505-cffa5baa8cbd" xlink:to="loc_biib_HumanImmunologyBiosciencesMember_92d2a8d3-f0da-47ef-bd36-0e89e5462347" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementAxis_19b8fef3-56b4-4638-b8b9-9eb3b4c36f93" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7e7e98b1-e67d-4d84-9084-5dfe0afd3d77" xlink:to="loc_srt_RestatementAxis_19b8fef3-56b4-4638-b8b9-9eb3b4c36f93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RestatementDomain_eaba02b5-6981-4ce5-aa6b-237cb5bd736f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RestatementDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementAxis_19b8fef3-56b4-4638-b8b9-9eb3b4c36f93" xlink:to="loc_srt_RestatementDomain_eaba02b5-6981-4ce5-aa6b-237cb5bd736f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioPreviouslyReportedMember_894b4115-2486-42ad-b85b-71cb4cf93adf" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioPreviouslyReportedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RestatementDomain_eaba02b5-6981-4ce5-aa6b-237cb5bd736f" xlink:to="loc_srt_ScenarioPreviouslyReportedMember_894b4115-2486-42ad-b85b-71cb4cf93adf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_6d4724d2-f0e8-4cb4-9a7e-22a9eb4d7896" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7e7e98b1-e67d-4d84-9084-5dfe0afd3d77" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_6d4724d2-f0e8-4cb4-9a7e-22a9eb4d7896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c761baf8-e8a3-49cb-8402-cc375a82484a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6d4724d2-f0e8-4cb4-9a7e-22a9eb4d7896" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c761baf8-e8a3-49cb-8402-cc375a82484a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b6568bf3-a5f6-4e1b-b394-9f5e41573323" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c761baf8-e8a3-49cb-8402-cc375a82484a" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b6568bf3-a5f6-4e1b-b394-9f5e41573323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_17003101-6e72-43b0-93b5-4f2d6eb9e34c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c761baf8-e8a3-49cb-8402-cc375a82484a" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_17003101-6e72-43b0-93b5-4f2d6eb9e34c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_61c8e071-6524-4141-a83d-ab03b532f29d" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7e7e98b1-e67d-4d84-9084-5dfe0afd3d77" xlink:to="loc_srt_RangeAxis_61c8e071-6524-4141-a83d-ab03b532f29d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_752ea745-e902-4a43-8658-f44598e69684" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_61c8e071-6524-4141-a83d-ab03b532f29d" xlink:to="loc_srt_RangeMember_752ea745-e902-4a43-8658-f44598e69684" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5ddb765c-149c-41f9-8eee-55bf759efd90" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_752ea745-e902-4a43-8658-f44598e69684" xlink:to="loc_srt_MinimumMember_5ddb765c-149c-41f9-8eee-55bf759efd90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_2f02f4db-d599-42c2-abc2-339a0770a0e4" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_752ea745-e902-4a43-8658-f44598e69684" xlink:to="loc_srt_MaximumMember_2f02f4db-d599-42c2-abc2-339a0770a0e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_88b12faa-2aea-4094-af93-a711ac9c5fc8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7e7e98b1-e67d-4d84-9084-5dfe0afd3d77" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_88b12faa-2aea-4094-af93-a711ac9c5fc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_32d2bc1e-64e7-4075-94d7-cd93c7845b06" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_88b12faa-2aea-4094-af93-a711ac9c5fc8" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_32d2bc1e-64e7-4075-94d7-cd93c7845b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_840e77fd-c432-4d7e-97e1-4592258a0564" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_32d2bc1e-64e7-4075-94d7-cd93c7845b06" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_840e77fd-c432-4d7e-97e1-4592258a0564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MeasurementInputProbabilityRateMember_80c82bb1-123d-4373-b23d-9542e9d7638e" xlink:href="biib-20250930.xsd#biib_MeasurementInputProbabilityRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_32d2bc1e-64e7-4075-94d7-cd93c7845b06" xlink:to="loc_biib_MeasurementInputProbabilityRateMember_80c82bb1-123d-4373-b23d-9542e9d7638e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_c587ee3e-383f-4384-a5a4-d8f52b75b4ce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7e7e98b1-e67d-4d84-9084-5dfe0afd3d77" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_c587ee3e-383f-4384-a5a4-d8f52b75b4ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_8f2803d2-197f-40aa-ad21-790356b228ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_c587ee3e-383f-4384-a5a4-d8f52b75b4ce" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_8f2803d2-197f-40aa-ad21-790356b228ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Phase3ClinicalTrialFelzartamabOneMember_6f06a6d8-f529-410d-b000-284b8fb860fb" xlink:href="biib-20250930.xsd#biib_Phase3ClinicalTrialFelzartamabOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_8f2803d2-197f-40aa-ad21-790356b228ea" xlink:to="loc_biib_Phase3ClinicalTrialFelzartamabOneMember_6f06a6d8-f529-410d-b000-284b8fb860fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Phase3ClinicalTrialFelzartamabTwoMember_3cdf54ff-c5d4-4a14-9eea-3ad04385c18c" xlink:href="biib-20250930.xsd#biib_Phase3ClinicalTrialFelzartamabTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_8f2803d2-197f-40aa-ad21-790356b228ea" xlink:to="loc_biib_Phase3ClinicalTrialFelzartamabTwoMember_3cdf54ff-c5d4-4a14-9eea-3ad04385c18c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Phase3ClinicalTrialFelzartamabAMRMember_82dae44e-af08-4a6a-97c2-3be697df4501" xlink:href="biib-20250930.xsd#biib_Phase3ClinicalTrialFelzartamabAMRMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_8f2803d2-197f-40aa-ad21-790356b228ea" xlink:to="loc_biib_Phase3ClinicalTrialFelzartamabAMRMember_82dae44e-af08-4a6a-97c2-3be697df4501" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Phase3ClinicalTrialFelzartamabIgANMember_d9bf0d05-a7bc-4fac-8ed8-35cf84d77271" xlink:href="biib-20250930.xsd#biib_Phase3ClinicalTrialFelzartamabIgANMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_8f2803d2-197f-40aa-ad21-790356b228ea" xlink:to="loc_biib_Phase3ClinicalTrialFelzartamabIgANMember_d9bf0d05-a7bc-4fac-8ed8-35cf84d77271" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MilestonePaymentFutureDevelopmentMember_01b08581-a1f8-448c-8166-487bb13ae14c" xlink:href="biib-20250930.xsd#biib_MilestonePaymentFutureDevelopmentMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_8f2803d2-197f-40aa-ad21-790356b228ea" xlink:to="loc_biib_MilestonePaymentFutureDevelopmentMember_01b08581-a1f8-448c-8166-487bb13ae14c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MilestonePaymentRegulatoryMember_601a28e7-7843-46cc-92f1-9d73bbc7b016" xlink:href="biib-20250930.xsd#biib_MilestonePaymentRegulatoryMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_8f2803d2-197f-40aa-ad21-790356b228ea" xlink:to="loc_biib_MilestonePaymentRegulatoryMember_601a28e7-7843-46cc-92f1-9d73bbc7b016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MilestonePaymentCommercialMember_ec785440-9dab-4634-8a30-60d6073baf26" xlink:href="biib-20250930.xsd#biib_MilestonePaymentCommercialMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_8f2803d2-197f-40aa-ad21-790356b228ea" xlink:to="loc_biib_MilestonePaymentCommercialMember_ec785440-9dab-4634-8a30-60d6073baf26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_93c41c48-827d-4e9f-a884-924bf799b7de" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7e7e98b1-e67d-4d84-9084-5dfe0afd3d77" xlink:to="loc_srt_ProductOrServiceAxis_93c41c48-827d-4e9f-a884-924bf799b7de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_bdd2bae7-40a1-438b-a396-110968cee7c8" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_93c41c48-827d-4e9f-a884-924bf799b7de" xlink:to="loc_srt_ProductsAndServicesDomain_bdd2bae7-40a1-438b-a396-110968cee7c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FelzartamabAndIzastobartHIB210Member_496fb3be-6151-4da4-af7d-9fed67b7977f" xlink:href="biib-20250930.xsd#biib_FelzartamabAndIzastobartHIB210Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_bdd2bae7-40a1-438b-a396-110968cee7c8" xlink:to="loc_biib_FelzartamabAndIzastobartHIB210Member_496fb3be-6151-4da4-af7d-9fed67b7977f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FelzartamabIgANMember_935acb56-ff7e-4914-8f8e-f5c7389e1ebd" xlink:href="biib-20250930.xsd#biib_FelzartamabIgANMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_bdd2bae7-40a1-438b-a396-110968cee7c8" xlink:to="loc_biib_FelzartamabIgANMember_935acb56-ff7e-4914-8f8e-f5c7389e1ebd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FelzartamabAMRMember_828c5b93-39c5-45e6-a608-98da26648bec" xlink:href="biib-20250930.xsd#biib_FelzartamabAMRMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_bdd2bae7-40a1-438b-a396-110968cee7c8" xlink:to="loc_biib_FelzartamabAMRMember_828c5b93-39c5-45e6-a608-98da26648bec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FelzartamabPMNMember_4d112cec-9324-405a-9603-63b5b5d07437" xlink:href="biib-20250930.xsd#biib_FelzartamabPMNMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_bdd2bae7-40a1-438b-a396-110968cee7c8" xlink:to="loc_biib_FelzartamabPMNMember_4d112cec-9324-405a-9603-63b5b5d07437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_3530620a-9590-44d7-adcd-178cd053d78f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7e7e98b1-e67d-4d84-9084-5dfe0afd3d77" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_3530620a-9590-44d7-adcd-178cd053d78f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_37caa68a-a645-4d71-81fa-2c8338b2baf1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_3530620a-9590-44d7-adcd-178cd053d78f" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_37caa68a-a645-4d71-81fa-2c8338b2baf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_HumanImmunologyBiosciencesPreExistingInLicenseCommitmentsMember_fabe672b-a9b4-4e04-97b4-fe781feaf843" xlink:href="biib-20250930.xsd#biib_HumanImmunologyBiosciencesPreExistingInLicenseCommitmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_37caa68a-a645-4d71-81fa-2c8338b2baf1" xlink:to="loc_biib_HumanImmunologyBiosciencesPreExistingInLicenseCommitmentsMember_fabe672b-a9b4-4e04-97b4-fe781feaf843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_27c2d4f3-f13b-410a-9d39-b79aa022e14b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7e7e98b1-e67d-4d84-9084-5dfe0afd3d77" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_27c2d4f3-f13b-410a-9d39-b79aa022e14b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_aa008903-99ad-4a4d-b3b5-f9ed9af39bf5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_27c2d4f3-f13b-410a-9d39-b79aa022e14b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_aa008903-99ad-4a4d-b3b5-f9ed9af39bf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_19ebb11b-072a-43eb-aa8b-3c50a3d4e4df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_aa008903-99ad-4a4d-b3b5-f9ed9af39bf5" xlink:to="loc_us-gaap_SubsequentEventMember_19ebb11b-072a-43eb-aa8b-3c50a3d4e4df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_f7d67cd1-3cd1-4159-aaca-2d8c9b582bbf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7e7e98b1-e67d-4d84-9084-5dfe0afd3d77" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_f7d67cd1-3cd1-4159-aaca-2d8c9b582bbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_d56b93ba-0291-4ecf-93e1-71aca12f1c69" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f7d67cd1-3cd1-4159-aaca-2d8c9b582bbf" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_d56b93ba-0291-4ecf-93e1-71aca12f1c69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentOwnedAtCost_9dc93466-259f-44bf-8ee9-1e8a822a2c8c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentOwnedAtCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f7d67cd1-3cd1-4159-aaca-2d8c9b582bbf" xlink:to="loc_us-gaap_InvestmentOwnedAtCost_9dc93466-259f-44bf-8ee9-1e8a822a2c8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_532785a9-13f2-4e50-b2b4-7ba1f1bf2893" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f7d67cd1-3cd1-4159-aaca-2d8c9b582bbf" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_532785a9-13f2-4e50-b2b4-7ba1f1bf2893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_a0effd61-55e2-455f-a53d-b4b9a65a0e45" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f7d67cd1-3cd1-4159-aaca-2d8c9b582bbf" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_a0effd61-55e2-455f-a53d-b4b9a65a0e45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsToAcquireBusinessGrossNonVestedEquityAwards_262cdbcc-afa8-46ad-9a32-ffc9736080c8" xlink:href="biib-20250930.xsd#biib_PaymentsToAcquireBusinessGrossNonVestedEquityAwards"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f7d67cd1-3cd1-4159-aaca-2d8c9b582bbf" xlink:to="loc_biib_PaymentsToAcquireBusinessGrossNonVestedEquityAwards_262cdbcc-afa8-46ad-9a32-ffc9736080c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_1b8d6a2a-bb46-4f7b-982d-0df3c990dd78" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f7d67cd1-3cd1-4159-aaca-2d8c9b582bbf" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_1b8d6a2a-bb46-4f7b-982d-0df3c990dd78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationConsiderationTransferredWorkingCapitalAdjustment_b61db1ab-a4d4-4edc-bad5-d2f80ce28e15" xlink:href="biib-20250930.xsd#biib_BusinessCombinationConsiderationTransferredWorkingCapitalAdjustment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f7d67cd1-3cd1-4159-aaca-2d8c9b582bbf" xlink:to="loc_biib_BusinessCombinationConsiderationTransferredWorkingCapitalAdjustment_b61db1ab-a4d4-4edc-bad5-d2f80ce28e15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_96e99efd-c6f0-4369-b7c8-6cc4ef2d9834" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f7d67cd1-3cd1-4159-aaca-2d8c9b582bbf" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_96e99efd-c6f0-4369-b7c8-6cc4ef2d9834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_72fbe50f-ac2f-4462-a1c2-b156bb0f1713" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f7d67cd1-3cd1-4159-aaca-2d8c9b582bbf" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_72fbe50f-ac2f-4462-a1c2-b156bb0f1713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_dade706f-fa85-43f5-9d03-af1411382084" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f7d67cd1-3cd1-4159-aaca-2d8c9b582bbf" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_dade706f-fa85-43f5-9d03-af1411382084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_56a5008b-ad82-4ce2-a20c-23e76574a108" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f7d67cd1-3cd1-4159-aaca-2d8c9b582bbf" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_56a5008b-ad82-4ce2-a20c-23e76574a108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_74b89006-2bdb-436c-9f92-d77a15c877c1" xlink:href="biib-20250930.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f7d67cd1-3cd1-4159-aaca-2d8c9b582bbf" xlink:to="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_74b89006-2bdb-436c-9f92-d77a15c877c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_ea089e34-fcbf-4994-8daa-2fd4ec8e4df3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f7d67cd1-3cd1-4159-aaca-2d8c9b582bbf" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_ea089e34-fcbf-4994-8daa-2fd4ec8e4df3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IntangibleAssetMeasurementInput_a2330d4a-f995-492c-9b0a-e58bae684ee9" xlink:href="biib-20250930.xsd#biib_IntangibleAssetMeasurementInput"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f7d67cd1-3cd1-4159-aaca-2d8c9b582bbf" xlink:to="loc_biib_IntangibleAssetMeasurementInput_a2330d4a-f995-492c-9b0a-e58bae684ee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_8bd899cc-2a42-45eb-92d6-e520ef620b3d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f7d67cd1-3cd1-4159-aaca-2d8c9b582bbf" xlink:to="loc_us-gaap_Goodwill_8bd899cc-2a42-45eb-92d6-e520ef620b3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_37b0e47b-66b3-4374-a8f4-12dbe7b12aed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_f7d67cd1-3cd1-4159-aaca-2d8c9b582bbf" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_37b0e47b-66b3-4374-a8f4-12dbe7b12aed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsPurchasePriceConsiderationDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#AcquisitionsPurchasePriceConsiderationDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AcquisitionsPurchasePriceConsiderationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_0ab012e7-b00f-4bca-9cbe-3f0fddc0a114" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ea229f88-3c72-4f3d-95c8-455cb958535b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_0ab012e7-b00f-4bca-9cbe-3f0fddc0a114" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ea229f88-3c72-4f3d-95c8-455cb958535b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_a99c29cb-87fb-44ed-a14b-e6f3f7b23040" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ea229f88-3c72-4f3d-95c8-455cb958535b" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_a99c29cb-87fb-44ed-a14b-e6f3f7b23040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ae7b455a-0b7d-4dbd-8cd0-045eb5a9cdd1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_a99c29cb-87fb-44ed-a14b-e6f3f7b23040" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ae7b455a-0b7d-4dbd-8cd0-045eb5a9cdd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_HumanImmunologyBiosciencesMember_dfdfaf8e-e149-48d5-83f2-84ae9aedcb5c" xlink:href="biib-20250930.xsd#biib_HumanImmunologyBiosciencesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ae7b455a-0b7d-4dbd-8cd0-045eb5a9cdd1" xlink:to="loc_biib_HumanImmunologyBiosciencesMember_dfdfaf8e-e149-48d5-83f2-84ae9aedcb5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_60e07ecf-0f6a-42d8-b934-483d5b8e8fcf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_ea229f88-3c72-4f3d-95c8-455cb958535b" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_60e07ecf-0f6a-42d8-b934-483d5b8e8fcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_f8a7ad0a-f625-4204-9f21-cf1492838a67" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_60e07ecf-0f6a-42d8-b934-483d5b8e8fcf" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_f8a7ad0a-f625-4204-9f21-cf1492838a67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_43131edb-6333-410f-8efc-c5401f67f597" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_60e07ecf-0f6a-42d8-b934-483d5b8e8fcf" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_43131edb-6333-410f-8efc-c5401f67f597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_83c4a909-6e7d-420d-8281-f69c1e3dbac2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_60e07ecf-0f6a-42d8-b934-483d5b8e8fcf" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_83c4a909-6e7d-420d-8281-f69c1e3dbac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#AcquisitionsPreliminatyPurchasePriceAllocationDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_6c6cc3dc-b8eb-4b88-b9b1-bfcbdae28da3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f1835275-8d78-4ce3-8c69-cbebffcdc299" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_6c6cc3dc-b8eb-4b88-b9b1-bfcbdae28da3" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f1835275-8d78-4ce3-8c69-cbebffcdc299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1e313502-03e7-4a90-9654-0b8c3293e3c4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f1835275-8d78-4ce3-8c69-cbebffcdc299" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1e313502-03e7-4a90-9654-0b8c3293e3c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fb61c96d-d5c6-45ab-835f-1c3b4c61e513" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1e313502-03e7-4a90-9654-0b8c3293e3c4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fb61c96d-d5c6-45ab-835f-1c3b4c61e513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_HumanImmunologyBiosciencesMember_55254a21-8aa2-456f-aac5-562139c1d6b0" xlink:href="biib-20250930.xsd#biib_HumanImmunologyBiosciencesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fb61c96d-d5c6-45ab-835f-1c3b4c61e513" xlink:to="loc_biib_HumanImmunologyBiosciencesMember_55254a21-8aa2-456f-aac5-562139c1d6b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b927ac48-e36b-4665-a283-6fee43b61012" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f1835275-8d78-4ce3-8c69-cbebffcdc299" xlink:to="loc_srt_ProductOrServiceAxis_b927ac48-e36b-4665-a283-6fee43b61012" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_279c900a-79e0-4b23-b78c-1cf53024c338" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_b927ac48-e36b-4665-a283-6fee43b61012" xlink:to="loc_srt_ProductsAndServicesDomain_279c900a-79e0-4b23-b78c-1cf53024c338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FelzartamabIgANMember_4b95ee88-2680-416e-9e9c-d705118bf251" xlink:href="biib-20250930.xsd#biib_FelzartamabIgANMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_279c900a-79e0-4b23-b78c-1cf53024c338" xlink:to="loc_biib_FelzartamabIgANMember_4b95ee88-2680-416e-9e9c-d705118bf251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FelzartamabAMRMember_320bfb74-1328-4b0c-bfb9-c78ab380f110" xlink:href="biib-20250930.xsd#biib_FelzartamabAMRMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_279c900a-79e0-4b23-b78c-1cf53024c338" xlink:to="loc_biib_FelzartamabAMRMember_320bfb74-1328-4b0c-bfb9-c78ab380f110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FelzartamabPMNMember_efac30a9-7b06-4e7e-9c6d-67c8c796c75f" xlink:href="biib-20250930.xsd#biib_FelzartamabPMNMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_279c900a-79e0-4b23-b78c-1cf53024c338" xlink:to="loc_biib_FelzartamabPMNMember_efac30a9-7b06-4e7e-9c6d-67c8c796c75f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_58e43337-f981-485f-823d-c30bb49c67fa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f1835275-8d78-4ce3-8c69-cbebffcdc299" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_58e43337-f981-485f-823d-c30bb49c67fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_dadcc16a-eba3-48db-8adf-1e84c4cd1138" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_58e43337-f981-485f-823d-c30bb49c67fa" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_dadcc16a-eba3-48db-8adf-1e84c4cd1138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_2014d73a-be84-4887-b1af-77285ab5021e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_dadcc16a-eba3-48db-8adf-1e84c4cd1138" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_2014d73a-be84-4887-b1af-77285ab5021e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherClinicalProgramsMember_fadc1ab2-60cd-4b7d-9593-f7d324d63bf1" xlink:href="biib-20250930.xsd#biib_OtherClinicalProgramsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_dadcc16a-eba3-48db-8adf-1e84c4cd1138" xlink:to="loc_biib_OtherClinicalProgramsMember_fadc1ab2-60cd-4b7d-9593-f7d324d63bf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_bad494bc-85df-4584-a49a-a818b1ef1f8a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_f1835275-8d78-4ce3-8c69-cbebffcdc299" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_bad494bc-85df-4584-a49a-a818b1ef1f8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_a77202af-3b0f-45c6-b964-0dff620f7962" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bad494bc-85df-4584-a49a-a818b1ef1f8a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_a77202af-3b0f-45c6-b964-0dff620f7962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_ae82d449-79f5-47f8-af0d-3faeb28ec455" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bad494bc-85df-4584-a49a-a818b1ef1f8a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_ae82d449-79f5-47f8-af0d-3faeb28ec455" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_d8f34be0-d4df-47b1-963e-fea912207f9f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bad494bc-85df-4584-a49a-a818b1ef1f8a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_d8f34be0-d4df-47b1-963e-fea912207f9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets_a01d61c5-4fd7-49e2-ac4b-4ad006e37da3" xlink:href="biib-20250930.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bad494bc-85df-4584-a49a-a818b1ef1f8a" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets_a01d61c5-4fd7-49e2-ac4b-4ad006e37da3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_aea01524-614d-4162-bf22-fb0cd963fc04" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bad494bc-85df-4584-a49a-a818b1ef1f8a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_aea01524-614d-4162-bf22-fb0cd963fc04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities_48556654-32b4-4c03-8135-19e5344ffc98" xlink:href="biib-20250930.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bad494bc-85df-4584-a49a-a818b1ef1f8a" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities_48556654-32b4-4c03-8135-19e5344ffc98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_b23146ab-f516-47a9-9326-cc3dec4745c7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bad494bc-85df-4584-a49a-a818b1ef1f8a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_b23146ab-f516-47a9-9326-cc3dec4745c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities_affa0085-98f8-4123-9bc1-d929d83b8d1b" xlink:href="biib-20250930.xsd#biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bad494bc-85df-4584-a49a-a818b1ef1f8a" xlink:to="loc_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities_affa0085-98f8-4123-9bc1-d929d83b8d1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_5224dd4d-74c2-4fdc-889e-8dd153f33405" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bad494bc-85df-4584-a49a-a818b1ef1f8a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_5224dd4d-74c2-4fdc-889e-8dd153f33405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_c2679f3f-afd1-43be-afc0-a96511c78179" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bad494bc-85df-4584-a49a-a818b1ef1f8a" xlink:to="loc_us-gaap_Goodwill_c2679f3f-afd1-43be-afc0-a96511c78179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_2db7f113-b996-488d-bf90-9137e38b117f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bad494bc-85df-4584-a49a-a818b1ef1f8a" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_2db7f113-b996-488d-bf90-9137e38b117f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpenseAndOther_4c862c54-0a72-4356-a880-71b0b0878245" xlink:href="biib-20250930.xsd#biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpenseAndOther"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bad494bc-85df-4584-a49a-a818b1ef1f8a" xlink:to="loc_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpenseAndOther_4c862c54-0a72-4356-a880-71b0b0878245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability_2c476de9-562a-47e1-8331-bd24c745a3c6" xlink:href="biib-20250930.xsd#biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bad494bc-85df-4584-a49a-a818b1ef1f8a" xlink:to="loc_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability_2c476de9-562a-47e1-8331-bd24c745a3c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill_9835dacd-b699-431d-ae07-9d61933db437" xlink:href="biib-20250930.xsd#biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_bad494bc-85df-4584-a49a-a818b1ef1f8a" xlink:to="loc_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill_9835dacd-b699-431d-ae07-9d61933db437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DispositionsDetailsTextual" xlink:type="simple" xlink:href="biib-20250930.xsd#DispositionsDetailsTextual"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DispositionsDetailsTextual" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_DivestituresAbstract_d1000860-ff86-494c-9ead-8a9955d4c641" xlink:href="biib-20250930.xsd#biib_DivestituresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e04b440f-d5ec-4efe-8063-a3c8434f2d66" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_DivestituresAbstract_d1000860-ff86-494c-9ead-8a9955d4c641" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e04b440f-d5ec-4efe-8063-a3c8434f2d66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_b3059bf5-2b02-481c-8fea-8d66bf2adf8d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e04b440f-d5ec-4efe-8063-a3c8434f2d66" xlink:to="loc_us-gaap_TypeOfArrangementAxis_b3059bf5-2b02-481c-8fea-8d66bf2adf8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cc6fc5a8-27ea-406c-be1e-ccd8e2f82f63" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_b3059bf5-2b02-481c-8fea-8d66bf2adf8d" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cc6fc5a8-27ea-406c-be1e-ccd8e2f82f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_18d9212a-08f2-4d73-aad8-44c6eee23c25" xlink:href="biib-20250930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_cc6fc5a8-27ea-406c-be1e-ccd8e2f82f63" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_18d9212a-08f2-4d73-aad8-44c6eee23c25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f98c9d40-4fda-4c7d-b45b-df070baf1fb7" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e04b440f-d5ec-4efe-8063-a3c8434f2d66" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f98c9d40-4fda-4c7d-b45b-df070baf1fb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_539c6050-b758-4149-ace4-b49520203ccc" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_f98c9d40-4fda-4c7d-b45b-df070baf1fb7" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_539c6050-b758-4149-ace4-b49520203ccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_e859d11f-dcac-44d6-ac26-13e08fdac83e" xlink:href="biib-20250930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_539c6050-b758-4149-ace4-b49520203ccc" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_e859d11f-dcac-44d6-ac26-13e08fdac83e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesAxis_d6c41310-7fc2-48bf-81ef-037d86ff5716" xlink:href="biib-20250930.xsd#biib_FutureContingentMilestoneTypesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e04b440f-d5ec-4efe-8063-a3c8434f2d66" xlink:to="loc_biib_FutureContingentMilestoneTypesAxis_d6c41310-7fc2-48bf-81ef-037d86ff5716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureContingentMilestoneTypesDomain_87e2823c-4321-45d8-961c-1cbfea8b35d1" xlink:href="biib-20250930.xsd#biib_FutureContingentMilestoneTypesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesAxis_d6c41310-7fc2-48bf-81ef-037d86ff5716" xlink:to="loc_biib_FutureContingentMilestoneTypesDomain_87e2823c-4321-45d8-961c-1cbfea8b35d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentDueAtFirstAnniversaryMember_344e80c8-c577-4366-a1a2-a14569852499" xlink:href="biib-20250930.xsd#biib_PaymentDueAtFirstAnniversaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_87e2823c-4321-45d8-961c-1cbfea8b35d1" xlink:to="loc_biib_PaymentDueAtFirstAnniversaryMember_344e80c8-c577-4366-a1a2-a14569852499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentDueAtSecondAnniversaryMember_b7537020-b8e6-4780-9ed2-d791584c6d9d" xlink:href="biib-20250930.xsd#biib_PaymentDueAtSecondAnniversaryMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FutureContingentMilestoneTypesDomain_87e2823c-4321-45d8-961c-1cbfea8b35d1" xlink:to="loc_biib_PaymentDueAtSecondAnniversaryMember_b7537020-b8e6-4780-9ed2-d791584c6d9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a72a1c41-9a2c-4676-9cf8-552c838431ba" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e04b440f-d5ec-4efe-8063-a3c8434f2d66" xlink:to="loc_srt_CounterpartyNameAxis_a72a1c41-9a2c-4676-9cf8-552c838431ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9267bafa-72f0-4284-b6ee-b65e62af8797" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_a72a1c41-9a2c-4676-9cf8-552c838431ba" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9267bafa-72f0-4284-b6ee-b65e62af8797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IonisPharmaceuticalsInc.Member_636b4968-5e56-4659-ba37-24d85aa36cd9" xlink:href="biib-20250930.xsd#biib_IonisPharmaceuticalsInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9267bafa-72f0-4284-b6ee-b65e62af8797" xlink:to="loc_biib_IonisPharmaceuticalsInc.Member_636b4968-5e56-4659-ba37-24d85aa36cd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_67baed22-d951-4d90-a97b-5439a6f2bc13" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_e04b440f-d5ec-4efe-8063-a3c8434f2d66" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_67baed22-d951-4d90-a97b-5439a6f2bc13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_7e514f23-9eb6-4444-a014-dddee40bfae4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_67baed22-d951-4d90-a97b-5439a6f2bc13" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_7e514f23-9eb6-4444-a014-dddee40bfae4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount_3f4fabf6-e38f-47c8-8e05-525628400ca1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentSoldCarryingAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_67baed22-d951-4d90-a97b-5439a6f2bc13" xlink:to="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount_3f4fabf6-e38f-47c8-8e05-525628400ca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture_5e42630a-0c15-4f59-bd08-c7236efcae1a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromDivestitureOfInterestInJointVenture"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_67baed22-d951-4d90-a97b-5439a6f2bc13" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture_5e42630a-0c15-4f59-bd08-c7236efcae1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PayablesToDivestitureOfInterestInJointVenture_ac77362c-fa20-47e2-884d-908bc8f795b0" xlink:href="biib-20250930.xsd#biib_PayablesToDivestitureOfInterestInJointVenture"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_67baed22-d951-4d90-a97b-5439a6f2bc13" xlink:to="loc_biib_PayablesToDivestitureOfInterestInJointVenture_ac77362c-fa20-47e2-884d-908bc8f795b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_51a52fae-e40a-45e7-bf6b-d69d8cccf728" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_67baed22-d951-4d90-a97b-5439a6f2bc13" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_51a52fae-e40a-45e7-bf6b-d69d8cccf728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_afb244d3-c50b-4e6d-8af0-3de25d41bd81" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfIntangibleAssets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_67baed22-d951-4d90-a97b-5439a6f2bc13" xlink:to="loc_us-gaap_ProceedsFromSaleOfIntangibleAssets_afb244d3-c50b-4e6d-8af0-3de25d41bd81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ProceedsPaidToCollaborativeArrangementCounterparty_090a0a53-752d-413c-9491-565c02591b44" xlink:href="biib-20250930.xsd#biib_ProceedsPaidToCollaborativeArrangementCounterparty"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_67baed22-d951-4d90-a97b-5439a6f2bc13" xlink:to="loc_biib_ProceedsPaidToCollaborativeArrangementCounterparty_090a0a53-752d-413c-9491-565c02591b44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_d7e91d85-a9d7-4e5d-afd8-73c898ae6143" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_67baed22-d951-4d90-a97b-5439a6f2bc13" xlink:to="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_d7e91d85-a9d7-4e5d-afd8-73c898ae6143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_4e55549b-b934-4578-8719-11cb91fbb127" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_84d9c36c-ba9e-4a5e-a9a1-8f0d18558ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_4e55549b-b934-4578-8719-11cb91fbb127" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_84d9c36c-ba9e-4a5e-a9a1-8f0d18558ff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_68057f01-a66c-4939-bc08-545750db5095" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_84d9c36c-ba9e-4a5e-a9a1-8f0d18558ff8" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_68057f01-a66c-4939-bc08-545750db5095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9cc45d23-a324-4522-999f-8eab9cf8f027" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_68057f01-a66c-4939-bc08-545750db5095" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9cc45d23-a324-4522-999f-8eab9cf8f027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_6aa047e4-1482-4656-addb-3214f40e9594" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9cc45d23-a324-4522-999f-8eab9cf8f027" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_6aa047e4-1482-4656-addb-3214f40e9594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b185655a-5543-48ca-b468-a37c96059624" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9cc45d23-a324-4522-999f-8eab9cf8f027" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_b185655a-5543-48ca-b468-a37c96059624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember_a4ba561d-a40a-48b5-9004-87cc09203eae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringChargesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9cc45d23-a324-4522-999f-8eab9cf8f027" xlink:to="loc_us-gaap_RestructuringChargesMember_a4ba561d-a40a-48b5-9004-87cc09203eae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_a8009977-a10e-46fb-86ab-b3848267f066" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_84d9c36c-ba9e-4a5e-a9a1-8f0d18558ff8" xlink:to="loc_us-gaap_RestructuringPlanAxis_a8009977-a10e-46fb-86ab-b3848267f066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_71e282d8-4b9f-4d67-9cac-0a6cc841536f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_a8009977-a10e-46fb-86ab-b3848267f066" xlink:to="loc_us-gaap_RestructuringPlanDomain_71e282d8-4b9f-4d67-9cac-0a6cc841536f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2023CostSavingInitiativesMember_b995a1ed-8922-4925-9b11-9ea4171cc72b" xlink:href="biib-20250930.xsd#biib_A2023CostSavingInitiativesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_71e282d8-4b9f-4d67-9cac-0a6cc841536f" xlink:to="loc_biib_A2023CostSavingInitiativesMember_b995a1ed-8922-4925-9b11-9ea4171cc72b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataIntegrationMember_69956d8c-66df-463a-aedb-37879e9d2e26" xlink:href="biib-20250930.xsd#biib_ReataIntegrationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_71e282d8-4b9f-4d67-9cac-0a6cc841536f" xlink:to="loc_biib_ReataIntegrationMember_69956d8c-66df-463a-aedb-37879e9d2e26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_6393a7ef-ab8f-4662-a23a-552538790825" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_84d9c36c-ba9e-4a5e-a9a1-8f0d18558ff8" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_6393a7ef-ab8f-4662-a23a-552538790825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_8902cfba-5d14-4cf0-b81f-5583cc3aadfa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_6393a7ef-ab8f-4662-a23a-552538790825" xlink:to="loc_us-gaap_SeveranceCosts1_8902cfba-5d14-4cf0-b81f-5583cc3aadfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringCosts_fd8fbf69-3f8b-4bee-81ce-20d95153a403" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherRestructuringCosts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_6393a7ef-ab8f-4662-a23a-552538790825" xlink:to="loc_us-gaap_OtherRestructuringCosts_fd8fbf69-3f8b-4bee-81ce-20d95153a403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_cf93ee59-c414-482c-8248-1ae40c4ff55b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_6393a7ef-ab8f-4662-a23a-552538790825" xlink:to="loc_us-gaap_RestructuringCharges_cf93ee59-c414-482c-8248-1ae40c4ff55b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_081aacb2-5d6a-4628-b73e-46e4a6f3d3c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9a6b8ba6-2f53-4485-96fd-bdffe90a1bd9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_081aacb2-5d6a-4628-b73e-46e4a6f3d3c0" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9a6b8ba6-2f53-4485-96fd-bdffe90a1bd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_3a95b401-b218-4549-a3b2-4b9f83ccb3bd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9a6b8ba6-2f53-4485-96fd-bdffe90a1bd9" xlink:to="loc_us-gaap_RestructuringPlanAxis_3a95b401-b218-4549-a3b2-4b9f83ccb3bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_f1aede96-8c1e-410b-bec7-4acd2e99d1f5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_3a95b401-b218-4549-a3b2-4b9f83ccb3bd" xlink:to="loc_us-gaap_RestructuringPlanDomain_f1aede96-8c1e-410b-bec7-4acd2e99d1f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2023CostSavingInitiativesMember_20a91af3-2bff-4df6-9589-416901ce83f8" xlink:href="biib-20250930.xsd#biib_A2023CostSavingInitiativesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_f1aede96-8c1e-410b-bec7-4acd2e99d1f5" xlink:to="loc_biib_A2023CostSavingInitiativesMember_20a91af3-2bff-4df6-9589-416901ce83f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataIntegrationMember_3f548ba6-a459-4785-89f6-719c433566e7" xlink:href="biib-20250930.xsd#biib_ReataIntegrationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_f1aede96-8c1e-410b-bec7-4acd2e99d1f5" xlink:to="loc_biib_ReataIntegrationMember_3f548ba6-a459-4785-89f6-719c433566e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_e7030e15-4fe1-4cc6-8a24-7995e9bf123e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9a6b8ba6-2f53-4485-96fd-bdffe90a1bd9" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_e7030e15-4fe1-4cc6-8a24-7995e9bf123e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e1267ca5-63fb-495e-8bc7-95a6b62a81a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e7030e15-4fe1-4cc6-8a24-7995e9bf123e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e1267ca5-63fb-495e-8bc7-95a6b62a81a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember_0be67af1-24a5-4c2e-a9a5-3d425f9ee1a9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringChargesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_e1267ca5-63fb-495e-8bc7-95a6b62a81a0" xlink:to="loc_us-gaap_RestructuringChargesMember_0be67af1-24a5-4c2e-a9a5-3d425f9ee1a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_02675edc-25a3-4f48-b2e9-ff4defc9b87a" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9a6b8ba6-2f53-4485-96fd-bdffe90a1bd9" xlink:to="loc_srt_RangeAxis_02675edc-25a3-4f48-b2e9-ff4defc9b87a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8207849c-514e-49bc-a82a-4e9b7a4838ff" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_02675edc-25a3-4f48-b2e9-ff4defc9b87a" xlink:to="loc_srt_RangeMember_8207849c-514e-49bc-a82a-4e9b7a4838ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_322145cb-7468-420d-aeda-e4b38610bbe1" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8207849c-514e-49bc-a82a-4e9b7a4838ff" xlink:to="loc_srt_MinimumMember_322145cb-7468-420d-aeda-e4b38610bbe1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_72cf42fe-a650-4ad9-9c1c-16cfc42f1bf2" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8207849c-514e-49bc-a82a-4e9b7a4838ff" xlink:to="loc_srt_MaximumMember_72cf42fe-a650-4ad9-9c1c-16cfc42f1bf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_571f0e69-367f-41ee-bfe6-b4d9c107acc9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9a6b8ba6-2f53-4485-96fd-bdffe90a1bd9" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_571f0e69-367f-41ee-bfe6-b4d9c107acc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_48fc4a14-1a9d-4532-ad93-7b43b36abc3a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_571f0e69-367f-41ee-bfe6-b4d9c107acc9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_48fc4a14-1a9d-4532-ad93-7b43b36abc3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_HumanImmunologyBiosciencesMember_2438091c-eda1-4390-8553-c62be75e2df9" xlink:href="biib-20250930.xsd#biib_HumanImmunologyBiosciencesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_48fc4a14-1a9d-4532-ad93-7b43b36abc3a" xlink:to="loc_biib_HumanImmunologyBiosciencesMember_2438091c-eda1-4390-8553-c62be75e2df9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember_af4d7823-1427-4fa8-9ddb-f299c89650d6" xlink:href="biib-20250930.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_48fc4a14-1a9d-4532-ad93-7b43b36abc3a" xlink:to="loc_biib_ReataPharmaceuticalsIncMember_af4d7823-1427-4fa8-9ddb-f299c89650d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_6ee5054f-83ba-4021-9f5a-60b932230971" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9a6b8ba6-2f53-4485-96fd-bdffe90a1bd9" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_6ee5054f-83ba-4021-9f5a-60b932230971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction_c95820e0-350e-477b-8350-bd65cb726933" xlink:href="biib-20250930.xsd#biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_6ee5054f-83ba-4021-9f5a-60b932230971" xlink:to="loc_biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction_c95820e0-350e-477b-8350-bd65cb726933" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated_e5a74287-92a0-43d5-9616-28e4c8d4d766" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_6ee5054f-83ba-4021-9f5a-60b932230971" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated_e5a74287-92a0-43d5-9616-28e4c8d4d766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeveranceCosts1_043a2cd4-30f2-4bf4-9269-8510fa25ee31" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeveranceCosts1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_6ee5054f-83ba-4021-9f5a-60b932230971" xlink:to="loc_us-gaap_SeveranceCosts1_043a2cd4-30f2-4bf4-9269-8510fa25ee31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1_6ce46798-7c3e-4389-82e2-29c2a0101d3d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_6ee5054f-83ba-4021-9f5a-60b932230971" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1_6ce46798-7c3e-4389-82e2-29c2a0101d3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_9919a836-fbc6-4a34-9358-6772dcb5671d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_6ee5054f-83ba-4021-9f5a-60b932230971" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_9919a836-fbc6-4a34-9358-6772dcb5671d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OperatingLeaseArea_56c4d51f-b435-4cd2-9513-93409e441eb9" xlink:href="biib-20250930.xsd#biib_OperatingLeaseArea"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_6ee5054f-83ba-4021-9f5a-60b932230971" xlink:to="loc_biib_OperatingLeaseArea_56c4d51f-b435-4cd2-9513-93409e441eb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_a23b2cf6-2ec7-4bed-aa74-f025fa8c507f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_6ee5054f-83ba-4021-9f5a-60b932230971" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_a23b2cf6-2ec7-4bed-aa74-f025fa8c507f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_ad3bc5f4-1736-4dab-a803-2a895b2a79b7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8a9f17a7-ffaf-4d10-aaf0-b868b319ddbd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_ad3bc5f4-1736-4dab-a803-2a895b2a79b7" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8a9f17a7-ffaf-4d10-aaf0-b868b319ddbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_1afd214f-fda9-4e2c-accd-30d25392b44d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8a9f17a7-ffaf-4d10-aaf0-b868b319ddbd" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_1afd214f-fda9-4e2c-accd-30d25392b44d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_f5721712-0b23-4d7a-8df5-ba3ed6886f9b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_1afd214f-fda9-4e2c-accd-30d25392b44d" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_f5721712-0b23-4d7a-8df5-ba3ed6886f9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_b666a6ee-c03a-4baf-ad6c-78d558990549" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_f5721712-0b23-4d7a-8df5-ba3ed6886f9b" xlink:to="loc_us-gaap_EmployeeSeveranceMember_b666a6ee-c03a-4baf-ad6c-78d558990549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_22fed26a-8b61-45c7-bf57-8526271c71af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8a9f17a7-ffaf-4d10-aaf0-b868b319ddbd" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_22fed26a-8b61-45c7-bf57-8526271c71af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_b98435bd-d31e-42a2-b9c7-c74806deaec0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_22fed26a-8b61-45c7-bf57-8526271c71af" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_b98435bd-d31e-42a2-b9c7-c74806deaec0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember_8553cbfa-eaaf-4385-90b0-c896e931ca43" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringChargesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_b98435bd-d31e-42a2-b9c7-c74806deaec0" xlink:to="loc_us-gaap_RestructuringChargesMember_8553cbfa-eaaf-4385-90b0-c896e931ca43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_6e5b289c-7c88-4434-931e-87b0e3f61d9c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8a9f17a7-ffaf-4d10-aaf0-b868b319ddbd" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_6e5b289c-7c88-4434-931e-87b0e3f61d9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_629bdf2c-88ed-43b5-ad17-34815ce0e6bf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_6e5b289c-7c88-4434-931e-87b0e3f61d9c" xlink:to="loc_us-gaap_RestructuringCharges_629bdf2c-88ed-43b5-ad17-34815ce0e6bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_b70a52f7-1cea-4a57-bfb5-5563b6a3c412" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5ab65e39-7b03-4092-87c5-81c07e8da125" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_b70a52f7-1cea-4a57-bfb5-5563b6a3c412" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5ab65e39-7b03-4092-87c5-81c07e8da125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_844dbdd3-7b49-437c-b632-17e2627ffe18" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5ab65e39-7b03-4092-87c5-81c07e8da125" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_844dbdd3-7b49-437c-b632-17e2627ffe18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_3e62f831-3395-45a2-8ef4-cbb36d67e1c1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_844dbdd3-7b49-437c-b632-17e2627ffe18" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_3e62f831-3395-45a2-8ef4-cbb36d67e1c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_d2aa9870-a779-4c12-afcf-9adac0506787" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_3e62f831-3395-45a2-8ef4-cbb36d67e1c1" xlink:to="loc_us-gaap_EmployeeSeveranceMember_d2aa9870-a779-4c12-afcf-9adac0506787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_24c6c1e8-00b6-4419-853d-fca7ea622e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5ab65e39-7b03-4092-87c5-81c07e8da125" xlink:to="loc_us-gaap_RestructuringPlanAxis_24c6c1e8-00b6-4419-853d-fca7ea622e8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_d99efd33-db6c-4eff-b9bb-2f52729506cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_24c6c1e8-00b6-4419-853d-fca7ea622e8e" xlink:to="loc_us-gaap_RestructuringPlanDomain_d99efd33-db6c-4eff-b9bb-2f52729506cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2023CostSavingInitiativesMember_7f0d5c71-ed40-4d18-a975-96bfb373853c" xlink:href="biib-20250930.xsd#biib_A2023CostSavingInitiativesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_d99efd33-db6c-4eff-b9bb-2f52729506cc" xlink:to="loc_biib_A2023CostSavingInitiativesMember_7f0d5c71-ed40-4d18-a975-96bfb373853c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2023And2022CostSavingInitiativesMember_c7ee3dc7-9211-4e14-b2b7-92ee4ff3f7aa" xlink:href="biib-20250930.xsd#biib_A2023And2022CostSavingInitiativesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_d99efd33-db6c-4eff-b9bb-2f52729506cc" xlink:to="loc_biib_A2023And2022CostSavingInitiativesMember_c7ee3dc7-9211-4e14-b2b7-92ee4ff3f7aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_e18a4fb0-beba-4030-ad6d-c638cc600aba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_5ab65e39-7b03-4092-87c5-81c07e8da125" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_e18a4fb0-beba-4030-ad6d-c638cc600aba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_6e12e44a-7cd9-4b9f-8233-908e40adfc11" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_e18a4fb0-beba-4030-ad6d-c638cc600aba" xlink:to="loc_us-gaap_RestructuringReserve_6e12e44a-7cd9-4b9f-8233-908e40adfc11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_d7282506-8116-45bd-bf6d-fc853b245d0a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_e18a4fb0-beba-4030-ad6d-c638cc600aba" xlink:to="loc_us-gaap_RestructuringCharges_d7282506-8116-45bd-bf6d-fc853b245d0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRestructuring_58654aaf-5354-49cb-96e6-bc9a27a3c1d0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRestructuring"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_e18a4fb0-beba-4030-ad6d-c638cc600aba" xlink:to="loc_us-gaap_PaymentsForRestructuring_58654aaf-5354-49cb-96e6-bc9a27a3c1d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveTranslationAdjustment_d5255eef-b94a-41c1-b2a3-910ba4a2bb4d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserveTranslationAdjustment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_e18a4fb0-beba-4030-ad6d-c638cc600aba" xlink:to="loc_us-gaap_RestructuringReserveTranslationAdjustment_d5255eef-b94a-41c1-b2a3-910ba4a2bb4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_2aa58fe1-f692-493c-b06b-f2761f22e73b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_e18a4fb0-beba-4030-ad6d-c638cc600aba" xlink:to="loc_us-gaap_RestructuringReserve_2aa58fe1-f692-493c-b06b-f2761f22e73b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#RevenuesRevenuesbyproductDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueAbstract_fea92025-67fe-4dab-911b-9be1ae0bb70f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_f63d7168-da8c-4b2f-ba19-76738d0354a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueAbstract_fea92025-67fe-4dab-911b-9be1ae0bb70f" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_f63d7168-da8c-4b2f-ba19-76738d0354a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0ccfe227-cdec-48c8-b59b-94f785fe4bb1" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_f63d7168-da8c-4b2f-ba19-76738d0354a4" xlink:to="loc_srt_ProductOrServiceAxis_0ccfe227-cdec-48c8-b59b-94f785fe4bb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b7318ba9-81a5-41d5-a548-1d538b7bcaf3" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_0ccfe227-cdec-48c8-b59b-94f785fe4bb1" xlink:to="loc_srt_ProductsAndServicesDomain_b7318ba9-81a5-41d5-a548-1d538b7bcaf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_7b439004-5663-4b81-a01e-0d56f48a22fa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b7318ba9-81a5-41d5-a548-1d538b7bcaf3" xlink:to="loc_us-gaap_ProductMember_7b439004-5663-4b81-a01e-0d56f48a22fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MSProductRevenuesMember_295b8686-a987-4959-8b0f-f80bd755c7ac" xlink:href="biib-20250930.xsd#biib_MSProductRevenuesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_7b439004-5663-4b81-a01e-0d56f48a22fa" xlink:to="loc_biib_MSProductRevenuesMember_295b8686-a987-4959-8b0f-f80bd755c7ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FumarateMember_dd91b5d3-167d-4fea-a755-3a7594466340" xlink:href="biib-20250930.xsd#biib_FumarateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MSProductRevenuesMember_295b8686-a987-4959-8b0f-f80bd755c7ac" xlink:to="loc_biib_FumarateMember_dd91b5d3-167d-4fea-a755-3a7594466340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TECFIDERAMember_204defd6-e93e-4309-a5cb-e56f9b5375c4" xlink:href="biib-20250930.xsd#biib_TECFIDERAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FumarateMember_dd91b5d3-167d-4fea-a755-3a7594466340" xlink:to="loc_biib_TECFIDERAMember_204defd6-e93e-4309-a5cb-e56f9b5375c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_VUMERITYMember_2e53aae3-e0b1-4c2b-bd3b-3d26472be820" xlink:href="biib-20250930.xsd#biib_VUMERITYMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_FumarateMember_dd91b5d3-167d-4fea-a755-3a7594466340" xlink:to="loc_biib_VUMERITYMember_2e53aae3-e0b1-4c2b-bd3b-3d26472be820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InterferonMember_b0f40e0e-d68f-47d6-bbe3-9d283f0f1875" xlink:href="biib-20250930.xsd#biib_InterferonMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_MSProductRevenuesMember_295b8686-a987-4959-8b0f-f80bd755c7ac" xlink:to="loc_biib_InterferonMember_b0f40e0e-d68f-47d6-bbe3-9d283f0f1875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AVONEXMember_8387ac62-b4d2-4041-97ec-1ab5151428e7" xlink:href="biib-20250930.xsd#biib_AVONEXMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InterferonMember_b0f40e0e-d68f-47d6-bbe3-9d283f0f1875" xlink:to="loc_biib_AVONEXMember_8387ac62-b4d2-4041-97ec-1ab5151428e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PLEGRIDYMember_1eab6b52-e09c-41ec-a125-f787a919f998" xlink:href="biib-20250930.xsd#biib_PLEGRIDYMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InterferonMember_b0f40e0e-d68f-47d6-bbe3-9d283f0f1875" xlink:to="loc_biib_PLEGRIDYMember_1eab6b52-e09c-41ec-a125-f787a919f998" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TysabriProductMember_5214f673-ea83-422f-a9c0-b7195487cc8c" xlink:href="biib-20250930.xsd#biib_TysabriProductMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_7b439004-5663-4b81-a01e-0d56f48a22fa" xlink:to="loc_biib_TysabriProductMember_5214f673-ea83-422f-a9c0-b7195487cc8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FAMPYRAMember_44a8ba4d-a1eb-48c9-88d7-7e77441a5369" xlink:href="biib-20250930.xsd#biib_FAMPYRAMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_7b439004-5663-4b81-a01e-0d56f48a22fa" xlink:to="loc_biib_FAMPYRAMember_44a8ba4d-a1eb-48c9-88d7-7e77441a5369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RareDiseaseProductRevenueMember_02f210f2-8f13-4b53-a3a6-0ffa9bf6219b" xlink:href="biib-20250930.xsd#biib_RareDiseaseProductRevenueMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_7b439004-5663-4b81-a01e-0d56f48a22fa" xlink:to="loc_biib_RareDiseaseProductRevenueMember_02f210f2-8f13-4b53-a3a6-0ffa9bf6219b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_QALSODYMember_497f96c3-7bf4-441d-988e-af8db6e02caa" xlink:href="biib-20250930.xsd#biib_QALSODYMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RareDiseaseProductRevenueMember_02f210f2-8f13-4b53-a3a6-0ffa9bf6219b" xlink:to="loc_biib_QALSODYMember_497f96c3-7bf4-441d-988e-af8db6e02caa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SPINRAZAMember_e9568cc8-5025-4039-b650-607826fda3e2" xlink:href="biib-20250930.xsd#biib_SPINRAZAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RareDiseaseProductRevenueMember_02f210f2-8f13-4b53-a3a6-0ffa9bf6219b" xlink:to="loc_biib_SPINRAZAMember_e9568cc8-5025-4039-b650-607826fda3e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SKYCLARYSMember_b7e9bbaa-6980-4bcf-aa09-e6aa82493b0c" xlink:href="biib-20250930.xsd#biib_SKYCLARYSMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_RareDiseaseProductRevenueMember_02f210f2-8f13-4b53-a3a6-0ffa9bf6219b" xlink:to="loc_biib_SKYCLARYSMember_b7e9bbaa-6980-4bcf-aa09-e6aa82493b0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BiosimilarsMember_477233a2-6f10-40c1-bde5-c16a883b01b0" xlink:href="biib-20250930.xsd#biib_BiosimilarsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_7b439004-5663-4b81-a01e-0d56f48a22fa" xlink:to="loc_biib_BiosimilarsMember_477233a2-6f10-40c1-bde5-c16a883b01b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BENEPALIMember_55bf2d47-b74b-427b-8e8a-730efc5543d6" xlink:href="biib-20250930.xsd#biib_BENEPALIMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BiosimilarsMember_477233a2-6f10-40c1-bde5-c16a883b01b0" xlink:to="loc_biib_BENEPALIMember_55bf2d47-b74b-427b-8e8a-730efc5543d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IMRALDIMember_d57aa97f-a66f-4cc6-9e57-e53b72c46a33" xlink:href="biib-20250930.xsd#biib_IMRALDIMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BiosimilarsMember_477233a2-6f10-40c1-bde5-c16a883b01b0" xlink:to="loc_biib_IMRALDIMember_d57aa97f-a66f-4cc6-9e57-e53b72c46a33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FLIXABIMember_75bd89e4-d270-477d-bbb0-debcbfc5f550" xlink:href="biib-20250930.xsd#biib_FLIXABIMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BiosimilarsMember_477233a2-6f10-40c1-bde5-c16a883b01b0" xlink:to="loc_biib_FLIXABIMember_75bd89e4-d270-477d-bbb0-debcbfc5f550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BYOOVIZMember_7f716630-a0dc-465c-b5c7-0c7a57636d05" xlink:href="biib-20250930.xsd#biib_BYOOVIZMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BiosimilarsMember_477233a2-6f10-40c1-bde5-c16a883b01b0" xlink:to="loc_biib_BYOOVIZMember_7f716630-a0dc-465c-b5c7-0c7a57636d05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TOFIDENCEMember_566bec5f-f635-4359-8f6c-47e3dd5de17f" xlink:href="biib-20250930.xsd#biib_TOFIDENCEMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BiosimilarsMember_477233a2-6f10-40c1-bde5-c16a883b01b0" xlink:to="loc_biib_TOFIDENCEMember_566bec5f-f635-4359-8f6c-47e3dd5de17f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherProductsMember_cb98bb96-7116-4fd1-a119-1b3f54acecc1" xlink:href="biib-20250930.xsd#biib_OtherProductsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ProductMember_7b439004-5663-4b81-a01e-0d56f48a22fa" xlink:to="loc_biib_OtherProductsMember_cb98bb96-7116-4fd1-a119-1b3f54acecc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ZURZUVAEMember_ac6b6514-eb96-4192-828e-cf4f54b8e5a7" xlink:href="biib-20250930.xsd#biib_ZURZUVAEMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_OtherProductsMember_cb98bb96-7116-4fd1-a119-1b3f54acecc1" xlink:to="loc_biib_ZURZUVAEMember_ac6b6514-eb96-4192-828e-cf4f54b8e5a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FUMADERMAndADUHELMMember_617c2e90-063d-49f2-b3c5-718d3de794e7" xlink:href="biib-20250930.xsd#biib_FUMADERMAndADUHELMMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_OtherProductsMember_cb98bb96-7116-4fd1-a119-1b3f54acecc1" xlink:to="loc_biib_FUMADERMAndADUHELMMember_617c2e90-063d-49f2-b3c5-718d3de794e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_713ec4c8-d661-4ed5-bea8-87a9d3d2ff5f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_f63d7168-da8c-4b2f-ba19-76738d0354a4" xlink:to="loc_srt_StatementGeographicalAxis_713ec4c8-d661-4ed5-bea8-87a9d3d2ff5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_769636b8-341a-4a81-a8f6-b755aa51c788" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_713ec4c8-d661-4ed5-bea8-87a9d3d2ff5f" xlink:to="loc_srt_SegmentGeographicalDomain_769636b8-341a-4a81-a8f6-b755aa51c788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_e26da37c-b943-4dec-9fd3-6d31f4a35ada" xlink:href="https://xbrl.sec.gov/country/2025/country-2025.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_769636b8-341a-4a81-a8f6-b755aa51c788" xlink:to="loc_country_US_e26da37c-b943-4dec-9fd3-6d31f4a35ada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_49f69c9b-da41-491d-9f68-52acc3370e36" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_769636b8-341a-4a81-a8f6-b755aa51c788" xlink:to="loc_us-gaap_NonUsMember_49f69c9b-da41-491d-9f68-52acc3370e36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_ce898dbf-8b0e-40e0-9368-343ea0ac9552" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_f63d7168-da8c-4b2f-ba19-76738d0354a4" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_ce898dbf-8b0e-40e0-9368-343ea0ac9552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_be6a1b8f-44e1-47f3-851a-adea80c79800" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_ce898dbf-8b0e-40e0-9368-343ea0ac9552" xlink:to="loc_us-gaap_Revenues_be6a1b8f-44e1-47f3-851a-adea80c79800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1" xlink:type="simple" xlink:href="biib-20250930.xsd#RevenuesReservesforDiscountsandAllowancesDetails1"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_551a2df5-4d98-4015-91c2-0aca89b87b64" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_5076763a-728e-495c-9cb8-076d009f55bc" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_551a2df5-4d98-4015-91c2-0aca89b87b64" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_5076763a-728e-495c-9cb8-076d009f55bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_0233fdc7-c2a0-41d2-b645-95293c61b90a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_5076763a-728e-495c-9cb8-076d009f55bc" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_0233fdc7-c2a0-41d2-b645-95293c61b90a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_2e68c2af-d9dd-4d4c-b2e4-71732a9b8792" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_0233fdc7-c2a0-41d2-b645-95293c61b90a" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_2e68c2af-d9dd-4d4c-b2e4-71732a9b8792" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReserveforCashDiscountsMember_998c3ad5-9272-4046-aea5-66e51cb7130b" xlink:href="biib-20250930.xsd#biib_ReserveforCashDiscountsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_2e68c2af-d9dd-4d4c-b2e4-71732a9b8792" xlink:to="loc_biib_ReserveforCashDiscountsMember_998c3ad5-9272-4046-aea5-66e51cb7130b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractualAdjustmentsMember_3489b713-85bb-4923-aea2-a040a6cc9ca7" xlink:href="biib-20250930.xsd#biib_ContractualAdjustmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_2e68c2af-d9dd-4d4c-b2e4-71732a9b8792" xlink:to="loc_biib_ContractualAdjustmentsMember_3489b713-85bb-4923-aea2-a040a6cc9ca7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesReturnsAndAllowancesMember_3541921e-9b2b-414d-a7b3-80611dcc1d9d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesReturnsAndAllowancesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_2e68c2af-d9dd-4d4c-b2e4-71732a9b8792" xlink:to="loc_us-gaap_SalesReturnsAndAllowancesMember_3541921e-9b2b-414d-a7b3-80611dcc1d9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_c1281fe2-c13a-425e-87ca-95fd8a54e56d" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_5076763a-728e-495c-9cb8-076d009f55bc" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_c1281fe2-c13a-425e-87ca-95fd8a54e56d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_b5be9b10-c4da-4cac-9524-c536b78f41ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_c1281fe2-c13a-425e-87ca-95fd8a54e56d" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_b5be9b10-c4da-4cac-9524-c536b78f41ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_49bf50f8-ffda-42a3-b049-e7aad26fc8f2" xlink:href="biib-20250930.xsd#biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_c1281fe2-c13a-425e-87ca-95fd8a54e56d" xlink:to="loc_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear_49bf50f8-ffda-42a3-b049-e7aad26fc8f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_be0952e6-cfbd-4782-a914-576d8e6fdb4a" xlink:href="biib-20250930.xsd#biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_c1281fe2-c13a-425e-87ca-95fd8a54e56d" xlink:to="loc_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears_be0952e6-cfbd-4782-a914-576d8e6fdb4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_b473d173-446d-473d-896d-07b071d4b124" xlink:href="biib-20250930.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_c1281fe2-c13a-425e-87ca-95fd8a54e56d" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear_b473d173-446d-473d-896d-07b071d4b124" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_2f2533a1-d67c-420f-8b6b-6ee74f159140" xlink:href="biib-20250930.xsd#biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_c1281fe2-c13a-425e-87ca-95fd8a54e56d" xlink:to="loc_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear_2f2533a1-d67c-420f-8b6b-6ee74f159140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_c6382139-4b74-4f98-9391-f5a809ca686c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_c1281fe2-c13a-425e-87ca-95fd8a54e56d" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_c6382139-4b74-4f98-9391-f5a809ca686c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2" xlink:type="simple" xlink:href="biib-20250930.xsd#RevenuesReservesforDiscountsandAllowancesDetails2"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_4b53787b-bd20-4f0c-bb4b-413eb72806ad" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_2bcae2bd-9267-471c-bb1c-bf1250ad71f1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_4b53787b-bd20-4f0c-bb4b-413eb72806ad" xlink:to="loc_us-gaap_StatementTable_2bcae2bd-9267-471c-bb1c-bf1250ad71f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_7aced7d7-46ce-4e3d-9f2d-032611d35e55" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2bcae2bd-9267-471c-bb1c-bf1250ad71f1" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_7aced7d7-46ce-4e3d-9f2d-032611d35e55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_0b3eb539-122b-4be4-8251-c92e2321cbdf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_7aced7d7-46ce-4e3d-9f2d-032611d35e55" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_0b3eb539-122b-4be4-8251-c92e2321cbdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_d9000f17-2184-401a-aefd-e567ed82b15d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_0b3eb539-122b-4be4-8251-c92e2321cbdf" xlink:to="loc_us-gaap_AccountsReceivableMember_d9000f17-2184-401a-aefd-e567ed82b15d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_1d0509f2-e2ce-4a23-a60c-1fd691ec3292" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_0b3eb539-122b-4be4-8251-c92e2321cbdf" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_1d0509f2-e2ce-4a23-a60c-1fd691ec3292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_5a0c89e9-d574-432d-9780-f07c9e9ef1e0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_2bcae2bd-9267-471c-bb1c-bf1250ad71f1" xlink:to="loc_us-gaap_StatementLineItems_5a0c89e9-d574-432d-9780-f07c9e9ef1e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_945b1955-637e-4a87-9474-5f78ff4ae6b4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_5a0c89e9-d574-432d-9780-f07c9e9ef1e0" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_945b1955-637e-4a87-9474-5f78ff4ae6b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4c23b218-5a15-4062-83a4-374f3c39c654" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_8c02e42b-a4ca-4d2f-a61e-a5dae7010b10" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_4c23b218-5a15-4062-83a4-374f3c39c654" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_8c02e42b-a4ca-4d2f-a61e-a5dae7010b10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_3d186023-fa05-432d-a564-a604fc801c96" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_8c02e42b-a4ca-4d2f-a61e-a5dae7010b10" xlink:to="loc_srt_ProductOrServiceAxis_3d186023-fa05-432d-a564-a604fc801c96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a05fcad4-6fbc-4d43-81c0-f532fa3c0270" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_3d186023-fa05-432d-a564-a604fc801c96" xlink:to="loc_srt_ProductsAndServicesDomain_a05fcad4-6fbc-4d43-81c0-f532fa3c0270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_d2dc7da5-8811-4e57-836f-6ed7cb66c42e" xlink:href="biib-20250930.xsd#biib_Revenuesfromanticd20therapeuticprogramsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a05fcad4-6fbc-4d43-81c0-f532fa3c0270" xlink:to="loc_biib_Revenuesfromanticd20therapeuticprogramsMember_d2dc7da5-8811-4e57-836f-6ed7cb66c42e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RoyaltyAttributedToOCREVUSMember_aace41ed-744a-4152-b4ee-2220675a5f44" xlink:href="biib-20250930.xsd#biib_RoyaltyAttributedToOCREVUSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a05fcad4-6fbc-4d43-81c0-f532fa3c0270" xlink:to="loc_biib_RoyaltyAttributedToOCREVUSMember_aace41ed-744a-4152-b4ee-2220675a5f44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_22d6d801-5124-47d8-85a9-d31a38082a02" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_8c02e42b-a4ca-4d2f-a61e-a5dae7010b10" xlink:to="loc_srt_MajorCustomersAxis_22d6d801-5124-47d8-85a9-d31a38082a02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_5c85afec-b255-40f0-abbe-8454eabdea99" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_22d6d801-5124-47d8-85a9-d31a38082a02" xlink:to="loc_srt_NameOfMajorCustomerDomain_5c85afec-b255-40f0-abbe-8454eabdea99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RocheGroupGenentechMember_fe4bc481-50be-43b7-bfb6-1b1f71a6d5be" xlink:href="biib-20250930.xsd#biib_RocheGroupGenentechMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_5c85afec-b255-40f0-abbe-8454eabdea99" xlink:to="loc_biib_RocheGroupGenentechMember_fe4bc481-50be-43b7-bfb6-1b1f71a6d5be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_4a12711c-a3da-4757-82ee-0da6a8fe5a47" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_8c02e42b-a4ca-4d2f-a61e-a5dae7010b10" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_4a12711c-a3da-4757-82ee-0da6a8fe5a47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfCoPromotionProfits_4b6753d6-2731-4038-8f4b-0343633a562b" xlink:href="biib-20250930.xsd#biib_ShareOfCoPromotionProfits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_4a12711c-a3da-4757-82ee-0da6a8fe5a47" xlink:to="loc_biib_ShareOfCoPromotionProfits_4b6753d6-2731-4038-8f4b-0343633a562b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_a624087f-d94a-44de-a4e8-9c95161890fe" xlink:href="biib-20250930.xsd#biib_OtherrevenuesfromantiCD20therapeuticprograms"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_4a12711c-a3da-4757-82ee-0da6a8fe5a47" xlink:to="loc_biib_OtherrevenuesfromantiCD20therapeuticprograms_a624087f-d94a-44de-a4e8-9c95161890fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_9886ebe3-5b91-43b9-ae68-39683f430696" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_4a12711c-a3da-4757-82ee-0da6a8fe5a47" xlink:to="loc_us-gaap_Revenues_9886ebe3-5b91-43b9-ae68-39683f430696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#RevenuesOtherRevenuesDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_OtherrevenuesAbstract_309de97a-be9e-4bfc-b143-86eadc603331" xlink:href="biib-20250930.xsd#biib_OtherrevenuesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_3b95e9ec-edb3-4642-95d2-e86eb67ec056" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_OtherrevenuesAbstract_309de97a-be9e-4bfc-b143-86eadc603331" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_3b95e9ec-edb3-4642-95d2-e86eb67ec056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_de6e9305-40e9-449e-902a-1e23932e2ae2" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_3b95e9ec-edb3-4642-95d2-e86eb67ec056" xlink:to="loc_srt_ProductOrServiceAxis_de6e9305-40e9-449e-902a-1e23932e2ae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_48531804-9a25-42e6-84ef-6b1324590284" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_de6e9305-40e9-449e-902a-1e23932e2ae2" xlink:to="loc_srt_ProductsAndServicesDomain_48531804-9a25-42e6-84ef-6b1324590284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractManufacturingAndOtherRevenueMember_29803d94-c45a-4c63-8bdc-5c8f73ba50e5" xlink:href="biib-20250930.xsd#biib_ContractManufacturingAndOtherRevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_48531804-9a25-42e6-84ef-6b1324590284" xlink:to="loc_biib_ContractManufacturingAndOtherRevenueMember_29803d94-c45a-4c63-8bdc-5c8f73ba50e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_bad51b97-467f-4cb4-8c93-c6bd5ec96bf8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_48531804-9a25-42e6-84ef-6b1324590284" xlink:to="loc_us-gaap_RoyaltyMember_bad51b97-467f-4cb4-8c93-c6bd5ec96bf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_ebfad02a-8039-4916-b7b0-3ed3aba731ff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_48531804-9a25-42e6-84ef-6b1324590284" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_ebfad02a-8039-4916-b7b0-3ed3aba731ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_b09a2001-c672-4411-99f1-f7c993a9162b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_3b95e9ec-edb3-4642-95d2-e86eb67ec056" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_b09a2001-c672-4411-99f1-f7c993a9162b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_f5f620b5-8bf8-43c0-9ae2-bb61e1119a2a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_b09a2001-c672-4411-99f1-f7c993a9162b" xlink:to="loc_us-gaap_Revenues_f5f620b5-8bf8-43c0-9ae2-bb61e1119a2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/RevenuesNarrativeDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#RevenuesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/RevenuesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_180536b3-0a40-42ce-b78a-fd438278895f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_482f297f-acbc-4908-8b75-2c37d5b717f2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_180536b3-0a40-42ce-b78a-fd438278895f" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_482f297f-acbc-4908-8b75-2c37d5b717f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ef1f7f15-2768-475f-a923-85bdd785d541" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_482f297f-acbc-4908-8b75-2c37d5b717f2" xlink:to="loc_srt_ProductOrServiceAxis_ef1f7f15-2768-475f-a923-85bdd785d541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_03848153-b251-4e45-b26e-201c6d65c6a5" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_ef1f7f15-2768-475f-a923-85bdd785d541" xlink:to="loc_srt_ProductsAndServicesDomain_03848153-b251-4e45-b26e-201c6d65c6a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductAndServiceOtherMember_63ee8170-abd4-4ddd-893f-bb555d6e5f4d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductAndServiceOtherMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_03848153-b251-4e45-b26e-201c6d65c6a5" xlink:to="loc_us-gaap_ProductAndServiceOtherMember_63ee8170-abd4-4ddd-893f-bb555d6e5f4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LEQEMBICollaborationMember_16cc753a-b64d-45a5-8e8d-19f8637fd1a5" xlink:href="biib-20250930.xsd#biib_LEQEMBICollaborationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_03848153-b251-4e45-b26e-201c6d65c6a5" xlink:to="loc_biib_LEQEMBICollaborationMember_16cc753a-b64d-45a5-8e8d-19f8637fd1a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AlzheimersCollaborationMember_81c7eedc-5378-49cf-ac54-97347c6a31d8" xlink:href="biib-20250930.xsd#biib_AlzheimersCollaborationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_03848153-b251-4e45-b26e-201c6d65c6a5" xlink:to="loc_biib_AlzheimersCollaborationMember_81c7eedc-5378-49cf-ac54-97347c6a31d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_826d84e1-ed44-4f5b-bf16-38d67047fff5" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_482f297f-acbc-4908-8b75-2c37d5b717f2" xlink:to="loc_srt_MajorCustomersAxis_826d84e1-ed44-4f5b-bf16-38d67047fff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_05a3aa7c-4039-4b4c-a0dc-611d3cce71a3" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_826d84e1-ed44-4f5b-bf16-38d67047fff5" xlink:to="loc_srt_NameOfMajorCustomerDomain_05a3aa7c-4039-4b4c-a0dc-611d3cce71a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DistributorOneMember_b92723d2-eb05-4399-bd8c-fa2eda3ca127" xlink:href="biib-20250930.xsd#biib_DistributorOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_05a3aa7c-4039-4b4c-a0dc-611d3cce71a3" xlink:to="loc_biib_DistributorOneMember_b92723d2-eb05-4399-bd8c-fa2eda3ca127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DistributorTwoMember_bd639c10-6e09-4c6d-941b-4f973a52bbe4" xlink:href="biib-20250930.xsd#biib_DistributorTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_05a3aa7c-4039-4b4c-a0dc-611d3cce71a3" xlink:to="loc_biib_DistributorTwoMember_bd639c10-6e09-4c6d-941b-4f973a52bbe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_e9c166f4-2b80-4bfa-94d5-261403e435f1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_482f297f-acbc-4908-8b75-2c37d5b717f2" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_e9c166f4-2b80-4bfa-94d5-261403e435f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_0862ef71-4814-4e6f-ac9b-516db558df76" xlink:href="biib-20250930.xsd#biib_EntityWidePercentageOfRevenueFromMajorDistributors"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e9c166f4-2b80-4bfa-94d5-261403e435f1" xlink:to="loc_biib_EntityWidePercentageOfRevenueFromMajorDistributors_0862ef71-4814-4e6f-ac9b-516db558df76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NumberOfWholesalers_f01d0551-1f53-49c8-8c74-eef9e587c557" xlink:href="biib-20250930.xsd#biib_NumberOfWholesalers"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e9c166f4-2b80-4bfa-94d5-261403e435f1" xlink:to="loc_biib_NumberOfWholesalers_f01d0551-1f53-49c8-8c74-eef9e587c557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_d7e9b526-00fa-4467-a432-5db5043f0857" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e9c166f4-2b80-4bfa-94d5-261403e435f1" xlink:to="loc_us-gaap_Revenues_d7e9b526-00fa-4467-a432-5db5043f0857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfNonControlingInterestRecognized_c9ce4b0f-15d9-401e-9b86-f5844b343500" xlink:href="biib-20250930.xsd#biib_ShareOfNonControlingInterestRecognized"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e9c166f4-2b80-4bfa-94d5-261403e435f1" xlink:to="loc_biib_ShareOfNonControlingInterestRecognized_c9ce4b0f-15d9-401e-9b86-f5844b343500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#InventoryComponentsofInventoryDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_9e9568d6-252e-4f74-b84c-2f0f44dab64e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_75aca766-0a26-4b29-8f24-25d650ef10fa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_9e9568d6-252e-4f74-b84c-2f0f44dab64e" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_75aca766-0a26-4b29-8f24-25d650ef10fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_a4bfd0be-e628-4e32-96bb-d18d05931a63" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_9e9568d6-252e-4f74-b84c-2f0f44dab64e" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_a4bfd0be-e628-4e32-96bb-d18d05931a63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_2ef552b5-e647-4c10-9ea1-25500d659113" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_9e9568d6-252e-4f74-b84c-2f0f44dab64e" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_2ef552b5-e647-4c10-9ea1-25500d659113" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InventoryNetCurrentAndNoncurrent_6c5bd322-0456-48db-bdcc-51d484f3756b" xlink:href="biib-20250930.xsd#biib_InventoryNetCurrentAndNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_9e9568d6-252e-4f74-b84c-2f0f44dab64e" xlink:to="loc_biib_InventoryNetCurrentAndNoncurrent_6c5bd322-0456-48db-bdcc-51d484f3756b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_4c3ff92c-69f5-43d1-85e1-357eece35538" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_9e9568d6-252e-4f74-b84c-2f0f44dab64e" xlink:to="loc_us-gaap_InventoryNet_4c3ff92c-69f5-43d1-85e1-357eece35538" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNoncurrent_14e3d112-c4a1-44fa-8697-4478c90ddb20" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_9e9568d6-252e-4f74-b84c-2f0f44dab64e" xlink:to="loc_us-gaap_InventoryNoncurrent_14e3d112-c4a1-44fa-8697-4478c90ddb20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InventoryNarrativeDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#InventoryNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InventoryNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_59c644c4-ce7f-47e1-96e5-375fa0a79c42" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_1db0b6e4-73d5-49cf-b932-a3be3827c5fe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryCurrentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_59c644c4-ce7f-47e1-96e5-375fa0a79c42" xlink:to="loc_us-gaap_InventoryCurrentTable_1db0b6e4-73d5-49cf-b932-a3be3827c5fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_d30464b7-4132-428f-97a7-067e2944ff29" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_1db0b6e4-73d5-49cf-b932-a3be3827c5fe" xlink:to="loc_us-gaap_TypeOfArrangementAxis_d30464b7-4132-428f-97a7-067e2944ff29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_90e65ebe-d5a5-45b4-82b1-adf176d5d2d9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d30464b7-4132-428f-97a7-067e2944ff29" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_90e65ebe-d5a5-45b4-82b1-adf176d5d2d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_158d6aa1-e42f-47e7-a989-ed5df1dac2a9" xlink:href="biib-20250930.xsd#biib_EisaiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_90e65ebe-d5a5-45b4-82b1-adf176d5d2d9" xlink:to="loc_biib_EisaiMember_158d6aa1-e42f-47e7-a989-ed5df1dac2a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_f4b0c814-df70-413e-b1fb-452962222454" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_1db0b6e4-73d5-49cf-b932-a3be3827c5fe" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_f4b0c814-df70-413e-b1fb-452962222454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_24729b73-4c39-4843-84a4-5cba803c63b8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f4b0c814-df70-413e-b1fb-452962222454" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_24729b73-4c39-4843-84a4-5cba803c63b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember_b0d6744c-5d34-4097-a756-b8e1cf7df38c" xlink:href="biib-20250930.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_24729b73-4c39-4843-84a4-5cba803c63b8" xlink:to="loc_biib_ReataPharmaceuticalsIncMember_b0d6744c-5d34-4097-a756-b8e1cf7df38c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrecurringAdjustmentAxis_e9d368b2-0f58-4f53-9b48-179bf7f9e506" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonrecurringAdjustmentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_1db0b6e4-73d5-49cf-b932-a3be3827c5fe" xlink:to="loc_us-gaap_NonrecurringAdjustmentAxis_e9d368b2-0f58-4f53-9b48-179bf7f9e506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonrecurringAdjustmentDomain_cf81bbef-b5cf-4058-85fe-3f53cbc4d079" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonrecurringAdjustmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonrecurringAdjustmentAxis_e9d368b2-0f58-4f53-9b48-179bf7f9e506" xlink:to="loc_us-gaap_NonrecurringAdjustmentDomain_cf81bbef-b5cf-4058-85fe-3f53cbc4d079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAdjustmentToInventoryMember_5efa30f1-5c21-4dd9-bb99-1f157b80ea1a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAdjustmentToInventoryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonrecurringAdjustmentDomain_cf81bbef-b5cf-4058-85fe-3f53cbc4d079" xlink:to="loc_us-gaap_FairValueAdjustmentToInventoryMember_5efa30f1-5c21-4dd9-bb99-1f157b80ea1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ab88ef47-1cfa-413d-b003-0a47ac72e86b" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_1db0b6e4-73d5-49cf-b932-a3be3827c5fe" xlink:to="loc_srt_ProductOrServiceAxis_ab88ef47-1cfa-413d-b003-0a47ac72e86b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_175d97be-873b-4b93-afc1-2dd1bd7c1229" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_ab88ef47-1cfa-413d-b003-0a47ac72e86b" xlink:to="loc_srt_ProductsAndServicesDomain_175d97be-873b-4b93-afc1-2dd1bd7c1229" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ClinicalInventoryMember_d2e2dd41-f345-46f2-938c-834f7f6dcf17" xlink:href="biib-20250930.xsd#biib_ClinicalInventoryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_175d97be-873b-4b93-afc1-2dd1bd7c1229" xlink:to="loc_biib_ClinicalInventoryMember_d2e2dd41-f345-46f2-938c-834f7f6dcf17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_91f20c8b-ac2c-4d15-953e-b5ada7fccb61" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InventoryLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_1db0b6e4-73d5-49cf-b932-a3be3827c5fe" xlink:to="loc_us-gaap_InventoryLineItems_91f20c8b-ac2c-4d15-953e-b5ada7fccb61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_6af4056f-f90c-4087-ae46-f555b6a8ff1e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_91f20c8b-ac2c-4d15-953e-b5ada7fccb61" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory_6af4056f-f90c-4087-ae46-f555b6a8ff1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_f2f999ea-42a0-45cd-be17-5b7194c8362b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_91f20c8b-ac2c-4d15-953e-b5ada7fccb61" xlink:to="loc_us-gaap_ProfitLoss_f2f999ea-42a0-45cd-be17-5b7194c8362b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_a54907bc-3129-44d2-b519-81362fbc24c7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_91f20c8b-ac2c-4d15-953e-b5ada7fccb61" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_a54907bc-3129-44d2-b519-81362fbc24c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5ff9ebc3-f3f8-4031-a81e-90fa95df7ca1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9c1c4458-fc6c-4d52-877b-2f49e692af04" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5ff9ebc3-f3f8-4031-a81e-90fa95df7ca1" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9c1c4458-fc6c-4d52-877b-2f49e692af04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_eba4ba20-e4c9-4460-a490-1d61c2e4ca87" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9c1c4458-fc6c-4d52-877b-2f49e692af04" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_eba4ba20-e4c9-4460-a490-1d61c2e4ca87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d2ffbcd8-5a7c-4510-8d4a-d5dedb44bbe4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_eba4ba20-e4c9-4460-a490-1d61c2e4ca87" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d2ffbcd8-5a7c-4510-8d4a-d5dedb44bbe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AcquiredAndInLicensedRightsAndPatentsMember_cb4fe8c6-1f34-4288-bd63-4e4980063f7a" xlink:href="biib-20250930.xsd#biib_AcquiredAndInLicensedRightsAndPatentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d2ffbcd8-5a7c-4510-8d4a-d5dedb44bbe4" xlink:to="loc_biib_AcquiredAndInLicensedRightsAndPatentsMember_cb4fe8c6-1f34-4288-bd63-4e4980063f7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2f0b964e-7cfd-4dee-8788-603360e9b3e7" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9c1c4458-fc6c-4d52-877b-2f49e692af04" xlink:to="loc_srt_RangeAxis_2f0b964e-7cfd-4dee-8788-603360e9b3e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_154be98c-bd0d-4d80-b5a9-957366dafa39" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2f0b964e-7cfd-4dee-8788-603360e9b3e7" xlink:to="loc_srt_RangeMember_154be98c-bd0d-4d80-b5a9-957366dafa39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_c1b05cd1-6796-437a-96af-6a87b35d95a3" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_154be98c-bd0d-4d80-b5a9-957366dafa39" xlink:to="loc_srt_MinimumMember_c1b05cd1-6796-437a-96af-6a87b35d95a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c2d9de09-dc57-42d6-bdc3-d894a78f7811" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_154be98c-bd0d-4d80-b5a9-957366dafa39" xlink:to="loc_srt_MaximumMember_c2d9de09-dc57-42d6-bdc3-d894a78f7811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_83be8ef7-837c-4dda-96c3-07089a0ac87b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_9c1c4458-fc6c-4d52-877b-2f49e692af04" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_83be8ef7-837c-4dda-96c3-07089a0ac87b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_0c7085e9-bfd4-43ca-9a9e-7df54a57c270" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_83be8ef7-837c-4dda-96c3-07089a0ac87b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_0c7085e9-bfd4-43ca-9a9e-7df54a57c270" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_047fd9c8-ffad-48ae-876d-d6e050cc197c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_83be8ef7-837c-4dda-96c3-07089a0ac87b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_047fd9c8-ffad-48ae-876d-d6e050cc197c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_aeb8cfce-dccc-4da4-ba0c-4ef9cc21d7a3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_047fd9c8-ffad-48ae-876d-d6e050cc197c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_aeb8cfce-dccc-4da4-ba0c-4ef9cc21d7a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_52037f4a-92e0-4a9d-8672-5b8298a24dfa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_047fd9c8-ffad-48ae-876d-d6e050cc197c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_52037f4a-92e0-4a9d-8672-5b8298a24dfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_4c7dab15-8082-406c-abb7-3e6567e085c4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_047fd9c8-ffad-48ae-876d-d6e050cc197c" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_4c7dab15-8082-406c-abb7-3e6567e085c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_237b3ebd-683f-461e-87bd-5d1a7293213c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5ff9ebc3-f3f8-4031-a81e-90fa95df7ca1" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_237b3ebd-683f-461e-87bd-5d1a7293213c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_1dad985e-6c35-4ceb-be2b-70dbfb885402" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_237b3ebd-683f-461e-87bd-5d1a7293213c" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_1dad985e-6c35-4ceb-be2b-70dbfb885402" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0a3c56d8-bcad-44d5-9a71-35fed64d68f1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_1dad985e-6c35-4ceb-be2b-70dbfb885402" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0a3c56d8-bcad-44d5-9a71-35fed64d68f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_4bda9138-539e-4fa6-ad92-44f604bd53bc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0a3c56d8-bcad-44d5-9a71-35fed64d68f1" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_4bda9138-539e-4fa6-ad92-44f604bd53bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PriorityReviewVoucherMember_8cf9d1b7-e922-4a1c-900a-2932ff37da8f" xlink:href="biib-20250930.xsd#biib_PriorityReviewVoucherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0a3c56d8-bcad-44d5-9a71-35fed64d68f1" xlink:to="loc_biib_PriorityReviewVoucherMember_8cf9d1b7-e922-4a1c-900a-2932ff37da8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksAndTradeNamesMember_77942702-437a-4615-ad92-268d19661db1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TrademarksAndTradeNamesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0a3c56d8-bcad-44d5-9a71-35fed64d68f1" xlink:to="loc_us-gaap_TrademarksAndTradeNamesMember_77942702-437a-4615-ad92-268d19661db1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_a8cb4b1d-7c8e-4d08-8f6f-221c2b4439d2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_237b3ebd-683f-461e-87bd-5d1a7293213c" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_a8cb4b1d-7c8e-4d08-8f6f-221c2b4439d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_faaf0525-cdad-467d-8cd1-e45908f5422c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_a8cb4b1d-7c8e-4d08-8f6f-221c2b4439d2" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_faaf0525-cdad-467d-8cd1-e45908f5422c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_89bc9363-78bd-44b8-99f3-bf6081e4790b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_5ff9ebc3-f3f8-4031-a81e-90fa95df7ca1" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_89bc9363-78bd-44b8-99f3-bf6081e4790b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_f7c5b8d3-791b-4cf3-9c66-f8254b24ccd9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_89bc9363-78bd-44b8-99f3-bf6081e4790b" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_f7c5b8d3-791b-4cf3-9c66-f8254b24ccd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2936e380-361c-4d44-ace8-65dc8c89069b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_89bc9363-78bd-44b8-99f3-bf6081e4790b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2936e380-361c-4d44-ace8-65dc8c89069b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_bf0c54ea-ed64-497d-a971-b02782b06db0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_89bc9363-78bd-44b8-99f3-bf6081e4790b" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_bf0c54ea-ed64-497d-a971-b02782b06db0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#IntangibleAssetsandGoodwillNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6d47739c-8edc-4b65-a407-14ee3b4df9ee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_6368c69d-c4c8-4c7b-b041-ccc5b2349125" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_6d47739c-8edc-4b65-a407-14ee3b4df9ee" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_6368c69d-c4c8-4c7b-b041-ccc5b2349125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_633469b6-c945-4336-81be-08e89960e021" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_6368c69d-c4c8-4c7b-b041-ccc5b2349125" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_633469b6-c945-4336-81be-08e89960e021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_34fbae99-cfd1-408b-8287-4d32260e65d3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_633469b6-c945-4336-81be-08e89960e021" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_34fbae99-cfd1-408b-8287-4d32260e65d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember_a0c2c5d0-93d2-49cc-821b-14a291422e64" xlink:href="biib-20250930.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_34fbae99-cfd1-408b-8287-4d32260e65d3" xlink:to="loc_biib_ReataPharmaceuticalsIncMember_a0c2c5d0-93d2-49cc-821b-14a291422e64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_HumanImmunologyBiosciencesMember_ffed3894-6483-4566-87bb-ba78286d283f" xlink:href="biib-20250930.xsd#biib_HumanImmunologyBiosciencesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_34fbae99-cfd1-408b-8287-4d32260e65d3" xlink:to="loc_biib_HumanImmunologyBiosciencesMember_ffed3894-6483-4566-87bb-ba78286d283f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5d149553-c194-4f9b-9ced-6fe0fb8abe60" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_6368c69d-c4c8-4c7b-b041-ccc5b2349125" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5d149553-c194-4f9b-9ced-6fe0fb8abe60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0ba85607-2105-4a41-81ec-31a21b7f808e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5d149553-c194-4f9b-9ced-6fe0fb8abe60" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0ba85607-2105-4a41-81ec-31a21b7f808e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AcquiredAndInLicensedRightsAndPatentsMember_f2ead4a0-adb5-4fa9-92ea-8a15d986902f" xlink:href="biib-20250930.xsd#biib_AcquiredAndInLicensedRightsAndPatentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0ba85607-2105-4a41-81ec-31a21b7f808e" xlink:to="loc_biib_AcquiredAndInLicensedRightsAndPatentsMember_f2ead4a0-adb5-4fa9-92ea-8a15d986902f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_c87d7b6c-1e1e-4907-9b0f-9af3c571f8bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0ba85607-2105-4a41-81ec-31a21b7f808e" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_c87d7b6c-1e1e-4907-9b0f-9af3c571f8bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SKYCLARYSMember_4235a197-411b-4025-b92f-cefd8e5ad07e" xlink:href="biib-20250930.xsd#biib_SKYCLARYSMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0ba85607-2105-4a41-81ec-31a21b7f808e" xlink:to="loc_biib_SKYCLARYSMember_4235a197-411b-4025-b92f-cefd8e5ad07e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PriorityReviewVoucherMember_2c1279b2-f0af-4964-ade2-e8f6f4900df5" xlink:href="biib-20250930.xsd#biib_PriorityReviewVoucherMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_0ba85607-2105-4a41-81ec-31a21b7f808e" xlink:to="loc_biib_PriorityReviewVoucherMember_2c1279b2-f0af-4964-ade2-e8f6f4900df5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_51dbf624-bb73-4d1c-84f6-d9b1cad8a0d0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_6368c69d-c4c8-4c7b-b041-ccc5b2349125" xlink:to="loc_srt_RangeAxis_51dbf624-bb73-4d1c-84f6-d9b1cad8a0d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_43705632-93b7-4885-89e9-71cb7a50db86" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_51dbf624-bb73-4d1c-84f6-d9b1cad8a0d0" xlink:to="loc_srt_RangeMember_43705632-93b7-4885-89e9-71cb7a50db86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5b10f89d-1068-4f20-9c0d-e84163ca7c08" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_43705632-93b7-4885-89e9-71cb7a50db86" xlink:to="loc_srt_MinimumMember_5b10f89d-1068-4f20-9c0d-e84163ca7c08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3556637e-1b7e-495f-9b3b-757c5cac0582" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_43705632-93b7-4885-89e9-71cb7a50db86" xlink:to="loc_srt_MaximumMember_3556637e-1b7e-495f-9b3b-757c5cac0582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_0a0b607a-7159-4816-a48a-1805b720f72d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_6368c69d-c4c8-4c7b-b041-ccc5b2349125" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_0a0b607a-7159-4816-a48a-1805b720f72d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_d96817e7-9fb9-485d-a9b0-a25ae1a866ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_0a0b607a-7159-4816-a48a-1805b720f72d" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_d96817e7-9fb9-485d-a9b0-a25ae1a866ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_2c771741-a3a3-4727-bf24-1f70719802fb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_d96817e7-9fb9-485d-a9b0-a25ae1a866ba" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_2c771741-a3a3-4727-bf24-1f70719802fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PriorityReviewVoucherMember_ac7b8548-8d08-4610-b7b5-594eac557814" xlink:href="biib-20250930.xsd#biib_PriorityReviewVoucherMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_d96817e7-9fb9-485d-a9b0-a25ae1a866ba" xlink:to="loc_biib_PriorityReviewVoucherMember_ac7b8548-8d08-4610-b7b5-594eac557814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SKYCLARYSMember_f9293e76-2208-47d8-8780-d976e9fe0a57" xlink:href="biib-20250930.xsd#biib_SKYCLARYSMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_d96817e7-9fb9-485d-a9b0-a25ae1a866ba" xlink:to="loc_biib_SKYCLARYSMember_f9293e76-2208-47d8-8780-d976e9fe0a57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_a68ed16f-85bb-4f63-a459-168fc6ba4251" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_6368c69d-c4c8-4c7b-b041-ccc5b2349125" xlink:to="loc_us-gaap_GoodwillLineItems_a68ed16f-85bb-4f63-a459-168fc6ba4251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_67d50564-0ce1-40a2-902f-60a83abc48c7" xlink:href="biib-20250930.xsd#biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_a68ed16f-85bb-4f63-a459-168fc6ba4251" xlink:to="loc_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets_67d50564-0ce1-40a2-902f-60a83abc48c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_ea48d777-bc03-45d4-9835-261f8bfd0033" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_a68ed16f-85bb-4f63-a459-168fc6ba4251" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_ea48d777-bc03-45d4-9835-261f8bfd0033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_d2b4c8aa-e2f2-425a-94b4-a2fe863f3b41" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_a68ed16f-85bb-4f63-a459-168fc6ba4251" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_d2b4c8aa-e2f2-425a-94b4-a2fe863f3b41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_7f6eadd7-8579-4e98-b5f0-82e0ed7e0dc5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_a68ed16f-85bb-4f63-a459-168fc6ba4251" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_7f6eadd7-8579-4e98-b5f0-82e0ed7e0dc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife_668a822c-5b15-4f34-9cf4-89b1ea088ac1" xlink:href="biib-20250930.xsd#biib_FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_a68ed16f-85bb-4f63-a459-168fc6ba4251" xlink:to="loc_biib_FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife_668a822c-5b15-4f34-9cf4-89b1ea088ac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_906762fc-c53c-4e94-b90a-2776913976b0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_a68ed16f-85bb-4f63-a459-168fc6ba4251" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_906762fc-c53c-4e94-b90a-2776913976b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_02ac482d-3215-4a83-b376-3ea94cc68108" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_a68ed16f-85bb-4f63-a459-168fc6ba4251" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_02ac482d-3215-4a83-b376-3ea94cc68108" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillEstimatedFutureAmortizationofIntangibleAssetsDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#IntangibleAssetsandGoodwillEstimatedFutureAmortizationofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillEstimatedFutureAmortizationofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b6bdc857-c865-49ed-8245-04980b459d12" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_b79fcb05-d40b-41bd-9706-549fdab796bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b6bdc857-c865-49ed-8245-04980b459d12" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear_b79fcb05-d40b-41bd-9706-549fdab796bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_85a7dc98-fc84-4873-9ad2-c413edc3746f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b6bdc857-c865-49ed-8245-04980b459d12" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_85a7dc98-fc84-4873-9ad2-c413edc3746f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_3914d6e7-8c35-4a1c-ab62-ee2c35c51d43" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b6bdc857-c865-49ed-8245-04980b459d12" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_3914d6e7-8c35-4a1c-ab62-ee2c35c51d43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_b0edf843-1b73-47f4-8451-029effbb48f5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b6bdc857-c865-49ed-8245-04980b459d12" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_b0edf843-1b73-47f4-8451-029effbb48f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_47a4a728-7203-42a7-9f9d-a37456a2ede5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b6bdc857-c865-49ed-8245-04980b459d12" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_47a4a728-7203-42a7-9f9d-a37456a2ede5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_a440752b-1ef5-4a15-9283-142cfc482c26" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b6bdc857-c865-49ed-8245-04980b459d12" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_a440752b-1ef5-4a15-9283-142cfc482c26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillChangesinGoodwillDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#IntangibleAssetsandGoodwillChangesinGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IntangibleAssetsandGoodwillChangesinGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f927c61a-4ead-4ff3-a02a-d75218596fb1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_0f6ac338-f0ea-495c-a249-da44b8387214" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f927c61a-4ead-4ff3-a02a-d75218596fb1" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_0f6ac338-f0ea-495c-a249-da44b8387214" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_58758a0d-b04f-429b-9125-430db14156a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_0f6ac338-f0ea-495c-a249-da44b8387214" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_58758a0d-b04f-429b-9125-430db14156a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9e03f663-7704-4ee2-b289-0ded3988bd76" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_58758a0d-b04f-429b-9125-430db14156a0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9e03f663-7704-4ee2-b289-0ded3988bd76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_HumanImmunologyBiosciencesMember_61a20354-bfb1-4cbb-9974-7acd1aab806a" xlink:href="biib-20250930.xsd#biib_HumanImmunologyBiosciencesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9e03f663-7704-4ee2-b289-0ded3988bd76" xlink:to="loc_biib_HumanImmunologyBiosciencesMember_61a20354-bfb1-4cbb-9974-7acd1aab806a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember_41b5d1b8-8f5c-4ed8-8f08-7e91b8ed01e3" xlink:href="biib-20250930.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_9e03f663-7704-4ee2-b289-0ded3988bd76" xlink:to="loc_biib_ReataPharmaceuticalsIncMember_41b5d1b8-8f5c-4ed8-8f08-7e91b8ed01e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_1f9781bf-a471-43cf-99b2-89b9406122e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_0f6ac338-f0ea-495c-a249-da44b8387214" xlink:to="loc_us-gaap_GoodwillLineItems_1f9781bf-a471-43cf-99b2-89b9406122e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_32eb03a0-4bc1-4065-b882-3511829995b4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_1f9781bf-a471-43cf-99b2-89b9406122e7" xlink:to="loc_us-gaap_GoodwillRollForward_32eb03a0-4bc1-4065-b882-3511829995b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_9a701614-939b-43d5-ad16-5c49db8b0b71" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_32eb03a0-4bc1-4065-b882-3511829995b4" xlink:to="loc_us-gaap_Goodwill_9a701614-939b-43d5-ad16-5c49db8b0b71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_08bc1f7a-1f48-4105-b0c0-dcd32414e615" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillPurchaseAccountingAdjustments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_32eb03a0-4bc1-4065-b882-3511829995b4" xlink:to="loc_us-gaap_GoodwillPurchaseAccountingAdjustments_08bc1f7a-1f48-4105-b0c0-dcd32414e615" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_887c133d-f206-41e7-a39c-0c0eed0c1f0b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_32eb03a0-4bc1-4065-b882-3511829995b4" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_887c133d-f206-41e7-a39c-0c0eed0c1f0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_da586d2e-5736-4331-b001-6cc845426361" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_32eb03a0-4bc1-4065-b882-3511829995b4" xlink:to="loc_us-gaap_Goodwill_da586d2e-5736-4331-b001-6cc845426361" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_506c8cda-87e2-48e1-bfcd-5f059d67f630" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_1f9781bf-a471-43cf-99b2-89b9406122e7" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_506c8cda-87e2-48e1-bfcd-5f059d67f630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_873faeb0-63dd-4e82-a0f7-cb501e0a38d6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_14d1ee2d-6e9f-4d28-a0cb-260431b78b06" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_873faeb0-63dd-4e82-a0f7-cb501e0a38d6" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_14d1ee2d-6e9f-4d28-a0cb-260431b78b06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_92ea03f1-5744-4746-b7fb-7e98ac9dd0a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_14d1ee2d-6e9f-4d28-a0cb-260431b78b06" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_92ea03f1-5744-4746-b7fb-7e98ac9dd0a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_23c0f137-9532-4b2d-ab9d-514af73ed473" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_92ea03f1-5744-4746-b7fb-7e98ac9dd0a4" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_23c0f137-9532-4b2d-ab9d-514af73ed473" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_b595354e-3363-4ada-baba-7c51b6f15e6e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_23c0f137-9532-4b2d-ab9d-514af73ed473" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_b595354e-3363-4ada-baba-7c51b6f15e6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_aa5f654c-3b1a-4b4a-b80d-4d7c95e7ff36" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_23c0f137-9532-4b2d-ab9d-514af73ed473" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_aa5f654c-3b1a-4b4a-b80d-4d7c95e7ff36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_f404a6e6-d03c-469b-87fa-08cbebf1e34a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_23c0f137-9532-4b2d-ab9d-514af73ed473" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_f404a6e6-d03c-469b-87fa-08cbebf1e34a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c787359d-b8b0-4bfc-9e50-3e9b3ce29df3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_14d1ee2d-6e9f-4d28-a0cb-260431b78b06" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c787359d-b8b0-4bfc-9e50-3e9b3ce29df3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_0274fc20-39ab-42be-9e6c-7a36697cffdd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_c787359d-b8b0-4bfc-9e50-3e9b3ce29df3" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_0274fc20-39ab-42be-9e6c-7a36697cffdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_b819e92d-6689-463b-b786-01dffa072873" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_0274fc20-39ab-42be-9e6c-7a36697cffdd" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_b819e92d-6689-463b-b786-01dffa072873" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_512ed7ba-1e5c-4d3c-b732-6d2823c09668" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_14d1ee2d-6e9f-4d28-a0cb-260431b78b06" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_512ed7ba-1e5c-4d3c-b732-6d2823c09668" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_22e88ea0-b1a1-4684-9e3d-1b0c866f05b7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_512ed7ba-1e5c-4d3c-b732-6d2823c09668" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_22e88ea0-b1a1-4684-9e3d-1b0c866f05b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_b8955259-52bb-43bd-84cf-7b65ffdfc481" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_22e88ea0-b1a1-4684-9e3d-1b0c866f05b7" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_b8955259-52bb-43bd-84cf-7b65ffdfc481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_80479a04-d5d1-4f5c-a75a-314bb51215f5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_22e88ea0-b1a1-4684-9e3d-1b0c866f05b7" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_80479a04-d5d1-4f5c-a75a-314bb51215f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_15b5452f-9cef-4d2d-8730-c48b26e3e649" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_14d1ee2d-6e9f-4d28-a0cb-260431b78b06" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_15b5452f-9cef-4d2d-8730-c48b26e3e649" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_71a0b86f-bec2-4a77-b8f9-6f5dbd996ef3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_15b5452f-9cef-4d2d-8730-c48b26e3e649" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_71a0b86f-bec2-4a77-b8f9-6f5dbd996ef3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_cfdf3980-e39d-4b80-bd0f-c7e8c3b0160d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosureAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_71a0b86f-bec2-4a77-b8f9-6f5dbd996ef3" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_cfdf3980-e39d-4b80-bd0f-c7e8c3b0160d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_783c28db-315f-4672-8589-1fba40ec6e1f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_cfdf3980-e39d-4b80-bd0f-c7e8c3b0160d" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_783c28db-315f-4672-8589-1fba40ec6e1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsFairValueDisclosure_9beba727-62be-4d62-99c6-ac9a5949f5bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_cfdf3980-e39d-4b80-bd0f-c7e8c3b0160d" xlink:to="loc_us-gaap_InvestmentsFairValueDisclosure_9beba727-62be-4d62-99c6-ac9a5949f5bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_fb2a2282-e2c0-40a6-a731-933ec00c2812" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyContractAssetFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_cfdf3980-e39d-4b80-bd0f-c7e8c3b0160d" xlink:to="loc_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure_fb2a2282-e2c0-40a6-a731-933ec00c2812" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesReceivableFairValueDisclosure_942af886-a3ff-4282-9197-d45aba9ddcb1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesReceivableFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_cfdf3980-e39d-4b80-bd0f-c7e8c3b0160d" xlink:to="loc_us-gaap_NotesReceivableFairValueDisclosure_942af886-a3ff-4282-9197-d45aba9ddcb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_ac203318-0c55-489a-8627-82b07bba07c2" xlink:href="biib-20250930.xsd#biib_PlanAssetsForDeferredCompensationFairValueDisclosure"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_cfdf3980-e39d-4b80-bd0f-c7e8c3b0160d" xlink:to="loc_biib_PlanAssetsForDeferredCompensationFairValueDisclosure_ac203318-0c55-489a-8627-82b07bba07c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_9799a140-aa99-42d1-8119-286e3beb745c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_cfdf3980-e39d-4b80-bd0f-c7e8c3b0160d" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_9799a140-aa99-42d1-8119-286e3beb745c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_4a9f4b8c-f0a9-404d-8889-6cda761b094c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_71a0b86f-bec2-4a77-b8f9-6f5dbd996ef3" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_4a9f4b8c-f0a9-404d-8889-6cda761b094c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesAbstract_da654fd4-b8db-4dbc-acea-b51c3e4c846e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_4a9f4b8c-f0a9-404d-8889-6cda761b094c" xlink:to="loc_us-gaap_DerivativeLiabilitiesAbstract_da654fd4-b8db-4dbc-acea-b51c3e4c846e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_d3d0f63d-c9f1-4d48-a7b6-414c3235471d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLiabilitiesAbstract_da654fd4-b8db-4dbc-acea-b51c3e4c846e" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_d3d0f63d-c9f1-4d48-a7b6-414c3235471d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_91b40387-7d04-437b-8008-1bfc2653195f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLiabilitiesAbstract_da654fd4-b8db-4dbc-acea-b51c3e4c846e" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_91b40387-7d04-437b-8008-1bfc2653195f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrentAbstract_f69fd8da-a652-402e-af61-b2c1d854f3c9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_4a9f4b8c-f0a9-404d-8889-6cda761b094c" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrentAbstract_f69fd8da-a652-402e-af61-b2c1d854f3c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_bc9a0e67-5070-4ae2-83fc-a5d7f8c4d02a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLiabilitiesNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrentAbstract_f69fd8da-a652-402e-af61-b2c1d854f3c9" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_bc9a0e67-5070-4ae2-83fc-a5d7f8c4d02a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_6f770536-ac59-4c4e-9ff5-2d6548a49b57" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrentAbstract_f69fd8da-a652-402e-af61-b2c1d854f3c9" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_6f770536-ac59-4c4e-9ff5-2d6548a49b57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_c5388c58-5fb9-4df3-9c6b-a05d8e0f0bb1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_4a9f4b8c-f0a9-404d-8889-6cda761b094c" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_c5388c58-5fb9-4df3-9c6b-a05d8e0f0bb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_08c6250a-1ef3-4650-ae16-e087a79a81ef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_71a0b86f-bec2-4a77-b8f9-6f5dbd996ef3" xlink:to="loc_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure_08c6250a-1ef3-4650-ae16-e087a79a81ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_003c146a-972a-4528-9924-a86e933860ca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract_71a0b86f-bec2-4a77-b8f9-6f5dbd996ef3" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_003c146a-972a-4528-9924-a86e933860ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_99ac9ced-e273-42df-b04c-abf675d7f59c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_15b5452f-9cef-4d2d-8730-c48b26e3e649" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_99ac9ced-e273-42df-b04c-abf675d7f59c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_1c868392-ea89-473b-ac14-662d678690ed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_3e0382b5-42be-4ab7-aa09-64f15f8f9827" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_1c868392-ea89-473b-ac14-662d678690ed" xlink:to="loc_us-gaap_DebtInstrumentTable_3e0382b5-42be-4ab7-aa09-64f15f8f9827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1d8c88d0-d43c-4962-ac65-15e28ede485e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3e0382b5-42be-4ab7-aa09-64f15f8f9827" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1d8c88d0-d43c-4962-ac65-15e28ede485e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_284f5c0e-bbf0-46f6-9d2c-995a6ba93b0a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1d8c88d0-d43c-4962-ac65-15e28ede485e" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_284f5c0e-bbf0-46f6-9d2c-995a6ba93b0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_HumanImmunologyBiosciencesMember_b5dfa71b-1084-4f67-a987-57babcc2c0c7" xlink:href="biib-20250930.xsd#biib_HumanImmunologyBiosciencesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_284f5c0e-bbf0-46f6-9d2c-995a6ba93b0a" xlink:to="loc_biib_HumanImmunologyBiosciencesMember_b5dfa71b-1084-4f67-a987-57babcc2c0c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_e37f54b6-abdc-45cf-9baf-41f3503b09e3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3e0382b5-42be-4ab7-aa09-64f15f8f9827" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_e37f54b6-abdc-45cf-9baf-41f3503b09e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_da2b7abe-c40c-405c-b704-4231de1894fb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_e37f54b6-abdc-45cf-9baf-41f3503b09e3" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_da2b7abe-c40c-405c-b704-4231de1894fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MeasurementInputProbabilityRateMember_26779190-5cd2-414c-a434-724db1ad74a8" xlink:href="biib-20250930.xsd#biib_MeasurementInputProbabilityRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_da2b7abe-c40c-405c-b704-4231de1894fb" xlink:to="loc_biib_MeasurementInputProbabilityRateMember_26779190-5cd2-414c-a434-724db1ad74a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c80b2fcc-c6ab-4dfa-b819-b070324298c4" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3e0382b5-42be-4ab7-aa09-64f15f8f9827" xlink:to="loc_srt_RangeAxis_c80b2fcc-c6ab-4dfa-b819-b070324298c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c2a2bcf0-2f8d-4d4c-84e3-1b8710f0b6a4" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_c80b2fcc-c6ab-4dfa-b819-b070324298c4" xlink:to="loc_srt_RangeMember_c2a2bcf0-2f8d-4d4c-84e3-1b8710f0b6a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a776bce2-5fb6-4f52-94e1-09969e934da5" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c2a2bcf0-2f8d-4d4c-84e3-1b8710f0b6a4" xlink:to="loc_srt_MaximumMember_a776bce2-5fb6-4f52-94e1-09969e934da5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_0d415657-3cd0-453a-9af6-ced13c884377" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3e0382b5-42be-4ab7-aa09-64f15f8f9827" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_0d415657-3cd0-453a-9af6-ced13c884377" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_0aa85944-13cf-4b27-8e88-cf17417ff0d3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_0d415657-3cd0-453a-9af6-ced13c884377" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_0aa85944-13cf-4b27-8e88-cf17417ff0d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Phase3ClinicalTrialFelzartamabOneMember_0f2003cf-3dfd-4f7a-8c35-142cd327a382" xlink:href="biib-20250930.xsd#biib_Phase3ClinicalTrialFelzartamabOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_0aa85944-13cf-4b27-8e88-cf17417ff0d3" xlink:to="loc_biib_Phase3ClinicalTrialFelzartamabOneMember_0f2003cf-3dfd-4f7a-8c35-142cd327a382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Phase3ClinicalTrialFelzartamabTwoMember_68d41f09-90dd-410a-867d-5f241dd159f6" xlink:href="biib-20250930.xsd#biib_Phase3ClinicalTrialFelzartamabTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_0aa85944-13cf-4b27-8e88-cf17417ff0d3" xlink:to="loc_biib_Phase3ClinicalTrialFelzartamabTwoMember_68d41f09-90dd-410a-867d-5f241dd159f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_72cea673-d083-4910-b75e-bd9d24ba16b8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_3e0382b5-42be-4ab7-aa09-64f15f8f9827" xlink:to="loc_us-gaap_DebtInstrumentLineItems_72cea673-d083-4910-b75e-bd9d24ba16b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_6acafe35-17ae-4a8d-bee4-d9463ddd407d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72cea673-d083-4910-b75e-bd9d24ba16b8" xlink:to="loc_us-gaap_AssetImpairmentCharges_6acafe35-17ae-4a8d-bee4-d9463ddd407d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_e993e4a4-eada-45de-8b0d-fea79647a20d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72cea673-d083-4910-b75e-bd9d24ba16b8" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_e993e4a4-eada-45de-8b0d-fea79647a20d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_eb649bd4-1044-4c7c-89fa-e246e8817e1a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72cea673-d083-4910-b75e-bd9d24ba16b8" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_eb649bd4-1044-4c7c-89fa-e246e8817e1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_8c746559-84d7-4c5e-86f5-c764b42d8627" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_72cea673-d083-4910-b75e-bd9d24ba16b8" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_8c746559-84d7-4c5e-86f5-c764b42d8627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasuresLevel3AssetsandLiabilitiesHeldatFairValueDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#FairValueMeasuresLevel3AssetsandLiabilitiesHeldatFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasuresLevel3AssetsandLiabilitiesHeldatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_a9667b3f-af35-4561-9d56-0e8411fc09f6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_7ae727e2-64f8-4843-bd8d-b1f63edab6a1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_a9667b3f-af35-4561-9d56-0e8411fc09f6" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_7ae727e2-64f8-4843-bd8d-b1f63edab6a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_be472a89-728b-41c5-b094-d53461e61ad3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_7ae727e2-64f8-4843-bd8d-b1f63edab6a1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_be472a89-728b-41c5-b094-d53461e61ad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d31becaa-34fe-45fd-82b3-2646efd5b47c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_be472a89-728b-41c5-b094-d53461e61ad3" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d31becaa-34fe-45fd-82b3-2646efd5b47c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_390ea95e-6d3f-45fa-8ac2-8ac6fd667857" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d31becaa-34fe-45fd-82b3-2646efd5b47c" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_390ea95e-6d3f-45fa-8ac2-8ac6fd667857" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_67b83ed8-8907-459f-bbda-20481e8310b5" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_7ae727e2-64f8-4843-bd8d-b1f63edab6a1" xlink:to="loc_srt_RangeAxis_67b83ed8-8907-459f-bbda-20481e8310b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_adc75c71-c257-4aac-b29c-f39f989bd865" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_67b83ed8-8907-459f-bbda-20481e8310b5" xlink:to="loc_srt_RangeMember_adc75c71-c257-4aac-b29c-f39f989bd865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_510a8258-a840-452f-9740-e7f67386f6d2" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_adc75c71-c257-4aac-b29c-f39f989bd865" xlink:to="loc_srt_MinimumMember_510a8258-a840-452f-9740-e7f67386f6d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d379d64c-01cd-4c68-bc84-55041faa1f05" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_adc75c71-c257-4aac-b29c-f39f989bd865" xlink:to="loc_srt_MaximumMember_d379d64c-01cd-4c68-bc84-55041faa1f05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_3b36772c-9851-4061-8d97-6f74ab7d4383" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_adc75c71-c257-4aac-b29c-f39f989bd865" xlink:to="loc_srt_WeightedAverageMember_3b36772c-9851-4061-8d97-6f74ab7d4383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_f60d7376-cd7b-4b27-b476-0e50d34af899" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_7ae727e2-64f8-4843-bd8d-b1f63edab6a1" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_f60d7376-cd7b-4b27-b476-0e50d34af899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_fb1180d0-c10c-42b1-8898-3c9a6fa8025a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_f60d7376-cd7b-4b27-b476-0e50d34af899" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_fb1180d0-c10c-42b1-8898-3c9a6fa8025a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_7044f6db-2053-4246-9a6c-477ff1708170" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_fb1180d0-c10c-42b1-8898-3c9a6fa8025a" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_7044f6db-2053-4246-9a6c-477ff1708170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_214c8cf6-97de-4155-9427-aef79f1e183f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_7ae727e2-64f8-4843-bd8d-b1f63edab6a1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_214c8cf6-97de-4155-9427-aef79f1e183f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_72500bf1-a6c3-479c-848e-6f64695cfe03" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_214c8cf6-97de-4155-9427-aef79f1e183f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_72500bf1-a6c3-479c-848e-6f64695cfe03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_7ba21797-5b67-49e6-9554-d68b2f928fe3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_214c8cf6-97de-4155-9427-aef79f1e183f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_7ba21797-5b67-49e6-9554-d68b2f928fe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsContingentConsiderationObligationsDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#FairValueMeasurementsContingentConsiderationObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsContingentConsiderationObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_78260ae1-5c2f-4290-abf0-f78f9ae32165" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1db25433-ad71-4d9e-9aad-2870983deb07" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_78260ae1-5c2f-4290-abf0-f78f9ae32165" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1db25433-ad71-4d9e-9aad-2870983deb07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_5fc16ee7-6027-47ba-b48e-37cca227e87f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1db25433-ad71-4d9e-9aad-2870983deb07" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_5fc16ee7-6027-47ba-b48e-37cca227e87f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_c35fb8de-eead-4b09-8892-4d2269bc7956" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1db25433-ad71-4d9e-9aad-2870983deb07" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases_c35fb8de-eead-4b09-8892-4d2269bc7956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_3d4638dc-a2c3-428d-8100-cb9acef4a1e5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1db25433-ad71-4d9e-9aad-2870983deb07" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_3d4638dc-a2c3-428d-8100-cb9acef4a1e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements_8bf4b90e-a99f-4dc6-a4a2-d6bcea473547" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1db25433-ad71-4d9e-9aad-2870983deb07" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements_8bf4b90e-a99f-4dc6-a4a2-d6bcea473547" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_91972a06-2840-4472-8057-89a851bbbc54" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1db25433-ad71-4d9e-9aad-2870983deb07" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_91972a06-2840-4472-8057-89a851bbbc54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FairValueMeasurementsDebtInstrumentsDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#FairValueMeasurementsDebtInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FairValueMeasurementsDebtInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_dde52642-533d-43fa-b0e2-2ba4cb788ae8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_ffae3fb3-1007-4b9e-8bae-0b3946225b38" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_dde52642-533d-43fa-b0e2-2ba4cb788ae8" xlink:to="loc_us-gaap_DebtInstrumentTable_ffae3fb3-1007-4b9e-8bae-0b3946225b38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_7092e690-92df-42e9-9517-8217d3c96a15" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ffae3fb3-1007-4b9e-8bae-0b3946225b38" xlink:to="loc_us-gaap_DebtInstrumentAxis_7092e690-92df-42e9-9517-8217d3c96a15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_d4c3db1c-1add-40c5-9dde-07ddf2f5f187" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_7092e690-92df-42e9-9517-8217d3c96a15" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_d4c3db1c-1add-40c5-9dde-07ddf2f5f187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_b34beec2-eada-4575-9030-1da361cab2da" xlink:href="biib-20250930.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4c3db1c-1add-40c5-9dde-07ddf2f5f187" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_b34beec2-eada-4575-9030-1da361cab2da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2.25SeniorNotesdueMay12030Member_71444e59-e2da-4418-9ae7-6cd2ebdee57b" xlink:href="biib-20250930.xsd#biib_A2.25SeniorNotesdueMay12030Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4c3db1c-1add-40c5-9dde-07ddf2f5f187" xlink:to="loc_biib_A2.25SeniorNotesdueMay12030Member_71444e59-e2da-4418-9ae7-6cd2ebdee57b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A5.050SeniorNotesDueJanuary152031Member_6d46b71c-1d6e-4964-98f6-ae8371251b76" xlink:href="biib-20250930.xsd#biib_A5.050SeniorNotesDueJanuary152031Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4c3db1c-1add-40c5-9dde-07ddf2f5f187" xlink:to="loc_biib_A5.050SeniorNotesDueJanuary152031Member_6d46b71c-1d6e-4964-98f6-ae8371251b76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A5.750SeniorNotesDueMay152035Member_033cc7b4-94bf-4215-a311-4e9cbd6a61b9" xlink:href="biib-20250930.xsd#biib_A5.750SeniorNotesDueMay152035Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4c3db1c-1add-40c5-9dde-07ddf2f5f187" xlink:to="loc_biib_A5.750SeniorNotesDueMay152035Member_033cc7b4-94bf-4215-a311-4e9cbd6a61b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_1ba06f0b-2457-483e-8e8d-7dac091038f8" xlink:href="biib-20250930.xsd#biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4c3db1c-1add-40c5-9dde-07ddf2f5f187" xlink:to="loc_biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember_1ba06f0b-2457-483e-8e8d-7dac091038f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A3.15SeniorNotesdueMay12050Member_260379bb-0c2b-408f-986c-978aad77a437" xlink:href="biib-20250930.xsd#biib_A3.15SeniorNotesdueMay12050Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4c3db1c-1add-40c5-9dde-07ddf2f5f187" xlink:to="loc_biib_A3.15SeniorNotesdueMay12050Member_260379bb-0c2b-408f-986c-978aad77a437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotes3.250DueFebruary152051Member_9a07b3ff-2087-4acd-b16d-17e01cd9f08f" xlink:href="biib-20250930.xsd#biib_SeniorNotes3.250DueFebruary152051Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4c3db1c-1add-40c5-9dde-07ddf2f5f187" xlink:to="loc_biib_SeniorNotes3.250DueFebruary152051Member_9a07b3ff-2087-4acd-b16d-17e01cd9f08f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A6.450SeniorNotesDueMay152055Member_c3ac5b62-1b0a-431a-984d-f414142ba7dc" xlink:href="biib-20250930.xsd#biib_A6.450SeniorNotesDueMay152055Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4c3db1c-1add-40c5-9dde-07ddf2f5f187" xlink:to="loc_biib_A6.450SeniorNotesDueMay152055Member_c3ac5b62-1b0a-431a-984d-f414142ba7dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NonCurrentPortionOfNotesPayableAndTermLoanMember_012c0c46-69c7-4dd1-8698-ce08a3af9a2f" xlink:href="biib-20250930.xsd#biib_NonCurrentPortionOfNotesPayableAndTermLoanMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_d4c3db1c-1add-40c5-9dde-07ddf2f5f187" xlink:to="loc_biib_NonCurrentPortionOfNotesPayableAndTermLoanMember_012c0c46-69c7-4dd1-8698-ce08a3af9a2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_47a94d76-99c8-405a-8ffb-6a02a15aef2b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ffae3fb3-1007-4b9e-8bae-0b3946225b38" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_47a94d76-99c8-405a-8ffb-6a02a15aef2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_8efb4807-c3e5-43f6-97ac-ac33ca45ab11" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_47a94d76-99c8-405a-8ffb-6a02a15aef2b" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_8efb4807-c3e5-43f6-97ac-ac33ca45ab11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_eed9dc94-6fd0-402d-a566-558be146744d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_8efb4807-c3e5-43f6-97ac-ac33ca45ab11" xlink:to="loc_us-gaap_SeniorNotesMember_eed9dc94-6fd0-402d-a566-558be146744d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_77f8cd89-0b59-435b-b492-3d552d601ce8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ffae3fb3-1007-4b9e-8bae-0b3946225b38" xlink:to="loc_us-gaap_DebtInstrumentLineItems_77f8cd89-0b59-435b-b492-3d552d601ce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_NotesPayableCurrentFairValueDisclosure_d0ad71da-9c7c-4c82-9ac0-a34b82fa9120" xlink:href="biib-20250930.xsd#biib_NotesPayableCurrentFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_77f8cd89-0b59-435b-b492-3d552d601ce8" xlink:to="loc_biib_NotesPayableCurrentFairValueDisclosure_d0ad71da-9c7c-4c82-9ac0-a34b82fa9120" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_a03fc63a-62c9-47e4-af46-4b7c1bae5a05" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_77f8cd89-0b59-435b-b492-3d552d601ce8" xlink:to="loc_us-gaap_NotesPayableCurrent_a03fc63a-62c9-47e4-af46-4b7c1bae5a05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableFairValueDisclosure_4097c647-6b0b-4488-be41-7c8e998a8a46" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayableFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_77f8cd89-0b59-435b-b492-3d552d601ce8" xlink:to="loc_us-gaap_NotesPayableFairValueDisclosure_4097c647-6b0b-4488-be41-7c8e998a8a46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayable_3f137267-b9ae-410c-9767-d78614304d08" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NotesPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_77f8cd89-0b59-435b-b492-3d552d601ce8" xlink:to="loc_us-gaap_NotesPayable_3f137267-b9ae-410c-9767-d78614304d08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9cf88d3e-f6c9-4a57-b415-d60f479a0ece" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_77f8cd89-0b59-435b-b492-3d552d601ce8" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9cf88d3e-f6c9-4a57-b415-d60f479a0ece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsSummaryoffinancialassetswithmaturitiesoflessthan90daysincludedwithincashandcashequivalentsDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#FinancialInstrumentsSummaryoffinancialassetswithmaturitiesoflessthan90daysincludedwithincashandcashequivalentsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsSummaryoffinancialassetswithmaturitiesoflessthan90daysincludedwithincashandcashequivalentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_41d76a87-6beb-4b31-9e93-6c4a843305ab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_9a33c62f-5e67-4c12-b97c-d475393f48a8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_41d76a87-6beb-4b31-9e93-6c4a843305ab" xlink:to="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_9a33c62f-5e67-4c12-b97c-d475393f48a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_d48b230d-0104-47ba-b01d-b2d9df7c320e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_9a33c62f-5e67-4c12-b97c-d475393f48a8" xlink:to="loc_us-gaap_InvestmentTypeAxis_d48b230d-0104-47ba-b01d-b2d9df7c320e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_febe4545-43a5-439e-b755-cb1592d9f321" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_d48b230d-0104-47ba-b01d-b2d9df7c320e" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_febe4545-43a5-439e-b755-cb1592d9f321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_fe788442-55e9-4943-8584-04b7a6bd9af1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_febe4545-43a5-439e-b755-cb1592d9f321" xlink:to="loc_us-gaap_CommercialPaperMember_fe788442-55e9-4943-8584-04b7a6bd9af1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_96eb1738-fc95-4d41-9bac-5ca8fd210068" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_febe4545-43a5-439e-b755-cb1592d9f321" xlink:to="loc_us-gaap_MoneyMarketFundsMember_96eb1738-fc95-4d41-9bac-5ca8fd210068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_a25c15b8-04a7-418a-b7a4-dd6dff3d7b04" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_febe4545-43a5-439e-b755-cb1592d9f321" xlink:to="loc_us-gaap_DebtSecuritiesMember_a25c15b8-04a7-418a-b7a4-dd6dff3d7b04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_d879c17f-82cf-456d-bfc4-b61419c43e50" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_9a33c62f-5e67-4c12-b97c-d475393f48a8" xlink:to="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_d879c17f-82cf-456d-bfc4-b61419c43e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_2caf7d1c-7380-4f20-bfb2-5173ec2a7fb3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_d879c17f-82cf-456d-bfc4-b61419c43e50" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_2caf7d1c-7380-4f20-bfb2-5173ec2a7fb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsMarketabledebtandequitysecuritiesDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#FinancialInstrumentsMarketabledebtandequitysecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsMarketabledebtandequitysecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_43dd2759-e846-4975-b912-1224c88634f7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_8f26c8fb-d140-454c-8275-1a7bceb84cd9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_43dd2759-e846-4975-b912-1224c88634f7" xlink:to="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_8f26c8fb-d140-454c-8275-1a7bceb84cd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_55cc3639-f7e6-4194-88f9-8d04fac8134f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_8f26c8fb-d140-454c-8275-1a7bceb84cd9" xlink:to="loc_us-gaap_FinancialInstrumentAxis_55cc3639-f7e6-4194-88f9-8d04fac8134f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e118f575-0f8e-4199-b357-cf5bfaa40392" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_55cc3639-f7e6-4194-88f9-8d04fac8134f" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e118f575-0f8e-4199-b357-cf5bfaa40392" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CorporateDebtSecuritiesCurrentMember_94862858-a414-426d-a44d-9ae268bab769" xlink:href="biib-20250930.xsd#biib_CorporateDebtSecuritiesCurrentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e118f575-0f8e-4199-b357-cf5bfaa40392" xlink:to="loc_biib_CorporateDebtSecuritiesCurrentMember_94862858-a414-426d-a44d-9ae268bab769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GovernmentSecuritiesCurrentMember_88bf6b8f-d27a-42ad-b972-36f54e664c8c" xlink:href="biib-20250930.xsd#biib_GovernmentSecuritiesCurrentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e118f575-0f8e-4199-b357-cf5bfaa40392" xlink:to="loc_biib_GovernmentSecuritiesCurrentMember_88bf6b8f-d27a-42ad-b972-36f54e664c8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesNonCurrentMember_ff96cc8d-7f3b-42a9-b061-2ee8b216ee5b" xlink:href="biib-20250930.xsd#biib_EquitySecuritiesNonCurrentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_e118f575-0f8e-4199-b357-cf5bfaa40392" xlink:to="loc_biib_EquitySecuritiesNonCurrentMember_ff96cc8d-7f3b-42a9-b061-2ee8b216ee5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_37e1a58a-532c-4151-b66d-64023b4fcc78" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_8f26c8fb-d140-454c-8275-1a7bceb84cd9" xlink:to="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_37e1a58a-532c-4151-b66d-64023b4fcc78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract_14227c70-4a22-4b3a-bd2d-08611f618510" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_37e1a58a-532c-4151-b66d-64023b4fcc78" xlink:to="loc_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract_14227c70-4a22-4b3a-bd2d-08611f618510" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_97bcd95b-5bbe-4116-85b2-20af7105da32" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract_14227c70-4a22-4b3a-bd2d-08611f618510" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_97bcd95b-5bbe-4116-85b2-20af7105da32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c4cb05b8-3538-4f0c-9bf1-dd5e7a96a8f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract_14227c70-4a22-4b3a-bd2d-08611f618510" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c4cb05b8-3538-4f0c-9bf1-dd5e7a96a8f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d21735d3-e461-4b3a-87f7-a27372f1e4eb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract_14227c70-4a22-4b3a-bd2d-08611f618510" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d21735d3-e461-4b3a-87f7-a27372f1e4eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4d55295f-672f-470e-b8ec-f7b86388f146" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract_14227c70-4a22-4b3a-bd2d-08611f618510" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4d55295f-672f-470e-b8ec-f7b86388f146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_e656aff7-58db-453b-a340-c7395a3cf6ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_37e1a58a-532c-4151-b66d-64023b4fcc78" xlink:to="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_e656aff7-58db-453b-a340-c7395a3cf6ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiCost_2d79f56c-7f5a-4f8d-b724-d09fb8263e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_e656aff7-58db-453b-a340-c7395a3cf6ad" xlink:to="loc_us-gaap_EquitySecuritiesFvNiCost_2d79f56c-7f5a-4f8d-b724-d09fb8263e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_6d5a1008-5079-45b2-8830-d442188aba23" xlink:href="biib-20250930.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_e656aff7-58db-453b-a340-c7395a3cf6ad" xlink:to="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax_6d5a1008-5079-45b2-8830-d442188aba23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_1ea6a2ee-4b71-4381-acc4-01dbd3525d02" xlink:href="biib-20250930.xsd#biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_e656aff7-58db-453b-a340-c7395a3cf6ad" xlink:to="loc_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax_1ea6a2ee-4b71-4381-acc4-01dbd3525d02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_6ed93b11-b01d-4f1c-a0a5-3a5eda251c94" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract_e656aff7-58db-453b-a340-c7395a3cf6ad" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_6ed93b11-b01d-4f1c-a0a5-3a5eda251c94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsSummaryofContractualMaturitiesDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#FinancialInstrumentsSummaryofContractualMaturitiesDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsSummaryofContractualMaturitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_bf79bc58-22a6-47be-8932-b27f8e09052c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_e96cac82-0259-44f5-9837-fd3dcf944e4b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_bf79bc58-22a6-47be-8932-b27f8e09052c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_e96cac82-0259-44f5-9837-fd3dcf944e4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_bb8b94ee-83fb-404d-a148-4460812b1f34" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_e96cac82-0259-44f5-9837-fd3dcf944e4b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_bb8b94ee-83fb-404d-a148-4460812b1f34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_e1f7e47b-1260-4f3c-b72f-f58cce71ae47" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_e96cac82-0259-44f5-9837-fd3dcf944e4b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_e1f7e47b-1260-4f3c-b72f-f58cce71ae47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_13a67516-0b94-42f5-9a78-c8542561ac94" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_bf79bc58-22a6-47be-8932-b27f8e09052c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_13a67516-0b94-42f5-9a78-c8542561ac94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_8e151b75-f4fc-4f4f-87b7-875a5f7585d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_13a67516-0b94-42f5-9a78-c8542561ac94" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_8e151b75-f4fc-4f4f-87b7-875a5f7585d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_7be0afc2-12c5-4867-81b8-045980a0c036" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_13a67516-0b94-42f5-9a78-c8542561ac94" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_7be0afc2-12c5-4867-81b8-045980a0c036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#FinancialInstrumentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c131a1eb-e558-40ff-9736-33a6728663bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_e4f317d8-732d-40fe-a2ba-7ca529fcebf5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_c131a1eb-e558-40ff-9736-33a6728663bb" xlink:to="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_e4f317d8-732d-40fe-a2ba-7ca529fcebf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_34ce332a-d39f-4fa3-95e0-05b41e0e291f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_e4f317d8-732d-40fe-a2ba-7ca529fcebf5" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_34ce332a-d39f-4fa3-95e0-05b41e0e291f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_fc7da3be-f625-45f6-8815-87ff8fc864a1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_34ce332a-d39f-4fa3-95e0-05b41e0e291f" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_fc7da3be-f625-45f6-8815-87ff8fc864a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_e2470ec8-8a6b-4b56-81b3-48f030c5cd80" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_fc7da3be-f625-45f6-8815-87ff8fc864a1" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_e2470ec8-8a6b-4b56-81b3-48f030c5cd80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_2252353a-ccba-45c4-961d-aa34dbf6f9c3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_e4f317d8-732d-40fe-a2ba-7ca529fcebf5" xlink:to="loc_us-gaap_FinancialInstrumentAxis_2252353a-ccba-45c4-961d-aa34dbf6f9c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4c366f1e-595d-4ae3-9a0e-1e9969dc973c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_2252353a-ccba-45c4-961d-aa34dbf6f9c3" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4c366f1e-595d-4ae3-9a0e-1e9969dc973c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StrategicInvestmentsMember_7349d9f2-b538-4ead-85e8-02d7f7abef3a" xlink:href="biib-20250930.xsd#biib_StrategicInvestmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_4c366f1e-595d-4ae3-9a0e-1e9969dc973c" xlink:to="loc_biib_StrategicInvestmentsMember_7349d9f2-b538-4ead-85e8-02d7f7abef3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_fc2b96e7-fee6-460f-8c4e-8e7d27b8711c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable_e4f317d8-732d-40fe-a2ba-7ca529fcebf5" xlink:to="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_fc2b96e7-fee6-460f-8c4e-8e7d27b8711c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DebtSecuritiesAvailableForSaleAverageMaturity_a7dcedb3-d79e-496c-bb0e-9fdd9b9b4ecc" xlink:href="biib-20250930.xsd#biib_DebtSecuritiesAvailableForSaleAverageMaturity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_fc2b96e7-fee6-460f-8c4e-8e7d27b8711c" xlink:to="loc_biib_DebtSecuritiesAvailableForSaleAverageMaturity_a7dcedb3-d79e-496c-bb0e-9fdd9b9b4ecc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StrategicInvestmentPortfolio_006e8bfe-af47-4ace-8247-3dcce4c9c72d" xlink:href="biib-20250930.xsd#biib_StrategicInvestmentPortfolio"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems_fc2b96e7-fee6-460f-8c4e-8e7d27b8711c" xlink:to="loc_biib_StrategicInvestmentPortfolio_006e8bfe-af47-4ace-8247-3dcce4c9c72d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsNarrativeDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#DerivativeInstrumentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_f04e21fa-b22e-49f1-a9a8-11a09ce6bd14" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_35efd3b5-ba13-44b2-84cf-605085f446ed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_f04e21fa-b22e-49f1-a9a8-11a09ce6bd14" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_35efd3b5-ba13-44b2-84cf-605085f446ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0846bff6-38e6-4041-8586-a4b5c724b937" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_35efd3b5-ba13-44b2-84cf-605085f446ed" xlink:to="loc_srt_RangeAxis_0846bff6-38e6-4041-8586-a4b5c724b937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a25739b0-d720-4aff-b54b-59a28f4b2c34" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_0846bff6-38e6-4041-8586-a4b5c724b937" xlink:to="loc_srt_RangeMember_a25739b0-d720-4aff-b54b-59a28f4b2c34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9092caa5-c1fe-4f5f-af43-28a4493ec722" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a25739b0-d720-4aff-b54b-59a28f4b2c34" xlink:to="loc_srt_MinimumMember_9092caa5-c1fe-4f5f-af43-28a4493ec722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1876fd04-d139-4f48-a335-2c409d321cb6" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a25739b0-d720-4aff-b54b-59a28f4b2c34" xlink:to="loc_srt_MaximumMember_1876fd04-d139-4f48-a335-2c409d321cb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_c168bbe3-795b-4c1f-8b21-2adf90b51cef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_35efd3b5-ba13-44b2-84cf-605085f446ed" xlink:to="loc_us-gaap_HedgingDesignationAxis_c168bbe3-795b-4c1f-8b21-2adf90b51cef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_95a8748d-cfb2-414c-8501-37cc450a52f9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_c168bbe3-795b-4c1f-8b21-2adf90b51cef" xlink:to="loc_us-gaap_HedgingDesignationDomain_95a8748d-cfb2-414c-8501-37cc450a52f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_9190c1f6-1b8f-4daf-be56-d48b4f6038e5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_95a8748d-cfb2-414c-8501-37cc450a52f9" xlink:to="loc_us-gaap_NondesignatedMember_9190c1f6-1b8f-4daf-be56-d48b4f6038e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_a0dd5028-d82b-4e32-b4b6-bc1d383a0fb7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_35efd3b5-ba13-44b2-84cf-605085f446ed" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_a0dd5028-d82b-4e32-b4b6-bc1d383a0fb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeRemainingMaturity1_ab93d3ef-a927-4957-b57b-b3e7845a0600" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeRemainingMaturity1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_a0dd5028-d82b-4e32-b4b6-bc1d383a0fb7" xlink:to="loc_us-gaap_DerivativeRemainingMaturity1_ab93d3ef-a927-4957-b57b-b3e7845a0600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months_83c6ab7c-d818-4cef-ae4e-553dd025e7ca" xlink:href="biib-20250930.xsd#biib_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_a0dd5028-d82b-4e32-b4b6-bc1d383a0fb7" xlink:to="loc_biib_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months_83c6ab7c-d818-4cef-ae4e-553dd025e7ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_84268e93-0e35-4b0f-97b1-05eae3ea0491" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_a0dd5028-d82b-4e32-b4b6-bc1d383a0fb7" xlink:to="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_84268e93-0e35-4b0f-97b1-05eae3ea0491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_4022df00-04ef-4c48-8609-a8ef66cdca9a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_a0dd5028-d82b-4e32-b4b6-bc1d383a0fb7" xlink:to="loc_us-gaap_DerivativeNotionalAmount_4022df00-04ef-4c48-8609-a8ef66cdca9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_41eef1f1-664d-4fd6-81a0-4b8c21734dca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_a0dd5028-d82b-4e32-b4b6-bc1d383a0fb7" xlink:to="loc_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments_41eef1f1-664d-4fd6-81a0-4b8c21734dca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsNotionalAmountofForeignCurrencyForwardContractsandForeignCurrencyOptionsDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#DerivativeInstrumentsNotionalAmountofForeignCurrencyForwardContractsandForeignCurrencyOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsNotionalAmountofForeignCurrencyForwardContractsandForeignCurrencyOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_c3ba9bab-8c74-4f1c-b7b9-9302836cb601" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_18b11584-d336-40a7-a226-89b7c51202db" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_c3ba9bab-8c74-4f1c-b7b9-9302836cb601" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_18b11584-d336-40a7-a226-89b7c51202db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CurrencyAxis_1687c563-198e-45e7-bc94-fb2c2e49af5b" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CurrencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_18b11584-d336-40a7-a226-89b7c51202db" xlink:to="loc_srt_CurrencyAxis_1687c563-198e-45e7-bc94-fb2c2e49af5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_AllCurrenciesDomain_b5a7b27f-807e-43bc-b39f-c0ec5d9801ff" xlink:href="https://xbrl.sec.gov/currency/2025/currency-2025.xsd#currency_AllCurrenciesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_1687c563-198e-45e7-bc94-fb2c2e49af5b" xlink:to="loc_currency_AllCurrenciesDomain_b5a7b27f-807e-43bc-b39f-c0ec5d9801ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_EUR_4369c9ed-12ee-47cd-9146-ac8d69e12e06" xlink:href="https://xbrl.sec.gov/currency/2025/currency-2025.xsd#currency_EUR"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_b5a7b27f-807e-43bc-b39f-c0ec5d9801ff" xlink:to="loc_currency_EUR_4369c9ed-12ee-47cd-9146-ac8d69e12e06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_GBP_7fccb827-487c-458b-8d9e-4d36a5ca7088" xlink:href="https://xbrl.sec.gov/currency/2025/currency-2025.xsd#currency_GBP"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_b5a7b27f-807e-43bc-b39f-c0ec5d9801ff" xlink:to="loc_currency_GBP_7fccb827-487c-458b-8d9e-4d36a5ca7088" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CHF_1a667af7-89fa-4628-bfff-45c24d1c702d" xlink:href="https://xbrl.sec.gov/currency/2025/currency-2025.xsd#currency_CHF"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_b5a7b27f-807e-43bc-b39f-c0ec5d9801ff" xlink:to="loc_currency_CHF_1a667af7-89fa-4628-bfff-45c24d1c702d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_currency_CAD_fcb9d51a-9533-4f68-bf05-87e791501562" xlink:href="https://xbrl.sec.gov/currency/2025/currency-2025.xsd#currency_CAD"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_b5a7b27f-807e-43bc-b39f-c0ec5d9801ff" xlink:to="loc_currency_CAD_fcb9d51a-9533-4f68-bf05-87e791501562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_e0f657ae-af8a-44d2-a356-b94a90693317" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_18b11584-d336-40a7-a226-89b7c51202db" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_e0f657ae-af8a-44d2-a356-b94a90693317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_90386b75-afaa-4c9c-b049-6c00fa62604e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_e0f657ae-af8a-44d2-a356-b94a90693317" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_90386b75-afaa-4c9c-b049-6c00fa62604e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_3341cd05-2fa3-4b6c-aaae-d197ccb080c1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_90386b75-afaa-4c9c-b049-6c00fa62604e" xlink:to="loc_us-gaap_ForeignExchangeContractMember_3341cd05-2fa3-4b6c-aaae-d197ccb080c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_ca2865b5-9c55-42d4-a18e-a7885cd7d30e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_18b11584-d336-40a7-a226-89b7c51202db" xlink:to="loc_us-gaap_HedgingDesignationAxis_ca2865b5-9c55-42d4-a18e-a7885cd7d30e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_6cacfb62-e873-4237-b452-45ea6ada12e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_ca2865b5-9c55-42d4-a18e-a7885cd7d30e" xlink:to="loc_us-gaap_HedgingDesignationDomain_6cacfb62-e873-4237-b452-45ea6ada12e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_b97ba3a8-e1b3-47e6-9c7b-c3924e880f95" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_6cacfb62-e873-4237-b452-45ea6ada12e7" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_b97ba3a8-e1b3-47e6-9c7b-c3924e880f95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_b1a6d5bd-e03a-45e5-a10b-e9b992050eab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_18b11584-d336-40a7-a226-89b7c51202db" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_b1a6d5bd-e03a-45e5-a10b-e9b992050eab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_e56f332c-3365-4b4c-ac64-328cf319c1b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_b1a6d5bd-e03a-45e5-a10b-e9b992050eab" xlink:to="loc_us-gaap_DerivativeNotionalAmount_e56f332c-3365-4b4c-ac64-328cf319c1b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsPretaxPortionoftheFairValueofForeignCurrencyForwardContractsandForeignCurrencyOptionsDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#DerivativeInstrumentsPretaxPortionoftheFairValueofForeignCurrencyForwardContractsandForeignCurrencyOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsPretaxPortionoftheFairValueofForeignCurrencyForwardContractsandForeignCurrencyOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_8b7932cc-d47b-4cc3-bd24-3ec01bfb0e39" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedGainOnDerivatives_a08f1096-28c4-4a70-90f5-ec6fe8a2ab0f" xlink:href="biib-20250930.xsd#biib_UnrealizedGainOnDerivatives"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_8b7932cc-d47b-4cc3-bd24-3ec01bfb0e39" xlink:to="loc_biib_UnrealizedGainOnDerivatives_a08f1096-28c4-4a70-90f5-ec6fe8a2ab0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UnrealizedLossOnDerivatives_3ec57425-1ea2-4196-8911-7d92d65a9d14" xlink:href="biib-20250930.xsd#biib_UnrealizedLossOnDerivatives"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_8b7932cc-d47b-4cc3-bd24-3ec01bfb0e39" xlink:to="loc_biib_UnrealizedLossOnDerivatives_3ec57425-1ea2-4196-8911-7d92d65a9d14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnDerivatives_fdd317cf-78c0-4c2b-8280-2ade5aa968af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrealizedGainLossOnDerivatives"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_8b7932cc-d47b-4cc3-bd24-3ec01bfb0e39" xlink:to="loc_us-gaap_UnrealizedGainLossOnDerivatives_fdd317cf-78c0-4c2b-8280-2ade5aa968af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsEffectofForeignCurrencyForwardContractsandForwardCurrencyOptionsDesignatedasHedgingInstrumentsDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#DerivativeInstrumentsEffectofForeignCurrencyForwardContractsandForwardCurrencyOptionsDesignatedasHedgingInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsEffectofForeignCurrencyForwardContractsandForwardCurrencyOptionsDesignatedasHedgingInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_31442c02-1b75-4677-b674-9e213b10c604" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b178afb5-37fb-4858-b73e-a7be6eadef32" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_31442c02-1b75-4677-b674-9e213b10c604" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b178afb5-37fb-4858-b73e-a7be6eadef32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_a81622c2-8028-4bb9-a0c1-c214cc85c34f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b178afb5-37fb-4858-b73e-a7be6eadef32" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_a81622c2-8028-4bb9-a0c1-c214cc85c34f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_f9a321f7-0ef2-4909-8658-89130bf19067" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_a81622c2-8028-4bb9-a0c1-c214cc85c34f" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_f9a321f7-0ef2-4909-8658-89130bf19067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_07b94c5d-0f63-4bcb-b27a-a3ab60979ace" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_f9a321f7-0ef2-4909-8658-89130bf19067" xlink:to="loc_us-gaap_ForeignExchangeContractMember_07b94c5d-0f63-4bcb-b27a-a3ab60979ace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_eed5620e-c9dd-4bc4-92d8-89862bc16a8c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b178afb5-37fb-4858-b73e-a7be6eadef32" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_eed5620e-c9dd-4bc4-92d8-89862bc16a8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_8c2bf510-7104-494b-9e58-3e866bdf825f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_eed5620e-c9dd-4bc4-92d8-89862bc16a8c" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_8c2bf510-7104-494b-9e58-3e866bdf825f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_215a0d97-104c-455b-932c-921632419513" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8c2bf510-7104-494b-9e58-3e866bdf825f" xlink:to="loc_us-gaap_SalesMember_215a0d97-104c-455b-932c-921632419513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenseMember_463951fc-3346-4da1-8a53-dce2ae9d30d6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_8c2bf510-7104-494b-9e58-3e866bdf825f" xlink:to="loc_us-gaap_OperatingExpenseMember_463951fc-3346-4da1-8a53-dce2ae9d30d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_8669092b-0278-4d1f-a15c-f3ceb11a4567" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b178afb5-37fb-4858-b73e-a7be6eadef32" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_8669092b-0278-4d1f-a15c-f3ceb11a4567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_78f224d8-ea35-48da-8835-ccb3321f7b4d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_8669092b-0278-4d1f-a15c-f3ceb11a4567" xlink:to="loc_us-gaap_HedgingRelationshipDomain_78f224d8-ea35-48da-8835-ccb3321f7b4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashflowsrevenueMember_87e6a219-99c6-42e4-b137-8fdfc833342d" xlink:href="biib-20250930.xsd#biib_CashflowsrevenueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_78f224d8-ea35-48da-8835-ccb3321f7b4d" xlink:to="loc_biib_CashflowsrevenueMember_87e6a219-99c6-42e4-b137-8fdfc833342d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CashflowsoperatingexpensesMember_2be4d217-3e06-4c52-85d1-8bca00c51a0d" xlink:href="biib-20250930.xsd#biib_CashflowsoperatingexpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_78f224d8-ea35-48da-8835-ccb3321f7b4d" xlink:to="loc_biib_CashflowsoperatingexpensesMember_2be4d217-3e06-4c52-85d1-8bca00c51a0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_3ee2fe3f-836d-4f7d-aeb5-d225a3b50840" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_b178afb5-37fb-4858-b73e-a7be6eadef32" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_3ee2fe3f-836d-4f7d-aeb5-d225a3b50840" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_07d3c4ac-46a2-4441-8665-96679956eee1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_3ee2fe3f-836d-4f7d-aeb5-d225a3b50840" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_07d3c4ac-46a2-4441-8665-96679956eee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_6686c415-ba49-4695-ad82-4eafe550cd64" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_3ee2fe3f-836d-4f7d-aeb5-d225a3b50840" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_6686c415-ba49-4695-ad82-4eafe550cd64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/DerivativeInstrumentsSummaryofFairValueandPresentationofDerivativesDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#DerivativeInstrumentsSummaryofFairValueandPresentationofDerivativesDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/DerivativeInstrumentsSummaryofFairValueandPresentationofDerivativesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_daa80460-907d-490d-b087-6484119d76ae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_85f2a9a1-570a-455a-a133-6b4e01896c4b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_daa80460-907d-490d-b087-6484119d76ae" xlink:to="loc_us-gaap_DerivativeTable_85f2a9a1-570a-455a-a133-6b4e01896c4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_7186f2be-df18-4a2b-8031-753210c434be" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_85f2a9a1-570a-455a-a133-6b4e01896c4b" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_7186f2be-df18-4a2b-8031-753210c434be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_622a0e40-5ee5-4d09-8097-8d53ad90aaef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_7186f2be-df18-4a2b-8031-753210c434be" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_622a0e40-5ee5-4d09-8097-8d53ad90aaef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_3fa567da-a0ec-4677-808b-2774fffadb7f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_622a0e40-5ee5-4d09-8097-8d53ad90aaef" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_3fa567da-a0ec-4677-808b-2774fffadb7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesMember_9404de19-8875-45a6-8403-674766ebba04" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_622a0e40-5ee5-4d09-8097-8d53ad90aaef" xlink:to="loc_us-gaap_AccruedLiabilitiesMember_9404de19-8875-45a6-8403-674766ebba04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_67e24dde-e646-4f4b-bf9a-e9a67bd1abeb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_622a0e40-5ee5-4d09-8097-8d53ad90aaef" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_67e24dde-e646-4f4b-bf9a-e9a67bd1abeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_bfb2c9b8-5e02-4ec8-943f-5eb65ec36fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_85f2a9a1-570a-455a-a133-6b4e01896c4b" xlink:to="loc_us-gaap_HedgingDesignationAxis_bfb2c9b8-5e02-4ec8-943f-5eb65ec36fe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_ada57321-ab33-48ea-a044-1fc5846626b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_bfb2c9b8-5e02-4ec8-943f-5eb65ec36fe2" xlink:to="loc_us-gaap_HedgingDesignationDomain_ada57321-ab33-48ea-a044-1fc5846626b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_86557774-73a9-4b8c-b978-15ebe03f6e14" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_ada57321-ab33-48ea-a044-1fc5846626b9" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_86557774-73a9-4b8c-b978-15ebe03f6e14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_e020c343-eb81-4200-8e3b-4873d041f173" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_ada57321-ab33-48ea-a044-1fc5846626b9" xlink:to="loc_us-gaap_NondesignatedMember_e020c343-eb81-4200-8e3b-4873d041f173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_abbc45ef-381c-4fa6-ad8f-ca1b0b450337" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_85f2a9a1-570a-455a-a133-6b4e01896c4b" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_abbc45ef-381c-4fa6-ad8f-ca1b0b450337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_8273dd0d-fee4-4490-bef9-98e2061e1934" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_abbc45ef-381c-4fa6-ad8f-ca1b0b450337" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_8273dd0d-fee4-4490-bef9-98e2061e1934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_ec012c95-2c23-42e3-9dff-6e54c47fb3ef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_8273dd0d-fee4-4490-bef9-98e2061e1934" xlink:to="loc_us-gaap_ForeignExchangeContractMember_ec012c95-2c23-42e3-9dff-6e54c47fb3ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_8d27f978-3d97-4d98-aaa1-eb866209dcd7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_85f2a9a1-570a-455a-a133-6b4e01896c4b" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_8d27f978-3d97-4d98-aaa1-eb866209dcd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_8e4c188e-79b2-4c5d-88c1-b49eb475b9c8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_8d27f978-3d97-4d98-aaa1-eb866209dcd7" xlink:to="loc_us-gaap_HedgingRelationshipDomain_8e4c188e-79b2-4c5d-88c1-b49eb475b9c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_d82d34a0-479e-44ca-9872-b775ce95b6ed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_8e4c188e-79b2-4c5d-88c1-b49eb475b9c8" xlink:to="loc_us-gaap_CashFlowHedgingMember_d82d34a0-479e-44ca-9872-b775ce95b6ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_7fae1a23-adb2-4f0e-b3d3-18dba1b694ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_85f2a9a1-570a-455a-a133-6b4e01896c4b" xlink:to="loc_us-gaap_DerivativeLineItems_7fae1a23-adb2-4f0e-b3d3-18dba1b694ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_3d9d0fc9-2a7d-4d30-98ec-3cb617ca2221" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_7fae1a23-adb2-4f0e-b3d3-18dba1b694ad" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_3d9d0fc9-2a7d-4d30-98ec-3cb617ca2221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_37529cac-df4f-445b-a56e-982d9421f8fc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_7fae1a23-adb2-4f0e-b3d3-18dba1b694ad" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_37529cac-df4f-445b-a56e-982d9421f8fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#PropertyPlantandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_df3732e4-382b-4680-9c97-5bb256336d13" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_bd609165-4828-4d57-bff0-3a32b65aba39" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_df3732e4-382b-4680-9c97-5bb256336d13" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_bd609165-4828-4d57-bff0-3a32b65aba39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_8678c582-82d6-4df5-a742-d35cff7acf1a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_df3732e4-382b-4680-9c97-5bb256336d13" xlink:to="loc_us-gaap_Depreciation_8678c582-82d6-4df5-a742-d35cff7acf1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_52107095-192d-4a5a-b747-1df854085bf4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_799e8d88-aa42-4d2f-bb15-441c5e374266" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_52107095-192d-4a5a-b747-1df854085bf4" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_799e8d88-aa42-4d2f-bb15-441c5e374266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_2efb24d6-2718-4854-bafd-5770aaff850f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_799e8d88-aa42-4d2f-bb15-441c5e374266" xlink:to="loc_us-gaap_LeaseContractualTermAxis_2efb24d6-2718-4854-bafd-5770aaff850f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_86ff991e-4a4f-4271-80bb-cede2de29425" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermAxis_2efb24d6-2718-4854-bafd-5770aaff850f" xlink:to="loc_us-gaap_LeaseContractualTermDomain_86ff991e-4a4f-4271-80bb-cede2de29425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_HeadquartersLeaseFiveYearRenewalOptionMember_0cac393c-b7eb-4148-92f6-22f5711b1f18" xlink:href="biib-20250930.xsd#biib_HeadquartersLeaseFiveYearRenewalOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_86ff991e-4a4f-4271-80bb-cede2de29425" xlink:to="loc_biib_HeadquartersLeaseFiveYearRenewalOptionMember_0cac393c-b7eb-4148-92f6-22f5711b1f18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_HeadquartersLeaseSixMonthRenewalOptionMember_e6a9c196-f2ab-4640-a448-9206356284fd" xlink:href="biib-20250930.xsd#biib_HeadquartersLeaseSixMonthRenewalOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_86ff991e-4a4f-4271-80bb-cede2de29425" xlink:to="loc_biib_HeadquartersLeaseSixMonthRenewalOptionMember_e6a9c196-f2ab-4640-a448-9206356284fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_01123649-8fdd-44b1-bd01-349a21ae4b10" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_799e8d88-aa42-4d2f-bb15-441c5e374266" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_01123649-8fdd-44b1-bd01-349a21ae4b10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_90dccb6a-2b7b-4c4a-b342-5b8208c488eb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_01123649-8fdd-44b1-bd01-349a21ae4b10" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_90dccb6a-2b7b-4c4a-b342-5b8208c488eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingMember_fbd8219b-c80e-44ca-9640-34255f4e292a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BuildingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_90dccb6a-2b7b-4c4a-b342-5b8208c488eb" xlink:to="loc_us-gaap_BuildingMember_fbd8219b-c80e-44ca-9640-34255f4e292a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_a014e81d-9a7f-488d-9baf-be46bbf87357" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_799e8d88-aa42-4d2f-bb15-441c5e374266" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_a014e81d-9a7f-488d-9baf-be46bbf87357" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OperatingLeaseArea_81a3fa94-ba7b-412d-bf97-2599ba5c0d66" xlink:href="biib-20250930.xsd#biib_OperatingLeaseArea"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a014e81d-9a7f-488d-9baf-be46bbf87357" xlink:to="loc_biib_OperatingLeaseArea_81a3fa94-ba7b-412d-bf97-2599ba5c0d66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReductionOfRealEstateFootprint_f7a3edfc-0cb1-4835-ac4e-80c9abc7a326" xlink:href="biib-20250930.xsd#biib_ReductionOfRealEstateFootprint"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a014e81d-9a7f-488d-9baf-be46bbf87357" xlink:to="loc_biib_ReductionOfRealEstateFootprint_f7a3edfc-0cb1-4835-ac4e-80c9abc7a326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_e1215b32-59a5-4b21-a04e-ef334ef47023" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a014e81d-9a7f-488d-9baf-be46bbf87357" xlink:to="loc_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1_e1215b32-59a5-4b21-a04e-ef334ef47023" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount_f1477ba3-224c-4e1d-951e-bfab36ddb101" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a014e81d-9a7f-488d-9baf-be46bbf87357" xlink:to="loc_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount_f1477ba3-224c-4e1d-951e-bfab36ddb101" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LesseeOperatingLeaseNumberOfRenewalOptions_ec881781-5796-4f29-89f5-8dba142be0b7" xlink:href="biib-20250930.xsd#biib_LesseeOperatingLeaseNumberOfRenewalOptions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a014e81d-9a7f-488d-9baf-be46bbf87357" xlink:to="loc_biib_LesseeOperatingLeaseNumberOfRenewalOptions_ec881781-5796-4f29-89f5-8dba142be0b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_23eb9273-d3aa-4250-ba5c-eb4f8e5829de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_a014e81d-9a7f-488d-9baf-be46bbf87357" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_23eb9273-d3aa-4250-ba5c-eb4f8e5829de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IndebtednessNarrativeDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#IndebtednessNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IndebtednessNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_609abe2d-532b-4e91-92ec-b4a8ca16f49a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_8657dc9b-0d64-4558-a355-adfed96f1cd7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_609abe2d-532b-4e91-92ec-b4a8ca16f49a" xlink:to="loc_us-gaap_DebtInstrumentTable_8657dc9b-0d64-4558-a355-adfed96f1cd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_19933f15-58a9-49c0-ac6b-1bbd18561798" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8657dc9b-0d64-4558-a355-adfed96f1cd7" xlink:to="loc_us-gaap_DebtInstrumentAxis_19933f15-58a9-49c0-ac6b-1bbd18561798" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_da87b828-1e92-4f46-8855-9d8860337f15" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_19933f15-58a9-49c0-ac6b-1bbd18561798" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_da87b828-1e92-4f46-8855-9d8860337f15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A5.050SeniorNotesDueJanuary152031Member_eed2c8a4-14b1-47f0-afb9-7bf1e6c7b17e" xlink:href="biib-20250930.xsd#biib_A5.050SeniorNotesDueJanuary152031Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_da87b828-1e92-4f46-8855-9d8860337f15" xlink:to="loc_biib_A5.050SeniorNotesDueJanuary152031Member_eed2c8a4-14b1-47f0-afb9-7bf1e6c7b17e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A5.750SeniorNotesDueMay152035Member_7e835fcf-c3cb-46b8-b2a5-aa3b8e11d03e" xlink:href="biib-20250930.xsd#biib_A5.750SeniorNotesDueMay152035Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_da87b828-1e92-4f46-8855-9d8860337f15" xlink:to="loc_biib_A5.750SeniorNotesDueMay152035Member_7e835fcf-c3cb-46b8-b2a5-aa3b8e11d03e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A6.450SeniorNotesDueMay152055Member_670dd7a4-3c2b-4e3e-866d-ebc8d2b177cc" xlink:href="biib-20250930.xsd#biib_A6.450SeniorNotesDueMay152055Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_da87b828-1e92-4f46-8855-9d8860337f15" xlink:to="loc_biib_A6.450SeniorNotesDueMay152055Member_670dd7a4-3c2b-4e3e-866d-ebc8d2b177cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2025SeniorNotesMember_38094599-06a3-4da1-8392-aaa48480c3bb" xlink:href="biib-20250930.xsd#biib_A2025SeniorNotesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_da87b828-1e92-4f46-8855-9d8860337f15" xlink:to="loc_biib_A2025SeniorNotesMember_38094599-06a3-4da1-8392-aaa48480c3bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_2b746eba-be72-4420-b5a1-ad3064961814" xlink:href="biib-20250930.xsd#biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_da87b828-1e92-4f46-8855-9d8860337f15" xlink:to="loc_biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember_2b746eba-be72-4420-b5a1-ad3064961814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TheCreditFacilityMember_0adf6741-e464-418a-9ced-b4f83a57daee" xlink:href="biib-20250930.xsd#biib_TheCreditFacilityMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_da87b828-1e92-4f46-8855-9d8860337f15" xlink:to="loc_biib_TheCreditFacilityMember_0adf6741-e464-418a-9ced-b4f83a57daee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TheCreditFacilityFloatingRate364DayTrancheMember_dae210d0-dd55-4418-8dfe-abc949dff387" xlink:href="biib-20250930.xsd#biib_TheCreditFacilityFloatingRate364DayTrancheMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_da87b828-1e92-4f46-8855-9d8860337f15" xlink:to="loc_biib_TheCreditFacilityFloatingRate364DayTrancheMember_dae210d0-dd55-4418-8dfe-abc949dff387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TheCreditFacilityFloatingRateThreeYearTrancheMember_ba8068b6-94d2-4fee-936b-a1a8bc3e86d9" xlink:href="biib-20250930.xsd#biib_TheCreditFacilityFloatingRateThreeYearTrancheMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_da87b828-1e92-4f46-8855-9d8860337f15" xlink:to="loc_biib_TheCreditFacilityFloatingRateThreeYearTrancheMember_ba8068b6-94d2-4fee-936b-a1a8bc3e86d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TheCreditFacilityTerminatedMember_8f4e7318-06dc-48d3-92f3-959ece5c2f7d" xlink:href="biib-20250930.xsd#biib_TheCreditFacilityTerminatedMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_da87b828-1e92-4f46-8855-9d8860337f15" xlink:to="loc_biib_TheCreditFacilityTerminatedMember_8f4e7318-06dc-48d3-92f3-959ece5c2f7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2023TermLoanMember_057990f4-df99-43e3-97cf-0b9f79d68845" xlink:href="biib-20250930.xsd#biib_A2023TermLoanMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_da87b828-1e92-4f46-8855-9d8860337f15" xlink:to="loc_biib_A2023TermLoanMember_057990f4-df99-43e3-97cf-0b9f79d68845" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_c845b140-b696-46ac-a68f-053f81bab882" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8657dc9b-0d64-4558-a355-adfed96f1cd7" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_c845b140-b696-46ac-a68f-053f81bab882" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_74637c4b-5ebf-4cab-8f5a-aa044dbfee3e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_c845b140-b696-46ac-a68f-053f81bab882" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_74637c4b-5ebf-4cab-8f5a-aa044dbfee3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_3851fc41-3a06-4c8e-88c3-bc650c630c4c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_74637c4b-5ebf-4cab-8f5a-aa044dbfee3e" xlink:to="loc_us-gaap_SeniorNotesMember_3851fc41-3a06-4c8e-88c3-bc650c630c4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_164897d0-343d-4781-8014-684c42864b1f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_74637c4b-5ebf-4cab-8f5a-aa044dbfee3e" xlink:to="loc_us-gaap_LineOfCreditMember_164897d0-343d-4781-8014-684c42864b1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_0439654f-c8ac-46de-9c08-38f5087c72f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8657dc9b-0d64-4558-a355-adfed96f1cd7" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_0439654f-c8ac-46de-9c08-38f5087c72f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2f90759b-380f-440c-abb9-5404a9b3a52b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_0439654f-c8ac-46de-9c08-38f5087c72f4" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2f90759b-380f-440c-abb9-5404a9b3a52b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReataPharmaceuticalsIncMember_1c667202-010f-47d4-9d96-f99ce03b41c0" xlink:href="biib-20250930.xsd#biib_ReataPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2f90759b-380f-440c-abb9-5404a9b3a52b" xlink:to="loc_biib_ReataPharmaceuticalsIncMember_1c667202-010f-47d4-9d96-f99ce03b41c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_63fb2382-1918-4207-9d2d-551bcd96ce9a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8657dc9b-0d64-4558-a355-adfed96f1cd7" xlink:to="loc_us-gaap_CreditFacilityAxis_63fb2382-1918-4207-9d2d-551bcd96ce9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_988e830d-79ed-48bd-bca2-89dcc9f1797d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_63fb2382-1918-4207-9d2d-551bcd96ce9a" xlink:to="loc_us-gaap_CreditFacilityDomain_988e830d-79ed-48bd-bca2-89dcc9f1797d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SecuredDebtMember_da2e16bc-24b0-474c-af95-7f0f11973ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SecuredDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_988e830d-79ed-48bd-bca2-89dcc9f1797d" xlink:to="loc_us-gaap_SecuredDebtMember_da2e16bc-24b0-474c-af95-7f0f11973ca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FloatingRate364DayTrancheMember_a5522cf1-5c92-466f-8c7e-146486fe8aab" xlink:href="biib-20250930.xsd#biib_FloatingRate364DayTrancheMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_988e830d-79ed-48bd-bca2-89dcc9f1797d" xlink:to="loc_biib_FloatingRate364DayTrancheMember_a5522cf1-5c92-466f-8c7e-146486fe8aab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TermLoan2023ThreeYearTrancheMember_cd074f85-66f1-4efb-94e1-5a63357876c5" xlink:href="biib-20250930.xsd#biib_TermLoan2023ThreeYearTrancheMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_988e830d-79ed-48bd-bca2-89dcc9f1797d" xlink:to="loc_biib_TermLoan2023ThreeYearTrancheMember_cd074f85-66f1-4efb-94e1-5a63357876c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_ba8b1c75-b50d-48e0-a7e3-7b82471f87ca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_8657dc9b-0d64-4558-a355-adfed96f1cd7" xlink:to="loc_us-gaap_DebtInstrumentLineItems_ba8b1c75-b50d-48e0-a7e3-7b82471f87ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_bef94cb7-9b60-4556-9c1c-182c75dc68e0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba8b1c75-b50d-48e0-a7e3-7b82471f87ca" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_bef94cb7-9b60-4556-9c1c-182c75dc68e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_2b60fa1b-694b-4c0c-87eb-a380a6c1bdaa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba8b1c75-b50d-48e0-a7e3-7b82471f87ca" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_2b60fa1b-694b-4c0c-87eb-a380a6c1bdaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageParValueOfSeniorNotes_93be783a-cc5f-46d1-bf65-7b46016e2829" xlink:href="biib-20250930.xsd#biib_PercentageParValueOfSeniorNotes"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba8b1c75-b50d-48e0-a7e3-7b82471f87ca" xlink:to="loc_biib_PercentageParValueOfSeniorNotes_93be783a-cc5f-46d1-bf65-7b46016e2829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_d26216e1-19e2-4fa4-850f-b26e29437d10" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba8b1c75-b50d-48e0-a7e3-7b82471f87ca" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_d26216e1-19e2-4fa4-850f-b26e29437d10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_1f57f6aa-0e7b-4134-b985-09b6f90222de" xlink:href="biib-20250930.xsd#biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba8b1c75-b50d-48e0-a7e3-7b82471f87ca" xlink:to="loc_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage_1f57f6aa-0e7b-4134-b985-09b6f90222de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfFinancingCosts_a2e964f1-569e-464f-85a1-579b6dd80967" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfFinancingCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba8b1c75-b50d-48e0-a7e3-7b82471f87ca" xlink:to="loc_us-gaap_PaymentsOfFinancingCosts_a2e964f1-569e-464f-85a1-579b6dd80967" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_ccbeab60-9ed2-4453-9c0f-e76116f185ce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba8b1c75-b50d-48e0-a7e3-7b82471f87ca" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_ccbeab60-9ed2-4453-9c0f-e76116f185ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_59f26757-3c73-485b-b83f-4c9751ead1fe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentCarryingAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba8b1c75-b50d-48e0-a7e3-7b82471f87ca" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_59f26757-3c73-485b-b83f-4c9751ead1fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths_f0a7cbf5-08d3-4cb7-8d7e-bb29037b2f2e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_ba8b1c75-b50d-48e0-a7e3-7b82471f87ca" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths_f0a7cbf5-08d3-4cb7-8d7e-bb29037b2f2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityNarrativeDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#EquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_f41b4e3d-f907-4c4d-9092-21a48e5a99e6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_2e2d3508-9492-4312-93c1-667567b8c5fe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f41b4e3d-f907-4c4d-9092-21a48e5a99e6" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_2e2d3508-9492-4312-93c1-667567b8c5fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramAxis_1dbcd75a-c767-4a18-8506-470bd29d04b5" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2e2d3508-9492-4312-93c1-667567b8c5fe" xlink:to="loc_srt_ShareRepurchaseProgramAxis_1dbcd75a-c767-4a18-8506-470bd29d04b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ShareRepurchaseProgramDomain_fd3b7f9a-417f-4860-9b43-9704eee358b7" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ShareRepurchaseProgramAxis_1dbcd75a-c767-4a18-8506-470bd29d04b5" xlink:to="loc_srt_ShareRepurchaseProgramDomain_fd3b7f9a-417f-4860-9b43-9704eee358b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_A2020ShareRepurchaseProgramMember_9488a852-bb2b-4aad-b0cc-ff52a6f83aaa" xlink:href="biib-20250930.xsd#biib_A2020ShareRepurchaseProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ShareRepurchaseProgramDomain_fd3b7f9a-417f-4860-9b43-9704eee358b7" xlink:to="loc_biib_A2020ShareRepurchaseProgramMember_9488a852-bb2b-4aad-b0cc-ff52a6f83aaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_b40d9727-0c5e-4dff-ac12-31d59b41b955" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_2e2d3508-9492-4312-93c1-667567b8c5fe" xlink:to="loc_us-gaap_ClassOfStockLineItems_b40d9727-0c5e-4dff-ac12-31d59b41b955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StockRepurchaseProgramAuthorizedAmount1_cbdb5843-489a-4905-ad00-5faaa6f9c3a3" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b40d9727-0c5e-4dff-ac12-31d59b41b955" xlink:to="loc_srt_StockRepurchaseProgramAuthorizedAmount1_cbdb5843-489a-4905-ad00-5faaa6f9c3a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_1d2669a4-ff15-4147-9941-ff15ad1257d2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b40d9727-0c5e-4dff-ac12-31d59b41b955" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_1d2669a4-ff15-4147-9941-ff15ad1257d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_7efd64b9-ec3f-4037-bd1c-7f107f7c597b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_b40d9727-0c5e-4dff-ac12-31d59b41b955" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_7efd64b9-ec3f-4037-bd1c-7f107f7c597b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#EquityAccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_8caea5fe-0354-4aff-9fb7-aa25fdc72b68" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_5d3f118b-e617-4947-b6a2-69b7052be62b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_8caea5fe-0354-4aff-9fb7-aa25fdc72b68" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_5d3f118b-e617-4947-b6a2-69b7052be62b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9ad93a31-4eeb-422f-b6ca-31522a1af98a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_5d3f118b-e617-4947-b6a2-69b7052be62b" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9ad93a31-4eeb-422f-b6ca-31522a1af98a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_c9385f94-645d-44ff-98be-d9c1e6df5db0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9ad93a31-4eeb-422f-b6ca-31522a1af98a" xlink:to="loc_us-gaap_EquityComponentDomain_c9385f94-645d-44ff-98be-d9c1e6df5db0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_1a22bf71-9e15-4561-b9e9-e9102296d32f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c9385f94-645d-44ff-98be-d9c1e6df5db0" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_1a22bf71-9e15-4561-b9e9-e9102296d32f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_b9df7803-02ed-408c-88e4-f591b2812e33" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c9385f94-645d-44ff-98be-d9c1e6df5db0" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_b9df7803-02ed-408c-88e4-f591b2812e33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_89a4866d-e74b-4b42-989c-183ba2237f13" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c9385f94-645d-44ff-98be-d9c1e6df5db0" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_89a4866d-e74b-4b42-989c-183ba2237f13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_66eee872-3628-4a25-ab31-5350ec777944" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_c9385f94-645d-44ff-98be-d9c1e6df5db0" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_66eee872-3628-4a25-ab31-5350ec777944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_d73d8dca-5233-489e-9930-c5a8d2af4007" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_5d3f118b-e617-4947-b6a2-69b7052be62b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_d73d8dca-5233-489e-9930-c5a8d2af4007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_faf3c22d-5922-4b7f-843e-c7bb0d6ecd1a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_d73d8dca-5233-489e-9930-c5a8d2af4007" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_faf3c22d-5922-4b7f-843e-c7bb0d6ecd1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_076a2fbb-7358-4a07-968c-539b11af5df8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_faf3c22d-5922-4b7f-843e-c7bb0d6ecd1a" xlink:to="loc_us-gaap_StockholdersEquity_076a2fbb-7358-4a07-968c-539b11af5df8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_ca8187ef-b237-4e78-998f-a663faf975f3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_faf3c22d-5922-4b7f-843e-c7bb0d6ecd1a" xlink:to="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_ca8187ef-b237-4e78-998f-a663faf975f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_a179033b-41c6-4c94-aea4-cc48b33e72eb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_faf3c22d-5922-4b7f-843e-c7bb0d6ecd1a" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_a179033b-41c6-4c94-aea4-cc48b33e72eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_b94cff59-5c15-42a4-83a9-10ec3a57db24" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_faf3c22d-5922-4b7f-843e-c7bb0d6ecd1a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_b94cff59-5c15-42a4-83a9-10ec3a57db24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f83506d2-06dd-437e-8ced-55a3756fdb87" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_faf3c22d-5922-4b7f-843e-c7bb0d6ecd1a" xlink:to="loc_us-gaap_StockholdersEquity_f83506d2-06dd-437e-8ced-55a3756fdb87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EquityReclassifiedFromAOCIDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#EquityReclassifiedFromAOCIDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EquityReclassifiedFromAOCIDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_737867a2-f858-4623-b01d-2d69ed86f32d" xlink:href="biib-20250930.xsd#biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_e86ebae8-8fa0-479a-8e38-4a45577c3002" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract_737867a2-f858-4623-b01d-2d69ed86f32d" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_e86ebae8-8fa0-479a-8e38-4a45577c3002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_dd4cc053-6f44-4641-8be0-fa1f8fb903fa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_e86ebae8-8fa0-479a-8e38-4a45577c3002" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_dd4cc053-6f44-4641-8be0-fa1f8fb903fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_e39ef7c8-0361-42c2-bc85-6dad25df77fc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_dd4cc053-6f44-4641-8be0-fa1f8fb903fa" xlink:to="loc_us-gaap_EquityComponentDomain_e39ef7c8-0361-42c2-bc85-6dad25df77fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_207526a3-a16a-4fbc-986f-f8d81d61f2cf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_e39ef7c8-0361-42c2-bc85-6dad25df77fc" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_207526a3-a16a-4fbc-986f-f8d81d61f2cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_240945da-d7f7-45c1-952e-bc47f8336e2d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_e86ebae8-8fa0-479a-8e38-4a45577c3002" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_240945da-d7f7-45c1-952e-bc47f8336e2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_7871ac58-6de7-4de4-b0ad-701a6ff6212b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis_240945da-d7f7-45c1-952e-bc47f8336e2d" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_7871ac58-6de7-4de4-b0ad-701a6ff6212b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_87afd186-0fe3-443a-99ca-9afb65a24e92" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain_7871ac58-6de7-4de4-b0ad-701a6ff6212b" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember_87afd186-0fe3-443a-99ca-9afb65a24e92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_2ecac9ca-fdb5-4fb4-b8e3-c0244f2826b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_e86ebae8-8fa0-479a-8e38-4a45577c3002" xlink:to="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_2ecac9ca-fdb5-4fb4-b8e3-c0244f2826b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_a4765d0c-ccd7-40f6-bde5-6397651796ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_2ecac9ca-fdb5-4fb4-b8e3-c0244f2826b6" xlink:to="loc_us-gaap_Revenues_a4765d0c-ccd7-40f6-bde5-6397651796ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_96343375-c7f6-4f55-8c17-531341b6b8e3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_2ecac9ca-fdb5-4fb4-b8e3-c0244f2826b6" xlink:to="loc_us-gaap_OperatingExpenses_96343375-c7f6-4f55-8c17-531341b6b8e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_b29c0109-31c9-4812-ab81-ed3eeec3accc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_2ecac9ca-fdb5-4fb4-b8e3-c0244f2826b6" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_b29c0109-31c9-4812-ab81-ed3eeec3accc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_6c20f344-5b95-4276-a928-1a65165e881e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_2ecac9ca-fdb5-4fb4-b8e3-c0244f2826b6" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_6c20f344-5b95-4276-a928-1a65165e881e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_799e0d6f-3b88-49bc-acf2-d0c45dfe498f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_2ecac9ca-fdb5-4fb4-b8e3-c0244f2826b6" xlink:to="loc_us-gaap_NetIncomeLoss_799e0d6f-3b88-49bc-acf2-d0c45dfe498f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/EarningsperShareDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#EarningsperShareDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/EarningsperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_efb47235-f8e0-4bb9-971a-cf3f37ec9b45" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5cfb5404-f808-4d64-af19-3855236e6a9a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_efb47235-f8e0-4bb9-971a-cf3f37ec9b45" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5cfb5404-f808-4d64-af19-3855236e6a9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4478065f-02c3-4922-bb78-59a32bd519d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5cfb5404-f808-4d64-af19-3855236e6a9a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4478065f-02c3-4922-bb78-59a32bd519d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9432660f-cc90-43c7-a1fa-92e89ebc59b8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_4478065f-02c3-4922-bb78-59a32bd519d5" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9432660f-cc90-43c7-a1fa-92e89ebc59b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_6bbbc5ed-7c44-49bd-8587-dd0b2eabf3fe" xlink:href="biib-20250930.xsd#biib_TimeVestedRestrictedStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9432660f-cc90-43c7-a1fa-92e89ebc59b8" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_6bbbc5ed-7c44-49bd-8587-dd0b2eabf3fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_3a82a7cf-47f7-4ce4-bf97-7bfbf20d5ec4" xlink:href="biib-20250930.xsd#biib_PerformanceStockUnitsSettledinStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_9432660f-cc90-43c7-a1fa-92e89ebc59b8" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_3a82a7cf-47f7-4ce4-bf97-7bfbf20d5ec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9a2e22a0-99f9-456e-9636-99a7524bc20b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_5cfb5404-f808-4d64-af19-3855236e6a9a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9a2e22a0-99f9-456e-9636-99a7524bc20b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_BasicAndDilutedEarningsPerShareAbstract_2d88358b-ee1e-4ce5-871b-e03d7c2b351e" xlink:href="biib-20250930.xsd#biib_BasicAndDilutedEarningsPerShareAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_9a2e22a0-99f9-456e-9636-99a7524bc20b" xlink:to="loc_biib_BasicAndDilutedEarningsPerShareAbstract_2d88358b-ee1e-4ce5-871b-e03d7c2b351e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAbstract_ee015258-8600-4ac8-9aa2-b06d32433281" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_2d88358b-ee1e-4ce5-871b-e03d7c2b351e" xlink:to="loc_us-gaap_NetIncomeLossAbstract_ee015258-8600-4ac8-9aa2-b06d32433281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_0868672d-f2e7-4bec-9701-450342032b9e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAbstract_ee015258-8600-4ac8-9aa2-b06d32433281" xlink:to="loc_us-gaap_NetIncomeLoss_0868672d-f2e7-4bec-9701-450342032b9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_f31af191-6097-448b-bc1f-dc7354373cda" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_BasicAndDilutedEarningsPerShareAbstract_2d88358b-ee1e-4ce5-871b-e03d7c2b351e" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_f31af191-6097-448b-bc1f-dc7354373cda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b1a07ae4-03f9-4255-86fc-ceef9a3627a3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_f31af191-6097-448b-bc1f-dc7354373cda" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b1a07ae4-03f9-4255-86fc-ceef9a3627a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_0127cec7-2725-46f9-aaef-3efed3dd09cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DilutiveSecuritiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_f31af191-6097-448b-bc1f-dc7354373cda" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_0127cec7-2725-46f9-aaef-3efed3dd09cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_fc2a10b4-d60c-4197-a815-be337ac5f2a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_0127cec7-2725-46f9-aaef-3efed3dd09cb" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_fc2a10b4-d60c-4197-a815-be337ac5f2a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_8e0c1605-e5aa-46dd-8564-05b16ecdc489" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_0127cec7-2725-46f9-aaef-3efed3dd09cb" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_8e0c1605-e5aa-46dd-8564-05b16ecdc489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7e518926-6aba-40bc-92f6-b9fe41a7c87b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_f31af191-6097-448b-bc1f-dc7354373cda" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7e518926-6aba-40bc-92f6-b9fe41a7c87b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_30f334d3-5b34-49e2-adff-4d9be6df6f8c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_36290e60-3684-47d8-9d87-5c5f354d76b4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_30f334d3-5b34-49e2-adff-4d9be6df6f8c" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_36290e60-3684-47d8-9d87-5c5f354d76b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_031465e7-64bb-44e8-aff2-4e52c44c75a6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_36290e60-3684-47d8-9d87-5c5f354d76b4" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_031465e7-64bb-44e8-aff2-4e52c44c75a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_25d8ae45-bdf4-4644-95b8-f9ea864872be" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_031465e7-64bb-44e8-aff2-4e52c44c75a6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_25d8ae45-bdf4-4644-95b8-f9ea864872be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7a235e3f-723e-439c-afc2-33b79191ebec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_25d8ae45-bdf4-4644-95b8-f9ea864872be" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_7a235e3f-723e-439c-afc2-33b79191ebec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_848d2bd5-b416-4aec-8194-4b4ca9e868c3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_25d8ae45-bdf4-4644-95b8-f9ea864872be" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_848d2bd5-b416-4aec-8194-4b4ca9e868c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ParentMember_68dbbe6c-afdf-45a3-865d-36d183088dab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ParentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_25d8ae45-bdf4-4644-95b8-f9ea864872be" xlink:to="loc_us-gaap_ParentMember_68dbbe6c-afdf-45a3-865d-36d183088dab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a74da35c-ef3d-4613-b5fe-7699a565c885" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_36290e60-3684-47d8-9d87-5c5f354d76b4" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a74da35c-ef3d-4613-b5fe-7699a565c885" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_1198b903-8e3f-4f8c-9eb8-87f4aac2924d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_a74da35c-ef3d-4613-b5fe-7699a565c885" xlink:to="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_1198b903-8e3f-4f8c-9eb8-87f4aac2924d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_a64fb206-3e30-4d81-9e8b-758dbb908f96" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_1198b903-8e3f-4f8c-9eb8-87f4aac2924d" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_a64fb206-3e30-4d81-9e8b-758dbb908f96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_13890d7b-9187-44d2-ae98-9c7984082741" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_1198b903-8e3f-4f8c-9eb8-87f4aac2924d" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_13890d7b-9187-44d2-ae98-9c7984082741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_58a09bb9-57c5-461d-ab07-9c0e41e9c8e3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_1198b903-8e3f-4f8c-9eb8-87f4aac2924d" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_58a09bb9-57c5-461d-ab07-9c0e41e9c8e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_7a82ac42-580f-4073-b608-77a12457219c" xlink:href="biib-20250930.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_1198b903-8e3f-4f8c-9eb8-87f4aac2924d" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_7a82ac42-580f-4073-b608-77a12457219c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_6719bd4f-a099-41fc-90e1-fd11390bec62" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract_1198b903-8e3f-4f8c-9eb8-87f4aac2924d" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_6719bd4f-a099-41fc-90e1-fd11390bec62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SharebasedPaymentsNarrativeDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#SharebasedPaymentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SharebasedPaymentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f24f0371-045b-4809-ae83-be7b338d072c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e28a60dc-8638-4204-8df6-898a3f72931f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f24f0371-045b-4809-ae83-be7b338d072c" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e28a60dc-8638-4204-8df6-898a3f72931f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_79b37483-2fe6-4591-a3e8-a0fbd70c68e5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e28a60dc-8638-4204-8df6-898a3f72931f" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_79b37483-2fe6-4591-a3e8-a0fbd70c68e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c54d7100-055b-4ae0-99a7-67185e7810c9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_79b37483-2fe6-4591-a3e8-a0fbd70c68e5" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c54d7100-055b-4ae0-99a7-67185e7810c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_HumanImmunologyBiosciencesMember_a5c9cbdd-288a-46d3-9ef4-b072fb504ab0" xlink:href="biib-20250930.xsd#biib_HumanImmunologyBiosciencesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_c54d7100-055b-4ae0-99a7-67185e7810c9" xlink:to="loc_biib_HumanImmunologyBiosciencesMember_a5c9cbdd-288a-46d3-9ef4-b072fb504ab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_fc3923de-7780-4350-b1a9-e6c54bd88279" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e28a60dc-8638-4204-8df6-898a3f72931f" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_fc3923de-7780-4350-b1a9-e6c54bd88279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_42b4af5b-79de-4b0b-a497-424b47958d62" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_fc3923de-7780-4350-b1a9-e6c54bd88279" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_42b4af5b-79de-4b0b-a497-424b47958d62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c24a4967-08c4-4fda-9978-0f2289515663" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_42b4af5b-79de-4b0b-a497-424b47958d62" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_c24a4967-08c4-4fda-9978-0f2289515663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_3e9a0549-5fa5-4cdc-9165-64071bad0e22" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_42b4af5b-79de-4b0b-a497-424b47958d62" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_3e9a0549-5fa5-4cdc-9165-64071bad0e22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_b8aadb9c-5f35-4397-80a1-9f3410cd2f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e28a60dc-8638-4204-8df6-898a3f72931f" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_b8aadb9c-5f35-4397-80a1-9f3410cd2f5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_4688784f-6661-48ee-b8f6-de454bc040cd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_b8aadb9c-5f35-4397-80a1-9f3410cd2f5c" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_4688784f-6661-48ee-b8f6-de454bc040cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_baa190eb-b213-42c7-89b1-1803afa2c12b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_e28a60dc-8638-4204-8df6-898a3f72931f" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_baa190eb-b213-42c7-89b1-1803afa2c12b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_94aaf298-3fe7-4a6a-bb1e-286b8365b928" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_baa190eb-b213-42c7-89b1-1803afa2c12b" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_94aaf298-3fe7-4a6a-bb1e-286b8365b928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6adfdf65-cd8c-48eb-8d29-4865c1ee4435" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9de6c384-3645-4806-ae8b-9190694408a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6adfdf65-cd8c-48eb-8d29-4865c1ee4435" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9de6c384-3645-4806-ae8b-9190694408a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_72d34b21-d3fa-458a-98f0-9ff26388efab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9de6c384-3645-4806-ae8b-9190694408a0" xlink:to="loc_us-gaap_AwardTypeAxis_72d34b21-d3fa-458a-98f0-9ff26388efab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a2464a3a-7a57-4f01-a665-dfaafd5a491d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_72d34b21-d3fa-458a-98f0-9ff26388efab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a2464a3a-7a57-4f01-a665-dfaafd5a491d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_TimeVestedRestrictedStockUnitsMember_44d7d03d-922c-433c-b6e6-c1f5508fd91b" xlink:href="biib-20250930.xsd#biib_TimeVestedRestrictedStockUnitsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a2464a3a-7a57-4f01-a665-dfaafd5a491d" xlink:to="loc_biib_TimeVestedRestrictedStockUnitsMember_44d7d03d-922c-433c-b6e6-c1f5508fd91b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinStockMember_4f892344-7529-4a9e-94c1-805abf137589" xlink:href="biib-20250930.xsd#biib_PerformanceStockUnitsSettledinStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a2464a3a-7a57-4f01-a665-dfaafd5a491d" xlink:to="loc_biib_PerformanceStockUnitsSettledinStockMember_4f892344-7529-4a9e-94c1-805abf137589" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EmployeeStockPurchasePlanMember_0778e956-c46e-4b0c-9c1b-f97c81ed1541" xlink:href="biib-20250930.xsd#biib_EmployeeStockPurchasePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a2464a3a-7a57-4f01-a665-dfaafd5a491d" xlink:to="loc_biib_EmployeeStockPurchasePlanMember_0778e956-c46e-4b0c-9c1b-f97c81ed1541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PerformanceStockUnitsSettledinCashMember_5703b15d-192d-4695-91c7-7263dd6499a8" xlink:href="biib-20250930.xsd#biib_PerformanceStockUnitsSettledinCashMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a2464a3a-7a57-4f01-a665-dfaafd5a491d" xlink:to="loc_biib_PerformanceStockUnitsSettledinCashMember_5703b15d-192d-4695-91c7-7263dd6499a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ff673677-8e61-4175-a4e3-745cba5c2bfb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a2464a3a-7a57-4f01-a665-dfaafd5a491d" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ff673677-8e61-4175-a4e3-745cba5c2bfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MarketStockUnitsMember_34e88326-0fd6-4044-8833-feb978104389" xlink:href="biib-20250930.xsd#biib_MarketStockUnitsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a2464a3a-7a57-4f01-a665-dfaafd5a491d" xlink:to="loc_biib_MarketStockUnitsMember_34e88326-0fd6-4044-8833-feb978104389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_b6d88784-542c-49e8-bf3f-bb3e57812d9b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9de6c384-3645-4806-ae8b-9190694408a0" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_b6d88784-542c-49e8-bf3f-bb3e57812d9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8f917de4-7bdb-4f0f-bb92-616cac9e3a50" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_b6d88784-542c-49e8-bf3f-bb3e57812d9b" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8f917de4-7bdb-4f0f-bb92-616cac9e3a50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_HumanImmunologyBiosciencesMember_78980fa2-470c-4d48-b722-d75eb0b43c06" xlink:href="biib-20250930.xsd#biib_HumanImmunologyBiosciencesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8f917de4-7bdb-4f0f-bb92-616cac9e3a50" xlink:to="loc_biib_HumanImmunologyBiosciencesMember_78980fa2-470c-4d48-b722-d75eb0b43c06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e0f85b38-4e72-4472-9f4f-68debec334e1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_9de6c384-3645-4806-ae8b-9190694408a0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e0f85b38-4e72-4472-9f4f-68debec334e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_d80b5c62-4037-41ba-96e9-de6db8a08267" xlink:href="biib-20250930.xsd#biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_e0f85b38-4e72-4472-9f4f-68debec334e1" xlink:to="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_d80b5c62-4037-41ba-96e9-de6db8a08267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_f9191ad4-b94a-4682-bc1e-62a660a841c2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_d80b5c62-4037-41ba-96e9-de6db8a08267" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_f9191ad4-b94a-4682-bc1e-62a660a841c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_ed232291-6303-4059-a92a-0894246e493b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_d80b5c62-4037-41ba-96e9-de6db8a08267" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_ed232291-6303-4059-a92a-0894246e493b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_0c02a140-d178-4a47-860f-acaf9841878c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_d80b5c62-4037-41ba-96e9-de6db8a08267" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_0c02a140-d178-4a47-860f-acaf9841878c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_21803203-c484-4283-89fc-0d294a6c11eb" xlink:href="biib-20250930.xsd#biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract_d80b5c62-4037-41ba-96e9-de6db8a08267" xlink:to="loc_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses_21803203-c484-4283-89fc-0d294a6c11eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#IncomeTaxesTaxRateDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_b7c9315c-a323-4370-9717-3b3ad957616e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_e9632aa4-cd8d-4f11-9eb4-3c53af43568a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b7c9315c-a323-4370-9717-3b3ad957616e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_e9632aa4-cd8d-4f11-9eb4-3c53af43568a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_810d9a89-9b45-42a5-8f7a-f8a3caca670f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_e9632aa4-cd8d-4f11-9eb4-3c53af43568a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_810d9a89-9b45-42a5-8f7a-f8a3caca670f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_7e0096df-907b-49d8-863a-205080ad59d4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_e9632aa4-cd8d-4f11-9eb4-3c53af43568a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_7e0096df-907b-49d8-863a-205080ad59d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_ce87154c-bdeb-443c-9b12-43f42408e8ab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_e9632aa4-cd8d-4f11-9eb4-3c53af43568a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_ce87154c-bdeb-443c-9b12-43f42408e8ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_a69ac048-c6f8-48c5-9973-4b1cbcf23e30" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_e9632aa4-cd8d-4f11-9eb4-3c53af43568a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_a69ac048-c6f8-48c5-9973-4b1cbcf23e30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_edb76266-0837-438b-972e-a29bf9e52f18" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_e9632aa4-cd8d-4f11-9eb4-3c53af43568a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization_edb76266-0837-438b-972e-a29bf9e52f18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent_72ab4a86-385b-4625-a206-48799f951b00" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_e9632aa4-cd8d-4f11-9eb4-3c53af43568a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent_72ab4a86-385b-4625-a206-48799f951b00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveTaxRateReconciliationShareBasedCompensationAwards_b6477ab8-6b73-4119-a202-3ba15654ed01" xlink:href="biib-20250930.xsd#biib_EffectiveTaxRateReconciliationShareBasedCompensationAwards"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_e9632aa4-cd8d-4f11-9eb4-3c53af43568a" xlink:to="loc_biib_EffectiveTaxRateReconciliationShareBasedCompensationAwards_b6477ab8-6b73-4119-a202-3ba15654ed01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EffectiveTaxRateReconciliationOneBigBeautifulBillActEnactment_5f5669cb-a92d-4a70-a50b-819ee87e6695" xlink:href="biib-20250930.xsd#biib_EffectiveTaxRateReconciliationOneBigBeautifulBillActEnactment"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_e9632aa4-cd8d-4f11-9eb4-3c53af43568a" xlink:to="loc_biib_EffectiveTaxRateReconciliationOneBigBeautifulBillActEnactment_5f5669cb-a92d-4a70-a50b-819ee87e6695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_36c07778-bdd7-4299-a747-d366438c105b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_e9632aa4-cd8d-4f11-9eb4-3c53af43568a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_36c07778-bdd7-4299-a747-d366438c105b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_d2515803-f79d-4715-8c03-b642600080c5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_e9632aa4-cd8d-4f11-9eb4-3c53af43568a" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_d2515803-f79d-4715-8c03-b642600080c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ed532e45-b85f-4491-8f78-ce211b69d294" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_24c9065a-72e7-444e-8bed-66aa2c37adba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ed532e45-b85f-4491-8f78-ce211b69d294" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_24c9065a-72e7-444e-8bed-66aa2c37adba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherIncomeExpenseNetDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#OtherConsolidatedFinancialStatementDetailOtherIncomeExpenseNetDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherIncomeExpenseNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_80ef5e2c-9cb3-4d48-8287-69ad3fb6b965" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_841e39c2-162f-45f4-86d2-62dc786b0b3b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_80ef5e2c-9cb3-4d48-8287-69ad3fb6b965" xlink:to="loc_us-gaap_InvestmentIncomeInterest_841e39c2-162f-45f4-86d2-62dc786b0b3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_12b852a3-3db9-4e7a-a95b-e133d739714e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_80ef5e2c-9cb3-4d48-8287-69ad3fb6b965" xlink:to="loc_us-gaap_InterestExpense_12b852a3-3db9-4e7a-a95b-e133d739714e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RealizedInvestmentGainsLosses_f2403468-f40b-4d32-bb17-c2f0c0347e36" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RealizedInvestmentGainsLosses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_80ef5e2c-9cb3-4d48-8287-69ad3fb6b965" xlink:to="loc_us-gaap_RealizedInvestmentGainsLosses_f2403468-f40b-4d32-bb17-c2f0c0347e36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_f7283024-eccd-47ac-a8df-a29fc2fe395c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_80ef5e2c-9cb3-4d48-8287-69ad3fb6b965" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_f7283024-eccd-47ac-a8df-a29fc2fe395c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_d88be27c-19a8-4371-a2bc-2229d1e976ea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_80ef5e2c-9cb3-4d48-8287-69ad3fb6b965" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_d88be27c-19a8-4371-a2bc-2229d1e976ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_a89deccb-2c51-4213-9440-5e6b7eb080be" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherOperatingIncomeExpenseNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_80ef5e2c-9cb3-4d48-8287-69ad3fb6b965" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_a89deccb-2c51-4213-9440-5e6b7eb080be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailGainsLossesonInvestmentsNetDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#OtherConsolidatedFinancialStatementDetailGainsLossesonInvestmentsNetDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailGainsLossesonInvestmentsNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_33412caf-9dee-43bc-a399-0a20fcf0cc55" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_3e6d651f-bb9a-4e58-a100-7501d9c684ee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiGainLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_33412caf-9dee-43bc-a399-0a20fcf0cc55" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_3e6d651f-bb9a-4e58-a100-7501d9c684ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_ab581c2c-3a1b-4597-8cae-5e8e581fe1c2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_33412caf-9dee-43bc-a399-0a20fcf0cc55" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_ab581c2c-3a1b-4597-8cae-5e8e581fe1c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_abb73d19-3f7f-4228-b9d5-a455fc6482b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_33412caf-9dee-43bc-a399-0a20fcf0cc55" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_abb73d19-3f7f-4228-b9d5-a455fc6482b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementNarrativeDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#OtherConsolidatedFinancialStatementNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_06ef04cd-e863-4cf7-8e7c-5bf4decf5b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_52b998da-c8c1-499e-894d-f7d31db37d38" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_06ef04cd-e863-4cf7-8e7c-5bf4decf5b2f" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_52b998da-c8c1-499e-894d-f7d31db37d38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_e66e6ffa-036e-4650-970d-f9cf98ac2052" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_52b998da-c8c1-499e-894d-f7d31db37d38" xlink:to="loc_dei_LegalEntityAxis_e66e6ffa-036e-4650-970d-f9cf98ac2052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_4ebd73b0-24da-4ee0-be86-89fb308eec38" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_e66e6ffa-036e-4650-970d-f9cf98ac2052" xlink:to="loc_dei_EntityDomain_4ebd73b0-24da-4ee0-be86-89fb308eec38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SageAndDenaliMember_519778ce-7967-4701-8aa7-a62750ad3ebb" xlink:href="biib-20250930.xsd#biib_SageAndDenaliMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_4ebd73b0-24da-4ee0-be86-89fb308eec38" xlink:to="loc_biib_SageAndDenaliMember_519778ce-7967-4701-8aa7-a62750ad3ebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SageAndSangamoMember_9ef14b35-295d-4070-a5f2-05a1e8c8d07d" xlink:href="biib-20250930.xsd#biib_SageAndSangamoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_4ebd73b0-24da-4ee0-be86-89fb308eec38" xlink:to="loc_biib_SageAndSangamoMember_9ef14b35-295d-4070-a5f2-05a1e8c8d07d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_85291a5f-e530-441d-b6ea-cead60ff4e13" xlink:href="biib-20250930.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_4ebd73b0-24da-4ee0-be86-89fb308eec38" xlink:to="loc_biib_DenaliTherapeuticsIncMember_85291a5f-e530-441d-b6ea-cead60ff4e13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SageTherapeuticsIncMember_275ffc31-f24f-4e0a-9db7-d7c8e81b5487" xlink:href="biib-20250930.xsd#biib_SageTherapeuticsIncMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_4ebd73b0-24da-4ee0-be86-89fb308eec38" xlink:to="loc_biib_SageTherapeuticsIncMember_275ffc31-f24f-4e0a-9db7-d7c8e81b5487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5fa8c30b-592c-4803-b33c-26585779a644" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_52b998da-c8c1-499e-894d-f7d31db37d38" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5fa8c30b-592c-4803-b33c-26585779a644" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_d0b46e4c-edb6-43c0-82ca-c07deb3a1e7f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5fa8c30b-592c-4803-b33c-26585779a644" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_d0b46e4c-edb6-43c0-82ca-c07deb3a1e7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_116d36e4-0dfa-4832-9959-d383c8228769" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5fa8c30b-592c-4803-b33c-26585779a644" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_116d36e4-0dfa-4832-9959-d383c8228769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_cc2ba6fc-484e-432e-8df5-62e88e3cdda8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5fa8c30b-592c-4803-b33c-26585779a644" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_cc2ba6fc-484e-432e-8df5-62e88e3cdda8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailAccruedExpenseandOtherDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#OtherConsolidatedFinancialStatementDetailAccruedExpenseandOtherDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailAccruedExpenseandOtherDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_de229771-3c26-4eda-b5b1-245c645d99bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_28afc469-5d54-43d5-bfbe-4fa83f1057a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_de229771-3c26-4eda-b5b1-245c645d99bb" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_28afc469-5d54-43d5-bfbe-4fa83f1057a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_14e32f3e-419c-4f40-9a27-b7fc7d106ab9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_28afc469-5d54-43d5-bfbe-4fa83f1057a5" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_14e32f3e-419c-4f40-9a27-b7fc7d106ab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_bb32572b-32c5-46d1-b040-2ac2b7dfd269" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_14e32f3e-419c-4f40-9a27-b7fc7d106ab9" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_bb32572b-32c5-46d1-b040-2ac2b7dfd269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_f2f3d9e7-0c93-4fd0-b008-ff886f628063" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_bb32572b-32c5-46d1-b040-2ac2b7dfd269" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_f2f3d9e7-0c93-4fd0-b008-ff886f628063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_76caf9ac-8348-412e-9190-522eba732d24" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_28afc469-5d54-43d5-bfbe-4fa83f1057a5" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_76caf9ac-8348-412e-9190-522eba732d24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_ccac2acd-ccf9-4103-aea0-520ccba2f46d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_76caf9ac-8348-412e-9190-522eba732d24" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_ccac2acd-ccf9-4103-aea0-520ccba2f46d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_5249cb8a-e38e-4b35-9569-a2e81efdd827" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_76caf9ac-8348-412e-9190-522eba732d24" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_5249cb8a-e38e-4b35-9569-a2e81efdd827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationexpensesaccrual_d4dcb4fc-efce-4278-9443-a1515a429aa2" xlink:href="biib-20250930.xsd#biib_Collaborationexpensesaccrual"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_76caf9ac-8348-412e-9190-522eba732d24" xlink:to="loc_biib_Collaborationexpensesaccrual_d4dcb4fc-efce-4278-9443-a1515a429aa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedRoyaltiesCurrent_1c95a46c-9376-4c72-898b-3094691c188c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedRoyaltiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_76caf9ac-8348-412e-9190-522eba732d24" xlink:to="loc_us-gaap_AccruedRoyaltiesCurrent_1c95a46c-9376-4c72-898b-3094691c188c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_7307f09c-9c00-4840-b77c-cd7ba6827199" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_76caf9ac-8348-412e-9190-522eba732d24" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_7307f09c-9c00-4840-b77c-cd7ba6827199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_9d7cab6a-054b-4ea1-8639-25a0a4f4d4f1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConstructionPayableCurrentAndNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_76caf9ac-8348-412e-9190-522eba732d24" xlink:to="loc_us-gaap_ConstructionPayableCurrentAndNoncurrent_9d7cab6a-054b-4ea1-8639-25a0a4f4d4f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_c65bc367-273a-4207-8dfa-a92869d1478c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_76caf9ac-8348-412e-9190-522eba732d24" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_c65bc367-273a-4207-8dfa-a92869d1478c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_ddedc5b9-85d3-423c-a12a-ecdfa090b82a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_76caf9ac-8348-412e-9190-522eba732d24" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_ddedc5b9-85d3-423c-a12a-ecdfa090b82a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#CollaborativeandOtherRelationshipsOCREVUSDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_78450775-7f64-46ba-be0a-18e360b5100a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2c3b6b28-7b1a-4adb-ac49-7fa24ad51f22" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_78450775-7f64-46ba-be0a-18e360b5100a" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2c3b6b28-7b1a-4adb-ac49-7fa24ad51f22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0e7a2ded-3314-4be4-8d35-7f5ac3419ab3" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2c3b6b28-7b1a-4adb-ac49-7fa24ad51f22" xlink:to="loc_srt_ProductOrServiceAxis_0e7a2ded-3314-4be4-8d35-7f5ac3419ab3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_37031531-304f-4fe9-872c-4f5a3b8001c7" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_0e7a2ded-3314-4be4-8d35-7f5ac3419ab3" xlink:to="loc_srt_ProductsAndServicesDomain_37031531-304f-4fe9-872c-4f5a3b8001c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_OCREVUSMember_3cbca0dc-1b74-421f-b4eb-c7a961211af4" xlink:href="biib-20250930.xsd#biib_OCREVUSMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_37031531-304f-4fe9-872c-4f5a3b8001c7" xlink:to="loc_biib_OCREVUSMember_3cbca0dc-1b74-421f-b4eb-c7a961211af4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_81a2933e-a896-4af1-bd81-ffdce8795b9f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2c3b6b28-7b1a-4adb-ac49-7fa24ad51f22" xlink:to="loc_srt_RangeAxis_81a2933e-a896-4af1-bd81-ffdce8795b9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d36222c0-84b8-4276-ab2e-ea9fc3203cb4" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_81a2933e-a896-4af1-bd81-ffdce8795b9f" xlink:to="loc_srt_RangeMember_d36222c0-84b8-4276-ab2e-ea9fc3203cb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_4751fd3f-75af-4035-a132-acf258818348" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d36222c0-84b8-4276-ab2e-ea9fc3203cb4" xlink:to="loc_srt_MinimumMember_4751fd3f-75af-4035-a132-acf258818348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a5ca6a95-4405-4040-9585-3bf7eb225952" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d36222c0-84b8-4276-ab2e-ea9fc3203cb4" xlink:to="loc_srt_MaximumMember_a5ca6a95-4405-4040-9585-3bf7eb225952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_48bf5883-8410-47be-8693-d1079b47c13d" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2c3b6b28-7b1a-4adb-ac49-7fa24ad51f22" xlink:to="loc_srt_StatementGeographicalAxis_48bf5883-8410-47be-8693-d1079b47c13d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_326f61b6-df79-41f9-8006-f92e819690f6" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_48bf5883-8410-47be-8693-d1079b47c13d" xlink:to="loc_srt_SegmentGeographicalDomain_326f61b6-df79-41f9-8006-f92e819690f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCountryMember_e20e271f-a049-479d-b683-7a8cb6e05ba4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_326f61b6-df79-41f9-8006-f92e819690f6" xlink:to="loc_us-gaap_ForeignCountryMember_e20e271f-a049-479d-b683-7a8cb6e05ba4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3f9b2dd5-8436-4326-878f-1d1461022807" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2c3b6b28-7b1a-4adb-ac49-7fa24ad51f22" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3f9b2dd5-8436-4326-878f-1d1461022807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_6e3b3434-b2ed-41fe-ae5b-9f8d6e858e87" xlink:href="biib-20250930.xsd#biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3f9b2dd5-8436-4326-878f-1d1461022807" xlink:to="loc_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct_6e3b3434-b2ed-41fe-ae5b-9f8d6e858e87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage_670711fb-cbf4-4604-a67a-7862af54ba1e" xlink:href="biib-20250930.xsd#biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3f9b2dd5-8436-4326-878f-1d1461022807" xlink:to="loc_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage_670711fb-cbf4-4604-a67a-7862af54ba1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Reductioninroyaltyrate_520518f5-157c-4e87-99d0-4f66ea457a10" xlink:href="biib-20250930.xsd#biib_Reductioninroyaltyrate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3f9b2dd5-8436-4326-878f-1d1461022807" xlink:to="loc_biib_Reductioninroyaltyrate_520518f5-157c-4e87-99d0-4f66ea457a10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PeriodOfCollaborationAgreement_d23f4365-fe6d-40c5-99bd-356b38e1284f" xlink:href="biib-20250930.xsd#biib_PeriodOfCollaborationAgreement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_3f9b2dd5-8436-4326-878f-1d1461022807" xlink:to="loc_biib_PeriodOfCollaborationAgreement_d23f4365-fe6d-40c5-99bd-356b38e1284f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCopromotionProfitSharingFormulaDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#CollaborativeandOtherRelationshipsCopromotionProfitSharingFormulaDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCopromotionProfitSharingFormulaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c478cbf3-5580-4e3f-8cd7-8d194f3d95ff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ef407031-a288-4865-9ef4-a229ab3c8cb3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c478cbf3-5580-4e3f-8cd7-8d194f3d95ff" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ef407031-a288-4865-9ef4-a229ab3c8cb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_44ad9d69-6e94-456c-bd98-92c5744133b5" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ef407031-a288-4865-9ef4-a229ab3c8cb3" xlink:to="loc_srt_ProductOrServiceAxis_44ad9d69-6e94-456c-bd98-92c5744133b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8984da6d-64e2-4449-b42e-bfac46fd3a30" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_44ad9d69-6e94-456c-bd98-92c5744133b5" xlink:to="loc_srt_ProductsAndServicesDomain_8984da6d-64e2-4449-b42e-bfac46fd3a30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RituxanMember_aa1a7f7d-6b07-4699-a725-c7af6a13b045" xlink:href="biib-20250930.xsd#biib_RituxanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8984da6d-64e2-4449-b42e-bfac46fd3a30" xlink:to="loc_biib_RituxanMember_aa1a7f7d-6b07-4699-a725-c7af6a13b045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LUNSUMIOMember_2c80d1a7-0c9c-472f-bad5-81fa21ae36f8" xlink:href="biib-20250930.xsd#biib_LUNSUMIOMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8984da6d-64e2-4449-b42e-bfac46fd3a30" xlink:to="loc_biib_LUNSUMIOMember_2c80d1a7-0c9c-472f-bad5-81fa21ae36f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_faaa16e0-2af2-4587-aaad-f8e33de2b7c2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_ef407031-a288-4865-9ef4-a229ab3c8cb3" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_faaa16e0-2af2-4587-aaad-f8e33de2b7c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_56007c6c-5690-4402-bce6-ab487b3beebb" xlink:href="biib-20250930.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_faaa16e0-2af2-4587-aaad-f8e33de2b7c2" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_56007c6c-5690-4402-bce6-ab487b3beebb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_aa6ccd7d-a4f5-4337-9e8e-1b80c3bbfaa8" xlink:href="biib-20250930.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_faaa16e0-2af2-4587-aaad-f8e33de2b7c2" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_aa6ccd7d-a4f5-4337-9e8e-1b80c3bbfaa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour_5a7b38ad-f53d-4f73-acb1-3e9ee9594f73" xlink:href="biib-20250930.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_faaa16e0-2af2-4587-aaad-f8e33de2b7c2" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour_5a7b38ad-f53d-4f73-acb1-3e9ee9594f73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_fd2c68bd-59dd-4228-bfff-d3e1a9dda03b" xlink:href="biib-20250930.xsd#biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_faaa16e0-2af2-4587-aaad-f8e33de2b7c2" xlink:to="loc_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment_fd2c68bd-59dd-4228-bfff-d3e1a9dda03b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#CollaborativeandOtherRelationshipsProfitSharingDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1d982ba7-8223-4022-a84d-ee88286bedf4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_237b5a5f-3a89-4c34-8aab-845faffeb8e2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1d982ba7-8223-4022-a84d-ee88286bedf4" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_237b5a5f-3a89-4c34-8aab-845faffeb8e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_339ba0f3-a508-440c-bbdf-1b5ed6350c25" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_237b5a5f-3a89-4c34-8aab-845faffeb8e2" xlink:to="loc_srt_ProductOrServiceAxis_339ba0f3-a508-440c-bbdf-1b5ed6350c25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ff83705b-d82f-4747-9e15-9006f8415efa" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_339ba0f3-a508-440c-bbdf-1b5ed6350c25" xlink:to="loc_srt_ProductsAndServicesDomain_ff83705b-d82f-4747-9e15-9006f8415efa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_RituxanMember_198e9108-beb0-4eb4-90a7-719b9fc433b1" xlink:href="biib-20250930.xsd#biib_RituxanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ff83705b-d82f-4747-9e15-9006f8415efa" xlink:to="loc_biib_RituxanMember_198e9108-beb0-4eb4-90a7-719b9fc433b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LUNSUMIOMember_2cd8fbaa-1b3c-47c0-a449-fa969c78ff10" xlink:href="biib-20250930.xsd#biib_LUNSUMIOMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ff83705b-d82f-4747-9e15-9006f8415efa" xlink:to="loc_biib_LUNSUMIOMember_2cd8fbaa-1b3c-47c0-a449-fa969c78ff10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GAZYVAMember_ad2dbc6b-6864-48bd-bcc0-06bb63a49334" xlink:href="biib-20250930.xsd#biib_GAZYVAMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ff83705b-d82f-4747-9e15-9006f8415efa" xlink:to="loc_biib_GAZYVAMember_ad2dbc6b-6864-48bd-bcc0-06bb63a49334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c14bc148-a6e7-4ed4-a15c-ec7fcec82a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_237b5a5f-3a89-4c34-8aab-845faffeb8e2" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c14bc148-a6e7-4ed4-a15c-ec7fcec82a1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_a5c071c2-ef99-48a0-93a2-603592e237c2" xlink:href="biib-20250930.xsd#biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c14bc148-a6e7-4ed4-a15c-ec7fcec82a1e" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion_a5c071c2-ef99-48a0-93a2-603592e237c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_02f1252a-d313-4eb4-99f8-a062c50a315b" xlink:href="biib-20250930.xsd#biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c14bc148-a6e7-4ed4-a15c-ec7fcec82a1e" xlink:to="loc_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_02f1252a-d313-4eb4-99f8-a062c50a315b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_aefc8bbb-e308-4b3d-a12c-4fc95c03bd3c" xlink:href="biib-20250930.xsd#biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c14bc148-a6e7-4ed4-a15c-ec7fcec82a1e" xlink:to="loc_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne_aefc8bbb-e308-4b3d-a12c-4fc95c03bd3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SalesTriggerGrossSalesThreshold_d6cc1316-4994-4501-8126-f4bba5305b12" xlink:href="biib-20250930.xsd#biib_SalesTriggerGrossSalesThreshold"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c14bc148-a6e7-4ed4-a15c-ec7fcec82a1e" xlink:to="loc_biib_SalesTriggerGrossSalesThreshold_d6cc1316-4994-4501-8126-f4bba5305b12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_01be8b4f-55cd-40fc-98a6-169905dfd1a8" xlink:href="biib-20250930.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c14bc148-a6e7-4ed4-a15c-ec7fcec82a1e" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_01be8b4f-55cd-40fc-98a6-169905dfd1a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_1154cc6f-d144-47b7-8dfc-7b00d641f0f0" xlink:href="biib-20250930.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_c14bc148-a6e7-4ed4-a15c-ec7fcec82a1e" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_1154cc6f-d144-47b7-8dfc-7b00d641f0f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsPretaxProfitSharingFormulaDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#CollaborativeandOtherRelationshipsPretaxProfitSharingFormulaDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsPretaxProfitSharingFormulaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_09f103a4-ace0-4eba-8563-d7719e970781" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3ff4dc1d-9704-4a36-ba53-3827706f84cf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_09f103a4-ace0-4eba-8563-d7719e970781" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3ff4dc1d-9704-4a36-ba53-3827706f84cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_1c415d3e-e316-4987-bb88-79daf24470b7" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3ff4dc1d-9704-4a36-ba53-3827706f84cf" xlink:to="loc_srt_ProductOrServiceAxis_1c415d3e-e316-4987-bb88-79daf24470b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6f9cb677-603f-4044-9ccc-2632ea4d001e" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_1c415d3e-e316-4987-bb88-79daf24470b7" xlink:to="loc_srt_ProductsAndServicesDomain_6f9cb677-603f-4044-9ccc-2632ea4d001e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GAZYVAMember_53b52fef-1b0b-4329-b9e1-271111e9dae8" xlink:href="biib-20250930.xsd#biib_GAZYVAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6f9cb677-603f-4044-9ccc-2632ea4d001e" xlink:to="loc_biib_GAZYVAMember_53b52fef-1b0b-4329-b9e1-271111e9dae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LUNSUMIOMember_c0ddf446-841b-4de4-9c9f-ea8e0bf21fd2" xlink:href="biib-20250930.xsd#biib_LUNSUMIOMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6f9cb677-603f-4044-9ccc-2632ea4d001e" xlink:to="loc_biib_LUNSUMIOMember_c0ddf446-841b-4de4-9c9f-ea8e0bf21fd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ec1bc6a3-47ca-4017-b613-9a1fe4664e65" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3ff4dc1d-9704-4a36-ba53-3827706f84cf" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ec1bc6a3-47ca-4017-b613-9a1fe4664e65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_7e614b95-f605-47c7-8455-704ad4f3381e" xlink:href="biib-20250930.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ec1bc6a3-47ca-4017-b613-9a1fe4664e65" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo_7e614b95-f605-47c7-8455-704ad4f3381e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_eff7458d-84e2-4015-8346-6c65c7dbe691" xlink:href="biib-20250930.xsd#biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ec1bc6a3-47ca-4017-b613-9a1fe4664e65" xlink:to="loc_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree_eff7458d-84e2-4015-8346-6c65c7dbe691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_6edf0984-3ca6-4ffd-aeac-8ca8f3ffbdc5" xlink:href="biib-20250930.xsd#biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ec1bc6a3-47ca-4017-b613-9a1fe4664e65" xlink:to="loc_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne_6edf0984-3ca6-4ffd-aeac-8ca8f3ffbdc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsIonisPharmaceuticalsIncDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#CollaborativeandOtherRelationshipsIonisPharmaceuticalsIncDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsIonisPharmaceuticalsIncDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ce14a728-c95b-4563-89d8-af0f96c55c41" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_62d80242-0c8e-4521-90b8-70d7be1ac98c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ce14a728-c95b-4563-89d8-af0f96c55c41" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_62d80242-0c8e-4521-90b8-70d7be1ac98c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_c0d0fb5f-e21c-41d7-93d2-f44fb0fbb536" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_62d80242-0c8e-4521-90b8-70d7be1ac98c" xlink:to="loc_us-gaap_TypeOfArrangementAxis_c0d0fb5f-e21c-41d7-93d2-f44fb0fbb536" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b7e9f2f0-c4e4-490c-a6c2-5467bb47e6c3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_c0d0fb5f-e21c-41d7-93d2-f44fb0fbb536" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b7e9f2f0-c4e4-490c-a6c2-5467bb47e6c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IonisPharmaceuticalsInc.Member_b0c592c5-4998-4390-a80a-709c0f210a6f" xlink:href="biib-20250930.xsd#biib_IonisPharmaceuticalsInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b7e9f2f0-c4e4-490c-a6c2-5467bb47e6c3" xlink:to="loc_biib_IonisPharmaceuticalsInc.Member_b0c592c5-4998-4390-a80a-709c0f210a6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5cec73c9-515d-424b-b41a-dd037c99b294" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_62d80242-0c8e-4521-90b8-70d7be1ac98c" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5cec73c9-515d-424b-b41a-dd037c99b294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_e25593ae-569f-40f7-98c1-8bcee283b095" xlink:href="biib-20250930.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5cec73c9-515d-424b-b41a-dd037c99b294" xlink:to="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_e25593ae-569f-40f7-98c1-8bcee283b095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponInitiationOfNewPhases_c012454d-279b-4bd7-b924-4302f8ed09d6" xlink:href="biib-20250930.xsd#biib_EstimatedAdditionalPaymentsUponInitiationOfNewPhases"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5cec73c9-515d-424b-b41a-dd037c99b294" xlink:to="loc_biib_EstimatedAdditionalPaymentsUponInitiationOfNewPhases_c012454d-279b-4bd7-b924-4302f8ed09d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_1384fa73-28af-4582-b963-4bb6a8c54706" xlink:href="biib-20250930.xsd#biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_5cec73c9-515d-424b-b41a-dd037c99b294" xlink:to="loc_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold_1384fa73-28af-4582-b963-4bb6a8c54706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#CollaborativeandOtherRelationshipsEisaiDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_432cfdbd-bc82-4061-acdc-f3197170a448" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9ecf05d0-e97f-411f-84b6-fb358f8c7c71" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_432cfdbd-bc82-4061-acdc-f3197170a448" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9ecf05d0-e97f-411f-84b6-fb358f8c7c71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_54e0b6be-cf94-433a-89c6-a793e333276a" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9ecf05d0-e97f-411f-84b6-fb358f8c7c71" xlink:to="loc_srt_ProductOrServiceAxis_54e0b6be-cf94-433a-89c6-a793e333276a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2ed12cb9-50a3-4610-8053-0dd746e33af5" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_54e0b6be-cf94-433a-89c6-a793e333276a" xlink:to="loc_srt_ProductsAndServicesDomain_2ed12cb9-50a3-4610-8053-0dd746e33af5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LEQEMBICollaborationMember_bf88d076-c58a-4c28-a9b9-d8c156e850f4" xlink:href="biib-20250930.xsd#biib_LEQEMBICollaborationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_2ed12cb9-50a3-4610-8053-0dd746e33af5" xlink:to="loc_biib_LEQEMBICollaborationMember_bf88d076-c58a-4c28-a9b9-d8c156e850f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_e3cbdd8b-4da1-4d1d-ba41-1c34f45d2c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9ecf05d0-e97f-411f-84b6-fb358f8c7c71" xlink:to="loc_us-gaap_TypeOfArrangementAxis_e3cbdd8b-4da1-4d1d-ba41-1c34f45d2c1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ce0d163a-cc09-426c-883e-a728981e8c52" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_e3cbdd8b-4da1-4d1d-ba41-1c34f45d2c1f" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ce0d163a-cc09-426c-883e-a728981e8c52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_ea078ca7-fe2b-453d-af57-c46d956f23f2" xlink:href="biib-20250930.xsd#biib_EisaiMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ce0d163a-cc09-426c-883e-a728981e8c52" xlink:to="loc_biib_EisaiMember_ea078ca7-fe2b-453d-af57-c46d956f23f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f84fdd27-ac64-473d-915f-960a9925a596" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9ecf05d0-e97f-411f-84b6-fb358f8c7c71" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f84fdd27-ac64-473d-915f-960a9925a596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfNonControlingInterestRecognized_6b0728ca-2c01-4a16-9958-47bff4041bab" xlink:href="biib-20250930.xsd#biib_ShareOfNonControlingInterestRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f84fdd27-ac64-473d-915f-960a9925a596" xlink:to="loc_biib_ShareOfNonControlingInterestRecognized_6b0728ca-2c01-4a16-9958-47bff4041bab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AccountsReceivableFromCollaborator_aa2bb41f-66e5-45d8-845b-cb9f4c502a7b" xlink:href="biib-20250930.xsd#biib_AccountsReceivableFromCollaborator"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f84fdd27-ac64-473d-915f-960a9925a596" xlink:to="loc_biib_AccountsReceivableFromCollaborator_aa2bb41f-66e5-45d8-845b-cb9f4c502a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_AccountsPayableToCollaborator_a28f3ed3-1fa1-488a-ab8b-2e4e562b85a3" xlink:href="biib-20250930.xsd#biib_AccountsPayableToCollaborator"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f84fdd27-ac64-473d-915f-960a9925a596" xlink:to="loc_biib_AccountsPayableToCollaborator_a28f3ed3-1fa1-488a-ab8b-2e4e562b85a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoLEQEMBICollaborationDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoLEQEMBICollaborationDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoLEQEMBICollaborationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_daf9d38f-8e0d-4420-a1e3-a44f54318c6d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4e8e37c0-cc66-472b-830e-250be5a1d306" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_daf9d38f-8e0d-4420-a1e3-a44f54318c6d" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4e8e37c0-cc66-472b-830e-250be5a1d306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_82d36eac-f9db-4aea-98b2-79e928cbb038" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4e8e37c0-cc66-472b-830e-250be5a1d306" xlink:to="loc_srt_ProductOrServiceAxis_82d36eac-f9db-4aea-98b2-79e928cbb038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_541c5cdf-e99b-481b-8d25-c6cb487512da" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_82d36eac-f9db-4aea-98b2-79e928cbb038" xlink:to="loc_srt_ProductsAndServicesDomain_541c5cdf-e99b-481b-8d25-c6cb487512da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LEQEMBIMember_c30188cc-4082-4753-9561-97d85cac7d3a" xlink:href="biib-20250930.xsd#biib_LEQEMBIMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_541c5cdf-e99b-481b-8d25-c6cb487512da" xlink:to="loc_biib_LEQEMBIMember_c30188cc-4082-4753-9561-97d85cac7d3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_E2609andBAN2401Member_72df79a8-ebe2-4571-bbd4-0faadd2313a3" xlink:href="biib-20250930.xsd#biib_E2609andBAN2401Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_541c5cdf-e99b-481b-8d25-c6cb487512da" xlink:to="loc_biib_E2609andBAN2401Member_72df79a8-ebe2-4571-bbd4-0faadd2313a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_df4a8965-61b7-4aac-8411-59df4c97aa35" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4e8e37c0-cc66-472b-830e-250be5a1d306" xlink:to="loc_us-gaap_TypeOfArrangementAxis_df4a8965-61b7-4aac-8411-59df4c97aa35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8e997131-207a-43c7-8122-6b9651966b90" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_df4a8965-61b7-4aac-8411-59df4c97aa35" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8e997131-207a-43c7-8122-6b9651966b90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LEQEMBICollaborationMember_8226b11b-bfe2-4a0b-b15f-19eee9c53a5b" xlink:href="biib-20250930.xsd#biib_LEQEMBICollaborationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8e997131-207a-43c7-8122-6b9651966b90" xlink:to="loc_biib_LEQEMBICollaborationMember_8226b11b-bfe2-4a0b-b15f-19eee9c53a5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EisaiMember_88d0f3c2-6e1a-4d98-bcac-92fd246fa5c3" xlink:href="biib-20250930.xsd#biib_EisaiMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8e997131-207a-43c7-8122-6b9651966b90" xlink:to="loc_biib_EisaiMember_88d0f3c2-6e1a-4d98-bcac-92fd246fa5c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_a7c3ff28-48cb-42bb-8cbb-9310eb7d69e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4e8e37c0-cc66-472b-830e-250be5a1d306" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_a7c3ff28-48cb-42bb-8cbb-9310eb7d69e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_88916b65-584b-4de9-8810-334fb99c8bee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a7c3ff28-48cb-42bb-8cbb-9310eb7d69e7" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_88916b65-584b-4de9-8810-334fb99c8bee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_4aacf6ca-6679-4623-a95b-f5eb4bbd7084" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_88916b65-584b-4de9-8810-334fb99c8bee" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_4aacf6ca-6679-4623-a95b-f5eb4bbd7084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4615b3f5-fdb1-4558-98c0-fc18c16c9f59" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4e8e37c0-cc66-472b-830e-250be5a1d306" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4615b3f5-fdb1-4558-98c0-fc18c16c9f59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ExpenseIncurredByCollaboration_37afc6d8-4d7b-45b4-afef-3c970b005662" xlink:href="biib-20250930.xsd#biib_ExpenseIncurredByCollaboration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4615b3f5-fdb1-4558-98c0-fc18c16c9f59" xlink:to="loc_biib_ExpenseIncurredByCollaboration_37afc6d8-4d7b-45b4-afef-3c970b005662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_d233cc34-d856-40f9-bea7-56a03dd22801" xlink:href="biib-20250930.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4615b3f5-fdb1-4558-98c0-fc18c16c9f59" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_d233cc34-d856-40f9-bea7-56a03dd22801" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration_14cbdf75-14c4-4b02-b66a-1b5febd7ce6c" xlink:href="biib-20250930.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4615b3f5-fdb1-4558-98c0-fc18c16c9f59" xlink:to="loc_biib_Expenseincurredbythecollaboration_14cbdf75-14c4-4b02-b66a-1b5febd7ce6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8d9ea974-b4ea-4d7a-9b63-1386fad8fcb4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4f94bbc1-c198-408b-a8e6-95ecce5ceb4d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_8d9ea974-b4ea-4d7a-9b63-1386fad8fcb4" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4f94bbc1-c198-408b-a8e6-95ecce5ceb4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_6dd044e0-d9ef-4112-824f-726c1c8593aa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4f94bbc1-c198-408b-a8e6-95ecce5ceb4d" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_6dd044e0-d9ef-4112-824f-726c1c8593aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2572668d-bc91-4bc4-8111-f76c1dc41df5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6dd044e0-d9ef-4112-824f-726c1c8593aa" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2572668d-bc91-4bc4-8111-f76c1dc41df5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_266dce96-451e-435e-9d97-054da808de27" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2572668d-bc91-4bc4-8111-f76c1dc41df5" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_266dce96-451e-435e-9d97-054da808de27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5e9d0773-aaad-4d6a-b4ee-fc39be8e9749" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4f94bbc1-c198-408b-a8e6-95ecce5ceb4d" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5e9d0773-aaad-4d6a-b4ee-fc39be8e9749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d3fabeec-7b11-4019-ac38-d9f27a025f91" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5e9d0773-aaad-4d6a-b4ee-fc39be8e9749" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d3fabeec-7b11-4019-ac38-d9f27a025f91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UCBPharmaSAMember_072de8c6-de84-435e-a77b-fba5178ba9cb" xlink:href="biib-20250930.xsd#biib_UCBPharmaSAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d3fabeec-7b11-4019-ac38-d9f27a025f91" xlink:to="loc_biib_UCBPharmaSAMember_072de8c6-de84-435e-a77b-fba5178ba9cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_46e520a2-f53c-47a5-aac2-785e6d813e23" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4f94bbc1-c198-408b-a8e6-95ecce5ceb4d" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_46e520a2-f53c-47a5-aac2-785e6d813e23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration_fe688c10-9c9e-457f-9e34-aaec34c3f95e" xlink:href="biib-20250930.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_46e520a2-f53c-47a5-aac2-785e6d813e23" xlink:to="loc_biib_Expenseincurredbythecollaboration_fe688c10-9c9e-457f-9e34-aaec34c3f95e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_f36d2675-952e-4f6a-a242-45f0ac632341" xlink:href="biib-20250930.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_46e520a2-f53c-47a5-aac2-785e6d813e23" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_f36d2675-952e-4f6a-a242-45f0ac632341" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSageTherapeuticsIncDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#CollaborativeandOtherRelationshipsSageTherapeuticsIncDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSageTherapeuticsIncDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7f8cb28f-b488-4ac4-8c03-75f0d18a60d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_757e7b53-9e78-4546-b75b-07f64776119d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_7f8cb28f-b488-4ac4-8c03-75f0d18a60d5" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_757e7b53-9e78-4546-b75b-07f64776119d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_7c260e08-5315-4bfa-b2f5-cb871f2c6c49" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_757e7b53-9e78-4546-b75b-07f64776119d" xlink:to="loc_srt_StatementScenarioAxis_7c260e08-5315-4bfa-b2f5-cb871f2c6c49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_ebf42d09-11eb-4f92-89fe-bced1dbf4b85" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_7c260e08-5315-4bfa-b2f5-cb871f2c6c49" xlink:to="loc_srt_ScenarioUnspecifiedDomain_ebf42d09-11eb-4f92-89fe-bced1dbf4b85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_528e7a39-f59e-4c77-bbde-0c782bae1060" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_ebf42d09-11eb-4f92-89fe-bced1dbf4b85" xlink:to="loc_srt_ScenarioForecastMember_528e7a39-f59e-4c77-bbde-0c782bae1060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_ecd1a3ed-d5cb-426a-9632-e6b8e9231915" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_757e7b53-9e78-4546-b75b-07f64776119d" xlink:to="loc_us-gaap_TypeOfArrangementAxis_ecd1a3ed-d5cb-426a-9632-e6b8e9231915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f0024b46-451a-4632-85ad-ffde61d6eeb6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_ecd1a3ed-d5cb-426a-9632-e6b8e9231915" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f0024b46-451a-4632-85ad-ffde61d6eeb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SageTherapeuticsIncMember_417f433b-ef4f-41b3-9886-1d74990cf00a" xlink:href="biib-20250930.xsd#biib_SageTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f0024b46-451a-4632-85ad-ffde61d6eeb6" xlink:to="loc_biib_SageTherapeuticsIncMember_417f433b-ef4f-41b3-9886-1d74990cf00a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ba92615f-08b4-4539-b23f-5aeabd1e756a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_757e7b53-9e78-4546-b75b-07f64776119d" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ba92615f-08b4-4539-b23f-5aeabd1e756a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_0d1b41f3-fb3b-4372-af2f-9271573972ab" xlink:href="biib-20250930.xsd#biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ba92615f-08b4-4539-b23f-5aeabd1e756a" xlink:to="loc_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately_0d1b41f3-fb3b-4372-af2f-9271573972ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationprofitlosssharing_0ed3b50c-12d3-4ce7-a12d-a34bc307c1ee" xlink:href="biib-20250930.xsd#biib_Collaborationprofitlosssharing"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ba92615f-08b4-4539-b23f-5aeabd1e756a" xlink:to="loc_biib_Collaborationprofitlosssharing_0ed3b50c-12d3-4ce7-a12d-a34bc307c1ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ShareOfNetProfitFromSageTherapeuticsPercent_b0b93239-bb7e-4803-92b0-599df3d09b5d" xlink:href="biib-20250930.xsd#biib_ShareOfNetProfitFromSageTherapeuticsPercent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ba92615f-08b4-4539-b23f-5aeabd1e756a" xlink:to="loc_biib_ShareOfNetProfitFromSageTherapeuticsPercent_b0b93239-bb7e-4803-92b0-599df3d09b5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_490e0381-5230-4716-b10d-ad934978cda3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3d97e3c8-db78-4af9-9855-ad1c9f0afeca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_490e0381-5230-4716-b10d-ad934978cda3" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3d97e3c8-db78-4af9-9855-ad1c9f0afeca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_dc5070f3-d8e8-405a-856e-6ce5eb0873fe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3d97e3c8-db78-4af9-9855-ad1c9f0afeca" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_dc5070f3-d8e8-405a-856e-6ce5eb0873fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0ebfe085-ce56-47ea-bfa2-d264dcde1a90" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_dc5070f3-d8e8-405a-856e-6ce5eb0873fe" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0ebfe085-ce56-47ea-bfa2-d264dcde1a90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1ab9b915-088c-43eb-89f8-1f6f036df70b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0ebfe085-ce56-47ea-bfa2-d264dcde1a90" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1ab9b915-088c-43eb-89f8-1f6f036df70b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_b0d687e1-5ff3-4c84-ad52-f272b2f0f93a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0ebfe085-ce56-47ea-bfa2-d264dcde1a90" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_b0d687e1-5ff3-4c84-ad52-f272b2f0f93a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3eebfa53-f40c-4a60-ade0-9a303b7a3d1b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3d97e3c8-db78-4af9-9855-ad1c9f0afeca" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3eebfa53-f40c-4a60-ade0-9a303b7a3d1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0b2951bf-fda4-4edd-bea5-591bd5fb9d17" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3eebfa53-f40c-4a60-ade0-9a303b7a3d1b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0b2951bf-fda4-4edd-bea5-591bd5fb9d17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SageTherapeuticsIncMember_24406832-5e72-4a53-9933-c7230329ac09" xlink:href="biib-20250930.xsd#biib_SageTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_0b2951bf-fda4-4edd-bea5-591bd5fb9d17" xlink:to="loc_biib_SageTherapeuticsIncMember_24406832-5e72-4a53-9933-c7230329ac09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_82df1531-c229-4804-97f8-8c97aae1b78d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3d97e3c8-db78-4af9-9855-ad1c9f0afeca" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_82df1531-c229-4804-97f8-8c97aae1b78d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration_75a0e4f8-aa83-4177-86e5-54fff9d28de2" xlink:href="biib-20250930.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_82df1531-c229-4804-97f8-8c97aae1b78d" xlink:to="loc_biib_Expenseincurredbythecollaboration_75a0e4f8-aa83-4177-86e5-54fff9d28de2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_5fe8cabc-0146-412c-86f7-5a0d73badcea" xlink:href="biib-20250930.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_82df1531-c229-4804-97f8-8c97aae1b78d" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_5fe8cabc-0146-412c-86f7-5a0d73badcea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_88e16259-4b06-485b-b8d4-817808a2ee27" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3d4047ad-30cb-43ef-a70e-afe5f128830f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_88e16259-4b06-485b-b8d4-817808a2ee27" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3d4047ad-30cb-43ef-a70e-afe5f128830f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_a70648e3-a3db-45c3-9709-238c5d09c337" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3d4047ad-30cb-43ef-a70e-afe5f128830f" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_a70648e3-a3db-45c3-9709-238c5d09c337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0f42cac9-a566-4f10-b710-75dfc0324755" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_a70648e3-a3db-45c3-9709-238c5d09c337" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0f42cac9-a566-4f10-b710-75dfc0324755" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1d3ba0fb-6fd3-4c17-b6e6-7bcd7acf6c28" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0f42cac9-a566-4f10-b710-75dfc0324755" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1d3ba0fb-6fd3-4c17-b6e6-7bcd7acf6c28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_8348b9d5-5d0f-4e82-9417-abfb038c1eed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3d4047ad-30cb-43ef-a70e-afe5f128830f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_8348b9d5-5d0f-4e82-9417-abfb038c1eed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_541d5113-2650-4d1b-aeb0-be27ab888c0c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_8348b9d5-5d0f-4e82-9417-abfb038c1eed" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_541d5113-2650-4d1b-aeb0-be27ab888c0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_DenaliTherapeuticsIncMember_4c41a538-c309-4d72-a849-73719a3efbac" xlink:href="biib-20250930.xsd#biib_DenaliTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_541d5113-2650-4d1b-aeb0-be27ab888c0c" xlink:to="loc_biib_DenaliTherapeuticsIncMember_4c41a538-c309-4d72-a849-73719a3efbac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_90691e29-125a-484b-9f74-f20936f78fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3d4047ad-30cb-43ef-a70e-afe5f128830f" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_90691e29-125a-484b-9f74-f20936f78fcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration_602c7bcb-a220-4c62-923c-beb6d9540fd2" xlink:href="biib-20250930.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_90691e29-125a-484b-9f74-f20936f78fcd" xlink:to="loc_biib_Expenseincurredbythecollaboration_602c7bcb-a220-4c62-923c-beb6d9540fd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_44206236-847b-4f9c-8111-37298470bdf5" xlink:href="biib-20250930.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_90691e29-125a-484b-9f74-f20936f78fcd" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_44206236-847b-4f9c-8111-37298470bdf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsStokeTherapeuticsIncDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#CollaborativeandOtherRelationshipsStokeTherapeuticsIncDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsStokeTherapeuticsIncDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a28df974-82dd-48fe-a4d8-2a0221f5cc4e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1dc155a9-83f6-48a6-b6c9-b579050410bf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a28df974-82dd-48fe-a4d8-2a0221f5cc4e" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1dc155a9-83f6-48a6-b6c9-b579050410bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_267a26fb-9649-4364-84e6-d50bd1dd4c2c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1dc155a9-83f6-48a6-b6c9-b579050410bf" xlink:to="loc_us-gaap_TypeOfArrangementAxis_267a26fb-9649-4364-84e6-d50bd1dd4c2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_67aebfa7-9035-40e1-b50c-d7b7868811ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_267a26fb-9649-4364-84e6-d50bd1dd4c2c" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_67aebfa7-9035-40e1-b50c-d7b7868811ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StokeTherapeuticsIncMember_97997a01-8af3-4c81-9c58-8129e9c62445" xlink:href="biib-20250930.xsd#biib_StokeTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_67aebfa7-9035-40e1-b50c-d7b7868811ad" xlink:to="loc_biib_StokeTherapeuticsIncMember_97997a01-8af3-4c81-9c58-8129e9c62445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_6090aa74-36d3-49bb-aa3a-d3cd6f8ce936" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1dc155a9-83f6-48a6-b6c9-b579050410bf" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_6090aa74-36d3-49bb-aa3a-d3cd6f8ce936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_2560f60b-5a32-4a93-aee9-ed2e0e52b94c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_6090aa74-36d3-49bb-aa3a-d3cd6f8ce936" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_2560f60b-5a32-4a93-aee9-ed2e0e52b94c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MilestonePaymentDevelopmentalMember_17ee12f0-f608-48e7-abba-10c110477a79" xlink:href="biib-20250930.xsd#biib_MilestonePaymentDevelopmentalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_2560f60b-5a32-4a93-aee9-ed2e0e52b94c" xlink:to="loc_biib_MilestonePaymentDevelopmentalMember_17ee12f0-f608-48e7-abba-10c110477a79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MilestonePaymentCommercialMember_85b00194-3b59-4b7d-902c-3e961596f0dc" xlink:href="biib-20250930.xsd#biib_MilestonePaymentCommercialMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_2560f60b-5a32-4a93-aee9-ed2e0e52b94c" xlink:to="loc_biib_MilestonePaymentCommercialMember_85b00194-3b59-4b7d-902c-3e961596f0dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2965917c-56f3-406f-a94b-d452d3fb8e7a" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1dc155a9-83f6-48a6-b6c9-b579050410bf" xlink:to="loc_srt_ProductOrServiceAxis_2965917c-56f3-406f-a94b-d452d3fb8e7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_99c9af74-1071-4183-99fa-702e77908662" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_2965917c-56f3-406f-a94b-d452d3fb8e7a" xlink:to="loc_srt_ProductsAndServicesDomain_99c9af74-1071-4183-99fa-702e77908662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ZorevunersenMember_fd3db454-a8af-4b6b-990f-94480c667458" xlink:href="biib-20250930.xsd#biib_ZorevunersenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_99c9af74-1071-4183-99fa-702e77908662" xlink:to="loc_biib_ZorevunersenMember_fd3db454-a8af-4b6b-990f-94480c667458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eabf8907-64dc-47f4-b6c6-c44613bbd2cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1dc155a9-83f6-48a6-b6c9-b579050410bf" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eabf8907-64dc-47f4-b6c6-c44613bbd2cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_PercentageOfFutureDevelopmentCosts_5b9fe583-ada8-4895-9df8-4770d7ec291d" xlink:href="biib-20250930.xsd#biib_PercentageOfFutureDevelopmentCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eabf8907-64dc-47f4-b6c6-c44613bbd2cb" xlink:to="loc_biib_PercentageOfFutureDevelopmentCosts_5b9fe583-ada8-4895-9df8-4770d7ec291d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_82274780-8c2b-411f-ab0e-b60de8e741fc" xlink:href="biib-20250930.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eabf8907-64dc-47f4-b6c6-c44613bbd2cb" xlink:to="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_82274780-8c2b-411f-ab0e-b60de8e741fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_c43e588a-1b4d-4a52-910e-532a5525e322" xlink:href="biib-20250930.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_eabf8907-64dc-47f4-b6c6-c44613bbd2cb" xlink:to="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_c43e588a-1b4d-4a52-910e-532a5525e322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoStokeTherapeuticsDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoStokeTherapeuticsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoStokeTherapeuticsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_750dcfe1-f0d2-49d6-a031-df100a23d4dc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_00bbcb24-dfca-4e2b-8160-85c23aa87017" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_750dcfe1-f0d2-49d6-a031-df100a23d4dc" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_00bbcb24-dfca-4e2b-8160-85c23aa87017" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_38c2901a-a113-4727-a0a6-6c7943712a21" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_00bbcb24-dfca-4e2b-8160-85c23aa87017" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_38c2901a-a113-4727-a0a6-6c7943712a21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_f3c9f327-d9de-4543-ac75-c31bd62c9ae7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_38c2901a-a113-4727-a0a6-6c7943712a21" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_f3c9f327-d9de-4543-ac75-c31bd62c9ae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f2fb40e4-e936-42f3-af67-447bec389759" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_f3c9f327-d9de-4543-ac75-c31bd62c9ae7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_f2fb40e4-e936-42f3-af67-447bec389759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_f32dbdc6-e566-4919-b78f-2167265f5cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_00bbcb24-dfca-4e2b-8160-85c23aa87017" xlink:to="loc_us-gaap_TypeOfArrangementAxis_f32dbdc6-e566-4919-b78f-2167265f5cb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c0796cda-6848-40fc-9120-94caee8d7e2c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_f32dbdc6-e566-4919-b78f-2167265f5cb1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c0796cda-6848-40fc-9120-94caee8d7e2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_StokeTherapeuticsIncMember_f13184a5-43c7-48f2-ba22-e2030ed5013c" xlink:href="biib-20250930.xsd#biib_StokeTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c0796cda-6848-40fc-9120-94caee8d7e2c" xlink:to="loc_biib_StokeTherapeuticsIncMember_f13184a5-43c7-48f2-ba22-e2030ed5013c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_249c4435-1f5f-4b0b-a795-2a584366c55b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_00bbcb24-dfca-4e2b-8160-85c23aa87017" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_249c4435-1f5f-4b0b-a795-2a584366c55b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expenseincurredbythecollaboration_ca6eab49-a50a-4119-ad7d-ff6665bc5552" xlink:href="biib-20250930.xsd#biib_Expenseincurredbythecollaboration"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_249c4435-1f5f-4b0b-a795-2a584366c55b" xlink:to="loc_biib_Expenseincurredbythecollaboration_ca6eab49-a50a-4119-ad7d-ff6665bc5552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Expensereflectedwithinstatementsofincome_a86b8bc5-1311-49ef-b0f7-c21cb9b216b3" xlink:href="biib-20250930.xsd#biib_Expensereflectedwithinstatementsofincome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_249c4435-1f5f-4b0b-a795-2a584366c55b" xlink:to="loc_biib_Expensereflectedwithinstatementsofincome_a86b8bc5-1311-49ef-b0f7-c21cb9b216b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#CollaborativeandOtherRelationshipsSamsungBioepisDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_15b577a6-1450-4686-8a77-4f2825433fee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6844e592-ed67-45f7-9dc3-afdd22cd4875" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_15b577a6-1450-4686-8a77-4f2825433fee" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6844e592-ed67-45f7-9dc3-afdd22cd4875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_dcfac655-f1af-4693-a899-6b77cf7a3447" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6844e592-ed67-45f7-9dc3-afdd22cd4875" xlink:to="loc_us-gaap_TypeOfArrangementAxis_dcfac655-f1af-4693-a899-6b77cf7a3447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bc96f08d-22b4-4798-bb42-0db01f7ebf1f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_dcfac655-f1af-4693-a899-6b77cf7a3447" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bc96f08d-22b4-4798-bb42-0db01f7ebf1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_76b17b7e-b918-4e5f-bb9b-c339e8fac10e" xlink:href="biib-20250930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_bc96f08d-22b4-4798-bb42-0db01f7ebf1f" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_76b17b7e-b918-4e5f-bb9b-c339e8fac10e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_dc9a7c20-e32e-4243-84b7-a7f868abd02f" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6844e592-ed67-45f7-9dc3-afdd22cd4875" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_dc9a7c20-e32e-4243-84b7-a7f868abd02f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_6d042f1d-ef57-4410-9229-5f0fb52976f3" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_dc9a7c20-e32e-4243-84b7-a7f868abd02f" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_6d042f1d-ef57-4410-9229-5f0fb52976f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_SamsungBiosimilarAgreementMember_26a55312-0ff9-461a-a2c8-778fb3aa5d57" xlink:href="biib-20250930.xsd#biib_SamsungBiosimilarAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_6d042f1d-ef57-4410-9229-5f0fb52976f3" xlink:to="loc_biib_SamsungBiosimilarAgreementMember_26a55312-0ff9-461a-a2c8-778fb3aa5d57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e5b3f037-8164-4dbe-ac91-0a977d3414bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6844e592-ed67-45f7-9dc3-afdd22cd4875" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e5b3f037-8164-4dbe-ac91-0a977d3414bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_94fd4805-79ef-4572-af15-cfd4ca7eeda6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e5b3f037-8164-4dbe-ac91-0a977d3414bb" xlink:to="loc_us-gaap_RelatedPartyDomain_94fd4805-79ef-4572-af15-cfd4ca7eeda6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyMember_60415dcd-1a9e-4400-b1b2-9e18d7a7c31b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_94fd4805-79ef-4572-af15-cfd4ca7eeda6" xlink:to="loc_us-gaap_RelatedPartyMember_60415dcd-1a9e-4400-b1b2-9e18d7a7c31b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9e5bb8f3-69d8-403e-9e1f-106c85edbd15" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6844e592-ed67-45f7-9dc3-afdd22cd4875" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9e5bb8f3-69d8-403e-9e1f-106c85edbd15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContingentCommercializedRightsNumberOfProducts_f60f1b93-231e-4f64-8901-edd3e25d5df9" xlink:href="biib-20250930.xsd#biib_ContingentCommercializedRightsNumberOfProducts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9e5bb8f3-69d8-403e-9e1f-106c85edbd15" xlink:to="loc_biib_ContingentCommercializedRightsNumberOfProducts_f60f1b93-231e-4f64-8901-edd3e25d5df9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EquityMethodInvestmentsExpectedProfitShare_ead47756-f971-4796-bacf-d90e6833991a" xlink:href="biib-20250930.xsd#biib_EquityMethodInvestmentsExpectedProfitShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9e5bb8f3-69d8-403e-9e1f-106c85edbd15" xlink:to="loc_biib_EquityMethodInvestmentsExpectedProfitShare_ead47756-f971-4796-bacf-d90e6833991a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_1823a3cd-ed1b-4bce-8bb0-55f502efcf45" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9e5bb8f3-69d8-403e-9e1f-106c85edbd15" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_1823a3cd-ed1b-4bce-8bb0-55f502efcf45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_f1872426-3f78-4cb4-8c59-9ea097edc139" xlink:href="biib-20250930.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9e5bb8f3-69d8-403e-9e1f-106c85edbd15" xlink:to="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_f1872426-3f78-4cb4-8c59-9ea097edc139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborativeArrangementTermExtension_46e548e4-9e6f-4959-a4a7-d63d207e91bd" xlink:href="biib-20250930.xsd#biib_CollaborativeArrangementTermExtension"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9e5bb8f3-69d8-403e-9e1f-106c85edbd15" xlink:to="loc_biib_CollaborativeArrangementTermExtension_46e548e4-9e6f-4959-a4a7-d63d207e91bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ContractOptionExerciseFee_222f21a1-eff9-4ae7-b221-305c1a1f6d9a" xlink:href="biib-20250930.xsd#biib_ContractOptionExerciseFee"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9e5bb8f3-69d8-403e-9e1f-106c85edbd15" xlink:to="loc_biib_ContractOptionExerciseFee_222f21a1-eff9-4ae7-b221-305c1a1f6d9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_Collaborationprofitlosssharing_686474f3-ee17-43a6-8f87-cc7eb8260f3d" xlink:href="biib-20250930.xsd#biib_Collaborationprofitlosssharing"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9e5bb8f3-69d8-403e-9e1f-106c85edbd15" xlink:to="loc_biib_Collaborationprofitlosssharing_686474f3-ee17-43a6-8f87-cc7eb8260f3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_35aacef2-3f90-499e-93d0-15688c3881df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9e5bb8f3-69d8-403e-9e1f-106c85edbd15" xlink:to="loc_us-gaap_AccountsReceivableNet_35aacef2-3f90-499e-93d0-15688c3881df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_2bf4e335-1c9d-49db-973d-f93020e41203" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrentAndNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_9e5bb8f3-69d8-403e-9e1f-106c85edbd15" xlink:to="loc_us-gaap_AccountsPayableCurrentAndNoncurrent_2bf4e335-1c9d-49db-973d-f93020e41203" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherResearchandDiscoveryArrangementsandFundingArrangementsDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#CollaborativeandOtherRelationshipsOtherResearchandDiscoveryArrangementsandFundingArrangementsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherResearchandDiscoveryArrangementsandFundingArrangementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_de01f809-f8d7-471b-b9ec-df3d122f1a57" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_89ac59ca-8fde-4f7f-89e5-1483374c7a63" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_de01f809-f8d7-471b-b9ec-df3d122f1a57" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_89ac59ca-8fde-4f7f-89e5-1483374c7a63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_593e9e2f-ee59-4bc4-b9bb-8bd08d01c26b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_89ac59ca-8fde-4f7f-89e5-1483374c7a63" xlink:to="loc_us-gaap_TypeOfArrangementAxis_593e9e2f-ee59-4bc4-b9bb-8bd08d01c26b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8d7fcec5-1860-48e2-a536-a92390120d47" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_593e9e2f-ee59-4bc4-b9bb-8bd08d01c26b" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8d7fcec5-1860-48e2-a536-a92390120d47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_8032802c-4523-4d8f-bdd5-064d375db143" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8d7fcec5-1860-48e2-a536-a92390120d47" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_8032802c-4523-4d8f-bdd5-064d375db143" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_1f613176-13dc-4dd5-a726-0ca8bd5f85b0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_89ac59ca-8fde-4f7f-89e5-1483374c7a63" xlink:to="loc_srt_ProductOrServiceAxis_1f613176-13dc-4dd5-a726-0ca8bd5f85b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_745f0559-b080-4381-a540-957a6310bf59" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_1f613176-13dc-4dd5-a726-0ca8bd5f85b0" xlink:to="loc_srt_ProductsAndServicesDomain_745f0559-b080-4381-a540-957a6310bf59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_FelzartamabAndIzastobartHIB210Member_43367e76-e86e-4db7-899d-6b4d78593212" xlink:href="biib-20250930.xsd#biib_FelzartamabAndIzastobartHIB210Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_745f0559-b080-4381-a540-957a6310bf59" xlink:to="loc_biib_FelzartamabAndIzastobartHIB210Member_43367e76-e86e-4db7-899d-6b4d78593212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_9acff1c4-ecbb-4f97-80a8-c3668d6135bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_89ac59ca-8fde-4f7f-89e5-1483374c7a63" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_9acff1c4-ecbb-4f97-80a8-c3668d6135bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_5a9e743c-dd69-436c-856a-f538e3556fe3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_9acff1c4-ecbb-4f97-80a8-c3668d6135bb" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_5a9e743c-dd69-436c-856a-f538e3556fe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_HumanImmunologyBiosciencesPreExistingInLicenseCommitmentsMember_c6489fca-dca2-423c-bce4-13c3ca04a443" xlink:href="biib-20250930.xsd#biib_HumanImmunologyBiosciencesPreExistingInLicenseCommitmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_5a9e743c-dd69-436c-856a-f538e3556fe3" xlink:to="loc_biib_HumanImmunologyBiosciencesPreExistingInLicenseCommitmentsMember_c6489fca-dca2-423c-bce4-13c3ca04a443" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_dbcb985f-1588-4d83-8c03-637d163c93c8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_89ac59ca-8fde-4f7f-89e5-1483374c7a63" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_dbcb985f-1588-4d83-8c03-637d163c93c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_e07c0779-e543-451a-b3f7-658ee7959e1b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_dbcb985f-1588-4d83-8c03-637d163c93c8" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_e07c0779-e543-451a-b3f7-658ee7959e1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MilestonePaymentOneMember_295be84e-6578-4552-b8d6-59b4f59a557d" xlink:href="biib-20250930.xsd#biib_MilestonePaymentOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_e07c0779-e543-451a-b3f7-658ee7959e1b" xlink:to="loc_biib_MilestonePaymentOneMember_295be84e-6578-4552-b8d6-59b4f59a557d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MilestonePaymentTwoMember_219088e2-35f7-4cbf-8bff-8f262ec435fe" xlink:href="biib-20250930.xsd#biib_MilestonePaymentTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_e07c0779-e543-451a-b3f7-658ee7959e1b" xlink:to="loc_biib_MilestonePaymentTwoMember_219088e2-35f7-4cbf-8bff-8f262ec435fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MilestonePaymentFutureDevelopmentMember_c65387ce-ef81-4fe8-ae38-bd43ae50844b" xlink:href="biib-20250930.xsd#biib_MilestonePaymentFutureDevelopmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_e07c0779-e543-451a-b3f7-658ee7959e1b" xlink:to="loc_biib_MilestonePaymentFutureDevelopmentMember_c65387ce-ef81-4fe8-ae38-bd43ae50844b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MilestonePaymentRegulatoryMember_5913b5c8-b9ef-444b-acdc-476484c3d53e" xlink:href="biib-20250930.xsd#biib_MilestonePaymentRegulatoryMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_e07c0779-e543-451a-b3f7-658ee7959e1b" xlink:to="loc_biib_MilestonePaymentRegulatoryMember_5913b5c8-b9ef-444b-acdc-476484c3d53e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MilestonePaymentCommercialMember_754a049f-f86e-4f6f-ae84-b65dfe7dbf69" xlink:href="biib-20250930.xsd#biib_MilestonePaymentCommercialMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_e07c0779-e543-451a-b3f7-658ee7959e1b" xlink:to="loc_biib_MilestonePaymentCommercialMember_754a049f-f86e-4f6f-ae84-b65dfe7dbf69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MilestonePaymentResearchMember_0a184846-4783-4121-97f4-4554e36a5dd3" xlink:href="biib-20250930.xsd#biib_MilestonePaymentResearchMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_e07c0779-e543-451a-b3f7-658ee7959e1b" xlink:to="loc_biib_MilestonePaymentResearchMember_0a184846-4783-4121-97f4-4554e36a5dd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MilestonePaymentDevelopmentalMember_a8f0cb7a-a5a0-4727-9e19-574b288ddbbb" xlink:href="biib-20250930.xsd#biib_MilestonePaymentDevelopmentalMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_e07c0779-e543-451a-b3f7-658ee7959e1b" xlink:to="loc_biib_MilestonePaymentDevelopmentalMember_a8f0cb7a-a5a0-4727-9e19-574b288ddbbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MilestonePaymentSalesBasedMember_9301e503-83f9-4a15-9e5f-f0f5324b8843" xlink:href="biib-20250930.xsd#biib_MilestonePaymentSalesBasedMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_e07c0779-e543-451a-b3f7-658ee7959e1b" xlink:to="loc_biib_MilestonePaymentSalesBasedMember_9301e503-83f9-4a15-9e5f-f0f5324b8843" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_3a910f35-8c2f-4c31-9cd0-d9ebb9fad362" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_89ac59ca-8fde-4f7f-89e5-1483374c7a63" xlink:to="loc_srt_CounterpartyNameAxis_3a910f35-8c2f-4c31-9cd0-d9ebb9fad362" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7793b331-4cde-4b20-9f6c-65c4a9a3ce9d" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_3a910f35-8c2f-4c31-9cd0-d9ebb9fad362" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7793b331-4cde-4b20-9f6c-65c4a9a3ce9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CityTherapeuticsInc.Member_21680640-9c16-43a7-9424-7a2394d78431" xlink:href="biib-20250930.xsd#biib_CityTherapeuticsInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_7793b331-4cde-4b20-9f6c-65c4a9a3ce9d" xlink:to="loc_biib_CityTherapeuticsInc.Member_21680640-9c16-43a7-9424-7a2394d78431" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4ff30919-b8d5-405c-bec8-4c2cd4771a75" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_89ac59ca-8fde-4f7f-89e5-1483374c7a63" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4ff30919-b8d5-405c-bec8-4c2cd4771a75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborativeArrangementExpectedDevelopmentCostFundsYearOne_dcad44fb-7160-4b1e-9b74-f24abd8417f9" xlink:href="biib-20250930.xsd#biib_CollaborativeArrangementExpectedDevelopmentCostFundsYearOne"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4ff30919-b8d5-405c-bec8-4c2cd4771a75" xlink:to="loc_biib_CollaborativeArrangementExpectedDevelopmentCostFundsYearOne_dcad44fb-7160-4b1e-9b74-f24abd8417f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborativeArrangementExpectedDevelopmentCostFundsYearTwo_4ed3eba7-3593-428c-a995-aeaa13a27f76" xlink:href="biib-20250930.xsd#biib_CollaborativeArrangementExpectedDevelopmentCostFundsYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4ff30919-b8d5-405c-bec8-4c2cd4771a75" xlink:to="loc_biib_CollaborativeArrangementExpectedDevelopmentCostFundsYearTwo_4ed3eba7-3593-428c-a995-aeaa13a27f76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReductionOfResearchAndDevelopmentExpense_b4a7a0b4-fc0c-444c-bd31-e3ee19291887" xlink:href="biib-20250930.xsd#biib_ReductionOfResearchAndDevelopmentExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4ff30919-b8d5-405c-bec8-4c2cd4771a75" xlink:to="loc_biib_ReductionOfResearchAndDevelopmentExpense_b4a7a0b4-fc0c-444c-bd31-e3ee19291887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_669ca649-8721-42b3-8cf5-3fdef7a6c059" xlink:href="biib-20250930.xsd#biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4ff30919-b8d5-405c-bec8-4c2cd4771a75" xlink:to="loc_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones_669ca649-8721-42b3-8cf5-3fdef7a6c059" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_deb40634-491c-45ea-9a36-e6294674efe9" xlink:href="biib-20250930.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4ff30919-b8d5-405c-bec8-4c2cd4771a75" xlink:to="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_deb40634-491c-45ea-9a36-e6294674efe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_CollaborativeArrangementsInvestmentsInCounterparty_d8c5b5f8-54b9-48ff-938e-de63ee63e7c6" xlink:href="biib-20250930.xsd#biib_CollaborativeArrangementsInvestmentsInCounterparty"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4ff30919-b8d5-405c-bec8-4c2cd4771a75" xlink:to="loc_biib_CollaborativeArrangementsInvestmentsInCounterparty_d8c5b5f8-54b9-48ff-938e-de63ee63e7c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#InvestmentsinVariableInterestEntitiesDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_451e7cfd-e70d-401f-910a-5a3b8b02635d" xlink:href="biib-20250930.xsd#biib_InvestmentsInVariableInterestEntitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_77157f46-97ce-4b89-b984-3604827b669a" xlink:href="biib-20250930.xsd#biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_biib_InvestmentsInVariableInterestEntitiesAbstract_451e7cfd-e70d-401f-910a-5a3b8b02635d" xlink:to="loc_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities_77157f46-97ce-4b89-b984-3604827b669a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/LitigationDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#LitigationDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/LitigationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_80b0214d-aaf5-426c-af47-036d10036930" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyInformationAboutLitigationMattersAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_8e8d9b64-d6c7-4fca-825f-017295edc79a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract_80b0214d-aaf5-426c-af47-036d10036930" xlink:to="loc_us-gaap_LossContingenciesTable_8e8d9b64-d6c7-4fca-825f-017295edc79a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_fdd949f8-5618-4d61-b262-5b7d2e8d6a91" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_8e8d9b64-d6c7-4fca-825f-017295edc79a" xlink:to="loc_srt_LitigationCaseAxis_fdd949f8-5618-4d61-b262-5b7d2e8d6a91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_07f3d8e5-457f-415e-a372-b525041a4e13" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_fdd949f8-5618-4d61-b262-5b7d2e8d6a91" xlink:to="loc_srt_LitigationCaseTypeDomain_07f3d8e5-457f-415e-a372-b525041a4e13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_IMRALDIPatentLitigationMember_40297f51-d2f5-4a53-9c44-a79d3b0103c9" xlink:href="biib-20250930.xsd#biib_IMRALDIPatentLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_07f3d8e5-457f-415e-a372-b525041a4e13" xlink:to="loc_biib_IMRALDIPatentLitigationMember_40297f51-d2f5-4a53-9c44-a79d3b0103c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ConvergenceMember_f265e71a-aaf4-4a32-b55f-86d11f27ba94" xlink:href="biib-20250930.xsd#biib_ConvergenceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_07f3d8e5-457f-415e-a372-b525041a4e13" xlink:to="loc_biib_ConvergenceMember_f265e71a-aaf4-4a32-b55f-86d11f27ba94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_GenentechMember_5317bcbe-afef-4b95-a3fa-db982d256771" xlink:href="biib-20250930.xsd#biib_GenentechMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_07f3d8e5-457f-415e-a372-b525041a4e13" xlink:to="loc_biib_GenentechMember_5317bcbe-afef-4b95-a3fa-db982d256771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_75fb51ef-2e12-41c7-a62e-dd59c73b793d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_8e8d9b64-d6c7-4fca-825f-017295edc79a" xlink:to="loc_us-gaap_LossContingenciesLineItems_75fb51ef-2e12-41c7-a62e-dd59c73b793d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_8ca7a996-7530-40e2-969f-f514efd023aa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_75fb51ef-2e12-41c7-a62e-dd59c73b793d" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_8ca7a996-7530-40e2-969f-f514efd023aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_67be47fd-6f2e-499c-9156-37d0ce047d85" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_75fb51ef-2e12-41c7-a62e-dd59c73b793d" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_67be47fd-6f2e-499c-9156-37d0ce047d85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementInterest_a0a47f85-ea0e-4d1e-8b13-d20089ef671b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LitigationSettlementInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_75fb51ef-2e12-41c7-a62e-dd59c73b793d" xlink:to="loc_us-gaap_LitigationSettlementInterest_a0a47f85-ea0e-4d1e-8b13-d20089ef671b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SegmentInformationNarrativeDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#SegmentInformationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SegmentInformationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_97b24407-7e0e-4f15-9cde-78d718dbcc99" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_888892d2-808c-420d-801b-59ff307643c3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_97b24407-7e0e-4f15-9cde-78d718dbcc99" xlink:to="loc_us-gaap_NumberOfReportableSegments_888892d2-808c-420d-801b-59ff307643c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SegmentInformationAdditionalSegmentInformationDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#SegmentInformationAdditionalSegmentInformationDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SegmentInformationAdditionalSegmentInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_8984543a-d48d-4e80-89cd-29bafbfdb196" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_7db722c2-dc44-4f65-99f3-d6eccc50f1d8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_8984543a-d48d-4e80-89cd-29bafbfdb196" xlink:to="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_7db722c2-dc44-4f65-99f3-d6eccc50f1d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_d81e3df8-af12-4c59-9ca7-f445d7cf4a3c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_7db722c2-dc44-4f65-99f3-d6eccc50f1d8" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_d81e3df8-af12-4c59-9ca7-f445d7cf4a3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_408c6aee-6ad1-474a-917d-f23448439b87" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d81e3df8-af12-4c59-9ca7-f445d7cf4a3c" xlink:to="loc_us-gaap_SegmentDomain_408c6aee-6ad1-474a-917d-f23448439b87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ReportableSegmentMember_95d152cd-bb1d-4084-8e3b-b70a1be08594" xlink:href="biib-20250930.xsd#biib_ReportableSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_408c6aee-6ad1-474a-917d-f23448439b87" xlink:to="loc_biib_ReportableSegmentMember_95d152cd-bb1d-4084-8e3b-b70a1be08594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0e6af525-4cf9-4fc5-a2ec-291e624c0efb" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_7db722c2-dc44-4f65-99f3-d6eccc50f1d8" xlink:to="loc_srt_ProductOrServiceAxis_0e6af525-4cf9-4fc5-a2ec-291e624c0efb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_92baefe2-3a42-4c1d-8274-c88e20e97539" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_0e6af525-4cf9-4fc5-a2ec-291e624c0efb" xlink:to="loc_srt_ProductsAndServicesDomain_92baefe2-3a42-4c1d-8274-c88e20e97539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_e9611d40-d40a-409d-9e01-ccc428808b84" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_92baefe2-3a42-4c1d-8274-c88e20e97539" xlink:to="loc_us-gaap_ProductMember_e9611d40-d40a-409d-9e01-ccc428808b84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyMember_5963419d-951e-4a4b-a3ff-2123dc3f1bb1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RoyaltyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_92baefe2-3a42-4c1d-8274-c88e20e97539" xlink:to="loc_us-gaap_RoyaltyMember_5963419d-951e-4a4b-a3ff-2123dc3f1bb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ff572c78-406d-42a3-a0f2-8107656f6139" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_7db722c2-dc44-4f65-99f3-d6eccc50f1d8" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ff572c78-406d-42a3-a0f2-8107656f6139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_19bfb6c5-e66d-4395-a9ad-5ca0cabb074b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_ff572c78-406d-42a3-a0f2-8107656f6139" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_19bfb6c5-e66d-4395-a9ad-5ca0cabb074b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchAndDiscoveryMember_8f396e89-40d5-4d51-b9ce-fc45e505820b" xlink:href="biib-20250930.xsd#biib_ResearchAndDiscoveryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_19bfb6c5-e66d-4395-a9ad-5ca0cabb074b" xlink:to="loc_biib_ResearchAndDiscoveryMember_8f396e89-40d5-4d51-b9ce-fc45e505820b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_EarlyStageProgramsMember_0bf131e1-7d5b-4af2-af05-7c7571ef4d67" xlink:href="biib-20250930.xsd#biib_EarlyStageProgramsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_19bfb6c5-e66d-4395-a9ad-5ca0cabb074b" xlink:to="loc_biib_EarlyStageProgramsMember_0bf131e1-7d5b-4af2-af05-7c7571ef4d67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_LateStageProgramsMember_c2f8fb01-44fd-46d9-87ac-92ed445793f7" xlink:href="biib-20250930.xsd#biib_LateStageProgramsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_19bfb6c5-e66d-4395-a9ad-5ca0cabb074b" xlink:to="loc_biib_LateStageProgramsMember_c2f8fb01-44fd-46d9-87ac-92ed445793f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_MarketedProductsMember_99366a39-0f4c-4a55-bca6-1e005eda1593" xlink:href="biib-20250930.xsd#biib_MarketedProductsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_19bfb6c5-e66d-4395-a9ad-5ca0cabb074b" xlink:to="loc_biib_MarketedProductsMember_99366a39-0f4c-4a55-bca6-1e005eda1593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceOtherMember_841691d1-8195-409a-a576-475db928baee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ServiceOtherMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_19bfb6c5-e66d-4395-a9ad-5ca0cabb074b" xlink:to="loc_us-gaap_ServiceOtherMember_841691d1-8195-409a-a576-475db928baee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_bfbe9772-2964-446f-9134-6c0efe85d607" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAssetReconcilingItemLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable_7db722c2-dc44-4f65-99f3-d6eccc50f1d8" xlink:to="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_bfbe9772-2964-446f-9134-6c0efe85d607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_b5139b9b-0150-49a1-bf1a-ec67ea683a60" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_bfbe9772-2964-446f-9134-6c0efe85d607" xlink:to="loc_us-gaap_Revenues_b5139b9b-0150-49a1-bf1a-ec67ea683a60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_37566419-4e32-47c6-aa69-1bed7774064f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_bfbe9772-2964-446f-9134-6c0efe85d607" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_37566419-4e32-47c6-aa69-1bed7774064f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_fdc1b1cd-15f8-4cb3-a83e-c6b6c9df330d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_bfbe9772-2964-446f-9134-6c0efe85d607" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_fdc1b1cd-15f8-4cb3-a83e-c6b6c9df330d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_ResearchAndDevelopmentExpenseIncludingAcquiredInProcessCost_34096662-90a5-4cc8-bc75-0dfb496fee9c" xlink:href="biib-20250930.xsd#biib_ResearchAndDevelopmentExpenseIncludingAcquiredInProcessCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_bfbe9772-2964-446f-9134-6c0efe85d607" xlink:to="loc_biib_ResearchAndDevelopmentExpenseIncludingAcquiredInProcessCost_34096662-90a5-4cc8-bc75-0dfb496fee9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_c32a5f5a-2c91-4978-abe6-ab6ef6ef25a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_bfbe9772-2964-446f-9134-6c0efe85d607" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_c32a5f5a-2c91-4978-abe6-ab6ef6ef25a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount_7ef7bb2b-6497-418f-bba8-134dd3a40484" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_bfbe9772-2964-446f-9134-6c0efe85d607" xlink:to="loc_us-gaap_SegmentReportingOtherItemAmount_7ef7bb2b-6497-418f-bba8-134dd3a40484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_fc5b03cc-50d7-4051-920f-dd6b084bfa72" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAssetReconcilingItemLineItems_bfbe9772-2964-446f-9134-6c0efe85d607" xlink:to="loc_us-gaap_NetIncomeLoss_fc5b03cc-50d7-4051-920f-dd6b084bfa72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.biogenidec.com/role/SubsequentEventsDetails" xlink:type="simple" xlink:href="biib-20250930.xsd#SubsequentEventsDetails"/>
  <link:presentationLink xlink:role="http://www.biogenidec.com/role/SubsequentEventsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_5fb1cc3a-ee8a-4d5f-ae6e-50bb59a5febf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTable_91e195bd-d6a5-4205-add7-31894e83ff14" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_5fb1cc3a-ee8a-4d5f-ae6e-50bb59a5febf" xlink:to="loc_us-gaap_SubsequentEventTable_91e195bd-d6a5-4205-add7-31894e83ff14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_66fca5aa-133a-467f-9865-5adb049f5d6d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_91e195bd-d6a5-4205-add7-31894e83ff14" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_66fca5aa-133a-467f-9865-5adb049f5d6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a5b735e9-3a2a-4733-8b11-a44c96566445" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_66fca5aa-133a-467f-9865-5adb049f5d6d" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_a5b735e9-3a2a-4733-8b11-a44c96566445" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_2d3a81fe-ead7-479a-92b4-fd28acd742f5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_a5b735e9-3a2a-4733-8b11-a44c96566445" xlink:to="loc_us-gaap_SubsequentEventMember_2d3a81fe-ead7-479a-92b4-fd28acd742f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_62bcbd43-956b-4380-893f-fa7343e64bb0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_91e195bd-d6a5-4205-add7-31894e83ff14" xlink:to="loc_us-gaap_TypeOfArrangementAxis_62bcbd43-956b-4380-893f-fa7343e64bb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_04831eba-449a-477e-bb48-f7dbe448902b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_62bcbd43-956b-4380-893f-fa7343e64bb0" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_04831eba-449a-477e-bb48-f7dbe448902b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_VanquaBioInc.Member_64c47b83-dad3-44dc-893c-5b1865f9550b" xlink:href="biib-20250930.xsd#biib_VanquaBioInc.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_04831eba-449a-477e-bb48-f7dbe448902b" xlink:to="loc_biib_VanquaBioInc.Member_64c47b83-dad3-44dc-893c-5b1865f9550b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5cd4d146-0704-4fa6-b704-cc8e31530c65" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_91e195bd-d6a5-4205-add7-31894e83ff14" xlink:to="loc_srt_ProductOrServiceAxis_5cd4d146-0704-4fa6-b704-cc8e31530c65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_c7a6033b-342a-4254-8081-8af2f237f356" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_5cd4d146-0704-4fa6-b704-cc8e31530c65" xlink:to="loc_srt_ProductsAndServicesDomain_c7a6033b-342a-4254-8081-8af2f237f356" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_b60d3b0d-9e30-438a-9789-c4877c2ee1b4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_c7a6033b-342a-4254-8081-8af2f237f356" xlink:to="loc_us-gaap_LicenseMember_b60d3b0d-9e30-438a-9789-c4877c2ee1b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventLineItems_bdac9a5b-9cc7-4b34-bbab-8229f1786afa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsequentEventLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_91e195bd-d6a5-4205-add7-31894e83ff14" xlink:to="loc_us-gaap_SubsequentEventLineItems_bdac9a5b-9cc7-4b34-bbab-8229f1786afa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_5016ffef-24a6-4f9a-ac4c-3854afe90280" xlink:href="biib-20250930.xsd#biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_bdac9a5b-9cc7-4b34-bbab-8229f1786afa" xlink:to="loc_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner_5016ffef-24a6-4f9a-ac4c-3854afe90280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrExpirationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>biib-20250930_g1.jpg
<TEXT>
begin 644 biib-20250930_g1.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M4D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0
M86-S<$U31E0     245#('-21T(                  /;6  $     TRU(
M4" @
M       18W!R=    5     S9&5S8P   80   !L=W1P=    ?     48FMP
M=    @0    4<EA96@   A@    49UA96@   BP    48EA96@   D     4
M9&UN9    E0   !P9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0
M   D;'5M:0   _@    4;65A<P  ! P    D=&5C:   !#     ,<E120P
M!#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG
M:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,
M    $G-21T(@245#-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV
M-BTR+C$
M             %A96B        #S40 !     1;,6%E:(
M      !865H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:
M6%E:(        "2@   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W
M=RYI96,N8V@              !9)14,@:'1T<#HO+W=W=RYI96,N8V@
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M"58 4    %<?YVUE87,          0                        */
M G-I9R      0U)4(&-U<G8        $      4 "@ / !0 &0 > ", *  M
M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T <@!W 'P @0"& (L D "5 )H
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M# P,# P,_\  $0@!(@-H P$B  (1 0,1 ?_$ !\   $% 0$! 0$!
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M5AT8'D&OVK@O.98W!>RJN\Z=D_-='^C]+]3VJ=^6S)****^R- HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MFCV):***_3"3Y1_X+6?\H]O%7_7[I_\ Z5Q5^(-?M]_P6L_Y1[>*O^OW3_\
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M8?#Z;PYXRTF.^MV!:VND 6[T^3_GI#)@E&X&>H8<,""17X/?M9?LSZU^R/\
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M#^IV>L:/J"E[:\M)1+#. Q4E6'!PP(^H-<>,CCE!?6E/EO\ :YK7^?4ZL)+
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MDAAC2&*,;51!A5'L*DK]3R;):6 IZ:S>[_1=E^9E*5PHHHKVR0HHHH ^4?\
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ML3#@BUC/$I!_Y:/\G'"N"&K\U?BC\8O%7QM\32:QXN\0:MXBU*0G]_?7+2E
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M,<7SN?QZ#]:]8HKUL)P=@Z;O6;F_N7W+7\2>=F/X9\#:9X23_0[95DQ@RO\
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MQ]@,U^D?_!/#_@BI>IK&G^-/C):10V]NXN+/PLQ$C3,.5:\(RH4<'R@23T?
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M^?X*RZ'\RYSFM7,<7+%5>NR[+HOE^=V%%%?6W_!);]@:+]L#XMW&M>)+=Y/
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MP_:XT_\ 8Q_9YU3Q9.L5SJTQ^PZ+9N3B[O'!*9QSL0!G;I\J$9!(KV:OQ/\
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M_P#E^!_-'XM\(ZKX!\2WNC:WI]YI.K:;*8;JTNXC%- XZJRMR#_C6?7[;_\
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M=O'%OXB\&ZY?:'JEN1EX'_=SK_<EC.5D0_W7!'Y U^;Y]X<X;%MUL+-QJ/\
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M#V(!K^<WXI?#V^^$OQ+\0>%]2&-0\.ZC/IMQQ@,\4C(2/8[<CV(K^DZOP_\
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MFOY)S'"_5L75P_\ )*4?N;1_4V7XGZQA:>(_FBG]Z3/P;_X*O_\ *0GXE_\
M7[;_ /I)!7SO7T1_P5?_ .4A/Q+_ .OVW_\ 22"OG>OZBR'_ )%F'_Z]P_\
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M4E_:6(U?\2?_ *4S^GLDIQ>78?3[$/\ TE&7_P (3HO_ $"-+_\  5/\*/\
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M^(F1QQ>7O%P7OTM?6/5?+?Y/N?>< YU+"X]863]RKIZ2Z/Y[?-=C];J^=_\
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M['Q__/B?_@,O\CPNBO=/^'9WQZ_Z)?XG_P"_2?\ Q5'_  [.^/7_ $2_Q/\
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M M]_Z M?M57\^^)G_(W7^"/YL_=O#C_D4O\ QR_)!1117YZ??!1110 4444
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MMG.8I+AWCQ[!2 /85Q-?UU@5-8:FJGQ<JOZVU/Y5QKB\1-PVYG;TOH%>S?\
M!.OQC-X%_;G^%=] TBO-XBM=..WKMNG^S-^!64Y]L]>E>,UZ!^R38R:G^U7\
M,K:$A9;CQ9I42$G #&\B Y^IK/,X*>$JPELXR3^YE9;-PQ=*<=U*+_%']%E?
M._\ P5A_Y1Z_$O\ Z\K?_P!*X*^B*^=_^"L/_*/7XE_]>5O_ .E<%?R_D/\
MR,\/_P!?(?\ I2/Z4SO_ )%V(_P3_P#26?@W1117]7'\OA7[R?\ !)[_ )1Z
M_#3_ *\KC_TKGK\&Z_>3_@D]_P H]?AI_P!>5Q_Z5SU^9>*?_(MI?]?%_P"D
MR/T;PS_Y&-3_  /_ -*B?1%?SR_MP>&&\'?MC_%'3V4JL7BC4'C!SGRWN'=/
M_'66OZ&J_$W_ (+=?#!_A_\ MWZMJ2Q[;;Q?IEIJT6!\N0GV9Q]=UN6/^^/4
M5\IX78I0S&I1?VH:>J:_1L^H\2L.YY?3K+[,OP:?ZI'R+1117[P?B)],_P#!
M'KQ*OAK_ (*&^ 3)M$5\;VS8GJ"]E.$QR.2X4=^"?:OW3K^<?]G#XG'X+_'_
M ,%^+-S+'X>UJTOIL?QQ)*ID7_@2;A^-?T:6]Q'>01S0R)+%*H='1MRNIY!!
M'4&OPWQ4PSCCJ.(Z2A;YQ;?_ +<C]I\,L0I8*K0ZQE?Y227_ +:R2BBBORT_
M2PHHHH *_'O_ (. /$":C^U[X=T^,JW]F^%8/,]0[W5RV#_P'8?^!5^PE?@W
M_P %6_B@OQ5_;U^(%U#)OM=)NTT:$9SM^RQK#(!_VU64_C7Z)X9X=U,V=7I"
M#?WM+]6? >(V(4,K5/K*27W7?^1\[T445_0!^%%K0M&F\1:Y9Z?;C=/?3I;Q
M#&<L[!1^I%?TN65G'IUE#;PKMAMT6.-<D[5 P!GKTK\ ?^"=OPU;XL?MO?#/
M2%C,D::W#J$RXX,5KFY<'V*Q$?C7] E?B?BMB%*OA\.OLJ3^]I+_ -)9^Q>&
M.':H5Z_=Q7W)O_VY&5XV\:Z3\.?".I:]KE];Z9H^DV[W5Y=3MB."-1DD_P"
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M4>OPT_Z\KC_TKGK\R\4_^1;2_P"OB_\ 29'Z-X9_\C&I_@?_ *5$^B*^ O\
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M'Y?C'A]YM@'2I_Q(OFCZ]5\U^-CZ3A//EE>.52I\$M)>G1_)_A<_H2HKSO\
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M\!?:W_ :_G-UG1[KP]K%UI]["]O>6,SV\\3_ 'HI$8JRGW!!'X5_3)7XO_\
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MA/Q+_P"OVW_])(*^=Z^B/^"K_P#RD)^)?_7[;_\ I)!7SO7]6Y#_ ,BS#_\
M7N'_ *2C^8,[_P"1C7_QS_\ 2F%?='_!OQ_R>7XF_P"Q+NO_ $NL*^%Z^Z/^
M#?C_ )/+\3?]B7=?^EUA7G\8_P#(EQ'^']4=W"?_ ".,/_B/V$HHHK^83^D@
MHHHH *_"[_@L;_RD>^(W_<,_]-=I7[HU^%W_  6-_P"4CWQ&_P"X9_Z:[2OT
MKPM_Y&M3_KV__2H'YWXF?\BNG_U\7_I,SYDHHHK]Z/P\^PO^"&O_ "?KI_\
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MU6V$5W=IS;Z;&<%K>WSR>0-TAY; P%'!^KJ_ >.>+EF4_J>$?[J+U?\ ,_\
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MU=;+JG<^KZ***^=/H HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\.>'4;@KIFFPV:G\(U%1B/%7"I?N:$F_-I?ES%4/#'$M_OJ\4O)-_G8_$O\
M9Y_X),?&K]H*YMY1X7F\):/*P+ZCX@#62A3SE82/.?(Y!";3Q\PSFOTH_8N_
MX)%_#O\ 92N+76]27_A-O&5N1(FI7\(6WLG'>W@R54CC#N68$9!7.*^L**^$
MSKCK,\QBZ5_9P?2/7U>[_!/L?;9/P3EV DJMN>:ZRZ>BV7XOS"BBBOC3ZX*X
M7]I'X\Z/^S+\$?$/C?7&W66AVQE6%6P]U,2%BA7_ &G<JN>@SD\ UW5?G/\
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M47!RW<_-%?TV5^)G_!9[]F;2/V>?VL5O/#]K#8:-XTL!JRVD*;(K6XWM',J
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MBA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %?EW_P '%.G3)XA^%%WM_P!'
MDM]3B#?[2M:DC\F'UY]#7ZB5\;_\%O/V?[CXP?L?-KVG0-/J7@&]&K,JKEFM
M"ICN,>R@I(3_ '837U/!6,AALZH5*FS;7_@2<5^+1\SQAA9XC)Z].&Z2?_@+
M3?X)GXMT445_39_.)[9^P'^V/?\ [%'Q^L_$T<4U[H=[']AUNQCQNN;5B"2F
M>/,1@&7D9P5) 8U^[?PE^+OASXZ> M/\3^%-6M=9T74X]\-Q V<'NC#JCJ>&
M1@&4\$"OYN*],_9D_; \?_LB^*VU3P3KDMBMP1]KL)AYUC?@=!+$>"1R XPX
M!.&&37P/&'!<<VMB<.U&LE;7:2[/LUT?R?2WW'"?&$LK_P!GKIRI-WTWB^Z[
MI]5\^]_Z(**_//X$?\' ?@_Q!:0VWQ$\*ZMX=OL!7O-)Q>V;GNQ1BLD8]AYA
M]Z^EO G_  4Q^ WQ#@1K'XG^&;7=_#JDS:8RGOG[0L?^%?B^.X7S7"2M6H2]
M4KK[U='[!@^),LQ2O1K1]&[/[G9GNU%<GH_QY\#^(51M/\:>$[Y9'"(;?5[>
M7>QQ@#:YR>1Q[UL?\)MHO_07TO\ \"D_QKQ94:D7:46OD>Q&M3DKQDOO-2BN
M/UW]H7P#X7B>34_''@_3DCW!FNM9MX57;UR6<=._I7DGQ._X*N_ 3X6V\WG^
M/M/UJXCX6WT6-]0:4^@>,&/\2X%=6'RO&5WRT:4I/RBW^ARXC,L)05ZU6,?6
M27ZGT77XJ_\ !;;]H#3?C5^V"=+T>X6ZL/ ^GKH\DJ-NCDN_,>2?:?\ 9++&
M?]J)NO%=[^V/_P %T_$'Q3T6\\/_  OTR\\':;= QRZQ=2*=4D0Y&(U0E("1
M_$&=AV93S7P [M*[,S%F8Y))R2:_8.!.#<3@:SQ^.7+*S48]5?=OY:)>;N?D
M_&W%V'QM'ZC@GS1O>4NCMLE\]6_)6"BBNJ^"7P9U_P#:#^*>C>#_  S9F\UC
M6YQ#"O\ !$.KR.>=J(H+,>P4]>E?J56I"G!U*CLDKMO9);L_-*=.52:A!7;T
M275L_2#_ (-ZO@]-IW@[Q[X\N(66/5+F#1K%SQN6$-+,1Z@M)",^J-[U^D5<
M/^SE\"])_9H^"/AWP/HN38Z!:B$RD8:YE)+RS-Z,\C.Y X&[ X %=Q7\L\19
MI_:.8U<6MI/3T2LOP5_4_IGA_+?[/R^EA7O%:^KU?XL****\4]@**** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?$QY\/-37=-/\C\UQ6#KX>7)B(.+\TU^8VBBBNHY0HHHH **** "BO0O@_\
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M2/IY^?X+J4445\&?<!1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MOP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
?!1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>biib-20250930_g10.jpg
<TEXT>
begin 644 biib-20250930_g10.jpg
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MI]S%'%(;R>TR(D+^2\0D(W/'\O4T >Y?M/>-_$7PS_9K^(?Q'\(7:6^K>'_
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M)?A7JW@)?A5JOPS\/W/A=(%A3PW<:- ]@L:G*H+<IY84'D#;@4WP?\(?A/\
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MRNWC'4T :\GA'PG-XIB\<S>&-.?6X+)K.'6&LHS=1VS,':%9<;Q&6 8H#@D
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M7,MQ);Z?:)"C32N7DD*H "[NS,S=68DG)-7J* "BBB@ HHHH **** "BBB@
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M=?$.R^+6L>(O&/C7Q+I4,D6AZQX_\6W.K2:4D@VR?9EE;9"6'!<+NQD9P3D
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M^+,VL+I,&K0ZB$T;57M'DFB5U0.R?>0%RVT\;E1NJB@#QZY_X2G_ (*+>/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_P#8@\ Z;XE\-Z'JCW^D?;M3:UL+"R?1;FTM)9V;=-Y<?G@E%5I/W>SY6.0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %?$OQ(_X+%_\*^^(FO\ @'_AG3[9_8>M76G_ &O_ (2[
MR_/\F9H]^W[(=N=N<9.,XR>M?;5?B7^TA_R<1X]_['35/_2N6MZ$(S;N<^(J
M3@ERL^P/^'W7_5LG_EZ?_<5'_#[K_JV3_P O3_[BKX+HKH]C2['+]8K=S[T_
MX?=?]6R?^7I_]Q4?\/NO^K9/_+T_^XJ^"Z*/8TNP?6*W<^]/^'W7_5LG_EZ?
M_<5'_#[K_JV3_P O3_[BKX+HH]C2[!]8K=S[T_X?=?\ 5LG_ )>G_P!Q4?\
M#[K_ *MD_P#+T_\ N*O@NBCV-+L'UBMW/O3_ (?=?]6R?^7I_P#<5>D?LI?\
M%.?^&G?C+9?"/_A2/]A_;+2XF_M#_A)?M.SRHR^/+^S)G.,9W<>]?F'7T?\
M\$I?^3R]%_[!5_\ ^D[5,Z5-0;2+IUZLII-GZLT445Q'>%%%% !7R[_P5X_Y
M-)'_ &-%E_Z#+7U%7R[_ ,%>/^321_V-%E_Z#+6E+^(C.K_"9^7-%%%>@>6%
M%%% !1110 4444 %%%% 'ZR_\$N/^3)_"O\ U\ZC_P"ET]?0=?/G_!+C_DR?
MPK_U\ZC_ .ET]?0=>=4_B,]6G_#7H%%%%06%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?B7^TA_R<1X]_P"Q
MTU3_ -*Y:_;2OQ+_ &D/^3B/'O\ V.FJ?^E<M=.&W9R8O9'%U):VMQ?74=E:
M0M)+-($BC4<LQ. !^-1U9T:VEO=7M+.#4(K1Y;F-$NIYO+2$E@ [-_"!U)[
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OQ+_ &D/^3B/'O\
MV.FJ?^E<M?MI7XE_M(?\G$>/?^QTU3_TKEKIPV[.3%[(XNBBBNLXCH+GXI>.
M[SX=VWPKN/$5PVAVFH2WD-D96VB1TC0@\\J!$I"] 2Q')-1>!_B7\1?AE?2Z
MG\.?'FL:#<3Q^7/-H^I2VS2+_=8QL-P]C6)12LAW9JV/CKQOIGBP>/=-\8ZK
M;ZZ)VF&M0:A*EWYC AG\X-OW$$@G.3D^M:'A'XT?&+X?PW-OX#^+'B71([R?
MSKQ-(UVXMA/+TWN(W&YO<\US5%%D%V=#XV^+GQ7^)<%O:_$;XG>(?$$5H[/:
MQZWK4]VL+, "4$KMM) &2.N*YZBBG9(3;85]'_\ !*7_ )/+T7_L%7__ *3M
M7SA7T?\ \$I?^3R]%_[!5_\ ^D[5%3^&RZ7\1>I^K-%%%><>J%%%% !7R[_P
M5X_Y-)'_ &-%E_Z#+7U%7R[_ ,%>/^321_V-%E_Z#+6E+^(C.K_"9^7-%%%>
M@>6%%%% !1110 4444 %%%% 'ZR_\$N/^3)_"O\ U\ZC_P"ET]?0=?/G_!+C
M_DR?PK_U\ZC_ .ET]?0=>=4_B,]6G_#7H%%%%06%%%% !1110 4444 %%%%
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M15\N_P#!7C_DTD?]C19?^@RUI2_B(SJ_PF?ES1117H'EA1110 4444 %%%%
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M_H,M?45?+O\ P5X_Y-)'_8T67_H,M:4OXB,ZO\)GY<T445Z!Y84444 %%%%
M!1110 4444 ?K+_P2X_Y,G\*_P#7SJ/_ *73U]!U\^?\$N/^3)_"O_7SJ/\
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M (*\?\FDC_L:++_T&6M*7\1&=7^$S\N:***] \L**** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "OQ+_:0_Y.(\>_\ 8Z:I_P"E<M?MI7XE_M(?\G$>/?\ L=-4_P#2N6NG
M#;LY,7LCBZ***ZSB"BBB@ HHHH **** "OH__@E+_P GEZ+_ -@J_P#_ $G:
MOG"OH_\ X)2_\GEZ+_V"K_\ ])VJ*G\-ETOXB]3]6:***\X]4**** "OEW_@
MKQ_R:2/^QHLO_09:^HJ^7?\ @KQ_R:2/^QHLO_09:TI?Q$9U?X3/RYHHHKT#
MRPHHHH **** "BBB@ HHHH _67_@EQ_R9/X5_P"OG4?_ $NGKZ#KY\_X)<?\
MF3^%?^OG4?\ TNGKZ#KSJG\1GJT_X:] HHHJ"PHHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\2_VD/^3B/'O_
M &.FJ?\ I7+7[:5^)?[2'_)Q'CW_ +'35/\ TKEKIPV[.3%[(XNBBBNLX@HH
MHH **** "BBB@ KZ/_X)2_\ )Y>B_P#8*O\ _P!)VKYPKZ/_ ."4O_)Y>B_]
M@J__ /2=JBI_#9=+^(O4_5FBBBO./5"BBB@ KY=_X*\?\FDC_L:++_T&6OJ*
MOEW_ (*\?\FDC_L:++_T&6M*7\1&=7^$S\N:***] \L**** "BBB@ HHHH *
M*** /UE_X)<?\F3^%?\ KYU'_P!+IZ^@Z^?/^"7'_)D_A7_KYU'_ -+IZ^@Z
M\ZI_$9ZM/^&O0****@L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MPH_X231?^?W_ ,AM_A7*T5[W]DX;N_P_R/FO[<Q?\L?N?^9U7_"2:+_S^_\
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M@X((J^97M?4SY9<O-;0PZ***8C]CO^"2?_)AWA#_ *^M3_\ 3A<5])5\V_\
M!)/_ ),.\(?]?6I_^G"XKZ2KX''?[Y4_Q/\ ,_4,N_W"E_AC^2"BBBN4[ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ K\&?VH?^3F/B)_V/6K_P#I;+7[S5^#/[4/_)S'Q$_['K5__2V6OH.'
M_P"+/T1\MQ1_ I^K_(X6BBBOJ#XP**** "BBB@ HHHH *^H/^"/O_)\.A_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQF7X=_ C^T;RRU/4?*T5]>2.&>.'&YGN#&2BK&H9GD&!M0N0O*CT?]I_X5?
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MX4444 %?)?\ P6B_Y,S_ .YLL?\ T&:OK2ODO_@M%_R9G_W-EC_Z#-79E_\
MOM/U1Y^:_P#(NJ_X6?DG1117WA^9A1110 4444 %%%% !1110!^QW_!)/_DP
M[PA_U]:G_P"G"XKZ2KYM_P""2?\ R8=X0_Z^M3_].%Q7TE7P.._WRI_B?YGZ
MAEW^X4O\,?R04445RG8%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MO_H%?^1X_P#XJO1:*/\ B,?$_P#SYH_^ S_^6!S,\Z_X03Q7_P! K_R/'_\
M%4?\()XK_P"@5_Y'C_\ BJ]%HH_XC'Q/_P ^:/\ X#/_ .6!S,_3C_@E%I]W
MI?[#/A*ROH=DJ76I;EW XS?SD<BOHRO!O^":'_)F_AC_ *^=0_\ 2V:O>:_0
ML#C:N98*GBZJ2E4BI.VUY*[M=MVU[L_4LNUR^E_AC^2"BBBNH[0HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1914CR_6*26^DXJ[^_\ +0[:OH7_ ()??\G=Z1_V"[[_ -$-7R)_PT5\&_\
MH<?_ "GW'_QNOI7_ (),?&+X<>,?VTM%T+PYXB^TW4FDZ@R1?8YDR!;L3RR
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M !NN)HH_XAUX??\ 0GPO_A/2_P#D _MO.O\ H)J?^!R_S.V_X:*^,G_0X_\
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M$EHD?V5PI4G5X8P4YMMNE3;;U;?(M6PHHHKQCWPHHHH **** "BBB@ HHHH
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M_BT**** "BBB@ HHHH **** /WI_X(?_ /*-CP+_ -?NK_\ ISN:^LZ^3/\
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MH **** /WI_X(?\ _*-CP+_U^ZO_ .G.YKZSKY,_X(?_ /*-CP+_ -?NK_\
MISN:^LZ_C/BS_DJ,=_U]J?\ I;/[:X1_Y)7 ?]>:?_I""BBBOGSZ(**** "B
MBB@ HHHH **** .(^/N@_$/Q'X(BL/AGX \$>)-1&H1N^G^/KJ:&Q6(*X,BM
M%;SMYH)4 ; ,,WS#H?&_^%4_M??]&F?LQ_\ @]U#_P"4]>_^-OAOX'^(_P#9
M'_";^'8=1_L'7+?6-(\XL/LM]!N\J==I'S+N;&<CGI7P_'\#/@K\9[J^^)'P
MC_X(_P"E>*/#^I:G=&Q\2ZOXTLM,EU4K,Z/<BWD9G1'=7*E\,PP=HR* /M7X
M.:3XOT/X;Z;I?CSPEX8T+5HO.^UZ5X-GDETV#,SE?):2&%CE"K-F-?G9NH^8
M]/7 _LP>#K?P#\#=#\)6OP1M?AS':?:=O@RRU6.]BT[=<RO\LT?ROYF[S3CH
M92.HKOJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OYJOVQ?^3NOBI_V
M4?7/_2^>OZ5:_FJ_;%_Y.Z^*G_91]<_]+YZ_:O!?_D88O_!'\V?AWC?_ ,BW
M!_XY?DCSBBBBOZ"/YT"BBB@ HHHH **** "OL3_@A+_RD5\.?]@+5?\ TE>O
MCNOL3_@A+_RD5\.?]@+5?_25Z^<XO_Y)7&_]>I_^DL^EX-_Y*S _]?8?^E(_
M=BBBBOXV/[7"BBB@ KXB_P"#@+_DP7_N=]-_] GK[=KXB_X. O\ DP7_ +G?
M3?\ T">OI^"_^2LP7_7R/YGRO''_ "2&._Z]R_(_$"BBBO[%/XM"BBB@ HHH
MH **** "BBB@#]Z?^"'_ /RC8\"_]?NK_P#ISN:^LZ^3/^"'_P#RC8\"_P#7
M[J__ *<[FOK.OXSXL_Y*C'?]?:G_ *6S^VN$?^25P'_7FG_Z0@HHHKY\^B"B
MBB@ HHHH **** "BBB@ KXN^!W@WXC>*M$U?66_;[E^&=[<>)]2DU#X<:!I^
MDFW\/2F[D_<JM_'-*-XQ,64K&YE,B+M<$_:->8W_ .Q/^QIJM]-J>I_LD?#&
MYN;F5I;BXG\!:<[RNQ)9V8PY9B222>230!T_P<TK5-$^&^FZ7K/Q9N/'-S%Y
MWF>*;J*V22]S,Y&5M42(; 1'\JCB/G)R:Z>LKP5X&\$_#;PS;>"OAUX.TK0-
M&LM_V/2-%T^.UM8-[M(^R*)51=SLS' &68D\DUJT %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %?S5?MB_P#)W7Q4_P"RCZY_Z7SU_2K7\U7[8O\ R=U\
M5/\ LH^N?^E\]?M7@O\ \C#%_P""/YL_#O&__D6X/_'+\D><4445_01_.@44
M44 %%%% !1110 5]B?\ !"7_ )2*^'/^P%JO_I*]?'=?8G_!"7_E(KX<_P"P
M%JO_ *2O7SG%_P#R2N-_Z]3_ /26?2\&_P#)68'_ *^P_P#2D?NQ1117\;']
MKA1110 5\1?\' 7_ "8+_P!SOIO_ *!/7V[7Q%_P<!?\F"_]SOIO_H$]?3\%
M_P#)68+_ *^1_,^5XX_Y)#'?]>Y?D?B!1117]BG\6A1110 4444 %%%% !11
M10!^]/\ P0__ .4;'@7_ *_=7_\ 3G<U]9U\F?\ !#__ )1L>!?^OW5__3G<
MU]9U_&?%G_)48[_K[4_]+9_;7"/_ "2N _Z\T_\ TA!1117SY]$%%%% !111
M0 4444 %%%% !7P]\,-1^$'QET_4M>^/_P#P4@\5^'?'$&OZA;^(?#.C?%N#
M1K32V2YD2*&WMXRH:$1",K+E_,R6+9) ^L?C=J'QUTWPC%-^SUH'A;4M>:_1
M7MO%VISVEK]GV.797@BD8R A,+MQ@L<\"OG>Y^#_ .VE>W,EY>?L7?LN2S2N
M7EEEO;MF=B<EB3IV22><T ?17P(TOPCHWPITK3? GQ2O_&NE1>?]E\3:IXB&
MK3WF9Y"VZZ!/F[&+1CGY0@7^&NNKD/@3I'B_PY\*])T3X@^#/"OAS6(_/^U:
M+X+D9M,@S/(R^07CC8[D*NV4'SL_7J>OH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *_FJ_;%_Y.Z^*G_91]<_\ 2^>OZ5:_FJ_;%_Y.Z^*G_91]<_\
M2^>OVKP7_P"1AB_\$?S9^'>-_P#R+<'_ (Y?DCSBBBBOZ"/YT"BBB@ HHHH
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M^RCZY_Z7SU_2K7\U7[8O_)W7Q4_[*/KG_I?/7[5X+_\ (PQ?^"/YL_#O&_\
MY%N#_P <OR1YQ1117]!'\Z!1110 4444 %%%% !7V)_P0E_Y2*^'/^P%JO\
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M% !1110 4444 %?S5?MB_P#)W7Q4_P"RCZY_Z7SU_2K7\U7[8O\ R=U\5/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^@3U]NU\1?\ !P%_R8+_ -SOIO\ Z!/7T_!?_)68+_KY'\SY7CC_ ))#'?\
M7N7Y'X@4445_8I_%H4444 %%%% !1110 4444 ?O3_P0_P#^4;'@7_K]U?\
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MXC_"?]I?1-?T?Q7K'Q(U?7++68?"M[?)XMM;J8R6TMO+;0R"1UC*Q&$D,A7
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M*_C8_M<**** "OB+_@X"_P"3!?\ N=]-_P#0)Z^W:^(O^#@+_DP7_N=]-_\
M0)Z^GX+_ .2LP7_7R/YGRO''_)(8[_KW+\C\0****_L4_BT**** "BBB@ HH
MHH **** /WI_X(?_ /*-CP+_ -?NK_\ ISN:^LZ^3/\ @A__ ,HV/ O_ %^Z
MO_Z<[FOK.OXSXL_Y*C'?]?:G_I;/[:X1_P"25P'_ %YI_P#I""BBBOGSZ(**
M** "BBB@ HHHH **** "BBB@ HHHH **** "H[VX^R6<MWLW>5$S[<XS@9Q4
ME5M9_P"0/=_]>TG_ *":%N!\*?\ #[K_ *MD_P#+T_\ N*C_ (?=?]6R?^7I
M_P#<5?!=%=_L:78\WZQ6[GWI_P /NO\ JV3_ ,O3_P"XJ/\ A]U_U;)_Y>G_
M -Q5\%T4>QI=@^L5NY]Z?\/NO^K9/_+T_P#N*C_A]U_U;)_Y>G_W%7P711[&
MEV#ZQ6[GWI_P^Z_ZMD_\O3_[BH_X?=?]6R?^7I_]Q5\%T4>QI=@^L5NY]Z?\
M/NO^K9/_ "]/_N*C_A]U_P!6R?\ EZ?_ '%7P711[&EV#ZQ6[GZM?L6_\% ?
M^&OO&FK^$/\ A4O_  CW]E:6+S[1_;WVOS<R*FS;Y$>W[V<Y/3I7T=7YQ_\
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MHH **** "BBB@ K[$_X(2_\ *17PY_V M5_])7KX[K[$_P""$O\ RD5\.?\
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M* "BBB@ HHHH **** "BBB@ HHHH **** "JVL_\@>[_ .O:3_T$U9JMK/\
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MAVDG9G@D$_+W/&:%RL;YT;5A\7WL= \+>'I/AKX3N8_"VK27PN+G26,VJ[I
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MN7[87@7XO_"'XJ?LU?'OX]?#;Q5%I&A^$_#%MXJU*ZTYVF?48M1O+NXM29"
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MXRN_CQJ.JW2Z'%XHL570[K6[@R06PN[V.:6[D#F1=R^0@+G87"98^SG>-QN
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M'(S1-&N#7IO[:UG\2KG]CGP9JO[0GB_2?B!XVO/'ER--^(OA^^AU2WM-*%J
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MHFD?<\A+-M'R@5VGCWXM_L<>)O"5M\,_!_B#XF^&O"EJ4D;1-/\ "^G,;ZX
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M,C!"G##J :KW?BSQ5?W.GWE]XFU">;2;>.#2I9KUV:SBC8M''$2<QJK$E57
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MW]#YO,<UP^%Q<J<T[JVUNWJ=517*_P#"2:U_S^_^0U_PH_X236O^?W_R&O\
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MHH **** "BBB@ HHHH _>G_@A_\ \HV/ O\ U^ZO_P"G.YKZSKY,_P""'_\
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M\"_]?NK_ /ISN:^LZ^3/^"'_ /RC8\"_]?NK_P#ISN:^LZ_C/BS_ )*C'?\
M7VI_Z6S^VN$?^25P'_7FG_Z0@HHHKY\^B"BBB@ HHHH **** "BBB@ HHHH
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M_P"&BOC)_P!#C_Y3[?\ ^-T?\-%?&3_H<?\ RGV__P ;KE_XE8\0?^@K"_\
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M8\4_^2QJ_P"&'_I*/ZS\)O\ DBJ/^*?_ *4PHHHK\Z/TD**** /S._X.3?\
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MO!?_ )&&+_P1_-GX=XW_ /(MP?\ CE^2/.****_H(_G0**** "BBB@ HHHH
M*^Q/^"$O_*17PY_V M5_])7KX[K[$_X(2_\ *17PY_V M5_])7KYSB__ ))7
M&_\ 7J?_ *2SZ7@W_DK,#_U]A_Z4C]V****_C8_M<**** "OB+_@X"_Y,%_[
MG?3?_0)Z^W:^(O\ @X"_Y,%_[G?3?_0)Z^GX+_Y*S!?]?(_F?*\<?\DACO\
MKW+\C\0****_L4_BT**** "BBB@ HHHH **** /WI_X(?_\ *-CP+_U^ZO\
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M/KG_ *7SU^U>"_\ R,,7_@C^;/P[QO\ ^1;@_P#'+\D><4445_01_.@4444
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M&;_D4X7_ !O_ -)/UCP2_P"1QBO^O:_]*/8****_G@_I **** "OYJOVQ?\
MD[KXJ?\ 91]<_P#2^>OZ5:_FJ_;%_P"3NOBI_P!E'US_ -+YZ_:O!?\ Y&&+
M_P $?S9^'>-__(MP?^.7Y(\XHHHK^@C^= HHHH **** "BBB@ K[$_X(2_\
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M(/\ LG&C_P#I''7\X=?T>?\ !/K_ ),7^$'_ &3C1_\ TCCK\G\9O^13A?\
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MA!1117SY]$%%%% !1110 4444 %%%% !1110 4444 %%%% !5/Q'_P B]?\
M_7E+_P"@&KE4_$?_ "+U_P#]>4O_ * :NG\:]29_ S^6^BBBO[I/X%"BBB@
MHHHH **** "BBB@#]&/^#<#_ )./\?\ _8D1_P#I9%7["5^/?_!N!_R<?X__
M .Q(C_\ 2R*OV$K^6/%/_DL:O^&'_I*/ZS\)O^2*H_XI_P#I3"BBBOSH_20H
MHHH _,[_ (.3?^29_"O_ +#NI?\ HF"OR4K]:_\ @Y-_Y)G\*_\ L.ZE_P"B
M8*_)2OZL\+_^2+P_K/\ ]+D?R/XJ_P#);XCTA_Z1$****_0#\["BBB@ HHHH
M **** "OZ//^"?7_ "8O\(/^R<:/_P"D<=?SAU_1Y_P3Z_Y,7^$'_9.-'_\
M2..OQKQF_P"13A?\;_\ 23]L\$O^1QBO^O:_]*/8****_G@_I **** "OYJO
MVQ?^3NOBI_V4?7/_ $OGK^E6OYJOVQ?^3NOBI_V4?7/_ $OGK]J\%_\ D88O
M_!'\V?AWC?\ \BW!_P".7Y(\XHHHK^@C^= HHHH **** "BBB@ K[$_X(2_\
MI%?#G_8"U7_TE>OCNOL3_@A+_P I%?#G_8"U7_TE>OG.+_\ DE<;_P!>I_\
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MU9X7_P#)%X?UG_Z7(_D?Q5_Y+?$>D/\ TB(4445^@'YV%%%% !1110 4444
M%?T>?\$^O^3%_A!_V3C1_P#TCCK^<.OZ//\ @GU_R8O\(/\ LG&C_P#I''7X
MUXS?\BG"_P"-_P#I)^V>"7_(XQ7_ %[7_I1[!1117\\'](!1110 5_-5^V+_
M ,G=?%3_ +*/KG_I?/7]*M?S5?MB_P#)W7Q4_P"RCZY_Z7SU^U>"_P#R,,7_
M ((_FS\.\;_^1;@_\<OR1YQ1117]!'\Z!1110 4444 %%%% !7V)_P $)?\
ME(KX<_[ 6J_^DKU\=U]B?\$)?^4BOAS_ + 6J_\ I*]?.<7_ /)*XW_KU/\
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MZ3^!0HHHH **** "BBB@ HHHH _1C_@W _Y./\?_ /8D1_\ I9%7["5^/?\
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M=<5Y_P 0T8TLPK<\8NZ7+"-GM]F*/;R3A'A[ARM.KEU'V<I*S?-.5UO]J3_
M\+_X:P^-G_1C_CO_ ,"K;_XJC_AK#XV?]&/^._\ P*MO_BJ]THKYT^D/"_\
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M\^GCO_P@K;_Y9T?\.4OC9_SZ>.__  @K;_Y9U^X5%'_$3.-_^@O_ ,ITO_D
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M]/'?_A!6W_RSH_X<I?&S_GT\=_\ A!6W_P LZ_<*BC_B)G&__07_ .4Z7_R
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MN[=E9+7LK'V^#PF'P&$IX:A&T()1BKMV25DKN[=EW=SPO_AK#XV?]&/^._\
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MKGA;XC2Z7&-,L8X+>SB.GV5R;:/8H,B1R7$BK(^790"Q[#WV@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+G4- FNQ.^G2N@9H&D"J&9"=I( Y!K<H **** "BBB@ HHHH **** "BBB@
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MOO\ !?[G3_PK\D?EV8?[_5_Q2_-GZ(?\$$O^:K_]P+_W(5^B%?G?_P $$O\
MFJ__ ' O_<A7Z(5\EF__ ",9_+\D?=9#_P BJG\__2F%>&_\% OBE\2OA1\&
MM$U+X5^/D\+ZEK'Q T+19M<DT^WN1:6UW>)#+)Y=PK1G"L3SZ=17N5>!_P#!
M1'X=ZO\ %#X3>$?"NF>!;GQ% WQ8\,3:MIL&F-=H;%-0C-P\T85AY*Q[BY8;
M0N=W%>:>N>=_';Q%^TY\ ?V<?B'\;M$_;\B\;W?AWPK+/8Z<G@W1HUM[@N@2
M=F@0DX&X!6!4YYZ5]9_;+C_A'?[0W_O?L7F;L#[VS.<?6OGC]M_]FCP%X?\
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M?P^_9@^$'Q;^ _P]U:'XB:4FM>$M6TJXT^:&>'3M7N+A8[J=-N]4M;I;2ZY
M4)O8D+DUZAIGP!U;X7?M/W_AKP1X)U5_"^C?LKV_AO2=333I#!/=0W]SBW$H
M7:UP4*N4!+G?NQSF@#C_  _\0/VU_#W[#%E^W+KW[:VGWKQ^!8O$T_A77_ 6
MG0V5TWDB8V7GV_ERJTA_=(RG.YEX.<5ZA^V1\>?CW;? SPCI7[,L8T;XC^/8
M'O-*MK^QCN'L;>VT^34+E7CE4J6)CBM<E>'N5(&<5X1IG_!/WPKX._8-^&GQ
MS\"?LUC_ (6OX&L=$\2ZEH-WI,K7FL2VX5KVPEMI03YKQM+M0)O$J1[<&O<=
M<^%_Q<_:*_:JU#XJ>&_B/XQ^&VF>#O"%GI'AJ]3PO:-)J,FH!;V_<)J=K*JA
M533X244,)(94+ JRT 2_&#]K/Q)JG[&?P_\ VD?@_K$5A-XOU[PJLI^SQS".
M&^OK:*ZMR)%8!@))(R>JD$@@C->K?M0^-?$?PV_9G^(GQ%\'7PM=7T#P+J^I
M:5<M"L@AN8+*66)RK@JV'53A@0<8((KXV\0_";XS?!S]ECQ;^S5<> ?&/B>U
M^'GQPT+5_#&HZ9X6FGDU;0Y]2MM2D>".VB"RO"YNA(L*[8R -JC KW/XS?M"
MVG[0W[.GQ3^%_@7X(_%6UU:^^%^O+8)K_P ,=4T^.ZE:QEC2"-YH5$DSLZA8
MURS<X!Q0!SPU+]N3X;_LWZ?^U38_M%VWC];3PI;^(M;\#ZYX.LK,7MH;=9[B
M&WNK,1O%,L9<QEE=690"O-=QX._:/U[XB_MA>#_"?A+7M_@7Q3\")O%]I9O:
M1AY)WU"R2"8OC>/W%PPV!MOS9P2 :\SF_:!^)OC;]DG3OV9O@S^S%\3_ /A-
MM5\"V_AS[?XI\"WFCZ5I,CVBV\UU/=7:(I2(%W"H'9RH 7G-=;\+_@7KOPB_
M;3^'V@Z/H6IW/AGPE^S5)X:3Q"UA(+9KB'4=/6.)I<;!*T<+2>7NW$*QP0":
M /IBBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /F+]H
M;X#?\$W?&GQAUCQ+\?/"GVGQ;<_9_P"UI_MVL)NVV\:1<6SB(?NEC'RCMSSF
MN+_X9=_X(^_]"-_Y4_$'_P =JK^UW_R</XA_[=/_ $DAKS:OY[SKQIXORK.<
M3@J,:?)2J3A&ZJ7M&3BKVJ)7LNB2\CXO%8Z,,5./L:;LWJXZO7KKN?7G[(7P
MN_8^^&W_  D/_#*&A_8OMOV3^W_]*U"3?L\[R/\ C\9L8W3?<QUY[5[17S;_
M ,$]O^9O_P"X?_[<U])5^O<'Y]C>)N'*&98M+VE3FO:]O=G**M=R>T5NV?2Y
M9457 PDHJ-[Z)66[Z!117G?[1'[-OP0_:'\/0Q_&?X?VVO+HL5Q+I8N)Y4^S
MNZ#<1Y;KG.Q>N>E?3'>>B45^>WP$\,?#;]DO_@E O[;GPM\"6UI\1IOA>8V\
M0M-+(\D]S.D:R,CN4(67RG(VX/EXZ$UZ3\=/V'/AQ^S]^ROX@^.'PSU#4+#X
MK^!O"\_B$_$E]5G?4=5OK.%KB;[6[N1<13[)$:%P8PLF HP, 'V!17P'\;[[
MX)?'+]L[P7XM^/WP,\2>,-*UG]G6QU:TT+PYH5]J,EG<S:BS^8T=I\ZJ$=DW
M-QD@=2*['0? 'P=^'/[3/[-D'P'^%^J>#-$UK4?&M]<:'J]A=6=SYXTN*$O+
M!<GS$)$*8!P"H5@/FR0#[+HKXM_9/_8Z_9T^/1^+_C;XG?#P7NNGX\>+[2+7
M+;4KFUO((DU%_+$<L,B,FW.01TKSWXS>--7\9?LKZ5\)_CG<ZMXT@^'_ .U=
M8^"]5NHX)+B_\1:9!*'3>D/SS7#VUPD3!/F=U/5B20#]%**^6?@I\%?V0]&T
M;QAX]^!G[,'B?P/K.E^&+J W_B;PWJ>FM+'-#)E8?MAQ+CR_FV@E<KG&X5P?
M[ OB'7?@'\%_#'[/GC/5[BYT'XA_"2V\6_#C4KR8N4NY--BFU;2MQ[K+(;N,
M?\\YY1G]W0!]Q45\'_":"Y_:#M/V9?V2?%VIW@\%K\ +3QAXLTRWO9(1K[Q0
M6=K;6LSQLK-$DDK2M'G:Y"[@0!7NVA_LG:-^SKJWB_Q#\%-;_L/P)JO@>YAO
M/A]$LCVL&IH&*7UMN<BVW1%HY(T4*Y"-P5Y />J*_/#]@OX%?L/_ !(^#'PS
MM_%W['WC2\\3:EH-F]_XJN_".L)IT]UY09K@W>1!L)&0X.TY&.M?H?0 4444
M %%%% !1110!X+_P[&_8>_Z(C_Y<NI__ "31_P .QOV'O^B(_P#ERZG_ /)-
M>]45?//NR/9T^R,'X8_#'P/\&_ ]C\-_AOH?]FZ+IOF_8K+[3+-Y?F2O*_SR
MLSG+NQY)QG X %;U%%1N6DD@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /B3]KO_DX?Q#_VZ?\
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M738Y)!<QSIJ'VA2$V;/)$0"YW[LC&W'-3_%GX(>+/'G[3/PD^,VD:AIT>E^
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MM]-BOYO&^KH\ZQ(%#E1I9 )QG&:^H:** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
5HHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>biib-20250930_g11.jpg
<TEXT>
begin 644 biib-20250930_g11.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!GP?^(7@;Q;H]Y%\6O\ A<MA)?>(+0W,2ZA:ZM.D"2ZJM[ TJLLSMF21&7!
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M)+JWP?OO'R^*AJ2^1'#;:G;6)MO*V<EC<B3S-^ $(VG.1^4FH_"7X4_MC_\
M!-'_ ()M_'K]I_X::)XY\9>(_C3X0\&>(?$WB73TN[W4]"4:TK6%Q-("TL+F
M%'=6)WN-S9))KZ7^.O[%OP ^*O\ P6Z^$_[-.N>!K6#X:>&_V0M4W> +!/(T
MK4+&V\0Z?%;Z=<0)@26B.T,OD'Y&:VC#!DW*0#])["_L=4LX]1TR]AN;>9 T
M,\$@='4]PPX(^E16>N:+J%]<:78:Q:SW-F0+NWAN%:2 GH'4'*Y]Z_-7]GCX
M!ZCX ^-7_!0_]@;]C[QI!\*_#T/A3PU>_#6WM+E[?3/!VL:WX?OA<W5L$YM(
MVN((9B(@-A!* 8 KQ;X0^ ?A%^P/XM^"NJ_MJ?\ !(+Q'\ ==\)>*M)TI?VD
M/@YXPL-3T[6]0F*VI;6Y[=EO&L;V9\2)=I(VZ11N_B(!^SM?!_P<_P""K7[;
M_P"TS'XK\1_LS_\ !*2?Q7X9\,>/-8\*_P!NW'QOTG3C=7.G73V\KB"X@#H"
M5!&<]>IQFOO"OR>_X) ?!']O;QY\'/BMX@_9Y_;P\/?#[PXW[2'CN./P[J7P
M9AUR5)EU>3?+]J?4("0QQA=GRXZF@#],O@/XR^*WQ ^%&D^+OC?\&?\ A7WB
MB\$_]J>$/^$B@U;^S]L\B1_Z7;@1R[XUCE^4?+YFT\J:ZC3M3TW5[;[9I.HP
M74.]E\VWF5UW*<$94D9!!!'8BOSY_P""JOP1L_CU^W]^PQ\"_B5XFOI-.UK7
M?'$'BJ?2)GL7U6VB\-&:XMB8FWQ0W(B:&1%<$Q32)NYS7(WGA+P1_P $S/\
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M(M+^(_@.WN/&&E7#1WWC&.;7K#S3J<P;.I>8Y^U@S;RLD2NFT B@#];J***
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M=_X6OX _Z#__ )*R_P#Q-'_"U_ '_0?_ /)67_XF@#HJ*YW_ (6OX _Z#_\
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MY)GX=_[ 5I_Z)2MV@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O-_CS_Q^:;_
M -<I?YK7I%>;_'G_ (_--_ZY2_S6@#S^BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KK_ (*?\CBW_7D_\UKD
M*Z_X*?\ (XM_UY/_ #6@#UFBBB@ HHHH **** "BBB@ HHHH **** "O*/VY
M_P#DT?Q[_P!@%_\ T-:]7KRC]N?_ )-'\>_]@%__ $-: .Z^%W_),_#O_8"M
M/_1*5NUA?"[_ ))GX=_[ 5I_Z)2MV@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "O-_CS_ ,?FF_\ 7*7^:UZ17F_QY_X_--_ZY2_S6@#S^BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KK_@I_
MR.+?]>3_ ,UKD*Z_X*?\CBW_ %Y/_-: /6:*** "BBB@ HHHH **** "BBB@
M HHHH *\H_;G_P"31_'O_8!?_P!#6O5Z\H_;G_Y-'\>_]@%__0UH [KX7?\
M),_#O_8"M/\ T2E;M87PN_Y)GX=_[ 5I_P"B4K=H **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ KS?X\_\ 'YIO_7*7^:UZ17F_QY_X_--_ZY2_S6@#S^BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ KK_@I_P CBW_7D_\ -:Y"NO\ @I_R.+?]>3_S6@#UFBBB@ HHHH ****
M"BBB@ HHHH **** "O*/VY_^31_'O_8!?_T-:]7KRC]N?_DT?Q[_ -@%_P#T
M-: .Z^%W_),_#O\ V K3_P!$I6[6%\+O^29^'?\ L!6G_HE*W: "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH *\W^//_'YIO_7*7^:UZ17F_P >?^/S3?\ KE+_
M #6@#S^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_P#0UKU>O*/VY_\ DT?Q[_V 7_\ 0UH [KX7?\DS\._]@*T_]$I6[6%\+O\
MDF?AW_L!6G_HE*W: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*5NUA?"[_DF?AW_L!6G_ *)2MV@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P"AK7J]>4?MS_\ )H_CW_L O_Z&M '=?"[_ ))GX=_[ 5I_Z)2MVL+X7?\
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MZH K4HH **** "BBB@ HHHH **** "BBB@ HHHH **** "O-_CS_ ,?FF_\
M7*7^:UZ17F_QY_X_--_ZY2_S6@#S^BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KK_@I_R.+?]>3_ ,UKD*Z_
MX*?\CBW_ %Y/_-: /6:*** "BBB@ HHHH **** "BBB@ HHHH *\H_;G_P"3
M1_'O_8!?_P!#6O5Z\H_;G_Y-'\>_]@%__0UH [KX7?\ ),_#O_8"M/\ T2E;
MM87PN_Y)GX=_[ 5I_P"B4K=H *\$\1_\C#?_ /7[+_Z&:][KP3Q'_P C#?\
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M %>">(_^1AO_ /K]E_\ 0S7O=>">(_\ D8;_ /Z_9?\ T,T 4J*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O
M8OA#_P B+;?]=9?_ $,UX[7L7PA_Y$6V_P"NLO\ Z&: .FHHHH **** "O-_
MCS_Q^:;_ -<I?YK7I%>;_'G_ (_--_ZY2_S6@#S^BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KK_ (*?\CBW
M_7D_\UKD*Z_X*?\ (XM_UY/_ #6@#UFBBB@ HHHH **** "BBB@ HHHH ***
M* "O*/VY_P#DT?Q[_P!@%_\ T-:]7KRC]N?_ )-'\>_]@%__ $-: .Z^%W_)
M,_#O_8"M/_1*5NUA?"[_ ))GX=_[ 5I_Z)2MV@ KP3Q'_P C#?\ _7[+_P"A
MFO>Z\$\1_P#(PW__ %^R_P#H9H I4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %>Q?"'_ )$6V_ZZR_\ H9KQ
MVO8OA#_R(MM_UUE_]#- '34444 %%%% !7F_QY_X_--_ZY2_S6O2*\W^//\
MQ^:;_P!<I?YK0!Y_1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 5U_P4_Y'%O^O)_YK7(5U_P4_P"1Q;_KR?\
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M4=5TK]G?XH'Q#/HD,4NJ)_8=]:>0DA8(<W,$8;)1N%)/'- 'K-%%% !1110
M4444 %%%% !77_!3_D<6_P"O)_YK7(5U_P %/^1Q;_KR?^:T >LT444 %%%%
M !1110 4444 %%%% !1110 5Y1^W/_R:/X]_[ +_ /H:UZO7E'[<_P#R:/X]
M_P"P"_\ Z&M '=?"[_DF?AW_ + 5I_Z)2MVL+X7?\DS\._\ 8"M/_1*5NT %
M>">(_P#D8;__ *_9?_0S7O=>">(_^1AO_P#K]E_]#- %*BBB@ HHHH ****
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M%% !1110 5[%\(?^1%MO^NLO_H9KQVO8OA#_ ,B+;?\ 767_ -#- '34444
M%%%% !7F_P >?^/S3?\ KE+_ #6O2*\W^//_ !^:;_URE_FM 'G]%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M110 4444 %%%% !1110 4444 %>4?MS_ /)H_CW_ + +_P#H:UZO7E'[<_\
MR:/X]_[ +_\ H:T =U\+O^29^'?^P%:?^B4K=K"^%W_),_#O_8"M/_1*5NT
M%>">(_\ D8;_ /Z_9?\ T,U[W7@GB/\ Y&&__P"OV7_T,T 4J*** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O8
MOA#_ ,B+;?\ 767_ -#->.U[%\(?^1%MO^NLO_H9H Z:BBB@ HHHH *\W^//
M_'YIO_7*7^:UZ17F_P >?^/S3?\ KE+_ #6@#S^BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KK_@I_R.+?\
M7D_\UKD*Z_X*?\CBW_7D_P#-: /6:*** "BBB@ HHHH **** "BBB@ HHHH
M*\H_;G_Y-'\>_P#8!?\ ]#6O5Z\H_;G_ .31_'O_ & 7_P#0UH [KX7?\DS\
M._\ 8"M/_1*5NUA?"[_DF?AW_L!6G_HE*W: "O!/$?\ R,-__P!?LO\ Z&:]
M[KP3Q'_R,-__ -?LO_H9H I4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %>Q?"'_D1;;_ *ZR_P#H9KQVO8OA
M#_R(MM_UUE_]#- '34444 %%%% !7F_QY_X_--_ZY2_S6O2*\W^//_'YIO\
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MFO[TC_EI.\<<:,Y[E44>U;=% !1110 4444 %%%% !1110 5[%\(?^1%MO\
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M7_T,T 4J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "O8OA#_R(MM_UUE_]#->.U[%\(?^1%MO^NLO_H9H Z:B
MBB@ HHHH *\W^//_ !^:;_URE_FM>D5YO\>?^/S3?^N4O\UH \_HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBBB@ HHHH *]B^$/_(BVW_767_T,UX[7L7PA_P"1%MO^NLO_ *&: .FHHHH
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M2*\W^//_ !^:;_URE_FM 'G]%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !77_  4_Y'%O^O)_YK7(5U_P4_Y'
M%O\ KR?^:T >LT444 %%%% !1110 4444 %%%% !1110 5Y1^W/_ ,FC^/?^
MP"__ *&M>KUY1^W/_P FC^/?^P"__H:T =U\+O\ DF?AW_L!6G_HE*W:POA=
M_P DS\._]@*T_P#1*5NT %>">(_^1AO_ /K]E_\ 0S7O=>">(_\ D8;_ /Z_
M9?\ T,T 4J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "O8OA#_P B+;?]=9?_ $,UX[7L7PA_Y$6V_P"NLO\
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M_P#XW7YS_P 1JX6_Y\UO_ 8?_+#@_M;#=G^'^9]+45\T_P##0'Q<_P"AM_\
M)"W_ /C='_#0'Q<_Z&W_ ,D+?_XW1_Q&KA;_ )\UO_ 8?_+ _M;#=G^'^9]+
M45\T_P##0'Q<_P"AM_\ )"W_ /C='_#0'Q<_Z&W_ ,D+?_XW1_Q&KA;_ )\U
MO_ 8?_+ _M;#=G^'^9]+45\T_P##0'Q<_P"AM_\ )"W_ /C='_#0'Q<_Z&W_
M ,D+?_XW1_Q&KA;_ )\UO_ 8?_+ _M;#=G^'^9]+45\T_P##0'Q<_P"AM_\
M)"W_ /C='_#0'Q<_Z&W_ ,D+?_XW1_Q&KA;_ )\UO_ 8?_+ _M;#=G^'^9]+
M45\T_P##0'Q<_P"AM_\ )"W_ /C='_#0'Q<_Z&W_ ,D+?_XW1_Q&KA;_ )\U
MO_ 8?_+ _M;#=G^'^9]+45\T_P##0'Q<_P"AM_\ )"W_ /C='_#0'Q<_Z&W_
M ,D+?_XW1_Q&KA;_ )\UO_ 8?_+ _M;#=G^'^9]+45\T_P##0'Q<_P"AM_\
M)"W_ /C='_#0'Q<_Z&W_ ,D+?_XW1_Q&KA;_ )\UO_ 8?_+ _M;#=G^'^9]+
M45\T_P##0'Q<_P"AM_\ )"W_ /C='_#0'Q<_Z&W_ ,D+?_XW1_Q&KA;_ )\U
MO_ 8?_+ _M;#=G^'^9]+45\T_P##0'Q<_P"AM_\ )"W_ /C='_#0'Q<_Z&W_
M ,D+?_XW1_Q&KA;_ )\UO_ 8?_+ _M;#=G^'^9]+45\T_P##0'Q<_P"AM_\
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M* "BBB@ KV+X0_\ (BVW_767_P!#->.U[%\(?^1%MO\ KK+_ .AF@#IJ***
M"BBB@ KY-_X*5_\ (<\)?]>EY_Z%%7UE7R;_ ,%*_P#D.>$O^O2\_P#0HJ_/
M/%3_ )(?$^M/_P!.1.',O]SE\OS/F&BBBOY&/F0HHHH **** "BBB@ HHHH
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MO_H9H I4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M]@*T_P#1*5NT %>">(_^1AO_ /K]E_\ 0S7O=>">(_\ D8;_ /Z_9?\ T,T
M4J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&GC+X<:+;V%A!$(H2MFT=O=W2F5"6<MY@)69!M& 2 >V5Y1^W/\ \FC^/?\
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MR_3_ "/7J***_J(^B"BBB@ KY-_X*5_\ASPE_P!>EY_Z%%7UE7R;_P %*_\
MD.>$O^O2\_\ 0HJ_//%3_DA\3ZT__3D3AS+_ '.7R_,^8:***_D8^9"BBB@
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M]5U:XU%KN(W5K=7\C22O PC"KL9LIN5L8&=U>77_ /P3:T;4_B#I_P 5K_\
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M!-Z-\D5&]NEVM%T5D35DI2TZ)+[@HHHKRS,**** "BBB@ HHHH *^\OV%_\
MDV_2/^ON[_\ 1[U\&U]Y?L+_ /)M^D?]?=W_ .CWK]:\&?\ DJZG_7F7_I4#
MTLJ_WE^G^1Z]1117]1'T04444 %?*'_!2:WFGUOPF8DSBUO,\C^]%7U?7RU_
MP46_Y#/A7_KUN_\ T**L,3POE_&5%Y3C92C3J:MP:4O=]Y6<HR6Z5]'H>!Q-
MBZF!R:I6II-KEWVUDEY'RU]@N_\ GE_X\*/L%W_SR_\ 'A6E17E_\2T<"?\
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MO_GE_P"/"C[!=_\ /+_QX5I44?\ $M' G_03B?\ P.E_\I#_ %JS#^6'W/\
M^2,W[!=_\\O_ !X4?8+O_GE_X\*TJ*/^):.!/^@G$_\ @=+_ .4A_K5F'\L/
MN?\ \D9OV"[_ .>7_CPH^P7?_/+_ ,>%:5%'_$M' G_03B?_  .E_P#*0_UJ
MS#^6'W/_ .2,W[!=_P#/+_QX4?8+O_GE_P"/"M*BC_B6C@3_ *"<3_X'2_\
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M4_R1X^;_  0^9S]%%%?SL>&%%%% !1110 4444 %%%% !1110 4444 %%%%
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M: "OS/\ BQ_R5+Q+_P!C!>?^CWK],*_,_P"+'_)4O$O_ &,%Y_Z/>OPSQO\
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M/_R:/X]_[ +_ /H:T =U\+O^29^'?^P%:?\ HE*W:POA=_R3/P[_ -@*T_\
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M% !7RU_P46_Y#/A7_KUN_P#T**OJ6OEK_@HM_P AGPK_ ->MW_Z%%7N\-_\
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M;SI/_7U=?^CWKX>K[A_8H_Y-YTG_ *^KK_T>]?,\6?\ (LC_ (E^3/MN ?\
MD=2_P/\ .)ZO1117YR?L04444 %?+7_!1;_D,^%?^O6[_P#0HJ^I:^6O^"BW
M_(9\*_\ 7K=_^A15[O#?_(XI_P#;W_I+/EN,_P#DG:OK'_TI'S91117Z>?B
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M(>&_AIXKD\2Z_P"+?'WAJ71II'%I-!%IUI!/B:;S6ES*^T1JL0^9B0*34_V
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M]>MW_P"A15[O#?\ R.*?_;W_ *2SY;C/_DG:OK'_ -*1\V4445^GGX@%%%%
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M$?\ V'KS_P!'/7V/!_\ 'J^B_-GYUXA_[M0]9?DC!HHHK[L_+ HHHH ****
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M1?FS\Z\0_P#=J'K+\D8-%%%?=GY8%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %?</[%'_ ";SI/\ U]77_H]Z^'J^
MX?V*/^3>=)_Z^KK_ -'O7S/%G_(LC_B7Y,^VX!_Y'4O\#_.)ZO1117YR?L04
M444 %?+7_!1;_D,^%?\ KUN__0HJ^I:^6O\ @HM_R&?"O_7K=_\ H45>[PW_
M ,CBG_V]_P"DL^6XS_Y)VKZQ_P#2D?-E%%%?IY^(!1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7MG[!/_ "7";_L
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^X?V*/\ DWG2?^OJZ_\
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M /*;_P#;*]6HH_XB)QC_ -!7_DE/_P"0#_4[AS_GQ_Y-/_Y(\I_X9C_ZG?\
M\IO_ -LH_P"&8_\ J=__ "F__;*]6HH_XB)QC_T%?^24_P#Y /\ 4[AS_GQ_
MY-/_ .2/*?\ AF/_ *G?_P IO_VRC_AF/_J=_P#RF_\ VRO5J*/^(B<8_P#0
M5_Y)3_\ D _U.X<_Y\?^33_^2/*?^&8_^IW_ /*;_P#;*/\ AF/_ *G?_P I
MO_VRO5J*/^(B<8_]!7_DE/\ ^0#_ %.X<_Y\?^33_P#DCRG_ (9C_P"IW_\
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M*?\ AF/_ *G?_P IO_VRC_AF/_J=_P#RF_\ VRO5J*/^(B<8_P#05_Y)3_\
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M*Z]5%/[F;8;A?(L)7C6I4;2B[I\TGK\Y6/7****^J/H HHHH **** "BBB@
MHHHH **** "O*/VY_P#DT?Q[_P!@%_\ T-:]7KRC]N?_ )-'\>_]@%__ $-:
M .Z^%W_),_#O_8"M/_1*5NUA?"[_ ))GX=_[ 5I_Z)2MV@ K\Y?BE_R4WQ'_
M -AZ\_\ 1SU^C5?G+\4O^2F^(_\ L/7G_HYZ^QX/_CU?1?FS\Z\0_P#=J'K+
M\D8-%%%?=GY8%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/?\ L O_ .AK0!W7PN_Y)GX=_P"P%:?^B4K=K"^%W_),_#O_ & K3_T2E;M
M!7QEX[_9R_M7QQK.J?\ "9>7]IU6XEV?V=G;NE8XSYG/6OLVO /$G_(Q7_\
MU^R_^AFO(S;/\VR&$9X&IR.3L](N]MOB3_ \[,<IR_-8QCBH<RCMJUOZ-'CG
M_#,?_4[_ /E-_P#ME'_#,?\ U.__ )3?_ME>K45X?_$1.,?^@K_R2G_\@>5_
MJ=PY_P ^/_)I_P#R1Y3_ ,,Q_P#4[_\ E-_^V4?\,Q_]3O\ ^4W_ .V5ZM11
M_P 1$XQ_Z"O_ "2G_P#(!_J=PY_SX_\ )I__ "1Y3_PS'_U._P#Y3?\ [91_
MPS'_ -3O_P"4W_[97JU%'_$1.,?^@K_R2G_\@'^IW#G_ #X_\FG_ /)'E/\
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M&*?5G=@,@RC*Z[K86GRR:M>\GI\VUT.GHHHKZ$]@**** "O-?C[_ ,?FF?\
M7*7^:UZ57FOQ]_X_-,_ZY2_S6O#XC_Y%%3Y?^E(#SVBBBOS, HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KL/@C_R
M.;?]>3_S6N/KL/@C_P CFW_7D_\ -:]+)_\ D:4?\2 ]<HHHK]6 **** "BB
MB@ HHHH **** "BBB@ KRC]N?_DT?Q[_ -@%_P#T-:]7KRC]N?\ Y-'\>_\
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MU_ZZR_\ H9KZ7A7_ )&4O\+_ #0'3T445^A@%%%% !7FOQ]_X_-,_P"N4O\
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M?"[_ ))GX=_[ 5I_Z)2MV@ KP#Q)_P C%?\ _7[+_P"AFO?Z\ \2?\C%?_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]2^#O^A;A_\ P33_ /D3\+_M_/?^@NK_ .#)?YGO'_#S3]M[_HMG_EMZ;_\
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M8K__ *_9?_0S7R'%W\"EZO\ ("E1117PP!1110 4444 %%%% !1110 4444
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M\MO3?_D:C_AYI^V]_P!%L_\ +;TW_P"1J/\ B /&/_/_  __ (%4_P#E0?\
M$2\B_P"?=7[H_P#R9^M%%?DO_P /-/VWO^BV?^6WIO\ \C4?\/-/VWO^BV?^
M6WIO_P C4?\ $ >,?^?^'_\  JG_ ,J#_B)>1?\ /NK]T?\ Y,_6BBOR7_X>
M:?MO?]%L_P#+;TW_ .1J/^'FG[;W_1;/_+;TW_Y&H_X@#QC_ ,_\/_X%4_\
ME0?\1+R+_GW5^Z/_ ,F?K117Y+_\/-/VWO\ HMG_ );>F_\ R-1_P\T_;>_Z
M+9_Y;>F__(U'_$ >,?\ G_A__ JG_P J#_B)>1?\^ZOW1_\ DS]:**_)?_AY
MI^V]_P!%L_\ +;TW_P"1J/\ AYI^V]_T6S_RV]-_^1J/^( \8_\ /_#_ /@5
M3_Y4'_$2\B_Y]U?NC_\ )GZT45^2_P#P\T_;>_Z+9_Y;>F__ "-1_P /-/VW
MO^BV?^6WIO\ \C4?\0!XQ_Y_X?\ \"J?_*@_XB7D7_/NK]T?_DS]:**_)?\
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M\/-/VWO^BV?^6WIO_P C4?\ $ >,?^?^'_\  JG_ ,J#_B)>1?\ /NK]T?\
MY,_6BBOR7_X>:?MO?]%L_P#+;TW_ .1J/^'FG[;W_1;/_+;TW_Y&H_X@#QC_
M ,_\/_X%4_\ E0?\1+R+_GW5^Z/_ ,F?K17LOP>_Y$.U_P"NLO\ Z&:_#+_A
MYI^V]_T6S_RV]-_^1J_6?_@E-\5_'WQJ_8I\._$+XFZ]_:>L7>H:BEQ>?98H
M=ZI=R(HV1*JC"@#@?6HGX7Y_P9'Z]C:M*4'[EH2FW=Z_:A%6]U]?D>SD?&&6
M9_C'AL/":DHN7O**5DTNDGKKV/HVBBBL3ZL**** "ORV_P"#B?\ Y'/X6?\
M8+U;_P!&6M?J37Y;?\'$_P#R.?PL_P"P7JW_ *,M:^T\/O\ DK*'I/\ ](D?
M'\>?\DO7]8?^EQ/S<HHHK^D#^>PHHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ K[5_X(+?\GP7?_8BW_P#Z/M:^*J^U
M?^""W_)\%W_V(M__ .C[6OG>+?\ DFL7_@9[_"W_ "46%_QH_9>BBBOY=/Z5
M"BBB@ HHHH **** "BBB@ HHHH *\H_;G_Y-'\>_]@%__0UKU>O*/VY_^31_
M'O\ V 7_ /0UH [KX7?\DS\._P#8"M/_ $2E;M87PN_Y)GX=_P"P%:?^B4K=
MH *_G-_:A_Y.8^(G_8]:O_Z6RU_1E7\YO[4/_)S'Q$_['K5__2V6OUGPI_WS
M%?X8_FS\M\3_ /=,-_BE^2.%HHHK]K/QT**** "BBB@ HHHH **** "BBB@
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M[Q;_ ,DUB_\  SW^%O\ DHL+_C1^R]%%%?RZ?TJ%%%% !1110 4444 %%%%
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MX_CS_DEZ_K#_ -+B?FY1117]('\]A1110 4444 %%%% !1110 4444 %%%%
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M%% !1110 4444 %%%% !1110 5]J_P#!!;_D^"[_ .Q%O_\ T?:U\55]J_\
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M^O<O_2HGU=1117X"?N84444 %?EM_P '$_\ R.?PL_[!>K?^C+6OU)K\MO\
M@XG_ .1S^%G_ &"]6_\ 1EK7VGA]_P E90])_P#I$CX_CS_DEZ_K#_TN)^;E
M%%%?T@?SV%%%% !1110 4444 %?7_P"PAX#_ &<O%>I6?B?P3\:3X4\9V7PY
M\4V?BC0_$T-PT<TCZ3?*-1M+FWB8+$D;JSQ,!(HA8KYAQGY J:QU'4-+F:YT
MR_FMY&B>-I()2C%'4JZDCLRD@CH02#7GYG@IX_"2I1J.#:>JMU35FFG=:^O9
MG=EV,A@<5&K*"FDUH[]&G=--6>GIW1]!_M3^.?"7[0?C'X:_!_P;\7;3Q)>>
M%O"PT75/B7XHG;3[?4YS/-.-TMUAU@A5Q$DDNUFP> ",]_KWP)TC4/V&?#OP
M$MOVF/@Z?$.F_$B_UJZC/Q+L1$+66SAA0A]^"V^-LKV%?&]%<DLGG&E2IT:O
M*J;YE>*=Y:W;V5O>>B22Z66AUQS:$JE6I5I\SFN71M66EEU=_=6K;;ZW>I]0
M_LA_LS_ *ZT/6/BO\9OC+\.=1U31=5ELO#_P_P!:\<P:=;ZE/&0/M=U.3N:S
MSRJQ F;&-R+G.)^U-_PN2S\9Z7^T5XY_:$^&'B?4-.U2TM]$T3P-XKM[M-)A
MAW2010VD( @M8_+V\<989)9B3\\T5I'+*WUYXB=7FOI9Q6D>J6NE^KM=]6TE
M:)9C2^I*A"ERVUNI/5]&]-;=%>RZ)7=_K;]H[X<^"/VT_CA>_M1>$_VJ/A]H
MNB^*Q;76KZ?XS\3+9ZGX?D6&..6V-JP\RZ5"A$;0!@Z[1QUKF_C;>_##]M_]
MLWQ7KND?&/2/"F@1:'$NF^)?&#^1_:OV"S@ME9MQ!$UP8RZJ?FP0",@U\VT5
M%#*)8=14*K]R#A#1>[%\N^GO/W4M>BVOJ57S6.(<G.DO?DISU?O-7_\  5[S
M>G?>VA]$_";7?!/[0'[(Q_94\1_$70_"WBCPOXODU_P;?^*+];33]0MKB%8K
MJR>X?Y() R)*C2$*V67(ZTSXMZYX-^ ?[)4?[*GAWXB:'XH\3>)?%Z>(/&-_
MX7OUO-/L+>W@:*TLDN$^2>0L[RNT9*KA5R>37SS16G]E1]OS<[Y.;GY;+XM]
M][7]ZW\W6VAG_:<O8VY%S\O)S7?P^FU[>[?^7I?4****]8\L**** "BBB@ H
MHHH *^U?^""W_)\%W_V(M_\ ^C[6OBJOM7_@@M_R?!=_]B+?_P#H^UKYWBW_
M ))K%_X&>_PM_P E%A?\:/V7HHHK^73^E0HHHH **** "BBB@ HHHH ****
M"O*/VY_^31_'O_8!?_T-:]7KRC]N?_DT?Q[_ -@%_P#T-: .Z^%W_),_#O\
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M[_@BG_RCV\*?]A35?_2Z:OQ!K]OO^"*?_*/;PI_V%-5_]+IJ_.?%#_DG8?\
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M<3_\CG\+/^P7JW_HRUK[3P^_Y*RAZ3_](D?'\>?\DO7]8?\ I<3\W****_I
M_GL**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *^U?^""W_ "?!=_\ 8BW_ /Z/M:^*J^U?^""W_)\%W_V(M_\ ^C[6
MOG>+?^2:Q?\ @9[_  M_R46%_P :/V7HHHK^73^E0HHHH **** "BBB@ HHH
MH **** "O*/VY_\ DT?Q[_V 7_\ 0UKU>O*/VY_^31_'O_8!?_T-: .Z^%W_
M "3/P[_V K3_ -$I6[6%\+O^29^'?^P%:?\ HE*W: "OYS?VH?\ DYCXB?\
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M%O\ D^"[_P"Q%O\ _P!'VM?%5?:O_!!;_D^"[_[$6_\ _1]K7SO%O_)-8O\
MP,]_A;_DHL+_ (T?LO1117\NG]*A1110 4444 %%%% !1110 4444 %>4?MS
M_P#)H_CW_L O_P"AK7J]>4?MS_\ )H_CW_L O_Z&M '=?"[_ ))GX=_[ 5I_
MZ)2MVL+X7?\ ),_#O_8"M/\ T2E;M !7\YO[4/\ R<Q\1/\ L>M7_P#2V6OZ
M,J_G-_:A_P"3F/B)_P!CUJ__ *6RU^L^%/\ OF*_PQ_-GY;XG_[IAO\ %+\D
M<+1117[6?CH4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5^WW_  13_P"4>WA3_L*:K_Z735^(-?M]_P $4_\ E'MX
M4_["FJ_^ETU?G/BA_P D[#_KY'_TF9^@^&W_ "/Y_P#7N7_I43ZNHHHK\!/W
M,**** "ORV_X.)_^1S^%G_8+U;_T9:U^I-?EM_P<3_\ (Y_"S_L%ZM_Z,M:^
MT\/O^2LH>D__ $B1\?QY_P DO7]8?^EQ/S<HHHK^D#^>PHHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K[5_P"""W_)
M\%W_ -B+?_\ H^UKXJK[5_X(+?\ )\%W_P!B+?\ _H^UKYWBW_DFL7_@9[_"
MW_)187_&C]EZ***_ET_I4**** "BBB@ HHHH **** "BBB@ KRC]N?\ Y-'\
M>_\ 8!?_ -#6O5Z\H_;G_P"31_'O_8!?_P!#6@#NOA=_R3/P[_V K3_T2E;M
M87PN_P"29^'?^P%:?^B4K=H *_G-_:A_Y.8^(G_8]:O_ .ELM?T95_.;^U#_
M ,G,?$3_ +'K5_\ TMEK]9\*?]\Q7^&/YL_+?$__ '3#?XI?DCA:***_:S\=
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "OV^_P""*?\ RCV\*?\ 84U7_P!+IJ_$&OV^_P""*?\ RCV\*?\ 84U7
M_P!+IJ_.?%#_ ))V'_7R/_I,S]!\-O\ D?S_ .O<O_2HGU=1117X"?N84444
M %?EM_P<3_\ (Y_"S_L%ZM_Z,M:_4FORV_X.)_\ D<_A9_V"]6_]&6M?:>'W
M_)64/2?_ *1(^/X\_P"27K^L/_2XGYN4445_2!_/84444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5]J_P#!!;_D^"[_
M .Q%O_\ T?:U\55]J_\ !!;_ )/@N_\ L1;_ /\ 1]K7SO%O_)-8O_ SW^%O
M^2BPO^-'[+T445_+I_2H4444 %%%% !1110 4444 %%%% !7E'[<_P#R:/X]
M_P"P"_\ Z&M>KUY1^W/_ ,FC^/?^P"__ *&M '=?"[_DF?AW_L!6G_HE*W:P
MOA=_R3/P[_V K3_T2E;M !7\YO[4/_)S'Q$_['K5_P#TMEK^C*OYS?VH?^3F
M/B)_V/6K_P#I;+7ZSX4_[YBO\,?S9^6^)_\ NF&_Q2_)'"T445^UGXZ%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M?M]_P13_ .4>WA3_ +"FJ_\ I=-7X@U^WW_!%/\ Y1[>%/\ L*:K_P"ETU?G
M/BA_R3L/^OD?_29GZ#X;?\C^?_7N7_I43ZNHHHK\!/W,**** "ORV_X.)_\
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M %%%% !1110 4444 %?:O_!!;_D^"[_[$6__ /1]K7Q57VK_ ,$%O^3X+O\
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M#T5^_'_#O?X)_P#0V^.__"RN?\:/^'>_P3_Z&WQW_P"%E<_XT?\ $6?^H/\
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M3_\ MS\!Z_;[_@BG_P H]O"G_84U7_TNFKNO^'>_P3_Z&WQW_P"%E<_XT?\
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MO_RG_P#;GX#T5^_'_#O?X)_]#;X[_P#"RN?\:/\ AWO\$_\ H;?'?_A97/\
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M:/\ B+/_ %!_^5/_ +F'_$+?^HO_ ,I__;GX#U]J_P#!!;_D^"[_ .Q%O_\
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M./P]J?Q"LM7?6/AEINJ:AB1[E+(,NI:992W#2F0M%,L9*D. -H!N_P#!*/\
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MB_"6#PY-ID>A?"B\UGSH8_+$<5M';W-K% EOM+*P!! Q@4 ?&/\ P4,U%_\
M@H]^Q[^TM^WCJ0,_P@^&'PM\5>'_ -GVU<?N==U+[++;:KXKQT=#B2PLVYQ$
MMU* //%?I;^R9_R:M\,_^R?:-_Z0PU\E?M>_\&]__!.GXJ?LN^/OAO\ LX?L
M8?"KPEX]UOPM>6?A#Q-/HQA33-0DB*PW!>)7= C$'*JQ&. :^F?V(?V/?@]^
MP]^SUHOP/^#OPWT#PU%%;07/B*'PY;&.WOM6^RP0W%WR 6:0PK\Q )"C(% '
MKE%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %-EBBGB:&:-71U*NC#(8'J"
M.XIU% %71]$T7P[8)I7A_2+6QM8R2EM9VZQ1J2<G"J !D\U:HHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** *=WX?T&_P!4M]<OM$LYKVS!%I>2VR-+ #UV.1E<]\&K
ME%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MHGC9-,\9:'!>>)_A+IVFG1O'5O-XNTJ"QO+I9(93:W5L%61HK61(OM D5PZ
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'P-^ &MWNIZM%!<P3OI\;/9,EU>P"Z:.2]AMBV68A?,"!S#^R5^S1X4\._\
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MUGX.^"M/T3Q'<:=(MG>W%O/JAG@BG(V2/&)(BZ@DKO7/45\T_&K]EWXF7O\
MP70C_9E\)QVTGP=^+]QH'QQ^)%BLO_'MJ/ADRV8@\D<&*\OQH4TC-]]K5\ [
M7H _3OP3J?B76_!FD:SXT\-1:+K%WI=O-JVCPW_VI+"Y>-6E@6;8GG!'+()-
MB[@N=JYP-.BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ KS;7?V0_V=_$NN7GB/6_A[Y][J%W)<W<W]K7:^9+(Q9VPLH RQ)P
M.U>DUYWK?[5_P!\.:U>>'M9\>^3>6%U);W</]E73;)48JRY6(@X((R"17/B,
MDPN=I0KX:-=1U2E!3MYV:=CDQ>(P&'BGBIQBGMS-+[KF?_PQ1^S)_P!$S_\
M*S>__'JMZ%^R'^SOX:URS\1Z)\/?(O=/NX[FTF_M:[;RY8V#(V&E(.& .""#
MWJ+_ (;(_9O_ .BC?^4B\_\ C-6M$_:O^ /B/6K3P]HWCWSKR_NH[>TA_LJZ
M7?*[!57+1 #)(&20*YH\"932DIK*X)K6_L(JUNM^72QQ1S#(')*-:E?I[T/\
MST2BBBO1/8"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *\6_9A_86^%'[+GC7Q/\4])\:>-_&GC'Q;#
M;VNJ^,?B/XJEU?44L+=I'M]/ADD 6"UC>:5Q&BC<TA9R[8(]IHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OSN^-G_)9O
M%W_8SW__ *425^B-?G=\;/\ DLWB[_L9[_\ ]*)*^OX0_P!YJ^B_,_//$+_<
MZ'^)_D<Q73_!/_DLWA'_ +&>P_\ 2B.N8KI_@G_R6;PC_P!C/8?^E$=?;XG_
M ':?H_R/S/!?[Y3_ ,4?S1^B-%%%?C)_1X4444 ?)_\ P6N_:8^.G[)/_!/[
M7OC+^SAXS@\/^+8_%/AS3+#5[G28;Y+:.]UBTM)F\F=2CGRYGQD=>A!YJ?P%
M^R9_P4X\/^.M%U_QQ_P5O_X2'1+'5K:XUC0/^%":+:?VG:I*K2VOGQREX?,0
M,GF*"R;MPY%>9_\ !RM;Z/=_\$F?%5KXAF6/3Y/'7@]+Z1[@PA83XBL Y+@@
MH N?F!!'7(KI?V9_ /\ P15_9_\ BYI_CC]G?]I#P2OBN=6T_38YOVC;S6#.
M9\1^4EK=ZK-'([$A5^0MDC;R: /0/C%_P5>_8S^"_P 0O$'PPU3Q#XQ\2:KX
M.=5\;GX>_#'7/$=MX:)0/B_N--LYH;9@A#&-GWJ.JCC/5^,?^"A/[&/@#X)^
M"/VD?%GQ_P!&M? ?Q&O8[7P?XK5)I;*]D>RNKX;I(XV%NHM[*Z=GF\M4\EE<
MJV%/Q-\*OVE_B+\8?$W[0_Q2B_;N\ _LJ>"/AO\ &/7]&U;P9X:^'^B2ZW?3
MV;(DFN:K-J*R^9<WI4,BQV^718U#RMS7SI\"?"F@?%+_ ((Z?\$Z/"/Q#T23
M4=.OOVY!%J&F:S9+&9435?&!\B>  *H^0(\.-N 4QMXH ^ZKO_@I[%\7OVP_
MV7;7]G3Q1JC_  G^*F@?$>\\1Q:KX)NK6\U,Z+:Z<]I-#%=0+=*FZ>9E\M1Y
MRNO#?**^A],_;E_94UG]D$_MZ:9\7;67X3#PY)KO_"6C3[H+]AC+!V^SF+[1
MY@963R?+\TN-@0M\M>!?ME_\IJOV)O\ L4_BM_Z;]%KY2\#>$?%FC_MPZQ_P
M00'AZ['@:+X^)\9X9A ?L2_#UC_;7]EJ/^>8\1K#:D'JDCCGK0!^OME=Q7]G
M%?0+($FB61!-"T;@$9&Y' 93SR" 1T(!KY9U?_@M1_P3LT/Q3<Z+J/Q?UE=$
MLM>.B7OQ#3P#K+^$[?41-Y)MGUQ;0V"D2?(7\[RP>"X-?5%U<):6TEU(DC+%
M&798HR[$ 9P%4$L?0 9-?BU8^*KS]D']@'Q5\8/^"=__  5)^$?CS]GWPM::
MQJ5M^SM^T#X&M3=6\?VF>YN=":X66&]%Q),TL<5M=0;]\D:G(8&@#[(_::_X
M++>"/V<_^"C_ (,_8TU+P7XEN_#]_P"&=6N_%NJ:?\+/$.H7:7L2V+V2V#6M
MNT=W;E+F3SI8EE2)E57>,\'V'X[?\%,_V4/@!\4K_P"!^NZOXN\3>,=&L8;W
MQ!X:^&_PYUGQ-=:+;3*7BEO1IEK.MH'3YU$I5F4A@I4YKYQ^(7QAT;5O^"IG
M[%/QT^(NE1> [3QE^S_XQDATS7KA+<6%[/;Z+=-IS,^U?-C0L"N ?W9XXK'T
MS]H?XC_'']LS]H_1/!?[9/PY_9<\,?"WQ)8VFORVG@W19_$7BT?V;!/_ &]?
MW>IEHEM#&ZQ0.(7S'&<R#: 0#Z[D_P""B?[%D7[)D/[<K_'[21\+;E0+?Q/Y
M%QF68SFW^RK;>7]I:Z\\&+[,(_.\P%-FX8KSOX/?\%8OAI^TM^U#I7[+_P"S
MG\%?'.K:C#I+ZOX_NO&&@W'A6;PKIK/Y=M<M9:O%!<WPFDX7[/&RJ.68'"U^
M7OA_XA6MK_P2FLOB_;?$B.76M$_X*576N>"_&7Q"L$TK0XK]-5GG2\\1)$B#
M3+&2)YS)Y4:F*>>%40< ?;/[+6MZW^V?^VIJO[9&N?M<?LW77CC1?@OJ?@OX
M=^!?@1\5T\3D?:;F.YGU*^NFB@D<++;Q".%8"B NS.6H ]Z\:_\ !8?]@+P#
MXZUKP;KOQ7UB6R\+ZU_8_BWQKIG@76+SPSH&H[@AM;[68+5[&VD5F"OOF C/
M$A0@X^FK6ZMKVVCO;*X2:&9 \4L3AE=2,A@1P01SFOQ._P""?]_X7\+_ /!%
MJX^'_P ;?^"J>D_#3P]X9\.:_P"'OB_\,-8\!:)+JFC7SW%W'J%C-'/_ *5/
M<S.\C("K23&9=NXD"OUC_8A\ Z3\*_V-_A7\-?#_ (KUW7--T+X?:18Z9JWB
MC37LM2N;6.SB6%KJ!P'AF\L('C8!E8$, 0: .+^._P#P5,_8H_9V^(6O_!WQ
M]\2M6NO&OALV7]H^"_#7@O5=6U1UNX'N(GA@M+:1KB,0HSR21[DAR@D9&D0-
MJZ%_P4@_8H\2_LU:)^U_HGQXL+CX=^(-?LM$T_Q#'I]T=FI75XEE%:SPB+SK
M:3[1(D;B9$\K.Z38H+5\M?L__&C]GCX5?\' /[6.C_%KQCH.@^)-;^'7@#_A
M%[_7;J*V\VVALKM[VWBFE(7<2UI(8@=SK 7P1$Q7X[^+>B^$/C1^QO\ M8>-
M?!T4.H_!SXD?M[^%AX4GM#_H.L@ZMI%KJMY:LORRP37 =1,A*NT;D$X- 'ZD
MZ5_P5K_8*U7]GO4?VJ$^,\\'@.S\7#PSI^MW7AC48VU[4F2-XXM+MS;^?J@D
M$@\MK6.19-CE20C$=5^RW^WY^S#^V#JGB#PK\'_&&IP>(_":POXG\'^+?#%_
MH6LZ7'*"8I9;+4(89A$X'RRA2AZ;LY%?-/\ P4XOO"OP6_X*._L._&GXKSV&
MB?"+PSXD\7:-J&I7VR#2M&UR^T6.'17F)Q'$"8KF*)VP(V;.1G(Y;]H7Q/\
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M.61\'V-KXNTI;M'A36K":PN)8;C[-$6::X,:$QNV2I?</U8H **** "BBB@
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MYXJ\/6=Y%X5UW5=+CEGTPW**LRQ38\R%)?+C$@C9=ZHH.<#'A?[(G[*7Q_\
M#7[0'C3]LW]L_P :>#-:^)?BCP]I_A?1[+P#IUS!I/A[P_9S3W"VT+7;---+
M/<W,DTSO@92)5 "9/TE10 5Y?K7[$/[%WB7XJ#XZ>(OV0_A?J'C<7*W(\8WO
M@#3I=5\Y3D2?:VA,V\'D-NR*]0HH X_XT?L\_ #]I'PW!X-_:(^!O@_Q[I%M
M="YMM*\:>&;75;:*8 @2K%<QNJN 2-P&<$UB^-_V,?V/?B9XIT;QS\1_V4/A
MKX@UOPY;0V_A[6-;\"Z?=W6EPQ?ZJ.WEEA9X%3 VJA 7'&*]*HH ^2_V^_\
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M=I][*'^^&GMX4=MV3G)Y[UZ9110 4444 %%%% !1110 4444 %%%% !1110
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M[L)8(KJXGB22.-C&VP8])^,'_!-#X1?%CX;_  @\&Z;\5_B#X.UWX%VT5O\
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M'[(?[&WPC_8M\"ZMX.^&%[K^JWOB7Q%<:_XO\5^+M8;4-7\0:I,J))=W=PP
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M_LX>"_%GQ+^(O@WQ?KU_X?MYM4\4_#V<RZ)J\I7_ (^K-B3F*08<8) W$ D
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M21B4W  G]%:* /B3P+^Q-^WM\2?^"@_PP_;R_:Y\?_#&"+P7X1\2^'KGX?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
.*** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>biib-20250930_g12.jpg
<TEXT>
begin 644 biib-20250930_g12.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[@ .061O8F4 90     !_]L 0P " 0$!
M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D*
M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\  $0@&
MP )Z P$B  (1 0,1 ?_$ !\   $% 0$! 0$!           ! @,$!08'" D*
M"__$ +40  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-180<B<10R@9&A
M""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H
MJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V
M]_CY^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'" D*"__$ +41  (!
M @0$ P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P
M%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E
M9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V
MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#
M 0 "$0,1 #\ _?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M"CQK^QE_P3,\%? [QCX'\=:1)??$.W^,%B]WXCTEIUCU'3M5=($EU4W<+/\
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MH.1D ]DHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K
MX4_:K_9G_P""@WP%_;^U?_@HO^P#X"\!_$Y/&/P]L/#'COX:>-=>?2+X?89Y
M9;>?3+_8T48<2E7CE 7<H;YRP\O[KKY,^._[%W[87@_]J'7?VO\ _@GO^TAX
M9\/:MXVTZQM/B%\._BEH-UJGAW6);.,Q6U_ UK/%<6%RL)\MO+)CE 1G7<I+
M 'C7PQ_X*B_![PUXM_:#^*WQ[_X)_P"N_!/]I3X=_ ^?Q=XN\+Z]<6]V_BKP
M]IB3M!)::E:_NKV%+AC!YFT;3*H!8(P3YQT?]MG]J*?]D72OVR?!7[2W[5/B
MK]H6^T>S\3#X<0?LZ^(#X U%I=D[^'X(%T7RQ;>0Q@2_6Y,C.!.)B&Q7VS\&
M_P#@F-\3?B+\9?B#^U#_ ,%)_BSX:\?>,_B!\*;CX:+X<\">'YM+T#0?"]Q(
MTMW:0"XFFN+B6>1MS3RL& ^4#;C'-?#W]@7_ (*J> ?@MHG[#VB_\% /!^F_
M";PY!:Z5I7Q#T;P;=P_$!-!MBHAL%F^TFQBG$*+;_;1$6V#?Y6^@#.^-OCW]
MJW]J/_@J-X._90^&O[1_B_X2> /$W[+L?C?Q99Z+9V\>MVTO]LB#RK9[F"06
M=TWG0QR2LC%(XI555=UD3PO]H*[_ &AI?@M^W%_P3/\ C5^U]\1/$5I\'/A!
M+X^^'_CU;NSAUK6]$O-"U+S=#UF5;;R[J!9XRK.B1RRHWWX]H4>K?M-_#_\
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MVAX@_;0U3X__ +.?CSQ$;VXA^'4WQ,\#:]>#P/I3L0MIIL%IJ%O;VSLFT2W
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M*")%"JB*H 50   !@ 8%3T %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %<S\9?B98_!OX7:W\4-3T
MR:]M]%LC<RVL#A7D (& 3P#S735Y1^W/_P FC^/?^P"__H:T >E>'-9B\1^'
MK#Q#!"T:7]E%<)&YR4#H& /N,U=K"^%W_),_#O\ V K3_P!$I6[0 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !7E'[<_\ R:/X]_[ +_\ H:UZO7E'[<__ ":/X]_[ +_^
MAK0!W7PN_P"29^'?^P%:?^B4K=K"^%W_ "3/P[_V K3_ -$I6[0 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !7E'[<_P#R:/X]_P"P"_\ Z&M>KUY1^W/_ ,FC^/?^P"__
M *&M '=?"[_DF?AW_L!6G_HE*W:POA=_R3/P[_V K3_T2E;M !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45BWWQ&\!Z9X_
MT[X5:AXNT^'Q)J^EW6I:7H<ERHNKJSMG@CN)TCZLD;W-NK,. 9D!^\*VJ "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "O*/VY_P#DT?Q[_P!@%_\ T-:]7KRC]N?_ )-'\>_]
M@%__ $-: .Z^%W_),_#O_8"M/_1*5NUA?"[_ ))GX=_[ 5I_Z)2MV@ HHHH
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MX\/WGB#Q$]H]KIUG965V%N#'!YTT\L[((R0J*23D_?% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5Y1^W/_P FC^/?^P"__H:U
MZO7E'[<__)H_CW_L O\ ^AK0!W7PN_Y)GX=_[ 5I_P"B4K=K"^%W_),_#O\
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M([,23M@MX8P!@!8P !5;_A:_@#_H/_\ DK+_ /$T?\+7\ ?]!_\ \E9?_B:
M.BHKG?\ A:_@#_H/_P#DK+_\31_PM?P!_P!!_P#\E9?_ (F@#HJ*YW_A:_@#
M_H/_ /DK+_\ $T?\+7\ ?]!__P E9?\ XF@#HJ*YW_A:_@#_ *#_ /Y*R_\
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ME'[<_P#R:/X]_P"P"_\ Z&M '=?"[_DF?AW_ + 5I_Z)2MVL+X7?\DS\._\
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M?PR^*GPKU.TLOB)\/->O8+M[#[7"9K.ZM[NW)BN[6>-7,<JA2=C94<%OH&@
MHHHH **** "BBB@ HHHH **** "BBB@ KS?X\_\ 'YIO_7*7^:UZ17F_QY_X
M_--_ZY2_S6@#S^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ KK_@I_P CBW_7D_\ -:Y"NO\ @I_R.+?]>3_S
M6@#UFBBB@ HHHH **** "BBB@ HHHH **** "O*/VY_^31_'O_8!?_T-:]7K
MRC]N?_DT?Q[_ -@%_P#T-: .Z^%W_),_#O\ V K3_P!$I6[6%\+O^29^'?\
ML!6G_HE*W: "BBB@ HHHH **** "BBB@ KP__@HE\-?V8OC=^RUJOP+_ &L_
MB:OA#PSXTU;3-*T[7H]:33[JVUEKV&337M)G!"W*W<4+Q@@@LF&!7<*]PKE/
MCA\#?A%^TI\*M9^"'QW^'^G>*/"?B"U^SZOHFJP[X;A P93P04=7575U(9&5
M64A@" #\G?@I\:_V_?\ @F=\??CI\2/'OQD\*_&?X:0?M-^&?"?Q-N=<\.C2
M?%5U<ZEH?AVUMM3LOLC?996BCNK..2W,8,@MGD!0R-L^U/\ @LC\+/AKI?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHKQG_A:_C_\ Z#__ )*Q?_$T?\+7\?\ _0?_ /)6+_XF@#V:BO&?^%K^/_\
MH/\ _DK%_P#$T?\ "U_'_P#T'_\ R5B_^)H ]FHKQG_A:_C_ /Z#_P#Y*Q?_
M !-'_"U_'_\ T'__ "5B_P#B: /9J*\9_P"%K^/_ /H/_P#DK%_\31_PM?Q_
M_P!!_P#\E8O_ (F@#V:BO&?^%K^/_P#H/_\ DK%_\31_PM?Q_P#]!_\ \E8O
M_B: /9J*\9_X6OX__P"@_P#^2L7_ ,31_P +7\?_ /0?_P#)6+_XF@#V:BO&
M?^%K^/\ _H/_ /DK%_\ $T?\+7\?_P#0?_\ )6+_ .)H ]FHKQG_ (6OX_\
M^@__ .2L7_Q-'_"U_'__ $'_ /R5B_\ B: /9J*\9_X6OX__ .@__P"2L7_Q
M-'_"U_'_ /T'_P#R5B_^)H ]FHKQG_A:_C__ *#_ /Y*Q?\ Q-'_  M?Q_\
M]!__ ,E8O_B: /9J*\9_X6OX_P#^@_\ ^2L7_P 37I/PXUG4M>\)P:GJUSYL
M[NX9]@7(#$#A0!0!NT444 %%%% !7F_QY_X_--_ZY2_S6O2*\W^//_'YIO\
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M'_R,-_\ ]?LO_H9H I4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MYIO_ %RE_FM>D5YO\>?^/S3?^N4O\UH \_HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Z_X*?\CBW_7D_P#-
M:Y"NO^"G_(XM_P!>3_S6@#UFBBB@ HHHH **** "BBB@ HHHH **** "O*/V
MY_\ DT?Q[_V 7_\ 0UKU>O*/VY_^31_'O_8!?_T-: .Z^%W_ "3/P[_V K3_
M -$I6[6%\+O^29^'?^P%:?\ HE*W: "O!/$?_(PW_P#U^R_^AFO>Z\$\1_\
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M *Y2_P UKTBO-_CS_P ?FF_]<I?YK0!Y_1110 4444 %%%% !1110 5^7O\
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M\7>-&U(^(?!^GW,CR?9UMH8FM]1:V,C>0\DT.0J!U(7%>D-^RE\=OV8?V,/
MG[,/_!.WQMX9T;4/"%W9076J^/;>2:.^L=\DE_*PBC<_:9Y9&ES@*&=N0,4
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M'%O^O)_YK7(5U_P4_P"1Q;_KR?\ FM 'K-%%% !1110 4444 %%%% !1110
M4444 %>4?MS_ /)H_CW_ + +_P#H:UZO7E'[<_\ R:/X]_[ +_\ H:T =U\+
MO^29^'?^P%:?^B4K=K"^%W_),_#O_8"M/_1*5NT %>">(_\ D8;_ /Z_9?\
MT,U[W7@GB/\ Y&&__P"OV7_T,T 4J*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "O8OA#_ ,B+;?\ 767_ -#-
M>.U[%\(?^1%MO^NLO_H9H Z:BBB@ HHHH *\W^//_'YIO_7*7^:UZ17F_P >
M?^/S3?\ KE+_ #6@#S^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ KK_@I_R.+?\ 7D_\UKD*Z_X*?\CBW_7D
M_P#-: /6:*** "BBB@ HHHH **** "BBB@ HHHH *\H_;G_Y-'\>_P#8!?\
M]#6O5Z\H_;G_ .31_'O_ & 7_P#0UH [KX7?\DS\._\ 8"M/_1*5NUA?"[_D
MF?AW_L!6G_HE*W: "O!/$?\ R,-__P!?LO\ Z&:][KP3Q'_R,-__ -?LO_H9
MH I4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %>Q?"'_D1;;_ *ZR_P#H9KQVO8OA#_R(MM_UUE_]#- '3444
M4 %%%% !7F_QY_X_--_ZY2_S6O2*\W^//_'YIO\ URE_FM 'G]%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7
M7_!3_D<6_P"O)_YK7(5U_P %/^1Q;_KR?^:T >LT444 %%%% !1110 4444
M%%%% !1110 5Y1^W/_R:/X]_[ +_ /H:UZO7E'[<_P#R:/X]_P"P"_\ Z&M
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M% !7F_QY_P"/S3?^N4O\UKTBO-_CS_Q^:;_URE_FM 'G]%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !77_!3_
M )'%O^O)_P":UR%=?\%/^1Q;_KR?^:T >LT444 %%%% !1110 4444 %%%%
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M@C5I;B4@$B.-&; )Q@&OBSP%^RG\+_V3_P#@L7\'O"W@&;5M4U'6/@SXMO\
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M3? .M_LP?$70/BG\0$\)^&M2\#ZK9:[XGDF$8TJTFM)8I;D,2 #&KEASU H
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M444 %%%% !1110 4444 %>4?MS_\FC^/?^P"_P#Z&M>KUY1^W/\ \FC^/?\
ML O_ .AK0!W7PN_Y)GX=_P"P%:?^B4K=K"^%W_),_#O_ & K3_T2E;M !7@G
MB/\ Y&&__P"OV7_T,U[W7@GB/_D8;_\ Z_9?_0S0!2HHHH **** "BBB@ HH
MHH \[_:E^ E_^TA\(+KX<Z'\6O$?@75TOK74="\5^%[LI<:??6TRS02-&3LN
M8MZ /!)E)%)!P<,OQ9\&O^"<G[:WQD^+OQ-\/?MG?'?1F^']S\:='\4ZO9>&
M_ AL)?'T^GZ5I!MI1-)=RBSLQ-9PK)$BEWEMI<2(C*%_1>B@#YR^,'PJ_P""
MA/@KX_:S\9/V3OBWX,\2^'?$^G6L.I?#7XLWU_:V>C7-NA076F7=E%,T2R@@
MRP/"P9UW!QG"UOV:OV3/V@/ASX]^)?[7?QR\<>%/$?QH\?:);:;IUCI$%S;>
M'M LK-)39Z?"[AKB2-IY&EFG9=[%OEC7;AOI:B@#X2\6?LV?\%;/%?[8GA#]
ML.XTG]G2'4O"'@W4_#UMHR>*M>,%Q%>S0RM*SG3]P93"  .#N.:]:^+7P?\
M^"A.LZKX'_: ^#OQD\':1XZT;09],\:?#36+W4;CP7KBS2+)YL;HBW%O<Q,@
MV7/DNQ5BA7;D-])T4 ?)G@7]D?\ :[^-?[7O@3]K;]N3Q1\/-.3X3V>JK\/_
M  1\,)+Z[@-YJ, MKB]O;V]BA>0B ;$B2%5!.[=P0W0_$/\ 92_:%_:J^%_Q
MY_9S_:]^)'AV7P+X^E>S^&S^#[:1+_1M..YE-WYD:K+,L@A; +*VQ@3@U])4
M4 ?(UQX#_P""QMS\,W^!TFO_ +.I@DTHZ2_Q%SK/VS[.8_*-U_8_D>1Y^SYO
M+^U^5O[;?EKW7]DK]G#PI^R'^S7X+_9H\$ZI=7VF^#="ATZ"_O0!+=,N3),P
M'"EW9WVCA=V!P*]$HH **** "BBB@ HHHH **** "O8OA#_R(MM_UUE_]#->
M.U[%\(?^1%MO^NLO_H9H Z:BBB@ HHHH *\W^//_ !^:;_URE_FM>D5YO\>?
M^/S3?^N4O\UH \_HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH *Z_X*?\ (XM_UY/_ #6N0KK_ (*?\CBW_7D_
M\UH ]9HHHH **** "BBB@ HHHH **** "BBB@ KRC]N?_DT?Q[_V 7_]#6O5
MZ\H_;G_Y-'\>_P#8!?\ ]#6@#NOA=_R3/P[_ -@*T_\ 1*5NUA?"[_DF?AW_
M + 5I_Z)2MV@ KP3Q'_R,-__ -?LO_H9KWNO!/$?_(PW_P#U^R_^AF@"E111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5[%\(?^1%MO^NLO_H9KQVO8OA#_P B+;?]=9?_ $,T =-1110 4444
M %>;_'G_ (_--_ZY2_S6O2*\W^//_'YIO_7*7^:T >?T444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %=?\%/\
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M--_ZY2_S6@#S^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ KK_@I_R.+?]>3_ ,UKD*Z_X*?\CBW_ %Y/_-:
M/6:*** "BBB@ HHHH **** "BBB@ HHHH *\H_;G_P"31_'O_8!?_P!#6O5Z
M\H_;G_Y-'\>_]@%__0UH [KX7?\ ),_#O_8"M/\ T2E;M87PN_Y)GX=_[ 5I
M_P"B4K=H *\$\1_\C#?_ /7[+_Z&:][KP3Q'_P C#?\ _7[+_P"AF@"E1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 5[%\(?^1%MO^NLO_H9KQVO8OA#_ ,B+;?\ 767_ -#- '34444 %%%%
M !7F_P >?^/S3?\ KE+_ #6O2*\W^//_ !^:;_URE_FM 'G]%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !77_
M  4_Y'%O^O)_YK7(5U_P4_Y'%O\ KR?^:T >LT444 %%%% !1110 4444 %%
M%% !1110 5Y1^W/_ ,FC^/?^P"__ *&M>KUY1^W/_P FC^/?^P"__H:T =U\
M+O\ DF?AW_L!6G_HE*W:POA=_P DS\._]@*T_P#1*5NT %>">(_^1AO_ /K]
ME_\ 0S7O=>">(_\ D8;_ /Z_9?\ T,T 4J*** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O8OA#_P B+;?]=9?_
M $,UX[7L7PA_Y$6V_P"NLO\ Z&: .FHHHH **** "O-_CS_Q^:;_ -<I?YK7
MI%>;_'G_ (_--_ZY2_S6@#S^BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ KK_ (*?\CBW_7D_\UKD*Z_X*?\
M(XM_UY/_ #6@#UFBBB@ HHHH **** "BBB@ HHHH **** "O*/VY_P#DT?Q[
M_P!@%_\ T-:]7KRC]N?_ )-'\>_]@%__ $-: .Z^%W_),_#O_8"M/_1*5NUA
M?"[_ ))GX=_[ 5I_Z)2MV@ KP3Q'_P C#?\ _7[+_P"AFO>Z\$\1_P#(PW__
M %^R_P#H9H I4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %>Q?"'_ )$6V_ZZR_\ H9KQVO8OA#_R(MM_UUE_
M]#- '34444 %%%% !7F_QY_X_--_ZY2_S6O2*^3?^"E?_(<\)?\ 7I>?^A15
M\[Q5GW^K.1U<Q]G[3DY?=ORWYI*.]I;7OL88FM]7HN=KV.JHKXWHK\C_ .(Y
M?]2__P J_P#W(\S^V/[GX_\  /LBBOC>BC_B.7_4O_\ *O\ ]R#^V/[GX_\
M /LBBOC>BC_B.7_4O_\ *O\ ]R#^V/[GX_\  /LBBOC>BC_B.7_4O_\ *O\
M]R#^V/[GX_\  /LBBOC>BC_B.7_4O_\ *O\ ]R#^V/[GX_\  /LBBOC>BC_B
M.7_4O_\ *O\ ]R#^V/[GX_\  /LBBOC>BC_B.7_4O_\ *O\ ]R#^V/[GX_\
M /LBBOC>BC_B.7_4O_\ *O\ ]R#^V/[GX_\  /LBBOC>BC_B.7_4O_\ *O\
M]R#^V/[GX_\  /LBBOC>BC_B.7_4O_\ *O\ ]R#^V/[GX_\  /LBBOC>BC_B
M.7_4O_\ *O\ ]R#^V/[GX_\  /LBBOC>BC_B.7_4O_\ *O\ ]R#^V/[GX_\
M /LBBOC>BC_B.7_4O_\ *O\ ]R#^V/[GX_\  /LBNO\ @I_R.+?]>3_S6O@B
MO=/^">W_ "7F;_L7[C_T9%7JY%XO_P!M9Q0P/U+D]I)1YO:7M?K;V:O]Z-*.
M:>UJJ'):_G_P#[<HHHK]I/6"BBB@ HHHH **** "BBB@ HHHH *\H_;G_P"3
M1_'O_8!?_P!#6O5Z\H_;G_Y-'\>_]@%__0UH [KX7?\ ),_#O_8"M/\ T2E;
MM87PN_Y)GX=_[ 5I_P"B4K=H *\$\1_\C#?_ /7[+_Z&:][KP3Q'_P C#?\
M_7[+_P"AF@"E1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 5[%\(?^1%MO^NLO_H9KQVO8OA#_ ,B+;?\ 767_
M -#- '34444 %%%% !7R;_P4K_Y#GA+_ *]+S_T**OK*ODW_ (*5_P#(<\)?
M]>EY_P"A15^>>*G_ "0^)]:?_IR)PYE_N<OE^9\PT445_(Q\R%%%% !1110
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M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>Z?\$]O^2\S?\
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M/_D8;_\ Z_9?_0S0!2HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *]B^$/_(BVW_767_T,UX[7L7PA_Y$6V_Z
MZR_^AF@#IJ*** "BBB@ KY-_X*5_\ASPE_UZ7G_H45?65?)O_!2O_D.>$O\
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MGK]B^&__ ,<K[7_X)XZ%IWA[X%WECIG_  3OT[]F6,^)+AS\/=,CT5([DF&
M?V@1HY-OF3'E\_O/]'&>-M 'N]>4?MS_ /)H_CW_ + +_P#H:UZO7E'[<_\
MR:/X]_[ +_\ H:T =U\+O^29^'?^P%:?^B4K=K"^%W_),_#O_8"M/_1*5NT
M%>">(_\ D8;_ /Z_9?\ T,U[W7@GB/\ Y&&__P"OV7_T,T 4J*** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O8
MOA#_ ,B+;?\ 767_ -#->.U[%\(?^1%MO^NLO_H9H Z:BBB@ HHHH *^3?\
M@I7_ ,ASPE_UZ7G_ *%%7UE7R;_P4K_Y#GA+_KTO/_0HJ_//%3_DA\3ZT_\
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MX/\ R/9**\;_ .&M?^J?_P#E5_\ M5'_  UK_P!4_P#_ "J__:J/^(H\"_\
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M_P#_ "J__:J/^&M?^J?_ /E5_P#M5'_$4>!?^@O_ ,IU?_D _M'!_P WX/\
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M:?D7^L&;_P#/W_R6/^13_LG_ *>/_'/_ *]']D_]/'_CG_UZN44?\0,\+/\
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MI6[0 5^9_P 6/^2I>)?^Q@O/_1[U^F%?F?\ %C_DJ7B7_L8+S_T>]?AGC?\
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M.0**** "BBB@ HHHH *]L_8)_P"2X3?]@&X_]&15XG7MG[!/_)<)O^P#<?\
MHR*O-SG_ )%=;_"SVN'/^1[A_P#$C[,HHHK\E/WX**** "BBB@ HHHH ****
M "BBB@ KRC]N?_DT?Q[_ -@%_P#T-:]7KRC]N?\ Y-'\>_\ 8!?_ -#6@#NO
MA=_R3/P[_P!@*T_]$I6[6%\+O^29^'?^P%:?^B4K=H *_,_XL?\ )4O$O_8P
M7G_H]Z_3"OS/^+'_ "5+Q+_V,%Y_Z/>OPSQO_P!PP?\ BG^2/'S?X(?,Y^BB
MBOYV/#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%[2/'/B[P-XQM].&GR>*? FLK:7-W9ABZV]PDL<L%Q&KDLHDC8J3P12?!?\
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M )$/[1R__G]#_P "7^9#14WV"[_YY?\ CPH^P7?_ #R_\>%'^H/'?_0JQ/\
MX(J__(A_:.7_ //Z'_@2_P R&BIOL%W_ ,\O_'A1]@N_^>7_ (\*/]0>._\
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M^P7?_/+_ ,>%'^H/'?\ T*L3_P""*O\ \B']HY?_ ,_H?^!+_,AHJ;[!=_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P#(KK?X6>UPY_R/</\ XD?9E%%%?DI^_!1110 4444 %%%% !1110 4444
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M]&15YN<_\BNM_A9[7#G_ "/</_B1]F4445^2G[\%%%% !1110 4444 %%%%
M!1110 5Y1^W/_P FC^/?^P"__H:UZO7E'[<__)H_CW_L O\ ^AK0!W7PN_Y)
MGX=_[ 5I_P"B4K=K"^%W_),_#O\ V K3_P!$I6[0 5^<OQ2_Y*;XC_[#UY_Z
M.>OT:K\Y?BE_R4WQ'_V'KS_T<]?8\'_QZOHOS9^=>(?^[4/67Y(P:***^[/R
MP**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[%SG_H&J?^ 2_P CE**ZO_A2/Q0_Z%C_ ,G8/_BZ/^%(_%#_ *%C_P G8/\
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M !(#URBBBOU8 HHHH **** "BBB@ HHHH **** "O*/VY_\ DT?Q[_V 7_\
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M "-*/^) >N4445^K %%%% !1110 4444 %%%% !1110 5Y1^W/\ \FC^/?\
ML O_ .AK7J]>4?MS_P#)H_CW_L O_P"AK0!W7PN_Y)GX=_[ 5I_Z)2MVL+X7
M?\DS\._]@*T_]$I6[0 5^<OQ2_Y*;XC_ .P]>?\ HYZ_1JOSE^*7_)3?$?\
MV'KS_P!'/7V/!_\ 'J^B_-GYUXA_[M0]9?DC!HHHK[L_+ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K[A_8H_P"3
M>=)_Z^KK_P!'O7P]7W#^Q1_R;SI/_7U=?^CWKYGBS_D61_Q+\F?;< _\CJ7^
M!_G$]7HHHK\Y/V(**** "O-?C[_Q^:9_URE_FM>E5YK\??\ C\TS_KE+_-:\
M/B/_ )%%3Y?^E(#SVBBBOS, HHHH **** "BBB@ KXV_;R_X*=^-/@;XFO\
MX3_LM_ ;6?'GB7POXO\ ">F^-]2#6EOI6E'5]0M(X=.,MS<1&2]N(+A0GEAH
MX?M$4DK*H85]DU^:'_!37]GW2=>U[Q7^T5^QG^UVNC^(=1^-/P^T3XI>"C:6
MVJZ3+X@M]9TJ'3KJ>,XFM+B!9+5Y%C<"9(0C $LU=^74Z-3$I55IIO>U[K>V
MNU[>=KZ ?;_P!_:L\%_''X6:Q\3-;\+ZYX!?PMJ5UIWC'1?'MM'8SZ)<VRJ\
MWFR!V@DA",LBW$<CQ,C ALA@/.OV7O\ @IQ\(/VO?VI_%7[/'P9\+ZI=Z-X<
M\(6^NV/CVX4Q6.O1R7<EJS62,@::W$D;J+D'9(T;[ 5"NT/['/QG\=_M;^%O
MBS^R]^VK\./!VH>)?AWXF'A?QJOAV*2?0/$-M<6<-U%(D5SN9-T4P26W<OM8
M$$X;:O(_"_3M/T?_ (+D^/\ 2=)L(;6TM?V9/#L-K:VT02.&-=8O55%5<!5
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M/?\ L O_ .AK0!W7PN_Y)GX=_P"P%:?^B4K=K"^%W_),_#O_ & K3_T2E;M
M!7YR_%+_ )*;XC_[#UY_Z.>OT:K\Y?BE_P E-\1_]AZ\_P#1SU]CP?\ QZOH
MOS9^=>(?^[4/67Y(P:***^[/RP**** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH *^X?V*/^3>=)_Z^KK_ -'O7P]7W#^Q
M1_R;SI/_ %]77_H]Z^9XL_Y%D?\ $OR9]MP#_P CJ7^!_G$]7HHHK\Y/V(**
M** "O-?C[_Q^:9_URE_FM>E5YK\??^/S3/\ KE+_ #6O#XC_ .114^7_ *4@
M//:***_,P"BBB@ HHHH **** "OE']NW_@D]\#?VPM9C^)>@?;?!_CNX\0:!
M<:[XG\/:_?:<^K6-AJ%O.T5PEK*B3SK#$RP3NID@<1,K+L&/JZBM:->KAZBG
M3=F!Y-X$_8R^#OP;^ .J?L\_L_S:WX T_5[B:ZN_$'AS5FDUAKV5E:6]>\O!
M.\UR^T RS>8=H"] H'CMG_P2'\/Z?\6;WXZV?[>W[1<?B_4=#AT:^U]?%^E>
M?-812O+';D_V9C8LCNPXZL:^NZ*N&+Q$&VI;[];_ '@> _&7_@G?\,?BYXNT
M+XLZ;\6_B+X*^(>A^'HM#;XD>!O$45GJVJV"$-Y%\'@DMKQ2X,F)(#M<DKMZ
M5=_9N_8$^$/[.GCK7?C!<^,?&/Q"\>>)-+32]7\=_$K7%U+4GTY&WK8Q[(XH
M;>WW_.8XHD#-@MN(&/<:*3Q-=T^3FT_3MZ>6P'R9_P .@?@WH^EW_P /OAM^
MTK\;O!?P[U.XFDNOA7X3\?+;Z$D<S,T]O"'MWNK6"0N^Z&"XC3YV  !KTGXO
M?L&?!+XI_L\>&/V7M U#Q%X"\)>$-1L+K0K;X?ZJ-/EA6T#". NR2%XFW'>#
M\SGDMG)/M5%-XO$R:;D]-?GW\WYL#R']I_\ 8N^%_P"U'J7A_P 8ZSXG\4^$
M/&/A)YCX7\>^ M9_L_5]-CF 6>%9"CQRPR!5WPRQR1G:#MSS5;]F?]AOX7_L
MU>,]<^+*>-O&/COQYXCLXK'5_'_Q$UQ=0U22QB8O'91F..*&VMU<E_*ABC5F
M(9MQ"D>ST5/UBM[+V?-I_3MZ7UL 4445B 4444 %%%% !1110 5V'P1_Y'-O
M^O)_YK7'UV'P1_Y'-O\ KR?^:UZ63_\ (TH_XD!ZY1117ZL 4444 %%%% !1
M110 4444 %%%% !7E'[<_P#R:/X]_P"P"_\ Z&M>KUY1^W/_ ,FC^/?^P"__
M *&M '=?"[_DF?AW_L!6G_HE*W:POA=_R3/P[_V K3_T2E;M !7YR_%+_DIO
MB/\ [#UY_P"CGK]&J^"_B-\&_B1?_$+7KZT\.;XIM9NI(F^V0C*F9B#@OGI7
MTO#>8Y?E]6I+%5HTTTK<TE&_I=JY\'QW@\7C,/05"G*;3=^5-VT78\[HKJ_^
M%(_%#_H6/_)V#_XNC_A2/Q0_Z%C_ ,G8/_BZ^M_UEX<_Z#*7_@R'^9^;?V+G
M/_0-4_\  )?Y'*45U?\ PI'XH?\ 0L?^3L'_ ,71_P *1^*'_0L?^3L'_P 7
M1_K+PY_T&4O_  9#_,/[%SG_ *!JG_@$O\CE**ZO_A2/Q0_Z%C_R=@_^+H_X
M4C\4/^A8_P#)V#_XNC_67AS_ *#*7_@R'^8?V+G/_0-4_P# )?Y'*45U?_"D
M?BA_T+'_ ).P?_%T?\*1^*'_ $+'_D[!_P#%T?ZR\.?]!E+_ ,&0_P P_L7.
M?^@:I_X!+_(Y2BNK_P"%(_%#_H6/_)V#_P"+H_X4C\4/^A8_\G8/_BZ/]9>'
M/^@RE_X,A_F']BYS_P! U3_P"7^1RE%=7_PI'XH?]"Q_Y.P?_%T?\*1^*'_0
ML?\ D[!_\71_K+PY_P!!E+_P9#_,/[%SG_H&J?\ @$O\CE**ZO\ X4C\4/\
MH6/_ "=@_P#BZ/\ A2/Q0_Z%C_R=@_\ BZ/]9>'/^@RE_P"#(?YA_8N<_P#0
M-4_\ E_D<I175_\ "D?BA_T+'_D[!_\ %T?\*1^*'_0L?^3L'_Q='^LO#G_0
M92_\&0_S#^Q<Y_Z!JG_@$O\ (Y2BNK_X4C\4/^A8_P#)V#_XNC_A2/Q0_P"A
M8_\ )V#_ .+H_P!9>'/^@RE_X,A_F']BYS_T#5/_  "7^1RE%=7_ ,*1^*'_
M $+'_D[!_P#%T?\ "D?BA_T+'_D[!_\ %T?ZR\.?]!E+_P &0_S#^Q<Y_P"@
M:I_X!+_(Y2BNK_X4C\4/^A8_\G8/_BZ/^%(_%#_H6/\ R=@_^+H_UEX<_P"@
MRE_X,A_F']BYS_T#5/\ P"7^1RE%=7_PI'XH?]"Q_P"3L'_Q='_"D?BA_P!"
MQ_Y.P?\ Q='^LO#G_092_P#!D/\ ,/[%SG_H&J?^ 2_R.4HKJ_\ A2/Q0_Z%
MC_R=@_\ BZ/^%(_%#_H6/_)V#_XNC_67AS_H,I?^#(?YA_8N<_\ 0-4_\ E_
MD<I7W#^Q1_R;SI/_ %]77_H]Z^2?^%(_%#_H6/\ R=@_^+K["_9&T#5O#/P,
MTS1];M/(N8[BY+Q^8K8!F<CE21T->%Q#G&4X_ JGAL1"I+F3M&<9.UGK9-NQ
M]AP3EV883-Y3KT907(U>46E>\>K1Z71117Q1^JA1110 5YK\??\ C\TS_KE+
M_-:]*KS7X^_\?FF?]<I?YK7A\1_\BBI\O_2D!Y[1117YF 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5V'P1_Y'-O
M^O)_YK7'UV'P1_Y'-O\ KR?^:UZ63_\ (TH_XD!ZY1117ZL 4444 %%%% !1
M110 4444 %%%% !7E'[<_P#R:/X]_P"P"_\ Z&M>KUY1^W/_ ,FC^/?^P"__
M *&M '=?"[_DF?AW_L!6G_HE*W:POA=_R3/P[_V K3_T2E;M !7@'B3_ )&*
M_P#^OV7_ -#->_UX!XD_Y&*__P"OV7_T,U\AQ=_ I>K_ " I4445\, 4444
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M_P#0UKU>O*/VY_\ DT?Q[_V 7_\ 0UH [KX7?\DS\._]@*T_]$I6[6%\+O\
MDF?AW_L!6G_HE*W: "O /$G_ ",5_P#]?LO_ *&:]_KP#Q)_R,5__P!?LO\
MZ&:^0XN_@4O5_D!2HHHKX8 HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ KV7X/?\B':_\ 767_ -#->-5[+\'O^1#M
M?^NLO_H9KZ7A7_D92_PO\T!T]%%%?H8!1110 5\:_P#!5+]N?_AC[7_!FF_\
M*N_X2+^W;.]EW_VW]D\CRGA&,>1)NSO]L8[YK[*K\MO^#B?_ )'/X6?]@O5O
M_1EK7T'"^2Y;Q!G=/ X^GSTI\UXWE&]HMK6+3W2>C/F^+<?B\LR&KB<-+EG'
MEL[)[R2>C36S['&?\/L_^K9O_+S_ /N.C_A]G_U;-_Y>?_W'7P?17ZS_ ,0?
M\.O^@'_RK6_^6'XY_KUQ5_T$?^20_P#D3[P_X?9_]6S?^7G_ /<='_#[/_JV
M;_R\_P#[CKX/HH_X@_X=?] /_E6M_P#+ _UZXJ_Z"/\ R2'_ ,B?>'_#[/\
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M6M_\L#_7KBK_ *"/_)(?_(GWA_P^S_ZMF_\ +S_^XZ/^'V?_ %;-_P"7G_\
M<=?!]%'_ !!_PZ_Z ?\ RK6_^6!_KUQ5_P!!'_DD/_D3[P_X?9_]6S?^7G_]
MQT?\/L_^K9O_ "\__N.O@^BC_B#_ (=?] /_ )5K?_+ _P!>N*O^@C_R2'_R
M)]X?\/L_^K9O_+S_ /N.C_A]G_U;-_Y>?_W'7P?11_Q!_P .O^@'_P JUO\
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M?X7^: Z>BBBOT, HHHH *_+;_@XG_P"1S^%G_8+U;_T9:U^I-?EM_P '$_\
MR.?PL_[!>K?^C+6OM/#[_DK*'I/_ -(D?'\>?\DO7]8?^EQ/S<HHHK^D#^>P
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ K[5_X(+?\GP7?_8BW_\ Z/M:^*J^U?\ @@M_R?!=_P#8BW__ */M:^=X
MM_Y)K%_X&>_PM_R46%_QH_9>BBBOY=/Z5"BBB@ HHHH **** "BBB@ HHHH
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M'@/2O!UH?AGK=DB-9V=\CQRI+9)]@C4,@1K@11N/N%@#C[K_ &E?C9;?LX_
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M%N(%<O&X,9=0&4 $CHPZUZ-1B\31Q%&*BFFFWO=6=MM%VT[( HHHK@ ****
M"BBB@ HHHH *]E^#W_(AVO\ UUE_]#->-5[+\'O^1#M?^NLO_H9KZ7A7_D92
M_P +_- =/1117Z& 4444 %?EM_P<3_\ (Y_"S_L%ZM_Z,M:_4FORV_X.)_\
MD<_A9_V"]6_]&6M?:>'W_)64/2?_ *1(^/X\_P"27K^L/_2XGYN4445_2!_/
M84444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 5]J_P#!!;_D^"[_ .Q%O_\ T?:U\55]J_\ !!;_ )/@N_\ L1;_ /\
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M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OM7_ ((+?\GP7?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M-1_P\T_8A_Z+9_Y;>I?_ "-7Y+T4?\0!X._Y_P"(_P# J?\ \J#_ (B7GO\
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M45^UGXZ%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %?M]_P13_ .4>WA3_ +"FJ_\ I=-7X@U^WW_!%/\ Y1[>%/\
ML*:K_P"ETU?G/BA_R3L/^OD?_29GZ#X;?\C^?_7N7_I43ZNHHHK\!/W,****
M "ORV_X.)_\ D<_A9_V"]6_]&6M?J37Y;?\ !Q/_ ,CG\+/^P7JW_HRUK[3P
M^_Y*RAZ3_P#2)'Q_'G_)+U_6'_I<3\W****_I _GL**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^U?^""W_)\%W_V
M(M__ .C[6OBJOM7_ ((+?\GP7?\ V(M__P"C[6OG>+?^2:Q?^!GO\+?\E%A?
M\:/V7HHHK^73^E0HHHH **** "BBB@ HHHH **** "O*/VY_^31_'O\ V 7_
M /0UKU>O*/VY_P#DT?Q[_P!@%_\ T-: .Z^%W_),_#O_ & K3_T2E;M87PN_
MY)GX=_[ 5I_Z)2MV@ K^<W]J'_DYCXB?]CUJ_P#Z6RU_1E7\YO[4/_)S'Q$_
M['K5_P#TMEK]9\*?]\Q7^&/YL_+?$_\ W3#?XI?DCA:***_:S\="BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OV^_
MX(I_\H]O"G_84U7_ -+IJ_$&OV^_X(I_\H]O"G_84U7_ -+IJ_.?%#_DG8?]
M?(_^DS/T'PV_Y'\_^O<O_2HGU=1117X"?N84444 %?EM_P '$_\ R.?PL_[!
M>K?^C+6OU)K\MO\ @XG_ .1S^%G_ &"]6_\ 1EK7VGA]_P E90])_P#I$CX_
MCS_DEZ_K#_TN)^;E%%%?T@?SV%%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %?:O_!!;_D^"[_[$6__ /1]K7Q57VK_
M ,$%O^3X+O\ [$6__P#1]K7SO%O_ "36+_P,]_A;_DHL+_C1^R]%%%?RZ?TJ
M%%%% !1110 4444 %%%% !1110 5Y1^W/_R:/X]_[ +_ /H:UZO7E'[<_P#R
M:/X]_P"P"_\ Z&M '=?"[_DF?AW_ + 5I_Z)2MVL+X7?\DS\._\ 8"M/_1*5
MNT %?SF_M0_\G,?$3_L>M7_]+9:_HRK^<W]J'_DYCXB?]CUJ_P#Z6RU^L^%/
M^^8K_#'\V?EOB?\ [IAO\4OR1PM%%%?M9^.A1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !7[??\$4_^4>WA3_L*:K_
M .ETU?B#7[??\$4_^4>WA3_L*:K_ .ETU?G/BA_R3L/^OD?_ $F9^@^&W_(_
MG_U[E_Z5$^KJ***_ 3]S"BBB@ K\MO\ @XG_ .1S^%G_ &"]6_\ 1EK7ZDU^
M6W_!Q/\ \CG\+/\ L%ZM_P"C+6OM/#[_ )*RAZ3_ /2)'Q_'G_)+U_6'_I<3
M\W****_I _GL**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MV\*?]A35?_2Z:OSGQ0_Y)V'_ %\C_P"DS/T'PV_Y'\_^O<O_ $J)]74445^
MG[F%%%% !7Y;?\'$_P#R.?PL_P"P7JW_ *,M:_4FORV_X.)_^1S^%G_8+U;_
M -&6M?:>'W_)64/2?_I$CX_CS_DEZ_K#_P!+B?FY1117]('\]A1110 4444
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M/#[_ )*RAZ3_ /2)'Q_'G_)+U_6'_I<3\W****_I _GL**** "BBB@ HHHH
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M.*;32G);MN[5MDF]WJHI5\NPV&BH5&W+EY]&I-)I\D7LDK+7=M+9:/ZPF_;
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MU?G/BA_R3L/^OD?_ $F9^@^&W_(_G_U[E_Z5$^KJ***_ 3]S"BBB@ K\MO\
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M_P!+B?FY1117]('\]A1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?S9^6^)_^Z8;_%+\D<+1117[6?CH4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5^WW_!%/_E'MX4_["FJ_^ETU?B#7
M[??\$4_^4>WA3_L*:K_Z735^<^*'_).P_P"OD?\ TF9^@^&W_(_G_P!>Y?\
MI43ZNHHHK\!/W,**** "ORV_X.)_^1S^%G_8+U;_ -&6M?J37Y;?\'$__(Y_
M"S_L%ZM_Z,M:^T\/O^2LH>D__2)'Q_'G_)+U_6'_ *7$_-RBBBOZ0/Y["BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"OM7_@@M_P GP7?_ &(M_P#^C[6OBJOM7_@@M_R?!=_]B+?_ /H^UKYWBW_D
MFL7_ (&>_P +?\E%A?\ &C]EZ***_ET_I4**** "BBB@ HHHH **** "BBB@
M KRC]N?_ )-'\>_]@%__ $-:]7KRC]N?_DT?Q[_V 7_]#6@#NOA=_P DS\._
M]@*T_P#1*5NUA?"[_DF?AW_L!6G_ *)2MV@ K^<W]J'_ ).8^(G_ &/6K_\
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M_I=-7YSXH?\ ).P_Z^1_])F?H/AM_P C^?\ U[E_Z5$^KJ***_ 3]S"BBB@
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M_P#0UKU>O*/VY_\ DT?Q[_V 7_\ 0UH [KX7?\DS\._]@*T_]$I6[6%\+O\
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MR2]?UA_Z7$_-RBBBOZ0/Y["BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "OM7_@@M_R?!=_]B+?_P#H^UKXJK[5_P""
M"W_)\%W_ -B+?_\ H^UKYWBW_DFL7_@9[_"W_)187_&C]EZ***_ET_I4****
M "BBB@ HHHH **** "BBB@ KRC]N?_DT?Q[_ -@%_P#T-:]7KCOV@OAG??&7
MX+^(OA?IFIQ65QK>G-;174Z%DC)(.2!R1Q0!J?"[_DF?AW_L!6G_ *)2MVO
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M .65'_#GWXV?] 3QW_X0]M_\LJ/]?^$O^@G_ ,DJ?_(!_J+Q5_T#_P#D\/\
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M_P#D\/\ Y(^/:*^PO^'/OQL_Z GCO_PA[;_Y94?\.??C9_T!/'?_ (0]M_\
M+*C_ %_X2_Z"?_)*G_R ?ZB\5?\ 0/\ ^3P_^2/CVBOL+_AS[\;/^@)X[_\
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M[-[Q:6B3>[['S?%N Q>9Y#5PV&CS3ERV5TMI)O5M+9=S\K**^PO^'/OQL_Z
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M+,Y)8L22<FO8** (-,TS3=$TVWT?1M/@M+.TA6&UM;6)8XX8U "HBJ %4
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M>,_#UCJ^CZO8RV6JZ3JEHEQ;7MM*A26&6*0%9(W1F5D8$,"000:\>_X=E?\
M!-S_ *1\_ __ ,-/H_\ \C5[?10!F>#/!7@WX<>%;#P+\//"6F:#H>E6RV^E
MZ-HMA':VEG"OW8XH8E5(U'95  J&S^'7P^T_QS>_$_3_  +HT'B74K"*QU'Q
M%#ID2WUU:Q,S1027 7S'C1G8JC,54L2 ,FMFB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH ***P;SXF>"+"[EL;O6]DL,C1RI]F
ME.U@<$9"X/(H WJ*YW_A:_@#_H/_ /DK+_\ $U)9_$SP1?W<5C::WOEFD6.)
M/LTHW,3@#)7 Y- &]1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %>$>+_P#D;=4_[",__HQJ
M]WKPCQ?_ ,C;JG_81G_]&-0!G5H^$/\ D;=+_P"PC!_Z,6LZM'PA_P C;I?_
M &$8/_1BT >[T444 %%%% 'S]_P4U_;6U#]@[]E._P#B_P"#_!47B?QGK&MZ
M?X8^'7A>>8QQZMK^HW"V]G"[ @B,,S2N 02D3@$$@U\X?M"W/_!8S_@G[^S]
M??MT>//VTO#GQIM/!-BNM?%#X/?\*OL='L3I*8>__LB_MR+I)+:+S'1KHRB1
M8R64'Y#UW_!?/P/XYNOV4?A_^TAX(\*7VO+^S_\ 'OPG\4==T/3(#+<7FEZ7
M<2?:PB#[VR*=IB.RPL>U4?\ @J'_ ,%(?V3O&O\ P3'\<:/^SW\;/#/Q#\3_
M !K\#7?A'X6>%/"6L0WNI:]J6L6S64"16J,9!Y?VCS) ZKY8C97VMA2 5_VA
MO^"Z'PD^$?[7/P.^#_A;PUXDUCP3\1O"NIZ[XEUNP^%GB#4;H6QTJRO]*;3#
M9P.EZ'%T?M'DK/Y "B3RCR=*3_@JAI7P8_X*'?M ? _]H+QEJ5SX6\+:!X%F
M^&?A'PQX)NM5UJZNM1LM3N+_ ,JUT^WEN[@ 6T+,S*4A &2F[GSWQA\-[+]C
MS]L+_@F9\)/B/XGL;.W\!?"WQAX.O-9O;M8K:2^@\,:3;I'YCD+ND-K*4&<M
MM('I7H/['>B>%-<_X+E_M??$*"SM+J]M_AO\,[;3-5C"NRVES::E)*L;C^"0
MV]NQP<-Y2'L* /HOX??MW_LC?$[]EZY_;/\ "OQRT<?#2PM;F?5?$^I&2RCT
M[[.Y2>*YCN%26WF1P4,4B+)N(&TEAGFOV?O^"GG[('[2GQ'TWX2^!/%7B;2_
M$&OZ=-J/A/3_ !Q\/M8\.GQ)91*&DN=-;4[6!;Y%0[R(2S*GS%0O-?EI^TMX
M7\37W[!O[4.HZ-J$^G^$?#/_  4ZGUKXDW%II0OEM/#T5SI4MW<O:D%;B.*:
M2*Y>-@5(B8MP":^I_B9HOPZ^,O[2/[-FE_$__@KO'\2M<@^*5IXK^&OA[P#X
M$TB:XOVM;2X:>2:?3=\D&G/:O-'+,Q$7[Q,DD# !]1WO_!4?]B.#XXVG[->F
M?%BZU3QU=>/;CP?)X;TGPOJ-Q/::G;I:O.9]MOMAMHQ>VN;MB("92!(2CA?5
MOCI\</A=^S5\'_$7Q[^-?B?^Q?"?A/2Y-1\0:M]BGN?LMM&,O)Y4"/*^!_"B
MLQ["OD+_ ()!>"?"UI^T]^VY\1[?1(%UO4/VH+S3+O4@@\V2TM])TZ6&$M_=
M5[J=@/60UW?_  70_P"4/_[1/_9+M2_] % '5:+_ ,%3OV%-<\+?$[XA0_'*
M&V\*_"&ZAM/&WB^_TB[M]*CN9))8A!:W4D0COY1+"T3);&5A(4CP6=0=']G3
M_@HS^RS^T]\0I/A%X"U[Q+H_BT:2=6L_#'CWP'JWAN_U#30P7[;:0ZG;0-=0
M9907BW;=R[MNX9^,?^"O7PUC^&/["W[(4_@[Q!%X&^&7PX^,W@B[\7ZW;Z-%
M=VGANP2SE@M=2N8)1Y3VT%W) S^9E=SHQR1FNN?POX ^)/\ P4/_ &>&^(?_
M  51;XH^/?#%QK?B#P/X=\&>!=+*BPDTYH+V2^NM.W?9;.6*1%5I2J2RK&J;
MF % 'N?Q5_X+%_L#_!SQYXC\"^+?B3XBN8_!>I-IWCGQ+X?^'>MZIH?AF[7&
M^WO]2M+22UMI$) =6D_='_6;,''I'[0'[;_[+_[,OPTT'XK_ !5^*4"Z5XMN
M(+?P;%H-E/JUYXCFFC\R&/3[6Q26:]9T(<>4C#:=Q(7FOSGBMKCX5:/\=/BK
M_P $V/\ @K1\-=#\''Q]XGUCXB? +]H?P/;M:V&N//)_:<$LTLMOJ%G;32(V
MV-XW4I("I.23S?BOXU^._CG^U/\ L*?MD^,_'5C^S?X9\:_ #6-/\'W]UX=L
M[G2?#_B2X%L[640O0L%JMW8H!;,VUWCC$:YR10!^G/[.O[<7[-?[4.D>)=0^
M&?C:[M+SP5(B>-O#_B_0;S0=5\/%XS*AO;+48H9[=&1699&01N$8JQVMCR[2
M/^"T_P#P3ZUG5=):W^(OBJ#PUKVK1:7HGQ(O_AAKUMX4OKR2411Q1:U+9+9,
M&D(59?-\ICC#G(S\[V.M?"_X;_M*_M%?M7R_M8W7[2WC[X<_LM7ECXU\#Z/X
M&L8-$O+));B_M+&ZN+)'@DO6,5U&('W2""Z<["N!7S!_P4@^*GQ5\2_\$*[O
MXJ?$+_@IMX/O(/'_ (!TJ7PM\!OA)\/-$M]*@3-O<?V;;$B>^6&PB0L\RR1>
M4MH<A.%H _5O]J'_ (*7?L7_ +''BRY^'WQ^^+<NE^(X=!LM7M_#MEX>O[Z\
MO[>[NY[2V6UCMH'^TS236TX$$9:15B>1E6,%ZPOCI_P5O_8<_9V\8'P#\1/'
M_B&;6+30;;6_$5AX:\ :QK#^&M.N$\R*YU3[#:RC3E9/FVS['V_-MQS7DW_"
M'>%O$_\ P<@6?B_7-'@O+_0OV*[:?1KF= QM)I?%%W$\L>?NN8GDCW#G9*ZY
MPQ!YS_@G1\=?@9^S-\>/VV_"7[6'Q-\.^$?&,'[0FJ>+-4F\5ZE%:R77A&YT
MZS.DW*&8@S6R01RQ@+N",&'!?! .]_:^_P""F'AWX#_M6?LO:MI?QOT6'X)_
M%+PIXSUGQ)K%K:)>QZM%:6&G2Z4UJ\2/,[/+=[8XX 7G:5$"NQ5:]S_95_;O
M_9K_ &RKSQ+H7P4\4ZJ-=\&W$$/BOPKXI\+7^AZOI1G4O \UEJ$,,RQRHI9)
M-NUL$ Y4@?#&AV'[,_Q(_;-_X)H>)_V??@;J'A#X>/X2^)^M> _"?B73A#<:
M="^F6$D$IB,LH3=YAFC^=L"1&&T@ >Y>#(8K3_@X<\>BUC6/[5^R'X=FN=@Q
MYLB^)-40,WJ0H"Y]!B@#ZJ^./QT^$7[-7PKUCXW?'?Q_I_ACPIH-NLVK:UJ<
MA6*$,ZHB@ %G=W941%!9W=54%B ?)?@I_P %1?V1_CI\8-)^ VAZKXT\.>*O
M$=I<77A+2_B%\,=<\-GQ#! GF3/8/J=I EULC_>%$)<)EMN 2.5_X+,_M%7O
M[-/['MGXOTOP!X,U>\UGXC^&]!LM9^(VEK>:#X4GN]0CCCUV^C)'[NT;$BMN
M3;)Y9W#O\@_M1ZQ\0O#/_!0+]C7P+\2_^"EI^-FOR?&Z*^N-"TGP5HFG66C0
MR:1J$:W#2:?&T\/G[G6**>=Q,L<S*'\DLH!]I_$__@L%^P)\*=?\1^$-7^*V
MM:MKG@_Q'>:+XJT+PKX UK5KW2I[2&WFN99H;2TD=+:..ZA)NL>0Q8JKLZ,J
M][XU_;T_9#\ ?LN:?^VAXC^.6DCX::O:6L^B^);)9;H:G]I8+!#;00HTT\[L
M=H@1&EW!@5!5@/GG_@D#X7\/VG[1G[;?C6WTB!-5O_VJ+ZRO+]8P)9;>#2--
MDAB9NI5'N9V [&5O4U\1?LVZUIGPW_8X_P""?'QE^*\\%K\)_!W[47CV'Q7>
MWI"V.DWUQJ_B*UT6[N&/R0Q17+[1*^$C+KR,B@#[9TK_ (*IZ5\=?^"E/P&_
M9Q_9_P#%^JV7A_Q-X7\9W?Q)\&^+_ UWHVLVT]G;Z?+ILDEOJ-O%=01-YUR4
MD0>7-M8!F,9"_;VNZ[HGA?1+SQ-XEUBUT_3M.M9+K4+^]G6*&V@C4O)+([$*
MB*H+%B0  2:_/KXV?&OX#_%?_@X#_9DT+X4>,=&U_6_#OPP\>)XHOM$N([E+
M=)[>Q>TMI)XR5\P!)Y/*)W(LRN0!*I;UW_@NOX/^*?CW_@D-\??"OP9L[NYU
MZX\!3LEK8*S33VD<L<EY&BKRQ:U2==HR6S@ YQ0!XQ^VU_P70^"C?LWP>)?V
M+?BMJUIXEU7QSX:LO"NL>)/AQJ-EIWB73[C7+*UOFTRXU*TCMM0 MY93F!G9
M5S*HVKO'U9^TE_P4*_9A_99\>Z;\(_B'XA\0:MXSU;3'U.S\%> _!6I^(]7&
MGJ^QKV2TTRWGDAMPP*^;(%5BK!2Q! ^(O^"PG[6O[$7Q7_X)B_"?0O@C\1O"
MNK)XE^(/P_N_AYH>B7D-Q/8VL.KV!:0PQDM:I# 6MW9@H1YEA.&D"FKX/LOB
M-X+_ ."UW[5^C^)OVZK#X*:_XNL?".K^#3KWAC2[I?$OAV#2S 39RZ@1A+:Y
M6X26.,XWN7(/4 'W-HO_  4<_8L\1^"_AQ\1-#^.=I=:)\6/%X\*^!=1ATJ]
M,=YK9$I_LZ;]SFQN<P2KY5T(6#QE"-WRUWGB[]H'X0>!?B]X9^ _BKQBEKXL
M\7Z5J>IZ#I0LYY/.L]/$)O+B25$,=O'']HA&Z9D#-(%7<V17YGC]CWP3^T=_
MP35_:>\4_LB_M0:O\5/%D_QCNOB'X4\8+X4BTVR_X3G1%M9VETGR%$-S%/):
M" W$):-Y))<,2&(S-/\ B%\0/^"M_P"RQ^UC_P %%/V>]&OS<:K^SI'\-/A)
MI]M&XN6?^R1JVOPPKC<TLE]>QV(9?O/IJX)P, 'VQX+_ ."Q'[ /C[QMI?A/
MPY\6-7;3M>U[^P_#GCJZ\"ZO;^%M8U/S#&+.TUN6U6PGE9P47;,5D;Y4+$@&
M2R_:3^+<W_!8_4_V/Y-=@/@2V_9FL?&,.F?88O,&KR^(;NR>;SMOF%3!$B^7
MG:",XR2:^!-6;X#?&G_@CYX)\ ?$;_@L':K\,/%/A+PYX>T[P'X2^&FC7&MP
MWJM:);Z7:VML&O&O8+A(P51#*AA9SC!-?1?Q/\-_$+4_^"T/Q$\(?#[79F\5
MW'_!/6&ST34W812'46\1ZFD,Q(X1O-*MGH#0![%KG_!:'_@G1X=\?7/@G5/C
M??+8V/B+^P-1\<Q>#-6D\+6>K>8(_L4NMK;'3XY Y"DF;8K<,P/%>@_M(_\
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M9U&Q\/W\EK"T]U!#JUQ;I9230QHYDC64LA1T(#JRCX._;1\2^$_B_P#M._\
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MNXFX:.6*0%)%/=6!!KA_ '[&G[('PGT>Q\._"S]E/X;>&M/TS7H]<TVQ\/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KXC^*_
M[(?[1'B7XI>)?$>B?#WS[+4/$%Y<VDW]K6B^9%).[(V&E!&5(." 1WK[<HKY
M;BGA'+>+L/3HXR<XJ#;7(XIW:MK>,CFQ.%IXI)2;T['P'_PQ1^TW_P!$S_\
M*S9?_'JZ#X4?LA_M$>&OBEX:\1ZW\/?(LM/\06=S=S?VM:-Y<4<Z,[864DX4
M$X )/:OMRBOC\/X.<,8;$0K1K5KQ::O*%KIW_P"?9S1RO#QDFF]/3_(****_
M63T@HHHH \K_ &QOV0OA?^W!\&#\"OB_J6M6FC'Q!I>L>=H-W'#<?:+"\BNX
M1NDCD789(E##;DJ2 0>0S]LW]CGX4_MR_!4_!+XM7^LZ=;P:]IVMZ-KWAJ[C
MM]2T?4K&Y2XM[NUEDCD6.160KDHV4D<8YS7J]% 'SM^TQ_P3:^%W[1'QFTW]
MI/PU\9OB3\*OB38:%_8ESXZ^%7B"WL+S5=,WF1;.]CN;:XMKF-9"SIOA+(Q^
M5A@ 5O#W_!*/]CW2_P!EOQA^R?XG\.:YXITCXA:L=8\>>)O%'B&:YU[7=7WQ
MNFIS7X*R+<QO#"T31[%B,2[%49!^DJ* /E3P%_P2;^'>C_$KP=\2/C7^UC\<
MOC$/A[K*:QX(T#XJ>-+:\T[2=3C1HX;[R[6SMVNKB)7<1RW+S,A<L/F.ZCXH
M?\$E?A1XP^,/BWXS?"#]I?XT_!V\^(4ZW/Q!TCX2^,X-/T_Q!=A!&UY+#<6L
M_D731JJO/:M!(V-Q8MEJ^JZ* /F7QW_P29_90\0_!3X8_!;X8_\ "3_#+_A3
M-])>?"_Q7\/-;%KK&@SS(Z73I/<1SK/]I663SQ<)*)B[%P2<T[X0?\$M/@M\
M*?VFO#_[9.J_%WXD^-/B=HFAZGI%UXN\:^(+>ZGU:SO/(_<3I%;11110&#=#
M%:I!$C3SN4=I68_3%% 'CW[/?[#GP)_9U_97NOV-]#T^]\0^!M0?7/[3L/%4
ML=R][%JUY=7=Y!*8XXU:-FNYD"[1A, DG+'R?X,_\$;O@%\(_&?@;6=7^//Q
MA\=>&OA;J"7_ ,+OAQX^\:1WV@^%;J)&CMIK>);:.:9[:-V2 W4T_D@_)@@$
M?7-% 'F?[.G[*7PV_9AUKXDZ[\/-1U>XF^*?Q'O/&WB,:K=1R+%J-S;6UO(D
M 2--D(2TB(5M[ EB6.0 ?L>_LI?#;]B3]GG0_P!F?X1:CJ]WX?\ #]SJ$]E/
MKMU'-=,UY?W%]+O>..-2!+<R!<*,*%!R02?3** /GC]H;_@G)\/_ (Y?M 6O
M[4_@OX[_ !-^%/Q!3PTOA[5?$GPPUNSMVUG2TE::*VO(+ZTNH)1'))(R2"-9
M5WD!\  <MX6_X(V_LG^#OAW\<_AKHWB/QT]I^T/X;M=)^(]]?^(TN[VX>*WN
M8)+]+B>%W-W/]KEDEDE,BE]NU$4;*^L** /'OCO^Q+\(_P!H?]GSPW^S7XYU
M778- \+:OH&HZ=/IMY%'=/+H]S!<6HD=XF5E9[= X"@L"P!7((X_X_?\$ROA
MC\:/CW=_M-^!/CQ\5/A)XUUK1(-'\7ZQ\)_$UOIY\364!;[/'?1W%M<([Q!W
M6.>,1SHK%1( % ^D:* /&?V)/V$/@1_P3_\  OB?X;_L]QZS'H_BKQI<>)[Z
MWUK4OM;Q7D]M:V\@25E$CJ5M(W+2M)(SO(S2,6X3]L+]AGX3_MFVWA35/%_B
MCQ5X2\6> M8DU/P)\0? 6K)8ZWH%Q+'Y4_D321RQM'-%^[EAECDCD4#<I*J1
M[/10!\V_LT_\$OO@C^S/^T3J/[6.F_$[XB>,/B)KO@V3PWXE\4^._$45]<:O
M;M=0W"RR[((UC>/R(HHTA$4"1J0L09F8Y$/_  1__98LOV0_AI^R#HWB/QUI
MEM\';HW?PT\?Z/XD%GXFT&Z+3;IX;R&)4)=)Y(WC:)HG0@,C8!'U310!\Z?L
M^_\ !-;X9?!7XSO^T9\0?CA\3?B_XZC\.3:#I7B3XL^(+:]?2=-F='GM[6WM
M+6VMHO-:./S)/*,CA I?!(/ >&/^"'_[+OA>\TKPG#\7_BU>?"G0O%">(-$^
M >H>,HY/!UE>)<_:HE6V^SBY>WCN?WR6LER\ < F,CBOLJB@#YM_:"_X)D?#
M/XU?'F[_ &G/A]\?/BK\'_'6L:)!I'BO7OA+XEMK$^([.#=]G2^AN[6YAE>$
M.ZQSJBS(K;1)M  [GX'_ +$O[.O[/O[,US^R5X!\&22>#]3M+^'Q!'J][)=W
M>N27V_[;<WMQ(3)<3SF1R\C')W8&%"J/6:* /!?V/_\ @F]^S)^Q?^QRW[#/
MP_T._P#$'@6[AU&'6X_&4\=Y<ZS'>EQ.ETR1QI(IB80 !% BC1><9/E_@[_@
MB1^SSX=@\.^!?%G[1'QN\:?#+PAJEO?>&/@QXS\>I>>&;%K:19+.%HQ;)=75
MO;NB&*"YN)HE\M05( %?95% 'F?A#]E/X;>"OVK/&G[86D:CJ[^*?'7A?2=!
MUFVGNHS91VNG/</ T48C#JY-U)N+.P.%P%P<_+_P1^"UW^V3_P %8K;_ (*3
M^,OV3/%_PZTWX7?"R;P;X4N_B+ID5CJNN:I=7<SSW,=LDLA6UMK:2:%)7*^:
MVH2[<K&#7W910 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *_.[XV?\EF\7?\
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M1F,,<:-Y$<<*1])"2P^_Z" P*L,@]0: /P\_91T#Q]^Q5^R#X6_;7\!>)O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>"^,?^
M1NU7_L)3_P#HQJ]ZK O/AAX&U"\EO[O0]\L\C22O]IE&YB<DX#8')KP\\RRO
MF=*$:32L[ZW_ $3 \2K2\'?\C=I7_82@_P#1BUZO_P *E^'W_0O_ /DW+_\
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M7]6DU779-*TV*W;4;^1$1[J<QJ/.F98XU,CY8B-03A10!^6_[6/QJT?XY_\
M!2_]DK]L[P+^U?:_#?X7^/\ X(:Y:_#+XB:IH5E>V=IX@NI;>>6RE^VGR+2Z
MGLQY0W$2%[>2$9.X5[?^QEX+^''B+_@IQ\1OBA9_M[WGQD^(6B_!RQ\,^,;;
M1/!ME9Z-96\FHR75D)[NQ!@>_0K<@1,WF"&<D@*!CZWU/]F']FK6OA,_P$UG
M]GGP-=^!9)I)9/!=SX2LY-):1Y6F=S9M&82S2N\A.W)=F8\DFM+X2?!/X,_
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MOVQ?"'[5GQ2\.>#?&.C?M-^*?$OBH^*]4AM)KC0;Q()M+OU$K!GM6LU5(\9
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>1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>biib-20250930_g2.jpg
<TEXT>
begin 644 biib-20250930_g2.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[@ .061O8F4 90     !_]L 0P " 0$!
M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D*
M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\  $0@
MM@)8 P$B  (1 0,1 ?_$ !\   $% 0$! 0$!           ! @,$!08'" D*
M"__$ +40  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-180<B<10R@9&A
M""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H
MJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V
M]_CY^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'" D*"__$ +41  (!
M @0$ P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P
M%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E
M9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V
MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#
M 0 "$0,1 #\ _?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BN%_:>_:!\$?LH_L[>-OVE/B0
M[C1/ _AF\UG4(XC^\G2")G$*>LDC (H[LX%?*?[5'[4/[:?[,O[/'[)>J>,/
M&FGP>//BE^TEX,\,?%&*'1+<P16&KO=37FEP*R'8L $=ND_^N*P!V;>[$@'W
M-17SU\;?^"IG[$_P"^(WB+X+^-OB9JMYXW\+R6*:IX*\->"]6U;56^UVQNH6
M@M[2VD:Y00KODDBW)#N02LC.@;TW]G/]I+X)?M:_"+2_CM^SUX^MO$GA?5_,
M6TU&WADB99(Y&CEAEAF5)8)4=65XI%5U(((% '<45Y3^T?\ MN?LO_LD:WX>
M\-_M"?%%/#U_XKM=0G\-VC:3>73ZB+(0>?'%]GADS-FYMTCA_P!9,\JI$LCG
M;7F>D_\ !8[]@O7? NI>+]'\?>)[C4M(U]M%U'P%%\.-:/BJ"^6'SS&VB?9/
MMP7R?WIE\GR@O)<8( !]145\M?'3]NOX.?$[]@NR_:Y_9J_;3TOP5X7U;Q)H
M]I9?$67P+<:TL3RZM!926$NG%!-%-+*YM6\Q%:!I-[ !":NZ7^TE\6[K_@L9
MK?[(,VNP'P)9?LTZ9XPM],^PQ>8NK3>(+ZRDF\[;YA4P01KLSM!&<9)- 'TQ
M17Y]?LE_MU?&;XS?\$U/V7/VC_C5^UEIO@CQ7\2/C!I^C:YJ+?#T:BGBP2:O
MJ%LNA1Q6Z!-/>YC@C07N L)C+$_-7T;^TO\ \%)_V2?V4/B#;_"+XF^+]=U'
MQ?/I)U:7PIX(\%:IXAU&STT,5-]<P:;;SM;6^00))0H;:=N[!P >\45XO=_\
M%$/V+;/]F_PW^UY)\?\ 2)/AMXLU>QTO0O%MM#/-;2WEW="UABD"1E[<^>?+
MD,JH(65O-,>UL8?[/_\ P5(_8I_::^,,7P)^%?Q,U,^)+_39M2\.VVO^#M4T
MF'Q%918\VZTR>]MHHM0B7():!G^7YQE/FH ^A**^9/C)_P %??V$O@9\0?$?
MP[\8_$#Q)>R^"K@6_CS6?"WPZUO6=)\+R[ YCU"_L;26WM756!=7?=&#\X6M
M#]K/]K'4/@AH'PD_:M\#^-],U?X1:WXMTS2/'$]J(IK>32]<:*UTW6H+E<D+
M#>RV8.TF-X+R9B"R1D 'T71110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110!\<_\ !?B*[;_@D_\ $R^B5FM=/U#PSJ&LJH/.FV_B/3)[W./X1;1S
M%O\ 9!KFO^"Y,B2VO['\L3AE;]NCX=E64Y!&^]YK[+^*_P +_!'QM^%_B/X-
M_$O1(]2\.^*]#NM(UW3Y3A;BTN8FAECR.1E'89'(ZBN%^ _[-1\,_L\?#_X-
M_M*'0?B/JWPXEM3HGB35M%CF=Y[!GBT_5-LRMY&H"W$;/+&01,TI0A6% 'SK
M^Q9X7\/S_P#!<#]MKQK/I$#ZK:^&_AE96U^T8,L-O+I-Y)+$K=0KO#$S#N8D
MS]T5H?\ !%P".V_:KM8U"Q0_MI>/1%&HP%!>S<X';+,Q^I-?7NC_  ^\!>'O
M%NL^/M \$:18Z[XB6V7Q!K5GIL45WJ8MT9+<7$RJ'F$2,RIO)V!B%P":/"/P
M_P# 7@#^T_\ A _!&D:)_;>KS:KK/]D:;%;?;[^;'G7<WEJ/-G?:NZ5LNVT9
M)Q0!\<?MVZ-I6L?\%E/V%#JNGPW'V1/B=<6PF0,(Y5T*S"N ?XADX/8\CFH_
MV=O#>@#_ (+[_M)>)QH]L-03X'^!8UO1"/,"2SZCY@W=<-]G@SZ^2G]T5]EZ
MQ\/O 7B'Q9HWCW7_  1I%]KOAT7(\/ZU>:;%+=Z8+A!'<"WF92\'FHJJ^PC>
MJ@-D"BP^'W@+2O&FH?$C2_!&D6WB+5[."TU77X--B2]O;>$N88I9POF2)&9'
M**Q(7>V ,F@#\;/B=%%:_P#!*O\ :LL+:-8X+?\ X*/7D<$*+A8T_P"$]T@[
M5 X R3P/6OM;0_\ E8G\3?\ 9E^B?^I9JE?4US^S]\!KWPWJG@V\^"7A&72-
M;\0'7=:TJ7PW:M;7^JF=+@W\\1CVRW)FC27SF!?>BMNR :UT^'_@./QY)\4X
M_!.D+XGFTA-*E\1KIL0OWL$E:9+0W&WS# LKO((RVT,[,!DDT ?C;\ ?^4+7
M_!.O_L\3PK_ZD6L5]0_L2?$[X:_L_P#_  52_;1\)?M+>/M$\,^,?$_B3P[X
MD\.7WB;4HK/^U_"B:0D%N]M),RB6&VE2XBDVDB-R=V":^VK']G[X#:9X1T'X
M?Z;\$O"-OH/A758M4\,:)!X;M4M-'OHY'DCNK6$1[+>97D=UDC"L&=B""2:H
M_&O]E?\ 9A_:4_L__AHO]G'P'X__ +(=GTK_ (37PA9:K]B9L;C%]JB?RR<#
M)7&<4 ?C=XI\+:!\4?\ @GI\6O&%AI$5Y\(OBK_P4DTO4?A[#)!_H>KZ'/KV
MFVUQ=6ZD8-I<7$=T5  4_.<?-S]\?\%&HX[/_@HM^PK=VL2QRQ_%3Q1!'(BX
M*QOX5OPZ ]E( R.AP*^M=<^$WPK\3^%M/\#>)?AIX?U'1-(N+6?2M'OM&@FM
M;*6V96MI(HG0I&T3*K1LH!0J"N,"K/B#X?\ @+Q9KVC>*?%7@C2-3U/PY=27
M/A[4=0TV*:?2YY(VB>6WD=2T#M&S(60@E6*DX)% 'Y=IHTW@3X@?'_XC?\$U
M_P#@KE\//!.FW/Q.U[5_BO\ !#]H'P5;/86GB-R!J,KSS26]_9V<YC# [)(F
M4EHV(K9_:V_:&U#]K;_@U_O?C=)\'+/P)JOCKP!H]MHG@_1[<P6UKJ$VLVMG
M8BSCQE(9)O)E@7DB.2/D_>/WK\4OV*_V-_CEXV@^)?QK_9+^&7C#Q':JBVWB
M#Q3X#T[4+V)5QM"SSPO(H&!C!XQ6/^TI^RO-^T?XW^%6GZWK=G:> ?A_XOC\
M5ZOX=BMSYFL:E8H/[)@)&$2V@G<W3+@EI+6V4#;OH ]CB$BQ*LSAG"C<P&,G
MN:=110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MARY\1>+O#/B34=+?6=/T[4K:X:*YCLYD2XN%@A=+>XD4R6\@B9'7RUP ;O[
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MPR^(GQ$@NM$NS!(LD"7:V]G#<WT:.J,$N9Y58H-X;% 'CW_!0#]N'X,_&O\
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MESBO2G_Z;@%%%%??'YZ%%%% !1110 4444 %%%% !1110 4444 ?2W_!'O\
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M%%% !1110!]+?\$>_P#E)%\+_P#L(WO_ *;KJOZ!J_GY_P""/?\ RDB^%_\
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MDU7_ .OS_P#2(!1117Y&?L04444 %%%% !1110 4444 %%%% !1110 4444
M?CK_ ,%<O^3[?%?_ %XZ9_Z0PU\TU]+?\%<O^3[?%?\ UXZ9_P"D,-?--??8
M'_<Z?^%?D?F&9?\ (PJ_XG^84445U'$%%%% !1110 4444 %%%% !1110 44
M44 ?H'_P09_Y&/XF?]>.E?\ H=U7Z.U^<7_!!G_D8_B9_P!>.E?^AW5?H[7Q
M6<?\C"?R_)'Z'D'_ "*X?/\ -A1117F'LA1110 4444 %%%% !1110 4444
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M_P ")/\ XB@#WRBO _\ AZ1_P3Y_Z.L\*_\ @1)_\11_P](_X)\_]'6>%?\
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MT.7A7_PL=._^/T?7<'_S\C]Z_P P_L_'_P#/J7_@+_R*E%6_[*M/^AR\*_\
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MEL(S33UT>CW9[Y17@?\ P](_X)\_]'6>%?\ P(D_^(H_X>D?\$^?^CK/"O\
MX$2?_$5YQZI[Y17@?_#TC_@GS_T=9X5_\")/_B*/^'I'_!/G_HZSPK_X$2?_
M !% 'OE%>!_\/2/^"?/_ $=9X5_\")/_ (BC_AZ1_P $^?\ HZSPK_X$2?\
MQ% 'OE%>!_\ #TC_ ()\_P#1UGA7_P ")/\ XBO5?A'\9_A;\>?!R?$'X/>-
MK+Q!HLEQ) FHV#$QM(APZY('()H Z>BBB@ HHHH **** "J^JZ3I>NZ?+I&M
MZ;;WEI.FV>UNH5DCD7T96!!'L:L44 <M_P *,^"7_1'?"O\ X3UM_P#$4?\
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M'?"O_A/6W_Q%=310!RW_  HSX)?]$=\*_P#A/6W_ ,11_P *,^"7_1'?"O\
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M-% '+?\ "C/@E_T1WPK_ .$];?\ Q%'_  HSX)?]$=\*_P#A/6W_ ,174T4
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MK_X3UM_\11_PHSX)?]$=\*_^$];?_$5U-% '+?\ "C/@E_T1WPK_ .$];?\
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MLS$LQ)Z^BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#YJ_;#_X)H_#S]I?Q]_PT5\-/BMXW^$WQ@L_#<NCV/Q%^
M&WB :?<WMKR\5GJ$;Q2PWMLLNUPLD9=<?(ZG&/BC_@W%_:V_9D_: \1?%/\
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.444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>biib-20250930_g3.jpg
<TEXT>
begin 644 biib-20250930_g3.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[@ .061O8F4 90     !_]L 0P " 0$!
M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D*
M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\  $0@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*^#/B(MGX8E6X=GNK>*,V[75I;3,\A>WMKF*(^8P"J#BOLRB@#Q;XX_\$_\
M]F+X[_L\^'?V9]8\&3^'_#W@J6QN/A_=>#;^33+_ ,)75DFRTNM-N(2'MI8D
MRH(R"K,K!E8@\G\ O^"7_P *_@[\<=-_:5^)/QX^*WQD\=>'].N+'PAX@^+W
MBF&_/AR"X0)<?8;>UMK:WADE0!'F\HS,ORE]I(/TK10 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110!^87_  <J?\BI\(O^PCK7_HNSK\H*_5__ (.5/^14^$7_ &$=:_\ 1=G7
MY05_5WAC_P D5AO6?_IR1_(OBG_R7.*]*?\ Z;@%%%%??'YZ%%%% !1110 4
M444 %%%% !1110 4444 ?2W_  1[_P"4D7PO_P"PC>_^FZZK^@:OY^?^"/?_
M "DB^%__ &$;W_TW75?T#5_-_C)_R4=#_KTO_2YG]->"O_)-5_\ K\__ $B
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M_M#'_P#/V7_@3_S/HC_AZ[^WW_T7K_RUM*_^1:/^'KO[??\ T7K_ ,M;2O\
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MKYIK[[ _[G3_ ,*_(_,,R_Y&%7_$_P PHHHKJ.(**** "BBB@ HHHH ****
M"BBB@ HHHH _0/\ X(,_\C'\3/\ KQTK_P!#NJ_1VOSB_P""#/\ R,?Q,_Z\
M=*_]#NJ_1VOBLX_Y&$_E^2/T/(/^17#Y_FPHHHKS#V0HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /S"_P"#E3_D5/A%_P!A
M'6O_ $79U^4%?J__ ,'*G_(J?"+_ +".M?\ HNSK\H*_J[PQ_P"2*PWK/_TY
M(_D7Q3_Y+G%>E/\ ]-P"BBBOOC\]"BBB@ HHHH **** "BBB@ HHHH ****
M/I;_ ((]_P#*2+X7_P#81O?_ $W75?T#5_/S_P $>_\ E)%\+_\ L(WO_INN
MJ_H&K^;_ !D_Y*.A_P!>E_Z7,_IKP5_Y)JO_ -?G_P"D0"BBBOR,_8@HHHH
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M_P#Z"WA7_P +K2?_ ))H_P"%-^+_ /H+>%?_  NM)_\ DFC_ %IX8_Z#J/\
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M(D_^(H_X>D?\$^?^CK/"O_@1)_\ $4 >^45X'_P](_X)\_\ 1UGA7_P(D_\
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M_P"B.^%?_">MO_B*/^%&?!+_ *([X5_\)ZV_^(KJ:* .6_X49\$O^B.^%?\
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M%&?!+_HCOA7_ ,)ZV_\ B*ZFB@#EO^%&?!+_ *([X5_\)ZV_^(H_X49\$O\
MHCOA7_PGK;_XBNIHH Y;_A1GP2_Z([X5_P#">MO_ (BC_A1GP2_Z([X5_P#"
M>MO_ (BNIHH Y;_A1GP2_P"B.^%?_">MO_B*/^%&?!+_ *([X5_\)ZV_^(KJ
M:* .6_X49\$O^B.^%?\ PGK;_P"(H_X49\$O^B.^%?\ PGK;_P"(KJ:* .6_
MX49\$O\ HCOA7_PGK;_XBMS0/#?AWPIIXTCPOH%EIMH'+"UL+5(8PQZG:@ R
M?6KM% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!
MX3^W+^W?X._8KT7PKHD'P\UOQ[\0_B+KC:-\-/AIX7:)=0\07JIYDI#S,L=O
M;0QXDFN9"$B0@G)(!\V^&O\ P4U^,'A;]HKP?^S5_P % /V*+WX)ZG\2YI;7
MX;>([+Q[:^)=$UB_CC\QM-FNH(8&L[QDYCC>,I*594D8@ \'^U!_Q)O^#AK]
ME_6?'+A-'U/X,^-=/\%/<$!/[;4P2W2QY_Y:&SQP,$J._2E_X."E&K?!;X!>
M#?#1#>--5_:O\#CP)'$?WR7\=U)(\Z <A4@$Q9^BAN2,T >K_&K]O;]H&']H
M#Q%^S;^Q;^POJWQ7UGP3:6DOC;Q!KOC&#PMH6GRW4?FP6D-W/!.][<&+YW6&
M$QQ[E#R!B5'4?L'?MW:1^VIHGC+1-<^$NM?#SX@_#/Q2WAWXC^ ->NH;F;2+
M[RUEC:*Y@)CNK>6-P\<RX#@'Y0,$Z?[0$'QM_:%\+7'AW]A;]M3P;X&\0>&?
M$DEAXMU&;P;;^+!!,D 9M/F@%[;_ &2X7S89#O)8*5RF'!KYD_X(MR:_\)_V
M@/VFOV0_CW:)K?QN\,>,M)\2_$SXIVM_YT'C9-7LFDL+E(?+C&G>3!!Y/V)1
MY<0 *,X9FH ^DO\ @HQ^VC%_P3\_9.US]J6X^%M[XRCT75=)LGT+3[X6TDIO
MM1M[%6$ACD VO<*V-IW8QQG-8O[8W[?6H_L]?%;PE^R_\!_V?]6^+?Q@\;Z=
M=:IH_@C2]9@TRWL=)MF5)]3U&^G#)9VPD=8U;8[R2'8B$U[A\1/AOX#^+7A.
M;P+\2O"MGK6CW%Q;3SZ=?Q;XI)+>>.XA8KW*311N/=!7'?M*_'#]F/\ 9&\&
MWW[4_P"T3K^A>'+?2[#^S1XBN[-7OITDD#II]ML4SW#RR(I6VB#,[J"%)&0
M>5_LM?\ !1#QC\3OVD]1_8K_ &K_ -EW4O@Y\5[?PO\ \)+HND-XGM]<TGQ#
MI"S+!+<6.H0)%YCQ2LJR0R11R*&5@&&2O!^!_P#@IA^W7\<)_$OB']FW_@E1
M-XP\(:)XZU[PUIWB>?XWZ3IIU-]+U*XT^6<6\\/F1*TENY .?J>M3?L>?!_X
M\_M2_MIW7_!53]IWX:WOP[TZQ\#2^$O@G\,=9VC5M/TBXN$N;K5]6521!>W)
MCC5;4$^1$-KYDR:X[]F;_@D)<:A\&+R7_AZE\7]1LM0\4>(-6\%:A\$_'?\
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7 "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>biib-20250930_g4.jpg
<TEXT>
begin 644 biib-20250930_g4.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[@ .061O8F4 90     !_]L 0P " 0$!
M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D*
M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\  $0@
MY@)8 P$B  (1 0,1 ?_$ !\   $% 0$! 0$!           ! @,$!08'" D*
M"__$ +40  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-180<B<10R@9&A
M""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H
MJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V
M]_CY^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'" D*"__$ +41  (!
M @0$ P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P
M%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E
M9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V
MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#
M 0 "$0,1 #\ _?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BN%_:>_:!\$?LH_L[>-OVE/B0
M[C1/ _AF\UG4(XC^\G2")G$*>LDC (H[LX%?*?[5'[4/[:?[,O[/'[)>J>,/
M&FGP>//BE^TEX,\,?%&*'1+<P16&KO=37FEP*R'8L $=ND_^N*P!V;>[$@'W
M-17SU\;?^"IG[$_P"^(WB+X+^-OB9JMYXW\+R6*:IX*\->"]6U;56^UVQNH6
M@M[2VD:Y00KODDBW)#N02LC.@;TW]G/]I+X)?M:_"+2_CM^SUX^MO$GA?5_,
M6TU&WADB99(Y&CEAEAF5)8)4=65XI%5U(((% '<45Y3^T?\ MN?LO_LD:WX>
M\-_M"?%%/#U_XKM=0G\-VC:3>73ZB+(0>?'%]GADS-FYMTCA_P!9,\JI$LCG
M;7F>D_\ !8[]@O7? NI>+]'\?>)[C4M(U]M%U'P%%\.-:/BJ"^6'SS&VB?9/
MMP7R?WIE\GR@O)<8( !]145\M?'3]NOX.?$[]@NR_:Y_9J_;3TOP5X7U;Q)H
M]I9?$67P+<:TL3RZM!926$NG%!-%-+*YM6\Q%:!I-[ !":NZ7^TE\6[K_@L9
MK?[(,VNP'P)9?LTZ9XPM],^PQ>8NK3>(+ZRDF\[;YA4P01KLSM!&<9)- 'TQ
M17Y]?LE_MU?&;XS?\$U/V7/VC_C5^UEIO@CQ7\2/C!I^C:YJ+?#T:BGBP2:O
MJ%LNA1Q6Z!-/>YC@C07N L)C+$_-7T;^TO\ \%)_V2?V4/B#;_"+XF^+]=U'
MQ?/I)U:7PIX(\%:IXAU&STT,5-]<P:;;SM;6^00))0H;:=N[!P >\45XO=_\
M%$/V+;/]F_PW^UY)\?\ 2)/AMXLU>QTO0O%MM#/-;2WEW="UABD"1E[<^>?+
MD,JH(65O-,>UL8?[/_\ P5(_8I_::^,,7P)^%?Q,U,^)+_39M2\.VVO^#M4T
MF'Q%918\VZTR>]MHHM0B7():!G^7YQE/FH ^A**^9/C)_P %??V$O@9\0?$?
MP[\8_$#Q)>R^"K@6_CS6?"WPZUO6=)\+R[ YCU"_L;26WM756!=7?=&#\X6M
M#]K/]K'4/@AH'PD_:M\#^-],U?X1:WXMTS2/'$]J(IK>32]<:*UTW6H+E<D+
M#>RV8.TF-X+R9B"R1D 'T71110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110!\<_\ !?B*[;_@D_\ $R^B5FM=/U#PSJ&LJH/.FV_B/3)[W./X1;1S
M%O\ 9!KFO^"Y,B2VO['\L3AE;]NCX=E64Y!&^]YK[+^*_P +_!'QM^%_B/X-
M_$O1(]2\.^*]#NM(UW3Y3A;BTN8FAECR.1E'89'(ZBN%^ _[-1\,_L\?#_X-
M_M*'0?B/JWPXEM3HGB35M%CF=Y[!GBT_5-LRMY&H"W$;/+&01,TI0A6% 'SK
M^Q9X7\/S_P#!<#]MKQK/I$#ZK:^&_AE96U^T8,L-O+I-Y)+$K=0KO#$S#N8D
MS]T5H?\ !%P".V_:KM8U"Q0_MI>/1%&HP%!>S<X';+,Q^I-?7NC_  ^\!>'O
M%NL^/M \$:18Z[XB6V7Q!K5GIL45WJ8MT9+<7$RJ'F$2,RIO)V!B%P":/"/P
M_P# 7@#^T_\ A _!&D:)_;>KS:KK/]D:;%;?;[^;'G7<WEJ/-G?:NZ5LNVT9
M)Q0!\<?MVZ-I6L?\%E/V%#JNGPW'V1/B=<6PF0,(Y5T*S"N ?XADX/8\CFH_
MV=O#>@#_ (+[_M)>)QH]L-03X'^!8UO1"/,"2SZCY@W=<-]G@SZ^2G]T5]EZ
MQ\/O 7B'Q9HWCW7_  1I%]KOAT7(\/ZU>:;%+=Z8+A!'<"WF92\'FHJJ^PC>
MJ@-D"BP^'W@+2O&FH?$C2_!&D6WB+5[."TU77X--B2]O;>$N88I9POF2)&9'
M**Q(7>V ,F@#\;/B=%%:_P#!*O\ :LL+:-8X+?\ X*/7D<$*+A8T_P"$]T@[
M5 X R3P/6OM;0_\ E8G\3?\ 9E^B?^I9JE?4US^S]\!KWPWJG@V\^"7A&72-
M;\0'7=:TJ7PW:M;7^JF=+@W\\1CVRW)FC27SF!?>BMNR :UT^'_@./QY)\4X
M_!.D+XGFTA-*E\1KIL0OWL$E:9+0W&WS# LKO((RVT,[,!DDT ?C;\ ?^4+7
M_!.O_L\3PK_ZD6L5]0_L2?$[X:_L_P#_  52_;1\)?M+>/M$\,^,?$_B3P[X
MD\.7WB;4HK/^U_"B:0D%N]M),RB6&VE2XBDVDB-R=V":^VK']G[X#:9X1T'X
M?Z;\$O"-OH/A758M4\,:)!X;M4M-'OHY'DCNK6$1[+>97D=UDC"L&=B""2:H
M_&O]E?\ 9A_:4_L__AHO]G'P'X__ +(=GTK_ (37PA9:K]B9L;C%]JB?RR<#
M)7&<4 ?C=XI\+:!\4?\ @GI\6O&%AI$5Y\(OBK_P4DTO4?A[#)!_H>KZ'/KV
MFVUQ=6ZD8-I<7$=T5  4_.<?-S]\?\%&HX[/_@HM^PK=VL2QRQ_%3Q1!'(BX
M*QOX5OPZ ]E( R.AP*^M=<^$WPK\3^%M/\#>)?AIX?U'1-(N+6?2M'OM&@FM
M;*6V96MI(HG0I&T3*K1LH!0J"N,"K/B#X?\ @+Q9KVC>*?%7@C2-3U/PY=27
M/A[4=0TV*:?2YY(VB>6WD=2T#M&S(60@E6*DX)% 'Y=IHTW@3X@?'_XC?\$U
M_P#@KE\//!.FW/Q.U[5_BO\ !#]H'P5;/86GB-R!J,KSS26]_9V<YC# [)(F
M4EHV(K9_:V_:&U#]K;_@U_O?C=)\'+/P)JOCKP!H]MHG@_1[<P6UKJ$VLVMG
M8BSCQE(9)O)E@7DB.2/D_>/WK\4OV*_V-_CEXV@^)?QK_9+^&7C#Q':JBVWB
M#Q3X#T[4+V)5QM"SSPO(H&!C!XQ6/^TI^RO-^T?XW^%6GZWK=G:> ?A_XOC\
M5ZOX=BMSYFL:E8H/[)@)&$2V@G<W3+@EI+6V4#;OH ]CB$BQ*LSAG"C<P&,G
MN:=110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M#_&GBN#RM4UCPMI][J46S;LN);:.208[89CQ74TD<<<,:Q11JJ*H"JHP !T
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M%XP^*?C3[-I]I\/?"U]'-9Z;JLEL99OMNIL%BM;"%D=6NV7GY L;,ZI7GO\
MP1K_ &GOVE?VJOV;O&?B_P#:QUS0[[QAX<^-'BGPQ<OX;L/L]A#%I]YY"10
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MK.@A-*TJVTVQ6YUO7C8QLBOY89%AMRR(SSQAC@%69^RG=?MY:)^T/H]O9_\
M!0'P%^T[\*;Z&[M?'U\FD:/I.L>#;Y(B]M);_P!DGRKJ*60-$\$RB2,8<2/@
M@^2?\%M?@C\.]5_;<_92_:#_ &F]<FT[X%6FI^(O!WQ:OI+IH+&%-2M[>;38
M;^52/)L+F\LDMYW8K&R.L4AV3,#G_&3P9^Q3X _X*B_LMV__  3 T?P%H_Q'
MNM>U"+XEZ9\(H;.&RE\ C39C<R:M%8 0A5N!9BV>8!C*0(R2H  .Y^#'C_\
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M:ZGZG45^6/\ Q$N_]65?^9'_ /O=1_Q$N_\ 5E7_ )D?_P"]U=__ !#/C?\
MZ!/_ "I2_P#DSS_^(H\"_P#07_Y3J_\ R!^IU%?EC_Q$N_\ 5E7_ )D?_P"]
MU'_$2[_U95_YD?\ ^]U'_$,^-_\ H$_\J4O_ ),/^(H\"_\ 07_Y3J__ "!^
MIU%?EC_Q$N_]65?^9'_^]U'_ !$N_P#5E7_F1_\ [W4?\0SXW_Z!/_*E+_Y,
M/^(H\"_]!?\ Y3J__('ZG45^6/\ Q$N_]65?^9'_ /O=1_Q$N_\ 5E7_ )D?
M_P"]U'_$,^-_^@3_ ,J4O_DP_P"(H\"_]!?_ )3J_P#R!^IU%?EC_P 1+O\
MU95_YD?_ .]U'_$2[_U95_YD?_[W4?\ $,^-_P#H$_\ *E+_ .3#_B*/ O\
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M10Z9$M]<VL3,T<$EP%\QXD9V94+%5+$@#)K9HH **** "BBB@ HHHH ****
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M** "BBB@ HHHH **** /I;_@CW_RDB^%_P#V$;W_ --UU7] U?S\_P#!'O\
MY21?"_\ ["-[_P"FZZK^@:OYO\9/^2CH?]>E_P"ES/Z:\%?^2:K_ /7Y_P#I
M$ HHHK\C/V(**** "BBB@ HHHH **** "BBB@ HHHH **** /QU_X*Y?\GV^
M*_\ KQTS_P!(8:^::^EO^"N7_)]OBO\ Z\=,_P#2&&OFFOOL#_N=/_"OR/S#
M,O\ D85?\3_,****ZCB"BBB@ HHHH **** "BBB@ HHHH **** /T#_X(,_\
MC'\3/^O'2O\ T.ZK]':_.+_@@S_R,?Q,_P"O'2O_ $.ZK]':^*SC_D83^7Y(
M_0\@_P"17#Y_FPHHHKS#V0HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** /S"_X.5/^14^$7_81UK_ -%V=?E!7ZO_ /!RI_R*
MGPB_[".M?^B[.OR@K^KO#'_DBL-ZS_\ 3DC^1?%/_DN<5Z4__3< HHHK[X_/
M0HHHH **** "BBB@ HHHH **** "BBB@#Z6_X(]_\I(OA?\ ]A&]_P#3==5_
M0-7\_/\ P1[_ .4D7PO_ .PC>_\ INNJ_H&K^;_&3_DHZ'_7I?\ I<S^FO!7
M_DFJ_P#U^?\ Z1 ****_(S]B"BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@#\=?^"N7_)]OBO_ *\=,_\ 2&&OFFOI;_@KE_R?;XK_ .O'3/\ TAAKYIK[
M[ _[G3_PK\C\PS+_ )&%7_$_S"BBBNHX@HHHH **** "BBB@ HHHH **** "
MBBB@#] _^"#/_(Q_$S_KQTK_ -#NJ_1VOSB_X(,_\C'\3/\ KQTK_P!#NJ_1
MVOBLX_Y&$_E^2/T/(/\ D5P^?YL****\P]D**** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@#\PO^#E3_D5/A%_V$=:_P#1=G7Y
M05^K_P#P<J?\BI\(O^PCK7_HNSK\H*_J[PQ_Y(K#>L__ $Y(_D7Q3_Y+G%>E
M/_TW ****^^/ST**** "BBB@ HHHH **** "BBB@ HHHH ^EO^"/?_*2+X7_
M /81O?\ TW75?T#5_/S_ ,$>_P#E)%\+_P#L(WO_ *;KJOZ!J_F_QD_Y*.A_
MUZ7_ *7,_IKP5_Y)JO\ ]?G_ .D0"BBBOR,_8@HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH _'7_@KE_R?;XK_P"O'3/_ $AAKYIKZ6_X*Y?\GV^*_P#K
MQTS_ -(8:^::^^P/^YT_\*_(_,,R_P"1A5_Q/\PHHHKJ.(**** "BBB@ HHH
MH **** "BBB@ HHHH _0/_@@S_R,?Q,_Z\=*_P#0[JOT=K\XO^"#/_(Q_$S_
M *\=*_\ 0[JOT=KXK./^1A/Y?DC]#R#_ )%</G^;"BBBO,/9"BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _,+_@Y4_Y%3X1
M?]A'6O\ T79U^4%?J_\ \'*G_(J?"+_L(ZU_Z+LZ_*"OZN\,?^2*PWK/_P!.
M2/Y%\4_^2YQ7I3_]-P"BBBOOC\]"BBB@ HHHH **** "BBB@ HHHH **** /
MI;_@CW_RDB^%_P#V$;W_ --UU7] U?S\_P#!'O\ Y21?"_\ ["-[_P"FZZK^
M@:OYO\9/^2CH?]>E_P"ES/Z:\%?^2:K_ /7Y_P#I$ HHHK\C/V(**** "BBB
M@ HHHH **** "BBB@ HHHH **** /QU_X*Y?\GV^*_\ KQTS_P!(8:^::^EO
M^"N7_)]OBO\ Z\=,_P#2&&OFFOOL#_N=/_"OR/S#,O\ D85?\3_,****ZCB"
MBBB@ HHHH **** "BBB@ HHHH **** /T#_X(,_\C'\3/^O'2O\ T.ZK]':_
M.+_@@S_R,?Q,_P"O'2O_ $.ZK]':^*SC_D83^7Y(_0\@_P"17#Y_FPHHHKS#
MV0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQTK_ -#NJ_1VOSB_X(,_\C'\3/\ KQTK_P!#NJ_1VOBLX_Y&$_E^2/T/(/\
MD5P^?YL****\P]D**** "BBB@ HHHH **** "BBB@ HHHH ***R/'WC[P=\+
MO!VH?$'X@^(+?2M%TJW,^HZC=$B.",$ LQ /&2* ->BO _\ AZ1_P3Y_Z.L\
M*_\ @1)_\11_P](_X)\_]'6>%?\ P(D_^(H ]\HKP/\ X>D?\$^?^CK/"O\
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M-^+_ /H+>%?_  NM)_\ DFC_ %IX8_Z#J/\ X-A_\D'^J?%/_0!6_P#!4_\
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M/2/^"?/_ $=9X5_\")/_ (BC_AZ1_P $^?\ HZSPK_X$2?\ Q% 'OE%>!_\
M#TC_ ()\_P#1UGA7_P ")/\ XBC_ (>D?\$^?^CK/"O_ ($2?_$4 >^45X'_
M ,/2/^"?/_1UGA7_ ,")/_B*/^'I'_!/G_HZSPK_ .!$G_Q% 'OE%>!_\/2/
M^"?/_1UGA7_P(D_^(H_X>D?\$^?^CK/"O_@1)_\ $4 >^45X'_P](_X)\_\
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ME6G_ $.7A7_PL=._^/T?V5:?]#EX5_\ "QT[_P"/T?7<'_S\C]Z_S#^S\?\
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MJ:* .6_X49\$O^B.^%?_  GK;_XBC_A1GP2_Z([X5_\ ">MO_B*ZFB@#EO\
MA1GP2_Z([X5_\)ZV_P#B*/\ A1GP2_Z([X5_\)ZV_P#B*ZFB@#EO^%&?!+_H
MCOA7_P )ZV_^(H_X49\$O^B.^%?_  GK;_XBNIHH Y;_ (49\$O^B.^%?_">
MMO\ XBC_ (49\$O^B.^%?_">MO\ XBNIHH Y;_A1GP2_Z([X5_\ ">MO_B*/
M^%&?!+_HCOA7_P )ZV_^(KJ:* .6_P"%&?!+_HCOA7_PGK;_ .(H_P"%&?!+
M_HCOA7_PGK;_ .(KJ:* .6_X49\$O^B.^%?_  GK;_XBC_A1GP2_Z([X5_\
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M  GK;_XBNIHH Y;_ (49\$O^B.^%?_">MO\ XBC_ (49\$O^B.^%?_">MO\
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M5(8PQZG:@ R?6KM% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MGQ#I"S+!+<6.H0)%YCQ2LJR0R11R*&5@&&2O!^!_^"F'[=?QPG\2^(?V;?\
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MX@66AZ[K-C:LRS7ECHD\#RR1GRY&C2>6"650"J990?JG]F;]HGX9?M;?L_\
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MJ=ZEPNH?%/Q%!J-Q9A4V^5 T-O $C/WB""<\Y[4[]H7]DCX9?M+^./AAX_\
MB!J6LP7OPE\<IXK\,II=U'''-?+;36P6X#QN7BV3N=JE&R =V 02B@#U&BBB
D@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>biib-20250930_g5.jpg
<TEXT>
begin 644 biib-20250930_g5.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[@ .061O8F4 90     !_]L 0P " 0$!
M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D*
M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\  $0@
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MN:=110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%*,;BX>VMI)VC4KY4;P,Q_?** /KBBBB@ HHHH **** "BBB@ HHHH ****
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M*03AMJ\5\(]+TS0_^#A+XD:+HNG06=G9_LE^&(+2TM85CB@B37+]51%4 *H
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M$_PTU/6KN3XI?%/5?'WB1]:NHI3'J>H+"LT<'EQILMU6",(C;V49R[4 9O\
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M;8Z4;D Y D^RQ)O /KF@#T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **^$?\ @M_^V7^TG^R!X?\
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M_P#Y6'_$:N%O^?-;_P !A_\ +#]]:*_ K_A]9_P4U_Z.6_\ +-T7_P"0Z/\
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M17\[]%'^KW_3W_R7_@A_K5_TY_\ )O\ [4_H@HK^=^BC_5[_ *>_^2_\$/\
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M\,?^2*PWK/\ ].2/Y%\4_P#DN<5Z4_\ TW ****^^/ST**** "BBB@ HHHH
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M[_Y21?"__L(WO_INNJ_H&K^;_&3_ )*.A_UZ7_I<S^FO!7_DFJ__ %^?_I$
MHHHK\C/V(**** "BBB@ HHHH **** "BBB@ HHHH **** /QU_X*Y?\ )]OB
MO_KQTS_TAAKYIKZ6_P""N7_)]OBO_KQTS_TAAKYIK[[ _P"YT_\ "OR/S#,O
M^1A5_P 3_,****ZCB"BBB@ HHHH **** "BBB@ HHHH **** /T#_P""#/\
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MY?\ )]OBO_KQTS_TAAKYIKZ6_P""N7_)]OBO_KQTS_TAAKYIK[[ _P"YT_\
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M* /QU_X*Y?\ )]OBO_KQTS_TAAKYIKZ6_P""N7_)]OBO_KQTS_TAAKYIK[[
M_P"YT_\ "OR/S#,O^1A5_P 3_,****ZCB"BBB@ HHHH **** "BBB@ HHHH
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M7_I<S^FO!7_DFJ__ %^?_I$ HHHK\C/V(**** "BBB@ HHHH **** "BBB@
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M_KQTS_TAAKYIK[[ _P"YT_\ "OR/S#,O^1A5_P 3_,****ZCB"BBB@ HHHH
M**** "BBB@ HHHH **** /T#_P""#/\ R,?Q,_Z\=*_]#NJ_1VOSB_X(,_\
M(Q_$S_KQTK_T.ZK]':^*SC_D83^7Y(_0\@_Y%</G^;"BBBO,/9"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _,+_@Y4_P"1
M4^$7_81UK_T79U^4%?J__P '*G_(J?"+_L(ZU_Z+LZ_*"OZN\,?^2*PWK/\
M].2/Y%\4_P#DN<5Z4_\ TW ****^^/ST**** "BBB@ HHHH **** "BBB@ H
MHHH ^EO^"/?_ "DB^%__ &$;W_TW75?T#5_/S_P1[_Y21?"__L(WO_INNJ_H
M&K^;_&3_ )*.A_UZ7_I<S^FO!7_DFJ__ %^?_I$ HHHK\C/V(**** "BBB@
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M!\L_\.A_V9O^A_\ BG_X<>]_QH_X=#_LS?\ 0_\ Q3_\./>_XU]344 ?+/\
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MT/\ \4__  X][_C7U-10!\L_\.A_V9O^A_\ BG_X<>]_QH_X=#_LS?\ 0_\
MQ3_\./>_XU]344 ?+/\ PZ'_ &9O^A_^*?\ X<>]_P :/^'0_P"S-_T/_P 4
M_P#PX][_ (U]344 ?+/_  Z'_9F_Z'_XI_\ AQ[W_&C_ (=#_LS?]#_\4_\
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MB]\//CY\,]&^,7PG\0'5?#FOVGVG2-1-G-;^?%N*[O+F1)%Y!X90:Z6O$_\
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MXWO/%6JMJ5]K7BWQ=J%NL,^NZS?7+W5Y>-&A*Q!Y9"%C!.Q%12S$%C[1110
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MP7X4^&W@S2/AWX#T"VTK0] TNWT[1M+LX]D-G:01K%##&O9$154#L *U***
C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>biib-20250930_g6.jpg
<TEXT>
begin 644 biib-20250930_g6.jpg
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M&R^_9Y_9^^ FJ_$CQ/H.G07WBU;36;;3K/18IP6@CEN+@[6GD4;UB R5^;(
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M5/#MA<ZEI(F&EZA<6B//9B50LOE2$;H]Z@!MI&X  YJ_2,RHI=V  &22> *
M*6B^%_#/AN6]G\.^';"P?4KQKO47LK1(C=7# !II"H&^0@ %FR3@<\5B^./@
M?\%?B;JMMKOQ)^$'A;Q#?60 L[S7/#]M=RP '("/*C%>23P17B]U_P %*O F
MKOJ.K?!W]G?XK?$3PUI-Q+#>>,?!GA:.;39'C8K+]G>6>-[H(0P)B1AQP6S7
MJWPV_:4^"OQ8^!T7[1O@_P =6K^#VT^:\N-6NLPK:1P[O.$P?!C:,HP8'IM[
MC!(!V\=M;Q6ZV<5NBQ*@18E0!0N,;0.F,<8KF/!OP+^"7PZUVX\4?#[X.^%=
M"U.[!%WJ.C>'K:UGF!Y.^2-%9L^YKQ%?^"H7PMMM'M/B-X@^!/Q2TCX=WUQ'
M':_$S4O"J)I)BD8+'=.!,;B.W<LNV5H0#N7CFOI2SO+34;2+4-/NHYX)XUD@
MGA<,DB,,AE(X(((((ZT 252L?#7AS3-9OO$>F^'[*WU'5!$-3OX+1$FNQ$I6
M/S7 W2;%)"[B=H) Q5VO*/VB/VP?AM^SMKNC> [[P]XC\5^+_$2/)HG@OP9I
M7VW4KF%.'G*%E2*%3UDD91PV,[6P >E:-X;\.^'#=GP]H-E8?;[U[R^^QVJ1
M?:;A\;YI-H&^1L#+G).!D\5%X<\&^$/!WA]/"?A'PKINE:5$'$6F:;8QP6Z!
MV+/B- %&YF8GCDDD]:\K^!G[;OPZ^,WQ(NO@GKG@7Q=X"\;VU@;Z/PIX[T=;
M2YO+0'!N+9XY)(IT!X.U\C!XPI(3XN_ML>#OAQ\3Y_@GX'^%GC3XB^+;"QCO
M-;T;P+I<5Q_9$$@S$UU+/+%'$T@!*1[B[#G;@@D ] \#_!+X,?#'4[K6OAM\
M(_#'AZ\OAB]N]#T"VM);@9SAVB12_//)/-;-OX7\,VGB&X\6VOAVPBU6[MT@
MN]3CM$6XFB0DI&\@&YE4DX4G R<5Q7[.O[3GPR_:;\,7^O> _P"TK&\T747T
M_P 1^'?$%@;34M'NUY,%S"2=C8Y!!93SAB0<>87O_!3'X>ZG>:I>_"']G[XJ
M_$3PYHEW);:EXQ\%>%4N--,D9Q*('DFC>ZV$'<8D88&06!% 'T):>%_#.GZ]
M>>*K#P[80:IJ$<<=_J4-HBW%RD8(C620#<X4$[02<9.*Q!\#?@HOBG4/'"_!
M_P +#6]7MI+?5=8'A^V^U7L,@Q)'++LWR(PX96)!'6N8B_; ^".J?LN:A^U]
MX2UV?7/!VFZ%<ZI*^F0#[2R6ZL981'*4VS J4V.5PW4@<UYA:_\ !3=KZUCO
M;+_@GQ^TS+#-&'BEC^&<)5U(R&!%YR".<T ?1W_"(^%/^$5_X07_ (1C3O[$
M^P_8O[&^Q1_9?LVS9Y'E8V>7L^79C;CC&*BU;P%X%U_PH/ >N^"])O=#%ND
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MR*\UL?#'ASP7_P %@/#?A/PAH-GI>EZ?^S1-!8:=86ZPPV\2ZV J(B@!5 [
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M@.Q:WT?P[I<-AIT3ON811(%!9OXF.,LW<DGO0!OT444 %%%% !1110 4444
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M^$/[&VJ?!_X3^&/%]KXI\9W7B'PC;Z%+K=W:$O:V,%E%\TB-(0TDK #"X!R
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M ,MW4?\ Y'H_MS)/^@JG_P"!Q_S#^T<O_P"?T?\ P)?YGN-%>'?\/(OV+O\
MHLW_ );NH_\ R/1_P\B_8N_Z+-_Y;NH__(]']N9)_P!!5/\ \#C_ )A_:.7_
M //Z/_@2_P SW&BO#O\ AY%^Q=_T6;_RW=1_^1Z/^'D7[%W_ $6;_P MW4?_
M )'H_MS)/^@JG_X''_,/[1R__G]'_P "7^9[C17AW_#R+]B[_HLW_ENZC_\
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MZ1(]C(/^1M3^?_I+/N"BBBOWL_2 HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *\,_P""DO\ R9AXP_WM._\
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MU)RO;;6;ISIJ25H\EK\VMU':U^LMU;6[>QX51117R)XA[G_P3:_Y//\ !_\
MNZC_ .F^YK]4:_*[_@FU_P GG^#_ /=U'_TWW-?JC7[/X=_\B2I_U\?_ *3
M^\X7_P"1?+_$_P D%%%%?>GT@4444 %%%% !1110 4444 %%%% !1110!\-_
M\%F?];\.?]W5_P#VRKX?K[@_X+,_ZWX<_P"[J_\ [95\/U^"<:_\E-7_ .W?
M_2(GYOG_ /R-JGR_])05]SZQ9^+?@S\-/&\?P8^$NBW'@N#P;HMUX8UA?#D5
M^OB!I+JT^TR7,C*QF;#39C. BJ&51M#5\-VR027$:74S1Q,X$DBIN*KGD@9&
M<#MD5]C_  6^"?[1WPH\!^/I/V?/&]SXBTW4=)T^7P/KNA7R""YE-_;M*?)>
M0B"41>8'5\8 8$D4N&O:\U50A)Z/WH6<H^Y/INT_*WO**;ULS*>>\^6+V>L=
MUI+IV?RUMJ>2? ;5?!WQ0_;;\&ZOX6^'=MX=LKO7+6:XT6WG,UNDT:;Y3&&4
M;(V92PC.=H. < 8]2G\1?\%*;U+BZTO5=#%V(VN4\,C3M!.J)!]X$VIB\W(7
M!VD;_;-<K\8;27QO^V)X;T_X??$K0O#OC.30+-/$?B&QNO*LSXA$+^>(Y(05
M#/\ )'D84N2#R37(?"W]G7]J*+]H+3)+[P+XBTS4[#7H[O4]>U&VDCAM0DH>
M6YDN6^1EP&;=N._MNSSUT98K#2E0A[1WJR3E2?(G=1W44]5KIHE=I-ZFT'6I
M-TX\SO-W<'R]NB3U7;;<L?LVZ-8:=H/Q(_:;\=:#;:I=^"K.$Z=8:E; POJU
M[<&**62+ #"-@S%, 9(Z8%=1\ _BSXQ_;$\3WO[.GQYOK;7&U_2KIO"^J3V$
M,=QI&H0PO-&T3QHI$95&5H^A& ,#.=FV\7>#?C?XW^/OP2^'MW;;_'=U%J/A
M!@ZHFH7=E<&5XXR< M/\S+G&?;-<G^Q_\/\ QI\$/B==?M#?%;P?J6A:)X%T
MV\GF?6+.2V^UWDD$D$-I&) "\C-)T'3'.,C+P\*E&OAJ-*7-0;DJK7PRM.2D
MY=/X?*U?9:H=*,J=2E"#O3NU/L_>=V_^W;/RW/.OAE^TS\;_ ():'/X0^'OB
M>VT^SDO7N)X)]!LKEC,55&.^>%V'"*,9QQTY->K?M4?''XI:5\&M*^!GQ-UZ
MUU+Q/KL,&K^*"NBVEL=+@;;):V(\B)/WA 6:0GD911QNSYI^R7X)M_BU^U#X
M1\,:U$LT-YK@N;V-AQ+'"&N)%/LPC(/L:Y[XX^.;OXF?&/Q/X]O)F<ZIK=S/
M'N.=L1D(C3Z*@51[ 5Y-+&XVAD\G[63C-^SBN9V223EI>W6*]&_(XH5Z]/ M
M\[M)\J5W:V[TVZI?-G+(H9PK,%!."Q[5]._M'?&[X@_LG?$Q_@)\ 9+/P[H.
MA:?9AKB+2;>676Y)+>.5[J>25&,NYG*X!V@+C'8>#ZU\'_B+X>^&FC_&'6/#
MOD^'->N98-)U'[7"WGR1LZNOEJYD7!C<990#CCJ*]XN-6_:UT3PSX8\/ZY\!
M/#?Q,M9-(MV\)>);CPHVKM#;LH*0K<1X!,9.TI*&VD=Q@U661Q%&C5C%3IS?
M(U*,7=1=]-+-*=TTUH[);,>$56G3FES1D^5II.]M=.]I73NNR[G)?MA> [&+
MPU\/?CU9^$K;0IO'^@27&JZ78P>5 +R%D#SQITC65)(W"CCDGG)KPZO?_P!N
M/QGK<MCX'^$'C'Q(FJ^)/#&F7=UXJN8I%98=0O9A*]KE/E'DHD:;5^50 HZ8
M'@%<N>*DLSFH=HWV^+E7-=+1/FO=+J8Y@H+%R4?*_K97^=[W"ON3_@C-_JOB
M-_O:1_[>U\-U]R?\$9O]5\1O][2/_;VO3X*_Y*:A_P!O?^D2.O(/^1M3^?\
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M\#^'?'Q<Z[8>#],MM:,C;F^UI:QK-D]SO#<T =A1110 4444 %%%% !1110
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M /&Z/^)6/$'_ *"L+_X'5_\ E ?\1!R7_GW4^Z/_ ,F?45%?+O\ PT5\9/\
MH<?_ "GV_P#\;H_X:*^,G_0X_P#E/M__ (W1_P 2L>(/_05A?_ ZO_R@/^(@
MY+_S[J?='_Y,^HJ*^7?^&BOC)_T./_E/M_\ XW1_PT5\9/\ H<?_ "GV_P#\
M;H_XE8\0?^@K"_\ @=7_ .4!_P 1!R7_ )]U/NC_ /)GU%17R[_PT5\9/^AQ
M_P#*?;__ !NC_AHKXR?]#C_Y3[?_ .-T?\2L>(/_ $%87_P.K_\ * _XB#DO
M_/NI]T?_ ),^HJ*^7?\ AHKXR?\ 0X_^4^W_ /C='_#17QD_Z''_ ,I]O_\
M&Z/^)6/$'_H*PO\ X'5_^4!_Q$')?^?=3[H__)GZ*_\ !-K_ )//\'_[NH_^
MF^YK]4:_#7_@CC\9_B5XM_X*,_#[P_X@\2?:+2=-7\V'['"F[;I-XPY5 1R
M>M?N5731X!SCPYC_ &;F52G.I/\ >)TW)QY7[J3<HP=[P?2UK:]OV+P_SG"Y
MWDLZ]!-)5''WK)W48OHWW"BBBM3[D**** "BBB@ HHHH **** "BBB@ HHHH
M ^&_^"S/^M^'/^[J_P#[95\/U]P?\%F?];\.?]W5_P#VRKX?K\$XU_Y*:O\
M]N_^D1/S?/\ _D;5/E_Z2@HHHKY8\<**** "BBB@ HHHH **** "BBB@ K[D
M_P"",W^J^(W^]I'_ +>U\-U]R?\ !&;_ %7Q&_WM(_\ ;VOJ>"O^2FH?]O?^
MD2/8R#_D;4_G_P"DL^X****_>S]("BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ KYHOO&/_!6Q;V9=.^"_P $6MQ*P@:7Q3J08IGY20(N#C&:^EZ^)=>^
M"?[-%IX9A^*.L?\ !8CXSZ;H.JZG<6MCJ4OQKLH+.2XC8^;!$SVP!*$$%021
MB@#OO^$R_P""O'_1%/@;_P"%5J7_ ,:KZ.\,2^(IO#>GS>+[6U@U9[&)M4AL
M9&>".X*#S%C9L%D#[@">2,9KX4_X1']B;_I.9\4__$@--_\ C%?<?@&/3(?
MNBQ:)XIGUVR72;86FMW5XMQ+J$0B79</*H E:1<.7  8L2.M &M1110 4444
M %%%% !1110 5\J_\%LO^49WQ&_ZZ:-_Z>+*OJJOE7_@ME_RC.^(W_731O\
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M2=*WLTI6E%PLZE]8QB_=LN9VC%^ZCS.BBBOLCXH^JO\ @B=_RDQ^''^YK/\
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M%O=GMG_#8G_5.O\ RK__ &FC_AL3_JG7_E7_ /M->)T5]#_Q+_X1_P#0M_\
M*V(_^6GQ7^N7$G_/_P#\EA_\B>V?\-B?]4Z_\J__ -IH_P"&Q/\ JG7_ )5_
M_M->)T4?\2_^$?\ T+?_ "MB/_EH?ZY<2?\ /_\ \EA_\B>V?\-B?]4Z_P#*
MO_\ ::/^&Q/^J=?^5?\ ^TUXG11_Q+_X1_\ 0M_\K8C_ .6A_KEQ)_S_ /\
MR6'_ ,B>V?\ #8G_ %3K_P J_P#]IH_X;$_ZIU_Y5_\ [37B=%'_ !+_ .$?
M_0M_\K8C_P"6A_KEQ)_S_P#_ "6'_P B>V?\-B?]4Z_\J_\ ]IH_X;$_ZIU_
MY5__ +37B=%'_$O_ (1_]"W_ ,K8C_Y:'^N7$G_/_P#\EA_\B>V?\-B?]4Z_
M\J__ -IH_P"&Q/\ JG7_ )5__M->)T4?\2_^$?\ T+?_ "MB/_EH?ZY<2?\
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M0 4444 %%%% !1110 4444 ?57_!$[_E)C\./]S6?_3/>U^^5?@;_P $3O\
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M(B3)C/)R2?4-5_:;_9,_:5\*>&;C]L[P=\0(/&?A318-&_X2CX>W%DW]OV$
MQ +N.[QY<Z+\GG(6+#EE. !\QT5=7*,/52O*?,I2DI<SYES;I/\ EZ*/PI)6
M6BM-+.<31;2A#E<8Q<>5<KY=FU_-U<OB;;N]7?U7]K']I5?VB_%NCQ>&?""^
M&O!WA#0H=#\$^&4N3,;&QC).Z20@>;/(Y9Y), DD#G:#7E5%%=F%PM#!X>-&
MBK1CMU^]O5MO5MZMZLX<7BJ^-Q$J]9WE+?I\DEHDEHDM$M%H%?JC_P &T?\
MQ[_&C_?\._RU.ORNK]4?^#:/_CW^-'^_X=_EJ=?&>)G_ "1.*_[A_P#IR!]Q
MX6_\EUA/^XG_ *:F?J71117\G']>!1110 4444 %%%% !1110 4444 %%%%
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M_P DMC_^O-7_ -(D?@;1117]G'\1A1110 4444 %%%% !1110 4444 %%%%
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MK\G/UX**** "BBB@ HHHH **** "BBB@ HHHH _*[_@Y<_X^?@O_ -<_$/\
M/3:_+2OU+_X.7/\ CY^"_P#US\0_STVORTK^LO#7_DB<)_V__P"G)G\@^*'_
M "76+_[A_P#IJ 4445]T? A1110 4444 %%%% !1110 4444 %?JC_P;1_\
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M[P6_Y):M_P!?I?\ I%,****_)S]>"BBB@ HHHH **** "BBB@ HHHH ****
M/RN_X.7/^/GX+_\ 7/Q#_/3:_+2OU+_X.7/^/GX+_P#7/Q#_ #TVORTK^LO#
M7_DB<)_V_P#^G)G\@^*'_)=8O_N'_P"FH!1117W1\"%%%% !1110 4444 %%
M%% !1110 5^J/_!M'_Q[_&C_ '_#O\M3K\KJ_5'_ (-H_P#CW^-'^_X=_EJ=
M?">)G_)$XK_N'_Z<@?H'A;_R76$_[B?^FIGZET445_)Q_7@4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?*O
M_!;+_E&=\1O^NFC?^GBRKZJKY5_X+9?\HSOB-_UTT;_T\65>]PK_ ,E/@?\
MK]2_]+B?/\6?\DMC_P#KS5_](D?@;1117]G'\1A1110 4444 %%%% !1110
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M^5U?JC_P;1_\>_QH_P!_P[_+4Z^$\3/^2)Q7_</_ -.0/T#PM_Y+K"?]Q/\
MTU,_4NBBBOY./Z\"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBL_Q7XK\.>!O#EWXM\6ZO#8:;80F6\O)SA(DZ;CCMS0!H45Y1_PW/\
MLC_]%ZT'_O\ /_\ $T?\-S_LC_\ 1>M!_P"_S_\ Q- 'J]%>4?\ #<_[(_\
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M_#'/Q\_Z 6@_^%QI'_R51_PQS\?/^@%H/_A<:1_\E4?ZT\,?]!U'_P &P_\
MD@_U3XI_Z *W_@J?_P B>M_\$3O^4F/PX_W-9_\ 3/>U^^5?AE_P2Z^$WB[]
MG3]N7P5\8OC)=:#H_AS2%U,:AJ/_  E>G7'E>;IMU#'^[@G>1LR2(ORJ<9R<
M $C]=O\ AN?]D?\ Z+UH/_?Y_P#XFOY]\5L?@<QXBI5<)5C4BJ45>,E)7YYN
MUTVKZK3S/Z+\(\OQ^6\-U:6+HRIR=63M.+B[<E-7LTG:Z>ODSU>BO*/^&Y_V
M1_\ HO6@_P#?Y_\ XFC_ (;G_9'_ .B]:#_W^?\ ^)K\R/U(]7HKRC_AN?\
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M_P!!U'_P;#_Y(/\ 5/BG_H K?^"I_P#R)YA17I__  QS\?/^@%H/_A<:1_\
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M$5+10!A?\*N^&?\ T3O0O_!1#_\ $T?\*N^&?_1.]"_\%$/_ ,36[10!A?\
M"KOAG_T3O0O_  40_P#Q-'_"KOAG_P!$[T+_ ,%$/_Q-;M% &%_PJ[X9_P#1
M.]"_\%$/_P 31_PJ[X9_]$[T+_P40_\ Q-;M% &%_P *N^&?_1.]"_\ !1#_
M /$T?\*N^&?_ $3O0O\ P40__$UNT4 87_"KOAG_ -$[T+_P40__ !-'_"KO
MAG_T3O0O_!1#_P#$UNT4 87_  J[X9_]$[T+_P %$/\ \31_PJ[X9_\ 1.]"
M_P#!1#_\36[10!A?\*N^&?\ T3O0O_!1#_\ $T?\*N^&?_1.]"_\%$/_ ,36
M[10!A?\ "KOAG_T3O0O_  40_P#Q-'_"KOAG_P!$[T+_ ,%$/_Q-;M% &%_P
MJ[X9_P#1.]"_\%$/_P 31_PJ[X9_]$[T+_P40_\ Q-;M% &%_P *N^&?_1.]
M"_\ !1#_ /$T?\*N^&?_ $3O0O\ P40__$UNT4 87_"KOAG_ -$[T+_P40__
M !-'_"KOAG_T3O0O_!1#_P#$UNT4 87_  J[X9_]$[T+_P %$/\ \31_PJ[X
M9_\ 1.]"_P#!1#_\36[10!A?\*N^&?\ T3O0O_!1#_\ $T?\*N^&?_1.]"_\
M%$/_ ,36[10!A?\ "KOAG_T3O0O_  40_P#Q-'_"KOAG_P!$[T+_ ,%$/_Q-
M;M% &%_PJ[X9_P#1.]"_\%$/_P 31_PJ[X9_]$[T+_P40_\ Q-;M% &%_P *
MN^&?_1.]"_\ !1#_ /$T?\*N^&?_ $3O0O\ P40__$UNT4 87_"KOAG_ -$[
MT+_P40__ !-'_"KOAG_T3O0O_!1#_P#$UNT4 87_  J[X9_]$[T+_P %$/\
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M_P %$/\ \31_PJ[X9_\ 1.]"_P#!1#_\36[10!A?\*N^&?\ T3O0O_!1#_\
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MO_!1#_\ $UJ:5HVCZ#:#3]#TJVLK<,6$%I L: GJ=J@#-6:* "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /-OVGOV
MH? ?[+7@FS\2^*M-U'5]3UK4X],\+^%]#M_.O]:OY/N00ID?5F) 4>I*J?*9
M_P#@H!\5_A/JVCW?[8W['6J_#/PMKVH16-IXO@\7V>LVMC<2G$:WRP*K6BL>
M-_SJ"<$]2,;]HM?[7_X*X?L^Z1XB^;3['PCXCO=&BEY1K\P,LA /!98U1O;
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MW_P2_;5U7Q;\95_9M_:'^!FI?##Q[=Z<^H:'IEYK$.I6.M6R?ZPVEY"%621
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MTPVPQ$@_?R<H/O/]EO7= \2?L]^$]7\+_&>7XAV#Z0B6WC.X4"75%0E/,E
MQ("I5PPW[E;=\V: .^HHHH **** "OAW_@LU_P TW_[C'_MC7W%7P[_P6:_Y
MIO\ ]QC_ -L:^6XU_P"29K_]N_\ I<3Q\_\ ^134^7_I2/AVBBBOP0_-S[B_
MX(R_\U(_[@__ +?5]Q5\._\ !&7_ )J1_P!P?_V^K[BK][X*_P"29H?]O?\
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ML6NGVW@M=.NM:O6N;J.V:PNWC@>9\O*(E81J[EG*HNYB<D@'V#1110 4444
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MA?\ L]>)O O[77Q4_:&U'6[";3/'FEZ#:Z=90E_/MVL8)8Y#)E0N&,@*[2>
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>biib-20250930_g7.jpg
<TEXT>
begin 644 biib-20250930_g7.jpg
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M!'C?PA^V!XO_ ."<WAW1[D>#_P!H#QCIGC%;J#Y8['3@7EUZ/<.C2M9J@48
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M&8==IGC?P7\,?^"L'CN;XC^+M,T&/7/A%HSZ/+K%_';)>".\G201M(0&*MU
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MQ U^#2]$T6RDN]3U"Y)V00H,LQ !)/8  DD@ $D"OGM?^"H7@2VT"+XD:_\
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MYJE[\(?V?OBK\1/#FB7<EMJ7C'P5X52XTTR1G$H@>2:-[K80=QB1A@9!8$4
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M1HFQN0M&@)4X&1T.*V])\)>%- \.)X.T+PSI]EI$4#0QZ5:64<=LD;9W((E
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MO^._[.?B#P_KR6OP=\>37)70+_P_KR:Q'$L?E2))(YAC^61O,B= N0GS Y(
M\_\ %>O?\%0OB=X"O/@I/\!? 'A74M2L'T_4_B7'XX>[LHXW4I)<VM@(!.)"
MI8HDCX5MNXD9P >Y_L]_&GPW^T7\$O#'QP\)6TL%AXFTB*]BMIR"]NS##Q,1
MP2CAD)'!*Y%>1?MU^*M(\,^(?"O_  M3]L.Z^&/@6>*X6]TKPK))%K_B"]R@
MBC@DACDG6% 27\E=Q+J">5(]>_9^^"_AO]G;X*>&?@AX1N)9M/\ #.D164-S
M. 'N&49>5@. SN6<@< M@5XY^T+\%/CUX>_;)\-_MF_!;X>Z1X\73_ D_A>_
M\(ZGKBZ=/:;[HW OK2:1'C$A!,3AMI*< G<=H!YY^R%\=].L/VWO^%#_  L^
M.OQ%\;>!=>^'D^KK!\3++4A>:9J5O=1)F"?4;>*:6!XI#E?G 89W#I57]DSX
M<?'O]LOP1XR\2?%;]K?XB:%I^B_$37=)\+6W@O718S!8KM_W]S-L9Y@NY8HX
M21&J0DD,7.._^'OP0_:P\4?MU:%^UM\:-%T#2=*3P)J&AQ^&=(U?[4VC*T\4
ML0>8HGVF60B4NR*J(!&HW8+'M_V$O@9X]^ 'PL\0^$OB);VL=YJ7Q"US6+9;
M2Y$JFUNKII(B2.C;3R.U 'S[I_[9O[0NK_\ !/WX?PV7C*%?B5X[^*2?#:W\
M7O8H?(E-_<6YU(P_=,@@M\XZ>8V[':JO[=_[-'B[X&^ ?ASJ>C_M(>/O%>EW
M'Q@\,PZ]I?CW7/[3\V7[8#'=6\CJ'MW#@JT:'RF63[H* UU&C?\ !/OXQ7O[
M$>G_  IDUC2]%^(?A#XIW7C?P5>R3F>S2]349[BV68H,['BE96P"5+ X.W!G
M^/\ \,OV_?VO]'\(Z3XO^#OA;P%IOA3QUH^M:A81>,%U*XUE[>Z0NR.L2)!
MD9E<*VZ1W\L?* V0#[(KB-)^'GP1^ %WXT^,5O:V/A\^([H:OXTUV_U!@DKQ
M1;!+(\SE8D5!@*NU!DD $G/;U\2_M)?!?]N_XW?M$7.I?$#X"^&O'/PLT&_W
M^$/ \GQ &EV5[(C92\U*/[/*UV_ *Q,5C3IM;+$@%_X%ZKXF^-7[0OQ7_P""
MC7@GP[=:?X23X;-X:^'LEY:M%+XD%LS7+ZEY3 ,(C*BQQ,PRZ=A@BNZ_X)&:
M3IVG?\$]OAW?63^;/JMI>:AJ5TQW/<74U[.\KNW5FW';D\X4#M7<_ GQK^U1
MXEU^?P_\<_V9_#7@S08=*;['=Z/XY74R\P>-5M_(%K$$0QF0[LD#8!CYLCR;
MX8_#+]LO]A[3-3^"'[/_ ,&?#WQ(^'[ZM=7O@>:^\9+I-UX=BN)6E>SN$DA<
M7$22N[*\9WD$Y'("@&!^RW\)_ GQ)^-?[7'[*WC70#>^!+SQSIU_-I<-U+!&
MT]_:^?=*KPLK)^\AC)"D>G0XKUK]M+X_^!_@%\''^$/AC0$UOQEXMTF71/ /
MP^TN(23ZA(\1A7]T/N6L8.9)&PBJI&<D"L7X;?L^_M%_LW_LU>.=?^'EQX>\
M4_&_QQK4VOZO=WSO!IC:C<21H8H]V&%O;P B-6P6*<[=^!Y;^SE\+/V\/@1J
MFH?$?Q#^QYX8\:?$37A_Q4?Q \0?%Y#>70SD00H+#;:6R\!8(\* %R6V@@ ]
M"T76=;_X)R_L#^!/A(88_$OQ"-C;Z!X4T*&3<-3UVY9G$*G@_9XG=V9S@"*(
MG@D"O,_%/P$7]GO]IS]D[POJVM'6/$FJ>+O%>K>-/$4@^?5]7N-+1KBX/ PN
M<(B_PQQHO:OH_P 3?LY> ?VM/ GAK5OVQO@#HYU_2EN7CT>/6Y;N+37E8*PC
MGC$7F;TBB))48Z=LGPWXS_\ !)+X$:U\>?A3K_PP^!FBV_A'2=1U-_B%:OJM
MPK7,#VH6U"AI"S8FR?E(QWR* /L^BJ/AGPWHG@WPWI_A#PSIZVFFZ58Q6>GV
MJ,2L,$2!(T!))("J!R2>*O4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#&0.&.?I2VMK:RMH[.SMTBAB0)%%$@544# 4 <  <8H ?1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %<1^T1\4/&?P9^$NI?$OP-\)[[QM=Z4T4
MMQX?TJY\NZFM?,43R0C8WFR1QEG$0P7V[002*[>B@#\F_CC\0?\ @GQ\=_BW
M\9?%/@K3/MOBO5/!^@'X10>$M$N[765\3!=0\SRHX41TE6;[)YQD&,*,Y(%?
M;WB7]I[1?@-X9^&7P@_;4T+R(O&O@V.Q\5>,]66%M"75Q:QK<6-TS95/.)F(
M+@1L,C)&[;Z[X>^#O@?PQ\5_$?QHTFRE77?%.GV%EJTS2Y1HK/SO)"KCY3^_
M?<?XOE]*W?$'AWP_XLT>?P]XIT*SU/3[I-ES8ZA:I-#,O7#(X*L/8B@#X)_:
MIB_9/\%_$KX72_\ !.JZ\)6'Q9O_ !]80QZ;\*9[=8;O2,L;P:C!9'R3;!,$
MM(N1@D' <C[+\0_M&?!KPK\<M _9MU[QCY'C7Q/ITU]H>B_V?<-]IMXEE:1_
M.6,Q)@0R'#NI.W@'(SH?#_X)?!CX32SS_"SX1^&/#+W0Q<OX?T"VLC*,YPQA
M1=W//-9NM_ KPUXC_:"T/]H#6Q;37WAKP]=:;HD/]GH)()+EU,TYFSN;]VOE
MHF $$LQY,GR@'SU^T]_P4@\,M\5;_P#9/_9_^,G@?PQXDL7,/B[X@^.M<M;3
M3O#0SM=((KB1#J%X.0(US&C8\QOO!?1?V(-._8]\ :!??#K]G?\ : \->/?$
M=](^L>,-;M?%UIJFK:O<LP62]NC#(S!=SJHX"+N '+$GT36?V;/V=/$6K7.O
M>(/@%X*OKZ\G::[O;SPK:2RSR,<L[NT9+,2222<DU?\ !7P6^#GPVU*76/AU
M\)O#.@7<T!AFNM%T&WM9)(R0Q1FB125RJG!XR >U 'S]^TU<2?%/_@H_\"/@
M5>$/I/AC3]5\=:I:-RLUQ"AMK%_K',SL/K7NW[0NI>!-(^!OBS4_B?X)N_$G
MAR#0;E]<T.QL/M4UY:!#YJ+%D;SMR<9'3.1BNAD\)>%9O$\?C:7PSI[:U%9F
MTBU=K*,W26Y;<81+C>$+<[<XSSBM"@#\]=9L/^"<WPS^!<7C_P *_M>^+O'W
MA>&U2;P9\%;CXD&_L[R\ZVE@--4?:9 )?+'D3,R)CYUP#7N/[-^J>!/^";7_
M  3Q\$1_M0^)SX?ATFR4Z[<-8SW1M[^^N9;EH2EM&[$K).R$A2/EZXYKVO1_
M@!\"/#OC!OB'X?\ @GX1L?$#NSOKEGX;M8KQF.<DS+&').3DY[UM^+?!7@WQ
M_HS>'/'?A+3-;T]W5WL-7L([F%F4Y5BDBE20>AQQ0!\A_P#!0/P/X"T?]JKX
M%_M>_%FR-W\-=(ENM*\7W,MNTEM9&91-IMS<IC_CW%V$9F<;49(B>PIG_!0O
MXL?!+]H2W^&GPK_9Z\=Z#XN^)\OQ&TG4?"$WA748;V;1H89EDN;V62!F\FW$
M*MNW$!N" =A*_95YI6EZCIDFBZAIMO/9S0F&:TFA5HGC(P4*$8*D<8(QBL'P
M!\%O@Y\*)+B;X6_";PSX:>[_ ./M] T&WLS-SGYS"B[N>>: .FHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH BO89[BSEM[6[:WDDB98YT56,;$8# ,""0><$$<<U\#?%/
MXB?MZ?#?X[? [PG\8_@#;_$#Q!X=\6ZW_P (]XH\.>([&QA\7!]&O8UWPR[/
ML$J1/YDF08R(VV$D@'[^JO=:5I=]=VU_>Z;;S3V;L]G/+"K/ S*59D)&5)4E
M21C()'>@#Y:^$_P&_;"_9X_93\5:O\++/PJ/B;XH^(E[XTO?"+/NTV%+F:-I
M=(MYB56-O*C $I&P2,W0$2"O\8_VO?BC\9?@[XA^"WA#_@GU\77\5^)="N-*
M%CXF\.06VC6\L\31,\U^TWE/"NXME>7  PN<CZUHH ^7]7\7_$C_ ()G_L >
M!-+@^&EQ\2M8\.1:9H>J6>G:F]LJ-,2GF))Y,I,:RM'"@* MO0<$XKU_XW_M
M ?\ "DKC3K?_ (4G\0?%W]HI*V_P1X;^WK:["HQ,?,786W?+USM;TKK/%7@C
MPMXW73D\5:2MXFE:K#J5C')(X1+J$DQ2%5(#E&.Y0V0&56 W*I&K0!\0_P#!
M/KXN^//@CH/B;P#\0/V2/C%;7'BKXL:MK%C>+X(;[-;VE[.AB>9VD'E[1DOP
M0H!Y-1_MI_&_]ICXB?&B^_9_;]G/XSV/PEL,1Z[KOPT\-I<ZCXJRJEK:.XDF
MB6TM#DJS1EY'"E?D#''W%10!X%^R%\:/!UREC\!/AO\ L2?%/X7Z#I&EN]A-
MXJ\(6]AIR!67,?F1W,K-,Y<ME@2Y#LS9Z^._\%$/B_X\^/7PQM_A3\._V1OC
M'<7VD^/]+OY;R7P.PM9H+.[#R/%(LA+AE7*<#=D=*^WZ* /,OAG^TA>_%30_
M$.I:9^S_ /$/0+G0[#S[>S\9^'?[..IN5D*Q0'?)O;,8!X^7>O!S5[]F/XL_
M$+XW?!S3OB-\4O@EJ/P\UJ\FN$N?"FJW333VJQS.B,SM%$3O50X^0<,.O6N_
MHH ^</V,/AU\0+']I+]H;XS_ !)\(ZCIMQXF\>6VGZ%/J%LR"[TK3[;R;>6$
ML/FC;>W(X)%?1]%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M9O\ RW=._P#D>C_AY%^VC_T6;_RW=._^1Z/^(BY)_P ^ZGW1_P#DP_UHR_\
MEE]R_P#DC]4Z*_*S_AY%^VC_ -%F_P#+=T[_ .1Z^J_^"9O[2'QH_:#C\:M\
M7O&7]KG2&T[^S_\ B76UOY7F_:O,_P!1&F[/EI][.,<8R:]#*^,\KS;'0PE&
M$U*5[74;:)OI)OIV.G!Y]@\;B(T81DF[[I6T5^[/JBBBBOKCVPHHHH ****
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M*_>S]("BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MT^"T<[>);,O>Z:+2=$E!A0R,4WD!R%4G9R6&1@YQ7UM_P69_UOPY_P!W5_\
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MI\'K6WL]4U'P'#IL_B9K..:6W%FQ22W@,BL(6,LDC2,/F8",9 '//>.KN?\
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M](D;9!_R-J?S_P#26?<%%%%?O9^D!1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% 'PW_ ,%F?];\.?\ =U?_ -LJ^'Z^X/\
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M_!9G_6_#G_=U?_VRKX?K[@_X+,_ZWX<_[NK_ /ME7P_7X)QK_P E-7_[=_\
M2(GYOG__ "-JGR_])04445\L>.%%%% !1110 4444 %%%% !1110 5]R?\$9
MO]5\1O\ >TC_ -O:^&Z^Y/\ @C-_JOB-_O:1_P"WM?4\%?\ )34/^WO_ $B1
M[&0?\C:G\_\ TEGW!1117[V?I 4444 %%%% !1110 4444 %%%% !1110 44
M44 %?-%]XQ_X*V+>S+IWP7^"+6XE80-+XIU(,4S\I($7!QC-?2]?$NO?!/\
M9HM/#,/Q1UC_ (+$?&?3=!U74[BUL=2E^-=E!9R7$;'S8(F>V )0@@J"2,4
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MMO\ [N'_ !$?_J%_\G_^T/MBBOB>BC_B4K_J<_\ EM_]W#_B(_\ U"_^3_\
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M/PWIZ>,9K.35UL8AJLFG*RV[7.P>:8@_S!-^[:&YQC/-<?\ \-6?LN_]')>
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MMA!;HRR!W\K*MDC "G/J*^?/A7^RW\-?$O[2C_ ?XL?M8>"_#.CPV#3R>/\
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MGP/_ %^I?^EQ/G^+/^26Q_\ UYJ_^D2/P-HHHK^SC^(PHHHH **** "BBB@
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M_P"FIGZET445_)Q_7@4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %?*O_  6R_P"49WQ&_P"NFC?^GBRKZJKY
M5_X+9?\ *,[XC?\ 731O_3Q95[W"O_)3X'_K]2_]+B?/\6?\DMC_ /KS5_\
M2)'X&T445_9Q_$84444 %%%% !1110 4444 %%%% !1110!]5?\ !$[_ )28
M_#C_ '-9_P#3/>U^^5?@;_P1._Y28_#C_<UG_P!,][7[Y5_-?C%_R4]+_KS'
M_P!+J']/>"W_ "2U;_K]+_TBF%%%%?DY^O!1110 4444 %%%% !1110 4444
M %%%% 'Y7?\ !RY_Q\_!?_KGXA_GIM?EI7ZE_P#!RY_Q\_!?_KGXA_GIM?EI
M7]9>&O\ R1.$_P"W_P#TY,_D'Q0_Y+K%_P#</_TU ****^Z/@0HHHH ****
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M5_P1._Y28_#C_<UG_P!,][7[Y5^!O_!$[_E)C\./]S6?_3/>U^^5?S7XQ?\
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M\.>!O#EWXM\6ZO#8:;80F6\O)SA(DZ;CCMS0!H45Y1_PW/\ LC_]%ZT'_O\
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M?^"I_P#R)YA17I__  QS\?/^@%H/_A<:1_\ )5'_  QS\?/^@%H/_A<:1_\
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M_B:/^&Y_V1_^B]:#_P!_G_\ B: /5Z*\H_X;G_9'_P"B]:#_ -_G_P#B:/\
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MTYR3M3@G9I-.S37J>845Z?\ \,<_'S_H!:#_ .%QI'_R51_PQS\?/^@%H/\
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M_#'/Q\_Z 6@_^%QI'_R51_PQS\?/^@%H/_A<:1_\E4?ZT\,?]!U'_P &P_\
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M^'WQ(\"_%7PXOB[X=^)K;5M->5XEO+1B4+J<,O('(H VZ*** "BBB@ HHHH
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M_P#1.]"_\%$/_P 31_PJ[X9_]$[T+_P40_\ Q-;M% &%_P *N^&?_1.]"_\
M!1#_ /$T?\*N^&?_ $3O0O\ P40__$UNT4 87_"KOAG_ -$[T+_P40__ !-'
M_"KOAG_T3O0O_!1#_P#$UNT4 87_  J[X9_]$[T+_P %$/\ \31_PJ[X9_\
M1.]"_P#!1#_\36[10!A?\*N^&?\ T3O0O_!1#_\ $T?\*N^&?_1.]"_\%$/_
M ,36[10!A?\ "KOAG_T3O0O_  40_P#Q-'_"KOAG_P!$[T+_ ,%$/_Q-;M%
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M7X<)"MU>:['XILKG5;&S//VFXTM0'C55(9U\PL@R6 Q7N6D?LX_ _1_@_8?
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MSFT_2I/'.GW[:P)IO*D"R6N\0>66C)WCYM_'0US_ /P5F_Y)S\(_^S@O"_\
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MA_4;AXO+GMI[220-+;N,A68F2/)*G).>)\7?LO?MA_M5SZ3X._;)\>_#W3_
M>F:M;ZEJGACX<VE\\GB&2"0210W,]X1Y4 =58HBDG;C=G#+]1T4 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7C/[#/[-GBK]EG
MX0ZG\._&&NZ?J-U?>,=4UB.?32_EK%=3>8B'>JG<!P>,9Z$U[-10!XS^VK^S
M;XJ_:9\*^"-!\)Z[I]A)X8^)NC^);M]1+[9;>T:0O&FQ6^=MXQG XY(K0_;?
M^ ?B/]J']E;QA\!O".LV.GZCXBLH8;6\U+?Y$12YBE)?8K-C$9' /)%>K44
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M"+8?8+/[42R%29-X^48*XZ\]*^:_'OC[XR_M,:S^SA^RU\9CKG@^3QYX>O\
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MP_L9_P#"0_#KX(_"WX3ZG::=I/PC^(OA_6@FIN[/<6&FPS1&-2BG=,PD4Y;
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(H **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>biib-20250930_g8.jpg
<TEXT>
begin 644 biib-20250930_g8.jpg
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M-.T;Q1H_@V31+W5-,EMA=>5870E1?,4?/&SJKKU1CAL&O"/&_P"R=\6_B-\
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M%:^%;VS;QWXTLKO3=1%U=+Y+6]G9W1,C)Y1<O*P1<A0N[K7COPD^#G@[X,_
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MM)4&G78>UN"T$#1S*70@!7C<*Q##;BO4)?VK?C=\2_''B[1/V6?@%I'BG1O
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MH [FBN'^-O[0OPX^ 5EI<GC:;4;G4->O39^']!T+2IK[4-4G5"[)!!"K,VU
M69CA%'+,,C.;\&_VI_AW\9_&.J?#:ST/Q)X=\4:/8QWUYX;\7Z#+I]V;.1RB
M7,8?*RQ%U*[D9L,,'!(R >E45\ZV?_!43]EK4_"UG\0]&/BZ_P#"TJ1'5?%M
MCX-O)=,T0R$!5O;A4VPMAE++\Q0.I;;N%>B_&G]J'X8?!"?0M(UF/5]<UKQ.
MTG_".^'/">E2:C?ZA'&H>2:.*+I$BD%I&(49'.2!0!Z+17SG^R[^U'JOQ^_:
MV^*GA73->U$^&?#OAWP\]AH&K:,;*ZTF^F^V"[CFCDC69)"8H\JY(P 5^5@3
MZ/\ M/ZQ^T#IOPTCT[]F?P_:77BC5]9M-.35+_RVM]"MII-LVI21.ZF<0IDB
M-<DLRDJ5#"@#T6BODGXO3?M)_L2:GX%^)%W^U/KGQ&TGQ'X[TSPYXG\,>+-(
ML(VG-](8Q<6#VL,3PR1MEA"2ZLN<GY:Z/Q!XK^+W[4O[4GC/X$_#KXR:OX!\
M'?#*SL(O$&J^&+:U;4M8U:\B,ZPI+<PS)#!#%LW;4W,[XS@< 'TG17S1\'OC
MO^T#X-\1_%G]F?QQ&/B%XY^'NB0ZUX(OUCM[";Q387,4AMXYP-D4<T<\9ADD
M4*K JP7.<\S\2/ G[<?PG_9TUC]JGQ-^V=>)XT\/^')M?U;P=<>'; >&PL,)
MGDTU8Q%YXX4Q"?SMY.&XS0!]>T5YJ_[3'A+P_P#LJZ;^U/\ $"RGTO3[SPC9
M:S-IBKYEP);F"-X[.->#),TDBQ*O5G8#O7DO["WQ:_:@\9?M&_%[P!^TIXEB
MDET?3?#>J:9X<MK2%(O#_P#:,5Y.]DLB('G,:K#&SNS;FB9A@-0!]24444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 (VX*2@!.. 3@9KXA\57__  2U
M_:OGU;7_ -K7PAX5^&OQ,T6\EM_$EAK_ (C71=:LIX6*QS+<(\)O$*"-XY5\
MQ2K*/:OM^L/Q/\,OAOXWO8-2\:?#[0]7N+88MKC5-)AN'B&<_*TBDKSSQ0!^
M;^JCXL>+OV&M \:ZQ\2_&.H?#OP'^TQ!J&@>.+RU%QJI\%V[-%!JC+/$XN%A
MFE\P&2-@4C!*!4 KW/1+3X'_ !+_ &E_A?96W[>7C7XM:_I&HW&NZ%9:(=!N
M;/3HUMG22>^FL+*-H(9$D,0#."[.H )Y'V,+>W%O]D$">5LV>5M&W;C&,=,8
M[5F>%O 7@7P,D\?@GP7I.CK=/ON5TK3HK<3-_>;RU&X\GD^M 'R/^QS^TQ^S
MQ\%_'/[16B?%KXC:)X5OHOC?KNI//KETEJ+ZT\NW3]RSX^T,C(P:--S+YB<?
MO%SY=X'TR]^&_P"PQ^SWXX\;6CZ!X>A_:7M?$$0U0>1'I&C75WJ)MI)BV%AC
M(GB?)PH$RYQFOL?X/_LF^#?AT_C4^,1IGBM?%GQ+U#Q?:IJ>@QXTR2Z2!?)3
M>TFYD\G/FC83N^Z,<^GZQHNC>(=+FT/7])MKZRN8]EQ9WD"RQ2K_ '61@0P]
MB* /B/X[ZIX?7_@HIHWQAU7]JV[\ ^$/%_PF&D^$/'^A7.ERZ?<WD&H22W&G
MM<WMO<0(S I*,;2Q3;N)&VL[Q1HWPGUCX%_M5?%#X<?M >,?B3?3?#&72/$'
MBO58-.&DWDL%A<O%':2V-O#'<20K(5D8!@OF*,FOMV;X<_#VX\*)X$N/ FC/
MH<8 CT9]+B-H@R6XA*[!R2>G4U:MO"OA>S\._P#"(6GANPBTGR&@_LN.S1;?
MRCG*>6!MVG)R,8YH ^4/VHM(TN3]E[]F;2)-/A:U7XL_#R);<QC8$W(NW'3&
MTD8]#BNT^+H"_P#!3+X,NH +?#[Q6K$=2 ]@0#^->_W7A_0;ZVMK*]T2TFAL
MIHY;.*6V5E@DC_U;H",*R_PD8([4Z;1](N-3@UNXTNVDO+:-X[:[>!3+$CXW
M*KD94' R ><#TH ^#OV._P!I/]F_X7?\$PM2\ _$SQ9I.DZS8Z5KRZEX5U*5
M(;_4_MES=RVQA@?#W*W$4T01D#*V=H/RG'+67PT\<_ KQE^S1J_Q[^-NN_##
M3(/@I)X;7Q3;1V6S1]:+Q3_8KF2_MYH;??;_ +H,54EK;:&P&!_0NX^'G@"\
MU#3]6N_ VCRW6D($TFYDTR)I+)1T6)BN8P/1<5=US0=#\3:5-H?B31K34+*X
M7;<6=];K+%*,YPR."&&?44 ?'7@K1OA)XD\>?&'XD>"?VF?&7Q4UO2O@_<:%
MK/B*[ATMM%2-O.N(K5)["VA2:ZC(=B!NV)/@G. OM7_!.S1]+T+]A+X1V6D6
M,=O%)\/],N'CB7 ,LUNDLK_5I'=B>Y8FO5]'\*>%O#VACPQH'AK3['3%1D73
MK.S2* *WWAY:@+@Y.1CG-6=/T^PTFQATO2K&&VMK>)8[>WMX@D<2 8"JHX4
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M&$@@B0)&@]@J@?A537_AA\-/%>H'5_%'P\T+4KLH%-U?Z3#-(5'0;G4G ]*
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M-\(>)M"'A?Q)X4TW4-,4*!IU]8QRP +]T>6P*\=N.* /F/\ 9$^)/@3XM?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MX@:O-XF7PCI*ZGX&NM;N--L9+:-[MX+M!&8OMI0SSJ6#R1Q,Q!"N1C!_9?\
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M_-7O]0:9IFFZ+IT&D:-I\%I:6L2Q6UK;1+''#&HPJ*J@!5 & !P*GH ****
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M\;_,_I_AC_DG<+_U[C^04445Y)[H4444 %%%% !1110 4444 %%%% !1110
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M%L]OIZCPIX2TBZ^RVVIW[RJN+RY1O.CA1"SA(5WR,%7?&.3ZO^T_\'/@]/\
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M*** "BBB@ HHHH **** "BBB@ HHHH **** "OY]O^#BW_E)9JO_ &*.D_\
MHIJ_H)K^?;_@XM_Y26:K_P!BCI/_ **:OK^"?^1P_P# _P T?GWB5_R3L?\
MKY'\I'PI1117ZR?@@4444 2W=]>W[I)?7DLS1Q)$C2R%BJ* JJ,]    .@ Q
M45%% ;A1110 4444 %%%% !1110!_05_P;J?\HTM(_[&W5O_ $:M?=5?"O\
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M (B9QO\ ]!?_ )3I?_('/]1PO\OXO_,\W_X9\_ZF[_R0_P#ME'_#/G_4W?\
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M\PHHHKZ0^8"BBB@ HHHH **** "BBB@ HHHH *_<W_@@I_RCVTO_ +&C5/\
MT:M?AE7[F_\ !!3_ )1[:7_V-&J?^C5K\N\7?^25C_U]C^4C]7\&_P#DK9?]
M>I?G$^SZ***_F0_J4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MTU=7CHG:Y\H_'[X*ZK\ _B/+X#U'7K/5H)=.L]3TC6+!76*_L+NWCN;:=5D
M="T4J$HP!5LCG&3Q=?0/_!2GPS#I7[15MXR;5]<>[\:>$-+\1:AHOB61'O\
MP_+<P\:9*41 !$B1^6NQ-L31+M&*^?J]W*<3/%Y91K3=Y2BFWYVU_'MIVT/
MS?#0P>:5J,%:,9-);Z7T_#OJMGJ%%%%>@><?N;_P04_Y1[:7_P!C1JG_ *-6
MOL^OC#_@@I_RCVTO_L:-4_\ 1JU]GU_''&/_ "56-_Z^S_-G]J\%?\DE@?\
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MQ(N?VD?'TGB*VL&L;;7W\87IO8K5FWM LYE\Q8RWS% =I/.,U+XK_:Z_:O\
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M[@U31]/LK?1[ 6NG-KEM!/'J9MXE54&T&TCD*#!DC;J<FOIB@ HHHH ****
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M6>-+._U2RM+=M-DB#>9"8X(8GC=MZ%DE4,-J\ 'GVR@ HHHH **** "BBB@
MHHHH *_#+_@O7_RD)U3_ +%?2_\ T4U?N;7X9?\ !>O_ )2$ZI_V*^E_^BFK
M]2\(O^2JE_UZE^<3\H\8_P#DD8_]?8?E(^,****_IH_EH**** "BBB@ HHHH
M **** "BBB@ HHHH _<W_@@I_P H]M+_ .QHU3_T:M?9]?&'_!!3_E'MI?\
MV-&J?^C5K[/K^..,?^2JQO\ U]G^;/[5X*_Y)+ _]>H?D@HHHKYH^G"BBB@
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MPB_Y*J7_ %ZE^<3\H\8_^21C_P!?8?E(^,****_IH_EH**** "BBB@ HHHH
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MR]TB8:O@2?,W]FD@>5T'F?\ /4[?XJ]DKYX_8$^(OP9^(%CXH?X0?MG^+?C
MEK+9B_E\5%<Z46$VQ8]MI;\2;6)^]_JAT[_0] !1110 4444 %%%% !1110
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MT&@ HHHH **** "BBB@ HHHH *_#+_@O7_RD)U3_ +%?2_\ T4U?N;7XY_\
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M /\ \F9?_BJ/^(BY)_S[J?='_P"3#_B'F=?\_*?WR_\ D#R*BO7?^%7^!O\
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M_P"*KUVBO5_XB+G?_/NG]TO_ ),\?_B'F2_\_*GWQ_\ D#R+_A5_CG_H!_\
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M/77_ +$?]AV'A7XDZG\6REO\-+S0+?2_&-_#.Z7T<LL_F6:V01'\R<RP$[&
MC*JV]@,9UE6DL,JB6K2_'^M%U,(8>$L8Z3>B;_"_W>;Z;GEWQ+^ OQ5^$>GV
MFL^./#<4>GWTSPVFJ:=JEM?VDDJC+1B>UDDCW@'.S=NQSBN/KZ4^+/A[X4/^
MQU<#]E+Q%>ZOX:L?%EG?>/CXH7R=7M+QHIX++;"@\E;8J\PW([N7(R0!@?-=
M50J2JP;>Z=NWX=",31C1FE'9J^]_QTO_ )Z= HHHK<YPK]>/^"-__)D^G_\
M8PZA_P"C!7Y#U^O'_!&__DR?3_\ L8=0_P#1@KQL]_W)>J_4^@X:_P"1@_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>UAW1Y#17KWE2?W?UH\J3^[^M'^O'&'_ $3]?[JG_P I#VL.Z/T:_P""-_\
MR9/I_P#V,.H?^C!7U17SI_P2T4K^R99 C_F-WO\ Z&*^BZWCB<1C(JO7I.E.
M6KA*]XM[Q=TG=>:7H?J65M/+J37\J_(****H[PHHHH **** "BBB@ HHHH *
M*** "BBB@#\B/^"R/_)[&H?]B]I__HLU\K5]M?\ !5SPGHFL?M=WM[?:?YDA
MT*Q!;S6' 0]@17S9_P *_P##'_0(_P#)A_\ XJO1I\48C"TU165XN:CIS0H.
M496ZQ?-JGT9^79I4@LQJIO[3_,\XHKT?_A7_ (8_Z!'_ ),/_P#%4?\ "O\
MPQ_T"/\ R8?_ .*K3_6_%?\ 0HQO_A.__DC@]K3[GG%6-(TC5?$&K6N@Z%IT
M]Y>WUPEO9VEM$7DGE=@J(BCEF9B  .237?\ _"O_  Q_T"/_ "8?_P"*KZ'_
M & M#^&FA^+HK?3+G0=)\83>+-&;3KW7X/-\[3EF;[5;6KR*ZPW+DQ8;Y68
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MK+_L-WO_ *&*_,ROTS_X)<_\FG67_8;O?_0Q7R7&G_(G7^-?DSZCA'_D:O\
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M'FA1110 4444 %%%% !1110 4444 %?IG_P2Y_Y-.LO^PW>_^ABOS,K],_\
M@ES_ ,FG67_8;O?_ $,5\EQI_P B=?XU^3/J.$?^1J_\+_-'T31117Y0?I@4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %?F;_P %1_\ D["]_P"P)9?^@&OTRK\S?^"H_P#R=A>_]@2R_P#0
M#7UW!?\ R.'_ ('^:/E^+O\ D5+_ !+\F?.M%%%?JQ^9A1110 4444 %%%%
M!1110 4444 %%%% 'Z9_\$N?^33K+_L-WO\ Z&*^B:^=O^"7/_)IUE_V&[W_
M -#%?1-?B&>?\CBO_C?YG[%D_P#R*J/^%?D%%%%>4>D%%%% !1110 4444 %
M%%% !1110 4444 ?F;_P5'_Y.PO?^P)9?^@&OG6OHK_@J/\ \G87O_8$LO\
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M9^C?^<U<-&GAXU8MM-VU5ONU=UZV_P N4HKWG]DOQ)X%AM-:\*:5X%1]:N?
M7B"75]>U"42L@6SG,<5JF (5V[2[G<['(!5<AO!JTI8AU*\Z;C;EM\[W_P O
M^&(JT%3HPJ*5^:_RM;_,****Z3G"OTS_ ."7/_)IUE_V&[W_ -#%?F97Z9_\
M$N?^33K+_L-WO_H8KY+C3_D3K_&OR9]1PC_R-7_A?YH^B:***_*#],"BBB@
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M+ITN3/$.=%4^5)+UOY]>M@HHHKI.<*_3/_@ES_R:=9?]AN]_]#%?F97Z9_\
M!+G_ )-.LO\ L-WO_H8KY+C3_D3K_&OR9]1PC_R-7_A?YH^B:***_*#],"BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ K\S?^"H__ "=A>_\ 8$LO_0#7Z95^9O\ P5'_ .3L+W_L"67_ * :
M^NX+_P"1P_\  _S1\OQ=_P BI?XE^3/G6BBBOU8_,PHHHH **** "BBB@ HH
MHH **** "BBB@#],_P#@ES_R:=9?]AN]_P#0Q7T37SM_P2Y_Y-.LO^PW>_\
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M*E_B7Y,^=:***_5C\S"BBB@ HHHH **** "BBB@ HHHH **** /TS_X)<_\
M)IUE_P!AN]_]#%?1-?.W_!+G_DTZR_[#=[_Z&*^B:_$,\_Y'%?\ QO\ ,_8L
MG_Y%5'_"OR"BBBO*/2"BBB@ HHHH **** "BBB@ HHHH **** /S-_X*C_\
M)V%[_P!@2R_] -?.M?17_!4?_D["]_[ EE_Z :^=:_<,C_Y$]#_ OR/QW./^
M1K6_Q/\ ,****]0\T**** "BBB@ HHHH **** "BBB@ K],_^"7/_)IUE_V&
M[W_T,5^9E?IG_P $N?\ DTZR_P"PW>_^ABODN-/^1.O\:_)GU'"/_(U?^%_F
MCZ)HHHK\H/TP**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "OS-_X*C_\ )V%[_P!@2R_] -?IE7YF_P#!4?\
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M7/>?!_XK^%](T4P($LM6T)[B82 ?.Q<$<$]!0!ZA17A?_" _\%!/^B_^!/\
MPE)/_BJ/^$!_X*"?]%_\"?\ A*2?_%4 >Z45X7_P@/\ P4$_Z+_X$_\ "4D_
M^*H_X0'_ (*"?]%_\"?^$I)_\50![I17A?\ P@/_  4$_P"B_P#@3_PE)/\
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MOP)_X#:K_P#)5'^N^4_R3^Z/_P D'^IV9_SP^^7_ ,B?$U%?;/\ PZE\;_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 >%?\ !1CXV^._@?\
MLRWE_P#"K4%LO%/B76]/\.>'=0=-PL[F]N%B\_!ZLD9D9>VX+D$<5YW\8O\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?+/_!73_DV[1/\
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M['I#2)Y<DD$4442"5D)4R,K/@GD4 >ULP52S'@#)KY%\*_LR_%_2$U3XP?\
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M27\(:EXKU&YTCQS\,_AMIGBKP_K 3_2=,U73=/6=0<]RJ-"X.?O$\D"O5/\
M@GMX)DTO]FO1?B[XBU/^TO%7Q2M8/&/BW5VCVM<75]!',D2C)VQ00F*"-!P%
MBX R: /<**Y#XM_$#X@^ ;&SN?A_\"-<\=2W,K+<VVB:KIMJUHH (=S?7,"L
M"20 A8\<@5T?AW4=1U?P_8ZMK&@3Z5=W5G%-=:7=3122V<C(&:%VB9XV9"2I
M*,RD@D$C!H X3]GS]H>R^/FJ?$'3+/PM+IA\!?$"]\+3/)=B7[8]O%#(9QA1
ML#><!M.<;>IS5OX4_'*T^*/Q&^(?P\M_#LEF_@#Q!;Z7-=/<AQ>F6Q@NQ(JA
M1L $X7!)SMSGG%>1?\$ZV6+QK^T98R'$R_M":Q*T9ZA'M;,JV/0X./I6S^R$
MRW'[1O[1U[ P>)OB581"13D%TT.P#KGU!X([4 >@?M*_M#^&OV:?AU%XXUW0
M=1UF\U'6+71_#V@:0BFZU;4KE]D%K'O(52QR2S$ *I/)P#P.F?M?_&/P9XU\
M.^'?VG?V4;OP/I7BS5HM*T?Q'I7BVWUNVAOY<^3;W8BCC:WWD%0X$D>[ + '
M-=%^V+\+_@]\</ FC_"#XH?$>7PMJ>J^([:X\"ZO8WRP7MOK5L&F@DMBW#2*
M%<[>ZEL8."/%/B7\2/V^?V"=,T_XD_&/XN>%OB[\.(];LM/UZYE\.#2->LXK
MF=((YHE@8P3E6=<@C<W^SDLH!]CT444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7@'_!1SX)?$[X\
M_!#2O"'PH\,_VKJ-MXJ@O)K?[;!!M@6VN4+[IG13\TB# .>>G!KW^OC/_@N1
M_P FF^'O^RB6G_I!?UE6RREG-)X*I)QC4T;6Z]+GGYIR++ZG.KJW1V_&S_(^
M>/\ AV[^VC_T1G_RXM._^2*/^';O[:/_ $1G_P N+3O_ )(KXRHKRO\ B#62
M?]!-3_R7_(_/>;+_ /GW+_P-?_('[0_\$X_@E\3O@-\$-5\(?%?PS_96HW/B
MJ>\AM_ML$^Z!K:V0/NA=U'S1N,$YXZ<BO?Z^,_\ @AO_ ,FF^(?^RB7?_I!8
M5]F5ZM'+*634E@J<G*-/1-[OUL?H>5\G]GT^165NKO\ C9?D8GQ(^''@?XO>
M!-4^&?Q*\-VVKZ%K5HUMJ6G72DI-&>>H(*D$!@P(96 (((!KX[^+_P"QU\1?
MA=\4/#23>'OBG\=_A-86*2VO@2_\=6K_ -EZO#,&MVFBN&@%Y:"/:$65Y"C1
MDMN4@5]4?M%?'OP;^S1\(]3^+_CBUO;JTT]H8H-/TR 2W5]<S2K#!;Q*2 7>
M1U49( R22 ":\NF_;+^.'PXOM(U?]IC]CV^\&>$]8U*VL!XETWQC;:Q_9<]P
MZQP?;H(HT:!&D94,B-*JLP!/(K4[SUCP]\'/#&D_&'6OCXTM_+KWB#0K#2IH
MKR=&BL;2V::188 J@KNDG=WRS;F"XP!BJ/BK]G+P'XL^.FE?M#7%[J=IX@TO
MPQ>>'V^Q7"+#>V%PRN8IU9"6V2+O3:RX8DG=TJL/VA[,_M=-^R=_PBTOV@?#
M@>+?[;^UC9L-^;/[/Y6W.<C?OW8QQCO61H'[4M_\2/B)X^\%?!7X92>)+'P!
M8/!>:^=66VM;[754M_9$!,;!G5=HDESMB9PI!- ' ^!_^"8/AGX:>%++P+\/
MOVQOCUHVC:=$8[#3-.\=P10VZ%BQ5%6TPHR2?QKMOB?^Q%\/OB)XPL_B=H?Q
M*\=>#/%\&E0Z;?>+?!>OK:WFJVT0^1+P2120W)!R0SQEAG@@  7/@Y^V1\*?
MBM^R\_[4]_</H.D:;874OBBRU%OW^BW%KN%S;2C .]&4@# +@H0/F KG_%W[
M<)\$?!_P%XMUSX*:T_CGXFR"/P;\,K.\B>_N6*^8#+*X1(%2$QR3.W$._:=V
M,D ZKX!?LF?#O]G_ %W6?'%AXB\2>*/%?B%(HM9\8>,]7^W:C<PQY\N .%1(
MHE))"1HJYQD' QQ.J_\ !-WX5&XUC3O /QA^)G@KPSX@O);G6? _A#Q4MKI-
MP\IS/MC:%Y+=9,G<L$D:D$@ #BM#X>_M@>.XOC'HOP,_:;_9YN?ASK/BN"XD
M\'WL/B6#5]/U22!=\MMY\21F&X"?.$9,, =K$X!Z_P" _P"T/9?''Q7\1/"U
MIX6ETYOA_P"-)/#TTTEV)!>LD,4OG* HV ^;C:<].M %+XJ_L<_!GXI?LW0_
MLJ1VE]X;\)6BV2Z?#X8N$@FM!:SI-%Y;R)(,[XP69@68DDG)S7&V7_!-_P"%
MNIZ]INK_ !@^,_Q2^)-II-ZEY9:!X_\ &;7FFBX0Y25[>..-)2IY ?<O7(()
M%>I_M#?&?1OV>/@IXD^-&NZ;+?0Z!IS3Q:? ^V2]G)"0VZ'!PTDKQQ@X/+C@
M]*S?V6/VB='_ &HO@7I7QHTKP]/H[WKW,&H:)=S"2;3[JWGD@E@D( RP>,\X
M&00<<T =7\1_ NC?%'X>:]\,_$4UQ'I_B+1;K3+Z2T<+*L-Q"T3E"P(#;7."
M00#C@]*9\+OA[H?PD^&?AWX4^&)KF33?#&A6FDZ?)>2*\SP6T*0QEV55!<J@
MR0 "<X Z5\X_"#]OG]I_XY_"+3?CG\-?^"?E_JGAS58))[*6W^).G+<2QQRO
M&^V&5$8L&C?"G!...HKI;S_@HG\.H_A]\,OC=8^#M1/@3X@:\VB:KK]Y,L$O
MA>_+-%'%>0$'"_:(WA=]X5"H.6#+D ^AJ*\^^*OQ[L_AY\3/!'P>T/PU)KGB
M+QIJ,H2QANA$-/TV!-]UJ$S%6Q''F- O!DDE1 1R1Y_J7[8_Q:\:_$#Q5X._
M9=_9:G\=V'@G67T?Q%X@U'QA;Z-;'4HU5IK2V$D<C3O&'4,S"- QQNQ@D O_
M !-_8-\ ^.OBEJGQD\$?%_XB_#K7M?BB3Q)/\/?$B646KF)=D<EQ%+#*AD5/
ME#J%;'?))/6_#W]E[X8_"WX)ZM\#/!,FK6MCKL5Z=8UF34WFU2]NKM"L][+<
MR;F>Y;.?,(."J@ !0!/^SI\?]#_:)\"W'BG3_#&JZ#J.E:M<:3XB\.ZW"$NM
M+U" @2P.5)1Q\RLKH2K*P/!R!WU 'D][^QG\'==_9QTK]F/QG+K>NZ+HOER:
M9J^J:LQU6WN8Y&DBNTNHPC).C,=KJ!QP002#S.C_ /!/7P)+XFT77OBO\>/B
ME\1K7P[J$=_H^@^._%,=S80W<9S%.\4,$1G=#RIF+^^<G/O-]<BRLIKPIN$,
M3.5SC.!G%<%^RG\?K/\ :C_9\\,_'VP\,RZ-#XDLY)TTR:Z$S0!9I(L%PJAO
MN9Z#K0!8;X!>'&_:*'[2O_"6>(O[5'A?^PO[%_M,?V7Y/G>;YWD;,^?GC?N^
M[QBNZK@_V:/CE:?M'_!S3_B]9>'9-)CO[_4;46,MR)F0VE_<69;<%7.XP%\8
MX#8YQFL3]HW]IZ3X*>)/"WPO\$?#+4/&OCCQK+<CP[X;L;V*T0PVR*]Q<W%S
M+\D$2*Z\X9F+ *IYP >KT5XO\*/VJ/'.L?%VV^ W[0GP O/A_P")M5TR?4/#
MDD&NQ:MINKPP%?/2*ZB2,K-&'5FCDC4[3D$Y&?:* "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OC/_@N1_R:
M;X>_[*):?^D%_7V97S-_P56_9\^+W[27[/6C>!O@MX1_MK5;3QG;W]Q:_;[>
MVV6ZVEW&S[IY$4X:5!@'/S9Q@''9E\HPQL)2=E<X,TA.IE]2,%=M;(_'BBOH
MC_AU%^WW_P!$%_\ +ITK_P"2J/\ AU%^WW_T07_RZ=*_^2J^S^NX/_GY'[U_
MF?GO]GX__GU+_P !?^1]F?\ !#?_ )--\0_]E$N__2"PK[,KYF_X)4_L^?%[
M]FW]GK6? WQI\(_V+JMWXSN+^WM?M]O<[[=K2TC5]T$CJ,M$XP3GY<XP1GZ9
MKXS,)1GC9RB[JY^A97"=/+Z<9*S2V9Y=^U_X!^"GQ<^#<GP>^.?C(:#8>*M6
ML]/T;48K];:Y353*)+3[,[9_?B2,%5P=VT@@@FO!/B_XH_X*%?L!_#^Y^-'B
MSXX^&?C'X \.O"WB"RUSPZNDZY%9-*D9:":!C%-(N\9:09;G@DU]2_&/X.?#
MGX^?#O4/A9\5?#D>J:+J2*)[=I&1T=6#)+&Z$-'(C ,KJ000,&O'U_X)Q> -
M;ET_3OBQ^T%\6O'_ (>TV[BN8/"'C/Q>ESILLD3!XO/2.".2Y5&"D+-(X)4;
M@:XSO/'?VCY/C7XW_P""H>G>#OV>+DZ9?>,/V=8+._\ %<G#>'-,?6Y9)[U$
M/+S[5$42\8EF1B0$->A_\$Y+FX^ NH^,/^"?/C)E&K?#O4)-2\,:@\2H^O>'
M[V9Y8;QMH DE25WBF8#[^T9)R:]O'P#\%C]H\_M0B\U'_A(CX('A;[/YZ?9/
ML0O#=[MFS=YOF'&[?C;QMSS47C7]G;P+XV^-WA+]H2>]U+3_ !+X/MKNTM+G
M3+A(TOK2X4"2UNE9&\V(,-Z@%2K_ # @T ?*GQ/_ &;K9O\ @I1:? _3?$TE
MM\./BA;+\0/''@Y8 8;_ %32Y0@7.<+%/*]M-,N#YC08/!&/0/C2B:5_P5E^
M#&L>*&5;#4/AWX@L?#CS'Y1J2E))@N>CFW('J17N&L_ /P7KGQ_T7]I"\O-1
M&O:#X=NM%LH(YT%JUO<2)([.A3<7R@P0P &>#4/[0G[-_P ,OVF?"%MX3^(U
MM?12:;J$>H:'K>C7S6FH:1>1_<N;:=/FCD&3Z@]P: +/Q0\8?!'P]XN\%Z#\
M4QIDFM:SK[0^!X;S2S=3?V@D$CL\)",8&6(29E^4*&P6&X ^-_L ?\E=_:1_
M[+==?^D-K7:_"+]BOP)\,/B5#\9/$_Q+\<?$#Q596$EEHVM_$#7$O'TJ"3 E
M2VCBBBBB,@ #.$WL."V"0><U?_@G3X1G^(7BGXB^#OVF/C#X2G\8:V^K:SI_
MA/Q=#:6CW3*JEPGV9C]U5'))P!S0!B_\%!/B$\GQ&^$OP3M/ ?B/Q1;S^*?^
M$M\4:-X4TT7EVVG:44>$-$64&-[^:SR6(&(VZ]*YK]@'XE'1?VI?C;\"+KP#
MXD\*V/B#4(_B!X4T7Q9I@M+ORKP"#4&$8=@(Q=QKMVDCYST.17NOP8_96\+_
M  <\92?$2;XC^,?%VO2>'(]#76/&>KQWEPEFEW/=; Z11DEI)\$G/RPQ 8V\
MZWBK]GSP/XK^.WAC]HFXO-1M?$/A;2;[3(/L4Z+#?6ET%W0W"E"SJCJ)$VLN
M'R3D<4 ?!?[+/CS_ (*#_![_ ().Z/\ %OX*ZM\-)_#>@^'+^]M+"X\-7\^L
MQ6R7TYN)0_VM;=WC'FR@&/:50*03R?J_X,_LD_ CQ-^P/9_LYVFNW/B?PEXO
M\/27D^OW:J+C4);YC=F_ &0DGFR"5!SL*(,G;D^B? +]G?X?_LZ_ K2?V=_!
MQO+_ ,/:/:3VT(UN1)I9HII9)'60JB*P)E88VCC J?\ 9\^!?A7]FSX3:7\%
M_ NKZK>:-HQF73/[9NEFF@B>5Y!"'5%RB%RJY!(4 9.* /G?_@DYX3\6>*?
MNL_M#_&7QK)XG\8-=/X,L]4GAV_9=)TF5K=(D!).Z:99+B5LY=V7/W<U<B_9
MH^(5]XS\5?'?_@GC^V=9Z%9>*?$EU>>)O"NI:)!K&BW6LHWDW3ALB6TD9X_W
MFS<21Z;0/>?@!\ _!?[.'@6?X?> KS49[&?6K[5'?4YTDD$UU.TT@!1$&T,Y
MVC&0,9)ZUP?C']@KP'JWC[6/B-\,?C+\1_AK>^([DW7B.V^'_B..UM-2NB,-
M<R6\\$T:S, -TD:HS$9)))) #]BO]H_XK?&.X\<_"GX_>%-&TWQU\-M?BTS7
MI_#4TCZ;?K-")H+B#S,NFY"<HQ)'!.-VU>X^(_Q1^*7@[QC9>'O!W[-7B/Q;
MIUS!&]SK^E:WI-O!:,TC*T;QW=W%,Q555R41@0X )8$ _9^_9S^&W[-?A*Z\
M*_#R&_GDU/4I-1US6M:U![O4-6O9,;[FYG?F20@ =@ . *[N@"MK$4DVD74,
M2%F>V=54=22IXKYX_P""14T4_P#P3E^%[0R!@NE72,0>C+?7"L/J""/PKZ0K
MYSOO^":7PO@U/5X_A_\ '3XK^"_#NO7TUWJG@GPCXR%KI,DDS%I]D;0O) LA
M)W+%(@YP,# H N?\$O"K_L3^&9T8,DVN>(I8G!R'1]>U!E8>H*D$'T-3_M5?
M WP7\?OBAX3L/!O[0=S\/_B[X1T^[U;PGJ>DK#<7*6$Q2WN?-M)?EN+=F$:D
M'&& YP6!ZSXB?LG_  O\=_LY)^RWH]UK'A+PO;VMI;6)\(ZA]DNK2*WD21%C
ME97/)0!B02P9LG))I/CG^R=\,_CW9:#/X@U37]&U[PL6/AOQAX8U=K+5M.W(
M$D"3J"&5U #HZLC8Y6@#R+PE\:OVS/V<?VBO OP(_:J\0>$?'?AWXB7-W8>'
M_&/AW2WT[4+:]@@,V+JUW-$4=5P#']TDDG  /U77C/PK_8C\!_#SXH6GQI\7
M_$_QU\0O%&EVDUMH6K>/]=CNSI$<J[9OLT4,,,43.HVL^PN1QNP2#UGPN^ 7
MASX4?$'QM\1=&\6>(K^Z\=:E#>ZA9ZQJ0FMK%XU<!+5 @\E#O.02V<#GB@#N
MJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *^!?^#B__DR7PM_V52Q_]-NIU]]5\"_\'%__ "9+X6_[*I8_^FW4
MZ^LX%_Y*[!_XU^3/C^/_ /DC<;_@?YH_%VBBBO[ /XS/VB_X-T/^3)?%/_95
M+[_TVZ97WU7P+_P;H?\ )DOBG_LJE]_Z;=,K[ZK^0.._^2OQG^/]$?V;P#_R
M1N"_P+\V<1^T5\>_!O[-'PCU/XO^.+6]NK33VAB@T_3(!+=7US-*L,%O$I(!
M=Y'51D@#))( )KRZ;]LOXX?#B^TC5_VF/V/;[P9X3UC4K:P'B73?&-MK']ES
MW#K'!]N@BC1H$:1E0R(TJJS $\BNW_:_\ _!3XN?!N3X/?'/QD-!L/%6K6>G
MZ-J,5^MM<IJIE$EI]F=L_OQ)&"JX.[:00037@GQ?\4?\%"OV _A_<_&CQ9\<
M?#/QC\ >'7A;Q!9:YX=72=<BLFE2,M!- QBFD7>,M(,MSP2:^2/KSTWXD?MA
M?%K2/VD=9_9N^"_[+TOC:_T'P]9:OJ-\?&=KIJ)%<LZHH6>,[B#&>A_"CPU^
MW=;7G@/XJ7GCWX-:OX6\:?"/PY-K/B/P5J6H02FXMQ:RW,,EM=0[HY8I!$R[
MP,HW#+TSY1>ZI^T5J'_!3CQ]JG[,UCX)GGN?A5X?EOQXYN;R!!"TMP4\O[-&
M[;LDY#8 %:_Q(_9R^*G@[X"_M(?M)_M#^,-#U3QMXP^$>IZ>+'PM:RQZ;I&G
MVNFW1C@A,Q\R5F=V=W<#G   H ZOXY?\%'O#OP*^&/PF^*^M?"?4[_3?B9IT
M>HWRV%X&DT*R^R17<\[*(R9Q%%(S,!MR(B>.WJ7QO_:#T3X/>!_#OCRSTL:Y
M9^)/%>BZ-9O9WBJFW4;J.".X#X8.JB0/@?>'0C.:^<M"T?2O$-S^Q+H&N:?#
M=V5]X$U&WO+2XC#QS1/X2"NC*>"I4D$'J#7G_P 1M7U7X!:=HW[ ?CG4)IE\
M+_&+P=J_POU&[<LVH^&9=<@5(-Q^_+9RDP-T.PQ$#'- 'T?\0?VP_B[I_P"T
M?K_[.7P6_9;E\:WOAO1+'4]3OV\:6NFHL=UOV*%GC.2#&PX)_"N@_9]_:MO/
MBS\1-=^!_P 4/@_JWP_\>>'].@U*Y\/:G?P7D5WI\SLB7=M<P$I-'O4HW *M
MQUSCPZ_M/VE;K_@J!\51^S?KW@:QN1\/_#G]JMXWTF\NT=,W&P1"UN(2ISNR
M6)!&,8K0_8@U;6/$7Q0^,/[5'[5'C"S'Q&\%R3^$/$&F:=8&UT[0=&LV-XCV
MRN[R217 8W'FR-DX*@?*20#TH?MW>#O^&X5_8L?P;>++)8R"'Q2;D?9I-2CM
M8[Q]/";?OK:RI*6W=\;>]=1\9OBI^TEX)\51:3\(?V4_^$WTQ[%)9=7_ .$Y
ML]-\N8NX:'RIE+'"JC;^AWX[&O@3Q;\3?&6G?LM:+^TF_P"S7\3+;QII?Q8/
MQ5O]?F\,JNFR6L\Y$EO]H\W<(/[,:&/)7!\E>@Y'VE^UC^TYK'AWP%X:\!?L
MXW-OJGQ#^*P6V^'Z_>BMH'C$DVK2C!Q!;PMYI)!W,47!!. !_P"RO^UWX_\
MVAOB?XV^&GBO]GJ7PH? DL-IJVJ1>*8-3MFOW <V:O#&JF1$.YPK-L)"M@D"
MF_#W]N[P=\0?VR_$G[(=KX-O+9M$M9_[/\4RW(-MJMW;):M=VD2;00\/VI=W
MS'[C=.*W?!?@OX:?L#_LG7R6UQ+<:9X.T&\U?7=4NW_TG5KI4:>YNI6.2TTT
M@8\D\LJC@ 5\-:CX_P#$WP2^$/P5^/'B?]G[XDZ/XF\!>/Y?$/Q%\5ZQX7$%
MA-:ZY,ZZN/-$K,<FXB5"RC(B7.* /T_HJ-[C-H;NT3S_ -WOB6)A^\XR "3C
MGUSCFN+^$?Q-^)WC^[O;?X@?LX^(O L=M&C6T^MZUI5VMVQ)!5!8W<Y4K@$[
MPH.1@GF@#E_VK/VH?$/[.^H^"/#7@WX0R^,M:\=^()-)TK38]<BT\+*L#S;F
MDE1EQA".<?6N?T7]L_XD>%OB=X9^'?[3?[+.J_#ZW\9ZF-+\->(H_$UGJUC-
MJ)1G2TE:##0/($8)E2&(QV)''_\ !2:+X@S?%W]G>+X57NC6WB$_$RX_LJ?Q
M!:RS622?V=/S*D+H[+C/"L#G'-<W?:;^T+\5/V\O 'P+_;8\:>%8],\.67_"
M=^!;3P)H=Q:VFNZM:2-%LGDNKB6026RR><(TPK*^2>,4 ?9UUJ%A8M&M]?0P
MF:0)")90N]C_  C/4^PJ5F55+,P  R23TKX#^&WA'7OVH_B_\:/B%\5_V/\
M1_BO)IGQ-U7PIH\GB7Q1;PQZ%IUEY<<5O;6\T;_9W8-YS31[6<R@YXR>EU[]
MG7]J[QK^PIX<^$&O_P!EZYJOAKXC+<3>$]3\9[U\5>';>>9HM&N+Y!AI C1H
M2PP?LHW@Y- 'VC:ZKI=]9_VC9:E;S6_/[^*963CK\P..*Y'X&?'OP)^T)X6O
M/%O@/[4EO9:Y?Z5-'?(B2&:TN'MY'"H[?(70E3D$@@D#I7S#^SEI'[/=I^T!
M>?!3X@_L3ZW\&M<\=^#[JUF\%23VESX6\46T#(TY46I,$MS&C<MM4^6Y!)W
M5T/_  2=^"?PB\%?"OQ%X]\(_#C1]-UN7Q[XETJ75+.Q2.=K*'59EBMRX&?+
M01H O0;1Z4 ?650V>H6&HHTFGWL,ZI(4=H9 P5AU4XZ$>E?.O_!236-8NO"_
MPQ^#L>L7FG:'\1_BYI/ASQ9=6-RT$DNG2+-+):"1"&C\\Q+&2""5++_%7&_%
M?X(?"C]E7]K'X*K^SOX#T_PW9_$'4]1\,>-/#&BP^39ZUIPL))EFF@7Y6D@9
M-WFXWD.P8D'% 'K_ (0_:9\>_$G]H;Q)\*/AU\%(KWPMX,UB+2?%'C.]\3I;
MO%>M;)<-';V8A=IU198E9FDCY8X! R=KX_\ [15G\ /$/P^T[6O"LMYI_COQ
MM;^&6U..["#3KFXCD:W9D*G>KO&4ZK@D=<XKP3_@GA^S-\ ?!7QZ^-GBSPG\
M)=%T_4O"WQ4N=+\.WMM:!9-/LVTVS+01'^%"9)#C_;->D?\ !3CP'JWC?]BG
MQEJ/AE<:UX3@@\4:),HRT5QILR7>Y1ZF.*1?7Y^* -OXT?MD^!?@I^TM\,OV
M:M>TJ2:^^),EXD6H)<A4TXQ(/(WH02_G29C7!&"I/-=)>?'2UB_::L?V:K'P
MW)<74W@J?Q)J&J_:0J6<"W26T,93:2S2.9"#D8$+=>WQ3\:[B3]K;P)\8OVZ
M/AO#]IF^'MIX5NOAS= Y\IM)BCUN^VXZY^W/$2.\7MBNON_CIJWB+X??M0_M
M[?!ZY:8VWA6PT+P-J&T,UO#::6MW+,HY&%N-1D<]03!ST- 'V\FH6$MX^G1W
ML+7$2AI(%D!= >A*]0#3KN[M+"W>\OKJ.&*,9>65PJJ/4D\"O@[]H[]FCX+_
M +-W_!/ZR_:K^#.EQ:=\2/"6F:1KUA\0HIW;4=7O9IK83?:Y]VZZ2Y\UU:-R
MR'S    !75:O^S_X"_:7_P""E'CC1?C/HSZEX>L?AIX:U"Z\*7,K"VNKWSKY
M87G52/-$(>?"-E2T@8@E%P ?17P;^/=I\7_'?Q#\#VWAJ2Q?X?\ BA-%FN7N
MA(+UFM(;CS5 4;!B8+M)/W<YYQ47[07[1.C? CP_H>NG1AK/]L^.M*\,O#;7
MRH;66]N%A$C'#?<W;BG!/J*^0_B]\2?%_P *?A%^V+XL\#:Y/I6H/\4]*T\:
MO;-MDL(;NWTJUFG5ARK+%,Y##E3@Y&*Z/]L[]CK]F_\ 9^\(?"/7/@WX!L_#
M5];?&CPE8SW.FN8Y-8B-\A*W9S_I;@J)!))N<,I((#," ?;]%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 5\A_\ !:3]E[XZ?M9_LMZ#\.?V
M?O _]OZS9>/[74KFS_M.UM-EJEC?1-)ON98T.'FC&T$M\V<8!(^O*^&O^#@#
M_DS?PU_V4VS_ /3=J-;X;.Z_#=>.9T8J4Z3YDG>S];69X'%.'P^*X>Q-*NFX
M..O*TG;39M22^YGYW_\ #E/_ (*:_P#1M/\ Y>6B_P#R91_PY3_X*:_]&T_^
M7EHO_P F5XA17T'_ !,AQ/\ ] ='_P G_P#DC^=_]5^%OY*W_@V'_P H/VH_
MX(N?LO?'3]DS]EO7_AS^T#X'_L#6;WQ_=:E;6?\ :=K=[[5[&QB63?;2R(,O
M#(-I(;Y<XP03]>5\-?\ !O\ _P#)F_B7_LIMY_Z;M.K[EKY_%9W7XDQ$LSK1
M49U?>:5[+TO=G]$<+4,/A>'L-2H)J$8V7,TW;S:44_N1S'QC^#GPY^/GP[U#
MX6?%7PY'JFBZDBB>W:1D='5@R2QNA#1R(P#*ZD$$#!KQ]?\ @G%X UN73].^
M+'[07Q:\?^'M-NXKF#PAXS\7I<Z;+)$P>+STC@CDN51@I"S2."5&X&O6OCI\
M;?A]^SI\*]7^,7Q0U-[71]&@#S>1%YDT\C,$CAB3^.1W945>,EAD@9(\3UG]
MN_XS_"[1K/XH_M&_L6ZUX,^'MU<0QW?B9/%=KJ%WH\<SA(IKZQB0-!'EEWE'
MD,><$9X.![Y[%H7P#\%^'_CYKW[1EC>:B=>\1:!9Z1?023H;58+9W>,H@0,'
M)D;)+$'C %;7Q0^'VA_%OX9^(OA3XFFN8]-\3:%=Z3J$EG(J3)!<PO#(49E8
M!PKG!((!QD'I6%^T/\=M$^ 'P.UGXV7&EOK,6G6L1T_3K*<!]2N)Y4AMH(WP
M1F666-0<'[V<&J7[.'[1V@_M(?LZ:/\ M":#H<UA#J=A/+<:3<3!I;.X@DDB
MFMW; RRR1NN<#. <#- !IG[+WP[TJ\^%M[;:AJQ?X1:;+8^& ]S&1-')8"Q8
MW'[OYV\H9!79\W.,<5!^T+^R1\(?VF=>\$^*?B+:7J:G\/\ Q/!KGA[4--F2
M.5)8W1S"Y9&W0NT<9=1@DQKAABKW[+'QZM/VG_V?O#'QZL/#4FCP^);%KE-,
MFNA,T $KQ[2X50WW,YP.M<G\5_VL?&6D?&FY_9X_9[^ ]QX_\5:5H\.J>(S/
MX@ATG3](@G9A LMQ(DC-+)L8B-(V.T9SC. #MO#OP$\%^&/CQXD_:'T^\U%M
M=\4Z-8Z9J,$LZ&V2&U+F,QJ$#*Q\QMQ+$'C %<I\2/V)OA5\2?%/Q \5W7B'
MQ'I4OQ.\)V^@>,;?1KZ***\@A)"38:)B)_)9X"V<>4Y&T'#"Y^S_ /M-3?%O
M6/$GP^^(OPPU+P)XR\(""37_  _JEW%<P_9YE9H;JWNHOW=Q"P1QN 5E92&5
M>,^=Z7^WA\9?B=I-_P#$W]FW]C'6/&_P]LKJ>*V\4-XLMM/N=82%RDLUA921
MLUQ'E6"%GC,A&%&>  ?07B'P)X5\3^ K[X9:MI$3:)J.D2Z9<V"+A#:R1&)H
MP.PV$BOGE/\ @EE\,-/U[0?%/AC]HKXO:)J?ASP=;>%]-O\ 1O%=O!*NF0,6
M2$L+4X&=N0N =BDC/-='\2/V^OA[X>_8WMOVROAEX<N?%6DWUQ96]GI)NELI
M_/GO$M&AE+*XBDBE8JX((RAP<8-9?B+]N+XM?!E;?Q-^U/\ L=ZWX*\'R745
MO?>,=-\56.LVVEM(X1)+J.#;+%#N(!E"L!D9ZB@"^O\ P3[\-ZEX>U7P?X^_
M::^,'B[1]:AMXK_2O%/BZ&Z@=(KN"ZP%^S#&\P"-B#DQR2+QNR/7?BU\+_"?
MQK^&&O\ PC\=6KRZ/XCTF?3]06%@L@CE0J60D$*ZYW*V#A@#VKB]<_:FTGPI
M^U%X=_9R\5^%GL[3QIX?FO\ P9XM6_62UU2YAPTUCMVC9*L9$H.YE92,<G%:
ML/Q[L]6_:2F_9U\*^&I-1ETCPZNJ^+-:2Z"PZ.9GVV=LR[27FF"RR!<KMCCW
M<[@* .J^'_@ZT^'G@31? &GZK>WUOH>E6]A!>ZE*KW$Z0QK&KRLJJ&<A06(4
M DDX%:]%% '$_%/X">"_B[XT\$>.O$]YJ,5YX!UY]6T5+*=$CDG:%X2)@R,6
M3:YX4J<XY[4SXL_L^^"/C!XQ\$?$#7KS4;'6? &OG5-!U#2ITCDR\1BFMI"Z
M-N@F0A9%&UB%7##%>1Z'^VW^T'\1O&'CG0O@C^Q7-XGT[P-XUOO#-YJK_$.R
ML3<75L$9BL4\8(!62,CDCYL9X->E?LR_M+:+^TAX<UBX'@[5/#'B#POK4FD>
M*_"VM^6;G3+Q%5]NZ-F26-E=6213M8'CH0 #G_'O[#O@KQ1\2-9^*?@/XO\
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M , E_D?<W_!O_P#\F;^)?^RFWG_INTZON6OE/_@C_P#LV?&K]EO]FG7/A_\
M';P7_86KWGCFYU"VM/[1MKK?;/9V4:OOMY)%&7BD&"<_+G&""?JROTC*H3IY
M=2C-6:6S/V;(*52CDU"%2+4E'5-6:^1\N?\ !5?_ $7X=_";7=58+X?TOX_^
M%KKQ9)(<1)IPFE5FDSQL\QHLY]J]&_;]U'PSI?[$/Q9NO%TD2V1^'VJQ'S2
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M+ZO\=/VM[G2_C+^Q-\?M*\.7_CJ#X'ZIXD\&>*?!"310ZE;/'-:(LL,A+0W
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MYTCQS\,_AMIGBKP_K 3_ $G3-5TW3UG4'/<JC0N#G[Q/) KU3_@GMX)DTO\
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M3\#M1_9@G_9(TZQU'3/"MRT4ES+8WNZ]FF2[2[:=YIE<R2R3(&=V!)W$#'&
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M*H"@ ]/HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<(D"I"8Y)G;B'?M.[&3XE\3_ -FZV;_@I1:? _3?$TEM\./BA;+\0/''@Y8
M8;_5-+E"!<YPL4\KVTTRX/F-!@\$8] ^-*)I7_!67X,:QXH95L-0^'?B"Q\.
M/,?E&I*4DF"YZ.;<@>I% '8_#W]L#QW%\8]%^!G[3?[/-S\.=9\5P7$G@^]A
M\2P:OI^J20+OEMO/B2,PW 3YPC)A@#M8G /7_ ?]H>R^./BOXB>%K3PM+IS?
M#_QI)X>FFDNQ(+UDABE\Y0%&P'S<;3GIUK3^*'C#X(^'O%W@O0?BF-,DUK6=
M?:'P/#>:6;J;^T$@D=GA(1C RQ"3,ORA0V"PW 'QO]@#_DKO[2/_ &6ZZ_\
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M&_\ @J[_ -&J_P#E\Z%_\G5_1O17U/\ KSFW\D/NE_\ )'PO_$,,@_Y^U?\
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MDSX2:G^U78?MC7-M>CQ?IWAAM#@"3H+4P,[MYK)LW&8+(Z!MV-AQC@&O3:*
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B%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>biib-20250930_g9.jpg
<TEXT>
begin 644 biib-20250930_g9.jpg
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MIKG@?68-"UW_ (2K;K;6[V\T46IM8F (EN6(<KY_FK'^\"MPM?4O[/$DDWP
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MZDHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M8RZ1X@\5ZK!IPTF\E@L+EXH[26QMX8[B2%9"LC ,%\Q1DU]NS?#GX>W'A1/
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M]ZU?$_A#PGXVTS^Q?&?AC3M7LRX<VFIV4=Q%N'1ML@(R,]<4 ?+?P?\ B1X
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "HKZ]M-,LIM2O[A8H+>)I)Y7.
MB*,EC[  FI:I^(KV#3O#]_J%UI4]_%!9RR26-K;^;+<*J$F-$_C9@,!>Y.*
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M8L2%*ECLX /H"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M_G[_ .#B;_E)3JW_ &*6D_\ HIJ_H$K^?O\ X.)O^4E.K?\ 8I:3_P"BFKZ[
M@O\ Y'#_ ,#_ #1^>^)G_).+_KY'\I'PO1117ZL?@(445[AK7_!.C]K[P_\
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M ,D[A/\ KW'\C8HK'_X275_^A0O?^^EH_P"$EU?_ *%"]_[Z6O*/>-BBL?\
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M;^&GC/Q[\/\ 7M=A@C\0S^%;BPD@U4PIY<4D]O?6UQ%YJQX02(JOM5020H%
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M/^%??]1?_P E_P#[*C_A7W_47_\ )?\ ^RKIO*D_N_K1Y4G]W]:]3ZSXM?\
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M\)PM))J[E?7_ +=/@L?XB9+EV-J86I3J.4&XNRC:Z[7FOR/Z,:*_G._X?O\
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M^""G_*/;2_\ L:-4_P#1JU]GU\8?\$%/^4>VE_\ 8T:I_P"C5K[/K^..,?\
MDJL;_P!?9_FS^U>"O^22P/\ UZA^2"BBBOFCZ<**** "BBB@ HHHH **** "
MBBB@ HHHH _!7_@X*\'-K7_!1K5;Y;_R\^%-*&WRL](F]Q7Q'_PKF3_H*_\
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MHKYH^G"BBB@ HHHH **** "BBB@ HHHH **** /PR_X+U_\ *0G5/^Q7TO\
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M_P!]+0!L45C_ /"2ZO\ ]"A>_P#?2T?\)+J__0H7O_?2T ;%%8__  DNK_\
M0H7O_?2T?\)+J_\ T*%[_P!]+0!L5^&7_!>O_E(3JG_8KZ7_ .BFK]M?^$EU
M?_H4+W_OI:_$+_@NS>3WW_!0#4Y[BPDMF/AC3!Y4I&?]4>>*_4O"+_DJI?\
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MC1JG_HU:^SZ^'_\ @A-K6H6/_!/_ $R"W\/7-RH\3ZF?-B88_P!:..:^R/\
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M>??%+XG>-_C/\0=5^*/Q(UQ]2UO6KHW%_=N@7<V  JJH"HBJ%544!550H
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MC[0=9M;6>#SHB88VOIGC,A8(V% ;:C'. :^HZ "BBB@ HHHH **** "BBB@
MK\,O^"]?_*0G5/\ L5]+_P#135^YM?AE_P %Z_\ E(3JG_8KZ7_Z*:OU+PB_
MY*J7_7J7YQ/RCQC_ .21C_U]A^4CXPHHHK^FC^6@HHHH **** "BBB@ HHHH
M **** "BBB@#]S?^""G_ "CVTO\ [&C5/_1JU]GU\8?\$%/^4>VE_P#8T:I_
MZ-6OL^OXXXQ_Y*K&_P#7V?YL_M7@K_DDL#_UZA^2"BBBOFCZ<**** "BBB@
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MC^$DOA\S6OFQ@Q>>]K$)/G,;>7N.=N['RY'T)0 4444 %%%% !1110 4444
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MC   UR8FM.BXVVZO?^O4[L)AZ=>,K[Z65[?GI\M+GRG\+_V=OC#\8]+NM>\
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M,GT__L8=0_\ 1@K\AZ_7C_@C?_R9/I__ &,.H?\ HP5XV>_[DO5?J?0<-?\
M(P?^%_FCZHHHHKY ^\"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBL[4M9U"QNC!;^'KFY7:#YL3#'TYH T:*Q_^$EU?_H4+W_OI:/\
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MR3X]16"PM!1LH];G3]<Q+ES.6MK?UZ]3TRU_:?UWP]\0H?B!\._ACX0\+?\
M$IETS4]#T?3YWT_5;64GS8KJ*ZGF,BN" 0& ^12,, U2^(_VHM1N?!&K> ?A
MQ\)/"/@BR\0QI%X@G\-6]VUQ?Q*X<0-+=7$S1P[U5C''M!V@'(XKRZBJ]A2N
MG;^OU^9/UFM9J^_Z[V[7ZV/5O"_[6/B'1="T/3?%'PN\'^*;_P +6ZP>%]<\
M1V$\EUIT*N7CB_=SI'<1QL242=) N<#Y?EKG=(^./B2UOO&&L^)?#VA^)-2\
M:V4\&I:IXCT_[1<6LLK[WNK=@R^5/G.'P0 2,5Q=%"HTE>RW$\16=KO;_AOR
M-'P?XGO_  5XMTOQEI4,,EUI&HP7MM'<*3&TD4BNH8 @E<J,X(..XJ7Q[XQU
M/XB^.M:^(.MP017NNZM<ZA=Q6JLL22S2M(X0,6(4%C@$DXQDGK6316G*N;FZ
MF?-+EY>@4444R0K]>/\ @C?_ ,F3Z?\ ]C#J'_HP5^0]?K/_ ,$@=:U"Q_8Q
ML(+?P]<W*C7[\^;$PQ_K!QS7C9[_ +DO5?J?0<-?\C!_X7^:/KFBL?\ X275
M_P#H4+W_ +Z6C_A)=7_Z%"]_[Z6OD#[PV**Q_P#A)=7_ .A0O?\ OI:/^$EU
M?_H4+W_OI: -BBL?_A)=7_Z%"]_[Z6C_ (275_\ H4+W_OI: -BBL?\ X275
M_P#H4+W_ +Z6M#3;R>^M1/<6$ELQ8CRI2,_7B@"Q1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 5^7'_!5[PMH6K?M>7MYJ%CYDAT*
MQ!;S6' 0^AK]1Z_,W_@J/_R=A>_]@2R_] -:TN'\;Q++ZIA<7+#2^+GBFW9:
M<NDH.SOWZ;'S?%4_9Y8G_>7Y,^5O^$$\*?\ 0*_\CR?_ !5'_"">%/\ H%?^
M1Y/_ (JM^BNG_B$7$_\ T4-;_P !G_\ +S\Y^M/M^)@?\()X4_Z!7_D>3_XJ
MN\_9K\-?!C1?BY8ZA\0].T^*T6UNELKG5X'N;*WOC;R"UEN(?F\R)9C&S*5(
MP.01D5A5O_#;Q1X7\)^)#>^,_!,.OZ7<6LMM>6,DQBD577'FPR8/ERH<,K%6
M&1@@@TX^$_$]"2J?V]5G;7E<9V?D[UUOZFU#&<M:,FMGUV^=M3V;]MKP=\1-
M6\$Z;J'C'P?X8\1Z FAZ&(?%VD);M+87/V)!($DMBDB0S')595\LC:4 .*RO
M@]\8/B1XU^)GA[X7_!7PY;:%X-M8[>&]\)%(YM.:RC5?M=S?ET"SAAYCO+*-
MPW8!! J3XW?'#X3Q>$KKP7\'M+U2X?Q!X5T+3]6U+5KY'6WM[.*%UMTC2-09
MA)$@DD)QE&"J V:N:E\5/V2D^'D7PP\$:U\1O#VES1(=>:T\.V$ESK$PYW7$
MQO06C!^["H5!U(+<USU/#3/ZDX36:5HTW)/DY6[):O55+J]VDK.]E?2UO9J8
MR#Q<I0J:*U_>U;N]%)I:=7O;SLC@!\1O 'P4\7^.G_9T\*PZ?<ZIXDD'A_Q6
MLQ>?3]*624B&V#J3"SYC/FJP8*FWN36E^U)HEMXG^%/@+7/C+ID4OQ#O%O)[
MZY=/*O9M*8Q_9'O-N"\A/FE&?YC'@GJ*O?!#QQ^R]\-M6UKQ!XCM/%=YJ<=V
M5\'W[:#9W*647:XEMY+E4:X'\()>-3@X8XQSOQ-U?X,^(O$MMXFTKQIXZURY
MO=2\WQ%<^(].MHII(B1N:-TN)=TF,@;L <5HO#+B.>)J*6<UKM64O9S5M5)V
MM5[>ZFY)[K56.66+E]5=Y)W^RFK1UO>W5_IUZ+F/@7J7_"M?$TS^ ]"T.WUO
M5HDL=.U_69!G2&>1=TT4DS^5 Q'RF9AE%)(9>37JW[4?A/5=4_9V\-:A\:-0
ML?&/B63Q-/\ 8O&.E7HODAL/( -E/?Q';-(9?WBQEG**IY&[ Y73=:_9KB\2
M>(] OO#'B0^'-1>,^'M;+1/JNE[#GYX@ZP3!\D,N0<!2K#D&WXN^)7PP\/?!
MFY^"OPF;7-1BU76X-2U?6=?M(K8YAC=(XH8(Y)0H_>,6<ODX QBBGX7\0Q3B
M\XK2FTDI.,ERIV;?\9ZK5:M/HM+,5/%JGAIQE)-6>SZW_EMK?OT7FK'B/_""
M>%/^@5_Y'D_^*H_X03PI_P! K_R/)_\ %5OT5?\ Q"+B?_HH:W_@,_\ Y>>7
M]:?;\3 _X03PI_T"O_(\G_Q5'_"">%/^@5_Y'D_^*K?HH_XA%Q/_ -%#6_\
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MU>9TL\:@G97P].3:TUO==;].G4Y,9B.6JM+-K5::>3LDO/9;ZZG$_P#"K/\
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MFM^ _&/B#P-XUU[X@:Q):V-^&ECDU66RM!/:K<1E'@B8;50NAQN93@ &O/\
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MGQ=HGANRT_4K7PV3+9QVB0AK1;IC&6AE,;KY@@$@P<\,3CQS]J>T\:6WQ_\
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MR/\ Y$]#_ OR/QW./^1K6_Q/\PHHHKU#S0HHHH **** "BBB@ HHHH ****
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MT8SX[_\  F"C_AKGXX?]&,^._P#P)@H ]ZK\S?\ @J/_ ,G87O\ V!++_P!
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M0_U:SO\ Y]?^31_S/&Z*]D_X8E^.'_1)O'?_ (3,'_R71_PQ+\</^B3>._\
MPF8/_DNC_6K(/^?W_DL__D0_U:SO_GU_Y-'_ #/&Z*]D_P"&)?CA_P!$F\=_
M^$S!_P#)='_#$OQP_P"B3>.__"9@_P#DNC_6K(/^?W_DL_\ Y$/]6L[_ .?7
M_DT?\S[/_P""7/\ R:=9?]AN]_\ 0Q7T37R!^RYX\^.'[-?PG@^%_P#PR)X[
MUKR;V>X^W>5!;9\QL[=F]^GKNYKT7_AKGXX?]&,^._\ P)@K\KS6O2Q.95:M
M-WC*3:?E?S/TG+:-3#Y?2IU%:2BD_4]ZHKP7_AKGXX?]&,^._P#P)@H_X:Y^
M.'_1C/CO_P "8*X#N/>J*\%_X:Y^.'_1C/CO_P "8*/^&N?CA_T8SX[_ / F
M"@#WJBO!?^&N?CA_T8SX[_\  F"C_AKGXX?]&,^._P#P)@H ]ZHKP7_AKGXX
M?]&,^.__  )@H_X:Y^.'_1C/CO\ \"8* />J*\%_X:Y^.'_1C/CO_P "8*/^
M&N?CA_T8SX[_ / F"@#WJBO!?^&N?CA_T8SX[_\  F"C_AKGXX?]&,^._P#P
M)@H ]ZHKP7_AKGXX?]&,^.__  )@H_X:Y^.'_1C/CO\ \"8* /D?_@J/_P G
M87O_ &!++_T U\ZU]4_M2?"/XX?M*?%B;XH?\,]>.]%\ZQAM_L/]D07./+!&
M[?\ :$ZYZ;>*\Z_X8E^.'_1)O'?_ (3,'_R77ZIE7$F2X;+:5*I5M*,4FN66
M]O)'YKF609OB,PJU*=.\7)M:QV^\\;HKV3_AB7XX?]$F\=_^$S!_\ET?\,2_
M'#_HDWCO_P )F#_Y+KO_ -:L@_Y_?^2S_P#D3B_U:SO_ )]?^31_S/&Z*]D_
MX8E^.'_1)O'?_A,P?_)='_#$OQP_Z)-X[_\ "9@_^2Z/]:L@_P"?W_DL_P#Y
M$/\ 5K._^?7_ )-'_,\;HKV3_AB7XX?]$F\=_P#A,P?_ "71_P ,2_'#_HDW
MCO\ \)F#_P"2Z/\ 6K(/^?W_ )+/_P"1#_5K._\ GU_Y-'_,\;HKV3_AB7XX
M?]$F\=_^$S!_\ET?\,2_'#_HDWCO_P )F#_Y+H_UJR#_ )_?^2S_ /D0_P!6
ML[_Y]?\ DT?\SQNBO9/^&)?CA_T2;QW_ .$S!_\ )='_  Q+\</^B3>._P#P
MF8/_ )+H_P!:L@_Y_?\ DL__ )$/]6L[_P"?7_DT?\SQNBO9/^&)?CA_T2;Q
MW_X3,'_R71_PQ+\</^B3>.__  F8/_DNC_6K(/\ G]_Y+/\ ^1#_ %:SO_GU
M_P"31_S/&Z_3/_@ES_R:=9?]AN]_]#%?&'_#$OQP_P"B3>.__"9@_P#DNOIG
M]ESQY\</V:_A/!\+_P#AD3QWK7DWL]Q]N\J"VSYC9V[-[]/7=S7SO$^>97F.
M6JEAZG-+F3M:2TL^Z1[W#N3YE@,P=2O"T>5K=/73LV?7]%>"_P##7/QP_P"C
M&?'?_@3!1_PUS\</^C&?'?\ X$P5^?'W)[U17@O_  US\</^C&?'?_@3!1_P
MUS\</^C&?'?_ ($P4 >]45X+_P -<_'#_HQGQW_X$P4?\-<_'#_HQGQW_P"!
M,% 'O5%>"_\ #7/QP_Z,9\=_^!,%>I_"/QWXD^(O@]?$GBKX;:GX4NVN'C.D
MZLZM,%7&'RO&#V^E '3T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M/#%I;73[OO9ECC#G.3G)YS79444 %%%% !1110 4444 %%%% !1110 4444
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MYL3,"8WVL5W+@X)&>:T** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHKP+_@HO\:_B;\"/@EI?B_X4^)O[*U&Y\506<UQ]BAG
MW0M;7+E-LR.H^:-#D#/'7DUTX/"U,=BH4*;2<G97V_4Y\7B:>#PTJTTVHJ^F
MY[[17Y9?\/'?VS?^BR?^6]IW_P CT?\ #QW]LW_HLG_EO:=_\CU]3_J1FW\\
M/OE_\B?-_P"N.6?R3^Z/_P D?J;17@7_  3H^-?Q-^._P2U3Q?\ %;Q-_:NH
MVWBJ>SAN/L4,&V%;:V<)MA1%/S2.<D9YZ\"O?:^6QF%J8'%3H5&FXNSMM^A]
M)A,33QF&C6@FE)75]PHK/\6>+?"_@/PU?>,O&OB"STK2=-MFN-0U+4+A8H;>
M)1EG=V("@>IKRWX:_M^_LB?%OQE8^ /!'QC@EU75<C1X-0TF\L4U(@9Q;274
M,<=R<<@1,V>U<QT'L5%>3?%S]N3]ECX%>.I/AG\5/BO%I>NQ6<=U+IPTJ\N'
M6&3.QR8874 [3W[5L>"OVJOV>/B/\*]9^-?@7XKZ7JGAGP[;7%QKVI6CLQT]
M((S++YT6WS(V5%+;2H8CH#D4 >@T5YYXL_:O_9X\":5X+UWQA\4;'3K/XAR0
M)X-NKF*54U$S+&T>#LQ&&66,YDV@;N<<UT_CSXD>"?ACIMGJ_CO7X].MM0U>
MTTNSEDC=A+=W,JPP1#8"07D95!/ SR0* -RBO)?BS^W1^RK\#O'<WPR^*/Q8
MBTS7;>UBN9].&DWD[I%("48F&%UP<'OVKI/@C^T?\#?VD-%NM?\ @A\2]-\1
M6]A.(;];-V66UD.2%EB<+)&3@XW*,X.,X- ';45QR_M ?!M_C8W[.2^/K,^-
MET?^U&\/[7\T6F<>9NV[.^=N[=CG&.:P?C-^V7^S;^S[XJB\$_%[XC_V1J<]
MBEY%:_V/>7&Z%G=%?=#"ZC+1N,9SQTY% 'I]%>9?!#]L7]F[]H[Q)J'A#X+_
M !,BUK4M*M%NM0LUTVZ@:"%FVJY\^)!R3@8YK<T+]H#X-^)OC+K/[/>A>/K.
MY\9^'M/CO=9T"-7\ZUMW$95V)7:01-%P"2/,7(&: .QHHHH **Y[QI\5OA]\
M.];\/>'/&?B6*PO?%6J?V;X?MY(G8WEUY;2>4I52%.Q6.6P..M2^-_B3X(^'
M!T=?&NOQV!U_7(-'TCS(W;[3?3!C%"-H."VQN3@<<D4 ;E%%>._$K]OW]D3X
M1^,;[P#XX^,<$6JZ40-8M].TF\OUTTD9Q<R6L,B6QQR1*RX[T >Q45G^$_%O
MA?QYX:LO&7@KQ#9ZMI.I6ZSZ?J6GW"S0W$3#(='4D,#[5H4 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !7RS_P5T_Y-NT3_ +'BV_\ 2.\KZFKY9_X*Z?\ )MVB?]CQ;?\ I'>5[/#_
M /R.J'^(\G/?^116]#\Z:***_:S\A/T6_P""1?\ R;=K?_8\7/\ Z1V=?4U?
M+/\ P2+_ .3;M;_['BY_]([.OJ:OQ3B'_D=5_P#$?KV1_P#(HH_X3R#]NW]G
MWQ5^T[^S/K?PH\#:K86NL2W5E?Z:FK*S65U-:W45PMO<!028I#'M/!QD'!QB
MO#_BI^UB\.@Z5X,_X*5?L'Z_X2\/0:Y8S1>,]&U6/5=%TZ]BF1K>[:YM&2:R
M7S N.K88H<AF!^D/VD_@YXD^-GPX7P[X'^)VH^#_ !!INJ6VJ^']>T\EE@O+
M=]R+/"&"W,#<J\+?*P.>H%>*?%CX _M__M3?#^7X _'SQ+\)M \'ZO)"GBG6
M/!9U*XU*^M8Y4D,4$-U&L5L9-@!8O+M!. :\8]8YC6_CI9?!7_@J+\1-6E^&
M'C;Q4FH_"_042+P/X9EU22$":X;?(L9^13G@GJ:QO$'A/X@>+O"7[6?[5NI?
M"36? /AOQA\'KG3M*T/Q%:I;:AJDUII=YYFH7%NK'R3^\$:!CO9020*^B/ '
M[./B+P7^V+XM_:!34=.&@:YX&TG0]-T^*20W,,EI)*S%P5V["KJ 0Q/!R!78
M_M$?#O5_B]^S_P".OA-X?O+:WO\ Q1X.U/2+&XO&80Q37-I+"C.5#,$#."<
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M0R.O4IR<9*.C3LUZ-'GYK.=/+JDH.S2W1\J_\/(OVT?^BS?^6[IW_P CT?\
M#R+]M'_HLW_ENZ=_\CUX=17X5_;F=_\ 054_\#E_F?G?]HYA_P _I?\ @3_S
M/U%_X)Q_&WXG?'GX(:KXO^*_B;^U=1MO%4]G#<?8H(-L"VULX3;"B*?FD<Y(
MSSUX%>_U\K?\$A/^3:]<_P"QYN?_ $CLJ^J:_=>'*M6OD="I4DY2<=6W=OU;
M/T3*ISJ9=3E-W;6[(-5U72]"TRXUO6]2M[.RLX'FN[NZF6.*")069W=B J@
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MLY_"_C!-4CU/1K+5U;%O(;ZT=&@W,<!64J02'&T,0 ?8E%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 5\K?\%>_^3:]#_P"QYMO_ $CO:^J:^9O^"JW[0?Q>_9M_9ZT;QS\%O%W]
MBZK=^,[>PN+K[!;W.^W:TNY&3;/&ZC+1(<@9^7&<$YY<=E<LZPD\#&7*ZBM>
MU[?(\_-5!Y?44W96Z*_X77YGYJ45UG_#UW]OO_HO7_EK:5_\BT?\/7?V^_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4^''QB^$OQHUO_@EE\-FDM/A]\4+U_$6A:]!=!)/#7AR1W;6M.B'4,T@6*'
M(5;QF)S]WTKXO^$/#NL?\%)/@/\  JZT:"#P?X*\!:IKOA[0UC_T7[=#LM8/
MDZ$P1@-'G[AY'6O6_%7[/WBS7?VV/"?[2UKJVG)HV@>!=2T2ZLI'D^U23W$\
M4B.@";"@$9!)8')& :J_M7_LS^+_ (O:WX/^,OP5\:67AWXC?#V^GG\-:AJE
MJ\UC>07$8CN;&[1"',,JA?F7YD(RO)H ZWXC?L\^ /B9\4O!7QEU=[ZS\0^
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MOBCX7_%V/2+^U\'WNO,LMIJ5NRA[FUM[RV?RKK:J;]DBX7JF&;GZHKYQT/\
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MM=-N;S^S+6[WVKV-]*T>RYBD09>&,[@ WRXS@D'Z\KX%_P"#B_\ Y,E\+?\
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MI-Y8IJ1 SBVDNH8X[DXY B9L]J?^W;^S[XJ_:=_9GUOX4>!M5L+76);JRO\
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MK]G;Q+XC^'VH2>$=2^'VH>*=7US1]4AU"Z36(6O;DW MI;<P&%E1GD'FB;)
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M'_TVZG7+C?\ =9^A\QQG_P DOB_\'ZH_%BBBBOE3^6C]I_\ @W)_Y,B\4_\
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MF+QS^R7JOCNTL?#S>,Y=:^$NJ::'EN?#L?VE;VWADC=54B&Y#\*QWQR$90T
M<;H_[3OB[X6_$'P%/X<_:P\3?%J+Q'XIM-&\;>']8\ +91VL=T3'_:-D\%E"
M;=(9-A:*1Y0T;-R& -0_'/\ :C\1:-^T_P"-/AO\=OVQ-<^!.GZ7-:I\-EM?
M"=K+8:W"UNKR7LUW=6LR3XF+(80\04)C);<1[1X1\(_\% /%GBWPVOQE^('P
M^\.:#H5\MWK#^ 1=W-WXC**P6WD%Y"J6<#$AG"&5SM"JZ_>I/'O@/]N'3_%_
MB2T\#:W\-/'7@_Q!=&XL=)^(R7-I/HH:-5:U4VEO+'=VX*EU$BI)\Q!=OO4
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M]->JUZN1TZ=;-Z,*B33>J>J?R/G^*:U;#\/8FI2DXR4=&G9KT:U/SF_X?O\
M_!5K_HZC_P L?0O_ )!H_P"'[_\ P5:_Z.H_\L?0O_D&OD2BOU_^R,I_Z!X?
M^ 1_R/YW_P!8<_\ ^@NK_P"#)_YG]#7_  0I_:T_:"_;)_9(\1?$[]I'Q_\
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MV;HW[4OPHUC3;.TU70)-$^)ND7LDB'5+>/Y[*ZAV(RFXA?*$OC,1VAA7L]%
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M:]H&J:O\(O#=UX?:S\;WEQ;0ZM93V=M;F5I[>*9XYE-JC_ZM@V]@2.*^BJ*
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
+ **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Oct. 29, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">0-19311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">BIOGEN INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000875045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">33-0112644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">225 Binney Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Cambridge<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">617<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">679-2000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0005 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">BIIB<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146,702,272<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Income (Unaudited) - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 2,534.7<span></span>
</td>
<td class="nump">$ 2,465.8<span></span>
</td>
<td class="nump">$ 7,611.2<span></span>
</td>
<td class="nump">$ 7,221.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Cost and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales, excluding amortization and impairment of acquired intangible assets</a></td>
<td class="nump">674.4<span></span>
</td>
<td class="nump">638.7<span></span>
</td>
<td class="nump">1,908.7<span></span>
</td>
<td class="nump">1,726.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">436.1<span></span>
</td>
<td class="nump">516.2<span></span>
</td>
<td class="nump">1,269.2<span></span>
</td>
<td class="nump">1,467.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_ResearchAndDevelopmentExpenseIncludingAcquiredInProcessCost', window );">Acquired in-process research and development, upfront and milestone expense</a></td>
<td class="nump">2.1<span></span>
</td>
<td class="nump">26.5<span></span>
</td>
<td class="nump">249.4<span></span>
</td>
<td class="nump">42.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">594.8<span></span>
</td>
<td class="nump">588.4<span></span>
</td>
<td class="nump">1,751.1<span></span>
</td>
<td class="nump">1,723.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets', window );">Amortization and impairment of acquired intangible assets</a></td>
<td class="nump">135.7<span></span>
</td>
<td class="nump">130.3<span></span>
</td>
<td class="nump">378.4<span></span>
</td>
<td class="nump">295.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Collaborationprofitlosssharing', window );">Collaboration profit sharing/(loss reimbursement)</a></td>
<td class="nump">87.2<span></span>
</td>
<td class="nump">69.3<span></span>
</td>
<td class="nump">220.3<span></span>
</td>
<td class="nump">197.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Business Combination, Contingent Consideration, Change in Contingent Consideration, Liability, Increase (Decrease)</a></td>
<td class="nump">5.6<span></span>
</td>
<td class="nump">23.8<span></span>
</td>
<td class="nump">28.4<span></span>
</td>
<td class="nump">23.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">7.4<span></span>
</td>
<td class="nump">6.8<span></span>
</td>
<td class="nump">42.0<span></span>
</td>
<td class="nump">24.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfIntangibleAssets', window );">Gain on sale of priority review voucher, net</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(88.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other (income) expense, net</a></td>
<td class="nump">34.1<span></span>
</td>
<td class="nump">14.8<span></span>
</td>
<td class="nump">151.2<span></span>
</td>
<td class="nump">193.7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total cost and expense</a></td>
<td class="nump">1,977.4<span></span>
</td>
<td class="nump">2,014.8<span></span>
</td>
<td class="nump">5,998.7<span></span>
</td>
<td class="nump">5,606.7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income before income tax (benefit) expense</a></td>
<td class="nump">557.3<span></span>
</td>
<td class="nump">451.0<span></span>
</td>
<td class="nump">1,612.5<span></span>
</td>
<td class="nump">1,614.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) expense</a></td>
<td class="nump">90.8<span></span>
</td>
<td class="nump">62.5<span></span>
</td>
<td class="nump">270.7<span></span>
</td>
<td class="nump">249.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">$ 466.5<span></span>
</td>
<td class="nump">$ 388.5<span></span>
</td>
<td class="nump">$ 1,341.8<span></span>
</td>
<td class="nump">$ 1,365.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic earnings per share attributable to Biogen Inc. (in USD per share)</a></td>
<td class="nump">$ 3.18<span></span>
</td>
<td class="nump">$ 2.67<span></span>
</td>
<td class="nump">$ 9.16<span></span>
</td>
<td class="nump">$ 9.38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted earnings per share attributable to Biogen Inc. (in USD per share)</a></td>
<td class="nump">$ 3.17<span></span>
</td>
<td class="nump">$ 2.66<span></span>
</td>
<td class="nump">$ 9.14<span></span>
</td>
<td class="nump">$ 9.35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares used in calculating:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic earnings per share attributable to Biogen Inc. (in USD per share)</a></td>
<td class="nump">146,600<span></span>
</td>
<td class="nump">145,700<span></span>
</td>
<td class="nump">146,400<span></span>
</td>
<td class="nump">145,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted earnings per share attributable to Biogen Inc. (in USD per share)</a></td>
<td class="nump">147,100<span></span>
</td>
<td class="nump">146,100<span></span>
</td>
<td class="nump">146,800<span></span>
</td>
<td class="nump">146,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 1,846.9<span></span>
</td>
<td class="nump">$ 1,769.4<span></span>
</td>
<td class="nump">$ 5,452.1<span></span>
</td>
<td class="nump">$ 5,380.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember', window );">Revenue from anti-CD20 therapeutic programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">493.9<span></span>
</td>
<td class="nump">446.2<span></span>
</td>
<td class="nump">1,339.4<span></span>
</td>
<td class="nump">1,284.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_LEQEMBICollaborationMember', window );">Alzheimer's collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">42.7<span></span>
</td>
<td class="nump">18.6<span></span>
</td>
<td class="nump">130.6<span></span>
</td>
<td class="nump">33.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Contract manufacturing, royalty and other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 151.2<span></span>
</td>
<td class="nump">$ 231.6<span></span>
</td>
<td class="nump">$ 689.1<span></span>
</td>
<td class="nump">$ 522.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization and Impairment of Acquired Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Collaborationprofitlosssharing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration profit (loss) sharing</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Collaborationprofitlosssharing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResearchAndDevelopmentExpenseIncludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Expense (Including Acquired in Process Cost)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResearchAndDevelopmentExpenseIncludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in value of liability in contingent consideration arrangement in business combination, including, but not limited to, difference arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-21<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_LEQEMBICollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_LEQEMBICollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">$ 466.5<span></span>
</td>
<td class="nump">$ 388.5<span></span>
</td>
<td class="nump">$ 1,341.8<span></span>
</td>
<td class="nump">$ 1,365.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Unrealized gains (losses) on cash flow hedges, net of tax</a></td>
<td class="nump">26.5<span></span>
</td>
<td class="num">(41.0)<span></span>
</td>
<td class="num">(137.1)<span></span>
</td>
<td class="num">(6.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Unrealized gains (losses) on pension benefit obligation, net of tax</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Currency translation adjustments, net of tax</a></td>
<td class="num">(3.2)<span></span>
</td>
<td class="nump">41.0<span></span>
</td>
<td class="nump">57.5<span></span>
</td>
<td class="nump">14.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income (loss), net of tax</a></td>
<td class="nump">23.3<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="num">(78.6)<span></span>
</td>
<td class="nump">8.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss) attributable to Biogen Inc.</a></td>
<td class="nump">$ 489.8<span></span>
</td>
<td class="nump">$ 388.8<span></span>
</td>
<td class="nump">$ 1,263.2<span></span>
</td>
<td class="nump">$ 1,373.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (j)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (k)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 3,862.8<span></span>
</td>
<td class="nump">$ 2,375.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">97.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">2,209.4<span></span>
</td>
<td class="nump">2,460.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">916.8<span></span>
</td>
<td class="nump">752.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">8,936.6<span></span>
</td>
<td class="nump">7,456.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">3,075.7<span></span>
</td>
<td class="nump">3,181.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease assets</a></td>
<td class="nump">330.5<span></span>
</td>
<td class="nump">356.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">9,331.9<span></span>
</td>
<td class="nump">9,691.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">6,490.7<span></span>
</td>
<td class="nump">6,478.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax asset</a></td>
<td class="nump">312.4<span></span>
</td>
<td class="nump">324.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Investments and other assets</a></td>
<td class="nump">729.7<span></span>
</td>
<td class="nump">560.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">29,207.5<span></span>
</td>
<td class="nump">28,049.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Current portion of notes payable</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1,748.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Taxes payable</a></td>
<td class="nump">103.3<span></span>
</td>
<td class="nump">548.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">413.1<span></span>
</td>
<td class="nump">424.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Accrued expense and other</a></td>
<td class="nump">2,773.6<span></span>
</td>
<td class="nump">2,807.7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">3,290.0<span></span>
</td>
<td class="nump">5,528.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Notes payable</a></td>
<td class="nump">6,285.1<span></span>
</td>
<td class="nump">4,547.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="nump">358.1<span></span>
</td>
<td class="nump">190.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liabilities</a></td>
<td class="nump">305.0<span></span>
</td>
<td class="nump">334.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">761.8<span></span>
</td>
<td class="nump">732.3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">11,000.0<span></span>
</td>
<td class="nump">11,333.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments, contingencies and guarantees</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Biogen Inc. shareholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, par value $0.001 per share</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.0005 per share</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">797.7<span></span>
</td>
<td class="nump">569.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="num">(214.8)<span></span>
</td>
<td class="num">(136.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">20,601.6<span></span>
</td>
<td class="nump">19,259.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost</a></td>
<td class="num">(2,977.1)<span></span>
</td>
<td class="num">(2,977.1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">18,207.5<span></span>
</td>
<td class="nump">16,716.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">29,207.5<span></span>
</td>
<td class="nump">28,049.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember', window );">Nonrelated Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net of allowance for doubtful accounts of $3.1 and $2.2, respectively</a></td>
<td class="nump">1,374.1<span></span>
</td>
<td class="nump">1,404.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net of allowance for doubtful accounts of $3.1 and $2.2, respectively</a></td>
<td class="nump">$ 475.9<span></span>
</td>
<td class="nump">$ 464.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-41<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478064/805-740-55-13<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 39<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-39<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 42: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 47: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 51: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 52: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 54: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 55: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Accounts Receivable, Allowance for Credit Loss, Current</a></td>
<td class="nump">$ 2.2<span></span>
</td>
<td class="nump">$ 3.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.0005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479344/326-20-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481962/310-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flow from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 1,341.8<span></span>
</td>
<td class="nump">$ 1,365.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash flow from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">579.7<span></span>
</td>
<td class="nump">489.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="nump">3.5<span></span>
</td>
<td class="nump">20.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Excess and obsolescence charges related to inventory</a></td>
<td class="nump">13.9<span></span>
</td>
<td class="nump">68.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_AmortizationOfInventoryStepUp', window );">Amortization of acquired inventory step-up</a></td>
<td class="nump">165.4<span></span>
</td>
<td class="nump">185.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation</a></td>
<td class="nump">231.2<span></span>
</td>
<td class="nump">216.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Contingent consideration</a></td>
<td class="nump">28.4<span></span>
</td>
<td class="nump">23.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="nump">194.7<span></span>
</td>
<td class="num">(99.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi', window );">(Gain) loss on strategic investments</a></td>
<td class="nump">33.7<span></span>
</td>
<td class="nump">22.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain on sale of priority review voucher, net</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(88.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="nump">49.3<span></span>
</td>
<td class="nump">95.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net of effects of business acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(35.3)<span></span>
</td>
<td class="num">(207.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expense and other current liabilities</a></td>
<td class="num">(32.7)<span></span>
</td>
<td class="num">(84.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable', window );">Income tax assets and liabilities</a></td>
<td class="num">(764.1)<span></span>
</td>
<td class="nump">62.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet', window );">Other changes in operating assets and liabilities, net</a></td>
<td class="num">(179.9)<span></span>
</td>
<td class="num">(65.7)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash flow provided by (used in) operating activities</a></td>
<td class="nump">1,692.7<span></span>
</td>
<td class="nump">2,114.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flow from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(109.9)<span></span>
</td>
<td class="num">(114.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable securities</a></td>
<td class="num">(91.0)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisition of HI-Bio, net of cash acquired</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(1,074.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments', window );">Proceeds from sale of equity interest in Samsung Bioepis</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">406.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of priority review voucher</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">88.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquisitions of intangible assets</a></td>
<td class="num">(15.3)<span></span>
</td>
<td class="num">(179.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfOtherInvestments', window );">Proceeds from sales of strategic investments</a></td>
<td class="nump">56.6<span></span>
</td>
<td class="nump">96.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other</a></td>
<td class="nump">20.2<span></span>
</td>
<td class="num">(4.4)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash flow provided by (used in) investing activities</a></td>
<td class="num">(139.4)<span></span>
</td>
<td class="num">(780.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flow from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Payments related to issuance of stock for share-based compensation arrangements, net</a></td>
<td class="num">(13.0)<span></span>
</td>
<td class="num">(34.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from borrowings</a></td>
<td class="nump">1,733.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of borrowings</a></td>
<td class="num">(1,750.0)<span></span>
</td>
<td class="num">(650.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Cash paid for contingent consideration</a></td>
<td class="num">(141.3)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="nump">6.3<span></span>
</td>
<td class="num">(6.6)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash flow provided by (used in) financing activities</a></td>
<td class="num">(164.9)<span></span>
</td>
<td class="num">(691.4)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">1,388.4<span></span>
</td>
<td class="nump">642.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="nump">99.4<span></span>
</td>
<td class="nump">6.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of the period</a></td>
<td class="nump">2,375.0<span></span>
</td>
<td class="nump">1,049.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of the period</a></td>
<td class="nump">3,862.8<span></span>
</td>
<td class="nump">1,699.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember', window );">Nonrelated Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net of effects of business acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">74.9<span></span>
</td>
<td class="nump">127.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities, net of effects of business acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">$ (11.8)<span></span>
</td>
<td class="num">$ (15.9)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AmortizationOfInventoryStepUp">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization Of Inventory Step-Up</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AmortizationOfInventoryStepUp</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in value of liability in contingent consideration arrangement in business combination, including, but not limited to, difference arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding effect from change in exchange rate, of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 321<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479567/321-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activity, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfOtherInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from the sale of investments classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfOtherInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_NonrelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statement of Equity Statement - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Preferred stock</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Accumulated other comprehensive income (loss)</div></th>
<th class="th"><div>Retained earnings</div></th>
<th class="th"><div>Treasury stock</div></th>
<th class="th"><div>Parent</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">168.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 302.5<span></span>
</td>
<td class="num">$ (153.7)<span></span>
</td>
<td class="nump">$ 17,627.6<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">$ 14,799.4<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Beginning balance, treasury stock, shares at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 1,365.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,365.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,365.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock under stock award plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock under stock award plan</a></td>
<td class="num">(66.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(66.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Compensation related to share-based payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">224.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">224.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.2)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2024</a></td>
<td class="nump">16,358.9<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">488.5<span></span>
</td>
<td class="num">(145.7)<span></span>
</td>
<td class="nump">18,993.1<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">16,358.9<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Sep. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">169.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Ending balance, treasury stock, shares at Sep. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares at Jun. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">169.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Jun. 30, 2024</a></td>
<td class="nump">15,889.1<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">407.5<span></span>
</td>
<td class="num">(146.0)<span></span>
</td>
<td class="nump">18,604.6<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Beginning balance, treasury stock, shares at Jun. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">388.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">388.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans</a></td>
<td class="nump">7.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock under stock award plan</a></td>
<td class="num">(1.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Compensation related to share-based payments</a></td>
<td class="nump">75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2024</a></td>
<td class="nump">16,358.9<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">488.5<span></span>
</td>
<td class="num">(145.7)<span></span>
</td>
<td class="nump">18,993.1<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="nump">$ 16,358.9<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Sep. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">169.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Ending balance, treasury stock, shares at Sep. 30, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">169.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2024</a></td>
<td class="nump">16,716.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">569.4<span></span>
</td>
<td class="num">(136.2)<span></span>
</td>
<td class="nump">19,259.8<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Beginning balance, treasury stock, shares at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">1,341.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,341.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="num">(78.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(78.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans</a></td>
<td class="nump">28.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock under stock award plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock under stock award plan</a></td>
<td class="num">(41.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(41.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Compensation related to share-based payments</a></td>
<td class="nump">240.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2025</a></td>
<td class="nump">18,207.5<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">797.7<span></span>
</td>
<td class="num">(214.8)<span></span>
</td>
<td class="nump">20,601.6<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Sep. 30, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">170.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Ending balance, treasury stock, shares at Sep. 30, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance, shares at Jun. 30, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">170.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Jun. 30, 2025</a></td>
<td class="nump">17,634.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">714.0<span></span>
</td>
<td class="num">(238.1)<span></span>
</td>
<td class="nump">20,135.1<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Beginning balance, treasury stock, shares at Jun. 30, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">466.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">466.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">23.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued', window );">Issuance of common stock under stock option and stock purchase plans</a></td>
<td class="nump">6.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock under stock award plan (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Issuance of common stock under stock award plan</a></td>
<td class="num">(1.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Compensation related to share-based payments</a></td>
<td class="nump">78.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2025</a></td>
<td class="nump">$ 18,207.5<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="nump">$ 797.7<span></span>
</td>
<td class="num">$ (214.8)<span></span>
</td>
<td class="nump">$ 20,601.6<span></span>
</td>
<td class="num">$ (2,977.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance, shares at Sep. 30, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">170.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Ending balance, treasury stock, shares at Sep. 30, 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479832/842-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-24<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-23<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483421/250-10-45-5<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-5<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-6<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482615/740-10-65-8<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br><br>Reference 42: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-3<br><br>Reference 45: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 47: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 49: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 50: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 51: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 52: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 53: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-15<br><br>Reference 54: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-16<br><br>Reference 55: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4I<br><br>Reference 56: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476166/350-60-65-1<br><br>Reference 57: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of significant accounting policies</a></td>
<td class="text"><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 1:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Summary of Significant Accounting Policies</span></div></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References in these notes to "Biogen," the "company," "we," "us" and "our" refer to Biogen Inc. and its consolidated subsidiaries.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Business Overview</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering innovative therapies for people living with serious and complex diseases. We have a broad portfolio of medicines to treat MS, have introduced the first approved treatment for SMA, co-developed treatments to address a defining pathology of Alzheimer&#8217;s disease and launched the first approved treatment to target a genetic cause of ALS. We market the first and only drug approved in the U.S., the E.U. and certain international markets for the treatment of FA in adults and adolescents aged 16 years and older. We are focused on advancing our pipeline in neurology, specialized immunology and rare diseases. We support our drug discovery and development efforts through internal research and development programs, external collaborations and acquisitions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY and TYSABRI for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of FA; and QALSODY for the treatment of ALS.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Supernus on the commercialization of ZURZUVAE for the treatment of PPD. We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, CLL and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL, follicular lymphoma and, following its approval in October 2025, lupus nephritis; OCREVUS for the treatment of PPMS and RMS; LUNSUMIO for the treatment of relapsed or refractory follicular lymphoma; COLUMVI, a bispecific antibody for the treatment of non-Hodgkin's lymphoma; and have the option to add other potential anti-CD20 therapies, pursuant to our collaboration arrangements with Genentech, a wholly-owned member of the Roche Group.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We commercialize a portfolio of biosimilars of advanced biologics including: BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS, in certain international markets. We also have commercialization rights related to OPUVIZ, an aflibercept biosimilar referencing EYLEA, in certain international markets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these unaudited condensed consolidated financial statements (condensed consolidated financial statements).</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair statement of our financial statements for interim periods in accordance with U.S.&#160;GAAP. The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our 2024 Form&#160;10-K. Our accounting policies are described in the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2024 Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the three and nine</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, 2025, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate as one operating segment, focused on discovering, developing and delivering innovative therapies for people living with serious and complex diseases.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2025 we began presenting acquired in-process research and development, upfront and milestone expense as a separate line item in our condensed consolidated statements of income. Acquired in-process research and development, upfront and milestone expense includes costs incurred in connection with collaboration and license agreements such as upfront and milestone payments and, when applicable, premiums on equity securities and asset acquisitions of acquired in-process research and development, which were previously </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">included in research and development expense. Prior periods have been reclassified to conform to the current period presentation. The reclassification had no impact on our total cost and expense, net income attributable to Biogen Inc., earnings per share or total equity.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Consolidation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than 100.0% of the economics, we record net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenue and expense and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and assumptions. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results may differ from these estimates.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to our significant accounting policies disclosed in </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1, Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our audited consolidated financial statements included in our 2024 Form&#160;10-K.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">New Accounting Pronouncements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have had, or may have, a material impact on our condensed consolidated financial statements or disclosures.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:16.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.303%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.028%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.635%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Standard</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effective Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Effects on the financial statements</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:112%">ASU No. 2023-09, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:112%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:112%">This standard establishes incremental disaggregation of income tax disclosures pertaining to the effective tax rate reconciliation and income taxes paid. The amendments in this update are required to be applied on a prospective basis with the option to apply it retrospectively.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Annual reporting for fiscal years beginning after December 15, 2024. Early adoption is permitted.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:112%">We are currently evaluating the potential impact that this new standard will have on our consolidated financial statements and related disclosures, and expect to apply this standard prospectively upon adoption.</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:112%">ASU No. 2024-03, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:112%">Income Statement (Subtopic 220-40): Reporting Comprehensive Income - Expense Disaggregation Disclosures</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:112%">This standard requires disclosure in the notes to the financial statements, at each interim and annual reporting period, of specified information about certain costs and expense including purchases of inventory, employee compensation, depreciation and intangible asset amortization included in each relevant expense caption. This standard also requires a qualitative description of the amounts remaining in relevant expense captions that are not separately disaggregated, as well as disclosure of the total amount of selling expenses, and, in annual reporting periods, an entity&#8217;s definition of selling expenses.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Annual reporting for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:112%">We are currently evaluating the potential impact that this new standard will have on our consolidated financial statements and related disclosures.</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:112%">ASU No. 2025-07, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:112%">Derivatives and Hedging (Topic 815) and Revenue from Contracts with Customers (Topic 606): Derivatives Scope Refinements and Scope Clarification for Share-Based Noncash Consideration from a Customer in a Revenue Contract</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:112%">This standard refines and expands the existing scope exceptions that exclude certain contracts, including certain R&amp;D funding arrangements, from derivative accounting, and clarifies the accounting for share-based noncash consideration received from a customer.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Annual reporting for fiscal years beginning after December 15, 2026, and interim periods within those annual reporting periods. Early adoption is permitted.</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:112%">We have early adopted this new standard on a modified retrospective basis as of January 1, 2025. Adoption did not have a material impac</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:112%">t on our condensed consolidated financial statements and related disclosures.</span></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combination [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisitions</a></td>
<td class="text"><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 2:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Acquisitions</span></div></td></tr></table></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Alcyone Therapeutics, Inc.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2025 we entered into a definitive agreement to acquire all of the issued and outstanding shares of Alcyone Therapeutics, Inc., a clinical-stage biotechnology company focused on pediatric care through precision CNS therapeutics and dosing platforms. Alcyone's lead asset is ThecaFlex DRx, an implantable subcutaneous port and catheter device being investigated for the intrathecal delivery of ASOs, which is designed to provide an alternative to repeat lumbar punctures in chronic intrathecal administration of medicines.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have agreed to pay an upfront cash payment of $85.0&#160;million upon closing, plus additional potential amounts payable upon the achievement of certain milestones related to the development and regulatory approval of ThecaFlex DRx for administering SPINRAZA and additional pipeline products.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to account for this proposed acquisition as an asset acquisition as the value being acquired primarily relates to a single asset and plan to record the upfront payment within acquired in-process research and development, upfront and milestone expense within our condensed consolidated statements of income upon the completion of this proposed acquisition. We anticipate the</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> proposed acquisition to close during the fourth quarter of 2025, subject to the satisfaction of customary closing conditions. U</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nder the terms of this proposed acquisition, we expect to oversee the end-to-end development, manufacturing and commercialization of ThecaFlex DRx</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alcyone's remaining therapeutic assets would be divested from Alcyone into Neela Therapeutics, Inc., a newly formed independent company, prior to the closing of this proposed acquisition. We anticipate to make a convertible debt investment of up to</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> $5.0&#160;million in Neela Therapeutics. Inc.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Human Immunology Biosciences</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 2, 2024, we completed the acquisition of all of the issued and outstanding shares of HI-Bio, a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases. HI-Bio's lead asset, felzartamab, an anti-CD38 antibody, is currently being evaluated for several indications, including three leading indications, AMR, PMN and IgAN. Felzartamab has received Breakthrough Therapy Designation and ODD from the FDA for development in the treatment of PMN and AMR. Subsequent to our acquisition, felzartamab received ODD in the E.U. in IgAN and solid organ transplantation. The acquisition of HI-Bio is expected to augment our pipeline and build on our expertise in immunology.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of this acquisition, we paid shareholders of HI-Bio approximately $1.15&#160;billion at closing and may pay up to a total of </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$650.0&#160;million in contingent development and regulatory milestone payments.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The $1.15&#160;billion paid includes approximately $74.5&#160;million related to HI-Bio's outstanding, non-vested equity awards, inclusive of employer taxes, of which $56.4&#160;million was recognized as share-based compensation payments to settle non-vested equity awards attributable to the post-acquisition service period and therefore not reflected as a component of total purchase price paid. Of the total $56.4&#160;million, we recognized approximately $42.5&#160;million as a charge to research and development expense with the remaining $13.9&#160;million as a charge to selling, general and </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">administrative expense within our condensed consolidated statements of income for the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three and nine months ended September 30, 2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These amounts were associated with the accelerated vesting of stock options and RSUs previously granted to HI-Bio employees and required no future services to vest.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon closing we also paid an additional </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$43.7&#160;million related to working capital adjustments as of the transaction close date, which was included as a component of total purchase price paid.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We funded this acquisition through available cash on hand and accounted for this acquisition as a business combination using the acquisition method of accounting in accordance with</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ASC Topic 805, Business Combinations</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and recorded assets acquired and liabilities assumed at their respective fair values as of the acquisition date.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Purchase Price Consideration</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total consideration transferred for the acquisition of HI-Bio is summarized as follows:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.823%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.393%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of July&#160;2, 2024</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash consideration paid to HI-Bio shareholders</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,137.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">485.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total consideration</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,622.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Represents total consideration paid to shareholders of HI-Bio of $1.15&#160;billion, plus an additional $43.7&#160;million related to working capital adjustments as of the transaction close date, less $56.4&#160;million of cash paid for HI-Bio's outstanding, non-vested equity awards, inclusive of employer taxes, which were recognized as compensation attributable to the post-acquisition service period and therefore not reflected as a component of total consideration. </span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingent Consideration:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We may make certain contingent payments to the former shareholders of HI-Bio upon the achievement of certain development and regulatory milestones. As of the acquisition date, the maximum aggregate amount payable for these potential milestones was $650.0&#160;million. The acquisition-date fair value of these milestones was approximately $485.1&#160;million and was estimated utilizing a probability-adjusted discounted cash flow calculation using an appropriate discount rate dependent on the nature and timing of the milestone payments, which ranged from </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.2% to 7.0%, and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">probabilities of technological and regulatory success ranging from 67.0% to near-certain probability.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Of the total contingent consideration, approximately $279.3&#160;million related to milestones classified as short-term and reflected as a component of accrued expense and other with the remaining $205.8&#160;million reflected as a component of other long-term liabilities within our condensed consolidated balance sheets. The short-term liability related to the fourth patient dosed in a Phase 3 clinical trial of felzartamab in a first and s</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">econd indication, which would each result in the achievement of a $150.0&#160;million milestone payment. During the second quarter of 2025 the first milestone related to the fourth patient dosed in a phase 3 clinical trial of felzartamab for AMR was achieved, resulting in a $150.0&#160;million milestone payment made to the former shareholders of HI-Bio, which was paid during the third quarter of 2025. In October 2025 the second milestone related to the fourth patient dosed in a phase 3 clinical trial of felzartamab for IgAN was achieved, resulting in a $150.0&#160;million milestone payment to be made to the former shareholders of HI-Bio, which we expect will be paid during the fourth quarter of 2025.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subsequent changes in the fair value of the contingent consideration obligation are being recognized as (gain) loss on fair value remeasurement of contingent consideration within our condensed consolidated statements of income. This fair value measurement is based on significant inputs that are not observable in the market and thus represent Level 3 fair value measurements. For additional information related to the fair value of this obligation, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 8, Fair Value Measurements</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Contractual Commitments: </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We acquired HI-Bio's pre-existing in-license commitments under third-party agreements with MorphoSys, which included tiered royalties on potential future sales ranging from high-single digit to mid-teen percentages, as well as potential development, regulatory and commercial milestone payments of up to $130.0&#160;million, $230.0&#160;million and $640.0&#160;million, respectively. At the transaction close date the achievement of these milestones was not considered probable and therefore not recorded in our financial statements.</span></div><div style="margin-bottom:3pt;margin-top:9pt;padding-left:9pt;text-indent:-9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">Purchase Price Allocation</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We finalized purchase accounting for this acquisition in the second quarter of 2025.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date, and reflects measurement period adjustments made to the amounts initially recorded as of the acquisition date on July&#160;2, 2024. The related impact to our condensed consolidated statements of income that would have been recognized in previous periods if the adjustments were recognized as of the acquisition date is immaterial.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.847%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:19.369%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts Recognized as of Acquisition Date<br/>(as adjusted)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intangible assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IPR&amp;D - felzartamab (IgAN)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">920.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IPR&amp;D - felzartamab (AMR)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">450.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IPR&amp;D - felzartamab (PMN)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">265.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other clinical programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expense and other assets</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(35.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax liability</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(309.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,361.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">261.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets acquired and liabilities assumed</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,622.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Includes measurement period adjustments recorded in 2025 that increased prepaid expense and other assets by $0.4&#160;million, net deferred tax liability by $4.9&#160;million and goodwill by $4.5&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intang</span><span style="background-color:#ffffff;color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ible assets:</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Intangible assets comprised of approximately $1.6&#160;billion of IPR&amp;D related to HI-Bio's lead asset felzartamab. This includes $920.0&#160;million of IPR&amp;D related to felzartamab indication for IgAN, $450.0&#160;million of IPR&amp;D related to felzartamab indication for AMR and $265.0&#160;million of IPR&amp;D related to felzartamab indication for PMN. The estimated fair values of the program related intangible assets were determined using a multi-period excess earnings method, a form of the income approach, utilizing cash flow analyses and a discount rate of 14.5%. These fair value measurements were based on significant inputs that are not observable in the market and thus represent Level 3 fair value measurements.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Goodwill was calculated as the excess of the consideration transferred over the net assets recognized and represents the future economic benefits arising from the other assets acq</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">uired that could not be individually identified and separately recognized. We recognized goodwill of approximately $261.0&#160;million, which includes measurement period adjustments, and is not deductible for tax purposes. The goodwill recognized from our acquisition of HI-Bio is primarily the result of the deferred tax consequences from the transaction recorded for financial statement purposes.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Acquisition-related expense:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Acquisition-related expense, primarily comprised</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of advisory and legal fees, and other transaction costs, totaled approximately $2.8&#160;million and were recorded within selling, general and administrative expense within our consolidated statements of income for the year ended December 31, 2024, included in our </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Form 10-K</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-38<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 46<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-46<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 43<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-43<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 45<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-45<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-29<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-29<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-4<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479326/805-40-45-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/805-30/tableOfContent<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/805-20/tableOfContent<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-5<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/805-10/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Dispositions<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_DivestituresAbstract', window );"><strong>Divestitures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock', window );">Dispositions</a></td>
<td class="text"><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 3:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Dispositions</span></div></td></tr></table></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Sale of Joint Venture Equity Interest in Samsung Bioepis</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2022 we completed the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics in exchange for total consideration of approximately $2.3&#160;billion. Under the terms of this transaction, we received approximately $1.0&#160;billion in cash at closing, with approximately $1.3&#160;billion in cash to be deferred over two payments. The first deferred payment of </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$812.5&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was received in April 2023 and</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the second deferred payment of $437.5&#160;million</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was received in April 2024.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">nine</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> months ended September 30, 2024, we recognized</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> a gain</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> of approximately </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$7.5&#160;million </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">to reflect the change in fair value associated with the passage of time related to the second deferred payment </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">due to us, which was received in April 2024 and</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> recorded in other (income) expense, net within our condensed consolidated statements of income.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on the sale of our equity interest in Samsung Bioepis, please read </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 3, Dispositions</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2024 Form 10-K.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Sale of Priority Review Voucher</span></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In April 2024 we completed the sale of our rare pediatric disease PRV, generated by the development associated with SPINRAZA, to a third party. In consideration for the PRV we received a cash payment of $103.0&#160;million upon the closing of the PRV purchase, of which approximately $14.4&#160;million was paid to Ionis. Our net portion of approximately $88.6&#160;million was recognized in gain on sale of priority review voucher, net within our condensed consolidated statements of income for the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">nine</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> months ended September 30, 2024.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Sale of TOFIDENCE</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2025 we completed the sale of our regulatory and commercial rights in the U.S. for TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA, to Organon. Under the terms of this transaction, we received a payment of approximately $51.0&#160;million </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in July 2025 a</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nd recognized a de minimis loss within our condensed consolidated statements of income for the nine months ended September 30, 2025.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DivestituresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Divestitures [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DivestituresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205-20/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring, Business Transformation and Other Cost Saving Initiatives<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring, Business Transformation and Other Cost Saving Initiatives</a></td>
<td class="text"><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 4:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Restructuring</span></div></td></tr></table></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2023 Fit for Growth Restructuring Program</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023 we initiated cost saving measures as part of our Fit for Growth program to reduce operating costs, while improving operating efficiency and effectiveness. The Fit for Growth program is expected to generate approximately $1.0&#160;billion in gross operating expense savings by the end of 2025, some of which will be reinvested in various initiatives. The Fit for Growth program is currently estimated to include net headcount reductions of approximately 1,400 employees and we expect to incur total restructuring charges of approximately $310.0&#160;million, which were substantially achieved as of September 30, 2025.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total charges incurred from our 2023 Fit for Growth program are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.092%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.434%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accelerated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total charges</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accelerated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total charges</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.1&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.3&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Costs:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Includes costs associated with items such as asset abandonment and write-offs, facility closure costs, pre-tax gains and losses resulting from the termination of certain leases, employee non-severance expense, consulting fees and other costs.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Reata Integration</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the close of our Reata acquisition in September 2023, we implemented an integration plan designed to realize operating synergies through cost savings and avoidance. Under this initiative, we estimated we would incur total integration charges of approximately $35.0&#160;million related to severance and employment costs, which were substantially incurred during 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total charges incurred from our Reata integration are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.753%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.606%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accelerated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total charges</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accelerated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total charges</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.8&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Reata we assumed responsibility for a single-tenant, build-to-suit building of approximately 327,400 square feet of office and laboratory space located in Plano, Texas, with an initial lease term of 16 years. We do not intend to occupy this building and are evaluating opportunities to sublease the property. For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Form 10-K.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Restructuring Reserve</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Charges and spending related to workforce reductions are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Workforce Reductions</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of January 1</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(42.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency and other adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of March 31</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency and other adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of June 30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency and other adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of September 30</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.2&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/420/tableOfContent<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenues</a></td>
<td class="text"><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 5:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Revenue</span></div></td></tr></table></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Product Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue by product is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:31.550%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.445%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TECFIDERA</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">123.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">168.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">192.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">232.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">VUMERITY</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">189.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">214.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">134.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Fumarate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">234.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">382.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">175.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">215.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">390.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AVONEX</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">133.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">188.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">115.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">176.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PLEGRIDY</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Interferon</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">161.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">85.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">246.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">94.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">237.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TYSABRI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">247.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">184.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">431.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">227.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">178.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">406.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FAMPYRA</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Multiple Sclerosis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">642.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">418.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,061.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">546.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">507.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,053.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rare Disease:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SPINRAZA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">153.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">220.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">374.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">153.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">228.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">381.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SKYCLARYS</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">102.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">QALSODY</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Rare Disease</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">235.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">298.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">533.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">240.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">254.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">494.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biosimilars:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BENEPALI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">118.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">118.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IMRALDI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FLIXABI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BYOOVIZ</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TOFIDENCE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Biosimilars</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">194.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">196.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">192.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">196.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ZURZUVAE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue, net</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">935.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">911.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,846.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">813.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">956.4&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,769.4&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Effective January 1, 2025, our collaboration and license agreement for FAMPYRA global commercialization rights was terminated.</span></div><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> SKYCLARYS became commercially available in the E.U. during the first quarter of 2024.</span></div><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> QALSODY became commercially available in the E.U. during the second quarter of 2024.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Other includes FUMADERM and ADUHELM.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:31.550%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.445%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TECFIDERA</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">436.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">567.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">611.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">739.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">VUMERITY</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">494.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">565.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">385.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">451.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Fumarate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">626.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">507.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,133.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">512.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">677.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,190.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AVONEX</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">363.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">169.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">533.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">344.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">193.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">537.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PLEGRIDY</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">106.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">186.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">109.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">194.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Interferon</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">443.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">276.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">719.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">428.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">303.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">732.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TYSABRI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">720.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">547.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,267.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">690.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">609.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,299.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FAMPYRA</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Multiple Sclerosis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,790.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,331.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,121.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,631.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,648.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,279.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rare Disease:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SPINRAZA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">456.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">733.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,190.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">458.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">692.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,151.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SKYCLARYS</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">221.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">165.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">387.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">230.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">280.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">QALSODY</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Rare Disease</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">700.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">938.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,639.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">703.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">749.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,452.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biosimilars:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BENEPALI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">345.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">345.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">354.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">354.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IMRALDI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">162.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">162.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FLIXABI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BYOOVIZ</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TOFIDENCE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Biosimilars</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">550.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">559.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">572.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">591.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ZURZUVAE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue, net</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,630.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,821.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,452.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,405.8&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,975.1&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,380.9&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Effective January 1, 2025, our collaboration and license agreement for FAMPYRA global commercialization rights was terminated.</span></div><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> SKYCLARYS became commercially available in the E.U. during the first quarter of 2024.</span></div><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> QALSODY became commercially available in the E.U. during the second quarter of 2024.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Other includes FUMADERM and ADUHELM.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized revenue from two wholesalers accounting for 27.8% and 16.0% of gross product revenue for the three months ended September 30, 2025, and 27.3% and 15.4% of gross product revenue for the nine months ended September 30, 2025.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized revenue from two wholesalers accounting for 25.9% and 14.8% of gross product revenue for the three months ended September 30, 2024, and 25.6% and 12.9% of gross product revenue for the nine months ended September 30, 2024.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An analysis of the change in reserves for discounts and allowances is summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.155%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.109%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.109%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.109%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.114%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">162.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">880.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,091.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current provisions relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">607.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,052.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,680.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments relating to prior years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(82.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(79.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/credits relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(497.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,271.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,768.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/credits relating to sales in prior years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(111.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(479.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(602.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, September 30, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">163.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,101.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,322.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.253%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reduction of accounts receivable</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">154.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Component of accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,062.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">937.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue-related reserves</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,322.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,091.6&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Revenue from Anti-CD20 Therapeutic Programs</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from anti-CD20 therapeutic programs is summarized in the table below. For the purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.309%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalty revenue on sales of OCREVUS</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">386.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">346.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,029.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">985.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen&#8217;s share of pre-tax profits in the U.S. for RITUXAN, GAZYVA and LUNSUMIO</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">94.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">292.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">285.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">493.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">446.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,339.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,284.7&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt;padding-right:2.25pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Genentech, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships, </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to these condensed consolidated financial statements.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Alzheimer's Collaboration Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Alzheimer's collaboration revenue consists of our 50.0% share of LEQEMBI product revenue, net and cost of sales, including royalties, as we are not the principal. We began recognizing Alzheimer's collaboration revenue upon the accelerated approval of LEQEMBI in the U.S. during the first quarter of 2023.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2025, we recognized Alzheimer's collaboration revenue of approximately $42.7 million and $130.6 million, respectively, compared to $18.6 million and $33.2 million, respectively, in the prior year comparative periods.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Eisai, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Contract Manufacturing, Royalty and Other Revenue</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract manufacturing, royalty and other revenue is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.285%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract manufacturing revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">141.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">221.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">648.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">474.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalty and other revenue</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total contract manufacturing, royalty and other revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">151.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">231.6&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">689.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">522.4&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Manufacturing Revenue</span></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract manufacturing revenue primarily reflects amounts earned under contract manufacturing agreements with our strategic customers and batches of LEQEMBI related to our collaboration with Eisai.</span></div><div style="margin-top:7pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalty and Other Revenue</span></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty and other revenue primarily reflects royalty revenue on biosimilar products from our license arrangements with Samsung Bioepis and royalties we receive from net sales on products related to patents that we have out-licensed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our license arrangements with Samsung Bioepis and our collaboration arrangements with Eisai, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory</a></td>
<td class="text"><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 6:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Inventory</span></div></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventory are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">296.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">317.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,635.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,882.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">440.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">353.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,371.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,554.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Classification:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,209.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,460.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments and other assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">162.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">93.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,371.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,554.4&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-term inventory is included in investments and other assets within our condensed consolidated balance sheets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of our acquisition of Reata in September 2023 we recorded a fair value step-up adjustment related to the acquired inventory of SKYCLARYS of approximately $1.3&#160;billion. This fair value step-up adjustment is being amortized to cost of sales within our condensed consolidated statements of income as the inventory is sold or used for clinical purposes. We expect this amount to be fully amortized by the end of 2028. For the three and nine months ended September 30, 2025, amortization from the fair value step-up adjustment was approximately $61.5&#160;million and $165.4 million, respectively. For the three and nine months ended September 30, 2024, amortization from the fair value step-up adjustment was approximately $50.9&#160;million and $185.1 million, respectively, which includes approximately $2.5 million and $48.5 million, respectively, of inventory used for clinical purposes, which is reflected in research and development expense within our condensed consolidated statements of income. For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Form 10-K.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Intangible Assets and Goodwill</a></td>
<td class="text"><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 7:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Intangible Assets and Goodwill</span></div></td></tr></table></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Intangible Assets</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net of accumulated amortization, impairment charges and adjustments are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.607%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.684%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Life</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Completed technology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2-31 years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,087.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,558.7)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,528.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,138.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,254.1)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,884.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite until commercialization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,639.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,639.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,642.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,642.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Priority review voucher</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks&#160;and trade names</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,890.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,558.7)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,331.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,945.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,254.1)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,691.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amortization and Impairments</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, 2025, amortization and impairment of acquired intangible assets totale</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d $135.7 million and $378.4 million, respectively, compared to $130.3 million and $295.5 million, respectively, </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the prior year comparative periods.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, 2025, amortization of acquired intangible assets, excluding impairment charges, totaled </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$135.7 million and $374.9 million, respectively, </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compared to </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$110.1 million and $275.3 million, respectively, in the prior year comparative periods. </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Th</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e increases were primarily due to amortization for the acquired intangible assets associated with SKYCLARYS and TYSABRI.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2025, we had no impairment charges. For the nine months ended September 30, 2025, amortization and impairment of acquired intangible assets reflects the impact of a $3.5 million impairment charge related to a compound acquired from HI-Bio. For the three and nine months ended September 30, 2024, amortization and impairment of acquired intangible assets reflects impairment charges of approximately $20.2 million related to intangible assets associated with the termination of Samsung Bioepis' commercialization rights during the third quarter of 2024.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Completed Technology</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Completed technology primarily relates to our other marketed products and programs acquired through asset acquisitions, licenses and business combinations. Completed technology intangible assets are amortized over their estimated useful lives, which range between 2 to 31 years, with a remaining weighted average useful life of 12 years.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">IPR&amp;D Related to Business Combinations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IPR&amp;D represents the fair value assigned to research and development assets that we acquired as part of a business combination and had not yet reached technological feasibility at the date of acquisition. Included in IPR&amp;D balances are adjustments related to foreign currency exchange rate fluctuations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value associated with our IPR&amp;D assets as of September 30, 2025 and December 31, 2024, primarily relates to the IPR&amp;D programs we acquired in connection with our acquisition of HI-Bio in July 2024, with an estimated fair value of approximately $1.6&#160;billion.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Priority Review Voucher</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Reata in September 2023 we acquired a rare pediatric disease PRV which may be used to obtain priority review by the FDA for a future regulatory submission or sold to a third party. We recorded the PRV based on its estimated fair value of $100.0&#160;million as an intangible asset.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Estimated Future Amortization of Intangible Assets</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future amortization of finite-lived intangible assets for the next five years is expected to be as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025 (remaining three months)</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">130.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">485.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">490.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">525.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">580.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2030</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">650.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Goodwill</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a roll forward of the changes in our goodwill balance:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill, December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,478.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill resulting from HI-Bio acquisition</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill, September 30, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,490.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Goodwill resulting from the HI-Bio acquisition relates to HI-Bio measurement period adjustments recognized during 2025 related to certain income tax adjustments. For additional information on our acquisition of HI-Bio, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Other includes adjustments related to foreign currency exchange rate fluctuations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2025, we had</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> no </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">impairment losses related to goodwill.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 8:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Fair Value Measurements</span></div></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.796%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements on a Recurring Basis</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,398.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,398.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable debt securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-current assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Convertible note</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan assets for deferred compensation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,691.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,557.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-current liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">242.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">242.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">490.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">391.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As part of our strategic research arrangement with City Therapeutics we invested in a convertible note, for which we elected the fair value option. For additional information on the arrangement with City Therapeutics, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> to these condensed consolidated financial statements.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.796%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements on a Recurring Basis</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,664.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,664.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">179.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">179.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-current assets:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan assets for deferred compensation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,949.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">179.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,770.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">291.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">291.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-current liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">221.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">221.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">524.5&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">512.8&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketable equity securities represent investments in publicly traded equity securities. Our ability to liquidate our investment in Denali may be limited by the size of our interest, the volume of market-related activity, our concentrated level of ownership and potential restrictions resulting from our status as a collaborator. Therefore, we may realize significantly less than the current value of such investments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2025 Sage was acquired by Supernus. Prior to this acquisition, we disposed of all of our shares of Sage common stock in a block trade.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our investments in Denali and Sage common stock, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2024 Form 10-K.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material impairments of our assets measured and carried at fair value as of September 30, 2025 and December 31, 2024. In addition, there have been no changes to our valuation techniques as of September 30, 2025 and December 31, 2024.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of our validation procedures related to prices provided by third-party pricing services and our option pricing valuation model, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1, Summary of Significant Accounting Policies - Fair Value Measurements,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2024 Form 10-K. </span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Level 3 Assets and Liabilities Held at Fair Value</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present quantitative information, as of the dates indicated, about the valuation techniques and significant unobservable inputs used in the valuation of our Level 3 financial assets and liabilities measured at fair value on a recurring basis:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.069%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.772%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quantitative Information about Level 3 Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable Input(s)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">391.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discounted cash flow</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.4% - 5.5%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected timing of achievement of development milestones</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025 - 2030</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.069%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.772%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quantitative Information about Level 3 Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable Input(s)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">512.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discounted cash flow</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.2% - 6.3%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected timing of achievement of development milestones</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025 - 2030</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average discount rates were calculated based on the relative fair values of each distinct contingent consideration obligation related to our acquisition of HI-Bio in July 2024. In addition, we apply various probabilities of technological and regulatory success to the valuation models to estimate the fair values of these contingent consideration obligations, which ranged from approximately 70.0% to near certain probability as of September 30, 2025 and December 31, 2024.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> no tr</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ansfers of assets or liabilities into or out of Level 3 as of September 30, 2025 and December 31, 2024.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingent Consideration Obligations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of HI-Bio in July 2024 we agreed to make additional payments based upon the achievement of certain milestone events. The following table provides a roll forward of the fair value of our contingent consideration obligations, which were classified as Level 3 measurements:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.683%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value, beginning of period</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">534.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">512.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration resulting from HI-Bio acquisition</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">485.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">485.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in fair value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(149.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(150.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value, end of period</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">391.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">508.9&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">391.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">508.9&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the fair value of our contingent consideration obligations, other than changes due to payments, are recognized as a (gain) loss on fair value remeasurement of contingent consideration in our condensed consolidated statements of income. The fair values of the contingent consideration liabilities were based on a probability-adjusted discounted cash flow calculation using Level 3 fair value measurements and inputs. For additional information on the valuation techniques and inputs utilized in the valuation of our financial assets and liabilities, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1, Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2024 Form 10-K.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2025 and December 31, 2024, approximately $148.6 million and $291.2 million, respectively, of the fair value of the total contingent consideration obligations were classified as short-term and reflected as a component of accrued expense and other with the remaining $242.6 million and $221.6 million, respectively, reflected as a component of other long-term liabilities in our condensed consolidated balance sheets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or the three and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, 2025</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, changes in fair value of our contingent consideration obligations were primarily due to the passage of time.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2025 the first milestone related to the fourth patient dosed in a phase 3 clinical trial of felzartamab for AMR was achieved, resulting in a $150.0&#160;million milestone payment made to the former shareholders of HI-Bio, which was paid during the third quarter of 2025. In October 2025 the second milestone related to the fourth patient dosed in a phase 3 clinical trial of felzartamab for IgAN was achieved, resulting in a $150.0&#160;million milestone payment to be made to the former shareholders of HI-Bio, which we expect will be paid during the fourth quarter of 2025.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Financial Instruments Not Carried at Fair Value</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Financial Instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the short-term nature of certain financial instruments, the carrying value reflected in our condensed consolidated balance sheets for current accounts receivable, due from anti-CD20 therapeutic programs, other current assets, accounts payable and accrued expense and other, approximates fair value.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:42.091%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.374%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Current portion:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.050% Senior Notes due September 15, 2025</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,741.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,748.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of notes payable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,741.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,748.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Non-current portion:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.250% Senior Notes due May 1, 2030</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,367.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,495.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,295.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,494.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.050% Senior Notes due January 15, 2031</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">410.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">397.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.750% Senior Notes due May 15, 2035</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">680.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">645.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.200% Senior Notes due September 15, 2045</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,026.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,101.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,008.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,101.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.150% Senior Notes due May 1, 2050</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">970.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,475.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">943.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,475.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.250% Senior Notes due February 15, 2051</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">458.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">479.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">448.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">476.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.450% Senior Notes due May 15, 2055</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">748.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">690.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current portion of notes payable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,663.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,285.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,696.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,547.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total notes payable</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,663.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,285.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,437.2&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,295.8&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> In May 2025 we issued our 2025 Senior Notes for an aggregate principal amount of $1.75&#160;billion. In June 2025 we used the net proceeds from the sale of our 2025 Senior Notes to redeem in full our 4.050% Senior Notes due September 15, 2025, prior to maturity. For additional information, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 13, Indebtedness</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair values of each of our series of Senior Notes were determined through market, observable and corroborated sources. The changes in the fair values of our Senior Notes as of September 30, 2025, compared to December 31, 2024, are primarily related to decreases in U.S. treasury yields and credit spreads used to value our Senior Notes since December 31, 2024. For additional information related to our Senior Notes, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 13,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Indebtedness,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2024 Form 10-K.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Financial Instruments</a></td>
<td class="text"><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 9:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Financial Instruments</span></div></td></tr></table></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,116.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,664.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">202.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,398.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,664.9&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying values of our money market funds, short-term debt securities and commercial paper, including accrued interest, approximate fair value due to their short-term maturities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketable equity securities gains (losses) are recorded in other (income) expense, net in our condensed consolidated statements of income. The following tables summarize our marketable debt and equity securities, classified as available-for-sale:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.252%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.580%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">227.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(123.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">227.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(123.9)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.252%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.580%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">668.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(489.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">179.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">668.7&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(489.0)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">179.7&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Summary of Contractual Maturities: Available-for-Sale Debt Securities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value and amortized cost of our marketable debt securities classified as available-for-sale by contractual maturity are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.537%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.353%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2025</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The average maturity of our marketable debt securities classified as available-for-sale as of September 30, 2025, was approximately 2 months.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Strategic Investments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies, which are reflected within our disclosures included in </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 8, Fair Value Measurements,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these condensed consolidated financial statements, as well as venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2025 and December 31, 2024, our strategic investment portfolio was comprised of investments totaling $167.1 million and $226.7 million, respectively, which are included in investments and other assets within our condensed consolidated balance sheets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in our strategic investment portfolio as of September 30, 2025, compared to December 31, 2024, was primarily due to the decrease in the fair value of our investment in Denali common stock as well as the sale of our remaining investment in Sage common stock during the third quarter of 2025.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our investments in Denali and Sage common stock, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2024 Form 10-K.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalent, and debt and equity securities, including realized and unrealized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivative Instruments</a></td>
<td class="text"><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 10:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Derivative Instruments</span></div></td></tr></table></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Foreign Currency Forward Contracts - Hedging Instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to the global nature of our operations, portions of our revenue and operating expense are recorded in currencies other than the U.S.&#160;dollar. The value of revenue and operating expense measured in U.S.&#160;dollars is therefore subject to changes in foreign currency exchange rates. We enter into foreign currency forward contracts and foreign currency options with financial institutions with the primary objective to mitigate the impact of foreign currency exchange rate fluctuations on our international revenue and operating expense.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foreign currency forward contracts and foreign currency options in effect as of September 30, 2025 and December 31, 2024, had durations of 1 to 24 months and 1 to 12 months, respectively. These contracts have been designated as cash flow hedges and unrealized gains and losses on the portion of these foreign currency forward contracts and foreign currency options that are included in the effectiveness test are reported in AOCI. Realized gains and losses of such contracts and options are recognized in revenue when the sale of product in the currency being hedged is recognized and in operating expense when the expense in the currency being hedged is recorded. We recognize all cash flow hedge reclassifications from AOCI and fair value changes of excluded portions in the same line item in our condensed consolidated statements of income that have been impacted by the hedged item.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notional amount of foreign currency forward contracts and foreign currency options that were entered into to hedge forecasted revenue and operating expense is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Euro</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,524.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,062.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">British pound</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">133.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Swiss franc</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canadian dollar</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total foreign currency forward contracts and options</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,637.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,235.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pre-tax portion of the fair value of these foreign currency forward contracts and foreign currency options that were included in AOCI in total equity is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.785%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gains</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized (losses)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(112.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unrealized gains (losses)</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(103.4)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50.3&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect net unrealized losses of approximately $103.4&#160;million to be settled over the next 24 months, of which approximately $90.8&#160;million of these net unrealized losses are expected to be settled over the next 12 months, with any amounts in AOCI to be reported as an adjustment to revenue or operating expense. We consider the impact of our and our counterparties&#8217; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of September 30, 2025 and December 31, 2024, credit risk did not materially change the fair value of our foreign currency forward contracts and forward currency options.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the effect of foreign currency forward contracts and forward currency options designated as hedging instruments in our condensed consolidated statements of income:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:22.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.345%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.154%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Reclassified from AOCI into Operating Income (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses) Excluded from Effectiveness Testing and<br/>Recognized in Operating Income (in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29.1)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.6)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Reclassified from AOCI into Operating Income (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses) Excluded from Effectiveness Testing and<br/>Recognized in Operating Income (in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(41.1)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Foreign Currency Forward Contracts - Other Derivative Instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also enter into other foreign currency forward contracts, usually with durations of one month or less, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate notional amount of these outstanding foreign currency forward contracts was $1,066.6 million and $738.7 million as of September 30, 2025 and December 31, 2024, respectively. Net losses of $0.5 million and net gains of $34.9 million</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">related to these contracts were recorded as a component of other (income) expense, net for the three and nine months ended September 30, 2025, respectively, compared to net gains of $23.4 million and net losses of $6.6 million, respectively, in the prior year comparative periods.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Summary of Derivative Instruments</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While certain of our derivative instruments are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our condensed consolidated balance sheets. The amounts in the table below would not be substantially different if the derivative assets and liabilities were offset.</span></div><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:28.328%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.328%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.376%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Cash Flow Hedging Instruments:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other Derivative Instruments:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 182<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480401/815-10-55-182<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 185<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480401/815-10-55-185<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 184<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480401/815-10-55-184<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 181<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480401/815-10-55-181<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4K<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4K<br> -Subparagraph (a)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4K<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4K<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4K<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4H<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4H<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4H<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4H<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 15<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480960/815-15-50-3<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 183<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480401/815-10-55-183<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4K<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4K<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4K<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4K<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4I<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4F<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4F<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/815/tableOfContent<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-5<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-5C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 11:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Property, Plant and Equipment</span></div></td></tr></table></div>Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Accumulated depreciation on property, plant and equipment was $2,868.4 million and $2,670.8 million as of September 30, 2025 and December 31, 2024, respectively. For the three and nine months ended September 30, 2025, depreciation expense totaled approximately $66.5 million and $204.8 million, respectively, compared to $72.7 million and $213.9 million, respectively, in the prior year comparative peri<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 12:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Leases</span></div></td></tr></table></div><div style="margin-top:6pt"><span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">New Corporate Headquarters Lease</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2025 we entered into a lease agreement with MIT Investment Management Company and BioMed Realty for the lease of approximately 580,000 square feet of office and research and development space located at 75 Broadway, Cambridge, Massachusetts, which will be used as our new global corporate headquarters, as well as integrating our research and development and technical operations teams alongside our North American commercial organization. As part of a multi-year real estate consolidation plan that is expected to result in a reduction of approximately 40% of our real estate footprint in Massachusetts, this new lease is intended to replace two existing leases, both in Cambridge, Massachusetts, including our current corporate headquarters. We expect the initial lease term of approximately 15.5 years to commence on May 31, 2028. The estimated minimum lease payments as a result of the new lease total approximately $1.5&#160;billion over the initial lease term. We have an option to extend the lease for three extension periods of five years each and one six month short-term extension, at then market-based rates. We will account for this lease as a right-of-use asset and lease liability upon the lease commencement date.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our accounting policies relating to leases, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1, Summary of Significant Accounting Policies - Leases</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2024 Form 10-K.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Indebtedness<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Indebtedness</a></td>
<td class="text"><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 13:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Indebtedness</span></div></td></tr></table></div><div style="margin-top:6pt"><span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2025 Senior Notes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 12, 2025, we issued senior unsecured notes for an aggregate principal amount of $1.75&#160;billion, consisting of the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$400.0&#160;million of 5.050% Senior Notes due January 15, 2031, valued at 99.981% of par;</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$650.0&#160;million of 5.750% Senior Notes due May 15, 2035, valued at 99.924% of par; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">$700.0&#160;million of 6.450% Senior Notes due May 15, 2055, valued at 99.657% of par.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our 2025 Senior Notes are senior unsecured obligations and may be redeemed at our option at any time at 100% of the principal amount plus accrued interest and, until a specified period before maturity, a specified make-whole amount. Our 2025 Senior Notes contain a change-of-control provision that, under certain circumstances, may require us to purchase our 2025 Senior Notes at a price equal to 101% of the principal amount plus accrued and unpaid interest to the date of repurchase.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incurred approximately $13.9&#160;million of costs associated with this offering which have been recorded as a reduction to the carrying amount of the debt on our condensed consolidated balance sheets. These costs will be amortized as additional interest expense using the effective interest rate method over the period from issuance through maturity. The discounts will be amortized as additional interest expense over the period from issuance through maturity using the effective interest rate method.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest on our 2031 Senior Notes is payable January 15 and July 15 of each year, commencing January 15, 2026. Interest on our 2035 Senior Notes and 2055 Senior Notes is payable May 15 and November 15 of each year, commencing on November 15, 2025.</span></div><div style="margin-top:6pt"><span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">4.050% Senior Notes due September 15, 2025</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 15, 2015, we issued $1.75&#160;billion aggregate principal amount of 4.050% Senior Notes due September 15, 2025, at 99.764% of par. In June 2025 we used the net proceeds from the sale of our 2025 Senior Notes to redeem our 4.050% Senior Notes due September 15, 2025, prior to their maturity. No gain or loss was recognized upon redemption.</span></div><div style="margin-top:6pt"><span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2023 Term Loan Credit Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of Reata in September 2023 we entered into a $1.5&#160;billion term loan credit agreement. On the closing date of the Reata acquisition we drew $1.0 billion from the 2023 Term Loan, comprised of a $500.0&#160;million floating rate 364-day tranche and a $500.0&#160;million floating rate three-year tranche. The remaining unused commitment of $500.0&#160;million was terminated. As of December 31, 2023, we repaid </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$350.0&#160;million of the 364--day tranche. The remaining $150.0&#160;million portion of the 364-day tranche was repaid during the first quarter of 2024. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, during the first quarter of 2024 we repaid $250.0&#160;million of the three-year tranche, with the remaining $250.0&#160;million portion being subsequently repaid in full during the second quarter of 2024. For additional information on our acquisition of Reata, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2024 Form 10-K.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity</a></td>
<td class="text"><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 14:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Equity</span></div></td></tr></table></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Share Repurchases</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020 our Board of Directors authorized our 2020 Share Repurchase Program, which is a program to repurchase up to $5.0 billion of our common stock. Our 2020 Share Repurchase Program does not have an expiration date. All shares repurchased under our 2020 Share Repurchase Program were retired. There were no share repurchases of our common stock during the three and nine months ended September 30, 2025 and 2024. Approximately $2.1 billion remained available under our 2020 Share Repurchase Program as of September 30, 2025.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Income (Loss)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the changes in AOCI, net of tax by component:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.648%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.981%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.981%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.981%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.989%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30, 2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges,<br/>Net of Tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency<br/>Translation Adjustments,<br/>Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, June 30, 2025</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(112.0)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15.6)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(110.5)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(238.1)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from AOCI</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, September 30, 2025</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(85.5)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15.6)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(113.7)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(214.8)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30, 2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency<br/>Translation Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16.6)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(171.2)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(136.2)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(161.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(103.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from AOCI</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(137.1)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(78.6)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, September 30, 2025</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(85.5)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15.6)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(113.7)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(214.8)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.981%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.981%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.981%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.989%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges,<br/>Net of Tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Pension Benefit Obligation,<br/>Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency<br/>Translation Adjustments,<br/>Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(153.1)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(146.0)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(49.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from AOCI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(41.0)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31.2)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(112.1)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(145.7)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency Translation Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25.0)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(126.1)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(153.7)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from AOCI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31.2)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(112.1)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(145.7)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts reclassified from AOCI:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.192%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.814%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts Reclassified from AOCI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income Statement Location</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on cash flow hedges</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29.1)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.6)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(41.1)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax (benefit) expense</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total reclassifications, net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20.2)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.1)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24.5)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.2)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings per Share</a></td>
<td class="text"><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 15:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Earnings per Share</span></div></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted shares outstanding used in our earnings per share calculation are calculated as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.806%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Biogen Inc.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">466.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">388.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,341.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,365.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time-vested restricted stock units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dilutive potential common shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares used in calculating diluted earnings per share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">147.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Payments<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-based Payments</a></td>
<td class="text"><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 16:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Share-Based Payments</span></div></td></tr></table></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Share-based Compensation Expense</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.285%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">91.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">124.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">149.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">240.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">275.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalized share-based compensation costs </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in total cost and expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">231.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">267.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax effect</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(45.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(50.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in net income attributable to Biogen Inc.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104.5&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">185.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">216.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our acquisition of HI-Bio in July 2024 we recognized HI-Bio equity-based compensation expense, inclusive of employer taxes, of approximately $56.4&#160;million attributable to the post-acquisition service period, of which $42.5&#160;million was recognized as a charge to research and development expense with the remaining $13.9&#160;million as a charge to selling, general and administrative expense within our condensed consolidated statements of income for the three and nine months ended September 30, 2024. These amounts were associated with the accelerated vesting of stock options and RSUs previously granted to HI-Bio employees and required no future services to vest. For additional information on our acquisition of HI-Bio, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.285%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time-vested restricted stock units</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">186.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">174.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in cash</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Market stock units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">HI-Bio equity awards</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">240.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">275.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalized share-based compensation costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in total cost and expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128.7&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">231.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">267.4&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Relates to the HI-Bio equity-based compensation expense attributable to the post-acquisition service period, associated with the accelerated vesting of stock options and RSUs previously granted to HI-Bio employees and required no future services to vest. For additional information on our acquisition of HI-Bio, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 17:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Income Taxes</span></div></td></tr></table></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:112%">2025 OBBBA Tax Provisions</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 4, 2025, the U.S. signed into law the H.R.1 legislation formally titled "An Act to Provide for Reconciliation Pursuant to Title II of H. Con. Res. 14", commonly referred to as the OBBBA.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The OBBBA contains tax provisions, such as the permanent extension or revision of certain expiring provisions of the Tax Cuts and Jobs Act enacted in 2017, modifications to the international tax framework and the restoration of favorable tax treatment for certain business provisions. The provisions of the OBBBA have multiple effective dates, with certain provisions effective in 2025 and others implemented through 2027. The OBBBA did not result in any material adjustments to our total income tax provision for the three and nine months ended September 30, 2025, and we have adjusted our deferred tax balances to reflect the impacts of the OBBBA enactment.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Tax Rate</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.683%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Statutory rate</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Taxes on foreign earnings, including valuation allowances</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchased inventory valuation step-up and intangible assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GILTI</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation awards</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OBBBA enactment</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, including permanent items</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.4&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Tax Rate</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2025, compared to the same periods in 2024, the increases in our effective tax rates were partially driven by changes in the territorial mix of our profitability, partially offset by the impact of the OBBBA enactment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The nine months ended September 30, 2025, compared to the same period in 2024, also reflects the impacts of certain share-based compensation awards that vested during the first quarter of 2025 and a decrease in our estimate of Pillar Two minimum tax liabilities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three and nine months ended September 30, 2024, our effective tax rates benefited from a decrease in our valuation allowance, partially offset by the impact of certain foreign uncertain tax positions. </span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Accounting for Uncertainty in Income Taxes</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in various U.S. states and in U.S. federal and other foreign jurisdictions. With few exceptions, we are no longer subject to U.S. federal tax examination for years before 2021 or state, local or non-U.S. income tax examinations for years before 2013.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. Internal Revenue Service and other national tax authorities routinely examine our intercompany transfer pricing with respect to intellectual property related transactions and it is possible that they may disagree with one or more positions we have taken with respect to such valuations.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is reasonably possible that we will adjust the value of our uncertain tax positions related to certain transfer pricing, collaboration matters, withholding taxes and other issues as we receive additional information from various taxing authorities, including reaching settlements with such authorities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate that it is reasonably possible that our gross unrecognized tax benefits, exclusive of interest, could</span></div><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">decrease by up to approximately $35.0&#160;million in the next 12 months as a result of various audit closures, settlements and expiration of the statute of limitations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477617/942-740-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478822/944-740-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock', window );">Other Consolidated Financial Statement Detail</a></td>
<td class="text"><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 18:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Other Consolidated Financial Statement Detail</span></div></td></tr></table></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Other (Income) Expense, Net</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of other (income) expense, net, are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:44.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.825%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31.6)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11.6)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(87.8)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(49.1)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">190.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gains) losses on investments, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(39.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange (gains) losses, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other (income) expense, net</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">151.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">193.7&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The (gains) losses on investments, net, as reflected in the table above, relate to equity securities of certain biotechnology companies, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes our (gains) losses on investments, net that relate to our equity securities held during the following periods:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.514%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.771%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net (gains) losses recognized on equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(39.1)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Net (gains) losses realized on equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unrealized (gains) losses recognized on equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(28.2)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net unrealized gains recognized during the three months ended September 30, 2025, primarily reflect an increase in the aggregate fair value of our investment in Denali common stock of approximately $3.8&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net unrealized gains recognized during the three months ended September 30, 2024, primarily reflect an increase in the aggregate fair value of our investments in Denali and Sangamo common stock of approximately $53.3&#160;million, partially offset by a decrease in the fair value of Sage common stock of approximately $22.7&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net unrealized losses recognized during the nine months ended September 30, 2025, primarily reflect a decrease in the aggregate fair value of our investment in Denali common stock of approximately $41.9&#160;million, partially offset by an increase in the fair value of Sage common stock of approximately $23.0&#160;million.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net unrealized losses recognized during the nine months ended September 30, 2024, primarily reflect a decrease in the aggregate fair value of our investments in Sage common stock of approximately $90.2&#160;million, partially offset by an increase in the fair value of Denali and Sangamo common stock of approximately $70.1&#160;million.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Accrued Expense and Other</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expense and other consists of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue-related reserves for discounts and allowances</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,062.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">937.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee compensation and benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">310.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">375.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">268.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">309.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalties and licensing fees</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">320.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">190.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">291.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">574.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">692.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,773.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,807.7&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Long-term Liabilities</span></div>Other long-term liabilities were $761.8 million and $732.3 million as of September 30, 2025 and December 31, 2024, respectively, and included accrued income taxes totaling $164.7 million and $156.7 million, respectively<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalFinancialInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaborative and Other Relationships</a></td>
<td class="text"><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 19:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Collaborative and Other Relationships</span></div></td></tr></table></div><div style="margin-top:9pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Genentech, Inc. (Roche Group)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, CLL and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL, follicular lymphoma,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and, following its approval in October 2025, lupus nephritis; OCREVUS for the treatment of PPMS and RMS; LUNSUMIO for the treatment of relapsed or refractory follicular lymphoma; COLUMVI, a bispecific antibody for the treatment of non-Hodgkin's lymphoma; and have the option to add other potential anti-CD20 therapies, pursuant to our collaboration arrangements with Genentech, a wholly-owned member of the Roche Group. For purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RITUXAN</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Genentech and its affiliates are responsible for the worldwide manufacture of RITUXAN as well as all development and commercialization activities as follows:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.67pt">U.S.:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have co-exclusively licensed our rights to develop, commercialize and market RITUXAN in the U.S.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.67pt">Canada:</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have co-exclusively licensed our rights to develop, commercialize and market RITUXAN in Canada.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">GAZYVA</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Roche Group and its sub-licensees maintain sole responsibility for the development, manufacture and commercialization of GAZYVA in the U.S. The level of gross sales of GAZYVA in the U.S. has impacted our percentage of the co-promotion profits for RITUXAN and LUNSUMIO, as summarized in the table below.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">OCREVUS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the terms of our collaboration arrangements with Genentech, we receive a tiered royalty on U.S. net sales from 13.5% and increasing up to 24.0% if annual net sales exceed $900.0&#160;million. There will be a 50.0% reduction to these royalties upon the first entry of an FDA approved biosimilar to OCREVUS.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we receive a gross 3.0% royalty on net sales of OCREVUS outside the U.S., with the royalty period lasting 11 years from the first commercial sale of OCREVUS on a country-by-country basis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The commercialization of OCREVUS does not impact the percentage of the co-promotion profits we receive for RITUXAN, LUNSUMIO or GAZYVA. Genentech is solely responsible for development and commercialization of OCREVUS and funding future costs. Genentech cannot develop OCREVUS in CLL, non-Hodgkin's lymphoma or rheumatoid arthritis.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OCREVUS royalty revenue is based on our estimates from third party and market research data of OCREVUS sales occurring during the corresponding period. Differences between actual and estimated royalty revenue will be adjusted for in the period in which they become known, which is generally expected to be the following quarter.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">LUNSUMIO</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are entitled to a tiered share of co-promotion operating profits and losses in the U.S., as summarized in the table below. In addition, we receive low-single digit royalties on sales of LUNSUMIO outside the U.S.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">COLUMVI</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Genentech has sole decision-making rights on the commercialization of COLUMVI within the U.S. and we receive tiered royalties in the mid-single digit range on net sales of COLUMVI in the U.S. Under the terms of this agreement, we have no payment obligations. The commercialization of COLUMVI does not impact the percentage of the co-promotion profits we receive for RITUXAN, LUNSUMIO or GAZYVA.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Profit-sharing Formulas</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">RITUXAN and LUNSUMIO Profit Share</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current pretax co-promotion profit-sharing formula for RITUXAN and LUNSUMIO in the U.S. provides for a 30.0% share on the first $50.0&#160;million of combined co-promotion operating profits earned each calendar year. As a result of the FDA approval of LUNSUMIO our share of the combined annual co-promotion profits for RITUXAN and LUNSUMIO in excess of $50.0&#160;million varies upon the following events, as summarized in the table below:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:80.891%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.909%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After LUNSUMIO Approval until the First Threshold Date</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After First Threshold Date until the Second Threshold Date</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After Second Threshold Date</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:6pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">First Threshold Date</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means the earlier of (i)&#160;the first day of the calendar quarter following the date U.S. gross sales of GAZYVA within any consecutive 12-month period have reached $500.0&#160;million or (ii)&#160;the first date in any calendar year in which U.S. gross sales of LUNSUMIO have reached $150.0&#160;million.</span></div><div style="margin-top:6pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Second Threshold Date</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> means the later of (i) the first date in any calendar year in which U.S. gross sales of LUNSUMIO have reached $350.0&#160;million or (ii) January 1 of the calendar year following the calendar year in which the First Threshold Date occurs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023 the First Threshold Date was achieved. As a result, beginning in April 2023 the pre-tax profit share for RITUXAN and LUNSUMIO was 35.0%.</span></div><div style="margin-top:6pt"><span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">GAZYVA Profit Share</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current pretax profit-sharing formula for GAZYVA provides for a 35.0% share of operating profits earned each calendar year.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Genentech, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2024 Form 10-K.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Ionis Pharmaceuticals, Inc.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2017 SMA Collaboration Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017 we entered into a collaboration agreement with Ionis to identify new ASO drug candidates for the potential treatment of SMA. Under this agreement, we have options to license therapies arising out of this collaboration and will be responsible for the development and commercialization of such therapies.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2021 we exercised our option with Ionis and obtained a worldwide, exclusive, royalty-bearing license to develop and commercialize salanersen (BIIB115), an investigational ASO in development for SMA.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may pay Ionis up to $155.0&#160;million in additional development and regulatory milestone payments related to salanersen, including a $45.0&#160;million milestone payment due upon the initiation of a Phase 3 trial. Upon commercialization, we may also pay Ionis up to $400.0&#160;million in additional performance-based milestone payments and tiered royalties on potential net sales of such therapies ranging from the mid-teens to high-twenties percentages.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Ionis, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2024 Form 10-K.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Eisai Co., Ltd.</span></div><div style="margin-top:5pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">LEQEMBI (lecanemab) Collaboration</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration agreement with Eisai to jointly develop and commercialize LEQEMBI (lecanemab), an anti-amyloid antibody for the treatment of Alzheimer's disease. The FDA granted traditional approval of LEQEMBI in July 2023. Prior to receiving traditional approval, LEQEMBI had been granted accelerated approval by the FDA in January 2023, at which time it became commercially available in the U.S. Outside of the U.S., LEQEMBI is now approved in the E.U. (April 2025), Australia (September 2025), China (January 2024), Japan (September 2023) and other international markets. LEQEMBI monthly IV maintenance dosing for the treatment of early Alzheimer's disease was approved in the U.S. and China in January 2025 and September 2025, respectively, and LEQEMBI subcutaneous autoinjector (IQLIK) for weekly maintenance dosing was approved in the U.S. in August 2025.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All costs, including research, development, sales and marketing expense, are shared equally between us and Eisai. We also share profits and losses equally. We currently have a supply agreement with Eisai to manufacture LEQEMBI drug substance and drug product through the end of 2031.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to the limitations in the LEQEMBI Collaboration Agreement, Eisai has final decision-making authority on all matters relating to the collaboration and serves as the lead of LEQEMBI development and regulatory submissions globally. We co-commercialize and co-promote LEQEMBI with Eisai. Our Collaboration Agreement provides that each commercialization plan shall allocate the responsibilities for the activities under the plan in an equitable fashion taking into account Biogen's and Eisai's respective capabilities and provides a meaningful role for each party.   </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon commercialization of LEQEMBI in the U.S., we began recognizing our 50.0% share of LEQEMBI product revenue, net and cost of sales, including royalties, within Alzheimer's collaboration revenue in our condensed consolidated statements of income, as we are not the principal.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our share of LEQEMBI sales and marketing expense and development expense are recorded within selling, general and administrative expense and research and development expense, respectively, within our condensed consolidated statements of income.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of development and sales and marketing expense related to the LEQEMBI Collaboration is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.285%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total development expense incurred by the collaboration related to the advancement of LEQEMBI</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">178.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">255.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of the LEQEMBI Collaboration development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total sales and marketing expense incurred by the LEQEMBI Collaboration</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">176.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">164.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">525.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">476.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of the LEQEMBI Collaboration sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">262.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">238.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts receivable from Eisai related to the agreements discussed above were approximately $103.8&#160;million and $16.7&#160;million as of September 30, 2025 and December 31, 2024, respectively. Amounts payable to Eisai related to the agreements discussed above were approximately $97.9&#160;million and $138.0&#160;million as of September 30, 2025 and December 31, 2024, respectively.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arra</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ngements with Eisai, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2024 Form 10-K.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">UCB</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a collaboration agreement with UCB, effective November 2003, to jointly develop and commercialize dapirolizumab pegol, an anti-CD40L pegylated Fab, for the potential treatment of SLE and other future agreed indications. Either we or UCB may propose development of dapirolizumab pegol in additional indications. If the parties do not agree to add an indication as an agreed indication to the collaboration, we or UCB may, at the sole expense of the applicable party, pursue development in such excluded indication(s), subject to an opt-in right of the non-pursuing party after proof of clinical activity.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All costs incurred for agreed indications, including research, development, sales and marketing expense, are shared equally between us and UCB. If marketing approval is obtained, both companies will jointly commercialize dapirolizumab pegol and share profits and losses equally.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of development expense related to the UCB collaboration agreement is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.285%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total UCB collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of the UCB collaboration development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Supernus Pharmaceuticals, Inc. (previously Sage Therapeutics, Inc.)</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020 we entered into a global collaboration and license agreement with Sage to jointly develop and commercialize ZURZUVAE (zuranolone) for the treatment of PPD. In July 2025 Sage was acquired by Supernus. ZURZUVAE was approved in the U.S. in August 2023 and in the E.U. in September 2025.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under this collaboration, both companies will share equal responsibility and costs for development as well as profits and losses for commercialization in the U.S. Outside of the U.S., we are responsible for development and commercialization, excluding Japan, Taiwan and South Korea, with respect to zuranolone and may pay Supernus </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">potential tiered royalties in the high-teens to low-twenties percentages. During the fourth quarter of 2023 we accrued a milestone payment due t</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o Supernus</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of $75.0&#160;million upon the first commercial sale of ZURZUVAE for PPD in the U.S., which was recorded within intangible assets, net in our condensed consolidated balance sheets, and subsequently paid in January 2024.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We share 50.0% of the net collaboration results in the U.S. with Supernus, which are recognized in collaboration profit sharing/(loss reimbursement) in our condensed consolidated statements of income. For the three and nine months ended September 30, 2025, we recognized net profit-sharing expense of approximately $20.7 million and $48.6 million, respectively, to reflect Supernus' 50.0% share of the net collaboration results in the U.S., compared to net profit-sharing expense of approximately $9.0 million and $20.5 million, respectively, in the prior year comparative periods.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A summary of development and sales and marketing expense related to the Supernus collaboration is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.379%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.700%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Supernus collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of the Supernus collaboration development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total sales and marketing expense incurred by the Supernus collaboration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of the Supernus collaboration sales and marketing expense reflected in selling, general and administrative expense and collaboration profit sharing/(loss reimbursement) in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Denali Therapeutics Inc.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2020 we entered into a collaboration and license agreement with Denali to co-develop and co-commercialize BIIB122, a small molecule inhibitor of LRRK2 for Parkinson's disease (LRRK2 Collaboration).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the LRRK2 Collaboration, both companies share responsibility and costs for global development based on specified percentages as well as profits and losses for commercialization in the U.S. and China. Outside the U.S. and China we are responsible for commercialization and may pay Denali potential tiered royalties.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A summary of development expense related to the Denali collaboration is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.285%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Denali collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of the Denali collaboration development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Stoke Therapeutics, Inc.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2025 we entered into a collaboration and license agreement with Stoke to co-develop and commercialize zorevunersen, an investigational ASO that targets the SCN1A gene for the potential treatment of Dravet syndrome, a rare form of genetic epilepsy associated with refractory seizures and neurodevelopmental impairments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of this agreement, Stoke will continue to lead global development and retain exclusive development and commercialization rights for zorevunersen in the U.S., Canada and Mexico and we will have exclusive rights to commercialize zorevunersen in the rest of the world. Both companies will share responsibility for external clinical development costs, where Stoke is responsible for 70.0% of these development costs and we are responsible for the remaining 30.0% of these development costs.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the closing of this transaction we made an upfront payment of $165.0&#160;million to Stoke, which was recognized as acquired in-process research and development, upfront and milestone expense within our condensed consolidated statements of income for the nine months ended September 30, 2025. We may also pay Stoke potential development and commercial milestone payments of up to $50.0&#160;million and $335.0&#160;million, respectively, if all the specified milestones set forth in this collaboration are achieved. In addition, we may pay Stoke tiered royalties on potential net sales of any products developed under this collaboration in the low-double digit to high-teen percentages.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have an exclusive option to license certain future follow-on ASO products targeting the SCN1A gene in all territories worldwide other than the U.S., Canada and Mexico, in exchange for separate milestone, cost sharing and royalty considerations.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of development expense related to the Stoke collaboration agreement is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.221%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.932%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30, 2025</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30, 2025</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Stoke collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of the Stoke collaboration development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Samsung Bioepis Co., Lt</span><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">d.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2019 Development and Commercialization Agreement</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019 we completed a transaction with Samsung Bioepis and secured the exclusive rights to commercialize two potential ophthalmology biosimilar products, BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS, and OPUVIZ, an aflibercept biosimilar referencing EYLEA, in major markets worldwide, including the U.S., Canada, Europe, Japan and Australia. The agreement established that Samsung Bioepis will be responsible for development and will supply both products to us at a pre-specified gross margin of approximately 45.0%.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2024 we notified Samsung Bioepis of our decision to terminate our 2019 Development and Commercialization Agreement (the DCA Agreement) solely within the U.S. and Canada. As a result of this termination we recognized impairment charges of approximately $20.2 million, </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which were recorded within amortization and impairment of acquired intangible assets within our condensed consolidated statements of income for the</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine months ended September 30, 2024. Biogen will transfer commercialization rights for BYOOVIZ and OPUVIZ in the U.S. and Canada back to Samsung Bioepis over a period of up to 18 months. During this transition period, we will continue to commercialize BYOOVIZ. The termination does not impact the other markets in the DCA Agreement.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may pay Samsung Bioepis up to approximately $150.0 million for achieving additional sales-based milestones associated with the remaining major markets covered by the agreement.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2013 Commercial Agreement</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2013 we entered into an agreement with Samsung Bioepis to commercialize, over a 10-year term, three anti-TNF biosimilar product candidates which include IMRALDI, an adalimumab biosimilar referencing HUMIRA, FLIXABI, an infliximab biosimilar referencing REMICADE, and BENEPALI, an etanercept biosimilar referencing ENBREL, in Europe.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2024 we exercised an option to extend this agreement by an additional five years and paid Samsung Bioepis an option exercise fee of $60.0 million, which was recognized in intangible assets, net within our condensed consolidated balance sheets as of December 31, 2024.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We reflect revenue on sales of BENEPALI, IMRALDI and FLIXABI to third parties in product revenue, net in our condensed consolidated statements of income and record the related cost of revenue and sales and marketing expense in our condensed consolidated statements of income to their respective line items when these costs are incurred. Royalty payments to AbbVie on sales of IMRALDI are recognized in cost of sales within our condensed consolidated statements of income.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We share 50.0% of the profit or loss related to our 2013 commercial agreement with Samsung Bioepis, which is recognized in collaboration profit sharing/(loss reimbursement) in our condensed consolidated statements of income. For the </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine months ended September 30, 2025, we recognized net profit-sharing expense of approximately $66.5&#160;million and $171.7&#160;million, respectively, to reflect Samsung Bioepis' 50.0% sharing of the net collaboration profits, compared to net profit-sharing expense of approximately $60.3 million and $176.8 million, respectively, in the prior year comparative periods.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Services</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Simultaneous with the formation of Samsung Bioepis, we also entered into a license agreement with Samsung Bioepis. Under this license agreement, we granted Samsung Bioepis an exclusive license to use, develop, manufacture and commercialize biosimilar products created by Samsung Bioepis using Biogen product-specific technology. In exchange, we receive single-digit royalties on biosimilar products developed and commercialized by Samsung Bioepis. Royalty revenue under the license agreement is recognized as a component of contract manufa</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">cturing, royalty and other revenue in our condensed consolidated statements of income.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts receivable from Samsung Bioepis related to the agreements discussed above were approximately $4.8&#160;million and $7.6&#160;million as of September 30, 2025 and December 31, 2024, respectively. Amounts payable to Samsung Bioepis related to the agreements discussed above were $45.3&#160;million and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$60.8&#160;million as of </span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 30, 2025 and </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2024, respectively.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements with Samsung Bioepis and our other significant collaboration arrangements, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2024 Form 10-K. </span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Other Research and Discovery Arrangements and Funding Arrangements</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These arrangements may include the potential for future milestone payments based on the achievement of certain clinical and commercial development payable over a period of several years.</span></div><div style="margin-top:6pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Royalty Pharma Funding Arrangement</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2025 we entered into a funding agreement with Royalty Pharma under which we will receive up to $200.0&#160;million in 2025 and up to $50.0&#160;million in 2026 to co-fund our development costs for the litifilimab program. As there is a substantive transfer of risk to the financial partner for the amount invested, the development funding will be recognized by us as an obligation to perform contractual services. We plan to recognize this funding as a reduction to research and development expense within our condensed consolidated statements of income, proportionate to the related expense. For the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three and nine months ended September 30, 2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we recorded reductions to research and development e</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">xpense of $50.0 million and $150.0&#160;million, respectiv</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ely, within our condensed consolidated statements of income.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the litifilimab clinical trials are successful for the indications based on the applicable clinical trials, upon regulatory approval in the U.S. or certain major markets in the world, Royalty Pharma will be eligible to receive approval-based fixed milestone payments of up to a total of $250.0&#160;million. The milestone payments due upon approval will be recorded as a component of other (income) expense, net within our condensed consolidated statements of income, when incurred.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If litifilimab receives regulatory approval, Royalty Pharma will be eligible to receive royalties of a mid-single digit percentage of the applicable net sales. Royalties on net sales will be recorded as cost of sales within our condensed consolidated statements of income.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MorphoSys AG</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of our acquisition of HI-Bio in July 2024, we </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">acquired HI-Bio's pre-existing in-license commitments under third-party agreements with MorphoSys, which included tiered royalties on potential future sales ranging from high-single digit to mid-teen percentages, as well as potential development, regulatory and commercial milestone payments of up to $130.0&#160;million, $230.0&#160;million and $640.0&#160;million, respectively. These amounts included milestone payments due upon the first patient dosed in a Phase 3 clinical trial of felzartamab in a first and second indication of $35.0&#160;million and $30.0&#160;million, respectively. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2025 we accrued a milestone payment due to MorphoSys of $35.0&#160;million upon the first patient dosed in a Phase 3 clinical trial of felzartamab for the treatment of AMR, which was recorded within acquired in-process research and development, upfront and milestone expense in our condensed consolidated statements of income for the nine months ended September 30, 2025, and paid in April 2025.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2025 we accrued a milestone payment due to MorphoSys of $30.0&#160;million upon the first patient dosed in a Phase 3 clinical trial of felzartamab for the treatment of IgAN, which was recorded within acquired in-process research and development, upfront and milestone expense in our condensed consolidated statements of income for the nine months ended September 30, 2025, and paid in July 2025.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">City Therapeutics, Inc.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2025 we entered into a strategic research arrangement with City Therapeutics to develop select novel RNAi therapies. Through this arrangement, City Therapeutics will leverage its next-generation RNAi engineering technologies to develop an RNAi trigger molecule combined with our proprietary drug delivery technology. The collaboration will initially focus on a single target that mediates key CNS diseases, utilizing tissue enhanced delivery technologies with the aim of allowing for systemic administration of medicines. We will be responsible for IND-enabling studies and global clinical development along with any regulatory submissions and all activities related to commercialization.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the closing of this transaction we made an upfront payment of $16.0&#160;million to City Therapeutics, which was recognized as acquired in-process research and development, upfront and milestone expense within our condensed consolidated statements of income for the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nine months ended September 30, 2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and invested $30.0&#160;million in exchange for a City Therapeutics convertible note, representing a minority equity interest in City Therapeutics, if converted. This convertible note was recorded as a component of investments and other assets within our condensed consolidated balance sheets as of</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> September 30, 2025.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also pay City Therapeutics potential research, development and sales-based milestone payments of up to $21.5&#160;million, $360.0&#160;million and $625.0&#160;million, respectively, plus tiered royalties on potential future net sales, ranging from high-single digit to low-double digit percentages.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have the option to select one additional target in the collaboration, subject to an additional payment and availability of the target.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments in Variable Interest Entities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_InvestmentsInVariableInterestEntitiesAbstract', window );"><strong>Investments in Variable Interest Entities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableInterestEntityDisclosureTextBlock', window );">Investments in Variable Interest Entities</a></td>
<td class="text"><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 20:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Investments in Variable Interest Entities</span></div></td></tr></table></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Unconsolidated Variable Interest Entities</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have relationships with various variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September 30, 2025 and December 31, 2024, the carrying value of our investments in certain biotechnology companies representing potential unconsolidated variable interest entities totaled $44.8 million and $23.6 million, respectively. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our condensed consolidated statements of income as they are incurred. We have provided no financing to these variable interest entities other than previous contractually required amounts. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our investments in variable interest entities, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 20, Investments in Variable Interest Entities,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2024 Form 10-K.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentsInVariableInterestEntitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investments In Variable Interest Entities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentsInVariableInterestEntitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableInterestEntityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/810/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableInterestEntityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Litigation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract', window );"><strong>Loss Contingency, Information about Litigation Matters [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">Litigation</a></td>
<td class="text"><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 21:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Litigation</span></div></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently involved in various claims, investigations and legal proceedings, including the matters described below. For information as to our accounting policies relating to claims and legal proceedings, including use of estimates and contingencies, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1, Summary of Significant Accounting Policies,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our consolidated financial statements included in our 2024 Form 10-K.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to some loss contingencies, an estimate of the possible loss or range of loss cannot be made until management has further information, including, for example, (i) which claims, if any, will survive dispositive motion practice; (ii) information to be obtained through discovery; (iii) information as to the parties' damages claims and supporting evidence; (iv) the parties&#8217; legal theories; and (v) the parties' settlement positions. If an estimate of the possible loss or range of loss can be made at this time, it is included in the potential loss contingency description below.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The claims and legal proceedings in which we are involved also include challenges to the scope, validity or enforceability of the patents relating to our products, pipeline or processes and challenges to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability to continue to engage in certain activities; and (iii) payment of significant damages, royalties, penalties and/or license fees to third parties.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Loss Contingencies</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Securities Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and certain current and former officers are defendants in three securities actions pending in the District Court, one filed by Nadia Shash and Amjad Khan in November 2020, which relates to statements about ADUHELM, one filed by the Oklahoma Firefighters Pension and Retirement System in February 2022, which relates to statements about ADUHELM, and one filed by Thomas Allen Gray in June 2024, which relates to statements about LEQEMBI, TECFIDERA and VUMERITY. All allege violations of federal securities laws under 15 U.S.C. &#167;78j(b) and &#167;78t(a) and 17 C.F.R. &#167;240.10b-5 and seek declarations of the actions as class actions and monetary relief.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Derivative Actions</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and members of the Board of Directors are named as defendants in five derivative actions pending in the District Court, one filed by The Booth Family Trust in February 2022, one filed by Elaine Wang in July 2022, one filed by Jonathan Blaufarb (Blaufarb I) in July 2024, one filed by Lawrence Hollin in October 2024 and one filed by Jonathan Blaufarb (Blaufarb II) in October 2024. The Booth, Wang and Blaufarb II actions relate to ADUHELM and other matters, and the Blaufarb I and Hollin actions relate to statements about LEQEMBI, our compliance controls, 2023 earnings guidance and other matters. The actions allege breach of fiduciary duty, waste of corporate assets and other common law claims, and violations of the Securities Exchange Act of 1934, 15 U.S.C. &#167;78a et seq. The actions seek declaratory and injunctive relief, monetary relief payable to Biogen, and attorneys&#8217; fees and costs payable to the plaintiffs. All derivative actions are stayed.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">IMRALDI Patent Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IMRALDI is an adalimumab biosimilar manufactured by Samsung Bioepis that Biogen commercializes in Europe.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, Fresenius Kabi filed a claim for damages and injunctive relief against Biogen France SAS in the Tribunal de Grande Instance de Paris alleging infringement of the French counterpart of EP &#8216;3 145 488 Patent (the EP '488 Patent) by a formulation of IMRALDI no longer commercialized in France. Fresenius Kabi alleges damages of &#8364;13,450,000 plus interest and costs. Biogen disputes infringement and the validity of the patent.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2025 the Higher Regional Court of D&#252;sseldorf held that a formulation of IMRALDI we no longer commercialize in Germany infringed the German counterpart of the EP '488 Patent and enjoined infringement and declared Fresenius Kabi's right to seek damages. Biogen has requested review of the decision by Germany's Federal Court of Justice and has challenged the validity of the patent in a separate proceeding.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation with Former Convergence Shareholders</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015 Biogen acquired Convergence, a U.K. company. In 2019 Shareholder Representative Services LLC, on behalf of former shareholders of Convergence, asserted claims of $200.0 million for alleged breaches of the contract pursuant to which we acquired Convergence and in June 2023 it and former Convergence shareholders filed a suit against us in the High Court of Justice of England and Wales asserting one of the 2019 claims and seeking payment of $49.9&#160;million, plus interest and costs. A final decision is pending.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Humana Patient Assistance Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2025 Humana filed suit against Biogen Inc., Biogen U.S. Corp. and Advanced Care Scripts, Inc. in Jefferson Circuit Court in Kentucky alleging damages related to providing MS patients with free medications and to charitable contributions to non-profit organizations that provide financial assistance to MS patients. Humana alleges breach of contract, fraud and other claims under various state laws and seeks damages, attorneys' fees and costs.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Genentech Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023 Genentech Inc. filed suit in the U.S. District Court for the Northern District of California claiming that it was owed royalties on sales of TYSABRI that occurred after the expiration of a patent licensed by Genentech to Biogen. In September 2025 the Court ordered that Biogen is liable to pay Genentech damages of approximately $88.3&#160;million plus interest (approximately $35.9&#160;million as of September 30, 2025), which continues to accrue. Final judgment has not yet entered.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lender Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2025, by agreement of the parties, the court discontinued with prejudice the previously disclosed suit filed in 2024 by BioPharma Credit PLC, BPCR Limited Partnership, and BioPharma Credit Investments V (Master) LP against us and Reata Pharmaceuticals, Inc. in the Supreme Court of the State of New York alleging breach of a loan agreement.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Antitrust Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2024 we were sued by Local No. 1 Health Fund and in September 2024 we were sued by the Mayor and City Council of Baltimore, New York State Teamsters Council Health and Hospital Fund, Teamsters Local 237 Welfare Fund and Teamsters Local 237 Retirees' Benefit Fund, in cases filed in the U.S. District Court for the Northern District of Illinois. After the cases were consolidated for pre-trial purposes, these plaintiffs and UFCW Local 1500 Welfare Fund sued us in a consolidated amended complaint filed in November 2024. The plaintiffs allege violations of federal antitrust laws including 15 U.S.C. &#167;&#167; 1, 2 and 13(c) and of various state laws, based on our contracts with </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pharmacy benefit managers related to TECFIDERA and VUMERITY. Plaintiffs seek declarations of the actions as class actions, monetary, declaratory and equitable relief, and attorneys' fees and costs. In June 2025 the court dismissed the case without prejudice and granted the plaintiffs leave to amend the complaint. In August 2025 plaintiffs filed a second amended complaint adding Jacksonville Police Officers and Fire Fighters Health Insurance Trust as a plaintiff, alleging violation of the same laws as alleged in the dismissed complaint, and adding a claim under the Racketeer Influenced and Corrupt Organizations Act, 18 U.S.C. &#167;1962(c). The plaintiffs filed a third amended complaint in October 2025, removing the New York State Teamsters Council Health and Hospital Fund as a party.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2025 Walgreen Co. and The Kroger Co. filed a complaint alleging violations of 15 U.S.C. &#167;&#167; 1 and 2 based on our contracts with pharmacy benefit managers related to TECFIDERA and VUMERITY and seeking monetary, declaratory and equitable relief, and attorneys' fees and costs.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Neurimmune Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2025 we filed suit against Neurimmune Holding AG and Neurimmune Subone AG (collectively, "Neurimmune") in the District Court seeking declaratory judgment and permanent injunctive relief regarding our rights under a terminated collaboration agreement related to aducanumab. In September 2025 Neurimmune asserted counterclaims for declaratory judgment, breach of contract and unfair competition under Massachusetts G.L. 93A and seeking monetary, declaratory and equitable relief and attorneys' fees and costs.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">TECFIDERA E.U. Litigation</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023 we sued Neuraxpharm Pharmaceuticals S.L. and Neuraxpharm Netherlands B.V. (collectively, Neuraxpharm), Zaklady Farmaceutyzne Polpharma S.A. (Polpharma), Sandoz B.V. (Sandoz), Mylan Ireland Ltd. and Mylan B.V. in the District Court of Amsterdam, Netherlands for damages, alleging violation of our regulatory marketing protection by their sales of generic versions of TECFIDERA. In March 2024 we obtained an injunction against Sandoz enjoining Netherlands sales of its generic version of TECFIDERA. In October 2024 Neuraxpharm, Polpharma and Sandoz counterclaimed for damages based on our actions to enforce TECFIDERA's regulatory marketing protection.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2024 we obtained an injunction in the Danish Maritime and Commercial High Court against Sandoz A/S (reversed on appeal) enjoining Danish sales of its generic version of TECFIDERA and in June 2024 we sued Sandoz A/S for damages, alleging violation of our regulatory marketing protection. In November 2024 Sandoz A/S counterclaimed for damages based on our actions to enforce TECFIDERA's regulatory marketing protection. These cases are stayed.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2025 the European General Court annulled the May 2023 European Commission decision granting TECFIDERA an additional year of regulatory marketing protection extending until February 2025.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Other Matters</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Government Investigations</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2025 the SEC Division of Enforcement informed us that it has closed the matter in which we had received subpoenas seeking information relating to ADUHELM and its launch and our equity plans, and in April and May 2025 the DOJ and SEC informed us that they closed the matters in which we had received subpoenas seeking information relating to our business operations in several foreign countries.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Italian Competition Authority is investigating Biogen and other companies in relation to our biosimilar product BYOOVIZ.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2025 we received a Civil Investigative Demand from the Louisiana Department of Justice for information regarding our policies relating to the purchase of drugs by healthcare organizations that are covered entities under Section 340B of the Public Health Service Act.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">TYSABRI Biosimilar Patent Matter</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022 we filed an action in the U.S. District Court for the District of Delaware against Sandoz Inc., other Sandoz entities and Polpharma Biologics S.A. under the Biologics Price Competition and Innovation Act, 42 U.S.C. &#167;262, seeking a declaratory judgment of patent infringement. No trial date is set.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Hatch-Waxman Act Litigation relating to VUMERITY Orange-Book Listed Patents</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2023 Biogen and Alkermes Pharma Ireland Limited filed patent infringement proceedings relating to VUMERITY Orange-Book listed patents (U.S. Patent Nos. 8,669,281, 9,090,558 and 10,080,733) pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984 (the Hatch-Waxman Act) in the U.S. District Court for the District of Delaware against Zydus Worldwide DMCC, Zydus Pharmaceuticals (USA) Inc. and Zydus Lifesciences Limited. In July 2025 the parties reached a settlement and the court dismissed the case pursuant to the parties' stipulation of dismissal.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Eisai Matter</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2025 we filed a request for arbitration in the International Court of Arbitration of the International Chamber of Commerce seeking adoption of a budget and commercialization plan for the European Territory that allocates commercialization activities to Biogen and Eisai in an equitable fashion taking into account our respective capabilities and provides a meaningful role for each party.</span></div><div style="margin-top:6pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Liability and Other Legal Proceedings</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also involved in product liability claims and other legal proceedings incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyInformationAboutLitigationMattersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyInformationAboutLitigationMattersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 22:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Segment Information</span></div></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate and are managed as one operating segment, and derive revenue from activities related to the discovery, development and delivery of innovative therapies for people living with serious and complex diseases.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development organization is responsible for the research and discovery of new product candidates and supports development and registration efforts for potential future products. Our pharmaceutical, operations and technology organization manages the development of the manufacturing processes, clinical trial supply, commercial product supply, distribution, buildings and facilities. Our commercial organization is responsible for U.S. and international development of our commercial products. We are also supported by corporate staff functions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our CEO, as the CODM, manages and allocates resources to the operations of our company on a total company basis by assessing the overall level of resources available and deciding how to best deploy these resources across functions, therapeutic areas and research and development projects that are in line with our long-term company-wide strategic goals. In making these decisions, our CEO is provided with and uses consolidated financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets. The CODM performs this assessment based on the segment&#8217;s net income. Through this analysis, which includes a comparison to budgeted results, the CODM assesses performance and how to allocate resources across the functions discussed above. The measure of segment assets used in determining how to manage and allocate resources is reported within our condensed consolidated balance sheets as total assets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table presented below, which was prepared in accordance with the accounting policies discussed in </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1, Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements included in our 2024 Form 10-K, contains additional information on enterprise-wide disclosures about product revenue, other revenue and long-lived assets, as well as our segment&#8217;s revenue and profits, including significant segment expense and other segment items. Revenue is primarily attributed to individual countries based on location of the customer or licensee.</span></div><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Additional Segment Information</span></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes additional information about reported segment revenue, significant segment expense and segment measure of profitability:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.116%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,534.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,465.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,611.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,221.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less cost and expense:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of sales, excluding amortization and impairment of acquired intangible assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product cost of sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">384.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">468.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,261.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,204.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalty cost of sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">290.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">647.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">522.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and discovery</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">141.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Early stage programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">184.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">214.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Late stage programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">154.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">135.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketed products</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">107.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">126.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">284.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">414.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other research and development costs</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">167.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">221.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">513.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">560.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquired in-process research and development, upfront and milestone expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">249.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">594.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">588.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,751.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,723.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other segment expense</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">360.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">307.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,091.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">895.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net Income attributable to Biogen Inc.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">466.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">388.5&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,341.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,365.5&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:37.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.353%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.355%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Other research and development costs primarily consist of indirect costs incurred in support of overall research and development activities and non-specific programs, including activities that benefit multiple programs, such as management costs, as well as depreciation, information technology and facility-based expenses and are not allocated to a specific program or stage.</span></div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span> Other segment expense includes: amortization and impairment of acquired intangible assets; collaboration profit sharing/(loss reimbursement); (gain) loss on fair value remeasurement of contingent consideration; restructuring charges; gain on sale of priority review voucher, net; other (income) expense, net; and income tax (benefit) expense<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.205%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Note 23:</span></div></td><td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:14pt"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Subsequent Events</span></div></td></tr></table></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Vanqua Bio, Inc.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2025 we entered into a license agreement with Vanqua to acquire the worldwide rights to Vanqua's preclinical oral C5aR1 antagonist compound. In connection with the closing of this transaction, we expect to make an upfront payment to Vanqua of $70.0&#160;million during the fourth quarter of 2025, which will be recognized within acquired in-process research and development, upfront and milestone expense in our condensed consolidated statements of income.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Sale of BYOOVIZ and OPUVIZ Rights</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2025 we completed the sale of our remaining commercial rights to two ophthalmology assets in Europe: BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS, and OPUVIZ, an aflibercept biosimilar referencing EYLEA. Samsung Bioepis will have full responsibility for commercialization of BYOOVIZ upon the transfer of commercial rights from Biogen back to Samsung Bioepis, effective as of January 2026.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to recognize a minimal gain within our condensed consolidated statements of income during the fourth quarter of 2025.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_BusinessOverviewPolicyTextBlock', window );">Business Overview</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biogen is a global biopharmaceutical company focused on discovering, developing and delivering innovative therapies for people living with serious and complex diseases. We have a broad portfolio of medicines to treat MS, have introduced the first approved treatment for SMA, co-developed treatments to address a defining pathology of Alzheimer&#8217;s disease and launched the first approved treatment to target a genetic cause of ALS. We market the first and only drug approved in the U.S., the E.U. and certain international markets for the treatment of FA in adults and adolescents aged 16 years and older. We are focused on advancing our pipeline in neurology, specialized immunology and rare diseases. We support our drug discovery and development efforts through internal research and development programs, external collaborations and acquisitions.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY and TYSABRI for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of FA; and QALSODY for the treatment of ALS.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Supernus on the commercialization of ZURZUVAE for the treatment of PPD. We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, CLL and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL, follicular lymphoma and, following its approval in October 2025, lupus nephritis; OCREVUS for the treatment of PPMS and RMS; LUNSUMIO for the treatment of relapsed or refractory follicular lymphoma; COLUMVI, a bispecific antibody for the treatment of non-Hodgkin's lymphoma; and have the option to add other potential anti-CD20 therapies, pursuant to our collaboration arrangements with Genentech, a wholly-owned member of the Roche Group.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We commercialize a portfolio of biosimilars of advanced biologics including: BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS, in certain international markets. We also have commercialization rights related to OPUVIZ, an aflibercept biosimilar referencing EYLEA, in certain international markets.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For additional information on our collaboration arrangements, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to these unaudited condensed consolidated financial statements (condensed consolidated financial statements).</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair statement of our financial statements for interim periods in accordance with U.S.&#160;GAAP. The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our 2024 Form&#160;10-K. Our accounting policies are described in the </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Notes to Consolidated Financial Statements</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in our 2024 Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the three and nine</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">months ended September 30, 2025, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate as one operating segment, focused on discovering, developing and delivering innovative therapies for people living with serious and complex diseases.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2025 we began presenting acquired in-process research and development, upfront and milestone expense as a separate line item in our condensed consolidated statements of income. Acquired in-process research and development, upfront and milestone expense includes costs incurred in connection with collaboration and license agreements such as upfront and milestone payments and, when applicable, premiums on equity securities and asset acquisitions of acquired in-process research and development, which were previously </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">included in research and development expense. Prior periods have been reclassified to conform to the current period presentation. The reclassification had no impact on our total cost and expense, net income attributable to Biogen Inc., earnings per share or total equity.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than 100.0% of the economics, we record net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of estimates</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenue and expense and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and assumptions. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results may differ from these estimates.</span></div><div style="margin-top:9pt"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no material changes to our significant accounting policies disclosed in </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1, Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our audited consolidated financial statements included in our 2024 Form&#160;10-K.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New accounting pronouncements</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have had, or may have, a material impact on our condensed consolidated financial statements or disclosures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessOverviewPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describes an overview of the company and its operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessOverviewPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combination [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">Business Combination</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total consideration transferred for the acquisition of HI-Bio is summarized as follows:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.823%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.393%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of July&#160;2, 2024</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash consideration paid to HI-Bio shareholders</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,137.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">485.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total consideration</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,622.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span> Represents total consideration paid to shareholders of HI-Bio of $1.15&#160;billion, plus an additional $43.7&#160;million related to working capital adjustments as of the transaction close date, less $56.4&#160;million of cash paid for HI-Bio's outstanding, non-vested equity awards, inclusive of employer taxes, which were recognized as compensation attributable to the post-acquisition service period and therefore not reflected as a component of total consideration.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock', window );">Business Combination, Recognized Asset Acquired and Liability Assumed</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date, and reflects measurement period adjustments made to the amounts initially recorded as of the acquisition date on July&#160;2, 2024. The related impact to our condensed consolidated statements of income that would have been recognized in previous periods if the adjustments were recognized as of the acquisition date is immaterial.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:77.847%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:19.369%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts Recognized as of Acquisition Date<br/>(as adjusted)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Intangible assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IPR&amp;D - felzartamab (IgAN)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">920.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IPR&amp;D - felzartamab (AMR)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">450.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IPR&amp;D - felzartamab (PMN)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">265.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other clinical programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expense and other assets</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(35.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Deferred tax liability</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(309.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total identifiable net assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,361.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">261.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total assets acquired and liabilities assumed</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,622.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Includes measurement period adjustments recorded in 2025 that increased prepaid expense and other assets by $0.4&#160;million, net deferred tax liability by $4.9&#160;million and goodwill by $4.5&#160;million.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of business combination. Includes, but is not limited to, recognized asset and liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-41<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of asset acquired and liability assumed in business combination and recognized at acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring, Business Transformation and Other Cost Saving Initiatives (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Restructuring and Related Costs</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total charges incurred from our 2023 Fit for Growth program are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.092%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.434%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accelerated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total charges</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accelerated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.8)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">12.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total charges</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.1&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.3&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total charges incurred from our Reata integration are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.753%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.326%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.606%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance<br/>Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accelerated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total charges</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accelerated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Severance Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Depreciation and Other Costs</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring charges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total charges</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.8&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">17.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Schedule of Restructuring Reserve by Type of Cost</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Charges and spending related to workforce reductions are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.443%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.546%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Workforce Reductions</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of January 1</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(42.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency and other adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of March 31</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">45.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency and other adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of June 30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(17.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(4.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency and other adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Restructuring reserve as of September 30</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.2&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Revenues by product</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue by product is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:31.550%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.445%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TECFIDERA</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">123.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">168.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">192.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">232.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">VUMERITY</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">189.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">214.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">134.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">158.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Fumarate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">234.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">382.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">175.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">215.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">390.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AVONEX</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">133.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">188.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">115.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">176.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PLEGRIDY</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Interferon</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">161.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">85.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">246.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">143.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">94.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">237.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TYSABRI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">247.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">184.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">431.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">227.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">178.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">406.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FAMPYRA</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Multiple Sclerosis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">642.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">418.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,061.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">546.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">507.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,053.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rare Disease:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SPINRAZA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">153.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">220.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">374.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">153.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">228.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">381.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SKYCLARYS</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">74.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">102.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">QALSODY</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Rare Disease</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">235.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">298.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">533.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">240.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">254.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">494.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biosimilars:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BENEPALI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">121.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">118.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">118.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IMRALDI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">54.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FLIXABI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BYOOVIZ</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TOFIDENCE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Biosimilars</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">194.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">196.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">192.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">196.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ZURZUVAE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">55.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue, net</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">935.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">911.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,846.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">813.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">956.4&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,769.4&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Effective January 1, 2025, our collaboration and license agreement for FAMPYRA global commercialization rights was terminated.</span></div><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> SKYCLARYS became commercially available in the E.U. during the first quarter of 2024.</span></div><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> QALSODY became commercially available in the E.U. during the second quarter of 2024.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Other includes FUMADERM and ADUHELM.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:31.550%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.445%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">United<br/>States</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Rest of<br/>World</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Multiple Sclerosis:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TECFIDERA</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">436.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">567.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">611.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">739.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">VUMERITY</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">494.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">565.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">385.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">66.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">451.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Fumarate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">626.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">507.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,133.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">512.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">677.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,190.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">AVONEX</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">363.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">169.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">533.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">344.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">193.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">537.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">PLEGRIDY</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">80.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">106.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">186.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">84.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">109.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">194.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Interferon</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">443.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">276.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">719.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">428.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">303.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">732.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TYSABRI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">720.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">547.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,267.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">690.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">609.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,299.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FAMPYRA</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Multiple Sclerosis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,790.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,331.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,121.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,631.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,648.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,279.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Rare Disease:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SPINRAZA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">456.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">733.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,190.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">458.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">692.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,151.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">SKYCLARYS</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">221.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">165.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">387.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">230.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">280.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">QALSODY</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">39.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Rare Disease</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">700.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">938.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,639.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">703.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">749.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,452.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biosimilars:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BENEPALI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">345.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">345.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">354.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">354.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">IMRALDI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">162.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">162.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">FLIXABI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">47.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">BYOOVIZ</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">TOFIDENCE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Biosimilars</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">550.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">559.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">572.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">591.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ZURZUVAE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal: Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">129.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total product revenue, net</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,630.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,821.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,452.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,405.8&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,975.1&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,380.9&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Effective January 1, 2025, our collaboration and license agreement for FAMPYRA global commercialization rights was terminated.</span></div><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> SKYCLARYS became commercially available in the E.U. during the first quarter of 2024.</span></div><div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> QALSODY became commercially available in the E.U. during the second quarter of 2024.</span></div><div style="margin-top:1pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Other includes FUMADERM and ADUHELM.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock', window );">Analysis of change In reserves</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An analysis of the change in reserves for discounts and allowances is summarized as follows:</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.155%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.109%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.109%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.109%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.114%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Discounts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual<br/>Adjustments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Returns</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">162.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">880.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,091.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current provisions relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">607.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,052.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,680.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Adjustments relating to prior years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(82.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(79.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/credits relating to sales in current year</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(497.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,271.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1,768.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments/credits relating to sales in prior years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(111.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(479.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11.5)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(602.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, September 30, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">163.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,101.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,322.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock', window );">Total reserves included in consolidated balance sheets</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:66.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.397%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.253%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Reduction of accounts receivable</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">259.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">154.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Component of accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,062.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">937.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue-related reserves</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,322.0&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,091.6&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock', window );">Revenues from anti-CD20 therapeutic programs</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from anti-CD20 therapeutic programs is summarized in the table below. For the purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.309%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.431%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalty revenue on sales of OCREVUS</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">386.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">346.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,029.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">985.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen&#8217;s share of pre-tax profits in the U.S. for RITUXAN, GAZYVA and LUNSUMIO</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">101.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">94.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">292.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">285.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">18.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue from anti-CD20 therapeutic programs</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">493.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">446.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,339.4&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,284.7&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_OtherrevenuesTableTextBlock', window );">Other revenues</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract manufacturing, royalty and other revenue is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.285%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contract manufacturing revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">141.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">221.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">648.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">474.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalty and other revenue</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">40.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total contract manufacturing, royalty and other revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">151.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">231.6&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">689.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">522.4&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Analysis of amount of and change in product revenue reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_OtherrevenuesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other revenues [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_OtherrevenuesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenues from anti-CD20 therapeutic programs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of total product revenue reserves included in consolidated balance sheets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Components of inventory</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of inventory are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Raw materials</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">296.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">317.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,635.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,882.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">440.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">353.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,371.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,554.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet Classification:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,209.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,460.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Investments and other assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">162.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">93.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total inventory</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,371.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,554.4&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_IntangibleAssetsExcludingGoodwillTableTextBlock', window );">Intangible assets</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets, net of accumulated amortization, impairment charges and adjustments are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.607%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.987%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.684%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Life</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Amortization</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Completed technology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2-31 years</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,087.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,558.7)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,528.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14,138.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,254.1)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,884.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">In-process research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite until commercialization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,639.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,639.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,642.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,642.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Priority review voucher</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Trademarks&#160;and trade names</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Indefinite</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total intangible assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,890.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,558.7)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,331.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15,945.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6,254.1)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9,691.2&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Estimated future amortization for acquired intangible assets</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated future amortization of finite-lived intangible assets for the next five years is expected to be as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025 (remaining three months)</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">130.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">485.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">490.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">525.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2029</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">580.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2030</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">650.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Summary of roll forward of the changes in goodwill</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a roll forward of the changes in our goodwill balance:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:78.724%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.346%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill, December 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,478.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill resulting from HI-Bio acquisition</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Goodwill, September 30, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,490.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Goodwill resulting from the HI-Bio acquisition relates to HI-Bio measurement period adjustments recognized during 2025 related to certain income tax adjustments. For additional information on our acquisition of HI-Bio, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Other includes adjustments related to foreign currency exchange rate fluctuations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_IntangibleAssetsExcludingGoodwillTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intangible assets excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_IntangibleAssetsExcludingGoodwillTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Summary of assets and liabilities recorded at fair value</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.796%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements on a Recurring Basis</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,398.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,398.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable debt securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-current assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Convertible note</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan assets for deferred compensation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,691.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,557.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">30.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-current liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">242.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">242.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">490.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">391.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As part of our strategic research arrangement with City Therapeutics we invested in a convertible note, for which we elected the fair value option. For additional information on the arrangement with City Therapeutics, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 19, Collaborative and Other Relationships,</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> to these condensed consolidated financial statements.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.420%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.796%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Measurements on a Recurring Basis</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quoted&#160;Prices<br/>in Active<br/>Markets<br/>(Level 1)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Other Observable<br/>Inputs<br/>(Level 2)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable<br/>Inputs<br/>(Level 3)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,664.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,664.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">179.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">179.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-current assets:</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Plan assets for deferred compensation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,949.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">179.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,770.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">291.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">291.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other non-current liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">221.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">221.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">524.5&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">512.8&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Fair Value Measurement Inputs and Valuation Techniques</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables present quantitative information, as of the dates indicated, about the valuation techniques and significant unobservable inputs used in the valuation of our Level 3 financial assets and liabilities measured at fair value on a recurring basis:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.069%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.772%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quantitative Information about Level 3 Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable Input(s)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">391.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discounted cash flow</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.4% - 5.5%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected timing of achievement of development milestones</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025 - 2030</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.069%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.772%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Quantitative Information about Level 3 Fair Value Measurements</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Valuation Technique</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Significant<br/>Unobservable Input(s)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Range</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">512.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discounted cash flow</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.2% - 6.3%</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Expected timing of achievement of development milestones</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2025 - 2030</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation</a></td>
<td class="text">The following table provides a roll forward of the fair value of our contingent consideration obligations, which were classified as Level 3 measurements:<div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.683%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value, beginning of period</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">534.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">512.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration resulting from HI-Bio acquisition</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">485.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">485.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Changes in fair value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(149.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(150.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Fair value, end of period</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">391.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">508.9&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">391.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">508.9&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock', window );">Summary of fair and carrying value of debt instruments</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:</span></div><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:42.091%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.369%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.374%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Carrying<br/>Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Current portion:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.050% Senior Notes due September 15, 2025</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,741.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,748.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of notes payable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,741.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,748.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Non-current portion:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.250% Senior Notes due May 1, 2030</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,367.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,495.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,295.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,494.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.050% Senior Notes due January 15, 2031</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">410.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">397.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.750% Senior Notes due May 15, 2035</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">680.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">645.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.200% Senior Notes due September 15, 2045</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,026.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,101.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,008.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,101.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.150% Senior Notes due May 1, 2050</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">970.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,475.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">943.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,475.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.250% Senior Notes due February 15, 2051</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">458.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">479.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">448.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">476.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.450% Senior Notes due May 15, 2055</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">748.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">690.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Non-current portion of notes payable</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,663.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,285.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,696.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,547.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total notes payable</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,663.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,285.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,437.2&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,295.8&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> In May 2025 we issued our 2025 Senior Notes for an aggregate principal amount of $1.75&#160;billion. In June 2025 we used the net proceeds from the sale of our 2025 Senior Notes to redeem in full our 4.050% Senior Notes due September 15, 2025, prior to maturity. For additional information, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 13, Indebtedness</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents</a></td>
<td class="text"><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,116.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,664.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Short-term debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">202.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">79.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,398.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,664.9&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Marketable debt and equity securities</a></td>
<td class="text">The following tables summarize our marketable debt and equity securities, classified as available-for-sale:<div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.252%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.580%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">71.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Government securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">227.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(123.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">227.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(123.9)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:41.252%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.576%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.580%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Gains</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross<br/>Unrealized<br/>Losses</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair<br/>Value</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable equity securities, non-current</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">668.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(489.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">179.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">668.7&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(489.0)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">179.7&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated fair value and amortized cost of our marketable debt securities classified as available-for-sale by contractual maturity are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.537%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.353%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2025</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated<br/>Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized<br/>Cost</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Due in one year or less</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable debt securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">97.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock', window );">Foreign currency forward contracts that were entered into to hedge forecasted revenue</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The notional amount of foreign currency forward contracts and foreign currency options that were entered into to hedge forecasted revenue and operating expense is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Notional Amount</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Euro</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,524.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,062.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">British pound</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">133.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Swiss franc</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">68.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Canadian dollar</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total foreign currency forward contracts and options</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,637.7&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,235.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock', window );">Derivative Instruments, Unrealized Gain (Loss)</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The pre-tax portion of the fair value of these foreign currency forward contracts and foreign currency options that were included in AOCI in total equity is summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.964%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.785%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized gains</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Unrealized (losses)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(112.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unrealized gains (losses)</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(103.4)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">50.3&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Summary of the effect of cash flow derivatives designated as hedging instruments on the condensed consolidated statements of income</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the effect of foreign currency forward contracts and forward currency options designated as hedging instruments in our condensed consolidated statements of income:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:22.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.198%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.345%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.154%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.641%"></td><td style="width:0.1%"></td></tr><tr><td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Reclassified from AOCI into Operating Income (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses) Excluded from Effectiveness Testing and<br/>Recognized in Operating Income (in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29.1)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.6)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses)<br/>Reclassified from AOCI into Operating Income (in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Gains/(Losses) Excluded from Effectiveness Testing and<br/>Recognized in Operating Income (in millions)</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(41.1)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Summary of fair value and presentation of derivatives</a></td>
<td class="text"><div style="margin-bottom:3pt;margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:28.328%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.328%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.372%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.376%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance Sheet Location</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Cash Flow Hedging Instruments:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">58.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">87.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Other Derivative Instruments:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset derivative instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Liability derivative instruments</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative Instruments, Unrealized Gain (Loss)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4CC<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4CC<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 182<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480401/815-10-55-182<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4E<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the notional amounts of outstanding derivative positions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables summarize the changes in AOCI, net of tax by component:</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.648%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.981%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.981%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.981%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.989%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30, 2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges,<br/>Net of Tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency<br/>Translation Adjustments,<br/>Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, June 30, 2025</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(112.0)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15.6)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(110.5)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(238.1)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from AOCI</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, September 30, 2025</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(85.5)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15.6)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(113.7)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(214.8)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30, 2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency<br/>Translation Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">51.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(16.6)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(171.2)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(136.2)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(161.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(103.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from AOCI</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">24.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(137.1)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">57.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(78.6)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, September 30, 2025</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(85.5)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15.6)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(113.7)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(214.8)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.648%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.981%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.981%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.981%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.989%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges,<br/>Net of Tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Pension Benefit Obligation,<br/>Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency<br/>Translation Adjustments,<br/>Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, June 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(153.1)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(146.0)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(49.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from AOCI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(41.0)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31.2)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(112.1)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(145.7)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Currency Translation Adjustments</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, December 31, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(25.0)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(126.1)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(153.7)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amounts reclassified from AOCI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Balance, September 30, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31.2)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(112.1)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(145.7)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock', window );">Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the amounts reclassified from AOCI:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.192%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.911%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.814%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts Reclassified from AOCI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income Statement Location</span></td></tr><tr style="height:20pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Gains (losses) on cash flow hedges</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29.1)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.6)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(41.1)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Operating expense</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax (benefit) expense</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total reclassifications, net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(20.2)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.1)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24.5)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.2)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Basic and diluted earnings per share</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted shares outstanding used in our earnings per share calculation are calculated as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.806%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net income attributable to Biogen Inc.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">466.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">388.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,341.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,365.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Weighted average number of common shares outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">145.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effect of dilutive securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time-vested restricted stock units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Dilutive potential common shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Shares used in calculating diluted earnings per share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">147.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">146.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Share-based compensation expense included in condensed consolidated statements of income</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.285%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">69.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">91.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">124.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">49.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">61.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">149.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">150.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">240.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">275.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalized share-based compensation costs </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in total cost and expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">231.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">267.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Income tax effect</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(14.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(24.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(45.3)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(50.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in net income attributable to Biogen Inc.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">104.5&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">185.9&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">216.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Summary of share-based compensation expense associated with each of our share-based compensating programs</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.285%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Time-vested restricted stock units</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59.1&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">186.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">174.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee stock purchase plan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Performance stock units settled in cash</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Market stock units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:0.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">HI-Bio equity awards</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">78.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">240.6&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">275.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Capitalized share-based compensation costs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9.4)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(8.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense included in total cost and expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">75.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">128.7&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">231.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">267.4&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:33.017%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.105%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.578%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Relates to the HI-Bio equity-based compensation expense attributable to the post-acquisition service period, associated with the accelerated vesting of stock options and RSUs previously granted to HI-Bio employees and required no future services to vest. For additional information on our acquisition of HI-Bio, please read </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">Note 2, Acquisitions</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">, to these condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Reconciliation between the U.S. federal statutory tax rate and effective tax rate</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.683%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Statutory rate</span></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Taxes on foreign earnings, including valuation allowances</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(7.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Purchased inventory valuation step-up and intangible assets</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">GILTI</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation awards</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">OBBBA enactment</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(2.1)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, including permanent items</span></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Effective tax rate</span></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.3&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">13.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.4&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Other income (expense), net</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of other (income) expense, net, are summarized as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:44.714%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.387%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.825%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(31.6)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(11.6)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(87.8)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(49.1)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">67.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">200.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">190.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Gains) losses on investments, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(39.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">22.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign exchange (gains) losses, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">16.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">25.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(15.8)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(12.0)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total other (income) expense, net</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.1&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">151.2&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">193.7&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestmentsTextBlock', window );">Gain (loss) on investments in equity securities</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes our (gains) losses on investments, net that relate to our equity securities held during the following periods:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.514%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.765%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.771%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net (gains) losses recognized on equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(39.1)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">34.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less: Net (gains) losses realized on equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(10.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(5.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net unrealized (gains) losses recognized on equity securities</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(28.2)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">32.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">27.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Accrued expenses and other</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expense and other consists of the following:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Revenue-related reserves for discounts and allowances</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,062.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">937.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee compensation and benefits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">310.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">375.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Collaboration expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">268.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">309.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalties and licensing fees</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">320.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">190.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Current portion of contingent consideration obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">148.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">291.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Derivative liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">574.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">692.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total accrued expense and other</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,773.6&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,807.7&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of realized and unrealized gain (loss) on investment in security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_CoPromotionProfitSharingFormulaTableTextBlock', window );">Co Promotion Profit Sharing Formula</a></td>
<td class="text">As a result of the FDA approval of LUNSUMIO our share of the combined annual co-promotion profits for RITUXAN and LUNSUMIO in excess of $50.0&#160;million varies upon the following events, as summarized in the table below:<div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:80.891%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.909%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After LUNSUMIO Approval until the First Threshold Date</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.5&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After First Threshold Date until the Second Threshold Date</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After Second Threshold Date</span></td><td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.0&#160;</span></td><td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock', window );">Summary of Activity Related to BAN2401 and Elenbecestat Collaboration</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of development and sales and marketing expense related to the LEQEMBI Collaboration is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.285%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total development expense incurred by the collaboration related to the advancement of LEQEMBI</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">70.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">77.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">178.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">255.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of the LEQEMBI Collaboration development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">35.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">38.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">89.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">127.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total sales and marketing expense incurred by the LEQEMBI Collaboration</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">176.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">164.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">525.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">476.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of the LEQEMBI Collaboration sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">88.3&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">262.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">238.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock', window );">Summary of activity related to the UCB collaboration</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of development expense related to the UCB collaboration agreement is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.285%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total UCB collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">23.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">19.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">62.8&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">52.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of the UCB collaboration development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">31.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock', window );">Summary of Activity Related to Sage Therapeutics</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A summary of development and sales and marketing expense related to the Supernus collaboration is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.379%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.700%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Supernus collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.4&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">29.6&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of the Supernus collaboration development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total sales and marketing expense incurred by the Supernus collaboration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">28.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">82.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of the Supernus collaboration sales and marketing expense reflected in selling, general and administrative expense and collaboration profit sharing/(loss reimbursement) in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">20.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">65.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock', window );">Summary of Activity Related to Denali Therapeutics Collaboration</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A summary of development expense related to the Denali collaboration is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.455%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.285%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Denali collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">36.3&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">44.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of the Denali collaboration development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_SummaryOfActivityRelatedToCollaborationTableTextBlock', window );">Summary of Activity Related to Stoke Therapeutics Collaboration</a></td>
<td class="text"><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of development expense related to the Stoke collaboration agreement is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.087%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.221%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.932%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30, 2025</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30, 2025</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total Stoke collaboration development expense</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">21.9&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Biogen's share of the Stoke collaboration development expense reflected in research and development expense in our condensed consolidated statements of income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CoPromotionProfitSharingFormulaTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Co-promotion profit sharing formula.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CoPromotionProfitSharingFormulaTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfActivityRelatedToCollaborationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary Of Activity Related To Collaboration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfActivityRelatedToCollaborationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of Activity Related to Denali Therapeutics Collaboration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of Activity Related to Sage Therapeutics</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of Activity Related to the UCB Collaboration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>[Table Text Block] for Summary of Activity Related to E2609 and BAN2401 Collaboration [Table]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock', window );">Reconciliation of revenue from segments to consolidated</a></td>
<td class="text"><div style="margin-top:5pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes additional information about reported segment revenue, significant segment expense and segment measure of profitability:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.116%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Three Months Ended September 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">For the Nine Months Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,534.7&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,465.8&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,611.2&#160;</span></td><td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,221.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Less cost and expense:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cost of sales, excluding amortization and impairment of acquired intangible assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Product cost of sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">384.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">468.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,261.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,204.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Royalty cost of sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">290.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">170.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">647.5&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">522.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and development:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Research and discovery</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">41.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">48.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">141.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Early stage programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">59.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">64.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">184.2&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">214.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Late stage programs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">60.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">56.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">154.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">135.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketed products</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">107.7&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">126.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">284.9&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">414.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other research and development costs</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">167.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">221.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">513.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">560.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Acquired in-process research and development, upfront and milestone expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">249.4&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">594.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">588.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,751.1&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,723.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other segment expense</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">360.8&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">307.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,091.0&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">895.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net Income attributable to Biogen Inc.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">466.5&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">388.5&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,341.8&#160;</span></td><td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,365.5&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:37.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.353%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.355%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> Other research and development costs primarily consist of indirect costs incurred in support of overall research and development activities and non-specific programs, including activities that benefit multiple programs, such as management costs, as well as depreciation, information technology and facility-based expenses and are not allocated to a specific program or stage.</span></div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span> Other segment expense includes: amortization and impairment of acquired intangible assets; collaboration profit sharing/(loss reimbursement); (gain) loss on fair value remeasurement of contingent consideration; restructuring charges; gain on sale of priority review voucher, net; other (income) expense, net; and income tax (benefit) expense<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2025 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_InterestInSubsidiary', window );">Interest in subsidiary (less than given percentage)</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InterestInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest in subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InterestInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 02, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentOwnedAtCost', window );">Investment owned, cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Contingent consideration obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">148.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 291.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">242.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">242.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">221.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,490.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,490.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,478.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=biib_MilestonePaymentFutureDevelopmentMember', window );">Milestone Payment, Future Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones', window );">Estimated additional payments upon achievement of development and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=biib_MilestonePaymentFutureDevelopmentMember', window );">Milestone Payment, Future Development | Felzartamab And Izastobart/HIB210 | Human Immunology Biosciences Pre-Existing In License Commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones', window );">Estimated additional payments upon achievement of development and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=biib_MilestonePaymentRegulatoryMember', window );">Milestone Payment, Regulatory | Felzartamab And Izastobart/HIB210 | Human Immunology Biosciences Pre-Existing In License Commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones', window );">Estimated additional payments upon achievement of development and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=biib_MilestonePaymentCommercialMember', window );">Milestone Payment, Commercial | Felzartamab And Izastobart/HIB210 | Human Immunology Biosciences Pre-Existing In License Commitments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones', window );">Estimated additional payments upon achievement of development and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">640.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">640.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment arrangement, expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28.8<span></span>
</td>
<td class="nump">$ 69.8<span></span>
</td>
<td class="nump">91.0<span></span>
</td>
<td class="nump">$ 124.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment arrangement, expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.6<span></span>
</td>
<td class="nump">61.3<span></span>
</td>
<td class="nump">149.6<span></span>
</td>
<td class="nump">150.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember', window );">Human Immunology Biosciences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Total transaction value</a></td>
<td class="nump">$ 1,137.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Range of outcomes, value, high</a></td>
<td class="nump">650.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PaymentsToAcquireBusinessGrossNonVestedEquityAwards', window );">Non-vested equity awards</a></td>
<td class="nump">74.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment arrangement, expense</a></td>
<td class="nump">56.4<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">$ 56.4<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">$ 56.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_BusinessCombinationConsiderationTransferredWorkingCapitalAdjustment', window );">Working capital adjustment</a></td>
<td class="nump">43.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">485.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Contingent consideration obligations</a></td>
<td class="nump">279.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration obligations</a></td>
<td class="nump">205.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets:</a></td>
<td class="nump">1,600.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">261.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition related costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember', window );">Human Immunology Biosciences | Felzartamab (IgAN)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets:</a></td>
<td class="nump">920.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember', window );">Human Immunology Biosciences | Felzartamab (AMR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets:</a></td>
<td class="nump">450.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember', window );">Human Immunology Biosciences | Felzartamab (PMN)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets:</a></td>
<td class="nump">$ 265.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember', window );">Human Immunology Biosciences | Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_IntangibleAssetMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0.145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember', window );">Human Immunology Biosciences | Measurement Input, Probability Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Discount rate</a></td>
<td class="nump">0.670<span></span>
</td>
<td class="nump">0.700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember', window );">Human Immunology Biosciences | Minimum | Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Discount rate</a></td>
<td class="nump">0.062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember', window );">Human Immunology Biosciences | Maximum | Phase 3 Clinical Trial, Felzartamab One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Contingent consideration obligations</a></td>
<td class="nump">$ 150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember', window );">Human Immunology Biosciences | Maximum | Phase 3 Clinical Trial, Felzartamab Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Contingent consideration obligations</a></td>
<td class="nump">$ 150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember', window );">Human Immunology Biosciences | Maximum | Phase 3 Clinical Trial, Felzartamab AMR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Contingent consideration obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember', window );">Human Immunology Biosciences | Maximum | Phase 3 Clinical Trial, Felzartamab IgAN | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Contingent consideration obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember', window );">Human Immunology Biosciences | Maximum | Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Discount rate</a></td>
<td class="nump">0.070<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember', window );">Human Immunology Biosciences | Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment arrangement, expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember', window );">Human Immunology Biosciences | Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment arrangement, expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember', window );">Human Immunology Biosciences | Previously Reported</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Total transaction value</a></td>
<td class="nump">$ 1,150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=biib_AlcyoneTherapeuticsInc.Member', window );">Alcyone Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Payments to acquire productive assets</a></td>
<td class="nump">$ 85.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessCombinationConsiderationTransferredWorkingCapitalAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration Transferred, Working Capital Adjustment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessCombinationConsiderationTransferredWorkingCapitalAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated additional payments upon achievement of development and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_IntangibleAssetMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Intangible Asset, Measurement Input</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_IntangibleAssetMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PaymentsToAcquireBusinessGrossNonVestedEquityAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments To Acquire Business, Gross, Non-Vested Equity Awards</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PaymentsToAcquireBusinessGrossNonVestedEquityAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-47<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 37: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for acquisition-related cost incurred to effect business combination. Includes, but is not limited to, finder's fee; advisory, legal, accounting, valuation, and other professional and consulting fees; and general administrative cost, including cost of maintaining internal acquisition department.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-7<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479405/805-10-25-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of estimate for undiscounted range of outcomes in contingent consideration arrangement in business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 43<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-43<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 43<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-43<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure liability in contingent consideration arrangement in business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 43<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-43<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of identifiable finite-lived intangible asset acquired in business combination and recognized at acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-41<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478064/805-740-55-13<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 39<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-39<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentOwnedAtCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of the investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477439/946-210-55-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478795/946-210-50-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.12-12(Column C)(Footnote 8)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-12B(Column C)(Footnote 11)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Subparagraph (SX 210.12-14(Column F)(Footnote 5)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentOwnedAtCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-41<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480060/805-50-25-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 50<br> -Name Accounting Standards Codification<br> -Section 30<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480027/805-50-30-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=biib_MilestonePaymentFutureDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=biib_MilestonePaymentFutureDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FelzartamabAndIzastobartHIB210Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FelzartamabAndIzastobartHIB210Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=biib_HumanImmunologyBiosciencesPreExistingInLicenseCommitmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=biib_HumanImmunologyBiosciencesPreExistingInLicenseCommitmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=biib_MilestonePaymentRegulatoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=biib_MilestonePaymentRegulatoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=biib_MilestonePaymentCommercialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=biib_MilestonePaymentCommercialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FelzartamabIgANMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FelzartamabIgANMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FelzartamabAMRMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FelzartamabAMRMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FelzartamabPMNMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FelzartamabPMNMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=biib_MeasurementInputProbabilityRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=biib_MeasurementInputProbabilityRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=biib_Phase3ClinicalTrialFelzartamabOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=biib_Phase3ClinicalTrialFelzartamabOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=biib_Phase3ClinicalTrialFelzartamabTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=biib_Phase3ClinicalTrialFelzartamabTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=biib_Phase3ClinicalTrialFelzartamabAMRMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=biib_Phase3ClinicalTrialFelzartamabAMRMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=biib_Phase3ClinicalTrialFelzartamabIgANMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=biib_Phase3ClinicalTrialFelzartamabIgANMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=biib_AlcyoneTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=biib_AlcyoneTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Acquisitions - Purchase Price Consideration (Details) - Human Immunology Biosciences<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jul. 02, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Total transaction value</a></td>
<td class="nump">$ 1,137.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Contingent consideration</a></td>
<td class="nump">485.1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Total consideration</a></td>
<td class="nump">$ 1,622.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-47<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 37: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-41<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-41<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-41<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions - Preliminaty Purchase Price Allocation (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jul. 02, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 6,490.7<span></span>
</td>
<td class="nump">$ 6,478.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember', window );">Human Immunology Biosciences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expense and other assets(1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets', window );">Operating lease assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(35.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(309.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.2)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Total identifiable net assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,361.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">261.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Total assets acquired and liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,622.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpenseAndOther', window );">Adjustment, prepaid expense and other</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability', window );">Deferred tax liability, measurement period adjustment</a></td>
<td class="nump">4.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill', window );">Goodwill, measurement period adjustment</a></td>
<td class="nump">4.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember', window );">Human Immunology Biosciences | In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets:</a></td>
<td class="nump">$ 1,600.0<span></span>
</td>
<td class="nump">$ 1,600.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember', window );">Human Immunology Biosciences | Other clinical programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember', window );">Human Immunology Biosciences | Felzartamab (IgAN)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">920.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember', window );">Human Immunology Biosciences | Felzartamab (IgAN) | In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">920.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember', window );">Human Immunology Biosciences | Felzartamab (AMR)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember', window );">Human Immunology Biosciences | Felzartamab (AMR) | In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember', window );">Human Immunology Biosciences | Felzartamab (PMN)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">265.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember', window );">Human Immunology Biosciences | Felzartamab (PMN) | In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Combination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 265.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Tax Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Goodwill</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpenseAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Prepaid Expense And Other</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpenseAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Operating Lease Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Operating Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-47<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br><br>Reference 37: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent acquired in business combination and recognized at acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of prepaid expense and asset classified as other, acquired in business combination and recognized at acquisition date, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accounts payable assumed in business combination and recognized at acquisition date, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability assumed in business combination and recognized at acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of identifiable finite-lived intangible asset acquired in business combination and recognized at acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset acquired in excess of (less than) liability assumed in business combination and recognized at acquisition date. Excludes goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-41<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset acquired in excess of (less than) liability assumed plus goodwill in business combination and recognized at acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-41<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478064/805-740-55-13<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 39<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-39<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OtherClinicalProgramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_OtherClinicalProgramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FelzartamabIgANMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FelzartamabIgANMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FelzartamabAMRMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FelzartamabAMRMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FelzartamabPMNMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FelzartamabPMNMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Dispositions (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Apr. 30, 2024</div></th>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfIntangibleAssets', window );">Proceeds from sale of intangible assets</a></td>
<td class="nump">$ 51.0<span></span>
</td>
<td class="nump">$ 103.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfIntangibleAssets', window );">Gain on sale of priority review voucher, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 88.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=biib_IonisPharmaceuticalsInc.Member', window );">Ionis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_ProceedsPaidToCollaborativeArrangementCounterparty', window );">Proceeds Paid To Collaborative Arrangement Counterparty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity, ownership interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Equity Method Investment, Amount Sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture', window );">Proceeds from divestiture of interest in joint venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PayablesToDivestitureOfInterestInJointVenture', window );">Payables to divestiture of interest in joint venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis | Payment Due At First Anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PayablesToDivestitureOfInterestInJointVenture', window );">Payables to divestiture of interest in joint venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">812.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis | Payment Due At Second Anniversary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PayablesToDivestitureOfInterestInJointVenture', window );">Payables to divestiture of interest in joint venture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 437.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Gain (loss) on sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PayablesToDivestitureOfInterestInJointVenture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payables To Divestiture Of Interest In Joint Venture</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PayablesToDivestitureOfInterestInJointVenture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ProceedsPaidToCollaborativeArrangementCounterparty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds Paid To Collaborative Arrangement Counterparty</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ProceedsPaidToCollaborativeArrangementCounterparty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the entity's equity method investment which has been sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentSoldCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfInterestInJointVenture">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of an investment interest in a joint venture that the reporting entity has not previously accounted for using consolidation or the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfInterestInJointVenture</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=biib_IonisPharmaceuticalsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=biib_IonisPharmaceuticalsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureContingentMilestoneTypesAxis=biib_PaymentDueAtFirstAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureContingentMilestoneTypesAxis=biib_PaymentDueAtFirstAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureContingentMilestoneTypesAxis=biib_PaymentDueAtSecondAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureContingentMilestoneTypesAxis=biib_PaymentDueAtSecondAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring, Business Transformation and Other Cost Saving Initiatives - FIt for Growth Initiative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 7.4<span></span>
</td>
<td class="nump">$ 6.8<span></span>
</td>
<td class="nump">$ 42.0<span></span>
</td>
<td class="nump">$ 24.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=biib_A2023CostSavingInitiativesMember', window );">2023 Cost Saving Initiatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="nump">7.4<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
<td class="nump">41.6<span></span>
</td>
<td class="nump">20.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherRestructuringCosts', window );">Accelerated Depreciation and Other Costs</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="nump">12.6<span></span>
</td>
<td class="nump">4.1<span></span>
</td>
<td class="nump">23.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">8.3<span></span>
</td>
<td class="nump">17.2<span></span>
</td>
<td class="nump">45.7<span></span>
</td>
<td class="nump">43.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=biib_ReataIntegrationMember', window );">Reata Integration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherRestructuringCosts', window );">Accelerated Depreciation and Other Costs</a></td>
<td class="nump">5.4<span></span>
</td>
<td class="nump">4.5<span></span>
</td>
<td class="nump">15.3<span></span>
</td>
<td class="nump">13.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">5.4<span></span>
</td>
<td class="nump">5.2<span></span>
</td>
<td class="nump">15.1<span></span>
</td>
<td class="nump">17.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | 2023 Cost Saving Initiatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherRestructuringCosts', window );">Accelerated Depreciation and Other Costs</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">9.1<span></span>
</td>
<td class="num">(2.8)<span></span>
</td>
<td class="nump">12.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">9.1<span></span>
</td>
<td class="num">(2.8)<span></span>
</td>
<td class="nump">12.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative | Reata Integration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherRestructuringCosts', window );">Accelerated Depreciation and Other Costs</a></td>
<td class="nump">1.6<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
<td class="nump">5.2<span></span>
</td>
<td class="nump">4.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">1.6<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
<td class="nump">5.2<span></span>
</td>
<td class="nump">4.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | 2023 Cost Saving Initiatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherRestructuringCosts', window );">Accelerated Depreciation and Other Costs</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">3.5<span></span>
</td>
<td class="nump">6.9<span></span>
</td>
<td class="nump">10.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">3.5<span></span>
</td>
<td class="nump">6.9<span></span>
</td>
<td class="nump">10.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development | Reata Integration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherRestructuringCosts', window );">Accelerated Depreciation and Other Costs</a></td>
<td class="nump">3.8<span></span>
</td>
<td class="nump">2.9<span></span>
</td>
<td class="nump">10.1<span></span>
</td>
<td class="nump">8.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">3.8<span></span>
</td>
<td class="nump">2.9<span></span>
</td>
<td class="nump">10.1<span></span>
</td>
<td class="nump">8.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember', window );">Restructuring charges | 2023 Cost Saving Initiatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="nump">7.4<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
<td class="nump">41.6<span></span>
</td>
<td class="nump">20.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherRestructuringCosts', window );">Accelerated Depreciation and Other Costs</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">7.4<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
<td class="nump">41.6<span></span>
</td>
<td class="nump">20.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember', window );">Restructuring charges | Reata Integration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherRestructuringCosts', window );">Accelerated Depreciation and Other Costs</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="num">$ (0.2)<span></span>
</td>
<td class="nump">$ 3.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherRestructuringCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherRestructuringCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-21<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=biib_A2023CostSavingInitiativesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=biib_A2023CostSavingInitiativesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=biib_ReataIntegrationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=biib_ReataIntegrationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring, Business Transformation and Other Cost Saving Initiatives - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 26, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($) </div>
<div>Employee</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jul. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_OperatingLeaseArea', window );">Operating lease area | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">580,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember', window );">Reata Pharmaceuticals, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_OperatingLeaseArea', window );">Operating lease area | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">327,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">16 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1', window );">Restructuring and Related Cost, Expected Cost Remaining</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 310.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=biib_A2023CostSavingInitiativesMember', window );">2023 Cost Saving Initiatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction', window );">Expected operating expense reduction</a></td>
<td class="nump">$ 1,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated', window );">Expected number of positions eliminated | Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.4<span></span>
</td>
<td class="nump">$ 4.6<span></span>
</td>
<td class="nump">$ 41.6<span></span>
</td>
<td class="nump">$ 20.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=biib_A2023CostSavingInitiativesMember', window );">2023 Cost Saving Initiatives | Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.4<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
<td class="nump">41.6<span></span>
</td>
<td class="nump">20.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=biib_ReataIntegrationMember', window );">Reata Integration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=biib_ReataIntegrationMember', window );">Reata Integration | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Expected cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=biib_ReataIntegrationMember', window );">Reata Integration | Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Severance Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="num">$ (0.2)<span></span>
</td>
<td class="nump">$ 3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_OperatingLeaseArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Area</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_OperatingLeaseArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Restructuring And Related Activities, Expected Operating Expense Reduction</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount expected to be recognized in earnings for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expected cost remaining for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The expected number of positions to be eliminated as a result of restructuring activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=biib_A2023CostSavingInitiativesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=biib_A2023CostSavingInitiativesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=biib_ReataIntegrationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=biib_ReataIntegrationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring, Business Transformation and Other Cost Saving Initiatives - Total Charges cost saving initiative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="nump">$ 7.4<span></span>
</td>
<td class="nump">$ 6.8<span></span>
</td>
<td class="nump">$ 42.0<span></span>
</td>
<td class="nump">$ 24.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-21<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring, Business Transformation and Other Cost Saving Initiatives - Restructuring Reserve Roll Forward (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="6">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Mar. 31, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Expense</a></td>
<td class="nump">$ 7.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42.0<span></span>
</td>
<td class="nump">$ 24.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=biib_A2023CostSavingInitiativesMember', window );">2023 Cost Saving Initiatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Expense</a></td>
<td class="nump">8.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45.7<span></span>
</td>
<td class="nump">43.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Severance Costs | 2023 and 2022 Cost Saving Initiatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, beginning</a></td>
<td class="nump">29.2<span></span>
</td>
<td class="nump">$ 40.4<span></span>
</td>
<td class="nump">$ 31.9<span></span>
</td>
<td class="nump">40.2<span></span>
</td>
<td class="nump">$ 45.5<span></span>
</td>
<td class="nump">$ 75.4<span></span>
</td>
<td class="nump">31.9<span></span>
</td>
<td class="nump">75.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Expense</a></td>
<td class="nump">7.4<span></span>
</td>
<td class="num">(0.7)<span></span>
</td>
<td class="nump">35.3<span></span>
</td>
<td class="nump">6.8<span></span>
</td>
<td class="nump">6.6<span></span>
</td>
<td class="nump">11.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRestructuring', window );">Payment</a></td>
<td class="num">(17.4)<span></span>
</td>
<td class="num">(9.5)<span></span>
</td>
<td class="num">(25.8)<span></span>
</td>
<td class="num">(4.7)<span></span>
</td>
<td class="num">(11.9)<span></span>
</td>
<td class="num">(42.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveTranslationAdjustment', window );">Foreign currency and other adjustments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(1.0)<span></span>
</td>
<td class="num">(1.0)<span></span>
</td>
<td class="num">(2.1)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve, ending</a></td>
<td class="nump">$ 19.2<span></span>
</td>
<td class="nump">$ 29.2<span></span>
</td>
<td class="nump">$ 40.4<span></span>
</td>
<td class="nump">$ 40.2<span></span>
</td>
<td class="nump">$ 40.2<span></span>
</td>
<td class="nump">$ 45.5<span></span>
</td>
<td class="nump">$ 19.2<span></span>
</td>
<td class="nump">$ 40.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-21<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveTranslationAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which decreases (increases) the restructuring reserve.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveTranslationAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=biib_A2023CostSavingInitiativesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=biib_A2023CostSavingInitiativesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=biib_A2023And2022CostSavingInitiativesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=biib_A2023And2022CostSavingInitiativesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Revenues by product (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 2,534.7<span></span>
</td>
<td class="nump">$ 2,465.8<span></span>
</td>
<td class="nump">$ 7,611.2<span></span>
</td>
<td class="nump">$ 7,221.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">1,846.9<span></span>
</td>
<td class="nump">1,769.4<span></span>
</td>
<td class="nump">5,452.1<span></span>
</td>
<td class="nump">5,380.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue, net | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">935.3<span></span>
</td>
<td class="nump">813.0<span></span>
</td>
<td class="nump">2,630.2<span></span>
</td>
<td class="nump">2,405.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue, net | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">911.6<span></span>
</td>
<td class="nump">956.4<span></span>
</td>
<td class="nump">2,821.9<span></span>
</td>
<td class="nump">2,975.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_MSProductRevenuesMember', window );">MS Product Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">1,061.5<span></span>
</td>
<td class="nump">1,053.9<span></span>
</td>
<td class="nump">3,121.7<span></span>
</td>
<td class="nump">3,279.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_MSProductRevenuesMember', window );">MS Product Revenues | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">642.9<span></span>
</td>
<td class="nump">546.0<span></span>
</td>
<td class="nump">1,790.7<span></span>
</td>
<td class="nump">1,631.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_MSProductRevenuesMember', window );">MS Product Revenues | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">418.6<span></span>
</td>
<td class="nump">507.9<span></span>
</td>
<td class="nump">1,331.0<span></span>
</td>
<td class="nump">1,648.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FumarateMember', window );">Fumarate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">382.8<span></span>
</td>
<td class="nump">390.9<span></span>
</td>
<td class="nump">1,133.6<span></span>
</td>
<td class="nump">1,190.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FumarateMember', window );">Fumarate | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">234.2<span></span>
</td>
<td class="nump">175.0<span></span>
</td>
<td class="nump">626.3<span></span>
</td>
<td class="nump">512.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FumarateMember', window );">Fumarate | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">148.6<span></span>
</td>
<td class="nump">215.9<span></span>
</td>
<td class="nump">507.3<span></span>
</td>
<td class="nump">677.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TECFIDERAMember', window );">TECFIDERA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">168.2<span></span>
</td>
<td class="nump">232.8<span></span>
</td>
<td class="nump">567.9<span></span>
</td>
<td class="nump">739.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TECFIDERAMember', window );">TECFIDERA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">44.6<span></span>
</td>
<td class="nump">40.1<span></span>
</td>
<td class="nump">131.6<span></span>
</td>
<td class="nump">127.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TECFIDERAMember', window );">TECFIDERA | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">123.6<span></span>
</td>
<td class="nump">192.7<span></span>
</td>
<td class="nump">436.3<span></span>
</td>
<td class="nump">611.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_VUMERITYMember', window );">VUMERITY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">214.6<span></span>
</td>
<td class="nump">158.1<span></span>
</td>
<td class="nump">565.7<span></span>
</td>
<td class="nump">451.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_VUMERITYMember', window );">VUMERITY | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">189.6<span></span>
</td>
<td class="nump">134.9<span></span>
</td>
<td class="nump">494.7<span></span>
</td>
<td class="nump">385.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_VUMERITYMember', window );">VUMERITY | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">25.0<span></span>
</td>
<td class="nump">23.2<span></span>
</td>
<td class="nump">71.0<span></span>
</td>
<td class="nump">66.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_InterferonMember', window );">Interferon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">246.9<span></span>
</td>
<td class="nump">237.5<span></span>
</td>
<td class="nump">719.9<span></span>
</td>
<td class="nump">732.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_InterferonMember', window );">Interferon | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">161.2<span></span>
</td>
<td class="nump">143.5<span></span>
</td>
<td class="nump">443.9<span></span>
</td>
<td class="nump">428.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_InterferonMember', window );">Interferon | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">85.7<span></span>
</td>
<td class="nump">94.0<span></span>
</td>
<td class="nump">276.0<span></span>
</td>
<td class="nump">303.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_AVONEXMember', window );">AVONEX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">188.5<span></span>
</td>
<td class="nump">176.2<span></span>
</td>
<td class="nump">533.0<span></span>
</td>
<td class="nump">537.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_AVONEXMember', window );">AVONEX | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">133.4<span></span>
</td>
<td class="nump">115.6<span></span>
</td>
<td class="nump">363.7<span></span>
</td>
<td class="nump">344.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_AVONEXMember', window );">AVONEX | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">55.1<span></span>
</td>
<td class="nump">60.6<span></span>
</td>
<td class="nump">169.3<span></span>
</td>
<td class="nump">193.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_PLEGRIDYMember', window );">PLEGRIDY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">58.4<span></span>
</td>
<td class="nump">61.3<span></span>
</td>
<td class="nump">186.9<span></span>
</td>
<td class="nump">194.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_PLEGRIDYMember', window );">PLEGRIDY | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">27.8<span></span>
</td>
<td class="nump">27.9<span></span>
</td>
<td class="nump">80.2<span></span>
</td>
<td class="nump">84.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_PLEGRIDYMember', window );">PLEGRIDY | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">30.6<span></span>
</td>
<td class="nump">33.4<span></span>
</td>
<td class="nump">106.7<span></span>
</td>
<td class="nump">109.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TysabriProductMember', window );">TYSABRI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">431.8<span></span>
</td>
<td class="nump">406.1<span></span>
</td>
<td class="nump">1,267.9<span></span>
</td>
<td class="nump">1,299.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TysabriProductMember', window );">TYSABRI | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">247.5<span></span>
</td>
<td class="nump">227.5<span></span>
</td>
<td class="nump">720.5<span></span>
</td>
<td class="nump">690.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TysabriProductMember', window );">TYSABRI | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">184.3<span></span>
</td>
<td class="nump">178.6<span></span>
</td>
<td class="nump">547.4<span></span>
</td>
<td class="nump">609.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FAMPYRAMember', window );">FAMPYRA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">19.4<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">57.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FAMPYRAMember', window );">FAMPYRA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FAMPYRAMember', window );">FAMPYRA | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">19.4<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">57.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_RareDiseaseProductRevenueMember', window );">Rare Disease Product Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">533.3<span></span>
</td>
<td class="nump">494.8<span></span>
</td>
<td class="nump">1,639.6<span></span>
</td>
<td class="nump">1,452.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_RareDiseaseProductRevenueMember', window );">Rare Disease Product Revenue | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">235.1<span></span>
</td>
<td class="nump">240.4<span></span>
</td>
<td class="nump">700.9<span></span>
</td>
<td class="nump">703.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_RareDiseaseProductRevenueMember', window );">Rare Disease Product Revenue | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">298.2<span></span>
</td>
<td class="nump">254.4<span></span>
</td>
<td class="nump">938.7<span></span>
</td>
<td class="nump">749.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_QALSODYMember', window );">QALSODY</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">26.4<span></span>
</td>
<td class="nump">11.1<span></span>
</td>
<td class="nump">61.9<span></span>
</td>
<td class="nump">20.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_QALSODYMember', window );">QALSODY | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">7.3<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
<td class="nump">22.3<span></span>
</td>
<td class="nump">14.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_QALSODYMember', window );">QALSODY | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">19.1<span></span>
</td>
<td class="nump">5.6<span></span>
</td>
<td class="nump">39.6<span></span>
</td>
<td class="nump">6.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">374.0<span></span>
</td>
<td class="nump">381.4<span></span>
</td>
<td class="nump">1,190.6<span></span>
</td>
<td class="nump">1,151.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">153.2<span></span>
</td>
<td class="nump">153.1<span></span>
</td>
<td class="nump">456.9<span></span>
</td>
<td class="nump">458.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember', window );">SPINRAZA | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">220.8<span></span>
</td>
<td class="nump">228.3<span></span>
</td>
<td class="nump">733.7<span></span>
</td>
<td class="nump">692.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_SKYCLARYSMember', window );">SKYCLARYS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">132.9<span></span>
</td>
<td class="nump">102.3<span></span>
</td>
<td class="nump">387.1<span></span>
</td>
<td class="nump">280.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_SKYCLARYSMember', window );">SKYCLARYS | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">74.6<span></span>
</td>
<td class="nump">81.8<span></span>
</td>
<td class="nump">221.7<span></span>
</td>
<td class="nump">230.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_SKYCLARYSMember', window );">SKYCLARYS | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">58.3<span></span>
</td>
<td class="nump">20.5<span></span>
</td>
<td class="nump">165.4<span></span>
</td>
<td class="nump">49.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BiosimilarsMember', window );">Biosimilars</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">196.8<span></span>
</td>
<td class="nump">196.6<span></span>
</td>
<td class="nump">559.3<span></span>
</td>
<td class="nump">591.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BiosimilarsMember', window );">Biosimilars | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">2.0<span></span>
</td>
<td class="nump">4.3<span></span>
</td>
<td class="nump">8.8<span></span>
</td>
<td class="nump">19.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BiosimilarsMember', window );">Biosimilars | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">194.8<span></span>
</td>
<td class="nump">192.3<span></span>
</td>
<td class="nump">550.5<span></span>
</td>
<td class="nump">572.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BENEPALIMember', window );">BENEPALI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">121.9<span></span>
</td>
<td class="nump">118.1<span></span>
</td>
<td class="nump">345.3<span></span>
</td>
<td class="nump">354.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BENEPALIMember', window );">BENEPALI | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BENEPALIMember', window );">BENEPALI | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">121.9<span></span>
</td>
<td class="nump">118.1<span></span>
</td>
<td class="nump">345.3<span></span>
</td>
<td class="nump">354.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_IMRALDIMember', window );">IMRALDI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">52.6<span></span>
</td>
<td class="nump">54.1<span></span>
</td>
<td class="nump">146.7<span></span>
</td>
<td class="nump">162.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_IMRALDIMember', window );">IMRALDI | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_IMRALDIMember', window );">IMRALDI | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">52.6<span></span>
</td>
<td class="nump">54.1<span></span>
</td>
<td class="nump">146.7<span></span>
</td>
<td class="nump">162.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FLIXABIMember', window );">FLIXABI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">15.3<span></span>
</td>
<td class="nump">16.2<span></span>
</td>
<td class="nump">42.7<span></span>
</td>
<td class="nump">47.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FLIXABIMember', window );">FLIXABI | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FLIXABIMember', window );">FLIXABI | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">15.3<span></span>
</td>
<td class="nump">16.2<span></span>
</td>
<td class="nump">42.7<span></span>
</td>
<td class="nump">47.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BYOOVIZMember', window );">BYOOVIZ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">7.0<span></span>
</td>
<td class="nump">8.0<span></span>
</td>
<td class="nump">24.5<span></span>
</td>
<td class="nump">27.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BYOOVIZMember', window );">BYOOVIZ | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">2.0<span></span>
</td>
<td class="nump">4.1<span></span>
</td>
<td class="nump">8.7<span></span>
</td>
<td class="nump">18.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_BYOOVIZMember', window );">BYOOVIZ | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">5.0<span></span>
</td>
<td class="nump">3.9<span></span>
</td>
<td class="nump">15.8<span></span>
</td>
<td class="nump">9.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TOFIDENCEMember', window );">TOFIDENCE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TOFIDENCEMember', window );">TOFIDENCE | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_TOFIDENCEMember', window );">TOFIDENCE | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_OtherProductsMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">55.3<span></span>
</td>
<td class="nump">24.1<span></span>
</td>
<td class="nump">131.5<span></span>
</td>
<td class="nump">56.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_OtherProductsMember', window );">Other | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">55.3<span></span>
</td>
<td class="nump">22.3<span></span>
</td>
<td class="nump">129.8<span></span>
</td>
<td class="nump">51.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_OtherProductsMember', window );">Other | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
<td class="nump">5.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_ZURZUVAEMember', window );">ZURZUVAE</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">55.3<span></span>
</td>
<td class="nump">22.0<span></span>
</td>
<td class="nump">129.4<span></span>
</td>
<td class="nump">49.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_ZURZUVAEMember', window );">ZURZUVAE | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">55.3<span></span>
</td>
<td class="nump">22.0<span></span>
</td>
<td class="nump">129.4<span></span>
</td>
<td class="nump">49.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_ZURZUVAEMember', window );">ZURZUVAE | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FUMADERMAndADUHELMMember', window );">FUMADERM And ADUHELM</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">2.1<span></span>
</td>
<td class="nump">2.1<span></span>
</td>
<td class="nump">7.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FUMADERMAndADUHELMMember', window );">FUMADERM And ADUHELM | U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FUMADERMAndADUHELMMember', window );">FUMADERM And ADUHELM | Rest of World</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 1.8<span></span>
</td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="nump">$ 5.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_MSProductRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_MSProductRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FumarateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FumarateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_TECFIDERAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_TECFIDERAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_VUMERITYMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_VUMERITYMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_InterferonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_InterferonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_AVONEXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_AVONEXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_PLEGRIDYMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_PLEGRIDYMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_TysabriProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_TysabriProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FAMPYRAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FAMPYRAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_RareDiseaseProductRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_RareDiseaseProductRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_QALSODYMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_QALSODYMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_SPINRAZAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_SPINRAZAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_SKYCLARYSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_SKYCLARYSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_BiosimilarsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_BiosimilarsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_BENEPALIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_BENEPALIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_IMRALDIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_IMRALDIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FLIXABIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FLIXABIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_BYOOVIZMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_BYOOVIZMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_TOFIDENCEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_TOFIDENCEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_OtherProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_OtherProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_ZURZUVAEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_ZURZUVAEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FUMADERMAndADUHELMMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FUMADERMAndADUHELMMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues Reserves for Discounts and Allowances (Details 1)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning Balance</a></td>
<td class="nump">$ 1,091.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current Provisions Relating To Sales In Current Year</a></td>
<td class="nump">2,680.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments Relating To Prior Years</a></td>
<td class="num">(79.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/Returns Relating To Sales in Current Year</a></td>
<td class="num">(1,768.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/Returns Relating To Sales in Prior Year</a></td>
<td class="num">(602.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending Balance</a></td>
<td class="nump">1,322.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ReserveforCashDiscountsMember', window );">Discounts</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning Balance</a></td>
<td class="nump">162.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current Provisions Relating To Sales In Current Year</a></td>
<td class="nump">607.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments Relating To Prior Years</a></td>
<td class="nump">1.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/Returns Relating To Sales in Current Year</a></td>
<td class="num">(497.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/Returns Relating To Sales in Prior Year</a></td>
<td class="num">(111.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending Balance</a></td>
<td class="nump">163.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember', window );">Contractual adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning Balance</a></td>
<td class="nump">880.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current Provisions Relating To Sales In Current Year</a></td>
<td class="nump">2,052.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments Relating To Prior Years</a></td>
<td class="num">(82.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/Returns Relating To Sales in Current Year</a></td>
<td class="num">(1,271.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/Returns Relating To Sales in Prior Year</a></td>
<td class="num">(479.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending Balance</a></td>
<td class="nump">1,101.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember', window );">Returns</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Beginning Balance</a></td>
<td class="nump">48.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear', window );">Current Provisions Relating To Sales In Current Year</a></td>
<td class="nump">20.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears', window );">Adjustments Relating To Prior Years</a></td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear', window );">Payments/Returns Relating To Sales in Current Year</a></td>
<td class="num">(0.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear', window );">Payments/Returns Relating To Sales in Prior Year</a></td>
<td class="num">(11.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Ending Balance</a></td>
<td class="nump">$ 57.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to product revenue reserves relating to sales in prior years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Current provisions to product revenue reserves relating to sales in current year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments/ returns applied against product revenue reserves relating to current year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments/ returns applied against product revenue reserves relating to prior year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ValuationAndQualifyingAccountsDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 09<br> -Paragraph Column E<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 09<br> -Paragraph Column D<br> -Publisher SEC<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 09<br> -Paragraph Column C<br> -Subparagraph (1)<br> -Publisher SEC<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 09<br> -Paragraph Column C<br> -Subparagraph (2)<br> -Publisher SEC<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 09<br> -Paragraph Column B<br> -Publisher SEC<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ValuationAndQualifyingAccountsDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ReserveforCashDiscountsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ReserveforCashDiscountsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=biib_ContractualAdjustmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_SalesReturnsAndAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Revenues- Reserves for Discounts and Allowances (Details 2) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Total Reserves</a></td>
<td class="nump">$ 1,322.0<span></span>
</td>
<td class="nump">$ 1,091.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember', window );">Reduction of accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Total Reserves</a></td>
<td class="nump">259.7<span></span>
</td>
<td class="nump">154.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Component of accrued expenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Total Reserves</a></td>
<td class="nump">$ 1,062.3<span></span>
</td>
<td class="nump">$ 937.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Revenues from Anti-CD20 Therapeutic Programs (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues from anti-CD20 therapeutic programs</a></td>
<td class="nump">$ 2,534.7<span></span>
</td>
<td class="nump">$ 2,465.8<span></span>
</td>
<td class="nump">$ 7,611.2<span></span>
</td>
<td class="nump">$ 7,221.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=biib_RocheGroupGenentechMember', window );">Genentech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_ShareOfCoPromotionProfits', window );">Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA</a></td>
<td class="nump">101.0<span></span>
</td>
<td class="nump">94.8<span></span>
</td>
<td class="nump">292.4<span></span>
</td>
<td class="nump">285.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_OtherrevenuesfromantiCD20therapeuticprograms', window );">Other revenues from anti-CD20 therapeutic programs</a></td>
<td class="nump">6.5<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
<td class="nump">18.0<span></span>
</td>
<td class="nump">13.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember', window );">Revenue from anti-CD20 therapeutic programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues from anti-CD20 therapeutic programs</a></td>
<td class="nump">493.9<span></span>
</td>
<td class="nump">446.2<span></span>
</td>
<td class="nump">1,339.4<span></span>
</td>
<td class="nump">1,284.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_RoyaltyAttributedToOCREVUSMember', window );">Royalty Attributed To OCREVUS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues from anti-CD20 therapeutic programs</a></td>
<td class="nump">$ 386.4<span></span>
</td>
<td class="nump">$ 346.8<span></span>
</td>
<td class="nump">$ 1,029.0<span></span>
</td>
<td class="nump">$ 985.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_OtherrevenuesfromantiCD20therapeuticprograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other revenues from anti-CD20 therapeutic programs consists of revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada and royalty revenue on sales of Ocrevus.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_OtherrevenuesfromantiCD20therapeuticprograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareOfCoPromotionProfits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share of co promotion profits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareOfCoPromotionProfits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_RocheGroupGenentechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_RocheGroupGenentechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_Revenuesfromanticd20therapeuticprogramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_RoyaltyAttributedToOCREVUSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_RoyaltyAttributedToOCREVUSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Other Revenues (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 2,534.7<span></span>
</td>
<td class="nump">$ 2,465.8<span></span>
</td>
<td class="nump">$ 7,611.2<span></span>
</td>
<td class="nump">$ 7,221.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_ContractManufacturingAndOtherRevenueMember', window );">Contract manufacturing revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">141.5<span></span>
</td>
<td class="nump">221.9<span></span>
</td>
<td class="nump">648.8<span></span>
</td>
<td class="nump">474.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty and other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">9.7<span></span>
</td>
<td class="nump">9.7<span></span>
</td>
<td class="nump">40.3<span></span>
</td>
<td class="nump">48.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Contract manufacturing, royalty and other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 151.2<span></span>
</td>
<td class="nump">$ 231.6<span></span>
</td>
<td class="nump">$ 689.1<span></span>
</td>
<td class="nump">$ 522.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_ContractManufacturingAndOtherRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_ContractManufacturingAndOtherRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($) </div>
<div>wholesaler</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>wholesaler</div>
</th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($) </div>
<div>wholesaler</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($) </div>
<div>wholesaler</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_NumberOfWholesalers', window );">Number of wholesalers | wholesaler</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 2,534.7<span></span>
</td>
<td class="nump">$ 2,465.8<span></span>
</td>
<td class="nump">$ 7,611.2<span></span>
</td>
<td class="nump">$ 7,221.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=biib_DistributorOneMember', window );">Distributor One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EntityWidePercentageOfRevenueFromMajorDistributors', window );">Percentage of revenues from major distributors</a></td>
<td class="nump">27.80%<span></span>
</td>
<td class="nump">25.90%<span></span>
</td>
<td class="nump">27.30%<span></span>
</td>
<td class="nump">25.60%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=biib_DistributorTwoMember', window );">Distributor Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EntityWidePercentageOfRevenueFromMajorDistributors', window );">Percentage of revenues from major distributors</a></td>
<td class="nump">16.00%<span></span>
</td>
<td class="nump">14.80%<span></span>
</td>
<td class="nump">15.40%<span></span>
</td>
<td class="nump">12.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember', window );">Contract manufacturing, royalty and other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 151.2<span></span>
</td>
<td class="nump">$ 231.6<span></span>
</td>
<td class="nump">$ 689.1<span></span>
</td>
<td class="nump">$ 522.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_LEQEMBICollaborationMember', window );">Alzheimer's collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 42.7<span></span>
</td>
<td class="nump">18.6<span></span>
</td>
<td class="nump">$ 130.6<span></span>
</td>
<td class="nump">33.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_ShareOfNonControlingInterestRecognized', window );">Share of non-controling interest recognized</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_AlzheimersCollaborationMember', window );">Alzheimer's Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 42.7<span></span>
</td>
<td class="nump">$ 18.6<span></span>
</td>
<td class="nump">$ 130.6<span></span>
</td>
<td class="nump">$ 33.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EntityWidePercentageOfRevenueFromMajorDistributors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity wide percentage of revenue from major distributors.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EntityWidePercentageOfRevenueFromMajorDistributors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NumberOfWholesalers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Wholesalers</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NumberOfWholesalers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareOfNonControlingInterestRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Of Non-Controling Interest Recognized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareOfNonControlingInterestRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_DistributorOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_DistributorOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=biib_DistributorTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=biib_DistributorTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductAndServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_LEQEMBICollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_LEQEMBICollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_AlzheimersCollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_AlzheimersCollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventory - Components of Inventory (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 296.2<span></span>
</td>
<td class="nump">$ 317.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">1,635.0<span></span>
</td>
<td class="nump">1,882.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">440.5<span></span>
</td>
<td class="nump">353.8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_InventoryNetCurrentAndNoncurrent', window );">Inventory</a></td>
<td class="nump">2,371.7<span></span>
</td>
<td class="nump">2,554.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory, current</a></td>
<td class="nump">2,209.4<span></span>
</td>
<td class="nump">2,460.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Inventory, noncurrent</a></td>
<td class="nump">$ 162.3<span></span>
</td>
<td class="nump">$ 93.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InventoryNetCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventory, Net Current and Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InventoryNetCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 26, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 466.5<span></span>
</td>
<td class="nump">$ 388.5<span></span>
</td>
<td class="nump">$ 1,341.8<span></span>
</td>
<td class="nump">$ 1,365.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales, excluding amortization and impairment of acquired intangible assets</a></td>
<td class="nump">674.4<span></span>
</td>
<td class="nump">638.7<span></span>
</td>
<td class="nump">1,908.7<span></span>
</td>
<td class="nump">1,726.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember', window );">Reata Pharmaceuticals, Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory', window );">Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember', window );">Reata Pharmaceuticals, Inc | Business Combination, Pro Forma Information, Nonrecurring Adjustment, Inventory, Fair Value Adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">$ 61.5<span></span>
</td>
<td class="nump">50.9<span></span>
</td>
<td class="nump">$ 165.4<span></span>
</td>
<td class="nump">185.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember', window );">Reata Pharmaceuticals, Inc | Business Combination, Pro Forma Information, Nonrecurring Adjustment, Inventory, Fair Value Adjustment | Clinical Inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales, excluding amortization and impairment of acquired intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of inventory acquired in business combination and recognized at acquisition date, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-41<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 37: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J<br><br>Reference 38: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-2<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonrecurringAdjustmentAxis=us-gaap_FairValueAdjustmentToInventoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonrecurringAdjustmentAxis=us-gaap_FairValueAdjustmentToInventoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_ClinicalInventoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_ClinicalInventoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets and Goodwill - Summary of Intangible Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Finite-Lived Intangible Assets, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-Lived Intangible Assets, Gross</a></td>
<td class="nump">$ 14,087.2<span></span>
</td>
<td class="nump">$ 14,138.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="num">(6,558.7)<span></span>
</td>
<td class="num">(6,254.1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">7,528.5<span></span>
</td>
<td class="nump">7,884.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract', window );"><strong>Intangible Assets, Net (Excluding Goodwill) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Cost</a></td>
<td class="nump">15,890.6<span></span>
</td>
<td class="nump">15,945.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">6,558.7<span></span>
</td>
<td class="nump">6,254.1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Net</a></td>
<td class="nump">$ 9,331.9<span></span>
</td>
<td class="nump">9,691.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life (in years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life (in years)</a></td>
<td class="text">31 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Cost and net</a></td>
<td class="nump">$ 1,639.4<span></span>
</td>
<td class="nump">1,642.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=biib_PriorityReviewVoucherMember', window );">Priority review voucher</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Cost and net</a></td>
<td class="nump">100.0<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember', window );">Trademarks and trade names</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Cost and net</a></td>
<td class="nump">$ 64.0<span></span>
</td>
<td class="nump">$ 64.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-20<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-20<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-29<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 29<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-29<br><br>Reference 21: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-20<br><br>Reference 22: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-20<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 24: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 26: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 27: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 28: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 38<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-38<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-31<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479876/805-20-55-14<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=biib_PriorityReviewVoucherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=biib_PriorityReviewVoucherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksAndTradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Jul. 02, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets', window );">Amortization and impairment of acquired intangible assets</a></td>
<td class="nump">$ 135,700,000<span></span>
</td>
<td class="nump">$ 130,300,000<span></span>
</td>
<td class="nump">$ 378,400,000<span></span>
</td>
<td class="nump">$ 295,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">135,700,000<span></span>
</td>
<td class="nump">110,100,000<span></span>
</td>
<td class="nump">374,900,000<span></span>
</td>
<td class="nump">275,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 20,200,000<span></span>
</td>
<td class="nump">3,500,000<span></span>
</td>
<td class="nump">$ 20,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated impairment losses related to goodwill</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life (in years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated life (in years)</a></td>
<td class="text">31 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">31 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_AcquiredAndInLicensedRightsAndPatentsMember', window );">Acquired and in-licensed rights and patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife', window );">Weighted-Average remaining useful life</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember', window );">Reata Pharmaceuticals, Inc | Priority review voucher</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember', window );">Human Immunology Biosciences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember', window );">Human Immunology Biosciences | In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillLineItems', window );"><strong>Goodwill [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Intangible assets:</a></td>
<td class="nump">$ 1,600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortization and Impairment of Acquired Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Asset, Weighted-Average Remaining Useful Life</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of identifiable finite-lived intangible asset acquired in business combination and recognized at acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_AcquiredAndInLicensedRightsAndPatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_AcquiredAndInLicensedRightsAndPatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_PriorityReviewVoucherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=biib_PriorityReviewVoucherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets and Goodwill - Estimated Future Amortization of Intangible Assets (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear', window );">2025 (remaining three months)</a></td>
<td class="nump">$ 130.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2026</a></td>
<td class="nump">485.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2027</a></td>
<td class="nump">490.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2028</a></td>
<td class="nump">525.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2029</a></td>
<td class="nump">580.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2030</a></td>
<td class="nump">$ 650.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 40<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill - Changes in Goodwill (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Summary of roll forward of the changes in goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, beginning of period</a></td>
<td class="nump">$ 6,478,900,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Other(2)</a></td>
<td class="nump">7,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, end of period</a></td>
<td class="nump">6,490,700,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Accumulated impairment losses related to goodwill</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember', window );">Human Immunology Biosciences</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Summary of roll forward of the changes in goodwill</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillPurchaseAccountingAdjustments', window );">Goodwill resulting from HI-Bio acquisition</a></td>
<td class="nump">$ 4,500,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-41<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478064/805-740-55-13<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 39<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-39<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillOtherIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of asset representing future economic benefit from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillOtherIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillPurchaseAccountingAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from measurement period adjustment of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-5<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479405/805-10-25-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillPurchaseAccountingAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Assets and Liabilities at Fair Value (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesAbstract', window );"><strong>Other current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Contingent consideration obligations</a></td>
<td class="nump">$ 148.6<span></span>
</td>
<td class="nump">$ 291.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrentAbstract', window );"><strong>Other non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration obligations</a></td>
<td class="nump">242.6<span></span>
</td>
<td class="nump">221.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">97.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">3,398.8<span></span>
</td>
<td class="nump">1,664.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">103.9<span></span>
</td>
<td class="nump">179.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">9.6<span></span>
</td>
<td class="nump">62.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesReceivableFairValueDisclosure', window );">Convertible note</a></td>
<td class="nump">30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">51.8<span></span>
</td>
<td class="nump">42.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">3,691.7<span></span>
</td>
<td class="nump">1,949.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesAbstract', window );"><strong>Other current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative contracts</a></td>
<td class="nump">89.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Contingent consideration obligations</a></td>
<td class="nump">148.6<span></span>
</td>
<td class="nump">291.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrentAbstract', window );"><strong>Other non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative contracts</a></td>
<td class="nump">10.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration obligations</a></td>
<td class="nump">242.6<span></span>
</td>
<td class="nump">221.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">490.5<span></span>
</td>
<td class="nump">524.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">490.5<span></span>
</td>
<td class="nump">524.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements Recurring | Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrentAbstract', window );"><strong>Other non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">71.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements Recurring | US Treasury and Government [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrentAbstract', window );"><strong>Other non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">26.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">103.9<span></span>
</td>
<td class="nump">179.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesReceivableFairValueDisclosure', window );">Convertible note</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">103.9<span></span>
</td>
<td class="nump">179.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesAbstract', window );"><strong>Other current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Contingent consideration obligations</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrentAbstract', window );"><strong>Other non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration obligations</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements Recurring | Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrentAbstract', window );"><strong>Other non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Quoted Prices in Active Markets (Level 1) | Fair Value, Measurements Recurring | US Treasury and Government [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrentAbstract', window );"><strong>Other non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">3,398.8<span></span>
</td>
<td class="nump">1,664.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">9.6<span></span>
</td>
<td class="nump">62.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesReceivableFairValueDisclosure', window );">Convertible note</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">51.8<span></span>
</td>
<td class="nump">42.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">3,557.8<span></span>
</td>
<td class="nump">1,770.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesAbstract', window );"><strong>Other current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative contracts</a></td>
<td class="nump">89.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Contingent consideration obligations</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrentAbstract', window );"><strong>Other non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative contracts</a></td>
<td class="nump">10.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration obligations</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">99.3<span></span>
</td>
<td class="nump">11.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">99.3<span></span>
</td>
<td class="nump">11.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements Recurring | Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrentAbstract', window );"><strong>Other non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">71.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Significant Other Observable Inputs (Level 2) | Fair Value, Measurements Recurring | US Treasury and Government [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrentAbstract', window );"><strong>Other non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">26.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsFairValueDisclosure', window );">Marketable equity securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesReceivableFairValueDisclosure', window );">Convertible note</a></td>
<td class="nump">30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure', window );">Plan assets for deferred compensation</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">30.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesAbstract', window );"><strong>Other current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Contingent consideration obligations</a></td>
<td class="nump">148.6<span></span>
</td>
<td class="nump">291.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrentAbstract', window );"><strong>Other non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Derivative contracts</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration obligations</a></td>
<td class="nump">242.6<span></span>
</td>
<td class="nump">221.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">391.2<span></span>
</td>
<td class="nump">512.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure', window );">Derivative contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">391.2<span></span>
</td>
<td class="nump">$ 512.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements Recurring | Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrentAbstract', window );"><strong>Other non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Significant Unobservable Inputs (Level 3) | Fair Value, Measurements Recurring | US Treasury and Government [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrentAbstract', window );"><strong>Other non-current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PlanAssetsForDeferredCompensationFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair values as of the balance sheet date of all assets of deferred compensation plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PlanAssetsForDeferredCompensationFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractAssetFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractAssetFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesReceivableFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of an agreement for an unconditional promise by the maker to pay the holder a definite sum of money at a future date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesReceivableFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 02, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairment charges</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Contingent consideration obligations</a></td>
<td class="nump">148,600,000<span></span>
</td>
<td class="nump">148,600,000<span></span>
</td>
<td class="nump">$ 291,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration obligations</a></td>
<td class="nump">$ 242,600,000<span></span>
</td>
<td class="nump">$ 242,600,000<span></span>
</td>
<td class="nump">$ 221,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember', window );">Human Immunology Biosciences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Contingent consideration obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 279,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">205,800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember', window );">Human Immunology Biosciences | Maximum | Phase 3 Clinical Trial, Felzartamab One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Contingent consideration obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember', window );">Human Immunology Biosciences | Maximum | Phase 3 Clinical Trial, Felzartamab Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Contingent consideration obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember', window );">Human Immunology Biosciences | Measurement Input, Probability Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Discount rate</a></td>
<td class="nump">0.700<span></span>
</td>
<td class="nump">0.700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.670<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 942<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480095/942-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 942<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480035/942-10-S99-6<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure liability in contingent consideration arrangement in business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 43<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-43<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=biib_Phase3ClinicalTrialFelzartamabOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=biib_Phase3ClinicalTrialFelzartamabOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=biib_Phase3ClinicalTrialFelzartamabTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=biib_Phase3ClinicalTrialFelzartamabTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=biib_MeasurementInputProbabilityRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=biib_MeasurementInputProbabilityRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measures - Level 3 Assets and Liabilities Held at Fair Value (Details) - Fair Value, Inputs, Level 3 [Member]<br> $ in Millions</strong></div></th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration obligations</a></td>
<td class="nump">$ 391.2<span></span>
</td>
<td class="nump">$ 512.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Minimum | Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Discount rate</a></td>
<td class="nump">0.054<span></span>
</td>
<td class="nump">0.062<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Maximum | Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Discount rate</a></td>
<td class="nump">0.055<span></span>
</td>
<td class="nump">0.063<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Weighted Average | Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Discount rate</a></td>
<td class="nump">0.054<span></span>
</td>
<td class="nump">0.062<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 43<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-43<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure liability in contingent consideration arrangement in business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 43<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-43<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479328/805-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 805<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 43<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479303/805-10-55-43<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Contingent Consideration Obligations (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Business Combination, Contingent Consideration, Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value, beginning of period</a></td>
<td class="nump">$ 534.9<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 512.8<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases', window );">Contingent consideration resulting from HI-Bio acquisition</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">485.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">485.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Changes in fair value</a></td>
<td class="nump">5.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements', window );">Payments</a></td>
<td class="num">(149.3)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(150.0)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value, end of period</a></td>
<td class="nump">$ 391.2<span></span>
</td>
<td class="nump">$ 508.9<span></span>
</td>
<td class="nump">$ 391.2<span></span>
</td>
<td class="nump">$ 508.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of settlement of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 101<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-101<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2G<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2G<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Debt Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>May 12, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Current portion of carrying value</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,748.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">5,663.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,437.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Carrying Value</a></td>
<td class="nump">6,285.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,295.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_NotesPayableCurrentFairValueDisclosure', window );">Notes payable, current, fair value disclosure</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,741.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Current portion of carrying value</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,748.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember', window );">4.050% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate, stated percentage</a></td>
<td class="nump">4.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember', window );">4.050% Senior Notes due 2025 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_NotesPayableCurrentFairValueDisclosure', window );">Notes payable, current, fair value disclosure</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,741.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Current portion of carrying value</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,748.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate, stated percentage</a></td>
<td class="nump">4.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A2.25SeniorNotesdueMay12030Member', window );">2.250% Senior Notes due May 1, 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,295.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate, stated percentage</a></td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A2.25SeniorNotesdueMay12030Member', window );">2.250% Senior Notes due May 1, 2030 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">$ 1,367.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Carrying Value</a></td>
<td class="nump">$ 1,495.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,494.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A5.050SeniorNotesDueJanuary152031Member', window );">5.050% Senior Notes due January 15, 2031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate, stated percentage</a></td>
<td class="nump">5.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A5.050SeniorNotesDueJanuary152031Member', window );">5.050% Senior Notes due January 15, 2031 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">$ 410.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Carrying Value</a></td>
<td class="nump">$ 397.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A5.750SeniorNotesDueMay152035Member', window );">5.750% Senior Notes due May 15, 2035</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate, stated percentage</a></td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A5.750SeniorNotesDueMay152035Member', window );">5.750% Senior Notes due May 15, 2035 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">$ 680.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Carrying Value</a></td>
<td class="nump">$ 645.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember', window );">5.200% Senior Notes due September 15, 2045</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,008.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate, stated percentage</a></td>
<td class="nump">5.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember', window );">5.200% Senior Notes due September 15, 2045 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">$ 1,026.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Carrying Value</a></td>
<td class="nump">$ 1,101.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,101.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A3.15SeniorNotesdueMay12050Member', window );">3.150% Senior Notes due May 1, 2050</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">943.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate, stated percentage</a></td>
<td class="nump">3.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A3.15SeniorNotesdueMay12050Member', window );">3.150% Senior Notes due May 1, 2050 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">$ 970.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Carrying Value</a></td>
<td class="nump">$ 1,475.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,475.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotes3.250DueFebruary152051Member', window );">3.250% Senior Notes due February 15, 2051</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">448.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate, stated percentage</a></td>
<td class="nump">3.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotes3.250DueFebruary152051Member', window );">3.250% Senior Notes due February 15, 2051 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">$ 458.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Carrying Value</a></td>
<td class="nump">$ 479.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">476.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A6.450SeniorNotesDueMay152055Member', window );">6.450% Senior Notes due May 15, 2055</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate, stated percentage</a></td>
<td class="nump">6.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A6.450SeniorNotesDueMay152055Member', window );">6.450% Senior Notes due May 15, 2055 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">$ 748.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Carrying Value</a></td>
<td class="nump">690.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_NonCurrentPortionOfNotesPayableAndTermLoanMember', window );">Non-current portion of notes payable | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayableFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">5,663.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,696.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Carrying Value</a></td>
<td class="nump">$ 6,285.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,547.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_NotesPayableCurrentFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Notes Payable, Current, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_NotesPayableCurrentFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of notes payable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_A2.25SeniorNotesdueMay12030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_A2.25SeniorNotesdueMay12030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_A5.050SeniorNotesDueJanuary152031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_A5.050SeniorNotesDueJanuary152031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_A5.750SeniorNotesDueMay152035Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_A5.750SeniorNotesDueMay152035Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_A3.15SeniorNotesdueMay12050Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_A3.15SeniorNotesdueMay12050Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotes3.250DueFebruary152051Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotes3.250DueFebruary152051Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_A6.450SeniorNotesDueMay152055Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_A6.450SeniorNotesDueMay152055Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_NonCurrentPortionOfNotesPayableAndTermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_NonCurrentPortionOfNotesPayableAndTermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems', window );"><strong>Net Investment Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents, at carrying value</a></td>
<td class="nump">$ 3,398.8<span></span>
</td>
<td class="nump">$ 1,664.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems', window );"><strong>Net Investment Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents, at carrying value</a></td>
<td class="nump">79.2<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems', window );"><strong>Net Investment Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents, at carrying value</a></td>
<td class="nump">3,116.7<span></span>
</td>
<td class="nump">1,664.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember', window );">Short-term debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems', window );"><strong>Net Investment Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents, at carrying value</a></td>
<td class="nump">$ 202.9<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Marketable debt and equity securities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract', window );"><strong>Debt Securities, Available-for-Sale, Amortized Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 97.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">97.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract', window );"><strong>Debt Securities, Trading, and Equity Securities, FV-NI, Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCost', window );">Amortized Cost</a></td>
<td class="nump">227.8<span></span>
</td>
<td class="nump">$ 668.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(123.9)<span></span>
</td>
<td class="num">(489.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Fair Value</a></td>
<td class="nump">103.9<span></span>
</td>
<td class="nump">179.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesCurrentMember', window );">Corporate Debt Securities Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract', window );"><strong>Debt Securities, Available-for-Sale, Amortized Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">71.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">71.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesCurrentMember', window );">Government Securities Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract', window );"><strong>Debt Securities, Available-for-Sale, Amortized Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">26.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">26.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=biib_EquitySecuritiesNonCurrentMember', window );">Equity Securities, Non-Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract', window );"><strong>Debt Securities, Trading, and Equity Securities, FV-NI, Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiCost', window );">Amortized Cost</a></td>
<td class="nump">227.8<span></span>
</td>
<td class="nump">668.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(123.9)<span></span>
</td>
<td class="num">(489.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Fair Value</a></td>
<td class="nump">$ 103.9<span></span>
</td>
<td class="nump">$ 179.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_CorporateDebtSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_GovernmentSecuritiesCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_EquitySecuritiesNonCurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_EquitySecuritiesNonCurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Summary of Contractual Maturities (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract', window );"><strong>Estimated Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due in one year or less</a></td>
<td class="nump">$ 97.6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate', window );">Total marketable debt securities</a></td>
<td class="nump">97.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract', window );"><strong>Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Due in one year or less</a></td>
<td class="nump">97.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis', window );">Total marketable debt securities</a></td>
<td class="nump">$ 97.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems', window );"><strong>Net Investment Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_DebtSecuritiesAvailableForSaleAverageMaturity', window );">Average maturity of our marketable debt securities classified as available-for-sale</a></td>
<td class="text">2 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other noncurrent assets | Strategic Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems', window );"><strong>Net Investment Income [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_StrategicInvestmentPortfolio', window );">Strategic investment portfolio</a></td>
<td class="nump">$ 167.1<span></span>
</td>
<td class="nump">$ 226.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DebtSecuritiesAvailableForSaleAverageMaturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-Sale, Average Maturity</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DebtSecuritiesAvailableForSaleAverageMaturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_StrategicInvestmentPortfolio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Strategic investment portfolio.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_StrategicInvestmentPortfolio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=biib_StrategicInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=biib_StrategicInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months', window );">Foreign currency cash flow hedge gain (loss) to be reclassified during next 15 months</a></td>
<td class="nump">$ 103.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 103.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months', window );">Foreign currency cash flow hedge gain (loss) to be reclassified during next 12 months</a></td>
<td class="nump">90.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments', window );">Gain (loss) on foreign currency derivative instruments not designated as hedging instruments</a></td>
<td class="num">(0.5)<span></span>
</td>
<td class="nump">$ 23.4<span></span>
</td>
<td class="nump">34.9<span></span>
</td>
<td class="num">$ (6.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="nump">$ 1,066.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,066.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 738.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Derivative, remaining maturity</a></td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 month<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeRemainingMaturity1', window );">Derivative, remaining maturity</a></td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Foreign Currency Cash Flow Hedge Gain (Loss) To Be Reclassified During Next 15 Months</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 181<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480401/815-10-55-181<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1B<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeRemainingMaturity1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period remaining until the derivative contract matures, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeRemainingMaturity1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 182<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480401/815-10-55-182<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated net amount of unrealized gains or losses on foreign currency cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4CC<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4CC<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivative Instruments - Notional Amount of Foreign Currency Forward Contracts and Foreign Currency Options (Details) - Foreign Exchange Contract - Designated as Hedging Instrument - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Total foreign currency forward contracts and options</a></td>
<td class="nump">$ 1,637.7<span></span>
</td>
<td class="nump">$ 1,235.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_EUR', window );">Euro</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Total foreign currency forward contracts and options</a></td>
<td class="nump">1,524.8<span></span>
</td>
<td class="nump">1,062.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_GBP', window );">British pound</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Total foreign currency forward contracts and options</a></td>
<td class="nump">35.0<span></span>
</td>
<td class="nump">133.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_CHF', window );">Swiss franc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Total foreign currency forward contracts and options</a></td>
<td class="nump">68.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CurrencyAxis=currency_CAD', window );">Canadian dollar</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Total foreign currency forward contracts and options</a></td>
<td class="nump">$ 9.9<span></span>
</td>
<td class="nump">$ 38.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 181<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480401/815-10-55-181<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1B<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 182<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480401/815-10-55-182<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_GBP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_GBP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CHF">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CHF</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_CAD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_CAD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments - Pre-tax Portion of the Fair Value of Foreign Currency Forward Contracts and Foreign Currency Options (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_UnrealizedGainOnDerivatives', window );">Unrealized gains</a></td>
<td class="nump">$ 9.5<span></span>
</td>
<td class="nump">$ 50.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_UnrealizedLossOnDerivatives', window );">Unrealized (losses)</a></td>
<td class="num">(112.9)<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Net unrealized gains (losses)</a></td>
<td class="num">$ (103.4)<span></span>
</td>
<td class="nump">$ 50.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UnrealizedGainOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrealized Gain on Derivatives</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UnrealizedGainOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UnrealizedLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrealized Loss on Derivatives</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UnrealizedLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7)(c)(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5A<br> -Subparagraph (SX 210.12-13A(Column F))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477271/946-320-S99-5A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative Instruments - Effect of Foreign Currency Forward Contracts and Forward Currency Options Designated as Hedging Instruments (Details) - Foreign Exchange Contract - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Net Gains/(Losses) Reclassified from AOCI into Operating Income (in millions)</a></td>
<td class="num">$ (29.1)<span></span>
</td>
<td class="num">$ (7.6)<span></span>
</td>
<td class="num">$ (41.1)<span></span>
</td>
<td class="nump">$ 2.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Revenue | Cash flows, revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Net Gains/(Losses) Excluded from Effectiveness Testing and Recognized in Operating Income (in millions)</a></td>
<td class="nump">8.0<span></span>
</td>
<td class="nump">2.9<span></span>
</td>
<td class="nump">7.6<span></span>
</td>
<td class="nump">4.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Operating expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Net Gains/(Losses) Reclassified from AOCI into Operating Income (in millions)</a></td>
<td class="nump">6.7<span></span>
</td>
<td class="num">(1.5)<span></span>
</td>
<td class="nump">14.0<span></span>
</td>
<td class="num">(8.5)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Operating expense | Cash flows, operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Net Gains/(Losses) Excluded from Effectiveness Testing and Recognized in Operating Income (in millions)</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="num">$ (1.8)<span></span>
</td>
<td class="num">$ (1.6)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 182<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480401/815-10-55-182<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 182<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480401/815-10-55-182<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4C<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsrevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsrevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OperatingExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsoperatingexpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=biib_CashflowsoperatingexpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivative Instruments - Summary of Fair Value and Presentation of Derivatives (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other current assets | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value</a></td>
<td class="nump">$ 7.8<span></span>
</td>
<td class="nump">$ 58.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other current assets | Not designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Derivative asset, fair value</a></td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">4.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember', window );">Accrued expenses and other | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value</a></td>
<td class="nump">87.3<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember', window );">Accrued expenses and other | Not designated as hedging instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value</a></td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">11.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other long-term liabilities | Foreign Exchange Contract | Cash Flow Hedging [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Derivative liability, fair value</a></td>
<td class="nump">$ 10.2<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-20<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-15<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -SubTopic 20<br> -Topic 860<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481326/860-20-50-4D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-22<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-20<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483444/210-20-55-15<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483466/210-20-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -SubTopic 20<br> -Topic 860<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481326/860-20-50-4D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 6A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480682/815-20-25-6A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480237/815-40-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccruedLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Accumulated depreciation</a></td>
<td class="nump">$ 2,868.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,868.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,670.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 66.5<span></span>
</td>
<td class="nump">$ 72.7<span></span>
</td>
<td class="nump">$ 204.8<span></span>
</td>
<td class="nump">$ 213.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-24<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-12<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2025 </div>
<div>product</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_OperatingLeaseArea', window );">Operating lease area | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">580,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_ReductionOfRealEstateFootprint', window );">Reduction of real estate footprint</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1', window );">Term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount', window );">Estimated minimum lease payments | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=biib_HeadquartersLeaseFiveYearRenewalOptionMember', window );">Headquarters Lease, Five Year Renewal Option | Building</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_LesseeOperatingLeaseNumberOfRenewalOptions', window );">Number of renewal options</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=biib_HeadquartersLeaseSixMonthRenewalOptionMember', window );">Headquarters Lease, Six Month Renewal Option | Building</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_LesseeOperatingLeaseNumberOfRenewalOptions', window );">Number of renewal options</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_LesseeOperatingLeaseNumberOfRenewalOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Number Of Renewal Options</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_LesseeOperatingLeaseNumberOfRenewalOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_OperatingLeaseArea">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease Area</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_OperatingLeaseArea</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ReductionOfRealEstateFootprint">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction Of Real Estate Footprint</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ReductionOfRealEstateFootprint</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecorded obligation to transfer funds in future for fixed or minimum amount or quantity of product and service at fixed or minimum price. Includes, but is not limited to, lease not yet commenced and take-or-pay and throughput contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=biib_HeadquartersLeaseFiveYearRenewalOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=biib_HeadquartersLeaseFiveYearRenewalOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=biib_HeadquartersLeaseSixMonthRenewalOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=biib_HeadquartersLeaseSixMonthRenewalOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Indebtedness - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>May 12, 2025</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 15, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A5.050SeniorNotesDueJanuary152031Member', window );">5.050% Senior Notes due January 15, 2031</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate, stated percentage</a></td>
<td class="nump">5.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A5.050SeniorNotesDueJanuary152031Member', window );">5.050% Senior Notes due January 15, 2031 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PercentageParValueOfSeniorNotes', window );">Percentage par value of senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.981%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A5.750SeniorNotesDueMay152035Member', window );">5.750% Senior Notes due May 15, 2035</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate, stated percentage</a></td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A5.750SeniorNotesDueMay152035Member', window );">5.750% Senior Notes due May 15, 2035 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PercentageParValueOfSeniorNotes', window );">Percentage par value of senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.924%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A6.450SeniorNotesDueMay152055Member', window );">6.450% Senior Notes due May 15, 2055</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate, stated percentage</a></td>
<td class="nump">6.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A6.450SeniorNotesDueMay152055Member', window );">6.450% Senior Notes due May 15, 2055 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate, stated percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PercentageParValueOfSeniorNotes', window );">Percentage par value of senior notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99.657%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A2025SeniorNotesMember', window );">2025 Senior Notes | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Debt instrument, redemption price, percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage', window );">Debt instrument, make whole provision redemption price, percentage</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Payments of financing costs</a></td>
<td class="nump">$ 13,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember', window );">4.050% Senior Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate, stated percentage</a></td>
<td class="nump">4.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember', window );">4.050% Senior Notes due 2025 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,750,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument, interest rate, stated percentage</a></td>
<td class="nump">4.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Debt instrument, redemption price, percentage</a></td>
<td class="nump">99.764%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityMember', window );">The Credit Facility | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityMember', window );">The Credit Facility | Line of Credit | Reata Pharmaceuticals, Inc | Secured Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Long-term debt, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityFloatingRate364DayTrancheMember', window );">Credit Facility Floating Rate 364-Day Tranche | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityFloatingRateThreeYearTrancheMember', window );">The Credit Facility Floating Rate Three-Year Tranche | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityFloatingRateThreeYearTrancheMember', window );">The Credit Facility Floating Rate Three-Year Tranche | Line of Credit | Floating Rate 364-Day Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityTerminatedMember', window );">The Credit Facility, Terminated | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A2023TermLoanMember', window );">2023 Term Loan | Line of Credit | Floating Rate 364-Day Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths', window );">Repayments of short-term debt, maturing in more than three months</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=biib_A2023TermLoanMember', window );">2023 Term Loan | Line of Credit | 2023 Term Loan Three-Year Tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility, maximum borrowing capacity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Make Whole Provision Redemption Price, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageParValueOfSeniorNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Par Value Of Senior Notes</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageParValueOfSeniorNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 470<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from a repayment of a borrowing having initial term of repayment of more than three months but less than one year or one operating cycle (if the normal cycle is more than one year).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_A5.050SeniorNotesDueJanuary152031Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_A5.050SeniorNotesDueJanuary152031Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_A5.750SeniorNotesDueMay152035Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_A5.750SeniorNotesDueMay152035Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_A6.450SeniorNotesDueMay152055Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_A6.450SeniorNotesDueMay152055Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_A2025SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_A2025SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_ReataPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityFloatingRate364DayTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityFloatingRate364DayTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityFloatingRateThreeYearTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityFloatingRateThreeYearTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=biib_FloatingRate364DayTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=biib_FloatingRate364DayTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityTerminatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_TheCreditFacilityTerminatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=biib_A2023TermLoanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=biib_A2023TermLoanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=biib_TermLoan2023ThreeYearTrancheMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=biib_TermLoan2023ThreeYearTrancheMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Oct. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock, at cost (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ShareRepurchaseProgramAxis=biib_A2020ShareRepurchaseProgramMember', window );">2020 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StockRepurchaseProgramAuthorizedAmount1', window );">Stock repurchase program, authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Amount remaining under 2019 share repurchase program</a></td>
<td class="nump">$ 2,100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount remaining authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ShareRepurchaseProgramAxis=biib_A2020ShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ShareRepurchaseProgramAxis=biib_A2020ShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="nump">$ 3.1<span></span>
</td>
<td class="num">$ (7.8)<span></span>
</td>
<td class="num">$ (103.1)<span></span>
</td>
<td class="nump">$ 2.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent', window );">Amounts reclassified from AOCI</a></td>
<td class="nump">20.2<span></span>
</td>
<td class="nump">8.1<span></span>
</td>
<td class="nump">24.5<span></span>
</td>
<td class="nump">5.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Net current period other comprehensive income (loss)</a></td>
<td class="nump">23.3<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="num">(78.6)<span></span>
</td>
<td class="nump">8.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Gains (losses) on cash flow hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance</a></td>
<td class="num">(112.0)<span></span>
</td>
<td class="nump">9.8<span></span>
</td>
<td class="nump">51.6<span></span>
</td>
<td class="num">(25.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="nump">6.3<span></span>
</td>
<td class="num">(49.1)<span></span>
</td>
<td class="num">(161.6)<span></span>
</td>
<td class="num">(11.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent', window );">Amounts reclassified from AOCI</a></td>
<td class="nump">20.2<span></span>
</td>
<td class="nump">8.1<span></span>
</td>
<td class="nump">24.5<span></span>
</td>
<td class="nump">5.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Net current period other comprehensive income (loss)</a></td>
<td class="nump">26.5<span></span>
</td>
<td class="num">(41.0)<span></span>
</td>
<td class="num">(137.1)<span></span>
</td>
<td class="num">(6.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance</a></td>
<td class="num">(85.5)<span></span>
</td>
<td class="num">(31.2)<span></span>
</td>
<td class="num">(85.5)<span></span>
</td>
<td class="num">(31.2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember', window );">Unfunded status of postretirement benefit plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance</a></td>
<td class="num">(15.6)<span></span>
</td>
<td class="num">(2.7)<span></span>
</td>
<td class="num">(16.6)<span></span>
</td>
<td class="num">(2.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent', window );">Amounts reclassified from AOCI</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Net current period other comprehensive income (loss)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance</a></td>
<td class="num">(15.6)<span></span>
</td>
<td class="num">(2.4)<span></span>
</td>
<td class="num">(15.6)<span></span>
</td>
<td class="num">(2.4)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Currency translation adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance</a></td>
<td class="num">(110.5)<span></span>
</td>
<td class="num">(153.1)<span></span>
</td>
<td class="num">(171.2)<span></span>
</td>
<td class="num">(126.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent', window );">Other comprehensive income (loss) before reclassifications</a></td>
<td class="num">(3.2)<span></span>
</td>
<td class="nump">41.0<span></span>
</td>
<td class="nump">57.5<span></span>
</td>
<td class="nump">14.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent', window );">Amounts reclassified from AOCI</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Net current period other comprehensive income (loss)</a></td>
<td class="num">(3.2)<span></span>
</td>
<td class="nump">41.0<span></span>
</td>
<td class="nump">57.5<span></span>
</td>
<td class="nump">14.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance</a></td>
<td class="num">(113.7)<span></span>
</td>
<td class="num">(112.1)<span></span>
</td>
<td class="num">(113.7)<span></span>
</td>
<td class="num">(112.1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balance</a></td>
<td class="num">(238.1)<span></span>
</td>
<td class="num">(146.0)<span></span>
</td>
<td class="num">(136.2)<span></span>
</td>
<td class="num">(153.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balance</a></td>
<td class="num">$ (214.8)<span></span>
</td>
<td class="num">$ (145.7)<span></span>
</td>
<td class="num">$ (214.8)<span></span>
</td>
<td class="num">$ (145.7)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of other comprehensive income (loss), attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482739/220-10-55-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Reclassified From AOCI (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 2,534.7<span></span>
</td>
<td class="nump">$ 2,465.8<span></span>
</td>
<td class="nump">$ 7,611.2<span></span>
</td>
<td class="nump">$ 7,221.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other (income) expense, net</a></td>
<td class="num">(34.1)<span></span>
</td>
<td class="num">(14.8)<span></span>
</td>
<td class="num">(151.2)<span></span>
</td>
<td class="num">(193.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="nump">90.8<span></span>
</td>
<td class="nump">62.5<span></span>
</td>
<td class="nump">270.7<span></span>
</td>
<td class="nump">249.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">466.5<span></span>
</td>
<td class="nump">388.5<span></span>
</td>
<td class="nump">1,341.8<span></span>
</td>
<td class="nump">1,365.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember', window );">Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="num">(20.2)<span></span>
</td>
<td class="num">(8.1)<span></span>
</td>
<td class="num">(24.5)<span></span>
</td>
<td class="num">(5.2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Gains (losses) on cash flow hedges | Reclassification out of Accumulated Other Comprehensive Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems', window );"><strong>Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="num">(29.1)<span></span>
</td>
<td class="num">(7.6)<span></span>
</td>
<td class="num">(41.1)<span></span>
</td>
<td class="nump">2.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating Expenses</a></td>
<td class="nump">6.7<span></span>
</td>
<td class="num">(1.5)<span></span>
</td>
<td class="nump">14.0<span></span>
</td>
<td class="num">(8.5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other (income) expense, net</a></td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="num">(0.3)<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit)</a></td>
<td class="nump">$ 2.3<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="nump">$ 2.9<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis=us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings per Share (Details) - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">$ 466.5<span></span>
</td>
<td class="nump">$ 388.5<span></span>
</td>
<td class="nump">$ 1,341.8<span></span>
</td>
<td class="nump">$ 1,365.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted-average shares used in calculating:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding</a></td>
<td class="nump">146,600<span></span>
</td>
<td class="nump">145,700<span></span>
</td>
<td class="nump">146,400<span></span>
</td>
<td class="nump">145,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Dilutive potential common shares</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Shares used in calculating diluted earnings per share</a></td>
<td class="nump">147,100<span></span>
</td>
<td class="nump">146,100<span></span>
</td>
<td class="nump">146,800<span></span>
</td>
<td class="nump">146,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember', window );">Time-vested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock units</a></td>
<td class="nump">500<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="nump">400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_PerformanceStockUnitsSettledinStockMember', window );">Performance stock units settled in stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>Effect of dilutive securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Stock units</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480454/718-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-22<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-28A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_TimeVestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_PerformanceStockUnitsSettledinStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=biib_PerformanceStockUnitsSettledinStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Share-Based Compensation Expense Included In Statements Of Income (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Subtotal</a></td>
<td class="nump">$ 78.4<span></span>
</td>
<td class="nump">$ 131.1<span></span>
</td>
<td class="nump">$ 240.6<span></span>
</td>
<td class="nump">$ 275.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Capitalized share-based compensation costs</a></td>
<td class="num">(3.1)<span></span>
</td>
<td class="num">(2.4)<span></span>
</td>
<td class="num">(9.4)<span></span>
</td>
<td class="num">(8.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses', window );">Share-based compensation expense included in total cost and expense</a></td>
<td class="nump">75.3<span></span>
</td>
<td class="nump">128.7<span></span>
</td>
<td class="nump">231.2<span></span>
</td>
<td class="nump">267.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Income tax effect</a></td>
<td class="num">(14.4)<span></span>
</td>
<td class="num">(24.2)<span></span>
</td>
<td class="num">(45.3)<span></span>
</td>
<td class="num">(50.5)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">28.8<span></span>
</td>
<td class="nump">69.8<span></span>
</td>
<td class="nump">91.0<span></span>
</td>
<td class="nump">124.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">49.6<span></span>
</td>
<td class="nump">61.3<span></span>
</td>
<td class="nump">149.6<span></span>
</td>
<td class="nump">150.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember', window );">Share-based compensation expense included in net income attributable to Biogen Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract', window );"><strong>Share-based Compensation Expense included in consolidated statements of income</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 60.9<span></span>
</td>
<td class="nump">$ 104.5<span></span>
</td>
<td class="nump">$ 185.9<span></span>
</td>
<td class="nump">$ 216.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation expense included in costs and expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of expense for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-based Payments - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 02, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment arrangement, expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28.8<span></span>
</td>
<td class="nump">$ 69.8<span></span>
</td>
<td class="nump">$ 91.0<span></span>
</td>
<td class="nump">$ 124.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment arrangement, expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.6<span></span>
</td>
<td class="nump">61.3<span></span>
</td>
<td class="nump">149.6<span></span>
</td>
<td class="nump">150.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember', window );">Human Immunology Biosciences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment arrangement, expense</a></td>
<td class="nump">$ 56.4<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">$ 56.4<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">$ 56.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember', window );">Human Immunology Biosciences | Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment arrangement, expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember', window );">Human Immunology Biosciences | Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment arrangement, expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Share-Based Compensation Expense by Share-Based Compensation Program (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 02, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Subtotal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78.4<span></span>
</td>
<td class="nump">$ 131.1<span></span>
</td>
<td class="nump">$ 240.6<span></span>
</td>
<td class="nump">$ 275.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Capitalized share-based compensation costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3.1)<span></span>
</td>
<td class="num">(2.4)<span></span>
</td>
<td class="num">(9.4)<span></span>
</td>
<td class="num">(8.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses', window );">Share-based compensation expense included in total cost and expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.3<span></span>
</td>
<td class="nump">128.7<span></span>
</td>
<td class="nump">231.2<span></span>
</td>
<td class="nump">267.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember', window );">Human Immunology Biosciences</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="nump">$ 56.4<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">56.4<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">56.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember', window );">Time-vested restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.1<span></span>
</td>
<td class="nump">59.1<span></span>
</td>
<td class="nump">186.8<span></span>
</td>
<td class="nump">174.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinStockMember', window );">Performance stock units settled in stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.5<span></span>
</td>
<td class="nump">13.0<span></span>
</td>
<td class="nump">44.1<span></span>
</td>
<td class="nump">35.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_EmployeeStockPurchasePlanMember', window );">Employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">1.9<span></span>
</td>
<td class="nump">6.9<span></span>
</td>
<td class="nump">8.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinCashMember', window );">Performance stock units settled in cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.5)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(2.5)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">2.8<span></span>
</td>
<td class="nump">2.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember', window );">Market stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract', window );"><strong>Summary of share based compensation expense associated with different programs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation expense included in costs and expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of share-based compensation expense associated with different programs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of expense for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost capitalized for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=biib_HumanImmunologyBiosciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_TimeVestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinCashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_PerformanceStockUnitsSettledinCashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=biib_MarketStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Reconciliation between the U.S. federal statutory tax rate and effective tax rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes</a></td>
<td class="nump">1.70%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Taxes on foreign earnings, including valuation allowances</a></td>
<td class="num">(5.00%)<span></span>
</td>
<td class="num">(11.90%)<span></span>
</td>
<td class="num">(7.20%)<span></span>
</td>
<td class="num">(7.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Tax credits</a></td>
<td class="num">(1.60%)<span></span>
</td>
<td class="num">(1.20%)<span></span>
</td>
<td class="num">(1.80%)<span></span>
</td>
<td class="num">(1.70%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization', window );">Purchased inventory valuation step-up and intangible assets</a></td>
<td class="nump">2.40%<span></span>
</td>
<td class="nump">3.30%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent', window );">GILTI</a></td>
<td class="num">(1.20%)<span></span>
</td>
<td class="num">(1.10%)<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
<td class="num">(1.40%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EffectiveTaxRateReconciliationShareBasedCompensationAwards', window );">Share-based compensation awards</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0.011<span></span>
</td>
<td class="nump">0.002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EffectiveTaxRateReconciliationOneBigBeautifulBillActEnactment', window );">OBBBA enactment</a></td>
<td class="num">(0.021)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(0.007)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other, including permanent items</a></td>
<td class="nump">1.10%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="nump">16.30%<span></span>
</td>
<td class="nump">13.90%<span></span>
</td>
<td class="nump">16.80%<span></span>
</td>
<td class="nump">15.40%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EffectiveTaxRateReconciliationOneBigBeautifulBillActEnactment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Tax Rate Reconciliation, One Big Beautiful Bill Act Enactment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EffectiveTaxRateReconciliationOneBigBeautifulBillActEnactment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EffectiveTaxRateReconciliationShareBasedCompensationAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Tax Rate Reconciliation, Share-Based Compensation Awards</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EffectiveTaxRateReconciliationShareBasedCompensationAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of reported income tax expense from difference to expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to global intangible low-taxed income (GILTI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to depreciation and amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible', window );">Decrease in unrecognized tax benefits is reasonably possible</a></td>
<td class="nump">$ 35.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail - Other (Income) Expense, Net (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="num">$ (31.6)<span></span>
</td>
<td class="num">$ (11.6)<span></span>
</td>
<td class="num">$ (87.8)<span></span>
</td>
<td class="num">$ (49.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest Expense</a></td>
<td class="nump">67.4<span></span>
</td>
<td class="nump">59.8<span></span>
</td>
<td class="nump">200.0<span></span>
</td>
<td class="nump">190.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RealizedInvestmentGainsLosses', window );">(Gains) losses on investments, net</a></td>
<td class="nump">3.8<span></span>
</td>
<td class="num">(39.1)<span></span>
</td>
<td class="nump">34.1<span></span>
</td>
<td class="nump">22.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Gain (Loss), Foreign Currency Transaction, before Tax</a></td>
<td class="nump">10.3<span></span>
</td>
<td class="nump">4.9<span></span>
</td>
<td class="nump">16.9<span></span>
</td>
<td class="nump">25.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other, net</a></td>
<td class="num">(15.8)<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="num">(12.0)<span></span>
</td>
<td class="nump">4.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other (income) expense, net</a></td>
<td class="nump">$ 34.1<span></span>
</td>
<td class="nump">$ 14.8<span></span>
</td>
<td class="nump">$ 151.2<span></span>
</td>
<td class="nump">$ 193.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482014/830-20-35-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481956/830-20-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481926/830-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481839/830-10-45-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (o)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-24<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483013/835-20-50-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RealizedInvestmentGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RealizedInvestmentGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail - (Gains) Losses on Investments, Net (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Net (gains) losses recognized on equity securities</a></td>
<td class="nump">$ 3.8<span></span>
</td>
<td class="num">$ (39.1)<span></span>
</td>
<td class="nump">$ 34.1<span></span>
</td>
<td class="nump">$ 21.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss', window );">Less: Net (gains) losses realized on equity securities</a></td>
<td class="nump">7.0<span></span>
</td>
<td class="num">(10.9)<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
<td class="num">(5.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net unrealized (gains) losses recognized on equity securities</a></td>
<td class="num">$ (3.2)<span></span>
</td>
<td class="num">$ (28.2)<span></span>
</td>
<td class="nump">$ 32.5<span></span>
</td>
<td class="nump">$ 27.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Consolidated Financial Statement - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net unrealized (gains) losses recognized on equity securities</a></td>
<td class="num">$ (3.2)<span></span>
</td>
<td class="num">$ (28.2)<span></span>
</td>
<td class="nump">$ 32.5<span></span>
</td>
<td class="nump">$ 27.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities, noncurrent</a></td>
<td class="nump">761.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">761.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 732.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesNoncurrent', window );">Accrued income taxes</a></td>
<td class="nump">164.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">164.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 156.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=biib_SageAndDenaliMember', window );">Sage and Denali</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net unrealized (gains) losses recognized on equity securities</a></td>
<td class="nump">$ 3.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=biib_SageAndSangamoMember', window );">Sage and Sangamo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net unrealized (gains) losses recognized on equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=biib_DenaliTherapeuticsIncMember', window );">Denali Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net unrealized (gains) losses recognized on equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.7<span></span>
</td>
<td class="nump">41.9<span></span>
</td>
<td class="nump">$ 70.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=biib_SageTherapeuticsIncMember', window );">Sage Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net unrealized (gains) losses recognized on equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(d)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 321<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479536/321-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=biib_SageAndDenaliMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=biib_SageAndDenaliMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=biib_SageAndSangamoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=biib_SageAndSangamoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=biib_DenaliTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=biib_DenaliTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=biib_SageTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=biib_SageTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Consolidated Financial Statement Detail - Accrued Expense and Other (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Revenue-related reserves for discounts and allowances</a></td>
<td class="nump">$ 1,322.0<span></span>
</td>
<td class="nump">$ 1,091.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee compensation and benefits</a></td>
<td class="nump">310.7<span></span>
</td>
<td class="nump">375.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Collaborationexpensesaccrual', window );">Collaboration expense</a></td>
<td class="nump">268.7<span></span>
</td>
<td class="nump">309.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedRoyaltiesCurrent', window );">Royalties and licensing fees</a></td>
<td class="nump">320.2<span></span>
</td>
<td class="nump">190.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Contingent consideration obligations</a></td>
<td class="nump">148.6<span></span>
</td>
<td class="nump">291.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConstructionPayableCurrentAndNoncurrent', window );">Derivative liabilities</a></td>
<td class="nump">89.1<span></span>
</td>
<td class="nump">11.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">574.0<span></span>
</td>
<td class="nump">692.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Total accrued expense and other</a></td>
<td class="nump">2,773.6<span></span>
</td>
<td class="nump">2,807.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Component of accrued expenses and other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Revenue-related reserves for discounts and allowances</a></td>
<td class="nump">$ 1,062.3<span></span>
</td>
<td class="nump">$ 937.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Collaborationexpensesaccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration expenses accrual</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Collaborationexpensesaccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRoyaltiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRoyaltiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 805<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for the acquisition of merchandise, materials, supplies and services pertaining to construction projects such as a housing development or factory expansion not classified as trade payables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - OCREVUS (Details) - OCREVUS<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage', window );">Royalty operating profit threshold for highest royalty rate percentage</a></td>
<td class="nump">$ 900.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Reductioninroyaltyrate', window );">Reduction in royalty rate</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PeriodOfCollaborationAgreement', window );">Collaboration agreement term</a></td>
<td class="text">11 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_OCREVUSMember', window );">Foreign Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct', window );">Royalty percentage to be received</a></td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_OCREVUSMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct', window );">Royalty percentage to be received</a></td>
<td class="nump">13.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_OCREVUSMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct', window );">Royalty percentage to be received</a></td>
<td class="nump">24.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future royalties percentage to be received on sale of product.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PeriodOfCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period Of Collaboration Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PeriodOfCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Reductioninroyaltyrate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction in royalty rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Reductioninroyaltyrate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty operating profit threshold for highest royalty rate percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_OCREVUSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_OCREVUSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Co-promotion Profit Sharing Formula (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_RituxanMember', window );">RITUXAN</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo', window );">After LUNSUMIO Approval until the First Threshold Date</a></td>
<td class="nump">37.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree', window );">After First Threshold Date until the Second Threshold Date</a></td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour', window );">After Second Threshold Date</a></td>
<td class="nump">30.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_LUNSUMIOMember', window );">LUNSUMIO</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree', window );">After First Threshold Date until the Second Threshold Date</a></td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment', window );">Co promotion operating profit threshold to determine share of co promotion operating profit prior to amendment</a></td>
<td class="nump">$ 50.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Co promotion operating profit threshold to determine share of co promotion operating profit prior to amendment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of co promotion operating profits greater than first fifty million option two sub option three.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of co promotion operating profits greater than first fifty million option two sub option two.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_RituxanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_RituxanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_LUNSUMIOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_LUNSUMIOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Profit Sharing (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_RituxanMember', window );">RITUXAN</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion', window );">Percentage of co promotion operating profits first fifty million</a></td>
<td class="nump">30.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree', window );">After Second GAZYVA Threshold Date</a></td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo', window );">Until Second GAZYVA Threshold Date</a></td>
<td class="nump">37.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_LUNSUMIOMember', window );">LUNSUMIO</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne', window );">Limit of gross sale of GAZYVA to be achieved in preceding 12 months under option one</a></td>
<td class="nump">$ 500.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne', window );">Limit of gross sale of GAZYVA to be achieved in any 12 months under option one</a></td>
<td class="nump">150.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_SalesTriggerGrossSalesThreshold', window );">Sales trigger gross sales threshold</a></td>
<td class="nump">$ 350.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree', window );">After Second GAZYVA Threshold Date</a></td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_GAZYVAMember', window );">GAZYVA</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree', window );">After Second GAZYVA Threshold Date</a></td>
<td class="nump">35.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of co promotion operating profits first fifty million.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of co promotion operating profits greater than first fifty million option two sub option three.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of co promotion operating profits greater than first fifty million option two sub option two.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_SalesTriggerGrossSalesThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales trigger gross sales threshold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_SalesTriggerGrossSalesThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold of gross sales of to be achieved in preceding twelve consecutive months under option one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold of gross sales to be achieved in any twelve consecutive months under option one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_RituxanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_RituxanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_LUNSUMIOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_LUNSUMIOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_GAZYVAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_GAZYVAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Pretax Profit Sharing Formula (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_GAZYVAMember', window );">GAZYVA</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree', window );">After Second GAZYVA Threshold Date</a></td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_LUNSUMIOMember', window );">LUNSUMIO</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree', window );">After Second GAZYVA Threshold Date</a></td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne', window );">Threshold of Gross Sales Of To Be Achieved In Preceding Twelve Consecutive Months Under Option One</a></td>
<td class="nump">$ 500.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of co promotion operating profits greater than first fifty million option two sub option three.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Threshold of gross sales of to be achieved in preceding twelve consecutive months under option one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_GAZYVAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_GAZYVAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_LUNSUMIOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_LUNSUMIOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Ionis Pharmaceuticals, Inc (Details) - Ionis<br> $ in Millions</strong></div></th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones', window );">Estimated additional payments upon achievement of development and commercial milestones</a></td>
<td class="nump">$ 155.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EstimatedAdditionalPaymentsUponInitiationOfNewPhases', window );">Estimated additional payments upon initiation of new phases</a></td>
<td class="nump">45.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold', window );">Expected additional milestone payments when meeting certain sales threshold</a></td>
<td class="nump">$ 400.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated additional payments upon achievement of development and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EstimatedAdditionalPaymentsUponInitiationOfNewPhases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated Additional Payments Upon Initiation Of New Phases</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EstimatedAdditionalPaymentsUponInitiationOfNewPhases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected Additional Milestone Payments When Meeting Certain Sales Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_IonisPharmaceuticalsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R104.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Eisai (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember', window );">Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_AccountsReceivableFromCollaborator', window );">Amounts receivable</a></td>
<td class="nump">$ 103.8<span></span>
</td>
<td class="nump">$ 16.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_AccountsPayableToCollaborator', window );">Amounts payable</a></td>
<td class="nump">$ 97.9<span></span>
</td>
<td class="nump">$ 138.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_LEQEMBICollaborationMember', window );">Alzheimer's collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_ShareOfNonControlingInterestRecognized', window );">Share of non-controling interest recognized</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AccountsPayableToCollaborator">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Payable, To Collaborator</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AccountsPayableToCollaborator</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_AccountsReceivableFromCollaborator">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, From Collaborator</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_AccountsReceivableFromCollaborator</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareOfNonControlingInterestRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Of Non-Controling Interest Recognized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareOfNonControlingInterestRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_LEQEMBICollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_LEQEMBICollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R105.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Summary of Activity Related to LEQEMBI Collaboration (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_LEQEMBIMember', window );">LEQEMBI | Alzheimer's collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_ExpenseIncurredByCollaboration', window );">Total development expense incurred by the collaboration related to the advancement of LEQEMBI</a></td>
<td class="nump">$ 70.9<span></span>
</td>
<td class="nump">$ 77.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="nump">35.4<span></span>
</td>
<td class="nump">38.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_LEQEMBIMember', window );">LEQEMBI | Alzheimer's collaboration revenue | Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="nump">88.3<span></span>
</td>
<td class="nump">82.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="nump">$ 176.8<span></span>
</td>
<td class="nump">$ 164.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_E2609andBAN2401Member', window );">E2609 and BAN2401 | Eisai</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_ExpenseIncurredByCollaboration', window );">Total development expense incurred by the collaboration related to the advancement of LEQEMBI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 178.4<span></span>
</td>
<td class="nump">$ 255.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89.2<span></span>
</td>
<td class="nump">127.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_E2609andBAN2401Member', window );">E2609 and BAN2401 | Eisai | Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">262.8<span></span>
</td>
<td class="nump">238.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 525.7<span></span>
</td>
<td class="nump">$ 476.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ExpenseIncurredByCollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total expense incurred by collaboration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ExpenseIncurredByCollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Expenseincurredbythecollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expense incurred by the collaboration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Expenseincurredbythecollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Expensereflectedwithinstatementsofincome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expense reflected within statements of income</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Expensereflectedwithinstatementsofincome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_LEQEMBIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_LEQEMBIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_LEQEMBICollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_LEQEMBICollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_E2609andBAN2401Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_E2609andBAN2401Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_EisaiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_EisaiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R106.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Summary of Activity Related to the UCB Collaboration (Details) - Research and development - UCB Pharma S.A. - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="nump">$ 23.2<span></span>
</td>
<td class="nump">$ 19.2<span></span>
</td>
<td class="nump">$ 62.8<span></span>
</td>
<td class="nump">$ 52.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="nump">$ 11.6<span></span>
</td>
<td class="nump">$ 9.5<span></span>
</td>
<td class="nump">$ 31.4<span></span>
</td>
<td class="nump">$ 26.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Expenseincurredbythecollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expense incurred by the collaboration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Expenseincurredbythecollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Expensereflectedwithinstatementsofincome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expense reflected within statements of income</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Expensereflectedwithinstatementsofincome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_UCBPharmaSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_UCBPharmaSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R107.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Sage Therapeutics, Inc. (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Collaborationprofitlosssharing', window );">Collaboration profit sharing/(loss reimbursement)</a></td>
<td class="nump">$ 87.2<span></span>
</td>
<td class="nump">$ 69.3<span></span>
</td>
<td class="nump">$ 220.3<span></span>
</td>
<td class="nump">$ 197.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_ShareOfNetProfitFromSageTherapeuticsPercent', window );">Share of net profit from sage therapeutics, Percent</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SageTherapeuticsIncMember', window );">Sage Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Collaborationprofitlosssharing', window );">Collaboration profit sharing/(loss reimbursement)</a></td>
<td class="nump">$ 20.7<span></span>
</td>
<td class="nump">$ 9.0<span></span>
</td>
<td class="nump">$ 48.6<span></span>
</td>
<td class="nump">$ 20.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast | Sage Therapeutics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately', window );">Potential future milestone payments commitment to third party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Collaborationprofitlosssharing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration profit (loss) sharing</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Collaborationprofitlosssharing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential future milestone payments commitment to third party approximately.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ShareOfNetProfitFromSageTherapeuticsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Of Net Profit From Sage Therapeutics, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ShareOfNetProfitFromSageTherapeuticsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_SageTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_SageTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R108.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Summary of Activity Related to Sage Therapeutics (Details) - Sage Therapeutics - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="num">$ (1.7)<span></span>
</td>
<td class="nump">$ 8.4<span></span>
</td>
<td class="nump">$ 2.2<span></span>
</td>
<td class="nump">$ 29.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="num">(0.9)<span></span>
</td>
<td class="nump">4.2<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
<td class="nump">14.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="nump">41.8<span></span>
</td>
<td class="nump">28.4<span></span>
</td>
<td class="nump">131.0<span></span>
</td>
<td class="nump">82.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="nump">$ 20.9<span></span>
</td>
<td class="nump">$ 14.2<span></span>
</td>
<td class="nump">$ 65.5<span></span>
</td>
<td class="nump">$ 41.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Expenseincurredbythecollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expense incurred by the collaboration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Expenseincurredbythecollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Expensereflectedwithinstatementsofincome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expense reflected within statements of income</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Expensereflectedwithinstatementsofincome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_SageTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_SageTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R109.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Summary of Activity Related To Denali Therapeutics (Details) - Research and development - Denali Therapeutics - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="nump">$ 11.4<span></span>
</td>
<td class="nump">$ 14.9<span></span>
</td>
<td class="nump">$ 36.3<span></span>
</td>
<td class="nump">$ 44.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="nump">$ 6.9<span></span>
</td>
<td class="nump">$ 8.9<span></span>
</td>
<td class="nump">$ 21.8<span></span>
</td>
<td class="nump">$ 26.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Expenseincurredbythecollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expense incurred by the collaboration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Expenseincurredbythecollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Expensereflectedwithinstatementsofincome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expense reflected within statements of income</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Expensereflectedwithinstatementsofincome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_DenaliTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_DenaliTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R110.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Stoke Therapeutics, Inc. (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2025</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_ZorevunersenMember', window );">Zorevunersen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PercentageOfFutureDevelopmentCosts', window );">Percentage of future development costs</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_StokeTherapeuticsIncMember', window );">Stoke Therapeutics Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront and milestone paymentsmade to collaborative partner</a></td>
<td class="nump">$ 165.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_StokeTherapeuticsIncMember', window );">Stoke Therapeutics Inc | Zorevunersen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_PercentageOfFutureDevelopmentCosts', window );">Percentage of future development costs</a></td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_StokeTherapeuticsIncMember', window );">Stoke Therapeutics Inc | Milestone Payment, Developmental</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones', window );">Estimated additional payments upon achievement of development and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_StokeTherapeuticsIncMember', window );">Stoke Therapeutics Inc | Milestone Payment, Commercial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones', window );">Estimated additional payments upon achievement of development and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 335.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated additional payments upon achievement of development and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_PercentageOfFutureDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage Of Future Development Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_PercentageOfFutureDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total upfront and milestone payments made to collaborative partner.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_ZorevunersenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_ZorevunersenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_StokeTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_StokeTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=biib_MilestonePaymentDevelopmentalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=biib_MilestonePaymentDevelopmentalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=biib_MilestonePaymentCommercialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=biib_MilestonePaymentCommercialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R111.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships Summary of Activity Related to Stoke Therapeutics (Details) - Research and development - Stoke Therapeutics Inc - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Expenseincurredbythecollaboration', window );">Expense incurred by the collaboration</a></td>
<td class="nump">$ 9.1<span></span>
</td>
<td class="nump">$ 21.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Expensereflectedwithinstatementsofincome', window );">Expense reflected within statements of income</a></td>
<td class="nump">$ 2.8<span></span>
</td>
<td class="nump">$ 6.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Expenseincurredbythecollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expense incurred by the collaboration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Expenseincurredbythecollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Expensereflectedwithinstatementsofincome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expense reflected within statements of income</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Expensereflectedwithinstatementsofincome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_StokeTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_StokeTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R112.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Samsung Bioepis (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>product</div>
</th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Collaborationprofitlosssharing', window );">Collaboration profit sharing/(loss reimbursement)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 87.2<span></span>
</td>
<td class="nump">$ 69.3<span></span>
</td>
<td class="nump">$ 220.3<span></span>
</td>
<td class="nump">$ 197.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_Collaborationprofitlosssharing', window );">Collaboration profit sharing/(loss reimbursement)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66.5<span></span>
</td>
<td class="nump">$ 60.3<span></span>
</td>
<td class="nump">$ 171.7<span></span>
</td>
<td class="nump">$ 176.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_ContingentCommercializedRightsNumberOfProducts', window );">Contingent Commercialized Rights, Number Of Products | product</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EquityMethodInvestmentsExpectedProfitShare', window );">Expected profit share percentage</a></td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets (excluding goodwill)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones', window );">Estimated additional payments upon achievement of development and commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_CollaborativeArrangementTermExtension', window );">Collaboration agreement term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_ContractOptionExerciseFee', window );">Option exercise fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember', window );">Samsung Bioepis | Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrentAndNoncurrent', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_Collaborationprofitlosssharing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration profit (loss) sharing</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_Collaborationprofitlosssharing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CollaborativeArrangementTermExtension">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Term Extension</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CollaborativeArrangementTermExtension</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ContingentCommercializedRightsNumberOfProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contingent Commercialized Rights, Number Of Products</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ContingentCommercializedRightsNumberOfProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ContractOptionExerciseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract Option Exercise Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ContractOptionExerciseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EquityMethodInvestmentsExpectedProfitShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investments, Expected Profit Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EquityMethodInvestmentsExpectedProfitShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated additional payments upon achievement of development and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479196/954-310-45-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482665/350-30-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_SamsungBiosimilarAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R113.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaborative and Other Relationships - Other Research and Discovery Arrangements and Funding Arrangements (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Feb. 11, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_ReductionOfResearchAndDevelopmentExpense', window );">Reduction of research and development expense</a></td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="nump">$ 150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=biib_MilestonePaymentFutureDevelopmentMember', window );">Milestone Payment, Future Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones', window );">Estimated additional payments upon achievement of development and commercial milestones</a></td>
<td class="nump">250.0<span></span>
</td>
<td class="nump">250.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FelzartamabAndIzastobartHIB210Member', window );">Felzartamab And Izastobart/HIB210 | Human Immunology Biosciences Pre-Existing In License Commitments | Milestone Payment, One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones', window );">Estimated additional payments upon achievement of development and commercial milestones</a></td>
<td class="nump">35.0<span></span>
</td>
<td class="nump">35.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FelzartamabAndIzastobartHIB210Member', window );">Felzartamab And Izastobart/HIB210 | Human Immunology Biosciences Pre-Existing In License Commitments | Milestone Payment, Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones', window );">Estimated additional payments upon achievement of development and commercial milestones</a></td>
<td class="nump">30.0<span></span>
</td>
<td class="nump">30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FelzartamabAndIzastobartHIB210Member', window );">Felzartamab And Izastobart/HIB210 | Human Immunology Biosciences Pre-Existing In License Commitments | Milestone Payment, Future Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones', window );">Estimated additional payments upon achievement of development and commercial milestones</a></td>
<td class="nump">130.0<span></span>
</td>
<td class="nump">130.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FelzartamabAndIzastobartHIB210Member', window );">Felzartamab And Izastobart/HIB210 | Human Immunology Biosciences Pre-Existing In License Commitments | Milestone Payment, Regulatory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones', window );">Estimated additional payments upon achievement of development and commercial milestones</a></td>
<td class="nump">230.0<span></span>
</td>
<td class="nump">230.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=biib_FelzartamabAndIzastobartHIB210Member', window );">Felzartamab And Izastobart/HIB210 | Human Immunology Biosciences Pre-Existing In License Commitments | Milestone Payment, Commercial</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones', window );">Estimated additional payments upon achievement of development and commercial milestones</a></td>
<td class="nump">640.0<span></span>
</td>
<td class="nump">640.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember', window );">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_CollaborativeArrangementExpectedDevelopmentCostFundsYearOne', window );">Expected receipts to co-fund development costs, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_CollaborativeArrangementExpectedDevelopmentCostFundsYearTwo', window );">Expected receipts to co-fund development costs, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember', window );">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | City Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront and milestone paymentsmade to collaborative partner</a></td>
<td class="nump">16.0<span></span>
</td>
<td class="nump">16.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_CollaborativeArrangementsInvestmentsInCounterparty', window );">Collaborative arrangements, investments in counterparty</a></td>
<td class="nump">30.0<span></span>
</td>
<td class="nump">30.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember', window );">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Milestone Payment, Research | City Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones', window );">Estimated additional payments upon achievement of development and commercial milestones</a></td>
<td class="nump">21.5<span></span>
</td>
<td class="nump">21.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember', window );">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Milestone Payment, Developmental | City Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones', window );">Estimated additional payments upon achievement of development and commercial milestones</a></td>
<td class="nump">360.0<span></span>
</td>
<td class="nump">360.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember', window );">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Milestone Payment, Sales-Based | City Therapeutics, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative arrangements and non-collaborative arrangement transactions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones', window );">Estimated additional payments upon achievement of development and commercial milestones</a></td>
<td class="nump">$ 625.0<span></span>
</td>
<td class="nump">$ 625.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CollaborativeArrangementExpectedDevelopmentCostFundsYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Expected Development Cost Funds, Year One</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CollaborativeArrangementExpectedDevelopmentCostFundsYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CollaborativeArrangementExpectedDevelopmentCostFundsYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Expected Development Cost Funds, Year Two</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CollaborativeArrangementExpectedDevelopmentCostFundsYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_CollaborativeArrangementsInvestmentsInCounterparty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangements, Investments In Counterparty</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_CollaborativeArrangementsInvestmentsInCounterparty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated additional payments upon achievement of development and commercial milestones.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ReductionOfResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reduction Of Research And Development Expense</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ReductionOfResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total upfront and milestone payments made to collaborative partner.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=biib_MilestonePaymentFutureDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=biib_MilestonePaymentFutureDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=biib_FelzartamabAndIzastobartHIB210Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=biib_FelzartamabAndIzastobartHIB210Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=biib_HumanImmunologyBiosciencesPreExistingInLicenseCommitmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=biib_HumanImmunologyBiosciencesPreExistingInLicenseCommitmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=biib_MilestonePaymentOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=biib_MilestonePaymentOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=biib_MilestonePaymentTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=biib_MilestonePaymentTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=biib_MilestonePaymentRegulatoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=biib_MilestonePaymentRegulatoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=biib_MilestonePaymentCommercialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=biib_MilestonePaymentCommercialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=biib_CityTherapeuticsInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=biib_CityTherapeuticsInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=biib_MilestonePaymentResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=biib_MilestonePaymentResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=biib_MilestonePaymentDevelopmentalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=biib_MilestonePaymentDevelopmentalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=biib_MilestonePaymentSalesBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=biib_MilestonePaymentSalesBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>R114.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Investments in Variable Interest Entities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_InvestmentsInVariableInterestEntitiesAbstract', window );"><strong>Investments in Variable Interest Entities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities', window );">Investment in biotechnology companies that are determined to be unconsolidated variable interest entities</a></td>
<td class="nump">$ 44.8<span></span>
</td>
<td class="nump">$ 23.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investment in biotechnology companies that are determined to be unconsolidated variable interest entities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_InvestmentsInVariableInterestEntitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Investments In Variable Interest Entities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_InvestmentsInVariableInterestEntitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>R115.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Litigation (Details)<br> &#8364; in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=biib_IMRALDIPatentLitigationMember', window );">IMRALDI Patent Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Loss contingency, damages sought, value | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 13,450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=biib_ConvergenceMember', window );">Convergence</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Loss contingency, estimate of possible loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 49.9<span></span>
</td>
<td class="nump">$ 200.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=biib_GenentechMember', window );">Genentech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Loss contingency, damages sought, value</a></td>
<td class="nump">$ 88.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementInterest', window );">Litigation Settlement Interest</a></td>
<td class="nump">$ 35.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest expense (income) directly attributable to an award in settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(6))<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 27<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=biib_IMRALDIPatentLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=biib_IMRALDIPatentLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=biib_ConvergenceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=biib_ConvergenceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=biib_GenentechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=biib_GenentechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>R116.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2025 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>R117.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Additional Segment Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Sep. 30, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAssetReconcilingItemLineItems', window );"><strong>Segment Reporting, Asset Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 2,534.7<span></span>
</td>
<td class="nump">$ 2,465.8<span></span>
</td>
<td class="nump">$ 7,611.2<span></span>
</td>
<td class="nump">$ 7,221.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales, excluding amortization and impairment of acquired intangible assets</a></td>
<td class="nump">674.4<span></span>
</td>
<td class="nump">638.7<span></span>
</td>
<td class="nump">1,908.7<span></span>
</td>
<td class="nump">1,726.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development:</a></td>
<td class="nump">436.1<span></span>
</td>
<td class="nump">516.2<span></span>
</td>
<td class="nump">1,269.2<span></span>
</td>
<td class="nump">1,467.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_ResearchAndDevelopmentExpenseIncludingAcquiredInProcessCost', window );">Acquired in-process research and development, upfront and milestone expense</a></td>
<td class="nump">2.1<span></span>
</td>
<td class="nump">26.5<span></span>
</td>
<td class="nump">249.4<span></span>
</td>
<td class="nump">42.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">594.8<span></span>
</td>
<td class="nump">588.4<span></span>
</td>
<td class="nump">1,751.1<span></span>
</td>
<td class="nump">1,723.7<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">466.5<span></span>
</td>
<td class="nump">388.5<span></span>
</td>
<td class="nump">1,341.8<span></span>
</td>
<td class="nump">1,365.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product revenue, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAssetReconcilingItemLineItems', window );"><strong>Segment Reporting, Asset Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">1,846.9<span></span>
</td>
<td class="nump">1,769.4<span></span>
</td>
<td class="nump">5,452.1<span></span>
</td>
<td class="nump">5,380.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty and other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAssetReconcilingItemLineItems', window );"><strong>Segment Reporting, Asset Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">9.7<span></span>
</td>
<td class="nump">9.7<span></span>
</td>
<td class="nump">40.3<span></span>
</td>
<td class="nump">48.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=biib_ReportableSegmentMember', window );">Reportable Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAssetReconcilingItemLineItems', window );"><strong>Segment Reporting, Asset Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">2,534.7<span></span>
</td>
<td class="nump">2,465.8<span></span>
</td>
<td class="nump">7,611.2<span></span>
</td>
<td class="nump">7,221.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherItemAmount', window );">Other segment expense</a></td>
<td class="nump">360.8<span></span>
</td>
<td class="nump">307.5<span></span>
</td>
<td class="nump">1,091.0<span></span>
</td>
<td class="nump">895.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Biogen Inc.</a></td>
<td class="nump">466.5<span></span>
</td>
<td class="nump">388.5<span></span>
</td>
<td class="nump">1,341.8<span></span>
</td>
<td class="nump">1,365.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=biib_ReportableSegmentMember', window );">Reportable Segment | Research and discovery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAssetReconcilingItemLineItems', window );"><strong>Segment Reporting, Asset Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development:</a></td>
<td class="nump">41.0<span></span>
</td>
<td class="nump">48.3<span></span>
</td>
<td class="nump">131.9<span></span>
</td>
<td class="nump">141.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=biib_ReportableSegmentMember', window );">Reportable Segment | Early stage programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAssetReconcilingItemLineItems', window );"><strong>Segment Reporting, Asset Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development:</a></td>
<td class="nump">59.9<span></span>
</td>
<td class="nump">64.1<span></span>
</td>
<td class="nump">184.2<span></span>
</td>
<td class="nump">214.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=biib_ReportableSegmentMember', window );">Reportable Segment | Late stage programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAssetReconcilingItemLineItems', window );"><strong>Segment Reporting, Asset Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development:</a></td>
<td class="nump">60.4<span></span>
</td>
<td class="nump">56.3<span></span>
</td>
<td class="nump">154.4<span></span>
</td>
<td class="nump">135.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=biib_ReportableSegmentMember', window );">Reportable Segment | Marketed products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAssetReconcilingItemLineItems', window );"><strong>Segment Reporting, Asset Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development:</a></td>
<td class="nump">107.7<span></span>
</td>
<td class="nump">126.0<span></span>
</td>
<td class="nump">284.9<span></span>
</td>
<td class="nump">414.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=biib_ReportableSegmentMember', window );">Reportable Segment | Other research and development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAssetReconcilingItemLineItems', window );"><strong>Segment Reporting, Asset Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development:</a></td>
<td class="nump">167.1<span></span>
</td>
<td class="nump">221.5<span></span>
</td>
<td class="nump">513.8<span></span>
</td>
<td class="nump">560.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=biib_ReportableSegmentMember', window );">Reportable Segment | Product revenue, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAssetReconcilingItemLineItems', window );"><strong>Segment Reporting, Asset Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales, excluding amortization and impairment of acquired intangible assets</a></td>
<td class="nump">384.0<span></span>
</td>
<td class="nump">468.2<span></span>
</td>
<td class="nump">1,261.2<span></span>
</td>
<td class="nump">1,204.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=biib_ReportableSegmentMember', window );">Reportable Segment | Royalty and other revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAssetReconcilingItemLineItems', window );"><strong>Segment Reporting, Asset Reconciling Item [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales, excluding amortization and impairment of acquired intangible assets</a></td>
<td class="nump">$ 290.4<span></span>
</td>
<td class="nump">$ 170.5<span></span>
</td>
<td class="nump">$ 647.5<span></span>
</td>
<td class="nump">$ 522.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_ResearchAndDevelopmentExpenseIncludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Expense (Including Acquired in Process Cost)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_ResearchAndDevelopmentExpenseIncludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAssetReconcilingItemLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAssetReconcilingItemLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingOtherItemAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingOtherItemAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-11<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=biib_ReportableSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=biib_ReportableSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=biib_ResearchAndDiscoveryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=biib_ResearchAndDiscoveryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=biib_EarlyStageProgramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=biib_EarlyStageProgramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=biib_LateStageProgramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=biib_LateStageProgramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=biib_MarketedProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=biib_MarketedProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_ServiceOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_ServiceOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>140
<FILENAME>R118.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.3</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details) - Subsequent Event<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Oct. 31, 2025 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">License</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront and milestone paymentsmade to collaborative partner</a></td>
<td class="nump">$ 50.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Vanqua Bio, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner', window );">Upfront and milestone paymentsmade to collaborative partner</a></td>
<td class="nump">$ 70.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total upfront and milestone payments made to collaborative partner.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>biib_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=biib_VanquaBioInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=biib_VanquaBioInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>141
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>142
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>144
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>840</ContextCount>
  <ElementCount>421</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>196</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>9952151 - Statement - Condensed Consolidated Statements of Income (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Income (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952152 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952153 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952154 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952155 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952156 - Statement - Condensed Consolidated Statement of Equity Statement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement</Role>
      <ShortName>Condensed Consolidated Statement of Equity Statement</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952157 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - Acquisitions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Acquisitions</Role>
      <ShortName>Acquisitions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - Dispositions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Dispositions</Role>
      <ShortName>Dispositions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiatives</Role>
      <ShortName>Restructuring, Business Transformation and Other Cost Saving Initiatives</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Revenues</Role>
      <ShortName>Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - Intangible Assets and Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsandGoodwill</Role>
      <ShortName>Intangible Assets and Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>9952165 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9952166 - Disclosure - Derivative Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstruments</Role>
      <ShortName>Derivative Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9952167 - Disclosure - Property, Plant and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/PropertyPlantandEquipment</Role>
      <ShortName>Property, Plant and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9952168 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9952169 - Disclosure - Indebtedness</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Indebtedness</Role>
      <ShortName>Indebtedness</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9952170 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9952171 - Disclosure - Earnings per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsperShare</Role>
      <ShortName>Earnings per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9952172 - Disclosure - Share-based Payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SharebasedPayments</Role>
      <ShortName>Share-based Payments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9952173 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9952174 - Disclosure - Other Consolidated Financial Statement Detail</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail</Role>
      <ShortName>Other Consolidated Financial Statement Detail</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9952175 - Disclosure - Collaborative and Other Relationships</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationships</Role>
      <ShortName>Collaborative and Other Relationships</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9952176 - Disclosure - Investments in Variable Interest Entities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities</Role>
      <ShortName>Investments in Variable Interest Entities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9952177 - Disclosure - Litigation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/Litigation</Role>
      <ShortName>Litigation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9952178 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9952179 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9955511 - Disclosure - Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9955512 - Disclosure - Acquisitions (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AcquisitionsTables</Role>
      <ShortName>Acquisitions (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Acquisitions</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9955513 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTables</Role>
      <ShortName>Restructuring, Business Transformation and Other Cost Saving Initiatives (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiatives</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9955514 - Disclosure - Revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesTables</Role>
      <ShortName>Revenues (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Revenues</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9955515 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Inventory</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9955516 - Disclosure - Intangible Assets and Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables</Role>
      <ShortName>Intangible Assets and Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IntangibleAssetsandGoodwill</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9955517 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FairValueMeasurements</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9955518 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/FinancialInstruments</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9955519 - Disclosure - Derivative Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstrumentsTables</Role>
      <ShortName>Derivative Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/DerivativeInstruments</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9955520 - Disclosure - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EquityTables</Role>
      <ShortName>Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Equity</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9955521 - Disclosure - Earnings per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsperShareTables</Role>
      <ShortName>Earnings per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EarningsperShare</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9955522 - Disclosure - Share-Based Payments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsTables</Role>
      <ShortName>Share-Based Payments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9955523 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/IncomeTaxes</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9955524 - Disclosure - Other Consolidated Financial Statement Detail (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables</Role>
      <ShortName>Other Consolidated Financial Statement Detail (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9955525 - Disclosure - Collaborative and Other Relationships (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables</Role>
      <ShortName>Collaborative and Other Relationships (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/CollaborativeandOtherRelationships</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9955526 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SegmentInformation</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9955527 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9955528 - Disclosure - Acquisitions - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AcquisitionsNarrativeDetails</Role>
      <ShortName>Acquisitions - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9955529 - Disclosure - Acquisitions - Purchase Price Consideration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AcquisitionsPurchasePriceConsiderationDetails</Role>
      <ShortName>Acquisitions - Purchase Price Consideration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9955530 - Disclosure - Acquisitions - Preliminaty Purchase Price Allocation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails</Role>
      <ShortName>Acquisitions - Preliminaty Purchase Price Allocation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9955531 - Disclosure - Dispositions (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DispositionsDetailsTextual</Role>
      <ShortName>Dispositions (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Dispositions</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9955532 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives - FIt for Growth Initiative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails</Role>
      <ShortName>Restructuring, Business Transformation and Other Cost Saving Initiatives - FIt for Growth Initiative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9955533 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails</Role>
      <ShortName>Restructuring, Business Transformation and Other Cost Saving Initiatives - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9955534 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives - Total Charges cost saving initiative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails</Role>
      <ShortName>Restructuring, Business Transformation and Other Cost Saving Initiatives - Total Charges cost saving initiative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9955535 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives - Restructuring Reserve Roll Forward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails</Role>
      <ShortName>Restructuring, Business Transformation and Other Cost Saving Initiatives - Restructuring Reserve Roll Forward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9955536 - Disclosure - Revenues - Revenues by product (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails</Role>
      <ShortName>Revenues - Revenues by product (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9955537 - Disclosure - Revenues Reserves for Discounts and Allowances (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1</Role>
      <ShortName>Revenues Reserves for Discounts and Allowances (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9955538 - Disclosure - Revenues- Reserves for Discounts and Allowances (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2</Role>
      <ShortName>Revenues- Reserves for Discounts and Allowances (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9955539 - Disclosure - Revenues - Revenues from Anti-CD20 Therapeutic Programs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails</Role>
      <ShortName>Revenues - Revenues from Anti-CD20 Therapeutic Programs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9955540 - Disclosure - Revenues - Other Revenues (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails</Role>
      <ShortName>Revenues - Other Revenues (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9955541 - Disclosure - Revenues - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/RevenuesNarrativeDetails</Role>
      <ShortName>Revenues - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9955542 - Disclosure - Inventory - Components of Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails</Role>
      <ShortName>Inventory - Components of Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9955543 - Disclosure - Inventory - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InventoryNarrativeDetails</Role>
      <ShortName>Inventory - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9955544 - Disclosure - Intangible Assets and Goodwill - Summary of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets and Goodwill - Summary of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9955545 - Disclosure - Intangible Assets and Goodwill - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails</Role>
      <ShortName>Intangible Assets and Goodwill - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>9955546 - Disclosure - Intangible Assets and Goodwill - Estimated Future Amortization of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsandGoodwillEstimatedFutureAmortizationofIntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets and Goodwill - Estimated Future Amortization of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>9955547 - Disclosure - Intangible Assets and Goodwill - Changes in Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IntangibleAssetsandGoodwillChangesinGoodwillDetails</Role>
      <ShortName>Intangible Assets and Goodwill - Changes in Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>9955548 - Disclosure - Fair Value Measurements - Assets and Liabilities at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails</Role>
      <ShortName>Fair Value Measurements - Assets and Liabilities at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>9955549 - Disclosure - Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>9955550 - Disclosure - Fair Value Measures - Level 3 Assets and Liabilities Held at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasuresLevel3AssetsandLiabilitiesHeldatFairValueDetails</Role>
      <ShortName>Fair Value Measures - Level 3 Assets and Liabilities Held at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>9955551 - Disclosure - Fair Value Measurements - Contingent Consideration Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsContingentConsiderationObligationsDetails</Role>
      <ShortName>Fair Value Measurements - Contingent Consideration Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>9955552 - Disclosure - Fair Value Measurements - Debt Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FairValueMeasurementsDebtInstrumentsDetails</Role>
      <ShortName>Fair Value Measurements - Debt Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>9955553 - Disclosure - Financial Instruments - Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsSummaryoffinancialassetswithmaturitiesoflessthan90daysincludedwithincashandcashequivalentsDetails</Role>
      <ShortName>Financial Instruments - Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>9955554 - Disclosure - Financial Instruments - Marketable debt and equity securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsMarketabledebtandequitysecuritiesDetails</Role>
      <ShortName>Financial Instruments - Marketable debt and equity securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>9955555 - Disclosure - Financial Instruments - Summary of Contractual Maturities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsSummaryofContractualMaturitiesDetails</Role>
      <ShortName>Financial Instruments - Summary of Contractual Maturities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>9955556 - Disclosure - Financial Instruments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/FinancialInstrumentsNarrativeDetails</Role>
      <ShortName>Financial Instruments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>9955557 - Disclosure - Derivative Instruments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstrumentsNarrativeDetails</Role>
      <ShortName>Derivative Instruments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>9955558 - Disclosure - Derivative Instruments - Notional Amount of Foreign Currency Forward Contracts and Foreign Currency Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstrumentsNotionalAmountofForeignCurrencyForwardContractsandForeignCurrencyOptionsDetails</Role>
      <ShortName>Derivative Instruments - Notional Amount of Foreign Currency Forward Contracts and Foreign Currency Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>9955559 - Disclosure - Derivative Instruments - Pre-tax Portion of the Fair Value of Foreign Currency Forward Contracts and Foreign Currency Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstrumentsPretaxPortionoftheFairValueofForeignCurrencyForwardContractsandForeignCurrencyOptionsDetails</Role>
      <ShortName>Derivative Instruments - Pre-tax Portion of the Fair Value of Foreign Currency Forward Contracts and Foreign Currency Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>9955560 - Disclosure - Derivative Instruments - Effect of Foreign Currency Forward Contracts and Forward Currency Options Designated as Hedging Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstrumentsEffectofForeignCurrencyForwardContractsandForwardCurrencyOptionsDesignatedasHedgingInstrumentsDetails</Role>
      <ShortName>Derivative Instruments - Effect of Foreign Currency Forward Contracts and Forward Currency Options Designated as Hedging Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>9955561 - Disclosure - Derivative Instruments - Summary of Fair Value and Presentation of Derivatives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/DerivativeInstrumentsSummaryofFairValueandPresentationofDerivativesDetails</Role>
      <ShortName>Derivative Instruments - Summary of Fair Value and Presentation of Derivatives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>9955562 - Disclosure - Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails</Role>
      <ShortName>Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/PropertyPlantandEquipment</ParentRole>
      <Position>83</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>9955563 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>9955564 - Disclosure - Indebtedness - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IndebtednessNarrativeDetails</Role>
      <ShortName>Indebtedness - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>9955565 - Disclosure - Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EquityNarrativeDetails</Role>
      <ShortName>Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>9955566 - Disclosure - Equity - Accumulated Other Comprehensive Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails</Role>
      <ShortName>Equity - Accumulated Other Comprehensive Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>9955567 - Disclosure - Equity - Reclassified From AOCI (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EquityReclassifiedFromAOCIDetails</Role>
      <ShortName>Equity - Reclassified From AOCI (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>9955568 - Disclosure - Earnings per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/EarningsperShareDetails</Role>
      <ShortName>Earnings per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/EarningsperShareTables</ParentRole>
      <Position>89</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>9955569 - Disclosure - Share-Based Payments - Share-Based Compensation Expense Included In Statements Of Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails</Role>
      <ShortName>Share-Based Payments - Share-Based Compensation Expense Included In Statements Of Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>9955570 - Disclosure - Share-based Payments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SharebasedPaymentsNarrativeDetails</Role>
      <ShortName>Share-based Payments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>9955571 - Disclosure - Share-Based Payments - Share-Based Compensation Expense by Share-Based Compensation Program (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails</Role>
      <ShortName>Share-Based Payments - Share-Based Compensation Expense by Share-Based Compensation Program (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>9955572 - Disclosure - Income Taxes - Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails</Role>
      <ShortName>Income Taxes - Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>9955573 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>9955574 - Disclosure - Other Consolidated Financial Statement Detail - Other (Income) Expense, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherIncomeExpenseNetDetails</Role>
      <ShortName>Other Consolidated Financial Statement Detail - Other (Income) Expense, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables</ParentRole>
      <Position>95</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>9955575 - Disclosure - Other Consolidated Financial Statement Detail - (Gains) Losses on Investments, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailGainsLossesonInvestmentsNetDetails</Role>
      <ShortName>Other Consolidated Financial Statement Detail - (Gains) Losses on Investments, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables</ParentRole>
      <Position>96</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>9955576 - Disclosure - Other Consolidated Financial Statement - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementNarrativeDetails</Role>
      <ShortName>Other Consolidated Financial Statement - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>9955577 - Disclosure - Other Consolidated Financial Statement Detail - Accrued Expense and Other (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailAccruedExpenseandOtherDetails</Role>
      <ShortName>Other Consolidated Financial Statement Detail - Accrued Expense and Other (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>9955578 - Disclosure - Collaborative and Other Relationships - OCREVUS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails</Role>
      <ShortName>Collaborative and Other Relationships - OCREVUS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>9955579 - Disclosure - Collaborative and Other Relationships - Co-promotion Profit Sharing Formula (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCopromotionProfitSharingFormulaDetails</Role>
      <ShortName>Collaborative and Other Relationships - Co-promotion Profit Sharing Formula (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>100</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>9955580 - Disclosure - Collaborative and Other Relationships - Profit Sharing (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails</Role>
      <ShortName>Collaborative and Other Relationships - Profit Sharing (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>101</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>9955581 - Disclosure - Collaborative and Other Relationships - Pretax Profit Sharing Formula (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsPretaxProfitSharingFormulaDetails</Role>
      <ShortName>Collaborative and Other Relationships - Pretax Profit Sharing Formula (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>102</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>9955582 - Disclosure - Collaborative and Other Relationships - Ionis Pharmaceuticals, Inc (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsIonisPharmaceuticalsIncDetails</Role>
      <ShortName>Collaborative and Other Relationships - Ionis Pharmaceuticals, Inc (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>103</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R104.htm</HtmlFileName>
      <LongName>9955583 - Disclosure - Collaborative and Other Relationships - Eisai (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails</Role>
      <ShortName>Collaborative and Other Relationships - Eisai (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables</ParentRole>
      <Position>104</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R105.htm</HtmlFileName>
      <LongName>9955584 - Disclosure - Collaborative and Other Relationships - Summary of Activity Related to LEQEMBI Collaboration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoLEQEMBICollaborationDetails</Role>
      <ShortName>Collaborative and Other Relationships - Summary of Activity Related to LEQEMBI Collaboration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>105</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R106.htm</HtmlFileName>
      <LongName>9955585 - Disclosure - Collaborative and Other Relationships - Summary of Activity Related to the UCB Collaboration (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails</Role>
      <ShortName>Collaborative and Other Relationships - Summary of Activity Related to the UCB Collaboration (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>106</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R107.htm</HtmlFileName>
      <LongName>9955586 - Disclosure - Collaborative and Other Relationships - Sage Therapeutics, Inc. (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSageTherapeuticsIncDetails</Role>
      <ShortName>Collaborative and Other Relationships - Sage Therapeutics, Inc. (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>107</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R108.htm</HtmlFileName>
      <LongName>9955587 - Disclosure - Collaborative and Other Relationships - Summary of Activity Related to Sage Therapeutics (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails</Role>
      <ShortName>Collaborative and Other Relationships - Summary of Activity Related to Sage Therapeutics (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>108</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R109.htm</HtmlFileName>
      <LongName>9955588 - Disclosure - Collaborative and Other Relationships - Summary of Activity Related To Denali Therapeutics (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails</Role>
      <ShortName>Collaborative and Other Relationships - Summary of Activity Related To Denali Therapeutics (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>109</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R110.htm</HtmlFileName>
      <LongName>9955589 - Disclosure - Collaborative and Other Relationships - Stoke Therapeutics, Inc. (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsStokeTherapeuticsIncDetails</Role>
      <ShortName>Collaborative and Other Relationships - Stoke Therapeutics, Inc. (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>110</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R111.htm</HtmlFileName>
      <LongName>9955590 - Disclosure - Collaborative and Other Relationships Summary of Activity Related to Stoke Therapeutics (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoStokeTherapeuticsDetails</Role>
      <ShortName>Collaborative and Other Relationships Summary of Activity Related to Stoke Therapeutics (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>111</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R112.htm</HtmlFileName>
      <LongName>9955591 - Disclosure - Collaborative and Other Relationships - Samsung Bioepis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails</Role>
      <ShortName>Collaborative and Other Relationships - Samsung Bioepis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>112</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R113.htm</HtmlFileName>
      <LongName>9955592 - Disclosure - Collaborative and Other Relationships - Other Research and Discovery Arrangements and Funding Arrangements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherResearchandDiscoveryArrangementsandFundingArrangementsDetails</Role>
      <ShortName>Collaborative and Other Relationships - Other Research and Discovery Arrangements and Funding Arrangements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>113</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R114.htm</HtmlFileName>
      <LongName>9955593 - Disclosure - Investments in Variable Interest Entities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails</Role>
      <ShortName>Investments in Variable Interest Entities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities</ParentRole>
      <Position>114</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R115.htm</HtmlFileName>
      <LongName>9955594 - Disclosure - Litigation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/LitigationDetails</Role>
      <ShortName>Litigation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/Litigation</ParentRole>
      <Position>115</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R116.htm</HtmlFileName>
      <LongName>9955595 - Disclosure - Segment Information - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SegmentInformationNarrativeDetails</Role>
      <ShortName>Segment Information - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>116</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R117.htm</HtmlFileName>
      <LongName>9955596 - Disclosure - Segment Information - Additional Segment Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SegmentInformationAdditionalSegmentInformationDetails</Role>
      <ShortName>Segment Information - Additional Segment Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>117</Position>
    </Report>
    <Report instance="biib-20250930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R118.htm</HtmlFileName>
      <LongName>9955597 - Disclosure - Subsequent Events (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.biogenidec.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.biogenidec.com/role/SubsequentEvents</ParentRole>
      <Position>118</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" isDefinitelyFs="true" isUsgaap="true" original="biib-20250930.htm">biib-20250930.htm</File>
    <File>biib-20250930.xsd</File>
    <File>biib-20250930_cal.xml</File>
    <File>biib-20250930_def.xml</File>
    <File>biib-20250930_lab.xml</File>
    <File>biib-20250930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>biib-20250930_g1.jpg</File>
    <File>biib-20250930_g10.jpg</File>
    <File>biib-20250930_g11.jpg</File>
    <File>biib-20250930_g12.jpg</File>
    <File>biib-20250930_g2.jpg</File>
    <File>biib-20250930_g3.jpg</File>
    <File>biib-20250930_g4.jpg</File>
    <File>biib-20250930_g5.jpg</File>
    <File>biib-20250930_g6.jpg</File>
    <File>biib-20250930_g7.jpg</File>
    <File>biib-20250930_g8.jpg</File>
    <File>biib-20250930_g9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2025</BaseTaxonomy>
    <BaseTaxonomy items="1615">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>147
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "biib-20250930.htm": {
   "nsprefix": "biib",
   "nsuri": "http://www.biogenidec.com/20250930",
   "dts": {
    "inline": {
     "local": [
      "biib-20250930.htm"
     ]
    },
    "schema": {
     "local": [
      "biib-20250930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/currency/2025/currency-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "biib-20250930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "biib-20250930_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "biib-20250930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "biib-20250930_pre.xml"
     ]
    }
   },
   "keyStandard": 329,
   "keyCustom": 92,
   "axisStandard": 47,
   "axisCustom": 1,
   "memberStandard": 67,
   "memberCustom": 119,
   "hidden": {
    "total": 11,
    "http://fasb.org/us-gaap/2025": 2,
    "http://www.biogenidec.com/20250930": 3,
    "http://xbrl.sec.gov/dei/2025": 6
   },
   "contextCount": 840,
   "entityCount": 1,
   "segmentCount": 196,
   "elementCount": 923,
   "unitCount": 10,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 1615,
    "http://xbrl.sec.gov/dei/2025": 30,
    "http://xbrl.sec.gov/ecd/2025": 4,
    "http://fasb.org/srt/2025": 1
   },
   "report": {
    "R1": {
     "role": "http://www.biogenidec.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
     "longName": "9952151 - Statement - Condensed Consolidated Statements of Income (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Income (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
     "longName": "9952152 - Statement - Condensed Consolidated Statements of Comprehensive Income (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Comprehensive Income (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
     "longName": "9952153 - Statement - Condensed Consolidated Balance Sheets (Unaudited)",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-22",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-22",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical",
     "longName": "9952154 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-22",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-22",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
     "longName": "9952155 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
     "longName": "9952156 - Statement - Condensed Consolidated Statement of Equity Statement",
     "shortName": "Condensed Consolidated Statement of Equity Statement",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-77",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-77",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "9952157 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.biogenidec.com/role/Acquisitions",
     "longName": "9952158 - Disclosure - Acquisitions",
     "shortName": "Acquisitions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.biogenidec.com/role/Dispositions",
     "longName": "9952159 - Disclosure - Dispositions",
     "shortName": "Dispositions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiatives",
     "longName": "9952160 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives",
     "shortName": "Restructuring, Business Transformation and Other Cost Saving Initiatives",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.biogenidec.com/role/Revenues",
     "longName": "9952161 - Disclosure - Revenues",
     "shortName": "Revenues",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.biogenidec.com/role/Inventory",
     "longName": "9952162 - Disclosure - Inventory",
     "shortName": "Inventory",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.biogenidec.com/role/IntangibleAssetsandGoodwill",
     "longName": "9952163 - Disclosure - Intangible Assets and Goodwill",
     "shortName": "Intangible Assets and Goodwill",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.biogenidec.com/role/FairValueMeasurements",
     "longName": "9952164 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.biogenidec.com/role/FinancialInstruments",
     "longName": "9952165 - Disclosure - Financial Instruments",
     "shortName": "Financial Instruments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.biogenidec.com/role/DerivativeInstruments",
     "longName": "9952166 - Disclosure - Derivative Instruments",
     "shortName": "Derivative Instruments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.biogenidec.com/role/PropertyPlantandEquipment",
     "longName": "9952167 - Disclosure - Property, Plant and Equipment",
     "shortName": "Property, Plant and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.biogenidec.com/role/Leases",
     "longName": "9952168 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.biogenidec.com/role/Indebtedness",
     "longName": "9952169 - Disclosure - Indebtedness",
     "shortName": "Indebtedness",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.biogenidec.com/role/Equity",
     "longName": "9952170 - Disclosure - Equity",
     "shortName": "Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.biogenidec.com/role/EarningsperShare",
     "longName": "9952171 - Disclosure - Earnings per Share",
     "shortName": "Earnings per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.biogenidec.com/role/SharebasedPayments",
     "longName": "9952172 - Disclosure - Share-based Payments",
     "shortName": "Share-based Payments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.biogenidec.com/role/IncomeTaxes",
     "longName": "9952173 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail",
     "longName": "9952174 - Disclosure - Other Consolidated Financial Statement Detail",
     "shortName": "Other Consolidated Financial Statement Detail",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationships",
     "longName": "9952175 - Disclosure - Collaborative and Other Relationships",
     "shortName": "Collaborative and Other Relationships",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities",
     "longName": "9952176 - Disclosure - Investments in Variable Interest Entities",
     "shortName": "Investments in Variable Interest Entities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:VariableInterestEntityDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.biogenidec.com/role/Litigation",
     "longName": "9952177 - Disclosure - Litigation",
     "shortName": "Litigation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.biogenidec.com/role/SegmentInformation",
     "longName": "9952178 - Disclosure - Segment Information",
     "shortName": "Segment Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.biogenidec.com/role/SubsequentEvents",
     "longName": "9952179 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:Rule10b51ArrTrmntdFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-19",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:Rule10b51ArrTrmntdFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies",
     "longName": "9955511 - Disclosure - Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "biib:BusinessOverviewPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "biib:BusinessOverviewPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.biogenidec.com/role/AcquisitionsTables",
     "longName": "9955512 - Disclosure - Acquisitions (Tables)",
     "shortName": "Acquisitions (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTables",
     "longName": "9955513 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives (Tables)",
     "shortName": "Restructuring, Business Transformation and Other Cost Saving Initiatives (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.biogenidec.com/role/RevenuesTables",
     "longName": "9955514 - Disclosure - Revenues (Tables)",
     "shortName": "Revenues (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.biogenidec.com/role/InventoryTables",
     "longName": "9955515 - Disclosure - Inventory (Tables)",
     "shortName": "Inventory (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables",
     "longName": "9955516 - Disclosure - Intangible Assets and Goodwill (Tables)",
     "shortName": "Intangible Assets and Goodwill (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "biib:IntangibleAssetsExcludingGoodwillTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "biib:IntangibleAssetsExcludingGoodwillTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsTables",
     "longName": "9955517 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsTables",
     "longName": "9955518 - Disclosure - Financial Instruments (Tables)",
     "shortName": "Financial Instruments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.biogenidec.com/role/DerivativeInstrumentsTables",
     "longName": "9955519 - Disclosure - Derivative Instruments (Tables)",
     "shortName": "Derivative Instruments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.biogenidec.com/role/EquityTables",
     "longName": "9955520 - Disclosure - Equity (Tables)",
     "shortName": "Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.biogenidec.com/role/EarningsperShareTables",
     "longName": "9955521 - Disclosure - Earnings per Share (Tables)",
     "shortName": "Earnings per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.biogenidec.com/role/ShareBasedPaymentsTables",
     "longName": "9955522 - Disclosure - Share-Based Payments (Tables)",
     "shortName": "Share-Based Payments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.biogenidec.com/role/IncomeTaxesTables",
     "longName": "9955523 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables",
     "longName": "9955524 - Disclosure - Other Consolidated Financial Statement Detail (Tables)",
     "shortName": "Other Consolidated Financial Statement Detail (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables",
     "longName": "9955525 - Disclosure - Collaborative and Other Relationships (Tables)",
     "shortName": "Collaborative and Other Relationships (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "biib:CoPromotionProfitSharingFormulaTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "biib:CoPromotionProfitSharingFormulaTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.biogenidec.com/role/SegmentInformationTables",
     "longName": "9955526 - Disclosure - Segment Information (Tables)",
     "shortName": "Segment Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "longName": "9955527 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "biib:InterestInSubsidiary",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:ConsolidationPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
     "longName": "9955528 - Disclosure - Acquisitions - Narrative (Details)",
     "shortName": "Acquisitions - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-22",
      "name": "us-gaap:InvestmentOwnedAtCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-92",
      "name": "us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.biogenidec.com/role/AcquisitionsPurchasePriceConsiderationDetails",
     "longName": "9955529 - Disclosure - Acquisitions - Purchase Price Consideration (Details)",
     "shortName": "Acquisitions - Purchase Price Consideration (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-93",
      "name": "us-gaap:PaymentsToAcquireBusinessesGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-93",
      "name": "us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails",
     "longName": "9955530 - Disclosure - Acquisitions - Preliminaty Purchase Price Allocation (Details)",
     "shortName": "Acquisitions - Preliminaty Purchase Price Allocation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-22",
      "name": "us-gaap:Goodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-92",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.biogenidec.com/role/DispositionsDetailsTextual",
     "longName": "9955531 - Disclosure - Dispositions (Details Textual)",
     "shortName": "Dispositions (Details Textual)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-127",
      "name": "us-gaap:ProceedsFromSaleOfIntangibleAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-127",
      "name": "us-gaap:ProceedsFromSaleOfIntangibleAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails",
     "longName": "9955532 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives - FIt for Growth Initiative (Details)",
     "shortName": "Restructuring, Business Transformation and Other Cost Saving Initiatives - FIt for Growth Initiative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:RestructuringCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-137",
      "name": "us-gaap:OtherRestructuringCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails",
     "longName": "9955533 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives - Narrative (Details)",
     "shortName": "Restructuring, Business Transformation and Other Cost Saving Initiatives - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-40",
      "name": "biib:OperatingLeaseArea",
      "unitRef": "sqft",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-163",
      "name": "biib:OperatingLeaseArea",
      "unitRef": "sqft",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails",
     "longName": "9955534 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives - Total Charges cost saving initiative (Details)",
     "shortName": "Restructuring, Business Transformation and Other Cost Saving Initiatives - Total Charges cost saving initiative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:RestructuringCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R56": {
     "role": "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails",
     "longName": "9955535 - Disclosure - Restructuring, Business Transformation and Other Cost Saving Initiatives - Restructuring Reserve Roll Forward (Details)",
     "shortName": "Restructuring, Business Transformation and Other Cost Saving Initiatives - Restructuring Reserve Roll Forward (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:RestructuringCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-174",
      "name": "us-gaap:RestructuringCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails",
     "longName": "9955536 - Disclosure - Revenues - Revenues by product (Details)",
     "shortName": "Revenues - Revenues by product (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-310",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1",
     "longName": "9955537 - Disclosure - Revenues Reserves for Discounts and Allowances (Details 1)",
     "shortName": "Revenues Reserves for Discounts and Allowances (Details 1)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-23",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2",
     "longName": "9955538 - Disclosure - Revenues- Reserves for Discounts and Allowances (Details 2)",
     "shortName": "Revenues- Reserves for Discounts and Allowances (Details 2)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-22",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-467",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails",
     "longName": "9955539 - Disclosure - Revenues - Revenues from Anti-CD20 Therapeutic Programs (Details)",
     "shortName": "Revenues - Revenues from Anti-CD20 Therapeutic Programs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-475",
      "name": "biib:ShareOfCoPromotionProfits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:RevenuesfromantiCD20therapeuticprogramsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
     "longName": "9955540 - Disclosure - Revenues - Other Revenues (Details)",
     "shortName": "Revenues - Other Revenues (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-484",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:OtherrevenuesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
     "longName": "9955541 - Disclosure - Revenues - Narrative (Details)",
     "shortName": "Revenues - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "biib:NumberOfWholesalers",
      "unitRef": "wholesaler",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "biib:NumberOfWholesalers",
       "biib:NumberOfWholesalers",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-19",
      "name": "biib:NumberOfWholesalers",
      "unitRef": "wholesaler",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "biib:NumberOfWholesalers",
       "biib:NumberOfWholesalers",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails",
     "longName": "9955542 - Disclosure - Inventory - Components of Inventory (Details)",
     "shortName": "Inventory - Components of Inventory (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-22",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-22",
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.biogenidec.com/role/InventoryNarrativeDetails",
     "longName": "9955543 - Disclosure - Inventory - Narrative (Details)",
     "shortName": "Inventory - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-492",
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails",
     "longName": "9955544 - Disclosure - Intangible Assets and Goodwill - Summary of Intangible Assets (Details)",
     "shortName": "Intangible Assets and Goodwill - Summary of Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c-22",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:IntangibleAssetsExcludingGoodwillTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-22",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:IntangibleAssetsExcludingGoodwillTableTextBlock",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
     "longName": "9955545 - Disclosure - Intangible Assets and Goodwill - Narrative (Details)",
     "shortName": "Intangible Assets and Goodwill - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillEstimatedFutureAmortizationofIntangibleAssetsDetails",
     "longName": "9955546 - Disclosure - Intangible Assets and Goodwill - Estimated Future Amortization of Intangible Assets (Details)",
     "shortName": "Intangible Assets and Goodwill - Estimated Future Amortization of Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c-22",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-22",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillChangesinGoodwillDetails",
     "longName": "9955547 - Disclosure - Intangible Assets and Goodwill - Changes in Goodwill (Details)",
     "shortName": "Intangible Assets and Goodwill - Changes in Goodwill (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c-23",
      "name": "us-gaap:Goodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillOtherIncreaseDecrease",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails",
     "longName": "9955548 - Disclosure - Fair Value Measurements - Assets and Liabilities at Fair Value (Details)",
     "shortName": "Fair Value Measurements - Assets and Liabilities at Fair Value (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c-22",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-511",
      "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails",
     "longName": "9955549 - Disclosure - Fair Value Measurements - Narrative (Details)",
     "shortName": "Fair Value Measurements - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:AssetImpairmentCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:AssetImpairmentCharges",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:AssetImpairmentCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:AssetImpairmentCharges",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.biogenidec.com/role/FairValueMeasuresLevel3AssetsandLiabilitiesHeldatFairValueDetails",
     "longName": "9955550 - Disclosure - Fair Value Measures - Level 3 Assets and Liabilities Held at Fair Value (Details)",
     "shortName": "Fair Value Measures - Level 3 Assets and Liabilities Held at Fair Value (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c-527",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-527",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsContingentConsiderationObligationsDetails",
     "longName": "9955551 - Disclosure - Fair Value Measurements - Contingent Consideration Obligations (Details)",
     "shortName": "Fair Value Measurements - Contingent Consideration Obligations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c-40",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-40",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.biogenidec.com/role/FairValueMeasurementsDebtInstrumentsDetails",
     "longName": "9955552 - Disclosure - Fair Value Measurements - Debt Instruments (Details)",
     "shortName": "Fair Value Measurements - Debt Instruments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c-22",
      "name": "us-gaap:NotesPayableCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-22",
      "name": "us-gaap:NotesPayableFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsSummaryoffinancialassetswithmaturitiesoflessthan90daysincludedwithincashandcashequivalentsDetails",
     "longName": "9955553 - Disclosure - Financial Instruments - Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents (Details)",
     "shortName": "Financial Instruments - Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c-22",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-22",
      "name": "us-gaap:CashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsMarketabledebtandequitysecuritiesDetails",
     "longName": "9955554 - Disclosure - Financial Instruments - Marketable debt and equity securities (Details)",
     "shortName": "Financial Instruments - Marketable debt and equity securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c-22",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-22",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R76": {
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsSummaryofContractualMaturitiesDetails",
     "longName": "9955555 - Disclosure - Financial Instruments - Summary of Contractual Maturities (Details)",
     "shortName": "Financial Instruments - Summary of Contractual Maturities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c-22",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-22",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R77": {
     "role": "http://www.biogenidec.com/role/FinancialInstrumentsNarrativeDetails",
     "longName": "9955556 - Disclosure - Financial Instruments - Narrative (Details)",
     "shortName": "Financial Instruments - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "biib:DebtSecuritiesAvailableForSaleAverageMaturity",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "biib:DebtSecuritiesAvailableForSaleAverageMaturity",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R78": {
     "role": "http://www.biogenidec.com/role/DerivativeInstrumentsNarrativeDetails",
     "longName": "9955557 - Disclosure - Derivative Instruments - Narrative (Details)",
     "shortName": "Derivative Instruments - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "c-22",
      "name": "biib:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "unique": true
     }
    },
    "R79": {
     "role": "http://www.biogenidec.com/role/DerivativeInstrumentsNotionalAmountofForeignCurrencyForwardContractsandForeignCurrencyOptionsDetails",
     "longName": "9955558 - Disclosure - Derivative Instruments - Notional Amount of Foreign Currency Forward Contracts and Foreign Currency Options (Details)",
     "shortName": "Derivative Instruments - Notional Amount of Foreign Currency Forward Contracts and Foreign Currency Options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "c-594",
      "name": "us-gaap:DerivativeNotionalAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock",
       "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-594",
      "name": "us-gaap:DerivativeNotionalAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock",
       "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R80": {
     "role": "http://www.biogenidec.com/role/DerivativeInstrumentsPretaxPortionoftheFairValueofForeignCurrencyForwardContractsandForeignCurrencyOptionsDetails",
     "longName": "9955559 - Disclosure - Derivative Instruments - Pre-tax Portion of the Fair Value of Foreign Currency Forward Contracts and Foreign Currency Options (Details)",
     "shortName": "Derivative Instruments - Pre-tax Portion of the Fair Value of Foreign Currency Forward Contracts and Foreign Currency Options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "biib:UnrealizedGainOnDerivatives",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:DerivativeInstrumentsUnrealizedGainLossTableTextBlock",
       "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "biib:UnrealizedGainOnDerivatives",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:DerivativeInstrumentsUnrealizedGainLossTableTextBlock",
       "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R81": {
     "role": "http://www.biogenidec.com/role/DerivativeInstrumentsEffectofForeignCurrencyForwardContractsandForwardCurrencyOptionsDesignatedasHedgingInstrumentsDetails",
     "longName": "9955560 - Disclosure - Derivative Instruments - Effect of Foreign Currency Forward Contracts and Forward Currency Options Designated as Hedging Instruments (Details)",
     "shortName": "Derivative Instruments - Effect of Foreign Currency Forward Contracts and Forward Currency Options Designated as Hedging Instruments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "c-596",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-596",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R82": {
     "role": "http://www.biogenidec.com/role/DerivativeInstrumentsSummaryofFairValueandPresentationofDerivativesDetails",
     "longName": "9955561 - Disclosure - Derivative Instruments - Summary of Fair Value and Presentation of Derivatives (Details)",
     "shortName": "Derivative Instruments - Summary of Fair Value and Presentation of Derivatives (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "c-614",
      "name": "us-gaap:DerivativeFairValueOfDerivativeAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-614",
      "name": "us-gaap:DerivativeFairValueOfDerivativeAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R83": {
     "role": "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails",
     "longName": "9955562 - Disclosure - Property, Plant and Equipment (Details)",
     "shortName": "Property, Plant and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "c-22",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-23",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "unique": true
     }
    },
    "R84": {
     "role": "http://www.biogenidec.com/role/LeasesNarrativeDetails",
     "longName": "9955563 - Disclosure - Leases - Narrative (Details)",
     "shortName": "Leases - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "c-40",
      "name": "biib:OperatingLeaseArea",
      "unitRef": "sqft",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "span",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-40",
      "name": "biib:ReductionOfRealEstateFootprint",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "unique": true
     }
    },
    "R85": {
     "role": "http://www.biogenidec.com/role/IndebtednessNarrativeDetails",
     "longName": "9955564 - Disclosure - Indebtedness - Narrative (Details)",
     "shortName": "Indebtedness - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "c-571",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-571",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R86": {
     "role": "http://www.biogenidec.com/role/EquityNarrativeDetails",
     "longName": "9955565 - Disclosure - Equity - Narrative (Details)",
     "shortName": "Equity - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:TreasuryStockSharesAcquired",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "us-gaap:TreasuryStockSharesAcquired",
       "us-gaap:TreasuryStockSharesAcquired",
       "span",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:TreasuryStockSharesAcquired",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "0",
      "ancestors": [
       "us-gaap:TreasuryStockSharesAcquired",
       "us-gaap:TreasuryStockSharesAcquired",
       "span",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R87": {
     "role": "http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails",
     "longName": "9955566 - Disclosure - Equity - Accumulated Other Comprehensive Income (Loss) (Details)",
     "shortName": "Equity - Accumulated Other Comprehensive Income (Loss) (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R88": {
     "role": "http://www.biogenidec.com/role/EquityReclassifiedFromAOCIDetails",
     "longName": "9955567 - Disclosure - Equity - Reclassified From AOCI (Details)",
     "shortName": "Equity - Reclassified From AOCI (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "88",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-679",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "unique": true
     }
    },
    "R89": {
     "role": "http://www.biogenidec.com/role/EarningsperShareDetails",
     "longName": "9955568 - Disclosure - Earnings per Share (Details)",
     "shortName": "Earnings per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "89",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "unique": true
     }
    },
    "R90": {
     "role": "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails",
     "longName": "9955569 - Disclosure - Share-Based Payments - Share-Based Compensation Expense Included In Statements Of Income (Details)",
     "shortName": "Share-Based Payments - Share-Based Compensation Expense Included In Statements Of Income (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "90",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "unique": true
     }
    },
    "R91": {
     "role": "http://www.biogenidec.com/role/SharebasedPaymentsNarrativeDetails",
     "longName": "9955570 - Disclosure - Share-based Payments - Narrative (Details)",
     "shortName": "Share-based Payments - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "91",
     "firstAnchor": {
      "contextRef": "c-691",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R92": {
     "role": "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails",
     "longName": "9955571 - Disclosure - Share-Based Payments - Share-Based Compensation Expense by Share-Based Compensation Program (Details)",
     "shortName": "Share-Based Payments - Share-Based Compensation Expense by Share-Based Compensation Program (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "92",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-703",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "unique": true
     }
    },
    "R93": {
     "role": "http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails",
     "longName": "9955572 - Disclosure - Income Taxes - Tax Rate (Details)",
     "shortName": "Income Taxes - Tax Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "93",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R94": {
     "role": "http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails",
     "longName": "9955573 - Disclosure - Income Taxes - Narrative (Details)",
     "shortName": "Income Taxes - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "94",
     "firstAnchor": {
      "contextRef": "c-22",
      "name": "us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-22",
      "name": "us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R95": {
     "role": "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherIncomeExpenseNetDetails",
     "longName": "9955574 - Disclosure - Other Consolidated Financial Statement Detail - Other (Income) Expense, Net (Details)",
     "shortName": "Other Consolidated Financial Statement Detail - Other (Income) Expense, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "95",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:InvestmentIncomeInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:InvestmentIncomeInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R96": {
     "role": "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailGainsLossesonInvestmentsNetDetails",
     "longName": "9955575 - Disclosure - Other Consolidated Financial Statement Detail - (Gains) Losses on Investments, Net (Details)",
     "shortName": "Other Consolidated Financial Statement Detail - (Gains) Losses on Investments, Net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "96",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:EquitySecuritiesFvNiGainLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:GainLossOnInvestmentsTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:EquitySecuritiesFvNiGainLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:GainLossOnInvestmentsTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R97": {
     "role": "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementNarrativeDetails",
     "longName": "9955576 - Disclosure - Other Consolidated Financial Statement - Narrative (Details)",
     "shortName": "Other Consolidated Financial Statement - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "97",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:GainLossOnInvestmentsTextBlock",
       "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-23",
      "name": "us-gaap:AccruedIncomeTaxesNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "unique": true
     }
    },
    "R98": {
     "role": "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailAccruedExpenseandOtherDetails",
     "longName": "9955577 - Disclosure - Other Consolidated Financial Statement Detail - Accrued Expense and Other (Details)",
     "shortName": "Other Consolidated Financial Statement Detail - Accrued Expense and Other (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "98",
     "firstAnchor": {
      "contextRef": "c-22",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-22",
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "unique": true
     }
    },
    "R99": {
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails",
     "longName": "9955578 - Disclosure - Collaborative and Other Relationships - OCREVUS (Details)",
     "shortName": "Collaborative and Other Relationships - OCREVUS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "99",
     "firstAnchor": {
      "contextRef": "c-738",
      "name": "biib:Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-738",
      "name": "biib:Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R100": {
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCopromotionProfitSharingFormulaDetails",
     "longName": "9955579 - Disclosure - Collaborative and Other Relationships - Co-promotion Profit Sharing Formula (Details)",
     "shortName": "Collaborative and Other Relationships - Co-promotion Profit Sharing Formula (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "100",
     "firstAnchor": {
      "contextRef": "c-740",
      "name": "biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-740",
      "name": "biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "unique": true
     }
    },
    "R101": {
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails",
     "longName": "9955580 - Disclosure - Collaborative and Other Relationships - Profit Sharing (Details)",
     "shortName": "Collaborative and Other Relationships - Profit Sharing (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "101",
     "firstAnchor": {
      "contextRef": "c-740",
      "name": "biib:PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-740",
      "name": "biib:PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R102": {
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsPretaxProfitSharingFormulaDetails",
     "longName": "9955581 - Disclosure - Collaborative and Other Relationships - Pretax Profit Sharing Formula (Details)",
     "shortName": "Collaborative and Other Relationships - Pretax Profit Sharing Formula (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "102",
     "firstAnchor": {
      "contextRef": "c-743",
      "name": "biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R103": {
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsIonisPharmaceuticalsIncDetails",
     "longName": "9955582 - Disclosure - Collaborative and Other Relationships - Ionis Pharmaceuticals, Inc (Details)",
     "shortName": "Collaborative and Other Relationships - Ionis Pharmaceuticals, Inc (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "103",
     "firstAnchor": {
      "contextRef": "c-744",
      "name": "biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-744",
      "name": "biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R104": {
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails",
     "longName": "9955583 - Disclosure - Collaborative and Other Relationships - Eisai (Details)",
     "shortName": "Collaborative and Other Relationships - Eisai (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "104",
     "firstAnchor": {
      "contextRef": "c-753",
      "name": "biib:AccountsReceivableFromCollaborator",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-753",
      "name": "biib:AccountsReceivableFromCollaborator",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R105": {
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoLEQEMBICollaborationDetails",
     "longName": "9955584 - Disclosure - Collaborative and Other Relationships - Summary of Activity Related to LEQEMBI Collaboration (Details)",
     "shortName": "Collaborative and Other Relationships - Summary of Activity Related to LEQEMBI Collaboration (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "105",
     "firstAnchor": {
      "contextRef": "c-745",
      "name": "biib:ExpenseIncurredByCollaboration",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-745",
      "name": "biib:ExpenseIncurredByCollaboration",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R106": {
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails",
     "longName": "9955585 - Disclosure - Collaborative and Other Relationships - Summary of Activity Related to the UCB Collaboration (Details)",
     "shortName": "Collaborative and Other Relationships - Summary of Activity Related to the UCB Collaboration (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "106",
     "firstAnchor": {
      "contextRef": "c-755",
      "name": "biib:Expenseincurredbythecollaboration",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-755",
      "name": "biib:Expenseincurredbythecollaboration",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R107": {
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSageTherapeuticsIncDetails",
     "longName": "9955586 - Disclosure - Collaborative and Other Relationships - Sage Therapeutics, Inc. (Details)",
     "shortName": "Collaborative and Other Relationships - Sage Therapeutics, Inc. (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "107",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "biib:Collaborationprofitlosssharing",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-760",
      "name": "biib:Collaborationprofitlosssharing",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "unique": true
     }
    },
    "R108": {
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails",
     "longName": "9955587 - Disclosure - Collaborative and Other Relationships - Summary of Activity Related to Sage Therapeutics (Details)",
     "shortName": "Collaborative and Other Relationships - Summary of Activity Related to Sage Therapeutics (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "108",
     "firstAnchor": {
      "contextRef": "c-764",
      "name": "biib:Expenseincurredbythecollaboration",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-764",
      "name": "biib:Expenseincurredbythecollaboration",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R109": {
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails",
     "longName": "9955588 - Disclosure - Collaborative and Other Relationships - Summary of Activity Related To Denali Therapeutics (Details)",
     "shortName": "Collaborative and Other Relationships - Summary of Activity Related To Denali Therapeutics (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "109",
     "firstAnchor": {
      "contextRef": "c-772",
      "name": "biib:Expenseincurredbythecollaboration",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-772",
      "name": "biib:Expenseincurredbythecollaboration",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R110": {
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsStokeTherapeuticsIncDetails",
     "longName": "9955589 - Disclosure - Collaborative and Other Relationships - Stoke Therapeutics, Inc. (Details)",
     "shortName": "Collaborative and Other Relationships - Stoke Therapeutics, Inc. (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "110",
     "firstAnchor": {
      "contextRef": "c-777",
      "name": "biib:PercentageOfFutureDevelopmentCosts",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-777",
      "name": "biib:PercentageOfFutureDevelopmentCosts",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R111": {
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoStokeTherapeuticsDetails",
     "longName": "9955590 - Disclosure - Collaborative and Other Relationships Summary of Activity Related to Stoke Therapeutics (Details)",
     "shortName": "Collaborative and Other Relationships Summary of Activity Related to Stoke Therapeutics (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "111",
     "firstAnchor": {
      "contextRef": "c-781",
      "name": "biib:Expenseincurredbythecollaboration",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:SummaryOfActivityRelatedToCollaborationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-781",
      "name": "biib:Expenseincurredbythecollaboration",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "biib:SummaryOfActivityRelatedToCollaborationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R112": {
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
     "longName": "9955591 - Disclosure - Collaborative and Other Relationships - Samsung Bioepis (Details)",
     "shortName": "Collaborative and Other Relationships - Samsung Bioepis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "112",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "biib:Collaborationprofitlosssharing",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-787",
      "name": "biib:Collaborationprofitlosssharing",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "unique": true
     }
    },
    "R113": {
     "role": "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherResearchandDiscoveryArrangementsandFundingArrangementsDetails",
     "longName": "9955592 - Disclosure - Collaborative and Other Relationships - Other Research and Discovery Arrangements and Funding Arrangements (Details)",
     "shortName": "Collaborative and Other Relationships - Other Research and Discovery Arrangements and Funding Arrangements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "113",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "biib:ReductionOfResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-19",
      "name": "biib:ReductionOfResearchAndDevelopmentExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R114": {
     "role": "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails",
     "longName": "9955593 - Disclosure - Investments in Variable Interest Entities (Details)",
     "shortName": "Investments in Variable Interest Entities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "114",
     "firstAnchor": {
      "contextRef": "c-22",
      "name": "biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:VariableInterestEntityDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-22",
      "name": "biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:VariableInterestEntityDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R115": {
     "role": "http://www.biogenidec.com/role/LitigationDetails",
     "longName": "9955594 - Disclosure - Litigation (Details)",
     "shortName": "Litigation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "115",
     "firstAnchor": {
      "contextRef": "c-803",
      "name": "us-gaap:LossContingencyDamagesSoughtValue",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-4",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-803",
      "name": "us-gaap:LossContingencyDamagesSoughtValue",
      "unitRef": "eur",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-4",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    },
    "R116": {
     "role": "http://www.biogenidec.com/role/SegmentInformationNarrativeDetails",
     "longName": "9955595 - Disclosure - Segment Information - Narrative (Details)",
     "shortName": "Segment Information - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "116",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfReportableSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R117": {
     "role": "http://www.biogenidec.com/role/SegmentInformationAdditionalSegmentInformationDetails",
     "longName": "9955596 - Disclosure - Segment Information - Additional Segment Information (Details)",
     "shortName": "Segment Information - Additional Segment Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "117",
     "firstAnchor": {
      "contextRef": "c-19",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-807",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "unique": true
     }
    },
    "R118": {
     "role": "http://www.biogenidec.com/role/SubsequentEventsDetails",
     "longName": "9955597 - Disclosure - Subsequent Events (Details)",
     "shortName": "Subsequent Events (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "118",
     "firstAnchor": {
      "contextRef": "c-839",
      "name": "biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-839",
      "name": "biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "biib-20250930.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "biib_A2.25SeniorNotesdueMay12030Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "A2.25SeniorNotesdueMay12030Member",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2.250% Senior Notes due May 1, 2030",
        "label": "2.25% Senior Notes due May 1, 2030 [Member]",
        "documentation": "2.25% Senior Notes due May 1, 2030 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_A2020ShareRepurchaseProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "A2020ShareRepurchaseProgramMember",
     "presentation": [
      "http://www.biogenidec.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2020 Share Repurchase Program",
        "label": "2020 Share Repurchase Program [Member]",
        "documentation": "2020 Share Repurchase Program [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_A2023And2022CostSavingInitiativesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "A2023And2022CostSavingInitiativesMember",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 and 2022 Cost Saving Initiatives",
        "label": "2023 and 2022 Cost Saving Initiatives [Member]",
        "documentation": "2023 and 2022 Cost Saving Initiatives"
       }
      }
     },
     "auth_ref": []
    },
    "biib_A2023CostSavingInitiativesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "A2023CostSavingInitiativesMember",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 Cost Saving Initiatives",
        "label": "2023 Cost Saving Initiatives [Member]",
        "documentation": "2023 Cost Saving Initiatives"
       }
      }
     },
     "auth_ref": []
    },
    "biib_A2023TermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "A2023TermLoanMember",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 Term Loan",
        "label": "2023 Term Loan [Member]",
        "documentation": "2023 Term Loan"
       }
      }
     },
     "auth_ref": []
    },
    "biib_A2025SeniorNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "A2025SeniorNotesMember",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025 Senior Notes",
        "label": "2025 Senior Notes [Member]",
        "documentation": "2025 Senior Notes"
       }
      }
     },
     "auth_ref": []
    },
    "biib_A3.15SeniorNotesdueMay12050Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "A3.15SeniorNotesdueMay12050Member",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "3.150% Senior Notes due May 1, 2050",
        "label": "3.15% Senior Notes due May 1, 2050 [Member]",
        "documentation": "3.15% Senior Notes due May 1, 2050 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_A5.050SeniorNotesDueJanuary152031Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "A5.050SeniorNotesDueJanuary152031Member",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDebtInstrumentsDetails",
      "http://www.biogenidec.com/role/IndebtednessNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "5.050% Senior Notes due January 15, 2031",
        "label": "5.050% Senior Notes due January 15, 2031 [Member]",
        "documentation": "5.050% Senior Notes due January 15, 2031"
       }
      }
     },
     "auth_ref": []
    },
    "biib_A5.750SeniorNotesDueMay152035Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "A5.750SeniorNotesDueMay152035Member",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDebtInstrumentsDetails",
      "http://www.biogenidec.com/role/IndebtednessNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "5.750% Senior Notes due May 15, 2035",
        "label": "5.750% Senior Notes due May 15, 2035 [Member]",
        "documentation": "5.750% Senior Notes due May 15, 2035"
       }
      }
     },
     "auth_ref": []
    },
    "biib_A6.450SeniorNotesDueMay152055Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "A6.450SeniorNotesDueMay152055Member",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDebtInstrumentsDetails",
      "http://www.biogenidec.com/role/IndebtednessNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "6.450% Senior Notes due May 15, 2055",
        "label": "6.450% Senior Notes due May 15, 2055 [Member]",
        "documentation": "6.450% Senior Notes due May 15, 2055"
       }
      }
     },
     "auth_ref": []
    },
    "biib_AVONEXMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "AVONEXMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AVONEX",
        "label": "AVONEX [Member]",
        "documentation": "AVONEX"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r1254"
     ]
    },
    "us-gaap_AccountsPayableCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r1681"
     ]
    },
    "biib_AccountsPayableToCollaborator": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "AccountsPayableToCollaborator",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amounts payable",
        "label": "Accounts Payable, To Collaborator",
        "documentation": "Accounts Payable, To Collaborator"
       }
      }
     },
     "auth_ref": []
    },
    "biib_AccountsReceivableFromCollaborator": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "AccountsReceivableFromCollaborator",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amounts receivable",
        "label": "Accounts Receivable, From Collaborator",
        "documentation": "Accounts Receivable, From Collaborator"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reduction of accounts receivable",
        "label": "Accounts Receivable [Member]",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r1102",
      "r1485"
     ]
    },
    "us-gaap_AccountsReceivableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsReceivableNet",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "label": "Accounts Receivable, after Allowance for Credit Loss",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business."
       }
      }
     },
     "auth_ref": [
      "r1032",
      "r1101",
      "r1281",
      "r1685",
      "r1686"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts receivable, net of allowance for doubtful accounts of $3.1 and $2.2, respectively",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1492"
     ]
    },
    "us-gaap_AccruedIncomeTaxesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedIncomeTaxesNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued income taxes",
        "label": "Accrued Income Taxes, Noncurrent",
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent."
       }
      }
     },
     "auth_ref": [
      "r70",
      "r123"
     ]
    },
    "us-gaap_AccruedLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedLiabilitiesMember",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsSummaryofFairValueandPresentationofDerivativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses and other",
        "label": "Accrued Liabilities [Member]",
        "documentation": "This item represents obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_AccruedRoyaltiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedRoyaltiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailAccruedExpenseandOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalties and licensing fees",
        "label": "Accrued Royalties, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r1121"
     ]
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember",
     "presentation": [
      "http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unfunded status of postretirement benefit plans",
        "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]",
        "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r4",
      "r12",
      "r20",
      "r85",
      "r1412",
      "r1413",
      "r1414"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r198",
      "r942"
     ]
    },
    "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember",
     "presentation": [
      "http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/EquityReclassifiedFromAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gains (losses) on cash flow hedges",
        "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]",
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r224",
      "r225",
      "r693",
      "r767",
      "r768",
      "r769",
      "r770",
      "r1130",
      "r1412"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r223",
      "r224",
      "r767",
      "r768",
      "r769",
      "r770",
      "r815",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accumulated other comprehensive income (loss)",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r20",
      "r86",
      "r207",
      "r938",
      "r984",
      "r988",
      "r1636"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "presentation": [
      "http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r223",
      "r224",
      "r767",
      "r768",
      "r769",
      "r770",
      "r815",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive income (loss)",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r12",
      "r20",
      "r762",
      "r765",
      "r836",
      "r979",
      "r980",
      "r1412",
      "r1413",
      "r1414",
      "r1477",
      "r1478",
      "r1479",
      "r1482"
     ]
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedTranslationAdjustmentMember",
     "presentation": [
      "http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency translation adjustments",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r12",
      "r20",
      "r83",
      "r84",
      "r224",
      "r225",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r1412"
     ]
    },
    "biib_AcquiredAndInLicensedRightsAndPatentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "AcquiredAndInLicensedRightsAndPatentsMember",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquired and in-licensed rights and patents",
        "label": "Acquired And In Licensed Rights And Patents [Member]",
        "documentation": "Acquired And In Licensed Rights And Patents"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1325"
     ]
    },
    "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalFinancialInformationDisclosureTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetail"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other Consolidated Financial Statement Detail",
        "label": "Additional Financial Information Disclosure [Text Block]",
        "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r75",
      "r1254",
      "r1721"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r1002",
      "r1477",
      "r1478",
      "r1479",
      "r1482",
      "r1637",
      "r1724"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1338"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1338"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1338"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1338"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation related to share-based payments",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r550"
     ]
    },
    "biib_AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Adjustments Relating To Prior Years",
        "label": "Adjustments To Product Revenue Reserves Relating To Sales In Prior Years",
        "documentation": "Adjustments to product revenue reserves relating to sales in prior years."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Adjustments to reconcile net income to net cash flow from operating activities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table",
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r1371"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1297",
      "r1307",
      "r1317",
      "r1349"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1300",
      "r1310",
      "r1320",
      "r1352"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Pension Adjustments Service Cost",
        "label": "Aggregate Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r1372"
     ]
    },
    "biib_AlcyoneTherapeuticsInc.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "AlcyoneTherapeuticsInc.Member",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Alcyone Therapeutics, Inc.",
        "label": "Alcyone Therapeutics, Inc. [Member]",
        "documentation": "Alcyone Therapeutics, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r1338"
     ]
    },
    "currency_AllCurrenciesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2025",
     "localname": "AllCurrenciesDomain",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsNotionalAmountofForeignCurrencyForwardContractsandForeignCurrencyOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Currencies [Domain]",
        "label": "All Currencies [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r1345"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r1301",
      "r1311",
      "r1321",
      "r1345",
      "r1353",
      "r1357",
      "r1365"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r1363"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails",
      "http://www.biogenidec.com/role/SharebasedPaymentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment arrangement, expense",
        "verboseLabel": "Share-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r580",
      "r586",
      "r587"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpenseNetOfTax",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Subtotal",
        "verboseLabel": "Subtotal",
        "label": "Share-Based Payment Arrangement, Expense, after Tax",
        "documentation": "Amount, after tax, of expense for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1587"
     ]
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Receivable, Allowance for Credit Loss, Current",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r342",
      "r383"
     ]
    },
    "biib_AlzheimersCollaborationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "AlzheimersCollaborationMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Alzheimer's Collaboration",
        "label": "Alzheimer's Collaboration [Member]",
        "documentation": "Alzheimer's Collaboration"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "biib_AmortizationAndImpairmentOfAcquiredIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "AmortizationAndImpairmentOfAcquiredIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization and impairment of acquired intangible assets",
        "label": "Amortization and Impairment of Acquired Intangible Assets",
        "documentation": "Amortization and Impairment of Acquired Intangible Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of intangible assets",
        "label": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r237",
      "r411",
      "r418",
      "r1118",
      "r1131",
      "r1132",
      "r1134",
      "r1136"
     ]
    },
    "biib_AmortizationOfInventoryStepUp": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "AmortizationOfInventoryStepUp",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of acquired inventory step-up",
        "label": "Amortization Of Inventory Step-Up",
        "documentation": "Amortization Of Inventory Step-Up"
       }
      }
     },
     "auth_ref": []
    },
    "biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Analysis of change In reserves",
        "label": "Analysis Of Amount Of And Change In Product Revenue Reserves [Table Text Block]",
        "documentation": "Analysis of amount of and change in product revenue reserves."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, by Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r294"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r294"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r294"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsIonisPharmaceuticalsIncDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherResearchandDiscoveryArrangementsandFundingArrangementsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSageTherapeuticsIncDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsStokeTherapeuticsIncDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoLEQEMBICollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoStokeTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails",
      "http://www.biogenidec.com/role/DispositionsDetailsTextual",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails",
      "http://www.biogenidec.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "us-gaap_AssetAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetAcquisitionAxis",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Acquisition [Axis]",
        "label": "Asset Acquisition [Axis]",
        "documentation": "Information by asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r991",
      "r1620"
     ]
    },
    "us-gaap_AssetAcquisitionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetAcquisitionDomain",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Acquisition [Domain]",
        "label": "Asset Acquisition [Domain]",
        "documentation": "Asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r991",
      "r1620"
     ]
    },
    "us-gaap_AssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetImpairmentCharges",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset impairment charges",
        "label": "Asset Impairment Charges",
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r32",
      "r1264",
      "r1265"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r134",
      "r202",
      "r247",
      "r251",
      "r252",
      "r298",
      "r310",
      "r329",
      "r333",
      "r378",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r689",
      "r694",
      "r806",
      "r920",
      "r921",
      "r932",
      "r1037",
      "r1148",
      "r1149",
      "r1162",
      "r1254",
      "r1274",
      "r1275",
      "r1288",
      "r1552",
      "r1553",
      "r1670"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r196",
      "r211",
      "r247",
      "r251",
      "r252",
      "r378",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r689",
      "r694",
      "r806",
      "r1254",
      "r1552",
      "r1553",
      "r1670"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r778",
      "r779",
      "r1241"
     ]
    },
    "us-gaap_AssetsFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsFairValueDisclosureAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Assets:",
        "label": "Assets, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsMarketabledebtandequitysecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross unrealized gains",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r349"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsMarketabledebtandequitysecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Gross Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r350"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsMarketabledebtandequitysecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortized Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r346",
      "r389",
      "r931"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsSummaryofContractualMaturitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsSummaryofContractualMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total marketable debt securities",
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date."
       }
      }
     },
     "auth_ref": [
      "r1500",
      "r1501",
      "r1680"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsSummaryofContractualMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated Fair Value",
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsSummaryofContractualMaturitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsSummaryofContractualMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total marketable debt securities",
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date."
       }
      }
     },
     "auth_ref": [
      "r1500",
      "r1501",
      "r1679"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsSummaryofContractualMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract]",
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsSummaryofContractualMaturitiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsSummaryofContractualMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due in one year or less",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r1502"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/FinancialInstrumentsSummaryofContractualMaturitiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsSummaryofContractualMaturitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Due in one year or less",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r353",
      "r926"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsMarketabledebtandequitysecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "label": "Debt Securities, Available-for-Sale",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r347",
      "r389",
      "r778",
      "r801",
      "r802",
      "r803",
      "r804",
      "r916",
      "r1115",
      "r1241",
      "r1245",
      "r1252",
      "r1494",
      "r1642",
      "r1643",
      "r1644"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities",
        "label": "Debt Securities, Available-for-Sale, Current",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current."
       }
      }
     },
     "auth_ref": [
      "r344",
      "r389"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r1360"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r1361"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1356"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1356"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1356"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1356"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1356"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1356"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r1359"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1358"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r1357"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1357"
     ]
    },
    "biib_BENEPALIMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "BENEPALIMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BENEPALI",
        "label": "BENEPALI [Member]",
        "documentation": "BENEPALI [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_BYOOVIZMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "BYOOVIZMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "BYOOVIZ",
        "label": "BYOOVIZ [Member]",
        "documentation": "BYOOVIZ"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BalanceSheetLocationAxis",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsSummaryofFairValueandPresentationofDerivativesDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailAccruedExpenseandOtherDetails",
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2",
      "http://www.biogenidec.com/role/SharebasedPaymentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Location [Axis]",
        "label": "Statement of Financial Position Location, Balance [Axis]",
        "documentation": "Information by location in statement of financial position where disaggregated cumulative balance is reported."
       }
      }
     },
     "auth_ref": [
      "r435",
      "r707",
      "r713",
      "r714",
      "r715",
      "r716",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r805",
      "r1236",
      "r1237",
      "r1385",
      "r1688"
     ]
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BalanceSheetLocationDomain",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsSummaryofFairValueandPresentationofDerivativesDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailAccruedExpenseandOtherDetails",
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2",
      "http://www.biogenidec.com/role/SharebasedPaymentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Balance Sheet Location [Domain]",
        "label": "Statement of Financial Position Location, Balance [Domain]",
        "documentation": "Location in statement of financial position where disaggregated cumulative balance is reported."
       }
      }
     },
     "auth_ref": [
      "r435",
      "r707",
      "r713",
      "r714",
      "r715",
      "r716",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r805",
      "r1236",
      "r1237",
      "r1385",
      "r1688"
     ]
    },
    "biib_BasicAndDilutedEarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "BasicAndDilutedEarningsPerShareAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basic and diluted earnings per share",
        "label": "Basic And Diluted Earnings Per Share [Abstract]",
        "documentation": "Basic and diluted earnings per share."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basis of presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r1465"
     ]
    },
    "biib_BiosimilarsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "BiosimilarsMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Biosimilars",
        "label": "Biosimilars [Member]",
        "documentation": "Biosimilars"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BuildingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BuildingMember",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Building",
        "label": "Building [Member]",
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities."
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails",
      "http://www.biogenidec.com/role/AcquisitionsPurchasePriceConsiderationDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.biogenidec.com/role/IndebtednessNarrativeDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillChangesinGoodwillDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails",
      "http://www.biogenidec.com/role/SharebasedPaymentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combination [Domain]",
        "label": "Business Combination [Domain]",
        "documentation": "Business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r679",
      "r680",
      "r681",
      "r991",
      "r1177",
      "r1178",
      "r1601",
      "r1607",
      "r1609"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails",
      "http://www.biogenidec.com/role/AcquisitionsPurchasePriceConsiderationDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.biogenidec.com/role/IndebtednessNarrativeDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillChangesinGoodwillDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails",
      "http://www.biogenidec.com/role/SharebasedPaymentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combination [Axis]",
        "label": "Business Combination [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r621",
      "r622",
      "r623",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r679",
      "r680",
      "r681",
      "r991",
      "r1177",
      "r1178",
      "r1601",
      "r1607",
      "r1609"
     ]
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessAcquisitionLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails",
      "http://www.biogenidec.com/role/AcquisitionsPurchasePriceConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combination [Line Items]",
        "label": "Business Combination [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r621",
      "r622",
      "r623",
      "r624",
      "r630",
      "r631",
      "r632",
      "r633",
      "r639",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r675",
      "r676",
      "r677",
      "r681",
      "r1182",
      "r1191",
      "r1601",
      "r1607",
      "r1609"
     ]
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisition related costs",
        "label": "Business Combination, Acquisition-Related Cost, Expense",
        "documentation": "Amount of expense for acquisition-related cost incurred to effect business combination. Includes, but is not limited to, finder's fee; advisory, legal, accounting, valuation, and other professional and consulting fees; and general administrative cost, including cost of maintaining internal acquisition department."
       }
      }
     },
     "auth_ref": [
      "r1598",
      "r1605"
     ]
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationConsiderationTransferred1",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/AcquisitionsPurchasePriceConsiderationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsPurchasePriceConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total consideration",
        "label": "Business Combination, Consideration Transferred",
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer."
       }
      }
     },
     "auth_ref": [
      "r665",
      "r677",
      "r1182",
      "r1187"
     ]
    },
    "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/AcquisitionsPurchasePriceConsiderationDetails": {
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsPurchasePriceConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration",
        "label": "Business Combination, Consideration Transferred, Liabilities Incurred",
        "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination."
       }
      }
     },
     "auth_ref": [
      "r668",
      "r1182",
      "r1187",
      "r1220"
     ]
    },
    "biib_BusinessCombinationConsiderationTransferredWorkingCapitalAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "BusinessCombinationConsiderationTransferredWorkingCapitalAdjustment",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Working capital adjustment",
        "label": "Business Combination, Consideration Transferred, Working Capital Adjustment",
        "documentation": "Business Combination, Consideration Transferred, Working Capital Adjustment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 7.0
      },
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combination, Contingent Consideration, Change in Contingent Consideration, Liability, Increase (Decrease)",
        "verboseLabel": "Contingent consideration",
        "label": "Business Combination, Contingent Consideration, Change in Contingent Consideration, Liability, Increase (Decrease)",
        "documentation": "Amount of increase (decrease) in value of liability in contingent consideration arrangement in business combination, including, but not limited to, difference arising upon settlement."
       }
      }
     },
     "auth_ref": [
      "r679",
      "r1463"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range of outcomes, value, high",
        "label": "Business Combination, Contingent Consideration, Range of Outcomes, Maximum, Amount",
        "documentation": "Maximum amount of estimate for undiscounted range of outcomes in contingent consideration arrangement in business combination."
       }
      }
     },
     "auth_ref": [
      "r672",
      "r677",
      "r1182",
      "r1188"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/FairValueMeasuresLevel3AssetsandLiabilitiesHeldatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration obligations",
        "label": "Business Combination, Contingent Consideration, Liability",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination."
       }
      }
     },
     "auth_ref": [
      "r670",
      "r677",
      "r780",
      "r781",
      "r782",
      "r1182",
      "r1188"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailAccruedExpenseandOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration obligations",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1613",
      "r1616"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.biogenidec.com/role/FairValueMeasuresLevel3AssetsandLiabilitiesHeldatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount rate",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "documentation": "Value of input used to measure liability in contingent consideration arrangement in business combination."
       }
      }
     },
     "auth_ref": [
      "r671",
      "r677",
      "r780",
      "r781",
      "r782",
      "r1182",
      "r1188"
     ]
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent consideration obligations",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1613",
      "r1616"
     ]
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationDisclosureTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/Acquisitions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquisitions",
        "label": "Business Combination [Text Block]",
        "documentation": "The entire disclosure for business combination."
       }
      }
     },
     "auth_ref": [
      "r620",
      "r621",
      "r625",
      "r634",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r645",
      "r646",
      "r652",
      "r655",
      "r656",
      "r662",
      "r663",
      "r664",
      "r672",
      "r676",
      "r677",
      "r678",
      "r680",
      "r682",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1188",
      "r1189",
      "r1190"
     ]
    },
    "biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liability, measurement period adjustment",
        "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Tax Liability",
        "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Deferred Tax Liability"
       }
      }
     },
     "auth_ref": []
    },
    "biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill, measurement period adjustment",
        "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Goodwill",
        "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Goodwill"
       }
      }
     },
     "auth_ref": []
    },
    "biib_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpenseAndOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpenseAndOther",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment, prepaid expense and other",
        "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Prepaid Expense And Other",
        "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Prepaid Expense And Other"
       }
      }
     },
     "auth_ref": []
    },
    "biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Accrued liabilities",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Liabilities",
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Accrued Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "label": "Business Combination, Recognized Asset Acquired, Cash and Cash Equivalent",
        "documentation": "Amount of cash and cash equivalent acquired in business combination and recognized at acquisition date."
       }
      }
     },
     "auth_ref": [
      "r1608",
      "r1610"
     ]
    },
    "biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Operating Lease Assets",
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Operating Lease Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expense and other assets(1)",
        "label": "Business Combination, Recognized Asset Acquired, Prepaid Expense and Other Asset, Current",
        "documentation": "Amount of prepaid expense and asset classified as other, acquired in business combination and recognized at acquisition date, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1608",
      "r1610"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Accounts payable",
        "label": "Business Combination, Recognized Liability Assumed, Accounts Payable, Current",
        "documentation": "Amount of accounts payable assumed in business combination and recognized at acquisition date, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1608",
      "r1610"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Deferred tax liabilities",
        "label": "Business Combination, Recognized Liability Assumed, Deferred Tax Liability",
        "documentation": "Amount of deferred tax liability assumed in business combination and recognized at acquisition date."
       }
      }
     },
     "auth_ref": [
      "r1608",
      "r1610"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets:",
        "label": "Business Combination, Recognized Asset Acquired, Identifiable Intangible Asset, Finite-Lived",
        "documentation": "Amount of identifiable finite-lived intangible asset acquired in business combination and recognized at acquisition date."
       }
      }
     },
     "auth_ref": [
      "r1608",
      "r1610"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory",
        "label": "Business Combination, Recognized Asset Acquired, Inventory, Current",
        "documentation": "Amount of inventory acquired in business combination and recognized at acquisition date, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1182",
      "r1187",
      "r1608",
      "r1610"
     ]
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total identifiable net assets",
        "label": "Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less)",
        "documentation": "Amount of asset acquired in excess of (less than) liability assumed in business combination and recognized at acquisition date. Excludes goodwill."
       }
      }
     },
     "auth_ref": [
      "r1182",
      "r1187",
      "r1608",
      "r1610"
     ]
    },
    "biib_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Operating lease liabilities",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Operating Lease Liabilities",
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Operating Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets acquired and liabilities assumed",
        "label": "Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less), and Goodwill",
        "documentation": "Amount of asset acquired in excess of (less than) liability assumed plus goodwill in business combination and recognized at acquisition date."
       }
      }
     },
     "auth_ref": [
      "r1608",
      "r1610"
     ]
    },
    "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationSeparatelyRecognizedTransactionsAxis",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherResearchandDiscoveryArrangementsandFundingArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combination, Separately Recognized Transaction [Axis]",
        "label": "Business Combination, Separately Recognized Transaction [Axis]",
        "documentation": "Information by transaction recognized separately from acquisition of asset and assumption of liability in business combination."
       }
      }
     },
     "auth_ref": [
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r639"
     ]
    },
    "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationSeparatelyRecognizedTransactionsDomain",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherResearchandDiscoveryArrangementsandFundingArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combination, Separately Recognized Transaction [Domain]",
        "label": "Business Combination, Separately Recognized Transaction [Domain]",
        "documentation": "Transaction recognized separately from acquisition of asset and assumption of liability in business combination."
       }
      }
     },
     "auth_ref": [
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r639"
     ]
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessCombinationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combination [Abstract]",
        "label": "Business Combination [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_BusinessOverviewPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "BusinessOverviewPolicyTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Business Overview",
        "label": "Business Overview [Policy Text Block]",
        "documentation": "Describes an overview of the company and its operations."
       }
      }
     },
     "auth_ref": []
    },
    "currency_CAD": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2025",
     "localname": "CAD",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsNotionalAmountofForeignCurrencyForwardContractsandForeignCurrencyOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Canadian dollar",
        "label": "Canada, Dollars"
       }
      }
     },
     "auth_ref": []
    },
    "currency_CHF": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2025",
     "localname": "CHF",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsNotionalAmountofForeignCurrencyForwardContractsandForeignCurrencyOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Swiss franc",
        "label": "Switzerland, Francs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash equivalents",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r802",
      "r803",
      "r804",
      "r1640",
      "r1641"
     ]
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstruments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Financial Instruments",
        "label": "Cash, Cash Equivalent, and Marketable Security [Text Block]",
        "documentation": "The entire disclosure of cash, cash equivalent, and debt and equity securities, including realized and unrealized gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r1493"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash and cash equivalents",
        "periodStartLabel": "Cash and cash equivalents, beginning of the period",
        "periodEndLabel": "Cash and cash equivalents, end of the period",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r100",
      "r244"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase (decrease) in cash and cash equivalents",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Excluding Exchange Rate Effect, Including Discontinued Operation",
        "documentation": "Amount, excluding effect from change in exchange rate, of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r100"
     ]
    },
    "us-gaap_CashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsSummaryoffinancialassetswithmaturitiesoflessthan90daysincludedwithincashandcashequivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash equivalents, at carrying value",
        "label": "Cash Equivalents, at Carrying Value",
        "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r1399",
      "r1684"
     ]
    },
    "us-gaap_CashFlowHedgingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashFlowHedgingMember",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsSummaryofFairValueandPresentationofDerivativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash Flow Hedging [Member]",
        "label": "Cash Flow Hedging [Member]",
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk."
       }
      }
     },
     "auth_ref": []
    },
    "biib_CashflowsoperatingexpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "CashflowsoperatingexpensesMember",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsEffectofForeignCurrencyForwardContractsandForwardCurrencyOptionsDesignatedasHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows, operating expenses",
        "label": "Cash flows, operating expenses [Member]",
        "documentation": "Cash flows, operating expenses [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_CashflowsrevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "CashflowsrevenueMember",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsEffectofForeignCurrencyForwardContractsandForwardCurrencyOptionsDesignatedasHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows, revenue",
        "label": "Cash flows, revenue [Member]",
        "documentation": "Cash flows, revenue [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1336"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year",
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1333"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested",
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r1331"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "biib_CityTherapeuticsInc.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "CityTherapeuticsInc.Member",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherResearchandDiscoveryArrangementsandFundingArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Therapeutics, Inc.",
        "label": "City Therapeutics, Inc. [Member]",
        "documentation": "City Therapeutics, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r204",
      "r205",
      "r206",
      "r300",
      "r501",
      "r508",
      "r509",
      "r510",
      "r512",
      "r515",
      "r520",
      "r522",
      "r759",
      "r994",
      "r995",
      "r996",
      "r997",
      "r1163",
      "r1375",
      "r1466",
      "r1468"
     ]
    },
    "biib_ClinicalInventoryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "ClinicalInventoryMember",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Clinical Inventory",
        "label": "Clinical Inventory [Member]",
        "documentation": "Clinical Inventory"
       }
      }
     },
     "auth_ref": []
    },
    "biib_CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCopromotionProfitSharingFormulaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Co promotion operating profit threshold to determine share of co promotion operating profit prior to amendment",
        "label": "Co Promotion Operating Profit Threshold To Determine Share Of Co Promotion Operating Profit Prior To Amendment",
        "documentation": "Co promotion operating profit threshold to determine share of co promotion operating profit prior to amendment."
       }
      }
     },
     "auth_ref": []
    },
    "biib_CoPromotionProfitSharingFormulaTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "CoPromotionProfitSharingFormulaTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Co Promotion Profit Sharing Formula",
        "label": "Co Promotion Profit Sharing Formula [Table Text Block]",
        "documentation": "Co-promotion profit sharing formula."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r1337"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r1337"
     ]
    },
    "biib_Collaborationexpensesaccrual": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "Collaborationexpensesaccrual",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailAccruedExpenseandOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration expense",
        "label": "Collaboration expenses accrual",
        "documentation": "Collaboration expenses accrual"
       }
      }
     },
     "auth_ref": []
    },
    "biib_Collaborationprofitlosssharing": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "Collaborationprofitlosssharing",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSageTherapeuticsIncDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration profit sharing/(loss reimbursement)",
        "label": "Collaboration profit (loss) sharing",
        "documentation": "Collaboration profit (loss) sharing"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationships"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Collaborative and Other Relationships",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r685",
      "r686"
     ]
    },
    "biib_CollaborativeArrangementExpectedDevelopmentCostFundsYearOne": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "CollaborativeArrangementExpectedDevelopmentCostFundsYearOne",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherResearchandDiscoveryArrangementsandFundingArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected receipts to co-fund development costs, current",
        "label": "Collaborative Arrangement, Expected Development Cost Funds, Year One",
        "documentation": "Collaborative Arrangement, Expected Development Cost Funds, Year One"
       }
      }
     },
     "auth_ref": []
    },
    "biib_CollaborativeArrangementExpectedDevelopmentCostFundsYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "CollaborativeArrangementExpectedDevelopmentCostFundsYearTwo",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherResearchandDiscoveryArrangementsandFundingArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected receipts to co-fund development costs, noncurrent",
        "label": "Collaborative Arrangement, Expected Development Cost Funds, Year Two",
        "documentation": "Collaborative Arrangement, Expected Development Cost Funds, Year Two"
       }
      }
     },
     "auth_ref": []
    },
    "biib_CollaborativeArrangementTermExtension": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "CollaborativeArrangementTermExtension",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration agreement term",
        "label": "Collaborative Arrangement, Term Extension",
        "documentation": "Collaborative Arrangement, Term Extension"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherResearchandDiscoveryArrangementsandFundingArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement",
        "label": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]",
        "documentation": "Collaborative arrangement transaction between parties to collaborative arrangement."
       }
      }
     },
     "auth_ref": [
      "r1624"
     ]
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCopromotionProfitSharingFormulaDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsIonisPharmaceuticalsIncDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherResearchandDiscoveryArrangementsandFundingArrangementsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsPretaxProfitSharingFormulaDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSageTherapeuticsIncDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsStokeTherapeuticsIncDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoLEQEMBICollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoStokeTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailAccruedExpenseandOtherDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative arrangements and non-collaborative arrangement transactions",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "biib_CollaborativeArrangementsInvestmentsInCounterparty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "CollaborativeArrangementsInvestmentsInCounterparty",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherResearchandDiscoveryArrangementsandFundingArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative arrangements, investments in counterparty",
        "label": "Collaborative Arrangements, Investments In Counterparty",
        "documentation": "Collaborative Arrangements, Investments In Counterparty"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommercialPaperMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommercialPaperMember",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsSummaryoffinancialassetswithmaturitiesoflessthan90daysincludedwithincashandcashequivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial Paper",
        "label": "Commercial Paper [Member]",
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r457",
      "r1282",
      "r1283",
      "r1284",
      "r1285"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Commitments, contingencies and guarantees",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r71",
      "r126",
      "r935",
      "r1023"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r1278",
      "r1279",
      "r1280",
      "r1282",
      "r1283",
      "r1284",
      "r1285",
      "r1477",
      "r1478",
      "r1482",
      "r1637",
      "r1719",
      "r1724"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock, par value (in dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance, shares",
        "periodEndLabel": "Ending balance, shares",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r74",
      "r1024",
      "r1043",
      "r1724",
      "r1725"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common stock, par value $0.0005 per share",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r499",
      "r505",
      "r937",
      "r1254"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1342"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1341"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1343"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1340"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive income (loss) attributable to Biogen Inc.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r220",
      "r222",
      "r228",
      "r918",
      "r949",
      "r950"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r1138"
     ]
    },
    "us-gaap_ConstructionPayableCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConstructionPayableCurrentAndNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailAccruedExpenseandOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative liabilities",
        "label": "Construction Payable",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for the acquisition of merchandise, materials, supplies and services pertaining to construction projects such as a housing development or factory expansion not classified as trade payables."
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "biib_ContingentCommercializedRightsNumberOfProducts": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "ContingentCommercializedRightsNumberOfProducts",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent Commercialized Rights, Number Of Products",
        "label": "Contingent Commercialized Rights, Number Of Products",
        "documentation": "Contingent Commercialized Rights, Number Of Products"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContingentConsiderationByTypeAxis",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherResearchandDiscoveryArrangementsandFundingArrangementsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsStokeTherapeuticsIncDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combination, Contingent Consideration, Type [Axis]",
        "label": "Business Combination, Contingent Consideration, Type [Axis]",
        "documentation": "Information by type of contingent consideration arrangement in business combination."
       }
      }
     },
     "auth_ref": [
      "r1613",
      "r1614",
      "r1615",
      "r1616",
      "r1617",
      "r1618"
     ]
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContingentConsiderationTypeDomain",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherResearchandDiscoveryArrangementsandFundingArrangementsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsStokeTherapeuticsIncDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combination, Contingent Consideration, Type [Domain]",
        "label": "Business Combination, Contingent Consideration, Type [Domain]",
        "documentation": "Type of contingent consideration arrangement in business combination."
       }
      }
     },
     "auth_ref": [
      "r1613",
      "r1614",
      "r1615",
      "r1616",
      "r1617",
      "r1618"
     ]
    },
    "biib_ContractManufacturingAndOtherRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "ContractManufacturingAndOtherRevenueMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract manufacturing revenue",
        "label": "Contract manufacturing and other revenue [Member]",
        "documentation": "Other corporate revenues [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_ContractOptionExerciseFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "ContractOptionExerciseFee",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option exercise fee",
        "label": "Contract Option Exercise Fee",
        "documentation": "Contract Option Exercise Fee"
       }
      }
     },
     "auth_ref": []
    },
    "biib_ContractualAdjustmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "ContractualAdjustmentsMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractual adjustments",
        "label": "Contractual Adjustments [Member]",
        "documentation": "Contractual adjustments."
       }
      }
     },
     "auth_ref": []
    },
    "biib_ConvergenceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "ConvergenceMember",
     "presentation": [
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convergence",
        "label": "Convergence [Member]",
        "documentation": "Convergence"
       }
      }
     },
     "auth_ref": []
    },
    "biib_CorporateDebtSecuritiesCurrentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "CorporateDebtSecuritiesCurrentMember",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsMarketabledebtandequitysecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate Debt Securities Current",
        "label": "Corporate Debt Securities Current [Member]",
        "documentation": "Corporate debt securities Current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CorporateDebtSecuritiesMember",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate Debt Securities [Member]",
        "label": "Corporate Debt Securities [Member]",
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": [
      "r1172",
      "r1174",
      "r1176",
      "r1241",
      "r1255",
      "r1276",
      "r1716"
     ]
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.biogenidec.com/role/SegmentInformationAdditionalSegmentInformationDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails",
      "http://www.biogenidec.com/role/SegmentInformationAdditionalSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of sales, excluding amortization and impairment of acquired intangible assets",
        "label": "Cost of Product and Service Sold",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r88",
      "r89",
      "r877",
      "r1132",
      "r1137",
      "r1226",
      "r1455"
     ]
    },
    "us-gaap_CostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total cost and expense",
        "label": "Costs and Expenses",
        "documentation": "Total costs of sales and operating expenses for the period."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CostsAndExpensesAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cost and expenses:",
        "label": "Costs and Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherResearchandDiscoveryArrangementsandFundingArrangementsDetails",
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]",
        "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r182",
      "r247",
      "r256",
      "r257",
      "r471",
      "r510",
      "r840",
      "r860",
      "r930",
      "r1126",
      "r1128",
      "r1129",
      "r1401",
      "r1402",
      "r1403",
      "r1404",
      "r1405",
      "r1406",
      "r1407",
      "r1408",
      "r1409",
      "r1630",
      "r1631",
      "r1632",
      "r1633"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CreditFacilityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CreditFacilityAxis",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Axis]",
        "label": "Credit Facility [Axis]",
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r457",
      "r1551"
     ]
    },
    "us-gaap_CreditFacilityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CreditFacilityDomain",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility [Domain]",
        "label": "Credit Facility [Domain]",
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing."
       }
      }
     },
     "auth_ref": [
      "r457",
      "r1551"
     ]
    },
    "srt_CurrencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "CurrencyAxis",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsNotionalAmountofForeignCurrencyForwardContractsandForeignCurrencyOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Currency [Axis]",
        "label": "Currency [Axis]",
        "documentation": "Information by currency."
       }
      }
     },
     "auth_ref": [
      "r1662"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "biib_CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Provisions Relating To Sales In Current Year",
        "label": "Current Provisions To Product Revenue Reserves Relating To Sales In Current Year",
        "documentation": "Current provisions to product revenue reserves relating to sales in current year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Disclosure [Abstract]",
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/Indebtedness"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indebtedness",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r247",
      "r250",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r456",
      "r457",
      "r467",
      "r473",
      "r474",
      "r475",
      "r476",
      "r477",
      "r478",
      "r483",
      "r490",
      "r491",
      "r493",
      "r759",
      "r824"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDebtInstrumentsDetails",
      "http://www.biogenidec.com/role/IndebtednessNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Axis]",
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r64",
      "r65",
      "r122",
      "r125",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r474",
      "r479",
      "r480",
      "r481",
      "r482",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r1157",
      "r1158",
      "r1159",
      "r1160",
      "r1161",
      "r1253",
      "r1466",
      "r1467",
      "r1469",
      "r1476",
      "r1539",
      "r1540",
      "r1541",
      "r1663",
      "r1664",
      "r1678"
     ]
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentCarryingAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term debt, gross",
        "label": "Long-Term Debt, Gross",
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r125",
      "r494"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Face Amount",
        "label": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r468",
      "r824",
      "r825",
      "r1158",
      "r1159",
      "r1253"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDebtInstrumentsDetails",
      "http://www.biogenidec.com/role/IndebtednessNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, interest rate, stated percentage",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r469"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDebtInstrumentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.biogenidec.com/role/IndebtednessNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Line Items]",
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r474",
      "r479",
      "r480",
      "r481",
      "r482",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r492",
      "r759",
      "r924",
      "r1157",
      "r1158",
      "r1159",
      "r1160",
      "r1161",
      "r1253",
      "r1466",
      "r1467",
      "r1469",
      "r1476",
      "r1663",
      "r1664"
     ]
    },
    "biib_DebtInstrumentMakeWholeProvisionRedemptionPricePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "DebtInstrumentMakeWholeProvisionRedemptionPricePercentage",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, make whole provision redemption price, percentage",
        "label": "Debt Instrument, Make Whole Provision Redemption Price, Percentage",
        "documentation": "Debt Instrument, Make Whole Provision Redemption Price, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDebtInstrumentsDetails",
      "http://www.biogenidec.com/role/IndebtednessNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Name [Domain]",
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r474",
      "r479",
      "r480",
      "r481",
      "r482",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r1157",
      "r1158",
      "r1159",
      "r1160",
      "r1161",
      "r1253",
      "r1466",
      "r1467",
      "r1469",
      "r1476",
      "r1539",
      "r1540",
      "r1541",
      "r1663",
      "r1664",
      "r1678"
     ]
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument, redemption price, percentage",
        "label": "Debt Instrument, Redemption Price, Percentage",
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer."
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDebtInstrumentsDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.biogenidec.com/role/IndebtednessNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r40",
      "r43",
      "r51",
      "r116",
      "r117",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472",
      "r474",
      "r479",
      "r480",
      "r481",
      "r482",
      "r484",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r492",
      "r759",
      "r924",
      "r1157",
      "r1158",
      "r1159",
      "r1160",
      "r1161",
      "r1253",
      "r1466",
      "r1467",
      "r1469",
      "r1476",
      "r1663",
      "r1664"
     ]
    },
    "biib_DebtSecuritiesAvailableForSaleAverageMaturity": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "DebtSecuritiesAvailableForSaleAverageMaturity",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Average maturity of our marketable debt securities classified as available-for-sale",
        "label": "Debt Securities, Available-for-Sale, Average Maturity",
        "documentation": "Debt Securities, Available-for-Sale, Average Maturity"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable debt and equity securities",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r1495",
      "r1496",
      "r1497",
      "r1498",
      "r1499",
      "r1500",
      "r1501",
      "r1502",
      "r1503",
      "r1504",
      "r1505",
      "r1506"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableforsaleAmortizedCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableforsaleAmortizedCostAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsMarketabledebtandequitysecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-Sale, Amortized Cost [Abstract]",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesMember",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsSummaryoffinancialassetswithmaturitiesoflessthan90daysincludedwithincashandcashequivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term debt securities",
        "label": "Debt Securities [Member]",
        "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r1280",
      "r1727"
     ]
    },
    "us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesTradingAndEquitySecuritiesFvNiCostAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsMarketabledebtandequitysecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Trading, and Equity Securities, FV-NI, Cost [Abstract]",
        "label": "Debt Securities, Trading, and Equity Securities, FV-NI, Cost [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Decrease in unrecognized tax benefits is reasonably possible",
        "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible",
        "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit."
       }
      }
     },
     "auth_ref": [
      "r135"
     ]
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax asset",
        "label": "Deferred Income Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r591",
      "r592"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income taxes",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r144",
      "r1466",
      "r1472"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred tax liability",
        "label": "Deferred Income Tax Liabilities, Net",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r591",
      "r592",
      "r933"
     ]
    },
    "biib_DenaliTherapeuticsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "DenaliTherapeuticsIncMember",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Denali Therapeutics",
        "label": "Denali Therapeutics Inc [Member]",
        "documentation": "Denali Therapeutics Inc"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r33",
      "r236",
      "r1131",
      "r1132",
      "r1134",
      "r1136"
     ]
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r238",
      "r298",
      "r315",
      "r333",
      "r1131",
      "r1148",
      "r1149"
     ]
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeContractTypeDomain",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsEffectofForeignCurrencyForwardContractsandForwardCurrencyOptionsDesignatedasHedgingInstrumentsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsNotionalAmountofForeignCurrencyForwardContractsandForeignCurrencyOptionsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsSummaryofFairValueandPresentationofDerivativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Contract [Domain]",
        "label": "Derivative Contract [Domain]",
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r707",
      "r709",
      "r710",
      "r713",
      "r714",
      "r715",
      "r716",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r1012",
      "r1015",
      "r1029",
      "r1030",
      "r1031",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1081",
      "r1082",
      "r1084",
      "r1085",
      "r1125",
      "r1126",
      "r1129",
      "r1236",
      "r1237",
      "r1278",
      "r1280",
      "r1401",
      "r1402",
      "r1403",
      "r1404",
      "r1405",
      "r1406",
      "r1407",
      "r1408",
      "r1409",
      "r1630",
      "r1631",
      "r1632",
      "r1633",
      "r1645",
      "r1646",
      "r1647",
      "r1648",
      "r1649",
      "r1650",
      "r1652",
      "r1653"
     ]
    },
    "us-gaap_DerivativeFairValueOfDerivativeAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeFairValueOfDerivativeAsset",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsSummaryofFairValueandPresentationofDerivativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative asset, fair value",
        "label": "Derivative Asset, Subject to Master Netting Arrangement, before Offset",
        "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r212",
      "r758",
      "r1125",
      "r1127",
      "r1128",
      "r1129"
     ]
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsSummaryofFairValueandPresentationofDerivativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative liability, fair value",
        "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset",
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r212",
      "r758",
      "r1125",
      "r1127",
      "r1128",
      "r1129"
     ]
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeInstrumentRiskAxis",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsEffectofForeignCurrencyForwardContractsandForwardCurrencyOptionsDesignatedasHedgingInstrumentsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsNotionalAmountofForeignCurrencyForwardContractsandForeignCurrencyOptionsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsSummaryofFairValueandPresentationofDerivativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Instrument [Axis]",
        "label": "Derivative Instrument [Axis]",
        "documentation": "Information by type of derivative contract."
       }
      }
     },
     "auth_ref": [
      "r232",
      "r707",
      "r709",
      "r710",
      "r713",
      "r714",
      "r715",
      "r716",
      "r718",
      "r719",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r729",
      "r730",
      "r731",
      "r732",
      "r733",
      "r734",
      "r1012",
      "r1015",
      "r1029",
      "r1030",
      "r1031",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1081",
      "r1082",
      "r1084",
      "r1085",
      "r1125",
      "r1126",
      "r1129",
      "r1236",
      "r1237",
      "r1278",
      "r1280",
      "r1401",
      "r1402",
      "r1403",
      "r1404",
      "r1405",
      "r1406",
      "r1407",
      "r1408",
      "r1409",
      "r1630",
      "r1631",
      "r1632",
      "r1633",
      "r1645",
      "r1646",
      "r1647",
      "r1648",
      "r1649",
      "r1650",
      "r1652",
      "r1653"
     ]
    },
    "us-gaap_DerivativeInstrumentsAndHedgesLiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeInstrumentsAndHedgesLiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current liabilities:",
        "label": "Derivative Instruments and Hedges, Liabilities, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstruments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Derivative Instruments",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts."
       }
      }
     },
     "auth_ref": [
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r760",
      "r771",
      "r1236",
      "r1237",
      "r1238",
      "r1239",
      "r1240"
     ]
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsEffectofForeignCurrencyForwardContractsandForwardCurrencyOptionsDesignatedasHedgingInstrumentsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsSummaryofFairValueandPresentationofDerivativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedging Relationship [Axis]",
        "label": "Hedging Relationship [Axis]",
        "documentation": "Information by type of hedging relationship."
       }
      }
     },
     "auth_ref": []
    },
    "biib_DerivativeInstrumentsUnrealizedGainLossTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "DerivativeInstrumentsUnrealizedGainLossTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative Instruments, Unrealized Gain (Loss)",
        "label": "Derivative Instruments, Unrealized Gain (Loss) [Table Text Block]",
        "documentation": "Derivative Instruments, Unrealized Gain (Loss)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeLiabilitiesAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current liabilities:",
        "label": "Derivative Liability [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative contracts",
        "label": "Derivative Liability, Current",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r213"
     ]
    },
    "us-gaap_DerivativeLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeLiabilitiesNoncurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative contracts",
        "label": "Derivative Liability, Noncurrent",
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset."
       }
      }
     },
     "auth_ref": [
      "r213"
     ]
    },
    "us-gaap_DerivativeLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsSummaryofFairValueandPresentationofDerivativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative [Line Items]",
        "label": "Derivative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r771",
      "r1634"
     ]
    },
    "us-gaap_DerivativeNotionalAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeNotionalAmount",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsNotionalAmountofForeignCurrencyForwardContractsandForeignCurrencyOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative, notional amount",
        "verboseLabel": "Total foreign currency forward contracts and options",
        "label": "Derivative, Notional Amount",
        "documentation": "Nominal or face amount used to calculate payment on derivative."
       }
      }
     },
     "auth_ref": [
      "r1236",
      "r1625",
      "r1626"
     ]
    },
    "us-gaap_DerivativeRemainingMaturity1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeRemainingMaturity1",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative, remaining maturity",
        "label": "Derivative, Remaining Maturity",
        "documentation": "Period remaining until the derivative contract matures, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DerivativeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativeTable",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsSummaryofFairValueandPresentationofDerivativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative [Table]",
        "label": "Derivative [Table]",
        "documentation": "Disclosure of information about derivative instrument or group of derivative instruments, including, but not limited to, type of derivative instrument, risk being hedged, notional amount, hedge designation, related hedged item, inception date, and maturity date."
       }
      }
     },
     "auth_ref": [
      "r771",
      "r1634"
     ]
    },
    "us-gaap_DerivativesFairValueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DerivativesFairValueLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsEffectofForeignCurrencyForwardContractsandForwardCurrencyOptionsDesignatedasHedgingInstrumentsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsNotionalAmountofForeignCurrencyForwardContractsandForeignCurrencyOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivatives [Line Items]",
        "label": "Derivatives, Fair Value [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r707",
      "r713",
      "r714",
      "r715",
      "r716",
      "r1237"
     ]
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DesignatedAsHedgingInstrumentMember",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsNotionalAmountofForeignCurrencyForwardContractsandForeignCurrencyOptionsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsSummaryofFairValueandPresentationofDerivativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Designated as Hedging Instrument",
        "label": "Designated as Hedging Instrument [Member]",
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DilutiveSecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DilutiveSecuritiesAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Effect of dilutive securities:",
        "label": "Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisaggregationOfRevenueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisaggregationOfRevenueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Abstract]",
        "label": "Disaggregation of Revenue [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Line Items]",
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r532",
      "r533",
      "r1165",
      "r1166",
      "r1167",
      "r1168",
      "r1169",
      "r1170",
      "r1171"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Table]",
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r532",
      "r533",
      "r1165",
      "r1166",
      "r1167",
      "r1168",
      "r1169",
      "r1170",
      "r1171"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues by product",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r1556"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/SharebasedPayments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share-based Payments",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r549",
      "r552",
      "r582",
      "r583",
      "r584",
      "r1180"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement [Abstract]",
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/Dispositions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dispositions",
        "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]",
        "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r105"
     ]
    },
    "biib_DistributorOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "DistributorOneMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Distributor One",
        "label": "Distributor One [Member]",
        "documentation": "Distributor one."
       }
      }
     },
     "auth_ref": []
    },
    "biib_DistributorTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "DistributorTwoMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Distributor Two",
        "label": "Distributor Two [Member]",
        "documentation": "Distributor two."
       }
      }
     },
     "auth_ref": []
    },
    "biib_DivestituresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "DivestituresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Divestitures [Abstract]",
        "label": "Divestitures [Abstract]",
        "documentation": "Divestitures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Quarterly Report",
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r1292"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r1324"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year",
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1335"
     ]
    },
    "biib_E2609andBAN2401Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "E2609andBAN2401Member",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoLEQEMBICollaborationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "E2609 and BAN2401",
        "label": "E2609 and BAN2401 [Member]",
        "documentation": "E2609 and BAN2401 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "currency_EUR": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2025",
     "localname": "EUR",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsNotionalAmountofForeignCurrencyForwardContractsandForeignCurrencyOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Euro",
        "label": "Euro Member Countries, Euro"
       }
      }
     },
     "auth_ref": []
    },
    "biib_EarlyStageProgramsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "EarlyStageProgramsMember",
     "presentation": [
      "http://www.biogenidec.com/role/SegmentInformationAdditionalSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Early stage programs",
        "label": "Early Stage Programs [Member]",
        "documentation": "Early Stage Programs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net income per share:",
        "terseLabel": "Earnings Per Share [Abstract]",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basic earnings per share attributable to Biogen Inc. (in USD per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r229",
      "r269",
      "r270",
      "r271",
      "r272",
      "r274",
      "r275",
      "r276",
      "r278",
      "r284",
      "r286",
      "r291",
      "r292",
      "r293",
      "r297",
      "r497",
      "r585",
      "r618",
      "r684",
      "r775",
      "r776",
      "r919",
      "r951",
      "r1139"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Diluted earnings per share attributable to Biogen Inc. (in USD per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r229",
      "r269",
      "r270",
      "r271",
      "r272",
      "r274",
      "r275",
      "r276",
      "r278",
      "r286",
      "r291",
      "r292",
      "r293",
      "r297",
      "r497",
      "r585",
      "r618",
      "r684",
      "r775",
      "r776",
      "r919",
      "r951",
      "r1139"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Earnings per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r283",
      "r294",
      "r295",
      "r296"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of exchange rate changes on cash and cash equivalents",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "documentation": "Amount of increase (decrease) from effect of exchange rate change on cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; held in foreign currency; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r814"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Effective tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r594",
      "r1181"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Reconciliation between the U.S. federal statutory tax rate and effective tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Statutory rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r247",
      "r253",
      "r594",
      "r608",
      "r1181"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Taxes on foreign earnings, including valuation allowances",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile."
       }
      }
     },
     "auth_ref": [
      "r595",
      "r598",
      "r1181",
      "r1466",
      "r1473",
      "r1590"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationGiltiPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationGiltiPercent",
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GILTI",
        "label": "Effective Income Tax Rate Reconciliation, GILTI, Percent",
        "documentation": "Percentage of reported income tax expense from difference to expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to global intangible low-taxed income (GILTI)."
       }
      }
     },
     "auth_ref": [
      "r1181",
      "r1590",
      "r1592"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization",
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Purchased inventory valuation step-up and intangible assets",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Depreciation and Amortization, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to depreciation and amortization."
       }
      }
     },
     "auth_ref": [
      "r1466",
      "r1473",
      "r1590",
      "r1592"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other, including permanent items",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r1181",
      "r1466",
      "r1473",
      "r1590",
      "r1591"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "State taxes",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r597",
      "r1181",
      "r1466",
      "r1473",
      "r1590"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Tax credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits."
       }
      }
     },
     "auth_ref": [
      "r599",
      "r600",
      "r1466",
      "r1473",
      "r1590"
     ]
    },
    "biib_EffectiveTaxRateReconciliationOneBigBeautifulBillActEnactment": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "EffectiveTaxRateReconciliationOneBigBeautifulBillActEnactment",
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OBBBA enactment",
        "label": "Effective Tax Rate Reconciliation, One Big Beautiful Bill Act Enactment",
        "documentation": "Effective Tax Rate Reconciliation, One Big Beautiful Bill Act Enactment"
       }
      }
     },
     "auth_ref": []
    },
    "biib_EffectiveTaxRateReconciliationShareBasedCompensationAwards": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "EffectiveTaxRateReconciliationShareBasedCompensationAwards",
     "calculation": {
      "http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation awards",
        "label": "Effective Tax Rate Reconciliation, Share-Based Compensation Awards",
        "documentation": "Effective Tax Rate Reconciliation, Share-Based Compensation Awards"
       }
      }
     },
     "auth_ref": []
    },
    "biib_EisaiMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "EisaiMember",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoLEQEMBICollaborationDetails",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Eisai",
        "label": "Eisai [Member]",
        "documentation": "Eisai [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailAccruedExpenseandOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee compensation and benefits",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails": {
       "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Capitalized share-based compensation costs",
        "label": "Share-Based Payment Arrangement, Amount Capitalized",
        "documentation": "Amount of cost capitalized for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r581"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails",
      "http://www.biogenidec.com/role/SharebasedPaymentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r1586"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Income tax effect",
        "label": "Share-Based Payment Arrangement, Expense, Tax Benefit",
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r580"
     ]
    },
    "us-gaap_EmployeeSeveranceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeSeveranceMember",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Severance Costs",
        "label": "Employee Severance [Member]",
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r1560",
      "r1561",
      "r1562",
      "r1563",
      "r1564",
      "r1565",
      "r1566",
      "r1567",
      "r1568",
      "r1569",
      "r1570",
      "r1571",
      "r1572",
      "r1573",
      "r1574",
      "r1575",
      "r1576",
      "r1577",
      "r1578",
      "r1579",
      "r1580",
      "r1581",
      "r1582",
      "r1583",
      "r1584",
      "r1585"
     ]
    },
    "biib_EmployeeStockPurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "EmployeeStockPurchasePlanMember",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Employee stock purchase plan",
        "label": "Employee Stock Purchase Plan [Member]",
        "documentation": "Employee stock purchase plan."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1290"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity [Domain]",
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1290"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r1290"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r1374"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1290"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r1290"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r1290"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1290"
     ]
    },
    "biib_EntityWidePercentageOfRevenueFromMajorDistributors": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "EntityWidePercentageOfRevenueFromMajorDistributors",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of revenues from major distributors",
        "label": "Entity Wide Percentage Of Revenue From Major Distributors",
        "documentation": "Entity wide percentage of revenue from major distributors."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Footnote",
        "label": "Equity Awards Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1329"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table",
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r1370"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments",
        "label": "Equity Awards Adjustments [Member]"
       }
      }
     },
     "auth_ref": [
      "r1370"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table",
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r1370"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity [Abstract]",
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/EquityReclassifiedFromAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r187",
      "r189",
      "r190",
      "r223",
      "r224",
      "r225",
      "r264",
      "r265",
      "r266",
      "r268",
      "r276",
      "r279",
      "r281",
      "r299",
      "r379",
      "r382",
      "r425",
      "r496",
      "r523",
      "r585",
      "r606",
      "r607",
      "r615",
      "r616",
      "r617",
      "r619",
      "r683",
      "r684",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r774",
      "r815",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r826",
      "r829",
      "r836",
      "r947",
      "r979",
      "r980",
      "r981",
      "r1002",
      "r1063"
     ]
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment, Name [Domain]",
        "label": "Investment, Name [Domain]",
        "documentation": "Name of investment including named security. Excludes entity that is consolidated."
       }
      }
     },
     "auth_ref": [
      "r375",
      "r376",
      "r377",
      "r614",
      "r806",
      "r1377",
      "r1378",
      "r1379",
      "r1593",
      "r1594",
      "r1595",
      "r1596"
     ]
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity, ownership interest",
        "label": "Equity Method Investment, Ownership Percentage",
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r375",
      "r806"
     ]
    },
    "us-gaap_EquityMethodInvestmentSoldCarryingAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestmentSoldCarryingAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Method Investment, Amount Sold",
        "label": "Equity Method Investment, Amount Sold",
        "documentation": "Amount of the entity's equity method investment which has been sold."
       }
      }
     },
     "auth_ref": []
    },
    "biib_EquityMethodInvestmentsExpectedProfitShare": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "EquityMethodInvestmentsExpectedProfitShare",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected profit share percentage",
        "label": "Equity Method Investments, Expected Profit Share",
        "documentation": "Equity Method Investments, Expected Profit Share"
       }
      }
     },
     "auth_ref": []
    },
    "biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsMarketabledebtandequitysecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Unrealized Gains",
        "label": "Equity Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Equity Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax"
       }
      }
     },
     "auth_ref": []
    },
    "biib_EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsMarketabledebtandequitysecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Gross Unrealized Losses",
        "label": "Equity Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax",
        "documentation": "Equity Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Before Tax"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquitySecuritiesFvNi",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsMarketabledebtandequitysecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "label": "Equity Securities, FV-NI, Current",
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r801",
      "r1120"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquitySecuritiesFvNiCost",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsMarketabledebtandequitysecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortized Cost",
        "label": "Equity Securities, FV-NI, Cost",
        "documentation": "Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value."
       }
      }
     },
     "auth_ref": [
      "r931"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquitySecuritiesFvNiGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailGainsLossesonInvestmentsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net (gains) losses recognized on equity securities",
        "label": "Equity Securities, FV-NI, Gain (Loss)",
        "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r955",
      "r1510"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquitySecuritiesFvNiRealizedGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailGainsLossesonInvestmentsNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less: Net (gains) losses realized on equity securities",
        "label": "Equity Securities, FV-NI, Realized Gain (Loss)",
        "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r953",
      "r1510"
     ]
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailGainsLossesonInvestmentsNetDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net unrealized (gains) losses recognized on equity securities",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r954",
      "r1510"
     ]
    },
    "biib_EquitySecuritiesNonCurrentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "EquitySecuritiesNonCurrentMember",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsMarketabledebtandequitysecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Securities, Non-Current",
        "label": "Equity Securities, Non-Current [Member]",
        "documentation": "Equity Securities, Non-Current"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1339"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1297",
      "r1307",
      "r1317",
      "r1349"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r1294",
      "r1304",
      "r1314",
      "r1346"
     ]
    },
    "biib_EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsIonisPharmaceuticalsIncDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherResearchandDiscoveryArrangementsandFundingArrangementsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsStokeTherapeuticsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated additional payments upon achievement of development and commercial milestones",
        "label": "Estimated Additional Payments Upon Achievement Of Development And Commercial Milestones",
        "documentation": "Estimated additional payments upon achievement of development and commercial milestones."
       }
      }
     },
     "auth_ref": []
    },
    "biib_EstimatedAdditionalPaymentsUponInitiationOfNewPhases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "EstimatedAdditionalPaymentsUponInitiationOfNewPhases",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsIonisPharmaceuticalsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated additional payments upon initiation of new phases",
        "label": "Estimated Additional Payments Upon Initiation Of New Phases",
        "documentation": "Estimated Additional Payments Upon Initiation Of New Phases"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1345"
     ]
    },
    "biib_ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsIonisPharmaceuticalsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected additional milestone payments when meeting certain sales threshold",
        "label": "Expected Additional Milestone Payments When Meeting Certain Sales Threshold",
        "documentation": "Expected Additional Milestone Payments When Meeting Certain Sales Threshold"
       }
      }
     },
     "auth_ref": []
    },
    "biib_ExpenseIncurredByCollaboration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "ExpenseIncurredByCollaboration",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoLEQEMBICollaborationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total development expense incurred by the collaboration related to the advancement of LEQEMBI",
        "label": "Expense Incurred By Collaboration",
        "documentation": "Total expense incurred by collaboration."
       }
      }
     },
     "auth_ref": []
    },
    "biib_Expenseincurredbythecollaboration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "Expenseincurredbythecollaboration",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoLEQEMBICollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoStokeTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expense incurred by the collaboration",
        "label": "Expense incurred by the collaboration",
        "documentation": "Expense incurred by the collaboration"
       }
      }
     },
     "auth_ref": []
    },
    "biib_Expensereflectedwithinstatementsofincome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "Expensereflectedwithinstatementsofincome",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoLEQEMBICollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoStokeTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expense reflected within statements of income",
        "label": "Expense reflected within statements of income",
        "documentation": "Expense reflected within statements of income"
       }
      }
     },
     "auth_ref": []
    },
    "biib_FAMPYRAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "FAMPYRAMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FAMPYRA",
        "label": "FAMPYRA [Member]",
        "documentation": "FAMPYRA [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_FLIXABIMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "FLIXABIMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FLIXABI",
        "label": "FLIXABI [Member]",
        "documentation": "FLIXABI [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_FUMADERMAndADUHELMMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "FUMADERMAndADUHELMMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FUMADERM And ADUHELM",
        "label": "FUMADERM And ADUHELM [Member]",
        "documentation": "FUMADERM And ADUHELM"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAdjustmentToInventoryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAdjustmentToInventoryMember",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combination, Pro Forma Information, Nonrecurring Adjustment, Inventory, Fair Value Adjustment",
        "label": "Business Combination, Pro Forma Information, Nonrecurring Adjustment, Inventory, Fair Value Adjustment [Member]",
        "documentation": "Nonrecurring fair value adjustment for inventory at acquisition date attributable to business combination included in reported pro forma earnings."
       }
      }
     },
     "auth_ref": [
      "r1182",
      "r1192",
      "r1602",
      "r1603"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of assets and liabilities recorded at fair value",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r778",
      "r779",
      "r793",
      "r1241"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r778",
      "r779",
      "r793",
      "r1241"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasuresLevel3AssetsandLiabilitiesHeldatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r780",
      "r781",
      "r782",
      "r1182",
      "r1188",
      "r1245"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasuresLevel3AssetsandLiabilitiesHeldatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r780",
      "r781",
      "r782",
      "r1182",
      "r1188",
      "r1245"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r780",
      "r781",
      "r1245"
     ]
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Class [Domain]",
        "label": "Asset Class [Domain]",
        "documentation": "Class of asset."
       }
      }
     },
     "auth_ref": [
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r794",
      "r1115",
      "r1243",
      "r1252"
     ]
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByAssetClassAxis",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Class [Axis]",
        "label": "Asset Class [Axis]",
        "documentation": "Information by class of asset."
       }
      }
     },
     "auth_ref": [
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r794",
      "r1115",
      "r1243",
      "r1252"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails",
      "http://www.biogenidec.com/role/FairValueMeasuresLevel3AssetsandLiabilitiesHeldatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r481",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r543",
      "r544",
      "r777",
      "r779",
      "r780",
      "r781",
      "r782",
      "r791",
      "r793",
      "r795",
      "r802",
      "r847",
      "r848",
      "r849",
      "r1115",
      "r1158",
      "r1159",
      "r1172",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1241",
      "r1245",
      "r1252"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Axis]",
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r778",
      "r779",
      "r780",
      "r782",
      "r1241",
      "r1643",
      "r1654"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Disclosures [Abstract]",
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fair Value Measurements",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r780",
      "r787",
      "r789",
      "r790",
      "r791",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r914",
      "r1241",
      "r1246"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Quoted Prices in Active Markets (Level 1)",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r481",
      "r536",
      "r541",
      "r543",
      "r779",
      "r793",
      "r802",
      "r847",
      "r1115",
      "r1172",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1241",
      "r1252"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Significant Other Observable Inputs (Level 2)",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r481",
      "r536",
      "r541",
      "r543",
      "r545",
      "r779",
      "r780",
      "r793",
      "r802",
      "r848",
      "r1115",
      "r1158",
      "r1159",
      "r1172",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1241",
      "r1252"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails",
      "http://www.biogenidec.com/role/FairValueMeasuresLevel3AssetsandLiabilitiesHeldatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Significant Unobservable Inputs (Level 3)",
        "terseLabel": "Fair Value, Inputs, Level 3 [Member]",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r481",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r543",
      "r544",
      "r779",
      "r780",
      "r781",
      "r782",
      "r793",
      "r802",
      "r849",
      "r1115",
      "r1158",
      "r1159",
      "r1172",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1241",
      "r1245",
      "r1252"
     ]
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsContingentConsiderationObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combination, Contingent Consideration, Liability [Roll Forward]",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability."
       }
      }
     },
     "auth_ref": [
      "r783",
      "r788",
      "r794"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Domain]",
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r778",
      "r779",
      "r780",
      "r782",
      "r1241",
      "r1643",
      "r1654"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsContingentConsiderationObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Settlements",
        "documentation": "Amount of settlement of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r786",
      "r794",
      "r1243"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsContingentConsiderationObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in fair value",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)."
       }
      }
     },
     "auth_ref": [
      "r784",
      "r794"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsContingentConsiderationObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Contingent consideration resulting from HI-Bio acquisition",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases",
        "documentation": "Amount of purchases of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r786",
      "r792",
      "r794"
     ]
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsContingentConsiderationObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Fair value, beginning of period",
        "periodEndLabel": "Fair value, end of period",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r783",
      "r794"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails",
      "http://www.biogenidec.com/role/FairValueMeasuresLevel3AssetsandLiabilitiesHeldatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r481",
      "r536",
      "r537",
      "r538",
      "r539",
      "r540",
      "r541",
      "r543",
      "r544",
      "r777",
      "r779",
      "r780",
      "r781",
      "r782",
      "r791",
      "r793",
      "r795",
      "r802",
      "r847",
      "r848",
      "r849",
      "r1115",
      "r1158",
      "r1159",
      "r1172",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1241",
      "r1245",
      "r1252"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Fair Value, Measurements Recurring",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r1241",
      "r1640",
      "r1641",
      "r1642",
      "r1643",
      "r1644",
      "r1654"
     ]
    },
    "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsEffectofForeignCurrencyForwardContractsandForwardCurrencyOptionsDesignatedasHedgingInstrumentsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsNotionalAmountofForeignCurrencyForwardContractsandForeignCurrencyOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]",
        "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]",
        "documentation": "Disclosure of information about location and fair value of derivative instrument and nonderivative instrument designated as hedging instrument."
       }
      }
     },
     "auth_ref": [
      "r707",
      "r713",
      "r714",
      "r715",
      "r716",
      "r1237"
     ]
    },
    "biib_FelzartamabAMRMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "FelzartamabAMRMember",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Felzartamab (AMR)",
        "label": "Felzartamab (AMR) [Member]",
        "documentation": "Felzartamab (AMR)"
       }
      }
     },
     "auth_ref": []
    },
    "biib_FelzartamabAndIzastobartHIB210Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "FelzartamabAndIzastobartHIB210Member",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherResearchandDiscoveryArrangementsandFundingArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Felzartamab And Izastobart/HIB210",
        "label": "Felzartamab And Izastobart/HIB210 [Member]",
        "documentation": "Felzartamab And Izastobart/HIB210"
       }
      }
     },
     "auth_ref": []
    },
    "biib_FelzartamabIgANMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "FelzartamabIgANMember",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Felzartamab (IgAN)",
        "label": "Felzartamab (IgAN) [Member]",
        "documentation": "Felzartamab (IgAN)"
       }
      }
     },
     "auth_ref": []
    },
    "biib_FelzartamabPMNMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "FelzartamabPMNMember",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Felzartamab (PMN)",
        "label": "Felzartamab (PMN) [Member]",
        "documentation": "Felzartamab (PMN)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsMarketabledebtandequitysecuritiesDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument [Axis]",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r390",
      "r391",
      "r392",
      "r492",
      "r520",
      "r759",
      "r771",
      "r800",
      "r805",
      "r808",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r929",
      "r948",
      "r1154",
      "r1241",
      "r1243",
      "r1245",
      "r1246",
      "r1247",
      "r1248",
      "r1249",
      "r1250",
      "r1251",
      "r1255",
      "r1390",
      "r1391",
      "r1392",
      "r1393",
      "r1394",
      "r1395",
      "r1396",
      "r1506",
      "r1507",
      "r1508",
      "r1509",
      "r1639",
      "r1642",
      "r1643",
      "r1644",
      "r1651",
      "r1654",
      "r1655",
      "r1656"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated life (in years)",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "biib_FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average remaining useful life",
        "label": "Finite-Lived Intangible Asset, Weighted-Average Remaining Useful Life",
        "documentation": "Finite-Lived Intangible Asset, Weighted-Average Remaining Useful Life"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails_1": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accumulated Amortization",
        "verboseLabel": "Accumulated Amortization",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r200",
      "r395",
      "r417",
      "r1118"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillEstimatedFutureAmortizationofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2026",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r419",
      "r1114",
      "r1118"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillEstimatedFutureAmortizationofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025 (remaining three months)",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year."
       }
      }
     },
     "auth_ref": [
      "r1731"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillEstimatedFutureAmortizationofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2030",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r419",
      "r1114",
      "r1118"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillEstimatedFutureAmortizationofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2029",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r419",
      "r1114",
      "r1118"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillEstimatedFutureAmortizationofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2028",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r419",
      "r1114",
      "r1118"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillEstimatedFutureAmortizationofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "2027",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r419",
      "r1114",
      "r1118"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r412",
      "r413",
      "r414",
      "r416",
      "r417",
      "r421",
      "r422",
      "r878",
      "r879",
      "r991",
      "r1114",
      "r1118",
      "r1193",
      "r1194",
      "r1195",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204",
      "r1205",
      "r1206",
      "r1207",
      "r1208",
      "r1209",
      "r1210",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1217",
      "r1218",
      "r1219"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets, Gross",
        "label": "Finite-Lived Intangible Assets, Gross",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r395",
      "r417",
      "r879",
      "r1118"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r417",
      "r421",
      "r422",
      "r424",
      "r878",
      "r1114",
      "r1118",
      "r1193",
      "r1194",
      "r1195",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204",
      "r1205",
      "r1206",
      "r1207",
      "r1208",
      "r1209",
      "r1210",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1217",
      "r1218",
      "r1219"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r412",
      "r413",
      "r414",
      "r416",
      "r417",
      "r421",
      "r422",
      "r991",
      "r1114",
      "r1118",
      "r1193",
      "r1194",
      "r1195",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204",
      "r1205",
      "r1206",
      "r1207",
      "r1208",
      "r1209",
      "r1210",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1217",
      "r1218",
      "r1219"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net",
        "label": "Finite-Lived Intangible Assets, Net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r878",
      "r1533"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets, Net [Abstract]",
        "label": "Finite-Lived Intangible Assets, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_FloatingRate364DayTrancheMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "FloatingRate364DayTrancheMember",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Floating Rate 364-Day Tranche",
        "label": "Floating Rate 364-Day Tranche [Member]",
        "documentation": "Floating Rate 364-Day Tranche"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCountryMember",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Tax Authority",
        "label": "Foreign Tax Jurisdiction [Member]",
        "documentation": "Designated foreign jurisdiction entitled to levy and collect income tax outside country of domicile."
       }
      }
     },
     "auth_ref": [
      "r594",
      "r595"
     ]
    },
    "us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency cash flow hedge gain (loss) to be reclassified during next 12 months",
        "label": "Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months",
        "documentation": "The estimated net amount of unrealized gains or losses on foreign currency cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months."
       }
      }
     },
     "auth_ref": [
      "r1635"
     ]
    },
    "biib_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency cash flow hedge gain (loss) to be reclassified during next 15 months",
        "label": "Foreign Currency Cash Flow Hedge Gain (Loss) To Be Reclassified During Next 15 Months",
        "documentation": "Foreign Currency Cash Flow Hedge Gain (Loss) To Be Reclassified During Next 15 Months"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyContractAssetFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCurrencyContractAssetFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Derivative contracts",
        "label": "Foreign Currency Contract, Asset, Fair Value Disclosure",
        "documentation": "Fair value portion of asset contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward contracts, and swaps."
       }
      }
     },
     "auth_ref": [
      "r778",
      "r779",
      "r1655",
      "r1656",
      "r1657"
     ]
    },
    "us-gaap_ForeignCurrencyContractsLiabilityFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCurrencyContractsLiabilityFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Derivative contracts",
        "label": "Foreign Currency Contracts, Liability, Fair Value Disclosure",
        "documentation": "Fair value portion of liability contracts related to the exchange of different currencies, including, but not limited to, foreign currency options, forward (delivery or nondelivery) contracts, and swaps entered into."
       }
      }
     },
     "auth_ref": [
      "r778",
      "r779",
      "r1655",
      "r1656",
      "r1657"
     ]
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherIncomeExpenseNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Gain (Loss), Foreign Currency Transaction, before Tax",
        "label": "Gain (Loss), Foreign Currency Transaction, before Tax",
        "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction."
       }
      }
     },
     "auth_ref": [
      "r233",
      "r810",
      "r811",
      "r812",
      "r813",
      "r1060"
     ]
    },
    "us-gaap_ForeignExchangeContractMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignExchangeContractMember",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsEffectofForeignCurrencyForwardContractsandForwardCurrencyOptionsDesignatedasHedgingInstrumentsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsNotionalAmountofForeignCurrencyForwardContractsandForeignCurrencyOptionsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsSummaryofFairValueandPresentationofDerivativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Exchange Contract",
        "label": "Foreign Exchange Contract [Member]",
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates."
       }
      }
     },
     "auth_ref": [
      "r1129",
      "r1172",
      "r1174",
      "r1224",
      "r1225",
      "r1227",
      "r1228",
      "r1229",
      "r1230",
      "r1231",
      "r1232",
      "r1233",
      "r1234",
      "r1235",
      "r1237",
      "r1241",
      "r1401",
      "r1402",
      "r1403",
      "r1404",
      "r1405",
      "r1406",
      "r1407",
      "r1408",
      "r1409",
      "r1410",
      "r1411",
      "r1630"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r1301",
      "r1311",
      "r1321",
      "r1353"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r1301",
      "r1311",
      "r1321",
      "r1353"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r1301",
      "r1311",
      "r1321",
      "r1353"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1301",
      "r1311",
      "r1321",
      "r1353"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1301",
      "r1311",
      "r1321",
      "r1353"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year",
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1334"
     ]
    },
    "biib_FumarateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "FumarateMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fumarate",
        "label": "Fumarate [Member]",
        "documentation": "Fumarate [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_FutureContingentMilestoneTypesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "FutureContingentMilestoneTypesAxis",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future Contingent Milestone Types [Axis]",
        "label": "Future Contingent Milestone Types [Axis]",
        "documentation": "Future Contingent Milestone Types [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_FutureContingentMilestoneTypesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "FutureContingentMilestoneTypesDomain",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future Contingent Milestone Types [Domain]",
        "label": "Future Contingent Milestone Types [Domain]",
        "documentation": "[Domain] for Future Contingent Milestone Types [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty percentage to be received",
        "label": "Future Royalties Percentage To Be Received On Sale Of Product",
        "documentation": "Future royalties percentage to be received on sale of product."
       }
      }
     },
     "auth_ref": []
    },
    "biib_GAZYVAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "GAZYVAMember",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsPretaxProfitSharingFormulaDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GAZYVA",
        "label": "GAZYVA [Member]",
        "documentation": "GAZYVA [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "currency_GBP": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/currency/2025",
     "localname": "GBP",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsNotionalAmountofForeignCurrencyForwardContractsandForeignCurrencyOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "British pound",
        "label": "United Kingdom, Pounds"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GainLossOnDerivativeInstrumentsNetPretax",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsEffectofForeignCurrencyForwardContractsandForwardCurrencyOptionsDesignatedasHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Gains/(Losses) Excluded from Effectiveness Testing and Recognized in Operating Income (in millions)",
        "label": "Gain (Loss) on Derivative Instruments, Net, Pretax",
        "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects."
       }
      }
     },
     "auth_ref": [
      "r1627"
     ]
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GainLossOnDispositionOfAssets1",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain (loss) on sale",
        "label": "Gain (Loss) on Disposition of Assets",
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee."
       }
      }
     },
     "auth_ref": [
      "r1464"
     ]
    },
    "us-gaap_GainLossOnDispositionOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GainLossOnDispositionOfIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Gain on sale of priority review voucher, net",
        "terseLabel": "Gain on sale of priority review voucher, net",
        "label": "Gain (Loss) on Disposition of Intangible Assets",
        "documentation": "Amount of gain (loss) on sale or disposal of intangible assets."
       }
      }
     },
     "auth_ref": [
      "r1464"
     ]
    },
    "us-gaap_GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Gain (loss) on foreign currency derivative instruments not designated as hedging instruments",
        "label": "Gain (Loss) on Foreign Currency Derivative Instruments Not Designated as Hedging Instruments",
        "documentation": "Amount of gain (loss) recognized in earnings in the period from the increase (decrease) in fair value of foreign currency derivatives not designated as hedging instruments."
       }
      }
     },
     "auth_ref": [
      "r1627",
      "r1628"
     ]
    },
    "us-gaap_GainLossOnInvestmentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GainLossOnInvestmentsTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gain (loss) on investments in equity securities",
        "label": "Gain (Loss) on Securities [Table Text Block]",
        "documentation": "Tabular disclosure of realized and unrealized gain (loss) on investment in security."
       }
      }
     },
     "auth_ref": [
      "r1416",
      "r1417"
     ]
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Gain on sale of priority review voucher, net",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "biib_GenentechMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "GenentechMember",
     "presentation": [
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Genentech",
        "label": "Genentech [Member]",
        "documentation": "Genentech"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails": {
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillChangesinGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Goodwill",
        "terseLabel": "Goodwill",
        "periodStartLabel": "Goodwill, beginning of period",
        "periodEndLabel": "Goodwill, end of period",
        "label": "Goodwill",
        "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r396",
      "r915",
      "r1149",
      "r1155",
      "r1182",
      "r1186",
      "r1187",
      "r1221",
      "r1242",
      "r1254",
      "r1516",
      "r1523",
      "r1619"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwill"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Intangible Assets and Goodwill",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r1514",
      "r1526"
     ]
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillChangesinGoodwillDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated impairment losses related to goodwill",
        "verboseLabel": "Accumulated impairment losses related to goodwill",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "documentation": "Amount of accumulated impairment loss for asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r398",
      "r405",
      "r409",
      "r681",
      "r1155"
     ]
    },
    "us-gaap_GoodwillLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GoodwillLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillChangesinGoodwillDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill [Line Items]",
        "label": "Goodwill [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r1155"
     ]
    },
    "us-gaap_GoodwillOtherIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GoodwillOtherIncreaseDecrease",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillChangesinGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other(2)",
        "label": "Goodwill, Other Increase (Decrease)",
        "documentation": "Amount of increase (decrease) of asset representing future economic benefit from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized, classified as other."
       }
      }
     },
     "auth_ref": [
      "r404",
      "r681"
     ]
    },
    "us-gaap_GoodwillPurchaseAccountingAdjustments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GoodwillPurchaseAccountingAdjustments",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillChangesinGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill resulting from HI-Bio acquisition",
        "label": "Goodwill, Measurement Period Adjustment",
        "documentation": "Amount of increase (decrease) from measurement period adjustment of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r1522",
      "r1597",
      "r1604",
      "r1611",
      "r1619"
     ]
    },
    "us-gaap_GoodwillRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GoodwillRollForward",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillChangesinGoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of roll forward of the changes in goodwill",
        "label": "Goodwill [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "biib_GovernmentSecuritiesCurrentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "GovernmentSecuritiesCurrentMember",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsMarketabledebtandequitysecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government Securities Current",
        "label": "Government Securities Current [Member]",
        "documentation": "Government securities Current."
       }
      }
     },
     "auth_ref": []
    },
    "biib_HeadquartersLeaseFiveYearRenewalOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "HeadquartersLeaseFiveYearRenewalOptionMember",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Headquarters Lease, Five Year Renewal Option",
        "label": "Headquarters Lease, Five Year Renewal Option [Member]",
        "documentation": "Headquarters Lease, Five Year Renewal Option"
       }
      }
     },
     "auth_ref": []
    },
    "biib_HeadquartersLeaseSixMonthRenewalOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "HeadquartersLeaseSixMonthRenewalOptionMember",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Headquarters Lease, Six Month Renewal Option",
        "label": "Headquarters Lease, Six Month Renewal Option [Member]",
        "documentation": "Headquarters Lease, Six Month Renewal Option"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_HedgingDesignationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "HedgingDesignationAxis",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsNotionalAmountofForeignCurrencyForwardContractsandForeignCurrencyOptionsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsSummaryofFairValueandPresentationofDerivativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedging Designation [Axis]",
        "label": "Hedging Designation [Axis]",
        "documentation": "Information by designation of purpose of derivative instrument."
       }
      }
     },
     "auth_ref": [
      "r1627",
      "r1628"
     ]
    },
    "us-gaap_HedgingDesignationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "HedgingDesignationDomain",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsNotionalAmountofForeignCurrencyForwardContractsandForeignCurrencyOptionsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsSummaryofFairValueandPresentationofDerivativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedging Designation [Domain]",
        "label": "Hedging Designation [Domain]",
        "documentation": "Designation of purpose of derivative instrument."
       }
      }
     },
     "auth_ref": [
      "r1627",
      "r1628"
     ]
    },
    "us-gaap_HedgingRelationshipDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "HedgingRelationshipDomain",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsEffectofForeignCurrencyForwardContractsandForwardCurrencyOptionsDesignatedasHedgingInstrumentsDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsSummaryofFairValueandPresentationofDerivativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Hedging Relationship [Domain]",
        "label": "Hedging Relationship [Domain]",
        "documentation": "Nature or intent of a hedge."
       }
      }
     },
     "auth_ref": []
    },
    "biib_HumanImmunologyBiosciencesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "HumanImmunologyBiosciencesMember",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails",
      "http://www.biogenidec.com/role/AcquisitionsPurchasePriceConsiderationDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillChangesinGoodwillDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails",
      "http://www.biogenidec.com/role/SharebasedPaymentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Human Immunology Biosciences",
        "label": "Human Immunology Biosciences [Member]",
        "documentation": "Human Immunology Biosciences"
       }
      }
     },
     "auth_ref": []
    },
    "biib_HumanImmunologyBiosciencesPreExistingInLicenseCommitmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "HumanImmunologyBiosciencesPreExistingInLicenseCommitmentsMember",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherResearchandDiscoveryArrangementsandFundingArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Human Immunology Biosciences Pre-Existing In License Commitments",
        "label": "Human Immunology Biosciences Pre-Existing In License Commitments [Member]",
        "documentation": "Human Immunology Biosciences Pre-Existing In License Commitments"
       }
      }
     },
     "auth_ref": []
    },
    "biib_IMRALDIMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "IMRALDIMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IMRALDI",
        "label": "IMRALDI [Member]",
        "documentation": "IMRALDI [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_IMRALDIPatentLitigationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "IMRALDIPatentLitigationMember",
     "presentation": [
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "IMRALDI Patent Litigation",
        "label": "IMRALDI Patent Litigation [Member]",
        "documentation": "IMRALDI Patent Litigation"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of intangible assets (excluding goodwill)",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r230",
      "r411",
      "r423"
     ]
    },
    "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of intangible assets",
        "label": "Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)",
        "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value."
       }
      }
     },
     "auth_ref": [
      "r411",
      "r1464",
      "r1535",
      "r1538"
     ]
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InProcessResearchAndDevelopmentMember",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "In-process research and development",
        "verboseLabel": "In-process research and development",
        "label": "In Process Research and Development [Member]",
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process."
       }
      }
     },
     "auth_ref": [
      "r1527",
      "r1528",
      "r1529",
      "r1530",
      "r1531",
      "r1532",
      "r1533",
      "r1535",
      "r1536",
      "r1537"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Income before income tax (benefit) expense",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r128",
      "r133",
      "r920",
      "r922",
      "r944",
      "r1133",
      "r1135",
      "r1137",
      "r1143",
      "r1148",
      "r1484",
      "r1487",
      "r1488",
      "r1489",
      "r1490"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r428",
      "r429"
     ]
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r14",
      "r18",
      "r53",
      "r54",
      "r55",
      "r56",
      "r57",
      "r58",
      "r59",
      "r60",
      "r61",
      "r107",
      "r428",
      "r429"
     ]
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoLEQEMBICollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoStokeTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsEffectofForeignCurrencyForwardContractsandForwardCurrencyOptionsDesignatedasHedgingInstrumentsDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails",
      "http://www.biogenidec.com/role/SharebasedPaymentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Axis]",
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r426",
      "r435",
      "r440",
      "r709",
      "r718",
      "r735",
      "r744",
      "r784",
      "r788",
      "r794",
      "r807",
      "r808",
      "r809",
      "r976",
      "r978",
      "r1047",
      "r1114",
      "r1115",
      "r1182",
      "r1187",
      "r1237",
      "r1239",
      "r1244",
      "r1252",
      "r1600",
      "r1603",
      "r1689"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoLEQEMBICollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoStokeTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsEffectofForeignCurrencyForwardContractsandForwardCurrencyOptionsDesignatedasHedgingInstrumentsDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails",
      "http://www.biogenidec.com/role/SharebasedPaymentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Domain]",
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r435",
      "r440",
      "r709",
      "r718",
      "r735",
      "r744",
      "r784",
      "r788",
      "r794",
      "r807",
      "r808",
      "r809",
      "r976",
      "r978",
      "r1047",
      "r1114",
      "r1115",
      "r1182",
      "r1187",
      "r1237",
      "r1239",
      "r1244",
      "r1252",
      "r1600",
      "r1603",
      "r1689"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Disclosure [Abstract]",
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r247",
      "r253",
      "r590",
      "r594",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605",
      "r609",
      "r611",
      "r612",
      "r613",
      "r928",
      "r990",
      "r999",
      "r1181"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/EquityReclassifiedFromAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income tax (benefit) expense",
        "terseLabel": "Income Tax Expense (Benefit)",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r138",
      "r145",
      "r247",
      "r280",
      "r281",
      "r298",
      "r318",
      "r333",
      "r593",
      "r594",
      "r610",
      "r956",
      "r1133",
      "r1135",
      "r1137",
      "r1181"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax assets and liabilities",
        "label": "Increase (Decrease) in Income Taxes Payable",
        "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expense and other current liabilities",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInEquitySecuritiesFvNi": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInEquitySecuritiesFvNi",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "(Gain) loss on strategic investments",
        "label": "Increase (Decrease) in Equity Securities, FV-NI",
        "documentation": "Amount of increase (decrease) of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)."
       }
      }
     },
     "auth_ref": [
      "r136",
      "r241"
     ]
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Inventory",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Changes in operating assets and liabilities, net of effects of business acquired:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingCapitalNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherOperatingCapitalNet",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 16.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other changes in operating assets and liabilities, net",
        "label": "Increase (Decrease) in Other Operating Assets and Liabilities, Net",
        "documentation": "Amount of increase (decrease) in operating assets after deduction of operating liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "calculation": {
      "http://www.biogenidec.com/role/EarningsperShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock units",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method."
       }
      }
     },
     "auth_ref": [
      "r287",
      "r288",
      "r289",
      "r293",
      "r551"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-lived Intangible Assets by Major Class [Axis]",
        "label": "Indefinite-Lived Intangible Assets [Axis]",
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r415",
      "r420",
      "r1118",
      "r1193",
      "r1194",
      "r1195",
      "r1204",
      "r1205",
      "r1219"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-Lived Intangible Assets [Line Items]",
        "label": "Indefinite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r420",
      "r424",
      "r1118",
      "r1193",
      "r1194",
      "r1195",
      "r1204",
      "r1205",
      "r1219"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cost and net",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)",
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit."
       }
      }
     },
     "auth_ref": [
      "r395",
      "r420",
      "r1118"
     ]
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]",
        "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r415",
      "r420",
      "r1118",
      "r1193",
      "r1194",
      "r1195",
      "r1204",
      "r1205",
      "r1219"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1301",
      "r1311",
      "r1321",
      "r1345",
      "r1353",
      "r1357",
      "r1365"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1363"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1293",
      "r1369"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1293",
      "r1369"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1293",
      "r1369"
     ]
    },
    "biib_IntangibleAssetMeasurementInput": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "IntangibleAssetMeasurementInput",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement input",
        "label": "Intangible Asset, Measurement Input",
        "documentation": "Intangible Asset, Measurement Input"
       }
      }
     },
     "auth_ref": []
    },
    "biib_IntangibleAssetsExcludingGoodwillTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "IntangibleAssetsExcludingGoodwillTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Intangible assets",
        "label": "Intangible Assets Excluding Goodwill [Table Text Block]",
        "documentation": "Intangible assets excluding goodwill."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails_1": {
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r199"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Intangible assets, net",
        "totalLabel": "Net",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r1533",
      "r1535"
     ]
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Assets, Net (Excluding Goodwill) [Abstract]",
        "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherIncomeExpenseNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest Expense",
        "label": "Interest Expense, Operating and Nonoperating",
        "documentation": "Amount of interest expense classified as operating and nonoperating. Includes, but is not limited to, cost of borrowing accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r298",
      "r310",
      "r314",
      "r320",
      "r333",
      "r823",
      "r1148",
      "r1149",
      "r1723"
     ]
    },
    "biib_InterestInSubsidiary": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "InterestInSubsidiary",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Interest in subsidiary (less than given percentage)",
        "label": "Interest In Subsidiary",
        "documentation": "Interest in subsidiary."
       }
      }
     },
     "auth_ref": []
    },
    "biib_InterferonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "InterferonMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interferon",
        "label": "Interferon [Member]",
        "documentation": "Interferon"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryCurrentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryCurrentTable",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory, Current [Table]",
        "label": "Inventory, Current [Table]",
        "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory Disclosure [Abstract]",
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/Inventory"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Inventory",
        "label": "Inventory Disclosure [Text Block]",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r393"
     ]
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails": {
       "parentTag": "biib_InventoryNetCurrentAndNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Finished goods",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r1122"
     ]
    },
    "us-gaap_InventoryLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory [Line Items]",
        "label": "Inventory [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Inventory",
        "terseLabel": "Inventory, current",
        "label": "Inventory, Net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r209",
      "r1119",
      "r1254"
     ]
    },
    "biib_InventoryNetCurrentAndNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "InventoryNetCurrentAndNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Inventory",
        "label": "Inventory, Net Current and Noncurrent",
        "documentation": "Inventory, Net Current and Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryNoncurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory, noncurrent",
        "label": "Inventory, Noncurrent",
        "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle."
       }
      }
     },
     "auth_ref": [
      "r1400"
     ]
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryRawMaterialsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails": {
       "parentTag": "biib_InventoryNetCurrentAndNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Raw materials",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r1124"
     ]
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryWorkInProcessNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails": {
       "parentTag": "biib_InventoryNetCurrentAndNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/InventoryComponentsofInventoryDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Work in process",
        "label": "Inventory, Work in Process, Net of Reserves",
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r1123"
     ]
    },
    "us-gaap_InventoryWriteDown": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InventoryWriteDown",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Excess and obsolescence charges related to inventory",
        "label": "Inventory Write-down",
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels."
       }
      }
     },
     "auth_ref": [
      "r394"
     ]
    },
    "biib_InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment in biotechnology companies that are determined to be unconsolidated variable interest entities",
        "label": "Investment in biotechnology companies that are determined to be unconsolidated variable interest entities",
        "documentation": "Investment in biotechnology companies that are determined to be unconsolidated variable interest entities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherIncomeExpenseNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Interest income",
        "label": "Investment Income, Interest",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r298",
      "r313",
      "r333",
      "r1148",
      "r1415"
     ]
    },
    "us-gaap_InvestmentOwnedAtCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentOwnedAtCost",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment owned, cost",
        "label": "Investment Owned, Cost",
        "documentation": "Cost of the investment."
       }
      }
     },
     "auth_ref": [
      "r993",
      "r1010",
      "r1011",
      "r1072",
      "r1073",
      "r1079",
      "r1088",
      "r1280",
      "r1288",
      "r1720"
     ]
    },
    "us-gaap_InvestmentTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentTypeAxis",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsSummaryoffinancialassetswithmaturitiesoflessthan90daysincludedwithincashandcashequivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment Type [Axis]",
        "label": "Investment Type [Axis]",
        "documentation": "Information by type of investments."
       }
      }
     },
     "auth_ref": [
      "r1005",
      "r1007",
      "r1008",
      "r1010",
      "r1013",
      "r1069",
      "r1071",
      "r1075",
      "r1078",
      "r1080",
      "r1086",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1280"
     ]
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentTypeCategorizationMember",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsSummaryoffinancialassetswithmaturitiesoflessthan90daysincludedwithincashandcashequivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment Type Categorization [Domain]",
        "label": "Investments [Domain]",
        "documentation": "Asset obtained to generate income or appreciate in value."
       }
      }
     },
     "auth_ref": [
      "r1005",
      "r1007",
      "r1008",
      "r1010",
      "r1013",
      "r1069",
      "r1071",
      "r1075",
      "r1078",
      "r1080",
      "r1086",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1093",
      "r1280"
     ]
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]",
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentsFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable equity securities",
        "label": "Investments, Fair Value Disclosure",
        "documentation": "Fair value portion of investment securities, including, but not limited to, marketable securities, derivative financial instruments, and investments accounted for under the equity method."
       }
      }
     },
     "auth_ref": [
      "r1640",
      "r1641",
      "r1651",
      "r1655",
      "r1656",
      "r1657",
      "r1658"
     ]
    },
    "biib_InvestmentsInVariableInterestEntitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "InvestmentsInVariableInterestEntitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments in Variable Interest Entities [Abstract]",
        "label": "Investments in Variable Interest Entities [Abstract]",
        "documentation": "Investments In Variable Interest Entities."
       }
      }
     },
     "auth_ref": []
    },
    "biib_IonisPharmaceuticalsInc.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "IonisPharmaceuticalsInc.Member",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsIonisPharmaceuticalsIncDetails",
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ionis",
        "label": "Ionis Pharmaceuticals Inc. [Member]",
        "documentation": "Ionis Pharmaceuticals Inc."
       }
      }
     },
     "auth_ref": []
    },
    "biib_LEQEMBICollaborationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "LEQEMBICollaborationMember",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoLEQEMBICollaborationDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Alzheimer's collaboration revenue",
        "label": "LEQEMBI Collaboration [Member]",
        "documentation": "LEQEMBI Collaboration"
       }
      }
     },
     "auth_ref": []
    },
    "biib_LEQEMBIMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "LEQEMBIMember",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoLEQEMBICollaborationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LEQEMBI",
        "label": "LEQEMBI [Member]",
        "documentation": "LEQEMBI"
       }
      }
     },
     "auth_ref": []
    },
    "biib_LUNSUMIOMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "LUNSUMIOMember",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCopromotionProfitSharingFormulaDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsPretaxProfitSharingFormulaDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LUNSUMIO",
        "label": "LUNSUMIO [Member]",
        "documentation": "LUNSUMIO"
       }
      }
     },
     "auth_ref": []
    },
    "biib_LateStageProgramsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "LateStageProgramsMember",
     "presentation": [
      "http://www.biogenidec.com/role/SegmentInformationAdditionalSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Late stage programs",
        "label": "Late Stage Programs [Member]",
        "documentation": "Late Stage Programs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseContractualTermAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseContractualTermAxis",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Contractual Term [Axis]",
        "label": "Lease Contractual Term [Axis]",
        "documentation": "Information by contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r834",
      "r1384"
     ]
    },
    "us-gaap_LeaseContractualTermDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseContractualTermDomain",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Contractual Term [Domain]",
        "label": "Lease Contractual Term [Domain]",
        "documentation": "Contractual term of lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r834",
      "r1384"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases [Abstract]",
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal Entity [Axis]",
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LegalMattersAndContingenciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LegalMattersAndContingenciesTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/Litigation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Litigation",
        "label": "Legal Matters and Contingencies [Text Block]",
        "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies."
       }
      }
     },
     "auth_ref": [
      "r112"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Line Items]",
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r832",
      "r834"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Table]",
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r832",
      "r834"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Term of contract",
        "label": "Lessee, Operating Lease, Lease Not yet Commenced, Term of Contract",
        "documentation": "Term of lessee's operating lease not yet commenced, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1666"
     ]
    },
    "biib_LesseeOperatingLeaseNumberOfRenewalOptions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "LesseeOperatingLeaseNumberOfRenewalOptions",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of renewal options",
        "label": "Lessee, Operating Lease, Number Of Renewal Options",
        "documentation": "Lessee, Operating Lease, Number Of Renewal Options"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Renewal term",
        "label": "Lessee, Operating Lease, Renewal Term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1665"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease term",
        "label": "Lessee, Operating Lease, Term of Contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1665"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r64",
      "r65",
      "r66",
      "r69",
      "r70",
      "r71",
      "r72",
      "r247",
      "r251",
      "r252",
      "r378",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r690",
      "r694",
      "r695",
      "r806",
      "r1022",
      "r1142",
      "r1162",
      "r1288",
      "r1552",
      "r1670",
      "r1671"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r127",
      "r940",
      "r1254",
      "r1274",
      "r1275",
      "r1466",
      "r1471",
      "r1511",
      "r1659"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "LIABILITIES AND EQUITY",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r197",
      "r247",
      "r251",
      "r252",
      "r378",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r690",
      "r694",
      "r695",
      "r806",
      "r1254",
      "r1552",
      "r1670",
      "r1671"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total",
        "label": "Liabilities, Fair Value Disclosure",
        "documentation": "Fair value of financial and nonfinancial obligations."
       }
      }
     },
     "auth_ref": [
      "r779",
      "r1640"
     ]
    },
    "us-gaap_LiabilitiesFairValueDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesFairValueDisclosureAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Liabilities:",
        "label": "Liabilities, Fair Value Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LicenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LicenseMember",
     "presentation": [
      "http://www.biogenidec.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License",
        "label": "License [Member]",
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark."
       }
      }
     },
     "auth_ref": [
      "r1556",
      "r1557"
     ]
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of credit facility, maximum borrowing capacity",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r68"
     ]
    },
    "us-gaap_LineOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LineOfCreditMember",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Line of Credit",
        "label": "Line of Credit [Member]",
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars."
       }
      }
     },
     "auth_ref": []
    },
    "srt_LitigationCaseAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "LitigationCaseAxis",
     "presentation": [
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Case [Axis]",
        "label": "Litigation Case [Axis]",
        "documentation": "Information by type of judicial proceeding, alternative dispute resolution or claim."
       }
      }
     },
     "auth_ref": []
    },
    "srt_LitigationCaseTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "LitigationCaseTypeDomain",
     "presentation": [
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Case [Domain]",
        "label": "Litigation Case [Domain]",
        "documentation": "Judicial proceeding, alternative dispute resolution or claim. For example, but not limited to, name of case, category of litigation, or other differentiating information."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LitigationSettlementInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LitigationSettlementInterest",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Settlement Interest",
        "label": "Litigation Settlement Interest",
        "documentation": "Interest expense (income) directly attributable to an award in settlement of litigation."
       }
      }
     },
     "auth_ref": [
      "r1389"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Notes payable",
        "label": "Long-Term Debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r125",
      "r248",
      "r258",
      "r480",
      "r495",
      "r924",
      "r1158",
      "r1159",
      "r1253",
      "r1682"
     ]
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDebtInstrumentsDetails",
      "http://www.biogenidec.com/role/IndebtednessNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Axis]",
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r1539",
      "r1540",
      "r1541"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDebtInstrumentsDetails",
      "http://www.biogenidec.com/role/IndebtednessNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Domain]",
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r37",
      "r1539",
      "r1540",
      "r1541"
     ]
    },
    "us-gaap_LossContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingenciesLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingencies [Line Items]",
        "label": "Loss Contingencies [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r449",
      "r450",
      "r451",
      "r455",
      "r588",
      "r1156",
      "r1547",
      "r1548"
     ]
    },
    "us-gaap_LossContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingenciesTable",
     "presentation": [
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingencies [Table]",
        "label": "Loss Contingencies [Table]",
        "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r449",
      "r450",
      "r451",
      "r455",
      "r588",
      "r1156",
      "r1547",
      "r1548"
     ]
    },
    "us-gaap_LossContingencyDamagesSoughtValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingencyDamagesSoughtValue",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss contingency, damages sought, value",
        "label": "Loss Contingency, Damages Sought, Value",
        "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter."
       }
      }
     },
     "auth_ref": [
      "r1546",
      "r1547",
      "r1548"
     ]
    },
    "us-gaap_LossContingencyEstimateOfPossibleLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingencyEstimateOfPossibleLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/LitigationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss contingency, estimate of possible loss",
        "label": "Loss Contingency, Estimate of Possible Loss",
        "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r305",
      "r450",
      "r451",
      "r454",
      "r455",
      "r588",
      "r1156"
     ]
    },
    "us-gaap_LossContingencyInformationAboutLitigationMattersAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingencyInformationAboutLitigationMattersAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss Contingency, Information about Litigation Matters [Abstract]",
        "label": "Loss Contingency, Information about Litigation Matters [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_MSProductRevenuesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "MSProductRevenuesMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MS Product Revenues",
        "label": "MS Product Revenues [Member]",
        "documentation": "MS Product Revenues [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Axis]",
        "label": "Customer [Axis]",
        "documentation": "Information by name or description of a single external customer or a group of external customers."
       }
      }
     },
     "auth_ref": [
      "r340",
      "r1164",
      "r1167",
      "r1267",
      "r1272",
      "r1687",
      "r1690",
      "r1691",
      "r1693",
      "r1694",
      "r1695",
      "r1696",
      "r1697",
      "r1698",
      "r1699",
      "r1700",
      "r1701",
      "r1702",
      "r1703",
      "r1704",
      "r1705",
      "r1706",
      "r1707",
      "r1708",
      "r1709",
      "r1710",
      "r1711",
      "r1712",
      "r1713",
      "r1714",
      "r1715",
      "r1717",
      "r1718"
     ]
    },
    "biib_MarketStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "MarketStockUnitsMember",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Market stock units",
        "label": "Market Stock Units [Member]",
        "documentation": "Market stock units."
       }
      }
     },
     "auth_ref": []
    },
    "biib_MarketedProductsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "MarketedProductsMember",
     "presentation": [
      "http://www.biogenidec.com/role/SegmentInformationAdditionalSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketed products",
        "label": "Marketed Products [Member]",
        "documentation": "Marketed Products"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.biogenidec.com/role/FairValueMeasuresLevel3AssetsandLiabilitiesHeldatFairValueDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "verboseLabel": "Maximum",
        "label": "Maximum [Member]",
        "documentation": "Upper limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r155",
      "r157",
      "r158",
      "r160",
      "r177",
      "r179",
      "r180",
      "r185",
      "r186",
      "r305",
      "r450",
      "r451",
      "r452",
      "r453",
      "r547",
      "r576",
      "r577",
      "r578",
      "r588",
      "r782",
      "r876",
      "r975",
      "r977",
      "r989",
      "r1014",
      "r1015",
      "r1070",
      "r1074",
      "r1076",
      "r1077",
      "r1087",
      "r1096",
      "r1097",
      "r1099",
      "r1100",
      "r1112",
      "r1113",
      "r1153",
      "r1163",
      "r1179",
      "r1182",
      "r1188",
      "r1191",
      "r1245",
      "r1246",
      "r1250",
      "r1251",
      "r1268",
      "r1554",
      "r1672",
      "r1673",
      "r1674",
      "r1675",
      "r1676",
      "r1677"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1337"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r1337"
     ]
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputDiscountRateMember",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/FairValueMeasuresLevel3AssetsandLiabilitiesHeldatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discount rate",
        "label": "Measurement Input, Discount Rate [Member]",
        "documentation": "Measurement input using interest rate to determine present value of future cash flows."
       }
      }
     },
     "auth_ref": [
      "r1182",
      "r1188",
      "r1191",
      "r1642",
      "r1643",
      "r1644"
     ]
    },
    "biib_MeasurementInputProbabilityRateMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "MeasurementInputProbabilityRateMember",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input, Probability Rate",
        "label": "Measurement Input, Probability Rate [Member]",
        "documentation": "Measurement Input, Probability Rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputTypeAxis",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.biogenidec.com/role/FairValueMeasuresLevel3AssetsandLiabilitiesHeldatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type [Axis]",
        "label": "Measurement Input Type [Axis]",
        "documentation": "Information by type of measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r780",
      "r781",
      "r782",
      "r1182",
      "r1188",
      "r1191",
      "r1245"
     ]
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MeasurementInputTypeDomain",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.biogenidec.com/role/FairValueMeasuresLevel3AssetsandLiabilitiesHeldatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Input Type [Domain]",
        "label": "Measurement Input Type [Domain]",
        "documentation": "Measurement input used to determine value of asset and liability."
       }
      }
     },
     "auth_ref": [
      "r780",
      "r781",
      "r782",
      "r1182",
      "r1188",
      "r1191",
      "r1245"
     ]
    },
    "biib_MilestonePaymentCommercialMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "MilestonePaymentCommercialMember",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherResearchandDiscoveryArrangementsandFundingArrangementsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsStokeTherapeuticsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone Payment, Commercial",
        "label": "Milestone Payment, Commercial [Member]",
        "documentation": "Milestone Payment, Commercial"
       }
      }
     },
     "auth_ref": []
    },
    "biib_MilestonePaymentDevelopmentalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "MilestonePaymentDevelopmentalMember",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherResearchandDiscoveryArrangementsandFundingArrangementsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsStokeTherapeuticsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone Payment, Developmental",
        "label": "Milestone Payment, Developmental [Member]",
        "documentation": "Milestone Payment, Developmental"
       }
      }
     },
     "auth_ref": []
    },
    "biib_MilestonePaymentFutureDevelopmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "MilestonePaymentFutureDevelopmentMember",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherResearchandDiscoveryArrangementsandFundingArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone Payment, Future Development",
        "label": "Milestone Payment, Future Development [Member]",
        "documentation": "Milestone Payment, Future Development"
       }
      }
     },
     "auth_ref": []
    },
    "biib_MilestonePaymentOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "MilestonePaymentOneMember",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherResearchandDiscoveryArrangementsandFundingArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone Payment, One",
        "label": "Milestone Payment, One [Member]",
        "documentation": "Milestone Payment, One"
       }
      }
     },
     "auth_ref": []
    },
    "biib_MilestonePaymentRegulatoryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "MilestonePaymentRegulatoryMember",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherResearchandDiscoveryArrangementsandFundingArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone Payment, Regulatory",
        "label": "Milestone Payment, Regulatory [Member]",
        "documentation": "Milestone Payment, Regulatory"
       }
      }
     },
     "auth_ref": []
    },
    "biib_MilestonePaymentResearchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "MilestonePaymentResearchMember",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherResearchandDiscoveryArrangementsandFundingArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone Payment, Research",
        "label": "Milestone Payment, Research [Member]",
        "documentation": "Milestone Payment, Research"
       }
      }
     },
     "auth_ref": []
    },
    "biib_MilestonePaymentSalesBasedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "MilestonePaymentSalesBasedMember",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherResearchandDiscoveryArrangementsandFundingArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone Payment, Sales-Based",
        "label": "Milestone Payment, Sales-Based [Member]",
        "documentation": "Milestone Payment, Sales-Based"
       }
      }
     },
     "auth_ref": []
    },
    "biib_MilestonePaymentTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "MilestonePaymentTwoMember",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherResearchandDiscoveryArrangementsandFundingArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone Payment, Two",
        "label": "Milestone Payment, Two [Member]",
        "documentation": "Milestone Payment, Two"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://www.biogenidec.com/role/FairValueMeasuresLevel3AssetsandLiabilitiesHeldatFairValueDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "verboseLabel": "Minimum",
        "label": "Minimum [Member]",
        "documentation": "Lower limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r155",
      "r157",
      "r158",
      "r160",
      "r177",
      "r179",
      "r180",
      "r185",
      "r186",
      "r305",
      "r450",
      "r451",
      "r452",
      "r453",
      "r547",
      "r576",
      "r577",
      "r578",
      "r588",
      "r782",
      "r876",
      "r975",
      "r977",
      "r989",
      "r1014",
      "r1015",
      "r1070",
      "r1074",
      "r1076",
      "r1077",
      "r1087",
      "r1096",
      "r1097",
      "r1099",
      "r1100",
      "r1112",
      "r1113",
      "r1153",
      "r1163",
      "r1179",
      "r1182",
      "r1188",
      "r1191",
      "r1245",
      "r1246",
      "r1250",
      "r1268",
      "r1554",
      "r1672",
      "r1673",
      "r1674",
      "r1675",
      "r1676",
      "r1677"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1356"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsSummaryoffinancialassetswithmaturitiesoflessthan90daysincludedwithincashandcashequivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market funds",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r1558",
      "r1559"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1364"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Domain]",
        "label": "Customer [Domain]",
        "documentation": "Single external customer or group of external customers."
       }
      }
     },
     "auth_ref": [
      "r340",
      "r1164",
      "r1167",
      "r1267",
      "r1272",
      "r1687",
      "r1690",
      "r1691",
      "r1693",
      "r1694",
      "r1695",
      "r1696",
      "r1697",
      "r1698",
      "r1699",
      "r1700",
      "r1701",
      "r1702",
      "r1703",
      "r1704",
      "r1705",
      "r1706",
      "r1707",
      "r1708",
      "r1709",
      "r1710",
      "r1711",
      "r1712",
      "r1713",
      "r1714",
      "r1715",
      "r1717",
      "r1718"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1338"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash flow provided by (used in) financing activities",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r243"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash flow from financing activities:",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash flow provided by (used in) investing activities",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r243"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash flow from investing activities:",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash flow provided by (used in) operating activities",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r101",
      "r102"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flow from operating activities:",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.biogenidec.com/role/SegmentInformationAdditionalSegmentInformationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/EarningsperShareDetails",
      "http://www.biogenidec.com/role/EquityReclassifiedFromAOCIDetails",
      "http://www.biogenidec.com/role/SegmentInformationAdditionalSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net income attributable to Biogen Inc.",
        "terseLabel": "Net income attributable to Biogen Inc.",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r102",
      "r129",
      "r190",
      "r195",
      "r218",
      "r221",
      "r225",
      "r247",
      "r251",
      "r252",
      "r255",
      "r267",
      "r271",
      "r272",
      "r274",
      "r275",
      "r276",
      "r280",
      "r281",
      "r290",
      "r378",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r497",
      "r500",
      "r502",
      "r506",
      "r585",
      "r618",
      "r684",
      "r776",
      "r806",
      "r946",
      "r1044",
      "r1061",
      "r1062",
      "r1133",
      "r1135",
      "r1137",
      "r1286",
      "r1552"
     ]
    },
    "us-gaap_NetIncomeLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLossAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Numerator:",
        "label": "Net Income (Loss) Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New accounting pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "biib_NonCurrentPortionOfNotesPayableAndTermLoanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "NonCurrentPortionOfNotesPayableAndTermLoanMember",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-current portion of notes payable",
        "label": "Non-Current Portion Of Notes Payable And Term Loan [Member]",
        "documentation": "Non-Current Portion Of Notes Payable And Term Loan"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1337"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r1301",
      "r1311",
      "r1321",
      "r1345",
      "r1353"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r1328"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1327"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r1345"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1364"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1364"
     ]
    },
    "us-gaap_NonUsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonUsMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rest of World",
        "label": "Non-US [Member]",
        "documentation": "Countries excluding the United States of America (US)."
       }
      }
     },
     "auth_ref": [
      "r1726",
      "r1728",
      "r1729",
      "r1730"
     ]
    },
    "us-gaap_NondesignatedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NondesignatedMember",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsSummaryofFairValueandPresentationofDerivativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Not designated as hedging instrument",
        "label": "Not Designated as Hedging Instrument [Member]",
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NonrecurringAdjustmentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonrecurringAdjustmentAxis",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combination, Pro Forma Information, Nonrecurring Adjustment [Axis]",
        "label": "Business Combination, Pro Forma Information, Nonrecurring Adjustment [Axis]",
        "documentation": "Information by nonrecurring adjustment directly attributable to business combination included in reported pro forma revenue and earnings."
       }
      }
     },
     "auth_ref": [
      "r638",
      "r639",
      "r1182",
      "r1192"
     ]
    },
    "us-gaap_NonrecurringAdjustmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonrecurringAdjustmentDomain",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combination, Pro Forma Information, Nonrecurring Adjustment [Domain]",
        "label": "Business Combination, Pro Forma Information, Nonrecurring Adjustment [Domain]",
        "documentation": "Nonrecurring adjustment directly attributable to business combination included in reported pro forma revenue and earnings."
       }
      }
     },
     "auth_ref": [
      "r638",
      "r639",
      "r1182",
      "r1192"
     ]
    },
    "us-gaap_NonrelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonrelatedPartyMember",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nonrelated Party",
        "label": "Nonrelated Party [Member]",
        "documentation": "Party not related to reporting entity."
       }
      }
     },
     "auth_ref": [
      "r1466",
      "r1474",
      "r1475"
     ]
    },
    "us-gaap_NotesPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NotesPayable",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Carrying Value",
        "label": "Notes Payable",
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r125",
      "r1682",
      "r1683"
     ]
    },
    "us-gaap_NotesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NotesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/FairValueMeasurementsDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current portion of notes payable",
        "verboseLabel": "Current portion of carrying value",
        "label": "Notes Payable, Current",
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r65"
     ]
    },
    "biib_NotesPayableCurrentFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "NotesPayableCurrentFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Notes payable, current, fair value disclosure",
        "label": "Notes Payable, Current, Fair Value Disclosure",
        "documentation": "Notes Payable, Current, Fair Value Disclosure"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NotesPayableFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NotesPayableFairValueDisclosure",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "label": "Notes Payable, Fair Value Disclosure",
        "documentation": "Fair value portion of notes payable."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r64",
      "r65",
      "r1641",
      "r1651",
      "r1655",
      "r1656",
      "r1657",
      "r1658"
     ]
    },
    "us-gaap_NotesReceivableFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NotesReceivableFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Convertible note",
        "label": "Notes Receivable, Fair Value Disclosure",
        "documentation": "Fair value portion of an agreement for an unconditional promise by the maker to pay the holder a definite sum of money at a future date."
       }
      }
     },
     "auth_ref": [
      "r1655",
      "r1656",
      "r1657",
      "r1658"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.biogenidec.com/role/SegmentInformationNarrativeDetails",
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reportable segments",
        "verboseLabel": "Number of reportable segment",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r1144",
      "r1152",
      "r1486"
     ]
    },
    "biib_NumberOfWholesalers": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "NumberOfWholesalers",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of wholesalers",
        "label": "Number of Wholesalers",
        "documentation": "Number of Wholesalers"
       }
      }
     },
     "auth_ref": []
    },
    "biib_OCREVUSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "OCREVUSMember",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "OCREVUS",
        "label": "OCREVUS [Member]",
        "documentation": "OCREVUS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OciBeforeReclassificationsNetOfTaxAttributableToParent",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income (loss) before reclassifications",
        "label": "OCI, before Reclassifications, Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax, before reclassification adjustments, of other comprehensive income (loss), attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r20"
     ]
    },
    "us-gaap_OperatingExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpenseMember",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsEffectofForeignCurrencyForwardContractsandForwardCurrencyOptionsDesignatedasHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expense",
        "label": "Operating Expense [Member]",
        "documentation": "Primary financial statement caption encompassing expenses associated with normal operations."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/EquityReclassifiedFromAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Operating Expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r1137"
     ]
    },
    "biib_OperatingLeaseArea": {
     "xbrltype": "areaItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "OperatingLeaseArea",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesNarrativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease area",
        "label": "Operating Lease Area",
        "documentation": "Operating Lease Area"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term operating lease liabilities",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailAccruedExpenseandOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Accrued Liabilities, Current",
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r65"
     ]
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other current assets",
        "label": "Other Assets, Current",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r1254"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Investments and other assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r201"
     ]
    },
    "biib_OtherClinicalProgramsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "OtherClinicalProgramsMember",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other clinical programs",
        "label": "Other Clinical Programs [Member]",
        "documentation": "Other Clinical Programs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gains (losses) on cash flow hedges, net of tax",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax",
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness."
       }
      }
     },
     "auth_ref": [
      "r214",
      "r215",
      "r947"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsEffectofForeignCurrencyForwardContractsandForwardCurrencyOptionsDesignatedasHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Gains/(Losses) Reclassified from AOCI into Operating Income (in millions)",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax",
        "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r217",
      "r721",
      "r1237"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Currency translation adjustments, net of tax",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r947"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive income (loss), net of tax",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r16",
      "r219",
      "r222",
      "r227",
      "r276",
      "r815",
      "r816",
      "r821",
      "r917",
      "r947",
      "r1412",
      "r1413"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited",
      "http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other comprehensive income (loss), net of tax",
        "terseLabel": "Net current period other comprehensive income (loss)",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r12",
      "r120",
      "r219",
      "r222",
      "r276"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other comprehensive income (loss):",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Unrealized gains (losses) on pension benefit obligation, net of tax",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax",
        "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r4",
      "r85",
      "r86",
      "r947"
     ]
    },
    "us-gaap_OtherCurrentAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherCurrentAssetsMember",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsSummaryofFairValueandPresentationofDerivativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current assets",
        "label": "Other Current Assets [Member]",
        "documentation": "Primary financial statement caption encompassing other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCurrentLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherCurrentLiabilitiesMember",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailAccruedExpenseandOtherDetails",
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Component of accrued expenses and other",
        "label": "Other Current Liabilities [Member]",
        "documentation": "Primary financial statement caption encompassing other current liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailAccruedExpenseandOtherDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued expense and other",
        "terseLabel": "Total accrued expense and other",
        "label": "Other Liabilities, Current",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r1254"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other long-term liabilities",
        "terseLabel": "Other liabilities, noncurrent",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNoncashIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other",
        "label": "Other Noncash Income (Expense)",
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNoncurrentAssetsMember",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other noncurrent assets",
        "label": "Other Noncurrent Assets [Member]",
        "documentation": "Primary financial statement caption encompassing other noncurrent assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNoncurrentLiabilitiesMember",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsSummaryofFairValueandPresentationofDerivativesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other long-term liabilities",
        "label": "Other Noncurrent Liabilities [Member]",
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherIncomeExpenseNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other, net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r1226"
     ]
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherOperatingIncomeExpenseNet",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/EquityReclassifiedFromAOCIDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherIncomeExpenseNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other (income) expense, net",
        "terseLabel": "Other (income) expense, net",
        "negatedTerseLabel": "Other (income) expense, net",
        "label": "Other Operating Income (Expense), Net",
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r1337"
     ]
    },
    "biib_OtherProductsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "OtherProductsMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Products [Member]",
        "documentation": "Other Products"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherRestructuringCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherRestructuringCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accelerated Depreciation and Other Costs",
        "label": "Other Restructuring Costs",
        "documentation": "Amount of other expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses associated with a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "biib_OtherrevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "OtherrevenuesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other revenues [Abstract]",
        "label": "Other revenues [Abstract]",
        "documentation": "Other revenues [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_OtherrevenuesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "OtherrevenuesTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other revenues",
        "label": "Other revenues [Table Text Block]",
        "documentation": "Other revenues [Table Text Block]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_OtherrevenuesfromantiCD20therapeuticprograms": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "OtherrevenuesfromantiCD20therapeuticprograms",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other revenues from anti-CD20 therapeutic programs",
        "label": "Other revenues from anti-CD20 therapeutic programs",
        "documentation": "Other revenues from anti-CD20 therapeutic programs consists of revenue on sales of RITUXAN outside the U.S., which consist of our share of pre-tax co-promotion profits in Canada and royalty revenue on sales of Ocrevus."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1299",
      "r1309",
      "r1319",
      "r1351"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1302",
      "r1312",
      "r1322",
      "r1354"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1302",
      "r1312",
      "r1322",
      "r1354"
     ]
    },
    "biib_PLEGRIDYMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "PLEGRIDYMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PLEGRIDY",
        "label": "PLEGRIDY [Member]",
        "documentation": "PLEGRIDY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ParentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ParentMember",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Parent",
        "verboseLabel": "Share-based compensation expense included in net income attributable to Biogen Inc.",
        "label": "Parent [Member]",
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1326"
     ]
    },
    "biib_PayablesToDivestitureOfInterestInJointVenture": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "PayablesToDivestitureOfInterestInJointVenture",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payables to divestiture of interest in joint venture",
        "label": "Payables To Divestiture Of Interest In Joint Venture",
        "documentation": "Payables To Divestiture Of Interest In Joint Venture"
       }
      }
     },
     "auth_ref": []
    },
    "biib_PaymentDueAtFirstAnniversaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "PaymentDueAtFirstAnniversaryMember",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment Due At First Anniversary",
        "label": "Payment Due At First Anniversary [Member]",
        "documentation": "Payment Due At First Anniversary"
       }
      }
     },
     "auth_ref": []
    },
    "biib_PaymentDueAtSecondAnniversaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "PaymentDueAtSecondAnniversaryMember",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payment Due At Second Anniversary",
        "label": "Payment Due At Second Anniversary [Member]",
        "documentation": "Payment Due At Second Anniversary"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Cash paid for contingent consideration",
        "label": "Payment for Contingent Consideration Liability, Financing Activities",
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other",
        "label": "Payment for (Proceeds from) Other Investing Activity",
        "documentation": "Amount of cash (inflow) outflow from investing activity, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1381",
      "r1460"
     ]
    },
    "us-gaap_PaymentsForRestructuring": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForRestructuring",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payment",
        "label": "Payments for Restructuring",
        "documentation": "Amount of cash payments made as the result of exit or disposal activities. Excludes payments associated with a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r439",
      "r1462"
     ]
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsOfFinancingCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments of financing costs",
        "label": "Payments of Financing Costs",
        "documentation": "The cash outflow for loan and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments related to issuance of stock for share-based compensation arrangements, net",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r240"
     ]
    },
    "biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments/Returns Relating To Sales in Current Year",
        "label": "Payments Returns Applied Against Product Revenue Reserves Relating To Current Year",
        "documentation": "Payments/ returns applied against product revenue reserves relating to current year."
       }
      }
     },
     "auth_ref": []
    },
    "biib_PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payments/Returns Relating To Sales in Prior Year",
        "label": "Payments Returns Applied Against Product Revenue Reserves Relating To Prior Year",
        "documentation": "Payments/ returns applied against product revenue reserves relating to prior year."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Purchases of marketable securities",
        "label": "Payments to Acquire Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r239",
      "r343"
     ]
    },
    "biib_PaymentsToAcquireBusinessGrossNonVestedEquityAwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "PaymentsToAcquireBusinessGrossNonVestedEquityAwards",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-vested equity awards",
        "label": "Payments To Acquire Business, Gross, Non-Vested Equity Awards",
        "documentation": "Payments To Acquire Business, Gross, Non-Vested Equity Awards"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireBusinessesGross",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/AcquisitionsPurchasePriceConsiderationDetails": {
       "parentTag": "us-gaap_BusinessCombinationConsiderationTransferred1",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/AcquisitionsPurchasePriceConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total transaction value",
        "label": "Payments to Acquire Businesses, Gross",
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r666",
      "r1182",
      "r1187",
      "r1220"
     ]
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Acquisition of HI-Bio, net of cash acquired",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireIntangibleAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Acquisitions of intangible assets",
        "label": "Payments to Acquire Intangible Assets",
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireProductiveAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments to acquire productive assets",
        "label": "Payments to Acquire Productive Assets",
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r1621",
      "r1622",
      "r1623"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property, plant and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r98"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1336"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1336"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1328"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r1345"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r1338"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1327"
     ]
    },
    "biib_PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of co promotion operating profits first fifty million",
        "label": "Percentage Of Co Promotion Operating Profits First Fifty Million",
        "documentation": "Percentage of co promotion operating profits first fifty million."
       }
      }
     },
     "auth_ref": []
    },
    "biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCopromotionProfitSharingFormulaDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "After Second Threshold Date",
        "label": "Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option Four",
        "documentation": "Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option Four"
       }
      }
     },
     "auth_ref": []
    },
    "biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCopromotionProfitSharingFormulaDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsPretaxProfitSharingFormulaDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "After First Threshold Date until the Second Threshold Date",
        "terseLabel": "After Second GAZYVA Threshold Date",
        "label": "Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option Three",
        "documentation": "Percentage of co promotion operating profits greater than first fifty million option two sub option three."
       }
      }
     },
     "auth_ref": []
    },
    "biib_PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCopromotionProfitSharingFormulaDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsPretaxProfitSharingFormulaDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "After LUNSUMIO Approval until the First Threshold Date",
        "terseLabel": "Until Second GAZYVA Threshold Date",
        "label": "Percentage Of Co Promotion Operating Profits Greater Than First Fifty Million Option Two Sub Option Two",
        "documentation": "Percentage of co promotion operating profits greater than first fifty million option two sub option two."
       }
      }
     },
     "auth_ref": []
    },
    "biib_PercentageOfFutureDevelopmentCosts": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "PercentageOfFutureDevelopmentCosts",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsStokeTherapeuticsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of future development costs",
        "label": "Percentage Of Future Development Costs",
        "documentation": "Percentage Of Future Development Costs"
       }
      }
     },
     "auth_ref": []
    },
    "biib_PercentageParValueOfSeniorNotes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "PercentageParValueOfSeniorNotes",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage par value of senior notes",
        "label": "Percentage Par Value Of Senior Notes",
        "documentation": "Percentage Par Value Of Senior Notes"
       }
      }
     },
     "auth_ref": []
    },
    "biib_PerformanceStockUnitsSettledinCashMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "PerformanceStockUnitsSettledinCashMember",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance stock units settled in cash",
        "label": "Performance Stock Units Settled in Cash [Member]",
        "documentation": "Performance Stock Units Settled in Cash [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_PerformanceStockUnitsSettledinStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "PerformanceStockUnitsSettledinStockMember",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance stock units settled in stock",
        "label": "Performance Stock Units Settled in Stock [Member]",
        "documentation": "Performance Stock Units Settled in Stock [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_PeriodOfCollaborationAgreement": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "PeriodOfCollaborationAgreement",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration agreement term",
        "label": "Period Of Collaboration Agreement",
        "documentation": "Period Of Collaboration Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "biib_Phase3ClinicalTrialFelzartamabAMRMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "Phase3ClinicalTrialFelzartamabAMRMember",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Phase 3 Clinical Trial, Felzartamab AMR",
        "label": "Phase 3 Clinical Trial, Felzartamab AMR [Member]",
        "documentation": "Phase 3 Clinical Trial, Felzartamab AMR"
       }
      }
     },
     "auth_ref": []
    },
    "biib_Phase3ClinicalTrialFelzartamabIgANMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "Phase3ClinicalTrialFelzartamabIgANMember",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Phase 3 Clinical Trial, Felzartamab IgAN",
        "label": "Phase 3 Clinical Trial, Felzartamab IgAN [Member]",
        "documentation": "Phase 3 Clinical Trial, Felzartamab IgAN"
       }
      }
     },
     "auth_ref": []
    },
    "biib_Phase3ClinicalTrialFelzartamabOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "Phase3ClinicalTrialFelzartamabOneMember",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Phase 3 Clinical Trial, Felzartamab One",
        "label": "Phase 3 Clinical Trial, Felzartamab One [Member]",
        "documentation": "Phase 3 Clinical Trial, Felzartamab One"
       }
      }
     },
     "auth_ref": []
    },
    "biib_Phase3ClinicalTrialFelzartamabTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "Phase3ClinicalTrialFelzartamabTwoMember",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Phase 3 Clinical Trial, Felzartamab Two",
        "label": "Phase 3 Clinical Trial, Felzartamab Two [Member]",
        "documentation": "Phase 3 Clinical Trial, Felzartamab Two"
       }
      }
     },
     "auth_ref": []
    },
    "biib_PlanAssetsForDeferredCompensationFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "PlanAssetsForDeferredCompensationFairValueDisclosure",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Plan assets for deferred compensation",
        "label": "Plan Assets For Deferred Compensation Fair Value Disclosure",
        "documentation": "Fair values as of the balance sheet date of all assets of deferred compensation plans."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Prior Service Cost",
        "label": "Pension Adjustments Prior Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r1329"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Service Cost",
        "label": "Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r1373"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Benefits Adjustments, Footnote",
        "label": "Pension Benefits Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1328"
     ]
    },
    "biib_PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSageTherapeuticsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potential future milestone payments commitment to third party",
        "label": "Potential Future Milestone Payments Commitment To Third Party Approximately",
        "documentation": "Potential future milestone payments commitment to third party approximately."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock",
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r1278",
      "r1279",
      "r1282",
      "r1283",
      "r1284",
      "r1285",
      "r1719",
      "r1724"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.biogenidec.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Preferred stock, par value (in dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r508"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Preferred stock, par value $0.001 per share",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r499",
      "r504",
      "r936",
      "r1254"
     ]
    },
    "biib_PriorityReviewVoucherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "PriorityReviewVoucherMember",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Priority review voucher",
        "label": "Priority Review Voucher [Member]",
        "documentation": "Priority Review Voucher"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromDivestitureOfInterestInJointVenture": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromDivestitureOfInterestInJointVenture",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from divestiture of interest in joint venture",
        "label": "Proceeds from Divestiture of Interest in Joint Venture",
        "documentation": "The cash inflow from the sale of an investment interest in a joint venture that the reporting entity has not previously accounted for using consolidation or the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from borrowings",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r994"
     ]
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Proceeds from (Payment for) Other Financing Activity",
        "documentation": "Amount of cash inflow (outflow) from financing activity, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1382",
      "r1461"
     ]
    },
    "us-gaap_ProceedsFromSaleOfEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromSaleOfEquityMethodInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of equity interest in Samsung Bioepis",
        "label": "Proceeds from Sale of Equity Method Investments",
        "documentation": "The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_ProceedsFromSaleOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromSaleOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of intangible assets",
        "label": "Proceeds from Sale of Intangible Assets",
        "documentation": "The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "us-gaap_ProceedsFromSaleOfOtherInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromSaleOfOtherInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sales of strategic investments",
        "label": "Proceeds from Sale of Other Investments",
        "documentation": "Amount of cash inflow from the sale of investments classified as other."
       }
      }
     },
     "auth_ref": [
      "r1381"
     ]
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of priority review voucher",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "biib_ProceedsPaidToCollaborativeArrangementCounterparty": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "ProceedsPaidToCollaborativeArrangementCounterparty",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds Paid To Collaborative Arrangement Counterparty",
        "label": "Proceeds Paid To Collaborative Arrangement Counterparty",
        "documentation": "Proceeds Paid To Collaborative Arrangement Counterparty"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProductAndServiceOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProductAndServiceOtherMember",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract manufacturing, royalty and other revenue",
        "label": "Product and Service, Other [Member]",
        "documentation": "Article or substance produced by nature, labor or machinery and act of providing assistance, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1556",
      "r1557"
     ]
    },
    "us-gaap_ProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProductMember",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails",
      "http://www.biogenidec.com/role/SegmentInformationAdditionalSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product revenue, net",
        "label": "Product [Member]",
        "documentation": "Article or substance produced by nature, labor or machinery."
       }
      }
     },
     "auth_ref": [
      "r1132",
      "r1137",
      "r1164",
      "r1165"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCopromotionProfitSharingFormulaDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherResearchandDiscoveryArrangementsandFundingArrangementsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsPretaxProfitSharingFormulaDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsStokeTherapeuticsIncDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoLEQEMBICollaborationDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails",
      "http://www.biogenidec.com/role/SegmentInformationAdditionalSegmentInformationDetails",
      "http://www.biogenidec.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]",
        "documentation": "Information by product and service, or group of similar products and similar services."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r183",
      "r336",
      "r877",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r1116",
      "r1132",
      "r1135",
      "r1137",
      "r1164",
      "r1165",
      "r1266",
      "r1268",
      "r1269",
      "r1273",
      "r1277",
      "r1383",
      "r1398",
      "r1418",
      "r1419",
      "r1420",
      "r1421",
      "r1422",
      "r1423",
      "r1424",
      "r1425",
      "r1426",
      "r1427",
      "r1428",
      "r1429",
      "r1430",
      "r1431",
      "r1432",
      "r1433",
      "r1434",
      "r1435",
      "r1436",
      "r1437",
      "r1438",
      "r1439",
      "r1440",
      "r1441",
      "r1442",
      "r1443",
      "r1444",
      "r1445",
      "r1446",
      "r1447",
      "r1448",
      "r1449",
      "r1450",
      "r1451",
      "r1452",
      "r1453",
      "r1454",
      "r1456",
      "r1457",
      "r1458",
      "r1459",
      "r1549",
      "r1550",
      "r1687",
      "r1690",
      "r1691",
      "r1692",
      "r1693",
      "r1694",
      "r1695",
      "r1696",
      "r1697",
      "r1698",
      "r1699",
      "r1700",
      "r1701",
      "r1702",
      "r1703",
      "r1704",
      "r1705",
      "r1706",
      "r1707",
      "r1708",
      "r1709",
      "r1710",
      "r1711",
      "r1712",
      "r1713",
      "r1714",
      "r1715",
      "r1717",
      "r1718"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCopromotionProfitSharingFormulaDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherResearchandDiscoveryArrangementsandFundingArrangementsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsPretaxProfitSharingFormulaDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsStokeTherapeuticsIncDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoLEQEMBICollaborationDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails",
      "http://www.biogenidec.com/role/SegmentInformationAdditionalSegmentInformationDetails",
      "http://www.biogenidec.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]",
        "documentation": "Product or service, or a group of similar products or similar services."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r163",
      "r164",
      "r165",
      "r166",
      "r167",
      "r183",
      "r336",
      "r877",
      "r968",
      "r969",
      "r970",
      "r971",
      "r972",
      "r973",
      "r974",
      "r1116",
      "r1132",
      "r1135",
      "r1137",
      "r1164",
      "r1165",
      "r1266",
      "r1268",
      "r1269",
      "r1273",
      "r1277",
      "r1383",
      "r1398",
      "r1418",
      "r1419",
      "r1420",
      "r1421",
      "r1422",
      "r1423",
      "r1424",
      "r1425",
      "r1426",
      "r1427",
      "r1428",
      "r1429",
      "r1430",
      "r1431",
      "r1432",
      "r1433",
      "r1434",
      "r1435",
      "r1436",
      "r1437",
      "r1438",
      "r1439",
      "r1440",
      "r1441",
      "r1442",
      "r1443",
      "r1444",
      "r1445",
      "r1446",
      "r1447",
      "r1448",
      "r1449",
      "r1450",
      "r1451",
      "r1452",
      "r1453",
      "r1454",
      "r1456",
      "r1457",
      "r1458",
      "r1459",
      "r1549",
      "r1550",
      "r1687",
      "r1690",
      "r1691",
      "r1692",
      "r1693",
      "r1694",
      "r1695",
      "r1696",
      "r1697",
      "r1698",
      "r1699",
      "r1700",
      "r1701",
      "r1702",
      "r1703",
      "r1704",
      "r1705",
      "r1706",
      "r1707",
      "r1708",
      "r1709",
      "r1710",
      "r1711",
      "r1712",
      "r1713",
      "r1714",
      "r1715",
      "r1717",
      "r1718"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net income",
        "terseLabel": "Net income",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r190",
      "r195",
      "r218",
      "r221",
      "r242",
      "r247",
      "r251",
      "r252",
      "r255",
      "r267",
      "r276",
      "r280",
      "r281",
      "r378",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r497",
      "r585",
      "r618",
      "r684",
      "r688",
      "r691",
      "r692",
      "r776",
      "r806",
      "r920",
      "r922",
      "r945",
      "r1001",
      "r1044",
      "r1061",
      "r1062",
      "r1222",
      "r1223",
      "r1287",
      "r1414",
      "r1552"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Abstract]",
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Axis]",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r833"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/PropertyPlantandEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r141",
      "r142",
      "r143"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Property, plant and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r833",
      "r927",
      "r943",
      "r1254"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Domain]",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r833"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r1326"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1326"
     ]
    },
    "biib_QALSODYMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "QALSODYMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "QALSODY",
        "label": "QALSODY [Member]",
        "documentation": "QALSODY"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.biogenidec.com/role/FairValueMeasuresLevel3AssetsandLiabilitiesHeldatFairValueDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]",
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r155",
      "r157",
      "r158",
      "r160",
      "r177",
      "r179",
      "r180",
      "r185",
      "r186",
      "r305",
      "r450",
      "r451",
      "r452",
      "r453",
      "r535",
      "r547",
      "r576",
      "r577",
      "r578",
      "r584",
      "r588",
      "r782",
      "r850",
      "r859",
      "r876",
      "r975",
      "r977",
      "r989",
      "r1014",
      "r1015",
      "r1070",
      "r1074",
      "r1076",
      "r1077",
      "r1087",
      "r1096",
      "r1097",
      "r1099",
      "r1100",
      "r1112",
      "r1113",
      "r1153",
      "r1163",
      "r1179",
      "r1182",
      "r1188",
      "r1191",
      "r1245",
      "r1246",
      "r1250",
      "r1251",
      "r1268",
      "r1280",
      "r1542",
      "r1554",
      "r1643",
      "r1673",
      "r1674",
      "r1675",
      "r1676",
      "r1677"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails",
      "http://www.biogenidec.com/role/DerivativeInstrumentsNarrativeDetails",
      "http://www.biogenidec.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.biogenidec.com/role/FairValueMeasuresLevel3AssetsandLiabilitiesHeldatFairValueDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]",
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r155",
      "r157",
      "r158",
      "r160",
      "r177",
      "r179",
      "r180",
      "r185",
      "r186",
      "r305",
      "r450",
      "r451",
      "r452",
      "r453",
      "r535",
      "r547",
      "r576",
      "r577",
      "r578",
      "r584",
      "r588",
      "r782",
      "r850",
      "r859",
      "r876",
      "r975",
      "r977",
      "r989",
      "r1014",
      "r1015",
      "r1070",
      "r1074",
      "r1076",
      "r1077",
      "r1087",
      "r1096",
      "r1097",
      "r1099",
      "r1100",
      "r1112",
      "r1113",
      "r1153",
      "r1163",
      "r1179",
      "r1182",
      "r1188",
      "r1191",
      "r1245",
      "r1246",
      "r1250",
      "r1251",
      "r1268",
      "r1280",
      "r1542",
      "r1554",
      "r1643",
      "r1673",
      "r1674",
      "r1675",
      "r1676",
      "r1677"
     ]
    },
    "biib_RareDiseaseProductRevenueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "RareDiseaseProductRevenueMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rare Disease Product Revenue",
        "label": "Rare Disease Product Revenue [Member]",
        "documentation": "Rare Disease Product Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RealizedInvestmentGainsLosses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RealizedInvestmentGainsLosses",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailOtherIncomeExpenseNetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "(Gains) losses on investments, net",
        "label": "Realized Investment Gains (Losses)",
        "documentation": "Amount of realized gain (loss) on investment."
       }
      }
     },
     "auth_ref": [
      "r952"
     ]
    },
    "biib_ReataIntegrationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "ReataIntegrationMember",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reata Integration",
        "label": "Reata Integration [Member]",
        "documentation": "Reata Integration"
       }
      }
     },
     "auth_ref": []
    },
    "biib_ReataPharmaceuticalsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "ReataPharmaceuticalsIncMember",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessNarrativeDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillChangesinGoodwillDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reata Pharmaceuticals, Inc",
        "label": "Reata Pharmaceuticals, Inc [Member]",
        "documentation": "Reata Pharmaceuticals, Inc"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/EquityReclassifiedFromAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]",
        "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r225"
     ]
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Amounts reclassified from AOCI",
        "label": "Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r20"
     ]
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis",
     "presentation": [
      "http://www.biogenidec.com/role/EquityReclassifiedFromAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]",
        "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r225"
     ]
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain",
     "presentation": [
      "http://www.biogenidec.com/role/EquityReclassifiedFromAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]",
        "documentation": "Item reclassified out of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r225"
     ]
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.biogenidec.com/role/EquityReclassifiedFromAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]",
        "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r225"
     ]
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable",
     "presentation": [
      "http://www.biogenidec.com/role/EquityReclassifiedFromAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Table]",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]",
        "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r225"
     ]
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/EquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]",
        "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": []
    },
    "biib_ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "ReclassificationOutofAccumulatedOtherComprehensiveIncomeLossAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]",
        "label": "Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]",
        "documentation": "Reclassification Out of Accumulated Other Comprehensive Income (Loss) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReconciliationOfAssetsFromSegmentToConsolidatedTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReconciliationOfAssetsFromSegmentToConsolidatedTable",
     "presentation": [
      "http://www.biogenidec.com/role/SegmentInformationAdditionalSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of Assets from Segment to Consolidated [Table]",
        "label": "Reconciliation of Assets from Segment to Consolidated [Table]",
        "documentation": "Disclosure of information about identification, description, and amounts of all significant reconciling items in the reconciliation of total assets from reportable segments to the entity's consolidated assets."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r30"
     ]
    },
    "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/SegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of revenue from segments to consolidated",
        "label": "Reconciliation of Revenue from Segments to Consolidated [Table Text Block]",
        "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues."
       }
      }
     },
     "auth_ref": [
      "r28",
      "r30"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1294",
      "r1304",
      "r1314",
      "r1346"
     ]
    },
    "biib_ReductionOfRealEstateFootprint": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "ReductionOfRealEstateFootprint",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reduction of real estate footprint",
        "label": "Reduction Of Real Estate Footprint",
        "documentation": "Reduction Of Real Estate Footprint"
       }
      }
     },
     "auth_ref": []
    },
    "biib_ReductionOfResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "ReductionOfResearchAndDevelopmentExpense",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherResearchandDiscoveryArrangementsandFundingArrangementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reduction of research and development expense",
        "label": "Reduction Of Research And Development Expense",
        "documentation": "Reduction Of Research And Development Expense"
       }
      }
     },
     "auth_ref": []
    },
    "biib_Reductioninroyaltyrate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "Reductioninroyaltyrate",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reduction in royalty rate",
        "label": "Reduction in royalty rate",
        "documentation": "Reduction in royalty rate"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RelatedPartyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyDomain",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party, Type [Domain]",
        "label": "Related and Nonrelated Parties [Domain]",
        "documentation": "Related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r247",
      "r254",
      "r255",
      "r341",
      "r542",
      "r546",
      "r837",
      "r838",
      "r934",
      "r941",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1042",
      "r1068",
      "r1722"
     ]
    },
    "us-gaap_RelatedPartyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyMember",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party",
        "label": "Related Party [Member]",
        "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family."
       }
      }
     },
     "auth_ref": [
      "r247",
      "r254",
      "r255",
      "r837",
      "r838",
      "r839",
      "r840",
      "r934",
      "r941",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1042",
      "r1068"
     ]
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Related Party, Type [Axis]",
        "label": "Related and Nonrelated Parties [Axis]",
        "documentation": "Information by related and nonrelated parties. Related party includes, but is not limited to, affiliate, other entity for which investment is accounted for under equity method, trust for benefit of employee, principal owner, management, and member of immediate family, and other party that may be prevented from pursuing separate interests because of control, significant influence, or ownership interest."
       }
      }
     },
     "auth_ref": [
      "r247",
      "r254",
      "r255",
      "r341",
      "r542",
      "r546",
      "r837",
      "r838",
      "r934",
      "r941",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1042",
      "r1068",
      "r1669",
      "r1722"
     ]
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RepaymentsOfLongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Repayments of borrowings",
        "label": "Repayments of Long-Term Debt",
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r99",
      "r997"
     ]
    },
    "us-gaap_RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repayments of short-term debt, maturing in more than three months",
        "label": "Repayments of Short-Term Debt, Maturing in More than Three Months",
        "documentation": "The cash outflow from a repayment of a borrowing having initial term of repayment of more than three months but less than one year or one operating cycle (if the normal cycle is more than one year)."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "biib_ReportableSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "ReportableSegmentMember",
     "presentation": [
      "http://www.biogenidec.com/role/SegmentInformationAdditionalSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reportable Segment",
        "label": "Reportable Segment [Member]",
        "documentation": "Reportable Segment"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherResearchandDiscoveryArrangementsandFundingArrangementsDetails",
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]",
        "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution."
       }
      }
     },
     "auth_ref": [
      "r181",
      "r182",
      "r247",
      "r256",
      "r257",
      "r471",
      "r510",
      "r840",
      "r860",
      "r930",
      "r1126",
      "r1128",
      "r1129",
      "r1401",
      "r1402",
      "r1403",
      "r1404",
      "r1405",
      "r1406",
      "r1407",
      "r1408",
      "r1409",
      "r1630",
      "r1631",
      "r1632",
      "r1633"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "presentation": [
      "http://www.biogenidec.com/role/SegmentInformationAdditionalSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "documentation": "Information by form of arrangement related to research and development."
       }
      }
     },
     "auth_ref": [
      "r589",
      "r1589"
     ]
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "presentation": [
      "http://www.biogenidec.com/role/SegmentInformationAdditionalSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others."
       }
      }
     },
     "auth_ref": [
      "r589",
      "r1589"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.biogenidec.com/role/SegmentInformationAdditionalSegmentInformationDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/SegmentInformationAdditionalSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research and development",
        "terseLabel": "Research and development:",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "documentation": "Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r1588"
     ]
    },
    "biib_ResearchAndDevelopmentExpenseIncludingAcquiredInProcessCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "ResearchAndDevelopmentExpenseIncludingAcquiredInProcessCost",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/SegmentInformationAdditionalSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Acquired in-process research and development, upfront and milestone expense",
        "label": "Research And Development Expense (Including Acquired in Process Cost)",
        "documentation": "Research And Development Expense (Including Acquired in Process Cost)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoStokeTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails",
      "http://www.biogenidec.com/role/SharebasedPaymentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "verboseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "biib_ResearchAndDiscoveryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "ResearchAndDiscoveryMember",
     "presentation": [
      "http://www.biogenidec.com/role/SegmentInformationAdditionalSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and discovery",
        "label": "Research And Discovery [Member]",
        "documentation": "Research And Discovery"
       }
      }
     },
     "auth_ref": []
    },
    "biib_ReserveforCashDiscountsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "ReserveforCashDiscountsMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discounts",
        "label": "Reserve for Cash Discounts [Member]",
        "documentation": "Reserve for Cash Discounts [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RestatementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RestatementAxis",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revision of Prior Period [Axis]",
        "label": "Revision of Prior Period [Axis]",
        "documentation": "Information by adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r188",
      "r189",
      "r190",
      "r191",
      "r234",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r271",
      "r272",
      "r273",
      "r274",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r297",
      "r380",
      "r381",
      "r496",
      "r497",
      "r585",
      "r616",
      "r617",
      "r618",
      "r619",
      "r683",
      "r684",
      "r773",
      "r774",
      "r775",
      "r776",
      "r827",
      "r835",
      "r836",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r992",
      "r1491"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1295",
      "r1305",
      "r1315",
      "r1347"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r1296",
      "r1306",
      "r1316",
      "r1348"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1303",
      "r1313",
      "r1323",
      "r1355"
     ]
    },
    "srt_RestatementDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RestatementDomain",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revision of Prior Period [Domain]",
        "label": "Revision of Prior Period [Domain]",
        "documentation": "Adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r188",
      "r189",
      "r190",
      "r191",
      "r234",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r271",
      "r272",
      "r273",
      "r274",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r297",
      "r380",
      "r381",
      "r496",
      "r497",
      "r585",
      "r616",
      "r617",
      "r618",
      "r619",
      "r683",
      "r684",
      "r773",
      "r774",
      "r775",
      "r776",
      "r827",
      "r835",
      "r836",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r992",
      "r1491"
     ]
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiatives"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring, Business Transformation and Other Cost Saving Initiatives",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled."
       }
      }
     },
     "auth_ref": [
      "r436",
      "r437",
      "r439",
      "r442",
      "r447"
     ]
    },
    "biib_RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected operating expense reduction",
        "label": "Restructuring And Related Activities, Expected Operating Expense Reduction",
        "documentation": "Restructuring And Related Activities, Expected Operating Expense Reduction"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedCostExpectedCost1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringAndRelatedCostExpectedCost1",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected cost",
        "label": "Restructuring and Related Cost, Expected Cost",
        "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r438",
      "r441",
      "r444",
      "r446"
     ]
    },
    "us-gaap_RestructuringAndRelatedCostExpectedCostRemaining1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringAndRelatedCostExpectedCostRemaining1",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring and Related Cost, Expected Cost Remaining",
        "label": "Restructuring and Related Cost, Expected Cost Remaining",
        "documentation": "Amount of expected cost remaining for the specified restructuring cost."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected number of positions eliminated",
        "label": "Restructuring and Related Cost, Expected Number of Positions Eliminated",
        "documentation": "The expected number of positions to be eliminated as a result of restructuring activities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringCharges",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring charges",
        "verboseLabel": "Expense",
        "label": "Restructuring Charges",
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r231",
      "r235",
      "r443",
      "r444",
      "r1134",
      "r1543"
     ]
    },
    "us-gaap_RestructuringChargesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringChargesMember",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring charges",
        "label": "Restructuring Charges [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about restructuring charges have been included."
       }
      }
     },
     "auth_ref": [
      "r108",
      "r111"
     ]
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringCostAndReserveAxis",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Type [Axis]",
        "label": "Restructuring Type [Axis]",
        "documentation": "Information by type of restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r235",
      "r438",
      "r439",
      "r444",
      "r445",
      "r1134"
     ]
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringCostAndReserveLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Cost and Reserve [Line Items]",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r438",
      "r439",
      "r440",
      "r441",
      "r444",
      "r445",
      "r446"
     ]
    },
    "us-gaap_RestructuringPlanAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringPlanAxis",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Plan [Axis]",
        "label": "Restructuring Plan [Axis]",
        "documentation": "Information by individual restructuring plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringPlanDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringPlanDomain",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Plan [Domain]",
        "label": "Restructuring Plan [Domain]",
        "documentation": "Identification of the individual restructuring plans."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringReserve",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Restructuring reserve, beginning",
        "periodEndLabel": "Restructuring reserve, ending",
        "label": "Restructuring Reserve",
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan."
       }
      }
     },
     "auth_ref": [
      "r439",
      "r445"
     ]
    },
    "us-gaap_RestructuringReserveTranslationAdjustment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringReserveTranslationAdjustment",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Foreign currency and other adjustments",
        "label": "Restructuring Reserve, Foreign Currency Translation Gain (Loss)",
        "documentation": "Amount of foreign currency translation gain (loss) which decreases (increases) the restructuring reserve."
       }
      }
     },
     "auth_ref": [
      "r1544",
      "r1545"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Retained earnings",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r118",
      "r939",
      "r983",
      "r988",
      "r998",
      "r1025",
      "r1254"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retained earnings",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r189",
      "r190",
      "r264",
      "r265",
      "r266",
      "r268",
      "r276",
      "r279",
      "r281",
      "r379",
      "r382",
      "r425",
      "r496",
      "r585",
      "r606",
      "r607",
      "r615",
      "r616",
      "r617",
      "r619",
      "r683",
      "r684",
      "r761",
      "r763",
      "r764",
      "r766",
      "r774",
      "r826",
      "r829",
      "r979",
      "r981",
      "r1002",
      "r1724"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from Contract with Customer [Abstract]",
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/Revenues"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues",
        "label": "Revenue from Contract with Customer [Text Block]",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r146",
      "r524",
      "r525",
      "r526",
      "r527",
      "r528",
      "r529",
      "r530",
      "r531",
      "r533",
      "r534"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.biogenidec.com/role/SegmentInformationAdditionalSegmentInformationDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/EquityReclassifiedFromAOCIDetails",
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails",
      "http://www.biogenidec.com/role/SegmentInformationAdditionalSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total revenue",
        "terseLabel": "Total revenue",
        "totalLabel": "Total revenues from anti-CD20 therapeutic programs",
        "label": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r132",
      "r226",
      "r247",
      "r251",
      "r252",
      "r298",
      "r311",
      "r312",
      "r327",
      "r333",
      "r336",
      "r338",
      "r340",
      "r378",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r806",
      "r920",
      "r922",
      "r1148",
      "r1226",
      "r1274",
      "r1275",
      "r1552"
     ]
    },
    "biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "RevenuesfromantiCD20therapeuticprogramsTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues from anti-CD20 therapeutic programs",
        "label": "Revenues from anti-CD20 therapeutic programs [Table Text Block]",
        "documentation": "Revenues from anti-CD20 therapeutic programs"
       }
      }
     },
     "auth_ref": []
    },
    "biib_Revenuesfromanticd20therapeuticprogramsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "Revenuesfromanticd20therapeuticprogramsMember",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from anti-CD20 therapeutic programs",
        "label": "Revenues from anti-cd20 therapeutic programs [Member]",
        "documentation": "Revenues from anti-cd20 therapeutic programs"
       }
      }
     },
     "auth_ref": []
    },
    "biib_RituxanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "RituxanMember",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCopromotionProfitSharingFormulaDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RITUXAN",
        "label": "RITUXAN [Member]",
        "documentation": "RITUXAN."
       }
      }
     },
     "auth_ref": []
    },
    "biib_RocheGroupGenentechMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "RocheGroupGenentechMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Genentech",
        "label": "Roche Group Genentech Member",
        "documentation": "Roche group Genentech."
       }
      }
     },
     "auth_ref": []
    },
    "biib_RoyaltyAttributedToOCREVUSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "RoyaltyAttributedToOCREVUSMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty Attributed To OCREVUS",
        "label": "Royalty Attributed To OCREVUS [Member]",
        "documentation": "Royalty Attributed To OCREVUS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RoyaltyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RoyaltyMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesOtherRevenuesDetails",
      "http://www.biogenidec.com/role/SegmentInformationAdditionalSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty and other revenue",
        "label": "Royalty [Member]",
        "documentation": "Money for usage-based right to asset."
       }
      }
     },
     "auth_ref": [
      "r1556",
      "r1557"
     ]
    },
    "biib_Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty operating profit threshold for highest royalty rate percentage",
        "label": "Royalty operating profit threshold for highest royalty rate percentage",
        "documentation": "Royalty operating profit threshold for highest royalty rate percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1364"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1364"
     ]
    },
    "biib_SKYCLARYSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "SKYCLARYSMember",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SKYCLARYS",
        "label": "SKYCLARYS [Member]",
        "documentation": "SKYCLARYS"
       }
      }
     },
     "auth_ref": []
    },
    "biib_SPINRAZAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "SPINRAZAMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SPINRAZA",
        "label": "SPINRAZA [Member]",
        "documentation": "SPINRAZA [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_SageAndDenaliMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "SageAndDenaliMember",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sage and Denali",
        "label": "Sage and Denali [Member]",
        "documentation": "Sage and Denali"
       }
      }
     },
     "auth_ref": []
    },
    "biib_SageAndSangamoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "SageAndSangamoMember",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sage and Sangamo",
        "label": "Sage and Sangamo [Member]",
        "documentation": "Sage and Sangamo"
       }
      }
     },
     "auth_ref": []
    },
    "biib_SageTherapeuticsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "SageTherapeuticsIncMember",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSageTherapeuticsIncDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sage Therapeutics",
        "label": "Sage Therapeutics Inc. [Member]",
        "documentation": "Sage Therapeutics Inc."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SalesMember",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsEffectofForeignCurrencyForwardContractsandForwardCurrencyOptionsDesignatedasHedgingInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Sales [Member]",
        "documentation": "Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business."
       }
      }
     },
     "auth_ref": [
      "r1237",
      "r1629"
     ]
    },
    "us-gaap_SalesReturnsAndAllowancesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SalesReturnsAndAllowancesMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Returns",
        "label": "Sales Returns and Allowances [Member]",
        "documentation": "A revision in the estimated reserve needed for product returns and price or other concessions granted to customers."
       }
      }
     },
     "auth_ref": []
    },
    "biib_SalesTriggerGrossSalesThreshold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "SalesTriggerGrossSalesThreshold",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales trigger gross sales threshold",
        "label": "Sales Trigger Gross Sales Threshold",
        "documentation": "Sales trigger gross sales threshold."
       }
      }
     },
     "auth_ref": []
    },
    "biib_SamsungBiosimilarAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "SamsungBiosimilarAgreementMember",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Samsung Bioepis",
        "label": "Samsung Biosimilar Agreement [Member]",
        "documentation": "Samsung bio-similar agreement."
       }
      }
     },
     "auth_ref": []
    },
    "srt_ScenarioForecastMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScenarioForecastMember",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSageTherapeuticsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forecast",
        "label": "Forecast [Member]",
        "documentation": "Information reported for future period. Excludes information expected to be reported in future period for effect on historical fact."
       }
      }
     },
     "auth_ref": [
      "r548",
      "r1397"
     ]
    },
    "srt_ScenarioPreviouslyReportedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScenarioPreviouslyReportedMember",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Previously Reported",
        "label": "Previously Reported [Member]",
        "documentation": "Represents amount as previously reported before adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision."
       }
      }
     },
     "auth_ref": [
      "r188",
      "r189",
      "r190",
      "r264",
      "r266",
      "r267",
      "r268",
      "r271",
      "r272",
      "r281",
      "r297",
      "r496",
      "r497",
      "r585",
      "r616",
      "r618",
      "r619",
      "r683",
      "r684",
      "r773",
      "r774",
      "r775",
      "r827",
      "r979",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r992",
      "r1386",
      "r1387",
      "r1388",
      "r1480",
      "r1481",
      "r1491",
      "r1512",
      "r1513",
      "r1638",
      "r1667",
      "r1668"
     ]
    },
    "srt_ScenarioUnspecifiedDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScenarioUnspecifiedDomain",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSageTherapeuticsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario [Domain]",
        "label": "Scenario [Domain]",
        "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r192",
      "r193",
      "r282",
      "r548",
      "r1376"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued expenses and other",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/EquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss)",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r1660",
      "r1661"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r294"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/AcquisitionsPreliminatyPurchasePriceAllocationDetails",
      "http://www.biogenidec.com/role/AcquisitionsPurchasePriceConsiderationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combination [Table]",
        "label": "Business Combination [Table]",
        "documentation": "Disclosure of information about business combination. Includes, but is not limited to, recognized asset and liability."
       }
      }
     },
     "auth_ref": [
      "r408",
      "r621",
      "r622",
      "r623",
      "r624",
      "r630",
      "r631",
      "r632",
      "r633",
      "r639",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r675",
      "r676",
      "r677",
      "r681",
      "r1182",
      "r1191",
      "r1601",
      "r1607",
      "r1609"
     ]
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combination",
        "label": "Business Combination [Table Text Block]",
        "documentation": "Tabular disclosure of business combination. Includes, but is not limited to, recognized asset and liability."
       }
      }
     },
     "auth_ref": [
      "r1182",
      "r1187",
      "r1599",
      "r1603",
      "r1606",
      "r1610",
      "r1612",
      "r1616"
     ]
    },
    "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of fair and carrying value of debt instruments",
        "label": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]",
        "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of financial assets with maturities of less than 90 days included within cash and cash equivalents",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "documentation": "Tabular disclosure of the components of cash and cash equivalents."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsCopromotionProfitSharingFormulaDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsIonisPharmaceuticalsIncDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherResearchandDiscoveryArrangementsandFundingArrangementsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsPretaxProfitSharingFormulaDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSageTherapeuticsIncDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsStokeTherapeuticsIncDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoLEQEMBICollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoStokeTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailAccruedExpenseandOtherDetails",
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of share-based compensation expense associated with each of our share-based compensating programs",
        "label": "Share-Based Payment Arrangement, Cost by Plan [Table Text Block]",
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of the effect of cash flow derivatives designated as hedging instruments on the condensed consolidated statements of income",
        "label": "Derivative Instruments, Gain (Loss) [Table Text Block]",
        "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments."
       }
      }
     },
     "auth_ref": [
      "r708",
      "r711",
      "r717",
      "r725",
      "r736"
     ]
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of fair value and presentation of derivatives",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r707",
      "r712",
      "r736",
      "r1237"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basic and diluted earnings per share",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1483"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Reconciliation between the U.S. federal statutory tax rate and effective tax rate",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r596",
      "r1181",
      "r1590"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails",
      "http://www.biogenidec.com/role/SharebasedPaymentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share-based compensation expense included in condensed consolidated statements of income",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
      "http://www.biogenidec.com/role/DispositionsDetailsTextual"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment, Name [Axis]",
        "label": "Investment, Name [Axis]",
        "documentation": "Information by name of investment including named security. Excludes entity that is consolidated."
       }
      }
     },
     "auth_ref": [
      "r375",
      "r376",
      "r377",
      "r614",
      "r806",
      "r1377",
      "r1378",
      "r1379",
      "r1593",
      "r1594",
      "r1595",
      "r1596"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of assets and liabilities recorded at fair value",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r1640",
      "r1641"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]",
        "label": "Intangible Asset, Finite-Lived [Table]",
        "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r417",
      "r421",
      "r422",
      "r424",
      "r878",
      "r1114",
      "r1118",
      "r1193",
      "r1194",
      "r1195",
      "r1196",
      "r1197",
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1202",
      "r1203",
      "r1204",
      "r1205",
      "r1206",
      "r1207",
      "r1208",
      "r1209",
      "r1210",
      "r1211",
      "r1212",
      "r1213",
      "r1214",
      "r1215",
      "r1216",
      "r1217",
      "r1218",
      "r1219"
     ]
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfGoodwillTable",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillChangesinGoodwillDetails",
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Goodwill [Table]",
        "label": "Goodwill [Table]",
        "documentation": "Disclosure of information about goodwill, including, but not limited to, change from acquisition, sale, impairment, and other reason."
       }
      }
     },
     "auth_ref": [
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r1155"
     ]
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfGoodwillTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Summary of roll forward of the changes in goodwill",
        "label": "Schedule of Goodwill [Table Text Block]",
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule."
       }
      }
     },
     "auth_ref": [
      "r1155",
      "r1515",
      "r1516",
      "r1517",
      "r1518",
      "r1519",
      "r1520",
      "r1521",
      "r1522",
      "r1523",
      "r1524",
      "r1525"
     ]
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table]",
        "label": "Intangible Asset, Indefinite-Lived [Table]",
        "documentation": "Disclosure of information about indefinite-lived intangible asset. Excludes finite-lived intangible asset."
       }
      }
     },
     "auth_ref": [
      "r410",
      "r420",
      "r424",
      "r1118",
      "r1193",
      "r1194",
      "r1195",
      "r1204",
      "r1205",
      "r1219"
     ]
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/InventoryTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Components of inventory",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r80",
      "r81",
      "r82"
     ]
    },
    "us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfInvestmentIncomeReportedAmountsByCategoryLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsMarketabledebtandequitysecuritiesDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsSummaryoffinancialassetswithmaturitiesoflessthan90daysincludedwithincashandcashequivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Investment Income [Line Items]",
        "label": "Net Investment Income [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r948"
     ]
    },
    "us-gaap_ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfInvestmentIncomeReportedAmountsByCategoryTable",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsMarketabledebtandequitysecuritiesDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsSummaryoffinancialassetswithmaturitiesoflessthan90daysincludedwithincashandcashequivalentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment Income [Table]",
        "label": "Investment Income [Table]",
        "documentation": "Disclosure of information about investment income, including, but not limited to, interest and dividend income and amortization of discount (premium) derived from debt and equity securities. Excludes realized and unrealized gain (loss) on investments."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r93",
      "r94",
      "r948"
     ]
    },
    "us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Foreign currency forward contracts that were entered into to hedge forecasted revenue",
        "label": "Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]",
        "documentation": "Tabular disclosure of the notional amounts of outstanding derivative positions."
       }
      }
     },
     "auth_ref": [
      "r1625"
     ]
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other income (expense), net",
        "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Combination, Recognized Asset Acquired and Liability Assumed",
        "label": "Business Combination, Recognized Asset Acquired and Liability Assumed [Table Text Block]",
        "documentation": "Tabular disclosure of asset acquired and liability assumed in business combination and recognized at acquisition date."
       }
      }
     },
     "auth_ref": [
      "r1608",
      "r1610"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]",
        "label": "Restructuring Cost [Table]",
        "documentation": "Disclosure of information about restructuring cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes restructuring cost recognized, and amount of restructuring reserve."
       }
      }
     },
     "auth_ref": [
      "r438",
      "r439",
      "r440",
      "r441",
      "r444",
      "r445",
      "r446"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring and Related Costs",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r108",
      "r109"
     ]
    },
    "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Restructuring Reserve by Type of Cost",
        "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r110"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.biogenidec.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock by Class [Table]",
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r39",
      "r40",
      "r41",
      "r42",
      "r43",
      "r116",
      "r117",
      "r118",
      "r204",
      "r205",
      "r206",
      "r300",
      "r508",
      "r509",
      "r510",
      "r512",
      "r515",
      "r520",
      "r522",
      "r759",
      "r994",
      "r995",
      "r996",
      "r997",
      "r1163",
      "r1375",
      "r1466",
      "r1468"
     ]
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated future amortization for acquired intangible assets",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r1118",
      "r1534"
     ]
    },
    "us-gaap_SecuredDebtMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SecuredDebtMember",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Secured Debt",
        "label": "Secured Debt [Member]",
        "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets."
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1289"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r1291"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentDomain",
     "presentation": [
      "http://www.biogenidec.com/role/SegmentInformationAdditionalSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Domain]",
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r132",
      "r133",
      "r134",
      "r298",
      "r307",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r321",
      "r322",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r333",
      "r334",
      "r335",
      "r340",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r424",
      "r441",
      "r446",
      "r674",
      "r677",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r1145",
      "r1148",
      "r1149",
      "r1155",
      "r1271",
      "r1687",
      "r1690",
      "r1691",
      "r1692",
      "r1693",
      "r1694",
      "r1695",
      "r1696",
      "r1697",
      "r1698",
      "r1699",
      "r1700",
      "r1701",
      "r1702",
      "r1703",
      "r1704",
      "r1705",
      "r1706",
      "r1707",
      "r1708",
      "r1709",
      "r1710",
      "r1711",
      "r1712",
      "r1713",
      "r1714",
      "r1715",
      "r1717",
      "r1718"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Domain]",
        "label": "Geographical [Domain]",
        "documentation": "Geographical area."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r156",
      "r159",
      "r161",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r178",
      "r179",
      "r180",
      "r302",
      "r338",
      "r339",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r920",
      "r921",
      "r922",
      "r923",
      "r1006",
      "r1009",
      "r1011",
      "r1071",
      "r1075",
      "r1080",
      "r1089",
      "r1096",
      "r1098",
      "r1099",
      "r1100",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1117",
      "r1140",
      "r1164",
      "r1166",
      "r1256",
      "r1257",
      "r1258",
      "r1259",
      "r1260",
      "r1261",
      "r1262",
      "r1263",
      "r1270",
      "r1280",
      "r1687",
      "r1690",
      "r1691",
      "r1693",
      "r1694",
      "r1695",
      "r1696",
      "r1697",
      "r1698",
      "r1699",
      "r1700",
      "r1701",
      "r1702",
      "r1703",
      "r1704",
      "r1705",
      "r1706",
      "r1707",
      "r1708",
      "r1709",
      "r1710",
      "r1711",
      "r1712",
      "r1713",
      "r1714",
      "r1715",
      "r1717",
      "r1718"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingAssetReconcilingItemLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingAssetReconcilingItemLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/SegmentInformationAdditionalSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting, Asset Reconciling Item [Line Items]",
        "label": "Segment Reporting, Asset Reconciling Item [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/SegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Segment Information",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r134",
      "r298",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r323",
      "r325",
      "r326",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r340",
      "r1144",
      "r1146",
      "r1147",
      "r1148",
      "r1150",
      "r1151",
      "r1152"
     ]
    },
    "us-gaap_SegmentReportingOtherItemAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingOtherItemAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/SegmentInformationAdditionalSegmentInformationDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/SegmentInformationAdditionalSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other segment expense",
        "label": "Segment Reporting, Other Segment Item, Amount",
        "documentation": "Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss)."
       }
      }
     },
     "auth_ref": [
      "r298",
      "r325",
      "r326",
      "r333",
      "r1148"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited": {
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.biogenidec.com/role/SegmentInformationAdditionalSegmentInformationDetails": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/SegmentInformationAdditionalSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Selling, general and administrative",
        "terseLabel": "Selling, general and administrative",
        "label": "Selling, General and Administrative Expense",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r1132",
      "r1133",
      "r1134",
      "r1137",
      "r1455"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoLEQEMBICollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails",
      "http://www.biogenidec.com/role/SharebasedPaymentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general and administrative",
        "verboseLabel": "Selling, general and administrative",
        "label": "Selling, General and Administrative Expenses [Member]",
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r1182",
      "r1187"
     ]
    },
    "biib_SeniorNotes3.250DueFebruary152051Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "SeniorNotes3.250DueFebruary152051Member",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "3.250% Senior Notes due February 15, 2051",
        "label": "Senior Notes 3.250%, Due February 15, 2051 [Member]",
        "documentation": "Senior Notes 3.250%, Due February 15, 2051"
       }
      }
     },
     "auth_ref": []
    },
    "biib_SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDebtInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "5.200% Senior Notes due September 15, 2045",
        "label": "Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]",
        "documentation": "Senior Notes Five Point Two Percent Due Twenty Forty Five [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDebtInstrumentsDetails",
      "http://www.biogenidec.com/role/IndebtednessNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "4.050% Senior Notes due 2025",
        "label": "Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]",
        "documentation": "Senior Notes Four Point Zero Five Percent Due Twenty Twenty Five [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeniorNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SeniorNotesMember",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsDebtInstrumentsDetails",
      "http://www.biogenidec.com/role/IndebtednessNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Senior Notes",
        "label": "Senior Notes [Member]",
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ServiceOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ServiceOtherMember",
     "presentation": [
      "http://www.biogenidec.com/role/SegmentInformationAdditionalSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other research and development costs",
        "label": "Service, Other [Member]",
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, financial service, and other financial service, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1135",
      "r1556",
      "r1557"
     ]
    },
    "us-gaap_SeveranceCosts1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SeveranceCosts1",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesFItforGrowthInitiativeDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Severance Costs",
        "label": "Severance Costs",
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationAllocationAndClassificationInFinancialStatementsAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share-based Compensation Expense included in consolidated statements of income",
        "label": "Share-Based Payment Arrangement, Recognized Amount [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r553",
      "r554",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579"
     ]
    },
    "biib_ShareBasedCompensationExpenseIncludedInCostsAndExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "ShareBasedCompensationExpenseIncludedInCostsAndExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails": {
       "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpenseIncludedInStatementsOfIncomeDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation expense included in total cost and expense",
        "label": "Share Based Compensation Expense Included In Costs And Expenses",
        "documentation": "Share based compensation expense included in costs and expenses."
       }
      }
     },
     "auth_ref": []
    },
    "biib_ShareOfCoPromotionProfits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "ShareOfCoPromotionProfits",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails": {
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesfromAntiCD20TherapeuticProgramsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA",
        "label": "Share Of Co Promotion Profits",
        "documentation": "Share of co promotion profits."
       }
      }
     },
     "auth_ref": []
    },
    "biib_ShareOfNetProfitFromSageTherapeuticsPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "ShareOfNetProfitFromSageTherapeuticsPercent",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSageTherapeuticsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share of net profit from sage therapeutics, Percent",
        "label": "Share Of Net Profit From Sage Therapeutics, Percent",
        "documentation": "Share Of Net Profit From Sage Therapeutics, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "biib_ShareOfNonControlingInterestRecognized": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "ShareOfNonControlingInterestRecognized",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails",
      "http://www.biogenidec.com/role/RevenuesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share of non-controling interest recognized",
        "label": "Share Of Non-Controling Interest Recognized",
        "documentation": "Share Of Non-Controling Interest Recognized"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ShareRepurchaseProgramAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ShareRepurchaseProgramAxis",
     "presentation": [
      "http://www.biogenidec.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Repurchase Program [Axis]",
        "label": "Share Repurchase Program [Axis]",
        "documentation": "Information by share repurchase program."
       }
      }
     },
     "auth_ref": [
      "r1555"
     ]
    },
    "srt_ShareRepurchaseProgramDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ShareRepurchaseProgramDomain",
     "presentation": [
      "http://www.biogenidec.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Repurchase Program [Domain]",
        "label": "Share Repurchase Program [Domain]",
        "documentation": "Name of share repurchase program."
       }
      }
     },
     "auth_ref": [
      "r1555"
     ]
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of significant accounting policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r245",
      "r246"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://www.biogenidec.com/role/SegmentInformationAdditionalSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Axis]",
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r132",
      "r133",
      "r134",
      "r194",
      "r298",
      "r307",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r321",
      "r322",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r333",
      "r334",
      "r335",
      "r340",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r424",
      "r427",
      "r441",
      "r446",
      "r674",
      "r677",
      "r957",
      "r958",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964",
      "r965",
      "r966",
      "r967",
      "r1145",
      "r1148",
      "r1149",
      "r1155",
      "r1271",
      "r1687",
      "r1690",
      "r1691",
      "r1692",
      "r1693",
      "r1694",
      "r1695",
      "r1696",
      "r1697",
      "r1698",
      "r1699",
      "r1700",
      "r1701",
      "r1702",
      "r1703",
      "r1704",
      "r1705",
      "r1706",
      "r1707",
      "r1708",
      "r1709",
      "r1710",
      "r1711",
      "r1712",
      "r1713",
      "r1714",
      "r1715",
      "r1717",
      "r1718"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.biogenidec.com/role/EquityReclassifiedFromAOCIDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r74",
      "r77",
      "r78",
      "r187",
      "r189",
      "r190",
      "r223",
      "r224",
      "r225",
      "r264",
      "r265",
      "r266",
      "r268",
      "r276",
      "r279",
      "r281",
      "r299",
      "r379",
      "r382",
      "r425",
      "r496",
      "r523",
      "r585",
      "r606",
      "r607",
      "r615",
      "r616",
      "r617",
      "r619",
      "r683",
      "r684",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r767",
      "r768",
      "r769",
      "r770",
      "r774",
      "r815",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r826",
      "r829",
      "r836",
      "r947",
      "r979",
      "r980",
      "r981",
      "r1002",
      "r1063"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOCREVUSDetails",
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Axis]",
        "label": "Geographical [Axis]",
        "documentation": "Information by geographical components."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r156",
      "r159",
      "r161",
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r176",
      "r178",
      "r179",
      "r180",
      "r302",
      "r338",
      "r339",
      "r880",
      "r881",
      "r882",
      "r883",
      "r884",
      "r885",
      "r886",
      "r887",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r893",
      "r894",
      "r895",
      "r896",
      "r897",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r905",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r911",
      "r912",
      "r913",
      "r920",
      "r921",
      "r922",
      "r923",
      "r1006",
      "r1009",
      "r1011",
      "r1071",
      "r1075",
      "r1080",
      "r1089",
      "r1096",
      "r1098",
      "r1099",
      "r1100",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1117",
      "r1140",
      "r1164",
      "r1166",
      "r1256",
      "r1257",
      "r1258",
      "r1259",
      "r1260",
      "r1261",
      "r1262",
      "r1263",
      "r1270",
      "r1280",
      "r1687",
      "r1690",
      "r1691",
      "r1693",
      "r1694",
      "r1695",
      "r1696",
      "r1697",
      "r1698",
      "r1699",
      "r1700",
      "r1701",
      "r1702",
      "r1703",
      "r1704",
      "r1705",
      "r1706",
      "r1707",
      "r1708",
      "r1709",
      "r1710",
      "r1711",
      "r1712",
      "r1713",
      "r1714",
      "r1715",
      "r1717",
      "r1718"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r264",
      "r265",
      "r266",
      "r299",
      "r498",
      "r499",
      "r501",
      "r503",
      "r829",
      "r877",
      "r993",
      "r1003",
      "r1004",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1024",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1045",
      "r1046",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1063",
      "r1135",
      "r1137",
      "r1281",
      "r1722"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Comprehensive Income [Abstract]",
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_StatementScenarioAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StatementScenarioAxis",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSageTherapeuticsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Scenario [Axis]",
        "label": "Scenario [Axis]",
        "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts."
       }
      }
     },
     "auth_ref": [
      "r184",
      "r192",
      "r193",
      "r282",
      "r548",
      "r1376",
      "r1380"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofCashFlowsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r264",
      "r265",
      "r266",
      "r299",
      "r341",
      "r498",
      "r499",
      "r501",
      "r503",
      "r829",
      "r877",
      "r993",
      "r1003",
      "r1004",
      "r1016",
      "r1017",
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1024",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1045",
      "r1046",
      "r1048",
      "r1049",
      "r1050",
      "r1051",
      "r1052",
      "r1053",
      "r1054",
      "r1055",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1063",
      "r1135",
      "r1137",
      "r1281",
      "r1722"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1298",
      "r1308",
      "r1318",
      "r1350"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": [
      "r1560",
      "r1561",
      "r1562",
      "r1563",
      "r1564",
      "r1565",
      "r1566",
      "r1567",
      "r1568",
      "r1569",
      "r1570",
      "r1571",
      "r1572",
      "r1573",
      "r1574",
      "r1575",
      "r1576",
      "r1577",
      "r1578",
      "r1579",
      "r1580",
      "r1581",
      "r1582",
      "r1583",
      "r1584",
      "r1585"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock under stock award plan (in shares)",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures",
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r73",
      "r74",
      "r118"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesTreasuryStockReissued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesTreasuryStockReissued",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock under stock option and stock purchase plans, shares",
        "label": "Stock Issued During Period, Shares, Treasury Stock Reissued",
        "documentation": "Number of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r74",
      "r118"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock under stock award plan",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures",
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r118"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueTreasuryStockReissued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueTreasuryStockReissued",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock under stock option and stock purchase plans",
        "label": "Stock Issued During Period, Value, Treasury Stock Reissued",
        "documentation": "Value of treasury shares or units reissued. Excludes reissuance of shares or units in treasury for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r44",
      "r73",
      "r74",
      "r118"
     ]
    },
    "srt_StockRepurchaseProgramAuthorizedAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock repurchase program, authorized amount",
        "label": "Share Repurchase Program, Authorized, Amount",
        "documentation": "Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership."
       }
      }
     },
     "auth_ref": [
      "r1555"
     ]
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount remaining under 2019 share repurchase program",
        "label": "Share Repurchase Program, Remaining Authorized, Amount",
        "documentation": "Amount remaining authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/EquityAccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning Balance",
        "periodEndLabel": "Ending Balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r77",
      "r78",
      "r103",
      "r1026",
      "r1043",
      "r1064",
      "r1065",
      "r1254",
      "r1288",
      "r1466",
      "r1470",
      "r1471",
      "r1511",
      "r1659",
      "r1724"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Biogen Inc. shareholders\u2019 equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r48",
      "r50",
      "r187",
      "r188",
      "r189",
      "r190",
      "r224",
      "r264",
      "r265",
      "r266",
      "r268",
      "r276",
      "r279",
      "r379",
      "r382",
      "r425",
      "r496",
      "r523",
      "r585",
      "r606",
      "r607",
      "r615",
      "r616",
      "r617",
      "r619",
      "r683",
      "r684",
      "r761",
      "r762",
      "r763",
      "r764",
      "r765",
      "r766",
      "r774",
      "r815",
      "r817",
      "r821",
      "r827",
      "r836",
      "r980",
      "r981",
      "r1000",
      "r1026",
      "r1043",
      "r1064",
      "r1065",
      "r1094",
      "r1274",
      "r1275",
      "r1287",
      "r1466",
      "r1470",
      "r1471",
      "r1511",
      "r1659",
      "r1724"
     ]
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Equity:",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/Equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r507",
      "r509",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r521",
      "r523",
      "r759",
      "r772",
      "r1066",
      "r1067",
      "r1095"
     ]
    },
    "us-gaap_StockholdersEquityOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityOther",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Other",
        "label": "Stockholders' Equity, Other",
        "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy."
       }
      }
     },
     "auth_ref": []
    },
    "biib_StokeTherapeuticsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "StokeTherapeuticsIncMember",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsStokeTherapeuticsIncDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoStokeTherapeuticsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stoke Therapeutics Inc",
        "label": "Stoke Therapeutics Inc [Member]",
        "documentation": "Stoke Therapeutics Inc"
       }
      }
     },
     "auth_ref": []
    },
    "biib_StrategicInvestmentPortfolio": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "StrategicInvestmentPortfolio",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Strategic investment portfolio",
        "label": "Strategic Investment Portfolio",
        "documentation": "Strategic investment portfolio."
       }
      }
     },
     "auth_ref": []
    },
    "biib_StrategicInvestmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "StrategicInvestmentsMember",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Strategic Investments",
        "label": "Strategic Investments [Member]",
        "documentation": "Strategic investments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Line Items]",
        "label": "Subsequent Event [Line Items]",
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event."
       }
      }
     },
     "auth_ref": [
      "r822",
      "r842"
     ]
    },
    "us-gaap_SubsequentEventMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventMember",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event",
        "label": "Subsequent Event [Member]",
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r822",
      "r842"
     ]
    },
    "us-gaap_SubsequentEventTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTable",
     "presentation": [
      "http://www.biogenidec.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event [Table]",
        "label": "Subsequent Event [Table]",
        "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued."
       }
      }
     },
     "auth_ref": [
      "r822",
      "r842"
     ]
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeAxis",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Axis]",
        "label": "Subsequent Event Type [Axis]",
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r822",
      "r842"
     ]
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventTypeDomain",
     "presentation": [
      "http://www.biogenidec.com/role/AcquisitionsNarrativeDetails",
      "http://www.biogenidec.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Event Type [Domain]",
        "label": "Subsequent Event Type [Domain]",
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued."
       }
      }
     },
     "auth_ref": [
      "r822",
      "r842"
     ]
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r841",
      "r843"
     ]
    },
    "biib_SummaryOfActivityRelatedToCollaborationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "SummaryOfActivityRelatedToCollaborationTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Activity Related to Stoke Therapeutics Collaboration",
        "label": "Summary Of Activity Related To Collaboration [Table Text Block]",
        "documentation": "Summary Of Activity Related To Collaboration"
       }
      }
     },
     "auth_ref": []
    },
    "biib_SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Activity Related to Denali Therapeutics Collaboration",
        "label": "Summary of Activity Related to Denali Therapeutics Collaboration [Table Text Block]",
        "documentation": "Summary of Activity Related to Denali Therapeutics Collaboration"
       }
      }
     },
     "auth_ref": []
    },
    "biib_SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Activity Related to Sage Therapeutics",
        "label": "Summary of Activity Related to Sage Therapeutics [Table Text Block]",
        "documentation": "Summary of Activity Related to Sage Therapeutics"
       }
      }
     },
     "auth_ref": []
    },
    "biib_SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of activity related to the UCB collaboration",
        "label": "Summary of Activity Related to the UCB Collaboration [Table Text Block]",
        "documentation": "Summary of Activity Related to the UCB Collaboration"
       }
      }
     },
     "auth_ref": []
    },
    "biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total reserves included in consolidated balance sheets",
        "label": "Summary Of Product Revenue Reserves Included In Consolidated Balance Sheets [Table Text Block]",
        "documentation": "Summary of total product revenue reserves included in consolidated balance sheets."
       }
      }
     },
     "auth_ref": []
    },
    "biib_SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "SummaryOfShareBasedCompensationExpenseAssociatedWithDifferentProgramsAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of share based compensation expense associated with different programs [Abstract]",
        "label": "Summary of share based compensation expense associated with different programs [Abstract]",
        "documentation": "Summary of share-based compensation expense associated with different programs."
       }
      }
     },
     "auth_ref": []
    },
    "biib_SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Activity Related to BAN2401 and Elenbecestat Collaboration",
        "label": "Summary of Activity Related to E2609 and BAN2401 Collaboration [Table Text Block]",
        "documentation": "[Table Text Block] for Summary of Activity Related to E2609 and BAN2401 Collaboration [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_TECFIDERAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "TECFIDERAMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TECFIDERA",
        "label": "TECFIDERA [Member]",
        "documentation": "TECFIDERA [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_TOFIDENCEMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "TOFIDENCEMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TOFIDENCE",
        "label": "TOFIDENCE [Member]",
        "documentation": "TOFIDENCE"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1344"
     ]
    },
    "us-gaap_TaxesPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxesPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Taxes payable",
        "label": "Taxes Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r65"
     ]
    },
    "biib_TermLoan2023ThreeYearTrancheMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "TermLoan2023ThreeYearTrancheMember",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2023 Term Loan Three-Year Tranche",
        "label": "Term Loan 2023 Three-Year Tranche [Member]",
        "documentation": "Term Loan 2023 Three-Year Tranche"
       }
      }
     },
     "auth_ref": []
    },
    "biib_TheCreditFacilityFloatingRate364DayTrancheMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "TheCreditFacilityFloatingRate364DayTrancheMember",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Credit Facility Floating Rate 364-Day Tranche",
        "label": "The Credit Facility Floating Rate 364-Day Tranche [Member]",
        "documentation": "Credit Facility Floating Rate 364-Day Tranche"
       }
      }
     },
     "auth_ref": []
    },
    "biib_TheCreditFacilityFloatingRateThreeYearTrancheMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "TheCreditFacilityFloatingRateThreeYearTrancheMember",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "The Credit Facility Floating Rate Three-Year Tranche",
        "label": "The Credit Facility Floating Rate Three-Year Tranche [Member]",
        "documentation": "The Credit Facility Floating Rate Three-Year Tranche"
       }
      }
     },
     "auth_ref": []
    },
    "biib_TheCreditFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "TheCreditFacilityMember",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "The Credit Facility",
        "label": "The Credit Facility [Member]",
        "documentation": "The Credit Facility"
       }
      }
     },
     "auth_ref": []
    },
    "biib_TheCreditFacilityTerminatedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "TheCreditFacilityTerminatedMember",
     "presentation": [
      "http://www.biogenidec.com/role/IndebtednessNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "The Credit Facility, Terminated",
        "label": "The Credit Facility, Terminated [Member]",
        "documentation": "The Credit Facility, Terminated"
       }
      }
     },
     "auth_ref": []
    },
    "biib_ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsPretaxProfitSharingFormulaDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Limit of gross sale of GAZYVA to be achieved in preceding 12 months under option one",
        "terseLabel": "Threshold of Gross Sales Of To Be Achieved In Preceding Twelve Consecutive Months Under Option One",
        "label": "Threshold Of Gross Sales Of To Be Achieved In Preceding Twelve Consecutive Months Under Option One",
        "documentation": "Threshold of gross sales of to be achieved in preceding twelve consecutive months under option one."
       }
      }
     },
     "auth_ref": []
    },
    "biib_ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsProfitSharingDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Limit of gross sale of GAZYVA to be achieved in any 12 months under option one",
        "label": "Threshold Of Gross Sales To Be Achieved In Any Twelve Consecutive Months Under Option One",
        "documentation": "Threshold of gross sales to be achieved in any twelve consecutive months under option one."
       }
      }
     },
     "auth_ref": []
    },
    "biib_TimeVestedRestrictedStockUnitsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "TimeVestedRestrictedStockUnitsMember",
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails",
      "http://www.biogenidec.com/role/ShareBasedPaymentsShareBasedCompensationExpensebyShareBasedCompensationProgramDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Time-vested restricted stock units",
        "label": "Time Vested Restricted Stock Units [Member]",
        "documentation": "Time vested restricted stock units."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1336"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1343"
     ]
    },
    "us-gaap_TrademarksAndTradeNamesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TrademarksAndTradeNamesMember",
     "presentation": [
      "http://www.biogenidec.com/role/IntangibleAssetsandGoodwillSummaryofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Trademarks and trade names",
        "label": "Trademarks and Trade Names [Member]",
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style, or rights either acquired through registration of a business name to gain or protect exclusive use thereof."
       }
      }
     },
     "auth_ref": [
      "r1194",
      "r1527",
      "r1528",
      "r1529",
      "r1530",
      "r1531",
      "r1532",
      "r1533",
      "r1535",
      "r1536",
      "r1537"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1363"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r1365"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.biogenidec.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.biogenidec.com/role/FinancialInstrumentsMarketabledebtandequitysecuritiesDetails",
      "http://www.biogenidec.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments [Domain]",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r492",
      "r520",
      "r759",
      "r771",
      "r800",
      "r805",
      "r808",
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858",
      "r861",
      "r862",
      "r863",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r929",
      "r948",
      "r1241",
      "r1243",
      "r1245",
      "r1246",
      "r1247",
      "r1248",
      "r1249",
      "r1250",
      "r1251",
      "r1255",
      "r1390",
      "r1391",
      "r1392",
      "r1393",
      "r1394",
      "r1395",
      "r1396",
      "r1506",
      "r1507",
      "r1508",
      "r1509",
      "r1639",
      "r1642",
      "r1643",
      "r1644",
      "r1651",
      "r1654",
      "r1655",
      "r1656"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r1366"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r1367"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Date",
        "label": "Trading Arrangement Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r1367"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1365"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r1365"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r1368"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r1366"
     ]
    },
    "us-gaap_TreasuryStockCommonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TreasuryStockCommonMember",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury stock",
        "label": "Treasury Stock, Common [Member]",
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_TreasuryStockCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TreasuryStockCommonShares",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementofEquityStatement"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance, treasury stock, shares",
        "periodEndLabel": "Ending balance, treasury stock, shares",
        "label": "Treasury Stock, Common, Shares",
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TreasuryStockSharesAcquired",
     "presentation": [
      "http://www.biogenidec.com/role/EquityNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Repurchase of common stock, at cost (in shares)",
        "label": "Treasury Stock, Shares, Acquired",
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r74",
      "r118"
     ]
    },
    "us-gaap_TreasuryStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TreasuryStockValue",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Treasury stock, at cost",
        "label": "Treasury Stock, Value",
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r45",
      "r74",
      "r77"
     ]
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsEisaiDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsIonisPharmaceuticalsIncDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherResearchandDiscoveryArrangementsandFundingArrangementsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSageTherapeuticsIncDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSamsungBioepisDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsStokeTherapeuticsIncDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedToDenaliTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoLEQEMBICollaborationDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoSageTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtoStokeTherapeuticsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails",
      "http://www.biogenidec.com/role/DispositionsDetailsTextual",
      "http://www.biogenidec.com/role/InventoryNarrativeDetails",
      "http://www.biogenidec.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r687"
     ]
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TypeOfRestructuringDomain",
     "presentation": [
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesRestructuringReserveRollForwardDetails",
      "http://www.biogenidec.com/role/RestructuringBusinessTransformationandOtherCostSavingInitiativesTotalChargescostsavinginitiativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Type of Restructuring [Domain]",
        "label": "Type of Restructuring [Domain]",
        "documentation": "Identification of the types of restructuring costs."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r235",
      "r438",
      "r439",
      "r444",
      "r445",
      "r1134"
     ]
    },
    "biib_TysabriProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "TysabriProductMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "TYSABRI",
        "label": "TYSABRI product [Member]",
        "documentation": "TYSABRI product [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "biib_UCBPharmaSAMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "UCBPharmaSAMember",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsSummaryofActivityRelatedtotheUCBCollaborationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "UCB Pharma S.A.",
        "label": "UCB Pharma S.A. [Member]",
        "documentation": "UCB Pharma S.A."
       }
      }
     },
     "auth_ref": []
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2025",
     "localname": "US",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S.",
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_USTreasuryAndGovernmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "USTreasuryAndGovernmentMember",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasurementsAssetsandLiabilitiesatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "US Treasury and Government [Member]",
        "label": "US Treasury and Government [Member]",
        "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac)."
       }
      }
     },
     "auth_ref": [
      "r925",
      "r1172",
      "r1174",
      "r1255",
      "r1276",
      "r1716"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r1362"
     ]
    },
    "us-gaap_UnrealizedGainLossOnDerivatives": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrealizedGainLossOnDerivatives",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/DerivativeInstrumentsPretaxPortionoftheFairValueofForeignCurrencyForwardContractsandForeignCurrencyOptionsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsPretaxPortionoftheFairValueofForeignCurrencyForwardContractsandForeignCurrencyOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net unrealized gains (losses)",
        "label": "Unrealized Gain (Loss) on Derivatives",
        "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r1056",
      "r1057",
      "r1058",
      "r1059",
      "r1083"
     ]
    },
    "biib_UnrealizedGainOnDerivatives": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "UnrealizedGainOnDerivatives",
     "crdr": "credit",
     "calculation": {
      "http://www.biogenidec.com/role/DerivativeInstrumentsPretaxPortionoftheFairValueofForeignCurrencyForwardContractsandForeignCurrencyOptionsDetails": {
       "parentTag": "us-gaap_UnrealizedGainLossOnDerivatives",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsPretaxPortionoftheFairValueofForeignCurrencyForwardContractsandForeignCurrencyOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gains",
        "label": "Unrealized Gain on Derivatives",
        "documentation": "Unrealized Gain on Derivatives"
       }
      }
     },
     "auth_ref": []
    },
    "biib_UnrealizedLossOnDerivatives": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "UnrealizedLossOnDerivatives",
     "crdr": "debit",
     "calculation": {
      "http://www.biogenidec.com/role/DerivativeInstrumentsPretaxPortionoftheFairValueofForeignCurrencyForwardContractsandForeignCurrencyOptionsDetails": {
       "parentTag": "us-gaap_UnrealizedGainLossOnDerivatives",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/DerivativeInstrumentsPretaxPortionoftheFairValueofForeignCurrencyForwardContractsandForeignCurrencyOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Unrealized (losses)",
        "label": "Unrealized Loss on Derivatives",
        "documentation": "Unrealized Loss on Derivatives"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Estimated minimum lease payments",
        "label": "Unrecorded Unconditional Purchase Obligation",
        "documentation": "Amount of unrecorded obligation to transfer funds in future for fixed or minimum amount or quantity of product and service at fixed or minimum price. Includes, but is not limited to, lease not yet commenced and take-or-pay and throughput contracts."
       }
      }
     },
     "auth_ref": [
      "r448",
      "r1666"
     ]
    },
    "biib_UpfrontAndMilestonePaymentsMadeToCollaborativePartner": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "UpfrontAndMilestonePaymentsMadeToCollaborativePartner",
     "crdr": "debit",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsOtherResearchandDiscoveryArrangementsandFundingArrangementsDetails",
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsStokeTherapeuticsIncDetails",
      "http://www.biogenidec.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront and milestone paymentsmade to collaborative partner",
        "label": "Upfront And Milestone Payments Made To Collaborative Partner",
        "documentation": "Total upfront and milestone payments made to collaborative partner."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.biogenidec.com/role/SummaryofSignificantAccountingPoliciesSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Use of estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r140",
      "r301",
      "r303",
      "r304",
      "r305",
      "r920",
      "r922",
      "r1141"
     ]
    },
    "biib_VUMERITYMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "VUMERITYMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "VUMERITY",
        "label": "VUMERITY [Member]",
        "documentation": "VUMERITY"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ValuationAllowancesAndReservesBalance",
     "crdr": "credit",
     "presentation": [
      "http://www.biogenidec.com/role/OtherConsolidatedFinancialStatementDetailAccruedExpenseandOtherDetails",
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1",
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning Balance",
        "periodEndLabel": "Ending Balance",
        "terseLabel": "Total Reserves",
        "verboseLabel": "Revenue-related reserves for discounts and allowances",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "documentation": "Amount of valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r249",
      "r259",
      "r263"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ValuationAllowancesAndReservesDomain",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "documentation": "Valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r249",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "documentation": "Information by valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r249",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263"
     ]
    },
    "srt_ValuationAndQualifyingAccountsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ValuationAndQualifyingAccountsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]",
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r249",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263"
     ]
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesReservesforDiscountsandAllowancesDetails1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "documentation": "Disclosure of information about valuation allowance and qualifying account and reserve."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r249",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263"
     ]
    },
    "biib_VanquaBioInc.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "VanquaBioInc.Member",
     "presentation": [
      "http://www.biogenidec.com/role/SubsequentEventsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vanqua Bio, Inc.",
        "label": "Vanqua Bio, Inc. [Member]",
        "documentation": "Vanqua Bio, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableInterestEntityDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "VariableInterestEntityDisclosureTextBlock",
     "presentation": [
      "http://www.biogenidec.com/role/InvestmentsinVariableInterestEntities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Investments in Variable Interest Entities",
        "label": "Variable Interest Entity Disclosure [Text Block]",
        "documentation": "The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year",
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1332"
     ]
    },
    "srt_WeightedAverageMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "WeightedAverageMember",
     "presentation": [
      "http://www.biogenidec.com/role/FairValueMeasuresLevel3AssetsandLiabilitiesHeldatFairValueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average",
        "label": "Weighted Average [Member]",
        "documentation": "Average of a range of values, calculated with consideration of proportional relevance."
       }
      }
     },
     "auth_ref": [
      "r576",
      "r577",
      "r782",
      "r859",
      "r1112",
      "r1113",
      "r1245",
      "r1672",
      "r1674",
      "r1677"
     ]
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "calculation": {
      "http://www.biogenidec.com/role/EarningsperShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Dilutive potential common shares",
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment",
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation."
       }
      }
     },
     "auth_ref": [
      "r1483"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://www.biogenidec.com/role/EarningsperShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted earnings per share attributable to Biogen Inc. (in USD per share)",
        "totalLabel": "Shares used in calculating diluted earnings per share",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r285",
      "r293"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted-average shares used in calculating:",
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "calculation": {
      "http://www.biogenidec.com/role/EarningsperShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.biogenidec.com/role/CondensedConsolidatedStatementsofIncomeUnaudited",
      "http://www.biogenidec.com/role/EarningsperShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Basic earnings per share attributable to Biogen Inc. (in USD per share)",
        "terseLabel": "Weighted average number of common shares outstanding",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r284",
      "r293"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested",
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r1330"
     ]
    },
    "biib_ZURZUVAEMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "ZURZUVAEMember",
     "presentation": [
      "http://www.biogenidec.com/role/RevenuesRevenuesbyproductDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ZURZUVAE",
        "label": "ZURZUVAE [Member]",
        "documentation": "ZURZUVAE"
       }
      }
     },
     "auth_ref": []
    },
    "biib_ZorevunersenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.biogenidec.com/20250930",
     "localname": "ZorevunersenMember",
     "presentation": [
      "http://www.biogenidec.com/role/CollaborativeandOtherRelationshipsStokeTherapeuticsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Zorevunersen",
        "label": "Zorevunersen [Member]",
        "documentation": "Zorevunersen"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(j)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(k)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(f)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(c)(2)",
   "SubTopic": "20",
   "Topic": "860",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4D"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "205",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "320",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "420",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-15"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-16"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4I"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205-20/tableOfContent"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-11"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3A"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4A"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4B"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5A"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5D"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481573/470-10-45-12A"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/505/tableOfContent"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/810/tableOfContent"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "470",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "321",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479567/321-10-45-1"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/808/tableOfContent"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "09",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "09",
   "Paragraph": "Column C",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "09",
   "Paragraph": "Column C",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "09",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "09",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column C",
   "Footnote": "5",
   "Publisher": "SEC"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column C",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(a)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(b)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column C",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column F",
   "Footnote": "7",
   "Publisher": "SEC"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column A",
   "Publisher": "SEC"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column G",
   "Publisher": "SEC"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column H",
   "Publisher": "SEC"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column I",
   "Publisher": "SEC"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column A",
   "Footnote": "3",
   "Publisher": "SEC"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column A",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "4",
   "Subsection": "08",
   "Paragraph": "m",
   "Subparagraph": "(1)(iii)",
   "Publisher": "SEC"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "4",
   "Subsection": "08",
   "Paragraph": "m",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 11",
   "Section": "L",
   "Publisher": "SEC"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 11",
   "Section": "M",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 4",
   "Publisher": "SEC"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483504/205-10-50-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481003/205-10-S50-2"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SAB Topic 1.B.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480922/205-10-S99-7"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-15"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-23"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-11"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-19"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-5"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-12"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-22"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-23"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-28A"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-24"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481962/310-10-50-4"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-2"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479344/326-20-45-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-2"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-4"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-5"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/420/tableOfContent"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-7"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480454/718-10-45-1"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-4"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-6"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/805-10/tableOfContent"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-4"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-5"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-7"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/805-20/tableOfContent"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-2"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-3"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/805-30/tableOfContent"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-3"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479326/805-40-45-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/815/tableOfContent"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4B"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CC"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CCC",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CCC",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CCC",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4E"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EE",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EE"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EE",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EE"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EE",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EE"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EE",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EE"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EEE",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EEE"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EEE",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EEE"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4EEE",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4EEE"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4H"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4H",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4H"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4I"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4K",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4K"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4K",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4K"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4K",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4K"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4K",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4K"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4K",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4K"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4K",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4K"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4K",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4K"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4K",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4K"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-5C"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "15",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480960/815-15-50-3"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2G",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2G"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-1A"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-17"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-1"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481956/830-20-45-1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481926/830-20-50-1"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483013/835-20-50-1"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-1"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/855/tableOfContent"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(d)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(d)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r982": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r983": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r984": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r985": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r986": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r987": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r988": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r989": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r990": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1"
  },
  "r991": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "805",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478072/944-805-50-1"
  },
  "r992": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-3"
  },
  "r993": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r994": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r995": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r996": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r997": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r998": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r999": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-19"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5A",
   "Subparagraph": "(SX 210.12-13A(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5A"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5B",
   "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5B"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5C",
   "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5C"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5D",
   "Subparagraph": "(SX 210.12-13D(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-5D"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 5)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "7",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-7"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-3"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479196/954-310-45-1"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "40",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-15"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-20"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482739/220-10-55-15"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-12"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-24"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-18"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1172": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1173": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1174": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r1175": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r1176": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r1177": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r1178": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r1179": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r1180": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1181": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r1182": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r1183": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-29"
  },
  "r1184": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-29"
  },
  "r1185": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-38"
  },
  "r1186": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "39",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-39"
  },
  "r1187": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r1188": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r1189": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "45",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-45"
  },
  "r1190": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "46",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-46"
  },
  "r1191": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r1192": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-50"
  },
  "r1193": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r1194": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r1195": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r1196": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r1197": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14"
  },
  "r1198": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r1199": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r1200": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r1201": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20"
  },
  "r1202": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-29"
  },
  "r1203": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-29"
  },
  "r1204": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r1205": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r1206": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r1207": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r1208": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r1209": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r1210": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r1211": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r1212": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r1213": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-31"
  },
  "r1214": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r1215": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r1216": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r1217": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r1218": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r1219": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38"
  },
  "r1220": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r1221": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478064/805-740-55-13"
  },
  "r1222": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J"
  },
  "r1223": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K"
  },
  "r1224": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r1225": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r1226": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r1227": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r1228": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r1229": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r1230": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r1231": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r1232": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CCC",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC"
  },
  "r1233": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CCC",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC"
  },
  "r1234": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CCC",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CCC"
  },
  "r1235": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r1236": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "181",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-181"
  },
  "r1237": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r1238": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "183",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-183"
  },
  "r1239": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "184",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184"
  },
  "r1240": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "185",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-185"
  },
  "r1241": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r1242": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r1243": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r1244": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r1245": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r1246": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1247": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1248": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1249": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1250": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1251": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r1252": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r1253": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r1254": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r1255": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r1256": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r1257": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r1258": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r1259": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r1260": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r1261": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r1262": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r1263": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r1264": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "942",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480095/942-10-S50-1"
  },
  "r1265": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "942",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480035/942-10-S99-6"
  },
  "r1266": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r1267": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r1268": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r1269": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r1270": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r1271": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r1272": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r1273": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r1274": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r1275": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r1276": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-17"
  },
  "r1277": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r1278": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r1279": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1280": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r1281": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r1282": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1283": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r1284": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1285": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1286": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r1287": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r1288": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r1289": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1290": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r1291": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r1292": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r1293": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r1294": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r1295": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1296": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1297": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1298": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1299": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1300": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1301": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1302": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1303": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r1304": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r1305": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r1306": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r1307": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r1308": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r1309": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r1310": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r1311": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r1312": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r1313": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r1314": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r1315": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r1316": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r1317": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r1318": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r1319": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r1320": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r1321": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r1322": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r1323": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r1324": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r1325": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r1326": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r1327": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1328": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1329": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r1330": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r1331": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r1332": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r1333": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r1334": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r1335": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r1336": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r1337": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r1338": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r1339": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r1340": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r1341": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r1342": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r1343": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r1344": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r1345": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r1346": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r1347": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1348": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1349": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1350": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1351": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1352": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1353": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1354": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1355": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r1356": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r1357": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r1358": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r1359": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r1360": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r1361": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r1362": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r1363": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r1364": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r1365": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r1366": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r1367": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r1368": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r1369": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1370": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r1371": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r1372": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r1373": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r1374": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r1375": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r1376": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r1377": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r1378": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r1379": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r1380": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-3"
  },
  "r1381": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r1382": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r1383": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1384": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1385": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "SubTopic": "310",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1386": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r1387": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r1388": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "SubTopic": "10",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r1389": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(6))",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1390": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r1391": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r1392": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r1393": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r1394": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r1395": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r1396": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r1397": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "11",
   "Subsection": "03",
   "Publisher": "SEC"
  },
  "r1398": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r1399": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1400": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1401": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1402": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1403": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1404": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1405": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1406": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1407": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1408": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r1409": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-12"
  },
  "r1410": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-15"
  },
  "r1411": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r1412": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r1413": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r1414": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r1415": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1416": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1417": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1418": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1419": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1420": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1421": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1422": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1423": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1424": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1425": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1426": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1427": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1428": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1429": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1430": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1431": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1432": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1433": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1434": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1435": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1436": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1437": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1438": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1439": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1440": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1441": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1442": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1443": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1444": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1445": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1446": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1447": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(r)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1448": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(s)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1449": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(t)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1450": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(u)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1451": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-30"
  },
  "r1452": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-31"
  },
  "r1453": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-32"
  },
  "r1454": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-33"
  },
  "r1455": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1456": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1457": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1458": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1459": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1460": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r1461": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r1462": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r1463": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1464": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1465": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r1466": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r1467": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r1468": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1469": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1470": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1471": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1472": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1473": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1474": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1475": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1476": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r1477": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1478": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1479": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1480": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-12"
  },
  "r1481": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r1482": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1483": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r1484": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1485": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1486": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r1487": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1488": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1489": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1490": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1491": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r1492": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r1493": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r1494": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r1495": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1496": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1497": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1498": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1499": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1500": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1501": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1502": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1503": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1504": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1505": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1506": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r1507": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1508": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1509": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1510": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-4"
  },
  "r1511": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1512": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r1513": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r1514": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-20/tableOfContent"
  },
  "r1515": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1516": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1517": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1518": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1519": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1520": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1521": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1522": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1523": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1524": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A"
  },
  "r1525": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2"
  },
  "r1526": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r1527": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1"
  },
  "r1528": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1529": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1530": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1531": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1532": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r1533": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1534": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1535": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1536": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1537": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2"
  },
  "r1538": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r1539": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1540": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1541": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1542": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1543": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3"
  },
  "r1544": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r1545": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r1546": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r1547": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r1548": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1549": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1550": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r1551": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r1552": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1553": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1554": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1555": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r1556": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r1557": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1558": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r1559": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r1560": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1561": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1562": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1563": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1564": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1565": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1566": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1567": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1568": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1569": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1570": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1571": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1572": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1573": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1574": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1575": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1576": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1577": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1578": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1579": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1580": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1581": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1582": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1583": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1584": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1585": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1586": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1587": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1588": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r1589": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483041/730-20-50-1"
  },
  "r1590": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1591": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1592": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r1593": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1594": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1595": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1596": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1597": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479405/805-10-25-16"
  },
  "r1598": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479405/805-10-25-23"
  },
  "r1599": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r1600": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r1601": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r1602": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r1603": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r1604": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-5"
  },
  "r1605": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-7"
  },
  "r1606": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r1607": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r1608": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r1609": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-1"
  },
  "r1610": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-2"
  },
  "r1611": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-4A"
  },
  "r1612": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r1613": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r1614": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r1615": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r1616": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r1617": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r1618": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r1619": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-4"
  },
  "r1620": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480123/805-50-15-3"
  },
  "r1621": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480060/805-50-25-1"
  },
  "r1622": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-1"
  },
  "r1623": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "30",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480027/805-50-30-2"
  },
  "r1624": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r1625": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A"
  },
  "r1626": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1B"
  },
  "r1627": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r1628": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4CC"
  },
  "r1629": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r1630": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A"
  },
  "r1631": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1632": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1633": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1634": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480682/815-20-25-6A"
  },
  "r1635": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-1"
  },
  "r1636": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r1637": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1638": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1639": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1640": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1641": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1642": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1643": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1644": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1645": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1646": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1647": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1648": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1649": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1650": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1651": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1652": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r1653": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r1654": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1655": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r1656": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r1657": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r1658": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1659": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1660": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r1661": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r1662": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479424/830-30-S99-1"
  },
  "r1663": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1664": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1665": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1666": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1667": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r1668": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r1669": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r1670": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1671": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1672": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1673": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1674": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1675": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1676": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1677": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1678": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r1679": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3"
  },
  "r1680": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r1681": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(15)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1682": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1683": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1684": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1685": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1686": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1687": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1688": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1689": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1690": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1691": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1692": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1693": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1694": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1695": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1696": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1697": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1698": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1699": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1700": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1701": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1702": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1703": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1704": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1705": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1706": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1707": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1708": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1709": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1710": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1711": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1712": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1713": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1714": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1715": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1716": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1"
  },
  "r1717": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1718": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1719": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1720": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r1721": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1722": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1723": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1724": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1725": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1726": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1727": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1728": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r1729": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1730": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r1731": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>148
<FILENAME>0000875045-25-000049-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000875045-25-000049-xbrl.zip
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M;AGMP'W8V:Y]":*V78JE:*:'K5?FH(!R2;I) *5QW*-#+")UV%LG?A< 3@K
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MD@$S,[.5BR#/6U>-=TI5[SF(A>NJT5!; 4!5I:A&$&7-&HORPJHQ49FUQJ(
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M^=T<CAW.4>!O@Y]&.*OOG90.0%!XOND:G+TBIZ9L<HK]CCD>:B[3P>Z8YN
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MOSDQ)Q3?62@NU=$4+"O5"%\T%?EB(SKJTQLQQQ^.(&+XX9M!BA:8V.]TB@R
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MP;)H.)[VX\G_E8W$/,D-@W#LK<.&Q [9T8A8<;T#1G&PX!/'D,3A2K1E.5^
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MUA,Y#[Y:G >?[;+8C3&;M#M<C=KSSD7WNG,.&43O:KWS6]5HCW<^'KP,)'C
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MVK5OF0-#PL61L@+V6*)?;11S3JK8PS=YUB3!@=-4Y:*L7QG+L4-L;.=,^4J
M2J-5U*>H8E?DP0Y?/%!K- ]+12"6T.*!&1]U, D4H[$UP=F^YD\>&#R27X &
M4==S;!JQM$7L]J[8;6":@]?'4-?>TC?_/_;>M3EQ9$D8_BL*]NSS]D1@!HF+
MH'L>(FC;/<-NM^UCW#//[)>- A5&9T#BZ&*WY]>_F542"",9"01(.,_&]F#0
MI2KOF967;J57QGKW=RI>$\RV_.FB70>Z:-=:9+(=8/+ T4RV ]"%"G31I-+,
MTDB,XU&&)@K<CBPQSM?:6LYR?XS,<F?)L]Q/+A1+8T6%SD@ X6#2%C!!?PVZ
M 1_$4#KV">HV,^>2D0PLEM6T-QU@MYU.I[B-T$@>9(EKI26#3&&(=DN<![54
M\K'*(BU.0B9M>6S8H%87N46K*+GJ^+&I*-"!-09+D-].5FY$".^^ '<,,V#8
MO]&BY(JR2,RWHE+Y4$1'MEIHD*55#AEQ<(+H5GH-/;/I32*B8$95?A2A8\"Z
MVZ+X4WY9Z]'V8 O'GIB>&'@'^_GYP\P6AW_F?.0[+D=D_41VT^YVTQJP):P1
MP@&X8ZA=K?0Z.J5%E$7\O64A9<8]9J5WR18J"]_GB?H&*#DMLQU,?%]$LR<S
M\C&UO*L?F_'/U\+Y\"LSK9\48<H (B=@=2I/.-<>#)LY9Z[O\#!:A&B%7>)?
M\-$U#2[11C;/7B=PGWT7GH\GRO.1:0F(7BXA?1D%=-^!?3P*?+B74_PXL/IB
M[O+M).&6KR8;F3/3>U%C>*E5Z;6H<V-9Q.B6 [S3D5$;FZIE/0@F4ZQ8IEA(
M1E]  ?R.\O_;2OC_87K3[Y8]@L4]X8CU@;7P/?>>PX/'0!6"0N OWT&=_9FY
MIKND%]0N7T&WR$0:C&%<,\>"R^*B%]C=B,)9I1%(6RCI= *I<PJ!M,5$-$QW
M,6,ON!Z>3%WO\:KSM:WON>LY?M#95QF#3_/(Z61U[XK-%4PO)4AC1 #VJR)-
M4A9-LKT0,P7.._5*KTUF:%GX/!>4JR+=.F-Q&_%Y02W&E$C7L/JB#*TE2F"B
MH'^&<3]LRX4QOH5CV@Z8U=@!V.3/RI/MCZ?<B9W_3A(MD^42NL*WUA58P+9K
MXA-O)YNG^M&DR8GY@QL7?W/'CF&$1@5HOJ.IVB<2@.40@%L,G?Q)I+DCB9!=
M5$R[*'\*:9$0.;T0^9"G&96:1C9HH5WI=>*FMFVD-9%1]18V;\78I@^F-;;G
M_*>PW0/94+O84"[L 3Z]IG$!XMN%B 9;CP,!Z:#JY(;'%.9V]$JOT:3ZH](:
M2GG1 2;19ZY:)6NH*-907F30I9%OI9('AR*$+@ZJ[9:AXK!$TZ/&K\81T!BI
M X64L D)]NH-*#SK8(ZN*EHXZ_F=E-%4EP+*SA3-X/<A(@S'5^O9C:JBT@I)
MHMVZRN]#0]A,IMKMYM=+OJC$]:X%T8&)"#O15-OU=F8BHC%3Z9 MS6EEQ $O
M7)'A+<5C/Y0/(V[QB>G]1!;?@2T^B0*,[GYQ[+E,CO0!)H'+8UON9X$=>=T#
M^\'=ZQ^>PP"FIL6<EX''Y^Z-;>%;'5LT<1G ^QT>U\VNBP4"K<S%-B24RR24
MMUB'QR6X=J77;*F9$WH*2E<DX;);D@>EMVSVA&B\WU8SM_,D^5<F^5<>>NQ(
M>FQFID>R;S/9M[E;M.]!JJ>R6X$] N?NLP1O#)5W*[UNG=K*ED5\IC(?4^ =
M7EWIM8_>.IM.9@]IQJ7".S;3U^O4Z+ L')\?YC4Y1J%8LXE.7Q!9U*L(< 2X
M0@&N;/[%#??"J#GS/,<<^1ZV4U \6_ELVH_<4D!XU@X358C51EFA=!0KY!\'
M L"9V5];'"Z@M57H(D[Y-BJ]9COS<*M"Q[;VCV<54FPD,L01Z+YXYN<6AW,K
MW3<KO4:G4YP86G;R)D5 BB"U(_Z*'S)%G-6Z&-S2:*JYQ>.*Q$>D)LY831R4
M+<2@FD8[<Z/U@Y_$A"\*X=8"HM\II+6Z+ TK-V#%ANVC+[.VFRV/3KN"H[VH
M5%L]7^=XP1W19)]_3#QU2X&T?#%S)$H[\&K.M]<:MIT<*SQH+KDBH3PC+>_$
MC#XC8_F..T.D@K>C)]IKZR#L41K>+HAK:0C45X8 5A77U/(=5J<]KBHDJR<1
M]!F9LTETNQ[]V)UNL4-JK7WDHL?\(ATDB,]&$.=#SY@T5%/+U\J>Y/#IM[&3
M',Z';M4ZTFVC6)VJ2^P$7)DSW^,&N0&D?0[A!@3D%<?(JG $RI?#1@KH]-LX
M@B/P!N5JPA7(:#J1*T#"^+2NP!L4W1#.0/F:_Y,L/OTVCN ,O$&Y3>$.G&9Z
M\S&/#NEH9M^CF<++@S_$']RX8+ R]LBE&^8JO@O^&;P'ECKV9Z)+&YWRT2G?
M$4_Y8LIVWDTAEV3"K+G$(2_W)2O?^/,1=VXG0INYM[[G>LQ",*V'N5;Y,BJF
MD37;-&JTB(9-/$EL2[/=FR0PA:K9.G;?32KWW$-*')@B="DDRN>WO5\A<6B2
MZ$@A<1J'Z S-IWS.1T@TYF1 !>C8X(<X5L"&Y4V=!AB42#KN9D)E( JM+E5F
M1J(@(ZIL1E06FE E390O)_']"HK#$X4FB>(4G39^%B8%_-<PGWJ_P#_ATR//
M&7-LB19@K/?+R,&;@R71;>=]6[X,JM:W<:B&'#KD8/&.Q_8<%O ")*Y8ML==
MM'N]*7<Y<"SS#1--96!5 ]O8B$^B8(OAUQ/38M;89#-8/GPQAQVYM<2]!^]N
M:M)-"&>R?70X1L"?^*=GT_"FH?2(W"AYZ6-]=0L;P2* [Q-O*12<.^L@B?Z+
M2T;Q9+:Z1I>K;*+66:<Y8=UN5YMTFVJGVVDS71_K_ZNU*N%-4V<EFQ[YQ<CA
M[*\+-H%=?F2S9_;BHMB) &-N6A>O@/\:;HG0F4QVAD[G%7#T&.!(.0IRWY9]
M)#^"[N4.7@7K8H5:CS)U4%/]QW94Z97>@_ @[8F"O3*1+7[YF?7BR" [S:KC
M%M.-W6E62P&&2N_SX/;7ZQME<'-94_HW5\KP^^?AX&K0OQ]<#_>5;L?9P>7M
MS=7US?#Z2H%/P]NO@ZO^ _PQ?(#_?+N^>1@JMU_@IV]W]]>_P76#WZ]QM[??
MKLNQO0]+Z5S%DT1XS0S[L/ZTL?K4@N_!G(/TO^'/RKT]9Q8L+ZO=)Q;VRIAZ
M#<0Y<QY!'F%Q9W"X+EAE*>I%Z2>L<L86+O\8?O@4-D4R+?%&<=.GX%F!?D"Y
M]LH*$QB3/Z]$7JTNQ5X0W K>'/Q<@Y]^WOR^I=54M1W[4[VFQGZ?]"@5;FCI
MF1Z5_'VCTRS>HEJ-^)?LL*BZFO7E1UE4Z\U'G5D20[QWM-Q8-\W&I+P\X=8V
MA*C8VA?;05M7>0#=SI5O</W45:Y!Y1O*D"_ H@4?4VG4JRER,]YTYL\!1C?P
M2UH0O2\.>#/71?PON>-+3-N+_6@BYWA?/$UH=:V5!AQI=IV^&<2!(7<4;@+(
M-?>5)D1O1&\[T]N9B>8C=Q-]301G7&R1'@8E/I\Z0$]1[5@]16,$T@G[Q1V$
M,TY:M'$D!CAY14?>S46UG)N+GH;.2360:CAFEU'M>%U&27&0XBA=NU$M]W:C
M>;#!F7E3M]Z4.PIF!#A\RBW7?%I../XP Z3]1%5JQZU2._WTD:)>=2#.BYQ4
M!H^XP.N1?T[(E]\MA\-"_^:&\LA,RY7<R-V?%!N+2-VI,IG9S\J4&X_<K2H6
M]S#WP&,_7J4<4.[Z+AZ_D(J74:&X4F.7 /PO /O?$/2_ F[PRS[FXMSS\8RY
MKCD!L. 2^I;QP'[$:3:]TM/RBQ=0KFIV:OFPGW_LPB;@T['IIE/I->/&A/^4
M0#*4\GXJDMDPC$]$,5@_TXBKGTDB&9(R)Y,R!:&9!DZDK6E'$S)D$)-!O*=!
MC!-7D;V"Z>6*/8(M"2HGT_B(IO&=1 -(%G'5G>UZ#O=,1]0)! -Q[V:PC[[Q
M+]_U\-L;[MU.A!R*!H<FY@]N7/S-'3M./JF8G]/15.T3&=#E"!/F83_O15R;
M1*15>O5:@RI(RR&4BD<_#3"LLQ86D@ JS#G%Z0FHB0)HT\HN6HL/4?%6]%.,
M2]]QN#5^43QXLCL3EI_"EFB(#Y"^'_LO6^1BPP#<@5>^V XLP KQ\H!HD>]&
MMW.%I'2LTL(NX^D=4A*SA;'S3D4Q[81 *9EWI3#O3D4V>J77TNE<IBSBIC!T
M(QJVG:3-R/EDHCS8'ILI]K9\E+Q,N?VRT\Y YNX1YPM9X<YV!(]$RC >[#L&
M'.7%<4FWTM,:66,N14]VC*.YXY)6\>3R'F;@;J35K.\0S2LP ;TGH77T8_4=
M24RM]/1.3"_OS%YH@>GNO0NN/0S*':E*J_0ZF</(E-^</C*8;$D>H'PTZ$O3
M +@;MH^/Q5TF<_P[*Q_:#SS%5V5YVM\Q8N8-#[2)):B=;MZ51'LA[)A%1J=G
MO"+4'YV0OXJGR[<X(1GY*ZAPS<I?I6$C4FRDV(X2S'^3[[(5"#9% :W6CCL;
M)+5':N]=JKTCLI^LS]4;.];G'IW+*-'\,(GFIU]@4:^*GP10HB[U=!O=1K?1
M;70;W4:WE>NV?%T5FC!3*#AW<YDPTZ$),R==#TV8.8L),Y_[7_LWE]?*\+?K
MZX>2;"5AFDQ5X3_&?.%%1^3.;1^HK6AS9DHQ1:;=K'4:;\\.2?LHM0T+R/:H
M(\Q&:=74+8]*F5"R:[>V]6#BH1NX:VUCS',+]\8W<.^[*.371FTH*=OA9^MX
M?R28Y1LB?PMF5WP<@$P5($O1!U^-KY@HR:Z'PZB^.<-F_[(^PU.8ZW+/+7(O
MRAU*:W5I-Q<>!]AMD%F&;#O(_^V;3VPF[<]U;*3%P)GG!)SQV;ZF;3E=! K!
M_[]>$<D]=SW''(.=B3_T+6/]B\B5F<\?P2=J5#MMK81#OV.D0OF/X\_Y6+U1
M),+O5'I:M:&WBEUQ6"8=]XTY?_' H^1CWS$]DV_H-ZK:SJ0,^D_,G"%(O]C.
M$$AXN 3L%1]YJ[\"&R^.T+N57E>/J;DINGA_I_786X1D9H)(W1*N5=^Q)5Q!
MJV626C"V3]J"L3\>BTB@XH"?#<H+,+FLQF:SF?W,K#%'I(E\+F_BS\11D+@%
M+OE'KK04O@]HZ2IX6[B^^^7RDD5+2\6>,IMM<86CDVVEV\3@OBO50-O'9+A6
M 0WN@H_QF&OV0KTMTZ"JN055&VBYX5ZL--INI+4:,CNR&4-DI+X*J;Y:1Z2.
M)E)'L][,ZKN2"9^$ZBL?=(]CST&">^;%Y956QY0#ARVX#^M4%H[]Z+ Y&?5;
MF*"]#Q-LTGFKTFN"H]HE&5@.&:CGBW[LP]8N>&>D,@FY@?4$D+:=%Q)C>QGE
M2S@"^6;6W3B]IZK5N[4F2;5R2+4MSN1>U"""L<UV/6L5% FY+3,)UXY^2=[M
M)>\$2/L"DF]H:PRWJNT2'J>16-L9Z>UZI:>WM!)(+[5; MDENUCF)[O.L>-;
MKM'5=?+.IKO;:J77J78;[=R.F*BW6UF%Y7Z$I($0K39;V77G"5NY%:0\^GR2
M%>\<>P%+>JDJL$N4_I8ATN466,0D3LK(BMU+V(< QBDK7M\RKD/@[N"WM1N8
M/5;76S6=S-VSD."Y4@?V^ZJJ'?78(\+.3"3> D:8AW6@,\Y<3LY\+LY\"-2O
M"--[?,OMY+O+A0D31\PX/Z>1.4!%@JZ@@BXS_MN ?[!-,X:K292].GKQF/5H
M8HJHE&)DT>5Q#A,"5?I?H*JO?XQG/L+E5]LVGLW9++/NUBN];K714.G4^4P$
MWD&HI(-4TNZJQ9[!6'BQ&,*?!.%>@G!G,NY6>NUJLULG-_9,A-VNE*#7!27H
MG:QJCP3:>AXAGW#'X08.&).6'HFVO41;"%#9;?:!_5@J\3@JQKQ\5:/4FC.1
M9MF0KP'RM2999'OG" 9SK\41A!RI2)&W?--H;FQKG)A4H3<J/5WKDDUV)E(L
M-=Z;E5ZK%*F )4JFB9=<*3,QXIO,U]_J,Y\J(>(\6I7D"*3WI0BD+,CLHK4J
M/:U;U>KYS1C/#X.GGUMR?*X\BA3;:7K)$9FO=-IX1^9K _-UJO5F=\=!P2?B
ML?-K6_=UT/\\^#IX&%P/11_8ZW]^'SS\^1[:V,U,-C)GHLG%CKWLQ/^HE]V^
MB%C(*;W8ED(V*%^P%ZQFI)9VU-)N7=G<('G<2>K(WIA&UW=L3%. 4$!:][^0
MC$X]ZK)3<@H;JH-M*_1F)VO!!!4[)L8XV(]D]4/AV4RR6L#R-85O$G$7B+C>
MR.P%G%XB4W!V=ZQWZI5>"P17H?.YRR2XEMW@2';E$E$,P+F=D-5*KZG&]:XC
M\55&\94>\1H@ONBGXR638([/#87_6. @LM5A.8FR_4_)OZY"73LZ&YT&=E;1
M]08U #X349<78321,#IU/6M^!9VSIVE:$0E24^>*PTG)'/@ Z_JJ6K>>M;\>
MM:\H!-OE*5ISH*8V.,C5EM8I4P^+LAT$WKQUV$1F9C8!:EN/#]R9X_" S,2N
M8[&$UFF1&WTN G ?:NB 9UUM-?5B^]:%EVYKI3.A&4FM:G,NGXFH^O@RBDX7
MZ_T[)-K.1+1EIX!NO=*#?XJ=AUYX<88JY<(#G:+8K]K8Y.0BDW1[U<LD).R7
M-ZLLNE@C6,\\_8[D6T'EVTXT@*6"C29)N!PZ;<^6<H[DVJ'.0-XF9BP7;*O4
M>/M<!%HFY#<!^0VM!(DI)3K+H#.,8Y]A9(VY=%O@HJA5 "2=7KQ[@;D/';4%
M'34:V1,ZZ=PB?=V,/9^;LJ=$5> 6%L^M,>!+9,T\^@S>Z/$WI.V;54T9^%=R
M6F8I]L,U/UKF[/]6/,?G&]/;5[OK6\9E='LK.M/AI:_IZZUMIBR^.MBF&WEL
MNI.XZ3,C<&P6[;WL6)2W;G47HBBO\ #_;-I ;<K &M<4=\H</K5GP BNJ);2
M/XG&^>\2(8FSOT52Y4G'&X3'.ZYGC_^J*@OF*$]LYO.W!V;?<6>("'[;N&QL
MMG,/7C?$M]TQY]89>LSCQN_XRM5# XN@OA):W4H/C,IZS'#O!7<DL=&X[%S&
M,40Q)-"2OC12J]?+6QI)88\#T(.Z(ST4U%0OK!Q'P\^V#B+$FW%&IFUEE.!:
M79,2O+X9W2<1GJL(C^ GX-=-OFP@,BB7X#QD=!J$-W= .%49)589P<H1?FP&
MLM8T+N#18[8P/48MT_>LF%P"]@[@.K N)53C*+I5Z>G=S.4B),0**L0R8!Z3
MVMN9)[63-'NC9M*?^S.TXH+&PF-[OG#XE%NN^<054^2H*1]FMNO^] X%W(?]
M))P+FX!/,37"(=3%V?)E%.8R+? K /R&>[>3!_8CCA'T2D]3FS$I!AM8(NEW
M:K+8$'^'(PMLZ--HQ^2])Y$%B<8D'-]SC\&7AL*98\$>*(5J/_LNA.=U ,X(
MM5_QB3DVL]9Y:/4N",%ZM5U7J:3\3$S!_(E$%;GS5:W5S9J/1Z(Q,2G+X<SU
MG9<PZ,@\V*#['@?K[&D?ONI\%8 U*=Z>@MA5;*70U?68> \9AL4W#'.G!RT[
M/1Q8[!FFNYBQ%UP*3Z:20UY5]@66/)=79H)0&N_A+&TA+X+\&YD(!<ZC'*]Z
M)QME]SW/,4>^AVT+'FS,9X<7./8,UO4XP";SW,UN:#7 T.H<8AH&90"7SHX_
M$0DV@03;55UM9TY"+T[R<-GD>:0V0R0/Q\OWE*Q>E$DRQ>S;7Y01,Z73B)&"
MA+YE; JGS(*&)C\5BU^/(N]H\M/AZH3R8<LRSX3Z69A"80)<)-TP\APY 2K
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MYH5J@#EW9>:FC:D.W!US:\R5\90YC]Q51,H$SH"R07(^ 19MY[Q&0)U"8H:
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M'R?F#VY<_,T=.RZ0J2WY(:=89CK4G4CN'I#NLK+GD<CN'X?!7VJ\%9+EXM)
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M/E2QW%IW%:%,&W\H 4W<@6O#'8<C#]OCOQ)WW\BP^UC..4_P749F"QX.=O
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MDL:1W-B,'-/"B&BUT>K4NL6V2 IS!!S^'%*"!FR\DQG5B#.C&@ PP_8!Q>O
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MDWR__2PS00UPV<;>&@TP8'A1'QSFTR)JGB2Z0W(1:Q+(^Z#))]HC,'W8,E4
M_"AGI""-B[NJ2A#-$H>T> 6\EIM"KR($,-[EV/-J].EB0V,1EU_F&\P09&N+
M$R3-0C")0^) E4F7$IU5U\T%!^A2CZ=X4"HBV_Q'<"#B1,\;193.Q_'4ZW0]
M9R]!: ]IVH_FVXI#%0?%TOI7EM#;<]M92N.5]V\[XDW(7<BM93SV^RZUS#4
M<0Z\[NZAT>%1MY/E@U9BNAUCPK;+<K+W(&A41JN"H[VLQWE!A-]%>@.*G;._
M@+M",%65?_G&X^JX"CC%GR\DM0J60I)EDTDH'^1!![R*S?%82@9],!0$3YH!
MPY@S(2.J@8U9A1N>.$ ^:L3*_,X@0V-U%H&/DHAZ1/M9/C6(;BT?7%-N,>(%
M?/%H(W^,Q+$Q,#1_8C,?(WH(GC3;$U("A[VMWX'V]Q1XVG9$5C0N&2P=/*^1
MV;=",&  5D;?-^ EPI<SDS])&8,]26Q+!M6\]>,4&?V2KL.4!SO!J"]@"+<6
M6?G(]B7XQ\QQQ"DB[I8G05\"6X;MEF>0 E\RH6P#(QC)]'R9'RN6AU@WS E6
M"HC#)IFZL 32%DGSIBOQ3J-T+8K2%6H]%*6C*%TAMI='E.ZM>%S[C7A<HO&G
MM?3&B!W:^,M4KU=4\\SAD=B@A?85'L)C[&[E):"%L>Y,;2;U!(:0='<+FLRC
MJ%4E>[WER;!3#6&?/F4K35Y6SG'3X_ :IME$<>2 G^^#6;N6?K6#UP7/C>18
MKCUU2\:E7@X/[(NP?\VYB,SA?S$*][S&PFN[%F:_"6Z!S*E"V_M+?_A9!-5D
MP@Y..&".H8#=+NX?V08*@-!]8(:]0/<GC+,$=1P8%Q5^& 9,D()KRG=+1$#%
M8Y]-5]3+C7T790CX(/:SB!<9ML@\"IT2\1;A$!A!48=P"5 /8DZ27'>XQ.#8
M8\H,$;M!KP"_P+3^I9A;/[;(XIABN&.5B;8]>E&65@GM6J>C96J5D/Q]H]/,
MI>E"HU5KU!L%6Y2JU^I:IV"+TIJU=F.O]A1O]%>0YF:VCG5[A>'2S4 ;!OR>
M./ L95/;,L/@2B14+]:.%=\A&*Z7.N8*!#5!8EE,&Z?"UL"S12J<OA=AX49%
MIFX'N:U%#3SAZ.;CUEZ@*M@ O?[PNW)CU]"/:%S4N]4#>G:=[(Z=6.) '@X_
ML!]@A'YXL!?P&KU9_^FC,IB+#A/+SABK*Y6KE>&6NB]12DGQ#JCB 6M&EGX
M=]%$-=VIK MR!,"9*--@CX\.?UP>_03G^'C\'ZWA6,A259%7+0_W5YX"7BLR
MG3'[ .37S%QE#:\>AP]AIB$3E,"_LXS0'9;U+;+\)3C1"%)\X54C>1QM!BT_
MT!-:I@ $)S.8K_RJ@EP<8)LBH6!U_6PC'XD(*85XL2QY;(.G<HA_/#^:F)BL
M$C1I&7%8J2 -<:*@7(&K)XI3U)8<<EM3KAF6Q2W]05,0U-STP'$CG&3'2= +
M)\@#!,@&1Y-AV<.J;T+@.@<NN>F*P,)2+#R;LYGTOU>^=8J"P\V#5;>Z/.N3
M'3HD!WIK0F@1947@=]'"1U)$'!&09H]H]N9%O5%@S;XLLU0^#/V1)Q2\IM4O
MA(Z_7XJ.2QO4/9]RRT7Q'=Q[H5P'A_97Z]J(#(#\#(!EAD8D&2*HZHTVODY(
MU<2\)\S]"JO_1)[#:[T@LY&K:$2LXHG1@FF98Q VO9 U2-&<C647$BQ)'4^9
M3.F"KY]@%3;6PO+Y8F:_<-&5 ^\1S\6R-Z"J\9K5 ?M^-#&2%Q01S7&1?V\6
M;HMM@3P# ;I*S%;&;!$F4T>!*+J"+"&YGA]GK'S[,*H:YJ^ M1683B(I//Y=
M07 VK.(,J\>P$]N**X+JX&>.9?/NJ\0642PKDJ]7B1@NE]F1P<NDF!8UQ0GH
M<V7?%Y&'MFH^)YK4A5M[_4Q2X*<PJMK5D-+7^AB@,0SKS/0HG>RSL[?/=C>P
MXGK\9ABS45XD1JROUD5=+Z+U=87=&H3^D8C_C1N/2&-!B*6CMGZ2/>""?#R1
M:(<)1EA&$'C.E[X+^.7.,C#3KK?!:(L^>CBV%QP> @07H3+Y[>6,.:LZ(]'\
M%"N!+CXS/*'#63',G8KN'*81]':0RV#+-PMUM%QCN+P#B9UW2\ZO[<&)R-X/
M["_XCRNC.F&RN2NPRW]@)[.5>0)_BQ8?*R,NH*5JQ'H+?[S_/VR^^'2E3'Q+
M?+_>_4L0@;&DLLAIM]1L8TE8W%WVMPG.PI'&1+79Q4C0F!70V'B-QH*\?R,D
MMG% ;(=29^^6K@YMRL@RL21S]22FR[%P?5(#1I@=? 5<T6_ZM8$B0K)SVY#.
MWEJT-8C.RB23_V* /N<%D[M0G=:4?H@OPS2$PQ,TY5[/^8C3N)N3&8(1"<>$
MST[)*/F99J<_=BO$F#,J M@L FCG,6ZKV:!Q6U0Y0)4#5#F0I7(@0^?4H-O[
MI3T?F;+Q\2K8'Y/'VXFIK^RDKJ_$\4$T*(L&9>4V*$LK\J"LE)1^@'+L=!#L
M1_JY'61<UG&*'?JS\0M6SC^(;HIBPI%;%8UQ=JLI.K!;D[ZCQ*JW:-@K46@A
M<5R&!_O+TZ"G2"] <>0O&_.)]J_!<520ZR_*FGU/>(TBMH31&U>.&4F"(A8
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M2MSV/[*,5N_6WQZM?A>TP'RP@S:>=W) $N"H+VKJLTY-U[J57J<5TP](FJ
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MR&QW$H@KY%9QU('AUD $1(9=U93O)PBJIH0,QC]D&@MWYNZ;B!5UAZMT0^R
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MV]K%I"GJPG9+B5DX5?'MG/TPY_Y<64Y!"0><A&UK@K,_-SI8(=*J!O/SSJC
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M%'+M1JY%9'%R[/0I[;V*'+M/CMV66\"S>2%GSO6V-QKD%&7E6/'ES%E3S>&
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M3,IN.>5P7QH@C&HH;O+J5UUHF8,&U1OES:+]W5=I;4!#_X+W[$C7(].U!,W
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MHV4;14MV$5#U!I3"'Q4V(:E7-PNG0(B"*$R1R8,/_ABSR5)TM<*7?@@# 6'
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M^Z9W.Y]D4C7/2T//JTQFM?E+HC0'/"_!2QW1M-X%'/RA<%VFIG7QE#4$1W7
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MX^/ME)K)9?M4,P?JT'WD3BP];]L!U"OU3K?Y6Z+8T!%(5THK8\Q' &P&A,V
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M/3MP[)51#NF#E=(IJWP;46<VHJ+9I;5W1I9 EBC5?N/GB=+L-P/L-]70,PK
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MY#J.HXX<7;$=VW0M:V#]+_4A[X'_@/4O@;=9RIS;6BN]<P//L"W^_:\ +^L
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MB:4F.4Q-LQH)PJN-5_ .ZK2_S^-6V=4 ._:C%.O"IAOX@PU*P(9<U:8JB Y
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M0Q.W$$<:5=T3>+!$^ K7SSWAWD; X*W]VJD1VTN@T02^R4NBUN;UG#<3_#W
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M!%LZ%'Z.[,//"7$ J!H]#C,I';^(Q\_T]LH%U>+"*"-G'_ED!;H<>UR@+;#
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M],/>5MY&!HD*)Q_VI<Y0R0L.O@M2(\._P 1P#4P5EB-P+?^M*WQ&1@%QQ<<
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MQN/V$FB5L)4MI$T>S3F9!@OR,$.= HID1[4\X9.3%$DOA\8(UPI<O8\-\_Q
M_SBOP"U"J*:");I(?Z+[!3I_8Q@,SR-@%%XM?Q[M.D*_< %V#7PWF(0NLIW=
MU'B+[=?0Q.!U*_#ZYNC%Q V+"41F#A;^0C;DCJQ.BO?];"P,]+&\.8%A[<@.
M_:<5:E<==%5%+Z1VTS]7>\DO*:K I4&WIRA-'-3AF&#[6H\?5'P?QK:P9#$2
M[Y=3<\X/YB;0GT-F@T6/:SP33Z;0*&4S6!ZQ2J7)6;B&T61OZ[E%D@OIW]U:
M>4\^!?L*TWH+ RC"#.33JS8_\-VG#+VOI"!5R\@*VMU*^[>&Z[X!-6BV0N&S
MU#[-0Y>D?E%\M$:7-YR>E-Y(W9.1@/"^4@Q4+2/'H&Q)H9#2_;Y2N/2_KC3\
M^FW_N_00'N>.ZU_CF8N (67!6P<XSU"2^A[J_;0,)*$LP4^0[7YG"/YWPT$]
M>+'^A@4R^@D4T?V'R_?[6BO*]QNO%6^=Y9*X-$BY,E;$Y;JP'$'(P*HY0A<B
MP)'><-!UK@HW') !7E.B*M0O2Q6FY5!*@UI!^&@)ZDDP<#FWZ/6G[3<Z\,1K
MU?+7JI6\U]9$C$KU]/+ GGE)32.]0EY24UI)3=DB*)T6[FI"D4UK,GO-<*EV
M<FJ7>V=-5X*7&ET*4WBWMUE781X'/MPP33>@"1TL$_Y*,%8KU_D)+.#'<WII
M0CM+K(:/8B_<9)3D3Z$.YZI@?L9^,<@Z+>-OV_Y8R#WBYA;C&7@E\--O22JC
MJFU1>_(.@6+_SMV-&7@AU\\N,?ZX-F8PXAMC\6J\><C-<58%/@T?WM>Z2,==
M$J1.](2LN,QS;*SNH30')8(IX[A(P*+$924\?S<:-1YA[J(:_4N./%<029J4
M!$)XBQJ8)K(9P[WDI<*,IPZT$[(4=QDOB0"=X:?QPV_W$V$\N>T*H\F=\/C[
MI\?QW7CT?7S_V(X93!Z>[A^9A7EZ$&X?)G?WD\?[._SM\>'+^&[T!']\'D]&
MD]OQZ(OP^ 0??+V?/+5D>A\"VP!U[)/IU2:S>1?U.\J+C.=JQW*BKZ74/-":
MC=D#6JUU:C?-%/3?XC;JQ;!L3_BP<#R/>+_0>@\7Y37*8 >;XPH?P&8Y2_*+
M0'ZN,*OPBM:8'4XUC*7$@^"R!W2%8LFE6#"V24<?_3"L!<4"<-Q'<(_24DNU
MI!QU+2%'/2&3T]ND<C*+OZ$=M>YHTO>("(RS,#S/FEDP;P/L?C30:_#QKK'P
M[F;/(F_Q5QIGL4$GS47NU)*O>5QALB)U954N+3.RG'Q[">N2^WQ0+1[4X'".
M;,XHY2DUXK+T;A-$6WL<=MZTX;S;ZS;DR"X1V?M/,OW[L_OK\-;Q_!QTRB;
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MP4:12\#%2L"S93WOL?_N%K"* &G_ A.5N!RU48X^-$&0=F*:"0*C=8:2W$N
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M2"W)^@V"L5CLKB)^&QZ*FZ%.F;G.DM*)K<(F:!Q9,)@=*'Q&^;6!MJ+I+XF
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MU;]MP]J&1!,WMQC/0*+ 3[]E#\^G3C#<WF ;S#;^+XX9><I2]:E.)&,FB<9
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M#E.D26JSWP[P]2<PB@P>'<-+H0H.EC! >(C'+&&X"&9\$0A;!+2>S,2&V.Q
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MOFK-789ID@4,'3_\03S:/!1>[OF.^8?@K) $'GWK]\??/6'EDA^6$WB@:E_
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M;ZDV1J@L#JWK:/YX'+HM&J&J.'1?%(]@!.X,;2WE5\/]@_@E5$)Q_;?#]A5
M)A[<+?9%B>\6ZQ>H8DQ2542^+\H85CIS1)YKBZ,9X=SAZ+[(P]&MTQ95%3GT
M11J$[C?*DZH_4;W=5U7DJ,8@RL)'7./U-R+M;56C*&T!90O&J^%.*P025;MR
MCE$E@'MB1= U[%KVH<<0!8W!1'Z0=K'ON"]^2MOILY_<]$5^<M,ZZUI584E?
M[!^$L>?.>-/414D1JP+J0N/JHFWJHJKJH[XXJ$-=7' [T^#9=WQC<8; 9C[
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M\4S K1 !,1.^FM!9Z-\J;HPM?-%?":H40"WU,9K[.4;UY*R2E.W\;\T8PDF
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M,\R=EQ 5]<XIW76U%>ZZ*U6JU FLK'N1J>\^ 6I+SS/^^VYX&0*Q8^D7P86
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M#3L#3![HG&B<-!T65;#LJ2=YF]+$!V!2H1(V).$H<_U/X1E4I@- "H7:D$/
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MV$$>\"^CWM;;O,R&Y1)KU8:LW6Y7ANU:N=5N-5BS.6C^O^;)&<5^4-)?(/L
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M0/ZJSCN;;S4M_VPLJQ)8EFIRO*A-R0A[34(\CG-WAPLB*]"#/6S[)?(^77^
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M4Z&2="5+B[>/\V.X0/<8\Q9O(&\#@,F)B/](!SB5!4A\1E#-4)X,-^V)E/>
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MHZ%.(Y$U18H0J5G_"QRX\A$$GJG;SE!XQXDW+,6O%[X,Q1##/G.X0&L6 %1
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M?RWZD<6F7$;'7RF:5W/$0S>5^L8 > "#?)!K$KL'"\'!EO7,$[J.T+P-4/U
M#O@D-V4J6L@V!4\./;Z V6 FHI,WF*\UW_@YGT@SGR51R;,DCFH_>99$GB5Q
M%,=[?9:$<%8G^;"73Z39W&O]!NZ^S6H#.J%P7NOY2Q4>>,!"?[3G:2'TB9&
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M]5ZC[^ W0WB3]LQ,G\.3$\Y<W^'JS>)0(T&ZP'I .-&+/B)#\1Q_X/GX(FT
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MT^51EG=4=O!OE!,1G$XF8JK$"G+62\>-Q4>"%8N0KQ(U(8,+='MAYB?Y>;/
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M+B..%"3+K(H&#\-CX!J5(N'(0>]AQ)'2M=SN=(PI!-Q;36F/D73EKNFZ!)C
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MV$/&\ZDP:VKWS6>'"DSE:H1U10PKG HY[)\V"'IEQ'.(WI?AN'(A!ELX$AF
M[XW\[,<YGO:%M=!^V, ZC(02^3N1Q*69[*/9Y"7TYEHN83$+/&K9KWTVWR5X
MATJ7F$^7J*IT"94N<4)+/LP0E;T6>"<!"WV= \L;Q>#C(JUU,(8AX)#MJ6S.
MB8UZAEUG+)*Z1R0M!;BXS/A^C:7312''N1P1J7"!OT36Z02 D\&\GBE,''$M
M@&A%+802XTACDY(Y+)'!#^X^??K4((>X0"C$T;&.EOO#\":) *V']]:,_SU
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MV/KMNO7/G^CI%\:^C5XUS.;WF4VY-+P:<2UAJ#9UMTW]AVF'?JVY794[2<X
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M=3K.\W24*=-\2S4PPZ=C$_W^8"<EI7;!S@VNC\L0:2E4WA8%YO02^"C&T0J
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M52:?9V7RNI6WY71#M[2;G6;[]V:'0."N6IW+N\?;APX)T<;U]=T?C=O+9A;
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ME@/323Z4YSL;B'+ ) *\*W>,*2Z=D'90R#BQHC<+?5/-+X:^V012KQ9 ZBG
MG','S#D8/&)I3<=?YX' $)O_NF_>=K* )=L0$#RD'OFB&1?<=7AG(S8?0I=:
MWCF \V *!2HG>P%X*1<W&VG1I(R\7C&*YSRI8JU\YI-:/M29I6PGA^\V3J@T
MS@ O9R-,H<RRP6K G!Q<%%U8>"1H>& 0'?KG6.@F>\X 4>@F1P;1V9UF;P%>
MY[UV22$\1= ]$?2')()NB[^S@@2IU!0N'>XR$XC;<$<(&'1S[,!,_Q0@QV!G
M('*PY8X%HK#9_=^4O+@67"7VP*)@O>>QXZ/W'"3A+-7IEF>135FIEG9,ED]7
MJN0;RH0\BT3'2G%5M57*V$SA^9P[GD^QO&VU91K ?#8IA]U-9J9S]\I[1V+:
M>?].1XP?SL.ML@@0P6.FBWD-H!;WV#,;.1/4BS.)D' 49:]4K&S;P%L5DF\A
MBHS*"D29=%X+&97\/];RNC'G2TTU8Y_=%AAEO7ST+3BS>ZT1^G0N)J[3Q898
M[H*[+J=-)WT7AN2%)=:(>;YC,QF-SN15>!Q(%741'K&:L;*BE%$)X7T*X4))
M+ZE[\*1;4"^<0!4YLWNPPT;PX2"G#9C-7"RNP]K;WMBR+<_GE:Z9O-^.8NJ5
MZZ45X*'IE 09O>'*M9H"Q#LB5NNV,2NU"_O$'S^5#GUF%UWCR#'^-W#]&=L'
M<=3UMPVY\WI177_'BW&IZ^_TNU!2U]^><M]&(_-)U$)A^6[?\C5O:+JPB)]_
M'#GD_K3&3U/7H[K G=.ES_?:JU55"X,CYB[5U:5W1&NCJM<SR-OGM@V%\JG\
M2F=V[?WXQ;3LGS2ZW^#>ZX/%ISV;(P(9&#/3F[I,6H (! )+P[]AT;S58_RR
M5!?AWK/ U#VXA4@HJCY5Q\RQJ.D%%=X[Z194*^E+<Y&( ;9CL\4[IIY:]-29
MJ1=MYOGN% $WL8RL"^;T8.L>+&] 8:AFTJ66486AHO2%XUU66[>F5KNP3\]<
M2JWFT]^[V7YJFUYN'!TM[0K$'4'#_VC976?,?I(9Q3G-9JK"9G'MX,F"0F]1
MCS!6Y;BI*VR?U%X5[D@G;Y_=-A3SI[)5MKCLJMFX[!X2P1R/C:'RY@%4LH:>
M8N3JU:T]!VE "Y!S/"9X11J14[(&FU+(Y5<J/VGBKQ2(0H6:<MB82+&Z1=59
M&GAT$YUQ!WY-Z;89>CTMNY8RG!0Y$?EDF<#'M^"KS5%<0_K.M/5<%S52O6B-
M%ZUISNPRL;/ ;K[%=C0*NEE!-ROHYE/PH()N5M#-Z27HH:&;LQ0R4RC.Y^"$
MS*8?,K\21U?A.&?%&YE!AZ21JQ8JJPITTL5HRB=Y[CY)HV9LFW9U-H[)#/LF
MC?P*V#B%Y7R&>6<*UGGSN[=0J:O"[V,J.Z5*5<^KU+/C1:GJ5;VFBMY.NP?%
M]!6]9?B>>^LPST>Y&@O8R%A=C,?BZ5)! 3T?$8HCO]+CDDKF/K=]*-56%32J
MZW%CHBKTY]V\L>63H;.^Q8L/W=_%%0$8)7/W>?=ELV#_W+;!.%5Q^?E>? H-
M>O]5N=55Z/SIE!89O0P+];(R X\(+5%05F *MJ%0RP8>=);NPDL%#;TW]BRL
M@NA/IYC(Z!V( 2L%#GT\X5M<$8Y-)W.?VS88QJFZKISO':APH@^KM"G#\'B&
MH0**/F982@$_IF 73H>:I9 ?%?*C@HX^O Y1*F32]LBJ#E%:X>U4M]=^FRYE
M,8O@W+:ALG5QI[*K%]$4S6HTJ+%8&XWGB6LYKN6_@EG];+$7[=F9=H?,58#'
M2ZGXU[_4"D;A8P9E1$;OOQ]K-;VR* U?"=U]QE5K&3*@UT =B<ZJ*F5U%C;"
M'K^1TD<%N;^-BEHV5.WC,0.;*L_UF%5W6%*C"A]/N@6%;3!23V!X*:S]A4@0
M?-%SD* *B7\?Y$F_CE#.U>N[XF/M1*/#"F&Y@K3P>AI0M4[(TD=9?CE7R5=6
ML71F.#?UXCO52%TGY?4CT*58WSK$EOXCL(D&?;#CD,Y]7X6QDZY=3Q4TV,^^
M">N%__:LYU_^!O^2\QJ;[L"RY>*QH0$^.'-C=#'O?N*Q#_(/'V7V@V73Z^E'
M'\58@LQH>\Q0ABC'O_[X8O7\(4Y8S].DI7$CWBR^UN&KG^<_+Q;UO%%-_"JO
M&XF?+QS*T(U\>3]#@6U>K2T=*KF71'%)*XDX[RY@T/TT2YA[+)EU#J'DE/7"
M*M8NY'_X.'$\"S-8/[AL1#7_'Y%Q+PIZ;9[9GDR/X0!1A_$)M+,",K=VZ_C:
MF)DVD+<_'07G<_8TBA^5"MQTGU]N<&KPQ$1^*-@C'_[$? (^F?J+?S*')7X0
M[=7(KT6@JA&G2?3?.&>K]_=W5KG>JS/#[!MYLU;JF_5ZO="OEXQ:O58QJ]5N
M]3\%PW@G?S5T0[8>L(LGEYG?+LP^K/.#.7HQ7SUD\*@@!,DU0_Y9RBVD3[^_
M-_Z90U5'MJ>MZK&NJ'SZ #<<<SEO_\U,U7RTH<OZ?W_WE]5[57WWRP-=-4Y?
MNX07 @MZ?_O9_"6)#Y+OJSI)S2TOV2LVMA:Q[#JBZ-TOEW>=!^WNL]9I7#<[
M.:WYK\OKQZO6[1>M<7/7?FC]N_'0NKO5&K=76NOFOM%JWS1OZ?G&Y6^/K783
M/KY]:-Q^:7VZ;FJ-3J?YT)D3"QFYC<ME/5]*_FK1%;KX\V*MM)?+N*X7:FI.
MV9W3\I&.T*NI?@:MFAY '*_=J^F-TDBULZ)V5H=M7;4ABGH&&MVHUE4':UVE
MV$RQV5[9;-O^4\O6GLH@V+WK]*;=;;/#]G.NSC^^<@81E%II1U]Z*L*$;RN$
MG?T@=:E26Y6;F2+N4F+PW,4@=DK9.ELX3:RJ!&&V!"$P7KZT"@C@8/R562_&
M@OITY]4<^:^9+(DX#AI6/:]@;8YXN*NK&M6E,YLHH]Q=*56W[0NHN'N+1--"
M844=Y"EJS(L9N*<BA0ZR*;BJ<GB;:;)'H4NE6MKVVD]_FFQB=IRJ<3CK&H=*
M<6713F;X5HEN);J7^0?J>56@IH3W&0EO;(FULC_AB3AW[1*)RES*Z?PI[-,_
M'S>@[;)<5&.-?-QWO]RW[ZX>+Q^T6$[JPBSSI0LZ:MJWS,'R*4]MS).PV'P2
MEH9I$#D0+^.)B<V.?(=^YIECIDW@U0[V/\*'2CGZHL>Z+C,]AI].>$P\;GAI
M+Z:'$%] "EB:UILR''/DO,#[Y(,(G^V:\,NQ:4_[I@3 =-DSL^'YGFO!'[2G
M5[X":XQ?PL^>3+\[A*=&. &/:MKYN)8-S_N.^ZJ]N);/+IQ^W\MIL"#?,D<P
M"?P[\W' (9 (?M#YY]?+ZT;[:R?R4\]GDXOI1#.C;:%PQIZ>H?VV,>=N?]MM
MV5MMMR#S_O9YJWU+9H'%+).%?;Y<3E+8K]&T!T2[;O[6O/G4BJR3;Q_L>1]8
MI6EYIJ5KE[&MA)TTD0LP^<@<4/V '!=WV>R!F/<8$-/L]UG7AZ& G/)%M&DP
M2.S <[KAR)[3M4S\R8OE#V&_+4][FGJP/"\39&\@:5SF34=$+V?J\OYPO"0(
M/VHSTS?QF(3G#8Y147O!]@%=O&![,$2DJ4# M[W_3CV?.@M0,5)X*B,=Z.0F
MPHN",Z!K#TC&Y4,BG1ERB#@>?/29(PQ;@A"-4SJQ/00)Z5%? ]0#:$*>#__!
M\3S\%8?-0G;A(D).#MX%/^EIP%]33S!:%VB)FH$VF;H3!XZSKOW!VZD##Q,;
MP,2F,%&8U1/3^E,\K.%<A6P 288O!H+6="U^M:%T6$_HQ01$WW7&-,IR\A'?
M3^#H? <)YR/OOZ\8TBDN$GQI"N^-2EDOR9S?'/(*+A$$W.@U+F_?EVKA@^*W
MQ8I>6?1;V!F<)Z%F:J_,=,5H5+8FA'8FSA#N&ZJ32']@",L&_ACSW7 D]T6[
M4)DN3&$@V([$!DDMD.IT,0"9S)YVN/K#<%4T[ ?+!^6VN\8Z;QV?:48]!](U
M6,XS9U2..]>FFD,X7T-K I?4,9:P=,+ E$O.?M^R31N$]R@J!<0]T^/<:6%W
ML F<+GXXEV]RDMS,QIX6<EHCG+QW\GW+:>'.;;!?^ O4\'"OQIJ1O_BG?L2E
M))M9VCKRJ[Q+6>(AN.(/5!VU*^?%]B+'^W(&QS^]$AENXB&<-]O1/##;K3Y<
MU'#G@='M <?T1DSKFA.SBU#-HC<!7>F;W[WT(++<6M?4DNK38UC\[;NOC>N'
MKQFW^)'B2:=Z'UZ5W>=*3'-R^;F+F>P%=G)Z9.?I%(B(IX (X_+$L5D[@[EL
MWE=@"N$2FDD];M-R9K;<GO:_*=CQL#/<!"A3=^ZX4FZ$27]2LXX84Z8V@BM[
MP-40^ F,M8ZF,O<C+R-ZBI'3KH.YGYP[HFK*S@JF OB8 _@H[ ?@HZ0 /DXZ
MGX,#?,PA442^F\&Y>!HYW6]SJ!;.1.QKJ:*7ZL;RK3T&4$B[V6DVVI>_$A;(
M5?/WYO7=/8*!),!]6..!YKE=..Z6]72!MTB^7LS_9V 8^G\G@W<:7%=_?U<(
MJ^[%>ZJ5RN3[-H ?1:,Z^?Z.'[X+PZ!86!SFZ9>_/;D__Y(PU45?SFUHXJ:-
MS>\7? I50O+ZB*>3?U#A'\QOZ[MU!U_.$855AWT'85C7B^NQ!/.8Z7:'I #W
MV#,;.1/RY 48_PE>;I_R!X6O.T=./Z.J%WX0=HM>_V'&\%G7WHG[\D[JI%N7
M@,<('+J+-FDFF!3$AWB_W2EI#A[ZR3$017H9[\N+Z@&PY)]<7X"G;<:_)[<A
MZAZH//1!Y7!D^R'I"+9L^#-I"-R&QX<_6SYM^!?7>8'?@Z8Y<,TQ<LX+&XWP
MO^\1+3ZN;P(?L?]-P5B^0'RT'E$&.(Z_17 ?Z;A@:8N)DA=FQNG_:^OB$\PR
MXB43?OZ @$@D$<["J!RHQI'()G ;+L(.'>^^"ZJ5EQ,:%2K6J-?VK1&0^8F6
MW&>C/V$4$_ZN:[^*T%WLYV+8R%2C8T0F!!-Y7X8+)O!O+]OM/EQ^/'C594#_
M'G?*BZ(3[1ZL@K%Y^#-SPWK6=+SCJ8%KZ/JKUGEH?&EJ]^V[+^W&31+HU"FG
M^%N1RZ9G3]?XGTOKT+9X8GGT,",[@)5&&/1%T2T/ICQ=R(BAT#!COZ.(\&P@
M\L,Z% A2H"PT7_P/%SO!H^V!)-@*K%#Y>#C#;KV)R.2@"TP*^U#42P6DB]E[
M!FLNZ)0>D2TD4ALW[9S6&C1N21K<W]R2,($-X5NZUG%/%4O2E9609F#:L>0)
MQ7['8;_H_<(=3Z:-60MVJ,'!GOCR^\Y-(QL7S'7CH:GNEP,=YNA!#671JNM%
M'?!3''!N2\0.^<H[YB/^06W%@65MU"1(%+:7UTW:D<YU,Q>Y*>,*?V 5P ]B
MID1&+(&;1ON?S8?FU;IB>A\!N73)[P.'&+<U'&#.WQ@*YM18#:L)=6H9DXJM
M7"1\^"[U0I>'3$5-%#Z-T9\PYIBY_P>[;7GXT[4DBI$)_DZ#%:+8>0=VMDY]
MQ;_[Q9X[4&&Z?>*1FL"U8_HNO/US0U\>A'SS0=KB?H*T516D54':M4-RY5H8
MI%T8 "U$ J"EV?AGK5+:1_RSL&;\<],09T6O%6,ASC+_X$ ASG+MK$*<%;T:
MA#B+88ASHXS.#$<X]UPJE_T 9VXVJZY42PAR)M;;12*#235Z06J?*&;Q&.:"
MS>3UE6AZLU-0<=9%<58#O2-QVF0^VEI*?[1UO2E^?;@*W2GB+_/^E%,[OE<$
M5KU]^D9B9D]]UIPTBOJARCLR[6NMZG7N[K \<4>8LG+J4ZOUR2@8"]P=]H"-
MQKB"5[L'!YU]5!MSD(V9B7>OY02W[%C0^S!;<Q0ADNJM671F2L7DK>E9YA,#
MY5^SV=1U)B;-;6):]O+XD=JD0VQ2OKQ L%UWYK64U-RCA_'#*@F]$X?%PY3(
M7?E:?NTHP<?%M:EJ7_:X+VNDZJB+\B@[,9M/$4O7XS@46%0747SBZLS!;DMU
M9E;LU&@ZF7J@ODR&Z  Z BK(7FSE4^:VG9,UOSR-;<Z85RI)6H_Q;@EL:FOV
MN#4'2&J;]]MF1$YOFMJFI/2F.6G*X9HB.;!S?IE2A ^W/5O&)E.;%?;NES7"
MIDLQ %4&UO(,K-)R^JR9@54HJ@RL\\[ 2@^BUZI$'RV Q4%LV2<'1 %/B7"X
MN.@[HY'S@FIG=P1: ^&[$7(A9CK$JVBXI1@,AJBQ--)TXDC1PY/F$:)G"FK*
MD)'Y.'5=UJ/A8%<<E^4B.3+B%UUG.NHAMBL\,>*PP4"DGM7OPV_@U7/3\((L
M$1P&I1T':_+@0=<<2?Q=J3+Q5RY,>S Q-0D$%F:_(/P4IG&($;IS^)P. ?BY
M47Q.7;N;ND+U$BN@'WM#' XSJU 3"!I0>2%5UJR>B-]OA>J<)E [..SASFK
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MR[5>7V73:''4F;3E[;MK8 ,++O^[0L\OM@P/B4GO=X*!G5)?A O6X$.:CF]
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M.(B229I-94'@_Y<\E2 /KW&640(?I#)!7&A:)EC6<!R\A'3=4_A/TD(%.YW
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M8IBI47J9T"_&C%6^AV#7C "0!]10? /*UH>7EYFZ!.$))F&4!==A7)I[*$K
MLRTHW "??J_@YHE00.#-L'#IZ&N#_&UW#SAL)1*W6/7)FNQL=?=W47C2G&ZW
MG^@^ _%[>Q.-BRL)A[E?E)#7IOU*. 2]7!:+OU*C87I-_;2_[Z^)^]]7AH9X
M%EZJC2'LU=>-< (C_BF,;\)YCB$X]P3"\:LL9'4-%LYT,GFR&&:-6@H%G18=
M+*XT(T/E)W %5(:?@G&%*S6>  [4Y'_^]%]WQPKVX;!BZ!,E_PA>B+?^?_\U
M_%O3CK:*<AT4Y<Z3*LK<T91X^YZ#MQ9.T[NTYJZ)]IN+NLFG"*T#(Z/RQW(.
M.N.N5VUM:5C"G1IZ]4RZY9SIV^RF1]MR6]W=BGW5W7N ,2?C6,ZFV^]N^^_<
M[>X\RJ1K+;J75U0F[]*DJ983[ 9%5=,(3VW0[?1TU?'MJJFN,1^@F[:[FP_2
M3:V@KI"@-M^H#Q144LW+R,ZA@2<]3D[O?WGO;VJ$R6*I73(3M;NYVIDH3D$%
M%_U_!I_/3G\=G ].3VJ3_=M_$SJ@ E2 <<;A+%<_Z7^\'4?Y+ [G/T4)O8B^
M]%;F*CX>^C,5) *=:_ZS=76ZF^SN2)&+O%G^W(4__;7^^]W=[N9.\Y]@0^_Y
M^^V#G7M]8]&@#KM;!^V8UG=,MS_I!?J''"Y3D[^B5-3:RK\@MVW)GBS?Z1H]
M0]N:U4,&WMT=I!.H/T8P<71L<,? 4'C2CB%M"YZ6-7^I#CRMF+5B]OJ-GKZ=
MW@P#1F ,U23-E,9C()#US5 E:A(5!O'R#;1H6.4RO?4OQ-O=W6];<:_< ?_F
MN79W=GLZFKD&3,ZM&OS6U6"OLW<W_7.K"%M%^!R"M]/RCC^I7?R4EO KL^^]
MA.X[W-2PM)9][_EE=.^N:^95%_5;D^VM_<V'$HVTPOV Y=XYO,.L;V\L;\&.
M)Q-&)]&EA2V7U_*>VMK=#T?#YS:5]AX:J7B4T+W>A/_\=+*PIOJDMWU'5X>G
MW]D7F=<3[NPW>,I?PQIM3_DKGO+=[LZW?\J?@AOF)>#DIV46J)I9$DQB),:
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M?L$4)3F"9N&4J&"<TMH.51PI%'P>I)V"N=)@62W]"6_%XL5K&0#J#  '+0/
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MX3]T<1#*=0.D"R8+2XR6!K@U$WAGRNGX&,R8(B<)#Z<8J\,- !.(<HEX;<#
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M6>6-4J9U.M+*<.20$7PG?M7K"_0GNA)U8KL22F61,JDCOA0_#2[ %=8EI?"
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MO#S17^;<S0R!?Q(407Q,IV)BBW-J]*Y[(6-1W#AB^I@%5P/W)<U#LBW8KS)
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M'9KLE@VK6'WCKH1$=3R%JT]1IU).HY]I:D@Z=CD[MP2[#-83/@(K/3(T!@P
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M\^\72[758JF^7RQ5>[<\Z=WRL^7M_H#&UB?AODLPQ,V9U+Z)'JS S2+C<]@
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M3ST#+(U345)TB63,8MJCSA[B$R8+(V:+7O4#?HK5AT:!Q_RC="0@Z+!$I]3
M\ U7<W!OS8RD-@M[- /8PK?1$GG&;VUZQNA=@/DW3<Y>#F3DP<<5);C(*1&
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M$NEF&F]Y&E' >)J<EW0&+>7?I[2@(JZ%H&M3V+N;;5:HH@.SWP9EL64EZ3I
MW&K&8J(GWLS?[>\OJ-+KH]\GN< 1IB1[OU>49YF<-Z9WD\0]9[?B$"/+1"R&
MR(<SU9;5:6PAT@>1F>JDY$17<; S;&.-;WNUA)UTE'*&>("IK;J$,X"^]F"D
M950MFVF[[6E3FYI5+$C4K2^+S,E"PO)S0".R25>XLXJA7W/\PRT.9O9X@$M+
M0S#&!P?'[VOWU\T"N.T%X+F..F%J@!-?Q@^ET\O';5UGR7=PK?-$&B4^?JH
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M#=D/Y+/A.RSEQGK)579N%4"HO@;.XP5_VA3$[TKC!2='Y!_=-J%3+?>M#IB
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M"9D!V?)@L9/<,R>)O7% *))TH#.2O[3D]NO _/(+EV^&F##6RIXQ)ID=!#C
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M%Y=_QAQ;C]#(%^9<3I]'@ID49@$2!J'DVPHRG"V*828 L8%A5(6AZC#6*CG
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MT"I(^XFW\-TQS[^6)KBQVIG!:7(;;JD)*7^GI#@E9D?<]=VJ2$"MK-E(2BU
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M#G-!XUSSH81%7)-B^X"G=::?XG2Y.'UE/??K>;\)PV9^]QO3V_*W^3S73_V
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M';=3<R=I_Z#B[SYSW8Z]\]FGC]@?UWVN2<"2M7.<!I1H0";2TC$8 )DL3(7
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M=M1#:[RUU<7F%XL)+U[%0BX06JPE(+I64QHR1>0'N>0L2GN'?@!W!S F7^$
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MBV7'X&?[>OTGA@7^]0__#U!+ P04    " #S,UY;R[%(*;WD  #&?PH %0
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MO:PC3#7RVB2/H**1$+4G#S@&*5A@PK+FBG,GJL/7G+;$#!"AN=9M<@<N@KT
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M;@>T>Q6+CG&MVH<S;(ORR2O/P,0,X*IN0/RW,#G!FP$S*[35-1J//&Q:'%&
M8Z[>QWCMDRR,N=8E\;8&>:B*U(B6 =SB6S7_//BO^]C1[V&>N[7TI]F\X'AY
M4NTH;63*2.*RV7A:4Y4#C\$ RAQ<804+;WU]OC/H0]6S@6@;H+;0;1.E%WY6
MDA+U+LF5&K>DDX!H=2;S'8VV0N426Z=K[8KY4+5N&-(&*#=TJ?S\AIO+;@K%
MJ]4@WN(_3\:+\1+?X?SS..'IP&L%^P^G''8R&)50/*NS*#I3F_.: )Y%"5HC
M3; 00PJM*ZD-/:8GK[2/BO0!"AY=/P[K7*&1"JFX(#Q$U.3KH"!?)]@,TJ@D
MN;+)L]:.Y@8H3UZ%6HAXB&Z1C4Y"(^>%3$X.R60+2CD+ 6,"5JQ(M>VXQ?:1
MT>V/LAO?"<5L1''("#S91DH9 U[*"(QG<O%\R":W+O;<_TZHY7DSS]HE8R((
MG6K:=K T,Q1Y()&FBO*B1-EZH;CCO+EQ5E%7F771/6CQ:YC7NAB?\7D-0I@L
M[I-"=.OSFN0+]4?<*#EH79[]PHO/E\Y"+H)-F8.L7Q37GI:Y%$!DEWRD937&
MUO$/M^'9>=5,'S&?U(*K-[QE\>.7"S^=IDA8M.A=Y("U4J;*3M$&3U]T+LA"
MR3+;YJ[&EACWE7343$^N;;%#DO)8$I2ZBM 71M+%V!O/DHM%DQ+(&NS$.409
M$;AB++!H@TFM3WAOPO%@Z4B#$G_5%]B5@"%BEJ]@6L7=]$$U4*+2S8@>)E-I
M=\;N4($=Q+T_9?!*\!2TJQ9ZK2%/QKE/&"%H&W7P0<OFA?OVJ01WY"CM2P>V
MD7)#[JN!.3J:I"^S*;XGMS)\PI/E."W((_K3.G:N,([2UB(OU3#GEH'76@,!
MME;6KH3!WV6UWOV:!^@'V8"(V2!2'"#P[(;]K=-DF9Q/-C!(KJ9'16[ J;JA
MT=[&-3H9=>N+N0U0O@H;H 4- \0#W03KM*,(KB-Q>P <R"*X$]S#& =-J.RA
M'KOS,("I<#=0Q8/5L1C(I;:$E$+2>L<TI%*"KE684MS'PK('1;G#@'@8/=E&
M_*W-B;^>'(?IR^/CD^EL,OOPY<?Q;)'&.$VX3K;Q(HO@LH3"<@V5PP*QEG]E
MZ#QJ9814MI=%<=>;]F]4-&9F-I18&YH8B_ER5"]@5[<>G7)S'UW!(D&;J$ 9
MZ2"Z6 NQDIVLDC3%]SK5IV=?F/GTT_FLO^&U!VU"["KFAC&G5Z"L%+L/F&U,
MA/[</X09L#,=-].Z@RP;+N,W@\(0 Q-1@_&.@TJH(=2&]T+:%'7,EF ]'6(W
M;-O#\KJ-"!OS^2[A-,S'LS=S_#R>G2PF7][BI]E\B7FU?3A?\Q"X!J$<;4PB
M9!JECF!YHD'2$$-N0>]=./:W9S>@:#:0? <X 3B-2#\/3JC_X.P\*ZL: "7(
M<JCU'PD/^& 1A BDXRI;YUN'4=X"YZ"W\=9T#) IL ':^K"Z![B!3@)N!?8P
MIP#-:.RG'CMP,, IP.T@DS4\AN( 79"@?(KDX#(!J28X!D>KH&H=VO$ "G*'
M]_\P^K&-Z ?0"]I4D1Y82_@^Q\\XF75-K%_\48,;UZ56HM'&1;*I@B9?6"&/
M$*4G"12-BFLKR3%NK!T]8.W_P* AD=<JG;1E88AT>.Q"ZG[&*<[#A( >Y6.2
M>&WI48..5EC7YQO<,B8YXV#0UOI>D8&79*BI(K+!Z%&V3T?;!N A*<]PS+1V
M4VNS@-/EE">'S!((79/BN.(0G*PM%!EAD:((W^O$^2[W=/W"@S93[R_:AOF&
M9R#6=Z@]8+0\83I_]0.<+=U/^%?IVT%R0TS4%1RK!0:K-*!G-1Y>27!&.RA*
M:>_0>.-ZI:H\-(&WG2$UY6\;@37F[1>2U/')\;I(5L[1&IV =PTD>?'@$!&T
MCL5JCR7[7H'I=S!WZ:5[/A&ZK]AG+636^%[FE_#'!2"B,%%4CI!U[8<GDB E
MI"]2^L"L98%ABVEWZ:5/D+Q[RVP 5^J7+E>AL^Y>3C^=+-_3O^M6%4<;NB@A
M@ @80#$RVD/Q9,A;SD/R29?4N@34)BP';0@U)6* '/J;<*WL_S[(!CJIVXSJ
M88[IVK#70R5V$/V>5H]U()'((B:.8!1:0FAK=?UL(=6*B-8I'5GK(_]]*\4=
M1W/[UHEM)+X'77@^7J39R719&^VM;Z@40VM+AJ1J ?5L$;S%KA"R$-H%IDWK
M#/*[4>W_5*45AW>HQHX$-+04N_"BJ_#>S&=QU;W[(D*6:BH5!R[(A5'22HCU
M.Z^50)^MD>[.%,;^KWORW \DV0&6APT=W'_\<K8L)NTLHD203A8"2(93T$%!
M=D6+:'54"1NO#G>"^BI,S[;4#%!/9P/ "W.G#\"!3-$[P3V,1=J8U'XJLR,C
M^UMV+IK213@FLP#N;6TY3799R(*#]4QJ$X5PV/H:^8%4Y@Y[]:$U9ALB6H>4
MO_D8%BB?T=_&*4S>S\=A\A-._A7FRW <XNOIV3EW82;4O"T:L ?%68;(& /A
M5'0E.L-*[&6>]'SA_@V4QCS-!A9R:ROU=HSO?Y^MF_^D7+0J!9+."E3@M-\B
M>7,R9$830R?N4@-%.'OA5Z0(]Q/R?E>$HU_>KLUJD0,JA>3",T<8:X$L6\]O
M(QIO<U&:\0:*</;"KT@1[B?DANF+/3"^_'#TZPID]K&PS#2$FM.K2DC@D%8Q
MJ5-QY,A985MHPOD;OR)5N*>8&^:DG'K:XPDNEK,IO@E?JKO]TTDM_7@A^FF%
MD?'(G'8< B^UO)8CC-P84,Z2!RX#\JN11)M.,?J]\* T80@A-XQBOA'C6_Q0
M&\#-YE_6-@SC@49HP;I:^=BD!%X4#CY;&6.RD5TM'-Q3 ZZ^Z:"IWTFL#0.%
M;@172[OA/(W/&D)BLDXKQ0A-B#6-1X$+DH%AV3#"%XJX'^=7WW30G.\DUH87
MH/6J_LU\ED_2\O5\522U\X*]3(HGY<")>M2&OD!P];Q-J%BL]]'F7N>4=T0Y
MW/3N@SZ.;"+PAH65+^!9'$WS"M%B7<:E!ZB&L8(;@>P_<G!WCJX3WDC C4/3
M-H.+.8L8NFN:VLA5N@A!>@.<,V]<0K3]HF,>%^NWA!ONB?1MY-K:X[_H>4[S
MRW\%VI4B_>*O+W\4G*TV(^5-Z4IQ&:X)8 [U[IX&[PMF8Z/UUI9>>WR?M^TW
MMJT1*[,A1=KZN.]F%]-+'5+4!DJQ",ISLCB*0R@Z6>D\<KQ:6^9NDA_";1^>
MU7L*;<BI>^'0R"4=O03IDP:ET4 PS(%W.0ACE(O8SPE_V&.X/4S->XFL]3G;
M!4!O?EDKE<J<BX3DY<D:V\YT &^8!".CCCHSJV2_2CXW/?V0.+R?R!J>CUTM
M4$1N7!Q/.R_Q'7X*Y"]BK5C0M9?X%^;W\S!=A-3Y#Z?EJK1D1M06I=JSVK'4
MDO^8,G#K4F::' 8W5!WN+:$>M!.V3QJO:]_._4+N 7L=?=4#^, %"+<&_;"%
M"0=5C=W5<0=>!RQH>(\!V!2"<8%V8J5KS"8'QTL D9RDK8)VCL(/6R%[%D!\
M(OJX!9W[*YSX9HXO2";+KO_,*[)-I@NL!['CT]Y2*].BT/.,%62>^%JG"AEM
M*):^*VAI#!B*4[*7-;8CD(<KNS@PW_W*,;8G:XC2"R=Q@?\\J14A/M.7LQ@R
M89/(JD@H7,8:W$/S+TL/Y.>'P(1 KF+CY6P#E*_"CFM!PPW+T!#JL9HP?9 -
M9(AM!/4PAE83[N[6AQWD/H"AM!D@H6#.DR?K?<@UWS;7I@@:BL?L0Y$^%OVT
M%>(.0V>_^K"-N(?7@W4A&(\Q<AZ!61% R=HW(;@(,FD69%:H^M60O+\./)0%
MTHBHV^F_AY0',!U6@0"UH^EI:>O5T=GX,W8]-1:CK$WT,@9@PG.R;5(!+Y&#
MY2$%+@I/QC=6@SM!/8I:X*^:]"MK2\ @M48_XVG;V]>_3S$?+9_-%LN1S\G+
MVLI2:%_(H8NEUL'PP-$%)T0@D[MU_:X;@1R0)NPNZ &VAFOJN1X^+GZ>SQ:+
MD9;".AT(D"R"M%,S($=+@8V!%QZ+</VJP^^R/%S!=$ ZT53\#6^1;O'5-X2O
M'<WGM9Y+-YJNLLOK\OID64O>+;KNUW\=?_@X"@Q+R8;7EM<T&JT+!"UICU71
M!Z-K?9;69F?;$1R0ZCT@M:U#R3?.HFX._3J;_HT67LRG_:./?@_S3(:^$2G'
ME""4X$ 9,O=\D )*2=Y*PVJ*=[\,@^U??@!:M!>Y-XPT7POB:-)]!G/71OK'
ML,!,$Z 6R.Q4?54K<\2CRR:0P1ZC,J"*C>"=R,!RD<E[EK-M7;&I'[(#4)T!
MJ6@=IG[S&GDA9KN>41><SS'_?3;_!ZV=S\*G\3),CO+_GIS:>J-H>(X\D-NG
M:N(=Y@0Q9 U9%-)U% ZY[K70- !S -KS(+P,4 NL__;[:KPJ0#+R!GTM00C)
M% 9*FGHNE1R8E!06D;V3K6O^W /F 2C9OD@:H+['/2!?K7DSLJ)$\C3(@DNB
M^J1&0.!)0.3:Q,@*M[RUS]< ]M>M=SN1V##38X<A/#NA!9M6YAPR6F8*D(6H
M:085#3XS218C5YQ+)UB_BL/#JM\*[=>M=?>A;#^A:G<A)^\DK<!K$S1C-5(T
M.U&[2-%,$2R!D&B-MBIPUMK8WPGPUZUR]R2NY<5[9X.^6"S'Q]5].<JYDTB8
MK/WAWS[53J(?Q_BY6X]?EPL)UT?3?"$K<YVON1A9%9UGS("(.5:S(8$O7D"V
M-G"=G+6I7\6#MK@.0-<>FJT;-&^($,CSR*F7F9"/R[@&O)S>,:V.9S(-9SV/
MQKB@OYT<T\>GRS#],*8/+T88F*L=0*"D2$:#]PI<KM552U:87+VLW(/EUV(H
M!Z"XCXGL&Y1XMQ25<R =ZFOF:Q!2LJP"%._)HO""9EAD 5"[&- XA>A[K8=W
MO.@ ]*2Y/&\@>^=<EI]GL_S[>#(9N9B=]XEVZ:#J10%&\"(; B(8%B-8E*V;
MS:_??0!<[R3.&WC=^4#]AL7IPF#?XJ1NNO6F>S&2-C)4-H(Q4=:JN0J"*PJX
MR!%MY")@:^;[HSL@W1B(DANT9W6Z_N\_7!$:C>,?W1^ZWU>AO,7R7?WO;V]?
MG@GP]]]__U,<S\C4)RL__2G-CG_HY'<QA/?-R3S5:E9OYN.$EQR"Y[@,X\GB
M,KK%^/C3Y,ZBUMN]X(?SD5P>X>HMEY1B@#'A'TN<9N*AS42]4=T,0V9KY!$K
M)H B+8/HR3)03F8=';J2ALH8O G/S@&/VX:%8Q#"%^=HNM6F>*6KY9U<O<=.
MT6NGI6X>2;\EQH8+5*"M\'[+TC9Z<BT^<DA2;@J-^JX*("__G":S!>:_?+^<
MG^#Y+V?3)<VL%Y/.1J*5 S]<OR%K,LNZN.) >[3HNCK:0@ZCP@R!JPAHBBPV
M"LE4KUY<NTVP)Y6JL17]&[; 76@8,'/Q(JQ3;^TL +D'P(%39S>">]@4V9VH
M[*$>N_/P, I#9AK-B  L=@E-,4--N01670$=?,IYJ)36/2M*S]35/>O)%N+?
M7PKJNKQKR274NC'(E:<].FMP-8S4J8">+/L4=;^J+7>]Z5$X3[LPTR]9]!YB
MW4=*Q]68X>*"#9D%(/=?DY%6LU6+X) *X15.NF!LXR7AB85L[V+&-A7_ .JQ
M16S4A>/AEZ>7:GFD))<<<P0CI:P)<#4?H21(6C%>C"W:MU:>W1 ?D&KMD;K]
ME.78A)Z/G$PJ>.9K%_I<)PFMSL)QFC,^<90YAB0>3LWXUZE4V]&R,=UDR./
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ML_EQ]]N7E;<P61U'D#GP<IIFM5C$$L][A=U\*CU2R1F1:HY@J 4*I38D<,?
M\L@B<]:)J]U,^YN+S=$>@,8^3F9;MG<88(0W>'A?1H)\.)/1UUS$0/X=<G!2
M<HA9J$3>79#)/(#FWH3UF]X.PFKS?@YMQW=F"7DG=0Z)]@[C/<U$GB$@L^"S
MX5[*')6T#Z"I!V1\/A;V-C>=:%Q/ZOEX\6FVRD1855)ZCW\L3\+D,I1^1:-N
M>5J3RE!]T38J_]31B>^68=D5O/DQ3,(TX;N/B+47TGGS)()5Z^6<S''QXY=3
MC&'R\WQV\JG6HYN<9%*-^IFNF=<)YM5Q"PWB7%N-C0&S$)"])B\G^^K@V A:
M21],$3$UKTFQQ^'M'ET]--15F6VFHE*L0-:80-'& HX9";1;."55$=F8)\?"
M7DMA/=8Y<STF_/%IU&,IR/6>/O>Z',WG8?JA>_)IHKADVL>B041&?H#CM+,6
M#.!H!+&(D(MKW;'F1B /E<;W*#5FUIJY 2(I+\"IR;*_DI#.?]-5W RI&_\J
M*K\/W('R_+:$^C!Y?@U(GNV?H4>@6"F9DG1P("R!5<PDB,@14LH.17&BF-8V
MUJ-0J#LR^AY>G[8AIG69@G?A>'$R_5!+5HV/QY,P/_HP1[R0%\9=]H*+ ,P5
M$D2VM!2'[$"I9!!1R"3ZG6S>]:;]^\^#\C0;2LB-ZX.=I^?7#)K:/'[Y<99?
M3C_CJ0-__;>(-3&MFR7%N^2S8O6ZD222++GW2D?(A5D60^$E]HH/NJ.&T"X8
MO]E+U^VEO?+>N)S9)ESK&GX]D#6L:78[FOT7-ML?J[-!*6E<!>T.A%KZ9)AF
M$*VN83[*0TBH"*;71#>3*:4GJBRWU$-[C+JR#1-[-X70:9\YIZ4V!5IJ538$
M3AC@$FG?SB$Y>><9\2,SA5I3LI75LXT\FY=8.UG2EONLVU4_5$CC"0U\-L7J
M#IR6[\@F*2XY UMJ0)6+!1S' DS:[$PIVO)^-Z-WO^N;D7+=2!F"IH9)4SW@
MK6LW] !XLTER+WUZ"--C$*[ZZ\$.@FY>]J\/4&=1.'+J0$G!06GR]+SAM4)>
M+!A<E/IJH\9'IPD;[(K'H0C;R+>U JQZPCT_P:/E3^/Y@A;2Z?@SSA=A_F5=
MEE(I="PY2-I:PFAHW^-!U%Z4VGBGA;K:.F8#_7>_:W^6Q$#LS(83;6N3XB*\
M=TA[8;Z.CVPH:<EH@NBP9M,X!AZS@&P]UTXEDWW>FOH-+SM8[EL(M[&#^:R&
MP.#\4Y@OOYSY2,&*P&F= Q\$C=A8 SX5!UH+,FW)\.&Q5SW0.]S*F][]S:"\
M^=1K9YX:)AQ7/&_QTZJOVYES=!7BNH=M#Y -#[9Z ]O_&=?N',[V14#C5:8_
M6"]J=$@)8$5AH(0C?]T@TA>-1H3B;+_6K8];2VXYW'H@)=E&[JTMSY>SZ7CQ
MYF.8'X>$)\M:\*\NIG]:[8Y&FJB\H=&BIMW1: \Q2 M"9:=#D";E?E;G[>_9
M[]G50,S,AA'K +7F;CZZ??W[E"RCC^-/;VCKII_#!QQ9U)PV1DDV422@]'\0
M&%>0<T94+): K>NM] :W_[O?IQ*H-PR_>U/$=[-)?A;F\R\DIJ/C.C-'LJ@2
M8C& TM727>2L.60:M-"&9B5C*?"]Z.%U;-_4<#LUW)'= 6*BNDK'F!<_D:2?
MCRO.<?5*7Y>7=4^@'U]._]\9<?4W0D^_'VE4PD@6@"5>RV[5U3LS!\D*:;"D
M@+QURX8M(7[3R4TZ.237K6L&KFI;+=[/^B -R5IIR$0M0;":O27 .97!,Q>3
M*];KGET8MWKM-TW;=/(T$'4#E/#[F<3^:K98O)Y>2!9Z74[SM?E(\Z %&0)
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M"=>SZ?7%I^Z9KMVD.VLAFM9+X)M7+WY^^_+Y>I9S#-%$+6B6^U1[@22H$85
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MMY=+ZPF6F#0/OB;:VSJ[+2APT4NR@T+2.7H32J?&]WU\Q8< 7K+B#Y?H %&
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M%Z_;=D)LG):](1_5"9-<'?:6DZK=^G2HS90,2)>,9<J64EH<TR\D^WY?H_Q
MP8Z6?=\%U ^3?=]+0YU2L?<1[VC9]TRC1*Q]0U?1Y* B(*-M:-41*<9L.<J7
MI_-^V??M5=Y'JJT/:]K*;DJ\9O-WT_7]8*C#861-)PFK*E'O(207H:#("66L
M^8R=SNA-GWXJ.?>]I#YK*;+69O0#0)_^G*T!)2-]Y Q,9K[>\2;PBH?:3-=*
MU"*$W*W6<=.GGY,.]Q-9Z_?PE^ERLOSV7Y.4WY,=DJ=+_)SO#(LW)([5\A_
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MO=HP0-J]@2?#HZ!_1-?Z4.P![UAAMJ$(\CCJ.I"BAHC3;X=Z#[36Y*ZOG#K
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M)I&!"K%>>AH-P3D!4G/NA/=>A]9.Q088IQ"N.,2U.%2R UPGWUTP>;2,&Z[
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M28F,I-8)' ? /2^ZC:6WAC4RJTUWTVOR]KK*L>["#V(YBXL<G>/6U81<7SL
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MM2)7U\1NRT(2/C$5.KT2])@'5*'O[FGR/()C)<,TT^^LN9P;ADJWHUHW7NN
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M0/#" 9W2FAN-SO'671^WB'*F43.@!DA_(@I_3WVYL-XCRZ: C,Z!\C%!2$4
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MKKF"$!4WH (F<-RK.MLH!8_.N-0Z@-5+P)=$GN&0&6"_^:&5F7$Y1C25R+F
MTD&",SJ3C9:YD\RY'%H[X0[;/6XX$NRLUP%\L4\9ZD31-S_4>[Z=_CR9AFF:
MA,OOOI]O7D;.O:O=%FL7,UI-<0D\DEJ<+2J$)+Q0K5M]M%W! ;H4'M/=_W!L
M&&(NYXW<:P_U-E_F13"J1,$,2)0,5'9UCJB+8'5]-3USQ;>^RG>3;'PN'A+_
MN]4)[<$;H@BFDY2;"1D77#K/LHW@N:M!F"P@H'?@D_5.,2>L:IU_VD_",^6&
M 7. D[O-N?$F?)XLPV7]Z:NKV?5T>:%=8)Y>'= VU8 TSQ!B'=N6&"J./K7O
MR#304DZ:S,= CX;M5U;)JAUCDBO)2=7?^EC96KN2E #M&.F163*)#'-@;>!"
M:2NXO^,4V5(7LJ, )TG$T1 ;8%Y4IY>'SH!U3Z)-W<U=X\18[F-6!>B5\:!X
M(;4QY% RY]*SB,FT[J[91O*3).P!P;]/83U<$DR\G>;Q>YC?N)[V36IY_%/;
M):GTD/Y(DTYB")R8$"$*NILKD2PX'SEPQV0H0:3V_:!/(ND$A0N&Y03.U [Z
M@BEPN1A2K@NR6.$E;]V+[9QTLB.OQTDZZ<.(8TDZ>7V]((TN%J_2OZXGB\FW
MJ*;U45KE)(B"!I3V'(*LH4U68K8L&8>M4]6VB/*RDDUZ<636'JL!G%(/B56_
MG..WIN0=!!PHV>1)X0Z3<-($R@[TV!^'@Q FU;0KSA@PK6.-1+)5IP @(]=I
MM(ZSU+JXXT!$>2+QY# \Z:/^ULTW_N/Z*DS?7EU=3V>7LX]?7T]FBS3!:?H6
MI0XZ^11S!N'<JII$TEVKU#$'5I2HF0J1=?*N//6D\6^EC9&9#:76 8)GCV58
ME22]D!G!6E?;S6@&D0</:$@=,3LG;.O=X&227_>Q1UIA-EC;]6W9%%V$.R>_
M]H:Q5W+C+AB,GORJ1%2AT$YK/4FJ(HL05*UG$RHJZ[7+S3VJSROY=3A^]%']
M@9)?DU DDK' 7%*@2JX#CZP#5H1P7G-M3.O0Y3-,?NT%Y [)KWU0.'CRJT0?
MF%8>= D:5**#UW.CP2AF>0R9H6B]H3SKY-=]R#,<,D/<B</EJBOB)\0?=]CH
M0LC1)ZC%2#6WVX)C@8,O4I&UGT71K3/LM\ERMGR;HC7 M)B'Y%J_25TD&\H'
MMU6J SG?FJ#7@1)[J'ZD+6:SS1KGK%,%C*E#RATB1$?O0D9%9EQBBJ1\YJ1X
MRM$V,B?Z:/Q@B:077H50A'<@2VVX&$R &#F"<"8Z:73THGE/]2/-53ZF\.4
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M/7//=D'H"'(9LRST(9C 1MJ7%>,>0I*.SO0B;" NE+OS65\&H7;*91R33WV
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M]PQ'[X+0$:0WL"B\YK% R4&!PIQKPT@-VO.8=8D^\];-*8Z"4#NE-XS)IS[
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M!F)(!;)G:)R4WO/0B43=GWFJ!!H(E2'*P:X^A\G\:M5MX>UT2?J8D"G^:K'
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M\H--(V>CG*\C!7(* I2@5<2$BBS:)%-@*JB[CJ8M]MR>@HSO,1H)[]F!P!K
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M#'G"#WW_R8>*=;6 <M9,I8WC#S]*<RM\VT6FAL&I;7*,'XO:%Y^M4.^IW+&
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MVDM]0([U$!RW+OD&*MPA;B;<UJVSUG-[PF#MR3 1W')V-ZV O1G(MMTTI)Z
M"HJ'MMUBWIHP?Y&2[V8A+-"&>_L%O>H!B][N2KJ@LKYV#Y:WEL*V!=_)3:\
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MW,RII0$$NTK@((LIKIJ3BI2;5:#36KO<:W:%);M<N7!*-R85D!O:=1CNM=@
MOT,JE<&=^:.$!R-F K=F*\]T9GPM70F60_A#;VLS;+=1K[7BRIU2M=NM>C9;
MCC&0DSH^ADT!3L!&>;L['DZ'*BRVZO0\X_!5384 GB@%7A& W3A&S-8L$8TY
MP)85LZY!"IRW8+GCI95Q;&(-+3&B!A_+;!^;3?398+10L3I<#] AT&&O/#($
MTNSH4Q WFB#9JEX7F]C^R  6TN>'50A9T)8VX.'IO-ID/==P9^.*S@!=#(HC
M3^L.Z*;&SQ1I5F,,<5XO3S%(@D,+<Q#&4G6TMP1S1TD7Y-/Z<IK/J!7?A.>+
M9A!.0+JI*L54L!E.,%!X7NIYG-/E<;^$P1783&:^'_5T7Y<[S*"7T\,N7Q5F
M^!*$<]T&51N)*BY'C6J67)N-E(SBE, /,='VL>DR4.4*PO6=HC\>S><]<QZS
M=L_C,2[(B[H;38N=FKU,  ;VYGUI G!(JQ^U&UQCY.=T<;!B(<7V(#@E!7]2
M1%?LV)Z-H5C)%K7.L)Z:ZA"D=PC22C0Z\28MI)Y6N19J3WRNZ+H0D!LH0]C$
M$DND*QM2)P[J?3'OL&TY!BC#"DRNV7;#, HF>J6-EZRAV<!#2U:7-79>;C7M
M7H>81WSD30;(J+?6Z:3I$ V)'%3'8;MBTZVV/Y,:<5!CPSQ+R[%+M+ N#3<Y
M/^PM.W8PJ,R*56/:Z6=VR?,'PT;/"-IV(F2:4]O:Q$N+:)6EZ6)I</(VMTY<
MPZR5C<\$?&+W8+%<ZL:&9JNPVIWU<:O=58#'LRO9SJ<^B*>&G8.R,RFY,$"#
MH-J?:Q.LBV=!K@W]"!)JOM7H4WD?8C,1Z3NY9UK1RJS87:Y-P0&G:!/*$"J0
M4B'AUF"EPH&>)Z2E>'4(X)!&4D4#9,00W18\ EZ^6H6)[N M7NP,A Y<M.Q,
M&#:PVF"EQ .8&P'<!@>\#_;7"#M!9LM= R]Y4 35*J#ZB&Q/'\ K'J&J> Z*
M,+NGU\O>:#AH!E) U1VY(?<YLCO'9S6;058#S.S3BL3P;EZEN>FTX@3&1)1#
M/+-!7E@NX&93+'G]5<TL IBHU'IQ:G7D,=]WJ)3GR<A(BM:BKFLS#]&6$L<N
MS7';SNO(S$+QHJ*I@RZBP<YHJ51!!HQI7$[@E.-'?32>D!D^Z+'SJI S2MD:
M6_!HM5J6?J^<A$;K3U>6\#KD ,0*0@[!4B"^C1!N5*IE7!FV!L&BV*U6!BE4
M;H $#S=0%,^A =\>V'TN"0)-4J@Y;]#%4A/66C$R]>NSJM1ICB;]! JJ79!E
M9,(W&Q7 FYXL-5Q)D2PM#8,2"9BEHPF<IS:V1!,8]R:069NL5JL1)N*I)9O]
M,3//>G+?RA&J-/)H0^MO;4:2Y(\T-UJ--%" KC(([RQ6%<NJ#TIL904I)<P=
MV '5U*6::B-M.6%J:KU<J:L,T[0&4&_*EZH.E*UZ9@1T*@SA/E>1J_H<[H>-
MRLCN<<$ NWMN:D_OP/%(J'&U6JML&W4+4G57!GB<JB]'_$H"UBLMBG&UV\PY
MO [4GUDQMZ3#L@)B8&9U<<*OK.0: BLM(,J&43*85JOLRJ"D@[GV*O#3M%%U
M!KUAA/=2@)'P<<UT (Q"B0K=Z5C)< 6-_"EG6F)-FWB5AA[T]#[4Y%W)S@9"
M+,EQFRLMVC%?<OUJN#(Q=1$D70'U2DV0%YRTY-%5B_#4"/)&1=1JES$Z;ZT"
MJJ^XMM %AIWA7LF*TLP:KL.;E8V%?HV%D$IS/N@CG.VJNE^U6R"_;&T.9A*#
MDQ4\U&M3;9AS]4[8=CA,MX-V"Q,7NMO12FUDFI0RH:@QS4HG$3EYD:%MBJ[J
MV+RM1W"=B!"^0T:U]2<84MM-5<,:VJM:,5>41F32\]C7T3[E*B5^(@USM,23
MG-=BS$4P['#S0/2-O(F'[;PVDP3-I>T +^(>!')]6\&+E26GH46]-8K2=M4L
M0E2SLX!@Q9-JOEWNKT:5L)=E$@"5D]AL3['1J-<9],,07G^8WZX8T%@#8)E=
MTNO?L%>B3H!)+'" 8%EML*Y469CHS"R/,6 =?;L3)% ?:[D#><+,_2*K]J<,
M7>5ED1Q,D=40J[6YUH M&C0YV]IL#..R%?, #I8A&UB$G8!<+[@2*'9T2,:[
M(5[B8;_5P@0#1RPCT8"GITIE-D2]Q!_QZ$1LX*UZ0BMQ $[J%(N&R$\0P^[.
M&B.9;D6U!MB3858#>;%0IZ4)"'%]>P@OV6ZI:IM!4AU,:HU:=6[E2DVLK7)=
M74*=U?J#?^ +4@OL1>GH.EOC:ZO9/$2XTG(&D.](0KL@;[;Z;-EM%L<T#6S>
M=5I<16UTC.FL8:BRA.<U:5K&.QT>#UKPUB;1*,-XQ+5 A,F$;F45]-$1;-O$
MHHWZL&FSV @"ON.E.@=/." )/%!7NCFU2PV ^A8Q@#W+,3XH^J&P!)[U^Q]Y
M A 9LC FV'V F8"C5L;#>64RKT+E"6XO6ZO![7[*Q3#6LB$9F@-$/6ETUWL3
MPF"EK!?+(#J!5LLU3 H[0SKL<DO(<!*U6(L'BMGL(Q8L]V-7DL2$X[+RQ"\;
MN;GT ZS*9\&J%54F6YO)@&\R5LPL<TD=0G8\S)!RB^R ^)3C31VN\A-AE726
M9'=)NV90*D=0DX4[:UD'W1F0?%&'UQ\6*&NDM[6YC?72J@@OIS9==6H\[E9&
MC5F(-5<5F^GTD(RU6E14S8U2DX8=1T""69AJ$;>8HFHPSC1M:>'M8J6J9:"N
M;R++3EM-1A&VZ+I#E.[!=+O:Z;+,9&ERU(#FN84]\'U+1:J:6/+G92^ICEE_
M['&29_1)"-#Z3-;F BX&2#5GQD-, .4?;2 6K2SY1=2LCD<Q(FEIHS3,&6-F
M-XALU:IVLT#M66K5U6">+T^P:I>T^4X@5WQL5;20R< 'T7+:,^8AO/:SG@V/
M>QV3G&%XIRGAH5A1.8 -NVV W3!+:TL+6YA4J/E$JMC#:7TENI$JJQ+9 )6(
M[M8)#M0+RX!#!X[+&W9O,4+]H!&F)I&'^++;7&):98FUYVB8Q%9YV>0J>'$>
MULW1K#AD9OE\!N>3=,4@@=T%Z+-!K''ORM<4<AQ.6 ? )I*$U"XV2&5*:G>=
M%ITT#!E@XK25"\OR:!*JV KIYO"P!"(56800?Q&B08@FD5</TZW-3%0!LB=+
M'#&+Z]VZ,]"%CN$JQD+W,Y=H<@V06 D!HS4-FQ3M'C*HH5,_F:HXE?;+&9S&
MV**3-T"F*B^F6YM5=5P3/! W.H9M]AP'"7NUMF>T&E::Y:)3-2:$.B.K^(BR
MHWR56"1P[ 4L(S5?(;QA#:YPBT!C2Y.ZW0:X%QM#*MRL(3JZF.:R!;#]B)@W
MQ_F,*-*=)K O4%%*JV:J=:P>DU4Z[1 Q!(GP$0GVEZM!9 <RXBU,/M2L)HB6
ML.*WI%PJ:CZ(H#,$+:'YLNV$;ENFNW0X\=C,;D*)C9L!#"+5T!W [F@U XX^
M*74![)QUE[9JN39N:.D:#5)#K06[Q,HSENM@U"_#4VXQ'$%6%VZ2.?!\0:&A
M.1;4 KM42EOC&O#I06:IMI> V%#/X'*V@K=#R];F'P@N]QA:_O3ZE$^Z '-K
M[7;23UITOQ4@B==HBIDLS)RY%CAD-6QA%9OCT:'C1^,P9'J4R(""L[J:Y[X2
M^U41X#==6="U<D>"F\,E%D%*"T=\..2P:1^D#74V6%+UCE9;CB8#-])4*;<@
M1.VH7N:V:PY"R)Z9Y)#3S3VXE0.=YLAHI8UG0P+1:CU^Z(BV-"8QHSFI32=B
M@H_#KAEIZ4A),\@#*+CN=81!J^+BTW582HEU6(()1H>);F_]-V9!Z<XB].@/
M,4&MJL/Y__8AYFJ%HW".+,T.TBPC)1G$$+HU-8N9OQB64UFWI*34Z-G5> @B
MW2(<!UFUBT0^(WIVKYN8=ERK#W.A#,OV?)A@&BS8*QTS$T733% _ U_H^;HU
M(GG7JWK3@:E!1%O(<7228;0Q7I077!\3AA$WHK05YN!%2T_D,;3(\U(-J;EK
M]T3594_*HJ9>+ &=SHQPDI9QP4R<+!^-L)%>]:L ,P(+4(NAORCI_7:O9T_=
MBN+R8Q$:U\T\D1!SB<X +N+BFEZ>EH>P#+8.:L#(Y,K#\M3N@<UW(2O),#W$
M4ZF>^Z/:R!4ES9T1=;[9+M+M 82K"45T0G5<'\&C8<#KL%(T6HF0"K7EK#('
M.6O1)A 4[;6-BFF*LY0FI_R()<FIB/ U'"7RM,N/4]H-.L-F'9H.0@AJ="%"
MAP*Y/"[-.TPM3Z;HK!)/^R O5&IC4U'-=%S2&H$(X+[36>8=RNH(F<2.?<J(
MZJEF52'55$!50:QLWB]-T9B0*F-*XMJ"6VL0G9Y0B=$8U%G%Y:I"8)& TU,C
M\CD?:M%+0\AFAC1IA5"[-.DLK %0GD^K?1E3960Q'&"H7^5Z/,Q4NPP,,K/:
M@?089)ZMS6"2+#I8$578+MVRA[4J7X97ZU_UZ!23JZL%J532(H\AN.DR,3PW
ML@DZ&"]J)9[35'4QX6I=L)\^5D(0%&1GQJ_9RIP&:#LH&L.*$0YIUW5,HNN1
M@=1M3%*QZA3%L;=2JCGDV0W8MU;XO$+KE;[.!</*TE!ZT:BA0B@&LDR93ED!
MBWNCE1^,V$I7*4L3AQ_CB8; &;KV&,QM@-.L@]K\GH(:C(TC4&NM0]K6YCT'
M-9SX4X(:T6WX<[2D#6JY/:Y5 ;9<XYBRS59'F ,+M)20"X![>KSN2UP*VY';
MF=0ESF0)&J\D%;W9C!$(;G/CHC=W%NU.):_,.D)1'[6#)@:\_JZ_]YG5@^)2
M:6"@O-?$/$\4KYI%J[H3-3T7C%/&.&\QJ6L-53M2I"6D4BB,L0U8H<OS!0Y\
M >]T#>YN][AL9(*D6JZE_:I53/21G"PIKQG.0(7MP ;I*7P8Y(S8D6-''D^3
M5C&WQ!QXENH)\[B'=7!- +Y+3?FXF(LA;[B9 &:P&@6:((E2S-8[+A_UI0%:
M)[PP\ "\7Z8-6:W@OM5K+7JK :A/)ZKAQ;9FI!+NVH:C8S;7P\AY@\,2(>E.
M.IC;]29MH<A)[199#U!V.<*729UJ\+D=](D&%/)*O@IK4F.TSO72I,83$MJ?
ME_+VC*D!G#MJ!18V""VU5L:]/'>730GL@::7_?$R'(J$0) Y;\F!W/#"4*^(
M> *#(E1>9YGBQ),A-VE-G6YO7O61B==?E+F6RW&+A8$$156I6_W)DBY:G#K$
M)J%4]2!;;3=D05Y::"6K3^FD"?!&O%C_!;A@##$STU?>I#0NCR 3!9;HVWU3
MFO>*XW(<X$G&MU#<B?I#;I(J"#FO-9E:9;1<K 159I1,IR-.JDU'0YD'OF"N
MD-$:N9>ABF2JD*>%,V/F#T$AT^R4XB1G%QPF='6_H52$S$+FCC#F !#!!B-5
M<!M^"8ZL*:BZM($![$T<&(R9$24TFO;[Q>ZJ[TC!=,([:#O49)=J-A6[3.(>
MOA@ '*@A,6PTE.JLM\8 ;<S&,DA7H'YFKR3<PP F;W6*\[)$:J*$XA0\<MU^
M3[0;?:+>RSU9;R2+"4/TV $_%76M/:4%5<N2/&O+"C-N-*!) VJTEBUZ;9N@
M^G!GLQG;(YJD2.@$,2*#Z0JM+0T)"KN,5S0UO,'2+5 PIXYG> R!(TU::;<=
MCYFS4YKE.Y-I?39O0N4ZL_9Z:R3R$L<WO62J*4R@UCMBX,OY>%:LF!(:.XS+
M!'P3F/R?\ <!  T>Z:LD"!_YI*BLVD8R8X18,V<ZP)Q5P1V7L2;EM#)D8.LS
MJFLM=%JN17)&399L:BH1C]&@O,3QQ1HYD'@I6\I493XM5KF0G]@R79>@CE[O
M:FAW1E7*-1_KC"DOQ"C(#(9$CC8).*FKL@-5A)"&FXO62H(;UB ?;6U*F GS
M5.8$LCV(RZ5A#VE/=2>+[)HFAH&$.\O5BEV9,>-&5-C,3-^I8T$I9A-=K25Z
M!F1<G_<8><Q''L#D_7Y?$@G"G"-DHS%?( 3!DKVT<4^_J+;AFG?1G<] 'GG6
M\?:'-?_(D[GW\,3G_]'SN8+POS]T&P1W/*0[3R3+_M^IY^M'2^';GRP%Y&?>
M.9E9)G_.9&9IA<F91SWM*PB'^7">:*%A\?3%8. "US4/%W&\B"#5<K&*%BLX
M@N H2M0H#"LB10HIHNRVQ.XZ]6B.=&0LUH]DW\;1_#,X'C7U:(Z=V'7<4/./
MNKU8 +88C1;Q&EJNE4B6)A&DAI0)'*L5Z1*"%7$*OYWM/<P_FKUDA::[UB?E
M:_/YQ=,XBNS#4].^??K=[M_EK%;L+BV3C:/@CST+?.&VK@^[=PIM^PP5K6*;
M-=0\9)9KR"&L4JX>TC%=/Z0;1<NNX66S9!<OA']O[EUXFO<@\=+=)%[$2PS#
M( 1=HFB:P&YG:=Y-)+>SC/YBD?_!^7?A'_]!F=_C_3L]]:Y"OXLR.'>>1'%^
M]"/;LC7[\Q_9WO:KPYJQ[?=S#2RUWM518W>C='_?A5BFRM[=X%FD1#)EBL1K
M%>QVAK^GT3N8IF,KO/,A>%1!RH=+Q<,(<OM#\$=1W6WF/+*35(LMP@%R_U.>
M@[^G:7?C:8RUT+',B^';J6\?N.<0^W]7V'\\NOQYPO[];QSX_[2PCUS>8>FW
M>\G1WO"7IS/WSK/<<Z8YBN#(UT_<MHNCQ@_+B18GBVDWCFS7MR[NQD :%\+_
M"\7_V9ZGYA](J> &V&/ICCV"Z\-@27-A6/%MNNO2[ '?U6,MS@\@Q0N*R(7P
M7:C^X,Z.#$HTN_X.%OB.+V$!5P?^+[2_+O+71?ZZR%\7^>LB?UWDKXO\=9&_
M+O+71?ZZR/_/%KGS&Q^MT+SHW/3<2RZ^]5O'#GB*>D17ZK!\BREL;!0*QW(M
M-XQV'%\H!&$22W7RP& X.K#W4X4=A?V%/06D4-",^520667]Q9,\0QV8 Z+"
M7=HOOE386+]__A#7/7"@\.>U$XQIG!0*&UW0+YF@# +])X&^GR;3]?@-H'^R
M[JW[.W:M^S'8(.C?=]UWCO0?O$USI'_INF\&H0GZZSU/S<!<]S\(^G^W7%B@
MO[,%^D]9NE8*^E\ _;/\1>""_LWKN8&ES0N%7<>NQQ/+&(-^$?2/C16) OT+
M"X5]QSI']?6C^HF5)>M#4=$TC]??LG?@/.-!!Y!:#3_ 6:EO)<FA+E"*%IL'
MJ"B8:F%>*!PY\W8[<2W; T#(%:16J1Q"+T".$M3_>O-/;&O='NG]3-S6V<8I
MG[QS[)[HHBL*!?PF()MGW3FFOZA0N.;)A<)]OW;GV%G_6"@<!_1V]:>/.L\I
M:WLYZOL[7<NX8"W0.]H?)?@3VE'K7;!F=X=X#M!'OE_SP%IN1N1'B_C '/B$
M=>#0W8WX+YYXS_MXL&395FR%8$8?6)D;.D#=MWT$>< -_Y 2_\)I=VM'[!JT
MDU[]N\+)C[B@</RG3R[L_)]/%G:==$QAY\->#NYLW*&WUOY^8>UYZAG?/6+W
MVVWC][GN>.;Z9>XZV_,H23E@+.+ED7MKMRSL+FP6CBN<7#BU<'KAS,)YA4,%
MM% M/*1P:8$I- J=@E(8%OZF8!3&A: 0%]+"HPN/+SRE\/3"LPK/+[RX\(K"
MJPM7%MY4>&OAFL*["^\O?+CPB<)G"E\L?+UP7>$[A1\6;BC\HG#+QL;&WHVM
MC9,V3MTX8^/L#6@#W< W+MY@-EH;TL9PXY$;SD:XL=AX],83-YZ^\9R-%V^\
M<N/*C;=LO'/C_1L?V_CLQE<WKM_X_L9/-WZ]8^>.8W><O.,!.\[9 >_ =Q [
MFCN4'0_?X>R8[5CM>-*.?]CQPAU7['CCCJMWO'_')W9\<<=U.WZXXZ:=A9W'
M[#QEYP-W'MJ)[Z1V=G:.=MH[XYV/W7G9SLMW7K'S33O?M?,C.S^_\[J=/]KY
MJUU[=IVTZ\"N0[L>LHO;U=ME[)KM>NRN9^QZ\:[7[;IZUP=W?7[7];MNV/6[
MW5N[[[\;VGUX-[][L-O9G>Y^RN[+=[]F]U6[/[3[B[N_L_L7>_;L.67/N7NJ
M>[@]PSV3/8_:\XP]+]OSYCWOV_/9/=_><]/>O7M/W0OMO6AO9Z^V-]G[E+TO
MVOO&O>_=^[F]W]E[\[YC]IVQ#]W'[AOM"_<]8=_E^UZ_[SW[/K?ON_MNV7_\
M_K/W'][?V6_NS_<_<_^K][]K_Z?W?V?_+9LG;)Z[>=&FLCG9?/SF"S??M/FA
MS6]L_NR88XXY>$SM&/$8]YB_/>:%Q_S+,1\]YOIC?G7LB<>>?RQU[,..71S[
M#\>^]MCW'?O58W^VM;5USM:E6Z.M9.L?MJ[<^L#6-[=NOM=)][K@7OR]S'L]
M[EXON=?5]_K<O7Y\W/[CSCZ...YOCEL==_EQ;SONT\?]Z/C]QY]S/'6\=OQC
MCW_)\>\\_LO'WW3"22<@)W1."$YXQ@FO/^%C)WSOQ+TGGG,B<Z)YXI-.?-6)
M'SCQVR?M/.G,DZB3C).>>-*K3_K02=\Y><_)YY[,GSPY^>DG__/)GSKYAGN?
M>._RO?OWSN[]DGO_V[VO.V7G*>><PI_BG_+,4]YZRI=.^?5]'G ?XC[6?9YV
MGS?=YW/W^>5][W??2^]KW?>R^[[YOE^\[Z]//7 J<ZIWZK-/O>;4_SAMUVGG
MGR:>EI[V\M,^=-J/[G?R_1YR/^-^E]WOK??[VOUWW/_\^TOW?]3]7W7_3][_
MI@><_H#Z Z8/>-$#/O" 'YU^RNF7GCXY_7FGO^?T[Y]QTAD7G^&>\;PSWGO&
M#P[<^P!QP#_PP@,?/'## ^__0.Z!BP>^\H&?>N M!\\]V#OXA(-O/O@?9VZ>
MB9]IG_F\,Z\]\X:SSCA+..O19[WAK*^=O?]L_.SQV2\X^R-G__*<<\]1SWGJ
M.=><\[US[WLN?^[JW#><^XWSMLZ[Y+S9>5><]X4'[7D0_B#O02][T&?.WW$^
M=O[X_)><_VEH!U2!7.AET&<?O/O!M0>'#[[BP5\^=.PAXM#RT!L.77_!*1>T
M+GC"!==<\&/X+'@$/QO^"/R[(E;TBZ\N?ATY$6D@3T#>A?P4/1\UT)>@7RAM
ME=C2XTKO*-U8ALI6^>7EKV G80+V5.Q:[+>5:B6NO*GR_>I9U4=67UK],GXR
MWL6?@7^TMKM&UAY7>W?M5X<KAY/#;SW\DX<<>HCWD-<_Y'L7GGNA=>&K+_SV
M10<OTBYZY47777S@XD=>_(\77W?) R_1+KGBDF]=>N:EYJ6ON?2[Q(.("?%&
MXL=DD8S)J\A?4H>IQU#OHW?2=?HR^E/,B4R/>3'S3?8@Z[!O8&^H8_5'U=_'
M[>::W+.Y+_,/X W^2OZ&1K7QF,8'F\<VY>:+F]]JG=^*6^\2=@@-X;G"-]IG
MM\/V-9U"A^\\M_,?W7.[L^Z_BGO$KO@2\;\E1'JT]!'Y)/D1\NOE7RBD\DSE
MZ[WS>HO>M?WC^@_K7]G_I4JKSU&O&\"#QPP^,3QMZ [?,=H[ZH]>,[KIH<Q#
MG__0[SP,>]A3'O:EAY_[\.SA'_N;T_[&_YM_>\1QC] >\;9'[GZD^LC7/_(W
M6D>[0KM)Y_67ZC<8E/$"XX?FI>;SS.];%UG/L;YK7V0_Q_Z><Y'S7.?[XTO&
MEX]_Y%+NB]T;)]SD%9-?>AWOM=ZMONJ_.=@7/#)X9WABZ(4?C$Z/LNBS4VCZ
ME.EUL\.SY\]NB)OQ:^8;\X?/WY&<#,#4)Q?G+9Z\N'YY\?(ERYO3?OJV[(0L
MS#Z9GY\_+?_NBEW]TZ-V/<IXU+6/?N"C'__HZQ]#/.:5C]UXK/[8:Q]WYN.>
M]+CO_&W];U_W^,W'>X__]R<4G_"<)_S\B>H3W_6D!SSI;Y_T[2?7G_R&I]SK
M*?%3OOS4ASSU%7^WZ^_<O_O4TTI/>]'3?G>9>=G'GUY\^N5/_\TSC&=\_.^1
MOW_AW]_Z#_8_?.J9E6>^_%E[GA4^ZTO/ON39KWO."<]9/>?;SQ6>>_7S#CSO
MLN?]_/F/>/['+B]?_HH7;+Y@\8+K7MAZX3M>=-:+GO6BW[QX_.(OOH1\R9M?
M>O^7/NVEOWR9^;+/O?S2E[_I%0]XQ=-?\>M_=/_Q*Z^LO_+J*\ZYXO)7[7G5
M\E7__>K^JS_R3_@_7?F:TU[S]-?\]K7A:Z][G?2Z#UY9O?+*U]__]<]\PXXW
M+-[P_3<^[(V?^6?ZG]_QID-O>N6;3WGST_^E\"^+?_G!6Q[YEB^]M?G6:]^&
MO^U-;S_[[2^]ZJ2K+KMZX^K\ZANN&5]SW3N&[_CL.QOOO/9=#WG75?]ZP;^^
M]MT/?/=+_NW>__;,]VR^YTGON?6]J_?>]+[I^W[T?N?]W[[V$==^_0.##WSA
M@^('/_6AYH<^^F'VPQ_X"/&1]W[THH^^^V.'/_;.C^,?O^83E4]<_4GLDU?]
M._;O5WVJ\JFK/UW]]#L^4_O,NSY[X6??\[E+/O?^S].?__ 7^"]\XHOM+W[V
M2[TO?>7+#_OR=5\QO_*]K_I?O?%KRZ_=\O6__<;N;USV'\?_Q^7?O/\WK_C/
M!_WGFZ^K7/=OU]/7?_);\K>^_FWCVS_\K_E__>8[3_KOK?^^_+MG?/?*[Z'?
M>_?WV>]_Y@</_<%W?CC]X2T_>LK_G/ _+_WQ>3]^^T\N_<DG;QC<\)T;XQMO
M_>DS?G;JSU[[\_+/K[VI>],W?Q'\XI9?7G;SJ3>_[E?XKS[R:_77W[TE_<W>
MW[SPMP_Z[;M^U_S=-VX-;KWUUJ\7J,*.C8WU_]O:SMT[UVW/KET[=^_= ](5
M^-FW_YC]^_9M[MN[=W-K<_.88T';N_]>QVT=>Z]U?\UD/7T]"_P_=M_>?<?^
MV>W6]Q5.V+=Q<.=XY\;!PHX3-G:>L''K!PMG $RS>V.[W0YH-G;LW+5[#]C2
MYC& X*KCP?9W[MP!-KM[%\ S&X\!]PN[3MA]X@,18L])HK;WX.QD]/'/?N6^
M,\FWO/_>TF=O.*NDQT_8OWG*?>Y[ZFEGGW/N>0\ZOXQ5JGCM,$4S;)WC&[+2
MZZL :!FF93MC=S)/%LLTRU=/?-*3G_+4OWO:9<]Y[O.>?_D+7OBB%U_QJE?_
MTVM>^[HK7__6M[W]JJNO><<[WW7M!S[XH0]_Y*,?^_CG/O^%+W[IRU_YZM>N
M_]:W_^L[__W=[WW_!S?^]&<_O^D7O[SY5[]>GVNCL'/C]G:/YSH!G&L'T,&N
MO>MS;>Q(UP0G[-K]0&3/B82X5YN==!!]_+Z3R6>_\BWOWW]F2;KAWGK\V<U3
MSBI??_:-ZZ-MG^Q/.]@3_J*3W7&P.\_UM<*Q.S> \G:>4+BD\-O?7''9>84K
M+KOVYB??>+_ZS0^]_D57!9,;@T"[;N?/+OSWKYZP>ML9Q$UXX<6O(^7G/*/W
M]7,D\6&?6W)??P[SA(IM]<3+]6GAS2]]W!B^^;QKGOJ>TZ[Z\"NNSUYUX\5O
MON_YCOJA9VS]^-LO0K[WPKVW?.O=E_SBN;_]Y]\0-[Z'?_LM_1>P-WR3.V7V
MGK/>=?K;BK=\]7??^U7]%MI^]SF__D3AQD?,GG?#N\M7/N/+M[SAIL==<7&U
M_"W>Z^R_M?#X2S[[N!?]^M M!W[WA5^\XNVO>.)9MY#O=[[U</B8UXWJSWK&
M<?_QXB+_D.-:YO,O//WUG3>7=NU^X9/%CYU[U6.;OSET\RO>\.@3;WZR]JU#
MIPO7].&??;CSL?FIM]QXS>O_Y3?_L.^_=JKO=5_Q]1=\^#]/_\F;_ B^'_.9
M4]\CG/^QCW_PAU__]\>>)O_NEY]X]K.N>,.]W__Y*R^[M>!,RM]\U\]_VGSS
ML[1WO/[X#SSVMU7L-2][]$\^_\E;GOGMSF].5J]_[[7[S[GJJ=WG?O!K;SSK
MRJL_]Y8'C[_Y]\A!Y--[7?OTY__TUL*'.C=#>Y_Y;OF[]>L?]8!SK_W,LQY]
MC7E+\-&+_^? ";<6_NOBW_[P.V=>"5]U_@\:WC=>^_YWQJ\Z7W[W2Y_[L"^_
M3?W!/U_AO>:[3[SL6_["^?%[>E]]W,MO+3S["]G7?_&6FU_V[7>^^N$/_<CI
MYSY[\*P;ZJM?W/#=]QC/>/UC_Q_JW3NHR>[=^XT%44!0%&E"5$"0(B#22QX?
M! 0$I$9 B(J(=)'>$A7I)=(?:1$0D!KI2@L=J9$:Z83>22A)2#UQGW/F?6?_
M?G/>=\Z<,WOV'RN9W)FYLNZUKO+]7.M.:IN+6OD$$I3I[^WE*TM<_=@8=*08
M;/;.EV<62%Y9$IH)"H71[%/3(0-7(1W?9Q!7<;^+576V^-6G# ]=2]:I&>[:
MER2W,HSJU[Z"=;#HN)S;.)_2F\F+B(O.<477IC;-M1F S]\J_&*. X9,_6-?
MC=QQGE68UQ*&M1EIR06<R ?C+ZO1:@)HW>4NR1'DGXV.(.)LJ!C.D\XNA)WU
M7:K%HR+W[O+SA2M/<'CL-$]^?'>#R_'@/#1@-!_N#2X.1U?^AD6X5Z A:,B/
M[$.%AY;B7W8;-4UFN")1EZB:>(>.C9( S\??)LJ <*6)1Q0NXF-?*P; \:W6
M>#,D&L1!%PV(Q"I'Y8\W*9=!7DU]"*#MU(3[PW<;:!@(X?&%4*D]Q*0VG2VT
MB(3?\0%%G?/,VT1'+8X['$M7F)C,G:(7P*_2VO4I83&4J]4Q7\$NV; WD+#C
MPV/:VNC3ZA+?YJF<+2H(N;F&J3%W2'RIX^CH^.SCO9\WLB$6P?=T+C\Z\=]N
M\'Q:9 "N/"8)=J0'510H)SLY\B=._]B^S+EM#!#JY3&-35ZQC3$S!0?S0ZYH
M26Z@6*EB2N7%\IX+]?7:T;=?;)=2>[=5"2!.ZE-2=EF(,_Y^1EJQR-FQU-I:
M*RVC/.$^3>,SML4BOP#*6E(A>F-:=TG=1F9$G]>W'6KJSJ?4P35.;/84:Z(_
M SA$\I^I@6<=5=WD$M=RJF&12323F$&%<\\+>KG>0;7<%I%WF_,+GFZFJ7O;
MAQ5OV%K@GW17.]0K'J:X/CDFIVR_#DJMMUFB.GU1G,W7OT [U'C+.B?4Y4_N
M:E$&*Q9WO7>=R!<9++[4.X0,F\C*0 U.9.+5]=VY3&V_8JX0]1#WH=^I073?
M@<+R/;!DO/H=!_;2[ ]JJ&8CZ5@_C2[*? \=M(;")!B?MT4TVRBIU4V88Z8G
M6EQC2'X1@6_3KA0FV;1#^F7W@Q6GA[I3EC?ZUB?S/ETMO7,&LLB_E17JO'E.
MD1H>US[>CLD1:%C)LC4*S!^+2P;_7;*KZ#)W=?1:I&*NJ_L3L\0R!R]"W62Y
MK;I!PA!&$>G@]*3VII]Y8:@(A1<Z(Q#9]LF]27W1N4(1>*[R8L=UL=611L?@
M&NT&O\WF<=1?->56&+M1F3VWBNL--0WQCA&OLNX8?'@A)_+^+/*GNQ:Z(%2/
MP@X=K0I1&</B<AJ]&(#+M,-,=[&/^**'/9@:-Q/-=ZH+5Q2/9A2Z.%,FN'AE
MO=8S-Y:I*%FCEO3;70:@QIQ9KN\2>3&T!\23,1*?_UN-%A-:>8NL,CS$F0$X
M>Q0W,&4?>]TZIK[?Z[6*PZ&Q1? N 1E RX7>A+47DVR_NLC_O$)^*N,6"5/=
M/\$ O'T[R "<0,9K*+X<;5F=&>@134XR"KVI'6:S6#2JLS6.4,]Y/F7(Q=F
M,HX:&SZTZU,I5[TKK4=T]>Z8NGUD+_5\Z]XDURQ-:JHXBE@6@,O/72'/I5?:
MQBSZ4C0;2\>;3(JVK1:;UCI_.?@&J=BDJWA=W@X<^L')#A8O*1QQK<&?I X^
MB:C(J@WE%,H1\_&B2P^+X,\D>KF*"S^GEL._S\(77-L\;XN-[*W6_>.6P2JQ
M]"N&?),2H<B,[!K92%BUY\Y1 )CH?UI;2UT%>(OZEPC]I*9K_D7>WJ$&OD?I
MS7T#ZNY@S2VS?@MBQ0V,>>^6#1E:D'/4(Q!I\3F(,ZR4NB6H=!'NW:J%6B.#
MM4];(]5'/:OA&<VGVL$,P%0=1/F.WGX]*I<!T$HE]<0^42HR<GKL6U+C$EB>
M+YO>3LW8=@]/:XH;JZT?=+:>.GA84SOH^GL*?+"B+URKPE55LV&K=.7)F-\5
M.REOX\J-)XJ2PO&2+S)\X0;K=Z<YGN>.NJE<!>M\<797*"E9B0\\<A$N%Q"?
M!%46=4=KW0@0I !-4WI+7[WZ*M1RU"ET$5X,:8 MB!<K;A_A9=L0ET'M# #O
M!CE._=/UD"<2#$!:93TGZ+;>=^%40FUMN]UTSUVW*CW)2"LA/N%[R*GOLJII
MRBS;)8U#V<D'=L!UFNP8H7@^;2 I1@)9=9=-(N_M?Y>A94YKTO"80L)K$%SW
M&8 ?(SOT43G6,.E(P,5-GGM,695Q@#X[[2%E ;U+BB-5+Z%B9-D](#OG9'Z1
MO^CU0:B^+"ZD>]_Z(;G#^=NO/Q8MMQ!+M=AJG< \:G#40HW>UP!E8^[PQ089
MV(,K$]GJ5N)A'FD7"NN:3,K.[300D-Q%RC6:-B%-D?\$=%]KW.IOLAPN':$Z
M^O#5!L)BG'I=R!QL&D_LUUB0.3;?9^U^N&R%:-\T! N5*>DCOW9LA]"\V8A[
M&(4EY'G96*I,:%&=L@G_?B^=]VHQM94J]:5IR\+$YC#%//[3VMS0^O'MN8V%
M[/R/=WKY)?N"BH5TW)WK?_3<15VM\23I:4FYL.6[^8=[)-//:'E2 Q1?.INO
M\2QL\:NT1%9^R?N2,&K8*'X5\VQAT(FB;!']F[[3HL< ^#  D:RX"E;]S (?
M\GV$7^G%\(*87 U%WP"CNYADJY?<39 [FGW=F-=GZMS<CBM@V% &@(".S#\_
MD-;3YUGD.=(8JM53 .-VFO1]6 \$GP('O7$=]X$IOFPV*6J?^G(98V:GU5/$
MTUSX6UCE:\V@1J,$>U( @+-V?+V%_SE/(>WW%GP1A(4HVN1N/\J;ZPQ2^HCA
M.(D<(_!@G 6>3TI,'\AONDA).;X[F1=N,UJ3\,.J8JW<&''KS9 :N9'@CK^'
M!W:P/W[A/NKLYBX(FN6[Q0 D? 0M*.X/ICS!U$-[U2K#;,>EV4/J+T@O "W<
MF'4@E)Y*H%Z*\5&0Z/DR&DO%+*(N%8HWFNKP4)R?_9<KE/_]P;H:GO!UJK!4
M<S1T*]K&C*N4&U;NWW*E8;(^8W^/:V:AW%_@3&Z-[""D9+'X4&\U('#++V@H
MO"S0%*GH8(6I[X1Z3GQO!ME,(8)B:?X24!>\O?#^C\U@3Q_D8K9A@(?K4).A
M_X^,!DV8Y8Q@!C;D7FBCXC;6^?$^7O&VM\WAL<R3M-*;^JOU1Z59NQ4.YNFB
MF%^/HA<G$I,#)A6MBGZXC[,$753)60NCCQ-*<F1'7DX?Z+O\-/D*%H6MZQU4
M\!KP=_G-UZSF9<#AY>[@526ESZ!J>1EXOS/5-7'$O3(&5RDPD:R'U#,P6"4D
M3S64B]1Z9SQ4Z?(A/[23<GG5G;L)//$R4,.<(":8L:\A^:[_SKX\R0.9>U<V
MTOM"N4\_&].O0P;IIXZ0V5JL=MGJBR_#Q8E(D5@X80A-RVAI1JX@A>10X"'G
MY]>+:@J16U?&Z5NRB4=9RGQC^;<]XLJ+7A'(-L_YQI3_[DD#Q=M%^UOX/C^-
M[/"8;M0JD3>\;UWW<"(UR]=X7,IX2&VSZ-+C/%J*Y0:J.FL5L^@;0\A1=0 1
MVSQ7\YIVNR4/N=Y5NI-2OS  +?/D4^#A%_X):G'I!WH'NL-Z(Q:F.E"JW/])
MI_\MQBDFWW4J&6%15UT%@L^7.X1J_N#K'DFZ<TB5@CP8(X2OUC  K@P )Y %
M.D*_&>GQ&UED2QK28@"R<G\S /../=@G'IG%SX(P6RE3Y7_S\%H@YN#]+N(&
M-<4M\<CO>S*U6>)SA;-;$/&YBN<RMNP3G[Q+5X(F[#O,3=QS71^/^Y\:?!,T
M3M\9=S4=.\AQS1KWK,[8RS7H$7*)\"CW3G+-0:7?K/$5S$I^C'FSC"DW$,\T
MT[&>S^C$(V-WFBY^-@I][5WC'B,'=894P0]:!]6[Z/)5N/#T;%_QH0ZBE^Q\
M"H5K:Z1)O1LJVH2?JR24(M/N_HRX 'T,_A64/$.DOI7G.>9)6\S7&9S=]J['
M* M?F[@M6Y$9VC46H:>U-OK;A\PV,NKFE2!I:*? 6N#ZV[GI$"DIY]^HR6^8
M>SO=>:3!2'*ZP'S4+2BD]I=S6K9479:Q39(Z\JT-NPL#<*DF_-R/9YD[Y^D_
M[S6"_@%&(TNE!I@X+AL^N$"[6&OX>\"?_!X0U7&>P^XOK9TVT#W[3Y!NNKR7
M& =&@Q  'F237VZ8[-OI14IMK+F6\Q-G0&&I'(IK3=ET.]# &TZ7L7./_OI1
M6M<+26T3/C1,2YPH3[&39'IQN0/O[&*C<^?$S? /FE+#+2=_'S, %\L$@=)2
M(@@*]BWM006[2:0*TI:668-0@#0WBJS4O]4[E)Y?*&PIBGP5_+ ]#GP@3G0E
M"Q[^V$YA.O2R_BJH%K,C[T"Y0>48H_H6._MG-!=FWKU06UX3>Q6^VE?YGMVK
MS0U1$!+,_"'. &5Z]'PT"J?&A4,^9P#>3\#Z-)LL&0"FMJ&G=D&B%,F84Z]S
M;#\Y[G<^7YA)F9HMYXY=IZ+[549C%#@:@0)\U@6\EPDF5E.;3?!Q-"G*NPUU
M:$PU8I;]7[!P(/["6AAL/9N4R0"<^LP L%'S\UKZZ=?GF)5/:Y[.(GN@I4>#
M#J'6F/*QU8&NM[E&O:^Z,$\6A]YD7E@'M</_DT&HZ; >5;L)3@]%4=D@J\ M
M@B\# .*EGP+N@\"@Q>OH,PS L#I>F<YZCWX9UJF=<YX!R/-?]*1RAE&E]A-B
M0(M"R["#'09@P8P!D&/>937RF(3"\3$ B>0?_VDYRHV4Z9S<),=;L3LY[/@9
MP<K58RGGV^C"EW;S"5+[6C%FN"W18'-7^AQL587T+JM\%4%K0/VD?<'!J;QZ
M"WK10E;[:UTYP/-QF;1K/WFW"/[I176N,UH\T)GYLUI*)I>U!$C1V."MQK Z
M*7V/KO*QR.%GF2\B<3;TH'6D @_6SU:1$I,<>ZQ(M 9U'GZ;$WMY =;RX46+
M,XWHB@,5]DGA] C,?7J?2K6D)1\)/CXL#UIZ@ML6/7=7QD;W>_6M&;WDADN]
MU[K_&KK#]QH& 3V'34^WP>KVPD0;?KUT5^X4"))RR1#KYZJ93.X^TA2-RCGU
M=?<$6P!RD!3['C]I1J@B;C  =S;H8J-X>W_0WS\#.E@R0([ -T7[+2UPY (5
M_B8O1FH)7<:VP  X(Q,(L&K95M2%@$UR^YIY->Y0OE^LC)-;7]L@<>'*PM/O
M&F1P($2= 6A[#%L11G$S %M]\PR P4(%M92+C31UUR7D3I;YH?O-UZNI:WJL
M5K6@&/ED^V(E>#8#\+_>51KQ?W8I$,?_\[XB:T$O(<SYUF!:45RDS>[VM8?5
M>(X[AD)EN\(/WO?A%U(7EG,U@C '"$@3 J>_=ZR'[# A[W]G $9^;"T&'(17
M;5>SL/U6412_FST=9-V"_$FY?6[1K4.^VSCAMGZ73FV>S>SMV 'R#::2[S,9
M;?\O9%&N!*:G?[4_Y6IDVP&5B@;YWW4OF)';[GN8"'W:SP"$P#M6&@VIG+5D
M?8I%R"W/.-0IQ5EA/N)\&<2E<DD<#5]]!)IK,\G/H+9%'.6[EZ<^:V.MA7YJ
M)Z5"6+?G<'['FN#-%KVU)OU('R_HL+L8+ =-I3L]RL@9GLA'6/3EN)[W%58;
M%1L+V()H;_MJ %_9M8R]49N0H:UZ&S6BVG-@"D\FFI?XW#JDGQ4E3^_">ZA2
MA=GJ5P^^/AF[/<[SZ9,E.$F_6^HM'MXEL6.)';4P4M:6XII%CF*.0UU044=2
M@[[P[.O[!YVN[7 \U97-77RJ)B7#ZKZN)#FKNTBH&QF X373& 59>2?30TOX
M#J%!8&,?A(O%B%3FY)8WS+D@3MU=BK7 >=(Y,]@J2\!$4VI4ZS2TWUZ2=%1R
M]M!(,ZWWJC0YO%5^JFTKK6< -OG(=KK9,0JI?5Y_HE-?5\IO-M%B2:WJ46'%
M_/W N?A\?7^OJW*=^X-2I^_KS QU+@!8S4Q<R(U8UFV1"I)MAQ]= B^6=-Q/
M^7V(;I:I.N(V:%:8]WC3Y)3U[A"\O4+A)T$(@?4)^$>NPC>F(\><[E'R=,^&
MJYY5.^B_NN_5>A3MB&PG37<Z.TB@9?ML/XB6K=4@2,'B\_[+H77F'9+9I<^/
MTG6&@XBPR.+]9L +#)*J1U+@K!9-SS#K\?3IK.X@.J108#YTA''M"J]-R)3C
M4H?7Y8^#_!TB<7+(53<KSH)S-K8^H5SYJ<I"76\M*8\WR\[96"6.F6M'O^F3
M_/TMMN!156R!VV^=D68V4Z7H@J*.D6:F=^F^HR4N%'QW[$S?YX<MB*Q EDV6
M[&474)R]BT9O)OJ S:^Q^CVS0OK4,R98R$-KZYZBR0Y/MIV8RQ?SR  YJ<,$
MUE95RS1)6QWKH&;ZRG&&9O2KO!B:7/(*D"3C1,V?[H(<48H8@(TGEJ0P2/T\
MS@9]K%<?@]HBFC#C\7LI_@P*BD/1=108 &02\\IS*.^B"37>@<YR_/-/_XB/
M2I5 -L$<N4@W3*B*K-M'6(0PK'V0WL$ ?(CAOTGAHHJ@G"E:O5_@PDY3R7Y^
M3KL)+9-('08@RANV60E;8?[T;.I^0()*K\1XJD!MN41=QDK.QN2.H$>H#B?[
MD*MYO(V/)[_HZ&H$VI( '\B0.IRF7Q]D $JZ&( T! /@9\H 7%AE ,:9M;6?
M.>5&*=DC!N Z \#\[EB4.2YY'O%J,#\"C^^"CD4.;L;0%-+IYX>\+@7"^"P1
MK*\\V=Q/$WHISWJ670>UI)D)]"1=DJ35;8CD<,WAP[_O/G>E7>];8S)M_",?
M2E7/H[DNMX=?R/J-]@7D:@$/L5?4P39,H<1T-95UW\MSUZ@:&R3UF83 97;.
MLS39*H4M#G*9X^A(SWY;^];G;WY<4UN+T Z+,+,@W/Q!)L?XBJ@4M\UJ9HPK
MK+J8IXAB%5_6/Y0J(BGBTSL1@!:1C18I7&&!4FJYLYEGC,7*$]AECV8AOA<\
M&A=<_\E+-7A=S&J<UQ!TE_#*9],@*V5A>Z*X?!3T>>]W)J%Q&.;.]2Y-6'ID
MW%WQ-,AQ_'"'DFG<^$A9O$%)6\3?BK_CC.G6.,F? 3C]GE:R2LM$N6HJ&#=]
M?X'#)$QI\IK^_3M!U;K2757H3I+2B,G]-.T-R/=4ZF@W/RO!2G.DB*H:/'RX
MV6*"JZ1=:@_<&I23+#!9U-,/(AXCN['_K@HA\Z368"0I+FH^9A%""[3]XV\\
M*\N@?06FGV!^PC8>'"F@CGF?@]I -#%$F(^I#@P,[,?^F_J \T %@A:2Y_?A
MD C$T0H3> N\,:OV3"[^69=."X&0'\*'FYC.FAAO@@/1),6'+S,EVP7H#/,-
M\%\U>([K*5#J!<\PD&"%K/LU^76H^&RHR]]8D7102Y0?-NJING2,.GA#[$5
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MTF-32TM+BZ< .4 1>-?:XPR?AL;K0S)4ME246<=V3_U_5P]IRTQJ,&%B'E0
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M_,,I,K!.<J0D58(!"-PB2J%:>J(_>1' $41G93/([/1>4"@&]!*J IT$L3,
M3F>9*_.AO[M!&.XKL*MD[X\(ZABS[6DP/YJ..8[IH+/G+J"$0OQQ16%4<6SH
M\_V.3K7QBE2MRF*#-&>/ZH>5Q]$7Y@;.;%-7SO88CY-HTN4:Y:)Q0[N&"O*]
MSX.27.8C%:?A[*2(#O-:]WH;WT[_1Y7;ZVWI1R=;#EBQ"1"#3,)^JO[D]';I
M=+ ,E(".["+!X:6FP7PE7@T'[GZ-H[L/Z/](E&A=Q;A3S;'3YXW'ZVTVE89G
M_PXU';N#^!G3#/F@?W<;/9TO.O[+5.=RQ&5S>YUH_D_O2^*23 #@B) _G<O4
MD(LDH$8=&=-Y7GB1S&U:?K=J*JYOJ>3;6Q5M^K'-1OL"GN_3_K.%58KH_++W
MHE>*''ZMTTC'WUUV@&@CM3#/!VMK1;#Y?,K1%&RG*T_PJW#KGV\N,_FY_K!L
M5F%<SR0D07>+SBGZRPS[ <1^Y'P=W8<NUXW3^W[Q*O1ERWO$Z35O\&/_ R](
MIEZ8>5S5*W6UK>5,:C+H@002C>9D>F4[@G.WR'*\Z?R2.A^IWZ;7W4</R8$_
M7-I"_Z* VQ$DJ9Y62,R!WDG28(AZH/@#WVFG2DMRW[T/T#M@):EP[Q"UU=+(
MU*94IE=E\T$E^DI;;'R78,J>0SVC=RWM>&VK\3?360B(0'>8@T\C]GM]JF.,
MXY&5V3WAQ7(PNF:T6G-Y%/P_GAL*3(]G -S0X<#S(>:!N:2P1> 'GU 'DZ?I
M2OY!*5Y&)R3YSIB]N5/&]2NFGP&(?$_E8@#RRA<@5,$NNN+LU7I^T0(!,^>=
M7=2^RLJG9S>.':UN(?=D#S0C8O![I #95@: +#G'PKSI)LB2'0/0(1NKQ4]"
M8R<F-,21SM ;(Q,OZUU+V<,SKM]X:^!A'O>V ^YE/=&ZZ*R74ZZJX^]<0,K[
MNO3MR+'?X,L+RDW$LH^%J<Z;['LZ(6N4OYA&+:%LT"%B\N]-84F[X,?U8B]&
M:_CHLW?D%DI5;EQ^&B Y<I++XWS(P2(SGH/;"!CI!I,.!+>]=F-$(RIB/*K'
MKD24'^W& (2'GN%BKJM%X/JO5 2X@*9:[MW6A=>RC$@7<\&C')'SKH@\"_!:
M?3@#L("%G9@=Y)O0.+4XJ\D7LN/DY>D'SFG+D,8?(C_3SS#G9*YU-B2X,6+4
M")]=D5AB_)>MD(M"T4_]]=QYXL.>0IY>-#8U#NLVS2X<]#O0M@$,4:JPNA1=
MU?3PAP0FGJ+L1/I-%HCA":O0NW:H50-^&_SNWYT[VK/CDPD '+ +&,4K+/E]
MU ,ZZWM@;W/O];/ZII#EOK^Q31TS$2<:CGJUCG2<32[:)$';/<Z7VM]&[^GR
MX&I*"P2&S0SM+-&<.' [G#-$(3SOUZ&FNC[(=XKOY,_Y/="<9V?&W,L3KDUX
MK@^Y$^\28=Y>DZW8%M32$]W:@B?KU6[?X].'4>$M$2C-P6\!);Y"-CM,V>@\
M2R-.K!XNG=5+8^NODORCRFW$TDKZ94*HJZ^X^RT+TJ(=2T;ZZ:%2:=ZW3E<Q
M  B#TC_B'9QFLYS5=\ZQ9"56N9:%.<0'=Y[LS)Q:)>2O$@HB>+^G.L1;+WN'
M6_)+AX8'\;Z#GC7RZ_4M\X@0SOL-S&8 YD#MF@TTJ?H3Z<_EDY=S!8FAO*67
M_%29WHKBO-WD'L ?IEW4#0M64F, JEJ*#H$?M68+G*W(8A_\ZBK+Y/Z6*U&'
M'=$V#0U5RF22^!P>/(]SM[@7;KHM:4 SN=GK_/361MG<WJ%=^JKCK2=,E4OH
M_8]''4S_W0D))919LLL8@)3@@%(ZRH<!H$G%H"ZX$O>8:7?9'$0^EJ7=%,="
M19GB>0*T ,EZ'R.!'(:CT7,F)%$B-1^#+:(%/H%M/#DZU G98R):#M-4$/4N
M4W9+P6E2.2U1R!4.(EWW,9Q\#*+=0HSQ ZFQWY@^&4E/^F-*XN@_VKTH3=0"
M-O[-6:U3)%:CEPR 02-FY4=<T!>K[7+R "(;^@&SB*1>R2?DU](^@UP<?]4$
MIS;\:@&VDY\_B/]QL^GEF8TQ\LG*GMUGXJ(7(>Y8^IE"$=4B,ZG9HD#E?>?0
M'60G:4Z]NSW"5,4P<.I6R"CLC0E.2Y,IILDJ]% V&HZY,'8D Q,6>BN,PVT9
MWN=<DP_EY>N;&11KSVGN_$S7; !CD6VP\*#T'JY8+2%<0E)!+==%2)?#Q>[[
MP;_/>-/[*A[GM!G!=',NX&H1[T+$"]8SW*#&B/PI'0=7(/%&],EK5!X=J.%B
MH9ID.(>XU4R+OG4H$>9%1D2HJ*J-5WJ^2(&ZS](F(($%_]L=GF-[;09 1 -$
M"XFDI\!'O?__;?'PZ'7:BXQ2KW^>W<PH/ZK(+-S WR4J@^]$Y=;'ZS+KZ D+
MSM5/BR@>YY8SN$%Z=9G]]$:#5?JIF=E98XI(??0)Z>U@P EDYSSIEBSU<K4M
MK3H$HA2?-QCX)41UU/'&2(>7WCB_"2_O-5^-DU_?7 BJTR=[\&.S=+T@2<+;
M(GC#^J3=><^FXSF110-^(\Y RFAZAS#=L\H.G<ND$Q3I=M..KS]V_CWNR^O"
MY\F=Q G*)W1Y&:<<*^5-6!;BXU-YZA8I$J_<";L2HJ]4N1CO;8D_4ZP\WS!V
M.V?Q8=#)3JS>4SG 1DQ''NKS/E2X=27E6.Y;]99X&:*4=B5';^%'76C\0(GW
M8I'OB-0#I YY;Y6Y*L%."7_Z3S;#BOU[')L3Y(C,0-^B>9OO2>R9SC:W<I\-
MIZ:\+YH1H"03F,'P'AN QNK,YL3B55_BZR/V1>C#? *U&<MO;,._ YPB.[)H
M='G(V6%[>^>DA0,!^WY>EMOHDL/@_)%^[SC[DT6U[8-=1W; DDG$B'@[,"Z'
MGW2TH ZZ%*#WN!ISUQ9+:8SUHY3)I_B"[JB@)5OE=J6^(M?V"**T>JHEA9MJ
M#'\\_")XAQN?JA@JH,\VO2D?1)R4/*C[ZPX7JZ2UR2YLFP' [W7 :GK:RQ6Z
MA2\W4UXF%Q?-/CT]4<6%XBA-KKNO<3'+Y]K'>R#T#+C=LBHH"T\L-G3VVT]'
MK!$+*/7L>,NK4PCIYJG*.4TJ)GV%J#PUK,.SSSK!<L?:ZFR&/K_IA2LO'=Y^
M]A4=W=J?I[,S/9P%V-2,.>(*RV$=$YAK'^#3,(>=>K9;L/<B3NU&@FC;\3\I
M*FQ86EFD"#)C<>)*1+;M>CILW\YZ:>W3.$<U&UZQ=CW=B@++7$\H)>S]6=UI
MDA:=V(XZTU58$'I._DE !O9T7:7<0NQC-/='V$H^->MUQ5D7ZC@I'Q_;!1$,
M,;I9N;AWP67NQM@7<2(1(W/K+UCX"2SOL 5 OI5G<!@R_$GV_,*;!A>55\&S
M+XZ2C^DQ/^FP(95(P4\6JYTFLQL\.&3ZYFY[C%0)R0@GU0T1JBT<I0IBXUT[
MTTV7!FS9=5.?LN8FOIT*FXWBV;$H9?/R_CIBZ#>;N#1:I);TJ##3,V\\JYSG
M*#T2M!#- -1P-CZM'L0VB^B_!$0A%3-A"D#"8!97KNK:)@N('];&#WH%/#M9
MVPGEKIYPL&3ISBZ9?K"%R5,HE=\@WMLZZDGXGGGKS?+C?R!40RK:&K?[*G\
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M&RV-N7/LL-Z/]K#?Z$ FC[AOX0M1CJB%]_/[+W@1!(4YV'IFT#&$6?27C1@
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M/E(#W#JB8K+7>*HU7E3ZU@??[G5#E<].TBXEK=RMFA%]71/D06E!DB>M6?X
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MK Y;8C,:;3Y**VC>*5PBY;(&'<?FS8G7UD<8*B%;MR9Q3,&L6A0GYB^T"G6
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M4@>NX@C_.TT=_K'1 WOP?P!02P,$%     @ \S->6PERE\T]\   [40! !4
M  !B:6EB+3(P,C4P.3,P7V<Q,"YJ<&?LNW=44U^T+KKIG= [1"FB(J#2%)"(
M2!,10>DEHO0($14($@A%>A,04!20)BHETJ6&CHK2BW024*1$$DO8DI#<_,X]
M][[WSCOCEG?'&>/\\6;&W&-G[+76GG.M->?\OKT3QA?&*B!TR<S2#&!A90%N
M,#\ XP<@:.R%O.D-> -,86$L "8 *\L_\L^1]1]A9_OGR,'.SL;.R<')^2_*
MQ</-5"Y.3FX^;A[>?X1YQL_'R__/EW\&^:]=63G8V#AXN3BY>/^WA=$-"'.S
M1[.BV%@4 59A%C9A%D8_ &7:R/$OYK$ _RHLK&SL')Q<3#/XF V:A)CFL[$Q
MC>9@6LR\&LF\#K +<X@</F7,*6KKR:48+'8Z)JN$6^E"78^XW3A)6>OFW5@>
M7@E)*6D9E2.J1X\=U];1U3MS5M_DHJF9N87EI6O7[1T<G9Q=;GEY^_CZ^0?<
MNQ\2&H8*?Q#W,#XA,2DY)3OG<6Y>_I.G!:5EY14O*U^]?E/?T-C4W/*NM:VW
MKW]@<.C]AX\3DU/3,[-?YN;QA+7UK]\VOF]ND7_^^OV'L@?^W?_'+Q: C>6_
MR;_KES#3+]9_UH#K'[]86,/^:2#,SG'X%*>(L2V79["HXND8;K$+625U/3Q*
M6G8D\9MWQWDEE+7Q*N1_7/L7S_[7'(O]_^39?W?L__)K'N!G8V$N'ILP  ,.
M:*4I1X'_D6*?8V[;)*U :V#^F%A< P/H@:;6H70UH:K)LL[3T+[F_1S(6Q?7
MQ8L29TE<ZHK/A?=^C7!$RL.5Z4MP?IHL&4/9.7C:!07W>PG;ESI3!VN"!6HK
M@OUVKEUIR@I6;R]/_774\.2HR2.+%Q!'$BPQ2@O-19\%GU*MZ',21<JDVL+2
MCWNV<)3NL$7*A]PL^L1D__JC5[7M$*Y/HU>/V\1#6R [7\DY@\T8B*$*H>;*
M@L-TH,*N<3.9*T'S-XZ8>E^VP%6W/4&G]2KNU!?+>;Y;;#H$> MV9Y2TLNJX
M$_?&':U!JGW5!<T<C%*81F.\@VM6MGPV+!IQYL5?VPKLA*_OWGC'<35O9%D'
M%XA,@D.B3H.CE$A2<8^FC+\, TBN  ?*$6W!8]BU=RAM!.I;Q/;+4SG-;#SS
M]Z*_/KZ7 9P+NWK0A/'E@R:?1"ND#FDMHPJ08BV)"V9OQX.^Y<E.6X7=._+E
M[:,W2^==[J)+OMV*LH\>/WA#/^=$_XQA19N0;VY<:6]OG?P]G#=!)#9&/)N*
M:(JU5!15KV\PY_'J>[]@:_PUOR;<=T<+_UD$.@^EY)!O/[AO8M<*UN;=<R?^
MG>?^O>!X<?2%O]O:=-4T T#P&=284YS!_,HO"QT-HR0&X)PA5>;6T.[TB35F
M,3OXO((H865AVY6LNO.,M+N&B]E5&</^@<N"URZ3T078A!\GB&56L]'+U9S[
MI[H$ZD\ZC]6O>IT=1'RA2T3-K32L#,*@F0E&?&3W_6VM+^<H^<@J,'3/QMUA
MW$(@V&?OZF"+;5IFP>E%=)_:9_0D.=^6!.O'@$?V=O9>]+SVGQ]XO*P$WO-_
M/3^@?[G=F;B6?4Q,- T_]?I'-<3$HYUJ9RH3M;C2(/!QD#VU%GQS<O6N<*-T
M,KSD>"5T)_,2L-UUF+[( !HP?9I2 47<LS3;*O<E,-*^P\8H!N]N<JUI+#?_
MCE[#?(]RZ.)=D[?'SQX21$S]EH^X2+Z2Z$M "@3,[.V'EB#D/\?_*>^UJ#T<
MPI^MI,E?72YDSBX#JE%T6\F06",HVIRTFX$)=-?$TYM*:":SM>CP$H0+9\'/
M$]F+C;'DY>_)*BE^EV_7WZTVLE<5_P/9$5YE %R@*,6$9)Y 5P!;'&?OBTV6
M%YM.ZRRI5]?Z-!40G,N6^ !;>R_>YW=3'M[Q8_N 62W1WR"646$HJ!MX0!JB
M-#4VC">TO'3QIPL_PR\]7O&VJGJE?B6H<-BR\?W$W><'R_HS^8.[8O1I3+U-
MKYJ-).W\P>O;'?#@-V@STG)!RR1*<=0JHW<P8EQ\_JUC2"3YW=\1WMOO#<D8
M.N\& SAB587Y,HM?.3!TN8XC7:]1NDSFZH8(^.E//P[3#5N10*LCPP)/)UC>
MC+RBXG7C02P/>\08%X:$HXP=%$5ITHQM$A0$R(&D&8UJCSV+1 ?2'^+#!YUO
M;J$I=]UZD\.DWAN4J@]].MTQX1PUCVM(J"$;+:R.Q*V]_@,56=S.+[#:#-57
M7\P,#$8<S@A]\M?5,]F+@_W3Q:#NAS[SP?U1TZ0!*+&0>FK)7*8ZF8 5-LO@
MY#8;J]4[2C$P5^A]QP#F9'L<]XH%80$1#" Q-)DK50>;9G2JH6Y*B)C[TB*Z
MR?W@0GEV \N8M-2>-LM6/IQTU6;.8;1?3T:[RZ@3(6OM2#W]:\ 6%73P6RUB
M"6\TLE_0&RC<(E3^5#>NYQ#9'3.8.6^ 5^U6GL"#B5BW=!/W0OQ8XSGHI7=3
M(?*6XV%G8F=FSJH\.GJH@6.^55I)L4L!U+JWZIH)'@G,CZ=%4N_.H2)ZF0G3
M&C+@P:\@-%E$[]W,*FVM$X;^3FC5DESX^3?M4^W9L[4M_5%29,V^XH6%[M V
M+%$X>'7!"CM''S4E85(-S4M<6Z>":G[$M#=[M_?VA7[W?/K8,^EOQ,UHHRY0
MC[R"QPQU\NYZ@+X$'HV$P@<S#VK2B0]GP@I"/D9?UI.8Y<[N!0_AI[R$S(P_
M.X--Y%0\MAO'9;FVDM*EEF@Q,4$PN%]@L6Q>$"[X!9]R=+J\P,SPA%_UT'-!
MM0&8EP!7CR.\,7, !@4QE,Q6,*;6VK_<OTBCM7'L4--D-DKD&F!9,Y2KO2G[
M^$YY/6M,77<-%#S*-9#NB*],[(+ZRPCD)ZAKTFS(,L-6;\F):=H#[76DCAJQ
M$<U>K:/4\[P?)-PY-P5=I=G9ZD%;J@=-#.Q92P2]7RPCVAR3!HN0^#&:,][@
M0.';M[&3UPR/A?-'W67M4SEM=O>\^ @JA\ZK0U5$W2(FK!'4#U8G=C5J_C1/
MH(^]=D]7W?GU :F=[V'?'EET^(3=T2P2MBY% B@@46O,/>H90&P>C8^4F0P+
M2(Y2V7)P4#@2:'QS[#?5Z7ZQGO5'\[:1DV%67R5^KH?>>%MU1TIT/JI' 3H>
M"/.%IN7G[7NI:;PFPP>QKV!Y6F<E[?KU'N"%'8MZH\\-$WR)ZB0;O&K?9RU"
M?IHA4GC\SYSZ&NEW@7='?OW6SROM^(P)V9!P#>G9;RQBM X2B\[78EX&<#NI
M2X>^&(Q6!B,)EL6]8[0C;=--UI+7QBKJ</7395-$/"NJ]I8EWNCB''>W&I>C
M-+O,7P9 B9J];2@+V;$F0PC>-(=E\<QN_<%\_S?P]R(S0TY%$\)!RJ%_;==3
MSM[*/-?',M,9UZM@! :3V>A\+&'W2%3GNFGH99 EV+,Z0 91G<67.U/C13V;
M=;=&4?F5L['*Q3>"$(!M"H?43*&? 66IA\%MPE"?^Q4#];"+$Q*1NENN7D]O
M/?HLLUX66].GP%T-FZNBI)(W,J-XP?8^C#A'4^4 )"$PI +\N,Q]84C]4[!V
MWBSY"/!3X^;<:9*DRA2_NC$#X+!F (^CT%<9P%M6S.9%^P_TE0<*=50C,!X3
M9,/JWV#CK1"GF4!7VVQ.LO+P:^ 4@L=#'[B>73QU9M$SV_A1U7G9%>XN(W!H
ML)@7YZLIB9I<"ZE-KT:?GRQYYC Q&D]C *!E9:#VHB&/\BWOC(D:#3H+W]L0
MUK9,:?H*KGXV5N<<_ *./%(6^>J[3.?@LYK--M7X)MGM5.D;%N5/US.XI?/$
MG,N.W [WRG[SZ6,W>I>T0K?<V)&F$QC EMZY!Z,[7*7^5]%V!V4=IN(/K2)#
MR!]_SA.^'UI1MG5R;O2SN5.C72ZX,%H#/)CII%Y&<Y%F>R*0\[).X+-*U3AD
M8$G1D&MZP<4VD4=*%EDLX<HW0Y-RK?+>+SPRO0["J-=H\N 200W' 9K;35<W
M4655.M^1]I([SD:4KQSD/@M8K);,,OMYX0K7DYC'(BR''JFM(B&N"!G,3B95
M YS8&U+#9_)\ATEU6+0-)?F\3?FV8MX::7,]U:8U[RPFM*[\J<TI4MU3L74Y
MQXDHJ3%#30)\ =$MDYG$W(U/#>\1=@50&*>V^O'?F@+.Y6J5BP-R=K(?B*<5
M+]"M^I65[@W]_*/-\@/>N)=.,R6-4A!@(AG:*^F/K$)ANN>;*RI&E:T4AX(Y
MGM</#C@)=>L?ZY$ZTX/58(9=$'T"*AIE0%.;06N1MZ\V%P]U069,FUMTFMZ<
MUR!JE%@-R]:) *_JC4_:QGQ(*KZW1%_ _/2!2F)VGB 8P'Y049<YB%^#R].'
M]+%]*_.B>(>XX'#-@=VXO"AN!.+ZQTQ14[_,TL4S]"/(TTZX19,_+R 6(!_5
MDQ8(MC/WF\RLD71SDY^1I,T+A C*[J,!-VTX67MA <%32Z,A[T=DH<1\@Z8]
MFK:ZU)G&/J1_5. A>Y3@ \,(\BOY90$F5V9#%FP$X8O^^O9SA]&IS\ 2A)_;
M*98X"UT%V4#4;!\#B*.LL,&0F0EPC@XE5'L'C'IZY4O?@S6CD(];)Y'O;O_1
M/.8O.U57#9]#$%:Z,Q,Q),O/\&ZH1(=5^>9^2V*C/,:"/)NH8_5N8(]2]?E^
MO;'RY; /)T96L>RX)^]>0-X8G:!/PP Z5X!^4!891A!S"1EI>#D:67XASU&2
MDR)5)(94^Y#>UQJ19*\$-4PX+^SZ_,9W!M "Z8:)T73)L'XX7\#\]"A-462
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MQ6*B:XZ)KFX=9-?OLS(^95C$@_79%I?'6E;L:4'*C[._6G<8 [VEM=-7S[R
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MU^ EGS,FM,_OHKLJ2J+>PSC16B23?BC+?35KAQ4KLLNB7G((G/BT^/K4QO/
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M-3>.TLW*Z KWJ'<8P'@0 QA&7&8 ZP$DEZ/KB5X*$Y6A$;,TPPT*G@&4+C&
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M4$[WLO7["-'\,R.>B6='^LI:2N\"2$Q!(_[C6+^9Q_R FEK"R:*&= <@:[@
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M)\_:^]:()>G[!OM&W[=O+G!%E7"@Q#4@0023 [0'$X3T3T^5K:EHS4J@E;;
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MGY$"=@_R$W'6.@__=4J)KL3:70:0S]S&":H<EO6\&9J9^/?)1< R+G?5H[B
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MHB"+Q5+VH#;\=\)VRQH'6;.VI)Y0CE;83/5+<[*PLWS].O8.8ULMTW;XNPD
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M,7WXDGRQ@6ZR1EJIXZ*H4:&F_&49X4^9WL7)4IG@,)NLHM32[VHK4.7$+97
M@V@!%GK@!GE!?@4+\+F_@@4(LK[ETE19>Z."EEG=8 %9;^Z.LP=OL1(EW7E=
M6.(B?(A(PZ('6-;IJ5^6M1*PK&YMZ^+G!TJ:K<"DX_SD&,&?7E?A:P\ 50#$
M. 5]4#(O"/*K8M[L0<4\(I2H5!$\0#0F>=D[IEG$-*:^^##[]I#CFR5H& 0
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M4!1O<81NV9!K_DL1_OXY?S&>079;=Y%KU/NAR^LLM''G H3?D]CV+G0X3T=
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M:[ VY2#VXZ4*G9K)F.%")"V$$!<:;"TW)UR=2@-G1@PCM^M2V8H\XS"LX_[
M<X9=5Z*0/)+<S6OIDVZB>]O19)YO9?!4?%\J6QT\@]_4V0$%</+7,$$[H)KB
MCI$=$*_I"[C]Z0]U)8YMD1UA)AK6?S+37Q3YY<=0@#_VIJ6Y@F/DUUK.;.*;
M#I1]#^*6LO[! I71J$A:7%[>5YV&DKCCV!*>NSZ7R5T![S93O 9)TS5XA*&"
MDWU#7,:=LST/1<EU%RM8WG YO[[G4>TAB;V4KD?U<&6V,1##<.T=(8/3E?G&
MD+95'75:RR7<(I$?[29E=7(++DYGEL)RX>H)L3]#LW!X42284\<5 C*L.56&
MH1DF7:\IP5D2$!&@S@W7B;%MJO@4C7%I]#Q9*6YP]HBM6BY8;_B*NWX$AG4<
M"1MCVU-&,[<;=D"T>,H&?QL[EG$8?6VIA%L:PG]7.V!$,R)8=?T6J7Q:Q0JT
MT%4'1+%,4:/$O8::49C[>#ZV$CE^B/)SL9V^D:*C795[HKS^\T!5MJ!@MI9&
M'^SUU%H692YZLU]9BU,(/1@45U$9OB6[G5U)BM]7TUH\%)!GJRSQZ:/MD0=J
M^2.@V*)^QUT(?BJ15D$4[7 55JA)9=NSH"N%13[G*@MM,*Z-BM2PA_(7Y-W"
MZQ]G6\9NK>&I1' 0N.4P4@KX8#"E? ((I4>XC35E.=F\]_:?8CF>C]>Q=;18
M?.?\]I.+\Z.#5UVGE.4!.)U7&VXC)&)JG$S>MG]AY)PA;N2PG,BSW#"5YK0G
M.;H2*PT_7LK>$927O@&H=H=0^1G[.E2>E2?@1M<6ID0QX%D13/%"0NFG6?PP
M<?-/[&Q[64 )"*!R]^601D7<4,-P(63H<^Z,\K$W!Y;U1B'WJAC*_Y2$7W?E
M])[[.G\G<TO9?QWU.P0)I<,&P0K<;W <$B_(A7DBC'9_[=!O">**IUX.G%Z2
M>>;MX>ZL+H#HY2^;:D'W"G/[B+\",$(P.C$0S[[>R6])=[V'-*P+,ME*11ZI
M#MPBM)\E--$*[H?9QUU+LQ0OGCSSL"JHMOT!X8745>&+@L-H!:C0"@^AD$+T
M#>990*<&HQC<I<E8F]=GW ,P'C(.+P?]PDN2U[9.].].4M%9G5&7.6S4/.KR
M$M[K0>S#IBILT$SICI3%NP9$H1$J'!0$/H TKPHT805%DS[X'2E\XD)N(!W)
M9)S1=-0.V1SU^LYYPY6C?ZM0RQEP0L3U-Z75^PSK.!-46NT#HJ(3[;-Z])<R
M+YO:7CGY7OIR'UB4"P8:+SL$]T/WC#69OO_%RMB[_EM$7_.9I^T[R=F4*#7+
M0U=$BPDLJS/]H-C!-3\&_[MPU#!F?^1)=DB5X09;:TX4_#K+3A52S-PK,%+:
MV&[F*S\2@::?)_XQ]G;E#L=DP'[]CO'>2,7[8F<4>TQHF'0S398V\N2$H3GT
MAZZVH1+L'?/ :(C^@2&U<#65W$>)%GQ[5=-I'2?(X/T(K0L)X.XNN0E<AJWN
ML]9X;_UA4P0AT&M(^]E%D/=<<7%;HYZ&VF>!K']MQU,C7;_!Z0OP[58Q=N,.
MB/4F!XB <+Q2N3RAY,S D]#/O1QV0%#8SYOHG]8+.Z!I^18VB^W+#7B[ ^HV
M1G__T,$SV# PY^2<Z]LI,98QDO<R!0E GB(/_;T5A 5GJ=)@##T6>(9--%K@
M?>CD1L+;32,.M;R5!S7]J)F"BW4IPTN7:AN.]FB^'+'4:"[%H._5F+B9W"GA
M">AVE?1/1YH6N1TB]?=N ;9T#9P=^+5C;P8]PO5AL(GHT^!@@_M!T19#D"BI
M6N?%L%TQ?@*BNP17@[Y#U7@BL NE[S,;!)?E[@4L^F.,+LG5KYO9DNL\%^_N
M&W(.I%Y_7&$C)_]RLXH.F^9ZRW;#FF/ZQ9*5Y8 <C3[$;?:)JM6XEIPFH??K
M38KV3[69RU7?1O>ZV=4'+EHJJ,7+V.K7>X8]8TFR1>BIB?@02-;VA0+S;VT!
MB4WV]H[\@<82*<V?KW[549F$C,_HI?7EMV6;J 4]38KXM9@(E4,: (Y/,")L
M;2"V$A%\(?!\UC4R1UWQI'UNTJS*%2_ZJ0%$71S\/E*C<K4$\P '%P[\&E?8
MHN84;)+<\"AL%,6P.IQ5G7LZT,[J1;I;^0N0'+_4KDWLFB6%)[7'&1N#D'MH
M<<-9<ZV^:*)L5(ZD@4+6<,]4W(7*'Z/!B.3W8G*GKVOK'^C%4>_ZB% 5@T<E
MD1#@'@L.Q W$C^[J9UU<JM#A&Y>)_(+3T6P(>;E!N0B+E;0]F'=;?L]5G?&N
M!:"4SD^"#Q0WZ**.(Q7H+>DW7HU.5S%$[X8B/O.%GY6_E)X4=[=[P]NP(O=9
M(,'90P93[=GM)\RW]Q8YV>4HA?^FY>GC4J+'!?3Z0<A17F\FSB FH2#<41-P
MMV-*A<Y$$^8 VY[A?T_LON]XJ$0,@O(E9$.]"ZZ=IY*^5RVZ:!TK;T;Z"6_&
M]CE*< ?AN*;%_E'^P$U[R$!HZAL@X$+2W#XQRJSQP*,-+CO&R?I7ZBRFF@OF
M?L+P,KPG]( W@"7'=(OM0T0X=SFUE&2GDF>#;1><PJ]4J+D<JK#YM&^AA6U+
MP@H 0[^6D7"RSHDK(:I..9?&/9U>94?XQ<H=-DV+>?[SQ\619LM>D4'!$M"?
M',I63X,J*61KK9B.MDA@SBLRV"Y\R C3P4JBUC"19KH>'E]H:,(^0X?08EF.
MT*=88,KV'KFH1^16=6EPS'-+!2"G7YP^=<3];GRP=H%%%M;T!%^/'MQ^U4><
M7O, @J-=[O.1F\"N1\8W1E5Y^<Q8:Q>>6+NQ><U_=Q]+:2J<1+M^(BDXJ8OS
M .]K?H$98N_$R>7*??/RLAO_YN5(TCDU[^I;Z.\KZI9GJ_;3]K&8S<1O(1&/
M3^;6]ETI"_-^<U+,GZG6RI6INYTG,>30?8#GNWEE'#TG"6E8L[3M<-_G2G;Q
M,_=GG9UM ::^V<>E!6Q)H%,-^_^O1\?_J\$.X%'/RQW0$ ?8XI+1VT&-V/+5
MI1S@V 8;0\Q!K\ON@*KK3/[,=_%2AKOHR-;Z:?UC)I7%@3/L-P.64MD'[+E!
M>,X[_)8*_(GT'R(/HR1V0"58'NQ!..]=EY*1A:&\+D>>C5=+^&JQ SK\ OWW
MA#DBE"TE1"GJPR:#!7 .]F1X3G[/=N%K!O_9,?\IM0G:NN6SICF*A7:%=P\N
M8'_?YO(7UU;7NSPY.H=2XMF5%%028=W3%G#W-M*2'^E&[R,TEPK\,W7SUN6+
MF=_,QI*O?:^/SRA4/+L8([U0T;J(5NJP9%U [N*4H538M\=@H>\[0F/(Q/T?
MS+/+*D3&GGK&)RU)1-\\D'_W[9ZKSHL5!;\QL[HPLA+W,Y%%?!U;^@K*_+@(
M]OA#91(Y)69[R#Q)3J5@4V$!H3,[()O77YM&A>5D>KM]I-*U&LX46FHI?[C9
M.VSEEMP]X! -%H/QL%&$;8/' 3$U;#D 6^T][VZKX .DDJ/K:F:LAOA/27@Y
M[A]4CI;V[KM]_<6I0Q<%<Q&7F4\Y3W"CTUC2%JV. A8O#[!-&M.%0I8?!AX0
M;)L(\%5<.9Y&%<X)ZO;3&TQ&L#_F/%)@HF?P%&QFEY$C!9Y=U#;LB33O?"M#
M%%OS(1BP' JZ&+I8M>08VMO\L >V^P^E&P_<4._0(,7T;F2B-#AI7!'4@#%T
M#T,C-;]/65Z5XO\\X9GCS<@&!0UH0O8?Z6CON2*WW>B$Z[%5[PA5>0@X=;$[
MYQ[^ .PJ7!@P[E=(P429ORRE8P>,2ASZ1SJK[]9Y9<165ORXDJ<9^3TOHNCJ
M>7M)$.BQ: U3@?.B2Q_I!0Q28$+(@,[$Y2YM^B^4$7!I=[2FD 7Y#^2E3J&\
MO+/\P4.-CQK]\.,)>EY;B2A5=@+0T,"^S!#@0>D>T&NZ-#89JK[:IE[PE(CP
MM<P3BM>R!:7;*D2ZNY^^)>$E(;D1H%X/4)G7@!&6.?L*8,QHZ47+F,$9$A/=
MV]]1LIV?2WNVPQ7%Q(@].E4%K@ZX=%N)?:I-#U._2?OZ4T4J-,A?,^BJW2@=
MH+,:-89_99S!OE;'2SU9]AET=5 N6[AULG#3L<3OI[!KRK?J'HN"PZ>?1J]E
M+B2:*_[=XL,,HF601SBE9E$-W0*IM6PKQO2$F6NP0,7NF.;K4Q=OY!TIMN_)
M3ZB0G]I]W)7_Y"<4%IO>H42O8Z8T ]=8AC-L"WIHFE_G&$K?.TC6*,;'[_?7
M>T\ZNVJUJ9W%,:1!X4*&;/2[(Q?+I@@XT+\,!_N? \( B*64:RUB<36&+:G(
M/1_3#=Z2^/N,U63\) +R;V_%3D*-5^)P/(SHY.N(Z>=]]9AGW#D?44#+K_X8
M(L(%B*@/:F$*$/1OM">M?SJ)^:C5>:?1QBAIU^@ADNMKUV1@M >JW<83D@Q
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M879VS@P?FPJ/M[P]\ZO5S]*5?]_1VOGM(W[M2U*7?&)8YU C^-VPFV@Q"_
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M7@Q=V(K1(;UO3U^90-L0[<L2_ _D^H'%YR"<<2"!$@93_T95#O.\N'9M;>U
M'/>1^==G$M>L%P\>*!%;@%%LV$F@U&(?QP+3RR:R:AG]]&4IC/.R9X/YL(%%
MB(WLL<JNC_%11\\<]PO==^OQ^&-\^TX!$*PCA(8F+^LB[YD?9(:G:=YC>"(/
MMX*MQ:7&G]A9JBZ2TF)'*WMV-R U,3V[ FC(R01AW"("!F(1U0* J]#+*!0
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MOI8+\V">,F0@9#=UWE-+:V$"ZA_%[<"8G 1AB3[0#4;3LM(6DE56\;0'+^_
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MZY*3O^+I 9 8/U8 _#(T$0!*=EQC/(#_@!< >D(=Q_ 7>_JT@0JY\P$!D"\
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M)6U 4]/X]OF6-)FB-,?4.E&?J_86T:H^:7&GNNMQ!_!7P":&$?M;MV- F?#
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M?M8$[K>A8%A"(CL65N)FM2NAJ A;R3,MR3.H?^9ISJ4&FA';T.,1!YC4]N$
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M+"QNF^=_Y6KLD.F<<(<@6?;N7?+0<[6/(;!">:=F,;,A$>J;CQ'K+D+N@>$
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MY[+$<M/COI5<>J69>Y[U(SE\V96X5VJ)FC5 G!)FJ#&YP%>T4'H96$A&AN@
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M\(7E^Y=F[_&Y?YDL<,G\30X0.G@*JH,#2X#TQDC:4"GLH]@%(Q$*3QS.N-G
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MD6_%S\KY-O2$@1*-O*Y%Y#Z8BH^G'/D/(/2SSKCP*\R;J8#IBU*7%G_#/.@
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MKB6$M?J%[/' K,,6K&]%)-#UUK=WZ:&4KI/:S(E DB*6.5P)>?"%TB@$%',
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MP!U;?C: ;P-VZM4@:>V.H E3*YA@] Z\P5Q7*"8T*CT#WG=L]_&AG>GT=0G
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MA57JAS'59.]79JX;Q U\BA1D[-=E'(RSW7O&M"2Z0@Z. #P'$V(@SS&NAHQ
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MC;I4UFX.Q?:1=\&\$4F;D/UM<KPQ,G A+9DL4\P4[+9'=9-%37% <\>#K,;
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M$CP%?OPYT7*9[8C,'8SW^W%_7F?LZDCA<,US>O/#!N6;1YCG\RT_9SP6^&2
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M.IB:?\E<;]E@\N2;NNN/CJ7@'Z26G1ATID-!3?B2#T4L&BO$+<2X,C<A5K4
MM LYSL! :;6V156MZ4OO"7'S:BFQ3<D1VB7^+_JOKKI>*_>"=Y%W$P-Q"<1]
M&'NV!>=*,FL9$%MZ2TF+VX3L6^<J. '^<6W0N8S%L)&)*O7<F7*C_*J_V<9%
M%JJ]J&S+%(O/4V-?\=LP6J\Q5_B@?PK7?LI4C2EV[NGE$0+QUAG9-\5(([O]
MF5*.S*A5C8>0,O/3:7N-*-(]TYK;E\N)H-820HYX$S81.L:ZS[0JY4L6WN$
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M>UD7E&774X/*[N"07=Q5JY(#4:_%JF"!!/!(?33,'P9J;D)B8#[V=NW8@\T
MEP]_(4BB[$(NKF-0?$$N,$)RO#5CW+"BV3KLUI49^"F7K*N)F8[3^NTL:"H9
M<(!-6% $N[4W(5'_E@FT%2ETKU5EW$:7LCR( F9=F8:CR<''LY/<AXK=OM9%
MC<Q>UG+R/1"=>9+P$GL XS54BP(/^R\Y,$=HNIER#QFFOFP8V&-S?^ !5:<[
M=HGU3V<D\,M@+6;\VP?MA[A0-*WRSR )2H/U0B?U66E#IG+L&YR3W&S38T!]
M5Y91+J<N3W3(GRF7;,VZ*;4)02%^+OCFNULHO+MT(G9-T?^XZ&MQL?>_MF:V
M\;K3L7U/>%,$)ML6*G+KJ@A.ZJ_<_BR?D_7LPY/AN$ DP71?VQ>UM9:/#G[4
MI#5B#!EPTHO#U]0S+(JV#%DUOAVAN$!Z?,IN@0=K8L;%W*&ZMF@75_\-'=/Q
M+>_>.0#D7I1;8E:5_GZNJ(/U!'$TF0H"1S*WG\:M[TKX/5H#![4<1QLIQ/V8
MLQ_LM2V2N(:NLW:#$NHV,1<J,S1>]OVV*M::C;TL"(FL9NL@'Y 9>'90$+'.
MJI%]#3LPYGEB""NR@!4!PRB(**C,2->OR.(9DYQU[<7B)&'%(W5,(:K+;A7=
M+[]+MT^W(/D!$L]]V+*=7H%L;UKICO1VUQ-91(SS=)CO<R@>WFN=IW85-!RH
M;1N]7ANA$"CS7'OEN="@I+0*?;[<O1PY&;!R\[UD@-]IIIU4G/.5X_LDVG?<
MR^5<Y#<CC@PB^%X7L"Q/B]^$*. H90_@G7 QM']G[B8DODV/<W34=&>^75G
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MLV31,D>-RL3E%+U;#R=!_NJQV/R^"^4K($4:()>"\VT6B_MG5$]!)(9A#8D
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M-^GD_/#GB2YO0AX1>?ON=4.!#WGM_-8 $9ZFO*E@':5@^UD68_"EUUX[(<[
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MEC)G_TM.]W/T8#;PNAC<9G7IL(&GU1&O_HVN\RA..93I32+0N5PP7QY4XWM
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M@M=\9:L _LW.4([*###;,XIDB&J1NO4^V\U$=C!1,0/>+#U7Y"3.DMN-LU[
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MR.=SIH+!1E47[4YCWCD/$4 YRJ0;ZR:N%@'IY6"B/4((*!?E:CI98RI9J E
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M6I6Y>.F1P>?))Q*JR<&>U\^^7FM,.,%Y7>+=/QU$>5M8A0HE"KC\4K:S"8L
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M>-E]WLSY&58MF#DD+GXEP3-JS]DNNTB<HT30CCT#3U:T%P.1E+><VIKV@+W
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MZA#_>R$9/>"XP4Z\/(AAPD2\*)L!#*&OJ^L;TQY?['_?J1UZ3(-I\?2&ZI"
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MJC4,0:0PCRB2 #41(V>@Q#G.E*G%@$?*@]VXY)POWS"N,''?TV>IV)(\,K/
M0WAH3I7EEO'O_21XC"M<,SFK]IZI,WK[U?OG\?:F@\T\Q [W*O]!L^31O5?$
MJ]I'_7TKSF8'DI/3Z$)JDR@P8!I^\ K<- ^Q.@0+V5GQ$&M#EXL_!RUA46AB
ML,&;=G"-N0 -M;0&=H8=P(S@5_(WE!3P&0U9BD$F("N:+0QM8C/SH:NI>CQ$
MM0(\T\330 V1L ?X+-$ @(;]P,R'N'E89O(8O**47L'K1W II@XS)P8K D;K
M\08'GE7"J3?"@./#0SQ16=97!,SQ1NXC&:.4V\2YE4P*M(Y%X>2E_;T<?- S
MIBV7'X[1#/B*B_,@O2'36LARZ+$U0V3.EBGRHILQ9]\"; .^Y0/&;AY8[JWP
M$F8?H!ET'9@Y1N1<!5Z66\-3Y2$6]=&+BD-]_ZA"T-W0>EA2(B<>AD:;D?^W
MU'$6E('6!#"1]&UQFB4T-V;8?+ENOGVC#O&&[Q?I,_W>KU1.8!XHK&Z@>_S)
M+$>N_#>?Y?]6H_^1,(-B?[BI-6MA\M0KO \W#G#/5J.B.;O)L1PC;G)0D"Z+
MU)N=K4_9'YRD8/MXVP"V/GC3D'X@*7KHT_;W^5DIVCN#2KZ^>%QRKN"8V64C
MS9=LA=6TK&F5YA&,C%FBIB@F!65#7]JSI#7Y00TV"RW+8 _0&@?"&EF1309?
MHW\_P+G)/;-P[!_ZIXB%8__%U@<RHPL)FZZ! YOJF@V%8_WK,6F2X!IF/FNI
MJWRYX5=U))-R$W[(QL*RB":HOHC,MDQMW1/ >GG)=V8)W_NE?Q,7+7A^KWYF
MI.=9_Y,C-R_G3 XR/3T20BH;FIE^_#+)PSH7>CQF+1R+;,T\M\W[:B0%S.3]
M0^8B^_S]LKD&COZU?/]_\.8S16B&&3%R*2(66ZE@3[J%/-T^^:RT--=R57]R
M6K1AV'G,E(C 7NIW]+'_>H*+SO^-)_B_V=[>?ZB[Y*-_IQ[G3K8 U$"10Y]%
MQ:[GN/$0889#9(G%4JGZA]R'\/SG"Q/UNZ,X+5I3\7,SS&*L7NFM@"%_&=D+
M77J*M2YCMN4CTO$C*67S_F;3!_ W;H Q H]/D.S#GF[<1M&63WJ6X/Y-0(H&
M_#X.(7\_0! B4$/2I885!+AID#HNOZY+85,7#W&.N,'C4E) Y&@GZ?OFG7TY
M8I]H%OYS\R3,SY'8_R@AH: UL%&5+&U@)C,-1\JV!.?Q$YY+SLG/#_H69.\7
M/M-W]%+LH)21NH79+WR-!\P1EC_+H?Y0T)"A(A=-5.)@1G6DC3SG:EMZ6GS\
MRCG[FRD%]H'"P>HNRJ5G3IM\VZ_J<^[:^$&)UI\L'/X?+CXFL5JLWVQ(L H)
MJJ)J@1X'5@^SGJAYFWY@*U:>@V ^;KXGO<MQS%^%<[S@<I^.25_(JE.;79,5
M5K25\/N>Q4LQT1Q)8TAH%R/#D9MAP _U[.2L9[A'XSW<0$/W8$9.@V/*1'5B
MZX%2C$62I<3SE)OLG';U(Q?4^8RG-Z7J06OMP8V,;OKT9 R#<IJ9$SZ#.8,/
M8'3==W_9YV2*#9"*S0S4YA[M=;L5+F[IJW9T_-$>R;LST5R1Y99><^@U8](&
M4HSZN]B,\5*W1S8I06&/MN[U?7)[A?'Z'8S7KU=<W8O@.XA\A&&8B09#0L5L
M.Z_!;6 :TQ42\LRPI$V'DQ6"6E9Y&XC?H/K=%V=*I=[%Y9I0O&/=0@PO)"-W
ME,3H:YV-ZY59;B*?31BT)<L9;,:I0$(N&7AT>[D8^S"NK,IY$Z.#O%([VUXR
MKQU[V"'YO*?+_9G8UP/ABP%EVRKXH=4PPU<*8=W@(?*KP1@>(D.*M!^^G3ZA
MFYP'O$.OAMJO"#:@^X)ITS=0=&XN0='9U(5.VM@S/IM=0CYN/M*RHZBF\$U/
M55_H=OXQ,J@B,_64&3-$CH2V$SX A<5AVN;((<MWW$LMELP$G.M'69L2EQ"^
MM^U!,3KWDF+U(N\O'/E8KWO[FN(66PPDE,F48^6!5FPY+X(N-WH#4!TJ$UVN
MYWF.W+MK,+&HM,MG2M-?,O+;P?#@LSV+4G9Y>[HC8+Z_H["#FTW&HOJPD) K
M54_O+J.F/HY&685'=;D7X@0CI^:\+R<NG+KMN((U%; K5G57N#CY\&HDX83@
M1TR1PC*>$  3V(:@)0O#C2LT(<B"SK,UMO8P+8/V?7/>$'&&+9.T_]"JN P'
MBT%#Y_=VZ<&/[=9+#;QNGNE>P];F$+BY!GRP&,9HV@"R,*G^BQ:=1:0#8<4*
MN@QT[5Y]-=\TKZZS?2P]LX?R1_M:I#]%?+2-I6O'*>V^OT\NQ!+<'LR1TJ-2
M)C5>C@&K N?>,"WKD;+]R?H2C"6G*Q3SV\\&QKE/7SH/[(RQ>&-CO.KR6L<T
M=5-%-8$1-/416<1 VI,L4V[%-N>X<M]4(CDNW#0\D-: I0L3!<#P+@>4V-AG
M=+)"5%I?E+U)UMF[Q=JDV19-Y221@P@%?D8&ZSGL%%JXBY;1% DRM1PM2E@-
MAWL[IG#=)0-!,)2.68%SG4+WE@*1I+DRK.JTW]:4T8M]J.:">(O=EBIS:=3I
M"$XP#1.VI!(!;>-8*>SIGO(1U[&4UKPK>K53>3@YK'QEP[K-<?=--P61;@+G
M5I.IE#$> @[2FW!I-9 HZ$F;DIYU[ )H7I[(C8F?O9="1_O.L\US,A2>S3@:
M%M[80%/Q."DDDJO22J9>VS.H#V>0ZVZ@D;[5VD*9B'[G;B3MEK/B+.$+\J9%
MQH5 ?]1#]L?0A*:9!:!)0GIO'2+TX4]&.\$6#./4M!2AARR*/M?L,.0^J1>"
M]1]"\3GW@^$+U<%7SMFJTBNV]<90/ ^6:M4IW<%Z#*J;5NH8H0]<#JZ#0Y11
MP]0^1C]5]SJ9^MA JQB[@="Z0M[5LOM\7O0TM(Z'$+;?;Y#[:N =+6WV&7I,
MO$[E0W> P&B3"\;;]BN%(R[#\@6U&"&L7F[A/"9B4"2\VEQQZ" #"G]V-+"M
M(*/8R7S2USI*FB%7UCNRJU[*5.WNC"9""Z ^@9,CPQ;=&TR'S6>N5H5DG.;N
M<5(<PC0X8 5Z/&?Q_&VZN(M=W]7*(H=G9<_KABM?<ZU9W33J[S;NA)ZJ&,*"
MJL:3-Q@Q5..J":!_J<F92:DC]V&/,\)XB%H2>-K>[65N*RF0730C8T%1TFS4
M>9/P<2"KOVB8K\4<=J!4..'7L"5XB%Z:!WK)KR,3#0EGTDDB.&0M.K?AEKXW
M74\4:=(.^!!%!KSVOWB%2V1UO<DAOI:.-SVWQ0HQG+]. '&*^Y2@#529 M1[
M*4>3V5:$=F0!'$0)!_#K;SCGM4,J*APU$WV]')S%IV^!1>;VG9.CN!QZK*?K
MK NNQG>?S;?&)4')7,OUS2+18]\VREL8\G^^,6#[E8?@2*>Q6KBPB%ZD7C$8
M"5T/(#3P$!LYRDPM^FA#R 12%.==DRK2[3OOZN*S<*<Q^-7@0UM_;U^!\E/[
MX@^G;7;=<H8T1@S31V-I:&'/2JF"5-.S[=J@[];$4[/[ZZ_Q&0R+I" 6,ZA
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M@=U7\YY5)S(N/N4/)&K*J O@*3S$RH[E;EY^R#X92&@-4X^6-'7(UYL&N\8
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M.!7"%JM)W5_*T"1A:;ZNIV9%SGYJ=TCL]%&Y_TC2*5_J;N5I=9-59J@^2_H
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M(07E5TY9CJF,MX39LZ3XV?(Q=H-KOS1A!='REZ;(:_]F? /=5^88\^<$P+S
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M>G7=OF9T39]@+SLW8LLX5N9?R9@MM=*3EZG3NH"^/IYRY5FVYWYYH>1GJ!,
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MVG\"Y,C09T 8WA]KFK+\?4^S["627!R_Q)_4G"-",=3G;B%MQ"P*\\I'$>H
MN":RAF./.LOL(1F/K4)5 7QG@Z+73N:+Q*[ETL#&@%BUU$-EYL\33Z=%_;KU
MZ3S8$%7UPAW(I36N;"/*!=[3&>J/3,'-<WN9EODORE''F,2TP9IR('#A&G-L
MU+.J?.Z\A,JE82OSL]D'NW\9/'AP&ER?_GJQZE5#5E/&;L9-V?I73U'MRB?G
M7$[-E!B.Y&R!G$=^/Y<9-]:-#8'Z)DD3+KW^<2'FX+=?/>_4)K]M@1CG.'+<
M7;Q'Q%OP.'!#3P=.TI+8/0NCVY#>9KK32;-]$55!];H<7<^SJA\V;B,"GK_/
MA]7BOI;'7I5Q^D?Z"F#'L4")"CPD4Q"/5V"!;XDS(;3\7-8."FW/:]J:*,J,
MB4D/2AS')A.6,P^9+Z[=:,1D!^LO9.,8JJBV1Z5O002A/Q4K#SA>BY3ZJH6N
M(GOSMM&?R31XMSV\34G*&,!QK.U$@WQ-$0_A>G#&:=%!N@GXR0+V1G,+893A
MTTILRA+5./OKLV'B^:N]6B4@]7JF'W>O8=M?)1)$%#U&V8."5%$"58(3.#X
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M(_=LAMQ,LOF0;ITU,;'BV?8K^B#]4/;.8W)'[:Z(+'Y4 ,:9ZWSQ!ZP>-E;
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MQ?R-HIO@.6'<RP(7RP>*^&)O.?K\T7LH'<"=*L!-=87)/1^]:3/['?X9>>2
M"9R(#(E6K;.]I]DX:TFZ>-!.1[3Y!^0TN%3>Y<<0XP3G$D(13*C \O>C!'HC
MOB]P"[0GHDK3L>=!JPIZB+)'@V5$-D[.2Y(H1D(S[]_=N%:\RFY_GNH8/'&C
MZVW1*(;Z$M.PUHT#=&Q6$"PB+:I32OH\:ZW; =M/E=ZW- K<-JWY& ]A<)2#
M"T=\*7L- [[,[?/V]\C[=:ZS<@K$NUA*-'->XXN?H$* P\\$ [@S@Z8T]:2@
M+.<IB=CY=I:.%S,X39!,"9%1'7V_!ML/$.R.0(?UNI[;O(\_LT/LM$M0U15
ME_U1<.M#U#%>$?'.4 )9_=T62*7U&'K0K<,==6JR&G5*,HK,>+'Z..B5N\1;
M.ZTL\Z*B\))+*=D6Z[*9S4^^"?^^E\;M$?S$?32YR4_ J/F[1Z&2F/80!OH8
M92GH(.H2 &-AVILB$]Z8WW\Z/6.3--<]0I^CB\7-WNE&#GC=A.1)8B[_?]M<
M^W^]"3>XEHG[Y=KBN07R%C@0/\\67FKD4I/[@SCMY N]'.P;Q/AKN/ ^68,_
M5R:.'LU]W%B_5O$&=F*Y M#9 FD7=<#8AE.8Q?,1?S6M8B.0S63'/,NL1;P
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M"'$H&/>">X19E;A:]<;?2Q<H.E0\GS0<9$K86+ S0[B?7I8,.5Z?LS;@>\5
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M^XJ!HFFXG1&Z T.:QU#_A?T.Q6WZ(\#<5#>TV/;6(KH-)X/R*T=!F2$]^(;
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M#7WE@==GP3I^LN#L=J6;+RQ=%A2"FL\D]_XCVZ(]OGUFL<!ILS.8^&4>D1!
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MBQ!F)L6':K0K]=4,7#1H(Z^W2O1A94^H=!40V:*5 RPC(&WX@F99U @"1*$
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MU6O$UXB*_1[(?VO%Q=;^?O-[D7^[55!82$A83&2UB-@_/?C-@-0:H%;034A
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M6LKYV)QH\$TWT[SP.+59Z->Z9-NWE7JV=]VBZ_>]ERP."OPG^H5E3T8$+)_
M$^UCIK#K$?\CJ? &FB0K1Y[-&GX9"G=OM ^L5=*::QRN,+@?I9.]WMN.G7#:
MNE.X,3KY_L-KEJ4%+]!C"FPBEPCZ2<:YHI3)@:04#]/KL'Z8YGDP9#IWEWM1
MMJ77MH*8A6[(W#?-G2("T$9D.$BE:CE$/A5&,>_PR+V&#@#3+X_5)?Y*V1?Q
M&.=[O(]4?=7)_-3^E&B_QRVKYM<=SC!Q*':/7([?NZ<[6>\M4N[0%!NV-S?%
M8D\!KH3]$.HJQNU_VW[ETQ7KZTO?MV9$X6BWDG?1;2XV3];.>3UCF*Z]=B5.
M[@W^ K3 #&$'0-@G^&"(R](^Q,R-N^1V/2^_OMP[\43"1>'C;R;OWXX[YN ^
M&O-8,]K'E[,=;,&03X91%+I&L&)@ !_(V!9,V%(]P!L?5Q[ZI7K AIPWL(MS
M9.=*6J.TUWY1Q2RMTXJ*%LG TDN]K^@4A&^[&T*;>YO!Y"M++9ADL+IZ=T02
MO/U*;1X[5S)N,:0PP"Q)2ZHZATU2#,W2.+&]^:3/6XX%KX^\FAS<&\<F*O($
M<>TSXTI-^8&A)AK%G\:6,V1N?U'S?G?^];9NZ\.TB=0/(F%6Y\#J@#DT4M)>
M\X%UFE =QQ9VZ<=KT'\UI ^;SSF=DNAY=^?G'"U)Z-#Y'2?FDDT"-AU"C"#%
M,?TW(Y#'WG9%H,1X:^  CFMR:/4$87S#"&Q6&GCE9FUTS-W$\G#SJ$C_1&F!
M+!,_Y7C;UZ]%ZONL9 ''_^9T_<('8#DB.Z@/;\,P5"0,HIX3YRKSM)-JT!EH
M"6/)%)[ SLLO.],,DT)K>M0DC'Y\U:B-TKL;GM7SQ>V1((XF]7Q5E>N,,#X$
M80\R2)0BC2M8MZY!H0.40 !?A3]8SS),,,!;,>;70MF._53W@5]SA\?H!?7I
M[T_;I<3%*-A%)<F^"=N8E#GRU@LXRVNF5B=T2(Z]M4& ,R%\(DLTBD=,@+'Y
MNQ+:Q@WKF>V2%^D]X9K5=8/ZAIN2YZ,.<K0P1@H&I[(L?BB*->WC>,,'AM"T
MZKYID(FACDJ;&1#$[E\>ITR0NXY-V.>,#7\UF_QP26<W=OPP2]?^PIV845'A
M^Y^V+&4@K+U%!_2S=V6KL]"SXLP)GC0Y87PMZ]: %W3W.#,@J<@^S"G_4&'.
M5\\43H5%G>$Y=:DC V&&4MN9+X1Z\<*(JB[]!#G(\ ATD3G $_/CN'Q36IWB
MGY-GG5(('^B?FSM#VQ>7OJ6P/Z8@^B-29JR[WX\<K4K 5$2?BEF3L^O4OE;U
M5&#/-3GFCSADK9:$"<DY0U;OQ%K$:1V)B9=Y*JS<]@WSV!8$9HO3XVK95D,G
M^L^<V9SBV%29^2S@OD9-G=[97I7S\5H%OIMMGN+/<5/A?2Q?]CP72:&!,V$;
M0M@O75OF--K#2HUFDI\'+_AXM 2%A>UY[O6N"S^R^M3^AW5B<JFC1TC)1.9A
M=)R/ =3#P&:@5B$WSZ=B5RW.*W=G0W.6ZZ':\>[>=E/=:.'/'>632 -Q\;GP
MCM8*VX]OMVMF";0B*.X"@R45\*:LNBX^,*K +N,^>LBROLO48_AD(R1)#'^,
M]:PP-#2\;"QX>+VW1]!2-N^'>0JDF3O;LU%L8<=FUPBL"N)&_?CUW+I&;:9S
M.Y)OP[KFQS!M1'ET0,9J7!/"4!K88!7S"N[4E%.?_N*:KW65V:[N/_)^48A:
M[_S-PU\$"NS2U+H:20<A+=*L*YTZJM<.5O@_9-9Z1[7D[VBZZ\AZ-*XQ],S0
MQ!X\EG<PQ]YI>IG:F_7KC<I9[;6*2L:CS]6CIQ00X*W0U_/-ZP;@39P#O%%4
M-;HC0S!HY(9729MA(E%JX\L^@W?26V]HC5%&VRY>5=I=N*H^__BI6-P9!Y$,
ML&4O^BPJ%JV$)$=R KH*T_E9KVL%TURN;#V 5*"O/]OHF$23Q,8@PKCW^\P'
MF<6C7EMJDQH;* _X@%[UN7WOM03K8"EG]@"7R-/BC:%K(J)AC2>X?'N;+E#-
M(+Q7HFBI[=6%]SI;"_N>WLJ+?+:U7T]GAPQ#/"?9A79]4RZZ.--*5FKKML['
MB0\=94]L4054XR(39I<XFG@C;EYC!.L  W7-1-\_:C[%QS1,#G?'Q.[QEV3E
M@1")"L]SF0]M:_<FA"B8:?YH:086E: 4=OB@R-P=Q/-P$)G5B_4-IX.C!=T4
M.K4MQ7_Y80:VJ=:N!W0 N)2XM-G96,EE?TV5,+,5&;8E-P.6X6S H=HMA9B&
M[1@E7 ZEG;"CB:4_1$TWZ2"_J'OQ4BJA+JX]J/(S_F&EA6K#W>R\7+8G]P9!
M@?>ZAZ6&B;^27W.)#\A:ZDSST"R-&5?'P\['!@^J!])_3MC?V!)C<C#TW8,+
M<WO52JUD'03^P2EDH+ZCF;FU5_&2KF8J_#9S,&J$/IQ STC',H]@,E#B9+^,
ML26V")@"2L*;F.:,G;D1Y?#FG2OE7:G5RCW8_?GSKDW]9_&E3KB8YCJ=)I=;
M/TP[WTF5L9=\^L[ -@]]H"B''+K^_)QF[?W9'U]BCMLX/75RZVX,C3DW?4"G
M9=5Z"<+)&3+3'@WIDJ+)(<0$HB1!EO?Y0["E\(>F]5!5VQ6%CC D@GA](WB3
MXL_C@467.$E6L^>Q5"-/G9BY"0?Y85_-"]N= ,N74!AG)Z\=K(FXC@[ C$70
M0ZNFQR6ADP_3G&D=]Q2<5'=N,#BC41L3I%^\JO'#_B?J1J=L579N&R6M9CTC
MTWLI$SQQ<R;8@?1<DXT>.;$<PQ:&%53!LCGJ<*:X:?",Y1N1>/T?KBGUF;<_
M>:GGV (.AU]W!$_-@4B"^L2MO43].$\WG15'WO5"9+JA*&S$S$\W)B7J,.:B
M' <6,Z3<VBO6S/DV#<P51>%^2(XI319(V5*&?$\[,1JH'^OH*%BVCHW/;44+
MA_?&4"M)L;SUWQQK:CJSF6W.(QUS3P5-=4,GZFML\ZUOEIG;CH:^;Z]2N2%9
MAG=ED"1P"JTKN6F- <_&OE^QS#AIPBXKI1[1B.D?TS2R,T[_I*NKM]VW&<B#
MPY!<DOO=4I/['*3E8Z71M"=H>6.[,G.4%)30,J8]RZ7W')7."LQ?9VG0KUIC
MFE8Q^7FZTD;U[;VS=H%S&I_;8I>HK7,H]C5N(1A$'(NB@7.N872B/%[(N2"0
ML.;#7>N/7KW%RROE16^K0]@W+#A.;CL>+!PY66>C3DHBC).99TFS.JPZMM]0
MDRKA-;42VYHA"/V8<>W7'FBTN_CHU<M]H:N+0O=\\:,?4HFLK>A=+V"[>:\H
MD 48(<2W$BN+MU> 9:/8%I!J,:QTEV'DA<65=:BI0E>U&!3WF7RMRNK:!/N<
MZ0!7MXT5GF4-(S?+;KHE'8L02QL>A_V@&1J*4D6[C-1A85NDQY,Y]!C*<!FL
M[HTA*O 40G)'@NB?+X0H*H7J3IM_4[\E,51]X<F1ZX6WF7W/#F$.<)%41,OU
MD:]BHEK3;'BBRR)Q33*X$1HJ,5P"2_>Z\*W<(&ER6D<W.,_ODY31BYI&=[>&
M]H.)TUD&AVE?<!?9:&XC&$0="Z#7=6&@+0G)37)!:LK0GC+,,\B</M]JEW9X
M90_&)VO8SFU1F?-Y_P9%EW&SXNV>'0K4[(NOFT,WJD@VD^*(3#=, M)_H0,3
M"0+P3@A-ZQ%!*H*:"2CSW4<+JM?BE1@FTO(Z6X>IL\,OO5A7<Z3DLOR#B@*V
M3AX4.JG]+0/2CI@K9( 4(:3VI%234D")4%B9I4>/2 ^S4&5IMUU6BFZH2G&J
MLYWTO&MVYWA1=;YB08Y1]X:SI\UTZE](V-&68'EQ&J8]3-&3UP,J\J3AHTQT
M,O[ Q:??UL/G!\.C[#U;5]-C+8FR+_$R1=R;H=EBZ$QUG8^G3P@=)T<3GW?-
MF7)T>*_)LD]YZ_ 7F%_K.%9X9Y;^4LHB%87+M<$9NXS\P-]<D_-8"_?T08QL
MO/$R97+K.;=K E^(3!]]3V>F=@;:GYJ.%3:<A>U89<UHJ;!PPWBB\%GCE+(I
MUI<+H\L*K )/C9HR2FOK\5>9!W?.7IAMN#F2CT.QJZ >CC-2D+TM5P=1F0ZD
MT3P.VX<,70U].H[78O)JSH4GL'CE8+%)T=#3*T.-00'2!\1S.>HY6:Y2IV.O
MDXJ:+ CMU)J15(OS3%?V .3,LFL^!X-0 "T(1C,:,-+?1S!T4*;CJD3]H(;+
M-?V.'(.31BU&&NO7=25%-W</D7U)E!%V)[3$+&,HS,T_05)I76S3.MRXH2($
MMH)BAC5[7!;<1C;&!(:>KB>3ZVI^ZC,6/L.WZ;Z;F@. M<#5?R:E__7$:R >
M3^96\H$@]*A0&T+#P\@!V"04,_TMR2?X_'0/-R,@8NJISAG?#2_C][XP0G_N
MO/C^G-["! _ECMQIP@<*<_C 6U,K/O!E-U=$G4FQ8*@\VP";' Z6>77S7G;?
MBX8QB;,-Q'M3/.W3%F9Y@V]9QD_J6T?.IRHM%3PJCRRIFJOGS%@1A,&V&32M
MF/SK G79_QL93K"!+:MX8@A5MD$ZKIRS2&"^#I\%VU48X#+7A@\((EQ-SR(,
M2O-"3EN&@+1M?& R8;Y<#D+Z7\FG2"K+XP-];\')NP5\X*<JBKG2"^F0N"IU
M//>7AGQ@4Q\?6'\QB0],+:)@,1!^BF:8G*N#E\OYP#4$A!Q44[4KS?5O1;CT
MMV+N>Z_-!XB#(%,'V>@Y'T@<:J4N?*WC"4GRW @K?=AH[)_L_2<2LD1V$7F@
M(Q]H+N$#W6T\#5=QL#>/"JU%+Y_\1Q&Z] > )/\/P"<#9-KW0KH!<U36 GL,
MR:"&*5A5L*;1O-SGLTUI$,(M4X/.17;G.+\N?!<_JGKN6\GDR0%5(SVV=)-&
M$BX U?KBX\GS%U*+MBP8N(Q5A8:GAO?]LIR)@TH,&9_6LMQV=6]/O8?=?>BS
MYLKAP\,ACQVMY!9*^N-D'?<*_[TIQQJ9^_T$PY\/Q+M"<T]@63X0)\1MX-X1
MKB:.@<Q;5W-[%AX<.C_)S;%_0<UHO)C*ZF\<X*$H?,"EB _DCO"!<R,/UY)4
MG<3.QV=XCRSG>Q^9TB]T; W?.E#5C_U"2'3$WD?TXE%7:@SA)C(G/@,"P[@>
MN3PLEMMVG)MYFP]H,\CO,N9FRW@$@C0?T/BU/QF>YP,);#XP5 I.+O*!3\9@
M&P><'B3_7.$#/Y30E3M07V#7Y00V^S@?0*-%P<R535:$"#[P5U?1N>3%8.SR
M57!) C6JF/&3H >W<:)T$0,1KY-?<]<7D,WYP'^^Z#\+.9O:M8R6XYWDOKH%
M]O:V_E>*V+"M?6%B,A_8QAOO)D]-T0U_H@]N(;WG __Y(AA=QRNWXP.&)!Z]
MD*.QG8?I &^#87[8A05F[C*J0-9U"ORK:_X:Y[Y_1PM=5TE:7H;LX(P^,;TI
MR8\[>&(B?$"BOA1W%X/8[Q ?6-,%:SSW.$3F1,V1 Q=2"S?\5!_-T*.:-_@2
M"V>2:Y1N7TF7D\O;HV*IGJZ;57IHW'!E6M;1ZO29?^;#5<))L*6;^%,7K\X'
MGJ?7\(&"V9F?,617A"!,8I;E+*7 CS8>2.1=#E_>AQT:W\ 'WLC%+Q)Y]S+A
M% 81SMU%.@RNG$5RLRL5E?_WO!1E![:H(?&LB448Y:Q&%!\HGGG"BRY;7D;B
M>@^2/6R;D)[LH_42'[ ?.<X5<ET 4XD_'3_P 1*"HMT=K@F-!&<C?C*SP ?Z
M-R)R$ZP)[?^?:NU&JJ,7^0L'CVCBLSN =Z,-:SS23V6Z&BY;4I&4,I*.-#V/
MMHWTF"Q]1"WM!NG8S.5X/\1SQ<@,\#82=(/G_UZ\H1Z S'W$Y0V\S>!(^BT^
M\/"SZ[<YPGFP937XQ1>Z\WL_5UY".+:PAN7>!:=J_X0S5]3V\0'U%W@^L!.1
M+C*A\E\F^I>)_F6B_SD3N:M9LI9BFQ1PY@Y0+$ND77[%):7(\\ZBJO6W3!6I
M& '_C6I&5D!(GP^2<B5M$?R01?N&<8B:@II\@+$%*5V/P!9+\-N,A1X?B)8&
M6;("\S==HY'RU(^F$=&_PO,1]9N3T% RFOX=Q<005W;WBB'F/DB$K8"H23D:
MR/R%="B]7-6 .)"ICN&I9T!7;&"9*5YZ52L9DD(XAM1>M64K' K>H\$312QB
MXT['PFNR$<)1R%/+1#IOQ*R%3YDDWBJD%+0[B'11F1=*X&3B&O*L1CGXK6$W
M_( T@((0*M/5&TU$?"Z!I_*1]YZLB-=CZ%Q2[CEJ[P[2-]95_Y0_72MU[[/%
MR4I?L.&>[[W3KE-=L X9<94/GH@DWD%H.!L[H*8Z-:HF<OW<K_.[GIS+N]CH
MMZNC[+V]]\[\,N?EB^WYJ-Z*3WY)I/C6X_>4XHJ4+F9=+I&=[0^Q*2GM[O-V
M_>-R-G^S?ABOFMG%%4'88@M"J;YDQ/&!8U )[YH>2"M%:):VGE4XEED,8_G
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M;H*:"$J%=_8U*>&-F0T'7R8D&AZW>&,;><>WKC;>XI#)N^N:MOO,-(6^4B5
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MFC]?HR4K,&W\#SSS _FC_P]02P,$%     @ \S->6RG'A5<<(@  Y#(  !0
M  !B:6EB+3(P,C4P.3,P7V<S+FIP9^UZ"SA4;=_ODC-E<@YE"N44RK$D2X\D
M/)(.B)A'%))$R51CEE3*.0JE,G)(0E..)4R.4U1"$<(,23ED!DUKS,Q:W_+L
MO=_]/8?W>Y_O^_:^KG?OZ[U=]V#-K/O^__Z'W_]WSPSZ 64 RQUW..P A)8(
M ;]@/P#Z#9#9YA]ZZ#!P&,"&$#H V )+A!;'XN.2Q2$BO/@H*B(B+"(F*B;V
MZQ27E,"FN)B8A+2$I-3BP/Y:*BVU=/&?Q47^QZU+1(6%1:7$Q<2E_M,#?0[(
M2@!52SR$A32 );)"PK)":#. QVP4_=4\(>!_#J$EPB*B8N*8&=+8"RJ78^8+
M"V-&BV(68\]&8<\#(K*B<FLV;A.3=_45UPA3,#Z?>E="\Z?'#8I[.EE:)H?"
M8R2EE)17J*BN7:>MHZMG:F9NL6FSI>UVNQWV.QT<]^[;[^;N<<#3S__PD8#
MH*,G3T6<CB2>.7OAXJ78RU?BXM.N74_/R+QQ,RLW+[_@7N']H@=EY1655=5/
MGM8T-C6WM-)?O&SKZG[WOJ?W0U\_<V3TT]CG\2]?)]BS<_/?.3]@[L(B+B%
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M%H^O)1@^912#X@/PY;TF08ATN;5&Y^HG"8Y5P-KRC]<#LL)5 ^94+*X@CH!
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M_.W/4,!M/PK<Q*- W7NNGUU4)-_66@(%<ESX1>XH<,UZ"Z*1L@IZ2T#V%J#
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M1[WS)6_" ^3^P#^%KD*!6#3&IV@L;22@$_\[\SM1 .<MJ$>!+W706&D!-&M
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M^CM:5RV#. ,*'2=F7\2[]:]^]2WGDI8_<(8P58GEUG)V2O-,OXNK(!X%CJ)
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M.WAXXCE[^!I;O$5]71<89#)*2,PV?5\O#I>UCC>KUO5DDHRH75ON&%H\77=
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MK-HU?O3ZL>C(7Y8[Z@B_"_P+'_2A??\&4$L#!!0    ( /,S7EO_]HFKDRT
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M5]LAKF/AS5 X<79 0E'7DJ;'_ WM;\C^'+"D_Q"R?P;VOW%- %)" A!Y0C(
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MT)$=B^W7%&"0^NX>I+D'H'?3B5U9WE_F]S%1J5IMG@U'^,!]%W6&)RI&=_^
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M#%/2 N-I0K.:,,1'Z6-&#4_8#1HIH4$,Y@K-Y!C(A4;1OGQ 4)</T V%II?
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M/YKQ.?N!W[?1Q/2S3WR\1IW,-*/OV%>,[WH2>%7VVF.-5&F9K<\=WX@84,7
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M00]I.W)HL#U.O[+F25#GI:_;AV(4!D^OZDV8U[2>"SW[Z>"WFKR+9E>,WO$
M\F.,*E<6/4':9FW!LD:/D>0V7!3!#JIH[KY(R@A")OC<W$B(E-NN",N-9)U3
M9@[J8:]G588W0J,QD@UD!&AD->#9GG7J&;WVR(F;!R6FY>4L?IQL6C04K $1
M+#]P@AJ388UX&(AOL6\+8\!ZE$O/AN"E33=_'7CLVTFPL[:JZ<[2"4S-5].U
M/>=U\S'HMI+#6&=F@P,\0*B;$=[,B.^-ZVXV)6 5^6PD_Y_9J'7$<DVL^Q\V
MVBZR]P/0+X@0#IGD;BN"D9_"H3W64#'P1"$/"-T3\@[&)S4U< \4U!W+Q,F.
M4&EFJ N/D*:#S+]#&:<W,&$MA>%1!CJ.%F]NO-1>O!7QZ\@./+].H7U;@*5A
MFZT(/"#S+'H$9\(P2+0V)=OHD 8J#W=,TJX%SANY5W>6SG]RDY\;DDHJ6?QC
MOXA2NF3B\X=/1GUT4M\L5#"(!.F6?X9<[<?*7W8!C[!MJET47T]>RY\+]ZOX
M7E&BG:;MYW^]>!U2]DS33;CU'WH[=?9?Z"U@MZA:?KH[]ID>MB$2*E^/]VN2
M0W_ MR#28(%-?(3V7*Z?EWE1UD.2;]5P#!JIFL\S)[U/6W6_D_3D%-#X*B%#
M2/$A) '499U!3@SAY5;1DFQ?3H7U<3J_ &O_Z\:LN-O9G7%NHHEFW:MJYC.+
MJKS6K)K5AY,YHJ4>QT%=8%FS+X'-]#'F#'UZ98:R.KL;EH^#,)33-]5H5[^G
M?XI?%;]_RS79HY'F)&?\OF_ORRN+WP6U.HB3 G^R^'/V%Q3D;Q? .M8^=^0T
M$\N(+N#33LE@Q_.=CSAU#)^M,_='G&>*C'LU-DZFC$@F;_>-_! )]P!'J+"5
M<?XW/W*P;,OG2#6"<D"OK1:CHN1.I$=(S([,5/BVP0UGZZ)AXZ.Z<VTJB]<#
MEW"A_(K%+QA//UT'GS$ZE<',G<2)#E%[&Y=Y ,)EQVAUW@F#V:6U[MY;J*^A
MLQW688,'FMPXW=9!].M4E]ZF9!K=;6!>9;K;,H!U NE\.JO;Z*GGG'N/;F'&
M3%+']1UA]D=?7)=P2Q1[*,,#CG!>HSQKV>?I^&3;0^AW\[O!A&IP_1QWC!Z0
MN9EP_MVW<(3$OD)/[Z,(79L[+W=7//V63[ZX(.5V@9I!RVKZ"5,SQ0=@9UCD
MG74,W?Z_,A7"6SFN$Q[M$_4;[K7"#_,]<U+::@OM-S.E2OZ\! Y\PY!K'N<T
MS2SR.<3*BE+ 48SWFEY99T![H2T=M''6421DH2-WWYCT/++%=8*?$?.<X;C\
M*0VWTZQ=6:GGWUWR?!MEZ'80NE]$X;8 9,63,>',,*5=9UUD>S#RVI]1\DQ/
MNDB,/O_)U=?T*K>::<V:6G%4O <XI!]_(ZG[5*:F),GF!(9^#J;J1 >YX[K,
M0XS;H*,.RXV],^S93,Y$;0#W&&SF/GNU)8RS%(D?^<.\UBVCZL]IV(3,/ED@
M&V#1UJ<?@A'6!Y@,\XJ+1VO&5/<NHGX>3.H//1!5Z"ZGLJ.9 MF.'BS#-_ME
MY%K[\1E!$'S0B:2G7D8WDR5=-(F<5R[,"*G.4]'2P&T<;=S8]TJC# UK"20$
M,!;X^"KH\X;V?@25^[;FK1D&_4'[04D"&EJY+\'53.[]EDB0HV/8IYUN09Z)
MZNK7]9 .F;96( ^@0MD*=4PT/:,?D;KC>^+F&PLGQJW.TKS8IX38H!BI=ME8
M^>.1X8,'!Z_=4=3VV>]S4>3\),KI"=*4>8Y3B_%'9/IH[VC/HL]#,I0K95],
MHJ[\* ITNWE<O7T<?N"/=LDXZL'W0+,7'Q3*9\#[# (%,T "=S?UV$ H!=FA
MFY_I2X74_L]1IW?Z58X;8,_DE7XYE5I],D>3><3IZ.X M30@H<Q.X:S _Q6[
MSH]V:!X">I K+E"M^J71TJ8GQD,?=TUN2A9%'Y60:MDNH,<$MCEI 4[;</%P
M<+=RDDFK&$XOA%_J00=/&_5<V/W..B&!W,8=RY]I;J>-[PQ)[=!:=+RVN#UB
M%$@XZ,%5HY>EH=3\=MZG0*1^_KW4.FT:88F[[WM;]_UW4^V+@-+UX>O#J^>1
MF/X=!CG[U$P5D &N'?B)-B/'W_6F#7X0Q7YS0]]"E1OOWAT5BA)I/"L2D]VM
M2X%I!%X X8-<E8FV"O,? I&UP>WGOA[=*ZJU[^:VAK&G3ZTA]%4*#R!H*'-E
M\>GSPN/=-K7B4LF$XQ,ZK2FQR[,ZE[P>R$00VW>795G;52./$SJXQ@R-'^T3
M&UV[PE=_>ZBFGAU,FZ,_+$X[?T/ ^H:A0*=H&MN"<CBHGFU"F97>KW;_V9Y&
MG0F:G&)IK(R/JQ@0\$\8-J?A]9B,>5MZV0!,\"=,#B5<E\.1]YZ@XCXUI9JJ
M5(HKF-O.*'K<%#MP!?*T(1OX5D9&].YCV%<O1($VE*L-(4J?9I>)K^B<#F+3
MU=O7')?*_/_(9DC5.^HVAEP!'?H"^O#T9*Q4T- )%N0+OADW )U!C[8$%'Z[
M'E#6\FTF[]6"2L,.0T&+LW1X2AM"$KIM&2<_L:?U>'#[D,.K%WFT4[L!]^XJ
MB5  4%914;S0 Y.T54'MFJ@9YRJC#GQ$60995_I.=8H4"#^X"=NZ=_62$*L\
M8P$R("U(+NO#RK*O,BY5?!N\1\E3^GX1G^*2IQFKG;R_<,HR^M*>8P^VO;.8
MS'Y#AJH&862[Q:O8Q\:U7F6/^'PR:5,[T%CB>C$;67I11N&%E&*BEIS% _FI
M1,LZVU]]:$4<0Z,IUQ1E43M:]Z6//A-<-*/K-3O( Q+DSEOI=-P0$WT3>.Z(
M@J6I)!C@\;F5@W&GT]+FF$5KMF7QD8%%I_T_=&E410L->J#/7\S-ARC 03CA
M4./K6O#^17['#S6/L]++GGI=UAWSUS_[\L]YV4Z;92#L<3@@6(YW?/^T9BX1
M\"U";DO<%8A3IH^E?WN#)> T7KQ(.,EHW%1^V>J8]YD [ B22,(= X3OZY$C
M!ZZ!"V1,+SRKLZ&]BV% $4WK/I[@"[1T3UO#PF*, ?7$@MUF/D[6LCZF4?Q4
MM9N^L_%O?@,]AAD#-C#D"9=/][^81P[U5BKEA^UWR,L>8<:4(N=_:$N)9ZE$
M](9.UZ'V<VIL)=CNH(8R38W, S0NXU-F7<K7%EP[WQL%J1_NINQ%J1#-<U4T
M[\?GR@G,#H4A%#MG!L)SY![:99T5ELP-$WQB-FATEX[HP2?#9=IF"Q10MN!A
MBK?DA2XA[^5#5AD-#0%W-<_\T;7S'WO=)/L/H/MFPS0GJ%:9MD+L\Y]L-4A>
M#AI-_:/.?4_+G;+M)34FDLQ>Y<^-[)FYO%WFVT+YW_,?UB;.M>:<G?A=72F^
MX*%5J2Q5I"N5?OZ 5K*8;@/@=+$>94D9M?# ,33O4UA&"0X79:7/<"5/.#7V
MGW2%6?;,[1S0VT.-3CXRX-UDR*F"A4+322WM7=5(&19A7I<!SV&?*-B91<:+
M!,'#)ANOGM&\F5:BD^;BH>>GOM^B[87 S\M6Z>S#%$(TRN;AC'L";G/5%#<4
M7)CPA,+ !>U/PMGWC#PH3BH>L*.,B8#'>^>A+N)\Z'2&E]2<4+=[$M1NUAN>
M]*6%ND_ ?LG?(-]);[/)"%1EA;,/@:,,G5_DRM=DN#)2<I Y)?(7)H%<=?!T
MOC]RY$:X2>5!O>Q;HBEM:WN1?47RU%5:,WDU RK_'30@8](J]X$YU%E)E57+
M-VH]G5YNT)GMCA;RWL[6S0[RC@*[-*DK!V>3Q8$-B"!;#C2C#UWHG,*IH73I
M0QE-INFFX1LVVXB?/),>4(AZY]GKP]93HWA^N@FBJA4H$<'H/A/7WW-:79,+
MK7:ORO7T'B.TU.Y=+$XS$#10'. 7>ZW?":9$!$'Y[U8B#VBM1^SSMMO@ ;)@
M3+^2R,3Y\=_3Q<+O]2KR\H\*WUE/UU./35ME*PQ1?M?&/O=A:W.PN-WL$_2E
MK!C]]IH%J##RTIY]$WH!<IF:3M7Q#:D:@WI7DVZ[RQZ!'KN,Y",+_2:66@>1
M^7+T>;#LD :W1KK*9."=O5B>[VWI#PKRK7(1Q=G]4$&TA&EV%$3=M)<'2$HC
MW-J+2)>F1#-HN,_Q4BER#L9=5F]S#_A=.ZH1<C>'V0/J/D>/E&?0$B@FT0F1
MO<3PM,CG)__Z"M*,2Y<'W4_<O#.[=_>%ZR6$**U(GZM\VA&V"OGEOAJ*)V.A
MK>]?C*H@:PHH#_2]'=]>L?NNE1]Y!.J Z=.EN(!V&(HP#TB]?H;;_Z]FRZ=M
M" &D,IS^D*[917ZS<^NXTD]@O''CQ^-662T!W36/DV%G 4$5%96Z<J6GQ*6L
M@(;]]Z)\$2;7'\S ^^7B$Y;51@J/:GM')@L<T%H+_@Q$<@'0A=Y"L7O0&=-'
M2J^$TC]WK^Q [I/>(;GO=GY:J<)9Q^%?WL(*9T6%#5::6'N==9U-5RCDG?YZ
M+58I*UD&D]SE]EOX%+C8/ALE$B'.M \K[?%SJK,\V+5=J5.Q^P8A[N[LS<RG
MBOXJ*K>E"8(BG2<I:!CWHX\4YP'*[#'8,OC7OS8JK!ZL)!QK.[U;96YJ:0V^
MV^"J7J;0U=?7Q+5N7?B4>.A-9!]7E7'PI:T^G99>=>L7N'IK/2&P.*'TI[D<
M<BOEI=W7+U$$J0>:(8>'2.)H1=2E=.(L-8, @R"+#N^2*HWX]==8.4?P@=_M
M4WFM](,J/[V%D4V#\-F"'J@DSM"J9U64;<7 ]KNHSL[H+SVCK H$_KSU]U+7
MNGK9^1&]B*/=-Y][1KQ[ +QS%*W_P=U.QV8T_6Z#0T#XF>9.7+[*:GCH2G6V
M<VK:_F.-[P1N9$<_/4@\H**8C=]F*]J4CZ$$-/4V24#D[J$(5%G*+*(#P=W"
MMKP?PZU,F[$.H*?ADCP@*&NS09!P.;SK(;*,8.$ S;)6H\X9SP27!T7<)3IF
M77G;X^>M>N?OFE$Q(X.MH-Q;'I"[R0/$4,:@(L. >A)YDM9@?:$.A!Q)7QIS
MZ3PB55KE%) Y=FB;I,/VFZ][OV<#S%4%Y(6^>:N/C=:F"R[207]Q]Z(?A;?2
MSH_NT;H7^<#ZYK9Z<X'%Z'J2-%L;/$W^TOK66IN.)W2>#WQRO7KG_:JCP L+
MH"56>WNL9X] ^\(-P8/UF'0^<&M[X=EXH0O,+'I9?IA+:EKN=$Q<S<Q>2;U4
MJ\J6.G+_..W*NSFSK]M=\JS8BE:4*A#)=N$!Z3?!'K2F()ZKM)=^EON>98M9
M6$?<9Q:T7,=:O/M)3+3%5K6P=U&;9)#?"8<PN6QH@^?R(=>Z (WY"DR0%K)1
MJ_"X7K;#V8LIX'0QV,+\#>ZBP(@C1SEYQ!$O/.-,IYA5>=0#EZNU(\S8/4+*
M<JW/1W:EVU!DU=.*S&^HG!5M/6>G /P'3> [M(VTP@,@-&?6?F076:'SYX1:
M?UQ ,>*IT%>M"CVG:_[GDH>7[.\G+C;:H7Y&L<ZBYS$M6,)W^A M@B5V? $A
M^9,(G[$L4$)93%5UYE/'=6?T"FK?68\^V>L<,'(J($T=4H,)PJ9J[@07Z(B+
M=-%D6X-EG,RTOIG7#YS.ISW>FE/+JDJ.[ %[S5#CD;8%:_/FU61K_U]4_D G
M8Z1&Z(O<]U!I?(=OQ_X%J@(:=K6FKK"#!KT2$AG!G1J=_T([HFY%.\Y"H/;1
MRU:VZ)X$S$M\'I7ND(K>'0P)"Z-Z2Q)H>ITB.8$/YTW:'I_#C=Q^_R)7-S3L
MNZI !HQ/\L3X'KPX/M TG>BVLL ZS78!\ZK CGY&H.8^^G1!F*7G6$O-6R.1
M6N%16KW_UZ']XSI&H7[%J=ZO->:&V/*80:PXWK\@A:O"P7;[/?F*.@KNJANM
M"YSNI%I'7^XO.ZV[K%04.D)0QUV5(.@?,[1QAARGVS:Q,.S+8 6%YC#$%?QH
M*P<>/U[QV_IX[0R8+AW-%_^(%\\]JSD5YZ=($5]'N:VTLS4W'8'U>&G!!0S-
MDG4+A01W/4-_TMQ+[TCLUC#-T.]HIN<_8QY>L)DJ5$\^T!C=XDEX[5_X>>^G
MP[7OM]U&;L(4VGB *'H<^X('#!045%I,SE+LB\J_I['A8<\S+6TNG.J<V+/3
MT^CG,<QC'3G%86"X\J&AH$MO>0?-@ (%=\%H9@NFB6B1<?;5,'GD,9(7/;^F
M(<\\))FH<S?<Y'?Y0=G+YB^-[)<%ZQ^F"P.V)2P8=QBN&&6(,V-[<ZH;;[TY
M/$C:43_5]\MYW,!J/U&D0OH^<=:S_K%IA9:;B2Z@>%?JK&@AZC"85L_ELQ;=
M,0=*=.B;/\0PS8QJN-[3*?$CSBUKTZ7MRT^WR.=V*FTY@6M5<.O7!08WTI0M
M!\$%YFUZ1A\D799?N9FP8MCNC(X!$[W9N?D?:.WQMIAQ:_OY:YPG'SV&?5]<
MMG_KN\:OX.["[U:&?&'KLG9S/\*5><#57TU?H,Q$,*@6Z6HBV#=5CLE )52#
M%:95;[I;2O>W582E!AD[LQX'2!W5O:$RIF' )+$5CP]5JK\$G6/HOWIM!2>G
M'*]-X4P\D.4V)PVR5$^U> 05( J-$[<K13;'J#-W"Q0SW ;QRF@S[E><"&A#
M=LG!:='+4KL]Z9<3 CPR3A5>[\I#S\I"Q*.N2O<*ZYC3C N[[T>W3_G$4Z83
M<8?&6.[([TR%UYPZZP2KQ(T&$4(_D[A")-VCGO#,&]<X&*5T_I= X:G[/7("
M.QY>T1AFOKE.=NF7Q,_R91BVU=I9"*?VB:LX'Z@<8_[5L*))#Y?OQ_DBJ%55
MY'Y%<'#7O!2HNC GSV0R.FCB&$2P]<%&4-#YD[&^YVU_J[TN1F]5#SVG#$+B
M@#^D"PRW_@IE9A"G&>8/U60[?V9?#:)/$[;$*7/Q_1>RVI1>XL;GOUVI#!6T
ML+]I]>+KS?@KDE-X 1X0B("@>^-<:#84/!$_.*5YF+Y%</:./_EQI4T1#M%_
M\R;[5'GDSV\2IZ3$=(.\RH+$$WK11[^">.8)<*#1&SV%\ NJ30,)51Y$T*P2
MA)@[;OBW(@X7S$'VY9]!+K5T'Z>W<"6$L"UU:$*<08JU;D2M,^4;_1T*CI&]
M^WD?QM"SM>G)'WMX>P)V5]KM0=\_6P(] !4?Z (:JC+6V#)T=1Z@$(5)[X3V
M%PC6YJ"BJ'S!//%UV94YJ"_[Y;+*M1*J*>QNPUZOYU6W8[5;\0%PXG5"I3+G
M!5N7'D+&#(U!V8YTT[R--\=,7*$:,\$67LC(<^T98^F^W6\Z\AVR;WGHFBG=
M:'STTEPXA@<H\H#KF$RL9%M!*@]0P?B*W:JC82BP=$@ZG(#6Z0X)1!VM:G5,
MU[WQ?/[4\O"2D2+18SA<!!) 1Z\RY\$"QLW9(;QJMTT5VXKN?^_)J 12^?1G
MRA3",N?U7N&!T2])KF+5@H:W;[_O7]6_82C(%W2^'$%F,N<ISH)]@@'OAQ =
M!G>XI:)5V/'3QBC80Q!SB74X>"P,]3(G?IKH_,4!4BPQ*R4RM\?S85/+;Q/:
MJLEB:U>2?O;%7<;G#?VB=(6V([7R/U-Y0#.\9TR3+9U"K4?;=+3E@ET+\$SK
MT]6<TD6GSCX&-="#L>65>M#G\R^T\?B>;F=*F#.A_?+F4HDE)W6*OEP>+V!S
MOU-1WMY]NX:XE+G86U611.N A8X"?!!BA@<XPT6X;TDOEDJH%2)#]G+N(U>I
MLR8[)0^.#'<J-!O6?#[BUF>^NN?BE=SI0:[Q:_J9 AX@%#')-J/S@"&KK76^
M)LA5@LOK=4VHG<$Z3^Z).N#[IB7^YONPOFL'F+^U2UJP6,&?)%$DEBL12P_I
M*R5)1!4D:<J!-9%/^DQ";74P?3U\2O=U7ANRI-5_M*Z,_JIJW7%E](%FS X>
M( ,C/V@)QK[$].-38*T&N2:F[',,3+\;3H?A\^Q13]_TF<DGR,6,E>>@?[ZJ
M3M[@BI)62J(]8+-%'4NRWD5%)&OJ@F'/@Z)'JN9!GU67THF1;7H=(=$%@1J
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MI3;>+\2'IFJ"UZ@DBFQVR'Q]28@<=!@\HR2=?W1H?WZ%HION"<GI_4G==P
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M2TC?B;2ZB=G4.0[+B:6[JZ-_5?Y8*H=V6[& J+1 N%]M=:@V(T*+P4]F$92
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MXA95H7F/OKKXN79MVU]E:V_[K*GV^O&#02EX45P7L8!0B[D_(LY,90&W4%O
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ME_Y\[=RFO 6"">&AHU&@*[X?"87WPDN"AT?[^"7B'S4)_.]N#Q3ZW4X/_+5
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MR+A])<]9^D[]0\&G,@X[9[S?;%.Z_<]O_2V[#?BOO:(BYXI&DU"\8)Y1MU>
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M38D2Q37CA;"R>0ZIBMVMV3F@-B5M,#/\0N6QW*5KUI:*ZKID]/JN3#Y7H6V
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MXGI@^RR7P86'[[^7FRXIMCDQ:& 5L:#X&?V$$PL0TMK"0#)?+59<2_]AE.-
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MDR<C0Q1ZG50[QB6W50TZ[)Y>.F]8/QGZ0_7_]@G$_X=/5##^'U!+ P04
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MN7C5[PPQ&RQ!M^N!9_.,'EW'S049A0U\;_@,CSFFYZFN<I?]O5  99Z=(7=
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MBPF\6T"C?M$K)SE0[]0&=&40&OL#J'?8H<Q@CPDIFLY-N6-546N="S2#(TS
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MR* ;@Q^RE.[Q3#XT</M4B.YZQ_WJCE1DV8D$W5R(:0K%AW1Z+ 8U#$V>0D)
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M)C%7R 9V)N.BU"4H CTRBAV\5L.7[L>^M4^[UJ#_64Q;?U!%Q+/V\K/+)S\
M$RA/ BB]X\TQW8X!.DDFRT&UW;X0C+^)/:'YV>1V_=('CH=7=[;@TRM/RX=E
M4$=QYR+GG?_J36D2[SU>\#QEY\)N[M/6MK7WN#]M]141Q+_VP I $X_,[YV+
M#H7;#K7E8.-FY\H7/BJ5EL_=K>+FZ.^V.H3E:2%7G6=8<R7Y59@V>)JN3-J6
M6B0'M?,(;$2@1HI*E9M\W^SI^6] _A<!9#N2>G.7/,-A#/X86QA72N/4I^*#
M,,?!C*6.QO+\6+2S1(6I3(I3P*D;\-[(USOJMNPE[W[Z":[3_P59!)N7I0NB
M'9D)SJNPIX2]E?IXGW,-YNU-./X4-,Q7K,?;^$M-*_^6R:%G%P=.QHH>Y19_
MJ(P;%&;MRJ,+8-IAVQC:M%E20#J4JA /@FJ7/_44(0]-6TE7$_D:]..?2AE0
MO+6[3(R>I)[471Q4<=S,(7E'*2Z&8;>C81#IYG-XUW&K7UTV<T8H]M6E:LV&
MOLX641_U)[D-UH,$]4HI <8![WJ6V$<:=[BZ"*VCL< A)G?0-GKLR!X+PH=B
M3Q6#8_=VD^P66LH"+N*[HO?,;F(C&(J9/JG:3^\5]^3>*2_1#1.2XE?9KQIR
MM?9JK:#A9W4AH.J7TN!? _[P;#V<E$98LCUZ"F(O-Z"X'5SL:[;("#^-7%W
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MD2GOE[..$MN1FS""@YG,1#.$M=C 438@!"=2%Y=Z9I?*";>PI$$XN YVLMA
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MMCI49FUM<:J\.!$7E3PV26R^#.5H#+Y$EG9''9RN+ \YZ!\MLTZLW9!F),=
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M-W4!<AL;$ #Q)D&(KI4*%9=5X=GXH2.5/%G>SZ/_.G@ $[MDUXC@A7*'[8?
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MF9&@((AAD%D%$KQ<0$1%1"\7$:(@DQCF2<"$068TB@)7E$$!45&BS,@0AD#
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M@K;# VSC\LY1Y<\5SR"6_;!?78-S_D-W&_6;@B]T0^P S7N'\6QY$M>YE*'
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M[NM[7=?W>IZ'\9FQ#!R^:&9I!K <8 &N,O\ QA; 9^P3>MT7\ 68C84Q#Y@
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MFP)^I6K,_K+Z(]_1V'BUSNK(DD1?2&;4K1SKKKP)6EJG] 9$B%:AOHWV6^)
M>I!P/<9X]U*R62KY LPD*()5">TCB91,D8J_R=;I31LIY/WZ*#9:CBKLM_Y]
M>$\0K(WTOTFVDKNWG7?F^JVJ\B'#^V<X.B-I!2@IIE\=01T+]!(@><8/9%>
M.,=QHIV5,%FVZFC>[CNGQ]X?>?*[DXC],<<H,0CGODY]6@I*!6'2W<K^O?+U
M.H2O(\YFHH%R)R_ZF=LI$0%AP0\VYSC@'U'BJ 4[!!1?GH@\6HGJQS0(M([_
M5+.RRN+O67O&F]'S<-[RL8_O93Y5UB*R,_$>.=2.5DSUIV@B^6D%U;]HT3U.
M9WTWUO>;DR&]Y3S1K]S.3YQLSEBYV6VK:"R?M7K=6^!%W2"=FZ7(G3YR=V8
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M9J9:F+DMHWCEDYM+1+ZWN<;TS(]Z<>)JF@A[7U:<Q([PZ="8UV< 3>;>S#$
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MHSA.$-M9V780HV93#5'5C49'^OE?#.M4QO[1H@XY'U^F5D45\ML5MY]$=U]
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M&8$R<I9+AT=-2_O-B&_47H1%V>,HOPLW7_6'O_@:/ C"\$OSSGM9X*%@BDL
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MR&3?L8^V;,EZ/YJG*]2V]2A\;7\@I021:/7<9.;G<_B&VM,]#]?%<W7]QQE
M1,8]7J.'A?P/Z0;K!7(P4/5E*CG1D5890F7%\XM1E25M'ABBBSS6;JW]UGL<
M)&@55MXX0NSHX_K ?5&KH=:Z+4D*;M OJ=<3X[T,(SJ23?"#1)85N22]":16
MK@69,_F7BS:^=-&*/7ZX7Z:T29<T&*:D)N\JSL'S7?4]MMD/#"?MK?0D+5NE
M'P@8+1H TLUB-!0#XHZ^?5#3_5ZEW-ZINET-'PWE8X8X^4!\&U<#1KZ0/IPV
M(KHT=&8HZFKPW*U;6FD!K-_XYU(LQK_2<G%^P0K6$-%&6 J47\$]7/RST"V-
M+[<'QLV,^-0:P%8F.>^^U,G;&LN#A)#=:F4L^*^>@Z9&TV82?TIMP.%J"X+C
M 3=>IKGKES4YN2BET]P+%;F'J4I7TR;7&F(45NSCW-^.$TO;FU)7FMH0PL."
M$+WC+1)7;IYB664=CX7PT=*8@(/.XO"15"$>.Q)_WZAHX-G+]=YE\.$*A+-=
MMCQNDCX;'JE>F\#9^Z6ZS_Z"P.-337?B=E[<FH8=,@PGJ0W ZLVPY.V5D#92
M[Z6XY=("*9CPO+EOO?ET2C_T<XT/KCE/*F:/ ;3R.EK"@XO>B,M]:DM/+ #:
M)[5I;MM=<X;-;N?9QD-\)A0"3SRY[?*TQIMU+,PY8H33A*R;K9M(L):<N%+W
MUK-9-')ZXX3=HU7>-*YK&-MS<C((-3/0DF CB[P&9BQCYOP'8"(Z'6K+M('X
M*C!Y2T:]P2&U?>-AM5TT3X =_-6[.T="/F<MOUC6;$1W&VC':)ZG/>@4F T4
MU9KO5^FEG<*O)-WDK7<OK<--E49>C\Y1[H"9D\KCVXV*TGD#9"4G-F_WFYE.
M5&V.JQYH7I1UBWU[YHSXJHZ_S<2F]G/QVQW'!Z3@<$2.070TXKZY($OLZY)X
MX":P?(7S&3/[-]CT+-T;/$]:':")[O ?!(?@^6H.9(<?)1?'4TQWS*,UEC]5
M49+55JX>V?)=@6J\3*=H()5I6)3H/-/VNH8V91[P3B7RP3B"5^+R"'+=[4:G
MM,N+D7"$J*5B<Z;*#O4ENT1*QNY-M2T*A4?&;LA3S[XN^?OB[6/:0@,R2O93
MKC9L<B:NG4(@>AG*8JS>? \I5!I0^[&[/-URXGJ3*]</%[,2E8US<B=1[_\^
M&9%&O6,  A!-U$<&((>,+$5<7(<]W,>D(+6B"49F!@8QSN:3%R_5F9SX4*EF
M>B3GS($7%;893@S !RV&"+T\B0O@!U4Y4S1>CE/Y"0NWU!94KA0,V:_^:(44
MJ#.3;.91>T5SC5E/P.[#:R[.FZ/CB\=(*O<-PWEU%W5)(=E5YL$JST)E*\M-
M;]9"?S^Q* _\+2*7UBX%7TD'UAD _]R>E;A.L'(T:QA<4*S9TEMKRS3"YTOA
M5PZ[%M8C::HL$!GD>5)B?SK+FIP01(XY8TY2MJ.\/Z;,BU9@T0XJ77E'47*,
M>'<$_T3@BW,"ZC.4= 7*BF0A9Y=W\7. 63V59"'G!J$^^ND9PH1VC.#"6['(
M9L&Z+9F+\_VMKEI=5TR<.Q'0'B\9$O^#GZ.L").+R8,7QS;EZR9N%(E;'$DZ
M8!;W^?@]T-$:C4_LM1%9YW0FF_>.\-BUJ0HOP-9.CLC;?@J)4/GK>&&@$&E^
M[R9YFUE-)F'XJ(<H+J ](;)O.\E+LEWV#-GI.<' H++B00X1+N&B_A5=[]J]
M>MQ<_,^5DQ)'7V,WL91@)"^H21$+0 F#,RLQ!KV=)T%O_%ND$<&&;6G17+9Z
M;U@\OM7T4"W$YWN8I+;9R2&"<5SWX 1*FAF_?G?/I+\"S;ONZF:'*9F=49FX
M_?;JG4MQ#76J2CZL:<\.Y*.7^5G6.Y6:R3D5R_D*J\X-@-MZL^0-FW N&=V+
MSK?H'+$0<]" /-BS1+J4_ID5OY5".7?N"!F3)+FW>HE4FIOAICTS$WG+LT'0
MVN"$4VV/AK>K;_;]P5&[\_FXV;A^.59#-+EI8J5Y4&Z>%8]^A%(+<L*6@_8]
MG:+DZNS^W(3@LF_$$PJ"SS14'O,O?LGHZ)HKNG*59DR L8)J RG<X&#WOE>5
M>HI46,4:>?1;R "Q;9+XD2-LAG7\U1J:"R7TX^X#M\XD4F]O4^2=[5:>2D]!
MKJ^I'8[9+)Q?KG F(#A7G#<%2*LKN+X5 ER='X]+]YE^BGBY,MA\T]5C(X=P
MU&4[N+3 R?7$5]N=*A^6^UXZWB.AH/)(=>K":/^H-/7TN,\;\!H!^G#<"VG0
M3#EMPD;F"<C<6I\[Q3$?&"(R>_+ "RW ^=/B,3!Z64ZZH[U EP1)K](I"6D,
M=KZ4O-P38__!OH$\UUB2IN_M<BW55N"<HVTL\ ,HY'^."T$_\CI.@O:C'S
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M!M':L(&75P^YN<QWW7O9V1;AE[9XQ,)S4^"CR^M73GZ^0!ZQ890/$6WZ]$O
M_J'LTM10Z4-'&U^;#:CN?AO,9OWFD5_YR6>E6J\/)4QJ?G3"^1(Y-*&!9C=[
M5+"LL\0OJ_@M&P?W<NS-/O^:@[\*^=/IAY'.H R9 :QPQ%&,45/0QO2>C,K
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MD:GP%<Z?(@R 8QT]I-V03I&*"*5)-OYV1*K]XQA*JH !O%L5H.O]P4Q0M1B
MTI88O6-PATE?VK,6_I^H\!D#Z'TYGDV(QB(RO(&4FH?(HU@F7GX[>8'G;:]P
MED5I6&_6Z01459$QWC3BB>TY\;G(7DQBJ_E]!H!W#X2PC54C#?8BXR@'EJR2
M3K27*[6CSK]*AXM>=Q8_FG9WVK^7/W:)#7*P>HXJ T+QZ=PI>QR_Z0)$[L4/
M7[Q?[@IJ;/HLRSXCM ZI'DA,-E3#ITN!J.T>+VW2MP1L&:SG>N>$CI7VV^:6
M1[\L%1^+1.P=28[K@S!QFE+3T+8M JI93G[_M.VT>^&Y[=]*AY+];Y5._Q&V
MV(W[1G"W9(#0J80:P=3C!HS<#J$),UT83K" /GO .!H+ADQO.1B_.[=3(H/;
M7)6=FOK1JIR*[U!>,B9M9<"O>0<>3AX?&EJXGBPLS7[ARH%7FT"_V[^@[J#'
MX)8)2W\L_2H9P/6T+ 90G(<KS/L/1CMQ]]%?;S* +@:@C8HA.%.S:AD -H-:
MBCQF*NR\H;)\CPD1MN;(F>:M3)B7U6ESP0NI)^*3BV-?EQ@! ' 6T+*U-65Y
M^W^_84%C1W>W8G92U17I PON#,"L.F8*QLT _G$P816W<Z8/G4KW9WH=+_J]
M =/OL&'4^\FJ6*7?YY-5"P_\!YW_'ZLJ_$4*]A_':*.*#" #(D<5H*9_YV/6
M,9DI3+3#COZ)9^*_ B_IQ4?R3V'&[N+!;MD#I'YZ8]5Z) ]'?EG@G72C_@_E
MQ4H!/%I[!SKT]O)H\?_V:%=CV&(:I4DU:FL:_Y4*&4+HI"!DB IOWS:YI]=:
M:BQ4A$G6.J4;/KE>]B3D%?KZTJ/35&[P[_L=Y6!D!?C<$L:[/H=.NM'@FB?U
M5GMX^-B-K9!K^;;T4:7 ,[Y/4@MC^5C].G-IK1 !A'D?CF.;KDC_@&N02S++
M*D2J@NCP%70"7?Z-;IUU:6-J?M/SNQ/&:L91"H:DQ$?%XHMF/B?8HQ"/?(/T
M0?LQXU_UD<%E<&QB!+S28&ZU^<$P"7Q44Q;L:=%1DYUIO3@2/6]0NI79D5[0
M?H@!L&W2ZNA*"#4;\G8<G=LFS+_*Y?D"W\>8ZP-+5Z:"$VSR Z]I;T3<?G#
MQ%0H8=,Z3(X+YY_^:$D&Z1BSO)0 X2C8_WVQ*3K_6DV-?'WSQ#4SKG&/+Q[M
M8>Y'KHO=KBD)8ZWHCP[MLE8AC!+9R<F#>QNT5ZBC(X4(E6ZWEWG[@VG^]]3S
M\%6"FO5K;@X";$*>3Y<ON."OU/(O6CC<6H -V"23D5=I]U"GJ"A26G*KT6@?
M>JY8"B/TV>VDNFC>GMY,D]-.QN_''I9J/LL2"IS5%VJ?OG6XB:Q>4"LEBBZ.
MPJ*M4:-69;?ATFTL=IFO6S(O7AZI"1Q0(UQ<7 ^UCLK9"\W&G$(&@:SDZ#T$
M^6AS/.HDXI2GPOI^O^;M-:?O4L_A&WY*)_9^'S;H#9,XDDINTW!X]%7 "06@
M1F"2Z"!-$1BHMAP:-^$Z>7ODZ"^C\\<BW-VU[X_Y)HMFE[;F:+-^*#@ZL)FY
MPEICA.[/K,$Q=_LAZ4X)X1EO[C[G8+6[-:DT"Y-GI!NL/$W84MUE "?Z1Y^L
M2H<^^:TS1!_$24 XD,=)V'Y/_A5L@J%UI2NBK5MWSC,_-\$_>='R:[KSF\Z=
MLK>/]9N3Z.\$2@7>=6G-M3W4J>LC^,8_*<[*R]5(,:_&PFORYNC.Z^&&LGSZ
M/\QN!;TH+JNTK!S8"QFMR?TVY3I?%$?>WCM-*V82(&O1WCZH9+N8=]E<4*1U
MJ.]1;++V_%[4@:TCU65]524RGUGFSV UL,4H):0&K0"E21^2'"2:DWCPWZN7
MF3[-#M;;C"$=\2G;AW7+_:/8?SKS!T?"M3-**Q0Z&I*4K-L/OUL?'L+D5R*/
M!DZ]_$-7VOS96$#Q\I1<_^B!DLWG'IY%"CI?ILZX52[ER-B[]1M!KC'CD&V?
MR#]&%#2D\1\'D>F2S"3U#)V*ND3C[(7]42UC %[?_O117C,#RGN;Q9Y_$E'^
MTX[CAB[CY ZB\2>9S"EQ_>X,54G.;P'OJ6Z(K0M=$PK/7_GCO-6!.L&,;S=Q
M7ZF_-"FB#4LTT:G>I_ZN!28F&_J2+[(ZL $=LNOCUK<]^9-7YAPV?()..WN0
MJ<_^,"W.^X<!V$?2+=![0U \!KH>P@#>\]-GO3),$1BRD/X2G9D%=_(UZ>>H
M_NOZL&]4V)^"T/]DEE<VY2A2ZA/*$'FC'HPAG E=_+R6%T^:N)TDH!GAJEY]
M]*V5E%^$K]"EL8>3V3="/DX?8;U-M5A);A163)EJ0PKC_K!>/./+_:ODLL"T
M]='*C5U(, -(0#* BC9FTH=2?.5(HYA?>NBO3,)\ ]N$"S$2VHOZQ)%;'(#F
MH!HOP\2,E[?Y/.8_)XW##5Z]G"@.7&DQ3SNFT)+TAK<7G4?Y7:SU10WAO\RY
M28+Z:";)&MJ(OR>DR_R0E?G4:/%M OFY@<9#S,NN4K]A%:SG#/&HJ9/I=/#_
M9K?)HWGI+0-(<W0U]A;Z9DT5WE?>N]GQDP@&W1E-_%%U8<UL-%MW80ZT#W;=
MB)'-V9VW)VR#_J/[SW$[)@R@R?;?[=C^\#(V%B6$<-Z+FD$';J= V'('>(()
M3$+YHT"</IGW<=+#*EC]0ZZ>W3DGNWN*W \?Q3][FA7?KSF8'H_FUT''HD1H
MK^F"",&-GE:_9NSB#\G11.5)G[;[<WN+^M\LJ_V>GVHX92[/[E%KGC3PG>TZ
ME" ?-EJWND^8V_M:'NTU0Y?!23UC -?&]F3'AT/@7L[?.K#S:(-?M3O^U-.K
M-.NE/_(,8%[UW^][-+9[B1-YEASY4*,,K"0?AQX*N.N;XN5E)5+BX06[-F9:
M76KR+?!+,X?9!4?>#Y\]9'%[/T!OTN_E;:)!#14*.I9X!.ZSU^27VEP+C+@S
M,80)&"=JR-U.'192JK$Q_LC,YZ<9P,.404CO'"W8;0TIC*W>OQ4E@?:QW:_$
M^L++VCHK.K!-Z>CL7Q#W_P01%L5US&6>#3" GV+,?+R&WN&$3M[$#8.X7<,E
MNL0N_>4V]3&3Y3Y!]T+0DPO,I"Q'J^M02(82E,-P-'8&\.TLC!H;8\Y#Q:4P
M@--[)G0N(3P:9!IQ.7_?*V5ONR&8?/D5/32[OJKDD0\#.$NQZSS/]$Q9I@,D
M!.+V3JW#]D\ZSS3^1"#]5$X625]6\)C(:\_/;(MN4]-LD?N$A(KW*O::WBB2
M>Z=:G/QY[Y_Y/3^3%('Z5EVR&F0QJG"DPV1#L,K'6-#FXA4Z$OXNJ;[WI Z3
MV%./0Q^B?VHR@*]?H%1/%%/B[@BJ.>T9!1UT!^>]E,X;F!CY+*VVN1$9Q@ .
M8F@FZ!T]!N#6^9LED9SL<CQ4<SCP<GRNTHOEY^EF$UBQ.^VY1=3>/O!+)D;@
M>HE3I9WCT0C_#F:)%(7^]U>2([VB,S'RB9E0LI@$CARQ+D=B(FJ2N;@B^M<K
M!O!@E%Z$^R/% *H],4[D"7J\ YJDC]XU7F8  <P)5#HZG+G49?CR0!'%C#ZZ
M:-0,9I%*&8!_T&-C];9GDM,$GLJH*Z5-N[W' E;C/V4'++A:&*:QWUTE>E)<
M_[["C8X/1LD@HO'HQ'8I?,OM0X(3?6?]$QJJ(2.-\'S(N/Z5X1/G#-S-UD<.
MU89J'''FOI@@;4Y51O]B$HYW2[0@*)Z)ME>A=#,&L.%LN#,J==S)T??)E5ON
M$ 1ZU_QR?JO,[5UJ39JD@WQ2YH-FI]SRG5]N$)J-,WF;N$2V)Z1E%/Z0A3+-
M'D,].%EEJ/E2 X.G<-9-%3>]:>8\>CU!W=?[4>V?9]G&=[XEZ7R'\4$TD7Z@
M/R%4?*0,R4.*F'F 1 PS#:+2Z_XMXZ>EW9E+;TY<]4QYZL:A,I3M+_C*3^J=
M'P?VGXCK=/,]-:B<D^N;\(W]:(O?.!K;C^WJZ6:=BKYGP4')I;6:SR*^U<]-
MWTEX/>>Z%LQ)=0(KR#A"03->9HG+4*T8X=V5F4-JCFU X BVP:V^>:%:?F\S
MX0G/II"S1[/S>^*_B#@<PO#3Q] -G ET-7">P)=/4NSB*:1>,$WIQQP2L[A
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M)?CY3"FJ+6/)%4ZLVH!DDXQ.;12<K=<KK<AN&NK[M8Q8RZRI -KKY<.!J/,
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MS:4,&NA'=\[N!IH&P=]-MN4:C%Y5;:'6MJR&;Z-?(5;UVJ@U:FN!1&^@Z?:
M#8%_:K\0+H;,AJ)J,>4@?J" _F<S4<.#>QAL.^8U;%57[5>'6THAB%5E8" -
MJ^&$W7EAE%:__VE'Z!YPO;B])R4BVS=#5G5-$0N+-) DPAH/)4?H@W>Q!Z!
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M^:\G,U@.WH_QQGFKJBTPGK0B&DD<S;!@J'7*>!/^ /G.AOWL62R_ K1O=E7
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M_1UGA\4@6TS?::#]9&2+(W+K3#\-Q$2N#Q(T8BU6FX5IAHX.JV8ZA>""+&9
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M@2CE!Z<=-C9\E<\W7DL+G5^YG9#Z.DX*XGB;[0>:!_%()55?A!I%$2/+>3(
M C68\JEZ&-^G?[:Z*6U1X]U1AF4PUT?\FU\>F$%['H."=Z<[_OM(7$?.[>-S
M>BQGR<LK-'7@#D'7&8C"B27U5$^H73G99T]IDI!H'WMVSB8P2@/6:YWQ(_%2
MR[,_6R1O(.83X(H3I3@#8P0^/#JI7<Y[(-NV0.FG/K^3P\PZZ3>>RMMWKO=)
M)?^[FN>[T7N7AD%L#?"?2#X]^^"2=73U=&?*PQT]7_QDYM!/I28$MT=Z6D-N
M$2*PXR&G2-_&ZJU"T48D($U+]\6.S&)ZV@6^-C9E3)@"Y3AS#G#=0NMPFE'8
M6-^GA8R9>\S24[^;R((P4X@$S):XA=W=B<6AN+R<E1P\?)66"5.I8?6DJ4T;
M,8_[>U,VKV04=^I,.8?MJ_O5!Q"=%]N/4P(!2RQ:" .S 1)PQG7-Q"DT"<&Y
M!1>OJ3%;W&VH*JM*D^[Y4?A&SE>6E[?L8B/H;]5_YX[6?W:T;N'1VY4$7U)2
M\WB@[\MFFT^2I85_BDRG#B2"MBS:ZLV"_GRM(%5+O8XH?RV- N'UIC^,714X
M2%&>N#;N$^# H_JMIL'T[/YG3["+W)VFF6S7J._2F9.Y7_\;C\C\[TJ,-:@$
M(V7ZQB!JG:8RRV'7Q^OD#BUXAD2-&]YO-=SWV:DV;QA*<:]+%R_:<2R4"6$3
M^=6R*&5>.Z:6YR38_6-/<6><';:1:S*3R/\T2.;-\G,SZ</S%?_WE<[_W&$[
M""'86O[1V.&C]2?Y4J5:JWZ@3QQ2GERD3/T*:D/Y9L>?UQ4X5!3?FJ.4D>8I
M(Z4EJ!X=A1WT).3O2X:Y@9!=5R#3T/^]F>;.JL#>"(57A6;1XD '?<6MT4&F
MVUN;7D!%]XE#SB<$RL)"U70=:F_R+X5;8:O1U+:N*6L'_8=5H <^!I5D,(@:
M3&J2I@+@IDB;$Y8>+C&6$V=X%Z&.0_+=K*TW3%F73.Z)G.',, 7E[FV@GZ!?
M@;E5:E.@I#?45-]6$>P5U[OU7R1E)F"N/A4(MY%G6^+@I]%R8^^-T[,X7XZ7
MU8 LSS6^JEE/5.C0EX;/0 5K4^=,[*EY[1RTP7%@CN'9"(?9J!(,6&1NHR3=
ML:9,SAZO^_)203RAJ!O:$%BW%DF3=PXY6IY"87U%85*$E;F1EQ2!4J]3-YXJ
M]58T7/SN$\B]OIIHP*=,N)S2K7(S,IPJL _M5P'DCN+AK+!+@ 41>A^P+,5L
MH/G4U@_%5K^T<IV/=2.95JWEOS:^B9/[^/B!QLHU2XDV<SQBA^T#3)( B8>%
MNG]*>3[24Z P%N"M6=-ZSZ(Y9?*9R3,PIX2U*9AYE_N%NQK3NK7M"!UT"O$$
MDM2,V &C:,-05K1;$\P['-O&VV\UN3O?E]WLI1CL0&)T2?M,7W<TXN0ZQ!TS
M5[^/&^FQ"%Y&]/+$_&WH_N>]NXA;,7>;"*1B!.N*;1AL^%M.T/1%WDR3MAN:
MH'*_:2T0Z:1"%]O.XO(N\%2 F@3N;$A2S+[,#KO[U&3VXV11W2OB 2$/_G=N
M("-[$2,6/GV'F(<KWI%91@I<_T@Y2V48.ZSFA&2O3(XMP\_\&K'8^Z6,+=S[
M?+?_9,G\7PE@VX-Y8AUUDII%!WFCP;11#!_%AS#1BZB9;.?79\D6LW"P3NJ]
MZ!4T!%_6KK&-4[<Z=W8!:U_/*_#%E!\3CVX(CFD_0YN%2U/3=F!BH4_F9"KH
MH%G:A>P5,1^;W[-*]W^/2\^QA\ G6]I=C\2*^9E^'_Q3 F7[#O:,6KC=?A+8
MPHY$*[<J*;]G#&>K78#64ZF6TTGGR7J9H14G\_%'(7/L6^]^HE^AQ2OUV2$Q
MO%O=U5X0PAM@WY+P ^[T+74;%2!SSC]+M^L/(CAYK>0]]UZBPIJY[[PE'M(S
M!(6V4-] 'GFCQ0#7[MR?PYG^.%TZ2/3^!GA.*&C[;F!UG-W"C[+EDO0Y&1=N
MGN.1^DD?&M&18/%6)?(URN5:( =KH7EW8MPA84>=2]:^;D]%;>N;M$=Q_=O+
M0<VF%<4L,9TL,4Z?_LO%7_^M@C$&R@4F&"B_]@_*YQDHWU78]"(P0AW=:9F
MEJ"=\(2? JRPR!TGX_G>V\X6OJ29!_,GYQT+(R9T+OSY:!#I/W*+*ZQ)XD:
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M,5&A#@@K@,#_:B,;VRUYR3H3!:/</T(-I-=];#C<@Y,_L'"*OQ63_LJ6S.0
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M^#T_T.]7@OTKBYX;L:\?76OJC8A$$RS17)O.DC]A8/SNG#>>+:DVPDLL!'6
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MML")# 78EHM[1V*>PR2!-?S9]S,AY38U$P<^Q@J']4T6U@/2M635>@1<.EG
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M2@5^BXYT0%BW&/P'G3/<V[\C2HK!SE<*#K"O&7A-'?%*OQJ.U10:X#S5P53
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MZM74Q-UF*2Y_F5:"A>B/#JYQXY(?QF;2&5=Y9E"D5*"2^ K?#SD)AX18&4_
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MVO:CC].&P.R'D"2:5EU;<^W$G/#[B8-O+ VVTZHWOG3Z\F8P!:?_-#9EELX
MG6]M]IU7P<=W)^U(V5(_0USG=X^'6-I-5E:P)01@A.>]P;/^"SK];//O$]4\
M3G]T,SJG5E;1P?>M"D-"$W@Z+9.0QU> *\21/B.#+T2;2O?B];EDVRV?Y[FE
MK\T\2>Y/:!0S8?E&W?HT Y;I:!B4:$+A5R Q PA_8E$O4ARF2DSMD)0(<>@1
MO+\6;VLV?:[:\^[E40MFX<_IP<FU,4HC++E_I+9&+(!T\D/8_7&(IX0[Z2F@
M0E8QQWM3V;JG[K<7P6#NWI\_7'\^7%+HGOS[3%\8N"N5"[XX-5W #)2&XC$Q
M]]&QK0PMV)WIK2]%L/E48G"AL4&P>J%;IFY2MRC[ LO-EHX!3<XVU56AYN(=
M@1)$YRV]B#+XCRG]$P7AR%AG<#8EY->O/993M0VL>N@:XYT6Z14-D "**$5Z
M#I0N[T:B:^-W9,E&0+?13ST?/,^+L(("19B2MV+8T_3BN8T&8ZVSJN#+-NY!
MP<',[T"@]]PH? Z%/[P;?:Q=F'(>0%7"9"=W#S )N0%A*7LSSL<S#:O)TK;^
MPP-2Y_WX[ZI>%'M^3O;5TB<BFA0SIL\3 NYNUZL9[VMRQUD*K#>KY\TNR7]>
M--[4DFKDB>,ND^:).HHW5,W],V@X=H ZM4#K:3[>5-P=[!:Q;&&\M#>.NT@<
MX@-,%8HN+)?>-6 K45^C@T[71=@N"^87P3O@VI/GW\)4B$F=<^@NJO'.H$81
M]FW@-X$S"W!*_?-,Y@!=SFN<_E?!)A0#ZA>:\@8=5 M'D[5A@M3L56+E;MR!
MN82E%=I7]/Y&R==%WQG&?*S$B'&?H"B\IR(17O,C29#3ZI@H.HA?GV<3PT,)
MQ5)UN&ZL=<_E4X32G3;V=<\YS3MVW+"0/)1;.%;9[XCO1NU /!U0@#Q;[QVR
MYM;2\:]-8!Z*-K5L27/<5WEL0E.,Q7 *QUNL6VV79GPI<93Z4MW'M0?*KW^1
M]A-<9Y*LV-_CR_H=\D+/X+/GU/'I6Z,!WAJ:+TD#O_?,!#I<_7Y]F]629QLP
M QT4DH-#=&EBL0B7?H(/;E F.1K,GY=.\E27VW%MC= [CVFOK_[XJ2&X;^EP
M$O88*"6;A<CVWO&$L"/<((#%0?]7,[>?=!!6NV8"UI34Z $K??VUJTR#%@_7
M%07X>M%\,+=B^.!]E7^6DFJ@/8.^HIX(09Y>!RK<E[-LH_K^B#:O [5H:.$,
M[8>'ZW='L$P8M\D<M"YU1[LB)+C#690@M(WW]RV#&0$5@O/8O]3URO<A/9E>
MX\GB!KX<H1_3@B]=[V199J*#JM$[P0Q2F1/#(5+:14-0I+"<KOB.C&[/<J_T
MD,]<MV91"VP:7H2^LD?7=-\I:'09UI\XED<X(OTF!/> YU5ZD-42J!A?I;QK
M=4@RI/?R0HQ/V>*\3+G3W+4\ QZ>N9S@'W!\ *X!)K2,CD-^@6SGP[*G>1<\
M"[A'?=4C@JU;$ ?Y]S?N%#<U9[TRMU"+2I7>&RB*9(6IEP!T4 ^&I?T410 @
MXA"S9-RM5)PO4P@->HIRG>C\%>O'^F*J>66XN7'_6D7_>9R,X<#E<XZX2(CE
M>LD27B/N]QA#ORWN)K@\) ]?!DGCD8[X7!SM-,4"R,>36^81+\$UJ2];.21J
M/:8FML*FLH(:GIBQWK9;'+:N8M+MBDF/#GW/#2554$M@1F3=37UVPG0,_-0@
M7LF['WXFTVR\=N;P6RVANH)'XU>&M5O?J5=^AU6(Z]0:FG2( RXX#BY!FT!4
M#Y<3_F+ZPMZ,4]1Q<A0+]W*[H9+7[N9F]SG5>,X8G\@Z^[+?Q01,![&>3\)Q
M8H00[B'M L[K4TMG(7S*D.IB(FM%C;TT<G9B7]YP?;MQY&3'FOBT9L1GVBA:
M .*K H)Q4.OU/+%V!R/<]HBNX&4'RV,>P8+UN;\K/:6N5X<J5\FDF3VI#NU2
MZZIN-\/S,Y$"IPH?NHQ5'AY<?/OQ!'OV[989.HA]Q&I;WL;MGN(/$+-TYG@[
M,^"#E0@G%0%H8A%.J!?!^(D)@#K_EJAYC_ Y538!=L>7,TPPWVVU7Z"MKG4,
M/;L8$SJD%F[_X_U:<D&.,S4?X;4K2NLJ$ <,4'20VU8N*JY=2JEGB6^2XMX&
MNX>=#_WE4>N=M"+L>4S-PYP37)VRO#+*-J?17)43X4XM<BMU&/(=V<6]M=?:
MVF=^I9 .B!!W.Y"ULK$H/8=E2)U,6W83XI.%Q-XYT\>UC>&AXO*ZL-C1+&V6
MZ!/,GV#=9&U/<,UB\0Y3*,$*Q[-M64D1G=8+7B:7V[<*2)-R] 6)UVLY4[3O
M>-WD7>A+&?2Q6FUBR>^P-:*#6/(!64)2)_0DY3H>PT[1&CM8? J5!')NY%C7
M?#5=\Y8+M,]6>+[L/F@@"FH[/K9Q%6QOK1$6&_<AY3PRG',S@S\H[FJG7:#5
MJQ=AML-HPET+5[MF KH;'/-U2R@W*)X(QOW*Q(X(.MDMU/*:%YO6F,N\3V?W
MH.SS]IF>R5)$]SKZ]B*BP2<A;M"Y_N4RVC"->8*BZ4YDLYJ$7<);<GI\^:,1
M-O5.4?KMXUS6/_=-131#&Y>,OK@8](+"Z* 7$$^D),6,6MAJ1BC"3G>:HF!*
MRT,N2K*]DJIM1!V'5MO*)SE<$FUO8N<"KV?+//:46GW%Q"SKS0#^CH [@;D'
MPE.[X]U5O>1)TR76H>,<K%YMGYFH>BJ57CF;5KI417R]V2@=.*S0"5DN -=H
M=H!986' +&[D!$5F+(!JWH414 Y <R_-WV?-M*SQT?A1>QJ,-7R4AJ?6.*<S
MPEN+(%F)1\P4]]U/C;,5G7ZQ'-,K*CUP><S1LT9F:57RL]9'*!29")H'QLB/
M *'EXATEPB#):[JV]'P[D"F#NUXB\\UZ(ME4+V7=0&7-[,TTRX-2O6FS4.+X
ME,J<5S_)ZRMA(4?(*D0>P>LEBIHS_/2.(R![M,_*4W%<.RTF/8HC<(=HV=>2
M /'V/09SH3;KBW63WK9+SH78;&&'1K7W\LP2KSPE/]59VQDY+=7J/%/5OHO_
M7(E3B<?4\>SL$,)6/VLL"7P9;>4J\>&<(LQY>@<K#F@+.Z08FUPQN.@_.LHV
M_[W$SCSD;T#PE[J>&Z*F@E>=F-9O'((FJG[O*"HM[?W=U'))=EO-ZBI+O6MY
MC.&HB]"/4Z,9O!Y,X?L[2"H'5#_U%L-,"=EO/WI/@4]]R)^_\W/W<>Z,!:GI
MZ&FS.5+]9]'S;[ .$(C)R09%A@ <I)Q_;F:$X*\#(T7ZG[!;X+@"T4GEU@O^
M"AS>Y1B=/P]#?YKN7SN[UJ5A71OU4D8(!+X.$P../(F(?L0I"H\/ME01BJ6#
M$OFNYZ[^?A%]F#LNEJI^]<X7EP<M9I!@[34!H1U6\K5US#$]2.%6L;'H"&GD
M52V*LU5C>B!NRF$^]H5I/]>1YM,+G?H?VHV -J)L+QUT$GX:/M.N2-!HTL\J
M@?1>4; 4;:OQR>@2:XF0G_+\&2\_R#]LQ&V]O.+2#)G7)>E0\Q@>=I<=)C6M
MSP4<'^FVG<*(ZLFX7AG._:6M_C)EC[?!';+Q]&0"2\;39P.F9U2/,9&H_V\_
M+P%C6"W6C]2<=AWX%*)Z*8:P1H(3("1:C1N>['3CUPCYUM2$6YD=YMJX;U.V
MFE9HD9B!TKZ[,$LJ2@&+ K28:3<QW5"2U1,ZZ&"Q9 IX\AO--?W*W5C>ZN.?
MC.":P[JWRWZWP#R)V&T+^8U&K:V!\:")QY,9Y+=_,'00MQ5C#G/IH+%:.FAU
M]0,=M.<&)JQ"@ LHJI@ES?F^"D.\V[Z\ S6@@_C.]C#^@<V$#I*E@U92UQ"'
MT%AT1@.-BW'Y<A OR'(2LOJHWW)6E>0P31.GC>JST3JF?&&(P%('>SK(<VYQ
MMRY<3#C;@C3^+4:%,\;S;+LCGH7O<!6F3@<=IX/HH.]Y0 YMP&>-EE>[2<YN
M1PCD3^-N7JO1&;N3#PW]%*YBOH@<$U<RXHG%;JO+GR@QUG <TO35>&U%3O\!
M<P6T"6OXM>XV(ZQ[+Y3;I,RC.4.N8/'CHX# !]\5G[Y0>RX%&M@T8.$4)1XR
M>NP7PNR08SG1K@@?A0JV(K [&K\5WNB=Q4.$/@WG*:9?#&D]>,6^TF3]X*/B
MN):,\;+W5+L.S >((.O %'[2+L%N3RY-FXR]Y]%,%WJKMJ?*\DHX$U@)=KON
M?-GN452&GJ4]M86F2E$>JZ#)T<;07Y_6+8_$-]B>Z@_&/2(Z514&%_6KODCT
MWA).4SN]FA-JDM;_[G0!-UM[N& LPYK P< ?%'PL6S,W8;KU^GO[#:%1,QVQ
M>]&SBWBY*&:V\\;?%0WP()OI7I[X.7 O.@Y^#K#">5:Y3L L"ITV=%YD/Y>_
MF>;81?AVYZT=V\DUEFBF/H,-.V@MI-^';YFM8\<=[]:7_??'_< *$\N)BF*F
M0X6$55.?]RD$8[=LNTEQ<-L[T4]D+?C8',_.6;*.!T,KGX\I''K(7?Q0KT'4
MHJ?S4TUCM-FYW,5Y9L5JXZUWG,OBG*-,G^&#&.Z#\I'8AOJYN HH5C!/*36.
M>:'OVMCW!XIV"_#=-5^Y1P*S^_[)?K?AH^AJDR[PG+LSP3(1?F[.^7,Q@2&S
M"-X%DI-JLQG:=^T6Q;M6TQL,=\3=)A]DBF+CY(^VOQ(W)TA(*K+U$G&SN_NN
M!P'([JVRNIF[?G.42:&_MO$>UY'J.^ZZ[Q1;:@7,[2/,LXE: '%'1QY)0H@V
M647=92')(SCV@'R(:730PV.#?N=,AQ3SA%^.:^@:^R<O,]<3=CLL60%7?'\"
MQ"-"?_^.3W"OCOJKMR6=BNL^&6)W?ZF*ON"L@/4MF)\*Z1 8@)E2$]H%8&9$
MRQX>@<60^)XP:S1?JZSO^Y ^C'%[HASJS(NTS(<?7&3W[)>5WH7>,AY]UK6V
M30>1+2R(OG9$V>[=EVA.=95C(8-=QTXP ,"SF>/GV$T*S<H5*P\O00?[<;#X
M-;*ZN9W-"AG)WT TQ/=!$^8L_M&BLPVD2U-ZO@32P&9(9>OM)<7ZB=^!+V('
MS-5C7Z?7.)ID/8@M4#TK?*< Q#;J_'^H@'G:A.$A_P+AV-V9I7G2 ."&'40*
M>&I."]J0PLR:'2Y0_NSRCA6^KFY,-/WD4L4N)??,+\8>?H[:V*X$$W% \,$G
MZ:"O2PW+*+;O@0)M1\D!& &[+8TY!U,LKWG)\KSB[=]G1 R_B(ALRAW[^T]5
M*T6S-"3\'@&1BO9$)4LJCQV6^.#0XZU6N/6G[P,2?W-4L)(O]NV#4EYJ7_I^
MCM@B-0U7@JD0D'WH.%$ZJ LB<;^U&?+RX.T!U>#A@VKV5<-/:6F&S6O/Z[F%
MF><:V_X'ZKI F^U@0&<"NQ:E!@5Y_JW<.6R/_^0P8Q!>>@/EIV,DVH=2D"]Q
M/VO@PG_,3$L =9V?J8=B]4\E?5*[&L'D5:ME:$EOZ+)$Z*&/@&+QM5=F<T(O
M$F*D!"VJ0NX6:ZW5J>)&MLG+J<F2EP@F/5QA^W>^3L&84/E6!I-JI>/:EXG"
MG^O3FC76SQL*7A>SBW6\V!LJ&4_VH8TB3K<^Q.=S+*=NVVHF'.PRATR1NS5S
MRRE&U5\UA6PZ11)[]1Y$VIA^6TG-$UF>_@3_@:ZM3R*;AOC;-4IR_]2[A./A
MV+KK*:E J&]8S<N_3!2 /EV?S;";=;*7MJJ+PA>"F)'$W6W=910_S'0*?@'@
MP3$B&!S?C$S(A@ WI B2:($*T=:7A8*>KKDG#&^>8MUWV<.(_QY1][]/C=<'
M>4%9 WBBFC722SW"$+'J3"6 N^WHH>>#R8-Y2HOZ2K"]\H1VAN$V.697-PHO
M6>-38N=LKB@8/#I T/\^KFTD/#\6N1Z1(K/TJ=C.C%]SFF"XW_Y-T-[PK=B8
M@1[RX55)*T(+28^ [-Y-"$(+PQR(5OV2^D3EO&(+UP]>!5H_L4BR\HG$/UU+
M"B%G$T0M7HH:QGZ[K>EZK@HF0\V":1(L<1H->%\0Y08Q0-2FK<S9RQ;.GDM;
MLI!4F"_FM= S?;"/5URN']/H</K22FPB%N&GH^ L1MBF5A]2/4,L%_?.(>(#
M5FNNN3389@CC0C5U=EZ>,K_XG?G]%86:1+OB9 O.Q/5N^8'G[']'V62(@\O!
MW9@Y*>P0IAN<$!:P[WETN5=/=7:A5DC#]I)6R-,'6?H>GTR8LN)'5WAYI C%
M)&U"<'?JRRF,$.P>$=*W!"%JY!>;/?S@1=.;.M?L([]T,[3<5_Q4MZA:E+7>
M)\[DXQRN9_ZVK5+CWB4I%X9SGOQ]6M3S6)SKF'%8YH9C\,Y9XN!5:BZ-#4C"
M(Q("6O+(3L>^W5!48N=UNO'[ZW7>S*Z<]+%@R;R:X4M7^6"* 'B9T4/],\2<
M!#V58(1,_RN]FW._OS342%4$*['<%G@I?\%Z_N0S<_',D8>3WCK&^3BN<[L&
M4THVX>9;GDJ_W_OUI#=GN>GW\"J\ S1QB*0")4*F%UI4G]\.T+0EW[$[2('T
M=-L8<?<HG'UCP,[5V/SZY-79M![UA[ 3U \5[6K ($XE\JF>@G)*&4R7&.XQ
MG;WOE #_R6PD/G44<[)%T/JYH3C>\T\*Z#I9F_8=RHY^#(DT(VL")^=(^]V-
M+4(F]ODR!;L[BGV6ZNFG'59]8D[JW[OS742!K$O[#F&C@QXC9VF0V?+.("&&
MEPAREED)V^_7:RA__GN\HO>.0*?M;$K1RFWN4%DP29=:2Y.DS6"X6TV(LETV
M7)_M ?^>HUR+@44GA=U7 F:\6V>X2J5O55W1%M$:"H34I/:+(>;8EC7C:;J#
MV%(U#LM3]E=VVK)61X,2YW_X\2>3K6'$,K-D/[2(UG?0/I(#T:E%XPT)<^*[
M_K-=#F9$9'L!4RVY'HK%Q"^=)9YS])CB-9ROG#P3^SA7ZQ:GWY#BRQ83%B;G
MH@\P'@(\BCCH3'W_I&IWN &G='+0K#W.+&U>41"ET'?'\#CWS9$,NYBH2-W#
MJ2/!HV<R0Q4;BL_E/%928A281Z-U$O<Q<TA2W#CB,3BJ0 J8B"BD@YZ _U=O
M7_X.9?OW/R)C"2%$&+*694HD8H9;MF2O)-FR[]P2U9BQ9"<W;B;$V%66R9XE
M8Y>4R;YFS"")R4QI7#6+[_3\ =_C.9[C>3['=5R_7M?[N*[S?+]>K_-\O=^G
MX)))A'*VP-=!]3&EH?"$DW4AH+%G9,/S1L>766,8<-$XR28'&X"^W8NANMCK
MEJI/MYW)K_"].+DLEG&WSJS[M(.@%?>O1,'S_:/_Y67R1*[*LL?1WKKM$%YL
ME"AP=]">\DQ6D:IX8;1J+, @TJSIY7(9XE?0*4O-7XCF=\V:-/Q')_3<[7O<
M.W8]Z3S_QGD7&;WDO21=JC\/IA#6/V&&W)^XB\!X^XDO-'R Z(MYTDL9KF"7
MO0[GC+(;%Q-E^^X_RROMN5<F9/P_Z83\_^V2G(Q;6Q/Z=0$E@%JT;CD$3=^O
M=/][_AV*<DMHL67=B6Q)U_Z"$F)Q 5!ZM%,+]4-[>60 LS(DJ'E1?<_+CQ"A
M&!C^?>2<(#)X'92SY?NQY%I7O4?CTF)HS"_FV?SF0$JM^,9ZQ54R(WOHH=HV
M!HC$,4Z$L;+F#T&:9(5#4.Z70U#*93:BF1V"OGQ"??\V!?^EB;O$FG@/WWI_
M"*)(L,S7X0N+HTQ.-C#W*;',5PB4L$,0HQ"7AMJM645M=]M@.X/8LH#]K-U%
M:AW-A5D4A?^S0]0CP4RJ6XWYO&77WLJ:;.\B!-/NV]?M=>2:2L94G52!:T8D
M\/YNQEF\*]=_$*7ZP;FZ!>[[]LSURCR[)(LV)1G'FT$;B$ZV_'$Z!)D"T91B
MU]E;T)1]7#9+O(OJG2M]I2B\Z(9OGD'P#RGUK:4WIVC,&<2%:M807#RTQU71
MRAL)"6R":,=).;7ER-MC2%JMGJBETV_X2>:#V9P,-XKR"PJ>Y)1,;HOEO]T:
M%&)ET^7@X(\W-#YJ(7?.PT0-9,S%Z2[#<&<^Z3W-T 3*B57%@X03K,L,Y5=-
MEB$(7M1ZG1-K?);X5*?;6FS0"*K!]>@O=:R\66;!2A7?OI!'PW^J:@&&^3^V
M9,893+/^T%#578"MU3S.H/9?/JREAM&BBDE8L@ 6X<[,A0<Y422&2A1L6J<,
M(GU":I:_MD?;)UVX7;U9516<-Q[9;A3YBJ*?!XX_!*T]A4D" 40KZ!$&C-G4
M:^B_=+%$^,G@M>F>:"Z[Y?*[P_8WI_FT+!E![0"&+HR  6GK_/"T)<@05B;F
MPC EP&Z[8U6#XM;;WE'4T&JR8=6OZ&#RM_'8,6J!Y%H<""0+K6/<8S9\NX?+
MQ#7ICI+5!M$L_<0UY N2+7=,;3^OMMW7FWCIN=3F07D-@;YGC4<8M6#..)=E
M^!I&JC:I+6PAB*BQE;B95(\FLM#\)RT&\#+-YOK/4,<+O058'W6J*?RT:T T
M';[3A7^B;F!*LCT1@QTZ<^(V/M/ KX[9;=^9;/ K',R7=N*JI;R"Z9UUN36O
MM%G46C&.+VNDJ38&O"XTA#\:XS<DD;NR P-34M(+YBU?/[#Q6S[UUW>7^L++
M!;P*#KP@CF$0H@3+\8"=Z!8 '*E$+I'X*9I66<HFK%#)][8U':G!.<=BVR5%
M[GBM]FXR.W[BN(%'M,L YB7"*)>C*OO(UXB5^@T.!<M@ZNA)/+4U,_W-@=9Z
M4=BP^\+6&GX8NM@%672X;+4G %R=#$;;I@Q*\'+-)<S=*X)J;%AR1X_P7SCR
MWE)QX_/K92B@S'[I)UNWZ2A4)D22=09AV3H5YO!]W(AZ",I<^F$MP?-W[IN>
MB)'<?(,X.KK1F"L=M(948@C-&[ '"Q>:DEQ->F.V94'%#\*3E_S2>^#U7(<@
MRVD=5UU;YQGI@[-9_(F8'EM%OI^V@$I'@O<4&S_?2)#V4MO@9*@8PJ$M<02F
M,;MDV! 1%<L5J7A5Z_XPE[*J@G'?K=><RF]<2/#X>V'I<"&=/;;2+2(9PH=N
M:\P5QBI5)N5[ODZJ^#LIGJ.]LU\N+J)_^QK@2CDP 2PI^$$<'^*\SONBL&1M
M-6L5V]SOI@]*^?T=3HXWOTS8M/..X]#KDU'EU/V_*H%HM#>"@%GO7]!#C$GP
MI0N.S*<Z[LD8CP[@!TE7/RSSGLNO;]_""O@=V_5"OE5D*?A\_S?4P214\1\C
MZ6)@?-CM%%N3N>^PA7=M'./1"U?@Q[I3YJ[H:-'7H]/54YI^/>D#I(GCO/2S
M?S6U=5D,O?IA,*%5CMP$H!2A?M211H17U-KR!S-?*BXKS,"^[A#D;_-$X4VG
M1:YI1J#F0EQ2>&V$I)[7<@G[/]S%Q[?#C@%IE&F[J3T=Z#&$]7RH3BQJ</Z
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MKB!T,FG5YXGO#;LIT\V6$*[<!V5"A3"=&#C-%?A%UT9.L+0I>X^A;3NW>K6
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M"I_2.Z9_6IM8&9+';4:0]+][M^R%$O@2*0ZF!8Q68P"5;RU4B36G>,H_B&L
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M9T!HK3R9A2[L.-7[L49F^>&/CC9$YXMA9A95A63.$(TW<QS!M,)RZFXO8;D
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MCG7,?Z1B</[CC!T8S3C)S.^!4B)''!!7BDGP3(0KUI+X=E]GSL"O;O1!>$%
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MC >BEOYERDE)K.A8Z5C3!?ES%Z;S-"$*08BS).C@+C:/7$8J^E 4!Q560X(
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ML<@S\.C7)7PC]-H"G!]0>QP@OEC9!^4<E+>4D'$=\YW.B/QX]L7'LW_KH'S
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MZ:!L;T\P67US^5#-^]<SP/6_O4>]ID,'90PB29BOM!(\\D#Z2='^+TBZM9'
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MY0"$$^8ZU+D[L*A"F'68U7$NY:@I..G^9"?TD6V&;^4]7SM0->HS/PA$T),
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MU:@&\U.1+%7OU,JIN4_E,YR_U8K_X/GXME4JT9Q7;M=[QV7]3F/!S2GJR8
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M613!\C/P%QCM^4_=N&9*XUO*2.%F'.K,O)M0TX7(,U8MG\[/6X63&+@GJ*D
MS#K:19;1&G&;"=(N0()?U<@>Q0@9#TL40/TE!B@F0WJPQV\$-M;<A#?9#\D=
MIJ:>?R,&][WL[Z[1^SY4DC2P8_E_F;V<[].3KLE3.UFL<L'6XR&G<!IKT8>^
M*P*F+; (V"D-A45>KRRR9(NI>7*5 1K^X6["K/V)!K?#5Y-/^C_(SDS*4]3]
MK)!)P(TE41)(W@'0)K=#_E_J% ?4U&=+;?X:H-WV9LO6WNTXJ[LW4+W^M/K2
MB_>5J>P'%K1CL@3O+N?GUYX8+/K48FYLK/M$S]O;>W$GA;4)$P;F\&>'S[?
M#C&$X:D\@V/"I_#?5?*'8^1M9](0";I&5]K5W T1242'9C=>:A=-FQR,+BLP
M;693N>G9K7,G#MY[\: XXTD1LO# ,41]VXWF]Z44#O6\G/;*Q+)EK.O(Y*0V
MZBYV.5;&NR.EO[IL=QR^G=2/O$W%**%[6WS\A9>ZB3&>E!BBR;"8RO.DTS_\
M^ZJ[\)%*KMU0LM*T4@L^0B5?9:V5/510B*P_6V-M5=;[2B$$*\BQ:'PT?US;
MI[Z^^\D=H[M(E63[=UA.V^7">-L=62%$\K67[^96Q+P*E_%>5;@+P.3;''\?
M*LZRI<0X>![P0 HPB\N.0Y -YY'137(P[?AMAN$*,'-?^W)_+M:7+%&GPU$S
MN:U OAAE/&0,36&W13Y"-A?!T8?%W]<Y[CSZ0]\CRV]<I963@J)Q8QE&IW)1
M7[& D>\?L.&2N\(O<#.Q#:B?^8@A,0W;EBS";U)0;PVU.#>"N_;[.BS#=\]]
M]>^SEOHXQ#B#6!QILCZ*;C77>)X-:Q>!)RUU;B<\*"Z].XW"JVC)N3T2#I>9
M4^>@IOBY U%5%$9Y54RN2\FER9):(X@XUEZR<%,Y0Y'4/9=<\6-ARHKEP,>/
M>^8L7GG?X%HX>+"-/1;+_<I=@92@95YJGR92ZI(Y8J&8. >_/F%.4>_A;[I/
M3NB6,)Z:Y]K451K0RQB8A9J938ZHA;6!BS,7D3:D^49\ /B$/$20G<?YW$!3
MM!,WFT#S$[]W]?=K*A*,]$Q->*0Z9XN1BUWOII^T@(M[E[?@68BPOTC@E:RT
M)4$I4BM&?6@RR8^P+;\B9W3A:#=;4)I4LZ5NDX\S66O>A>^0U)X=TP9_-JH8
M*9CRC<I-?M(".^JJP>4LJ#A$NV9#A+!..-\^X2QX66K9\VY+WZ6Q-G?ISN,B
MHIH5,I@SA>P$F?1I7"A#@3R_S 3M7O/OUN EM3U34R6HN_II"I'4R\(9!^.&
M^YVD'?0V0UQ%WGP3N8!1,6-K2WQ2K? #,_YV,>KVR[&70AGC%*?.K9CPV )1
MQ4JNU^Y&<[A+KN([L&7^_9<_&9QXDJ-T.G.%WV;WDX',5E@ <G7U?1):NM+<
MR*%=D)V4BIO&<RWX'R!E/J\>4BC0/B*@.'271:&Y7\K]G=CSN'N7$'-U+TKH
M+_VYJ7EMW$P0J.XT8]C<'T?6@T;.<C>%$,RF^C>/=-IZI_8,&#I!D\379^[(
M[G-O[P#Y:VKPL#?"0I5X!8.)<%2P^;=$5,C:9&=3?-'"X]*GF1W*VD$3 40G
MEM>9IF(B1^WK8DCH)O!)@#YJ3,>W[J #R_1]I^UZ$N1Y96(^W-55CP\(;);F
MF[#J>I:_1;Q\6K3JY.N8*FV9?3;?>B[&WHMN'"G33@PW"IN+]JH9-_@2UF\R
M"X?_4$YO_/S(PWZ\Y?Z:OG*E?J7,W3)?S7/8R](V_K9;L[-&#I\]#+7\#OVX
M_W._!U@E[E_I&NYHWF\B<W92A@GZ+ G>V05WZ"PRV( /%K([F[(]8J,;AEJH
M2^#!M/^=_29@03"2-6[[N@%@^D%=_#_:KY[ ?Q.XB]8G4)^-_\WBK"# )C\+
M ^?"WJ'3R@&8UP=W:O[!!.NJVZ^(,LW^&^9*;CL-#&L<P01A2VBC]+P&V+KN
M/=32($0$,('LVR#\R0(A_E=( =R;*@NC98@!HQ?! #M]^K#3IA0=5M1GR0#
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MV=VQPMH=$J21_.5 !">:"3HD@V6"K@:NT3=*48UZ>4S0ES1?)LA/&O30\"[
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M0_6,JW1%7E%J5T_+1(C(3/33?D,M7[%7/]FY_QS $?Z%A-2! 40_!3</1-,
M)G@S -\THB2A!LW!*)X[S029*\_5M?]3MQE#>1J\+5&$VZ2@DB!E"$F&KA3[
M3WKQ=XW#@&SK_G^J-YB]&?L;,?FS0\HJZ?,:;NH=;_(6UTF+BZ36MVHYUWMW
MTGLYR2THVT?>M.A/LCN;[)_!+99P)DC42Y51U_OC<"5A5.%TC::-##K+KWC%
M[:QB>:IF?&\,8BR)53;F>46=^YU%"[ZE"9D= >C-FKC)N4GCN$GBH<-J!ED2
M'4VQ0L\T^0,DO\]@N=")8:4QD+\4#I"@*^BI;D@+Y)"&***-8-H"YJ+=(TL-
M\YH4\B(^D/?M6*=6/$5ZORY]/':EPU#XDG:+=\W#O<_@'64)&GL0K(Q#XR13
M0VI>)GQGI1R+122NPUBI;G?1^A83!I*?5B87UQ?2DMQBG,MS>*7LDGI1"2#5
M;3\'QF$4N=J8JLL:E-9'4X5/WRYTYO;&'Y=&RMIPI4EYF\0-KYV]7L0B,"YE
M4&PE(^IIR_?<")I($Z5G;6*"!?=]HD*)O4&I7.21E[.#/9EN[Q#E8S.9$0M7
M(M1KADN:Y*46LPO3*,I:WS*>Z33<6Y?JC^7X4'#PCM&M</H\1ZY6IJK6.#X,
M+3?7M\0UA+O2ZK"M[]S=,.EY?KVR0W QQB,C.6?R!F/F3:6I3%&_KBJ=-0T1
M3( VN DB9(GZO2U0;@ND,C6'!+<D >1* 7RB:V0G^%FBF<Q#N[].[/]Q+W36
M]DS:]='TE';]^E7LKCI-A&I'PDVYK;"\6X2 U52G'7!40RGB0"/$.1Y:=@%F
M7E;0W3QR_.K^AD^.T:=?RX%^<)U_QM>L(#NN2NS))*-UJ/4>*+:K=>#^8^AT
MA('Z(3ZMLOY1$5VI_7EQ$T?R^U>E6K6=>,)6F_91HW;-%B=EJ6Z^I##"5B.8
M%:E!HF!]V>9?/42"7;S IG%GS4^X*TPTKY].MY=ZG2=U/W(%N$5WBBT[;ERH
MMOP6:4!V$K_S6'>WYEN'HFE8:6;>[%!GW.5)4^[SHQK&"AS3(N,I"EQ#F9T=
ML]Y.DHTJ,BX<3]D#Z]BI);MWJ(6=TVZMN%<%!":(A<H[8#!0YB8PT5S^Q<G+
M*RIW?-1,Y$:=)S[N16> J$S/.)['H5"8\I$Z<']7R[_?7X&*SW34N5E*EGTE
M5EM:?$^IY93B*?])I5A0$;^KM'7"/ZK;LAQ4[B;8,21L]PR2?T@><VBAL?>O
MTD_]FXCIERC^.DN5:)WYZ_Y.(H=Y>D62C_J48W:OMF0XURGC^NOVTR!!['R.
MO5DHA[HP^2_?)<91?ED\6=X!]RN"'6+XT(3O4]G3Z2&Q3]_ZFW)V'LP2-.86
M]4L9]]+_'ET<:EH=GQ19\"R.2_X\\?(;C/S,8'+R&ZL*$UVK%N?QZABO8G0N
M=57V!;X,T@@-4HG K8@2T"Q6U",-AM0GS=8\9$NESMFWKF+Q*Q24?46L*Y*L
M.!_N\OIZS<SQO\"D.S$$"S2ZCF=(3<[=5RT>=Q@IIY'Y)+?UY#K1YEX8_XC$
MH7&Y\8+JXIG7%CS*W>ZI>^F%,R3<\PW8/NHXQ8?Z9-J=@+Z <#,BF\0\=GV8
M[F-^^TA909>DY_&HB6;O(T+[7^UFN?ALM<B&3"I1>\FLQM1TLK"EGY[%<&%$
M"WW\G57WL[VYV8=?Y7(:<^PWOO4.!,JNGWU;=3G9^<9B"L0QVE6&M@[5$UG)
MQ"OFC/J.?9Z$*#0,=\P:*'I*^"J=>Q-;>7:XP@5F(6/%6XVLTKKWLQ[4UKG_
MU^1 NX0=[Z6>42S+!JAH V2C79JF_N1Q>O-.PH\']]&;Z9'P]35NU$PLFNZ'
MGA7>1!U@@F8*XNE/X^=/K1[^,_3^7*?4_T\"=?@U_9K4G4&H^WW1$B[ACC?A
M=,2[([\LW:V#5\ZD(^_1,1!']A-('U+;"H:41(@/IMT7>-^91AW7LV?T?ZHH
MCY0MO>B;@;\ *OQ^U?XB[Z<'H4U+'51<B[4X/89QTG\,?V*3"1IONMDW-5A6
M,8 G5+Q"PC/H608N7*JGH_7@NB(ZH8>,UE:D)6CYD\X576P@7['E%")DC*4-
MK12I]F17AR9+?4[071Z3UI@FS$6)^+HVI77J4W*BGNE/?=BS_\V,#>NXY QJ
M%&Q.Y9G&CM]NKE.GAY5*(C0$E)ZU9(5[JK/JP=7Y#$=:9ES@,^<&=1TBQU<T
M;*,"+DK=BX8O_1^M*O^I</VK'J3X(>__LE"ZO/,GVA  &$C42/[3^+1+P/C
M7>^XZ@G=Y=SXV7Q.#O3#_++&.'V8T3ZUMBWZ"/:S@@H)_33"N+'L_7-A!7
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M_8_;Z,!?K_Y7[,WSG_1%B#CD%VD$0,9^5$WJ+J4'ETILU+/7 '_\V<*U*HC
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MMC7'[2PVW81<MXL2_'/6;0$Z6WV^_GSD8Q;IAQ\ZL[]\G98MK3Y,UI<Z1*M
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M0#:YML)_-NS%(0$@$$XTV=@[/\## ";:\'":D9I8*>4!510D%2'M07?*+=0
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M07^AY\U/W7%[U,SW_O0%?3V;ZH]SY?[O4AC MZS";Z@A-+NV,:D*UPH&?6,
M_#50=C#"E"D/X9"5J6"%SPZVS;]L<%Q""X=^.PCM64OL'&B\C>_Z!IUF .1\
M$*W\#9J4>1(T_2_%?6=44\V_=1247J57!:1(>U2:M%"DB0**TB$B("4"*BU
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M3-Q^CBME9KV[DQ^LI77JT>!%MW(ODCP,VH]I%,/PP8/6QCC\NG@F=1G<U\9
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MPF;,)W4*G4/RDW]+.^)B](8GMI0,;10[*6BDSS[W#TP39PK!V)P>H%23$;R
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M_K@(>XU:1_6&(]AIH#ZCH76H'>'N>'H#I8.?7/L^D=RGLMQ._3ZZW-XP>'D
MKO/&U0UV^<B+6$?'L-]3-6ZSU,#TD=5:SJ57/0E7YP(\.NV.3HY:'FFM,]^X
M?/VR+[)>I9-><S,WS+G=>O$D=NTP2R=;83Q@/^^V!>IQN;4@&W77>]R&Z;MI
M]MOYG?P[-2VO/WLV=[18X#?D1]HT;88?=O-DF#&>O#  _Q*"JTW[N^. UP&8
M5N?Z M,6$_IJF<G**59UK6V$O1QOO:.ZRF5G2EG6\:-KF<Z]<6?N%7O?6WAP
MU[Z0.'4T02F#GR&=AULZ=SZ>).&L>Y')3M[Q >HI>MK,'G/X^]-*3X.$7-VT
M)"(CX]-Z4Z6]LL7N,NS00")D:X)<7Q6%Z3I0GECZ'MW_9])7F^^QZ6[ OIMF
MIKOH[=5G::/.#)L[DRU5ZYCT%09BSZIKX"HK.9 X3+T\%Z*ZR#F\%[X^Z=[0
M-'7L&]:]N"3C\2B.6<?):#0H]XKZ%$P10BFF@:#H% AO")H!,2&"ZOM[*9LN
M\(S*-Q[\1="XKLW?S*8Q6;:MK1-:47;IJN<STSK3>[]M"GNZ_$!_&-:P?^."
MXX2*KAGA5__%[5"[ML+9PD>Z-]L86UMR2O)UM6-S0KSD7@TQ)J_4YB-7GV&6
ML(3/^;7D\[+SVTA"@ZXUI>Q!SE-]Y%$9E;X@LLZ$/LJRNIC_Q^G_>4_0_U<A
M;]'Y^DO,1B]9F@;RBJ#W[T9$-2+UINL+A.JVT/R]*X'#^]!%&DC/6E-KA 9J
M>CS\P2K +02Z>/3;%;(/SM16_+-;TK5$@=- %4@RFEX#?)$>76[20#?1OZUI
MH!;P%1IH=1[[^Q^,('+!#4,#3;GE0$KY;D+XG]^C8M**I//R7JS,=79%2)9[
M_D8>V3E:LGSY\K$ZTHD&4FR/VCI!LB"+ 7*#8PEL:U@&LM4T7!+'H7F[>08.
MKO7=J.\)#R!E>C_]Q_FY: [,>?-NT#0K8)TB"4(&TD"+!6MD# BA#\M;TXA>
MI;B9VPYH#\6,OGY4"7$:NF!^+T:T8E;10[:;33#/1PXT-W/;GN>'Q&5?TN4=
M 4C+G1:\WJG!9VILJK$_UD1U3KJL& >W9;;^$E1H--L4?X%MOR(TI%9TCO)2
M%U*&6&C3Q%L22AVF'N#574_>.(,+R(R420RQA%$C%2M"I14^Q/U\VG699U'(
MOF'"0,($5[M &LC?Q]>M@1>=YNRFLDW'==DJ??+L;NFB_;(BDW"9XJ ;<:#4
M&$N&K'\X[E#HDNH^4I#L-DN6!/)6:].4.G0 T37\P2\BU&9&V0TJ^E%%FN?K
M_'()]S?AVZJ?,9=X<C;FZ"U)ZA+_I2-T<S//;)B>P#2/_(A5@.:Z'GHP<$G1
ME!CU3C][M7RB,8W)."9R1"B@O"N\1B7&K9^UP9 C]>[/Q_4'C/<7$1]+N['-
MJ@DTD$]M3$18@AH'9^!I""QR2.1\=>W"C45A.]PHS",>K%SF:*S8D*/O"!+X
MX?;#! 0SV\60)#\1YH[8)VD@#TA:F';HN]/1%;Y.&VVV[89J89='-P8GI=Z?
MDQ4Z;\A^29O!%;6;1]C"E?=R+6SU2;(B+L&RK69#,)P.2&]QY^M9INE[BP(*
M#_#?I-YG?^))$",/6ZWG'_C),WS$W$/1!PS=8-^SA$E 7)IIW%EJ1PEL_WE[
MXXUNFE#RWD^+]5NN?'NLJYI"HP^MG3;<B<:D$#@7H-'J3M*#D;I7E GI#54N
M?A&(%P"=2]Y,)AEGA:F>[[#7^*&YJ-R7ZVE_QY.CY1&#W/<V>88AL"=Z 3,H
M><H;0/>C4Q#_3!UBQ.$F<]FW ;W1E/L$!^?PF\QWFYK-SG]^5#QXK%-P17TW
M^*8!?TB[L+J>R/Z-N!DWW*QY9D&Q4ME)I#9@_0121R#D[?*\00R"A??>J9^C
MAYVFV;1J%]\'>+:D(MLN:2E%KZM/8FYS#W/=A2[[%',]EZ.@D#ZNQJN:O18!
MU//$<'U5LNB'^^,=AC)!7WW;7DK8+NIU?KR0%5<T-\)[*69XVUS9+8Y0T(MN
M%J@#9(B_CIX"<W%JA;)CU[(F^WH0#+Y[U7O>F<\*1@JJ/GADOC#"FT_PF^(L
M-8UW&FV8AC&\2&_D4A].M;<S\"@8:$G2YR&.&<[X[SVH)H?@JD3+9E9;"AZ>
MT4O]1]2[-<EY(SCW_-?$)5/."*Y$<#UJ ,/JAS[5 27I01=/5U:1I0C+<PF+
M8X/'>0+CV[.V"TO.+YPB86]@WVS]4-3JV,"[YKBNY)(GBC\XJO2S_?X<: !8
MT6#-ND7S,=Z1QD#FSWSU\:,LH,S4Z,DN9P)FMXGD#6<C"'22-!"CU"O$*,$^
MBND?"EF]>@=WX$<5;N[,M?"*T8&5_K/\O,B1_?KDT"?1: ;^0R^^$[^HKTE\
M*$Y8V*KJDR[^[>:,[QBF#DL._,+TQB.]71:/1P&?V[DK<S8*/I_%NSDS/E3\
MSBI?S%5P2.>H02XSF-52IT!\DC\N4HA\F3.6;1LA>1^IO^,2L[(WNO*]YDL<
M[RQ^FG<I-G3K[ P-Y/XEX)C*>L6#Y+% +!H$<\C&BFY',%S^?2RRH3&G8>/J
MO_"^9-&E_J3S0_=Q@MDDGPW36)$RA8[5/MAXR4;[Y"Y]ZG ^*J;V'#'6R[-+
ME3"7KA* ]T@_&I5FU\R=6AQ0.%5R3D+60*C8_[=ND/;^+M,ZQ?;H+F#=MU0K
M\4,D =41"7#V#:PHS\G&.$<*?$BQ:?P A7&SB+NGL[GSN==;_'Y>LXYZ2Y]9
MBI37^J=@I>N:R5T"T"ZQ&27E$H)F?PJ2>]LW8D\D$H97>:4@,'/7<UD[0]2G
M6_> *;Z%4D0#^2&CL?SDD!KJ2/[QDRW"6+]_\,YB'"I-!) =/_25,J\)..OL
MZ=6>;JTL<U''R%B%X8E%;2F]N;.4)+ W2@CQ&7(Z "%,7!^8_8,_*%*<:0+C
MG1\:?DC?WK/(W#AU6^FU@R"K1KR,@O3I3L3_>LKP_U9AH"W\'U!+ P04
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M%^K\<+LQ\"ZOV;*L5]5V/1J)(Y]F##LT2# A"</42T*<4,>)O=#E+O=AQQ_
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M$]N2@8'N?,-P@C'?%"Y!=N@ 0.KY W;A@1FB762^T*$.;J_LS9Y+H"^L)?=
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M3,4;*6@+3X/FQ 9DBRQ:TS5*V>C@I_=YMXP*S.X8 0+^W@-$M/3QUZ$XJR<
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M7^7?ZK8@[J.@]:H2X$Y$FLM-K%4C7M]S_4M?\M?SI.\:ZT)UVD6> "68:D(
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MD<41BQSL!7&(24 R3!W.,(LR$L99Q(+4U2Z2.$EN8H55Y)W_"W4<H)8%)'E
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MKN>[:2(]?>G80T]\':0$>5&-#G;U4SP:^AW]E'8T?S9K270,*\'#B 9NC$7
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MD>3;M*_@A\[C;CJ$^#X33(0I9IGCJ9XND1IFP+#(&(]\GF8T!74,,&%B\@3
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MIL*_=+&-W[-W++Y4Y8VHOHBJOYIDZ$B\>&WFE:JH09TC\.7CM;EG\%*RTY[
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M]>,H925/&<)IIE0(1QBB-(\A3E/EK,<196',TS PLG6M*<^L4\:L#"W!-#=
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M#QD4:8 APG$(\RR)89@':C6& >.1>9[]&8S,O%0'#D MF%"F6J/W,U9!J5@
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MKX3::=^3YGOO'^(XCFG*$8Q(E$#$4: V/\8@X[ED,8[3%)E[^:949UZM(S9
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M#RTPTU#$&<H8S$/&E+-#):1)+F >8YDH2"+,C"KFVQ*>63,,G'2GN25<]<R
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MLHFPVC$&]IRU*^BXF(JP<VKGN/Q99LK-G$TT26.C,"9!;YI(C+"L_LQHC$E
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MN=K^75/6OU]D24Z9XA2F4A&(,HDAQ3R#&5$YC0E*:>1T*.E(?V*E[[@!9LZ
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MS62[1??-!_U@(. ,;,P7,S@?I@?AA3.2]0RP,#50OZBZ*L;'7=$*F41(X51
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MR.),P0SEIIQEQ N2.W6CJ8=U4A'W),#[NMH)K4DYQD<W4MNM*.ZRN&G$[;
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M9D'9S8),!G"(?A=NX$S7 L.2CY_=%<,-+HM&&8X#>ER7?=4?8^/TO*_6791
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M2_(_J6"6&SB7RV8YCC,V.>5S?6%(E[>/IJ')(F$BB6/M,Z2)2+1)*01DQIG
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MC%H;&Z=VYLBT31NRRK1;-ZDW]Z9!R\?5NGSD:_6UN-%_,,/:FH:T3*1AEI,
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MLUP_?"B+0M4-.]5]S1^WV<89S]-02(5C2@6F<:RPWGMD.)0DBE(B:203:Y?
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M&Q<7%#S9&1#I64V."RAOK8_3&N?F/VY*EKX6VU\V].]8)F*:1A%F7,:8%HG
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M]J&QBK(X33(>A,R^#&B<WL06H&4 ;3E &Q90PP,HJ< 6PV$C, $R,!OP/J
MLES]@N.6NGHV2+"<5'N1!Q--+9:9+WO47J:]E%# ;>?TE3_2Z^Q.L#BA<1)B
M4DB]BU AP[DR@84DC<*(!VF@@,,<3]*"O,%.O5%NJS5?N#2;/P:,9?S/A[#
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MDNEM>9AI!R.06(0%3542B#P#=;,$TI_!U=_PT&Q!^^.[A@W@<#@@M':69T+
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MR$UL#+;TT9:!;JPDI QO'#:+:)E7,&#*/XB#2Z!L'!! G,PK,&YALAV 5@<
M_>0I1F8MYV"(;'R5^2)DUA+M!<CL[W+-FC)-SC>]T#^;IZ)?AB8XE)%(AD6J
M=_59I-V=0 C,@YAA'FG_AQ*F6&QU[FY!:_(,J:91_[:5?T_;J7G<$&9VOHTG
M)(!;D-U!!ATB/>4+]#-?-*63OOO(68CJ+6/G-*69\W1&13[,SAF_Q67.FWI1
MRV>U,CQR[29=?0B#G<8$?5KS+<\7:MM[*(@5#8LXT1";CI%!R'!>! 66:49"
M1E/MZ-CGVSBQ,+$YZ'EJVS48KK!A:[=G@TO*MQO:%M[0Y!C"# D$/O1[PQ6R
M:?WD"U'(X+FID76<1N?C!04.ISL'B>&)=4XKSSC&[AS)]V?;G;62DWTW8WS-
M<ET@K-M0%(F,"A$P'">AWI@F!<6<F'9;>9'G82JSG&4 "WZ4R.0VNJ>*.K(@
MNW$<%RM;>[:T4&OZ5E"G:9PG) ;9PK,E=[5VUH\::M,&)1JQ6L?OG=,N#7+_
MQO(,7^M@6_[C\O/WKQ_^T;U'K"@"(?,(*RD8IB(3F.5%B&4>AF% 5%$H9FU1
M]I:>V(YTM "JM"^XA<EP%@=F*#HR+M9A7R2 37 6S<T2C#TLF/H?97Y0Z??O
MF$_5CW*ZI^#'KW!,X>!EW43'?VVJ@E4[E:#_Y=]*[;#4XN&U.T8E@B:IB!2F
M<9QARCC!C!"!DUPRR7@N+;OW.5&?.NE#DVW/<M"&<%//].7R[XYGT#!P[<)%
MDT$&,T#GH05/'7&1VE=."8CVO,DF+K <9*$X+>*R0ZG$@_JEKIZ??E%+342)
MA_[P+ UH1HL,AZ'IV"%)BAGC"HLLH"&/5<BD_6CNDV2F/C3KJ4%<]9.0V&Q/
M? @*W* 8DJBAB39$44O5B]B0/8H/\1UW*0T,]_LP^#KN&I5K>*]R\NX9=RMC
M$NSO5T:O=G-MNE.,[P]*;8+H?5X<Y7E,0XES9G)4"5-Z!Q,H'(24)(H%09SD
M$#_F-*F);4Y_4M-0WCG)<G)7!@"S\TW\P'#&2=:G<JD9*$V#CFK5=)<Z=JKE
MW3L9E]N3*S) :%:_8US@MTZ&Q1W.A]9-U[L/JOW?Z^7U\D6_#E5=*C-3.TBC
M,):8%8$YM@YBS/,HUHY%&$G!4R(XAW4!&Z1G]9J?TQ"LIP7,1A\&R4ZYSQ?<
ML<M$U]7PAY[PCV;<Z YMK^?3XR+Z.Z$>H#7W&?6XV$=.J2UN<IDFH)9E57^I
MUFKUJ7Q1-U6Y7-_^476UM!^>U>T?^G]?/U6U_H^^H',<\UQ%@J4FP3TJ,*5A
MA',2,IS%64#B6%(""$JZ\3#QMS[^2=_^/U#+&VJ80_+9Q,F?U@U]1.(+% 8T
MAC3*=T/;8G<R/89 1V$7-T,0-2PUY?H=4TASA5JV4,-7>YU#D-415L@H@LGA
M=9Q*,!W,P"$%9P$T/*_ ;>D91Q><)?O^%(/SEG)I'J1I+=?:B?_TO'ZNU:_E
M0JW6U5+U,W.OJL?'LNE%>UO=/I2UO.&:]N734UW]63YJGVKQ>I=(F0>\D.9T
MBFB_KTAQ)E2 69QGB8HRDG-AWR;H?(8F_C1L.$1%PR)Z['G<].QNAB"T7)JV
MWFO#I_YC;5O8Z.W16'PZ9@8<]AW98MURAS;LH<U8[2V#Z+9"#8NHX1'M,3DS
M\I">/O,^ <?N/>>\]8CO,NLK=N<1M^%>/![HS-AUQQ\J^_UU/*[K.G!=+/AJ
M519EEZ2[Z9/^]7G]M;@4^KU^;F8IM,U.J\>G6CVHY4I_*=L\W[VIJY_+I;K6
MSKR9U)X'6::W,S+)3>6NS$P+G@ G"8MHI+(PLON 3<WHY)E?^VRC+=^H>FYB
M?CNLHZY+[R[S?7;[_MA@]+N1 #4B@,?%3_3([<(P?X4'"3PS>M=GZ##L?EJ
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M7P: !Q3V\@1\K.?P#;G\^]<O'_]75RT5<$(2JGV[.* <:V\NP;EDIIERIFA
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M-8,^_6#PZM)L6O(HY>KV_/HE=<E4WI0DDY0;YZ7;+DN,B(^*8# 8C(ARB(H
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M'.4$<FF=I4M<1+!(TQ2FF5R_4AHPDFO5U3>@Z7M5ZD(K4NFJNH)TPP<H!T9
ML^'$Q/+IP:FSNC@'R7#]Z/"Y$4!R +<L@)$'\,4C/B:VWSE.=M;=!5Z&MMI(
M\GEKK#?4@O;62+9=BVKVJETH[TY5.7UN7KZVTOYV%-?7]%_/92,_WBSB(B(L
MA"++F:IZSB#)BP"R,!5)@5",L59]'@U:WL-Z3_(OWU797FDH:?WX*!V.M6+C
M"N ^:P/\5%;]&<;Z;V;!OCD(]4)^CH QLXLC4?"UQZ&G>P5&RN[B?QKB.8H"
MSE%:-!:H(?)^1%#G%?/R&UTMA[O'+K7S5\V:3R??\_<Q=N3 7?DX9E$/J:J.
MRS6=E<RJYL3Q$1<K.C$KT+3JQ/R#E[;(^UC]D+Y&W;P,F81[NV <9ED:(@3S
M*!0P"5D,"QXR6&09(R*B"<J%V<&W+FGO!^$JVZ"NNF;P<G4I1V9L^^"= 5)O
M2?$!CJ'?/6D<N.'A:M/QWB N<T$[/#WAG3?#.T/VE5KAZ8%QNA&>YOMVAF2L
MMGM3*3+KMNO4OOWJ8Q3@.$X36.1%#I,HR2 .@QARDF,68(R3P*@%USPYS^YH
M7TBZ2QP$TA$MMQRH5A)<+OKM"UAOF@Z;&9(S0.J9#W?PF!F-28EMA<RV\;)7
M>Z$GK2,K<8;8HK9!3_!]BZ#YEF7)?EPVJOHC_]2YP]VEI@^-U E5G?M=_2AI
MW^>TB'&2I3"AB?0E>!! +!T(B%2G79J)@F.MRAT&-#U;A EAL*$,?N]I&R:?
MZ""H9P4<XV)F"BPA,2^KKR^DJW+Z&A27+:.O#\%!^7R#5QTDF\E?>/.#=U7Z
M5WV!6/;/Y]X$W5/.<I82#!-""4P0PY#$B?Q/$A8!(H2Q-+#HX*'-@)8N7-R_
M8VP\0<?&$^I(K>XRZ/&&%4.?01]C/</A%C('>6T##Z?:=O1L@8GWX2G[30<+
M'QEQLW1?+TM.!X[9S#FM 2ZI";AI_-55)_O"*_X'7JG^3_=AFJ>%NJ3,4!1)
M:T,$1"3"D#.&,Q:Q N6I>5W D_2\1\@[2D"^^FA3!? T3GH6PZ'T9G9BK :X
M;=TWU 4<$;F;0\2R(.!9.9T6!3Q-[14* YX5_7AQP/.O7;C=Z!LV7E=LTJYQ
M\&G83?5%;425P>GO1S?CKV_PNMPVO4T$)Z'<?\ 8APPF<9A#C'D.8Q*G-,HQ
M245H%N-TR9[W..@D >AX#]$N%:$K+8U;(*1HX(>2S7)[XV+&#/=!"\^"F253
M7':],*3Q.MY^%(R\@KZ@=\]>]]247] Q[.6VC@\D7>_*7+#V.MLWAZ">W.>Y
MI&%YY*0.2+_7*_G&^GT7*_U<MWQ[:#C)O!0D8R1-(2MP A,<(2@W@ARRD),X
M%U$8%D:EF[4I>W;6>MJ&YTO:J&D>,/G PLS@]63![W[.D$SE<W6(I$UWV5,D
M4S@.CI&,![!( GW'2;L],[C^@<N5.C60F_ZO>,6OI5>#'_@GW':UX^\1RV-$
M$P)95&2JY6(*$2?JSC$2!"<\HZC0S@4U(NW9/@S4P.- 3GED\EGY>_,_O"^7
MP"2[DR,F0%?292M%J7PSZ3>,[$-1-W"-=4M764S"O+7Q"ZV9N5%L3$ZDI).U
M@Y+B1?U;#_W(CC?<##)+O>%GEV#J%D>S5%,K*&8S3LU&7"[QU$K2G?Q3NQ'L
M?+K/O-V6Z;C/21*DF6 0417()R2%A.$(!CPAG J>TQ3=MW6+5WI^V\[H1K9W
M0T/[ZYY4Q<![]6G>E/4#KPRNLAY')Q8%PRP(81ZJ8HD2#5A00:'\,D.:H22)
M8Z/ HSTZYBN3?W3TO%=KF<V6#"7N3B&C$S6+W+FM1P5SY)KNCKVH^WE4K'T7
M\_A#EIO,9[+N3C';]S_&5*=[EA6!B'$.(Q:'<C^9Q[!@-($ISW 4QRQ*D=;E
MH3DBGA5P2Q)T-.TJ2A]%1W/?>*',9@IH+*[Y/G%&'E=;PF,DEMW]S0AYL-&;
M>_:" H;7E#;/?!IV&M(0[S/$**=%!#$M$$R"4$"$(P*S/*"4Y@FBH=$]E7ER
MGA6T(VY13? T/'IZZ4YH,PWM:_\-A*?!ZDVJL.,J?F=E=%F<[S2QY6ONG17\
M:"F]\V_9=.:2>\;JH926H0LG3W*'/E9/S^T]B4+!291(GS9,89(A 7$4$(A$
M1@J<Y2P76DUD=8@MF-E7*GHF_:G.P*01.W$HO)E>;PGWAU%78(K$1\=(F+3J
M<H>(9:^N"Y Q;-JE)^I\UZXS8RS8MDM/FMV^79KO6&X2\(JOO_#VN:G4B=CU
M:E7_H;HOK(=*3+'<)PA6J#QE)O<+:5Q %&(& R3B+"]"7$1&._4S]+RG"'6$
M#7<*9R#2W#2X$]QP_Z (@X%R=U"^I>VC"KJ>G*[V%6>H+;O%T!/]8+>A^=JE
MMQMU&G/ME\<JHA +=>:,2 "3L CE3ZK4+\$\SW*292BVO?%HSH[W[)]=XH#P
M]@_.*R!]2/#MYZ\_ \$E[G@%5$FL9W6+#+3X3]"H%G9*K_BFP=WXS[;W)RVF
M2M,*+02_H8F:W+/4[1*XT.U+>YB<W\BT8.65;FG:@W;ZYN8%8_IK:=IO+[=7
M%NXS%I <HQA&.9<&,\HCB,,HA5&8\R(G09R(S+ VN@4;W@UE1_!*'8,,7>.>
M>/.(JVZ#J&[DN^]\>H"TGKWSC9Z9G=/O@#J$E+9,O5(WU%/8+-@1]8"%OUQ7
MU%,@V71&/3F618AJN"@TWA-ZB]??/TC?\K\Y>^#C!=B[^HWB8),Z\ZZ[D_)9
MVM P_517[??U/6<LC4)$(2*JX15"ZI9(BJ5A(TG 49HPHI]CY(8GS]O$@_MI
M5+()A.03?%>,@H?)[?>VEHZB2@O?IA^Q_L96I5R3, 6/'<\&H2)'$Z<16UM^
M.LPLYL%=-\4A4"R"CL?I?3=P5X,WG2G=SD3/*_@\S,2G5YH)@]C>\C-B%P)<
M=F;,@H9N,9R-+3HBM5P(TBTV.Y%*QT.;5PJ[:]AU(U?/^DE]RN_DXJJS+AU_
MT_,2,Y("[[3#!"<DG+?REPMG9K#O&MQM""1!^<_]>8">K$85T$Z+9%7^[,AP
MB]4^.RW*M/#9S%/N[@:KRX@WHBO5J6Z699ADTL,C,!<"]]$_%,04TB!D84A#
M$H5:O3?T27I6NHZBH_O!>UCI;4?=(F"FF2=O"2L&5.1M9,'O3>'CXGJ\++Q'
M\-7O"Q\'0.?*\(DWS?1_W;3WG_ _Z^:MW&+*76BS[AH[Y4G(DBQD,,Q"N<DK
M2 )11E(8$I&E!0\C3+02D(X/[UFO1UI&C:Y. #&OR)>+9Z:TNI)IJ^:\ '-J
M*-^<J*#\;:M^)P9=1-7F!1K5ZLQ3EDMH67&ICPUG93N<!6<!Q33+ Q4<*6""
M0@&)4B-48!:%C&=A9E91XX"$[R52U:I5BT%'TG"9/,1#<UF\2$K#97!'0 \'
MX*>%<;7('1)8=E$[*>#!(G;Z29OV&+PJZT9=N5S'/\M]^+MG_H&3YADW+V$:
M!6DX?'-RAUZ$<M6"*,8()GDFE[)4_B>. E;DF*>49/K],?2(>M;*CO3_ 3TS
MH.,&L&<.1E9 F%X!Q8U)^P=-.#6BB!Y ,E/J'6!ZL*[ NV, V72HTT7*I%.&
M>\0L6V5H(^>J4X:9Y/.M,C3'6K!7AIETN\TR#-^UK4788FF6V=A7]YK*S^:Y
MZW/TCHN2EJH(81JD% D8YD4,$Q9)=P8+!$4@TB@)"(V%89WS\T07R.WI60!\
MX,&TO.!9V/1\';=0F)G)#0:;QM8_3<B#@;[3PH&ZPCJK&'B6X,*E G4!.*P1
MJ/VFC2_5JO2TAY)NRQ_?UDTKZE59W_,4Y0B%,10(AS A&86$A=( YTF1QRD6
MA=#:Q)REY-EKVI">E"<'3R-Q$P=@#BT=_\@1!H9.T4;\+5EPZUI\$Z?'$0R6
MGL[LU^"JA:^.C/,^S=P "SHR&G+L>B\Z+UR:PJS:E/!JW4W\VWK=JD(.JLW0
M&[SF[!:_**J3DZ>URJ6F?5Z-V#ZX/\KZS8MJ7[Z74!O%88BB)(()5A>X:(8A
M*F@.TT2D01C&$3*MA/@J<GAWK"8E$[O>8Y HWE2'L@US@/^I?N:JIF)-R\[9
M^*-LOTM?C'X?*_L<?UGE%C;U0X--DPI?YZ/1\P'_\A^"X4+3S5S'"1AXGI[_
M7@'%$R O0#&U4-[V*P#K/.%[21E>*5/\%:;I=(KY:S!CMR*^XTWY ZM4TB]<
M]2>09G*L8A3><R'D=CT2,$JY7+T*BB!*&(4LC(NHP%QZ]D8E/N:(>?;@MZ2O
M0#,2W]2$,UL09C'3L]NND# SKU,0-G0=5A4SD<Z1C9LEM:@ITA%ZWV)HO6.>
MO?9;\[YB'U2)VAOQ_E_MR_4?#5O_TE0M^UB]_=&PWYJ;YW;-NL*TWZH?ZY8-
M<6?-'#?;\3WK^&\<-Y!7#&R+/W?WP/K*J%W#QS7X15I=Y366E70FI)LJ?U3O
M@?8[;D'7[%FRWN**C<6@OW6[$-U^V!?!/V\[ED+>S*;X!=WAJ:H+^*Q2 JV)
M+I8X>"DLT_3"B\>R\V,^/C[)[T\Y4ZHUXTZ=@_7'BG$AC6O+5]+2LO=_#G?-
M?JEK]D>Y6MTS*E"280%#1"E,\IA C +I\0C&PS 7@8AC$S_G$F8\V\@M:WU[
MUDWUC;Y)@9DC=!'H>H[24E":&;U=%/=KF*ROP)8U^*OB#?RTX0Z,[#D\'7&!
MDB.'[")6%G787("V[] Y&=/. DZ.=<8K$I]YNW-UHJ^O.3@;14@1RY,,!DF<
M25.72J/'$(-!)N((XU3^WZAOI"%]SW9.L;#N+];QOGWJWLT[0U-GBJZ>=?.(
MF9E!FQ[>3JY;78'/JB33WH6LJZ%0JX>4-TM '-DN4^J+FBM+:/8ME.TP;BK'
MRE&&IJM1(%VNB'(H*)(^%PDH1"CD,*>H8 $7),+TDO*Q&TJ^CX;WBZHJRI;-
M:D^CI7D:X (#PXB]G?@75Y8]$,U3>=DMG5>M,7L@[KE"LX<O6+:$ZQR6SH?=
M]V>DV=BT#A-,)(2IRDY$=0]): B+(I'*+>(DCK(\9H09-:'6(NM9M3],'?@C
M3KXJ:*[1%^P27/7TWCU:9D; $5#F#=2,Y';5&DV/Z+)-SXR .&AG9O:V>3QZ
M$P?Z6*DS_N9%G6RMV^J.K#[4S?73BJQ^:\Q"T 9#>K82UP\/3=>_NH]R=E>3
M9X*AX/JQ?JY:54=1I0SU0=$Q\V%ZX@>Z<S[]J+,)R.<#S9[P-=R5>(76<6S9
M C&K<+()G<4BR!;"3X/&-J]?4#W_<UW5XWW8OH+2^SZMZ%XD&>9Y2&&$F:I0
ME&80$9;#@ @>BAAE01+?'[2KUZLG?Y*JE@*A7H$.:&LKTU!IK>*&=_'.(*;G
MH3@ X(*"^E/"FQ8T VV'45@](5U6U#]-;/F*^F<%/UI1__Q;MGU1I9H\;MJQ
M% 7+"<MR*+(8P:0(0HA$F$.4D@A'@B.1&#8_G0[O.\0P$K/L3[,+A68HP5I
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M_>KC^Y_>+-+%.<[7/[U>8EAC_NGWZ?K+3^LO^--_+99_G7X+/YW.PKHLEN<
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M0IBO?POG.(EHA/:)00R&;)H*!5PA:?"B$D=A38K8  &W5]T+!6;L*#A"DJ-
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MX_%LVG/D/H)RC.Y>=H=D*B_$V(?R.7P_K46AI+?U>CF-%^OZ>/7SXK33P[4
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MG(.E.X*"HM/EXBLNUS]JN6R=^E<=_Z^;,L")#AA=<!JL4:[V ;;D=N4,1<F
M10>C8NN'KH_1,P8ON$E2H)G01V%=KOMIOL>PPH_U.>Z'\I?59;?6B2R,\]IF
M17$60,5:8&<HA&2!!4>[H<3F%UV/$C0&?[<)B-J)?001T]T>O[01KJ<FU>%>
MOT]GLXG@(DN1$T1D9*0CV>>8 @-,4DEK!+K2NI!C'[K&X!<W051S)8S"/%U3
MKJ422=!YS)@CMRV+!%ZGZN>3K+@NR3/?&#[/@DC/3G$3B!PDS".>T:R;0.#-
M9M'KKI37^"9W+5HGLP"1N]Y0D1$?SI*=+-J41-^.K7-_#U,S!L^X"4P:"7P$
M!]-6^%<;X6Z<?%EB(OXM)+2"C&"]5ZXN6V *4W3>>M_<J=E%R+ -L%HZ,T>+
M>11GS69 07 N<!]K?MHG,HYUKIZE/VIG9/*^1+;-X?&,H1"]31MI?FWZ+$&.
M()B^&J$SQ6X8[7J1_OIE,2.AKVJ$M_YQ(QJEO"D^0HJ:^$J8(!22E!/9YZ#K
MT++6;6#VI6TD]3OOFQ1I]**045B:+<[NY;)J]3^Q $EI.F$EE\1&">!I.VHI
MG#*VM4OS,#7#7J7WH_^'07:,*D8!J]\6:UR=AA_UWNSF\M5H=#X DB$'Y10#
MYU4 5G2(PDBI8^NP>P<9HP'243J^5[!\G+A'X"!W4R/NL! SXSP:4_-."$K5
M-JA&<H@R.>9%L+JTON+>0<:P)UE/B#E6W*.P,E=W]'?X*(8EQXV&(E4=OU1K
MN9,U4'1VE0U!AKBGRH@#D--;CK@GY#00^BC TX6*]V4T$98EYNIL5\/K:)$Z
MO"MB!"8S_:]V+).]-#2Y3\JP">&>X--"[*/ SPX>L#"A3"UI3#7,%%Y"T"J#
MU+PDYK72J75AS8&HZ2U'W!-JCA3V&&+ZQ?SL,R[/:V'B1#K+"YVJ@-FI.D/.
M@U>&_BEJ<&J#T*IY:+6U_F@\FAZ#J4/%/0K;<B_OO26S;L"DXT5804>L):$H
M:01X%RS(XA+FB$7RUH7P3Y T&E>G/TBU5,HH4';[YO]Z;O=6XCQ9])JG"#(@
MJTU_4VVHGL&3\96&&X>A>2>KIX@:C5?4']+:*F8$P?U=IV^+DYQM"B$R2#8X
M4#XZ",9KH)VDHK:N6-7:9WJ8FM'X3CUBJXTJ1F' MMB8",>B,"Z#Y5:2.Q@$
MA"@BV.199#Y[R7J\"AGVQOVET]//$O8(?._7B_/S:=>4<M4U)*_S:\]PGBHK
MM;=1=-H"(NKZ7-]#5$P#<X:5P#+QTSHK_0@YPU[$OPB.6BEC%!;HOHS(.[RL
M=-O9%G#W$.2; 3:<,[09P;DJ5^%(KJHP.N5S2CDD;GWKN+ M!\,6#KP(?@=4
M^4@A?R-69UP,:&HYEJ<_5 ;':?M:YHLMN3#5?&S&D04(/7:)& XE3P+V((6-
M GRG5RMW3/UGF%W@A'FG5:Z!MN)8AQ:0;)!\$\.RT"5(9WCK"&('&6.#VV$Z
MOO? Y#AQCP(SU>%8S+<X\-K:9*.$6#0%SSE:B%)Y,%Y9*4T0OCE@[M(P='54
M+V@Y2M"C@,I)SEUCU# [#=/\;OXZ?)U2$#(I0F 0DJ32]?3*5H%'I"W@/<KB
M2638^@'; Z0,FV?M"3@MQ#X._*1T<7[1M83;IW/X!(-ST9&\F+?UYI.Q^AR&
M@]8<0Q:<(V_>,>1Y) Z;;>T+;SVJ:10X_(CK,)UCOIHZOL7P&RS3-%U/3'%%
MDJ3 F=J-QV8&/O%:$R\]'>^9E>:/X)ZF:MC\:T]H:ZR,40#L\Q+#ZF+Y8^NP
MCYX+'>I]O*Y/WY4QX#S65OS..BY8+KYU O8^%</F87L"T)'"'L7TJ3;Q\*2$
MC!&] I;K+"%N%$1#P7#1PH084S(]-/-O0?G8'/X192-Z!\((;B">RDQ.F V.
M%Y^AR*S(/FA-_"@' @46[;S+L77-ZE,T[059WQ=D7_I.ZWBUC'J^SNXA-)=3
MBK[@>IHHM+S%Q]ZC=?;YY'93=9[-QTL.U$E)"N]- .M4;2]H)01C/$'1%!V9
M-A+;7]_T/U#G9#9;_%Z%_<MB^69Q$=?E8G:_/=[U*X*0DL;(P%K.097$(2H;
M@#R2HERAR%TU;POU' *'3M0VQM&]V+8W98V@CNAV/IIV_8=E)]#<><6GN/ST
MA;0PD<A=(D\8,%>/6[-(7/$,=!X$%[5&;6QC".Y'V=!>8,_8ZT$]HXAVMQ+;
M#S*5BI4D(PU:%=I))"WR%+0#670ND2=/VZR_2X6C -=CNKAGP+563$.TO<R0
MQ&L)KQ;E:MI[#\,2GUBFSZ&)S^&PO:]WO>(U7(.I_0+0 <]*@R)P4KB1-!AF
MK0O!ZXBMWZ0^1D_C88E"61NYS2!XHG@G6 ?5(D-Q7)#SH.ID\[ZX&]>PQ.,T
M_\20Q.>(>01NUW-FM"$7M9\*9!>),[+I$&WMTA1]S1E9IYMOCS_HD,1G8>"(
M(8G/4,C(H'8UGZO$[&Q(X(EB4*98B-H5L(%KA=ZYV+QOQ!]Y2.)S]+W'D,1G
M"'\$\-D]N4\ZKU/@#HPC/U/QVM@@QP#>F"C)/4R*M[XU^(,,27R.=O<:DO@<
M48\ +SOF]TD;5#(Q@F2E4+Q0.:  HHHH%JT8,Z&U"_1'&))X!%*.%/((8+*C
MG5C.7)J<$6*QEKQ!^B-:9D$*R0.+IF#NS5-^/\HAB<<X-$<*> 00J=-A*&0X
M72Z^452;7_WXRZH^%;Y^RGE")_:WRYNFZ\Q'%K21! ):0P+#6E84I8<LLTG>
MI"A=ZU?<SZ=R)#[S@;BX>V;UJZ01P)!8*]-UK5Z;2&TRCVC!:E??HU/0ZJV+
MM#-=P."#=LV'B]^L/BQL^M;S_3D,APA]%+GMD_Q_+E:7S_$^+SYB6LS3M)MU
M=5,'^7GQ7&'&6M*D8^WC0X>Z"B:"C^0\",MT5%8'7YK? ?; Q[#'ZPN#>' @
MC&([O$%:.TT[)=/?9]AI>YY/SFMQTM^[KY.G(Y-6%L%P2:RASQ"BR5!0&6+7
M2.M;9R3VH6O@<:.#X^=>OY;&JAP%0-^=?PW3Y66.^NZ@C7?SC&4ZGZYQ-OV&
M^?[0#2.,=]Q)<.@I.O>:?"<ZDD S8QES50;-)Y\<0>_ @YK&!N@74_T(_-CK
MH8K_M22>WBQ^GT]DMIQ\JP0Y:I)?JF-<#4>0V6- S;0RK<.E^U0,//9I=) \
M3DT# JW>?$^VCX*ZIS;,?%KCU[]\G5@?->I2('2S/$/M5<C1@$2N? K>E'3'
MB[U_G?[T,@./?1H+HAKK8P0FK"L_>16Z>H;SKSA?77H<P6HA4AT1J6N;N'I5
MTTW]9-Z+9 +WV'QFPVY*!AXF-1;@-537*!S$5Q>KZ1Q7*^(B3N<=$]=-=M:U
MLH:$N=RH>4D^Q&5QS>LO]:_OYK0#+[KRA]V_<MV+CD]XMHKL.<FD( F\2 /D
M.'-R+912QA6O6&Z,XQ=B;>#Q66/;&&,$U"AVVKV&H&^_5[N!KW!.OOAZ8CE&
ME#4U[64$):6#6&?/,%N2=LDI[UIGP9X@:> Y7V-#=DL%CL#A(#;J2U%\@Y?_
M?3>_?,7T"=/%LI/:+]]^FTYR4,[(8@%%J2GJR,$G)4#RI%*TJ'SSJ1K[43;P
MU+&QH;,'=8[B*?"?PW1>I?EA_BG,\$.Y-<7Z>H3U1$;TUGH/'ID"Q1T'QS)"
M(9^?!Z^\T*T?4^U'V;#O(D<'TQ[4>2Q,/[=M7%R?()- +P6\.2(FW =>6!TI
M&)T'A;5Y0PH%A"C%2&Z$1&P,SP>)V2_QS_[;0+*-UL:#POLGP;7D-JV2KL56
MK ^QCE)&47LX6V? "4Y<YN2]EH99V;I3U?[4[8?3_SXW5#WI=13!T7W>[K]"
MG:08.;>N0.Z&1DF4="@4.AF\R3DY+B)O;43WH6O8B]2^4/$D^(Y4T"B<R_M<
M7661:W]I@]&&Y#DP29Z(TDQ"8"[0&> %)AF8:NY3/DK0L!><@P'M4)6,%&&T
M;Y87].E;#?)#[>I4> :9JKQ<]A C:M">]I!-ADG9.LF_#UW#WEX.:=B.4= H
M4SL;GJY35]?3/"<*#=J<#;#:V$$I42"F',$&D;,07O/8.NWX#/*&O>X<&H)'
MJFN42.RBK;MBK .Q%'+OZQ396I8(BEGR&\BV0W)2%*4X2YGW'XL\0-VPMY^#
MX;")LL83&>]?(SO)+'CK)0>--5 K=;9(S9@B<S4%94K!U@]V]J=NOXCCOT^I
M6T]Z'4$GP <XJR[QZ@%!6BZ4EL07R_7%B]8*G$D%M,4@=,(ZY_UED/L(E2-Y
MBO:^SW="K90TB@0-^1^;#7^2_G8Q7>*MQ/W)/&_E[HDGPW2&XJ*A+:81G K$
MH$I<% S:B-9IFOVI&^5+HV9(N?O2J!^EC2*POL?;R;<PG54?^9?%LMXMW5Q\
M=E-]N4I&UQDDHIA46RH+B"J2X3>,N\($%[YUG/-,$D?Y?NC%H-E0?>-Q..]Q
M>54=A9?C JK$-]_)D\((0+G6/FM1V[I+\MI+U)"UD(Y;DZUO72+W'/J&S08-
M#<]6BAL1-I>+A)A7OY"L+^_B+PM&?L7UET6^%&PG@XGQ,A>C"Z10YPT(QB'0
M#H3,#)8H* P4K4N ]B9NV 312Z.R%Y6-($UTG[&'/97@17"2)R@^U]T6>.WE
M7L 'Z;W(TB7?NO?Y,\@;-E$T.![;J&T,B+Q[ -Q]0C>QK 2,9.N-U%VF+4',
M5@ RC %SB26VOAU\DJAA:]&'/J./4M&8#^8N#;MMWJM@4GU78I)'4-%(B-I;
MB#%(P0(3EC7'WI-4#5LN/KCI.TI)([)X%']M,[?%UNU,JDC*>%,;. 51BSUB
M@1"D BF2MYU+K%N_#G\FB<-6B ]D#?M0WR@2/OO+<R(,YY$16\(G6R<.::!_
M(G"917:9&'^I5EF'HK*W@O 71F5/2AOOS<RF<_U.0?(2DU0I D],@@HZ0Q2:
M@['!&168IA#M96#Y")4CF0'0Z\U,*R6-ZF9FTS?S\^)S^/Y?T_67.IJ*6*SI
MU-UOE6V=(EGGH=4):)NG0/5*/R?M&;G&,C=_6GXHK:.\M6F&H@=.\EX5.HHC
M?=M1>;=:7=1!1!_*^\7\C**I\R[O3^Y(9DYK$%JE>O@(B+7MDN=6)FU8X:KY
M9>*35(WRIJ8W.+95T@@BG8_X=;/%[O"A8D1D.@(JG^H$<0.AF[TJ;.0H)7K6
M^CG,0[2,\K:E+X@U4<B($CB7S)"A?JJ-P0Z!3H)-%(%9"<0@(YYK8P/!-60;
M?7$F2JN;Y[>/(7B4-S ]G\TOH-H1P7GK -C*,G29A5U<*A^YSMW;W?I&PRL+
M3G,)4F:#2-]SKK45?2:)H[RD>8GSN[7Z1G"8[R_-22F:J^@M)%F(,^8<N2F"
MT6[DMK"D@O,O5--[*"9?^NJF+TSVI+01I(4J6_7_Z\7GMS"[C.-(8M-$-KFK
M&IGGVU_8^LE37$[K/?[M,OSK[ISTEZY-TD>R[V]+P5HUK6VTR1;0M<A?L83@
MDN-@0^$YE>B0MW867I;#8;V+QNFH$8-C!%OGDNH/99N3#_.C9#;QP@8CC0:G
M:GM1+\CC"L&!LU$E)3 P;%WUV0,;P_HKC3?!T&H>@<]R'+.2%?3)1?#<1U!.
M"6(;!83 4C!,BA!'9?.']6S&9,*?I;J#<?JU.RB([^5Z#&C5Q16;"Y!8'0F[
MT-9TBLXDI67F] W6O$R@?[3V5L4R+K0^0W5'HO7M?/M&X86G82\V9;377[C-
M5(M)V/>7>)$IV$]PUGX"=C=<O5Y4T5EYN?3-0.3,BW/2@C&*;)_Q 7RAO\5<
M1P)J)Y41C0W!7H0UGHE-/G<V/!80G"LR\:'V#',";-;1:\8EEZT]SI'.Q&Z$
MA2>&8S]'WB-P_:ZIOY1(O;]=S*NU[<;Q$M&UO4V!$NM01(X:O*I]1FSR7%G)
M=6P]>O91@D:"I0,T_1!HCA;["#!TAX?-S%49?1+,*2B(M*<XG=M.9@:8A<M)
M1%=2:T=K)R$CP<SQBKX;MQXM]1% Y_1JW<XX;\;K"I4TRR6#(E9 H>(0&1>
M/-$F4]G;YDG$770,"YP&ZKUW\7*DK$> %Y+'^6*^S8#'8$46%KB1@H("CA!D
M'=XKM>(B%$D[J74\=Y>(8>MOVB/E."F/ "8G.4^K^,/L-$SSN_FF4]#5^&Z6
MN'=$O?%6@NKN%K/(($L0W@ER!$OK0L-'"1JVMJ8]?-I)?PQ02NGB_**K?.RN
MJ*N@EOB%8MSI-[QL,+1AC&QG=#Y)B"IP4)J.=2>4!3K)<U+D$3+7VA+M3=RP
MUU8]0*P7K8P ;A]Q3;+!_#8LY]/YV>KJF*9M@E8QX,[+^AA!@,=:VQAE2HHK
MD61KEV@W)<->_;0'4@-YCP UG^O=ZT4=-4=']N7IO6%$EV*TDF1M.2/9U,(%
MYUT I7+Q+FJK2NOBIP>)&?;BI3UVVDA]!/ Y[02XH=W$P+)B&J*O18&E2/"6
MP@*9O4P!59:A]3&VO?ZP]QT]1%V'RG8$N-AQ^\.]=D+$0%%BK&T190'OI *+
M*10;(A,Q]I41O*9B)-WZ&J8!#Q/P"""R%2IVKX!6'R[6JW68UQ*@B4E%EF(C
ML%Q/T4S[)C!>@#BT3#&4/K1.'S]&ST@R@0?J^N$8_3C!C^9>__[]##GRE\5D
MIW6P+JEIO5Y.X\6Z[KO/BSHB9S%?$RWTB6?OY@1J7*TGPF=9=%%06[36$S=#
M4"R0H0TV2:L-%\TGU#:A?"16K0T\!U#F:("\PR^\W*(37[*NG2VA]NDGOY".
M?B=% A:$5]X5GT+K.^<'B1G=P^ICX-9&Y*-!T.ER4:;KVKAZ@LH'846MKZD!
MA-4:?'0.I/(BF%R0-Z^NNUE]=-7.QV#D0*&.P,EZ*,55>>G:/WX.WR<9<_;H
M!9@J'Y6-@2!Y #111UXD1AX: V4?ND97*WP,A)HK8@3@ZDQF?4B-^<W%LI[/
ME\:L,Y^W[.I'G'8_-J&]XU6,9$E+G;:0**"E.-@!G=;%HF-<J_8U1<^E<G1E
MOD>[4_TI:;PP_,\PN\#=##(KM-6U_%0K"G(L"G#,U4MLKWV2A3'7NC_QLXD<
M7?5N#R!LI*+Q8O!RE]W4)7<_=O)[6.;.YO^R6!:<KB^JMZF-3!E)O#8;3[9?
M.? 8#*#,P156L/#614]'$SUL6[J7-)3-53A>S':;<B]^64E*U MX5VK^4B<!
MT>I, 1(:;87*);9^A7PLS<.VK'M!J]I<@2, [*UI30^4BG3;-=YM*/41_W8Q
M74W7^ F7WZ8)+P55!SZ=S;M/Z60V*:%X5G=L=(:#\B: 9U&"UDB;.<200NMF
MM'WS-/"(],:('Q4"1K C[N=*NSASHD(J+@@/$34%DB@HD PV@S0J2:YL\JQU
M1/\ *0.//N\]-_U\>8^G'4ZC3'ODO)!KSB&9;$$I9R%@3,"*%4D%U!;;/_5X
ML6N3_H8/CO/>Y#G:;/I4LJ>;Y)B-* X9@8C\<:6, 2]E!,:SS\6';'+KD2_'
MWR3_42Y/FDE^)$AZ^#*(9^V2,1&$3K5'4+ D)<5 11*;\J)$V?I$/>[^C?]1
M+E?:R'S<K[8_79R?A^6/1?DT)7>S3%.=*9/2XJ+KO'>ZF$U3;9QUBY?]'FOO
M^<F-WF@?PD>CI]GWE[E^@YL(#(6A(YPX7V?:UX V5<_=Q:!*XM&V3IT]3,W1
M3MECDOU,PGQ%/_W7B4XY%FYILXE2@#Q,!DZ+!$5PKGE(+C9O3;@?9<.62C5"
MR3W?JKU2FD6/S8U5-X-HU07%!YFD6[_?R/ \3%,C\W(U%9$.H#B==S3>0$?&
M(J2*%F10JAYOY,D4J8&%D%!Z'UQL[4,^1L^Q)F;'9[^9KM)L0<<PWJ#9YCHP
M5UI@MI8ZR.@IJ$T>4*)6R*PTOG7#\OTH&];$-$/*72/3@UK&:V2(LZ^+(XS,
MK=]O9&0>INE((U/)G[R9=I-BNLS[-5Y<U!1AVP1:ZZZ/LH"0"#2&U5;S,45Y
M-U%W7Q0/?OJQ=N)2'F'VY^7BXNOJ.IM00=FUC+[ _.'KIEOT:A=4!>I@"T9(
M(7+:#;Q J">C2989[S 9W=J"'$OS,+:E#4#N&I07U=]X34UW%7:1UMT5V961
M_;P,\U59+,^[!<+\ZC'H:OTI?.OR860'Z'O?#@O+CEZSD4EKRWLC7^L645W?
MMNXY[H[.S$*;'%/%O$N9SKJ: ="<@<U69*?(PVYN0/8F[OCWND\LM&M'AL U
M)F; J5S?DYD"/NL Q24C<^ BQ-9IJ$/H'-9#ZP=?]]__]JR_,5O4;TBGQX&6
M<?.[S2S<+EJ:6:KNP^O @3HEHV*FSJ]Z?;%:+\YQ>8TC%:*,J IPX<CMEUJ"
M<\F"-1%EB5)*V[J@<$_2CK=2CRZSY2LH$YFV%<JZIH"MJJ\E-(@4$@MU5ZG6
MDRKWI6UH:]0>0_=M40]:&J_]J4,WYX3;'X<8H)M?;F2!'J"FD0FZ_O2;X^0:
M,EK*(+Q1=(8X.DTL8Q "N>LHLQ,^JE!\ZT=ACY!SK*G9\=$WP*7SF4G)+*1,
M_"JC(P0T!C27*8@8,LNM>PL\1L^P)J45)NZ:D68::#A.M ?CL0[SLVF<X<EJ
MA>L5Q3]_7BSR[]/9[#!S\O#'-3,P>U+<R.1<?3@YM7>7W@4X+714]9:#@%#S
MD0YBB 4TDZ'(H!)!H_'.?!:!QYJEO1:[V28Q"H_><7"!4TB1A03O@P 34#NG
M ^W.UG[0\R@<UG3UAZV[QJQ'O8W9O/T2ILNNEO77KJRB*]0X*%#;_4&-3-H>
M5#8R9M<KW2A]Z[JF\)@4!?R1>P,J\?K>"#F0RG5PJL3V<\P?H^=84[7KLV\0
M7IL&!1LB2#K)ZVB9 "%;7;&N@S:% HR78'8DAJ@9+N[:G79*&+69N1QP%V;O
MYC4-=KB5V?4YK8S,DS0VC-$VSQ+JL%\Z<3;#*C!=+&]G')DQ+,A<7Q34"V)3
M,OB2$C"!BI"51!%]A&S[4=?#?!U:[=>P_"MV1<<W*]YL".:4"RD4,%BOLR/%
M*R[5(9W>1&YC=)A;9[0/('/X>*\'?.TQ8Z>I^L9LS][@DGA>=WT9CC)HNS^H
M587"TU0V,FD[5R(T_ ?FLUMC37=X[4XDZ[QB$&(F##(CR:E6 5Q$AL5G*WCS
M:__#R3VZ2N+Y2]]LGV2MD_1_(&SMCIZ\A6"U!)2,Z>B-9ZSUB\-CZ!W6#+X4
M)N_54;R4AL=L($^7BZ^X7/\XG84:37<GT-=#1XP]_&&-#.6>U#8REK=6.]E:
M[1I^R&)&QAT@9G]9'AR20BA!)XU:6:U:5Y ^252#5F.[%]BU#7*LH_Y\@61J
M1,5* B^,!@J%>)2I6--\<L)SZ!O6L+7%SX[N9?WH:;P7A._K0.F#W+?-;S8R
M0[OH:&1S+C_Z)F-AO-*N1##.EGJQ&R'65YPE9<9U"2KJUF'4;0J.M2;O<;5"
MW-0CSL\N/WSK]LFAL5E)X'12@RJL7G"%1+ATCKZ4"^;6R:O'*1K68ARA_;OF
MH:'@QVL0WM&.BVO,M?SQL%N^K=]O=JWW$$W-8KBXWG6I8I7+R0A(,9!':EV]
MR)4:L.04K& ^N_8QQRY*CH^\XLXS+,B@-2\:?&W/V;V0\ P%<-*G+C+:PEKW
M)7J E*'CI:/U?S\4.E[DX[42EUFU0^S#YC<;689==#2R"7?&UV9I&6F+%&4]
M@C*BEL(6#KHD%ZW3B,W[<;:>67RWZ\5OBS7NA"@=5RIQ!2RY!$IA@)AS@E2,
M1J=9<:R7IH_[$#>&@9$'8>+I)B0MU#%BB[$9_D3>4]>TX"#;<?<S6EF11VEK
M94\VBYQN%KE!47!:!2;!(I8Z'I3\1IL,!!V3DIY0E5IW'W^(EJ.G%-_YW*UR
MVA*SK=W N\8FRI;N+2:%Y:4(:4I"F9J;SX>(&=B&M,#!O4'%300_YJSJ3;.Z
MT_#CX#NG'9_2JN''$_2UBE2N#X@/Y7;7ONY-37V:MKI/RC7&>%$Q>V$ 8S:$
MAE@O(6O2"@7/#CFJTKH#V7$4-WB9N]_JK[97O]D^6&0%3X Z[ >4L!(<L0BT
MIV+4)#+F6L_B.I+D@2.IE\/GCD>\+Z;J,5O*RW$)G\/WP_*ZV[_>+'_S $7-
MJHHVG[\CAB^Z,&,C0O2!M%HXG7_6)Z@1O)=&&(&M<SB/D'/\RX]['WT#8!.C
M<\XX,*4"6 8)'FNF(5"<8(P4:%L75#]&S]"50&TP<?_E1R,-C-F$;)ZYSU>+
MV317XWE=('C=TNY-'>I[T#N0_3^\D?DYD)M&QNG#\BS,IW_O*+\AHNZ">3[=
MXNI#N4_6UL%8WQ0Q3Z>1$ *4B0X<&@\F)JZTQI!L:S^D">''=S*_:EV]5:-Z
MW9%AUQ[4OB@ZK#T@TEFNN*$]J)4#R5 $G8,VNGUK\F<2.:QI?'E$WN].WJ=6
MQVQ97R]FA/+%LBN2NFHHTGFHM;7,E^G7@WRV/3ZUD2U]+OVC,J)"NRQM#F"5
MJF-'? #ODP>)4N08!&>^=1)J%$;TEM).ELLP/\.'REH2*ZH4G<'H4ANT>UD?
M="@(G/88+P95;MTN\QGD_2,8SN>@\'X;Z7XT.6:3N573/YW_9UA.:X7]51?V
MM_-U5U!Z6*2[SP<W['WP3"Y:]-+;6O;=@\M>0S/$4(3A GS!VM*>,W Q2U#1
M\9A*+.QN!/E D[UG+7NL>=OY^3M?YI/+$D3R!2*OTR>*Y;3UK()$>T(P)9AW
MK0^ O8D;L)]>?R"Y:[_Z4=68K==[$MY9]SD'%5G>_':K0LL'Z&E5;+FH;5F[
MKL\X3S^VO/J3N+A8WZS^:UC7.^>;PCP51*R-.- J0^&$]^ D<D@^N5Q8<;QY
MT<&AM!Y?P'D69E>?.<\W)-QZ+X922BZDA(RL/H=@B2(>+2&1;')&$45H70B_
M%V$#EW.^!+[N%WZV5MB8+=8G/*M'P99H#[IIO?\IK6Y:GZ"OD27;+/,1O]:9
M0/.SF\0'Z3/F6$BQM<[7&0T1G8=DHK.H4%C;?(K3 [0<71-VYW-W'<22.<*S
MRJ -@5DYX<#;0G_SVFNAC!6IM1W:@ZQAK5 3;-RK"&NLC%';F(NXPK]=T(>]
M_79P+<?=SV@VNN4QVEI9ESN+7"/(6R3G6M/II$TFO;)8^^([<"K109)L\*+Y
MJ-@':#G:NMSYW*U[,AFEKJ7/Q=8WICI&<-E90!.B#IXVBVC][OE!8@:V)"UP
M<,^2-!'\>&M)]QNNM-]/]3]2ZIETO.@ JF-DU/^X*AVX%JY.-+.N5N1X!R%P
M!!-T5E;P4$QK6]A^7%678;EJ*/_A6QVJB[]W'_YC:U\F$:Q.C,[U6/<EN0P^
M>0W6)J=S0.3I233NL]!H9TX]1]57YJZY9!MZ3(?OAU=A-5U]*'=D]>,N7X&"
M2EY00Q*1XEF5!7@ENG8R+F.Q*NG6Q3[[4;87Q'H;%=L88CTJ911@NW6+=9>;
MDJTQA1M@W$?B1@?:.A8AHPTF&!ZU:3\0]F%Z]@)6;_-@>P)6,P6, DY_6>&'
M\G:UGIZ'-:XF:!(R<E6!HTJ@3!T?H8,&SC&')*T-I;6;?YN"O2#3V_C7GB!S
MA)!' 9+?\/<MR2P7<_IKNKPCWVU5$[,E&K2D;9WK,SL'T<1 VT"0J(I.(K7N
MV/!<&O<"FOZ# :U718TWNMR>H/FY7E8>/=MS\RD]3/C<1=]+S/G4:(NH?5F+
M< Y4,$B:SAZ8<SRXJ!C+K9MS]CGG\U/Z@OEB1G;U:I5M(;_ZL?6O6WVP7=:.
M@_6<(HO($P2G$_!<FW'3V2UL\\'"!] YXAF@ST'1O1Q7WRIK9J!:P/(CIL79
M?/IWS.\R27U:II@O.[1W?!)I)_/\?AKB='99K+%:79QC[LS#5GAB>>1<6G#2
M<(J%<Z##0&9 9C!:E))(Z VQ35@8-KA\ 3"_O*+'>Q ?.Y+Q\,.[T<HC&4W9
MHY.P_P!!'97GKDZD2,K2]@@.7,H(7J62LZ7-45KG<E]L0.7V]MVY9/?V=*M2
MQ-EL<U" *!@HK@H$[A68'*-1*&/P_7D.>Y$X]""X/E#UF-%MK;61.0];[-$_
M</D-7_WX3)]3'TJOUELL*N]\5!R0,SK#I)7@@[$@"P875)9TJKP,,!\C<U@G
M8%!P-M/>F$_]RS&EQYS>MSZA\?C47D_3_09@!FFD*2R#[EYV%,$ARJ!!*B&-
MC9F7\@<=HOIFN@IG9TL\V[RCV2Q[Q[U%7E02-@#+EH">=(1H.0<>3?0\:B9U
M:_[W(FSH4[,]>G;TV&BLGP%/RN[^^&0>9C\N+_?.:ZJ3_CO/K[_4AU7OYJ?+
M12;3N^%R8WQ7=[BUP>AZ(P,88S</S4-4FI'59PEY3D&R_>[NCR9EZ(.Q/_P-
MH*JA@;DIS?E0=G/V;IYF%W3DO)MO=S9X%69AGO#3%\3U7>859I^<D\!9[/H(
M.HBZ("@6M0U29.?"7CAM3=FP%[N]PW9010Z-XBNOJ<H]S-?3UV\$JXF*\!4O
MUM/T=;DX6X;SNQR*'+PWTM8R:D\<%@NNF B)NQP$^=#^;LWY U ]:/EA;XU[
MQV/_*AD:=%TJ;+GMKV]M'L."83$"FJA!V> AH**@+%J3F2U)Z;(7M!Y99-C;
MX-X!U$J\XXU!K\=['QZ$WOV(AL_('Z2LX9#&AX:F>\Y4\;E ($>>0!,4.$8>
ME$U>.)]]UJIUZO(1<MKER*X7>7VQK)OL#JPU,]SJ)$&HVNFY5M [:10($VJG
M&QFW9L4W3XP]3MO0;=;:8.7A_%=#S8SY1=0CH^N/,4)/?6@SL_0LZAL9JN>-
M2#?1!&G)3TZ9$1P]@21( HX4*ABK90BL]6"<9Q%XE,MS]^/??J]1Q71^=DL-
M6\-JDHY:>@9<J5I:6IO#9.[!.I4ELFB9V;?3Q[,6'M9:]0>86PY2G\H810GG
ME75>U$9'TS6^GW[#>Q+]Y6)=I7E>7[->]DQZ^[TVY;V;+=3)YLPT B-3#2HI
M0Q;<*4@I"N:3%"&V;LK2DOYADV[](WIPG8_J+O5Z!]]L7G) 5%"*(A[IJI?C
M*=AA!J)*+M'7@[.M^TT^0LZPN;271^.Q&AFS2_A+F"[_,\PN\%<,57"7_<H/
M=@8?^[A&;N#>%#=R *_7NT'7S?6[4UJ76%]0>R-KR] "T7$)(?B@&?HH3.MB
MAL?H:6>#KE?9% ;>*@C<2#Y_F'^L0^B[DK'Z>.UNGD8R8S334*>5D@&V#(*A
MO6<<UT4;Y-B^B4E+!H;U(YOA[F&S]M)*'H5?^5RFZ0=^6\R7MV10?S]<EGVG
M+_/IW^[G*!%9"5@G:#E4H#"1JDHNY'B+K O)RLO6[XE>A+%A/='>]L3X0#$"
MC_1:*'M8A;_,%['>-5XV7OQZL:Y%YO-$OQ5N/X\(WF59/(+U#$$Y[TA+,M=&
MM4EE8;,*K=^4]\''L#YP__M@*)6/ /8WY^/KL%S^('8[B52C</4B-E_+:?6A
MU"FL[^:U@/+&%=T.%!A/4B7 VJ-+91/!B<"@,,5X+"KIW%^Y:P,&AKVH?@$G
MZ*65/.IH\&92PFU6#PL&'_ZT5K'@GO0VO+3<]#"N>*A8Z::J?JIV\79==E+H
M0LD<6# U[Q $>,$(I=);^I] GEN7C^Y/74L+N?I2"^3H/W6Q;V&V8W<$J3)M
M50^9D4"4H2WJ2Z3C0++$O(],^-:7(L^C</CKS1Y0]9C%:ZRT4<1U579;(OL6
MIK/*T2^+Y2=B\ YWJ;9D8K9 =N2.*R\Y>&8TL)*Z"^7$;//J[F?0-VR4]4*
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M^-KLPF0-CZ$X0%?+3'R*%",P 2E)JX.C+:3ZZ8#S $%CZ.O20.W[P>D '8P
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MJ4&CT?9+[1]>K-9-4O\H^3^?U#]:&)UBZL(COBJK(2N!&(+ PJ;R(22H5<[
MJA6KT<>4IBHG?Y2H/HZTO40_ $Z[RV'N^,/C5<2777=+*E@[!F6N/"B7-+B:
M#.P49D\6:0QZ6/^=Y][4'U+VD.JP0NT=6-SG073M*QF6F:W%*ZP8!$4N$@0O
M%:U*)AU<=B5V5[PVV77!W&IN-[%T +%G"Q.*0XN)(10C-*VG-B\H@D,LM(6$
MDPZ-;0RS)C4B\]R@CI+^V!J1,:+H %HCDAEOW#*\O;@33D=*<LES"F"DE+7J
MO19;E0A1*\:+L47[UL#;C^*.2^'V@>4!Q?BR0,N/G(P*/?-@<C54!"-#13A.
M^]-'GF4*&,5\$.4=U](=")#C1+0[_)9G>'RP4.\J'R].ZL*_WXJ/;DL6&H9\
M![]HBM#O;JN<)P1LHHE1UD1[E\G)#:ZB.7 ()8:$6;B$!TB Z"D$7+B36EAR
MKY)U-9]+D@MG/,200RDQ1>%;-SSXH4/ 8Q"V=PAXC/ Z4MEW0T]TO'.IF0 F
M:X]7T@+@C5; @HM2>)E)-?QO"'A?^0\, 8\11J>8NAVD*L'PZ$V"I*,!I3$
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MWYZ2_B"5L?Y(XB-*OI(:N3_R7#"NDI4(@59!BW(6 L<"U@JG,6@F^*"1OB/
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M(AG3V%L[T-+FR>1M [?[Q3+]H:&#$,9G^M[[\FJUPM,O&\9<-(N03/M0-(C
MR!QWG!1-R0B.B ]%8"JN]4RG!PF9-Y6\2\@L6\NO Q#>(+^6K/]&3+W^9-/A
ME'9_Y=>V1BE&4Z)&!\+2HA0S$4+F&6),+HOB1#&MVY&-)'%>X#8 Q?)P$IK;
MN_F$)^OSTR^U>];B9'&,JU=?5CG?J*#D+GG!R4MCKA#CDJ6MB<F!(H63<Q8R
MBF$QJ.?>-"]J)I7Q<BJ&S]Q_ZKJJKA;SG'W_-9]]7::WI]5ZJ2NZ_VG.M81S
MLR.+=]$GQ>KM%W$P6O*?E Z0"K,L('EQ85 "S3,MJO:A<=XJEIXU\$&E/S/*
M'UO'MA!92Q\-TPR"U35S07G F!4MQVM"(I,QQ@8X?IJ*^=IM'0X%RTE$TKT"
MSD[[Q#EMSXBT/54RM!AA@,M,&B)A=/+9:$S'"KBU.$?IVC&\G1LHOYS7>,#K
MS2G^I2YA<4R,6I[F:O!>M'5))BHN.0-;:E:)"P4<SP68M,F94K3EPVY.GG_7
MO$5J/:O&*835-_:VV]39+!R9IZ"DX* TV:S>\-I=+9"GY8+4=T<E[H2^.17>
M)+(=CIL=&#TW<K:CKGX^SZ_.?EFLUK0_3Q??Z-FX^G[91U&I[%AT$+6UM"9#
MAS!'4:=':N.=%NKN!(E'<//\N[I%S2Z274['YIY0\RG3\9SNKX>, 6E)^]=!
M&37CWC'P.0E(UG/MR%E./HV&S2,OF\<1/#!N6C!Z9E?M=;VNS2MBZ]GW*R<#
MK4!.YS%X%,0A8PWX6!QH+<B^(SW.PZ!&2,\X: ^]>]YJY9ZMI";2FAEM'_,?
MVX%55W[%W25M]Z<7QI([BV!%(6=7.')>3,[T'YV-P.+LL F'ST!P,$'SN7K[
MRWPYM0#F5GYOEZ>+]8>ON#HA+_?\K+:IJ_OP7[;'L9&&'%]#W,F:CF.C/024
M%H1*3B-*$],P<^GI]\P'D8FDNIR&Q1W<($Y_SK^['N=(#"?E3]K?:[(TDJ_U
M"3: 5M*C*2+$YL.0#KB\>=LC]*RO>\=:!]OPX?CW^S]/Z0U?%W]\R*M8T?0E
M']FL.;%9DAT=Z'RA_P$RKB"EE+-BH6!NW65D,'$_>M;)CO!:'D+6W8+XT_(X
MO<;5ZCNQ]=5)5<9'LJB"H1C(TM7&6M&!RTR#%MJ0(F8L(C\(AN_3]J-?VTX)
MX3TEW0&"-VW!<UK_0I*YD4CYOKRM)B3]]>WI_[=<G)[]C59+GQ_IK(21#(%%
M7IMB56,O,0?1"FERB9AYZS[)(TG\T>]:VN!Y2KG/[1)N.T^M/R^'K RCM=*0
M)UU0L%I=(\ YE< S%Z(KUNN!LR5'O?9'CW7MA]*)Q=C!N?L7\LC?+=?K]Z<W
M*C/>EXL:8'ZD.6I!Q@Z0T8.@=+9 .B5 ,CZY&&.QHO7XEJ<I^M%]O3:G:D.I
M=H#1FSKB$QY?[+U;LR:.L 2A5)(0-0OD')M:85$8R)2%3HJ'Y%K;M<]3-6_C
MNI>"U<;2G5WI;Y?S 1?I\_+U\IB^L*P,^Y9O9"O?#(T>,<^0H99@M:B=*64$
MKSP';70DU'D>E!JF^4>_>][6<;U#]! "[>!\?41;W-N&R6;/D]/$N-J#..M4
MF]XXL#(Z[S ;KEI'D0>2-F];M]YA/*6<^ZV,_DBV^>H\DE%.;+VL(=_4A%P5
MC..VE\?KY?KL$W[;5(S7$O*ZM]>_O#VC+Y)X_CS[>OWQMF;Y]O*'%5=/2U"C
M^NP#<FW/$N]+5-^BF/;;QWQ<VP6^BO3BBUY%E[6XA&2ME0\0O%1D]EH'SG(/
MG,?@>0F!B];-7P<3M^\9?IW0_\@KJ[2V-TGDCOHH:^T3^@P*=::=CAQ<88D[
MK5TIK9VZ$>3->Y4Q#9KNGL132:L#8^*.,GQ7_T&57<T8,8YI6Q@'-+0>Y:6'
M$)DCY:6M9BG06=FZ4>83Y,P+M,D@\/35[\[RZ!=:EVDE,2J=1+T0%W4_DHWD
MO2_@,H::EU18\]/]28*ZNI+=7>S#X+2###H U*=\3+_Z\I=\2H;V\<96/UF<
M+NH!7ZV6;<>WR^)A@\B4S0JX<J+F%QG E )(P551+'OM6]__CR*P2\#M HR[
MRG(R*74 P8?G(&_7=)G*36>\T1J![(TZ-#<B!&4<\=)&;YCV1K0&W@"RNKJO
M;PBWUA+I V37%L;KK[CZ<K5=4 74IO8^VUP%N*#!,Z;(E(V1><%DQM8CT1^G
MIJLK\[:0:L'_WI#TX1@O# ITC'EO+2!G9)^:$L#5J1I!.CJ$#=D:S=N)/4C(
MO$?2H2SZ_670(Y"VV\SR6A-5&Z<$VEPJ&0N^5GDS-#$ZQ;4TK?N(/T)*1W&(
MW83\'&QVX/C<EVNO2'CRP;CCI6+V7B//"9RG UIY0<=IX+SVW%/<\ABM&#:B
MYKDW=8:.762YG(JQ<Z/D8\8SK.DY7RZN3RX] UJ"22Z",;4!K9$(F*MG8)WU
MV2>1Q; ^"P\_?U[ETQP1#9C8FYJI^-YHXW5>?<LW[M2DEVAS 0PU5=88 2AD
M->Z%EK0LYNXV2VML S],U[S6\"S63 L)=8"Z3^0WKNH=\(9'_,AY)F()1&_B
M=1QCJ579O!#Y3L8H$5-IG:Q\AX2.U%43&=\+$>W.\ [PLKE.O<>D]5%)KH1B
M/,CB IW@.8/C,9.TZ^V_EN0SMDZX>(24CI3;%/AI(8 .</10G.$H%B]SUAZB
MJGO!B0A.* <<LV)1E:)UF%2[7= QKS:;'$%[L_['3:3YK?9DG3EWYAX-G:3+
M/,V;@V?(,,<18Q"D-PW2#A .@I4UTI 5FB*3C&S*LZ*7#!F/)KB !D31$I2J
M$TY-21!2*=DSY.%NMX;_S9#9#TW[9,B,D59O6OHJM"?1ZZ 8AR X>>NZMLN4
MQ+OJMU>C-<C0>G[![C'T+K)B1HE]4 Q]C QZ!-(VYE/(ODC9&W"1TV[C+$#(
MT9)C'I/(WB=>)HUG]!U#'R7D@3'T,1R?.SKZ;*A7,/0<BP012@T9%@->.T_+
M,IZ1]^/DW?30'RJ&/DJ6HV+H8Q@[-TH>"?_*HM7FS$5%;HVR=.8Z3^NPW$<E
MI38F#YM_]Y)BZ#LCH@$3.U S3Z429LLDRYM*_,Q!Q4A,0J' >J^S#X6+NVW.
M9\_H[>+^?Q_;I94\^H76=M]E+HR-J,'($D#1"L %VG=>$_>,0'(O6GNC+S2C
M=Y381V7TCI%!!X!Z(M.*A6PL%@Y"T7)4%)M+*@TR*:&+SYEC:Y]^STRWF7)U
M1XE\>*;;&/[/W2*V5O5N-A8C5NB<(@B-=$X7Y<AMR!Y*42F7Z(.S+;H07[WP
MY=SY[J+!=N=M#X#8XM@)9IWR$3179 WZ$ %=G8=-!ZU%Y:0K@S+4AD!B]J:N
MNPGKKKAWX-S, O]U<;HX.3^Y--B%X$K' +8F>2O!ZJCHA)!5D,Z0/Q#RH.XB
MSXC\UDMG%OHN(ENVX-_<@L=_WB#<BEB4**2IC&;D[R4//M8._2:62+_@H8@6
M@K_YTGF<F&:"WYE_'5B/#\ROWQQ^VO+"<DT#,+: XK59=<D&0LU[XLQBC*U-
MQT=(F;==VZ$\W!9RZ!1.]<=5OFR%KAQM ^0*R/9-H+040'M$@@U*!FDP1-DZ
M,>Q9HN9U39J(?@"<=I?#W)'9OYZ?X.G;DY/ST^7Q\LOW.B8O+O)IO XS*^F8
MIU.65"P')3T#IVD/1B-")B-.I#)LU,!S;^H/*7M(=3D5B^?&RR8(?7]JPF7]
M&=GOU@D)7 E+=CTZ\+5<M@COH_.DMM.(I/C'7C-O8'9"I+1C;@?Z:EB27,Z:
M:57 R5!': L.OF@$PX(G.U\R;UMW6FR6+#]97]!9TA9:2&C^P^F99*):=QW/
MKGJAG7[9%F)_)'YO1KL?1:_)6<D,I*XU<=8&6G@=.YL,N9Q6&"_EP!-L7UHZ
MNM!N H[E?)+J[3B\O94OU_K;>3WGWY</VV9ZZS?'BY/%:?W:4=9HE7 6O$#R
M?66J^YS3MG=919=(,TQ;%#V:XHXNWUNB=P9Q=@#>NQ4Q3$D4,2F0K-1<IZ)H
M(>1..<U90:%SEJW5]BXE2#,7 .P!KWT8W@%>!NR.^O/'7.UE^@H_,C$K8[T#
M&VM.KW2T-I$%"!]IAW#&DYPT874(D?.&RWHXTO80VLM!)3_RGGMTTD )T8!"
M2;M-:@?&6I%BT,;RF< X\\2"7C X3D1SNR57-NR[7 =:KC(>:1-5TKQ 4+*F
M+R0!7G-):U#,9Z5X#L.B:O>?/>^<@&G=ACTYV<$9]"ZOUSG?7L?GO#IY7^IX
M[TVA"PH91"QD#&[20D-.@&0M0B'A%W11,]NZ:<WS5,W;VG_R<Z>Q6'[<\LO/
MRS,\WJ9BQ6J;;KZPZ*&C^5#2.BG6W(F3!Z_AQ"1#U.1N<$O*5B4,@(Y)$.B\
M#@*M#_\SNIRC+]RBA5*P5EMP1KM_TPC"N"!Y#<2W-@E_P!K.,6C:J\OY"&EU
M8!0\H=XVU]4<2ZH-9Z$D]*"RB( Q)I L"2V]"$I-ZH_<)^GEU'6.@L+P"Y+1
M<ND 9I_I>W=8=EF3I*W@E@M@04ABDD5PJ>@Z\3XGXYPIOG57CT>)Z>@LVU?D
MRRGXWP&0WI YM_R>\U64\K*MGS$&R0R'R"19X($V'"83P;JDM?.>K//6F6V/
MD#(OB!H)^NZPY@9<[P \3U4>"5%R$H:8$@P'I6,=):DM."V,L#Q:VGZ- ?1#
M% #NH^1:R:-?:&WW7O!.21T2)%D+;P4*")Y6%*URS*2,N7D[FA=: #A*[*,*
M ,?(H - /5& 5C/T8B@(&>N6DS7QA@4&-1,K>\DC-A]?^#(+ $>)?'@!X!C^
M=X>D1R.8Y 0[3ZH[.@=*;2XUB&G.!I9E,3SYV&LV7!=EA!,Y>[M)J#O4;?L(
M&N%#*K5[H,N)=D[09"]R"U(YKF-FV81)F^*/:>$X=WK;"&D/:>$XAO4_[AW"
MK7^_9?K'Y?'Q+\O5G[A*,UXA#*2LDQN$7?AX\ N$8!EJ42SPF+%V\ZZV).%>
M:R.#01D5'U3T^-(O$#0&H[/T0&<'>?[,BSJ51]<.P,QFEY W;PO_ UX@C$'3
M/A<(8Z35G9Z_'[5T2I'EDS8E*)[TCHT0C!3 ;:X>72F9MY[1^\-<((R"PL@+
MA#%RZ0!FC\<U93:B.,E!2J]!:7+R7"X*8@C2)&,SCZT3@E_H!<(HD0^^0!C#
M_PZ ]%@H.PE$[RQY;=82<R(7@"46\)@P,LV,=:VS#5[8!<(H00^\0!C#]0[
M<XLM5XU8A8HF\NR L6#(5^,U.5XF*!%M1B-$=I..GGQY4P.;*;:=9- CD+9[
M+'F?2Y(24J@3K7,I$'P(M<126.%I0\1)PW!]=SP>)>2!'8_'<'SN;.YG&_/:
MPI*.ED-.BM4@I /TMA9XD:LBK21NW8'/#]7Q>)0L1W4\'L/8+E!"QR[](9Y:
M4[0YRU3[(0K.B5M<01"A_C5G58HL%G$X6)Y_84=EF<TPTYC-O6FFQZ+3Y"B@
M*H%!R)M\=\EJWD>":*2+T3"&H76[GQ_KMF@BSWXW"?6&NNUBCDSF(BN%8&/R
M%W,_G:"=ZIG+BF$JD4_:H6-+1T>ZKHFTGX+3+JS?&3Y_Y-5BF3Z=X>ILNBO'
M9(4CA65H:W&R&6LV0"BFVHRDLX-0.K%ICZH15X[S]B1H!J)=6+\SB+[E55@V
M.H4^X/>:1;+^97E[AN*1=D:KFNRAI5:@? QD^=6F;=&CL"@C3ZWSMQZCY05T
M']@'2$U$,!Y,_@),I_E+5=2?)]5KFVO6XPN1I?\X7Y_5!1\E+;3.N5J?=.PJ
M'NM<'Z03E[. "D4(TQ9:/$7<"^@^T%H#[B^DOD%X)!"UJT,6BB'C4WD9(3!3
M6[I9PXL0V<I)IZF.,:[F;2K0W+@:P_H]C:LWIVG:=)QO^?2\IH-<_!F^_[%:
MUBY9>R72///,9BDP8VAOE+SR\V*-7[ZLZ@XGDJNGN'GY59)!R>@K-\#8DB^J
M%#WG])^0.686@F6M$^2>(6G?P^>1QU^XP<7(9+EQD-!%<C,$G:S(R2LV5KK$
M2-.C.LQR.TA%:8F-N^=0,RG,W-7^P\46?;_Z1"?I(FY'.L18LA 6(FUP4"XZ
M"-H38U2Q3I>L0F@QU>"A=W>)F!VDNFS(XCX@LB95OEW!^K(<P$KN GKR1^O@
M'IXTH*Y3S).6+M@0L0RJFQB&D_L$S#<)8W^9W@?(G@SN(.BX7<CE%4^H[:^9
M FV,I/WB."#C&5C2IBB'0I36@:);!,R.CGT%>M>3WYF[<U^@_?II2_NE:7C9
M+-WK6LUAH*:LU'EBQ)? "A3'0K):1XO#;E<?><&\RF0/>2T;,V]N /QR?H(K
M\L$ODY22YT$G"=S85"<3(B!1#)+^ZY4B!BDV2.ZWGSN/N-L):=F&8W,+^_.;
MU[^\_?G-QU=7PXWK(+!D(/M-9TGFZ<R+ ;*N%?):6AW5(&G?>?",XMY'.LM&
MK)I;S'_[_=<W']]^_L<EZ5E+Q"R!'*<Z:%0$"$D&D$D8947(3@S;T[>?.\\U
M3U,A[\&HN65<)U2OZ+57 ZKI[%(LLPS)N +*$E1#H+7X))PLK'!G]2 IWWWR
MC')N?G;OQ;6Y1?[J;^]_>_-_+PNSI:-%&E&'*0E03''PEGP;CD%SS95P X>Z
MWWSJC.?V?I)9MF#3W/+]\.[-7SZ^_?GR-.(9@PE:T&GD8YV>%:&FR@!YK!8]
M]\5[-TC"MY\[XW9N)^,]6#6WE#]_7V-8+6Z[(+HVNS*6- \Z<D'(XZ"C+3((
MEGMR0FV,;IB[]=#3Y\W':.1K[<VVN>7^RZM?/_SCRIQ4"EU E0BG.=2 %&DP
MERS8;*U2'+4TPSI3WWKLO D3C22].Z/F%O%'8M//BW7M:GS;;KF<IBZ*X'6R
MA"N\LD1+0(D&6"GH0S&"W^W_]]C4HZ=?-&\.0R,8M&3FW,#XMU?O/KV_TE;*
MV^)-K+6)1=72C@3>N0Q87 HF,Q$')J/?>NR,MEM342V;\&UNB7_Z\/:WCZ_^
M_?(4RUX;1]H(=+W45$QZ"'6ZLF'6"5,2RBP&B?SV<V>TY2:3^1Z<FUWH_^<?
MK]^]^OB/3Y?FK<T^!$0PWC'B023S!)F';!"=4%X&-LRJN_/@>=3\Q&+?@W=S
MR[W.FEV<+(YQ=1F@4-8**5& *9RH9S5Y+F4-D1MTCFCG85C([=ZCYTTB:Z3;
M]V/8[.)^\]N;#Z_>O;UT0G0H(BE+7H<B"U74"8G9(5C)<HE:*SEP&N_MY\ZH
MS_<4S[(-K^86\]M?/[YZ]_,EY4E;1#)  (TIH&(TX+.VD+4,5D1E<.#$TEN/
MG5&!-Q3R[IR:6\:_O'O[?U_]=$FYU2$YGQ4D85F==9H@A, @Y1 #P;-H/?#R
M\^9C9]36#66\.Z?FEO%/_WC__F]O__VJNMERTE:,-%6*H(R.$&KG718M:FND
M26S8-<FMQ\[C<3<_K'?FU-PR_OR^7M;^]OK-I9XQ)F2"(113QY7)>D%4:LVS
MS3(EG3*_.]SKL7CJ[0?/8WVUEO,^W)I;TIL^C9=97)=EY\&[$+P!NRF^*XGL
M4,X]\""+5AASO-L6Z[$Q?_<?/N^<OT;V]KY,FUOH__[[QW___6^O+O&*T02C
MN8)<Z5>\5I0+ER$61:0'5\<^#Y+W[>?.:''O+:!E&V[-+>A??O_UU<]O/O[Z
MZC2]^OGWO[YY]^MV$8;;*+)GP(Q,H'P1$&34Q!N79,K6JX'7W8^]849+O*GP
MFW!PYK3VJQ[W?\G++RO\X^LBXO$FC]MRF:.*#I*I(Q-RTA R.JC7O+0*48H>
M5#/T3%K[HP3,>Y4Z20U$&V;/C9C\Y>X2MFG=UG@R58,#J7AM95MU)ADW$*S6
MB)I'ZP;U9'T.,8\1,%^J>R/!+EMS>4:HQ.7YZ=GJ^]'OGXZR, DW;4&]JB.B
M<@1?D@23)"\*I<;T5 G$.L=_^;+\]J_;)UY 8_N7:V1<OV]&&+01VG(O#G90
M ?/;\O3W*\_)%^.C#W16*MH OMXD%CHZM< 8I;0L2S/D4!A1_W+C]?,HD?98
MV)>S'8#B$8WZ[JH@/F;G70JEYI=FJ,EJX*6I;)(9&4:O=>N^^L_1-&^23W,;
M9!)1= "MRY3EHY -\E#S&U6F+6&+!*=IDV$BG<NB]8ZU;JAS^>XN2W9WE.B]
M;A,[L+?G82^7'1HV?3/J:!)BWT;;KI%<N>/CY9^UE_1ZV['A3FAF;+N)H2]I
MWG]BI]7MV9"B:KZ_X?'Y!?!/T[^=X_&B?*_]"N,%#5=]!S0A1]1)H2IY1XCD
M&CR/ @B,Z'QP-IA!31J>\1:&4;./0_3T&RKSCY?K\]7VW-:,3F@C$6P-#"FO
MR92+9 S0QXDQ7[0.@UHQ[[7L.T3-9S%/@)6;7M1THNE ZUTO[FI/7_<96M>&
M^Q?U^$+*4AO%1H&L%EL+(&X1 [7P,AH>?/-.A<,HZQ5U>\%B.;F,ND?>ULT1
MV3A:3H'D4Z*-J\A[%5F!Y58*K)O6MS;GA] UKYTV!1Y&06X'X<Q]4;$EG0R9
MU[C^>F7,;+U@[UV4F(@WPFZJS@Q@1@W&9'*E@^62#4ST?^HU/:-F%Y$N)^'O
MW$AYO3S=V MTI%]W5[Q<B%1D*1"YY+*$0,>XD'4A I IAB9&'P?>9#[UEGDO
M+:;%23/N=J#!/N%Q=9'.SE>GE477_+I<CJZ7MSR##X*6PVM1E VT.F8X3S%R
M8EYCY?4,2?.&HB9#UA0"F?F";*AU>2,XPX7C)0N(G,Q,)70=R!N1U'U)#K7*
MV@Q"6R.?<%SX<Y+H^?06^O22ZN"8>WK;_H3']:.CH$/V@3.(*M&B(L9J:"J(
M6II@75$<6Q]V@PCKWT'<$1BC+/9=I#3[[(0+@^%\51G]8;7\MEC3\M:?E[<+
MF2Z7N!ED0@S^O-RH@;>GVW_YCXSUFBL4S8J#4NJZ:U_LP)2';!&3,"6Z,JR>
MKPDY_1^)^V%R)L'-[3G<,&@'K_4#;95576F]&&&T%[.!6 )9/M:1X>NY DT*
MR&534E #9U[M1<<\-N*!P7E 4>W;:[]!GYKMW(I+R_B//XX7.;WZ0N;V^NRY
MQ=_<C$%9F<@.!Z5,7;9,X#S]Q&Q@EB<5N!C6?JX51?.4<1P8J[.([X6C]FJO
M'HDBM)3((1D;B>VLWEZ; "9GJPK7M&V'U8BUH6>>@I27A-C=1#<K7L?9X'4V
MA^"RCBZS"E3Q#KST'(I&QWQ$XTSK.;KM/*7FE3.]>DICI/12!J$,2^:X8T]/
MDZHBYDI5N;.ZPZ6JU-X:UMG:HE0P A2+$$(MJN<R!RL<,\,")+.FJEQ%6B]S
MU2]B9R)$S(),82^,)<N"U[75_Q1.&,%D>6D]#?,V!;U&>7:2_KVP]N[,[B!\
MN#U0/WW-^>Q=_7;EU::J 6-.-M$23,R@LJRIQX+,42EJ.%[JK'5CT#Q&R[PW
ML_O(=SD!LSL%S?:"B 7:,9H4,Q?U$B=D!4YH#M&++*3@,:368Z@>IV9>X+21
M]@ ([<#Z#D!T>0A_S#$OOM6]==GQQ#/&"K<@N%,U$Q !<TFU-[S-R8G =>N[
MBL=HZ0] N\AZ.0'C.P#0IM!W&T%YM\"P.%Z<+:YNDWEB9/\6 5G4388U6\&0
M7N<E&<]SE*)Y;MJ3!,V;-C(1E-J)H ,\72GZ:T=6(XO.9P])5S=3TB'MK6-0
MF(WT<2X\MRXVN4_%O,AI:/[LR> .(#(L..&5#MQK#4;:BGMGP2M:GB[6E:(P
MF]!Z-F7'E^VMI+]3G&B,*%Y".=/%GY6YKT[/%J]_%NPSG<#X1SX_6\0/JUJ(
M>K)N.$)WX)LF&JR[RSH;C=O=DO +47"9%/GWQ=G7U^?KL^5)7EU'#J*0@>PE
MT,AK0UTCP$E4(*TJ,DH?C6Z]UP>2-NGX71>9R(KL!5010:4Z*L#P#*@39LLX
M"[RU8NQW_.X46!DUAG>,-/J8L7I[GJA,W!E&YF%!IB_T &JCJK6H2G2,1S^H
M@<"/-89WE%2?&\,[AL5]0.2!H:)$>HF8%)@28LT^EN!X)'M!2U%0$K_LH%/G
M!QG#.TJF@\;PCF'PW/E<-XT$)",A)L'.KHV$/[9&PF5L0Z1H$VIPCM<F/=K2
MV6L*F)QL#,9$)9XUCL:_=G; ["OCY4$8/CN4EM_Q^.S[J[.SU2*<G^7T>?G^
M]<<W?_O]LGT^8LR*YP16*3J*N:X3T'(&(00S5J,N:EAJU7-OFB_W= K M&3K
MS$KI5_R/Y>K2HEMOCE\ADDETRH+F0M5Q:PZ<1G)F)4?IF!/(!D48G]%&]]_<
M<=N\76V6/=D[,SA^PY/\OMQ:PW;OZ$@TEURKI'0U^0L##"&#4UIE#"FC]PTP
M\B@!\RF@?26Z;,W>^95,_)K_LEJ>__&7?$K,R_'K]A@L686H'/&%A3H,.5@(
M)1C@@1?+T20=!MHFC[UB/A@TDMVR.2,[B"8_V]%)(1>6\P@H:WF%K3:4R+5#
M-1IT)6M4=LCI\3^C7=HNNF<24<Q]TGSZ2LQ\7U[7THF395T0_5 69[2*0&:5
M3 :$E;R._Z(3N*@ 3"III"3O40SKI/#H*[J,I^PHQF5SGLZ-C,U][>J.'U>C
MZP_X<4=HA&+.UEKO:IVK1%M)90<^>LT-=YZ586IIS%N[M&T;X&<RSG>@QZZ:
M!WKG3*X3IW7PO.I?#YAK!T)OG"Q*,C,LCCM5;\9#ZZ7]<+,7>W>'Q?(,CP]Q
MF;G9$9=_:7!E^>#S&E],/D_SGM>/]\^*J]LCR7S*WB*$[,FX#84L9UYC,29C
MBH9)*4>,9;G[^$EO"PFIFHB.D%.0H(P2X'42D"N>C<V1Z=;G0G^WA8U$.^IB
M< SC^[CUN7W#D;+)A-WJ'F9/BI"XXYE X%E(+T46>'?0[_^$B\%14GWN8G ,
MB_N R ,A:N6TY(XI\%C'&M?:;Z=R 1.X%$K3@ER+1K,OY6)PE$P'70R.8?#<
M3LYE#L:O>'I>:C.S52WY.4TWE?<V8"2\8Y*,;(A*UX8KAL[<D"+HZ(J5 37+
MP\87#G_G[%#95[H/]8MKS.H>?)J+NZO+\=F8- ^^5FS8.H0U*'#12X@F))VC
M-Z$,&GLSQK&Y24"/UX*[@&9_[G8 C2U+KCFR0?MV+3D43/6L);3[.K&C#OT(
M#&1.$@-:R4OK^J>GZ)FO7<PTP&G&^PYP]&S0(##B$&.<-D+MRZHX!^\+AV*C
M]Q)I?7>CM7V$_^>Y>M[%*IY$%!U ZRID5'0Q@@5-NK8X4#(RVG590 B&9\XY
MK:IU9_@7,BUEE$0?B\B-8>_.L/B65V%YF *#WW"UHL=]RPWB<?>>U3@6]S2M
M!RX#('U6>S1*8*@8Z;282?4XA)*4=,(ZYX=-TGQA90#*B2(\&6T8:VJ89XYV
M@M4@HK1)!\OMW<:-/V!@;TJLC(KVC9%&'Z&<VV&+7'BQA1/!UKAZ24(KJ5W&
MG0XI6:>35H/ZE/Q8T;Y14GTNVC>&Q7U Y $'@DFG'->R9@[5U&*EZ2>32<H\
MFF1T-#BH-<D/$NT;)=-!T;XQ#.[ VGW2*30R9\=M32Y+"E1*M:VB+&2B::V3
MR;JHUMTD]G;(#QS^&R7N,0[Y&-[/'35^]^;?WOSZT]O7RV/ZS7*U$<EE'P,3
MH]42ZX">!$K7HH;L$G!?G)&V)'[WO'DD2OSX.WH,\.T"BY:LG!L1KX[_^VM>
MU.SEAU;B>+0YUP"VM'3J^E@5M%;@K5266"-Y<H- \>1K>HS?[8R+=@SMKQC$
M"9-<'9F:DZH-*76H+3$,2)>,9<J64EK8)"^J&&17RW5/]G9;#,(T2L3:+'<3
MGPXJ C("_*;I5XS9<I0-,/(RBD%&2710,<@8]LZM6VC?7!3%+5?O3R^O2$.=
MOR9KR#ILZGF]AY!<A((B)Y2QYA .4BD//;W'$I!1$ENV9%]'\O_\Y_)R <E(
M'SD#DYFO5^0)O.*AMC>V$K4((0^K,GWHZ?-9F-/*?S?V=>"U/GM#D6DQQA0%
M(CA6LP*1UI-(?1I._,I*ZN9M>U]P]<\NQL8DHIC[:'ES>K8X^_[W1<H?\BI6
M^7S)5TNJP>G-3KRQ@]9'S!F1BR5CWG'2Q=E4+OH FIM$KKI+Q9I!!\_X=W<9
M>-U1\,O#26%ND/UV7H_<]^7O7^FA:SRFIQX55AL^DDO("SF'Y,#1#HQ60<[%
M9^ULU'J8^?+ P[OT<AK 9%\^=J#'KB[#D\T^:&& L5*KEHP%5%* )O0R)0MS
M=^7_/Z7Z9Q=X[,7>N8^';;7D;\O3S4WHDK[TY>TI/3ROSS[FN/QRNOCOG(ZB
MCUD%5H#KY&O#X3K[U1DHVBD5)/&%#9O^,^Q]\\RCFOX0F8#;_?;"?'M*;"/H
M?7^]//EC6>O_U\MR]>$>>2O#'MPHB66'533*:+E^R=7@GJO,!)^]-JZ6,FN1
MR6\BI1,<.66BL*)4PF!4;GR"/T'.OHKIZM$?\<]?D8"YP./U;_FL;KV++K%'
M5F-$:^A,13I851 >7!&T W4RFN7"Z:B=:L&/4C6O2=P*'W?U6&-I-,RF:X"P
MOR]7_UE'4"YC7M]9%-)!GFH[DFR$J\,>!'@3 B3NR,KSDJ,9%/3=!6*/DS6O
M/3TYQAK)HR^0_;(X7:R_YO27Y3+=613YC5J+H&E1RH*J03"?D1,/2:?3YO&<
M3P:RQ\F:URJ?'&2-Y#$KR#;VX]6*:!';80ZO3A.9D_'B+T<FZI"D$,"4IH/9
MI3HH*T;0/"FGBK3:#&L;\]R;YK706R.F/7.;=75H<!S1>HY4E*5X$<'X4J]<
M$@>G,P>I;<XQ2ZUEZ[JXF^^?9USKP0Z8L1SN(!AT3?LUP'F=<,6Y@*CH"%2*
M_%IG:K6?LBYZEE(0K7O%/T#&//-3#X>5W?C] OS\%C4ICS^LM3]_D*J4I]"D
M?31*104QUV):2V>%-UD#Z9&"#*V/JG5)QB%\^*WJO+CKXRFP8+("*Y.^2!4+
MG@QYE"'7$HJH[W8F:[?&FX3TZZF/0<&C9\K./.] $7VF[[TOKV@SGG[93!VZ
M:(PAF3(JV#K858 2KH"W:($9FX6GH[*(0>UX1P#G04(Z <[N EZVYG8'D+E!
M_OK"1,?K3S[33VO:622BRP[WGF6C<\B0:AJSTK5M@0@<,!5N3=))I-9@&DGB
MO#!K (J[DRLGE-#<5V9O%FM<7&;):S('D8RWK,3F]+: WGG(1'+A":- _YS)
M<_>A\V)A4LDM&["Q@_/GI_/UXC2OUZ_B?YTOUHNK<<%%!19K2D@JEFU&DD/@
M)1!7A#>"_J>:CQA[A)1.HL;-U%8+CG<*G/KC*N=MHJ505OA@):A8$RU=[2VH
M4(&. 1V3T<C0.D[S+%$SSU9N(?H!<-I=#G,KI(\9S_##5UR=8-RT)\;C]=O3
M>)ELRY*QY&& 3K+.BO9TMEIM(+C,8[&I2!<'J:@G7],?1O:0YW(2YG9P_I V
M7^4:?:K-W])_G*_/KJR][),T+@A@1;M:Y2'!!^6 6Q^*K?ELK'7GU\>IZ>0^
MJIGZ:L3W;A&TW62Q.!Y")L9HXHYBNHZ-*1DDK2J&J!*SK?VLI^B9]TQJ)?-!
M4-I! !V Z1=<K.ITZ'R]D,_+J]VW/6)U+BA9X714"UY+TSV$X#WPPK4-CF7D
MK3-_AM#5([AV0<%R8I'TT9OD=A\.#,[EHBR0CJ[3[&2"0.^M;7XL1BNRNWM+
M?MCV-=/?F^^MV9KPM@]L/% XSZU.WM815U:21T'< "R1@TB)AV0C%\.BSS](
MWYI1,AW4MV8,@^=VKU[3I]7LOWL*)I&)7,6A2$7;QA0!GLQ]<%*1$C<I%CZL
MBN:1%\P.@GWEMFS,Q XLEBORWUT5 WA>!(LN $91AZYR#5[78(3&A+;$&$SK
MXL_[5'227]/,8=J3SQT@Y3(D\7IY$A:G&U%<5WB\3;2Z15E4/KU:K_/9>ANN
M2+3EWM''B^/%V2*OZ7?G)_3U2VX<&2QDSYD"Q;-:C.TL8%:U,D3K4.<3%=[Z
M/GV2A71RK;HCNAZ))LXGZ@[P?C%D[]URO3XJHGCO,UD* ADH'<E<R-Q"K>WV
M*CK9OAOV]=L[N?EH@ZP=F=H!'%XOUV?ORR;A^H85\6EYG(Y0*\]LB""YJ#-/
MDB!>< ^.TQI*B$+%UM6GCU/32:2Q#5P:,;WG5,,S//VRN#I*\723T__GXOCX
MT_G)":Z^U]J\V]_9*QEQ]]<U2U=LM.)&"8V7+R=\W7OM \EMI?@<HB3KOG9=
M9Y(#NEK-R@IZG8J-V-HV'D7@OJ?<I_@UI_/C_+[4$I.S_&[Q+=][[84U["./
M2FD')9JZK[4@'\H2X(KRV7B!A;7.#1A.W;SFV'28NGM 3B2O#O3M$^OYZ?M%
M1Z=C7%\T=,L!54#!(*M8=8%A@*0=@"?#HZ /T;56P"/(FQ>+4R'D;IA](G'U
MC<3KA=5.8]N04A*%[(_D0&_ZBVG.P"6%D#1IJZ#4_5YJ4Z+Q(1+G1>1D4!D.
MR;WE-G<(]X;+_99,L)A/USE]7'SYNHEQ?L"SFNVXC4C&H$IVT0 O-:5#. >U
M7UUMG^L=8T86B\\9CF-?VBW"]I?\\@!BF/D>Z6--C]WL/U%8\$9EL+$D4@FY
M!LJ)\CH8V+#L@\R#-.LS]T97+YPWV#&QKMR=M3W@X2JS687L723PLDJV8]63
M]^336VE,PH*RQ4WBC5?.=VVTH[#NBGL'SLW=99S@?W)^<GER\<!T3!R,]0:4
MM C>8 %#RC=(G;QNTCSZUDMG%OHN(ENVX-_<@L=_WB1<))]J1]L4M265E4SM
M#R A.:_0NF(=;S$5Z=9+YVL6W$3P._.O;T?G.ISK9,@N%PM.5ELII0IF6A.S
MS'ED& G3A_-NQMT73Q;VGM_)WDU 78/N]W4NY\?O%B4?L4C$Z^PAE#K-1T9:
M$WK2QJEHA=I&85OW<1A"5[=>SHYH& RW'473-=QJ'Z6KF&R= I%J^]M2D,Y_
MA]7>,PF2R4RS&+FW\7"GW W*YG609H3<SN+I&W1_6=6[<,S!Q1(S&0JQL@P5
M!*Q)$KGX& 5/=IB%W09N&YJZ/=MVQL%PJ(T72M\@>Q7C^<GY,9[E].IDN3I;
M_/=&D$=:,&F+HOTI,@.%/H&K(ZEU<,([%"HU[T$ZGLIN3[P# +&%X,9#TU]
M\[3VB]Y^=UJU>Z2B31BX!L>< ,7(,L80+,ALM+&9#(QXP"N3H>W=)G,GY@7=
M6(%TT!GPVO]Z>YIR><X'$](&F4,"XV0!97AE'/U5)XY6>"FX;&W=C:-PWC-O
MCO2%YG+K0",_LZ9[EYT\8?+D2P%9RQI4S %"%@$L2Z$$Y[1B[?NGC2*QEU2&
M]FBYEZX_G>CZ1^:#EZ0,9=0F.0BQ:ILZ'L*CK>U 2TY&)>.:SP3;@<RY\_ G
MA,TXB.XMPRY@NNVC7KM;$R5?22/]G+_EX^4?M8YW&V57(:'GTH&6OC8Q10/$
M55';CQI&O]0RM-;F@PCK&HK[P^,>'%O+:O[NY!]6B^5J<?;]8_ZVR'_^;7D>
MKP?,NUA\XF029R^(?N21+!Z&4!5+*9+,9U<&9=4\\9*Y2S\.@Z"FK.[@U/J\
MPI1/</6?-0=H\Y?*H,LT(&N]$I:)BWM@LDKTQ0X0QB7NC>$IM%:C3Q(T=[W(
M84^I=K+I9$#'8'OC.CZ/+@85> (;'9W!J8XK+:: $#R*H)3T:48W8]R-[@%2
MP7KR-7838@=GXC-K?///>'R>%J=?+D,/1P6Q,"TTQ%0WN;$)7$VAR4I[YHI6
M0K0WZL;1V+5]UP UXV"ZGP@[.4WO!4+OK>HJ[.5\B%X:"=:%JH6" ^^+A$"&
MK.-96<]:Y\&,H6]>M7ZX".)D,NOBT'S@6O*!?6:C#B[1JGP=.1]I03X: \4)
MK8)0,39O!CZ,LKD/R*F0\0P$&XBI _#M<"M)=H[)TC&0AM<+<Z4 8W9@=(HN
M.L^,/V!J8)?7R0<#Y<3B>S'Z^B@4%K7*"-4W!.7)"D%/WF)@PCH1F$FA_0BH
MY^F:V^V>Z6S<6T3-+IL/V<JAS1RIX8^?OE7#069-C;,B35+62A_!Y43'5S :
M4#$+7.4L@TID8[;N)#53:X;+UUZ$'HPT+AJ?(*I(UG.T@3:.XA CV1M"*L^%
M;KSN1TAY24T7QJ#E\:R%W271@87WV!P"(Z4B56\@^MK!4$H#CH<,S&7GO6&9
MB=81ZGV&?AP@W6 /,0\<^S&&YYU"Y_9X JE*P.P]Q))X;?86P EGR:R40I@Z
M8B>USFA^H6,_1HE^]-B/,7*8NZG!TY,ID$41=6+@91*U^R:=W8(\::Y0>*Z$
MR$8]9T2]_+$?H^0Y?.S'&.;.#9._GI_@Z=N3D_/3Y?'RR_>?%LMU7.33>'6-
M5TI.TGD%1CD)2AM3+V/HE$9R)YQ)PLEA5_//O6G>6,*$8&G*X@[TU9B6,SIQ
MY;66$#FM3Q4?P,><P)3,2G#T<'.X6L/=,C /<"O:SB2:2C9]P^[AS(: 3AOR
M0@1G9 H@<=#Q7%M<(AW&MCBR"0X'O?[2*R>#RIZ=H\;(;6[M.:9E41$9DT(&
MF(*NV7J^%APA..0Z>6<\$\,4Z0_;.6J4Y'?M'#5&#!V<>L,R0:.SR083@6>>
MH?;R!1]8 8]%1FUY<:']_7FKK-TYR@V;X6\Z.<U]MGWZ/_]X_>[5QW]\NLPV
M%E(C]W7@<[UR)3Q \*) S"6YK#$Q^VS<_:$'=UL=V/:,VH>=<T/AJ7QB$;FP
M/@@H# M!VB@Z6;. 7'.A".$L%3T(%ONF;D\V%NM@$&G%YAX:W%V8C3R%8H2"
ML)FMFG@$IXJ!Y ./F!RR-,C[:]KP\ !]B_;WYW;G8P_"OSSBI&7:R#JS*= Y
MYYP&Y[,'RV.PJ%D*;M#0V)?5W7"4L![I;CB&<W,WN;O5G4\'SHHCK'-FZNQ2
MP<A19(F.*<6-C&@C&S2@_.5U-QPELD>[&X[AWZQI0_?[\TFMC9$V ^FX:MMJ
M,FN##&"UC3IB9-H-JH1X>?T-=Q;]SOSK)&-L7'TN0Q;(+$+BBZY#UKD!5 Z!
M.Z:#%:Q8D88 9.:*_,GLS"GBP5/*J(OHR/B*M^2-XS:3YUU"7:*N"7*! 0J-
MF:,S)K3NT_3#E]Z/@DV#TOLQ,NP"ID."0R):RRUM;)1(AJ,5%D(A.Y(7RRSW
MCHG2;Q"OJ]+[4?#8*9 W1E9]E]XCZ1.GE0-7"]B4X0R"#1JT5QFCUM;Q89D@
M/U3I_2X(:LKJN4-^=\.5Q0LOLS4@1*7=)E=[]C/R:JW)OF2&>M@XZZZBOP>%
MQCXL[4")71JE[ZX+8(W+B9L"3H= SJJ1I/5)_W/C2B0N**&GFM_WKH_1UE.8
M[/OQ>>YSXV815+V./?D#%ZNJ.-^7RUO:N[OLR-BDR8%6P&*NF55(GC0I4# ,
MG<00E;L[\O6QF_'Q+^\CS7Y'62\/R/@.3J";2WQ_;Z[I42:7(UE+EEAD-8TN
M*?!.:A"FWJN61!2USI)^FJ(^&D_NAZT)>-\!DF[NCKMKN;8)CJM-<+_"+HE
MISHB9%$$$-,0O J*#("2G9%%!M6\=]\>]/;1O* -"@\FMPXP.FA@A"TF8TJ6
MF&G)&,W>0="%@1.9Y60S2[%UO5JS61Z3!5+;8JZY'.8VT1Y?T-]SS9G+Z=6W
MO,(O^6.N#@]MH1L+-<:A$R*"K@VM59V^Z&-1X'S@&9ES&/D@6VT?*N8U^AL:
M;0<310?GV66%Q>OE25B<;J3U,<?EE]/%?]/J$S%^419XH['"54[G._IX<;PX
M6^0U_>[\Y":SUD>>&6M$B1"UK/,DO(+@:T-#:XWGDISIYCT))EK*(%B;OF'=
MD[0[ /TE4R\,%UK?=;N0:UOF71V0P@22OR422%%W,SE@$*0U(#-Z%:-Q?%CF
MQ [!E&>)&P1,^S* .8U$FD'MD)TTWJS/%B=UX;^<G]5R_ALNWO*>>3U-MXV=
M2)B^(\?^G)FE:T<P(46R0"$Z0XCU.9$!JC2P.A0[T Y)O'4STH-V[7BJ#],-
M$;WYYQ^U N3"9J*SJ0Z27$<\_D?&U5&POL3 -"3%Z.S@(8&WS(!6OB2DWYKF
MI1(-R.XC3-D>A6,Z;4TAX0Y,A'%+_HT.EL]_YN-O^=?EZ=G7]9'3:%/T=02J
M4Z"<E> Q"8B*RYRBM,J46?%\E^(^HJ*]07DON7:1#CANO76G?OYS>20]5\ED
M"VXSM*.VH\=@!.0LZ(.H>5(''-;X.*%]1%%[0^TN4GRI8"7TY:/ <BI.R9JD
M6_-^:KA%:0Y,^%Q*",K=K7:: ZZ5U#Y"L%T"=K0D7RAD?UF>KXZ41856.+"B
MWLP)K(DK/@&2!M$&14YY?L162OL(ZO8(V-%R?*EXI>\>H5+,:A& Y[)1)1J\
M<+1-E8BEQF.B&%0T-BU>Z;M]1&N[Q.M8.;[(Z-GKK[4$:+TXO?Q@F@C9HZ^9
M/@HV;(6S1+J*%S8:CJ!R'8=1B@1D B$1Y+C3WI3F@Y^ZZ$_+BL$H)7F%+&,M
M$B-#6R@/"6LK:>FLN)NM_;_]:<>A96A_VC&2Z"#*]%C#3.VLKB7)-3^UD%E1
M.SMQ45MGLA2XXF1:3'5[^B+ZTXX2\\#^M&-XWBET;K=&])G)8FI3>\L4;;(L
M( CG@9%:D-ZYD&QKF^V%]J<=)?K1_6G'R&'N+*1GNV+2>4V>CE80Z'0&%0.Q
MREL%%F/BB,$Q@\_95>T:C\[8I7:45$<U'AW#XKGQ\G3+7<6#3CS4"6RZIH74
M6IK"R%G.GC[-B?$L!X%E_W[&,[:HW1DI[9C;@;ZZGR_"B[>.AP*H+.%<QD(X
M#Z)FRGG%#!<BVXF\A7>C"I4.WFMV'_-F/SYW!)2/R^/C7Y:K/W&5CJ3(@4ED
MH$*L)3%&0W!.@-2<.^&]UZ&U@_4 &7TX5SL*]A&8[,KE+H*95T4$'BWCABOP
MDFPW)5.=:LP-Z*A\"BZP8*<*//0!BIW%^ @L1G%T9RS\D5>+9?ITAJNSIGCX
M<+Z*7W&=7\6X/#\]6YQ^>97^XWQ]5I,(UT?,$5^*1>!%.5"U'6!@D4&*20K%
M53:\]=W+(,+Z2,%HC:1VLNA(-[T_^YI79(JM,JWLYWSQYY%S-G(I$Q3!#"TF
M6\ Z?XD6E,D>HX4VGY?[)$%]9$>T!M3^O.\(2$<)=9TED4%;:>IHG#H3D'$P
M,3JEE3#2S*JY)L]%:*ZYQG!T3\WUYC0=N!Y!,Q-=3 C.DANI7*;%E9A %Z9]
M,K88V3HPW+8>X8"%U2W,X[82:6@T-[]3_846]3<\/L^_TGEZOLH;_7QU^7BC
M_ ?/KKZZQ]WJ/J]K=,?:;,6-[EJO7W)U5[:^GE!K94$Z'<'(E$!E.A61%0LQ
M:,8S0^E2\P2,)^C9.PWE\MG;E(5;_-[*([VOQ6GGJU6U&4_3;\O3U>5??\+U
M8GT1*^$J\9Q%@MJ=!U02CA@3"6V&*<F#)5=E,L;L2_S,@T!:X>U>;LHLPNW
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M:K F'.\4.=O=E5 $2_^"'%)&*V&Z=MFI&0E"\I2Y\ZJT+MQZG)IYCZ(VTAX
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MP37QQ*]:'B=E@JWB2B;7X8H*O"L&R$"4E@OR-.UF/:8W7+"G[H1-4', .7>
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M%^_/)^GJJ<R;'+B5#DKT))>DR#P(&$%'="4)SIAI;7*MIV38V.^!$=1 ^!U
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M7>#IP'!^F%9Q\^ BT5C-#3#:V:!$%3U:!]%I);3AV-Y-.P0?O;08Z=4X:0.
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M*N;[ZY_QI";"7S&T2O&34O&8Z&06M5N<"B8"(@DM<6_)<&..Q0,]MZ\GJ!=
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M:A^0^R]T3Y08/[E4;PC919WWZXW;R;8#%VMYUJY.WELN@&+)6V&!19U!I5(
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M,?5[YHZM^N'?A>>G\\6T;!AFN(:CE=89BP**J[Z6$1("XPE$,CXG9XH4FPV
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MP487>^1GGISG^0B5-3JQ"#$F.E98,1!2)A]&>OH%M]Y@>UO[<NV^CN-AD/
MGCNHI0,X??J19\OQ>[_^^8-$5$>'&*FDM!JB)=I5T1I<Y!:TY%+Q8*I(6K^^
MWR>B+\>L"X#MIZA]\T*^M0-<%=DU,Y?B6K'T,2]&0?C(./,@>?2@'!> P7'(
M2>9<7_]C;!TD?9JBON[;/J#83H4=G(!7!LJ?*Q96!80C$P4K4BG0P=<D%&L
MO7! 1KOF1F?G>.L^P(^0TE=V41<0;*&T#K!'V^7F:7=DO<\LF0(R.#**?8B
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M1.-/1;]W$GY_&!HQ9YRQ(D$1-1TOY%CGA7':;4PJP<BW\JW?];9_93G84=5
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MA'-/UUM1##P*"\&6:!-G!IMG4#U&RZM["-T*(_='6[=06*? 6T440Y!"6Q%
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MSM0.VZRF&]0>2=T= +LRLYB=+X7W&2^J-[CB9"7S%5L^V8C!(#"M JB,O Z
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M+Q8$IOG)]#25Z>QD_/TDSQ>SRS^DO\H_KJ4P,I99SDN &$I];60*T%@$ZXS
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M@ABLLP>=Y6IA[AV<T"[!/Q*5-'H./V[7FV[K%+6+!T]&C7Y"'1HUGCPN?Z\
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MLB3]OV]&L+AW$] O8:>S+(#+%#QQQ =$<H,\[AU#5K.(O 0]PX3$&"Y=1'K
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MDF#;";H64AG"AS=[#6HR6#3WR\U6>,&O;\_X57)<NW^"[:0T6#R/!&,K]/1
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MGOJ/TY$O\'W]&*H5. .(2#[9_! 0^15N@/DO=A[?VM'T3SN^*0#-AC%;832
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M'K9=YJD6["Z$<!LA#A#V/T?->/FFU3^:Z_@Z]^>>WOYF_SH&]CLGJQ<X+\F
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M!N+^/Q#G'?([_HF^_$7^A[.S^'_^U_\'4$L#!!0    ( /,S7EN#WA:M'@@
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M_Z/96*Q<"5TL*%<0-A<J/,2J*NW3*D_=1'SR?FGUZ6^[[KM;MO\#4$L#!!0
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M9;(GKPB6G^'"XKZ_*/D_4$L#!!0    ( /,S7EL8A^D)GP4  .,C   6
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M;3S$YWA@2 5U%X!$%0L61:.+U!QN3M+0]EE;PDW,YQ'UIQ1!0J*.CVJ-]G_
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M_:=J.\JV=Q);G[4L/[-'-J?F<<]?4$L! A0#%     @ \S->6WUA(ZRS/P,
M4N8N !$              ( !     &)I:6(M,C R-3 Y,S N:'1M4$L! A0#
M%     @ \S->6WZR8N6M(P  &;0! !$              ( !XC\# &)I:6(M
M,C R-3 Y,S N>'-D4$L! A0#%     @ \S->6Y[&3Y;0(P  ZV(! !4
M         ( !OF,# &)I:6(M,C R-3 Y,S!?8V%L+GAM;%!+ 0(4 Q0    (
M /,S7EO+L4@IO>0  ,9_"@ 5              "  <&' P!B:6EB+3(P,C4P
M.3,P7V1E9BYX;6Q02P$"% ,4    " #S,UY;I#+#TJ.^  "B]   %
M        @ &Q; 0 8FEI8BTR,#(U,#DS,%]G,2YJ<&=02P$"% ,4    " #S
M,UY;"7*7S3WP  #M1 $ %0              @ &&*P4 8FEI8BTR,#(U,#DS
M,%]G,3 N:G!G4$L! A0#%     @ \S->6VMF8Z6<!0$ .G@! !4
M     ( !]AL& &)I:6(M,C R-3 Y,S!?9S$Q+FIP9U!+ 0(4 Q0    ( /,S
M7ELPBKH(-!H! !B; 0 5              "  <4A!P!B:6EB+3(P,C4P.3,P
M7V<Q,BYJ<&=02P$"% ,4    " #S,UY;J"5>?R$O  "^0   %
M    @ $L/ @ 8FEI8BTR,#(U,#DS,%]G,BYJ<&=02P$"% ,4    " #S,UY;
M*<>%5QPB  #D,@  %               @ %_:P@ 8FEI8BTR,#(U,#DS,%]G
M,RYJ<&=02P$"% ,4    " #S,UY;__:)JY,M  !W0P  %
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M2P$"% ,4    " #S,UY;;/T&Y77D   U&0$ %               @ %-$0H
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M+3(P,C4Y,S!X97@S,3$N:'1M4$L! A0#%     @ \S->6QMH?,OW!P  +RD
M !8              ( !%+D. &)I:6(M,C R-3DS,'AE>#,Q,BYH=&U02P$"
M% ,4    " #S,UY;&(?I"9\%  #C(P  %@              @ $_P0X 8FEI
I8BTR,#(U.3,P>&5X,S(Q+FAT;5!+!08     %0 5 '$%   2QPX    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>149
<FILENAME>biib-20250930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:biib="http://www.biogenidec.com/20250930"
  xmlns:country="http://xbrl.sec.gov/country/2025"
  xmlns:currency="http://xbrl.sec.gov/currency/2025"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="biib-20250930.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2025-10-29</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:Revenuesfromanticd20therapeuticprogramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:LEQEMBICollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:LEQEMBICollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:LEQEMBICollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:LEQEMBICollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductAndServiceOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:NonrelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">biib:AlcyoneTherapeuticsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-02</startDate>
            <endDate>2024-07-02</endDate>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-02</startDate>
            <endDate>2024-07-02</endDate>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-02</instant>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-02</startDate>
            <endDate>2024-07-02</endDate>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-02</instant>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-02</instant>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">biib:MeasurementInputProbabilityRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-02</instant>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">biib:Phase3ClinicalTrialFelzartamabTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-02</instant>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">biib:Phase3ClinicalTrialFelzartamabOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-02</instant>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">biib:Phase3ClinicalTrialFelzartamabAMRMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">biib:Phase3ClinicalTrialFelzartamabIgANMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-10-31</instant>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FelzartamabAndIzastobartHIB210Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">biib:HumanImmunologyBiosciencesPreExistingInLicenseCommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">biib:MilestonePaymentFutureDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FelzartamabAndIzastobartHIB210Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">biib:HumanImmunologyBiosciencesPreExistingInLicenseCommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">biib:MilestonePaymentRegulatoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FelzartamabAndIzastobartHIB210Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">biib:HumanImmunologyBiosciencesPreExistingInLicenseCommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">biib:MilestonePaymentCommercialMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FelzartamabIgANMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-02</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FelzartamabAMRMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-02</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FelzartamabPMNMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-02</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:OtherClinicalProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-02</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FelzartamabIgANMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-02</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FelzartamabAMRMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-02</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FelzartamabPMNMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-02</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-02</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:PaymentDueAtFirstAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:PaymentDueAtSecondAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-04-30</instant>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="biib:FutureContingentMilestoneTypesAxis">biib:PaymentDueAtSecondAnniversaryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-04-30</endDate>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">biib:IonisPharmaceuticalsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-04-30</endDate>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
        </entity>
        <period>
            <startDate>2025-03-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-09-26</startDate>
            <endDate>2023-09-26</endDate>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-07-31</instant>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:ReataIntegrationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-03-31</instant>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">biib:A2023And2022CostSavingInitiativesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SKYCLARYSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SKYCLARYSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SKYCLARYSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SKYCLARYSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SKYCLARYSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SKYCLARYSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:QALSODYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:QALSODYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:QALSODYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:QALSODYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:QALSODYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-249">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:QALSODYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-250">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RareDiseaseProductRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-251">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RareDiseaseProductRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-252">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RareDiseaseProductRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-253">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RareDiseaseProductRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-254">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RareDiseaseProductRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-255">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RareDiseaseProductRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-256">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-257">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-259">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-261">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-262">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-263">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-264">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-265">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-266">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-267">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-268">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-271">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-272">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-273">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-274">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-275">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-276">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-277">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-278">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-279">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-280">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TOFIDENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TOFIDENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TOFIDENCEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-283">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TOFIDENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-284">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TOFIDENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-285">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TOFIDENCEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-286">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-287">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-289">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-290">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-291">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZURZUVAEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-293">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZURZUVAEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-294">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZURZUVAEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-295">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZURZUVAEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-296">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZURZUVAEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-297">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZURZUVAEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-298">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-299">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-300">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-301">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-302">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-303">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-304">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-305">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-306">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-307">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-308">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-309">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-310">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-311">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-312">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-313">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-314">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-315">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-317">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-318">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-319">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TECFIDERAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-321">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-324">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:VUMERITYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-326">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-327">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-328">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-329">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FumarateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-332">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-333">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-334">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-335">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-336">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-337">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AVONEXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-338">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-339">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-340">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-341">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-342">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-343">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:PLEGRIDYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-344">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-345">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-346">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-347">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-348">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-349">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:InterferonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-350">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-351">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-352">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-353">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-354">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-355">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TysabriProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-356">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-357">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-358">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-359">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-360">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-361">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FAMPYRAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-362">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-363">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-364">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-365">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-366">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-367">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:MSProductRevenuesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-368">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-369">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-370">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-371">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-372">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-373">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SPINRAZAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-374">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SKYCLARYSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-375">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SKYCLARYSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-376">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SKYCLARYSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-377">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SKYCLARYSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-378">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SKYCLARYSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-379">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:SKYCLARYSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-380">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:QALSODYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-381">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:QALSODYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-382">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:QALSODYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-383">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:QALSODYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-384">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:QALSODYMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-385">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:QALSODYMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-386">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RareDiseaseProductRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-387">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RareDiseaseProductRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-388">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RareDiseaseProductRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-389">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RareDiseaseProductRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-390">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RareDiseaseProductRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-391">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RareDiseaseProductRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-392">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-393">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-394">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-395">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-396">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-397">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BENEPALIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-398">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-399">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-400">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-401">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:IMRALDIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-405">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-406">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-407">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-408">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-409">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FLIXABIMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-410">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-411">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-412">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-413">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-414">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-415">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BYOOVIZMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-416">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TOFIDENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-417">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TOFIDENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-418">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TOFIDENCEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-419">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TOFIDENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-420">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TOFIDENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-421">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:TOFIDENCEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-422">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-423">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-424">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-425">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-426">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-427">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:BiosimilarsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-428">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZURZUVAEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-429">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZURZUVAEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZURZUVAEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-431">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZURZUVAEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-432">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZURZUVAEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-433">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZURZUVAEMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-434">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-435">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-436">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-437">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-438">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-439">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FUMADERMAndADUHELMMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-440">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-441">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-442">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-443">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-444">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OtherProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-445">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OtherProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-446">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-447">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-448">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-449">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-450">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-451">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-452">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-453">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-454">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-455">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-456">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-457">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:DistributorTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-458">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-459">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-460">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-461">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-462">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-463">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-464">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ReserveforCashDiscountsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-465">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">biib:ContractualAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-466">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:SalesReturnsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-467">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-468">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-469">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-470">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-471">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RoyaltyAttributedToOCREVUSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-472">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RoyaltyAttributedToOCREVUSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-473">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RoyaltyAttributedToOCREVUSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-474">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RoyaltyAttributedToOCREVUSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-475">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-476">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-477">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-478">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">biib:RocheGroupGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-479">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:LEQEMBICollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-480">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AlzheimersCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-481">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AlzheimersCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-482">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AlzheimersCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-483">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:AlzheimersCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-484">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ContractManufacturingAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-485">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ContractManufacturingAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-486">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ContractManufacturingAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-487">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ContractManufacturingAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-488">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-489">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-490">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-491">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-492">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-26</instant>
        </period>
    </context>
    <context id="c-493">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:NonrecurringAdjustmentAxis">us-gaap:FairValueAdjustmentToInventoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-494">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:NonrecurringAdjustmentAxis">us-gaap:FairValueAdjustmentToInventoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-495">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:NonrecurringAdjustmentAxis">us-gaap:FairValueAdjustmentToInventoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-496">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:NonrecurringAdjustmentAxis">us-gaap:FairValueAdjustmentToInventoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-497">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ClinicalInventoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:NonrecurringAdjustmentAxis">us-gaap:FairValueAdjustmentToInventoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-498">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ClinicalInventoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:NonrecurringAdjustmentAxis">us-gaap:FairValueAdjustmentToInventoryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-499">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-500">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-502">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-503">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">biib:PriorityReviewVoucherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-504">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">biib:PriorityReviewVoucherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-505">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-506">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksAndTradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-507">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:AcquiredAndInLicensedRightsAndPatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-508">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-509">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">biib:PriorityReviewVoucherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-511">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-512">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-513">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-514">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-515">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-516">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-517">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-518">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-519">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-520">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-521">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-522">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-523">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-524">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-525">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-526">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-527">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-528">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-529">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-530">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-532">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-533">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-534">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-535">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">biib:MeasurementInputProbabilityRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-536">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-537">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-538">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-539">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-540">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-541">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.25SeniorNotesdueMay12030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-542">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.25SeniorNotesdueMay12030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-543">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.25SeniorNotesdueMay12030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-544">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2.25SeniorNotesdueMay12030Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-545">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A5.050SeniorNotesDueJanuary152031Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-546">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A5.050SeniorNotesDueJanuary152031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-547">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A5.050SeniorNotesDueJanuary152031Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-548">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A5.050SeniorNotesDueJanuary152031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-549">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A5.750SeniorNotesDueMay152035Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-550">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A5.750SeniorNotesDueMay152035Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-551">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A5.750SeniorNotesDueMay152035Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-552">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A5.750SeniorNotesDueMay152035Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-553">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-554">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-555">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-556">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFivePointTwoPercentDueTwentyFortyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-557">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3.15SeniorNotesdueMay12050Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-558">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3.15SeniorNotesdueMay12050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-559">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3.15SeniorNotesdueMay12050Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-560">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A3.15SeniorNotesdueMay12050Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-561">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotes3.250DueFebruary152051Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-562">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotes3.250DueFebruary152051Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-563">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotes3.250DueFebruary152051Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-564">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotes3.250DueFebruary152051Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-565">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A6.450SeniorNotesDueMay152055Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-566">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A6.450SeniorNotesDueMay152055Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-567">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A6.450SeniorNotesDueMay152055Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-568">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A6.450SeniorNotesDueMay152055Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-569">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:NonCurrentPortionOfNotesPayableAndTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-570">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:NonCurrentPortionOfNotesPayableAndTermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-571">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-12</instant>
        </period>
    </context>
    <context id="c-572">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-573">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-574">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-575">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-576">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-577">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-578">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:CorporateDebtSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-579">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:GovernmentSecuritiesCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-580">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:EquitySecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-581">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:EquitySecuritiesNonCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-582">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-583">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">biib:StrategicInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-584">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-585">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-586">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-587">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-588">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-589">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:GBP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-590">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-591">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CHF</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-592">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-593">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:CAD</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-594">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-595">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-596">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-597">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-598">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-599">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-600">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-601">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-602">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-603">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-604">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-605">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-606">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-607">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsrevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-609">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-610">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-611">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">biib:CashflowsoperatingexpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OperatingExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-612">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-613">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-614">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-615">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-616">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-617">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-618">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-619">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-620">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-621">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-622">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-623">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccruedLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-624">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">biib:HeadquartersLeaseFiveYearRenewalOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-625">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">biib:HeadquartersLeaseFiveYearRenewalOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-626">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">biib:HeadquartersLeaseSixMonthRenewalOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-03-01</startDate>
            <endDate>2025-03-31</endDate>
        </period>
    </context>
    <context id="c-627">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">biib:HeadquartersLeaseSixMonthRenewalOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-628">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A5.050SeniorNotesDueJanuary152031Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-12</instant>
        </period>
    </context>
    <context id="c-629">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A5.750SeniorNotesDueMay152035Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-12</instant>
        </period>
    </context>
    <context id="c-630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A6.450SeniorNotesDueMay152055Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-05-12</instant>
        </period>
    </context>
    <context id="c-631">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2025SeniorNotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-632">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-09-15</instant>
        </period>
    </context>
    <context id="c-633">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:SeniorNotesFourPointZeroFivePercentDueTwentyTwentyFiveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-634">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:TheCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-635">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:ReataPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:SecuredDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:TheCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-636">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:TheCreditFacilityFloatingRate364DayTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-637">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:TheCreditFacilityFloatingRateThreeYearTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-638">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:TheCreditFacilityTerminatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-639">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">biib:FloatingRate364DayTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2023TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-640">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">biib:FloatingRate364DayTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2023TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-641">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">biib:FloatingRate364DayTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:TheCreditFacilityFloatingRateThreeYearTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-642">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">biib:TermLoan2023ThreeYearTrancheMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">biib:A2023TermLoanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-643">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="c-644">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ShareRepurchaseProgramAxis">biib:A2020ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-645">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-646">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-647">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-648">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-649">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-650">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-651">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-652">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-653">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-654">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-655">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-656">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-657">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-658">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-659">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-660">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-661">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-662">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="c-663">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-664">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-665">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-666">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-667">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-668">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-09-30</instant>
        </period>
    </context>
    <context id="c-669">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-670">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-671">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-672">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-673">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-674">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-675">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-676">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-677">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-678">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-679">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-680">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-681">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-682">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis">us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-683">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-684">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-685">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-686">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-687">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-688">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-689">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-690">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-691">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-692">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-693">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-694">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-695">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-696">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-697">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-698">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-699">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-700">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-701">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-704">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-705">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-706">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:TimeVestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-707">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-708">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-709">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-710">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-711">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-712">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-713">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-714">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-715">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-716">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-717">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-718">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:PerformanceStockUnitsSettledinCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-719">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-720">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-721">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-722">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-723">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-724">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-725">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-726">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">biib:MarketStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-727">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-728">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">biib:HumanImmunologyBiosciencesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-729">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:SageAndDenaliMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-730">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:SageAndSangamoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-732">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-733">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-734">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:SageAndSangamoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-735">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-736">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OCREVUSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-03-01</startDate>
            <endDate>2017-03-31</endDate>
        </period>
    </context>
    <context id="c-737">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OCREVUSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-03-01</startDate>
            <endDate>2017-03-31</endDate>
        </period>
    </context>
    <context id="c-738">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OCREVUSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-03-01</startDate>
            <endDate>2017-03-31</endDate>
        </period>
    </context>
    <context id="c-739">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:OCREVUSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-03-01</startDate>
            <endDate>2017-03-31</endDate>
        </period>
    </context>
    <context id="c-740">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:RituxanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-741">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:LUNSUMIOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-742">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:LUNSUMIOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-743">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:GAZYVAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-744">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:IonisPharmaceuticalsInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-745">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:LEQEMBIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:LEQEMBICollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-746">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:LEQEMBIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:LEQEMBICollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-747">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-748">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-749">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:LEQEMBIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:LEQEMBICollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-750">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:LEQEMBIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:LEQEMBICollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-751">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-752">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:E2609andBAN2401Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-753">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-754">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:EisaiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-755">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-756">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-757">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-758">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:UCBPharmaSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-759">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-760">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-761">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-762">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-763">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-764">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-765">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-766">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-767">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-768">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-769">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-770">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-771">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SageTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-772">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-773">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-774">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-775">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:DenaliTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-776">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZorevunersenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:StokeTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-01</startDate>
            <endDate>2025-02-28</endDate>
        </period>
    </context>
    <context id="c-777">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:ZorevunersenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-01</startDate>
            <endDate>2025-02-28</endDate>
        </period>
    </context>
    <context id="c-778">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:StokeTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-02-01</startDate>
            <endDate>2025-02-28</endDate>
        </period>
    </context>
    <context id="c-779">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">biib:MilestonePaymentDevelopmentalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:StokeTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-780">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">biib:MilestonePaymentCommercialMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:StokeTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-781">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:StokeTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-782">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:StokeTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-783">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c-784">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-785">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-786">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-787">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-788">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-789">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-790">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-791">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-792">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">us-gaap:RelatedPartyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:SamsungBiosimilarAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-793">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-02-11</instant>
        </period>
    </context>
    <context id="c-794">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">biib:MilestonePaymentFutureDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-795">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FelzartamabAndIzastobartHIB210Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">biib:HumanImmunologyBiosciencesPreExistingInLicenseCommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">biib:MilestonePaymentOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-796">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">biib:FelzartamabAndIzastobartHIB210Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">biib:HumanImmunologyBiosciencesPreExistingInLicenseCommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">biib:MilestonePaymentTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-797">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">biib:CityTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-798">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">biib:CityTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-799">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">biib:CityTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-800">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">biib:CityTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">biib:MilestonePaymentResearchMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-801">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">biib:CityTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">biib:MilestonePaymentDevelopmentalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-802">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">biib:CityTherapeuticsInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">biib:MilestonePaymentSalesBasedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-09-30</instant>
        </period>
    </context>
    <context id="c-803">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">biib:IMRALDIPatentLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="c-804">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">biib:ConvergenceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="c-805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">biib:ConvergenceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-806">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">biib:GenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-09-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-808">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-809">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-810">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-811">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-812">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-813">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-814">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-815">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-816">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-817">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-818">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-819">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">biib:ResearchAndDiscoveryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-820">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">biib:ResearchAndDiscoveryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-821">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">biib:ResearchAndDiscoveryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-822">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">biib:ResearchAndDiscoveryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-823">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">biib:EarlyStageProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-824">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">biib:EarlyStageProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-825">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">biib:EarlyStageProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-826">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">biib:EarlyStageProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-827">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">biib:LateStageProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-828">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">biib:LateStageProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-829">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">biib:LateStageProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-830">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">biib:LateStageProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">biib:MarketedProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-832">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">biib:MarketedProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-833">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">biib:MarketedProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-834">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">biib:MarketedProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-835">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:ServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-07-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-836">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:ServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-837">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:ServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-838">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:ServiceOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">biib:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-839">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">biib:VanquaBioInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-10-31</endDate>
        </period>
    </context>
    <context id="c-840">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000875045</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-10-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="segment">
        <measure>biib:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="employee">
        <measure>biib:Employee</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="wholesaler">
        <measure>biib:wholesaler</measure>
    </unit>
    <unit id="product">
        <measure>biib:product</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-25">0000875045</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-26">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-27">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-28">Q3</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag contextRef="c-1" id="f-29">false</dei:AmendmentFlag>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-2" decimals="INF" id="f-30" unitRef="shares">146702272</dei:EntityCommonStockSharesOutstanding>
    <biib:LesseeOperatingLeaseNumberOfRenewalOptions
      contextRef="c-624"
      decimals="INF"
      id="f-1379"
      unitRef="product">3</biib:LesseeOperatingLeaseNumberOfRenewalOptions>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-625" id="f-1380">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <biib:LesseeOperatingLeaseNumberOfRenewalOptions
      contextRef="c-626"
      decimals="INF"
      id="f-1381"
      unitRef="product">1</biib:LesseeOperatingLeaseNumberOfRenewalOptions>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-627" id="f-1382">P6M</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner contextRef="c-840" decimals="-5" id="f-1923" unitRef="usd">50000000</biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
    <dei:DocumentType contextRef="c-1" id="f-1">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="c-1" id="f-2">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2025-09-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-4">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">0-19311</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-6">BIOGEN INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-8">33-0112644</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-9">225 Binney Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-10">Cambridge</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-11">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-12">02142</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-13">617</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-14">679-2000</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-15">Common Stock, $0.0005 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-16">BIIB</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-17">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-18">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-19">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-20">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-21">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-22">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="c-1" id="f-23">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-2" decimals="INF" id="f-24" unitRef="shares">146702272</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:Revenues contextRef="c-3" decimals="-5" id="f-31" unitRef="usd">1846900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-4" decimals="-5" id="f-32" unitRef="usd">1769400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-5" decimals="-5" id="f-33" unitRef="usd">5452100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-6" decimals="-5" id="f-34" unitRef="usd">5380900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-7" decimals="-5" id="f-35" unitRef="usd">493900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-8" decimals="-5" id="f-36" unitRef="usd">446200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-9" decimals="-5" id="f-37" unitRef="usd">1339400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-10" decimals="-5" id="f-38" unitRef="usd">1284700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-11" decimals="-5" id="f-39" unitRef="usd">42700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-12" decimals="-5" id="f-40" unitRef="usd">18600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-13" decimals="-5" id="f-41" unitRef="usd">130600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-14" decimals="-5" id="f-42" unitRef="usd">33200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-15" decimals="-5" id="f-43" unitRef="usd">151200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-16" decimals="-5" id="f-44" unitRef="usd">231600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-17" decimals="-5" id="f-45" unitRef="usd">689100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-18" decimals="-5" id="f-46" unitRef="usd">522400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-19" decimals="-5" id="f-47" unitRef="usd">2534700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-20" decimals="-5" id="f-48" unitRef="usd">2465800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-1" decimals="-5" id="f-49" unitRef="usd">7611200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-21" decimals="-5" id="f-50" unitRef="usd">7221200000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-19" decimals="-5" id="f-51" unitRef="usd">674400000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-20" decimals="-5" id="f-52" unitRef="usd">638700000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-1" decimals="-5" id="f-53" unitRef="usd">1908700000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-21" decimals="-5" id="f-54" unitRef="usd">1726900000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-19" decimals="-5" id="f-55" unitRef="usd">436100000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-20" decimals="-5" id="f-56" unitRef="usd">516200000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-1" decimals="-5" id="f-57" unitRef="usd">1269200000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-21" decimals="-5" id="f-58" unitRef="usd">1467000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <biib:ResearchAndDevelopmentExpenseIncludingAcquiredInProcessCost contextRef="c-19" decimals="-5" id="f-59" unitRef="usd">2100000</biib:ResearchAndDevelopmentExpenseIncludingAcquiredInProcessCost>
    <biib:ResearchAndDevelopmentExpenseIncludingAcquiredInProcessCost contextRef="c-20" decimals="-5" id="f-60" unitRef="usd">26500000</biib:ResearchAndDevelopmentExpenseIncludingAcquiredInProcessCost>
    <biib:ResearchAndDevelopmentExpenseIncludingAcquiredInProcessCost contextRef="c-1" decimals="-5" id="f-61" unitRef="usd">249400000</biib:ResearchAndDevelopmentExpenseIncludingAcquiredInProcessCost>
    <biib:ResearchAndDevelopmentExpenseIncludingAcquiredInProcessCost contextRef="c-21" decimals="-5" id="f-62" unitRef="usd">42500000</biib:ResearchAndDevelopmentExpenseIncludingAcquiredInProcessCost>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-19" decimals="-5" id="f-63" unitRef="usd">594800000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-20" decimals="-5" id="f-64" unitRef="usd">588400000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-1" decimals="-5" id="f-65" unitRef="usd">1751100000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-21" decimals="-5" id="f-66" unitRef="usd">1723700000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets contextRef="c-19" decimals="-5" id="f-67" unitRef="usd">135700000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets contextRef="c-20" decimals="-5" id="f-68" unitRef="usd">130300000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets contextRef="c-1" decimals="-5" id="f-69" unitRef="usd">378400000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets contextRef="c-21" decimals="-5" id="f-70" unitRef="usd">295500000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:Collaborationprofitlosssharing contextRef="c-19" decimals="-5" id="f-71" unitRef="usd">87200000</biib:Collaborationprofitlosssharing>
    <biib:Collaborationprofitlosssharing contextRef="c-20" decimals="-5" id="f-72" unitRef="usd">69300000</biib:Collaborationprofitlosssharing>
    <biib:Collaborationprofitlosssharing contextRef="c-1" decimals="-5" id="f-73" unitRef="usd">220300000</biib:Collaborationprofitlosssharing>
    <biib:Collaborationprofitlosssharing contextRef="c-21" decimals="-5" id="f-74" unitRef="usd">197300000</biib:Collaborationprofitlosssharing>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-19" decimals="-5" id="f-75" unitRef="usd">5600000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-20" decimals="-5" id="f-76" unitRef="usd">23800000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-1" decimals="-5" id="f-77" unitRef="usd">28400000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-21" decimals="-5" id="f-78" unitRef="usd">23800000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:RestructuringCharges contextRef="c-19" decimals="-5" id="f-79" unitRef="usd">7400000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-20" decimals="-5" id="f-80" unitRef="usd">6800000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-1" decimals="-5" id="f-81" unitRef="usd">42000000.0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-21" decimals="-5" id="f-82" unitRef="usd">24900000</us-gaap:RestructuringCharges>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets contextRef="c-19" decimals="-5" id="f-83" unitRef="usd">0</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets contextRef="c-20" decimals="-5" id="f-84" unitRef="usd">0</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets contextRef="c-1" decimals="-5" id="f-85" unitRef="usd">0</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets contextRef="c-21" decimals="-5" id="f-86" unitRef="usd">88600000</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-19" decimals="-5" id="f-87" unitRef="usd">-34100000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-20" decimals="-5" id="f-88" unitRef="usd">-14800000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-1" decimals="-5" id="f-89" unitRef="usd">-151200000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-21" decimals="-5" id="f-90" unitRef="usd">-193700000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:CostsAndExpenses contextRef="c-19" decimals="-5" id="f-91" unitRef="usd">1977400000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-20" decimals="-5" id="f-92" unitRef="usd">2014800000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-1" decimals="-5" id="f-93" unitRef="usd">5998700000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses contextRef="c-21" decimals="-5" id="f-94" unitRef="usd">5606700000</us-gaap:CostsAndExpenses>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-19" decimals="-5" id="f-95" unitRef="usd">557300000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-20" decimals="-5" id="f-96" unitRef="usd">451000000.0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-5" id="f-97" unitRef="usd">1612500000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-21" decimals="-5" id="f-98" unitRef="usd">1614500000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-19" decimals="-5" id="f-99" unitRef="usd">90800000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-20" decimals="-5" id="f-100" unitRef="usd">62500000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-5" id="f-101" unitRef="usd">270700000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-21" decimals="-5" id="f-102" unitRef="usd">249000000.0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c-19" decimals="-5" id="f-103" unitRef="usd">466500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-20" decimals="-5" id="f-104" unitRef="usd">388500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-5" id="f-105" unitRef="usd">1341800000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-21" decimals="-5" id="f-106" unitRef="usd">1365500000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-19"
      decimals="2"
      id="f-107"
      unitRef="usdPerShare">3.18</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-20"
      decimals="2"
      id="f-108"
      unitRef="usdPerShare">2.67</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-109"
      unitRef="usdPerShare">9.16</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-21"
      decimals="2"
      id="f-110"
      unitRef="usdPerShare">9.38</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-19"
      decimals="2"
      id="f-111"
      unitRef="usdPerShare">3.17</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-20"
      decimals="2"
      id="f-112"
      unitRef="usdPerShare">2.66</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-113"
      unitRef="usdPerShare">9.14</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-21"
      decimals="2"
      id="f-114"
      unitRef="usdPerShare">9.35</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-19" decimals="-5" id="f-115" unitRef="shares">146600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-20" decimals="-5" id="f-116" unitRef="shares">145700000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-5" id="f-117" unitRef="shares">146400000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-21" decimals="-5" id="f-118" unitRef="shares">145500000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-19" decimals="-5" id="f-119" unitRef="shares">147100000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-20" decimals="-5" id="f-120" unitRef="shares">146100000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-5" id="f-121" unitRef="shares">146800000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-21" decimals="-5" id="f-122" unitRef="shares">146000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss contextRef="c-19" decimals="-5" id="f-123" unitRef="usd">466500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-20" decimals="-5" id="f-124" unitRef="usd">388500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-5" id="f-125" unitRef="usd">1341800000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-21" decimals="-5" id="f-126" unitRef="usd">1365500000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax contextRef="c-19" decimals="-5" id="f-127" unitRef="usd">26500000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax contextRef="c-20" decimals="-5" id="f-128" unitRef="usd">-41000000.0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax contextRef="c-1" decimals="-5" id="f-129" unitRef="usd">-137100000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax contextRef="c-21" decimals="-5" id="f-130" unitRef="usd">-6200000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax contextRef="c-19" decimals="-5" id="f-131" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax contextRef="c-20" decimals="-5" id="f-132" unitRef="usd">-300000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax contextRef="c-1" decimals="-5" id="f-133" unitRef="usd">-1000000.0</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax contextRef="c-21" decimals="-5" id="f-134" unitRef="usd">-200000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-19" decimals="-5" id="f-135" unitRef="usd">-3200000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-20" decimals="-5" id="f-136" unitRef="usd">41000000.0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-1" decimals="-5" id="f-137" unitRef="usd">57500000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-21" decimals="-5" id="f-138" unitRef="usd">14000000.0</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-19" decimals="-5" id="f-139" unitRef="usd">23300000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-20" decimals="-5" id="f-140" unitRef="usd">300000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-5" id="f-141" unitRef="usd">-78600000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-21" decimals="-5" id="f-142" unitRef="usd">8000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-19" decimals="-5" id="f-143" unitRef="usd">489800000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-20" decimals="-5" id="f-144" unitRef="usd">388800000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-5" id="f-145" unitRef="usd">1263200000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-21" decimals="-5" id="f-146" unitRef="usd">1373500000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-22" decimals="-5" id="f-147" unitRef="usd">3862800000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-23" decimals="-5" id="f-148" unitRef="usd">2375000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-22" decimals="-5" id="f-149" unitRef="usd">97600000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-23" decimals="-5" id="f-150" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c-23" decimals="-5" id="f-151" unitRef="usd">3100000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent contextRef="c-22" decimals="-5" id="f-152" unitRef="usd">2200000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-24" decimals="-5" id="f-153" unitRef="usd">1374100000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-25" decimals="-5" id="f-154" unitRef="usd">1404800000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-26" decimals="-5" id="f-155" unitRef="usd">475900000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-27" decimals="-5" id="f-156" unitRef="usd">464000000.0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="c-22" decimals="-5" id="f-157" unitRef="usd">2209400000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-23" decimals="-5" id="f-158" unitRef="usd">2460500000</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent contextRef="c-22" decimals="-5" id="f-159" unitRef="usd">916800000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-23" decimals="-5" id="f-160" unitRef="usd">752500000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-22" decimals="-5" id="f-161" unitRef="usd">8936600000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-23" decimals="-5" id="f-162" unitRef="usd">7456800000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-22" decimals="-5" id="f-163" unitRef="usd">3075700000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-23" decimals="-5" id="f-164" unitRef="usd">3181300000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-22" decimals="-5" id="f-165" unitRef="usd">330500000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-23" decimals="-5" id="f-166" unitRef="usd">356400000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-22" decimals="-5" id="f-167" unitRef="usd">9331900000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-23" decimals="-5" id="f-168" unitRef="usd">9691200000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill contextRef="c-22" decimals="-5" id="f-169" unitRef="usd">6490700000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-23" decimals="-5" id="f-170" unitRef="usd">6478900000</us-gaap:Goodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet contextRef="c-22" decimals="-5" id="f-171" unitRef="usd">312400000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet contextRef="c-23" decimals="-5" id="f-172" unitRef="usd">324200000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-22" decimals="-5" id="f-173" unitRef="usd">729700000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-23" decimals="-5" id="f-174" unitRef="usd">560500000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-22" decimals="-5" id="f-175" unitRef="usd">29207500000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-23" decimals="-5" id="f-176" unitRef="usd">28049300000</us-gaap:Assets>
    <us-gaap:NotesPayableCurrent contextRef="c-22" decimals="-5" id="f-177" unitRef="usd">0</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="c-23" decimals="-5" id="f-178" unitRef="usd">1748600000</us-gaap:NotesPayableCurrent>
    <us-gaap:TaxesPayableCurrent contextRef="c-22" decimals="-5" id="f-179" unitRef="usd">103300000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent contextRef="c-23" decimals="-5" id="f-180" unitRef="usd">548300000</us-gaap:TaxesPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-22" decimals="-5" id="f-181" unitRef="usd">413100000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-23" decimals="-5" id="f-182" unitRef="usd">424200000</us-gaap:AccountsPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-22" decimals="-5" id="f-183" unitRef="usd">2773600000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-23" decimals="-5" id="f-184" unitRef="usd">2807700000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-22" decimals="-5" id="f-185" unitRef="usd">3290000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-23" decimals="-5" id="f-186" unitRef="usd">5528800000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebt contextRef="c-22" decimals="-5" id="f-187" unitRef="usd">6285100000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="c-23" decimals="-5" id="f-188" unitRef="usd">4547200000</us-gaap:LongTermDebt>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c-22" decimals="-5" id="f-189" unitRef="usd">358100000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet contextRef="c-23" decimals="-5" id="f-190" unitRef="usd">190500000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-22" decimals="-5" id="f-191" unitRef="usd">305000000.0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-23" decimals="-5" id="f-192" unitRef="usd">334500000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-22" decimals="-5" id="f-193" unitRef="usd">761800000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-23" decimals="-5" id="f-194" unitRef="usd">732300000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-22" decimals="-5" id="f-195" unitRef="usd">11000000000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-23" decimals="-5" id="f-196" unitRef="usd">11333300000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-22" id="f-197" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-23" id="f-198" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-22"
      decimals="3"
      id="f-199"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockValue contextRef="c-22" decimals="-5" id="f-200" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-23" decimals="-5" id="f-201" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-22"
      decimals="4"
      id="f-202"
      unitRef="usdPerShare">0.0005</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockValue contextRef="c-22" decimals="-5" id="f-203" unitRef="usd">100000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-23" decimals="-5" id="f-204" unitRef="usd">100000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="c-22" decimals="-5" id="f-205" unitRef="usd">797700000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-23" decimals="-5" id="f-206" unitRef="usd">569400000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-22" decimals="-5" id="f-207" unitRef="usd">-214800000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-23" decimals="-5" id="f-208" unitRef="usd">-136200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-22" decimals="-5" id="f-209" unitRef="usd">20601600000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-23" decimals="-5" id="f-210" unitRef="usd">19259800000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:TreasuryStockValue contextRef="c-22" decimals="-5" id="f-211" unitRef="usd">2977100000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue contextRef="c-23" decimals="-5" id="f-212" unitRef="usd">2977100000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-22" decimals="-5" id="f-213" unitRef="usd">18207500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-23" decimals="-5" id="f-214" unitRef="usd">16716000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-22" decimals="-5" id="f-215" unitRef="usd">29207500000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-23" decimals="-5" id="f-216" unitRef="usd">28049300000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-5" id="f-217" unitRef="usd">1341800000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-21" decimals="-5" id="f-218" unitRef="usd">1365500000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-5" id="f-219" unitRef="usd">579700000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-21" decimals="-5" id="f-220" unitRef="usd">489200000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill contextRef="c-1" decimals="-5" id="f-221" unitRef="usd">3500000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill contextRef="c-21" decimals="-5" id="f-222" unitRef="usd">20200000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:InventoryWriteDown contextRef="c-1" decimals="-5" id="f-223" unitRef="usd">13900000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown contextRef="c-21" decimals="-5" id="f-224" unitRef="usd">68700000</us-gaap:InventoryWriteDown>
    <biib:AmortizationOfInventoryStepUp contextRef="c-1" decimals="-5" id="f-225" unitRef="usd">165400000</biib:AmortizationOfInventoryStepUp>
    <biib:AmortizationOfInventoryStepUp contextRef="c-21" decimals="-5" id="f-226" unitRef="usd">185100000</biib:AmortizationOfInventoryStepUp>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-5" id="f-227" unitRef="usd">231200000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-21" decimals="-5" id="f-228" unitRef="usd">216100000</us-gaap:ShareBasedCompensation>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-1" decimals="-5" id="f-229" unitRef="usd">28400000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-21" decimals="-5" id="f-230" unitRef="usd">23800000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-1" decimals="-5" id="f-231" unitRef="usd">194700000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-21" decimals="-5" id="f-232" unitRef="usd">-99700000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi contextRef="c-1" decimals="-5" id="f-233" unitRef="usd">-33700000</us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi>
    <us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi contextRef="c-21" decimals="-5" id="f-234" unitRef="usd">-22700000</us-gaap:IncreaseDecreaseInEquitySecuritiesFvNi>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-1" decimals="-5" id="f-235" unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-21" decimals="-5" id="f-236" unitRef="usd">88600000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-1" decimals="-5" id="f-237" unitRef="usd">-49300000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense contextRef="c-21" decimals="-5" id="f-238" unitRef="usd">-95100000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-28" decimals="-5" id="f-239" unitRef="usd">-74900000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-29" decimals="-5" id="f-240" unitRef="usd">-127600000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-30" decimals="-5" id="f-241" unitRef="usd">11800000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-31" decimals="-5" id="f-242" unitRef="usd">15900000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-1" decimals="-5" id="f-243" unitRef="usd">35300000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-21" decimals="-5" id="f-244" unitRef="usd">207400000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-1" decimals="-5" id="f-245" unitRef="usd">-32700000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-21" decimals="-5" id="f-246" unitRef="usd">-84200000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable contextRef="c-1" decimals="-5" id="f-247" unitRef="usd">-764100000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable contextRef="c-21" decimals="-5" id="f-248" unitRef="usd">62100000</us-gaap:IncreaseDecreaseInAccruedIncomeTaxesPayable>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet contextRef="c-1" decimals="-5" id="f-249" unitRef="usd">179900000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet contextRef="c-21" decimals="-5" id="f-250" unitRef="usd">65700000</us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-5" id="f-251" unitRef="usd">1692700000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-21" decimals="-5" id="f-252" unitRef="usd">2114600000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-5" id="f-253" unitRef="usd">109900000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-21" decimals="-5" id="f-254" unitRef="usd">114400000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="c-1" decimals="-5" id="f-255" unitRef="usd">91000000.0</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt contextRef="c-21" decimals="-5" id="f-256" unitRef="usd">0</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-1" decimals="-5" id="f-257" unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired contextRef="c-21" decimals="-5" id="f-258" unitRef="usd">1074800000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments contextRef="c-1" decimals="-5" id="f-259" unitRef="usd">0</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments contextRef="c-21" decimals="-5" id="f-260" unitRef="usd">406800000</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c-1" decimals="-5" id="f-261" unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c-21" decimals="-5" id="f-262" unitRef="usd">88600000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c-1" decimals="-5" id="f-263" unitRef="usd">15300000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets contextRef="c-21" decimals="-5" id="f-264" unitRef="usd">179100000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:ProceedsFromSaleOfOtherInvestments contextRef="c-1" decimals="-5" id="f-265" unitRef="usd">56600000</us-gaap:ProceedsFromSaleOfOtherInvestments>
    <us-gaap:ProceedsFromSaleOfOtherInvestments contextRef="c-21" decimals="-5" id="f-266" unitRef="usd">96700000</us-gaap:ProceedsFromSaleOfOtherInvestments>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="c-1" decimals="-5" id="f-267" unitRef="usd">-20200000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities contextRef="c-21" decimals="-5" id="f-268" unitRef="usd">4400000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-5" id="f-269" unitRef="usd">-139400000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-21" decimals="-5" id="f-270" unitRef="usd">-780600000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-1" decimals="-5" id="f-271" unitRef="usd">13000000.0</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation contextRef="c-21" decimals="-5" id="f-272" unitRef="usd">34800000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c-1" decimals="-5" id="f-273" unitRef="usd">1733100000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c-21" decimals="-5" id="f-274" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-1" decimals="-5" id="f-275" unitRef="usd">1750000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-21" decimals="-5" id="f-276" unitRef="usd">650000000.0</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities contextRef="c-1" decimals="-5" id="f-277" unitRef="usd">141300000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities contextRef="c-21" decimals="-5" id="f-278" unitRef="usd">0</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="c-1" decimals="-5" id="f-279" unitRef="usd">6300000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities contextRef="c-21" decimals="-5" id="f-280" unitRef="usd">-6600000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-5" id="f-281" unitRef="usd">-164900000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-21" decimals="-5" id="f-282" unitRef="usd">-691400000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c-1" decimals="-5" id="f-283" unitRef="usd">1388400000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c-21" decimals="-5" id="f-284" unitRef="usd">642600000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-1" decimals="-5" id="f-285" unitRef="usd">99400000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-21" decimals="-5" id="f-286" unitRef="usd">6700000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-23" decimals="-5" id="f-287" unitRef="usd">2375000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-32" decimals="-5" id="f-288" unitRef="usd">1049900000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-22" decimals="-5" id="f-289" unitRef="usd">3862800000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-33" decimals="-5" id="f-290" unitRef="usd">1699200000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-34" decimals="-5" id="f-291" unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-34" decimals="-5" id="f-292" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-35" decimals="-5" id="f-293" unitRef="shares">170400000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-35" decimals="-5" id="f-294" unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-36" decimals="-5" id="f-295" unitRef="usd">714000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-37" decimals="-5" id="f-296" unitRef="usd">-238100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-38" decimals="-5" id="f-297" unitRef="usd">20135100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares contextRef="c-39" decimals="-5" id="f-298" unitRef="shares">-23800000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-39" decimals="-5" id="f-299" unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-40" decimals="-5" id="f-300" unitRef="usd">17634000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c-41" decimals="-5" id="f-301" unitRef="usd">466500000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-19" decimals="-5" id="f-302" unitRef="usd">466500000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-42" decimals="-5" id="f-303" unitRef="usd">23300000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-19" decimals="-5" id="f-304" unitRef="usd">23300000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="c-43" decimals="-5" id="f-305" unitRef="usd">6500000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="c-19" decimals="-5" id="f-306" unitRef="usd">6500000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="c-44" decimals="-5" id="f-307" unitRef="shares">100000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-43" decimals="-5" id="f-308" unitRef="usd">-1200000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-19" decimals="-5" id="f-309" unitRef="usd">-1200000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-43" decimals="-5" id="f-310" unitRef="usd">78400000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-19" decimals="-5" id="f-311" unitRef="usd">78400000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-45" decimals="-5" id="f-312" unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-45" decimals="-5" id="f-313" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-46" decimals="-5" id="f-314" unitRef="shares">170500000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-46" decimals="-5" id="f-315" unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-47" decimals="-5" id="f-316" unitRef="usd">797700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-48" decimals="-5" id="f-317" unitRef="usd">-214800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-49" decimals="-5" id="f-318" unitRef="usd">20601600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares contextRef="c-50" decimals="-5" id="f-319" unitRef="shares">-23800000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-50" decimals="-5" id="f-320" unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-22" decimals="-5" id="f-321" unitRef="usd">18207500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-51" decimals="-5" id="f-322" unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-51" decimals="-5" id="f-323" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-52" decimals="-5" id="f-324" unitRef="shares">169500000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-52" decimals="-5" id="f-325" unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-53" decimals="-5" id="f-326" unitRef="usd">569400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-54" decimals="-5" id="f-327" unitRef="usd">-136200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-55" decimals="-5" id="f-328" unitRef="usd">19259800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares contextRef="c-56" decimals="-5" id="f-329" unitRef="shares">-23800000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-56" decimals="-5" id="f-330" unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-23" decimals="-5" id="f-331" unitRef="usd">16716000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c-57" decimals="-5" id="f-332" unitRef="usd">1341800000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-5" id="f-333" unitRef="usd">1341800000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-58" decimals="-5" id="f-334" unitRef="usd">-78600000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-1" decimals="-5" id="f-335" unitRef="usd">-78600000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued contextRef="c-59" decimals="-5" id="f-336" unitRef="shares">300000</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="c-60" decimals="-5" id="f-337" unitRef="usd">28600000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="c-1" decimals="-5" id="f-338" unitRef="usd">28600000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="c-59" decimals="-5" id="f-339" unitRef="shares">700000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-60" decimals="-5" id="f-340" unitRef="usd">-41500000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-1" decimals="-5" id="f-341" unitRef="usd">-41500000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-60" decimals="-5" id="f-342" unitRef="usd">240600000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-5" id="f-343" unitRef="usd">240600000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockholdersEquityOther contextRef="c-60" decimals="-5" id="f-344" unitRef="usd">-600000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther contextRef="c-1" decimals="-5" id="f-345" unitRef="usd">-600000</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-45" decimals="-5" id="f-346" unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-45" decimals="-5" id="f-347" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-46" decimals="-5" id="f-348" unitRef="shares">170500000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-46" decimals="-5" id="f-349" unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-47" decimals="-5" id="f-350" unitRef="usd">797700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-48" decimals="-5" id="f-351" unitRef="usd">-214800000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-49" decimals="-5" id="f-352" unitRef="usd">20601600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares contextRef="c-50" decimals="-5" id="f-353" unitRef="shares">-23800000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-50" decimals="-5" id="f-354" unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-22" decimals="-5" id="f-355" unitRef="usd">18207500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-61" decimals="-5" id="f-356" unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-61" decimals="-5" id="f-357" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-62" decimals="-5" id="f-358" unitRef="shares">169500000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-62" decimals="-5" id="f-359" unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-63" decimals="-5" id="f-360" unitRef="usd">407500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-64" decimals="-5" id="f-361" unitRef="usd">-146000000.0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-65" decimals="-5" id="f-362" unitRef="usd">18604600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares contextRef="c-66" decimals="-5" id="f-363" unitRef="shares">-23800000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-66" decimals="-5" id="f-364" unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-67" decimals="-5" id="f-365" unitRef="usd">15889100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c-68" decimals="-5" id="f-366" unitRef="usd">388500000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-20" decimals="-5" id="f-367" unitRef="usd">388500000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-69" decimals="-5" id="f-368" unitRef="usd">300000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-20" decimals="-5" id="f-369" unitRef="usd">300000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="c-70" decimals="-5" id="f-370" unitRef="usd">7600000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="c-20" decimals="-5" id="f-371" unitRef="usd">7600000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-70" decimals="-5" id="f-372" unitRef="usd">-1600000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-20" decimals="-5" id="f-373" unitRef="usd">-1600000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-70" decimals="-5" id="f-374" unitRef="usd">75000000.0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-20" decimals="-5" id="f-375" unitRef="usd">75000000.0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-71" decimals="-5" id="f-376" unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-71" decimals="-5" id="f-377" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-72" decimals="-5" id="f-378" unitRef="shares">169500000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-72" decimals="-5" id="f-379" unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-73" decimals="-5" id="f-380" unitRef="usd">488500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-74" decimals="-5" id="f-381" unitRef="usd">-145700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-75" decimals="-5" id="f-382" unitRef="usd">18993100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares contextRef="c-76" decimals="-5" id="f-383" unitRef="shares">-23800000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-76" decimals="-5" id="f-384" unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-33" decimals="-5" id="f-385" unitRef="usd">16358900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-77" decimals="-5" id="f-386" unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-77" decimals="-5" id="f-387" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-78" decimals="-5" id="f-388" unitRef="shares">168700000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-78" decimals="-5" id="f-389" unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-79" decimals="-5" id="f-390" unitRef="usd">302500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-80" decimals="-5" id="f-391" unitRef="usd">-153700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-81" decimals="-5" id="f-392" unitRef="usd">17627600000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares contextRef="c-82" decimals="-5" id="f-393" unitRef="shares">-23800000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-82" decimals="-5" id="f-394" unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-83" decimals="-5" id="f-395" unitRef="usd">14799400000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c-84" decimals="-5" id="f-396" unitRef="usd">1365500000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-85" decimals="-5" id="f-397" unitRef="usd">1365500000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-86" decimals="-5" id="f-398" unitRef="usd">8000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax contextRef="c-85" decimals="-5" id="f-399" unitRef="usd">8000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued contextRef="c-87" decimals="-5" id="f-400" unitRef="shares">200000</us-gaap:StockIssuedDuringPeriodSharesTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="c-88" decimals="-5" id="f-401" unitRef="usd">31200000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued contextRef="c-85" decimals="-5" id="f-402" unitRef="usd">31200000</us-gaap:StockIssuedDuringPeriodValueTreasuryStockReissued>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="c-87" decimals="-5" id="f-403" unitRef="shares">600000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-88" decimals="-5" id="f-404" unitRef="usd">-66000000.0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="c-21" decimals="-5" id="f-405" unitRef="usd">-66000000.0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-88" decimals="-5" id="f-406" unitRef="usd">224000000.0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-85" decimals="-5" id="f-407" unitRef="usd">224000000.0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockholdersEquityOther contextRef="c-88" decimals="-5" id="f-408" unitRef="usd">3200000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther contextRef="c-85" decimals="-5" id="f-409" unitRef="usd">3200000</us-gaap:StockholdersEquityOther>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-71" decimals="-5" id="f-410" unitRef="shares">0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-71" decimals="-5" id="f-411" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-72" decimals="-5" id="f-412" unitRef="shares">169500000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-72" decimals="-5" id="f-413" unitRef="usd">100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-73" decimals="-5" id="f-414" unitRef="usd">488500000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-74" decimals="-5" id="f-415" unitRef="usd">-145700000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-75" decimals="-5" id="f-416" unitRef="usd">18993100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:TreasuryStockCommonShares contextRef="c-76" decimals="-5" id="f-417" unitRef="shares">-23800000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-76" decimals="-5" id="f-418" unitRef="usd">-2977100000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-89" decimals="-5" id="f-419" unitRef="usd">16358900000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-420">&lt;div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:87.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%"&gt;Note 1:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:14pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;References in these notes to "Biogen," the "company," "we," "us" and "our" refer to Biogen Inc. and its consolidated subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Business Overview&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Biogen is a global biopharmaceutical company focused on discovering, developing and delivering innovative therapies for people living with serious and complex diseases. We have a broad portfolio of medicines to treat MS, have introduced the first approved treatment for SMA, co-developed treatments to address a defining pathology of Alzheimer&#x2019;s disease and launched the first approved treatment to target a genetic cause of ALS. We market the first and only drug approved in the U.S., the E.U. and certain international markets for the treatment of FA in adults and adolescents aged 16 years and older. We are focused on advancing our pipeline in neurology, specialized immunology and rare diseases. We support our drug discovery and development efforts through internal research and development programs, external collaborations and acquisitions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY and TYSABRI for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of FA; and QALSODY for the treatment of ALS.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also have collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Supernus on the commercialization of ZURZUVAE for the treatment of PPD. We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, CLL and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL, follicular lymphoma and, following its approval in October 2025, lupus nephritis; OCREVUS for the treatment of PPMS and RMS; LUNSUMIO for the treatment of relapsed or refractory follicular lymphoma; COLUMVI, a bispecific antibody for the treatment of non-Hodgkin's lymphoma; and have the option to add other potential anti-CD20 therapies, pursuant to our collaboration arrangements with Genentech, a wholly-owned member of the Roche Group.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We commercialize a portfolio of biosimilars of advanced biologics including: BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS, in certain international markets. We also have commercialization rights related to OPUVIZ, an aflibercept biosimilar referencing EYLEA, in certain international markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our collaboration arrangements, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 19, Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to these unaudited condensed consolidated financial statements (condensed consolidated financial statements).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair statement of our financial statements for interim periods in accordance with U.S.&#160;GAAP. The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our 2024 Form&#160;10-K. Our accounting policies are described in the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Notes to Consolidated Financial Statements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in our 2024 Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the three and nine&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;months ended September 30, 2025, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate as one operating segment, focused on discovering, developing and delivering innovative therapies for people living with serious and complex diseases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the first quarter of 2025 we began presenting acquired in-process research and development, upfront and milestone expense as a separate line item in our condensed consolidated statements of income. Acquired in-process research and development, upfront and milestone expense includes costs incurred in connection with collaboration and license agreements such as upfront and milestone payments and, when applicable, premiums on equity securities and asset acquisitions of acquired in-process research and development, which were previously &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;included in research and development expense. Prior periods have been reclassified to conform to the current period presentation. The reclassification had no impact on our total cost and expense, net income attributable to Biogen Inc., earnings per share or total equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than 100.0% of the economics, we record net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenue and expense and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and assumptions. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results may differ from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no material changes to our significant accounting policies disclosed in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1, Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to our audited consolidated financial statements included in our 2024 Form&#160;10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;New Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have had, or may have, a material impact on our condensed consolidated financial statements or disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.882%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.303%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.028%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.635%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Standard&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Description&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effective Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Effects on the financial statements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;ASU No. 2023-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:112%"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;This standard establishes incremental disaggregation of income tax disclosures pertaining to the effective tax rate reconciliation and income taxes paid. The amendments in this update are required to be applied on a prospective basis with the option to apply it retrospectively.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Annual reporting for fiscal years beginning after December 15, 2024. Early adoption is permitted.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;We are currently evaluating the potential impact that this new standard will have on our consolidated financial statements and related disclosures, and expect to apply this standard prospectively upon adoption.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;ASU No. 2024-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:112%"&gt;Income Statement (Subtopic 220-40): Reporting Comprehensive Income - Expense Disaggregation Disclosures&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;This standard requires disclosure in the notes to the financial statements, at each interim and annual reporting period, of specified information about certain costs and expense including purchases of inventory, employee compensation, depreciation and intangible asset amortization included in each relevant expense caption. This standard also requires a qualitative description of the amounts remaining in relevant expense captions that are not separately disaggregated, as well as disclosure of the total amount of selling expenses, and, in annual reporting periods, an entity&#x2019;s definition of selling expenses.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Annual reporting for fiscal years beginning after December 15, 2026, and interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;We are currently evaluating the potential impact that this new standard will have on our consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;ASU No. 2025-07, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:112%"&gt;Derivatives and Hedging (Topic 815) and Revenue from Contracts with Customers (Topic 606): Derivatives Scope Refinements and Scope Clarification for Share-Based Noncash Consideration from a Customer in a Revenue Contract&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;This standard refines and expands the existing scope exceptions that exclude certain contracts, including certain R&amp;amp;D funding arrangements, from derivative accounting, and clarifies the accounting for share-based noncash consideration received from a customer.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;Annual reporting for fiscal years beginning after December 15, 2026, and interim periods within those annual reporting periods. Early adoption is permitted.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;We have early adopted this new standard on a modified retrospective basis as of January 1, 2025. Adoption did not have a material impac&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:112%"&gt;t on our condensed consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <biib:BusinessOverviewPolicyTextBlock contextRef="c-1" id="f-421">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Biogen is a global biopharmaceutical company focused on discovering, developing and delivering innovative therapies for people living with serious and complex diseases. We have a broad portfolio of medicines to treat MS, have introduced the first approved treatment for SMA, co-developed treatments to address a defining pathology of Alzheimer&#x2019;s disease and launched the first approved treatment to target a genetic cause of ALS. We market the first and only drug approved in the U.S., the E.U. and certain international markets for the treatment of FA in adults and adolescents aged 16 years and older. We are focused on advancing our pipeline in neurology, specialized immunology and rare diseases. We support our drug discovery and development efforts through internal research and development programs, external collaborations and acquisitions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY and TYSABRI for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of FA; and QALSODY for the treatment of ALS.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also have collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Supernus on the commercialization of ZURZUVAE for the treatment of PPD. We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, CLL and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL, follicular lymphoma and, following its approval in October 2025, lupus nephritis; OCREVUS for the treatment of PPMS and RMS; LUNSUMIO for the treatment of relapsed or refractory follicular lymphoma; COLUMVI, a bispecific antibody for the treatment of non-Hodgkin's lymphoma; and have the option to add other potential anti-CD20 therapies, pursuant to our collaboration arrangements with Genentech, a wholly-owned member of the Roche Group.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We commercialize a portfolio of biosimilars of advanced biologics including: BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS, in certain international markets. We also have commercialization rights related to OPUVIZ, an aflibercept biosimilar referencing EYLEA, in certain international markets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our collaboration arrangements, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 19, Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to these unaudited condensed consolidated financial statements (condensed consolidated financial statements).&lt;/span&gt;&lt;/div&gt;</biib:BusinessOverviewPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-422">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the opinion of management, our condensed consolidated financial statements include all adjustments, consisting of normal recurring accruals, necessary for a fair statement of our financial statements for interim periods in accordance with U.S.&#160;GAAP. The information included in this quarterly report on Form&#160;10-Q should be read in conjunction with our audited consolidated financial statements and the accompanying notes included in our 2024 Form&#160;10-K. Our accounting policies are described in the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Notes to Consolidated Financial Statements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in our 2024 Form&#160;10-K and updated, as necessary, in this report. The year-end condensed consolidated balance sheet data presented for comparative purposes was derived from our audited financial statements, but does not include all disclosures required by U.S.&#160;GAAP. The results of operations for the three and nine&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;months ended September 30, 2025, are not necessarily indicative of the operating results for the full year or for any other subsequent interim period. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate as one operating segment, focused on discovering, developing and delivering innovative therapies for people living with serious and complex diseases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the first quarter of 2025 we began presenting acquired in-process research and development, upfront and milestone expense as a separate line item in our condensed consolidated statements of income. Acquired in-process research and development, upfront and milestone expense includes costs incurred in connection with collaboration and license agreements such as upfront and milestone payments and, when applicable, premiums on equity securities and asset acquisitions of acquired in-process research and development, which were previously &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;included in research and development expense. Prior periods have been reclassified to conform to the current period presentation. The reclassification had no impact on our total cost and expense, net income attributable to Biogen Inc., earnings per share or total equity.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-423"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c-1" id="f-424">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our condensed consolidated financial statements reflect our financial statements, those of our wholly-owned subsidiaries and variable interest entities where we are the primary beneficiary. For consolidated entities where we own or are exposed to less than 100.0% of the economics, we record net income (loss) attributable to noncontrolling interests, net of tax in our condensed consolidated statements of income equal to the percentage of the economic or ownership interest retained in such entities by the respective noncontrolling parties. Intercompany balances and transactions are eliminated in consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining whether we are the primary beneficiary of a variable interest entity, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. We continuously assess whether we are the primary beneficiary of a variable interest entity as changes to existing relationships or future transactions may result in us consolidating or deconsolidating one or more of our collaborators or partners.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <biib:InterestInSubsidiary contextRef="c-1" decimals="INF" id="f-425" unitRef="number">1.000</biib:InterestInSubsidiary>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-426">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of our condensed consolidated financial statements requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenue and expense and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and assumptions. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results may differ from these estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no material changes to our significant accounting policies disclosed in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1, Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to our audited consolidated financial statements included in our 2024 Form&#160;10-K.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-427">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that we adopt as of the specified effective date. Unless otherwise discussed below, we do not believe that the adoption of recently issued standards have had, or may have, a material impact on our condensed consolidated financial statements or disclosures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock contextRef="c-1" id="f-428">&lt;div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:87.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%"&gt;Note 2:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:14pt;padding-left:27pt;text-indent:-27pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%"&gt;Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Alcyone Therapeutics, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2025 we entered into a definitive agreement to acquire all of the issued and outstanding shares of Alcyone Therapeutics, Inc., a clinical-stage biotechnology company focused on pediatric care through precision CNS therapeutics and dosing platforms. Alcyone's lead asset is ThecaFlex DRx, an implantable subcutaneous port and catheter device being investigated for the intrathecal delivery of ASOs, which is designed to provide an alternative to repeat lumbar punctures in chronic intrathecal administration of medicines.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have agreed to pay an upfront cash payment of $85.0&#160;million upon closing, plus additional potential amounts payable upon the achievement of certain milestones related to the development and regulatory approval of ThecaFlex DRx for administering SPINRAZA and additional pipeline products.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We plan to account for this proposed acquisition as an asset acquisition as the value being acquired primarily relates to a single asset and plan to record the upfront payment within acquired in-process research and development, upfront and milestone expense within our condensed consolidated statements of income upon the completion of this proposed acquisition. We anticipate the&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; proposed acquisition to close during the fourth quarter of 2025, subject to the satisfaction of customary closing conditions. U&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;nder the terms of this proposed acquisition, we expect to oversee the end-to-end development, manufacturing and commercialization of ThecaFlex DRx&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Alcyone's remaining therapeutic assets would be divested from Alcyone into Neela Therapeutics, Inc., a newly formed independent company, prior to the closing of this proposed acquisition. We anticipate to make a convertible debt investment of up to&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; $5.0&#160;million in Neela Therapeutics. Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Human Immunology Biosciences&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 2, 2024, we completed the acquisition of all of the issued and outstanding shares of HI-Bio, a privately-held clinical-stage biotechnology company focused on targeted therapies for patients with severe immune-mediated diseases. HI-Bio's lead asset, felzartamab, an anti-CD38 antibody, is currently being evaluated for several indications, including three leading indications, AMR, PMN and IgAN. Felzartamab has received Breakthrough Therapy Designation and ODD from the FDA for development in the treatment of PMN and AMR. Subsequent to our acquisition, felzartamab received ODD in the E.U. in IgAN and solid organ transplantation. The acquisition of HI-Bio is expected to augment our pipeline and build on our expertise in immunology.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of this acquisition, we paid shareholders of HI-Bio approximately $1.15&#160;billion at closing and may pay up to a total of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$650.0&#160;million in contingent development and regulatory milestone payments.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The $1.15&#160;billion paid includes approximately $74.5&#160;million related to HI-Bio's outstanding, non-vested equity awards, inclusive of employer taxes, of which $56.4&#160;million was recognized as share-based compensation payments to settle non-vested equity awards attributable to the post-acquisition service period and therefore not reflected as a component of total purchase price paid. Of the total $56.4&#160;million, we recognized approximately $42.5&#160;million as a charge to research and development expense with the remaining $13.9&#160;million as a charge to selling, general and &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;administrative expense within our condensed consolidated statements of income for the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;three and nine months ended September 30, 2025&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These amounts were associated with the accelerated vesting of stock options and RSUs previously granted to HI-Bio employees and required no future services to vest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon closing we also paid an additional &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$43.7&#160;million related to working capital adjustments as of the transaction close date, which was included as a component of total purchase price paid.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We funded this acquisition through available cash on hand and accounted for this acquisition as a business combination using the acquisition method of accounting in accordance with&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;ASC Topic 805, Business Combinations&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and recorded assets acquired and liabilities assumed at their respective fair values as of the acquisition date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"&gt;Purchase Price Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total consideration transferred for the acquisition of HI-Bio is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.393%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of July&#160;2, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash consideration paid to HI-Bio shareholders&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,137.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;485.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,622.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.017%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Represents total consideration paid to shareholders of HI-Bio of $1.15&#160;billion, plus an additional $43.7&#160;million related to working capital adjustments as of the transaction close date, less $56.4&#160;million of cash paid for HI-Bio's outstanding, non-vested equity awards, inclusive of employer taxes, which were recognized as compensation attributable to the post-acquisition service period and therefore not reflected as a component of total consideration. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contingent Consideration:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; We may make certain contingent payments to the former shareholders of HI-Bio upon the achievement of certain development and regulatory milestones. As of the acquisition date, the maximum aggregate amount payable for these potential milestones was $650.0&#160;million. The acquisition-date fair value of these milestones was approximately $485.1&#160;million and was estimated utilizing a probability-adjusted discounted cash flow calculation using an appropriate discount rate dependent on the nature and timing of the milestone payments, which ranged from &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;6.2% to 7.0%, and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;probabilities of technological and regulatory success ranging from 67.0% to near-certain probability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Of the total contingent consideration, approximately $279.3&#160;million related to milestones classified as short-term and reflected as a component of accrued expense and other with the remaining $205.8&#160;million reflected as a component of other long-term liabilities within our condensed consolidated balance sheets. The short-term liability related to the fourth patient dosed in a Phase 3 clinical trial of felzartamab in a first and s&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;econd indication, which would each result in the achievement of a $150.0&#160;million milestone payment. During the second quarter of 2025 the first milestone related to the fourth patient dosed in a phase 3 clinical trial of felzartamab for AMR was achieved, resulting in a $150.0&#160;million milestone payment made to the former shareholders of HI-Bio, which was paid during the third quarter of 2025. In October 2025 the second milestone related to the fourth patient dosed in a phase 3 clinical trial of felzartamab for IgAN was achieved, resulting in a $150.0&#160;million milestone payment to be made to the former shareholders of HI-Bio, which we expect will be paid during the fourth quarter of 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subsequent changes in the fair value of the contingent consideration obligation are being recognized as (gain) loss on fair value remeasurement of contingent consideration within our condensed consolidated statements of income. This fair value measurement is based on significant inputs that are not observable in the market and thus represent Level 3 fair value measurements. For additional information related to the fair value of this obligation, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 8, Fair Value Measurements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Contractual Commitments: &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We acquired HI-Bio's pre-existing in-license commitments under third-party agreements with MorphoSys, which included tiered royalties on potential future sales ranging from high-single digit to mid-teen percentages, as well as potential development, regulatory and commercial milestone payments of up to $130.0&#160;million, $230.0&#160;million and $640.0&#160;million, respectively. At the transaction close date the achievement of these milestones was not considered probable and therefore not recorded in our financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:9pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%"&gt;Purchase Price Allocation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We finalized purchase accounting for this acquisition in the second quarter of 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date, and reflects measurement period adjustments made to the amounts initially recorded as of the acquisition date on July&#160;2, 2024. The related impact to our condensed consolidated statements of income that would have been recognized in previous periods if the adjustments were recognized as of the acquisition date is immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.847%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts Recognized as of Acquisition Date&lt;br/&gt;(as adjusted)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D - felzartamab (IgAN)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;920.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D - felzartamab (AMR)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;450.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D - felzartamab (PMN)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;265.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other clinical programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid expense and other assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(35.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred tax liability&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(309.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total identifiable net assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,361.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;261.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total assets acquired and liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,622.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.017%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Includes measurement period adjustments recorded in 2025 that increased prepaid expense and other assets by $0.4&#160;million, net deferred tax liability by $4.9&#160;million and goodwill by $4.5&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intang&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;ible assets:&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Intangible assets comprised of approximately $1.6&#160;billion of IPR&amp;amp;D related to HI-Bio's lead asset felzartamab. This includes $920.0&#160;million of IPR&amp;amp;D related to felzartamab indication for IgAN, $450.0&#160;million of IPR&amp;amp;D related to felzartamab indication for AMR and $265.0&#160;million of IPR&amp;amp;D related to felzartamab indication for PMN. The estimated fair values of the program related intangible assets were determined using a multi-period excess earnings method, a form of the income approach, utilizing cash flow analyses and a discount rate of 14.5%. These fair value measurements were based on significant inputs that are not observable in the market and thus represent Level 3 fair value measurements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Goodwill:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Goodwill was calculated as the excess of the consideration transferred over the net assets recognized and represents the future economic benefits arising from the other assets acq&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;uired that could not be individually identified and separately recognized. We recognized goodwill of approximately $261.0&#160;million, which includes measurement period adjustments, and is not deductible for tax purposes. The goodwill recognized from our acquisition of HI-Bio is primarily the result of the deferred tax consequences from the transaction recorded for financial statement purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Acquisition-related expense:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Acquisition-related expense, primarily comprised&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of advisory and legal fees, and other transaction costs, totaled approximately $2.8&#160;million and were recorded within selling, general and administrative expense within our consolidated statements of income for the year ended December 31, 2024, included in our &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2024&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Form 10-K&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:PaymentsToAcquireProductiveAssets contextRef="c-90" decimals="-5" id="f-429" unitRef="usd">85000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:InvestmentOwnedAtCost contextRef="c-22" decimals="-5" id="f-430" unitRef="usd">5000000</us-gaap:InvestmentOwnedAtCost>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c-91" decimals="-5" id="f-431" unitRef="usd">1150000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh contextRef="c-92" decimals="-5" id="f-432" unitRef="usd">650000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c-91" decimals="-5" id="f-433" unitRef="usd">1150000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <biib:PaymentsToAcquireBusinessGrossNonVestedEquityAwards contextRef="c-93" decimals="-5" id="f-434" unitRef="usd">74500000</biib:PaymentsToAcquireBusinessGrossNonVestedEquityAwards>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-93" decimals="-5" id="f-435" unitRef="usd">56400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-93" decimals="-5" id="f-436" unitRef="usd">56400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-94" decimals="-5" id="f-437" unitRef="usd">42500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-95" decimals="-5" id="f-438" unitRef="usd">42500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-96" decimals="-5" id="f-439" unitRef="usd">13900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-97" decimals="-5" id="f-440" unitRef="usd">13900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <biib:BusinessCombinationConsiderationTransferredWorkingCapitalAdjustment contextRef="c-93" decimals="-5" id="f-441" unitRef="usd">43700000</biib:BusinessCombinationConsiderationTransferredWorkingCapitalAdjustment>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock contextRef="c-1" id="f-442">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total consideration transferred for the acquisition of HI-Bio is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:76.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.393%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of July&#160;2, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash consideration paid to HI-Bio shareholders&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,137.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;485.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,622.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt; Represents total consideration paid to shareholders of HI-Bio of $1.15&#160;billion, plus an additional $43.7&#160;million related to working capital adjustments as of the transaction close date, less $56.4&#160;million of cash paid for HI-Bio's outstanding, non-vested equity awards, inclusive of employer taxes, which were recognized as compensation attributable to the post-acquisition service period and therefore not reflected as a component of total consideration.</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c-93" decimals="-5" id="f-443" unitRef="usd">1137300000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred contextRef="c-93" decimals="-5" id="f-444" unitRef="usd">485100000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="c-93" decimals="-5" id="f-445" unitRef="usd">1622400000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:PaymentsToAcquireBusinessesGross contextRef="c-91" decimals="-5" id="f-446" unitRef="usd">1150000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <biib:BusinessCombinationConsiderationTransferredWorkingCapitalAdjustment contextRef="c-93" decimals="-5" id="f-447" unitRef="usd">43700000</biib:BusinessCombinationConsiderationTransferredWorkingCapitalAdjustment>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-93" decimals="-5" id="f-448" unitRef="usd">56400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh contextRef="c-92" decimals="-5" id="f-449" unitRef="usd">650000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-92" decimals="-5" id="f-450" unitRef="usd">485100000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput contextRef="c-98" decimals="3" id="f-451" unitRef="number">0.062</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput contextRef="c-99" decimals="3" id="f-452" unitRef="number">0.070</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput contextRef="c-100" decimals="3" id="f-453" unitRef="number">0.670</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="c-92" decimals="-5" id="f-454" unitRef="usd">279300000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="c-92" decimals="-5" id="f-455" unitRef="usd">205800000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="c-101" decimals="-5" id="f-456" unitRef="usd">150000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="c-102" decimals="-5" id="f-457" unitRef="usd">150000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="c-103" decimals="-5" id="f-458" unitRef="usd">150000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="c-104" decimals="-5" id="f-459" unitRef="usd">150000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones contextRef="c-105" decimals="-5" id="f-460" unitRef="usd">130000000</biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones>
    <biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones contextRef="c-106" decimals="-5" id="f-461" unitRef="usd">230000000</biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones>
    <biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones contextRef="c-107" decimals="-5" id="f-462" unitRef="usd">640000000</biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones>
    <us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock contextRef="c-1" id="f-463">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amounts recognized for assets acquired and liabilities assumed as of the acquisition date, and reflects measurement period adjustments made to the amounts initially recorded as of the acquisition date on July&#160;2, 2024. The related impact to our condensed consolidated statements of income that would have been recognized in previous periods if the adjustments were recognized as of the acquisition date is immaterial.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.847%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts Recognized as of Acquisition Date&lt;br/&gt;(as adjusted)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D - felzartamab (IgAN)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;920.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D - felzartamab (AMR)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;450.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;IPR&amp;amp;D - felzartamab (PMN)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;265.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other clinical programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Prepaid expense and other assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(35.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Deferred tax liability&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(309.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total identifiable net assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,361.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;261.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total assets acquired and liabilities assumed&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#005b7f;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,622.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.017%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Includes measurement period adjustments recorded in 2025 that increased prepaid expense and other assets by $0.4&#160;million, net deferred tax liability by $4.9&#160;million and goodwill by $4.5&#160;million.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents contextRef="c-92" decimals="-5" id="f-464" unitRef="usd">62500000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-108" decimals="-5" id="f-465" unitRef="usd">920000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-109" decimals="-5" id="f-466" unitRef="usd">450000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-110" decimals="-5" id="f-467" unitRef="usd">265000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-111" decimals="-5" id="f-468" unitRef="usd">7900000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets contextRef="c-92" decimals="-5" id="f-469" unitRef="usd">1400000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets contextRef="c-92" decimals="-5" id="f-470" unitRef="usd">1200000</biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOperatingLeaseAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable contextRef="c-92" decimals="-5" id="f-471" unitRef="usd">1100000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities contextRef="c-92" decimals="-5" id="f-472" unitRef="usd">35000000.0</biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities contextRef="c-92" decimals="-5" id="f-473" unitRef="usd">309300000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities contextRef="c-92" decimals="-5" id="f-474" unitRef="usd">1200000</biib:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOperatingLeaseLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef="c-92" decimals="-5" id="f-475" unitRef="usd">1361400000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
    <us-gaap:Goodwill contextRef="c-92" decimals="-5" id="f-476" unitRef="usd">261000000.0</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet contextRef="c-92" decimals="-5" id="f-477" unitRef="usd">1622400000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <biib:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpenseAndOther contextRef="c-112" decimals="-5" id="f-478" unitRef="usd">400000</biib:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentPrepaidExpenseAndOther>
    <biib:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability contextRef="c-112" decimals="-5" id="f-479" unitRef="usd">4900000</biib:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentDeferredTaxLiability>
    <biib:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill contextRef="c-112" decimals="-5" id="f-480" unitRef="usd">4500000</biib:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-92" decimals="-8" id="f-481" unitRef="usd">1600000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-113" decimals="-5" id="f-482" unitRef="usd">920000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-114" decimals="-5" id="f-483" unitRef="usd">450000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-115" decimals="-5" id="f-484" unitRef="usd">265000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <biib:IntangibleAssetMeasurementInput contextRef="c-116" decimals="3" id="f-485" unitRef="number">0.145</biib:IntangibleAssetMeasurementInput>
    <us-gaap:Goodwill contextRef="c-92" decimals="-5" id="f-486" unitRef="usd">261000000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts contextRef="c-112" decimals="-5" id="f-487" unitRef="usd">2800000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts contextRef="c-117" decimals="-5" id="f-488" unitRef="usd">2800000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock contextRef="c-1" id="f-489">&lt;div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:87.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%"&gt;Note 3:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:14pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%"&gt;Dispositions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Sale of Joint Venture Equity Interest in Samsung Bioepis&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2022 we completed the sale of our 49.9% equity interest in Samsung Bioepis to Samsung BioLogics in exchange for total consideration of approximately $2.3&#160;billion. Under the terms of this transaction, we received approximately $1.0&#160;billion in cash at closing, with approximately $1.3&#160;billion in cash to be deferred over two payments. The first deferred payment of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$812.5&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; was received in April 2023 and&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the second deferred payment of $437.5&#160;million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; was received in April 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;For the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;nine&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; months ended September 30, 2024, we recognized&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; a gain&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; of approximately &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;$7.5&#160;million &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;to reflect the change in fair value associated with the passage of time related to the second deferred payment &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;due to us, which was received in April 2024 and&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; recorded in other (income) expense, net within our condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on the sale of our equity interest in Samsung Bioepis, please read &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 3, Dispositions&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to our consolidated financial statements included in our 2024 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:112%"&gt;Sale of Priority Review Voucher&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In April 2024 we completed the sale of our rare pediatric disease PRV, generated by the development associated with SPINRAZA, to a third party. In consideration for the PRV we received a cash payment of $103.0&#160;million upon the closing of the PRV purchase, of which approximately $14.4&#160;million was paid to Ionis. Our net portion of approximately $88.6&#160;million was recognized in gain on sale of priority review voucher, net within our condensed consolidated statements of income for the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;nine&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; months ended September 30, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:112%"&gt;Sale of TOFIDENCE&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2025 we completed the sale of our regulatory and commercial rights in the U.S. for TOFIDENCE, a tocilizumab biosimilar referencing ACTEMRA, to Organon. Under the terms of this transaction, we received a payment of approximately $51.0&#160;million &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in July 2025 a&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;nd recognized a de minimis loss within our condensed consolidated statements of income for the nine months ended September 30, 2025.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c-118" decimals="3" id="f-490" unitRef="number">0.499</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentSoldCarryingAmount contextRef="c-119" decimals="-5" id="f-491" unitRef="usd">2300000000</us-gaap:EquityMethodInvestmentSoldCarryingAmount>
    <us-gaap:ProceedsFromDivestitureOfInterestInJointVenture contextRef="c-120" decimals="-8" id="f-492" unitRef="usd">1000000000</us-gaap:ProceedsFromDivestitureOfInterestInJointVenture>
    <biib:PayablesToDivestitureOfInterestInJointVenture contextRef="c-121" decimals="-8" id="f-493" unitRef="usd">1300000000</biib:PayablesToDivestitureOfInterestInJointVenture>
    <biib:PayablesToDivestitureOfInterestInJointVenture contextRef="c-122" decimals="-5" id="f-494" unitRef="usd">812500000</biib:PayablesToDivestitureOfInterestInJointVenture>
    <biib:PayablesToDivestitureOfInterestInJointVenture contextRef="c-123" decimals="-5" id="f-495" unitRef="usd">437500000</biib:PayablesToDivestitureOfInterestInJointVenture>
    <us-gaap:GainLossOnDispositionOfAssets1 contextRef="c-124" decimals="-5" id="f-496" unitRef="usd">7500000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:ProceedsFromSaleOfIntangibleAssets contextRef="c-125" decimals="-5" id="f-497" unitRef="usd">103000000</us-gaap:ProceedsFromSaleOfIntangibleAssets>
    <biib:ProceedsPaidToCollaborativeArrangementCounterparty contextRef="c-126" decimals="-5" id="f-498" unitRef="usd">14400000</biib:ProceedsPaidToCollaborativeArrangementCounterparty>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets contextRef="c-21" decimals="-5" id="f-499" unitRef="usd">88600000</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets contextRef="c-21" decimals="-5" id="f-500" unitRef="usd">88600000</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:ProceedsFromSaleOfIntangibleAssets contextRef="c-127" decimals="-5" id="f-501" unitRef="usd">51000000</us-gaap:ProceedsFromSaleOfIntangibleAssets>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock contextRef="c-1" id="f-502">&lt;div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:87.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%"&gt;Note 4:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:14pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%"&gt;Restructuring&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;2023 Fit for Growth Restructuring Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2023 we initiated cost saving measures as part of our Fit for Growth program to reduce operating costs, while improving operating efficiency and effectiveness. The Fit for Growth program is expected to generate approximately $1.0&#160;billion in gross operating expense savings by the end of 2025, some of which will be reinvested in various initiatives. The Fit for Growth program is currently estimated to include net headcount reductions of approximately 1,400 employees and we expect to incur total restructuring charges of approximately $310.0&#160;million, which were substantially achieved as of September 30, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total charges incurred from our 2023 Fit for Growth program are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.092%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.434%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Severance&lt;br/&gt;Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accelerated Depreciation and Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Severance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Depreciation and Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Severance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accelerated Depreciation and Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Severance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Depreciation and Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Costs:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Includes costs associated with items such as asset abandonment and write-offs, facility closure costs, pre-tax gains and losses resulting from the termination of certain leases, employee non-severance expense, consulting fees and other costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Reata Integration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following the close of our Reata acquisition in September 2023, we implemented an integration plan designed to realize operating synergies through cost savings and avoidance. Under this initiative, we estimated we would incur total integration charges of approximately $35.0&#160;million related to severance and employment costs, which were substantially incurred during 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total charges incurred from our Reata integration are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.753%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.326%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.326%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.606%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Severance&lt;br/&gt;Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accelerated Depreciation and Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Severance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Depreciation and Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Severance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accelerated Depreciation and Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Severance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Depreciation and Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our acquisition of Reata we assumed responsibility for a single-tenant, build-to-suit building of approximately 327,400 square feet of office and laboratory space located in Plano, Texas, with an initial lease term of 16 years. We do not intend to occupy this building and are evaluating opportunities to sublease the property. For additional information on our acquisition of Reata, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2, Acquisitions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to our consolidated financial statements included in our &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2024&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Restructuring Reserve&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Charges and spending related to workforce reductions are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Workforce Reductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring reserve as of January 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;75.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(25.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(42.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring reserve as of March 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring reserve as of June 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(17.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring reserve as of September 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <biib:RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction contextRef="c-128" decimals="-8" id="f-503" unitRef="usd">1000000000</biib:RestructuringAndRelatedActivitiesExpectedOperatingExpenseReduction>
    <us-gaap:RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated
      contextRef="c-129"
      decimals="INF"
      id="f-504"
      unitRef="employee">1400</us-gaap:RestructuringAndRelatedCostExpectedNumberOfPositionsEliminated>
    <us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1 contextRef="c-130" decimals="-5" id="f-505" unitRef="usd">310000000</us-gaap:RestructuringAndRelatedCostExpectedCostRemaining1>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock contextRef="c-1" id="f-506">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total charges incurred from our 2023 Fit for Growth program are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.092%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.434%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Severance&lt;br/&gt;Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accelerated Depreciation and Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Severance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Depreciation and Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Severance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accelerated Depreciation and Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Severance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Depreciation and Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;12.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;43.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total charges incurred from our Reata integration are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.753%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.326%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.326%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.606%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Severance&lt;br/&gt;Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accelerated Depreciation and Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Severance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Depreciation and Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Severance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accelerated Depreciation and Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Severance Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Depreciation and Other Costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total charges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;17.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:SeveranceCosts1 contextRef="c-131" decimals="-5" id="f-507" unitRef="usd">0</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-131" decimals="-5" id="f-508" unitRef="usd">400000</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-131" decimals="-5" id="f-509" unitRef="usd">400000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-132" decimals="-5" id="f-510" unitRef="usd">0</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-132" decimals="-5" id="f-511" unitRef="usd">9100000</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-132" decimals="-5" id="f-512" unitRef="usd">9100000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-133" decimals="-5" id="f-513" unitRef="usd">0</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-133" decimals="-5" id="f-514" unitRef="usd">500000</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-133" decimals="-5" id="f-515" unitRef="usd">500000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-134" decimals="-5" id="f-516" unitRef="usd">0</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-134" decimals="-5" id="f-517" unitRef="usd">3500000</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-134" decimals="-5" id="f-518" unitRef="usd">3500000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-135" decimals="-5" id="f-519" unitRef="usd">7400000</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-135" decimals="-5" id="f-520" unitRef="usd">0</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-135" decimals="-5" id="f-521" unitRef="usd">7400000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-136" decimals="-5" id="f-522" unitRef="usd">4600000</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-136" decimals="-5" id="f-523" unitRef="usd">0</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-136" decimals="-5" id="f-524" unitRef="usd">4600000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-137" decimals="-5" id="f-525" unitRef="usd">7400000</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-137" decimals="-5" id="f-526" unitRef="usd">900000</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-137" decimals="-5" id="f-527" unitRef="usd">8300000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-138" decimals="-5" id="f-528" unitRef="usd">4600000</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-138" decimals="-5" id="f-529" unitRef="usd">12600000</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-138" decimals="-5" id="f-530" unitRef="usd">17200000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-139" decimals="-5" id="f-531" unitRef="usd">0</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-139" decimals="-5" id="f-532" unitRef="usd">-2800000</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-139" decimals="-5" id="f-533" unitRef="usd">-2800000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-140" decimals="-5" id="f-534" unitRef="usd">0</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-140" decimals="-5" id="f-535" unitRef="usd">12500000</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-140" decimals="-5" id="f-536" unitRef="usd">12500000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-141" decimals="-5" id="f-537" unitRef="usd">0</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-141" decimals="-5" id="f-538" unitRef="usd">6900000</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-141" decimals="-5" id="f-539" unitRef="usd">6900000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-142" decimals="-5" id="f-540" unitRef="usd">0</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-142" decimals="-5" id="f-541" unitRef="usd">10600000</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-142" decimals="-5" id="f-542" unitRef="usd">10600000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-143" decimals="-5" id="f-543" unitRef="usd">41600000</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-143" decimals="-5" id="f-544" unitRef="usd">0</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-143" decimals="-5" id="f-545" unitRef="usd">41600000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-144" decimals="-5" id="f-546" unitRef="usd">20200000</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-144" decimals="-5" id="f-547" unitRef="usd">0</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-144" decimals="-5" id="f-548" unitRef="usd">20200000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-129" decimals="-5" id="f-549" unitRef="usd">41600000</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-129" decimals="-5" id="f-550" unitRef="usd">4100000</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-129" decimals="-5" id="f-551" unitRef="usd">45700000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-145" decimals="-5" id="f-552" unitRef="usd">20200000</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-145" decimals="-5" id="f-553" unitRef="usd">23100000</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-145" decimals="-5" id="f-554" unitRef="usd">43300000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1 contextRef="c-146" decimals="-5" id="f-555" unitRef="usd">35000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <us-gaap:SeveranceCosts1 contextRef="c-147" decimals="-5" id="f-556" unitRef="usd">0</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-147" decimals="-5" id="f-557" unitRef="usd">1600000</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-147" decimals="-5" id="f-558" unitRef="usd">1600000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-148" decimals="-5" id="f-559" unitRef="usd">0</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-148" decimals="-5" id="f-560" unitRef="usd">1600000</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-148" decimals="-5" id="f-561" unitRef="usd">1600000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-149" decimals="-5" id="f-562" unitRef="usd">0</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-149" decimals="-5" id="f-563" unitRef="usd">3800000</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-149" decimals="-5" id="f-564" unitRef="usd">3800000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-150" decimals="-5" id="f-565" unitRef="usd">0</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-150" decimals="-5" id="f-566" unitRef="usd">2900000</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-150" decimals="-5" id="f-567" unitRef="usd">2900000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-151" decimals="-5" id="f-568" unitRef="usd">0</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-151" decimals="-5" id="f-569" unitRef="usd">0</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-151" decimals="-5" id="f-570" unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-152" decimals="-5" id="f-571" unitRef="usd">700000</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-152" decimals="-5" id="f-572" unitRef="usd">0</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-152" decimals="-5" id="f-573" unitRef="usd">700000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-153" decimals="-5" id="f-574" unitRef="usd">0</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-153" decimals="-5" id="f-575" unitRef="usd">5400000</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-153" decimals="-5" id="f-576" unitRef="usd">5400000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-154" decimals="-5" id="f-577" unitRef="usd">700000</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-154" decimals="-5" id="f-578" unitRef="usd">4500000</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-154" decimals="-5" id="f-579" unitRef="usd">5200000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-155" decimals="-5" id="f-580" unitRef="usd">0</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-155" decimals="-5" id="f-581" unitRef="usd">5200000</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-155" decimals="-5" id="f-582" unitRef="usd">5200000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-156" decimals="-5" id="f-583" unitRef="usd">0</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-156" decimals="-5" id="f-584" unitRef="usd">4900000</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-156" decimals="-5" id="f-585" unitRef="usd">4900000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-157" decimals="-5" id="f-586" unitRef="usd">0</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-157" decimals="-5" id="f-587" unitRef="usd">10100000</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-157" decimals="-5" id="f-588" unitRef="usd">10100000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-158" decimals="-5" id="f-589" unitRef="usd">0</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-158" decimals="-5" id="f-590" unitRef="usd">8900000</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-158" decimals="-5" id="f-591" unitRef="usd">8900000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-159" decimals="-5" id="f-592" unitRef="usd">-200000</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-159" decimals="-5" id="f-593" unitRef="usd">0</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-159" decimals="-5" id="f-594" unitRef="usd">-200000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-160" decimals="-5" id="f-595" unitRef="usd">3200000</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-160" decimals="-5" id="f-596" unitRef="usd">0</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-160" decimals="-5" id="f-597" unitRef="usd">3200000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-161" decimals="-5" id="f-598" unitRef="usd">-200000</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-161" decimals="-5" id="f-599" unitRef="usd">15300000</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-161" decimals="-5" id="f-600" unitRef="usd">15100000</us-gaap:RestructuringCharges>
    <us-gaap:SeveranceCosts1 contextRef="c-162" decimals="-5" id="f-601" unitRef="usd">3200000</us-gaap:SeveranceCosts1>
    <us-gaap:OtherRestructuringCosts contextRef="c-162" decimals="-5" id="f-602" unitRef="usd">13800000</us-gaap:OtherRestructuringCosts>
    <us-gaap:RestructuringCharges contextRef="c-162" decimals="-5" id="f-603" unitRef="usd">17000000.0</us-gaap:RestructuringCharges>
    <biib:OperatingLeaseArea contextRef="c-163" decimals="0" id="f-604" unitRef="sqft">327400</biib:OperatingLeaseArea>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-163" id="f-605">P16Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock contextRef="c-1" id="f-606">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Charges and spending related to workforce reductions are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.443%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.546%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Workforce Reductions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring reserve as of January 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;75.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(25.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(42.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring reserve as of March 31&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;45.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring reserve as of June 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(17.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(4.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign currency and other adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Restructuring reserve as of September 30&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
    <us-gaap:RestructuringReserve contextRef="c-164" decimals="-5" id="f-607" unitRef="usd">31900000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-165" decimals="-5" id="f-608" unitRef="usd">75400000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges contextRef="c-166" decimals="-5" id="f-609" unitRef="usd">35300000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-167" decimals="-5" id="f-610" unitRef="usd">11500000</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring contextRef="c-166" decimals="-5" id="f-611" unitRef="usd">25800000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-167" decimals="-5" id="f-612" unitRef="usd">42200000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserveTranslationAdjustment contextRef="c-166" decimals="-5" id="f-613" unitRef="usd">1000000.0</us-gaap:RestructuringReserveTranslationAdjustment>
    <us-gaap:RestructuringReserveTranslationAdjustment contextRef="c-167" decimals="-5" id="f-614" unitRef="usd">-800000</us-gaap:RestructuringReserveTranslationAdjustment>
    <us-gaap:RestructuringReserve contextRef="c-168" decimals="-5" id="f-615" unitRef="usd">40400000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-169" decimals="-5" id="f-616" unitRef="usd">45500000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges contextRef="c-170" decimals="-5" id="f-617" unitRef="usd">-700000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-171" decimals="-5" id="f-618" unitRef="usd">6600000</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring contextRef="c-170" decimals="-5" id="f-619" unitRef="usd">9500000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-171" decimals="-5" id="f-620" unitRef="usd">11900000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserveTranslationAdjustment contextRef="c-170" decimals="-5" id="f-621" unitRef="usd">1000000.0</us-gaap:RestructuringReserveTranslationAdjustment>
    <us-gaap:RestructuringReserveTranslationAdjustment contextRef="c-171" decimals="-5" id="f-622" unitRef="usd">0</us-gaap:RestructuringReserveTranslationAdjustment>
    <us-gaap:RestructuringReserve contextRef="c-172" decimals="-5" id="f-623" unitRef="usd">29200000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-173" decimals="-5" id="f-624" unitRef="usd">40200000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges contextRef="c-174" decimals="-5" id="f-625" unitRef="usd">7400000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-175" decimals="-5" id="f-626" unitRef="usd">6800000</us-gaap:RestructuringCharges>
    <us-gaap:PaymentsForRestructuring contextRef="c-174" decimals="-5" id="f-627" unitRef="usd">17400000</us-gaap:PaymentsForRestructuring>
    <us-gaap:PaymentsForRestructuring contextRef="c-175" decimals="-5" id="f-628" unitRef="usd">4700000</us-gaap:PaymentsForRestructuring>
    <us-gaap:RestructuringReserveTranslationAdjustment contextRef="c-174" decimals="-5" id="f-629" unitRef="usd">0</us-gaap:RestructuringReserveTranslationAdjustment>
    <us-gaap:RestructuringReserveTranslationAdjustment contextRef="c-175" decimals="-5" id="f-630" unitRef="usd">2100000</us-gaap:RestructuringReserveTranslationAdjustment>
    <us-gaap:RestructuringReserve contextRef="c-176" decimals="-5" id="f-631" unitRef="usd">19200000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-177" decimals="-5" id="f-632" unitRef="usd">40200000</us-gaap:RestructuringReserve>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="c-1" id="f-633">&lt;div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:87.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%"&gt;Note 5:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:14pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Product Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue by product is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.550%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.295%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.295%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Multiple Sclerosis:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TECFIDERA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;123.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;168.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;192.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;232.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;VUMERITY&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;189.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;214.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;134.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;158.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Fumarate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;234.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;148.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;382.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;175.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;215.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;390.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;AVONEX&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;133.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;188.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;115.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;176.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;PLEGRIDY&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Interferon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;161.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;85.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;246.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;143.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;94.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;237.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TYSABRI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;247.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;184.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;431.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;227.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;178.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;406.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FAMPYRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: Multiple Sclerosis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;642.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;418.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,061.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;546.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;507.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,053.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Rare Disease:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;SPINRAZA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;153.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;220.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;374.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;153.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;228.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;381.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;SKYCLARYS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;74.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;132.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;81.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;102.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;QALSODY&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: Rare Disease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;235.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;298.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;533.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;240.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;254.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;494.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biosimilars:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BENEPALI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;121.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;121.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;118.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;118.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;IMRALDI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FLIXABI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BYOOVIZ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TOFIDENCE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: Biosimilars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;194.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;196.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;192.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;196.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;ZURZUVAE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total product revenue, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;935.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;911.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,846.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;813.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;956.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,769.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.017%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Effective January 1, 2025, our collaboration and license agreement for FAMPYRA global commercialization rights was terminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; SKYCLARYS became commercially available in the E.U. during the first quarter of 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; QALSODY became commercially available in the E.U. during the second quarter of 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Other includes FUMADERM and ADUHELM.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.550%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.295%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.295%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Multiple Sclerosis:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TECFIDERA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;131.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;436.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;567.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;127.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;611.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;739.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;VUMERITY&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;494.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;71.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;565.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;385.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;451.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Fumarate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;626.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;507.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,133.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;512.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;677.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,190.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;AVONEX&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;363.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;169.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;533.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;344.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;193.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;537.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;PLEGRIDY&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;106.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;186.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;84.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;109.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;194.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Interferon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;443.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;276.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;719.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;428.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;303.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;732.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TYSABRI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;720.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;547.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,267.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;690.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;609.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,299.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FAMPYRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: Multiple Sclerosis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,790.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,331.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,121.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,631.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,648.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,279.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Rare Disease:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;SPINRAZA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;456.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;733.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,190.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;458.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;692.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,151.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;SKYCLARYS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;221.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;165.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;387.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;230.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;280.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;QALSODY&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: Rare Disease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;700.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;938.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,639.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;703.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;749.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,452.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biosimilars:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BENEPALI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;345.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;345.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;354.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;354.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;IMRALDI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;162.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;162.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FLIXABI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BYOOVIZ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TOFIDENCE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: Biosimilars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;550.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;559.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;572.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;591.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;ZURZUVAE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;129.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;129.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;129.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;131.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total product revenue, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,630.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,821.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,452.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,405.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,975.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,380.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.017%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Effective January 1, 2025, our collaboration and license agreement for FAMPYRA global commercialization rights was terminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; SKYCLARYS became commercially available in the E.U. during the first quarter of 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; QALSODY became commercially available in the E.U. during the second quarter of 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Other includes FUMADERM and ADUHELM.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized revenue from two wholesalers accounting for 27.8% and 16.0% of gross product revenue for the three months ended September 30, 2025, and 27.3% and 15.4% of gross product revenue for the nine months ended September 30, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We recognized revenue from two wholesalers accounting for 25.9% and 14.8% of gross product revenue for the three months ended September 30, 2024, and 25.6% and 12.9% of gross product revenue for the nine months ended September 30, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An analysis of the change in reserves for discounts and allowances is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.155%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.526%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.109%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.526%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.109%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.526%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.109%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.526%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.114%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;162.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;880.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,091.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current provisions relating to sales in current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;607.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,052.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,680.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Adjustments relating to prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(82.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(79.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments/credits relating to sales in current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(497.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,271.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,768.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments/credits relating to sales in prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(111.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(479.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(602.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;163.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,101.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,322.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.882%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.397%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.253%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reduction of accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;259.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;154.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Component of accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,062.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;937.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenue-related reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,322.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,091.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Revenue from Anti-CD20 Therapeutic Programs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from anti-CD20 therapeutic programs is summarized in the table below. For the purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.309%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.431%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Royalty revenue on sales of OCREVUS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;386.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;346.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,029.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;985.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen&#x2019;s share of pre-tax profits in the U.S. for RITUXAN, GAZYVA and LUNSUMIO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;101.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;94.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;292.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;285.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other revenue from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenue from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;493.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;446.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,339.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,284.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;padding-right:2.25pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our collaboration arrangements with Genentech, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 19, Collaborative and Other Relationships, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Alzheimer's Collaboration Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Alzheimer's collaboration revenue consists of our 50.0% share of LEQEMBI product revenue, net and cost of sales, including royalties, as we are not the principal. We began recognizing Alzheimer's collaboration revenue upon the accelerated approval of LEQEMBI in the U.S. during the first quarter of 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and nine months ended September 30, 2025, we recognized Alzheimer's collaboration revenue of approximately $42.7 million and $130.6 million, respectively, compared to $18.6 million and $33.2 million, respectively, in the prior year comparative periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our collaboration arrangements with Eisai, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 19, Collaborative and Other Relationships&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Contract Manufacturing, Royalty and Other Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract manufacturing, royalty and other revenue is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.455%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.285%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contract manufacturing revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;141.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;221.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;648.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;474.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Royalty and other revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total contract manufacturing, royalty and other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;151.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;231.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;689.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;522.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contract Manufacturing Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract manufacturing revenue primarily reflects amounts earned under contract manufacturing agreements with our strategic customers and batches of LEQEMBI related to our collaboration with Eisai.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalty and Other Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Royalty and other revenue primarily reflects royalty revenue on biosimilar products from our license arrangements with Samsung Bioepis and royalties we receive from net sales on products related to patents that we have out-licensed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our license arrangements with Samsung Bioepis and our collaboration arrangements with Eisai, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 19, Collaborative and Other Relationships&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="c-1" id="f-634">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue by product is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.550%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.295%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.295%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Multiple Sclerosis:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TECFIDERA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;123.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;168.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;192.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;232.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;VUMERITY&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;189.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;214.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;134.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;158.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Fumarate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;234.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;148.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;382.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;175.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;215.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;390.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;AVONEX&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;133.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;188.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;115.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;176.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;PLEGRIDY&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;33.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Interferon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;161.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;85.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;246.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;143.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;94.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;237.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TYSABRI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;247.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;184.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;431.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;227.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;178.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;406.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FAMPYRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: Multiple Sclerosis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;642.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;418.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,061.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;546.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;507.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,053.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Rare Disease:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;SPINRAZA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;153.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;220.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;374.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;153.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;228.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;381.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;SKYCLARYS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;74.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;132.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;81.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;102.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;QALSODY&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: Rare Disease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;235.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;298.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;533.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;240.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;254.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;494.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biosimilars:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BENEPALI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;121.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;121.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;118.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;118.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;IMRALDI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;54.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FLIXABI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BYOOVIZ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TOFIDENCE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: Biosimilars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;194.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;196.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;192.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;196.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;ZURZUVAE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;55.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total product revenue, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;935.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;911.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,846.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;813.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;956.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,769.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.017%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Effective January 1, 2025, our collaboration and license agreement for FAMPYRA global commercialization rights was terminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; SKYCLARYS became commercially available in the E.U. during the first quarter of 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; QALSODY became commercially available in the E.U. during the second quarter of 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Other includes FUMADERM and ADUHELM.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.550%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.295%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.295%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.441%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.445%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;United&lt;br/&gt;States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Rest of&lt;br/&gt;World&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Multiple Sclerosis:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TECFIDERA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;131.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;436.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;567.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;127.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;611.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;739.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;VUMERITY&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;494.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;71.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;565.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;385.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;66.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;451.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Fumarate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;626.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;507.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,133.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;512.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;677.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,190.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;AVONEX&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;363.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;169.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;533.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;344.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;193.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;537.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;PLEGRIDY&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;80.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;106.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;186.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;84.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;109.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;194.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Interferon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;443.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;276.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;719.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;428.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;303.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;732.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TYSABRI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;720.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;547.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,267.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;690.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;609.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,299.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FAMPYRA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: Multiple Sclerosis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,790.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,331.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,121.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,631.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,648.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,279.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Rare Disease:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;SPINRAZA&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;456.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;733.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,190.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;458.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;692.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,151.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;SKYCLARYS&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;221.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;165.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;387.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;230.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;280.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;QALSODY&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;39.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: Rare Disease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;700.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;938.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,639.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;703.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;749.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,452.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biosimilars:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BENEPALI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;345.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;345.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;354.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;354.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;IMRALDI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;162.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;162.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;FLIXABI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;47.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;BYOOVIZ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;TOFIDENCE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: Biosimilars&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;550.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;559.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;572.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;591.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;ZURZUVAE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;129.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;129.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal: Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;129.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;131.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total product revenue, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,630.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,821.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,452.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,405.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,975.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,380.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.017%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Effective January 1, 2025, our collaboration and license agreement for FAMPYRA global commercialization rights was terminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; SKYCLARYS became commercially available in the E.U. during the first quarter of 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; QALSODY became commercially available in the E.U. during the second quarter of 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Other includes FUMADERM and ADUHELM.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:Revenues contextRef="c-178" decimals="-5" id="f-635" unitRef="usd">44600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-179" decimals="-5" id="f-636" unitRef="usd">123600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-180" decimals="-5" id="f-637" unitRef="usd">168200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-181" decimals="-5" id="f-638" unitRef="usd">40100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-182" decimals="-5" id="f-639" unitRef="usd">192700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-183" decimals="-5" id="f-640" unitRef="usd">232800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-184" decimals="-5" id="f-641" unitRef="usd">189600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-185" decimals="-5" id="f-642" unitRef="usd">25000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-186" decimals="-5" id="f-643" unitRef="usd">214600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-187" decimals="-5" id="f-644" unitRef="usd">134900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-188" decimals="-5" id="f-645" unitRef="usd">23200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-189" decimals="-5" id="f-646" unitRef="usd">158100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-190" decimals="-5" id="f-647" unitRef="usd">234200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-191" decimals="-5" id="f-648" unitRef="usd">148600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-192" decimals="-5" id="f-649" unitRef="usd">382800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-193" decimals="-5" id="f-650" unitRef="usd">175000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-194" decimals="-5" id="f-651" unitRef="usd">215900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-195" decimals="-5" id="f-652" unitRef="usd">390900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-196" decimals="-5" id="f-653" unitRef="usd">133400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-197" decimals="-5" id="f-654" unitRef="usd">55100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-198" decimals="-5" id="f-655" unitRef="usd">188500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-199" decimals="-5" id="f-656" unitRef="usd">115600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-200" decimals="-5" id="f-657" unitRef="usd">60600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-201" decimals="-5" id="f-658" unitRef="usd">176200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-202" decimals="-5" id="f-659" unitRef="usd">27800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-203" decimals="-5" id="f-660" unitRef="usd">30600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-204" decimals="-5" id="f-661" unitRef="usd">58400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-205" decimals="-5" id="f-662" unitRef="usd">27900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-206" decimals="-5" id="f-663" unitRef="usd">33400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-207" decimals="-5" id="f-664" unitRef="usd">61300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-208" decimals="-5" id="f-665" unitRef="usd">161200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-209" decimals="-5" id="f-666" unitRef="usd">85700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-210" decimals="-5" id="f-667" unitRef="usd">246900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-211" decimals="-5" id="f-668" unitRef="usd">143500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-212" decimals="-5" id="f-669" unitRef="usd">94000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-213" decimals="-5" id="f-670" unitRef="usd">237500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-214" decimals="-5" id="f-671" unitRef="usd">247500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-215" decimals="-5" id="f-672" unitRef="usd">184300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-216" decimals="-5" id="f-673" unitRef="usd">431800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-217" decimals="-5" id="f-674" unitRef="usd">227500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-218" decimals="-5" id="f-675" unitRef="usd">178600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-219" decimals="-5" id="f-676" unitRef="usd">406100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-220" decimals="-5" id="f-677" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-221" decimals="-5" id="f-678" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-222" decimals="-5" id="f-679" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-223" decimals="-5" id="f-680" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-224" decimals="-5" id="f-681" unitRef="usd">19400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-225" decimals="-5" id="f-682" unitRef="usd">19400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-226" decimals="-5" id="f-683" unitRef="usd">642900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-227" decimals="-5" id="f-684" unitRef="usd">418600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-228" decimals="-5" id="f-685" unitRef="usd">1061500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-229" decimals="-5" id="f-686" unitRef="usd">546000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-230" decimals="-5" id="f-687" unitRef="usd">507900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-231" decimals="-5" id="f-688" unitRef="usd">1053900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-232" decimals="-5" id="f-689" unitRef="usd">153200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-233" decimals="-5" id="f-690" unitRef="usd">220800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-234" decimals="-5" id="f-691" unitRef="usd">374000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-235" decimals="-5" id="f-692" unitRef="usd">153100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-236" decimals="-5" id="f-693" unitRef="usd">228300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-237" decimals="-5" id="f-694" unitRef="usd">381400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-238" decimals="-5" id="f-695" unitRef="usd">74600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-239" decimals="-5" id="f-696" unitRef="usd">58300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-240" decimals="-5" id="f-697" unitRef="usd">132900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-241" decimals="-5" id="f-698" unitRef="usd">81800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-242" decimals="-5" id="f-699" unitRef="usd">20500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-243" decimals="-5" id="f-700" unitRef="usd">102300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-244" decimals="-5" id="f-701" unitRef="usd">7300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-245" decimals="-5" id="f-702" unitRef="usd">19100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-246" decimals="-5" id="f-703" unitRef="usd">26400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-247" decimals="-5" id="f-704" unitRef="usd">5500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-248" decimals="-5" id="f-705" unitRef="usd">5600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-249" decimals="-5" id="f-706" unitRef="usd">11100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-250" decimals="-5" id="f-707" unitRef="usd">235100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-251" decimals="-5" id="f-708" unitRef="usd">298200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-252" decimals="-5" id="f-709" unitRef="usd">533300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-253" decimals="-5" id="f-710" unitRef="usd">240400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-254" decimals="-5" id="f-711" unitRef="usd">254400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-255" decimals="-5" id="f-712" unitRef="usd">494800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-256" decimals="-5" id="f-713" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-257" decimals="-5" id="f-714" unitRef="usd">121900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-258" decimals="-5" id="f-715" unitRef="usd">121900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-259" decimals="-5" id="f-716" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-260" decimals="-5" id="f-717" unitRef="usd">118100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-261" decimals="-5" id="f-718" unitRef="usd">118100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-262" decimals="-5" id="f-719" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-263" decimals="-5" id="f-720" unitRef="usd">52600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-264" decimals="-5" id="f-721" unitRef="usd">52600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-265" decimals="-5" id="f-722" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-266" decimals="-5" id="f-723" unitRef="usd">54100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-267" decimals="-5" id="f-724" unitRef="usd">54100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-268" decimals="-5" id="f-725" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-269" decimals="-5" id="f-726" unitRef="usd">15300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-270" decimals="-5" id="f-727" unitRef="usd">15300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-271" decimals="-5" id="f-728" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-272" decimals="-5" id="f-729" unitRef="usd">16200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-273" decimals="-5" id="f-730" unitRef="usd">16200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-274" decimals="-5" id="f-731" unitRef="usd">2000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-275" decimals="-5" id="f-732" unitRef="usd">5000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-276" decimals="-5" id="f-733" unitRef="usd">7000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-277" decimals="-5" id="f-734" unitRef="usd">4100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-278" decimals="-5" id="f-735" unitRef="usd">3900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-279" decimals="-5" id="f-736" unitRef="usd">8000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-280" decimals="-5" id="f-737" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-281" decimals="-5" id="f-738" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-282" decimals="-5" id="f-739" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-283" decimals="-5" id="f-740" unitRef="usd">200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-284" decimals="-5" id="f-741" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-285" decimals="-5" id="f-742" unitRef="usd">200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-286" decimals="-5" id="f-743" unitRef="usd">2000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-287" decimals="-5" id="f-744" unitRef="usd">194800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-288" decimals="-5" id="f-745" unitRef="usd">196800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-289" decimals="-5" id="f-746" unitRef="usd">4300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-290" decimals="-5" id="f-747" unitRef="usd">192300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-291" decimals="-5" id="f-748" unitRef="usd">196600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-292" decimals="-5" id="f-749" unitRef="usd">55300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-293" decimals="-5" id="f-750" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-294" decimals="-5" id="f-751" unitRef="usd">55300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-295" decimals="-5" id="f-752" unitRef="usd">22000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-296" decimals="-5" id="f-753" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-297" decimals="-5" id="f-754" unitRef="usd">22000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-298" decimals="-5" id="f-755" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-299" decimals="-5" id="f-756" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-300" decimals="-5" id="f-757" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-301" decimals="-5" id="f-758" unitRef="usd">300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-302" decimals="-5" id="f-759" unitRef="usd">1800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-303" decimals="-5" id="f-760" unitRef="usd">2100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-304" decimals="-5" id="f-761" unitRef="usd">55300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-305" decimals="-5" id="f-762" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-306" decimals="-5" id="f-763" unitRef="usd">55300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-307" decimals="-5" id="f-764" unitRef="usd">22300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-308" decimals="-5" id="f-765" unitRef="usd">1800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-309" decimals="-5" id="f-766" unitRef="usd">24100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-310" decimals="-5" id="f-767" unitRef="usd">935300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-311" decimals="-5" id="f-768" unitRef="usd">911600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-3" decimals="-5" id="f-769" unitRef="usd">1846900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-312" decimals="-5" id="f-770" unitRef="usd">813000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-313" decimals="-5" id="f-771" unitRef="usd">956400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-4" decimals="-5" id="f-772" unitRef="usd">1769400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-314" decimals="-5" id="f-773" unitRef="usd">131600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-315" decimals="-5" id="f-774" unitRef="usd">436300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-316" decimals="-5" id="f-775" unitRef="usd">567900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-317" decimals="-5" id="f-776" unitRef="usd">127900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-318" decimals="-5" id="f-777" unitRef="usd">611400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-319" decimals="-5" id="f-778" unitRef="usd">739300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-320" decimals="-5" id="f-779" unitRef="usd">494700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-321" decimals="-5" id="f-780" unitRef="usd">71000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-322" decimals="-5" id="f-781" unitRef="usd">565700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-323" decimals="-5" id="f-782" unitRef="usd">385000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-324" decimals="-5" id="f-783" unitRef="usd">66400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-325" decimals="-5" id="f-784" unitRef="usd">451400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-326" decimals="-5" id="f-785" unitRef="usd">626300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-327" decimals="-5" id="f-786" unitRef="usd">507300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-328" decimals="-5" id="f-787" unitRef="usd">1133600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-329" decimals="-5" id="f-788" unitRef="usd">512900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-330" decimals="-5" id="f-789" unitRef="usd">677800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-331" decimals="-5" id="f-790" unitRef="usd">1190700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-332" decimals="-5" id="f-791" unitRef="usd">363700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-333" decimals="-5" id="f-792" unitRef="usd">169300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-334" decimals="-5" id="f-793" unitRef="usd">533000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-335" decimals="-5" id="f-794" unitRef="usd">344000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-336" decimals="-5" id="f-795" unitRef="usd">193500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-337" decimals="-5" id="f-796" unitRef="usd">537500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-338" decimals="-5" id="f-797" unitRef="usd">80200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-339" decimals="-5" id="f-798" unitRef="usd">106700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-340" decimals="-5" id="f-799" unitRef="usd">186900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-341" decimals="-5" id="f-800" unitRef="usd">84700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-342" decimals="-5" id="f-801" unitRef="usd">109800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-343" decimals="-5" id="f-802" unitRef="usd">194500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-344" decimals="-5" id="f-803" unitRef="usd">443900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-345" decimals="-5" id="f-804" unitRef="usd">276000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-346" decimals="-5" id="f-805" unitRef="usd">719900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-347" decimals="-5" id="f-806" unitRef="usd">428700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-348" decimals="-5" id="f-807" unitRef="usd">303300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-349" decimals="-5" id="f-808" unitRef="usd">732000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-350" decimals="-5" id="f-809" unitRef="usd">720500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-351" decimals="-5" id="f-810" unitRef="usd">547400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-352" decimals="-5" id="f-811" unitRef="usd">1267900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-353" decimals="-5" id="f-812" unitRef="usd">690000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-354" decimals="-5" id="f-813" unitRef="usd">609600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-355" decimals="-5" id="f-814" unitRef="usd">1299600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-356" decimals="-5" id="f-815" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-357" decimals="-5" id="f-816" unitRef="usd">300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-358" decimals="-5" id="f-817" unitRef="usd">300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-359" decimals="-5" id="f-818" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-360" decimals="-5" id="f-819" unitRef="usd">57300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-361" decimals="-5" id="f-820" unitRef="usd">57300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-362" decimals="-5" id="f-821" unitRef="usd">1790700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-363" decimals="-5" id="f-822" unitRef="usd">1331000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-364" decimals="-5" id="f-823" unitRef="usd">3121700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-365" decimals="-5" id="f-824" unitRef="usd">1631600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-366" decimals="-5" id="f-825" unitRef="usd">1648000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-367" decimals="-5" id="f-826" unitRef="usd">3279600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-368" decimals="-5" id="f-827" unitRef="usd">456900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-369" decimals="-5" id="f-828" unitRef="usd">733700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-370" decimals="-5" id="f-829" unitRef="usd">1190600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-371" decimals="-5" id="f-830" unitRef="usd">458900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-372" decimals="-5" id="f-831" unitRef="usd">692900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-373" decimals="-5" id="f-832" unitRef="usd">1151800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-374" decimals="-5" id="f-833" unitRef="usd">221700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-375" decimals="-5" id="f-834" unitRef="usd">165400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-376" decimals="-5" id="f-835" unitRef="usd">387100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-377" decimals="-5" id="f-836" unitRef="usd">230400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-378" decimals="-5" id="f-837" unitRef="usd">49900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-379" decimals="-5" id="f-838" unitRef="usd">280300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-380" decimals="-5" id="f-839" unitRef="usd">22300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-381" decimals="-5" id="f-840" unitRef="usd">39600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-382" decimals="-5" id="f-841" unitRef="usd">61900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-383" decimals="-5" id="f-842" unitRef="usd">14500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-384" decimals="-5" id="f-843" unitRef="usd">6200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-385" decimals="-5" id="f-844" unitRef="usd">20700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-386" decimals="-5" id="f-845" unitRef="usd">700900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-387" decimals="-5" id="f-846" unitRef="usd">938700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-388" decimals="-5" id="f-847" unitRef="usd">1639600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-389" decimals="-5" id="f-848" unitRef="usd">703800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-390" decimals="-5" id="f-849" unitRef="usd">749000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-391" decimals="-5" id="f-850" unitRef="usd">1452800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-392" decimals="-5" id="f-851" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-393" decimals="-5" id="f-852" unitRef="usd">345300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-394" decimals="-5" id="f-853" unitRef="usd">345300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-395" decimals="-5" id="f-854" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-396" decimals="-5" id="f-855" unitRef="usd">354100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-397" decimals="-5" id="f-856" unitRef="usd">354100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-398" decimals="-5" id="f-857" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-399" decimals="-5" id="f-858" unitRef="usd">146700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-400" decimals="-5" id="f-859" unitRef="usd">146700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-401" decimals="-5" id="f-860" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-402" decimals="-5" id="f-861" unitRef="usd">162100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-403" decimals="-5" id="f-862" unitRef="usd">162100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-404" decimals="-5" id="f-863" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-405" decimals="-5" id="f-864" unitRef="usd">42700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-406" decimals="-5" id="f-865" unitRef="usd">42700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-407" decimals="-5" id="f-866" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-408" decimals="-5" id="f-867" unitRef="usd">47100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-409" decimals="-5" id="f-868" unitRef="usd">47100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-410" decimals="-5" id="f-869" unitRef="usd">8700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-411" decimals="-5" id="f-870" unitRef="usd">15800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-412" decimals="-5" id="f-871" unitRef="usd">24500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-413" decimals="-5" id="f-872" unitRef="usd">18100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-414" decimals="-5" id="f-873" unitRef="usd">9200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-415" decimals="-5" id="f-874" unitRef="usd">27300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-416" decimals="-5" id="f-875" unitRef="usd">100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-417" decimals="-5" id="f-876" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-418" decimals="-5" id="f-877" unitRef="usd">100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-419" decimals="-5" id="f-878" unitRef="usd">1000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-420" decimals="-5" id="f-879" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-421" decimals="-5" id="f-880" unitRef="usd">1000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-422" decimals="-5" id="f-881" unitRef="usd">8800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-423" decimals="-5" id="f-882" unitRef="usd">550500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-424" decimals="-5" id="f-883" unitRef="usd">559300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-425" decimals="-5" id="f-884" unitRef="usd">19100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-426" decimals="-5" id="f-885" unitRef="usd">572500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-427" decimals="-5" id="f-886" unitRef="usd">591600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-428" decimals="-5" id="f-887" unitRef="usd">129400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-429" decimals="-5" id="f-888" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-430" decimals="-5" id="f-889" unitRef="usd">129400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-431" decimals="-5" id="f-890" unitRef="usd">49300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-432" decimals="-5" id="f-891" unitRef="usd">0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-433" decimals="-5" id="f-892" unitRef="usd">49300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-434" decimals="-5" id="f-893" unitRef="usd">400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-435" decimals="-5" id="f-894" unitRef="usd">1700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-436" decimals="-5" id="f-895" unitRef="usd">2100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-437" decimals="-5" id="f-896" unitRef="usd">2000000.0</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-438" decimals="-5" id="f-897" unitRef="usd">5600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-439" decimals="-5" id="f-898" unitRef="usd">7600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-440" decimals="-5" id="f-899" unitRef="usd">129800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-441" decimals="-5" id="f-900" unitRef="usd">1700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-442" decimals="-5" id="f-901" unitRef="usd">131500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-443" decimals="-5" id="f-902" unitRef="usd">51300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-444" decimals="-5" id="f-903" unitRef="usd">5600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-445" decimals="-5" id="f-904" unitRef="usd">56900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-446" decimals="-5" id="f-905" unitRef="usd">2630200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-447" decimals="-5" id="f-906" unitRef="usd">2821900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-5" decimals="-5" id="f-907" unitRef="usd">5452100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-448" decimals="-5" id="f-908" unitRef="usd">2405800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-449" decimals="-5" id="f-909" unitRef="usd">2975100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-6" decimals="-5" id="f-910" unitRef="usd">5380900000</us-gaap:Revenues>
    <biib:NumberOfWholesalers
      contextRef="c-20"
      decimals="INF"
      id="f-911"
      unitRef="wholesaler">2</biib:NumberOfWholesalers>
    <biib:NumberOfWholesalers
      contextRef="c-1"
      decimals="INF"
      id="f-912"
      unitRef="wholesaler">2</biib:NumberOfWholesalers>
    <biib:NumberOfWholesalers
      contextRef="c-19"
      decimals="INF"
      id="f-913"
      unitRef="wholesaler">2</biib:NumberOfWholesalers>
    <biib:NumberOfWholesalers
      contextRef="c-21"
      decimals="INF"
      id="f-914"
      unitRef="wholesaler">2</biib:NumberOfWholesalers>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="c-450"
      decimals="INF"
      id="f-915"
      unitRef="number">0.278</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="c-451"
      decimals="INF"
      id="f-916"
      unitRef="number">0.160</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="c-452"
      decimals="INF"
      id="f-917"
      unitRef="number">0.273</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors
      contextRef="c-453"
      decimals="INF"
      id="f-918"
      unitRef="number">0.154</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:NumberOfWholesalers
      contextRef="c-20"
      decimals="INF"
      id="f-919"
      unitRef="wholesaler">2</biib:NumberOfWholesalers>
    <biib:NumberOfWholesalers
      contextRef="c-1"
      decimals="INF"
      id="f-920"
      unitRef="wholesaler">2</biib:NumberOfWholesalers>
    <biib:NumberOfWholesalers
      contextRef="c-19"
      decimals="INF"
      id="f-921"
      unitRef="wholesaler">2</biib:NumberOfWholesalers>
    <biib:NumberOfWholesalers
      contextRef="c-21"
      decimals="INF"
      id="f-922"
      unitRef="wholesaler">2</biib:NumberOfWholesalers>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors contextRef="c-454" decimals="3" id="f-923" unitRef="number">0.259</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors contextRef="c-455" decimals="3" id="f-924" unitRef="number">0.148</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors contextRef="c-456" decimals="3" id="f-925" unitRef="number">0.256</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:EntityWidePercentageOfRevenueFromMajorDistributors contextRef="c-457" decimals="3" id="f-926" unitRef="number">0.129</biib:EntityWidePercentageOfRevenueFromMajorDistributors>
    <biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock contextRef="c-1" id="f-927">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An analysis of the change in reserves for discounts and allowances is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.155%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.526%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.109%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.526%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.109%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.526%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.109%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.526%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.114%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Discounts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;br/&gt;Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Returns&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;162.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;880.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,091.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current provisions relating to sales in current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;607.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,052.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,680.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Adjustments relating to prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(82.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(79.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments/credits relating to sales in current year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(497.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,271.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1,768.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments/credits relating to sales in prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(111.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(479.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(602.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;163.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,101.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,322.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-458" decimals="-5" id="f-928" unitRef="usd">162700000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-459" decimals="-5" id="f-929" unitRef="usd">880800000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-460" decimals="-5" id="f-930" unitRef="usd">48100000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-23" decimals="-5" id="f-931" unitRef="usd">1091600000</us-gaap:ValuationAllowancesAndReservesBalance>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="c-461" decimals="-5" id="f-932" unitRef="usd">607400000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="c-462" decimals="-5" id="f-933" unitRef="usd">2052600000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="c-463" decimals="-5" id="f-934" unitRef="usd">20700000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear contextRef="c-1" decimals="-5" id="f-935" unitRef="usd">2680700000</biib:CurrentProvisionsToProductRevenueReservesRelatingToSalesInCurrentYear>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="c-461" decimals="-5" id="f-936" unitRef="usd">-1800000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="c-462" decimals="-5" id="f-937" unitRef="usd">82000000.0</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="c-463" decimals="-5" id="f-938" unitRef="usd">-1000000.0</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears contextRef="c-1" decimals="-5" id="f-939" unitRef="usd">79200000</biib:AdjustmentsToProductRevenueReservesRelatingToSalesInPriorYears>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="c-461" decimals="-5" id="f-940" unitRef="usd">497300000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="c-462" decimals="-5" id="f-941" unitRef="usd">1271100000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="c-463" decimals="-5" id="f-942" unitRef="usd">500000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear contextRef="c-1" decimals="-5" id="f-943" unitRef="usd">1768900000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToCurrentYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="c-461" decimals="-5" id="f-944" unitRef="usd">111500000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="c-462" decimals="-5" id="f-945" unitRef="usd">479200000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="c-463" decimals="-5" id="f-946" unitRef="usd">11500000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear contextRef="c-1" decimals="-5" id="f-947" unitRef="usd">602200000</biib:PaymentsReturnsAppliedAgainstProductRevenueReservesRelatingToPriorYear>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-464" decimals="-5" id="f-948" unitRef="usd">163100000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-465" decimals="-5" id="f-949" unitRef="usd">1101100000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-466" decimals="-5" id="f-950" unitRef="usd">57800000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-22" decimals="-5" id="f-951" unitRef="usd">1322000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock contextRef="c-1" id="f-952">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.882%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.397%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.253%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Reduction of accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;259.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;154.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Component of accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,062.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;937.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenue-related reserves&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,322.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,091.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-467" decimals="-5" id="f-953" unitRef="usd">259700000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-468" decimals="-5" id="f-954" unitRef="usd">154100000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-469" decimals="-5" id="f-955" unitRef="usd">1062300000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-470" decimals="-5" id="f-956" unitRef="usd">937500000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-22" decimals="-5" id="f-957" unitRef="usd">1322000000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-23" decimals="-5" id="f-958" unitRef="usd">1091600000</us-gaap:ValuationAllowancesAndReservesBalance>
    <biib:RevenuesfromantiCD20therapeuticprogramsTableTextBlock contextRef="c-1" id="f-959">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue from anti-CD20 therapeutic programs is summarized in the table below. For the purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.309%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.426%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.431%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Royalty revenue on sales of OCREVUS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;386.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;346.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,029.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;985.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen&#x2019;s share of pre-tax profits in the U.S. for RITUXAN, GAZYVA and LUNSUMIO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;101.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;94.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;292.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;285.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other revenue from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;18.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenue from anti-CD20 therapeutic programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;493.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;446.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,339.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,284.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:RevenuesfromantiCD20therapeuticprogramsTableTextBlock>
    <us-gaap:Revenues contextRef="c-471" decimals="-5" id="f-960" unitRef="usd">386400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-472" decimals="-5" id="f-961" unitRef="usd">346800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-473" decimals="-5" id="f-962" unitRef="usd">1029000000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-474" decimals="-5" id="f-963" unitRef="usd">985800000</us-gaap:Revenues>
    <biib:ShareOfCoPromotionProfits contextRef="c-475" decimals="-5" id="f-964" unitRef="usd">101000000.0</biib:ShareOfCoPromotionProfits>
    <biib:ShareOfCoPromotionProfits contextRef="c-476" decimals="-5" id="f-965" unitRef="usd">94800000</biib:ShareOfCoPromotionProfits>
    <biib:ShareOfCoPromotionProfits contextRef="c-477" decimals="-5" id="f-966" unitRef="usd">292400000</biib:ShareOfCoPromotionProfits>
    <biib:ShareOfCoPromotionProfits contextRef="c-478" decimals="-5" id="f-967" unitRef="usd">285300000</biib:ShareOfCoPromotionProfits>
    <biib:OtherrevenuesfromantiCD20therapeuticprograms contextRef="c-475" decimals="-5" id="f-968" unitRef="usd">6500000</biib:OtherrevenuesfromantiCD20therapeuticprograms>
    <biib:OtherrevenuesfromantiCD20therapeuticprograms contextRef="c-476" decimals="-5" id="f-969" unitRef="usd">4600000</biib:OtherrevenuesfromantiCD20therapeuticprograms>
    <biib:OtherrevenuesfromantiCD20therapeuticprograms contextRef="c-477" decimals="-5" id="f-970" unitRef="usd">18000000.0</biib:OtherrevenuesfromantiCD20therapeuticprograms>
    <biib:OtherrevenuesfromantiCD20therapeuticprograms contextRef="c-478" decimals="-5" id="f-971" unitRef="usd">13600000</biib:OtherrevenuesfromantiCD20therapeuticprograms>
    <us-gaap:Revenues contextRef="c-7" decimals="-5" id="f-972" unitRef="usd">493900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-8" decimals="-5" id="f-973" unitRef="usd">446200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-9" decimals="-5" id="f-974" unitRef="usd">1339400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-10" decimals="-5" id="f-975" unitRef="usd">1284700000</us-gaap:Revenues>
    <biib:ShareOfNonControlingInterestRecognized contextRef="c-479" decimals="2" id="f-976" unitRef="number">0.500</biib:ShareOfNonControlingInterestRecognized>
    <us-gaap:Revenues contextRef="c-480" decimals="-5" id="f-977" unitRef="usd">42700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-481" decimals="-5" id="f-978" unitRef="usd">130600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-482" decimals="-5" id="f-979" unitRef="usd">18600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-483" decimals="-5" id="f-980" unitRef="usd">33200000</us-gaap:Revenues>
    <biib:OtherrevenuesTableTextBlock contextRef="c-1" id="f-981">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract manufacturing, royalty and other revenue is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.455%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.285%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contract manufacturing revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;141.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;221.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;648.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;474.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Royalty and other revenue&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;40.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total contract manufacturing, royalty and other revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;151.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;231.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;689.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;522.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:OtherrevenuesTableTextBlock>
    <us-gaap:Revenues contextRef="c-484" decimals="-5" id="f-982" unitRef="usd">141500000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-485" decimals="-5" id="f-983" unitRef="usd">221900000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-486" decimals="-5" id="f-984" unitRef="usd">648800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-487" decimals="-5" id="f-985" unitRef="usd">474100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-488" decimals="-5" id="f-986" unitRef="usd">9700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-489" decimals="-5" id="f-987" unitRef="usd">9700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-490" decimals="-5" id="f-988" unitRef="usd">40300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-491" decimals="-5" id="f-989" unitRef="usd">48300000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-15" decimals="-5" id="f-990" unitRef="usd">151200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-16" decimals="-5" id="f-991" unitRef="usd">231600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-17" decimals="-5" id="f-992" unitRef="usd">689100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-18" decimals="-5" id="f-993" unitRef="usd">522400000</us-gaap:Revenues>
    <us-gaap:InventoryDisclosureTextBlock contextRef="c-1" id="f-994">&lt;div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:87.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%"&gt;Note 6:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:14pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of inventory are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.347%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;296.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;317.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,635.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,882.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;440.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;353.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,371.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,554.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance Sheet Classification:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,209.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,460.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Investments and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;162.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;93.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,371.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,554.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-term inventory is included in investments and other assets within our condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of our acquisition of Reata in September 2023 we recorded a fair value step-up adjustment related to the acquired inventory of SKYCLARYS of approximately $1.3&#160;billion. This fair value step-up adjustment is being amortized to cost of sales within our condensed consolidated statements of income as the inventory is sold or used for clinical purposes. We expect this amount to be fully amortized by the end of 2028. For the three and nine months ended September 30, 2025, amortization from the fair value step-up adjustment was approximately $61.5&#160;million and $165.4 million, respectively. For the three and nine months ended September 30, 2024, amortization from the fair value step-up adjustment was approximately $50.9&#160;million and $185.1 million, respectively, which includes approximately $2.5 million and $48.5 million, respectively, of inventory used for clinical purposes, which is reflected in research and development expense within our condensed consolidated statements of income. For additional information on our acquisition of Reata, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2, Acquisitions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to our consolidated financial statements included in our &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2024&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Form 10-K.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="c-1" id="f-995">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of inventory are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.347%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;296.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;317.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,635.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,882.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;440.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;353.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,371.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,554.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance Sheet Classification:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,209.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,460.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Investments and other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;162.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;93.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total inventory&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,371.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,554.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="c-22" decimals="-5" id="f-996" unitRef="usd">296200000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves contextRef="c-23" decimals="-5" id="f-997" unitRef="usd">317800000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="c-22" decimals="-5" id="f-998" unitRef="usd">1635000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="c-23" decimals="-5" id="f-999" unitRef="usd">1882800000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="c-22" decimals="-5" id="f-1000" unitRef="usd">440500000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="c-23" decimals="-5" id="f-1001" unitRef="usd">353800000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <biib:InventoryNetCurrentAndNoncurrent contextRef="c-22" decimals="-5" id="f-1002" unitRef="usd">2371700000</biib:InventoryNetCurrentAndNoncurrent>
    <biib:InventoryNetCurrentAndNoncurrent contextRef="c-23" decimals="-5" id="f-1003" unitRef="usd">2554400000</biib:InventoryNetCurrentAndNoncurrent>
    <us-gaap:InventoryNet contextRef="c-22" decimals="-5" id="f-1004" unitRef="usd">2209400000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-23" decimals="-5" id="f-1005" unitRef="usd">2460500000</us-gaap:InventoryNet>
    <us-gaap:InventoryNoncurrent contextRef="c-22" decimals="-5" id="f-1006" unitRef="usd">162300000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent contextRef="c-23" decimals="-5" id="f-1007" unitRef="usd">93900000</us-gaap:InventoryNoncurrent>
    <biib:InventoryNetCurrentAndNoncurrent contextRef="c-22" decimals="-5" id="f-1008" unitRef="usd">2371700000</biib:InventoryNetCurrentAndNoncurrent>
    <biib:InventoryNetCurrentAndNoncurrent contextRef="c-23" decimals="-5" id="f-1009" unitRef="usd">2554400000</biib:InventoryNetCurrentAndNoncurrent>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory contextRef="c-492" decimals="-8" id="f-1010" unitRef="usd">1300000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory>
    <us-gaap:ProfitLoss contextRef="c-493" decimals="-5" id="f-1011" unitRef="usd">61500000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-494" decimals="-5" id="f-1012" unitRef="usd">165400000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-495" decimals="-5" id="f-1013" unitRef="usd">50900000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-496" decimals="-5" id="f-1014" unitRef="usd">185100000</us-gaap:ProfitLoss>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-497" decimals="-5" id="f-1015" unitRef="usd">2500000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-498" decimals="-5" id="f-1016" unitRef="usd">48500000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="c-1" id="f-1017">&lt;div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:87.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%"&gt;Note 7:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:14pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%"&gt;Intangible Assets and Goodwill&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets, net of accumulated amortization, impairment charges and adjustments are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.607%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.958%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.671%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.987%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.671%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.671%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.987%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.684%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Completed technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2-31 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,087.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6,558.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,528.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,138.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6,254.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,884.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;In-process research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Indefinite until commercialization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,639.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,639.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,642.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,642.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Priority review voucher&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks&#160;and trade names&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,890.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6,558.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,331.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,945.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6,254.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,691.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Amortization and Impairments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;nine &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;months ended September 30, 2025, amortization and impairment of acquired intangible assets totale&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;d $135.7 million and $378.4 million, respectively, compared to $130.3 million and $295.5 million, respectively, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in the prior year comparative periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;nine &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;months ended September 30, 2025, amortization of acquired intangible assets, excluding impairment charges, totaled &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$135.7 million and $374.9 million, respectively, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;compared to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$110.1 million and $275.3 million, respectively, in the prior year comparative periods. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Th&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;e increases were primarily due to amortization for the acquired intangible assets associated with SKYCLARYS and TYSABRI.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;three months ended &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;September 30, 2025, we had no impairment charges. For the nine months ended September 30, 2025, amortization and impairment of acquired intangible assets reflects the impact of a $3.5 million impairment charge related to a compound acquired from HI-Bio. For the three and nine months ended September 30, 2024, amortization and impairment of acquired intangible assets reflects impairment charges of approximately $20.2 million related to intangible assets associated with the termination of Samsung Bioepis' commercialization rights during the third quarter of 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Completed Technology&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Completed technology primarily relates to our other marketed products and programs acquired through asset acquisitions, licenses and business combinations. Completed technology intangible assets are amortized over their estimated useful lives, which range between 2 to 31 years, with a remaining weighted average useful life of 12 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;IPR&amp;amp;D Related to Business Combinations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;IPR&amp;amp;D represents the fair value assigned to research and development assets that we acquired as part of a business combination and had not yet reached technological feasibility at the date of acquisition. Included in IPR&amp;amp;D balances are adjustments related to foreign currency exchange rate fluctuations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value associated with our IPR&amp;amp;D assets as of September 30, 2025 and December 31, 2024, primarily relates to the IPR&amp;amp;D programs we acquired in connection with our acquisition of HI-Bio in July 2024, with an estimated fair value of approximately $1.6&#160;billion.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Priority Review Voucher&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our acquisition of Reata in September 2023 we acquired a rare pediatric disease PRV which may be used to obtain priority review by the FDA for a future regulatory submission or sold to a third party. We recorded the PRV based on its estimated fair value of $100.0&#160;million as an intangible asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Estimated Future Amortization of Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated future amortization of finite-lived intangible assets for the next five years is expected to be as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.724%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.346%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025 (remaining three months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;130.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;485.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;490.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;525.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;580.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;650.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a roll forward of the changes in our goodwill balance:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.724%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.346%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill, December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,478.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill resulting from HI-Bio acquisition&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill, September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,490.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.017%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Goodwill resulting from the HI-Bio acquisition relates to HI-Bio measurement period adjustments recognized during 2025 related to certain income tax adjustments. For additional information on our acquisition of HI-Bio, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2, Acquisitions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Other includes adjustments related to foreign currency exchange rate fluctuations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September 30, 2025, we had&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; no &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;impairment losses related to goodwill.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <biib:IntangibleAssetsExcludingGoodwillTableTextBlock contextRef="c-1" id="f-1018">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets, net of accumulated amortization, impairment charges and adjustments are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.607%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.958%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.671%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.987%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.671%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.671%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.987%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:7.684%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Completed technology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2-31 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,087.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6,558.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,528.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14,138.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6,254.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,884.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;In-process research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Indefinite until commercialization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,639.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,639.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,642.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,642.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Priority review voucher&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Trademarks&#160;and trade names&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Indefinite&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,890.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6,558.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,331.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15,945.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6,254.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9,691.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:IntangibleAssetsExcludingGoodwillTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-499" id="f-1019">P2Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-500" id="f-1020">P31Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-22" decimals="-5" id="f-1021" unitRef="usd">14087200000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-22" decimals="-5" id="f-1022" unitRef="usd">6558700000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-22" decimals="-5" id="f-1023" unitRef="usd">7528500000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-23" decimals="-5" id="f-1024" unitRef="usd">14138400000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-23" decimals="-5" id="f-1025" unitRef="usd">6254100000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-23" decimals="-5" id="f-1026" unitRef="usd">7884300000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-501" decimals="-5" id="f-1027" unitRef="usd">1639400000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-501" decimals="-5" id="f-1028" unitRef="usd">1639400000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-502" decimals="-5" id="f-1029" unitRef="usd">1642900000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-502" decimals="-5" id="f-1030" unitRef="usd">1642900000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-503" decimals="-5" id="f-1031" unitRef="usd">100000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-503" decimals="-5" id="f-1032" unitRef="usd">100000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-504" decimals="-5" id="f-1033" unitRef="usd">100000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-504" decimals="-5" id="f-1034" unitRef="usd">100000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-505" decimals="-5" id="f-1035" unitRef="usd">64000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-505" decimals="-5" id="f-1036" unitRef="usd">64000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-506" decimals="-5" id="f-1037" unitRef="usd">64000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill contextRef="c-506" decimals="-5" id="f-1038" unitRef="usd">64000000.0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="c-22" decimals="-5" id="f-1039" unitRef="usd">15890600000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-22" decimals="-5" id="f-1040" unitRef="usd">6558700000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-22" decimals="-5" id="f-1041" unitRef="usd">9331900000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill contextRef="c-23" decimals="-5" id="f-1042" unitRef="usd">15945300000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-23" decimals="-5" id="f-1043" unitRef="usd">6254100000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill contextRef="c-23" decimals="-5" id="f-1044" unitRef="usd">9691200000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets contextRef="c-19" decimals="-5" id="f-1045" unitRef="usd">135700000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets contextRef="c-1" decimals="-5" id="f-1046" unitRef="usd">378400000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets contextRef="c-20" decimals="-5" id="f-1047" unitRef="usd">130300000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets contextRef="c-21" decimals="-5" id="f-1048" unitRef="usd">295500000</biib:AmortizationAndImpairmentOfAcquiredIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-19" decimals="-5" id="f-1049" unitRef="usd">135700000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-1" decimals="-5" id="f-1050" unitRef="usd">374900000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-20" decimals="-5" id="f-1051" unitRef="usd">110100000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-21" decimals="-5" id="f-1052" unitRef="usd">275300000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill contextRef="c-19" decimals="-5" id="f-1053" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill contextRef="c-1" decimals="-5" id="f-1054" unitRef="usd">3500000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill contextRef="c-20" decimals="-5" id="f-1055" unitRef="usd">20200000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill contextRef="c-21" decimals="-5" id="f-1056" unitRef="usd">20200000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-499" id="f-1057">P2Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-500" id="f-1058">P31Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <biib:FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife contextRef="c-507" id="f-1059">P12Y</biib:FiniteLivedIntangibleAssetWeightedAverageRemainingUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-508" decimals="-8" id="f-1060" unitRef="usd">1600000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-509" decimals="-8" id="f-1061" unitRef="usd">1600000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles contextRef="c-510" decimals="-5" id="f-1062" unitRef="usd">100000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="c-1" id="f-1063">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated future amortization of finite-lived intangible assets for the next five years is expected to be as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.724%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.346%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025 (remaining three months)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;130.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;485.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;490.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;525.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;580.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2030&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;650.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear contextRef="c-22" decimals="-5" id="f-1064" unitRef="usd">130000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="c-22" decimals="-5" id="f-1065" unitRef="usd">485000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="c-22" decimals="-5" id="f-1066" unitRef="usd">490000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="c-22" decimals="-5" id="f-1067" unitRef="usd">525000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="c-22" decimals="-5" id="f-1068" unitRef="usd">580000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="c-22" decimals="-5" id="f-1069" unitRef="usd">650000000.0</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:ScheduleOfGoodwillTextBlock contextRef="c-1" id="f-1070">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a roll forward of the changes in our goodwill balance:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:78.724%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.346%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill, December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,478.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill resulting from HI-Bio acquisition&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Goodwill, September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,490.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.017%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Goodwill resulting from the HI-Bio acquisition relates to HI-Bio measurement period adjustments recognized during 2025 related to certain income tax adjustments. For additional information on our acquisition of HI-Bio, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2, Acquisitions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Other includes adjustments related to foreign currency exchange rate fluctuations.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill contextRef="c-23" decimals="-5" id="f-1071" unitRef="usd">6478900000</us-gaap:Goodwill>
    <us-gaap:GoodwillPurchaseAccountingAdjustments contextRef="c-112" decimals="-5" id="f-1072" unitRef="usd">4500000</us-gaap:GoodwillPurchaseAccountingAdjustments>
    <us-gaap:GoodwillOtherIncreaseDecrease contextRef="c-1" decimals="-5" id="f-1073" unitRef="usd">7300000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:Goodwill contextRef="c-22" decimals="-5" id="f-1074" unitRef="usd">6490700000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss contextRef="c-22" decimals="INF" id="f-1075" unitRef="usd">0</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-1076">&lt;div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:87.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%"&gt;Note 8:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:14pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:40.420%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.796%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements on a Recurring Basis&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&lt;br/&gt;in Active&lt;br/&gt;Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,398.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,398.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;71.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;71.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;103.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;103.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other non-current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Convertible note&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Plan assets for deferred compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,691.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;103.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,557.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;89.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;89.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;148.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;148.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other non-current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;242.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;242.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;490.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;99.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;391.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.017%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;As part of our strategic research arrangement with City Therapeutics we invested in a convertible note, for which we elected the fair value option. For additional information on the arrangement with City Therapeutics, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 19, Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:40.420%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.796%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements on a Recurring Basis&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&lt;br/&gt;in Active&lt;br/&gt;Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,664.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,664.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;179.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;179.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other non-current assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Plan assets for deferred compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,949.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;179.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,770.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;291.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;291.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other non-current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;221.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;221.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;524.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;512.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our marketable equity securities represent investments in publicly traded equity securities. Our ability to liquidate our investment in Denali may be limited by the size of our interest, the volume of market-related activity, our concentrated level of ownership and potential restrictions resulting from our status as a collaborator. Therefore, we may realize significantly less than the current value of such investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2025 Sage was acquired by Supernus. Prior to this acquisition, we disposed of all of our shares of Sage common stock in a block trade.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our investments in Denali and Sage common stock, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 19, Collaborative and Other Relationships&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to our consolidated financial statements included in our 2024 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no material impairments of our assets measured and carried at fair value as of September 30, 2025 and December 31, 2024. In addition, there have been no changes to our valuation techniques as of September 30, 2025 and December 31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For a description of our validation procedures related to prices provided by third-party pricing services and our option pricing valuation model, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1, Summary of Significant Accounting Policies - Fair Value Measurements,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to our consolidated financial statements included in our 2024 Form 10-K. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Level 3 Assets and Liabilities Held at Fair Value&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present quantitative information, as of the dates indicated, about the valuation techniques and significant unobservable inputs used in the valuation of our Level 3 financial assets and liabilities measured at fair value on a recurring basis:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.069%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.490%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.841%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quantitative Information about Level 3 Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Valuation Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable Input(s)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;391.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Discounted cash flow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.4% - 5.5%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected timing of achievement of development milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025 - 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.069%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.490%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.841%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quantitative Information about Level 3 Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Valuation Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable Input(s)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;512.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Discounted cash flow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.2% - 6.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected timing of achievement of development milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025 - 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average discount rates were calculated based on the relative fair values of each distinct contingent consideration obligation related to our acquisition of HI-Bio in July 2024. In addition, we apply various probabilities of technological and regulatory success to the valuation models to estimate the fair values of these contingent consideration obligations, which ranged from approximately 70.0% to near certain probability as of September 30, 2025 and December 31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; no tr&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ansfers of assets or liabilities into or out of Level 3 as of September 30, 2025 and December 31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingent Consideration Obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our acquisition of HI-Bio in July 2024 we agreed to make additional payments based upon the achievement of certain milestone events. The following table provides a roll forward of the fair value of our contingent consideration obligations, which were classified as Level 3 measurements:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.683%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.624%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;534.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;512.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent consideration resulting from HI-Bio acquisition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;485.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;485.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Changes in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(149.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(150.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value, end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;391.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;508.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;391.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;508.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the fair value of our contingent consideration obligations, other than changes due to payments, are recognized as a (gain) loss on fair value remeasurement of contingent consideration in our condensed consolidated statements of income. The fair values of the contingent consideration liabilities were based on a probability-adjusted discounted cash flow calculation using Level 3 fair value measurements and inputs. For additional information on the valuation techniques and inputs utilized in the valuation of our financial assets and liabilities, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1, Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to our consolidated financial statements included in our 2024 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September 30, 2025 and December 31, 2024, approximately $148.6 million and $291.2 million, respectively, of the fair value of the total contingent consideration obligations were classified as short-term and reflected as a component of accrued expense and other with the remaining $242.6 million and $221.6 million, respectively, reflected as a component of other long-term liabilities in our condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;F&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;or the three and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;nine &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;months ended September 30, 2025&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, changes in fair value of our contingent consideration obligations were primarily due to the passage of time.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the second quarter of 2025 the first milestone related to the fourth patient dosed in a phase 3 clinical trial of felzartamab for AMR was achieved, resulting in a $150.0&#160;million milestone payment made to the former shareholders of HI-Bio, which was paid during the third quarter of 2025. In October 2025 the second milestone related to the fourth patient dosed in a phase 3 clinical trial of felzartamab for IgAN was achieved, resulting in a $150.0&#160;million milestone payment to be made to the former shareholders of HI-Bio, which we expect will be paid during the fourth quarter of 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:120%"&gt;Financial Instruments Not Carried at Fair Value&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to the short-term nature of certain financial instruments, the carrying value reflected in our condensed consolidated balance sheets for current accounts receivable, due from anti-CD20 therapeutic programs, other current assets, accounts payable and accrued expense and other, approximates fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Debt Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.091%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Current portion:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.050% Senior Notes due September 15, 2025&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,741.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,748.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current portion of notes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,741.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,748.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Non-current portion:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.250% Senior Notes due May 1, 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,367.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,495.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,295.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,494.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.050% Senior Notes due January 15, 2031&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;410.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;397.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.750% Senior Notes due May 15, 2035&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;680.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;645.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.200% Senior Notes due September 15, 2045&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,026.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,101.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,008.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,101.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.150% Senior Notes due May 1, 2050&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;970.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,475.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;943.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,475.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.250% Senior Notes due February 15, 2051&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;458.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;479.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;448.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;476.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.450% Senior Notes due May 15, 2055&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;748.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;690.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current portion of notes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,663.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,285.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,696.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,547.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total notes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,663.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,285.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,437.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,295.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.017%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; In May 2025 we issued our 2025 Senior Notes for an aggregate principal amount of $1.75&#160;billion. In June 2025 we used the net proceeds from the sale of our 2025 Senior Notes to redeem in full our 4.050% Senior Notes due September 15, 2025, prior to maturity. For additional information, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 13, Indebtedness&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair values of each of our series of Senior Notes were determined through market, observable and corroborated sources. The changes in the fair values of our Senior Notes as of September 30, 2025, compared to December 31, 2024, are primarily related to decreases in U.S. treasury yields and credit spreads used to value our Senior Notes since December 31, 2024. For additional information related to our Senior Notes, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 13,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Indebtedness,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to our consolidated financial statements included in our 2024 Form 10-K.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c-1" id="f-1077">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The tables below present information about our assets and liabilities that are regularly measured and carried at fair value and indicate the level within the fair value hierarchy of the valuation techniques we utilized to determine such fair value:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:40.420%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.796%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements on a Recurring Basis&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&lt;br/&gt;in Active&lt;br/&gt;Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,398.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,398.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;71.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;71.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;103.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;103.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other non-current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Convertible note&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Plan assets for deferred compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,691.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;103.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,557.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;30.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;89.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;89.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;148.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;148.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other non-current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;242.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;242.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;490.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;99.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;391.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.017%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;As part of our strategic research arrangement with City Therapeutics we invested in a convertible note, for which we elected the fair value option. For additional information on the arrangement with City Therapeutics, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 19, Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:40.420%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.796%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements on a Recurring Basis&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quoted&#160;Prices&lt;br/&gt;in Active&lt;br/&gt;Markets&lt;br/&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other Observable&lt;br/&gt;Inputs&lt;br/&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable&lt;br/&gt;Inputs&lt;br/&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,664.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,664.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;179.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;179.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other non-current assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Plan assets for deferred compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,949.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;179.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,770.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;291.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;291.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other non-current liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;221.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;221.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;524.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;512.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-511" decimals="-5" id="f-1078" unitRef="usd">3398800000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-512" decimals="-5" id="f-1079" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-513" decimals="-5" id="f-1080" unitRef="usd">3398800000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-514" decimals="-5" id="f-1081" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-515" decimals="-5" id="f-1082" unitRef="usd">71000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-516" decimals="-5" id="f-1083" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-517" decimals="-5" id="f-1084" unitRef="usd">71000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-518" decimals="-5" id="f-1085" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-519" decimals="-5" id="f-1086" unitRef="usd">26600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-520" decimals="-5" id="f-1087" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-521" decimals="-5" id="f-1088" unitRef="usd">26600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-522" decimals="-5" id="f-1089" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-511" decimals="-5" id="f-1090" unitRef="usd">103900000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-512" decimals="-5" id="f-1091" unitRef="usd">103900000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-513" decimals="-5" id="f-1092" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-514" decimals="-5" id="f-1093" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="c-511" decimals="-5" id="f-1094" unitRef="usd">9600000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="c-512" decimals="-5" id="f-1095" unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="c-513" decimals="-5" id="f-1096" unitRef="usd">9600000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="c-514" decimals="-5" id="f-1097" unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:NotesReceivableFairValueDisclosure contextRef="c-511" decimals="-5" id="f-1098" unitRef="usd">30000000.0</us-gaap:NotesReceivableFairValueDisclosure>
    <us-gaap:NotesReceivableFairValueDisclosure contextRef="c-512" decimals="-5" id="f-1099" unitRef="usd">0</us-gaap:NotesReceivableFairValueDisclosure>
    <us-gaap:NotesReceivableFairValueDisclosure contextRef="c-513" decimals="-5" id="f-1100" unitRef="usd">0</us-gaap:NotesReceivableFairValueDisclosure>
    <us-gaap:NotesReceivableFairValueDisclosure contextRef="c-514" decimals="-5" id="f-1101" unitRef="usd">30000000.0</us-gaap:NotesReceivableFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="c-511" decimals="-5" id="f-1102" unitRef="usd">51800000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="c-512" decimals="-5" id="f-1103" unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="c-513" decimals="-5" id="f-1104" unitRef="usd">51800000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="c-514" decimals="-5" id="f-1105" unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-511" decimals="-5" id="f-1106" unitRef="usd">3691700000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-512" decimals="-5" id="f-1107" unitRef="usd">103900000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-513" decimals="-5" id="f-1108" unitRef="usd">3557800000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-514" decimals="-5" id="f-1109" unitRef="usd">30000000.0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="c-511" decimals="-5" id="f-1110" unitRef="usd">89100000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="c-512" decimals="-5" id="f-1111" unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="c-513" decimals="-5" id="f-1112" unitRef="usd">89100000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent contextRef="c-514" decimals="-5" id="f-1113" unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="c-511" decimals="-5" id="f-1114" unitRef="usd">148600000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="c-512" decimals="-5" id="f-1115" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="c-513" decimals="-5" id="f-1116" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="c-514" decimals="-5" id="f-1117" unitRef="usd">148600000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="c-511" decimals="-5" id="f-1118" unitRef="usd">10200000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="c-512" decimals="-5" id="f-1119" unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="c-513" decimals="-5" id="f-1120" unitRef="usd">10200000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent contextRef="c-514" decimals="-5" id="f-1121" unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="c-511" decimals="-5" id="f-1122" unitRef="usd">242600000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="c-512" decimals="-5" id="f-1123" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="c-513" decimals="-5" id="f-1124" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="c-514" decimals="-5" id="f-1125" unitRef="usd">242600000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-511" decimals="-5" id="f-1126" unitRef="usd">490500000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-512" decimals="-5" id="f-1127" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-513" decimals="-5" id="f-1128" unitRef="usd">99300000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-514" decimals="-5" id="f-1129" unitRef="usd">391200000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-523" decimals="-5" id="f-1130" unitRef="usd">1664900000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-524" decimals="-5" id="f-1131" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-525" decimals="-5" id="f-1132" unitRef="usd">1664900000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-526" decimals="-5" id="f-1133" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-523" decimals="-5" id="f-1134" unitRef="usd">179700000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-524" decimals="-5" id="f-1135" unitRef="usd">179700000</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-525" decimals="-5" id="f-1136" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:InvestmentsFairValueDisclosure contextRef="c-526" decimals="-5" id="f-1137" unitRef="usd">0</us-gaap:InvestmentsFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="c-523" decimals="-5" id="f-1138" unitRef="usd">62500000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="c-524" decimals="-5" id="f-1139" unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="c-525" decimals="-5" id="f-1140" unitRef="usd">62500000</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractAssetFairValueDisclosure contextRef="c-526" decimals="-5" id="f-1141" unitRef="usd">0</us-gaap:ForeignCurrencyContractAssetFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="c-523" decimals="-5" id="f-1142" unitRef="usd">42800000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="c-524" decimals="-5" id="f-1143" unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="c-525" decimals="-5" id="f-1144" unitRef="usd">42800000</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <biib:PlanAssetsForDeferredCompensationFairValueDisclosure contextRef="c-526" decimals="-5" id="f-1145" unitRef="usd">0</biib:PlanAssetsForDeferredCompensationFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-523" decimals="-5" id="f-1146" unitRef="usd">1949900000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-524" decimals="-5" id="f-1147" unitRef="usd">179700000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-525" decimals="-5" id="f-1148" unitRef="usd">1770200000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-526" decimals="-5" id="f-1149" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="c-523" decimals="-5" id="f-1150" unitRef="usd">11700000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="c-524" decimals="-5" id="f-1151" unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="c-525" decimals="-5" id="f-1152" unitRef="usd">11700000</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure contextRef="c-526" decimals="-5" id="f-1153" unitRef="usd">0</us-gaap:ForeignCurrencyContractsLiabilityFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="c-523" decimals="-5" id="f-1154" unitRef="usd">291200000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="c-524" decimals="-5" id="f-1155" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="c-525" decimals="-5" id="f-1156" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="c-526" decimals="-5" id="f-1157" unitRef="usd">291200000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="c-523" decimals="-5" id="f-1158" unitRef="usd">221600000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="c-524" decimals="-5" id="f-1159" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="c-525" decimals="-5" id="f-1160" unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="c-526" decimals="-5" id="f-1161" unitRef="usd">221600000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-523" decimals="-5" id="f-1162" unitRef="usd">524500000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-524" decimals="-5" id="f-1163" unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-525" decimals="-5" id="f-1164" unitRef="usd">11700000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="c-526" decimals="-5" id="f-1165" unitRef="usd">512800000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:AssetImpairmentCharges contextRef="c-1" decimals="INF" id="f-1166" unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges contextRef="c-19" decimals="INF" id="f-1167" unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock contextRef="c-1" id="f-1168">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables present quantitative information, as of the dates indicated, about the valuation techniques and significant unobservable inputs used in the valuation of our Level 3 financial assets and liabilities measured at fair value on a recurring basis:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.069%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.490%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.841%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quantitative Information about Level 3 Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Valuation Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable Input(s)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;391.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Discounted cash flow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.4% - 5.5%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected timing of achievement of development milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025 - 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:1pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:25.069%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.543%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.490%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.841%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.772%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Quantitative Information about Level 3 Fair Value Measurements&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Valuation Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Unobservable Input(s)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent consideration obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;512.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Discounted cash flow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.2% - 6.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Expected timing of achievement of development milestones&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2025 - 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-527" decimals="-5" id="f-1169" unitRef="usd">391200000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="c-528"
      decimals="3"
      id="f-1170"
      unitRef="number">0.054</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="c-529"
      decimals="3"
      id="f-1171"
      unitRef="number">0.055</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="c-530"
      decimals="3"
      id="f-1172"
      unitRef="number">0.054</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiability contextRef="c-531" decimals="-5" id="f-1173" unitRef="usd">512800000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="c-532"
      decimals="3"
      id="f-1174"
      unitRef="number">0.062</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="c-533"
      decimals="3"
      id="f-1175"
      unitRef="number">0.063</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="c-534"
      decimals="3"
      id="f-1176"
      unitRef="number">0.062</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="c-535"
      decimals="3"
      id="f-1177"
      unitRef="number">0.700</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="c-1" id="f-1178">The following table provides a roll forward of the fair value of our contingent consideration obligations, which were classified as Level 3 measurements:&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.683%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.624%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value, beginning of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;534.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;512.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Contingent consideration resulting from HI-Bio acquisition&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;485.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;485.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Changes in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(149.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(150.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Fair value, end of period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;391.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;508.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;391.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;508.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-40" decimals="-5" id="f-1179" unitRef="usd">534900000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-67" decimals="-5" id="f-1180" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-23" decimals="-5" id="f-1181" unitRef="usd">512800000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-32" decimals="-5" id="f-1182" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases contextRef="c-19" decimals="-5" id="f-1183" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases contextRef="c-20" decimals="-5" id="f-1184" unitRef="usd">485100000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases contextRef="c-1" decimals="-5" id="f-1185" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases contextRef="c-21" decimals="-5" id="f-1186" unitRef="usd">485100000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-19" decimals="-5" id="f-1187" unitRef="usd">5600000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-20" decimals="-5" id="f-1188" unitRef="usd">23800000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings contextRef="c-1" decimals="-5" id="f-1189" unitRef="usd">28400000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 contextRef="c-21" decimals="-5" id="f-1190" unitRef="usd">23800000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements contextRef="c-19" decimals="-5" id="f-1191" unitRef="usd">149300000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements contextRef="c-20" decimals="-5" id="f-1192" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements contextRef="c-1" decimals="-5" id="f-1193" unitRef="usd">150000000.0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements contextRef="c-21" decimals="-5" id="f-1194" unitRef="usd">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-22" decimals="-5" id="f-1195" unitRef="usd">391200000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-33" decimals="-5" id="f-1196" unitRef="usd">508900000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-22" decimals="-5" id="f-1197" unitRef="usd">391200000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="c-33" decimals="-5" id="f-1198" unitRef="usd">508900000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="c-22" decimals="-5" id="f-1199" unitRef="usd">148600000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="c-23" decimals="-5" id="f-1200" unitRef="usd">291200000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="c-22" decimals="-5" id="f-1201" unitRef="usd">242600000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent contextRef="c-23" decimals="-5" id="f-1202" unitRef="usd">221600000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="c-101" decimals="-5" id="f-1203" unitRef="usd">150000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="c-102" decimals="-5" id="f-1204" unitRef="usd">150000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="c-101" decimals="-5" id="f-1205" unitRef="usd">150000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="c-102" decimals="-5" id="f-1206" unitRef="usd">150000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock contextRef="c-1" id="f-1207">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair and carrying values of our debt instruments, which are Level&#160;2 liabilities, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.091%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.369%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.374%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Carrying&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Current portion:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.050% Senior Notes due September 15, 2025&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,741.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,748.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current portion of notes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,741.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,748.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Non-current portion:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.250% Senior Notes due May 1, 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,367.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,495.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,295.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,494.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.050% Senior Notes due January 15, 2031&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;410.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;397.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.750% Senior Notes due May 15, 2035&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;680.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;645.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.200% Senior Notes due September 15, 2045&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,026.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,101.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,008.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,101.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.150% Senior Notes due May 1, 2050&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;970.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,475.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;943.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,475.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.250% Senior Notes due February 15, 2051&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;458.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;479.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;448.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;476.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.450% Senior Notes due May 15, 2055&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;748.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;690.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Non-current portion of notes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,663.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,285.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,696.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4,547.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total notes payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,663.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,285.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5,437.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6,295.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.017%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; In May 2025 we issued our 2025 Senior Notes for an aggregate principal amount of $1.75&#160;billion. In June 2025 we used the net proceeds from the sale of our 2025 Senior Notes to redeem in full our 4.050% Senior Notes due September 15, 2025, prior to maturity. For additional information, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 13, Indebtedness&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-536"
      decimals="INF"
      id="f-1208"
      unitRef="number">0.04050</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <biib:NotesPayableCurrentFairValueDisclosure contextRef="c-537" decimals="-5" id="f-1209" unitRef="usd">0</biib:NotesPayableCurrentFairValueDisclosure>
    <us-gaap:NotesPayableCurrent contextRef="c-537" decimals="-5" id="f-1210" unitRef="usd">0</us-gaap:NotesPayableCurrent>
    <biib:NotesPayableCurrentFairValueDisclosure contextRef="c-538" decimals="-5" id="f-1211" unitRef="usd">1741000000</biib:NotesPayableCurrentFairValueDisclosure>
    <us-gaap:NotesPayableCurrent contextRef="c-538" decimals="-5" id="f-1212" unitRef="usd">1748600000</us-gaap:NotesPayableCurrent>
    <biib:NotesPayableCurrentFairValueDisclosure contextRef="c-539" decimals="-5" id="f-1213" unitRef="usd">0</biib:NotesPayableCurrentFairValueDisclosure>
    <us-gaap:NotesPayableCurrent contextRef="c-539" decimals="-5" id="f-1214" unitRef="usd">0</us-gaap:NotesPayableCurrent>
    <biib:NotesPayableCurrentFairValueDisclosure contextRef="c-540" decimals="-5" id="f-1215" unitRef="usd">1741000000</biib:NotesPayableCurrentFairValueDisclosure>
    <us-gaap:NotesPayableCurrent contextRef="c-540" decimals="-5" id="f-1216" unitRef="usd">1748600000</us-gaap:NotesPayableCurrent>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-541"
      decimals="INF"
      id="f-1217"
      unitRef="number">0.02250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:NotesPayableFairValueDisclosure contextRef="c-542" decimals="-5" id="f-1218" unitRef="usd">1367800000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable contextRef="c-542" decimals="-5" id="f-1219" unitRef="usd">1495500000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure contextRef="c-543" decimals="-5" id="f-1220" unitRef="usd">1295600000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable contextRef="c-544" decimals="-5" id="f-1221" unitRef="usd">1494700000</us-gaap:NotesPayable>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-545"
      decimals="INF"
      id="f-1222"
      unitRef="number">0.05050</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:NotesPayableFairValueDisclosure contextRef="c-546" decimals="-5" id="f-1223" unitRef="usd">410800000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable contextRef="c-546" decimals="-5" id="f-1224" unitRef="usd">397900000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure contextRef="c-547" decimals="-5" id="f-1225" unitRef="usd">0</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable contextRef="c-548" decimals="-5" id="f-1226" unitRef="usd">0</us-gaap:NotesPayable>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-549"
      decimals="INF"
      id="f-1227"
      unitRef="number">0.05750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:NotesPayableFairValueDisclosure contextRef="c-550" decimals="-5" id="f-1228" unitRef="usd">680200000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable contextRef="c-550" decimals="-5" id="f-1229" unitRef="usd">645400000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure contextRef="c-551" decimals="-5" id="f-1230" unitRef="usd">0</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable contextRef="c-552" decimals="-5" id="f-1231" unitRef="usd">0</us-gaap:NotesPayable>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-553"
      decimals="INF"
      id="f-1232"
      unitRef="number">0.05200</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:NotesPayableFairValueDisclosure contextRef="c-554" decimals="-5" id="f-1233" unitRef="usd">1026900000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable contextRef="c-554" decimals="-5" id="f-1234" unitRef="usd">1101400000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure contextRef="c-555" decimals="-5" id="f-1235" unitRef="usd">1008000000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable contextRef="c-556" decimals="-5" id="f-1236" unitRef="usd">1101100000</us-gaap:NotesPayable>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-557"
      decimals="INF"
      id="f-1237"
      unitRef="number">0.03150</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:NotesPayableFairValueDisclosure contextRef="c-558" decimals="-5" id="f-1238" unitRef="usd">970200000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable contextRef="c-558" decimals="-5" id="f-1239" unitRef="usd">1475500000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure contextRef="c-559" decimals="-5" id="f-1240" unitRef="usd">943700000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable contextRef="c-560" decimals="-5" id="f-1241" unitRef="usd">1475000000</us-gaap:NotesPayable>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-561"
      decimals="INF"
      id="f-1242"
      unitRef="number">0.03250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:NotesPayableFairValueDisclosure contextRef="c-562" decimals="-5" id="f-1243" unitRef="usd">458800000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable contextRef="c-562" decimals="-5" id="f-1244" unitRef="usd">479300000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure contextRef="c-563" decimals="-5" id="f-1245" unitRef="usd">448900000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable contextRef="c-564" decimals="-5" id="f-1246" unitRef="usd">476400000</us-gaap:NotesPayable>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-565"
      decimals="INF"
      id="f-1247"
      unitRef="number">0.06450</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:NotesPayableFairValueDisclosure contextRef="c-566" decimals="-5" id="f-1248" unitRef="usd">748900000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable contextRef="c-566" decimals="-5" id="f-1249" unitRef="usd">690100000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure contextRef="c-567" decimals="-5" id="f-1250" unitRef="usd">0</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable contextRef="c-568" decimals="-5" id="f-1251" unitRef="usd">0</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure contextRef="c-569" decimals="-5" id="f-1252" unitRef="usd">5663600000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable contextRef="c-569" decimals="-5" id="f-1253" unitRef="usd">6285100000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure contextRef="c-570" decimals="-5" id="f-1254" unitRef="usd">3696200000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable contextRef="c-570" decimals="-5" id="f-1255" unitRef="usd">4547200000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure contextRef="c-22" decimals="-5" id="f-1256" unitRef="usd">5663600000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable contextRef="c-22" decimals="-5" id="f-1257" unitRef="usd">6285100000</us-gaap:NotesPayable>
    <us-gaap:NotesPayableFairValueDisclosure contextRef="c-23" decimals="-5" id="f-1258" unitRef="usd">5437200000</us-gaap:NotesPayableFairValueDisclosure>
    <us-gaap:NotesPayable contextRef="c-23" decimals="-5" id="f-1259" unitRef="usd">6295800000</us-gaap:NotesPayable>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-571" decimals="-5" id="f-1260" unitRef="usd">1750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-537"
      decimals="5"
      id="f-1261"
      unitRef="number">0.04050</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock contextRef="c-1" id="f-1262">&lt;div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:87.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%"&gt;Note 9:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:14pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%"&gt;Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.347%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,116.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,664.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Short-term debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;202.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;79.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,398.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,664.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying values of our money market funds, short-term debt securities and commercial paper, including accrued interest, approximate fair value due to their short-term maturities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our marketable equity securities gains (losses) are recorded in other (income) expense, net in our condensed consolidated statements of income. The following tables summarize our marketable debt and equity securities, classified as available-for-sale:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.580%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;71.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;71.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;227.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(123.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;103.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;227.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(123.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;103.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.580%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;668.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(489.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;179.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;668.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(489.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;179.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Summary of Contractual Maturities: Available-for-Sale Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value and amortized cost of our marketable debt securities classified as available-for-sale by contractual maturity are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.537%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.353%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Due in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The average maturity of our marketable debt securities classified as available-for-sale as of September 30, 2025, was approximately 2 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Strategic Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our strategic investment portfolio includes investments in equity securities of certain biotechnology companies, which are reflected within our disclosures included in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 8, Fair Value Measurements,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to these condensed consolidated financial statements, as well as venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September 30, 2025 and December 31, 2024, our strategic investment portfolio was comprised of investments totaling $167.1 million and $226.7 million, respectively, which are included in investments and other assets within our condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The decrease in our strategic investment portfolio as of September 30, 2025, compared to December 31, 2024, was primarily due to the decrease in the fair value of our investment in Denali common stock as well as the sale of our remaining investment in Sage common stock during the third quarter of 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our investments in Denali and Sage common stock, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 19, Collaborative and Other Relationships&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to our consolidated financial statements included in our 2024 Form 10-K.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock contextRef="c-1" id="f-1263">&lt;div style="margin-bottom:6pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes our financial assets with maturities of less than 90&#160;days from the date of purchase included in cash and cash equivalents in our condensed consolidated balance sheets:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.347%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,116.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,664.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Short-term debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;202.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;79.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3,398.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,664.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c-572" decimals="-5" id="f-1264" unitRef="usd">3116700000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c-573" decimals="-5" id="f-1265" unitRef="usd">1664900000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c-574" decimals="-5" id="f-1266" unitRef="usd">202900000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c-575" decimals="-5" id="f-1267" unitRef="usd">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c-576" decimals="-5" id="f-1268" unitRef="usd">79200000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c-577" decimals="-5" id="f-1269" unitRef="usd">0</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c-22" decimals="-5" id="f-1270" unitRef="usd">3398800000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:CashEquivalentsAtCarryingValue contextRef="c-23" decimals="-5" id="f-1271" unitRef="usd">1664900000</us-gaap:CashEquivalentsAtCarryingValue>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock contextRef="c-1" id="f-1272">The following tables summarize our marketable debt and equity securities, classified as available-for-sale:&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.580%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Corporate debt securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;71.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;71.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Government securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;227.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(123.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;103.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;227.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(123.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;103.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:41.252%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.576%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.580%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketable equity securities, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;668.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(489.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;179.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;668.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(489.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;179.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated fair value and amortized cost of our marketable debt securities classified as available-for-sale by contractual maturity are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.537%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.353%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Due in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total marketable debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;97.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-578" decimals="-5" id="f-1273" unitRef="usd">71000000.0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-578" decimals="-5" id="f-1274" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-578" decimals="-5" id="f-1275" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-578" decimals="-5" id="f-1276" unitRef="usd">71000000.0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-579" decimals="-5" id="f-1277" unitRef="usd">26600000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-579" decimals="-5" id="f-1278" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-579" decimals="-5" id="f-1279" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-579" decimals="-5" id="f-1280" unitRef="usd">26600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-22" decimals="-5" id="f-1281" unitRef="usd">97600000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-22" decimals="-5" id="f-1282" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-22" decimals="-5" id="f-1283" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-22" decimals="-5" id="f-1284" unitRef="usd">97600000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:EquitySecuritiesFvNiCost contextRef="c-580" decimals="-5" id="f-1285" unitRef="usd">227800000</us-gaap:EquitySecuritiesFvNiCost>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-580" decimals="-5" id="f-1286" unitRef="usd">0</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-580" decimals="-5" id="f-1287" unitRef="usd">123900000</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-580" decimals="-5" id="f-1288" unitRef="usd">103900000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNiCost contextRef="c-22" decimals="-5" id="f-1289" unitRef="usd">227800000</us-gaap:EquitySecuritiesFvNiCost>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-22" decimals="-5" id="f-1290" unitRef="usd">0</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-22" decimals="-5" id="f-1291" unitRef="usd">123900000</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-22" decimals="-5" id="f-1292" unitRef="usd">103900000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNiCost contextRef="c-581" decimals="-5" id="f-1293" unitRef="usd">668700000</us-gaap:EquitySecuritiesFvNiCost>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-581" decimals="-5" id="f-1294" unitRef="usd">0</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-581" decimals="-5" id="f-1295" unitRef="usd">489000000.0</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-581" decimals="-5" id="f-1296" unitRef="usd">179700000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNiCost contextRef="c-23" decimals="-5" id="f-1297" unitRef="usd">668700000</us-gaap:EquitySecuritiesFvNiCost>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-23" decimals="-5" id="f-1298" unitRef="usd">0</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainBeforeTax>
    <biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-23" decimals="-5" id="f-1299" unitRef="usd">489000000.0</biib:EquitySecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:EquitySecuritiesFvNi contextRef="c-23" decimals="-5" id="f-1300" unitRef="usd">179700000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="c-22" decimals="-5" id="f-1301" unitRef="usd">97600000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost contextRef="c-22" decimals="-5" id="f-1302" unitRef="usd">97600000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate contextRef="c-22" decimals="-5" id="f-1303" unitRef="usd">97600000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis contextRef="c-22" decimals="-5" id="f-1304" unitRef="usd">97600000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis>
    <biib:DebtSecuritiesAvailableForSaleAverageMaturity contextRef="c-1" id="f-1305">P2M</biib:DebtSecuritiesAvailableForSaleAverageMaturity>
    <biib:StrategicInvestmentPortfolio contextRef="c-582" decimals="-5" id="f-1306" unitRef="usd">167100000</biib:StrategicInvestmentPortfolio>
    <biib:StrategicInvestmentPortfolio contextRef="c-583" decimals="-5" id="f-1307" unitRef="usd">226700000</biib:StrategicInvestmentPortfolio>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock contextRef="c-1" id="f-1308">&lt;div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:87.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%"&gt;Note 10:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:14pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%"&gt;Derivative Instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Foreign Currency Forward Contracts - Hedging Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Due to the global nature of our operations, portions of our revenue and operating expense are recorded in currencies other than the U.S.&#160;dollar. The value of revenue and operating expense measured in U.S.&#160;dollars is therefore subject to changes in foreign currency exchange rates. We enter into foreign currency forward contracts and foreign currency options with financial institutions with the primary objective to mitigate the impact of foreign currency exchange rate fluctuations on our international revenue and operating expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Foreign currency forward contracts and foreign currency options in effect as of September 30, 2025 and December 31, 2024, had durations of 1 to 24 months and 1 to 12 months, respectively. These contracts have been designated as cash flow hedges and unrealized gains and losses on the portion of these foreign currency forward contracts and foreign currency options that are included in the effectiveness test are reported in AOCI. Realized gains and losses of such contracts and options are recognized in revenue when the sale of product in the currency being hedged is recognized and in operating expense when the expense in the currency being hedged is recorded. We recognize all cash flow hedge reclassifications from AOCI and fair value changes of excluded portions in the same line item in our condensed consolidated statements of income that have been impacted by the hedged item.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The notional amount of foreign currency forward contracts and foreign currency options that were entered into to hedge forecasted revenue and operating expense is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.347%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notional Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Euro&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,524.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,062.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;British pound&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;133.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Swiss franc&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canadian dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total foreign currency forward contracts and options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,637.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,235.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The pre-tax portion of the fair value of these foreign currency forward contracts and foreign currency options that were included in AOCI in total equity is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.964%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.783%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.785%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized (losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(112.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net unrealized gains (losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(103.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We expect net unrealized losses of approximately $103.4&#160;million to be settled over the next 24 months, of which approximately $90.8&#160;million of these net unrealized losses are expected to be settled over the next 12 months, with any amounts in AOCI to be reported as an adjustment to revenue or operating expense. We consider the impact of our and our counterparties&#x2019; credit risk on the fair value of the contracts as well as the ability of each party to execute its contractual obligations. As of September 30, 2025 and December 31, 2024, credit risk did not materially change the fair value of our foreign currency forward contracts and forward currency options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the effect of foreign currency forward contracts and forward currency options designated as hedging instruments in our condensed consolidated statements of income:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.198%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.345%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.154%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.641%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Reclassified from AOCI into Operating Income (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses) Excluded from Effectiveness Testing and&lt;br/&gt;Recognized in Operating Income (in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(29.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Reclassified from AOCI into Operating Income (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses) Excluded from Effectiveness Testing and&lt;br/&gt;Recognized in Operating Income (in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(41.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Foreign Currency Forward Contracts - Other Derivative Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also enter into other foreign currency forward contracts, usually with durations of one month or less, to mitigate the foreign currency risk related to certain balance sheet positions. We have not elected hedge accounting for these transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate notional amount of these outstanding foreign currency forward contracts was $1,066.6 million and $738.7 million as of September 30, 2025 and December 31, 2024, respectively. Net losses of $0.5 million and net gains of $34.9 million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;related to these contracts were recorded as a component of other (income) expense, net for the three and nine months ended September 30, 2025, respectively, compared to net gains of $23.4 million and net losses of $6.6 million, respectively, in the prior year comparative periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Summary of Derivative Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;While certain of our derivative instruments are subject to netting arrangements with our counterparties, we do not offset derivative assets and liabilities in our condensed consolidated balance sheets. The amounts in the table below would not be substantially different if the derivative assets and liabilities were offset.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.328%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.328%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.372%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.376%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance Sheet Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cash Flow Hedging Instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;87.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Derivative Instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:DerivativeRemainingMaturity1 contextRef="c-499" id="f-1309">P1M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:DerivativeRemainingMaturity1 contextRef="c-500" id="f-1310">P24M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:DerivativeRemainingMaturity1 contextRef="c-584" id="f-1311">P1M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:DerivativeRemainingMaturity1 contextRef="c-585" id="f-1312">P12M</us-gaap:DerivativeRemainingMaturity1>
    <us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock contextRef="c-1" id="f-1313">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The notional amount of foreign currency forward contracts and foreign currency options that were entered into to hedge forecasted revenue and operating expense is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.347%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Notional Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Euro&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,524.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,062.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;British pound&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;133.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Swiss franc&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;68.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Canadian dollar&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total foreign currency forward contracts and options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,637.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,235.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock>
    <us-gaap:DerivativeNotionalAmount contextRef="c-586" decimals="-5" id="f-1314" unitRef="usd">1524800000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-587" decimals="-5" id="f-1315" unitRef="usd">1062600000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-588" decimals="-5" id="f-1316" unitRef="usd">35000000.0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-589" decimals="-5" id="f-1317" unitRef="usd">133800000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-590" decimals="-5" id="f-1318" unitRef="usd">68000000.0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-591" decimals="-5" id="f-1319" unitRef="usd">0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-592" decimals="-5" id="f-1320" unitRef="usd">9900000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-593" decimals="-5" id="f-1321" unitRef="usd">38600000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-594" decimals="-5" id="f-1322" unitRef="usd">1637700000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-595" decimals="-5" id="f-1323" unitRef="usd">1235000000</us-gaap:DerivativeNotionalAmount>
    <biib:DerivativeInstrumentsUnrealizedGainLossTableTextBlock contextRef="c-1" id="f-1324">&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The pre-tax portion of the fair value of these foreign currency forward contracts and foreign currency options that were included in AOCI in total equity is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.964%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.783%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.785%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Unrealized (losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(112.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net unrealized gains (losses)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(103.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;50.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:DerivativeInstrumentsUnrealizedGainLossTableTextBlock>
    <biib:UnrealizedGainOnDerivatives contextRef="c-1" decimals="-5" id="f-1325" unitRef="usd">9500000</biib:UnrealizedGainOnDerivatives>
    <biib:UnrealizedGainOnDerivatives contextRef="c-21" decimals="-5" id="f-1326" unitRef="usd">50600000</biib:UnrealizedGainOnDerivatives>
    <biib:UnrealizedLossOnDerivatives contextRef="c-1" decimals="-5" id="f-1327" unitRef="usd">112900000</biib:UnrealizedLossOnDerivatives>
    <biib:UnrealizedLossOnDerivatives contextRef="c-21" decimals="-5" id="f-1328" unitRef="usd">300000</biib:UnrealizedLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives contextRef="c-1" decimals="-5" id="f-1329" unitRef="usd">-103400000</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives contextRef="c-21" decimals="-5" id="f-1330" unitRef="usd">50300000</us-gaap:UnrealizedGainLossOnDerivatives>
    <biib:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months contextRef="c-22" decimals="-5" id="f-1331" unitRef="usd">103400000</biib:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext15Months>
    <us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months contextRef="c-22" decimals="-5" id="f-1332" unitRef="usd">90800000</us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months>
    <us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock contextRef="c-1" id="f-1333">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the effect of foreign currency forward contracts and forward currency options designated as hedging instruments in our condensed consolidated statements of income:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.198%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.345%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:21.154%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.637%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.641%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Reclassified from AOCI into Operating Income (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses) Excluded from Effectiveness Testing and&lt;br/&gt;Recognized in Operating Income (in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(29.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses)&lt;br/&gt;Reclassified from AOCI into Operating Income (in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Gains/(Losses) Excluded from Effectiveness Testing and&lt;br/&gt;Recognized in Operating Income (in millions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(41.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax contextRef="c-596" decimals="-5" id="f-1334" unitRef="usd">-29100000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax contextRef="c-597" decimals="-5" id="f-1335" unitRef="usd">-7600000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="c-598" decimals="-5" id="f-1336" unitRef="usd">8000000.0</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="c-599" decimals="-5" id="f-1337" unitRef="usd">2900000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax contextRef="c-600" decimals="-5" id="f-1338" unitRef="usd">6700000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax contextRef="c-601" decimals="-5" id="f-1339" unitRef="usd">-1500000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="c-602" decimals="-5" id="f-1340" unitRef="usd">0</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="c-603" decimals="-5" id="f-1341" unitRef="usd">300000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax contextRef="c-604" decimals="-5" id="f-1342" unitRef="usd">-41100000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax contextRef="c-605" decimals="-5" id="f-1343" unitRef="usd">2900000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="c-606" decimals="-5" id="f-1344" unitRef="usd">7600000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="c-607" decimals="-5" id="f-1345" unitRef="usd">4000000.0</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax contextRef="c-608" decimals="-5" id="f-1346" unitRef="usd">14000000.0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax contextRef="c-609" decimals="-5" id="f-1347" unitRef="usd">-8500000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="c-610" decimals="-5" id="f-1348" unitRef="usd">-1800000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax contextRef="c-611" decimals="-5" id="f-1349" unitRef="usd">-1600000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:DerivativeNotionalAmount contextRef="c-612" decimals="-5" id="f-1350" unitRef="usd">1066600000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount contextRef="c-613" decimals="-5" id="f-1351" unitRef="usd">738700000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments contextRef="c-19" decimals="-5" id="f-1352" unitRef="usd">500000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments contextRef="c-1" decimals="-5" id="f-1353" unitRef="usd">-34900000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments contextRef="c-20" decimals="-5" id="f-1354" unitRef="usd">-23400000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments contextRef="c-21" decimals="-5" id="f-1355" unitRef="usd">6600000</us-gaap:GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock contextRef="c-1" id="f-1356">&lt;div style="margin-bottom:3pt;margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the fair value and presentation in our condensed consolidated balance sheets of our outstanding derivative instruments, including those designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.328%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:28.328%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.372%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.376%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Balance Sheet Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Cash Flow Hedging Instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;58.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;87.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other long-term liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Other Derivative Instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Asset derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Liability derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="c-614" decimals="-5" id="f-1357" unitRef="usd">7800000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="c-615" decimals="-5" id="f-1358" unitRef="usd">58400000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="c-616" decimals="-5" id="f-1359" unitRef="usd">87300000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="c-617" decimals="-5" id="f-1360" unitRef="usd">300000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="c-618" decimals="-5" id="f-1361" unitRef="usd">10200000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="c-619" decimals="-5" id="f-1362" unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="c-620" decimals="-5" id="f-1363" unitRef="usd">1800000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset contextRef="c-621" decimals="-5" id="f-1364" unitRef="usd">4100000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="c-622" decimals="-5" id="f-1365" unitRef="usd">1800000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability contextRef="c-623" decimals="-5" id="f-1366" unitRef="usd">11400000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c-1" id="f-1367">&lt;div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:87.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%"&gt;Note 11:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:14pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%"&gt;Property, Plant and Equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Property, plant and equipment are recorded at historical cost, net of accumulated depreciation. Accumulated depreciation on property, plant and equipment was $2,868.4 million and $2,670.8 million as of September 30, 2025 and December 31, 2024, respectively. For the three and nine months ended September 30, 2025, depreciation expense totaled approximately $66.5 million and $204.8 million, respectively, compared to $72.7 million and $213.9 million, respectively, in the prior year comparative peri</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-22" decimals="-5" id="f-1368" unitRef="usd">2868400000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-23" decimals="-5" id="f-1369" unitRef="usd">2670800000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:Depreciation contextRef="c-19" decimals="-5" id="f-1370" unitRef="usd">66500000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-1" decimals="-5" id="f-1371" unitRef="usd">204800000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-20" decimals="-5" id="f-1372" unitRef="usd">72700000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-21" decimals="-5" id="f-1373" unitRef="usd">213900000</us-gaap:Depreciation>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c-1" id="f-1374">&lt;div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:87.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%"&gt;Note 12:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:14pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;New Corporate Headquarters Lease&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2025 we entered into a lease agreement with MIT Investment Management Company and BioMed Realty for the lease of approximately 580,000 square feet of office and research and development space located at 75 Broadway, Cambridge, Massachusetts, which will be used as our new global corporate headquarters, as well as integrating our research and development and technical operations teams alongside our North American commercial organization. As part of a multi-year real estate consolidation plan that is expected to result in a reduction of approximately 40% of our real estate footprint in Massachusetts, this new lease is intended to replace two existing leases, both in Cambridge, Massachusetts, including our current corporate headquarters. We expect the initial lease term of approximately 15.5 years to commence on May 31, 2028. The estimated minimum lease payments as a result of the new lease total approximately $1.5&#160;billion over the initial lease term. We have an option to extend the lease for three extension periods of five years each and one six month short-term extension, at then market-based rates. We will account for this lease as a right-of-use asset and lease liability upon the lease commencement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our accounting policies relating to leases, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1, Summary of Significant Accounting Policies - Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to our consolidated financial statements included in our 2024 Form 10-K.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <biib:OperatingLeaseArea contextRef="c-40" decimals="0" id="f-1375" unitRef="sqft">580000</biib:OperatingLeaseArea>
    <biib:ReductionOfRealEstateFootprint contextRef="c-40" decimals="2" id="f-1376" unitRef="number">0.40</biib:ReductionOfRealEstateFootprint>
    <us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1 contextRef="c-40" id="f-1377">P15Y6M</us-gaap:LesseeOperatingLeaseLeaseNotYetCommencedTermOfContract1>
    <us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount contextRef="c-40" decimals="-5" id="f-1378" unitRef="usd">1500000000</us-gaap:UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount>
    <us-gaap:DebtDisclosureTextBlock contextRef="c-1" id="f-1383">&lt;div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:87.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%"&gt;Note 13:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:14pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%"&gt;Indebtedness&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;2025 Senior Notes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 12, 2025, we issued senior unsecured notes for an aggregate principal amount of $1.75&#160;billion, consisting of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt"&gt;$400.0&#160;million of 5.050% Senior Notes due January 15, 2031, valued at 99.981% of par;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt"&gt;$650.0&#160;million of 5.750% Senior Notes due May 15, 2035, valued at 99.924% of par; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt"&gt;$700.0&#160;million of 6.450% Senior Notes due May 15, 2055, valued at 99.657% of par.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our 2025 Senior Notes are senior unsecured obligations and may be redeemed at our option at any time at 100% of the principal amount plus accrued interest and, until a specified period before maturity, a specified make-whole amount. Our 2025 Senior Notes contain a change-of-control provision that, under certain circumstances, may require us to purchase our 2025 Senior Notes at a price equal to 101% of the principal amount plus accrued and unpaid interest to the date of repurchase.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We incurred approximately $13.9&#160;million of costs associated with this offering which have been recorded as a reduction to the carrying amount of the debt on our condensed consolidated balance sheets. These costs will be amortized as additional interest expense using the effective interest rate method over the period from issuance through maturity. The discounts will be amortized as additional interest expense over the period from issuance through maturity using the effective interest rate method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest on our 2031 Senior Notes is payable January 15 and July 15 of each year, commencing January 15, 2026. Interest on our 2035 Senior Notes and 2055 Senior Notes is payable May 15 and November 15 of each year, commencing on November 15, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;4.050% Senior Notes due September 15, 2025&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 15, 2015, we issued $1.75&#160;billion aggregate principal amount of 4.050% Senior Notes due September 15, 2025, at 99.764% of par. In June 2025 we used the net proceeds from the sale of our 2025 Senior Notes to redeem our 4.050% Senior Notes due September 15, 2025, prior to their maturity. No gain or loss was recognized upon redemption.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#006ebf;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;2023 Term Loan Credit Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our acquisition of Reata in September 2023 we entered into a $1.5&#160;billion term loan credit agreement. On the closing date of the Reata acquisition we drew $1.0 billion from the 2023 Term Loan, comprised of a $500.0&#160;million floating rate 364-day tranche and a $500.0&#160;million floating rate three-year tranche. The remaining unused commitment of $500.0&#160;million was terminated. As of December 31, 2023, we repaid &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$350.0&#160;million of the 364--day tranche. The remaining $150.0&#160;million portion of the 364-day tranche was repaid during the first quarter of 2024. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, during the first quarter of 2024 we repaid $250.0&#160;million of the three-year tranche, with the remaining $250.0&#160;million portion being subsequently repaid in full during the second quarter of 2024. For additional information on our acquisition of Reata, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2, Acquisitions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to our consolidated financial statements included in our 2024 Form 10-K.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-571" decimals="-5" id="f-1384" unitRef="usd">1750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-628" decimals="-5" id="f-1385" unitRef="usd">400000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-628"
      decimals="5"
      id="f-1386"
      unitRef="number">0.05050</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <biib:PercentageParValueOfSeniorNotes
      contextRef="c-628"
      decimals="5"
      id="f-1387"
      unitRef="number">0.99981</biib:PercentageParValueOfSeniorNotes>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-629" decimals="-5" id="f-1388" unitRef="usd">650000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-629"
      decimals="5"
      id="f-1389"
      unitRef="number">0.05750</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <biib:PercentageParValueOfSeniorNotes
      contextRef="c-629"
      decimals="5"
      id="f-1390"
      unitRef="number">0.99924</biib:PercentageParValueOfSeniorNotes>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-630" decimals="-5" id="f-1391" unitRef="usd">700000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-630"
      decimals="5"
      id="f-1392"
      unitRef="number">0.06450</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <biib:PercentageParValueOfSeniorNotes
      contextRef="c-630"
      decimals="5"
      id="f-1393"
      unitRef="number">0.99657</biib:PercentageParValueOfSeniorNotes>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="c-631"
      decimals="0"
      id="f-1394"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <biib:DebtInstrumentMakeWholeProvisionRedemptionPricePercentage
      contextRef="c-631"
      decimals="2"
      id="f-1395"
      unitRef="number">1.01</biib:DebtInstrumentMakeWholeProvisionRedemptionPricePercentage>
    <us-gaap:PaymentsOfFinancingCosts contextRef="c-631" decimals="-5" id="f-1396" unitRef="usd">13900000</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-632" decimals="-5" id="f-1397" unitRef="usd">1750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-537"
      decimals="5"
      id="f-1398"
      unitRef="number">0.04050</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="c-633"
      decimals="5"
      id="f-1399"
      unitRef="number">0.99764</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-537"
      decimals="5"
      id="f-1400"
      unitRef="number">0.04050</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-634" decimals="-3" id="f-1401" unitRef="usd">1500000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtInstrumentCarryingAmount contextRef="c-635" decimals="-8" id="f-1402" unitRef="usd">1000000000.0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-636" decimals="-3" id="f-1403" unitRef="usd">500000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-637" decimals="-3" id="f-1404" unitRef="usd">500000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-638" decimals="-3" id="f-1405" unitRef="usd">500000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths contextRef="c-639" decimals="-5" id="f-1406" unitRef="usd">350000000</us-gaap:RepaymentsOfShortTermDebtMaturingInMoreThanThreeMonths>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-640" decimals="-5" id="f-1407" unitRef="usd">150000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-641" decimals="-5" id="f-1408" unitRef="usd">250000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity contextRef="c-642" decimals="-5" id="f-1409" unitRef="usd">250000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-1410">&lt;div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:87.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%"&gt;Note 14:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:14pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%"&gt;Equity&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Share Repurchases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2020 our Board of Directors authorized our 2020 Share Repurchase Program, which is a program to repurchase up to $5.0 billion of our common stock. Our 2020 Share Repurchase Program does not have an expiration date. All shares repurchased under our 2020 Share Repurchase Program were retired. There were no share repurchases of our common stock during the three and nine months ended September 30, 2025 and 2024. Approximately $2.1 billion remained available under our 2020 Share Repurchase Program as of September 30, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Accumulated Other Comprehensive Income (Loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the changes in AOCI, net of tax by component:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.648%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.981%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.981%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.981%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.989%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Cash Flow Hedges,&lt;br/&gt;Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Currency&lt;br/&gt;Translation Adjustments,&lt;br/&gt;Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(112.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(15.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(110.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(238.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(85.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(15.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(113.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(214.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Currency&lt;br/&gt;Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(16.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(171.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(136.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(161.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(103.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(137.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(78.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(85.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(15.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(113.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(214.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.648%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.981%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.981%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.981%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.989%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Cash Flow Hedges,&lt;br/&gt;Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Pension Benefit Obligation,&lt;br/&gt;Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Currency&lt;br/&gt;Translation Adjustments,&lt;br/&gt;Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(153.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(146.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(49.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(41.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(31.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(112.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(145.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Currency Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(25.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(126.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(153.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(31.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(112.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(145.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amounts reclassified from AOCI:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.192%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.911%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.911%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.814%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts Reclassified from AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Income Statement Location&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(29.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(41.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other (income) expense, net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax (benefit) expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total reclassifications, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(20.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(24.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <srt:StockRepurchaseProgramAuthorizedAmount1 contextRef="c-643" decimals="INF" id="f-1411" unitRef="usd">5000000000</srt:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:TreasuryStockSharesAcquired contextRef="c-21" decimals="0" id="f-1412" unitRef="shares">0</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired contextRef="c-20" decimals="0" id="f-1413" unitRef="shares">0</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired contextRef="c-19" decimals="0" id="f-1414" unitRef="shares">0</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired contextRef="c-1" decimals="0" id="f-1415" unitRef="shares">0</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1 contextRef="c-644" decimals="-8" id="f-1416" unitRef="usd">2100000000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock contextRef="c-1" id="f-1417">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables summarize the changes in AOCI, net of tax by component:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.648%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.981%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.981%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.981%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.989%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Cash Flow Hedges,&lt;br/&gt;Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Currency&lt;br/&gt;Translation Adjustments,&lt;br/&gt;Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, June 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(112.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(15.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(110.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(238.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(85.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(15.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(113.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(214.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Currency&lt;br/&gt;Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;51.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(16.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(171.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(136.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(161.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(103.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;24.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(137.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;57.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(78.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(85.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(15.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(113.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(214.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.648%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.981%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.981%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.981%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.989%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Cash Flow Hedges,&lt;br/&gt;Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Pension Benefit Obligation,&lt;br/&gt;Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Currency&lt;br/&gt;Translation Adjustments,&lt;br/&gt;Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, June 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(153.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(146.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(49.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(41.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(31.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(112.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(145.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Cash Flow Hedges, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gains (Losses) on Pension Benefit Obligation, Net of Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Currency Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, December 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(25.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(126.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(153.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(6.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Balance, September 30, 2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(31.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(112.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(145.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquity contextRef="c-645" decimals="-5" id="f-1418" unitRef="usd">-112000000.0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-646" decimals="-5" id="f-1419" unitRef="usd">-15600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-647" decimals="-5" id="f-1420" unitRef="usd">-110500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-37" decimals="-5" id="f-1421" unitRef="usd">-238100000</us-gaap:StockholdersEquity>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent contextRef="c-648" decimals="-5" id="f-1422" unitRef="usd">6300000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent contextRef="c-649" decimals="-5" id="f-1423" unitRef="usd">0</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent contextRef="c-650" decimals="-5" id="f-1424" unitRef="usd">-3200000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent contextRef="c-19" decimals="-5" id="f-1425" unitRef="usd">3100000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent contextRef="c-648" decimals="-5" id="f-1426" unitRef="usd">-20200000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent contextRef="c-649" decimals="-5" id="f-1427" unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent contextRef="c-650" decimals="-5" id="f-1428" unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent contextRef="c-19" decimals="-5" id="f-1429" unitRef="usd">-20200000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-648" decimals="-5" id="f-1430" unitRef="usd">26500000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-649" decimals="-5" id="f-1431" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-650" decimals="-5" id="f-1432" unitRef="usd">-3200000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-19" decimals="-5" id="f-1433" unitRef="usd">23300000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquity contextRef="c-651" decimals="-5" id="f-1434" unitRef="usd">-85500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-652" decimals="-5" id="f-1435" unitRef="usd">-15600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-653" decimals="-5" id="f-1436" unitRef="usd">-113700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-48" decimals="-5" id="f-1437" unitRef="usd">-214800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-654" decimals="-5" id="f-1438" unitRef="usd">51600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-655" decimals="-5" id="f-1439" unitRef="usd">-16600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-656" decimals="-5" id="f-1440" unitRef="usd">-171200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-54" decimals="-5" id="f-1441" unitRef="usd">-136200000</us-gaap:StockholdersEquity>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent contextRef="c-657" decimals="-5" id="f-1442" unitRef="usd">-161600000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent contextRef="c-658" decimals="-5" id="f-1443" unitRef="usd">1000000.0</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent contextRef="c-659" decimals="-5" id="f-1444" unitRef="usd">57500000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent contextRef="c-1" decimals="-5" id="f-1445" unitRef="usd">-103100000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent contextRef="c-657" decimals="-5" id="f-1446" unitRef="usd">-24500000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent contextRef="c-658" decimals="-5" id="f-1447" unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent contextRef="c-659" decimals="-5" id="f-1448" unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent contextRef="c-1" decimals="-5" id="f-1449" unitRef="usd">-24500000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-657" decimals="-5" id="f-1450" unitRef="usd">-137100000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-658" decimals="-5" id="f-1451" unitRef="usd">1000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-659" decimals="-5" id="f-1452" unitRef="usd">57500000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-5" id="f-1453" unitRef="usd">-78600000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquity contextRef="c-651" decimals="-5" id="f-1454" unitRef="usd">-85500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-652" decimals="-5" id="f-1455" unitRef="usd">-15600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-653" decimals="-5" id="f-1456" unitRef="usd">-113700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-48" decimals="-5" id="f-1457" unitRef="usd">-214800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-660" decimals="-5" id="f-1458" unitRef="usd">9800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-661" decimals="-5" id="f-1459" unitRef="usd">-2700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-662" decimals="-5" id="f-1460" unitRef="usd">-153100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-64" decimals="-5" id="f-1461" unitRef="usd">-146000000.0</us-gaap:StockholdersEquity>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent contextRef="c-663" decimals="-5" id="f-1462" unitRef="usd">-49100000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent contextRef="c-664" decimals="-5" id="f-1463" unitRef="usd">300000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent contextRef="c-665" decimals="-5" id="f-1464" unitRef="usd">41000000.0</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent contextRef="c-20" decimals="-5" id="f-1465" unitRef="usd">-7800000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent contextRef="c-663" decimals="-5" id="f-1466" unitRef="usd">-8100000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent contextRef="c-664" decimals="-5" id="f-1467" unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent contextRef="c-665" decimals="-5" id="f-1468" unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent contextRef="c-20" decimals="-5" id="f-1469" unitRef="usd">-8100000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-663" decimals="-5" id="f-1470" unitRef="usd">-41000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-664" decimals="-5" id="f-1471" unitRef="usd">300000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-665" decimals="-5" id="f-1472" unitRef="usd">41000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-20" decimals="-5" id="f-1473" unitRef="usd">300000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquity contextRef="c-666" decimals="-5" id="f-1474" unitRef="usd">-31200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-667" decimals="-5" id="f-1475" unitRef="usd">-2400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-668" decimals="-5" id="f-1476" unitRef="usd">-112100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-74" decimals="-5" id="f-1477" unitRef="usd">-145700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-669" decimals="-5" id="f-1478" unitRef="usd">-25000000.0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-670" decimals="-5" id="f-1479" unitRef="usd">-2600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-671" decimals="-5" id="f-1480" unitRef="usd">-126100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-80" decimals="-5" id="f-1481" unitRef="usd">-153700000</us-gaap:StockholdersEquity>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent contextRef="c-672" decimals="-5" id="f-1482" unitRef="usd">-11400000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent contextRef="c-673" decimals="-5" id="f-1483" unitRef="usd">200000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent contextRef="c-674" decimals="-5" id="f-1484" unitRef="usd">14000000.0</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent contextRef="c-21" decimals="-5" id="f-1485" unitRef="usd">2800000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent contextRef="c-672" decimals="-5" id="f-1486" unitRef="usd">-5200000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent contextRef="c-673" decimals="-5" id="f-1487" unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent contextRef="c-674" decimals="-5" id="f-1488" unitRef="usd">0</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent contextRef="c-21" decimals="-5" id="f-1489" unitRef="usd">-5200000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-672" decimals="-5" id="f-1490" unitRef="usd">-6200000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-673" decimals="-5" id="f-1491" unitRef="usd">200000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-674" decimals="-5" id="f-1492" unitRef="usd">14000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-21" decimals="-5" id="f-1493" unitRef="usd">8000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquity contextRef="c-666" decimals="-5" id="f-1494" unitRef="usd">-31200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-667" decimals="-5" id="f-1495" unitRef="usd">-2400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-668" decimals="-5" id="f-1496" unitRef="usd">-112100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-74" decimals="-5" id="f-1497" unitRef="usd">-145700000</us-gaap:StockholdersEquity>
    <us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock contextRef="c-1" id="f-1498">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the amounts reclassified from AOCI:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.192%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.911%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.911%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.034%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.814%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts Reclassified from AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Income Statement Location&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Gains (losses) on cash flow hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(29.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(41.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Operating expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other (income) expense, net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax (benefit) expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total reclassifications, net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(20.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(24.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock>
    <us-gaap:Revenues contextRef="c-675" decimals="-5" id="f-1499" unitRef="usd">-29100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-676" decimals="-5" id="f-1500" unitRef="usd">-7600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-677" decimals="-5" id="f-1501" unitRef="usd">-41100000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-678" decimals="-5" id="f-1502" unitRef="usd">2900000</us-gaap:Revenues>
    <us-gaap:OperatingExpenses contextRef="c-675" decimals="-5" id="f-1503" unitRef="usd">-6700000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-676" decimals="-5" id="f-1504" unitRef="usd">1500000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-677" decimals="-5" id="f-1505" unitRef="usd">-14000000.0</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-678" decimals="-5" id="f-1506" unitRef="usd">8500000</us-gaap:OperatingExpenses>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-675" decimals="-5" id="f-1507" unitRef="usd">-100000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-676" decimals="-5" id="f-1508" unitRef="usd">-100000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-677" decimals="-5" id="f-1509" unitRef="usd">-300000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-678" decimals="-5" id="f-1510" unitRef="usd">-200000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-675" decimals="-5" id="f-1511" unitRef="usd">2300000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-676" decimals="-5" id="f-1512" unitRef="usd">1100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-677" decimals="-5" id="f-1513" unitRef="usd">2900000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-678" decimals="-5" id="f-1514" unitRef="usd">600000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c-679" decimals="-5" id="f-1515" unitRef="usd">-20200000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-680" decimals="-5" id="f-1516" unitRef="usd">-8100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-681" decimals="-5" id="f-1517" unitRef="usd">-24500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-682" decimals="-5" id="f-1518" unitRef="usd">-5200000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-1519">&lt;div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:87.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%"&gt;Note 15:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:14pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%"&gt;Earnings per Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted shares outstanding used in our earnings per share calculation are calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.806%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.625%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income attributable to Biogen Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;466.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;388.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,341.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,365.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted average number of common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;145.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;145.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Time-vested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance stock units settled in stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Dilutive potential common shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shares used in calculating diluted earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;147.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts excluded from the calculation of net income per diluted share because their effects were anti-dilutive were insignificant.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c-1" id="f-1520">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted shares outstanding used in our earnings per share calculation are calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.806%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.625%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net income attributable to Biogen Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;466.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;388.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,341.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,365.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Weighted average number of common shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;145.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;145.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Time-vested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance stock units settled in stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Dilutive potential common shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Shares used in calculating diluted earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;147.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;146.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss contextRef="c-19" decimals="-5" id="f-1521" unitRef="usd">466500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-20" decimals="-5" id="f-1522" unitRef="usd">388500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-5" id="f-1523" unitRef="usd">1341800000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-21" decimals="-5" id="f-1524" unitRef="usd">1365500000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c-19"
      decimals="-5"
      id="f-1525"
      unitRef="shares">146600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c-20"
      decimals="-5"
      id="f-1526"
      unitRef="shares">145700000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-3" id="f-1527" unitRef="shares">146400000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c-21"
      decimals="-3"
      id="f-1528"
      unitRef="shares">145500000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-683"
      decimals="-5"
      id="f-1529"
      unitRef="shares">500000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-684"
      decimals="-5"
      id="f-1530"
      unitRef="shares">300000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-685"
      decimals="-5"
      id="f-1531"
      unitRef="shares">400000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-686"
      decimals="-5"
      id="f-1532"
      unitRef="shares">400000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-687"
      decimals="-5"
      id="f-1533"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-688"
      decimals="-5"
      id="f-1534"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-689"
      decimals="-5"
      id="f-1535"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="c-690"
      decimals="-5"
      id="f-1536"
      unitRef="shares">100000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="c-19"
      decimals="-5"
      id="f-1537"
      unitRef="shares">500000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="c-20"
      decimals="-5"
      id="f-1538"
      unitRef="shares">400000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="c-1" decimals="-5" id="f-1539" unitRef="shares">400000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="c-21"
      decimals="-5"
      id="f-1540"
      unitRef="shares">500000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c-19"
      decimals="-5"
      id="f-1541"
      unitRef="shares">147100000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c-20"
      decimals="-5"
      id="f-1542"
      unitRef="shares">146100000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-3" id="f-1543" unitRef="shares">146800000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c-21"
      decimals="-3"
      id="f-1544"
      unitRef="shares">146000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-1545">&lt;div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:87.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%"&gt;Note 16:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:14pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%"&gt;Share-Based Payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Share-based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.455%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.285%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;91.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;124.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;149.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;131.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;240.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;275.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Capitalized share-based compensation costs &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense included in total cost and expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;75.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;231.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;267.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax effect&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(24.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(45.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(50.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense included in net income attributable to Biogen Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;104.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;185.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;216.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with our acquisition of HI-Bio in July 2024 we recognized HI-Bio equity-based compensation expense, inclusive of employer taxes, of approximately $56.4&#160;million attributable to the post-acquisition service period, of which $42.5&#160;million was recognized as a charge to research and development expense with the remaining $13.9&#160;million as a charge to selling, general and administrative expense within our condensed consolidated statements of income for the three and nine months ended September 30, 2024. These amounts were associated with the accelerated vesting of stock options and RSUs previously granted to HI-Bio employees and required no future services to vest. For additional information on our acquisition of HI-Bio, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2, Acquisitions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.455%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.285%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Time-vested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;186.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;174.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance stock units settled in stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance stock units settled in cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Market stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:0.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;HI-Bio equity awards&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;131.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;240.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;275.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Capitalized share-based compensation costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense included in total cost and expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;75.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;231.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;267.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.017%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Relates to the HI-Bio equity-based compensation expense attributable to the post-acquisition service period, associated with the accelerated vesting of stock options and RSUs previously granted to HI-Bio employees and required no future services to vest. For additional information on our acquisition of HI-Bio, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2, Acquisitions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-1546">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes share-based compensation expense included in our condensed consolidated statements of income:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.455%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.285%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;69.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;91.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;124.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;49.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;61.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;149.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;150.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;131.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;240.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;275.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Capitalized share-based compensation costs &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense included in total cost and expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;75.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;231.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;267.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Income tax effect&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(14.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(24.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(45.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(50.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense included in net income attributable to Biogen Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;104.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;185.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;216.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-691" decimals="-5" id="f-1547" unitRef="usd">28800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-692" decimals="-5" id="f-1548" unitRef="usd">69800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-693" decimals="-5" id="f-1549" unitRef="usd">91000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-694" decimals="-5" id="f-1550" unitRef="usd">124500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-695" decimals="-5" id="f-1551" unitRef="usd">49600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-696" decimals="-5" id="f-1552" unitRef="usd">61300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-697" decimals="-5" id="f-1553" unitRef="usd">149600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-698" decimals="-5" id="f-1554" unitRef="usd">150900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c-19" decimals="-5" id="f-1555" unitRef="usd">78400000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c-20" decimals="-5" id="f-1556" unitRef="usd">131100000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c-1" decimals="-5" id="f-1557" unitRef="usd">240600000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c-21" decimals="-5" id="f-1558" unitRef="usd">275400000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="c-19" decimals="-5" id="f-1559" unitRef="usd">3100000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="c-20" decimals="-5" id="f-1560" unitRef="usd">2400000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="c-1" decimals="-5" id="f-1561" unitRef="usd">9400000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="c-21" decimals="-5" id="f-1562" unitRef="usd">8000000.0</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses contextRef="c-19" decimals="-5" id="f-1563" unitRef="usd">75300000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses contextRef="c-20" decimals="-5" id="f-1564" unitRef="usd">128700000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses contextRef="c-1" decimals="-5" id="f-1565" unitRef="usd">231200000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses contextRef="c-21" decimals="-5" id="f-1566" unitRef="usd">267400000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="c-19" decimals="-5" id="f-1567" unitRef="usd">14400000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="c-20" decimals="-5" id="f-1568" unitRef="usd">24200000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="c-1" decimals="-5" id="f-1569" unitRef="usd">45300000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense contextRef="c-21" decimals="-5" id="f-1570" unitRef="usd">50500000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-699" decimals="-5" id="f-1571" unitRef="usd">60900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-700" decimals="-5" id="f-1572" unitRef="usd">104500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-701" decimals="-5" id="f-1573" unitRef="usd">185900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-702" decimals="-5" id="f-1574" unitRef="usd">216900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-93" decimals="-5" id="f-1575" unitRef="usd">56400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-94" decimals="-5" id="f-1576" unitRef="usd">42500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-95" decimals="-5" id="f-1577" unitRef="usd">42500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-96" decimals="-5" id="f-1578" unitRef="usd">13900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-97" decimals="-5" id="f-1579" unitRef="usd">13900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock contextRef="c-1" id="f-1580">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes share-based compensation expense associated with each of our share-based compensation programs:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.455%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.285%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Time-vested restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;186.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;174.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance stock units settled in stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee stock purchase plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Performance stock units settled in cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Market stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:0.75pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;HI-Bio equity awards&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;78.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;131.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;240.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;275.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Capitalized share-based compensation costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(9.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(8.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation expense included in total cost and expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;75.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;128.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;231.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;267.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.017%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.105%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.578%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Relates to the HI-Bio equity-based compensation expense attributable to the post-acquisition service period, associated with the accelerated vesting of stock options and RSUs previously granted to HI-Bio employees and required no future services to vest. For additional information on our acquisition of HI-Bio, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 2, Acquisitions&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;, to these condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-703" decimals="-5" id="f-1581" unitRef="usd">60100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-704" decimals="-5" id="f-1582" unitRef="usd">59100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-705" decimals="-5" id="f-1583" unitRef="usd">186800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-706" decimals="-5" id="f-1584" unitRef="usd">174700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-707" decimals="-5" id="f-1585" unitRef="usd">15500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-708" decimals="-5" id="f-1586" unitRef="usd">13000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-709" decimals="-5" id="f-1587" unitRef="usd">44100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-710" decimals="-5" id="f-1588" unitRef="usd">35200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-711" decimals="-5" id="f-1589" unitRef="usd">1800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-712" decimals="-5" id="f-1590" unitRef="usd">1900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-713" decimals="-5" id="f-1591" unitRef="usd">6900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-714" decimals="-5" id="f-1592" unitRef="usd">8200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-715" decimals="-5" id="f-1593" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-716" decimals="-5" id="f-1594" unitRef="usd">-500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-717" decimals="-5" id="f-1595" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-718" decimals="-5" id="f-1596" unitRef="usd">-2500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-719" decimals="-5" id="f-1597" unitRef="usd">1000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-720" decimals="-5" id="f-1598" unitRef="usd">1000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-721" decimals="-5" id="f-1599" unitRef="usd">2800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-722" decimals="-5" id="f-1600" unitRef="usd">2800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-723" decimals="-5" id="f-1601" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-724" decimals="-5" id="f-1602" unitRef="usd">200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-725" decimals="-5" id="f-1603" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-726" decimals="-5" id="f-1604" unitRef="usd">600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-117" decimals="-5" id="f-1605" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-727" decimals="-5" id="f-1606" unitRef="usd">56400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-112" decimals="-5" id="f-1607" unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-728" decimals="-5" id="f-1608" unitRef="usd">56400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c-19" decimals="-5" id="f-1609" unitRef="usd">78400000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c-20" decimals="-5" id="f-1610" unitRef="usd">131100000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c-1" decimals="-5" id="f-1611" unitRef="usd">240600000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax contextRef="c-21" decimals="-5" id="f-1612" unitRef="usd">275400000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="c-19" decimals="-5" id="f-1613" unitRef="usd">3100000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="c-20" decimals="-5" id="f-1614" unitRef="usd">2400000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="c-1" decimals="-5" id="f-1615" unitRef="usd">9400000</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount contextRef="c-21" decimals="-5" id="f-1616" unitRef="usd">8000000.0</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses contextRef="c-19" decimals="-5" id="f-1617" unitRef="usd">75300000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses contextRef="c-20" decimals="-5" id="f-1618" unitRef="usd">128700000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses contextRef="c-1" decimals="-5" id="f-1619" unitRef="usd">231200000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses contextRef="c-21" decimals="-5" id="f-1620" unitRef="usd">267400000</biib:ShareBasedCompensationExpenseIncludedInCostsAndExpenses>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-1621">&lt;div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:87.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%"&gt;Note 17:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:14pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:112%"&gt;2025 OBBBA Tax Provisions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 4, 2025, the U.S. signed into law the H.R.1 legislation formally titled "An Act to Provide for Reconciliation Pursuant to Title II of H. Con. Res. 14", commonly referred to as the OBBBA.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The OBBBA contains tax provisions, such as the permanent extension or revision of certain expiring provisions of the Tax Cuts and Jobs Act enacted in 2017, modifications to the international tax framework and the restoration of favorable tax treatment for certain business provisions. The provisions of the OBBBA have multiple effective dates, with certain provisions effective in 2025 and others implemented through 2027. The OBBBA did not result in any material adjustments to our total income tax provision for the three and nine months ended September 30, 2025, and we have adjusted our deferred tax balances to reflect the impacts of the OBBBA enactment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Tax Rate&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.683%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.624%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Taxes on foreign earnings, including valuation allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Purchased inventory valuation step-up and intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;GILTI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;OBBBA enactment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other, including permanent items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Changes in Tax Rate&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and nine months ended September 30, 2025, compared to the same periods in 2024, the increases in our effective tax rates were partially driven by changes in the territorial mix of our profitability, partially offset by the impact of the OBBBA enactment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The nine months ended September 30, 2025, compared to the same period in 2024, also reflects the impacts of certain share-based compensation awards that vested during the first quarter of 2025 and a decrease in our estimate of Pillar Two minimum tax liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three and nine months ended September 30, 2024, our effective tax rates benefited from a decrease in our valuation allowance, partially offset by the impact of certain foreign uncertain tax positions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Accounting for Uncertainty in Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We and our subsidiaries are routinely examined by various taxing authorities. We file income tax returns in various U.S. states and in U.S. federal and other foreign jurisdictions. With few exceptions, we are no longer subject to U.S. federal tax examination for years before 2021 or state, local or non-U.S. income tax examinations for years before 2013.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The U.S. Internal Revenue Service and other national tax authorities routinely examine our intercompany transfer pricing with respect to intellectual property related transactions and it is possible that they may disagree with one or more positions we have taken with respect to such valuations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;It is reasonably possible that we will adjust the value of our uncertain tax positions related to certain transfer pricing, collaboration matters, withholding taxes and other issues as we receive additional information from various taxing authorities, including reaching settlements with such authorities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We estimate that it is reasonably possible that our gross unrecognized tax benefits, exclusive of interest, could&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;decrease by up to approximately $35.0&#160;million in the next 12 months as a result of various audit closures, settlements and expiration of the statute of limitations.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c-1" id="f-1622">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation between the U.S.&#160;federal statutory tax rate and our effective tax rate is summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.683%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.619%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.624%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;State taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Taxes on foreign earnings, including valuation allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(7.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Purchased inventory valuation step-up and intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;GILTI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Share-based compensation awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;OBBBA enactment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(2.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other, including permanent items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;13.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;15.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-19" decimals="3" id="f-1623" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-20" decimals="3" id="f-1624" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-1" decimals="3" id="f-1625" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-21" decimals="3" id="f-1626" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-19" decimals="3" id="f-1627" unitRef="number">0.017</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-20" decimals="3" id="f-1628" unitRef="number">0.025</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-1" decimals="3" id="f-1629" unitRef="number">0.017</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-21" decimals="3" id="f-1630" unitRef="number">0.017</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="c-19" decimals="3" id="f-1631" unitRef="number">-0.050</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="c-20" decimals="3" id="f-1632" unitRef="number">-0.119</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="c-1" decimals="3" id="f-1633" unitRef="number">-0.072</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="c-21" decimals="3" id="f-1634" unitRef="number">-0.070</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="c-19" decimals="3" id="f-1635" unitRef="number">0.016</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="c-20" decimals="3" id="f-1636" unitRef="number">0.012</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="c-1" decimals="3" id="f-1637" unitRef="number">0.018</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="c-21" decimals="3" id="f-1638" unitRef="number">0.017</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization contextRef="c-19" decimals="3" id="f-1639" unitRef="number">0.024</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization contextRef="c-20" decimals="3" id="f-1640" unitRef="number">0.033</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization contextRef="c-1" decimals="3" id="f-1641" unitRef="number">0.023</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization contextRef="c-21" decimals="3" id="f-1642" unitRef="number">0.020</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseDepreciationAndAmortization>
    <us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent contextRef="c-19" decimals="3" id="f-1643" unitRef="number">-0.012</us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent contextRef="c-20" decimals="3" id="f-1644" unitRef="number">-0.011</us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent contextRef="c-1" decimals="3" id="f-1645" unitRef="number">-0.010</us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent contextRef="c-21" decimals="3" id="f-1646" unitRef="number">-0.014</us-gaap:EffectiveIncomeTaxRateReconciliationGiltiPercent>
    <biib:EffectiveTaxRateReconciliationShareBasedCompensationAwards contextRef="c-19" decimals="3" id="f-1647" unitRef="number">0</biib:EffectiveTaxRateReconciliationShareBasedCompensationAwards>
    <biib:EffectiveTaxRateReconciliationShareBasedCompensationAwards contextRef="c-20" decimals="3" id="f-1648" unitRef="number">0</biib:EffectiveTaxRateReconciliationShareBasedCompensationAwards>
    <biib:EffectiveTaxRateReconciliationShareBasedCompensationAwards contextRef="c-1" decimals="3" id="f-1649" unitRef="number">0.011</biib:EffectiveTaxRateReconciliationShareBasedCompensationAwards>
    <biib:EffectiveTaxRateReconciliationShareBasedCompensationAwards contextRef="c-21" decimals="3" id="f-1650" unitRef="number">0.002</biib:EffectiveTaxRateReconciliationShareBasedCompensationAwards>
    <biib:EffectiveTaxRateReconciliationOneBigBeautifulBillActEnactment contextRef="c-19" decimals="3" id="f-1651" unitRef="number">-0.021</biib:EffectiveTaxRateReconciliationOneBigBeautifulBillActEnactment>
    <biib:EffectiveTaxRateReconciliationOneBigBeautifulBillActEnactment contextRef="c-20" decimals="3" id="f-1652" unitRef="number">0</biib:EffectiveTaxRateReconciliationOneBigBeautifulBillActEnactment>
    <biib:EffectiveTaxRateReconciliationOneBigBeautifulBillActEnactment contextRef="c-1" decimals="3" id="f-1653" unitRef="number">-0.007</biib:EffectiveTaxRateReconciliationOneBigBeautifulBillActEnactment>
    <biib:EffectiveTaxRateReconciliationOneBigBeautifulBillActEnactment contextRef="c-21" decimals="3" id="f-1654" unitRef="number">0</biib:EffectiveTaxRateReconciliationOneBigBeautifulBillActEnactment>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-19" decimals="3" id="f-1655" unitRef="number">0.011</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-20" decimals="3" id="f-1656" unitRef="number">0.013</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-1" decimals="3" id="f-1657" unitRef="number">0.014</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-21" decimals="3" id="f-1658" unitRef="number">0.006</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-19" decimals="3" id="f-1659" unitRef="number">0.163</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-20" decimals="3" id="f-1660" unitRef="number">0.139</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-1" decimals="3" id="f-1661" unitRef="number">0.168</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-21" decimals="3" id="f-1662" unitRef="number">0.154</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible contextRef="c-22" decimals="-5" id="f-1663" unitRef="usd">35000000</us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible>
    <us-gaap:AdditionalFinancialInformationDisclosureTextBlock contextRef="c-1" id="f-1664">&lt;div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:87.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%"&gt;Note 18:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:14pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%"&gt;Other Consolidated Financial Statement Detail&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Other (Income) Expense, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of other (income) expense, net, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.714%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.822%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.387%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.822%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.387%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.822%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.387%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.825%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(31.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(87.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(49.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;67.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;200.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;190.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Gains) losses on investments, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(39.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange (gains) losses, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(15.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other (income) expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;151.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;193.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The (gains) losses on investments, net, as reflected in the table above, relate to equity securities of certain biotechnology companies, venture capital funds where the underlying investments are in equity securities of certain biotechnology companies and non-marketable equity securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The following table summarizes our (gains) losses on investments, net that relate to our equity securities held during the following periods:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.514%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.771%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net (gains) losses recognized on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(39.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: Net (gains) losses realized on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net unrealized (gains) losses recognized on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(28.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net unrealized gains recognized during the three months ended September 30, 2025, primarily reflect an increase in the aggregate fair value of our investment in Denali common stock of approximately $3.8&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net unrealized gains recognized during the three months ended September 30, 2024, primarily reflect an increase in the aggregate fair value of our investments in Denali and Sangamo common stock of approximately $53.3&#160;million, partially offset by a decrease in the fair value of Sage common stock of approximately $22.7&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net unrealized losses recognized during the nine months ended September 30, 2025, primarily reflect a decrease in the aggregate fair value of our investment in Denali common stock of approximately $41.9&#160;million, partially offset by an increase in the fair value of Sage common stock of approximately $23.0&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The net unrealized losses recognized during the nine months ended September 30, 2024, primarily reflect a decrease in the aggregate fair value of our investments in Sage common stock of approximately $90.2&#160;million, partially offset by an increase in the fair value of Denali and Sangamo common stock of approximately $70.1&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Accrued Expense and Other&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expense and other consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.347%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue-related reserves for discounts and allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,062.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;937.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;310.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;375.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Collaboration expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;268.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;309.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Royalties and licensing fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;320.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;190.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current portion of contingent consideration obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;148.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;291.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;89.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;574.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;692.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,773.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,807.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:10pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Long-term Liabilities&lt;/span&gt;&lt;/div&gt;Other long-term liabilities were $761.8 million and $732.3 million as of September 30, 2025 and December 31, 2024, respectively, and included accrued income taxes totaling $164.7 million and $156.7 million, respectively</us-gaap:AdditionalFinancialInformationDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock contextRef="c-1" id="f-1665">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of other (income) expense, net, are summarized as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.714%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.822%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.387%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.822%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.387%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.822%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.387%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.825%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(31.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(11.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(87.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(49.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;67.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;200.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;190.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Gains) losses on investments, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(39.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;22.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Foreign exchange (gains) losses, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;10.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;16.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;25.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(15.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(12.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total other (income) expense, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;151.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;193.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:InvestmentIncomeInterest contextRef="c-19" decimals="-5" id="f-1666" unitRef="usd">31600000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-20" decimals="-5" id="f-1667" unitRef="usd">11600000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-1" decimals="-5" id="f-1668" unitRef="usd">87800000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-21" decimals="-5" id="f-1669" unitRef="usd">49100000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense contextRef="c-19" decimals="-5" id="f-1670" unitRef="usd">67400000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-20" decimals="-5" id="f-1671" unitRef="usd">59800000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-1" decimals="-5" id="f-1672" unitRef="usd">200000000.0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-21" decimals="-5" id="f-1673" unitRef="usd">190300000</us-gaap:InterestExpense>
    <us-gaap:RealizedInvestmentGainsLosses contextRef="c-19" decimals="-5" id="f-1674" unitRef="usd">-3800000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:RealizedInvestmentGainsLosses contextRef="c-20" decimals="-5" id="f-1675" unitRef="usd">39100000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:RealizedInvestmentGainsLosses contextRef="c-1" decimals="-5" id="f-1676" unitRef="usd">-34100000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:RealizedInvestmentGainsLosses contextRef="c-21" decimals="-5" id="f-1677" unitRef="usd">-22200000</us-gaap:RealizedInvestmentGainsLosses>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c-19" decimals="-5" id="f-1678" unitRef="usd">-10300000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c-20" decimals="-5" id="f-1679" unitRef="usd">-4900000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c-1" decimals="-5" id="f-1680" unitRef="usd">-16900000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="c-21" decimals="-5" id="f-1681" unitRef="usd">-25600000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-19" decimals="-5" id="f-1682" unitRef="usd">15800000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-20" decimals="-5" id="f-1683" unitRef="usd">-800000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-5" id="f-1684" unitRef="usd">12000000.0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-21" decimals="-5" id="f-1685" unitRef="usd">-4700000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-19" decimals="-5" id="f-1686" unitRef="usd">-34100000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-20" decimals="-5" id="f-1687" unitRef="usd">-14800000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-1" decimals="-5" id="f-1688" unitRef="usd">-151200000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:OtherOperatingIncomeExpenseNet contextRef="c-21" decimals="-5" id="f-1689" unitRef="usd">-193700000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:GainLossOnInvestmentsTextBlock contextRef="c-1" id="f-1690">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The following table summarizes our (gains) losses on investments, net that relate to our equity securities held during the following periods:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.514%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.765%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.771%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net (gains) losses recognized on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(39.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;34.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less: Net (gains) losses realized on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(10.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(5.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net unrealized (gains) losses recognized on equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(3.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(28.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;32.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;27.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:GainLossOnInvestmentsTextBlock>
    <us-gaap:EquitySecuritiesFvNiGainLoss contextRef="c-19" decimals="-5" id="f-1691" unitRef="usd">3800000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss contextRef="c-20" decimals="-5" id="f-1692" unitRef="usd">-39100000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss contextRef="c-1" decimals="-5" id="f-1693" unitRef="usd">34100000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss contextRef="c-21" decimals="-5" id="f-1694" unitRef="usd">21900000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss contextRef="c-19" decimals="-5" id="f-1695" unitRef="usd">7000000.0</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss contextRef="c-20" decimals="-5" id="f-1696" unitRef="usd">-10900000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss contextRef="c-1" decimals="-5" id="f-1697" unitRef="usd">1600000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss contextRef="c-21" decimals="-5" id="f-1698" unitRef="usd">-5400000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-19" decimals="-5" id="f-1699" unitRef="usd">-3200000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-20" decimals="-5" id="f-1700" unitRef="usd">-28200000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-1" decimals="-5" id="f-1701" unitRef="usd">32500000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-21" decimals="-5" id="f-1702" unitRef="usd">27300000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-729" decimals="-5" id="f-1703" unitRef="usd">3800000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-730" decimals="-5" id="f-1704" unitRef="usd">53300000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-731" decimals="-5" id="f-1705" unitRef="usd">22700000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-732" decimals="-5" id="f-1706" unitRef="usd">41900000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-733" decimals="-5" id="f-1707" unitRef="usd">23000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-734" decimals="-5" id="f-1708" unitRef="usd">90200000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss contextRef="c-735" decimals="-5" id="f-1709" unitRef="usd">70100000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="c-1" id="f-1710">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accrued expense and other consists of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.347%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Revenue-related reserves for discounts and allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,062.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;937.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Employee compensation and benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;310.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;375.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Collaboration expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;268.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;309.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Royalties and licensing fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;320.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;190.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Current portion of contingent consideration obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;148.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;291.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Derivative liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;89.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;574.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;692.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total accrued expense and other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,773.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,807.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-469" decimals="-5" id="f-1711" unitRef="usd">1062300000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-470" decimals="-5" id="f-1712" unitRef="usd">937500000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-22" decimals="-5" id="f-1713" unitRef="usd">310700000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-23" decimals="-5" id="f-1714" unitRef="usd">375800000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <biib:Collaborationexpensesaccrual contextRef="c-22" decimals="-5" id="f-1715" unitRef="usd">268700000</biib:Collaborationexpensesaccrual>
    <biib:Collaborationexpensesaccrual contextRef="c-23" decimals="-5" id="f-1716" unitRef="usd">309000000.0</biib:Collaborationexpensesaccrual>
    <us-gaap:AccruedRoyaltiesCurrent contextRef="c-22" decimals="-5" id="f-1717" unitRef="usd">320200000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:AccruedRoyaltiesCurrent contextRef="c-23" decimals="-5" id="f-1718" unitRef="usd">190200000</us-gaap:AccruedRoyaltiesCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="c-22" decimals="-5" id="f-1719" unitRef="usd">148600000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent contextRef="c-23" decimals="-5" id="f-1720" unitRef="usd">291200000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:ConstructionPayableCurrentAndNoncurrent contextRef="c-22" decimals="-5" id="f-1721" unitRef="usd">89100000</us-gaap:ConstructionPayableCurrentAndNoncurrent>
    <us-gaap:ConstructionPayableCurrentAndNoncurrent contextRef="c-23" decimals="-5" id="f-1722" unitRef="usd">11700000</us-gaap:ConstructionPayableCurrentAndNoncurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-22" decimals="-5" id="f-1723" unitRef="usd">574000000.0</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="c-23" decimals="-5" id="f-1724" unitRef="usd">692300000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-22" decimals="-5" id="f-1725" unitRef="usd">2773600000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-23" decimals="-5" id="f-1726" unitRef="usd">2807700000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-22" decimals="-5" id="f-1727" unitRef="usd">761800000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-23" decimals="-5" id="f-1728" unitRef="usd">732300000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent contextRef="c-22" decimals="-5" id="f-1729" unitRef="usd">164700000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent contextRef="c-23" decimals="-5" id="f-1730" unitRef="usd">156700000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="c-1" id="f-1731">&lt;div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:87.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%"&gt;Note 19:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:14pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%"&gt;Collaborative and Other Relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Genentech, Inc. (Roche Group)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have certain business and financial rights with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, CLL and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA for the treatment of CLL, follicular lymphoma,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and, following its approval in October 2025, lupus nephritis; OCREVUS for the treatment of PPMS and RMS; LUNSUMIO for the treatment of relapsed or refractory follicular lymphoma; COLUMVI, a bispecific antibody for the treatment of non-Hodgkin's lymphoma; and have the option to add other potential anti-CD20 therapies, pursuant to our collaboration arrangements with Genentech, a wholly-owned member of the Roche Group. For purposes of this footnote, we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;RITUXAN&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Genentech and its affiliates are responsible for the worldwide manufacture of RITUXAN as well as all development and commercialization activities as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.67pt"&gt;U.S.:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have co-exclusively licensed our rights to develop, commercialize and market RITUXAN in the U.S.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:10.67pt"&gt;Canada:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have co-exclusively licensed our rights to develop, commercialize and market RITUXAN in Canada.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;GAZYVA&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Roche Group and its sub-licensees maintain sole responsibility for the development, manufacture and commercialization of GAZYVA in the U.S. The level of gross sales of GAZYVA in the U.S. has impacted our percentage of the co-promotion profits for RITUXAN and LUNSUMIO, as summarized in the table below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;OCREVUS&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the terms of our collaboration arrangements with Genentech, we receive a tiered royalty on U.S. net sales from 13.5% and increasing up to 24.0% if annual net sales exceed $900.0&#160;million. There will be a 50.0% reduction to these royalties upon the first entry of an FDA approved biosimilar to OCREVUS.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, we receive a gross 3.0% royalty on net sales of OCREVUS outside the U.S., with the royalty period lasting 11 years from the first commercial sale of OCREVUS on a country-by-country basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The commercialization of OCREVUS does not impact the percentage of the co-promotion profits we receive for RITUXAN, LUNSUMIO or GAZYVA. Genentech is solely responsible for development and commercialization of OCREVUS and funding future costs. Genentech cannot develop OCREVUS in CLL, non-Hodgkin's lymphoma or rheumatoid arthritis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;OCREVUS royalty revenue is based on our estimates from third party and market research data of OCREVUS sales occurring during the corresponding period. Differences between actual and estimated royalty revenue will be adjusted for in the period in which they become known, which is generally expected to be the following quarter.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;LUNSUMIO&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are entitled to a tiered share of co-promotion operating profits and losses in the U.S., as summarized in the table below. In addition, we receive low-single digit royalties on sales of LUNSUMIO outside the U.S.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;COLUMVI&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Genentech has sole decision-making rights on the commercialization of COLUMVI within the U.S. and we receive tiered royalties in the mid-single digit range on net sales of COLUMVI in the U.S. Under the terms of this agreement, we have no payment obligations. The commercialization of COLUMVI does not impact the percentage of the co-promotion profits we receive for RITUXAN, LUNSUMIO or GAZYVA.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Profit-sharing Formulas&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;RITUXAN and LUNSUMIO Profit Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our current pretax co-promotion profit-sharing formula for RITUXAN and LUNSUMIO in the U.S. provides for a 30.0% share on the first $50.0&#160;million of combined co-promotion operating profits earned each calendar year. As a result of the FDA approval of LUNSUMIO our share of the combined annual co-promotion profits for RITUXAN and LUNSUMIO in excess of $50.0&#160;million varies upon the following events, as summarized in the table below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:80.891%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.909%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After LUNSUMIO Approval until the First Threshold Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After First Threshold Date until the Second Threshold Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After Second Threshold Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;First Threshold Date&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; means the earlier of (i)&#160;the first day of the calendar quarter following the date U.S. gross sales of GAZYVA within any consecutive 12-month period have reached $500.0&#160;million or (ii)&#160;the first date in any calendar year in which U.S. gross sales of LUNSUMIO have reached $150.0&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:22.5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Second Threshold Date&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; means the later of (i) the first date in any calendar year in which U.S. gross sales of LUNSUMIO have reached $350.0&#160;million or (ii) January 1 of the calendar year following the calendar year in which the First Threshold Date occurs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2023 the First Threshold Date was achieved. As a result, beginning in April 2023 the pre-tax profit share for RITUXAN and LUNSUMIO was 35.0%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#538235;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;GAZYVA Profit Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our current pretax profit-sharing formula for GAZYVA provides for a 35.0% share of operating profits earned each calendar year.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our collaboration arrangements with Genentech, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 19, Collaborative and Other Relationships&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to our consolidated financial statements included in our 2024 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Ionis Pharmaceuticals, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2017 SMA Collaboration Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2017 we entered into a collaboration agreement with Ionis to identify new ASO drug candidates for the potential treatment of SMA. Under this agreement, we have options to license therapies arising out of this collaboration and will be responsible for the development and commercialization of such therapies.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2021 we exercised our option with Ionis and obtained a worldwide, exclusive, royalty-bearing license to develop and commercialize salanersen (BIIB115), an investigational ASO in development for SMA.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may pay Ionis up to $155.0&#160;million in additional development and regulatory milestone payments related to salanersen, including a $45.0&#160;million milestone payment due upon the initiation of a Phase 3 trial. Upon commercialization, we may also pay Ionis up to $400.0&#160;million in additional performance-based milestone payments and tiered royalties on potential net sales of such therapies ranging from the mid-teens to high-twenties percentages.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our collaboration arrangements with Ionis, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 19, Collaborative and Other Relationships&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to our consolidated financial statements included in our 2024 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Eisai Co., Ltd.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;LEQEMBI (lecanemab) Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have a collaboration agreement with Eisai to jointly develop and commercialize LEQEMBI (lecanemab), an anti-amyloid antibody for the treatment of Alzheimer's disease. The FDA granted traditional approval of LEQEMBI in July 2023. Prior to receiving traditional approval, LEQEMBI had been granted accelerated approval by the FDA in January 2023, at which time it became commercially available in the U.S. Outside of the U.S., LEQEMBI is now approved in the E.U. (April 2025), Australia (September 2025), China (January 2024), Japan (September 2023) and other international markets. LEQEMBI monthly IV maintenance dosing for the treatment of early Alzheimer's disease was approved in the U.S. and China in January 2025 and September 2025, respectively, and LEQEMBI subcutaneous autoinjector (IQLIK) for weekly maintenance dosing was approved in the U.S. in August 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All costs, including research, development, sales and marketing expense, are shared equally between us and Eisai. We also share profits and losses equally. We currently have a supply agreement with Eisai to manufacture LEQEMBI drug substance and drug product through the end of 2031.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Subject to the limitations in the LEQEMBI Collaboration Agreement, Eisai has final decision-making authority on all matters relating to the collaboration and serves as the lead of LEQEMBI development and regulatory submissions globally. We co-commercialize and co-promote LEQEMBI with Eisai. Our Collaboration Agreement provides that each commercialization plan shall allocate the responsibilities for the activities under the plan in an equitable fashion taking into account Biogen's and Eisai's respective capabilities and provides a meaningful role for each party.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon commercialization of LEQEMBI in the U.S., we began recognizing our 50.0% share of LEQEMBI product revenue, net and cost of sales, including royalties, within Alzheimer's collaboration revenue in our condensed consolidated statements of income, as we are not the principal.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our share of LEQEMBI sales and marketing expense and development expense are recorded within selling, general and administrative expense and research and development expense, respectively, within our condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of development and sales and marketing expense related to the LEQEMBI Collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.455%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.285%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total development expense incurred by the collaboration related to the advancement of LEQEMBI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;70.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;77.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;178.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;255.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of the LEQEMBI Collaboration development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;89.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;127.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total sales and marketing expense incurred by the LEQEMBI Collaboration&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;176.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;164.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;525.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;476.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of the LEQEMBI Collaboration sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;88.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;82.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;262.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;238.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts receivable from Eisai related to the agreements discussed above were approximately $103.8&#160;million and $16.7&#160;million as of September 30, 2025 and December 31, 2024, respectively. Amounts payable to Eisai related to the agreements discussed above were approximately $97.9&#160;million and $138.0&#160;million as of September 30, 2025 and December 31, 2024, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our collaboration arra&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ngements with Eisai, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 19,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to our consolidated financial statements included in our 2024 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;UCB&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have a collaboration agreement with UCB, effective November 2003, to jointly develop and commercialize dapirolizumab pegol, an anti-CD40L pegylated Fab, for the potential treatment of SLE and other future agreed indications. Either we or UCB may propose development of dapirolizumab pegol in additional indications. If the parties do not agree to add an indication as an agreed indication to the collaboration, we or UCB may, at the sole expense of the applicable party, pursue development in such excluded indication(s), subject to an opt-in right of the non-pursuing party after proof of clinical activity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All costs incurred for agreed indications, including research, development, sales and marketing expense, are shared equally between us and UCB. If marketing approval is obtained, both companies will jointly commercialize dapirolizumab pegol and share profits and losses equally.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of development expense related to the UCB collaboration agreement is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.455%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.285%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total UCB collaboration development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of the UCB collaboration development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Supernus Pharmaceuticals, Inc. (previously Sage Therapeutics, Inc.)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2020 we entered into a global collaboration and license agreement with Sage to jointly develop and commercialize ZURZUVAE (zuranolone) for the treatment of PPD. In July 2025 Sage was acquired by Supernus. ZURZUVAE was approved in the U.S. in August 2023 and in the E.U. in September 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under this collaboration, both companies will share equal responsibility and costs for development as well as profits and losses for commercialization in the U.S. Outside of the U.S., we are responsible for development and commercialization, excluding Japan, Taiwan and South Korea, with respect to zuranolone and may pay Supernus &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;potential tiered royalties in the high-teens to low-twenties percentages. During the fourth quarter of 2023 we accrued a milestone payment due t&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;o Supernus&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of $75.0&#160;million upon the first commercial sale of ZURZUVAE for PPD in the U.S., which was recorded within intangible assets, net in our condensed consolidated balance sheets, and subsequently paid in January 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We share 50.0% of the net collaboration results in the U.S. with Supernus, which are recognized in collaboration profit sharing/(loss reimbursement) in our condensed consolidated statements of income. For the three and nine months ended September 30, 2025, we recognized net profit-sharing expense of approximately $20.7 million and $48.6 million, respectively, to reflect Supernus' 50.0% share of the net collaboration results in the U.S., compared to net profit-sharing expense of approximately $9.0 million and $20.5 million, respectively, in the prior year comparative periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;A summary of development and sales and marketing expense related to the Supernus collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.379%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.695%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.695%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.695%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.700%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Supernus collaboration development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of the Supernus collaboration development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total sales and marketing expense incurred by the Supernus collaboration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;131.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;82.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of the Supernus collaboration sales and marketing expense reflected in selling, general and administrative expense and collaboration profit sharing/(loss reimbursement) in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Denali Therapeutics Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2020 we entered into a collaboration and license agreement with Denali to co-develop and co-commercialize BIIB122, a small molecule inhibitor of LRRK2 for Parkinson's disease (LRRK2 Collaboration).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the LRRK2 Collaboration, both companies share responsibility and costs for global development based on specified percentages as well as profits and losses for commercialization in the U.S. and China. Outside the U.S. and China we are responsible for commercialization and may pay Denali potential tiered royalties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;A summary of development expense related to the Denali collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.455%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.285%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Denali collaboration development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;36.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of the Denali collaboration development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Stoke Therapeutics, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2025 we entered into a collaboration and license agreement with Stoke to co-develop and commercialize zorevunersen, an investigational ASO that targets the SCN1A gene for the potential treatment of Dravet syndrome, a rare form of genetic epilepsy associated with refractory seizures and neurodevelopmental impairments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of this agreement, Stoke will continue to lead global development and retain exclusive development and commercialization rights for zorevunersen in the U.S., Canada and Mexico and we will have exclusive rights to commercialize zorevunersen in the rest of the world. Both companies will share responsibility for external clinical development costs, where Stoke is responsible for 70.0% of these development costs and we are responsible for the remaining 30.0% of these development costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the closing of this transaction we made an upfront payment of $165.0&#160;million to Stoke, which was recognized as acquired in-process research and development, upfront and milestone expense within our condensed consolidated statements of income for the nine months ended September 30, 2025. We may also pay Stoke potential development and commercial milestone payments of up to $50.0&#160;million and $335.0&#160;million, respectively, if all the specified milestones set forth in this collaboration are achieved. In addition, we may pay Stoke tiered royalties on potential net sales of any products developed under this collaboration in the low-double digit to high-teen percentages.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also have an exclusive option to license certain future follow-on ASO products targeting the SCN1A gene in all territories worldwide other than the U.S., Canada and Mexico, in exchange for separate milestone, cost sharing and royalty considerations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of development expense related to the Stoke collaboration agreement is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.087%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.221%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.932%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Stoke collaboration development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of the Stoke collaboration development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="background-color:#ffffff;color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Samsung Bioepis Co., Lt&lt;/span&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;d.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2019 Development and Commercialization Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019 we completed a transaction with Samsung Bioepis and secured the exclusive rights to commercialize two potential ophthalmology biosimilar products, BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS, and OPUVIZ, an aflibercept biosimilar referencing EYLEA, in major markets worldwide, including the U.S., Canada, Europe, Japan and Australia. The agreement established that Samsung Bioepis will be responsible for development and will supply both products to us at a pre-specified gross margin of approximately 45.0%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2024 we notified Samsung Bioepis of our decision to terminate our 2019 Development and Commercialization Agreement (the DCA Agreement) solely within the U.S. and Canada. As a result of this termination we recognized impairment charges of approximately $20.2 million, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;which were recorded within amortization and impairment of acquired intangible assets within our condensed consolidated statements of income for the&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;three and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;nine months ended September 30, 2024. Biogen will transfer commercialization rights for BYOOVIZ and OPUVIZ in the U.S. and Canada back to Samsung Bioepis over a period of up to 18 months. During this transition period, we will continue to commercialize BYOOVIZ. The termination does not impact the other markets in the DCA Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may pay Samsung Bioepis up to approximately $150.0 million for achieving additional sales-based milestones associated with the remaining major markets covered by the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2013 Commercial Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2013 we entered into an agreement with Samsung Bioepis to commercialize, over a 10-year term, three anti-TNF biosimilar product candidates which include IMRALDI, an adalimumab biosimilar referencing HUMIRA, FLIXABI, an infliximab biosimilar referencing REMICADE, and BENEPALI, an etanercept biosimilar referencing ENBREL, in Europe.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2024 we exercised an option to extend this agreement by an additional five years and paid Samsung Bioepis an option exercise fee of $60.0 million, which was recognized in intangible assets, net within our condensed consolidated balance sheets as of December 31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We reflect revenue on sales of BENEPALI, IMRALDI and FLIXABI to third parties in product revenue, net in our condensed consolidated statements of income and record the related cost of revenue and sales and marketing expense in our condensed consolidated statements of income to their respective line items when these costs are incurred. Royalty payments to AbbVie on sales of IMRALDI are recognized in cost of sales within our condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We share 50.0% of the profit or loss related to our 2013 commercial agreement with Samsung Bioepis, which is recognized in collaboration profit sharing/(loss reimbursement) in our condensed consolidated statements of income. For the &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;three and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;nine months ended September 30, 2025, we recognized net profit-sharing expense of approximately $66.5&#160;million and $171.7&#160;million, respectively, to reflect Samsung Bioepis' 50.0% sharing of the net collaboration profits, compared to net profit-sharing expense of approximately $60.3 million and $176.8 million, respectively, in the prior year comparative periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Services&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Simultaneous with the formation of Samsung Bioepis, we also entered into a license agreement with Samsung Bioepis. Under this license agreement, we granted Samsung Bioepis an exclusive license to use, develop, manufacture and commercialize biosimilar products created by Samsung Bioepis using Biogen product-specific technology. In exchange, we receive single-digit royalties on biosimilar products developed and commercialized by Samsung Bioepis. Royalty revenue under the license agreement is recognized as a component of contract manufa&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;cturing, royalty and other revenue in our condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts receivable from Samsung Bioepis related to the agreements discussed above were approximately $4.8&#160;million and $7.6&#160;million as of September 30, 2025 and December 31, 2024, respectively. Amounts payable to Samsung Bioepis related to the agreements discussed above were $45.3&#160;million and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$60.8&#160;million as of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;September 30, 2025 and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2024, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our collaboration arrangements with Samsung Bioepis and our other significant collaboration arrangements, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 19,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative and Other Relationships,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to our consolidated financial statements included in our 2024 Form 10-K. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Other Research and Discovery Arrangements and Funding Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These arrangements may include the potential for future milestone payments based on the achievement of certain clinical and commercial development payable over a period of several years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Royalty Pharma Funding Arrangement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2025 we entered into a funding agreement with Royalty Pharma under which we will receive up to $200.0&#160;million in 2025 and up to $50.0&#160;million in 2026 to co-fund our development costs for the litifilimab program. As there is a substantive transfer of risk to the financial partner for the amount invested, the development funding will be recognized by us as an obligation to perform contractual services. We plan to recognize this funding as a reduction to research and development expense within our condensed consolidated statements of income, proportionate to the related expense. For the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;three and nine months ended September 30, 2025&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, we recorded reductions to research and development e&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;xpense of $50.0 million and $150.0&#160;million, respectiv&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ely, within our condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the litifilimab clinical trials are successful for the indications based on the applicable clinical trials, upon regulatory approval in the U.S. or certain major markets in the world, Royalty Pharma will be eligible to receive approval-based fixed milestone payments of up to a total of $250.0&#160;million. The milestone payments due upon approval will be recorded as a component of other (income) expense, net within our condensed consolidated statements of income, when incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If litifilimab receives regulatory approval, Royalty Pharma will be eligible to receive royalties of a mid-single digit percentage of the applicable net sales. Royalties on net sales will be recorded as cost of sales within our condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;MorphoSys AG&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of our acquisition of HI-Bio in July 2024, we &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;acquired HI-Bio's pre-existing in-license commitments under third-party agreements with MorphoSys, which included tiered royalties on potential future sales ranging from high-single digit to mid-teen percentages, as well as potential development, regulatory and commercial milestone payments of up to $130.0&#160;million, $230.0&#160;million and $640.0&#160;million, respectively. These amounts included milestone payments due upon the first patient dosed in a Phase 3 clinical trial of felzartamab in a first and second indication of $35.0&#160;million and $30.0&#160;million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the first quarter of 2025 we accrued a milestone payment due to MorphoSys of $35.0&#160;million upon the first patient dosed in a Phase 3 clinical trial of felzartamab for the treatment of AMR, which was recorded within acquired in-process research and development, upfront and milestone expense in our condensed consolidated statements of income for the nine months ended September 30, 2025, and paid in April 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the second quarter of 2025 we accrued a milestone payment due to MorphoSys of $30.0&#160;million upon the first patient dosed in a Phase 3 clinical trial of felzartamab for the treatment of IgAN, which was recorded within acquired in-process research and development, upfront and milestone expense in our condensed consolidated statements of income for the nine months ended September 30, 2025, and paid in July 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;City Therapeutics, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2025 we entered into a strategic research arrangement with City Therapeutics to develop select novel RNAi therapies. Through this arrangement, City Therapeutics will leverage its next-generation RNAi engineering technologies to develop an RNAi trigger molecule combined with our proprietary drug delivery technology. The collaboration will initially focus on a single target that mediates key CNS diseases, utilizing tissue enhanced delivery technologies with the aim of allowing for systemic administration of medicines. We will be responsible for IND-enabling studies and global clinical development along with any regulatory submissions and all activities related to commercialization.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the closing of this transaction we made an upfront payment of $16.0&#160;million to City Therapeutics, which was recognized as acquired in-process research and development, upfront and milestone expense within our condensed consolidated statements of income for the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;nine months ended September 30, 2025&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and invested $30.0&#160;million in exchange for a City Therapeutics convertible note, representing a minority equity interest in City Therapeutics, if converted. This convertible note was recorded as a component of investments and other assets within our condensed consolidated balance sheets as of&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; September 30, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may also pay City Therapeutics potential research, development and sales-based milestone payments of up to $21.5&#160;million, $360.0&#160;million and $625.0&#160;million, respectively, plus tiered royalties on potential future net sales, ranging from high-single digit to low-double digit percentages.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We also have the option to select one additional target in the collaboration, subject to an additional payment and availability of the target.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct
      contextRef="c-736"
      decimals="INF"
      id="f-1732"
      unitRef="number">0.135</biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct>
    <biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct
      contextRef="c-737"
      decimals="INF"
      id="f-1733"
      unitRef="number">0.240</biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct>
    <biib:Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage contextRef="c-738" decimals="-5" id="f-1734" unitRef="usd">900000000</biib:Royaltyoperatingprofitthresholdforhighestroyaltyratepercentage>
    <biib:Reductioninroyaltyrate
      contextRef="c-738"
      decimals="INF"
      id="f-1735"
      unitRef="number">0.500</biib:Reductioninroyaltyrate>
    <biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct
      contextRef="c-739"
      decimals="INF"
      id="f-1736"
      unitRef="number">0.030</biib:FutureRoyaltiesPercentageToBeReceivedOnSaleOfProduct>
    <biib:PeriodOfCollaborationAgreement contextRef="c-738" id="f-1737">P11Y</biib:PeriodOfCollaborationAgreement>
    <biib:PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion
      contextRef="c-740"
      decimals="INF"
      id="f-1738"
      unitRef="number">0.300</biib:PercentageOfCoPromotionOperatingProfitsFirstFiftyMillion>
    <biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment contextRef="c-741" decimals="-5" id="f-1739" unitRef="usd">50000000</biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment>
    <biib:CoPromotionProfitSharingFormulaTableTextBlock contextRef="c-1" id="f-1740">As a result of the FDA approval of LUNSUMIO our share of the combined annual co-promotion profits for RITUXAN and LUNSUMIO in excess of $50.0&#160;million varies upon the following events, as summarized in the table below:&lt;div style="margin-top:5pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:80.891%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.909%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After LUNSUMIO Approval until the First Threshold Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After First Threshold Date until the Second Threshold Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;After Second Threshold Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dddddd;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dddddd;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:CoPromotionProfitSharingFormulaTableTextBlock>
    <biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment contextRef="c-741" decimals="-5" id="f-1741" unitRef="usd">50000000</biib:CoPromotionOperatingProfitThresholdToDetermineShareOfCoPromotionOperatingProfitPriorToAmendment>
    <biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo
      contextRef="c-740"
      decimals="3"
      id="f-1742"
      unitRef="number">0.375</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionTwo>
    <biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree
      contextRef="c-740"
      decimals="3"
      id="f-1743"
      unitRef="number">0.350</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree>
    <biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour
      contextRef="c-740"
      decimals="3"
      id="f-1744"
      unitRef="number">0.300</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionFour>
    <biib:ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne contextRef="c-742" decimals="-5" id="f-1745" unitRef="usd">500000000</biib:ThresholdOfGrossSalesOfToBeAchievedInPrecedingTwelveConsecutiveMonthsUnderOptionOne>
    <biib:ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne contextRef="c-742" decimals="-5" id="f-1746" unitRef="usd">150000000</biib:ThresholdOfGrossSalesToBeAchievedInAnyTwelveConsecutiveMonthsUnderOptionOne>
    <biib:SalesTriggerGrossSalesThreshold contextRef="c-742" decimals="-5" id="f-1747" unitRef="usd">350000000</biib:SalesTriggerGrossSalesThreshold>
    <biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree
      contextRef="c-741"
      decimals="INF"
      id="f-1748"
      unitRef="number">0.350</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree>
    <biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree
      contextRef="c-743"
      decimals="INF"
      id="f-1749"
      unitRef="number">0.350</biib:PercentageOfCoPromotionOperatingProfitsGreaterThanFirstFiftyMillionOptionTwoSubOptionThree>
    <biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones contextRef="c-744" decimals="-5" id="f-1750" unitRef="usd">155000000</biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones>
    <biib:EstimatedAdditionalPaymentsUponInitiationOfNewPhases contextRef="c-744" decimals="-5" id="f-1751" unitRef="usd">45000000</biib:EstimatedAdditionalPaymentsUponInitiationOfNewPhases>
    <biib:ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold contextRef="c-744" decimals="-5" id="f-1752" unitRef="usd">400000000</biib:ExpectedAdditionalMilestonePaymentsWhenMeetingCertainSalesThreshold>
    <biib:ShareOfNonControlingInterestRecognized
      contextRef="c-479"
      decimals="2"
      id="f-1753"
      unitRef="number">0.500</biib:ShareOfNonControlingInterestRecognized>
    <biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock contextRef="c-1" id="f-1754">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of development and sales and marketing expense related to the LEQEMBI Collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.455%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.285%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total development expense incurred by the collaboration related to the advancement of LEQEMBI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;70.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;77.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;178.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;255.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of the LEQEMBI Collaboration development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;35.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;38.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;89.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;127.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total sales and marketing expense incurred by the LEQEMBI Collaboration&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;176.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;164.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;525.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;476.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of the LEQEMBI Collaboration sales and marketing expense reflected in selling, general and administrative expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;88.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;82.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;262.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;238.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:SummaryofActivityRelatedtoE2609andBAN2401CollaborationTableTextBlock>
    <biib:ExpenseIncurredByCollaboration contextRef="c-745" decimals="-5" id="f-1755" unitRef="usd">70900000</biib:ExpenseIncurredByCollaboration>
    <biib:ExpenseIncurredByCollaboration contextRef="c-746" decimals="-5" id="f-1756" unitRef="usd">77700000</biib:ExpenseIncurredByCollaboration>
    <biib:ExpenseIncurredByCollaboration contextRef="c-747" decimals="-5" id="f-1757" unitRef="usd">178400000</biib:ExpenseIncurredByCollaboration>
    <biib:ExpenseIncurredByCollaboration contextRef="c-748" decimals="-5" id="f-1758" unitRef="usd">255600000</biib:ExpenseIncurredByCollaboration>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-745" decimals="-5" id="f-1759" unitRef="usd">35400000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-746" decimals="-5" id="f-1760" unitRef="usd">38800000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-747" decimals="-5" id="f-1761" unitRef="usd">89200000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-748" decimals="-5" id="f-1762" unitRef="usd">127800000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expenseincurredbythecollaboration contextRef="c-749" decimals="-5" id="f-1763" unitRef="usd">176800000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration contextRef="c-750" decimals="-5" id="f-1764" unitRef="usd">164600000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration contextRef="c-751" decimals="-5" id="f-1765" unitRef="usd">525700000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration contextRef="c-752" decimals="-5" id="f-1766" unitRef="usd">476200000</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-749" decimals="-5" id="f-1767" unitRef="usd">88300000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-750" decimals="-5" id="f-1768" unitRef="usd">82300000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-751" decimals="-5" id="f-1769" unitRef="usd">262800000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-752" decimals="-5" id="f-1770" unitRef="usd">238100000</biib:Expensereflectedwithinstatementsofincome>
    <biib:AccountsReceivableFromCollaborator contextRef="c-753" decimals="-5" id="f-1771" unitRef="usd">103800000</biib:AccountsReceivableFromCollaborator>
    <biib:AccountsReceivableFromCollaborator contextRef="c-754" decimals="-5" id="f-1772" unitRef="usd">16700000</biib:AccountsReceivableFromCollaborator>
    <biib:AccountsPayableToCollaborator contextRef="c-753" decimals="-5" id="f-1773" unitRef="usd">97900000</biib:AccountsPayableToCollaborator>
    <biib:AccountsPayableToCollaborator contextRef="c-754" decimals="-5" id="f-1774" unitRef="usd">138000000</biib:AccountsPayableToCollaborator>
    <biib:SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock contextRef="c-1" id="f-1775">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of development expense related to the UCB collaboration agreement is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.455%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.285%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total UCB collaboration development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;23.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;19.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;62.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;52.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of the UCB collaboration development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;31.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:SummaryOfActivityRelatedToTheUCBCollaborationTableTextBlock>
    <biib:Expenseincurredbythecollaboration contextRef="c-755" decimals="-5" id="f-1776" unitRef="usd">23200000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration contextRef="c-756" decimals="-5" id="f-1777" unitRef="usd">19200000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration contextRef="c-757" decimals="-5" id="f-1778" unitRef="usd">62800000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration contextRef="c-758" decimals="-5" id="f-1779" unitRef="usd">52300000</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-755" decimals="-5" id="f-1780" unitRef="usd">11600000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-756" decimals="-5" id="f-1781" unitRef="usd">9500000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-757" decimals="-5" id="f-1782" unitRef="usd">31400000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-758" decimals="-5" id="f-1783" unitRef="usd">26100000</biib:Expensereflectedwithinstatementsofincome>
    <biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately contextRef="c-759" decimals="-5" id="f-1784" unitRef="usd">75000000</biib:PotentialFutureMilestonePaymentsCommitmentToThirdPartyApproximately>
    <biib:ShareOfNetProfitFromSageTherapeuticsPercent contextRef="c-22" decimals="2" id="f-1785" unitRef="number">0.500</biib:ShareOfNetProfitFromSageTherapeuticsPercent>
    <biib:Collaborationprofitlosssharing contextRef="c-760" decimals="-5" id="f-1786" unitRef="usd">20700000</biib:Collaborationprofitlosssharing>
    <biib:Collaborationprofitlosssharing contextRef="c-761" decimals="-5" id="f-1787" unitRef="usd">48600000</biib:Collaborationprofitlosssharing>
    <biib:ShareOfNetProfitFromSageTherapeuticsPercent contextRef="c-22" decimals="2" id="f-1788" unitRef="number">0.500</biib:ShareOfNetProfitFromSageTherapeuticsPercent>
    <biib:Collaborationprofitlosssharing contextRef="c-762" decimals="-5" id="f-1789" unitRef="usd">9000000.0</biib:Collaborationprofitlosssharing>
    <biib:Collaborationprofitlosssharing contextRef="c-763" decimals="-5" id="f-1790" unitRef="usd">20500000</biib:Collaborationprofitlosssharing>
    <biib:SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock contextRef="c-1" id="f-1791">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;A summary of development and sales and marketing expense related to the Supernus collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.379%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.695%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.695%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.695%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.700%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Supernus collaboration development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;29.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of the Supernus collaboration development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;4.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total sales and marketing expense incurred by the Supernus collaboration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;28.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;131.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;82.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of the Supernus collaboration sales and marketing expense reflected in selling, general and administrative expense and collaboration profit sharing/(loss reimbursement) in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;20.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;65.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:SummaryOfActivityRelatedToSageTherapeuticsTableTextBlock>
    <biib:Expenseincurredbythecollaboration contextRef="c-764" decimals="-5" id="f-1792" unitRef="usd">-1700000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration contextRef="c-765" decimals="-5" id="f-1793" unitRef="usd">8400000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration contextRef="c-766" decimals="-5" id="f-1794" unitRef="usd">2200000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration contextRef="c-767" decimals="-5" id="f-1795" unitRef="usd">29600000</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-764" decimals="-5" id="f-1796" unitRef="usd">-900000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-765" decimals="-5" id="f-1797" unitRef="usd">4200000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-766" decimals="-5" id="f-1798" unitRef="usd">1100000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-767" decimals="-5" id="f-1799" unitRef="usd">14800000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expenseincurredbythecollaboration contextRef="c-768" decimals="-5" id="f-1800" unitRef="usd">41800000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration contextRef="c-769" decimals="-5" id="f-1801" unitRef="usd">28400000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration contextRef="c-770" decimals="-5" id="f-1802" unitRef="usd">131000000.0</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration contextRef="c-771" decimals="-5" id="f-1803" unitRef="usd">82900000</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-768" decimals="-5" id="f-1804" unitRef="usd">20900000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-769" decimals="-5" id="f-1805" unitRef="usd">14200000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-770" decimals="-5" id="f-1806" unitRef="usd">65500000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-771" decimals="-5" id="f-1807" unitRef="usd">41500000</biib:Expensereflectedwithinstatementsofincome>
    <biib:SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock contextRef="c-1" id="f-1808">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;A summary of development expense related to the Denali collaboration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:54.455%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.280%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.285%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Denali collaboration development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;11.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;14.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;36.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;44.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of the Denali collaboration development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:SummaryOfActivityRelatedToDenaliTherapeuticsCollaborationTableTextBlock>
    <biib:Expenseincurredbythecollaboration contextRef="c-772" decimals="-5" id="f-1809" unitRef="usd">11400000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration contextRef="c-773" decimals="-5" id="f-1810" unitRef="usd">14900000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration contextRef="c-774" decimals="-5" id="f-1811" unitRef="usd">36300000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration contextRef="c-775" decimals="-5" id="f-1812" unitRef="usd">44500000</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-772" decimals="-5" id="f-1813" unitRef="usd">6900000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-773" decimals="-5" id="f-1814" unitRef="usd">8900000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-774" decimals="-5" id="f-1815" unitRef="usd">21800000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-775" decimals="-5" id="f-1816" unitRef="usd">26700000</biib:Expensereflectedwithinstatementsofincome>
    <biib:PercentageOfFutureDevelopmentCosts
      contextRef="c-776"
      decimals="3"
      id="f-1817"
      unitRef="number">0.700</biib:PercentageOfFutureDevelopmentCosts>
    <biib:PercentageOfFutureDevelopmentCosts
      contextRef="c-777"
      decimals="3"
      id="f-1818"
      unitRef="number">0.300</biib:PercentageOfFutureDevelopmentCosts>
    <biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner contextRef="c-778" decimals="-5" id="f-1819" unitRef="usd">165000000</biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
    <biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones contextRef="c-779" decimals="-5" id="f-1820" unitRef="usd">50000000</biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones>
    <biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones contextRef="c-780" decimals="-5" id="f-1821" unitRef="usd">335000000</biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones>
    <biib:SummaryOfActivityRelatedToCollaborationTableTextBlock contextRef="c-1" id="f-1822">&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of development expense related to the Stoke collaboration agreement is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:57.087%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.221%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.932%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dddddd;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#257acb;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30, 2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total Stoke collaboration development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;9.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;21.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Biogen's share of the Stoke collaboration development expense reflected in research and development expense in our condensed consolidated statements of income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#026dce;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</biib:SummaryOfActivityRelatedToCollaborationTableTextBlock>
    <biib:Expenseincurredbythecollaboration contextRef="c-781" decimals="-5" id="f-1823" unitRef="usd">9100000</biib:Expenseincurredbythecollaboration>
    <biib:Expenseincurredbythecollaboration contextRef="c-782" decimals="-5" id="f-1824" unitRef="usd">21900000</biib:Expenseincurredbythecollaboration>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-781" decimals="-5" id="f-1825" unitRef="usd">2800000</biib:Expensereflectedwithinstatementsofincome>
    <biib:Expensereflectedwithinstatementsofincome contextRef="c-782" decimals="-5" id="f-1826" unitRef="usd">6600000</biib:Expensereflectedwithinstatementsofincome>
    <biib:ContingentCommercializedRightsNumberOfProducts
      contextRef="c-783"
      decimals="INF"
      id="f-1827"
      unitRef="product">2</biib:ContingentCommercializedRightsNumberOfProducts>
    <biib:EquityMethodInvestmentsExpectedProfitShare
      contextRef="c-783"
      decimals="INF"
      id="f-1828"
      unitRef="number">0.450</biib:EquityMethodInvestmentsExpectedProfitShare>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill contextRef="c-784" decimals="-5" id="f-1829" unitRef="usd">20200000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones contextRef="c-785" decimals="-5" id="f-1830" unitRef="usd">150000000.0</biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones>
    <biib:CollaborativeArrangementTermExtension contextRef="c-786" id="f-1831">P5Y</biib:CollaborativeArrangementTermExtension>
    <biib:ContractOptionExerciseFee contextRef="c-786" decimals="-5" id="f-1832" unitRef="usd">60000000.0</biib:ContractOptionExerciseFee>
    <biib:EquityMethodInvestmentsExpectedProfitShare
      contextRef="c-786"
      decimals="INF"
      id="f-1833"
      unitRef="number">0.500</biib:EquityMethodInvestmentsExpectedProfitShare>
    <biib:Collaborationprofitlosssharing contextRef="c-787" decimals="-5" id="f-1834" unitRef="usd">66500000</biib:Collaborationprofitlosssharing>
    <biib:Collaborationprofitlosssharing contextRef="c-788" decimals="-5" id="f-1835" unitRef="usd">171700000</biib:Collaborationprofitlosssharing>
    <biib:EquityMethodInvestmentsExpectedProfitShare
      contextRef="c-786"
      decimals="INF"
      id="f-1836"
      unitRef="number">0.500</biib:EquityMethodInvestmentsExpectedProfitShare>
    <biib:Collaborationprofitlosssharing contextRef="c-789" decimals="-5" id="f-1837" unitRef="usd">60300000</biib:Collaborationprofitlosssharing>
    <biib:Collaborationprofitlosssharing contextRef="c-790" decimals="-5" id="f-1838" unitRef="usd">176800000</biib:Collaborationprofitlosssharing>
    <us-gaap:AccountsReceivableNet contextRef="c-791" decimals="-5" id="f-1839" unitRef="usd">4800000</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet contextRef="c-792" decimals="-5" id="f-1840" unitRef="usd">7600000</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsPayableCurrentAndNoncurrent contextRef="c-791" decimals="-5" id="f-1841" unitRef="usd">45300000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <us-gaap:AccountsPayableCurrentAndNoncurrent contextRef="c-792" decimals="-5" id="f-1842" unitRef="usd">60800000</us-gaap:AccountsPayableCurrentAndNoncurrent>
    <biib:CollaborativeArrangementExpectedDevelopmentCostFundsYearOne contextRef="c-793" decimals="-5" id="f-1843" unitRef="usd">200000000</biib:CollaborativeArrangementExpectedDevelopmentCostFundsYearOne>
    <biib:CollaborativeArrangementExpectedDevelopmentCostFundsYearTwo contextRef="c-793" decimals="-5" id="f-1844" unitRef="usd">50000000</biib:CollaborativeArrangementExpectedDevelopmentCostFundsYearTwo>
    <biib:ReductionOfResearchAndDevelopmentExpense contextRef="c-19" decimals="-5" id="f-1845" unitRef="usd">50000000.0</biib:ReductionOfResearchAndDevelopmentExpense>
    <biib:ReductionOfResearchAndDevelopmentExpense contextRef="c-1" decimals="-5" id="f-1846" unitRef="usd">150000000</biib:ReductionOfResearchAndDevelopmentExpense>
    <biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones contextRef="c-794" decimals="-5" id="f-1847" unitRef="usd">250000000</biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones>
    <biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones contextRef="c-105" decimals="-5" id="f-1848" unitRef="usd">130000000</biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones>
    <biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones contextRef="c-106" decimals="-5" id="f-1849" unitRef="usd">230000000</biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones>
    <biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones contextRef="c-107" decimals="-5" id="f-1850" unitRef="usd">640000000</biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones>
    <biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones contextRef="c-795" decimals="-5" id="f-1851" unitRef="usd">35000000</biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones>
    <biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones contextRef="c-796" decimals="-5" id="f-1852" unitRef="usd">30000000</biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones>
    <biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones contextRef="c-795" decimals="-5" id="f-1853" unitRef="usd">35000000</biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones>
    <biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones contextRef="c-796" decimals="-5" id="f-1854" unitRef="usd">30000000</biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones>
    <biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner contextRef="c-797" decimals="-5" id="f-1855" unitRef="usd">16000000</biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
    <biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner contextRef="c-798" decimals="-5" id="f-1856" unitRef="usd">16000000</biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
    <biib:CollaborativeArrangementsInvestmentsInCounterparty contextRef="c-799" decimals="-5" id="f-1857" unitRef="usd">30000000</biib:CollaborativeArrangementsInvestmentsInCounterparty>
    <biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones contextRef="c-800" decimals="-5" id="f-1858" unitRef="usd">21500000</biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones>
    <biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones contextRef="c-801" decimals="-5" id="f-1859" unitRef="usd">360000000</biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones>
    <biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones contextRef="c-802" decimals="-5" id="f-1860" unitRef="usd">625000000</biib:EstimatedAdditionalPaymentsUponAchievementOfDevelopmentAndCommercialMilestones>
    <us-gaap:VariableInterestEntityDisclosureTextBlock contextRef="c-1" id="f-1861">&lt;div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:87.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%"&gt;Note 20:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:14pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%"&gt;Investments in Variable Interest Entities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Unconsolidated Variable Interest Entities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have relationships with various variable interest entities that we do not consolidate as we lack the power to direct the activities that significantly impact the economic success of these entities. These relationships include investments in certain biotechnology companies and research collaboration agreements. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September 30, 2025 and December 31, 2024, the carrying value of our investments in certain biotechnology companies representing potential unconsolidated variable interest entities totaled $44.8 million and $23.6 million, respectively. Our maximum exposure to loss related to these variable interest entities is limited to the carrying value of our investments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have also entered into research collaboration agreements with certain variable interest entities where we are required to fund certain development activities. These development activities are included in research and development expense in our condensed consolidated statements of income as they are incurred. We have provided no financing to these variable interest entities other than previous contractually required amounts. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For additional information on our investments in variable interest entities, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 20, Investments in Variable Interest Entities,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to our consolidated financial statements included in our 2024 Form 10-K.&lt;/span&gt;&lt;/div&gt;</us-gaap:VariableInterestEntityDisclosureTextBlock>
    <biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities contextRef="c-22" decimals="-5" id="f-1862" unitRef="usd">44800000</biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities>
    <biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities contextRef="c-23" decimals="-5" id="f-1863" unitRef="usd">23600000</biib:InvestmentInBiotechnologyCompaniesThatAreDeterminedToBeUnconsolidatedVariableInterestEntities>
    <us-gaap:LegalMattersAndContingenciesTextBlock contextRef="c-1" id="f-1864">&lt;div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:87.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%"&gt;Note 21:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:14pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%"&gt;Litigation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are currently involved in various claims, investigations and legal proceedings, including the matters described below. For information as to our accounting policies relating to claims and legal proceedings, including use of estimates and contingencies, please read &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1, Summary of Significant Accounting Policies,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to our consolidated financial statements included in our 2024 Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;With respect to some loss contingencies, an estimate of the possible loss or range of loss cannot be made until management has further information, including, for example, (i) which claims, if any, will survive dispositive motion practice; (ii) information to be obtained through discovery; (iii) information as to the parties' damages claims and supporting evidence; (iv) the parties&#x2019; legal theories; and (v) the parties' settlement positions. If an estimate of the possible loss or range of loss can be made at this time, it is included in the potential loss contingency description below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The claims and legal proceedings in which we are involved also include challenges to the scope, validity or enforceability of the patents relating to our products, pipeline or processes and challenges to the scope, validity or enforceability of the patents held by others. These include claims by third parties that we infringe their patents. An adverse outcome in any of these proceedings could result in one or more of the following and have a material impact on our business or consolidated results of operations and financial position: (i) loss of patent protection; (ii) inability to continue to engage in certain activities; and (iii) payment of significant damages, royalties, penalties and/or license fees to third parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Loss Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Securities Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We and certain current and former officers are defendants in three securities actions pending in the District Court, one filed by Nadia Shash and Amjad Khan in November 2020, which relates to statements about ADUHELM, one filed by the Oklahoma Firefighters Pension and Retirement System in February 2022, which relates to statements about ADUHELM, and one filed by Thomas Allen Gray in June 2024, which relates to statements about LEQEMBI, TECFIDERA and VUMERITY. All allege violations of federal securities laws under 15 U.S.C. &#xa7;78j(b) and &#xa7;78t(a) and 17 C.F.R. &#xa7;240.10b-5 and seek declarations of the actions as class actions and monetary relief.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Derivative Actions&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We and members of the Board of Directors are named as defendants in five derivative actions pending in the District Court, one filed by The Booth Family Trust in February 2022, one filed by Elaine Wang in July 2022, one filed by Jonathan Blaufarb (Blaufarb I) in July 2024, one filed by Lawrence Hollin in October 2024 and one filed by Jonathan Blaufarb (Blaufarb II) in October 2024. The Booth, Wang and Blaufarb II actions relate to ADUHELM and other matters, and the Blaufarb I and Hollin actions relate to statements about LEQEMBI, our compliance controls, 2023 earnings guidance and other matters. The actions allege breach of fiduciary duty, waste of corporate assets and other common law claims, and violations of the Securities Exchange Act of 1934, 15 U.S.C. &#xa7;78a et seq. The actions seek declaratory and injunctive relief, monetary relief payable to Biogen, and attorneys&#x2019; fees and costs payable to the plaintiffs. All derivative actions are stayed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;IMRALDI Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;IMRALDI is an adalimumab biosimilar manufactured by Samsung Bioepis that Biogen commercializes in Europe.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2022, Fresenius Kabi filed a claim for damages and injunctive relief against Biogen France SAS in the Tribunal de Grande Instance de Paris alleging infringement of the French counterpart of EP &#x2018;3 145 488 Patent (the EP '488 Patent) by a formulation of IMRALDI no longer commercialized in France. Fresenius Kabi alleges damages of &#x20ac;13,450,000 plus interest and costs. Biogen disputes infringement and the validity of the patent.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2025 the Higher Regional Court of D&#xfc;sseldorf held that a formulation of IMRALDI we no longer commercialize in Germany infringed the German counterpart of the EP '488 Patent and enjoined infringement and declared Fresenius Kabi's right to seek damages. Biogen has requested review of the decision by Germany's Federal Court of Justice and has challenged the validity of the patent in a separate proceeding.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Litigation with Former Convergence Shareholders&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2015 Biogen acquired Convergence, a U.K. company. In 2019 Shareholder Representative Services LLC, on behalf of former shareholders of Convergence, asserted claims of $200.0 million for alleged breaches of the contract pursuant to which we acquired Convergence and in June 2023 it and former Convergence shareholders filed a suit against us in the High Court of Justice of England and Wales asserting one of the 2019 claims and seeking payment of $49.9&#160;million, plus interest and costs. A final decision is pending.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Humana Patient Assistance Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2025 Humana filed suit against Biogen Inc., Biogen U.S. Corp. and Advanced Care Scripts, Inc. in Jefferson Circuit Court in Kentucky alleging damages related to providing MS patients with free medications and to charitable contributions to non-profit organizations that provide financial assistance to MS patients. Humana alleges breach of contract, fraud and other claims under various state laws and seeks damages, attorneys' fees and costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Genentech Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2023 Genentech Inc. filed suit in the U.S. District Court for the Northern District of California claiming that it was owed royalties on sales of TYSABRI that occurred after the expiration of a patent licensed by Genentech to Biogen. In September 2025 the Court ordered that Biogen is liable to pay Genentech damages of approximately $88.3&#160;million plus interest (approximately $35.9&#160;million as of September 30, 2025), which continues to accrue. Final judgment has not yet entered.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Lender Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2025, by agreement of the parties, the court discontinued with prejudice the previously disclosed suit filed in 2024 by BioPharma Credit PLC, BPCR Limited Partnership, and BioPharma Credit Investments V (Master) LP against us and Reata Pharmaceuticals, Inc. in the Supreme Court of the State of New York alleging breach of a loan agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Antitrust Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2024 we were sued by Local No. 1 Health Fund and in September 2024 we were sued by the Mayor and City Council of Baltimore, New York State Teamsters Council Health and Hospital Fund, Teamsters Local 237 Welfare Fund and Teamsters Local 237 Retirees' Benefit Fund, in cases filed in the U.S. District Court for the Northern District of Illinois. After the cases were consolidated for pre-trial purposes, these plaintiffs and UFCW Local 1500 Welfare Fund sued us in a consolidated amended complaint filed in November 2024. The plaintiffs allege violations of federal antitrust laws including 15 U.S.C. &#xa7;&#xa7; 1, 2 and 13(c) and of various state laws, based on our contracts with &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;pharmacy benefit managers related to TECFIDERA and VUMERITY. Plaintiffs seek declarations of the actions as class actions, monetary, declaratory and equitable relief, and attorneys' fees and costs. In June 2025 the court dismissed the case without prejudice and granted the plaintiffs leave to amend the complaint. In August 2025 plaintiffs filed a second amended complaint adding Jacksonville Police Officers and Fire Fighters Health Insurance Trust as a plaintiff, alleging violation of the same laws as alleged in the dismissed complaint, and adding a claim under the Racketeer Influenced and Corrupt Organizations Act, 18 U.S.C. &#xa7;1962(c). The plaintiffs filed a third amended complaint in October 2025, removing the New York State Teamsters Council Health and Hospital Fund as a party.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2025 Walgreen Co. and The Kroger Co. filed a complaint alleging violations of 15 U.S.C. &#xa7;&#xa7; 1 and 2 based on our contracts with pharmacy benefit managers related to TECFIDERA and VUMERITY and seeking monetary, declaratory and equitable relief, and attorneys' fees and costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Neurimmune Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2025 we filed suit against Neurimmune Holding AG and Neurimmune Subone AG (collectively, "Neurimmune") in the District Court seeking declaratory judgment and permanent injunctive relief regarding our rights under a terminated collaboration agreement related to aducanumab. In September 2025 Neurimmune asserted counterclaims for declaratory judgment, breach of contract and unfair competition under Massachusetts G.L. 93A and seeking monetary, declaratory and equitable relief and attorneys' fees and costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;TECFIDERA E.U. Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023 we sued Neuraxpharm Pharmaceuticals S.L. and Neuraxpharm Netherlands B.V. (collectively, Neuraxpharm), Zaklady Farmaceutyzne Polpharma S.A. (Polpharma), Sandoz B.V. (Sandoz), Mylan Ireland Ltd. and Mylan B.V. in the District Court of Amsterdam, Netherlands for damages, alleging violation of our regulatory marketing protection by their sales of generic versions of TECFIDERA. In March 2024 we obtained an injunction against Sandoz enjoining Netherlands sales of its generic version of TECFIDERA. In October 2024 Neuraxpharm, Polpharma and Sandoz counterclaimed for damages based on our actions to enforce TECFIDERA's regulatory marketing protection.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2024 we obtained an injunction in the Danish Maritime and Commercial High Court against Sandoz A/S (reversed on appeal) enjoining Danish sales of its generic version of TECFIDERA and in June 2024 we sued Sandoz A/S for damages, alleging violation of our regulatory marketing protection. In November 2024 Sandoz A/S counterclaimed for damages based on our actions to enforce TECFIDERA's regulatory marketing protection. These cases are stayed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2025 the European General Court annulled the May 2023 European Commission decision granting TECFIDERA an additional year of regulatory marketing protection extending until February 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Other Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Government Investigations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2025 the SEC Division of Enforcement informed us that it has closed the matter in which we had received subpoenas seeking information relating to ADUHELM and its launch and our equity plans, and in April and May 2025 the DOJ and SEC informed us that they closed the matters in which we had received subpoenas seeking information relating to our business operations in several foreign countries.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Italian Competition Authority is investigating Biogen and other companies in relation to our biosimilar product BYOOVIZ.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2025 we received a Civil Investigative Demand from the Louisiana Department of Justice for information regarding our policies relating to the purchase of drugs by healthcare organizations that are covered entities under Section 340B of the Public Health Service Act.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;TYSABRI Biosimilar Patent Matter&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2022 we filed an action in the U.S. District Court for the District of Delaware against Sandoz Inc., other Sandoz entities and Polpharma Biologics S.A. under the Biologics Price Competition and Innovation Act, 42 U.S.C. &#xa7;262, seeking a declaratory judgment of patent infringement. No trial date is set.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Hatch-Waxman Act Litigation relating to VUMERITY Orange-Book Listed Patents&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2023 Biogen and Alkermes Pharma Ireland Limited filed patent infringement proceedings relating to VUMERITY Orange-Book listed patents (U.S. Patent Nos. 8,669,281, 9,090,558 and 10,080,733) pursuant to the Drug Price Competition and Patent Term Restoration Act of 1984 (the Hatch-Waxman Act) in the U.S. District Court for the District of Delaware against Zydus Worldwide DMCC, Zydus Pharmaceuticals (USA) Inc. and Zydus Lifesciences Limited. In July 2025 the parties reached a settlement and the court dismissed the case pursuant to the parties' stipulation of dismissal.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Eisai Matter&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2025 we filed a request for arbitration in the International Court of Arbitration of the International Chamber of Commerce seeking adoption of a budget and commercialization plan for the European Territory that allocates commercialization activities to Biogen and Eisai in an equitable fashion taking into account our respective capabilities and provides a meaningful role for each party.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Product Liability and Other Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We are also involved in product liability claims and other legal proceedings incidental to our normal business activities. While the outcome of any of these proceedings cannot be accurately predicted, we do not believe the ultimate resolution of any of these existing matters would have a material adverse effect on our business or financial condition.&lt;/span&gt;&lt;/div&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
    <us-gaap:LossContingencyDamagesSoughtValue contextRef="c-803" decimals="-4" id="f-1865" unitRef="eur">13450000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:LossContingencyEstimateOfPossibleLoss contextRef="c-804" decimals="-5" id="f-1866" unitRef="usd">200000000.0</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:LossContingencyEstimateOfPossibleLoss contextRef="c-805" decimals="-5" id="f-1867" unitRef="usd">49900000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:LossContingencyDamagesSoughtValue contextRef="c-806" decimals="-5" id="f-1868" unitRef="usd">88300000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:LitigationSettlementInterest contextRef="c-806" decimals="-5" id="f-1869" unitRef="usd">35900000</us-gaap:LitigationSettlementInterest>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c-1" id="f-1870">&lt;div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:87.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%"&gt;Note 22:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:14pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate and are managed as one operating segment, and derive revenue from activities related to the discovery, development and delivery of innovative therapies for people living with serious and complex diseases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our research and development organization is responsible for the research and discovery of new product candidates and supports development and registration efforts for potential future products. Our pharmaceutical, operations and technology organization manages the development of the manufacturing processes, clinical trial supply, commercial product supply, distribution, buildings and facilities. Our commercial organization is responsible for U.S. and international development of our commercial products. We are also supported by corporate staff functions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our CEO, as the CODM, manages and allocates resources to the operations of our company on a total company basis by assessing the overall level of resources available and deciding how to best deploy these resources across functions, therapeutic areas and research and development projects that are in line with our long-term company-wide strategic goals. In making these decisions, our CEO is provided with and uses consolidated financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets. The CODM performs this assessment based on the segment&#x2019;s net income. Through this analysis, which includes a comparison to budgeted results, the CODM assesses performance and how to allocate resources across the functions discussed above. The measure of segment assets used in determining how to manage and allocate resources is reported within our condensed consolidated balance sheets as total assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table presented below, which was prepared in accordance with the accounting policies discussed in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 1, Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to our consolidated financial statements included in our 2024 Form 10-K, contains additional information on enterprise-wide disclosures about product revenue, other revenue and long-lived assets, as well as our segment&#x2019;s revenue and profits, including significant segment expense and other segment items. Revenue is primarily attributed to individual countries based on location of the customer or licensee.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Additional Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table includes additional information about reported segment revenue, significant segment expense and segment measure of profitability:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.110%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.841%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.841%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.256%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.116%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,534.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,465.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,611.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,221.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less cost and expense:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cost of sales, excluding amortization and impairment of acquired intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Product cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;384.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;468.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,261.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,204.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Royalty cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;290.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;170.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;647.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;522.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and discovery&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;131.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;141.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Early stage programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;184.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;214.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Late stage programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;154.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;135.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketed products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;107.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;126.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;284.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;414.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other research and development costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;167.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;221.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;513.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;560.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Acquired in-process research and development, upfront and milestone expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;249.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;594.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;588.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,751.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,723.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other segment expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;360.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;307.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,091.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;895.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net Income attributable to Biogen Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;466.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;388.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,341.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,365.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.992%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.353%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Other research and development costs primarily consist of indirect costs incurred in support of overall research and development activities and non-specific programs, including activities that benefit multiple programs, such as management costs, as well as depreciation, information technology and facility-based expenses and are not allocated to a specific program or stage.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt; Other segment expense includes: amortization and impairment of acquired intangible assets; collaboration profit sharing/(loss reimbursement); (gain) loss on fair value remeasurement of contingent consideration; restructuring charges; gain on sale of priority review voucher, net; other (income) expense, net; and income tax (benefit) expense</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-1871"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock contextRef="c-1" id="f-1872">&lt;div style="margin-top:5pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table includes additional information about reported segment revenue, significant segment expense and segment measure of profitability:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.110%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.841%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.841%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.256%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.116%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Three Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;For the Nine Months Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Total revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,534.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2,465.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,611.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;7,221.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Less cost and expense:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Cost of sales, excluding amortization and impairment of acquired intangible assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Product cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;384.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;468.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,261.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,204.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Royalty cost of sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;290.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;170.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;647.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;522.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and development:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Research and discovery&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;41.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;48.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;131.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;141.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Early stage programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;59.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;64.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;184.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;214.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Late stage programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;60.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;56.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;154.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;135.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Marketed products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;107.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;126.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;284.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;414.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other research and development costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;167.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;221.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;513.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;560.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Acquired in-process research and development, upfront and milestone expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;26.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;249.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;42.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;594.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;588.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,751.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,723.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Other segment expense&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;360.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;307.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,091.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;895.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Net Income attributable to Biogen Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;466.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;388.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,341.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#dbdbdb;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;1,365.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.992%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.353%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:29.355%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt; Other research and development costs primarily consist of indirect costs incurred in support of overall research and development activities and non-specific programs, including activities that benefit multiple programs, such as management costs, as well as depreciation, information technology and facility-based expenses and are not allocated to a specific program or stage.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(2)&lt;/span&gt; Other segment expense includes: amortization and impairment of acquired intangible assets; collaboration profit sharing/(loss reimbursement); (gain) loss on fair value remeasurement of contingent consideration; restructuring charges; gain on sale of priority review voucher, net; other (income) expense, net; and income tax (benefit) expense</us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock>
    <us-gaap:Revenues contextRef="c-807" decimals="-5" id="f-1873" unitRef="usd">2534700000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-808" decimals="-5" id="f-1874" unitRef="usd">2465800000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-809" decimals="-5" id="f-1875" unitRef="usd">7611200000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-810" decimals="-5" id="f-1876" unitRef="usd">7221200000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-811" decimals="-5" id="f-1877" unitRef="usd">384000000.0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-812" decimals="-5" id="f-1878" unitRef="usd">468200000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-813" decimals="-5" id="f-1879" unitRef="usd">1261200000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-814" decimals="-5" id="f-1880" unitRef="usd">1204300000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-815" decimals="-5" id="f-1881" unitRef="usd">290400000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-816" decimals="-5" id="f-1882" unitRef="usd">170500000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-817" decimals="-5" id="f-1883" unitRef="usd">647500000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-818" decimals="-5" id="f-1884" unitRef="usd">522600000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-819" decimals="-5" id="f-1885" unitRef="usd">41000000.0</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-820" decimals="-5" id="f-1886" unitRef="usd">48300000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-821" decimals="-5" id="f-1887" unitRef="usd">131900000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-822" decimals="-5" id="f-1888" unitRef="usd">141600000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-823" decimals="-5" id="f-1889" unitRef="usd">59900000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-824" decimals="-5" id="f-1890" unitRef="usd">64100000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-825" decimals="-5" id="f-1891" unitRef="usd">184200000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-826" decimals="-5" id="f-1892" unitRef="usd">214800000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-827" decimals="-5" id="f-1893" unitRef="usd">60400000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-828" decimals="-5" id="f-1894" unitRef="usd">56300000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-829" decimals="-5" id="f-1895" unitRef="usd">154400000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-830" decimals="-5" id="f-1896" unitRef="usd">135600000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-831" decimals="-5" id="f-1897" unitRef="usd">107700000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-832" decimals="-5" id="f-1898" unitRef="usd">126000000.0</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-833" decimals="-5" id="f-1899" unitRef="usd">284900000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-834" decimals="-5" id="f-1900" unitRef="usd">414100000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-835" decimals="-5" id="f-1901" unitRef="usd">167100000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-836" decimals="-5" id="f-1902" unitRef="usd">221500000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-837" decimals="-5" id="f-1903" unitRef="usd">513800000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-838" decimals="-5" id="f-1904" unitRef="usd">560900000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <biib:ResearchAndDevelopmentExpenseIncludingAcquiredInProcessCost contextRef="c-19" decimals="-5" id="f-1905" unitRef="usd">2100000</biib:ResearchAndDevelopmentExpenseIncludingAcquiredInProcessCost>
    <biib:ResearchAndDevelopmentExpenseIncludingAcquiredInProcessCost contextRef="c-20" decimals="-5" id="f-1906" unitRef="usd">26500000</biib:ResearchAndDevelopmentExpenseIncludingAcquiredInProcessCost>
    <biib:ResearchAndDevelopmentExpenseIncludingAcquiredInProcessCost contextRef="c-1" decimals="-5" id="f-1907" unitRef="usd">249400000</biib:ResearchAndDevelopmentExpenseIncludingAcquiredInProcessCost>
    <biib:ResearchAndDevelopmentExpenseIncludingAcquiredInProcessCost contextRef="c-21" decimals="-5" id="f-1908" unitRef="usd">42500000</biib:ResearchAndDevelopmentExpenseIncludingAcquiredInProcessCost>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-19" decimals="-5" id="f-1909" unitRef="usd">594800000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-20" decimals="-5" id="f-1910" unitRef="usd">588400000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-1" decimals="-5" id="f-1911" unitRef="usd">1751100000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-21" decimals="-5" id="f-1912" unitRef="usd">1723700000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-807" decimals="-5" id="f-1913" unitRef="usd">360800000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-808" decimals="-5" id="f-1914" unitRef="usd">307500000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-809" decimals="-5" id="f-1915" unitRef="usd">1091000000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-810" decimals="-5" id="f-1916" unitRef="usd">895600000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:NetIncomeLoss contextRef="c-807" decimals="-5" id="f-1917" unitRef="usd">466500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-808" decimals="-5" id="f-1918" unitRef="usd">388500000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-809" decimals="-5" id="f-1919" unitRef="usd">1341800000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-810" decimals="-5" id="f-1920" unitRef="usd">1365500000</us-gaap:NetIncomeLoss>
    <us-gaap:SubsequentEventsTextBlock contextRef="c-1" id="f-1921">&lt;div style="margin-top:9pt;padding-left:27pt;text-indent:-27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.595%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:87.205%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#0070c0;border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%"&gt;Note 23:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #0070c0;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:14pt"&gt;&lt;span style="color:#0070c0;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:700;line-height:100%"&gt;Subsequent Events&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Vanqua Bio, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2025 we entered into a license agreement with Vanqua to acquire the worldwide rights to Vanqua's preclinical oral C5aR1 antagonist compound. In connection with the closing of this transaction, we expect to make an upfront payment to Vanqua of $70.0&#160;million during the fourth quarter of 2025, which will be recognized within acquired in-process research and development, upfront and milestone expense in our condensed consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#2573ba;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:700;line-height:120%"&gt;Sale of BYOOVIZ and OPUVIZ Rights&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2025 we completed the sale of our remaining commercial rights to two ophthalmology assets in Europe: BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS, and OPUVIZ, an aflibercept biosimilar referencing EYLEA. Samsung Bioepis will have full responsibility for commercialization of BYOOVIZ upon the transfer of commercial rights from Biogen back to Samsung Bioepis, effective as of January 2026.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We expect to recognize a minimal gain within our condensed consolidated statements of income during the fourth quarter of 2025.&lt;/span&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
    <biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner contextRef="c-839" decimals="-5" id="f-1922" unitRef="usd">70000000</biib:UpfrontAndMilestonePaymentsMadeToCollaborativePartner>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-19" id="f-1924">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-19" id="f-1925">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-19" id="f-1926">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-19" id="f-1927">false</ecd:NonRule10b51ArrAdoptedFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
